<SEC-DOCUMENT>0000950123-20-010063.txt : 20201110
<SEC-HEADER>0000950123-20-010063.hdr.sgml : 20201110
<ACCEPTANCE-DATETIME>20201002171339
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-20-010063
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		65
FILED AS OF DATE:		20201002
<PUBLIC-REL-DATE>20201110
DATE AS OF CHANGE:		20201005

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Silverback Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001671858
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				811489190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-03623
		FILM NUMBER:		201221170

	BUSINESS ADDRESS:	
		STREET 1:		500 FAIRVIEW AVENUE NORTH, SUITE 600
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109
		BUSINESS PHONE:		206-456-2900

	MAIL ADDRESS:	
		STREET 1:		500 FAIRVIEW AVENUE NORTH, SUITE 600
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on October 2, 2020. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>This draft registration statement has not been publicly filed with the Securities and Exchange Commission </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>and all information herein remains strictly confidential. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:15pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:15pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>THE SECURITIES ACT OF 1933 </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Exact name of
registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>81-1489190</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of<BR>incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial<BR>Classification Code Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification Number)</B></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>500 Fairview Ave N, Suite 600 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Seattle, Washington 98109 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(206) <FONT
STYLE="white-space:nowrap">456-2900</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s
principal executive offices) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Laura Shawver, Ph.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Chief Executive Officer
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>500
Fairview Ave N, Suite 600 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Seattle, Washington 98109 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(206) <FONT STYLE="white-space:nowrap">456-2900</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Kenneth J. Rollins<BR>Charles S. Kim<BR>James Pennington<BR>Cooley LLP<BR>4401 Eastgate Mall<BR>San Diego, California 92121<BR>(858) <FONT STYLE="white-space:nowrap">550-6000</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Brian J. Cuneo<BR>Phillip S. Stoup<BR>Latham&nbsp;&amp; Watkins LLP<BR>140 Scott Drive<BR>Menlo Park, California 94025<BR>(650) <FONT STYLE="white-space:nowrap">328-4600</FONT></B></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As soon as practicable after the effective date of this Registration Statement. </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act,
check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Each Class&nbsp;of<BR>Securities to be Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Proposed&nbsp;Maximum</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Offering&nbsp;Price<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Registration&nbsp;Fee<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Common Stock, $0.0001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the
Securities Act of 1933, as amended. Includes the aggregate offering price of additional shares of common stock that the underwriters have the option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.
</P></TD></TR></TABLE><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL"><B>The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant
shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall
become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the applicable provisions of the Fixing America&#146;s Surface Transportation Act, we are omitting our unaudited financial statements as of
June&nbsp;30, 2020 and for the six months ended June&nbsp;30, 2019 and 2020 because they relate to historical periods that we believe will not be required to be included in the prospectus at the time of the contemplated offering. We intend to amend
this registration statement to include all financial information required by Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> at the date of such amendment before distributing a preliminary prospectus to investors. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#de1a1e">The information in this preliminary prospectus is not complete and may be changed. We may
not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities
in any state or other jurisdiction where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#de1a1e">Subject to Completion, Dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020
</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g76j62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Common Stock </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This is the initial
public offering of shares of common stock of Silverback Therapeutics, Inc. We are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock. We currently expect the initial public offering price will be between
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have applied to list our common stock on the Nasdaq Global Market under the symbol &#147;SBTX.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as defined under the federal securities laws and, as such, have elected to comply with certain reduced
reporting requirements in this prospectus and may elect to do so in future filings. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>See the section titled
&#147;<A HREF="#rom67046_2">Risk Factors</A>&#148; beginning on page 12 to read about factors you should consider before deciding to invest in shares of our common stock. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Per&nbsp;Share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts and commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to Silverback Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See the section titled &#147;Underwriting&#148; for a description of the compensation payable to the underwriters.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have granted the underwriters an option for a period of 30 days to purchase up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock at the initial public offering price, less the underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver the shares against payment in New York, New York on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:13pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:13pt">
<TD VALIGN="top"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>SVB&nbsp;Leerink&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Stifel</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>H.C.&nbsp;Wainwright&nbsp;&amp;&nbsp;Co. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_4">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_9">Selected Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_10">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_13">Executive and Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_14">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_15">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_16">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_18">Material U.S. Federal Income Tax Consequences for <FONT STYLE="white-space:nowrap">Non-U.S.
</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_20">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_22">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom67046_23">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this
prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.
This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current
only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For investors outside the United States: Neither we nor the underwriters have done anything that would permit this offering or possession or
distribution of this prospectus or any free writing prospectus we may provide to you in connection with this offering in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform
yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus and any such free writing prospectus outside the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>This summary highlights selected information contained in greater detail elsewhere in this prospectus. This summary is not complete and does not
contain all of the information you should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus. You should carefully consider, among other things, the sections of this
prospectus titled &#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the
related notes included elsewhere in this prospectus. Unless the context otherwise requires, the terms &#147;Silverback Therapeutics,&#148; &#147;Silverback,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar references in this
prospectus refer to Silverback Therapeutics, Inc. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a clinical-stage biopharmaceutical company focused on leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered,
tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal
antibodies directed to specific disease sites. Initially, we are applying our platform to create a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment (TME) in solid tumors to promote
cancer cell killing. Our lead product candidate, SBT6050, is comprised of a TLR8 linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors such as certain breast, gastric and
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancers, among others. SBT6050 is currently in a Phase&nbsp;1/1b clinical trial in patients with advanced or metastatic HER2-expressing solid tumors. In this trial, we have observed single
agent pharmacological activity in the first dose cohort, and we anticipate providing an update on interim data from the Phase&nbsp;1 dose-escalation cohorts in the second half of 2021. SBT6290 is our second product candidate, expanding on the
potential of a TLR8 agonist as a payload. SBT6290 is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in certain bladder, triple negative breast, head and neck, and
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancers. We anticipate submitting an investigational new drug application (IND) for SBT6290 in the fourth quarter of 2021. Our third TLR8 program, SBT8230, is comprised of a TLR8
linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection (cHBV). We are also developing agents that localize therapies to modulate important pathways in additional
oncology and fibrosis indications using TLR8 and other linker-payloads. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our ImmunoTAC Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ImmunoTAC platform is the result of a focused effort to discover ways to systemically deliver disease-modifying small molecules in a directed fashion
to sites of disease. Many potentially promising systemic therapies fail to maximize their therapeutic potential due to toxicities in healthy tissues. Our approach is designed to increase the therapeutic window and avert unacceptable toxicities by
directly targeting specific disease sites where our therapeutics are locally active. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown in the figure below, our ImmunoTAC platform is
comprised of three components: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Antigen binding domain</B>&#151;which is responsible for localizing the therapeutic activity of the payload to the
site of the disease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Linker</B>-<B>payload</B>&#151;a disease-modifying small molecule optimized for potency when conjugated to a
monoclonal antibody via its linker; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Fc region</B>&#151;tuned for requisite effector function. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have built a library of proprietary small molecule linker-payloads and antigen binding domains that allows us to
mix and match these components to strategically pair and create new therapeutic agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Our ImmunoTAC Platform Strategically Pairs Antigen
Binding Domains with Linker-Payloads to Modulate Pathways Underlying <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Difficult-to-Treat</FONT></FONT> Diseases </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g02k15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Development Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ImmunoTAC platform drives our pipeline of tissue targeted therapeutic candidates as summarized in the chart below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g09g06.jpg" ALT="LOGO">
 </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Tumor-Localized Myeloid Cell Activation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Myeloid cells are a class of innate immune cells that develop from common monocyte-dendritic cell progenitor cells and are comprised of both
immunosuppressive and <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> subpopulations. Tumors are permeated with myeloid cells, which can comprise between 5% and 10% of the tumor. Activation of myeloid cells, either by reprogramming
immunosuppressive myeloid cells towards a more <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> phenotype or stimulating other myeloid cells that have been silenced (e.g., dendritic cells), results in direct tumor killing and recruitment of
immune cells. Further, activated myeloid cells can prime and amplify T cell and natural killer (NK) cell responses, bridging the innate and adaptive immunity to elicit broad, durable anti-tumor responses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>SBT6050 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our lead product candidate, SBT6050, is
comprised of a TLR8 linker-payload conjugated to a HER2-directed monoclonal antibody and is designed to activate myeloid cells in tumors expressing moderate or high levels of HER2. TLR8 is expressed in myeloid cell types prevalent in human tumors
and TLR8 agonism can activate a broad spectrum of anti-tumor immune mechanisms. Therefore, we believe that TLR8 is the optimal target for activating human myeloid cell types in the TME. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">SBT6050 utilizes HER2 to localize and facilitate the delivery of the TLR8 agonist conjugate into myeloid cells in the TME. Therefore, unlike HER2
targeted therapies that have been approved by the U.S. Food and Drug Administration (FDA) such as Herceptin (trastuzumab), SBT6050 does not require HER2 to be an oncogenic driver to elicit anti-tumor activity. Furthermore, SBT6050 recognizes the
HER2 <FONT STYLE="white-space:nowrap">sub-domain</FONT> II, the pertuzumab epitope, and does not cross-block trastuzumab, allowing for potential combinations with trastuzumab-based agents, which are standard of care therapies in some HER2-expressing
cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently evaluating the safety and tolerability of SBT6050 in a Phase&nbsp;1 dose-escalation trial in patients with advanced or
metastatic HER2-expressing solid tumors. Single agent pharmacological activity has been observed in the first dose-escalation cohort of this trial. We anticipate providing an update on interim data from the Phase&nbsp;1 dose-escalation cohorts in
the second half of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>SBT6290 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">SBT6290 is our
second product candidate, expanding on the potential of a TLR8 agonist as a payload. The same TLR8 linker-payload used in SBT6050 is conjugated to a monoclonal antibody that targets Nectin4. Nectin4 is expressed in subsets of solid tumors including
bladder, triple negative breast, head and neck, and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancers, and has been clinically validated by Seattle Genetics through the approval of the antibody-drug conjugate enfortumab vedotin
(Padcev). We anticipate submitting the IND for SBT6290 in the fourth quarter of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>SBT8230 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">SBT8230, an ASGR1-TLR8 ImmunoTAC therapeutic, is our third TLR8 program. SBT8230 is engineered to potently activate human myeloid cells in the liver for
the treatment of cHBV. Selgantolimod <FONT STYLE="white-space:nowrap">(GS-9688),</FONT> an existing untargeted, orally administered TLR8 agonist being developed by Gilead Sciences, generated anti-viral immune responses in a cHBV animal model. The
clinical development of this untargeted TLR8 agonist has shown promise, but we believe that toxicity prevented the use of a sufficient dose to elicit optimal clinical activity. We believe liver-localized TLR8
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
agonism could better realize the potential for effective therapy and potentially lead to functional cures in patients suffering from cHBV. We anticipate selecting a development candidate for this
program in the fourth quarter of 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Additional Immuno-Oncology Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to SBT6050 and SBT6290, we are evaluating other solid tumor targets to leverage the TLR8 linker-payload paired with additional tumor directed
antibodies. These targets are differentially expressed on tumors compared to normal tissue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>ASGR1-TGF&szlig; Receptor&#151;Fibrosis Program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">TGF&szlig; signaling is a key mediator of fibrosis across multiple organ systems, including the liver. In the liver, TGF&szlig; drives fibrosis
initiation and progression through multiple mechanisms, including hepatocyte apoptosis, hepatic stellate cell transdifferentiation to myofibroblasts, and <FONT STYLE="white-space:nowrap">pro-fibrotic</FONT> macrophage activation. Our <FONT
STYLE="white-space:nowrap">ASGR1-TGF&szlig;R1</FONT> antagonist conjugate pairs the ASGR1 antibody used in SBT8230 with a proprietary TGF&szlig;R1 antagonist to achieve liver-localized inhibition of TGF&szlig; signaling to treat fibrosis. Our
tissue-directed approach has been designed to prevent toxicities associated with untargeted systemically distributed TGF&szlig;R1 antagonist agents. Our <FONT STYLE="white-space:nowrap">ASGR1-TGF&szlig;R1</FONT> antagonist conjugates are currently
in preclinical testing and have demonstrated potent inhibition of TGF&szlig; signaling <I>in vitro</I>. We are currently evaluating conjugates <I>in vivo</I> in mouse disease models. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our goal is to transform the treatment of
cancer and other serious diseases with unmet need using our ImmunoTAC platform to deliver a new class of systemically delivered, tissue-directed, and locally active therapies. The key elements of our business strategy are to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Advance SBT6050 through development and seek expedited approval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Advance SBT6050 into earlier lines of therapy. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Maximize the therapeutic potential of TLR8 in oncology and other serious diseases. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Leverage our ImmunoTAC platform for promising new antibody-linker-payload combinations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Evaluate opportunities to accelerate development timelines and/or enhance the commercial potential of our programs in
partnership with third parties. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Team and Investors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have assembled an accomplished management team with a proven track record of therapeutic development expertise and of generating meaningful
shareholder value. The members of our team have deep experience in discovering, developing, and commercializing therapeutics with a particular focus on cancer, having worked at companies such as Synthorx (acquired by Sanofi), Juno Therapeutics
(acquired by Celgene), Cascadian Therapeutics (acquired by Seattle Genetics), Acerta Pharma (acquired by AstraZeneca), Ignyta (acquired by Roche), Roche/Genentech, Seattle Genetics, SUGEN (acquired by Pharmacia), and Trubion Pharmaceuticals
(acquired by Emergent Biosolutions). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our inception in 2016, we have raised over $215&nbsp;million in capital from leading investors including
OrbiMed Advisors, Alexandria Venture Investments, Boxer Capital of Tavistock Group, Celgene, Colt Ventures, EcoR1 Capital, Fidelity, Hunt Technology Ventures, Nantahala Capital Management, Nextech Invest, Pontifax, RA Capital, and U.S. Venture
Partners. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our business is subject to a number of risks that you should be aware of before making a decision to invest in our common stock. These risks are more
fully described in the section titled &#147;Risk Factors&#148; immediately following this prospectus summary. These risks include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have incurred significant net losses since inception, and we anticipate that we will continue to incur significant
losses for the foreseeable future and may never be able to achieve or sustain revenues or profitability in the future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Even if this offering is successful, we will need substantial additional funding. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have a limited operating history and face significant challenges and will incur substantial expenses as we build our
capabilities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Drug development involves a lengthy and expensive process with uncertain outcomes, and the results of preclinical studies
and early clinical trials are not necessarily predictive of future results. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our discovery and development activities are focused on developing systemically delivered and tissue targeted therapeutics
for the treatment of cancer and other serious diseases and it is difficult to predict the time and cost of product candidate development and obtaining regulatory approval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our approach to the discovery and development of product candidates is unproven, and we may not be successful in our
efforts to use and further develop our product engine to expand our pipeline of product candidates with commercial value. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The market opportunities for our product candidates may be relatively small as it will be limited to those patients who are
ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We rely, and expect to rely in the future, on third parties, including independent clinical investigators and contract
research organizations (CROs), to conduct certain aspects of our preclinical studies and planned clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could adversely impact our business, including our planned
clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our success depends on our ability to protect our intellectual property and our proprietary technologies.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We were
incorporated under the laws of the State of Delaware on January&nbsp;4, 2016. Our principal executive offices are located at 500 Fairview Ave N, Suite 600, Seattle, Washington 98109, and our telephone number is (206)
<FONT STYLE="white-space:nowrap">456-2900.</FONT> Our corporate website address is www.silverbacktx.com. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this prospectus or the
registration statement of which it forms a part. We have included our website in this prospectus solely as an inactive textual reference. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Trademarks and Service Marks </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">&#147;Silverback Therapeutics,&#148; &#147;Silverback,&#148; the Silverback logo and other trademarks, trade names or service marks of Silverback
Therapeutics, Inc. appearing in this prospectus are the property of Silverback Therapeutics, Inc. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience,
the trademarks and trade names in this prospectus may be referred to without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references should not be
construed as any indicator that their respective owners will not assert their rights thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an Emerging Growth Company and Smaller
Reporting Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act (JOBS Act), enacted in
April 2012, and we may remain an emerging growth company for up to five years following the completion of this offering. For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various
public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002
(Sarbanes-Oxley Act), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden
parachute payments not previously approved. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation-related information that would be required if we
were not an emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised
accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from new
or revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We would cease to be an &#147;emerging growth company&#148; upon the earliest to occur of: (i)&nbsp;the last day of the fiscal year in which we have
$1.07&nbsp;billion or more in annual revenue; (ii)&nbsp;the date on which we first qualify as a large accelerated filer under the rules of the Securities and Exchange Commission (SEC); (iii) the date on which we have, in any three-year period,
issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; and (iv)&nbsp;the last day of the fiscal year ending after the fifth anniversary of this offering. We may choose to take advantage of some
but not all of these reduced reporting burdens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also a &#147;smaller reporting company&#148; as defined in the Securities and Exchange Act
of 1934, as amended (Exchange Act). We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and
will be able to take advantage of these scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million
measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock
held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>The Offering </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock to be offered </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Option to purchase additional shares </P></TD>
<TD>The underwriters have a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock from us.
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock to be outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their option to purchase additional shares in full).
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise in full
their option to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock), based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the
price range set forth on the cover page of this prospectus), after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="52%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from this offering, along with our existing cash and cash equivalents, (i)&nbsp;to fund the development of SBT6050, including the ongoing Phase 1 dose-escalation trial and planned Phase
1b tumor-specific expansion trial of SBT6050 as a monotherapy in HER2-expressing tumors; (ii)&nbsp;to fund the planned Phase 1 dose-escalation trial and planned Phase 1b trial of SBT6050 in combination with a
<FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitor; (iii)&nbsp;to fund the development of SBT6290, including the ongoing <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and planned Phase 1 dose-escalation trial of SBT6290 in
Nectin4-expressing tumors; (iv)&nbsp;to fund the development of ASGR1-TLR8, including the planned development candidate selection for and planned <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies of our SBT8230 program in cHBV; and
(v)&nbsp;to fund our other research and development activities, as well as for working capital and other general corporate purposes. See the section of this prospectus titled &#147;Use of Proceeds.&#148; </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Risk factors </P></TD>
<TD>You should read the section of this prospectus titled &#147;Risk Factors&#148; for a discussion of factors to consider carefully, together with all the other information included in this prospectus, before deciding to invest in our common stock.
</TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Proposed Nasdaq Global Market symbol </P></TD>
<TD>&#147;SBTX&#148; </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Directed share program </P></TD>
<TD>At our request, the underwriters have reserved up to&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of our common stock offered by this prospectus, excluding the additional shares that the underwriters have a
<FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase, for sale, at the initial public offering price, to certain of our directors and officers and certain other parties related to us. Shares purchased by our directors and officers will
be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction described in the section of this prospectus titled &#147;Underwriting.&#148; The number of shares of common stock available
for sale to the general public will be reduced to the extent these individuals purchase such reserved shares. Any reserved shares that are not so purchased will be offered by the underwriters to the general public on the same basis as the other
shares offered by this prospectus. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding as of September&nbsp;30, 2020 (which includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
outstanding that are subject to forfeiture or our right to repurchase as of such date), and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon the
exercise of outstanding stock options as of September&nbsp;30, 2020, with a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon the
exercise of outstanding stock options granted subsequent to September&nbsp;30, 2020, with a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">33,995 shares of common stock which will become issuable to the lenders under our loan and security agreement (Loan
Agreement) upon the exercise of warrants outstanding as of September&nbsp;30, 2020 (Lender Warrants), at a weighted-average exercise price of $0.63&nbsp;per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance
under our 2020 Equity Incentive Plan (2020 Plan), as well as any automatic increases in the number of shares of our common stock reserved for future issuance under the 2020 Plan, which will become effective upon the execution and delivery of the
underwriting agreement for this offering (including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for issuance under our 2016 Equity Incentive Plan (Prior Plan), which shares will be
added to the 2020 Plan upon its effectiveness); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance
under our 2020 Employee Stock Purchase Plan (ESPP), as well as any automatic increases in the number of shares of our common stock reserved for future issuance under the ESPP, which will become effective upon the execution and delivery of the
underwriting agreement for this offering. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated, all information contained in this prospectus, including the number of
shares of common stock that will be outstanding after this offering, assumes or gives effect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the conversion of all outstanding shares of our redeemable convertible preferred stock as of September&nbsp;30, 2020 into
an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the closing of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise by the underwriters of their option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
additional shares of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise of the outstanding options and the Lender Warrants described above; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the closing of
this offering and the adoption of our amended and restated bylaws upon the closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT> reverse
stock split of our common stock to be effected prior to the consummation of this offering. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Summary Financial Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following tables set forth a summary of our financial data as of, and for the periods ended on, the periods indicated. We have derived the summary
statements of operations and comprehensive loss data for the years ended December&nbsp;31, 2018 and 2019 from our audited financial statements included elsewhere in this prospectus. We have derived the summary statements of operations and
comprehensive loss data for the nine months ended September&nbsp;30, 2019 and 2020 and the summary balance sheet data as of September&nbsp;30, 2020 from our unaudited interim condensed financial statements included elsewhere in this prospectus. Our
unaudited interim condensed financial statements have been prepared on a basis consistent with our audited financial statements and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary
for the fair presentation of the financial information in those statements. You should read the following summary financial data together with our financial statements and the related notes included elsewhere in this prospectus and in the sections
of this prospectus titled &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results are not necessarily indicative of results that should be
expected in any future period, and our results for any interim period are not necessarily indicative of results that should be expected for any full year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of redeemable convertible preferred stock purchase option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares of common stock used in computing net loss per share attributable to common
stockholders, basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,241,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,453,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted-average shares of common stock used in computing pro forma net loss per share
attributable to common stockholders, basic and diluted (unaudited)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See Notes 2, 16 and 17 to our financial statements included elsewhere in this prospectus for details on the calculation of
our basic and diluted net loss per share attributable to common stockholders and our basic and diluted pro forma net loss </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
per share attributable to common stockholders, and the weighted-average number of shares used in computing the per share amounts. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The pro forma balance sheet data gives effect to (i)&nbsp;the conversion of all outstanding shares of our redeemable
convertible preferred stock into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the closing of this offering and (ii)&nbsp;the filing and effectiveness of our
amended and restated certificate of incorporation immediately prior to the closing of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The pro forma as adjusted balance sheet data gives effect to (i)&nbsp;the pro forma adjustments set forth in footnote
(1)&nbsp;above and (ii)&nbsp;our receipt of net proceeds from the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus), after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable
by us. Each $1.00 increase or decrease in the assumed initial public offering price would increase or decrease, as applicable, the pro forma as adjusted amounts of each of our cash and cash equivalents, working capital, total assets and total
stockholders&#146; (deficit) equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&nbsp;million shares in the number of shares offered by us would increase or decrease, as applicable, the pro forma as
adjusted amounts of each of our cash and cash equivalents, working capital, total assets and total stockholders&#146; (deficit) equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the assumed initial public
offering price per share and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">This pro forma and pro forma as adjusted information is illustrative only and will depend on the actual initial public
offering price and other terms of this offering determined at pricing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Working capital is defined as current assets less current liabilities. See our financial statements and the related notes
included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Investing in our common stock is speculative and involves a high degree of risk. You should consider carefully the risks described below, together
with the other information contained in this prospectus, including our financial statements and the related notes included elsewhere in this prospectus and in the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition
and Results of Operations&#148; before deciding whether to invest in our common stock. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely
affected. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. Our actual results
could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described below. See the section titled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Limited Operating History, Financial Position and Capital Requirements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the
foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an early-stage biopharmaceutical company with a limited operating history that may make it difficult to evaluate the success of our business to
date and to assess our future viability. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing and optimizing our technology platform, identifying potential product
candidates, undertaking research and preclinical studies and a clinical trial for our lead program, engaging in manufacturing for our development programs, establishing and enhancing our intellectual property portfolio, and providing general and
administrative support for these operations. We have one product candidate in early clinical development and all of our other product candidates are in preclinical development, and none have been approved for commercial sale. We have never generated
any revenue from product sales and have incurred net losses each year since we commenced operations. For the years ended December&nbsp;31, 2018 and 2019, our net losses were $17.6&nbsp;million and $24.0&nbsp;million, respectively. We expect that it
will be several years, if ever, before we have a product candidate ready for regulatory approval and commercialization. We expect to incur increasing levels of operating losses over the next several years and for the foreseeable future as we advance
our product candidates through clinical development. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#146; deficit and working capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To become and remain profitable, we must develop and eventually commercialize a product or products with significant market potential. This will require
us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those
products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we succeed in commercializing one or more of our product candidates, we may never generate
revenue that is significant or large enough to achieve profitability. In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. If we do achieve profitability,
we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. Our failure to
become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company
could also cause you to lose all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if this offering is successful, we will need to obtain substantial additional funding to complete the
development and commercialization of our product candidates. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially during the next
few years. The development of biopharmaceutical product candidates is capital intensive. As our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our clinical,
regulatory, quality and manufacturing capabilities. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to marketing, sales, manufacturing and
distribution. Furthermore, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of September&nbsp;30, 2020, we had $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million in cash and cash equivalents. Based upon our current
operating plan, we estimate that our existing cash and cash equivalents as of the date of this prospectus, together with the estimated net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure
requirements for at least the next &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; months. However, the expected net proceeds from this offering will not be sufficient to fund any of our product candidates through regulatory approval, and we will
need to raise substantial additional capital to complete the development and commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have based these
estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on
many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the initiation, trial design, progress, timing, costs and results of drug discovery, preclinical studies and clinical
trials of our product candidates, and in particular the clinical trials for SBT6050; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number and characteristics of product candidates that we pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the length of our clinical trials, including, among other things, as a result of delays in enrollment, difficulties
enrolling sufficient subjects or delays or difficulties in clinical trial site initiations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the outcome, timing and costs of seeking FDA, European Medicines Agency (EMA) and any other regulatory approvals;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of manufacturing our product candidates, in particular for clinical trials in preparation for marketing approval
and in preparation for commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of any third-party products used in our combination clinical trials that are not covered by such third party or
other sources; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs associated with hiring additional personnel and consultants as our preclinical, manufacturing and clinical
activities increase; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the receipt of marketing approval and revenue received from any commercial sales of any of our product candidates, if
approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of commercialization activities for&nbsp;any of our product candidates, if approved, including marketing, sales
and distribution costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the emergence of competing therapies and other adverse market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to establish and maintain strategic collaboration, licensing or other arrangements and the financial terms of
such agreements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other products and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the amount and timing of any payments we may be required to make pursuant to our current or future license agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims,
including litigation costs and the outcome of such litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our need and ability to retain key management and hire scientific, technical, business, and medical personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our implementation of additional internal systems and infrastructure, including operational, financial and management
information systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">or costs associated with expanding our facilities or building out our laboratory space; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effects of the recent disruptions to and volatility in the credit and financial markets in the United States and
worldwide from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of operating as a public company.</P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because we do not expect to generate revenue from product sales for many years, if at all, we will need to obtain substantial additional funding in
connection with our continuing operations and expected increases in expenses. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through equity offerings, debt
financings or other capital sources, including potentially grants, collaborations, licenses or other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe
we have sufficient funds for our current or future operating plans. The impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on capital markets may affect the availability, amount and type of financing available to us in the
future. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to
relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Until such time, if ever, as we can generate substantial product revenue, we
expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially grants, collaborations, licenses or other similar arrangements. To the extent that we raise additional capital through the
sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Additional debt
financing, if available, may involve agreements that include covenants further limiting or restricting our ability to take specific actions beyond those contained in our existing loan agreement, such as further limitations on our ability to incur
additional debt, make capital expenditures or declare dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we raise funds through collaborations or licensing arrangements with third
parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when
needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The terms of our loan agreement place restrictions on our operating and financial flexibility. If we raise
additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of
September 30, 2020, we had an outstanding term loan including principal and final payment fee of $1.1 million under our loan and security agreement, as amended, with Silicon Valley Bank (SVB). The loan is secured by a lien covering substantially all
of our personal property, rights and assets, excluding intellectual property. The loan agreement contains customary affirmative and negative covenants and events of default applicable to us and any subsidiaries. The affirmative covenants include,
among others, covenants requiring us (and us to cause our subsidiaries, if any) to maintain governmental approvals, deliver certain financial reports, maintain insurance coverage, and protect material intellectual property. The negative covenants
include, among others, restrictions on us and our subsidiaries transferring collateral, changing our business, engaging in mergers or acquisitions, incurring additional indebtedness, paying cash dividends or making other distributions, making
investments, creating liens, selling assets and making any payment on subordinated debt, in each case subject to certain exceptions. The restrictive covenants of the loan agreement could cause us to be unable to pursue business opportunities that we
or our stockholders may consider beneficial. In addition, SVB could declare a default upon the occurrence of any event that it interprets as a material adverse change as defined under the loan agreement. If we default under the loan agreement, SVB
may accelerate all of our repayment obligations and take control of our pledged assets, potentially requiring us to renegotiate our agreement on terms less favorable to us or to immediately cease operations. Further, if we are liquidated, SVB&#146;s
right to repayment would be senior to the rights of the holders of our common stock to receive any proceeds from the liquidation. Any declaration by SVB of an event of default could significantly harm our business and prospects and could cause the
price of our common stock to decline. If we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are early in our development efforts and we have only one product candidate in clinical development. We have a limited history of conducting clinical trials to
test our product candidates in humans. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are early in our development efforts and most of our operations to date have been limited to
developing our platform technologies and conducting drug discovery and preclinical studies. Our lead product candidate, SBT6050, entered Phase 1/1b clinical trial in July 2020, which was the first time one of our product candidates had been tested
in humans. As a result, we have limited infrastructure, experience conducting clinical trials as a company and regulatory interactions, and cannot be certain that our current or planned clinical trials will be completed on time, if at all, that our
planned development programs would be acceptable to the FDA or other comparable foreign regulatory authorities, or that, if approval is obtained, such product candidates can be successfully commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because of the early stage of development of our products candidates, our ability to eventually generate significant revenues from product sales will
depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successful completion of additional preclinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">submission of our INDs or other regulatory applications to allow for initiation of our planned clinical trials or future
clinical trials and authorizations from regulators to initiate clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successful enrollment in, and completion of, clinical trials and achieving positive results from the trials;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">demonstrating a risk-benefit profile acceptable to regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing manufacturing capabilities or arrangements with third-party manufacturers for clinical supply and, if and when
approved, for commercial supply; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when
approved, whether alone or in combination with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">effectively competing with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developing and implementing marketing and reimbursement strategies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining and maintaining third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for
our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to obtain clearance or approval of companion diagnostic tests, on a timely basis, or at all; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintaining a continued acceptable safety profile of any product following approval, if any. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we do not achieve one or more of these requirements in a timely manner, we could experience significant delays or an inability to successfully
commercialize our product candidates, which would materially harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Preclinical and clinical development is a lengthy, expensive and uncertain
process. The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance into clinical trials, including SBT6050, may not achieve favorable results in later clinical
trials, if any, or receive marketing approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The research and development of drugs and biological products is extremely risky. Only a
small percentage of product candidates that enter the development process ever receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical
trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, can take many years to complete and its outcome is uncertain. We may face unforeseen challenges in our product candidate development
strategy, and we can provide no assurances that we will ultimately be successful in our current and future clinical trials or that our product candidates will be able to receive regulatory approval. The results of preclinical studies and early
clinical trials of our product candidates and other products, even those with the same or similar mechanisms of action, may not be predictive of the results of later-stage clinical trials. For example, it is not uncommon for product candidates to
exhibit unforeseen safety or efficacy issues when tested in humans despite promising results in preclinical animal models. In particular, while we have conducted preclinical studies of SBT6050, we do not know how SBT6050 will perform in the ongoing
Phase 1/1b clinical trial or in future clinical trials, whether any initial tumor responses that may be observed will be durable or whether adverse events will arise over time. Future results of preclinical and clinical testing of our product
candidates are also less certain due to the novel and relatively untested nature of our approach to TLR8 and related platform technologies. In general, clinical trial failure may result from a multitude of factors including flaws in study design,
dose selection, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the biopharmaceutical industry have suffered
setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to obtaining approval to commercialize any product candidate in the United States or abroad, we
must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidate is safe and effective for its intended uses. Results from
preclinical studies and clinical trials can be interpreted in different ways. Even if we believe that the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other
regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program, requiring
their alteration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the results of our clinical trials are inconclusive or if there are safety concerns or adverse events associated with our
product candidates, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">incur unplanned costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">be delayed in or prevented from continuing clinical development and obtaining marketing approval for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtain approval for indications or patient populations that are not as broad as intended or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings including boxed
warnings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">be subject to changes or limitations in the way the product is administered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing
requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">have regulatory authorities withdraw their approval of the product or impose restrictions on its distribution in the form
of a modified Risk Evaluation and Mitigation Strategy (REMS); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">be subject to the addition of labeling statements, such as warnings or contraindications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">be sued; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience damage to our reputation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Treatment of cancer patients with our oncology product candidates may be used in combination with other cancer drugs, such as other immune-oncology
agents, monoclonal antibodies or other protein-based drugs or small molecule anti-cancer agent such as targeted agents or chemotherapy, which can cause side effects or adverse events that are unrelated to our product candidate but may still impact
the success of our clinical trials. Additionally, our product candidates could potentially cause adverse events. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other
therapies or medications that such patients may be using. As described above, any of these events could prevent us from obtaining regulatory approval or achieving or maintaining market acceptance of our product candidates and impair our ability to
commercialize our products. Because all of our product candidates are derived from our platform technologies, a clinical failure of one of our product candidates may also increase the actual or perceived likelihood that our other product candidates
will experience similar failures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Of the large number of products in development, only a small percentage successfully complete the FDA or
comparable foreign regulatory authorities&#146; approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to
market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we eventually complete clinical testing and receive approval of a biologics license
application (BLA) or foreign marketing application for our product candidates, the FDA or the comparable foreign regulatory authorities may grant approval contingent on the performance of costly additional clinical trials, including post-market
clinical trials. The FDA or the comparable foreign regulatory authorities also may approve a product candidate for a more limited indication or patient population than we originally request, and the FDA or comparable foreign regulatory authorities
may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent
commercialization of that product candidate and would adversely impact our business and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the FDA or comparable foreign
regulatory authorities may change their policies, adopt additional regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely basis. Such
policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and
likelihood of obtaining regulatory approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have concentrated our research and development efforts on product candidates using our
platform technologies, and our future success depends on the successful development of this approach. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates based on our platform technologies in
clinical trials or in obtaining marketing approval thereafter, and use of our platform technologies may not ever result in marketable products. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing
process or transferring that process to commercial partners or establishing our own commercial manufacturing capabilities, which may prevent us from completing our clinical trials or commercializing any products on a timely or profitable basis, if
at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our product candidates are targeted to treat tumors that express specific antigens at certain levels, such as those that express moderate
or high levels of Her2 or Nectin4. This requires diagnostic assays that may be subject to scrutiny by regulatory authorities. We may not be successful in developing diagnostic assays or securing the assays for use. If we are successful in securing a
diagnostic assay for a specific antigen, it may be difficult to enroll patients with tumors that have the required level of antigen expression. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
addition, the clinical trial requirements of the FDA, EMA and other regulatory agencies such as Australia and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type,
complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied
pharmaceutical or other product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The immuno-oncology industry is also rapidly developing, and our competitors may introduce new
technologies improving the immune response to cancer that render our technologies obsolete or less attractive. New technology could emerge at any point in the development cycle of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The TLR field is also rapidly evolving and as competitors use or develop alternative TLR technologies, any failures of such technologies could adversely
impact our programs. For example, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
companies are developing TLR7, TLR7/8 and TLR9 agonists, some of which are conjugated to monoclonal antibodies. Regardless of our belief that our approach to activating the innate immune system
has advantages, issues encountered with other TLR programs will create a negative perception of or increase scrutiny for our technologies and product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We depend on enrollment of patients in our clinical trials for our product candidates. If we experience delays or difficulties enrolling in our clinical trials,
our research and development efforts and business, financial condition and results of operations could be materially adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patient candidates. These trials and other trials
we conduct may be subject to delays as a result of patient enrollment taking longer than anticipated, patient withdrawal or adverse events. For example, we have an ongoing Phase 1/1b clinical trial for our lead product candidate, SBT6050, which
could generate adverse events that may cause us to delay the trial or halt further development. As of September&nbsp;30, 2020, four patients were enrolled in the clinical trial, a very small number relative to the number of patients required for a
full clinical development program. As has been described with other immune agonists administered in the presence of ADA in preclinical species, anaphylaxis upon repeat intravenous dosing with SBT6050 was observed in animal models. While our product
candidate in humans is administered by the subcutaneous route of administration, If similar adverse events were to manifest, that could adversely impact our enrollment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our clinical trials will likely compete with other clinical trials that are in the same therapeutic areas as our product candidates, and this
competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Because the number of
qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for
our clinical trials at such clinical trial sites. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patient enrollment depends on many factors, including the size and nature of the patient
population, the severity of the disease under investigation, eligibility criteria for the trial, the proximity of patients to clinical sites, the design of the clinical protocol, the ability to obtain and maintain patient consents, the ability to
recruit clinical trial investigators with the appropriate competencies and experience, the risk that patients enrolled in clinical trials will drop out of the trials before the administration of our product candidates or trial completion, the
availability of competing clinical trials, the availability of new drugs approved for the indication the clinical trial is investigating, and clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug being studied in
relation to other available therapies. These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial of our product
candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead
to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be
identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval,
revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To date, we have only tested SBT6050 in a limited number of patients with cancer and these clinical trial participants have only been observed for a
limited period of time after dosing. As we continue developing our product candidates and initiate clinical trials of our additional product candidates, serious adverse events (SAEs), undesirable side effects, relapse of disease or unexpected
characteristics may emerge causing us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the SAEs or undesirable side effects or other characteristics are less prevalent, less severe or more
acceptable from a risk-benefit perspective or in which efficacy is more pronounced or durable. For example, a significant risk observed with systemic administration of motolimod, an unconjugated TLR8 small molecule agonist, was the induction of
significant injection site reactions (ISR), and cytokine-induced <FONT STYLE="white-space:nowrap">flu-like</FONT> symptoms that prevented dose-escalation. Should we observe severe cases of ISR and cytokine release syndrome in our clinical trials or
identify other undesirable side effects or other unexpected findings depending on their severity, our trials could be delayed or even stopped and our development programs may be halted entirely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our TLR8 agonist containing product candidates, including SBT6050, activate dendritic cells among other innate immune cells. As a result, significant
anti-drug antibodies (ADA) could develop that neutralize the effects of SBT6050 by reducing exposure. The development of ADA could also trigger hypersensitivity reactions that manifest as serious adverse events. For example, as has been described
with other immune agonists administered in the presence of ADA in preclinical species, anaphylaxis upon repeat intravenous dosing with SBT6050 was observed. As a result, we have modified our dosing to subcutaneous; however, if patients experience
adverse events (AEs), including anaphylaxis, our trials could be delayed or stopped and our development programs may be halted entirely if this is observed during clinical development. Even if ADAs are not detected in the early clinical trials, they
may be detected after product launch and may significantly reduce the commercial potential or even result in the product being pulled from the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if our product candidates initially show promise in early clinical trials, the side effects of biological products are frequently only detectable
after they are tested in larger, longer and more extensive clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or
unexpected side effects were caused by the product candidate or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking other medications. If serious adverse or unexpected side effects are
identified during development or after approval and are determined to be attributed to our product candidate, we may be required to develop a REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each
potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more
costly than what is typical for the industry. Product-related side effects could also result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or ADA
caused by such products, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory authorities may suspend, withdraw or limit approvals of such product, or seek an injunction against its
manufacture or distribution; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory authorities may require additional warnings on the label, including &#147;boxed&#148; warnings, or issue safety
alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be required to change the way a product is administered or conduct additional clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the product may become less competitive, and our reputation may suffer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may decide to remove the product from the marketplace; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be subject to fines, injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Interim, topline and preliminary data from our clinical trials may change as more patient data become available, and are subject to audit and verification
procedures that could result in material changes in the final data. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time to time, we may publicly disclose preliminary, interim or
topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change as patient enrollment and treatment continues
and more patient data become available. Adverse differences between previous preliminary or interim data and future interim or final data could significantly harm our business prospects. We may also announce topline data following the completion of
a preclinical study or clinical trial, which may be subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our
analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline or preliminary results that we report may differ from future results of the same studies, or different
conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different
from the preliminary data we previously published. As a result, interim, topline and preliminary data should be viewed with caution until the final data are available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may
interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the
information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine to be material or otherwise appropriate information
to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our
business. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product
candidates, our business, operating results, prospects or financial condition may be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may encounter substantial delays in our clinical trials or we
may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before obtaining marketing approval
from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
product candidate for its intended indications. Clinical trials are expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as
planned or completed on schedule, if at all. For example, we cannot begin our planned Phase 1 clinical trials for SBT6290, our Nectin4-targeted product candidate until we complete certain preclinical development and submit and receive authorization
to proceed under INDs. We also dosed the first patient in a Phase 1/1b clinical trial for SBT6050 in July 2020 and cannot predict how our technology may work in solid tumor indications until we have completed dose-escalation and dose expansion.
Finally, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has impacted clinical trials broadly, including our own with some sites pausing or slowing enrollment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical
development include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in reaching a consensus with regulatory authorities on trial design or implementation of any future potential
collaborators&#146;, clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in reaching agreement or failing to agree on acceptable terms with prospective CROs and clinical trial sites;
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL">delays in opening sites, including delays in obtaining required approvals from institutional review boards (IRBs) and recruiting
suitable patients to participate in our clinical trials </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in enrollment due to travel or quarantine policies, or other factors, related to
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> other pandemics or other events outside our control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure by our CROs, other third parties or us to adhere to the trial protocol or applicable regulatory requirements,
including the FDA&#146;s good clinical practices (GCPs) or applicable regulatory requirements in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory authorities may find deficiencies in the manufacturing processes or facilities of third-party manufacturers with
which we or any of our potential future collaborators contract for clinical and commercial supplies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in the testing, validation, manufacturing and delivery of our product candidates to the treatment sites, including
due to a facility manufacturing any of our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing
practices (cGMP) regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">imposition of a clinical hold by IRBs or regulatory authorities as a result of a serious adverse event, concerns with a
class of product candidates, after an inspection of our clinical trial operations or trial sites, or for other reasons; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">suspensions or terminations by us, the IRBs of the institutions at which such trials are being conducted, by the Safety
Review Committee or Data Safety Monitoring Board, for such trial or by regulatory authorities due to a number of factors, including those described above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in having patients complete participation in a trial or return for post-treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential
benefits or the discovery of other safety issues; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">lack of adequate funding; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For instance, the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the measures taken by the governmental
authorities could disrupt the supply chain and the manufacture or shipment of drug substances and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
finished drug products for our product candidates for use in our research and clinical trials, delay, limit or prevent our employees and CROs from continuing research and development activities,
impede the ability of patients to enroll or continue in clinical trials, or impede testing, monitoring, data collection and analysis or other related activities, any of which could delay our clinical trials and increase our development costs, and
have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our drug product is shipped from overseas and the
ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and measures taken by the governmental authorities could disrupt the timing and therefore our clinical trials may not proceed or may be delayed, interrupted, or stopped as a result.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any inability to timely and successfully complete preclinical and clinical development could result in additional costs to us or impair our ability
to achieve regulatory and commercialization milestones. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified product candidate to earlier versions.
Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring comparable drugs to market before we do, which could impair our
ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our
product candidates, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">be delayed in obtaining marketing approval, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtain approval for indications or patient populations that are not as broad as intended or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">be subject to additional post-marketing testing requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">be required to perform additional clinical trials to support approval or be subject to additional post- marketing testing
requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">have regulatory authorities withdraw, or suspend, their approval of the drug or impose restrictions on its distribution in
the form of a modified risk evaluation and mitigation strategy, or REMS; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">be subject to the addition of labeling statements, such as warnings or contraindications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">be sued; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience damage to our reputation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our
preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all. Any delay in, or termination of, our clinical trials will delay the submission of a BLA to the FDA or other similar
applications with other relevant foreign regulatory authorities and, ultimately, our ability to commercialize our product candidates, if approved, and generate product revenue. Even if our clinical trials are completed as planned, we cannot be
certain that their results will support our claims for differentiation or the effectiveness or safety of our product candidate. The FDA has substantial discretion in the review and approval process and may disagree that our data support the claims
we propose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, principal investigators for our clinical trials may serve and have served as scientific advisors or consultants to us from
time to time and receive compensation in connection with such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory
authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA or comparable foreign regulatory authority may therefore
question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or
comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, we, the FDA or an institutional review board may suspend our clinical trials at any time if it appears that we or our collaborators are failing
to conduct a trial in accordance with regulatory requirements, including the FDA&#146;s current GCP, regulations, that we are exposing participants to unacceptable health risks or if the FDA finds deficiencies in our INDs or the conduct of these
trials. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial
prior to completion, the commercial prospects of our product candidates could be negatively impacted, and our ability to generate revenues from our product candidates may be delayed or eliminated entirely. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may seek Breakthrough Therapy designation or Fast Track designation by the FDA for one or more of our product candidates, but we may not receive such
designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may seek Breakthrough Therapy or Fast Track designation for some of our product candidates. If a product candidate is intended for the treatment of a
serious or life-threatening condition and clinical or preclinical data demonstrate the potential to address unmet medical needs for this condition, the product candidate may be eligible for Fast Track Designation. The benefits of fast track
designation include more frequent meetings with FDA to discuss the drug&#146;s development plan and ensure collection of appropriate data needed to support drug approval, more frequent written communication from FDA about such things as the design
of the proposed clinical trials and use of biomarkers, eligibility for Accelerated Approval and Priority Review, if relevant criteria are met, and rolling review, which means that a drug company can submit completed sections of its BLA for review by
FDA, rather than waiting until every section of the BLA is completed before the entire application can be reviewed. BLA review usually does not begin until the entire application has been submitted to the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a
serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment
effects observed early in clinical development. Drugs or biologics designated as breakthrough therapies by the FDA may be eligible for all features of Fast Track designation, intensive guidance on an efficient drug development program, beginning as
early as Phase 1, and organizational commitment involving senior managers at FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA has broad discretion whether or not to grant these
designations, so even if we believe a particular product candidate is eligible, we cannot assure you that the FDA would decide to grant it. Even if we have obtained Fast Track Designation and/or Breakthrough Therapy Designation for one or more of
our product candidates, we may not experience a faster development process, review or approval compared to <FONT STYLE="white-space:nowrap">non-expedited</FONT> FDA review procedures. In addition, the FDA may withdraw Fast Track Designation or
Breakthrough Therapy Designation if it believes that the designation is no longer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
supported. These designations do not guarantee qualification for the FDA&#146;s priority review procedures or a faster review or approval process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are required by the FDA to obtain approval of a companion diagnostic test in connection with approval of any of our product candidates, and we do not obtain
or face delays in obtaining FDA approval of a diagnostic device, we will not be able to commercialize such product candidate and our ability to generate revenue will be materially impaired. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If safe and effective use of any of our product candidates depends on an in vitro diagnostic that is not otherwise commercially available, then the FDA
generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves our product candidates, if at all. The process of obtaining or creating such diagnostic is time consuming and
costly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as
medical devices by the FDA and comparable regulatory authorities. The approval of a companion diagnostic as part of the therapeutic product&#146;s labeling limits the use of the therapeutic product to only those patients who express the specific
genetic alteration that the companion diagnostic was developed to detect. If the FDA or a comparable regulatory authority requires approval of a companion diagnostic for any of our product candidates, whether before or after it obtains marketing
approval, we, and/or future collaborators, may encounter difficulties in developing and obtaining approval for such product candidate. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval of a companion
diagnostic could delay or prevent approval or continued marketing of such product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may also experience delays in developing a
sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial partners or negotiating insurance reimbursement plans, all of which may prevent us from completing our clinical
trials or commercializing our product candidate, if approved, on a timely or profitable basis, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we obtain regulatory approval for our
product candidates, they will remain subject to ongoing regulatory oversight. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to
penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we obtain regulatory approval for any of our product candidates, they will be subject to extensive and ongoing regulatory requirements for
manufacturing, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, sampling and record-keeping. These requirements include submissions of safety and other post-marketing information and reports, registration,
as well as continued compliance with cGMP regulations, as well as GCPs for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any
regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly
post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS as a condition of approval of our product candidates, which could include
requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Such regulatory requirements may differ from
country to country depending on where we have received regulatory approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA&#146;s and other regulatory authorities&#146; policies may change and additional government
regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action,
either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained and we may not achieve or sustain profitability. Moreover, if there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if
we or one of our distributors, licensees or <FONT STYLE="white-space:nowrap">co-marketers</FONT> fails to comply with regulatory requirements, the regulators could take various actions. These include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">issuing warning or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">mandating modifications to promotional materials or require us to provide corrective information to healthcare
practitioners, or require other restrictions on the labeling or marketing of such products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seeking an injunction or imposing civil or criminal penalties or monetary fines; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">suspension or imposition of restrictions on operations, including product manufacturing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seizure or detention of products, refusal to permit the import or export of products or request that we initiate a product
recall; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">suspension, modification or withdrawal of our marketing authorizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">suspension of any ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal to approve pending applications or supplements to applications submitted by us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for
marketing authorization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, the FDA and other regulatory authorities strictly regulates the promotional claims that may be
made about biologic products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#146;s approved labeling. The FDA and other agencies actively enforce the laws and regulations
prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant civil, criminal and
administrative penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any government investigation of alleged violations of law could require us to expend significant time and resources in
response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and harm our business, financial condition, results of operations and prospects.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with
regulatory requirements, which could harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The market opportunities for our product
candidates may be relatively small as it will be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Cancer therapies are sometimes characterized as first line, second line, or third line, and the FDA customarily approves new therapies only for a second
line or later lines of use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
without a cure. Whenever first line therapies, usually chemotherapy, antibody drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery or a combination of these, proves
unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules or a combination of these. Third line therapies can include chemotherapy,
antibody drugs and small molecule tumor-targeted therapies, more invasive forms of surgery and new technologies. We expect to initially seek approval of our product candidates in most instances at least as a second line therapy. Subsequently,
depending on the nature of the clinical data and experience with any approved products or product candidates, if any, we may pursue approval as an earlier line therapy and potentially as a first line therapy. But there is no guarantee that our
product candidates, even if approved as a second or subsequent line of therapy, would be approved for an earlier line of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our projections of both the number of people who have HER2 expression, are based on our assumptions and estimates. These estimates have been derived
from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new therapies may change the estimated incidence or prevalence of the cancers that we are
targeting. Consequently, even if our product candidates are approved for a second or third line of therapy, the number of patients who may be eligible for treatment with our product candidates may turn out to be much lower than expected. In
addition, we have not yet conducted market research to determine how treating physicians would expect to prescribe a product that is approved for multiple tumor types if there are different lines of approved therapies for each such tumor type. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy
key leadership and other personnel, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels,
statutory, regulatory, and policy changes, the FDA&#146;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#146;s ability to perform routine functions. Average review
times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and
unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last
several years, including for 35 days beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Separately, in response to the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020 the FDA announced its
intention to postpone most foreign inspections of manufacturing facilities and products, and on March&nbsp;18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities.
Subsequently, on July&nbsp;10, 2020 the FDA announced its intention to resume certain <FONT STYLE="white-space:nowrap">on-site</FONT> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to
use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities
outside the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to
prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse
effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product
candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because we have limited
financial and managerial resources, we must prioritize our research programs and will need to focus our discovery and development on select product candidates and indications. Correctly prioritizing our research and development activities is
particularly important for us due to the breadth of potential product candidates and indications that we believe could be pursued using our platform technologies. As a result, we may forego or delay pursuit of opportunities with other product
candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current
and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product
candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization
rights to such product candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be successful in our efforts to identify or discover additional product candidates in the future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical
development for a number of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to design such product candidates with the properties that we desire; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that
indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Research
programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable additional candidates for preclinical and clinical development, our opportunities to successfully develop
and commercialize therapeutic products will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Manufacturing, Commercialization and Reliance on Third Parties </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We rely on third parties to conduct, supervise, and monitor our clinical trials and perform some of our research and preclinical studies. If these third parties
do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we are and expect to remain
dependent on third parties to conduct our preclinical studies, including GLP toxicology studies and ongoing Phase 1/1b clinical trial and any future clinical trials of our product candidates. Specifically, CROs that manage preclinical studies, GLP
toxicology studies and our clinical studies as well as clinical investigators, and consultants play a significant role in the conduct of our preclinical studies and clinical trials and the subsequent collection
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and analysis of data. The timing of the initiation and completion of these studies and trials will therefore be partially controlled by such third parties and may result in delays to our
development programs. Nevertheless, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal requirements, and scientific standards, and our reliance on
the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GLP and GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the
Member States of the European Economic Area, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GLP and GCP requirements through periodic inspections of
preclinical study sites, trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites fail to comply with applicable GLP or GCP requirements, the data generated in our preclinical studies
and clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional preclinical or clinical trials before approving our marketing applications. In addition, our clinical trials
must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and resources
to our development activities or perform as contractually required. These risks are heightened as a result of the efforts of government agencies and the CROs themselves to limit the spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT>
including quarantines and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> orders. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory
requirements, otherwise performs in a substandard manner, or terminates its engagement with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If any of our
clinical trial sites terminates for any reason, we may experience the loss of <FONT STYLE="white-space:nowrap">follow-up</FONT> information on subjects enrolled in such clinical trials unless we are able to transfer those subjects to another
qualified clinical trial site, which may be difficult or impossible. In addition, clinical trial investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity
compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or any comparable foreign regulatory authority concludes that the financial
relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the
delay or rejection of any marketing application we submit by the FDA or any comparable foreign regulatory authority. Any such delay or rejection could prevent us from commercializing our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not
successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing
approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We contract with
third parties for the manufacturing and supply of certain of our product candidates for use in preclinical testing and clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not have any manufacturing facilities. We produce in our laboratory relatively small quantities of product for evaluation in our research programs.
We rely on third parties for the manufacture of a portion of our product candidates for preclinical testing and all of our product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
candidates for clinical testing and we will continue to rely on such third parties for commercial manufacture if any of our product candidates are approved. We currently have limited
manufacturing arrangements and expect that each of our product candidates, including SBT6050, will only be covered by single source suppliers for the foreseeable future. This reliance increases the risk that we will not have sufficient quantities of
our product candidates or products, if approved, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, all entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract
manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical trials must be manufactured in accordance with cGMP requirements. These
regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control
of production processes can lead to the introduction of contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must
supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#146;s Good Laboratory Practice regulations and cGMP regulations enforced by the FDA through its facilities inspection program. Comparable foreign
regulatory authorities may require compliance with similar requirements. The facilities and quality systems of our third-party contract manufacturers must pass a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection for compliance with the
applicable regulations as a condition of marketing approval of our product candidates. We do not control the manufacturing activities of, and are completely dependent on, our contract manufacturers for compliance with cGMP regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or
otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, including due to the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we may be forced to manufacture the
materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on commercially reasonable terms, if at all. In particular, any replacement of
our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or
proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. In addition, certain of our product candidates and our own proprietary
methods have never been produced or implemented outside of our company, and we may therefore experience delays to our development programs if and when we attempt to establish new third-party manufacturing arrangements for these product candidates or
methods. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to or voluntarily change
manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines and that the product produced is
equivalent to that produced in a prior facility. The delays associated with the verification of a new manufacturer and equivalent product could negatively affect our ability to develop product candidates in a timely manner or within budget. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our or a third-party&#146;s failure to execute on our manufacturing requirements, do so on commercially reasonable terms and timelines and comply with
cGMP requirements could adversely affect our business in a number of ways, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">inability to meet our product specifications and quality requirements consistently; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an inability to initiate or continue clinical trials of our product candidates under development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates, if at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">loss of the cooperation of future collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">requirements to cease development or to recall batches of our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for
our product or any other future product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Manufacturing antibody drug conjugate products is complex and our third-party
manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could
be delayed or prevented. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Manufacturing antibody drug conjugate products is complex and require the use of innovative technologies to handle
living cells. Manufacturing these products requires facilities specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing
process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide
preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at manufacturing facilities, such
facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. The use of biologically derived ingredients can also lead to allegations
of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, there are risks
associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process <FONT STYLE="white-space:nowrap">scale-up,</FONT> process reproducibility, stability issues,
compliance with good manufacturing practices, lot consistency, significant lead times and timely availability of raw materials. Even if we obtain marketing approval for any of our product candidates, there is no assurance that we or our
manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential commercial
launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, our development and commercialization efforts would be impaired, which would
have an adverse effect on our business, financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Due to the early nature of our product
candidates, the drug product may not be stable over time causing changes to be made to the manufacturing or storage process which may result in delays or stopping the development of the product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in methods of product candidate manufacturing may result in additional costs or delays. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As product candidates progress through preclinical to late-stage clinical trials to marketing approval and commercialization, it is common that various
aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize yield, manufacturing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
batch size, change drug product dosage form, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of
these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require
the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate
revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Any approved products may fail to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, healthcare
payors and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If any of our product candidates receive marketing approval,
they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. For example, current cancer treatments like chemotherapy and radiation therapy are well established in the
medical community, and physicians may continue to rely on these treatments. Most of our product candidates target mechanisms for which there are limited or no currently approved products, which may result in slower adoption by physicians, patients
and payors. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for
commercial sale, will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">efficacy and potential advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the strength of marketing and distribution support; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prevalence and severity of any side effects. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be able to successfully commercialize our product candidates, if approved, due to unfavorable pricing regulations or third-party coverage and
reimbursement policies, which could make it difficult for us to sell our product candidates profitably. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Obtaining coverage and reimbursement
approval for a product from a government or other third-party payor is a time-consuming and costly process, with uncertain results, that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our
products to the payor. There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may not be available, or may be more limited than the purposes for which the product is approved by the FDA
or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual
property, manufacture, sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of
the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory
discounts or rebates required by government healthcare programs or private payors, by any future laws limiting drug prices and by any future relaxation of laws that presently restrict imports of product from countries where they may be sold at lower
prices than in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved
products. In the United States, there is no uniform policy among third-party payors for coverage and reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting reimbursement policies, but also have
their own methods and approval process apart from Medicare coverage and reimbursement determinations. Therefore, one third-party payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide
coverage for the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party
payor&#146;s determination that use of a product is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot be sure that reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are available, what the
level of reimbursement will be. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded therapeutics and therapeutics administered under the supervision of a physician. Our
inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise
capital needed to commercialize products and our overall financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Reimbursement may impact the demand for, and the price of, any
product for which we obtain marketing approval. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT>
that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those
medications. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement are critical to a new
product&#146;s acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of
the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or
procedure in which our product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment System,
which may result in reduced Medicare payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to experience pricing pressures in connection with the sale of any of our product
candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription medicines,
medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the successful commercialization of new products. Further, the adoption and implementation of any future governmental cost containment or other health reform initiative may result in additional
downward pressure on the price that we may receive for any approved product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, we or collaborators may develop companion diagnostic
tests for use with our product candidates. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we may seek for our product candidates. While we have
not yet developed any companion diagnostic tests for our product candidates, if we do, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Outside of the United States, many countries require approval of the sale price of a product before it can be marketed, and the pricing review
period only begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some of these countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product
candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a
product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue, if any, we are able to generate from the sale
of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if such product candidates obtain marketing approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the Affordable Care Act) signed
into law on March&nbsp;23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA) which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT
STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed
by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of
exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled
clinical trials to demonstrate the safety, purity and potency of their product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that any of our product candidates approved as a
biological product under a BLA should qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action, court decisions or otherwise,
or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the
BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic
substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If any approved products are subject to biosimilar competition sooner than we expect, we will face significant pricing pressure and our commercial
opportunity will be limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If the market opportunities for any of our product candidates are smaller than we believe they are, our revenue
may be adversely affected, and our business may suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are focused initially on the development of treatments for cancer. Our
projections of addressable patient populations that have the potential to benefit from treatment with our product candidates are based on estimates. If any of our estimates are inaccurate, the market opportunities for any of our product candidates
could be significantly diminished and have an adverse material impact on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our reliance on third parties requires us to share our trade secrets,
which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because
we rely on third parties to research and develop and to manufacture our product candidates, we must share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable,
material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit
the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential
information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is
based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a
material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, these agreements typically restrict the ability of our advisors, employees, third-party
contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with will likely expect to
be granted rights to publish data arising out of such collaboration and any joint research and development programs may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to
protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#146;s
discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If any of our product candidates are
approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our
product candidates if and when they are approved. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have no sales, marketing or distribution capabilities or experience. To achieve
commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization, which would be expensive and time consuming, or outsource these functions to other third
parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform
these services. For example, recruiting and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish
marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our
sales and marketing personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Factors that may inhibit our efforts to commercialize future products on our own include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the benefits
of prescribing any future products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage
relative to companies with more extensive product portfolios; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or
the profitability of these product revenue to us are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and
market our product candidates or may be unable to do so on terms that are favorable to us. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and we cannot
assure you that such third parties will establish adequate sales and distribution capabilities or devote the necessary resources and attention to sell and market any future products effectively. If we do not establish sales and marketing
capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which
would limit our ability to realize their full market potential. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In order to market any products outside of the United States, we must
establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory
approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods.
Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary
widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition,
our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including
international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to
realize the full market potential of our products will be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our <FONT STYLE="white-space:nowrap">In-Licenses</FONT> and Other Strategic Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not realize the benefits of any acquisitions, <FONT STYLE="white-space:nowrap">in-license</FONT> or strategic alliances that we enter into. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have entered into <FONT STYLE="white-space:nowrap">in-license</FONT> agreements with multiple licensors and in the future may seek and form strategic
alliances, create joint ventures or collaborations, or enter into acquisitions or additional licensing arrangements with third parties that we believe will complement or augment our existing technologies and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and
diversion of our management&#146;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction
consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or
combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees
of any acquired business. As a result, if we enter into acquisition or <FONT STYLE="white-space:nowrap">in-license</FONT> agreements or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to
successfully integrate them with our existing operations and company culture, or if there are materially adverse impacts on our or the counterparty&#146;s operations resulting from <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which could delay
our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction or such other benefits that
led us to enter into the arrangement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may wish to form collaborations in the future with respect to our product candidates, but may not be able to do so
or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The development and potential commercialization of our product candidates will require substantial additional capital to fund expenses. We may, in the
future, decide to collaborate with other biopharmaceutical companies for the development and potential commercialization of those product candidates, including in territories outside the United States or for certain indications. We will face
significant competition in seeking appropriate collaborators. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of
a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third-party for development and
commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third-party. Our ability to reach a definitive agreement for a collaboration will depend, among
other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of our technologies, product candidates and market
opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our
product candidate. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business
combinations among large pharmaceutical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, we may not be able to negotiate
collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development programs, delay the potential
commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to
increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we
may not be able to further develop our product candidates or bring them to market and generate product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our product candidates may also
require specific components to work effectively and efficiently, and rights to those components may be held by others. We may be unable to <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other third
party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain a license, it may be <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Industry and Business Operations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic could continue to adversely impact our business, including our clinical trials, supply chain and business development activities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2019, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> a novel strain of coronavirus, was first reported in Wuhan, China and has since
become a global pandemic. The President of the United States declared the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic a national emergency and many states and municipalities in the Unites States have announced aggressive actions to
reduce the spread of the disease, including limiting <FONT STYLE="white-space:nowrap">non-essential</FONT> gatherings of people, ceasing all <FONT STYLE="white-space:nowrap">non-essential</FONT> travel, ordering certain businesses and government
agencies to cease <FONT STYLE="white-space:nowrap">non-essential</FONT> operations at physical locations and issuing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;shelter-in-place&#148;</FONT></FONT> orders which direct
individuals to shelter at their places of residence (subject to limited exceptions). For example, on March&nbsp;23, 2020, the Office of the Governor issued Proclamation <FONT STYLE="white-space:nowrap">20-25,</FONT> ordering all individuals in the
State of Washington to stay at their place of residence except as needed to maintain continuity of operations of the federal critical infrastructure sectors. As a result of the Washington state order, almost all of our
<FONT STYLE="white-space:nowrap">non-lab</FONT> based employees are currently telecommuting, which has impacted certain of our operations and may continue to do so over the long term. We may experience further limitations on employee resources in
the future, including because of sickness of employees or their families. The effects of government actions and our own policies and those of third parties to reduce the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> may negatively
impact productivity and slow down or delay our ongoing and future clinical trials, preclinical studies and research and development activities, and may cause disruptions to our supply chain and impair our ability to execute our business development
strategy. In the event that government authorities were to enhance current restrictions, our employees who currently are not telecommuting may no longer be able to access our facilities, and our operations may be further limited or curtailed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As <FONT STYLE="white-space:nowrap">COVID-19</FONT> continues to spread, we may experience ongoing disruptions that could severely impact our business,
preclinical studies and clinical trials, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">interruption or delays in our operations, which may impact our ability to conduct and produce preclinical results required
for submission of an IND; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays or difficulties in enrolling patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and
clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption
in global shipping that may affect the transport of clinical trial materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in local regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak which
may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as
our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed
or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval
timelines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">risk that participants enrolled in our clinical trials will acquire <FONT STYLE="white-space:nowrap">COVID-19</FONT> while
the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal of the FDA to accept data from clinical trials in affected geographies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These and other disruptions in our operations and the global economy could negatively impact our business, operating results and financial condition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our clinical trials have been, and may in the future be, affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. For example,
some of our clinical trial sites have slowed down or stop further enrollment of new patients in clinical trials, denied access to site monitors and otherwise curtailed certain operations. Similarly, our ability to recruit and retain principal
investigators and site staff who, as healthcare providers, may have heightened exposure to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> may be adversely impacted. Our ongoing or planned clinical trials may also be impacted by interruptions or
delays in the operations of the FDA and comparable foreign regulatory agencies. We and our CROs have also made certain adjustments to the operation of our trials in an effort to ensure the monitoring and safety of patients and minimize risks to
trial integrity during the pandemic in accordance with the guidance issued by the FDA on March&nbsp;18, 2020 and updated on April&nbsp;2, 2020, and may need to make further adjustments in the future. Many of these adjustments are new and untested,
may not be effective, and may have unforeseen effects on the enrollment, progress and completion of these trials and the findings from these trials. These events could delay our clinical trials, increase the cost of completing our clinical trials
and negatively impact the integrity, reliability or robustness of the data from our clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, quarantines, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related
to <FONT STYLE="white-space:nowrap">COVID-19</FONT> or other infectious diseases could impact personnel at third-party manufacturing facilities upon which we rely, or the availability or cost of materials, which could disrupt the supply chain for
our product candidates. To the extent our suppliers and service providers are unable to comply with their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
obligations under our agreements with them or they are otherwise unable to deliver or are delayed in delivering goods and services to us due to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, our ability to continue meeting clinical supply demand for our product candidates or otherwise advancing development of our product candidates may become impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and actions taken to reduce its spread may also materially affect us economically. While
the potential economic impact brought by, and the duration of, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may be difficult to assess or predict, there could be a significant disruption of global financial markets, reducing our
ability to access capital, which could in the future negatively affect our liquidity and financial position. In addition, the trading prices for other biopharmaceutical companies have been highly volatile as a result of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">COVID-19</FONT> and actions taken to reduce its spread continue to rapidly evolve. The extent to which <FONT
STYLE="white-space:nowrap">COVID-19</FONT> may impede the development of our product candidates, reduce the productivity of our employees, disrupt our supply chains, delay our clinical trials, reduce our access to capital or limit our business
development activities, will depend on future developments, which are highly uncertain and cannot be predicted with confidence. To the extent the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects our business and financial
results, it may also have the effect of heightening many of the other risks described in this &#147;Risk Factors&#148; section, such as those relating to the timing and results of our clinical trials and our financing needs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are exposed to the risk
of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulators, provide accurate information to the FDA and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulators, comply with healthcare fraud and abuse laws and regulations in the United States
and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to
prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and
other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible
to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions
or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us those actions could have a significant impact on our business, including the imposition of significant civil, criminal and
administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional
reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of our
operations. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We face potential product liability, and, if successful claims are brought against us, we may incur substantial
liability and costs. If the use of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we
could be subject to costly and damaging product liability claims. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The use of our product candidates in clinical trials and the sale of any
products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise
coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless
of merit or eventual outcome, product liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">impairment of our business reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs due to related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">distraction of management&#146;s attention from our primary business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">substantial monetary awards to patients or other claimants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability to commercialize our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">decreased demand for our product candidates, if approved for commercial sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe our product liability insurance coverage is sufficient in light of our current clinical programs; however, we may not be able to maintain
insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of
commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical
treatments that had unanticipated adverse effects. A successful product liability claims, or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our
results of operations and business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patients with cancer and other diseases targeted by our product candidates are often already in severe and
advanced stages of disease and have both known and unknown significant <FONT STYLE="white-space:nowrap">pre-existing</FONT> and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including
death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or
maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the
circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive
or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly
qualified personnel, we may not be able to successfully implement our business strategy. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to compete in the highly competitive
biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel. The loss of the
services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We conduct substantially all of our operations at our facilities in Seattle. This region is headquarters to many other biopharmaceutical companies and
many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time.
The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies.
Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with certain of our key employees, these
employment agreements provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#147;key person&#148; insurance
policies on the lives of these individuals or the lives of any of our employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, <FONT STYLE="white-space:nowrap">mid-level</FONT> and senior
managers as well as junior, <FONT STYLE="white-space:nowrap">mid-level</FONT> and senior scientific and medical personnel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We expect to expand our
development, regulatory and operational capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of September&nbsp;30, 2020, we had 52 employees which represents an increase of 29 employees since January&nbsp;1, 2019. As we advance our research
and development programs, we may be required to further increase the number of our employees and the scope of our operations, particularly in the areas of clinical development, quality, regulatory affairs and, if any of our product candidates
receives marketing approval, sales, marketing and distribution. To manage any future growth, we must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">identify, recruit integrate, maintain and motivate additional qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">manage our development efforts effectively, including the initiation and conduct of clinical trials for our product
candidates, both as monotherapy and in combination with other therapeutics; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">improve our operational, financial and management controls, reporting systems and procedures. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our future financial performance and our ability to develop, manufacture and commercialize our product candidates, if approved, will depend, in part, on
our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities in order to devote a substantial amount of time, to managing these growth activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be
able to successfully implement the tasks </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully
than us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The development and commercialization of new products is highly competitive. We largely compete in the segments of the
pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more
effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain
approval for ours, if ever, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. Moreover, with the proliferation of new drugs and therapies into
oncology, we expect to face increasingly intense competition as new technologies become available. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any product candidates that we successfully
develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and pharmaceutical industries could
render our product candidates or our technology obsolete, less competitive or uneconomical. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other products in a similar class as some of our
product candidates have already been approved and other products in the same class are further along in development. As more product candidates within a particular class of biopharmaceutical products proceed through clinical development to
regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Consequently, the results of our clinical trials for product candidates in those class will likely need to
show a risk benefit profile that is competitive with or more favorable than those products and product candidates in order to obtain marketing approval or, if approved, a product label that is favorable for commercialization. If the risk benefit
profile is not competitive with those products or product candidates, we may have developed a product that is not commercially viable, that we are not able to sell profitably or that is unable to achieve favorable pricing or reimbursement. In such
circumstances, our future product revenue and financial condition would be materially and adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Specifically, there are many
companies pursuing a variety of approaches to <FONT STYLE="white-space:nowrap">TLR-directed</FONT> therapies, including Apros Therapeutics, Ascendis, BioNTech, Bolt Biotherapeutics, Bristol Myers Squibb, Checkmate Pharmaceuticals, CureVac, Exicure,
Galaderma, Gilead, Idera, Mologen, Nektar, Novartis, Primmune Therapeutics, Roche, Seven&amp;Eight, Shanghai De Novo, Sumitomo Dainippon, TriSalus, and UroGen. Other companies using antibody-drug conjugates to target innate immune receptors include
Actym Therapeutics, Mersana, and Takeda Pharmaceuticals. Immunotherapy and validated pathway approaches are further being pursued by many smaller biotechnology companies as well as larger pharmaceutical companies. We also face competition from
validated pathway therapy treatments offered by companies such as AstraZeneca, Byondis, Daiichi Sankyo, Genentech, MacroGenics, Pieris, Puma, Seattle Genetics, Spectrum Pharmaceuticals, and Zymeworks. We also face competition from companies that
continue to invest in innovation in the antibody-drug conjugate field, including but not limited to AbbVie, ADC Therapeutics, Astellas, BioAtla, Celldex, CytomX, Eli Lilly and Company, GlaxoSmithKline, Genmab, ImmunoGen, Immunomedics, Millennium
Pharmaceuticals, MorphoSys AG, Novartis, Pfizer, Sanofi, Seattle Genetics, Sutro Biopharma, and VelosBio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of our competitors, either alone or
with their collaboration partners, have significantly greater financial resources and expertise in research and development, preclinical testing, clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
trials, manufacturing and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors. Smaller or
early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors will also compete with us in recruiting and retaining qualified scientific
and management personnel and establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety, and convenience. If we are not successful in
developing, commercializing and achieving higher levels of reimbursement than our competitors, we will not be able to compete against them and our business would be materially harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability.
Unused U.S. federal net operating losses, or NOLs, for taxable years beginning before January&nbsp;1, 2018, may be carried forward to offset future taxable income, if any, until such unused NOLs expire. Under legislation enacted in 2017, informally
titled the Tax Cuts and Jobs Act (the Tax Act) as modified by legislation enacted on March&nbsp;27, 2020, entitled the Coronavirus Aid, Relief, and Economic Security Act (the CASES Act), U.S. federal NOLs incurred in taxable years beginning after
December&nbsp;31, 2017, can be carried forward indefinitely, but the deductibility of such U.S. federal NOLs in taxable years beginning after December&nbsp;31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various
states will conform to the Tax Act or to the CARES Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019, we had $59.9&nbsp;million of U.S. federal NOLs. If not used,
$18.2&nbsp;million of the U.S. federal NOLs will begin to expire in 2036 and $41.7&nbsp;million can be carried forward indefinitely under current law. As of December&nbsp;31, 2019, we also had aggregate U.S. federal research and development
(R&amp;D) credits of approximately $0.9&nbsp;million. Our NOL carryforwards and R&amp;D credits are subject to review and possible adjustment by the U.S. and state tax authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or (the Code) and corresponding provisions of state law, if a
corporation undergoes an &#147;ownership change,&#148; which is generally defined as a greater than 50 percentage point change (by value) in its equity ownership over a three-year period, the corporation&#146;s ability to use its <FONT
STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards, R&amp;D credits and certain other tax attributes to offset its post-change income or taxes may be limited. This could limit the amount of NOLs, R&amp;D credit carryforwards or other
applicable tax attributes that we can utilize annually to offset future taxable income or tax liabilities. Subsequent ownership changes and changes to the U.S. tax rules in respect of the utilization of NOLs, R&amp;D credits and other applicable tax
attributes carried forward may further affect the limitation in future years. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state
taxes owed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and
customers are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, transparency laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face
substantial penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although we do not currently have any products on the market, our operations may be, directly or indirectly through
our prescribers, customers and third-party payors, subject to various U.S. federal and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal civil and criminal false claims laws and the Physician Payments
Sunshine Act and regulations. Healthcare providers and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws may impact, among other things, our current business
operations, including our clinical research activities, and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers and other parties through which we may
market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in
which we conduct our business. The laws that may affect our ability to operate include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and
willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for,
or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not
need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the U.S. federal false claims, including the False Claims Act, which can be enforced through whistleblower actions, and
civil monetary penalties laws, which, among other things, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that
are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money
to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False
Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which imposes criminal and civil
liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any
materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or
specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their
respective implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or
disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of such individually identifiable health information; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the U.S. Federal Food, Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of
drugs, biologics and medical devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the U.S. federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the Affordable
Care Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#146;s Health Insurance Program to report annually to
the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals,
as well as ownership and investment interests held by the physicians described above and their immediate family members. Beginning in 2022, such obligations will include payments and other transfers of value provided in the previous year to certain
other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse midwives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business
practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require
pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare
providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value
provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions
with and payments to healthcare providers. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Ensuring that our internal operations and future business arrangements with third
parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency
guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to
us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries
or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve
allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws and the delay, reduction, termination or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming, and may
require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities
with whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and
imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Enacted and future
legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may charge for such product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could
prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2010, the Affordable Care Act was enacted, which includes measures that have significantly
changed the way health care is financed by both governmental and private insurers. There remain executive, judicial and congressional challenges to certain aspects of the Affordable Care Act. On December&nbsp;14, 2018, a Texas U.S. District Court
Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress as part of the Tax Act. Additionally, on December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th
Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well.<U> </U>On
March&nbsp;2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case. It is unclear how such litigation and other efforts to challenge, repeal or replace the Affordable Care Act will impact the
Affordable Care Act or our business. We continue to evaluate the effect that the Affordable Care Act and its possible repeal and replacement has on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, the Budget
Control Act of 2011 was signed into law, which, among other things, included aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020
through December&nbsp;31, 2020, unless Congress takes additional action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Recently, there has been increasing legislative and enforcement interest
in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. congressional inquiries and legislation designed to, among other things, bring more transparency to drug pricing, reduce the
cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, the U.S. Presidential
administration&#146;s budget proposal for the fiscal year 2021 includes a $135&nbsp;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to
Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option to cap Medicare Part
D beneficiary monthly <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, and place limits on pharmaceutical price increases.&nbsp;Further, the Trump administration previously released a
&#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers
to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services (HHS) has solicited feedback on some of these measures and has implemented others under its
existing authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additionally, on July&nbsp;24, 2020, the Trump administration announced four executive orders related to prescription drug
pricing that attempt to implement several of the administration&#146;s proposals, including a policy that would tie Medicare Part B drug prices to international drug prices; one that directs HHS to finalize the Canadian drug importation proposed
rule previously issued by HHS and makes other changes allowing for personal importation of drugs from Canada; one that directs HHS to finalize the rulemaking process on modifying the anti-kickback law safe harbors for discounts for plans,
pharmacies, and pharmaceutical benefit managers; and one that reduces costs of insulin and epipens to patients of federally qualified health centers. Although a number of these and other measures may require additional authorization to become
effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Any reduction in reimbursement from Medicare and other government programs may
result in a similar reduction in payments from private payers. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control costs pharmaceutical and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
biological products. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers
will be included in their prescription drug and other healthcare programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that the healthcare reform measures that have been adopted,
and that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in
reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability or commercialize our products. Further, it is possible that additional governmental action is taken in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. For example, on August&nbsp;6, 2020, the
Trump administration issued another executive order that instructs the federal government to develop a list of &#147;essential&#148; medicines and then buy them and other medical supplies from U.S. manufacturers instead of from companies around the
world, including China. The order is meant to reduce regulatory barriers to domestic pharmaceutical manufacturing and catalyze manufacturing technologies needed to keep drug prices low and the production of drug products in the United States.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Failure to comply with current or future federal, state and foreign laws and regulations and industry standards relating to privacy and data protection laws could
lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and our collaborators and third-party providers may be subject to federal, state and foreign data privacy and security laws and regulations. In the
United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g.,
Section&nbsp;5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators and third-party
providers. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and
circumstances, we could be subject to significant penalties if we violate HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In many jurisdictions, enforcement actions and consequences for
noncompliance are rising. In the United States, these include enforcement actions in response to rules and regulations promulgated under the authority of federal agencies and state attorneys general and legislatures and consumer protection agencies.
In addition, privacy advocates and industry groups have regularly proposed, and may propose in the future, self-regulatory standards that may legally or contractually apply to us. If we fail to follow these security standards, even if no customer
information is compromised, we may incur significant fines or experience a significant increase in costs. Many state legislatures have adopted legislation that regulates how businesses operate online, including measures relating to privacy, data
security and data breaches. Laws in all 50 states require businesses to provide notice to customers whose personally identifiable information has been disclosed as a result of a data breach. The laws are not consistent, and compliance in the event
of a widespread data breach is costly. States are also constantly amending existing laws, requiring attention to frequently changing regulatory requirements. Furthermore, California recently enacted the California Consumer Privacy Act (the CCPA)
which became effective on January&nbsp;1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their
personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. At this time, we do not collect personal information
relating to residents </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
of California but should we begin to do so, the CCPA will impose new and burdensome privacy compliance obligations on our business and will raise new risks for potential fines and class actions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Foreign data protection laws, including the EU General Data Protection Regulation (the GDPR), may also apply to health-related and other personal
information obtained outside of the United States. The GDPR, which came into effect on May&nbsp;25, 2018, imposes strict requirements for processing the personal data of individuals within the European Economic Area, or (EEA)and the United Kingdom,
including clinical trial data, as well as potential fines for noncompliant companies of up to the greater of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million or 4% of annual global revenue. The GDPR imposes strict requirements
for the collection, use and disclosure of personal data, including stringent requirements relating to obtaining consent, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and
confidentiality of personal data, providing notification of data breaches and taking certain measures when engaging third-party processors. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third
countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example,
in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. At
this time, we do not believe we are subject to the GDPR, but should this change, the GDPR will increase our responsibility and potential liability in relation to personal data that we process, and we may be required to put in place additional
mechanisms to ensure compliance with the new EU data protection rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Compliance with U.S. and foreign data protection laws and regulations could
require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure by us or our collaborators and third-party
providers to comply with U.S. and foreign data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect
our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and
disclose such information. Claims that we have violated individuals&#146; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to
defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to obtain
and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize
products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We rely upon a
combination of patents, know-how and confidentiality agreements to protect the intellectual property related to our products and technologies and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive
position in our market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our success depends in large part on our ability to obtain and maintain patent protection for our platform technologies,
product candidates and their uses, as well as our ability to operate without infringing the proprietary rights of others. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel
discoveries and technologies that are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
important to our business. Our pending and future patent applications may not result in patents being issued or that issued patents will afford sufficient protection of our product candidates or
their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies,
products or product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file and prosecute all
necessary or desirable patent applications or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner, including delays as a result of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacting our or our licensors&#146; operations. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain
patent protection. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees,
corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a
patent application is filed, thereby jeopardizing our ability to seek patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Composition of matter patents for biological and
pharmaceutical product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our
pending patent applications directed to composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO) or by patent offices in foreign countries, or that the claims in any of
our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from
making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may
prescribe these products <FONT STYLE="white-space:nowrap">&#147;off-label.&#148;</FONT> Although <FONT STYLE="white-space:nowrap">off-label</FONT> prescriptions may infringe or contribute to the infringement of method of use patents, the practice is
common and such infringement is difficult to prevent or prosecute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent position of biopharmaceutical companies generally is highly
uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, which have increased uncertainties as to the ability to enforce
patent rights in the future. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future
collaborators will be successful in protecting our product candidates by obtaining and defending patents. For example, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their
intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to
operate, is highly uncertain. Patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first
to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, inventorship, scope, validity, enforceability and commercial value
of our patent rights are highly uncertain. Our pending patent applications may be challenged in patent offices in the United States and abroad. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in
proceedings instituted by third parties before various </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patent offices or in courts. For example, our pending patent applications may be subject to third-party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submissions of prior art to the USPTO
or our issued patents may be subject to post-grant review (PGR) proceedings, oppositions, derivations, reexaminations, or <I>inter partes</I> review (IPR) proceedings, in the United States or elsewhere, challenging our patent rights or the patent
rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using
or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new
product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may
not adequately protect our rights or permit us to gain or keep any competitive advantage. Any failure to obtain or maintain patent protection with respect to our product candidates or their uses could have a material adverse effect on our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to the protection afforded by patents, we rely on trade secret protection and
confidentiality agreements to protect proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that is not patentable, processes for which patents are difficult to enforce and any other elements of our discovery and development processes that
involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology that is not covered by patents. We may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent
filing. However, trade secret protection will not protect us from innovations that a competitor develops independently of our proprietary know how. If a competitor independently develops a technology that we protect as a trade secret and files a
patent application on that technology, then we may not be able to patent that technology in the future, may require a license from the competitor to use our own <FONT STYLE="white-space:nowrap">know-how,</FONT> and if the license is not available on
commercially-viable terms, then we may not be able to launch our product. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our
proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or
that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent
or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material
disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, and this scenario could materially adversely affect our business, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents
based on our patent applications will not be challenged and rendered invalid and/or unenforceable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent application process is subject
to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. We have pending U.S. and foreign
patent applications in our portfolio; however, we cannot predict: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">if and when patents may issue based on our patent applications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope of protection of any patent issuing based on our patent applications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether the claims of any patent issuing based on our patent applications will provide protection against competitors;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether or not third parties will find ways to invalidate or circumvent our patent rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which
will be costly whether we win or lose; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether the patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> will result in issued
patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
cannot be certain that the claims in our pending patent applications directed to our product candidates and/or technologies will be considered patentable by the USPTO or by patent offices in foreign countries. There can be no assurance that any such
patent applications will issue as granted patents. One aspect of the determination of patentability of our inventions depends on the scope and content of the &#147;prior art,&#148; information that was or is deemed available to a person of skill in
the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim.
Even if the patents do issue based on our patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they
are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect
to our product candidates is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize our product candidates. In the event of litigation or administrative proceedings, we cannot be
certain that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Intellectual property
rights do not necessarily address all potential threats to our competitive advantage. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The degree of future protection afforded by our
intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the
patents that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued
patent or pending patent application that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of
our inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that noncompliance with the USPTO and foreign governmental patent agencies requirement for a number of
procedural, documentary, fee payment and other provisions during the patent process can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that our pending patent applications will not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">issued patents that we own or have exclusively licensed may be revoked, modified, or held invalid or unenforceable, as a
result of legal challenges by our competitors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then
use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we cannot predict the scope of protection of any patent issuing based on our patent applications, including whether the
patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> will result in issued patents with claims that directed to our product candidates or uses thereof in the United States or in other foreign countries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent
protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts,
allowing foreign competitors a better opportunity to create, develop and market competing product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the claims of any patent issuing based on our patent applications may not provide protection against competitors or any
competitive advantages, or may be challenged by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">if enforced, a court may not hold that our patents are valid, enforceable and infringed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be
costly whether we win or lose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may choose not to file a patent application in order to maintain certain trade secrets or
<FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent application covering such intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may fail to adequately protect and police our trademarks and trade secrets; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject
matter similar to or improving that covered by our patents and patent applications. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Should any of these or similar events occur,
they could significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not identify relevant third-party patents or may incorrectly
interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the
expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the
commercialization of our product candidates in any jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The scope of a patent claim is determined by an interpretation of the law, the
written disclosure in a patent and the patent&#146;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not
covered by a third-party patent or may incorrectly predict whether a third-party&#146;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we
consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are currently party to an <FONT STYLE="white-space:nowrap">in-license</FONT> agreement under which we were
granted rights to manufacture certain components of our product candidates. If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these technologies or both, which would adversely affect our
business and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We rely, in part, on license and other strategic agreements, which subject us to various obligations, including
payment obligations for achievement of certain milestones on product sales. For example, with respect to SBT6050, we have licensed a cell line to manufacture these products under an agreement with WuXi Biologics. If we fail to comply with the
obligations under our license agreements, including as a result of <FONT STYLE="white-space:nowrap">COVID-19</FONT> impacting our operations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay
damages and our licensors may have the right to terminate the license. If our license agreements are terminated, we may experience significant delays, difficulties, and costs in developing new cell lines and identifying an alternative source to
manufacture components of our candidate products covered by our agreements and those being tested or approved in combination with such products. Such an occurrence could materially adversely affect the value of the product candidates being developed
under any such agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the agreements under which we license intellectual property or technology to or from third parties are
complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant
intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations
and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to
such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry.
Disputes may arise regarding intellectual property subject to a licensing agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to
the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the sublicensing of patent and other rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the creation or use of
intellectual property by us alone or with our licensors and partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope and duration of our payment obligations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current licensing
arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license
as we are for intellectual property that we own, which are described herein. If we or our licensor fail to adequately protect this intellectual property, our ability to develop, manufacture, or commercialize products could suffer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, while we cannot currently determine the amount of the royalty obligations we would be
required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and
commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property
rights we have, we may have to abandon development of the relevant research programs or product candidates and our business, financial condition, results of operations and prospects could suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially
unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
currently own intellectual property directed to our product candidates and other proprietary technologies. Other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant
to our business. From time to time, in order to avoid infringing these third-party patents, we may be required to license technology from additional third parties to further develop or commercialize our product candidates. Should we be required to
obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our product candidates, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any
third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue
strategies to license or acquire third-party intellectual property rights we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical
development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, some of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent applications or future patents are or may be <FONT
STYLE="white-space:nowrap">co-owned</FONT> with third parties. If we are unable to obtain an exclusive license to any such third-party <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patents or patent applications, such <FONT
STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any
such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Furthermore, our owned and
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents may be subject to a reservation of rights by one or more third parties. Any of the foregoing could have a material adverse effect on our competitive position, business, financial
conditions, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are sued for infringing intellectual property rights of third parties, such litigation could be costly
and time consuming and could prevent or delay us from developing or commercializing our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial success depends,
in part, on our ability to develop, manufacture, market and sell our product candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed or misappropriated
their intellectual property. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical
and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these
results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development
activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such
litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or
other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is a substantial amount of intellectual
property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our products candidates. We
cannot be certain that our product candidates and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. Third parties may assert infringement claims against us based on existing or future
intellectual property rights. For example, we have identified certain third party patents that may be asserted against us with respect to our lead product SBT6050. These patents may expire prior to commercial launch of SBT6050, if approved. We
believe that the relevant claims of these third party patents are likely invalid or unenforceable, and we may choose to challenge those patents, though the outcome of any challenge that we may initiate in the future is uncertain. We may also decide
in the future to seek a license to those third party patents, but we might not be able to do so on reasonable terms. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and
convincing evidence to overcome the presumption of validity enjoyed by issued patents. If we are found to infringe a third party&#146;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or
commercializing the infringing candidate product or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing
candidate product or product. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby
giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of
infringement could prevent us from commercializing our investigational products or force us to cease some of our business operations, which could materially harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing
our product candidates, might assert are infringed by our current or future product candidates, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates. It is also
possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by our product candidate. In
addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. Our competitors in both the United States and
abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent,
limit or otherwise interfere with our ability to make, use and sell our product candidates. The pharmaceutical and biotechnology </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
industries have produced a considerable number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use.
The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not
infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires
a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Even if we are
successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and
operations. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In
addition, we may not have sufficient resources to bring these actions to a successful conclusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may choose to challenge the enforceability or
validity of claims in a third party&#146;s U.S. patent by requesting that the USPTO review the patent claims in an <I><FONT STYLE="white-space:nowrap">ex-parte</FONT></I> <FONT STYLE="white-space:nowrap">re-exam,</FONT> <I>inter partes</I> review or
post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#146;s patent in patent opposition proceedings in the EPO, or other foreign patent office. The costs
of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that
the patent may be infringed by our product candidates or proprietary technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are found to infringe a third-party&#146;s intellectual
property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third-party in order to
use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain
a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and
attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, and could divert the time and
attention of our technical personnel and management, cause development delays, and/or require us to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be possible on a cost-effective basis, any of which could
materially harm our business. In the event of a successful claim of infringement against us, we may have to pay substantial monetary damages, including treble damages and attorneys&#146; fees for willful infringement, pay royalties and other fees,
redesign our infringing drug or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Claims that we have misappropriated the confidential information or trade secrets of third
parties could have a similar negative impact on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may become involved in lawsuits to protect or enforce our patents or other intellectual
property, which could be expensive, time consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Competitors or other third parties may infringe our patents, trademarks
or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Our
pending patent applications cannot be enforced against third parties practicing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the technology claimed in such applications unless and until a patent issues from such applications. Any claims we assert against perceived infringers could provoke these parties to assert
counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In patent litigation in the United States, defendant counterclaims alleging invalidity
and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, <FONT STYLE="white-space:nowrap">non-enablement</FONT> or
insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution.
The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and
that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#146;s claims narrowly or decide that we do not
have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention, or decide that the other party&#146;s use of our patented technology falls under the safe harbor to patent
infringement under 35 U.S.C. &#167;271(e)(1). An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to
exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark
infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could
ultimately be forced to cease use of such trademarks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we establish infringement, the court may decide not to grant an injunction against
further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a
risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or
investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such
infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could
outweigh any benefit we receive as a result of the proceedings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Because of the expense and uncertainty of litigation, we may not be in a position to enforce
our intellectual property rights against third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because of the expense and uncertainty of litigation, we may conclude that even if a
third-party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may
be too high or not in the best interest of our company or our stockholders, or it may be otherwise impractical or undesirable to enforce our intellectual property against some third parties. Our competitors or other third parties may be able to
sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. In such cases, we may decide that the more
prudent course of action is to simply monitor the situation or initiate or seek some other <FONT STYLE="white-space:nowrap">non-litigious</FONT> action or solution. In addition, the uncertainties associated with litigation could compromise our
ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">in-license</FONT> needed technology or other product candidates, or enter into development partnerships that would help us bring our product candidates to market.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have
wrongfully used or disclosed confidential information of third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As is common in the pharmaceutical industry, in addition to our
employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently
providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade
secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information,
<FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her <FONT STYLE="white-space:nowrap">non-competition</FONT> or
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could
be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such
technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to
form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if
we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in patent law in
the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and
enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the
United States could increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property
or narrow the scope of our owned and licensed patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leathy-Smith Act), signed into law on September&nbsp;16, 2011, could
increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include
provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior
art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <I>inter partes</I> review, and derivation proceedings. Further,
because of a lower evidentiary standard in these USPTO post-grant proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if
first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district
court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material
adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After March 2013, under the Leahy-Smith Act, the United
States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a
third-party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before we file an application covering the same invention, could therefore be awarded a patent covering an
invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United
States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (1)&nbsp;file any patent application related to our product candidates and
other proprietary technologies we may develop or (2)&nbsp;invent any of the inventions claimed in our or our licensor&#146;s patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from
practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. However, the Leahy-Smith Act and its implementation could increase
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations
and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly
uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on
future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant <FONT STYLE="white-space:nowrap">law-making</FONT> bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would
weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the 2013 case <I>Assoc. for Molecular Pathology v.</I> <I>Myriad Genetics, Inc.</I>, the U.S. Supreme Court
held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S.
Congress or the USPTO may impact the value of our patents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural,
document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to
be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse, including due to the effect of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on us or our patent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
maintenance vendors, can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in
abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of
a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal
documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may rely on trade secret and proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> which can be difficult to trace and enforce and, if we are unable to
protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to seeking patents for
some of our technology and product candidates, we may also rely on trade secrets, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position. Elements of
our product candidate, including processes for their preparation and manufacture, may involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology that is not covered by patents, and thus for these aspects we may
consider trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our
facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary
information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product
candidates, we must, at times, share trade secrets with them. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be
misappropriated or disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. We require our
employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We and any third parties with whom we share facilities enter
into written agreements that include confidentiality and intellectual property obligations to protect each party&#146;s property, potential trade secrets, proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> and information. We further seek
to protect our potential trade secrets, proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> and information in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who
are given access to them, such as our corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. With our consultants, contractors, and outside
scientific collaborators, these agreements typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary
technology and processes. We cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially
equivalent information and techniques. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches.
Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or
unwilling to protect trade secrets. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets,
including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
third-party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by
a competitor or other third-party, our competitive position would be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may become subject to claims challenging the inventorship or ownership of our
patents and other intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may be subject to claims that former employees, collaborators or other third parties have an
interest in our patents or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being
unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter
of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding <FONT STYLE="white-space:nowrap">co-ownership</FONT> of potential joint inventions. Litigation may be
necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our
licensors are not the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-licensed.</FONT> If other third parties have ownership rights or other rights to our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents,
they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of
operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or
development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as
our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to
determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patent rights are of limited duration. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20
years after its first effective filing date. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product
candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. As a result, our patent portfolio may not
provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. Upon issuance in the United States, the term of a patent can be increased by patent term adjustment, which is based on certain
delays caused by the USPTO, but this increase can be reduced or eliminated based on certain delays caused by the patent applicant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
during patent prosecution. The term of a United States patent may also be shortened if the patent is terminally disclaimed over an earlier-filed patent. A patent term extension (PTE) based on
regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of
the PTE does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous PTEs in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a
single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents
or otherwise fail to satisfy applicable requirements. If we are unable to obtain PTE or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be
shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their
product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If our trademarks and trade names are not adequately
protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or
may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in
other foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties
are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are
unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors.
Although these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the
goodwill associated with our trademarks and trade names. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, any name we have proposed to use with our product candidate in the United States
must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of
potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in
an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark
registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding
our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate
variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease
use of such trademarks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Common Stock and this Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>There has been no prior public market for our common stock, the stock price of our common stock may be volatile or may decline regardless of our operating
performance and you may not be able to resell your shares at or above the initial public offering price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There has been no public market for
our common stock prior to this offering. The initial public offering price for our common stock was determined through negotiations between the underwriters and us and may vary from the market price of our common stock following this offering. If
you purchase shares of our common stock in this offering, you may not be able to resell those shares at or above the initial public offering price. An active or liquid market in our common stock may not develop upon the completion of this offering
or, if it does develop, it may not be sustainable. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or
products by using our shares of common stock as consideration. The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our operating performance and the performance of other similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the published opinions and third-party valuations by banking and market analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">results from our ongoing clinical trials and future clinical trials with our current and future product candidates or of
our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">adverse results or delays in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure to commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unanticipated serious safety concerns related to immuno-oncology or related to the use of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes
in recommendations by securities analysts that elect to follow our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development
with respect to the applicable regulatory authority&#146;s review of such filings, including without limitation the FDA&#146;s issuance of a &#147;refusal to file&#148; letter or a request for additional information; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the level of expenses related to future product candidates or clinical development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our failure to achieve product development goals in the timeframe we announce; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcements of acquisitions, strategic alliances or significant agreements by us or by our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the economy as a whole and market conditions in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">trading activity by a limited number of stockholders who together beneficially own a majority of our outstanding common
stock; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the expiration of market standoff or contractual <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the size of our market float; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">political uncertainty and/or instability in the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ongoing and future impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and actions taken to slow
its spread; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any other factors discussed in this prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of
equity securities of many immuno-oncology companies. Stock prices of many immuno-oncology companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. The trading prices for common stock of
other biopharmaceutical companies have also been highly volatile as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. In the past, stockholders have filed securities class action litigation following periods of market
volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to
stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of September 30, 2020, our executive officers, directors, five percent stockholders and their affiliates
beneficially owned approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our voting stock and, upon closing of this offering, that same group will beneficially own approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding voting stock. Therefore, even after
this offering, these stockholders will have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may
be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for
our common stock that you may believe are in your best interest as one of our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Substantial amounts of our outstanding shares may be sold into
the market when <FONT STYLE="white-space:nowrap">lock-up</FONT> or market standoff periods end. If there are substantial sales of shares of our common stock, the price of our common stock could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our directors, executive officers
and significant stockholders, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur. After this offering, we will have
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;outstanding shares of our common stock, based on the number of shares outstanding as of September&nbsp;30, 2020. All of the shares of common stock sold
in this offering will be available for sale in the public market. Substantially all of our outstanding shares of common stock are currently restricted from resale as a result of market standoff and <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements, as more fully described in the section of this prospectus titled &#147;Shares Eligible for Future Sale.&#148; These shares will become available to be sold 181 days after the date of this prospectus, in addition to shares issuable
pursuant to outstanding option and warrants. Shares held by directors, executive officers and other affiliates will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended (the Securities Act) and various vesting
agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After the completion of this offering, certain of our stockholders will have rights, subject to some conditions, to require us to file
registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our stockholders, subject to market standoff </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and lockup agreements. We also intend to register shares of common stock that we have issued and may issue under our employee equity incentive plans. Once we register these shares, they will be
able to be sold freely in the public market upon issuance, subject to existing market standoff or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Goldman Sachs&nbsp;&amp; Co. LLC, SVB Leerink LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated may, in their discretion, permit our
stockholders to sell shares prior to the expiration of the restrictive provisions contained in those <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The market price of the shares of our common stock could decline as a result of the sale of a substantial number of our shares of common stock in the
public market or the perception in the market that the holders of a large number of shares intend to sell their shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If you purchase shares of our common
stock in this offering, you will experience substantial and immediate dilution. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If you purchase shares of our common stock in this offering,
you will experience substantial and immediate dilution in the pro forma net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share as of September&nbsp;30, 2020,
based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus),
because the price that you pay will be substantially greater than the pro forma net tangible book value per share of the common stock that you acquire. This dilution is due in large part to the fact that our earlier investors paid substantially less
than the initial public offering price when they purchased their shares of our capital stock. You will experience additional dilution upon exercise of options to purchase common stock under our equity incentive plans, upon vesting of options to
purchase common stock under our equity incentive plans, if we issue restricted stock to our employees under our equity incentive plans or if we otherwise issue additional shares of our common stock. See the section of this prospectus titled
&#147;Dilution&#148; for additional information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our
equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity
securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner, we determine from time to time. If we sell common
stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could
gain rights superior to our existing stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to our 2020 Plan, our management is authorized to grant stock options and other
equity-based awards to our employees, directors and consultants. The number of shares of our common stock reserved for issuance under our 2020 Plan will automatically increase on January&nbsp;1 of each calendar year, starting on January&nbsp;1, 2021
through January&nbsp;1, 2030, in an amount equal to the lesser of (i) &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of each automatic increase; or
(ii)&nbsp;a lesser number of shares determined by our board of directors prior to the applicable January 1st. If our board of directors elects to increase the number of shares available for future grant by the maximum amount each year, our
stockholders may experience additional dilution, which could cause our stock price to fall. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require
us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may seek additional capital through a combination of public and
private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be
diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive
covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business.
If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to
us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring
or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We could be
subject to securities class action litigation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the past, securities class action litigation has often been brought against a company
following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in
substantial costs and a diversion of management&#146;s attention and resources, which could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are an &#147;emerging growth company,&#148;
and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as defined in the JOBS Act, and we intend to take advantage of some of the exemptions from reporting
requirements that are applicable to other public companies that are not emerging growth companies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim
financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over
financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board
regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not being required to hold a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation or
obtain stockholder approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, as an &#147;emerging growth
company&#148; the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
made applicable to private companies, unless we later irrevocably elect not to avail ourselves of this exemption. We have elected to use this extended transition period under the JOBS Act. As a
result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make
comparison of our financials to those of other public companies more difficult. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot predict if investors will find our common stock less
attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage
of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (i)&nbsp;the last day of the fiscal year (1)&nbsp;following the fifth anniversary of the completion of
this offering, (2)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion or (3)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th and (ii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during
the prior three-year period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws that will
be in effect at the completion of this offering could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the completion of this offering, our status as a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law
may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control
would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect at the completion of this offering will contain provisions that may make the
acquisition of our company more difficult, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change
the membership of a majority of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of
those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board
of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special
meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board of
directors, the chairman of our board of directors or our chief executive officer, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the requirement for the affirmative vote of holders of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the
voting power of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend the provisions of our amended and restated certificate of incorporation relating to the management of our business or our amended and
restated bylaws, which may inhibit the ability of an acquirer to affect such amendments to facilitate an unsolicited takeover attempt; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to
propose matters to be acted upon at a stockholders&#146; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to obtain
control of us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, as a Delaware corporation, we are subject to Section&nbsp;203 of the Delaware General Corporation
Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by
express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more
difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving
our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For information regarding these and other provisions, see the section of this prospectus titled &#147;Description of Capital Stock.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our amended and restated certificate of incorporation, which will become effective upon the closing of this offering designates the state courts the State of
Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, and the federal district courts of the United States of America will be the exclusive forums for certain types of
actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against our company and our directors, officers and employees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation, which will become effective upon the closing of this offering, provides that, to the fullest
extent permitted by law, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any
state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall will be the sole and
exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action or proceeding asserting a claim of breach of a
fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (iii)&nbsp;any action or proceeding asserting a claim against us or any of our current or former directors, officers or other
employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; (iv)&nbsp;any action or proceeding to interpret, apply, enforce
or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws; (v)&nbsp;any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery
of the State of Delaware; and (vi)&nbsp;any action asserting a claim against us or any of our directors, officers or other employees, governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to
enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition,
our amended and restated certificate of incorporation will provide that, to the fullest extent permitted by law, the federal district courts of the United States of America will be the exclusive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
forum for resolving any complaint asserting a cause of action arising under the Securities Act, unless we consent in writing to the selection of an alternative forum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These exclusive-forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with
us or our directors, officers or other employees and may discourage these types of lawsuits, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. While the
Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect
to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other
jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General Risk Factors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will incur significantly increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new
compliance initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a
private company. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC, and the Nasdaq Global Market have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and
Consumer Protection Act (the Dodd-Frank Act) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas
such as &#147;say on pay&#148; and proxy access. Recent legislation permits smaller &#147;emerging growth companies&#148; to implement many of these requirements over a longer period and up to five years from the pricing of this offering. We intend
to take advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political
environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our
business in ways we cannot currently anticipate. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial
compliance costs and will make some activities more time-consuming and costlier. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be
required to incur substantial costs to maintain our current levels of such coverage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Failure to build our finance infrastructure and improve our accounting
systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a public company, we will operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act, the
regulations of the Nasdaq Global Market, the rules and regulations of the Securities and Exchange Commission, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required
by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports
and are important to help prevent financial fraud. Commencing with our fiscal year ending the year after this offering is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
completed, we must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls
over financial reporting in our Form <FONT STYLE="white-space:nowrap">10-K</FONT> filing for that year, as required by Section&nbsp;404 of the Sarbanes-Oxley Act. Prior to this offering, we have never been required to test our internal controls
within a specified period and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate
that the process of building our accounting and financial functions and infrastructure will require significant additional professional fees, internal costs and management efforts. We expect that we will need to implement a new internal system to
combine and streamline the management of our financial, accounting, human resources and other functions. However, such a system would likely require us to complete many processes and procedures for the effective use of the system or to run our
business using the system, which may result in substantial costs. Any disruptions or difficulties in implementing or using such a system could adversely affect our controls and harm our business. Moreover, such disruption or difficulties could
result in unanticipated costs and diversion of management attention. In addition, we may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial
statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control
system&#146;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and
instances of fraud will be detected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are not able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely
manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If we cannot provide reliable financial reports or prevent fraud, our business and results of
operations could be harmed, investors could lose confidence in our reported financial information and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to maintain effective internal controls, our business, financial position and results of operations could be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a public company, we will be subject to reporting and other obligations under the Exchange Act, including the requirements of SOX Section&nbsp;404,
which require annual management assessments of the effectiveness of our internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The rules governing the
standards that must be met for management to determine that our internal control over financial reporting is effective are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the
rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act of 2002. These reporting and other obligations place
significant demands on our management and administrative and operational resources, including accounting resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States. Any failure to maintain effective internal controls could have an adverse effect on our business, financial
position and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure
controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time
periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the
objectives of the control system are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These inherent limitations include the realities that judgments in decision-making can be faulty, and
that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction
disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control
system, misstatements due to error or fraud may occur and not be detected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Future changes in financial accounting standards or practices may cause adverse
and unexpected revenue fluctuations and adversely affect our reported results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Future changes in financial accounting
standards may cause adverse, unexpected revenue fluctuations and affect our reported financial position or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and varying
interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future. As a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition
and results of operations or the way in which such financial condition and results of operations are reported. We intend to invest resources to comply with evolving standards, and this investment may result in increased general and administrative
expenses and a diversion of management time and attention from business activities to compliance activities. See the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Recent
Accounting Pronouncements.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on
our business, cash flow, financial condition or results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">New income, sales, use, or other tax laws, statutes, rules,
regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted, changed, modified,
or applied adversely to us. For example, the Tax Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of
the Tax Act could be repealed or modified in future legislation. For example, the CARES Act modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or any newly
enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform
legislation could have a material impact on the value of our deferred tax assets, could result in significant <FONT STYLE="white-space:nowrap">one-time</FONT> charges, and could increase our future U.S. tax expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unstable market and economic conditions may have serious adverse consequences on our business, financial
condition and stock price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and actions taken to slow its
spread, the global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in
unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely
affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult,
more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or
abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our
operating goals on schedule and on budget. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will have broad discretion in the use of the net proceeds of this offering and may not use them effectively or
in ways that increase the value of our share price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot specify with any certainty the particular uses of the net proceeds that we
will receive from this offering, but we currently expect such uses will include advancing our clinical product candidates into later-stage clinical trials and combination trials, advancing our research product candidates into clinical development,
supporting our ongoing drug discovery efforts and supporting our growing infrastructure and needs in operating as a public company. We will have broad discretion in the application of the net proceeds, including working capital and other general
corporate purposes, and you and other stockholders may disagree with how we spend or invest these proceeds. The failure by our management to apply these funds effectively could adversely affect our business and financial condition. Pending their
use, we may invest the net proceeds from our initial public offering in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our internal information technology systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security breaches, loss or
leakage of data, and other disruptions, which could result in a material disruption of our product candidates&#146; development programs, compromise sensitive information related to our business or prevent us from accessing critical information,
potentially exposing us to liability or otherwise adversely affecting our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are increasingly dependent upon information
technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information
and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage
a number of third-party contractors who have access to our confidential information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Despite the implementation of security measures, given their
size and complexity and the increasing amounts of confidential information that they maintain, our internal information technology systems and those of our third-party CROs and other contractors and consultants are potentially vulnerable to
breakdown or other damage or interruption from service interruptions, system </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors,
consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information),
which may compromise our system infrastructure or lead to data leakage. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or
proprietary information, we could incur liability and reputational damage and the further development and commercialization of our product candidates could be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages,
breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it
could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts
and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access,
use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business,
and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation
directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and
security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster
recovery plans may not adequately protect us from a serious disaster. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our headquarters and main research facility are located in Seattle,
Washington, which in the past has experienced severe earthquakes and fires. If these earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevented us from using all or a significant portion of our
headquarters or research facility, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur
substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could
have a material adverse effect on our business. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an
event were to affect our supply chain, it could have a material adverse effect on our ability to conduct our clinical trials, our development plans and business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions,
and other trade laws and regulations. We can face serious consequences for violations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">U.S. and foreign anti-corruption, anti-money
laundering, export control, sanctions, and other trade laws and regulations, or collectively, Trade Laws, prohibit, among other things, companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other
partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can
result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect
interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> activities to increase over time. We
expect to rely on third parties for research, preclinical studies, and clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal
activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to comply
with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We, and the third parties with whom we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including
those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and
radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these
materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with whom we share our facilities, and any liability could exceed our
resources. We also could incur significant costs associated with civil or criminal fines and penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Although we maintain workers&#146;
compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These
current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patent protection is available on a national or regional level. Filing, prosecuting and defending patents throughout the world and on all of our product
candidates would be prohibitively expensive. As such, our intellectual property rights outside the United States may not extend to all other possible countries outside the United States and we may not be able to prevent third parties from practicing
our inventions in countries outside the United States where we do not have patent protection, or from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
selling in and importing products into other jurisdictions made using our inventions in such countries outside the United States. Competitors may use our technologies in jurisdictions where we
have not obtained patent protection to develop their own products or technology and may export otherwise infringing products or technology to territories where we have patent protection, but enforcement rights are not as strong as those in the
United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Further, the legal systems of certain countries particularly
certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals or biologics, which could make it difficult for us to stop the infringement of our
patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects
of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any such lawsuits that
we initiate and the damages and other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and
we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign
intellectual property laws. We currently have and may in the future enter into more contract research and manufacturing relationships with organizations that operate in certain countries that are at heightened risk of theft of technology, data and
intellectual property, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. In addition, certain developing countries, including China and India, have compulsory licensing
laws under which a patent owner may be compelled under certain circumstances to grant licenses to third parties at nominal or no consideration. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or
our licensors are compelled to grant a license to a third-party, which could materially diminish the value of those patents. In addition, many countries limit the enforceability of patents against government agencies or government contractors. This
could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or
license. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and
trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The trading market for our common stock will depend in part on the research and reports that securities or
industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no or only very few securities analysts commence coverage of us, or if industry analysts cease
coverage of us, the trading price for our common stock would be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price
would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other
than statements of historical facts contained in this prospectus, including statements regarding our strategy, future financial condition, future operations, research and development, planned clinical trials and preclinical studies, the timing and
likelihood of regulatory filings and approvals for our product candidates, our ability to commercialize our product candidates, the potential benefits of collaborations, projected costs, prospects, plans, objectives of management and expected market
growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;believe,&#148; &#147;contemplate,&#148;
&#147;continue,&#148; &#147;could,&#148; &#147;design,&#148; &#147;due,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;positioned,&#148;
&#147;potential,&#148; &#147;predict,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would&#148; and other similar expressions that are predictions of or indicate future events and future trends, or the
negative of these terms or other comparable terminology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have based these forward-looking statements largely on our current expectations and
projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of known and unknown
risks, uncertainties and assumptions described in the sections of this prospectus titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and elsewhere in this
prospectus. Other sections of this prospectus may include additional factors that could harm our business and financial performance. In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the
relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and
our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely
upon these statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and
it is not possible for our management to predict all risk factors nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those
contained in, or implied by, any forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In light of the significant uncertainties in these forward-looking statements, you
should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus, we cannot guarantee that the future results, levels
of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section of this prospectus titled &#147;Risk Factors&#148; for a discussion of important
factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as
required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. The Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the
Securities Act, do not protect any forward-looking statements that we make in connection with this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You should read this prospectus and
the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from
what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_4"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Certain market, industry and competitive data included in this prospectus were obtained from our own internal estimates and research, as well as from
publicly available information, reports of governmental agencies and industry publications and surveys. In some cases, we do not expressly refer to the sources from which this data is derived. All of the market and industry data used in this
prospectus is inherently subject to uncertainties and involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such information. The industry in which we operate is subject to a high degree of uncertainty
and risk due to a variety of factors, including those described in the section of this prospectus titled &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in the estimates made by the
independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that we will receive net proceeds of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million (or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters&#146; option to purchase additional shares is exercised in full) from the sale of the shares of common stock offered by us in this offering, based on an assumed initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus), and after deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase or decrease, as applicable, the net proceeds to us from this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions
and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&nbsp;million shares in the number of shares offered by us would increase or decrease, as applicable, the net proceeds to us by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share remains the same, and after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The principal purposes of this offering are to obtain additional capital
to support our operations, to create a public market for our common stock and to facilitate potential future access to the public equity markets. We anticipate that we will use the net proceeds of this offering, along with our existing cash and cash
equivalents, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the development of SBT6050, including the
ongoing Phase 1 dose-escalation trial and planned Phase 1b tumor-specific expansion trial of SBT6050 as a monotherapy in HER2-expressing tumors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the planned Phase 1 dose-escalation trial
and planned Phase 1b trial of SBT6050 in combination with a <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the development of SBT6290, including the
ongoing <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and planned Phase 1 dose-escalation trial of SBT6290 in Nectin4-expressing tumors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the development of ASGR1-TLR8, including the
planned development candidate selection for and planned <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies of our SBT8230 program in cHBV; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the remaining proceeds to fund our other research and development activities, as well as for working capital and other
general corporate purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may also use a portion of the net proceeds from this offering
<FONT STYLE="white-space:nowrap">to&nbsp;in-license,&nbsp;acquire</FONT> or invest in complementary businesses, technologies, products or assets. However, we have no current commitments or obligations to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our current operating plan, we estimate that our existing cash and cash equivalents as of the date of this prospectus, together with the
estimated net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months. In particular, we expect that these capital resources will
allow us to fund: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ongoing Phase 1 dose-escalation trial for STBT6050 as a monotherapy in HER2-expressing tumors though our anticipated
clinical data updates in the second half of 2021 and the second half of 2022; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our planned Phase 1b tumor-specific expansion trial for STBT6050 as a monotherapy in HER2-expressing tumors though our
anticipated initial clinical data update in the second half of 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our planned Phase 1 dose-escalation trial of SBT6050 in combination with a <FONT STYLE="white-space:nowrap">PD-1</FONT>
inhibitor through our anticipated clinical data updates in the first half of 2022 and the second half of 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our planned Phase 1b tumor-specific expansion trial for STBT6050 in combination with a
<FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitor though our anticipated initial clinical data update in the second half of 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ongoing <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and planned Phase 1 dose-escalation trial for
SBT6290 in Nectin4-expressing tumors through our anticipated IND submission in the fourth quarter of 2021 and initiation of the Phase 1 trial in the first quarter of 2022; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ongoing and planned preclinical study activities for SBT8230 in cHBV through our anticipated development candidate
selection in the fourth quarter of 2020 and submission of an IND in the second half of 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our expected use of net proceeds
from this offering described above represents our current intentions based upon our present plans and business conditions, which could change in the future as our plans and business conditions continue to evolve. As of the date of this prospectus,
we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering, or the amounts that we will actually spend on the uses set forth above. Further, due to the uncertainties
associated with the drug development process, it is difficult to predict the cost and timing required to complete our development programs. The amounts and timing of our actual use of the net proceeds will vary depending on numerous factors,
including the progress, cost and results of our preclinical and clinical development programs, our ability to obtain additional financing, whether we are able to enter into future strategic collaborations, licensing or other arrangements, and other
factors described in the section of this prospectus titled &#147;Risk Factors,&#148; as well as the amount of cash used in our operations and any unforeseen cash needs. We may find it necessary or advisable to use the net proceeds for other
purposes, and our management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our existing cash and cash equivalents as of the date of this prospectus, together with the estimated net proceeds from this offering, will not be
sufficient to fund development of our product candidates through regulatory approval and commercialization. To obtain the capital necessary to fund our product candidates through regulatory approval and commercialization, we expect to finance our
cash needs through public or private equity offerings, debt financings and/or other capital sources which may include strategic collaborations, licensing arrangements or other arrangements with third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pending their use, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade
instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have never declared or paid cash dividends on our capital stock, and we do not currently intend to pay any cash dividends on our capital stock in the
foreseeable future. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business. Any future determination related to dividend policy will be made at the discretion of our
board of directors, subject to applicable laws, and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions and capital requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, our Loan Agreement limits our ability to pay cash dividends. In addition, our ability to pay cash dividends on our capital stock in the
future may be further limited by the terms of any future debt or preferred securities we issue or any credit facilities we enter into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents and our capitalization as of September&nbsp;30, 2020: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma basis to give effect to (i)&nbsp;the conversion of all outstanding shares of our redeemable convertible
preferred stock into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the closing of this offering and (ii)&nbsp;the filing and effectiveness of our amended and
restated certificate of incorporation immediately prior to the closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma as adjusted basis to give further effect to our sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock in this offering at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the
price range set forth on the cover page of this prospectus), after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This pro forma as adjusted information is illustrative only and will depend on the actual initial public offering price and other terms of this offering
determined at pricing. The following table should be read together with the sections of this prospectus titled &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations,&#148; and our financial statements and the related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited)<BR>(in thousands, except share and per share<BR>amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred stock, $0.0001 par value;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, actual; no shares authorized, issued or outstanding,
pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Preferred stock, $0.0001 par value per share; no shares authorized, issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Common stock, $0.0001 par value;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>,
actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma as adjusted.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Each $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase or decrease, as applicable, the pro forma as adjusted amounts of each of our cash and cash
equivalents, common stock and additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; (deficit) equity, and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming
the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase
or decrease of 1.0&nbsp;million shares in the number of shares offered by us would increase or decrease, as applicable, the pro forma as adjusted amounts of each of our cash and cash equivalents, common stock, and additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; (deficit) equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial public offering price
remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">This pro forma as adjusted information is illustrative only and will depend on the actual initial public offering price
and other terms of this offering determined at pricing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The number of shares of common stock actually issued and outstanding
excludes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares outstanding that are subject to forfeiture or our right to repurchase as of September&nbsp;30, 2020 and which are therefore not considered outstanding for
accounting purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding as of September&nbsp;30, 2020 after giving effect to the pro forma adjustments described above (which
excludes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares outstanding that are subject to forfeiture or our right to repurchase as of such date, and which are therefore not considered outstanding for accounting
purposes), and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon the
exercise of outstanding stock options as of September&nbsp;30, 2020, with a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon the
exercise of outstanding stock options granted subsequent to September&nbsp;30, 2020, with a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">33,995 shares of common stock which will become issuable to the lenders under the Loan Agreement upon the exercise of the
Lender Warrants, at a weighted-average exercise price of $0.63&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for future
issuance under the 2020 Plan, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under the 2020 Plan, which will become effective upon the execution and delivery of the underwriting agreement
for this offering (including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for issuance under the Prior Plan, which shares will be added to the 2020 Plan upon its effectiveness); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for future
issuance under the ESPP, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under the ESPP, which will become effective upon the execution and delivery of the underwriting agreement for this
offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the
initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our historical net tangible book deficit as of September&nbsp;30, 2020 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of our common stock. Our historical net tangible book deficit is the amount of our total tangible assets less our total liabilities and redeemable convertible preferred stock, which is not
included within stockholders&#146; equity (deficit). Historical net tangible book deficit per share represents our historical net tangible book deficit divided by the number of shares of our common stock outstanding as of September&nbsp;30, 2020
(excluding&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares subject to forfeiture or our right to repurchase). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
pro forma net tangible book value as of September&nbsp;30, 2020 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of our common stock. Pro forma net tangible book value represents
the amount of our total tangible assets less our total liabilities, after giving effect to the conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the closing of this offering. Pro forma net tangible book value per share represents our pro forma net tangible book value
divided by the number of shares of our common stock outstanding as of September&nbsp;30, 2020, after giving effect to the pro forma adjustments described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After giving further effect to our issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common
stock in this offering at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus) and after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of September&nbsp;30, 2020 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This represents an immediate increase in pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to existing stockholders and immediate
dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in pro forma as adjusted net tangible book value per share to new investors purchasing common stock in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the
initial public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Historical net tangible book value (deficit) per share as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase per share attributable to the automatic conversion of redeemable convertible preferred stock upon
the closing of this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net tangible book value per share as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in pro forma as adjusted net tangible book value per share attributable to new investors
purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution per share to new investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase or decrease, as applicable, our pro forma as adjusted net tangible book value by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, our pro forma as adjusted net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and dilution per share to new investors purchasing shares
in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable
by us. Each increase of 1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase the pro forma as adjusted net tangible book value per share after this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and decrease the dilution per share to new investors participating in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering
price and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each decrease of 1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of
this prospectus, would decrease the pro forma as adjusted net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and increase the dilution per share to new investors participating in this offering
by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the assumed initial public offering price remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the underwriters exercise their option to purchase additional shares in full, our pro forma as adjusted net tangible book value per share after
this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, representing an immediate increase in pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to existing
stockholders and immediate dilution in pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to new investors purchasing common stock in this offering, assuming an initial public offering price
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus), and after deducting the estimated underwriting discounts and commissions and estimated offering expenses
payable by us. If any shares are issued upon exercise of outstanding options, you will experience further dilution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes,
on the pro forma as adjusted basis described above, the differences between the number of shares of common stock purchased from us, the total consideration paid to us and the average price per share paid by existing stockholders and by new investors
purchasing shares of common stock in this offering. The calculation below is based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover
page of this prospectus), before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Price&nbsp;Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Existing stockholders before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase or decrease, as applicable, the total consideration paid by new investors by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million and, in the case of an increase, would increase the percentage of total consideration paid by new investors by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. Similarly, each
increase or decrease of 1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease, as applicable, the total consideration paid by new investors by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and, in the case of an increase, would increase the percentage of total consideration paid by new investors
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points, assuming that the assumed initial public offering price remains the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares in this offering. If the underwriters&#146; option to
purchase additional shares is exercised in full, the number of shares of our common stock held by existing stockholders would be reduced to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the
total number of shares of our common stock outstanding after this offering, and the number of shares of common stock held by new investors participating in the offering would be increased to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The foregoing tables and calculations are based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock
outstanding as of September&nbsp;30, 2020 after giving effect to the pro forma adjustments described above (which excludes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares outstanding that are subject to forfeiture or
our right to repurchase as of such date, and which are therefore not considered outstanding for accounting purposes), and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon the
exercise of outstanding stock options as of September&nbsp;30, 2020, with a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon the
exercise of outstanding stock options granted subsequent to September&nbsp;30, 2020, with a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">33,995 shares of common stock which will become issuable to the lenders under the Loan Agreement upon the exercise of the
Lender Warrants, at a weighted-average exercise price of $0.63&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for future
issuance under the 2020 Plan, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under the 2020 Plan, which will become effective upon the execution and delivery of the underwriting agreement
for this offering (including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for issuance under the Prior Plan, which shares will be added to the 2020 Plan upon its effectiveness); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for future
issuance under the ESPP, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under the ESPP, which will become effective upon the execution and delivery of the underwriting agreement for this
offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that any outstanding options are exercised, or new options or other equity awards are issued under our
equity incentive plans, you will experience further dilution. In addition, to the extent that additional capital is raised through the sale of equity or convertible debt securities in the future, the issuance of these securities may result in
further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_9"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following tables set forth our selected financial data as of, and for the periods ended on, the dates indicated. We have derived the selected
statements of operations and comprehensive loss data for the years ended December&nbsp;31, 2018 and 2019 and the selected balance sheet data as of December&nbsp;31, 2018 and 2019 from our audited financial statements included elsewhere in this
prospectus. We have derived the selected statements of operations and comprehensive loss data for the nine months ended September&nbsp;30, 2019 and 2020 and the selected balance sheet data as of September&nbsp;30, 2020 from our unaudited interim
condensed financial statements included elsewhere this prospectus. Our unaudited interim condensed financial statements have been prepared in a basis consistent with our audited financial statements and, in the opinion of management, reflect all
adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the financial information in those statements. You should read the following selected financial data together with our financial statements and
the related notes included elsewhere in this prospectus and in the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results are not necessarily
indicative of results that should be expected in any future period, and our results for any interim period are not necessarily indicative of results that should be expected for any full year. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of redeemable convertible preferred stock purchase option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares of common stock used in computing net loss per share attributable to common
stockholders, basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,241,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,453,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma-weighted average shares of common stock used in computing pro forma net loss per share
attributable to common stockholders, basic and diluted (unaudited)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See Notes 2, 16 and 17 to our audited financial statements included elsewhere in this prospectus for details on the
calculation of our basic and diluted net loss per share attributable to common stockholders and our basic and diluted pro forma net loss per share attributable to common stockholders, and the weighted-average number of shares used in computing the
per share amounts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>As of<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Working capital is defined as current assets less current liabilities. See our financial statements and the related notes
included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>FINANCIAL CONDITION AND&nbsp;RESULTS&nbsp;OF&nbsp;OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the section of this
prospectus titled &#147;Selected Financial Data&#148; and our financial statements and related notes included elsewhere in this prospectus. Some of the information contained in this discussion and analysis are set forth elsewhere in this prospectus,
including information with respect to our plans and strategy for our business and related financing, and includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the
section of this prospectus titled &#147;Risk Factors,&#148; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a clinical-stage biopharmaceutical company
focused on leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to
strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are applying our platform to create a new class of targeted immuno-oncology
agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Our lead product candidate, SBT6050, is comprised of a TLR8 linker-payload conjugated to a HER2-directed monoclonal antibody
that targets tumors such as certain breast, gastric and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancers among others. SBT6050 is currently in a Phase 1/1b clinical trial in patients with advanced or metastatic HER2-expressing
solid tumors. In this trial, we have observed single agent pharmacological activity in the first dose cohort, and we anticipate providing an update on interim data from the Phase&nbsp;1 dose-escalation cohorts in the second half of 2021. SBT6290 is
our second product candidate, expanding on the potential of a TLR8 agonist as a payload. SBT6290 is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in certain bladder, triple negative breast, head
and neck, and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancers. We anticipate submitting an investigational new drug application for SBT6290 in the fourth quarter of 2021. Our third TLR8 program, SBT8230, is comprised of a TLR8
linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of cHBV. We are also developing agents that localize therapies to modulate important pathways in additional oncology and fibrosis indications using
TLR8 and other linker-payloads. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ImmunoTAC platform drives our pipeline of tissue targeted therapeutic candidates as summarized in
the chart below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g67046g09g06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We were incorporated in January 2016. To date, we have devoted substantially all of our resources to organizing and
staffing our company, business planning, raising capital, developing and optimizing our technology platform, identifying potential product candidates, undertaking research and preclinical studies and a clinical trial for our lead program, engaging
in manufacturing for our development programs, establishing and enhancing our intellectual property portfolio, and providing general and administrative support for these operations. We have one product candidate in early clinical development and all
of our other product candidates are in preclinical development, and none have been approved for commercial sale. We have never generated any revenue from product sales and have incurred net losses each year since we commenced operations. We have
funded our operations solely through private placements of our redeemable convertible preferred stock, convertible debt financings and term loan facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From inception to December&nbsp;31, 2019, we raised aggregate gross proceeds of $65.0&nbsp;million from the issuance of shares of our redeemable
convertible preferred stock and the issuance of convertible notes. In March 2020, we issued 10,027,666 shares of our Series B redeemable convertible preferred stock for gross proceeds of $21.5&nbsp;million and 4,673,388 shares upon conversion of
then outstanding convertible notes. In July 2020, we issued 10,669,834 additional shares of our Series B redeemable convertible preferred stock for gross proceeds of $23.0&nbsp;million. In September 2020, we issued 11,063,028 additional shares of
our Series B redeemable convertible preferred stock for gross proceeds of $23.9&nbsp;million and 24,926,685 shares of our Series C redeemable convertible preferred stock for gross proceeds of $84.9&nbsp;million. We have incurred significant
operating losses since our inception and have not yet generated any revenue. Our net losses were $17.6&nbsp;million and $24.0&nbsp;million for the years ended December&nbsp;31, 2018 and 2019, respectively. As of December&nbsp;31, 2019, we had an
accumulated deficit of $63.8&nbsp;million and cash and cash equivalents of $10.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect our expenses will increase substantially
and that we will to continue to incur significant losses for the foreseeable future as we continue our development of, and seek regulatory approvals </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
for, our product candidates and begin to commercialize any approved products, seek to expand our product pipeline, invest in our organization and technology platform, as well as incur expenses
associated with operating as a public company. Our net losses may fluctuate significantly <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">from&nbsp;quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">year-to-year,&nbsp;depending</FONT></FONT> on a variety of factors including the timing and scope of our preclinical studies and clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, we do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory
approval for one or more product candidates, which will not be for many years, if ever. Accordingly, until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through
public or private equity offerings, debt financings, or other capital sources which may include strategic collaborations, licensing arrangements or other arrangements with third parties. However, we may be unable to raise additional funds or enter
into such other agreements or arrangements when needed on favorable terms or at all. If we raise funds through strategic collaborations or other similar arrangements with third parties, we may have to relinquish valuable rights to our platform
technology, future revenue streams, research programs or product candidates or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through
equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts. Our ability to raise additional funds may be adversely impacted by potential worsening global
economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or otherwise. Because of the numerous
risks and uncertainties associated with product development, we cannot predict the timing or amount of increased expenses and cannot assure you that we will ever be profitable or generate positive cash flow from operating activities. Based upon our
current operating plan, we estimate that our existing cash and cash equivalents as of the date of this prospectus, together with the estimated net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure
requirements for at least the next &nbsp;&nbsp; months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our antibody drug conjugates are produced by chemical conjugation of <FONT
STYLE="white-space:nowrap">non-cytotoxic</FONT> linker-payloads to monoclonal antibodies. While we have significant internal expertise in engineering and humanization of antibodies and designing linker-payloads to customize drug conjugates for a
desired target profile, we do not own or operate, and currently have no plans to establish, any GMP manufacturing facilities. We operate on an outsourced model and rely on contracts with third-party
<FONT STYLE="white-space:nowrap">GMP-licensed</FONT> development and manufacturing organizations to produce and test the intermediates, drug substance and drug product to support clinical development, and commercialization, if any of our product
candidates obtain marketing approval. We are working with these manufacturers to scale up our manufacturing capabilities to support our clinical plans. We also rely on third parties to package, label, store and distribute our product candidates, as
well as for our commercial products if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest on our own manufacturing facilities, equipment and
personnel while also enabling us to focus our expertise and resources on the design and development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The global <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to rapidly evolve, and we will continue to monitor the <FONT STYLE="white-space:nowrap">COVID-19</FONT> situation closely. The extent of the impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> on our business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on
our clinical trial enrollment, trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. The ultimate impact of
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or a similar health epidemic is highly uncertain and subject to change. To the extent possible, we are conducting business as usual, with necessary or advisable
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
modifications to employee travel and most of our <FONT STYLE="white-space:nowrap">non-lab</FONT> based employees working remotely. We will continue to actively monitor the rapidly evolving
situation related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests
of our employees and other third parties with whom we do business. At this point, the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may affect our business, operations and clinical development timelines and plans,
including the resulting impact on our expenditures and capital needs, remains uncertain and is subject to change. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our License Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Below is a summary of the key terms for certain of our license agreements. For a more detailed description of these agreements, see the section of this
prospectus titled &#147;Business&#151;License Agreements.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of Our Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our operating expenses consist of
(i)&nbsp;research and development expenses and (ii)&nbsp;general and administrative expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of our ImmunoTAC
technology platform, product candidates, discovery efforts and preclinical study and clinical trial activities related to our program pipeline, including our lead product candidate,&nbsp;SBT6050. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our direct costs include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expenses incurred under agreements with CROs and other vendors that conduct our preclinical and clinical activities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expenses associated with manufacturing our product candidates including under agreements with CDMOs and other vendors; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">consulting fees. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our indirect costs include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">personnel-related expenses, consisting of employee salaries, bonuses, benefits, and stock-based compensation expense and
recruiting costs for personnel engaged in research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, and
equipment maintenance; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other unallocated research and development expenses incurred in connection with our research and development programs,
including laboratory materials and supplies and license fees. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expense research and development costs as incurred. <FONT
STYLE="white-space:nowrap">Non-refundable</FONT> advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are <FONT
STYLE="white-space:nowrap">performed.&nbsp;In-licensing</FONT> fees and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when
incurred.&nbsp;We track direct costs by stage of program, clinical or preclinical. However, we do not track indirect costs on a program specific or stage of program basis because these costs are deployed across multiple programs and, as such, are
not separately classified.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that our research and development expenses will substantially increase for the foreseeable future as we
continue the clinical development of&nbsp;SBT6050&nbsp;and discovery and development of our other and new product candidates, particularly as more of our product candidates moves into later stages of development later stage development typically
costs more. As of the date of this prospectus, we cannot reasonably determine the timing of initiation, the duration or the completion costs of future clinical trials and preclinical studies of product candidates due to the inherently unpredictable
nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which
product candidates and development programs to pursue and how much funding to direct to each product candidate or program on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory
developments and our ongoing assessments as to each product candidate&#146;s commercial potential. We will need to raise substantial additional capital in the future. In addition, we cannot forecast which product candidates may be subject to future
collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our future research and development costs may vary significantly based on a wide variety of factors, such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope, rate of progress, expense and results of our discovery and preclinical development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">per patient trial costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of trials required for approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of sites included in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the countries in which the trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the length of time required to enroll eligible patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of patients who participate in the trials, including the number needed to determine a recommended Phase 2 dose
for SBT6050; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of doses that patients receive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">the&nbsp;drop-out&nbsp;or</FONT> discontinuation rates of patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potential additional safety monitoring requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the duration of patient participation in the trials and <FONT STYLE="white-space:nowrap">follow-up;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the phase of development of the product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the efficacy and safety profiles of the product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing, receipt, and terms of any approvals from applicable regulatory authorities including the FDA and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product
candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">significant and changing government regulation and regulatory guidance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in
order to ensure that we or our third-party manufacturers are able to make product successfully; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the impact of any business interruptions to our operations or to those of the third parties with whom we work, particularly
in light of the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic environment; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we establish additional strategic collaborations or other arrangements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs
and timing associated with the development of that product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The process of conducting the necessary preclinical and clinical research to
obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors. We may never succeed in achieving regulatory approval for any of our product candidates.
Further, a number of factors, including those outside of our control, could adversely impact the timing and duration of our product candidates&#146; development, which could increase our research and development expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>General and Administrative </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">General and
administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses, benefits, and stock-based compensation, and recruiting costs for personnel in executive, finance, and other administrative functions.
Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, professional fees for accounting, tax and consulting services, insurance costs, travel expenses and facility related
expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that our general and administrative expenses will substantially increase for the foreseeable future as we continue to increase
our general and administrative headcount to support our continued research and development activities and, if any product candidates receive marketing approval, commercialization activities, as well as to support our operations generally. We also
expect to incur increased expenses associated with operating as a public company, including costs related to accounting, audit, legal, regulatory, <FONT STYLE="white-space:nowrap">and&nbsp;tax-related&nbsp;services</FONT> associated with maintaining
compliance with exchange listing and SEC requirements, director and officer insurance costs, and investor and public relations costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Change in Fair Value of
Redeemable Convertible Preferred Stock Purchase Option Liability </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As part of our Series A redeemable convertible preferred stock purchase
agreement, certain investors were granted an option to purchase up to 2,142,856 shares of additional Series A redeemable convertible preferred stock at a purchase price of $3.50 per share for a period of 180 days following the initial closing of
that financing. These preferred stock purchase options met the definition of freestanding instruments and were therefore recorded as a liability on our balance sheets at their fair value. The liability was revalued at each reporting period with
changes in its fair value recorded in our statements of operations and comprehensive loss as change in fair value of redeemable convertible preferred stock purchase option liability until its settlement in December 2018, at which time the final
liability balance was reclassified to redeemable convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Interest Income, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Interest income, net includes interest earned on our cash and cash equivalents carried at fair value, and interest expense on our borrowings.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comparison of the Years Ended December&nbsp;31, 2018 and 2019 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes our results of operations for the years ended December&nbsp;31, 2018 and 2019:</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Dollar</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,747</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of redeemable convertible preferred stock purchase option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Research and Development Expenses</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarized our research and development expenses for the years ended December&nbsp;31, 2018 and 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Dollar</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Direct costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SBT6050</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Preclinical programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total direct costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Indirect costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Personnel-related expenses, including stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Facility and equipment related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other unallocated research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Research and development expenses were $14.8&nbsp;million and $21.5&nbsp;million for the years ended December&nbsp;31,
2018 and 2019, respectively. The increase of $6.7&nbsp;million was due primarily to an increase of $5.7&nbsp;million of research and manufacturing expenses related to the development of SBT6050 as the program moved into the later stages of
preclinical development which typically have higher costs than earlier stages. To a lesser extent the increase was also due to increases in personnel-related expenses of $1.1&nbsp;million and facility and equipment related expenses of
$0.1&nbsp;million. These increases were, partially offset by decreases in other unallocated research and development expenses of $0.2&nbsp;million and preclinical programs of $0.1&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>General and Administrative Expenses</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">General and administrative expenses were $3.5&nbsp;million and $2.6&nbsp;million for the years ended December&nbsp;31, 2018 and 2019, respectively. The
decrease of $0.9&nbsp;million was due primarily to decreases of $0.8&nbsp;million in personnel-related expenses due to lower executive headcount in 2019, as well as decreasing severance, salaries, and stock-based compensation. To a lesser extent the
decrease in general and administrative expenses was due to a decrease in patent legal expenses of $0.3&nbsp;million, which was partially offset by an increase of $0.2&nbsp;million in consulting fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Change in Fair Value of Redeemable Convertible Preferred Stock Purchase Option Liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The change in the fair value of redeemable convertible preferred stock purchase option liability was $0.7&nbsp;million for the year ended
December&nbsp;31, 2018. The liability was settled in December 2018 upon issuance of shares of our Series A redeemable convertible preferred stock at which time the final liability balance was reclassified to redeemable convertible preferred stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Interest Income, Net </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Interest income,
net was $43,000 and $100,000 for the years ended December&nbsp;31, 2018 and 2019, respectively. The increase of $57,000 is primarily due to an increase in interest earned on our cash and cash equivalents due to changes in interest rates. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Sources of Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our inception, we have funded our operations almost exclusively with proceeds from the sale and issuance of shares of our redeemable convertible
preferred stock and debt financings, and we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital,&nbsp;developing and optimizing our technology platform, identifying potential
product candidates, undertaking research and preclinical studies and a clinical trial for our lead program, engaging in manufacturing for our development programs, establishing and enhancing our intellectual property portfolio, and providing general
and administrative support for these operations. From inception to December 31, 2019, we raised aggregate gross proceeds of $65.0 million from the issuance of shares of our redeemable convertible preferred stock and the issuance of convertible
notes. In March 2020, we issued 10,027,666 shares of our Series B redeemable convertible preferred stock for gross proceeds of $21.5&nbsp;million and 4,673,388 shares upon conversion of then outstanding convertible notes. In July 2020, we issued
10,669,834 additional shares of our Series B redeemable convertible preferred stock for gross proceeds of $23.0&nbsp;million. In September 2020, we issued 11,063,028 additional shares of our Series B redeemable convertible preferred stock for gross
proceeds of $23.9&nbsp;million and 24,926,685 shares of our Series C redeemable convertible preferred stock for gross proceeds of $84.9&nbsp;million. We do not have any products approved for sale and have not generated any revenue from product sales
or otherwise. We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. As of December&nbsp;31, 2019, we had $10.0&nbsp;million in cash and
cash equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Future Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our current operating plan, without giving effect to the anticipated net proceeds from this offering, we believe that our cash and cash
equivalents of $10.0&nbsp;million at December&nbsp;31, 2019 together with the net proceeds from our Series B and Series C redeemable convertible preferred stock financings received in 2020, will be sufficient to fund our operating expenses and
capital expenditure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
requirements through at least 12 months following the date of this prospectus. Further, based on our current operating plan, we estimate that our existing cash and cash equivalents as of the date
of this prospectus, together with the estimated net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months.
However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have
based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and
expenses in these trials is uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the initiation, trial design, progress, timing, costs and results of drug the discovery, preclinical studies and clinical
trials of our product candidates, and in particular the clinical trials for SBT6050; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number and characteristics of product candidates that we pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the length of our clinical trials, including, among other things, as a result of delays in enrollment, difficulties
enrolling sufficient subjects or delays or difficulties in clinical trial site initiations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the outcome, timing and costs of seeking FDA, EMA and any other regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of manufacturing our product candidates, in particular for clinical trials in preparation for marketing approval
and in preparation for commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of any third-party products used in our combination clinical trials that are not covered by such third party or
other sources; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs associated with hiring additional personnel and consultants as our preclinical, manufacturing and clinical
activities increase; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the receipt of marketing approval and revenue received from any commercial sales of any of our product candidates, if
approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of commercialization activities for&nbsp;any of our product candidates, if approved, including marketing, sales
and distribution costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the emergence of competing therapies and other adverse market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to establish and maintain strategic collaboration, licensing or other arrangements and the financial terms of
such agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other products and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the amount and timing of any payments we may be required to make pursuant to our current or future license agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims,
including litigation costs and the outcome of such litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our need and ability to retain key management and hire scientific, technical, business, and medical personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our implementation of additional internal systems and infrastructure, including operational, financial and management
information systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">or costs associated with expanding our facilities or building out our laboratory space; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effects of the recent disruptions to and volatility in the credit and financial markets in the United States and
worldwide from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of operating as a public company.</P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs through
public or private equity offerings, debt financings, or other capital sources which may include strategic collaborations, licensing arrangements or other arrangements with third parties. To the extent that we raise additional capital through the
sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common
stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring
dividends. If we raise funds through strategic collaborations or other similar arrangements with third parties, we may have to relinquish valuable rights to our platform technology, future revenue streams, research programs or product candidates or
may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce
or terminate our product development or future commercialization efforts. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial
markets in the United States and worldwide resulting from the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or otherwise. Because of the numerous risks and uncertainties associated with product development, we cannot predict the
timing or amount of increased expenses and cannot assure you that we will ever be profitable or generate positive cash flow from operating activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Cash
Flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth a summary of the net cash flow activity for the years ended December&nbsp;31, 2018 and 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net increase (decrease) in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,384</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2019, net cash used in operating activities was $18.9&nbsp;million. This consisted primarily of a net loss of
$24.0&nbsp;million, partially offset by a decrease in our operating assets and liabilities of $3.3&nbsp;million and <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.8&nbsp;million. The <FONT STYLE="white-space:nowrap">non-cash</FONT>
charges primarily consisted of <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense of $1.0&nbsp;million, depreciation expense of $0.5&nbsp;million, stock-based compensation expense of $0.2&nbsp;million, and amortization of debt issuance
costs of $0.1&nbsp;million. The decrease in our operating assets and liabilities was primarily due to an increase in accounts payable and accrued liabilities of $4.0&nbsp;million and a decrease in prepaid expenses and other assets of
$0.1&nbsp;million, partially offset by a decrease in our lease liability of $0.8&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2018, net cash used in operating activities was
$16.9&nbsp;million. This consisted primarily of a net loss of $17.6&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.1&nbsp;million and an increase in our operating assets and liabilities of
$0.4&nbsp;million.&nbsp;The <FONT STYLE="white-space:nowrap">non-cash</FONT> charges primarily consisted of <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense of $0.9&nbsp;million, depreciation expense of $0.5&nbsp;million, stock-based
compensation expense of $0.3&nbsp;million, and amortization of debt issuance costs of $0.1&nbsp;million, partially offset by the change in fair value of redeemable convertible preferred stock purchase option liability of $0.7&nbsp;million. The
increase in our operating assets and liabilities was due to a decrease in our lease liability of $0.7&nbsp;million and an increase in prepaid expenses and other assets of $0.3&nbsp;million, partially offset by an increase in accounts payable and
accrued liabilities of $0.5&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2019, cash used in investing activities was $0.1&nbsp;million due to purchases of property and equipment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2018, cash used in investing activities was $0.4&nbsp;million due to purchases of property and equipment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Financing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended
December&nbsp;31, 2019, cash provided by financing activities was $8.6&nbsp;million. This consisted primarily of net proceeds received from the issuance of our convertible notes of $10.0&nbsp;million, which was partially offset by principal payments
on term loan payable of $1.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2018, cash provided by financing activities was
$19.4&nbsp;million.&nbsp;This consisted primarily of net proceeds received from the issuance of shares of our redeemable convertible preferred stock of $20.0&nbsp;million and from proceeds from exercises of stock options of $0.3&nbsp;million, which
was partially offset by principal payments on term loan payable of $0.9&nbsp;million. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes our contractual obligations and commitments at December&nbsp;31, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">1-3</FONT><BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">3-5</FONT><BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease obligations<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Term loan payable<SUP STYLE="font-size:85%; vertical-align:top">(1),(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Refer to Notes 6 and 7 to our audited financial statements included elsewhere in this prospectus for additional
information. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Payments due for the term loan include both principal and interest portions calculated using the interest rate at
December&nbsp;31, 2019 of 1.75%. The contractual payments in the table above reflect the second amendment entered into in April 2020 as discussed further below. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under our license agreements, we have payment obligations that are contingent upon future events such as our achievement of specified development,
regulatory and commercial milestones and are required to make royalty payments in connection with the sales of products developed under those </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
agreements. As of December&nbsp;31, 2019, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales and, therefore, any related payments are
not included in the table above. For additional details regarding these agreements, see the section of this prospectus titled &#147;Business&#151;License Agreements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2016, we entered into a loan and security agreement with SVB that allowed borrowings up to $5.0&nbsp;million in two tranches, the first that
was immediately drawn and the second to be drawn before December&nbsp;31, 2017 if certain financing milestones were met. We drew $3.5&nbsp;million in the first tranche, and the second tranche expired undrawn. The outstanding principal amount of the
term loan accrues interest at an annual rate of 1.75% per annum. At closing, we incurred de minimis debt issuance costs and owed a final payment fee of $0.3&nbsp;million, both of which are amortized to interest expense over the remaining term of the
debt under the effective interest method. The effective interest rate of our term loan is 5.14%. In April 2020, SVB amended our term loan to defer principal payments for six months and extend the maturity date to May&nbsp;1, 2021, which we
determined to be a debt modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2019, we issued convertible promissory notes for gross proceeds of $10.0&nbsp;million. The notes
were unsecured, bore an interest rate of 3% per year, and had a maturity date of March&nbsp;31, 2020. In March 2020, these notes converted into 4,673,388 shares of our Series B redeemable convertible preferred stock at the Series B redeemable
convertible preferred stock issuance price of $2.16 per share. There was no settlement in the form of cash payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2019, we entered
into a cell line license agreement with WuXi Biologics (Hong Kong) Limited (WuXi Bio), pursuant to which we received a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, sublicensable license under certain of WuXi Bio&#146;s
intellectual property rights, <FONT STYLE="white-space:nowrap">know-how</FONT> and biological materials (the WuXi Bio Licensed Technology) to make, use, sell, offer for sale and import developed through the use of the WuXi Bio Licensed Technology
(the WuXi Bio Licensed Product). In consideration for the license, we paid a low six figures license fee to WuXi Bio which was recorded in research and development expense in 2019. We may be required to pay an additional license fee in the mid five
figures if we manufacture one or more additional WuXi Bio Licensed Products. Additionally, if we do not engage WuXi Bio to manufacture the WuXi Bio Licensed Products for our clinical and commercial supplies, we are required to make aggregate
milestone payments of up to an amount in the low eight figures to WuXi Bio upon the achievement of certain sales milestones. To date, other than the license fee, no payments have been made under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We enter into contracts in the normal course of business with clinical supply manufacturers and with vendors for preclinical studies, research supplies
and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included in the table above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our inception, we have not engaged in any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined in the rules and
regulations of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our management&#146;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have
been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued
expenses, stock-based compensation, and valuation allowances for deferred tax assets. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While our significant accounting policies are described in more detail in Note 2 to our audited financial statements included elsewhere in this
prospectus, we believe the following accounting policies and estimates to be most critical to the preparation of our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Research and
Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All research and development costs are expensed in the period incurred. Advance payments, including nonrefundable
amounts, for goods or services that will be used or rendered for future research and development activities are capitalized until such goods are delivered or the related services are performed, or such time when we do not expect the goods to be
delivered or services to be performed. We estimate the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, we will
adjust the amounts recorded accordingly. We have not experienced any material differences between accrued or prepaid costs and actual costs since our inception. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We maintain a stock-based
compensation plan as a long-term incentive for our employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants. The plan allows for the issuance of incentive stock options,
<FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, restricted stock units, and other forms of equity awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We recognize
stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as a reduction of stock-based compensation expense as they occur. Our stock-based compensation costs are based
upon the grant date fair value of options estimated using the Black-Scholes option pricing model. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is
determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized, and any previously recognized compensation expense is reversed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of
any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
option plan permits, but does not require, the inclusion of early exercise provisions in individual awards. Proceeds from early option exercises are recorded as a liability until the underlying restricted shares vest. While the restricted shares
have voting rights, they are not considered outstanding for accounting purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Black-Scholes option pricing model utilizes inputs which are
highly subjective assumptions and generally require significant judgment. These assumptions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Fair Value of Common Stock</I>. See the subsection titled &#147;&#151;Common Stock Valuations&#148; below.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Expected Term</I>. The expected term represents the period that the options granted are expected to be outstanding. The
expected term of stock options issued is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term) as we have concluded that our stock option
exercise history does not provide a reasonable basis upon which to estimate expected term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Expected Volatility</I>. Given that our common stock is privately held, there is no active trading market for our common
stock. We derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within our peer group that were deemed to be representative of future
stock price trends as we have limited trading history for our common stock. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>R</I><I><FONT STYLE="white-space:nowrap">isk-Free</FONT> Interest Rate</I>. The risk-free interest rate is based on the
U.S. Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> issues in effect at the time of grant for periods corresponding with the expected term of the options. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Expected Dividend Yield</I>. We have never paid dividends on our common stock and do not anticipate paying any dividends
in the foreseeable future. Therefore, we used an expected dividend yield of zero. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">See Note 10 to our audited financial statements
included elsewhere in this prospectus for more information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options. Certain of such
assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation could be materially
different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We recorded stock-based compensation expense of $0.3&nbsp;million and $0.1&nbsp;million for the years ended December&nbsp;31, 2018 and
2019, respectively. As of December&nbsp;31, 2019, there was $0.3&nbsp;million of total unrecognized stock-based compensation expense related to unvested stock options which we expect to recognize over a remaining weighted-average period of 2.7
years. We expect to continue to grant stock options and other equity-based awards in the future, and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The intrinsic value of all outstanding options as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2020 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million based on the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus), of which approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million was related to vested options and approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million was related to unvested options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Common Stock Valuations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Historically, for all periods prior to this offering, since there has been no public market of our common stock to date, the fair value of the shares of
common stock underlying our share-based awards was estimated on each grant date by our board of directors. To determine the fair value of our common stock underlying option grants, our board of directors considered, among other things, input from
management, valuations of our common stock prepared by unrelated third-party valuation firms in accordance with the guidance provided by the American Institute of Certified Public Accountants 2013 Practice Aid,<I>&nbsp;Valuation of
Privately-Held-Company Equity Securities Issued as Compensation</I> (the Practice Aid), and our board of directors&#146; assessment of additional objective and subjective factors that it believed were relevant, and factors that may have changed from
the date of the most recent valuation through the date of the grant. These factors include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our results of operations and financial position, including our levels of available capital resources;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our stage of development and material risks related to our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">progress of our research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our business conditions and projections; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of marketability of our common stock and our redeemable convertible preferred stock as a private company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prices at which we sold shares of our redeemable convertible preferred stock to outside investors in arms-length
transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rights, preferences, and privileges of our redeemable convertible preferred stock relative to those of our common
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the likelihood of achieving a liquidity event for our securityholders, such as an initial public offering or a sale of our
company, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the hiring of key personnel and the experience of management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">trends and developments in our industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">external market conditions affecting the life sciences and biotechnology industry sectors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For our valuations performed in 2019 and 2020, in accordance with the Practice Aid, we determined the hybrid method of the option pricing method (OPM)
and the Probability-Weighted Expected Return Method (PWERM) was the most appropriate method for determining the fair value of our common stock based on our stage of development and other relevant factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The OPM uses option theory to value the various classes of a company&#146;s securities in light of their respective claims to the enterprise value.
Total shareholders&#146; equity value is allocated to the various share classes based upon their respective claims on a series of call options with strike prices at various value levels depending upon the rights and preferences of each class. A
Black-Scholes closed form option pricing model is employed in this analysis, with an option term assumption that is consistent with the expected time to a liquidity event and a volatility assumption based on the estimated stock price volatility of a
peer group of comparable public companies over a similar term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The PWERM values each class of equity based on an analysis of the range of potential
future enterprise values of the company and the manner in which those values would accrue to the owners of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the different classes of equity. This method involves estimating the overall value of the subject company under various liquidity event scenarios and allocating the value to the various share
classes based on their respective claim on the proceeds as of the date of each event. These different scenarios typically include an initial public offering, an acquisition, or a liquidation of the business, each resulting in a different value. For
each scenario, the future value of each share class is calculated and discounted to a present value. The results of each scenario are then probability weighted in order to arrive at an estimate of fair value for each share class as of a current
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The hybrid method is a hybrid between the PWERM and OPM, estimating the probability-weighted value across multiple scenarios, but using the
OPM to estimate the allocation of value within one or more of the scenarios. In our hybrid method, two types of future event scenarios were considered: an initial public offering (IPO) and a merger or acquisition of our company (M&amp;A). Under both
scenarios, the enterprise value was determined at each valuation date using a combination of the cost approach; the income approach, specifically a discounted cash flow analysis; and the market approach, specifically a backsolve to the last round of
financing. The relative probabilities between the future exit scenarios were determined by our board of directors based on an analysis of performance and market conditions at the time, including then current IPO valuations of similarly situated
companies and expectations as to the timing and likely prospects of future event scenarios. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The assumptions underlying these valuations represented
management&#146;s best estimates, which involved inherent uncertainties and the application of management&#146;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common stock and our
stock-based compensation expense could have been materially different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the closing of this offering, our board of directors will
determine the fair market value of our common stock based on its closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We recognize deferred income taxes for
the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards.&nbsp;In evaluating our
valuation allowance, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance. Due to our lack of
earnings history and uncertainties surrounding our ability to generate future taxable income, the net deferred tax assets have been fully offset by a valuation allowance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019, we had net operating loss carryforwards for income tax purposes of approximately $59.9&nbsp;million. If not used,
$18.2&nbsp;million of this carryforward will begin to expire in 2036 and $41.7&nbsp;million has no expiration. We also have research and development tax credits of approximately $0.9&nbsp;million which will begin to expire in 2036 if left unused.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under Sections 382 and 383 of the Code, substantial changes in our ownership may limit the amount of NOL and research and development credit
carryforwards that could be used annually in the future to offset taxable income. The tax benefits related to future utilization of federal and state NOL carryforwards, credit carryforwards, and other deferred tax assets may be limited or lost if
cumulative changes in ownership exceeds 50% within any three-year period. We have not completed a Section&nbsp;382/383 analysis under the Code regarding the limitation of NOL and credit carryforwards. If a change in ownership were to have occurred,
the annual limitation may result in the expiration of NOL carryforwards and credits before utilization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019, we did not have any liabilities for unrecognized income tax benefits
associated with uncertain tax positions, including any interest and penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">See Note 2 to our audited financial statements included elsewhere in this prospectus for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Interest
Rate Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019, we had cash and cash equivalents of $10.0&nbsp;million, $10.0&nbsp;million of convertible notes and
a term loan payable of $1.5&nbsp;million. As of December&nbsp;31, 2018 and 2019, our cash equivalents consisted of money market funds. Our exposure to interest rate risk from these assets and liabilities is not significant and we believe a
hypothetical 100 basis point increase or decrease in interest rates during any of the periods presented would not have had a material impact on our financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Effects of Inflation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Inflation generally affects us
by increasing our cost of labor and research, manufacturing and clinical development costs. We believe that inflation has not had a material effect on our financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Foreign Currency Exchange Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of our employees
and our operations are currently located in the United States and our expenses and payment obligations are denominated in and have been satisfied with U.S. dollars. There was no material foreign currency risk for the years ended December&nbsp;31,
2018 or 2019. However, we have and will continue to enter into contracts with vendors outside of the United States for research and development services. In the future, some of these contracts may be denominated in foreign currencies and to the
extent they are, we will be subject to foreign currency transaction gains or losses. To date, we have had no foreign currency transaction gains and losses, and we have not had a formal hedging program with respect to foreign currency. We believe a
hypothetical 100 basis point increase or decrease in exchange rates during any of the periods presented would not have a material effect on our financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging Growth Company Status </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an emerging growth
company, as defined in the JOBS Act, and we may remain an emerging growth company for up to five years following the completion of this offering. For so long as we remain an emerging growth company, we are permitted and intend to rely on certain
exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&nbsp;404 of the
Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden
parachute payments not previously approved. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation-related information that would be required if we
were not an emerging growth company. Accordingly, the information contained </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
herein may be different than the information you receive from other public companies in which you hold stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act
until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies
until the earlier of the date that we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be
comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will remain an
emerging growth company until the earliest to occur of: (i)&nbsp;the last day of the fiscal year in which we have at least $1.07&nbsp;billion in annual revenue; (ii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large
accelerated filer,&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, which would occur if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded
$700.0&nbsp;million as of the last business day of the second fiscal quarter of such year; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt securities during the prior three-year period; and
(iv)&nbsp;the last day of the fiscal year ending after the fifth anniversary of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a clinical-stage biopharmaceutical company
focused on leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to
strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are applying our platform to create a new class of targeted immuno-oncology
agents that direct a myeloid cell activator to the tumor microenvironment (TME) in solid tumors to promote cancer cell killing. Our lead product candidate, SBT6050, is comprised of a TLR8 linker-payload conjugated to a HER2-directed monoclonal
antibody that targets tumors such as certain breast, gastric and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancers, among others. SBT6050 is currently in a Phase 1/1b clinical trial in patients with advanced or metastatic
HER2-expressing solid tumors. In this trial, we have observed single agent pharmacological activity in the first dose cohort, and we anticipate providing an update on interim data from the Phase 1 dose-escalation cohorts in the second half of 2021.
SBT6290 is our second product candidate, expanding on the potential of a TLR8 agonist as a payload. SBT6290 is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in certain bladder, triple negative
breast, head and neck, and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancers. We anticipate submitting an investigational new drug application (IND) for SBT6290 in the fourth quarter of 2021. Our third TLR8 program, SBT8230, is
comprised of a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection (cHBV). We are also developing agents that localize therapies to modulate important
pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our ImmunoTAC Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ImmunoTAC platform is the result of a focused effort to discover ways to systemically deliver disease-modifying small molecules in a directed fashion
to sites of disease. Many potentially promising systemic therapies fail to maximize their therapeutic potential due to toxicities in healthy tissues. Our approach is designed to increase the therapeutic window and avert unacceptable toxicities by
directly targeting specific disease sites where our therapeutics are locally active. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown in the figure below, our ImmunoTAC platform is
comprised of three components: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Antigen binding domain</B>&#151;which is responsible for localizing the therapeutic activity of the payload to the
site of the disease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Linker</B>-<B>payload</B>&#151;a disease-modifying small molecule optimized for potency when conjugated to a
monoclonal antibody via its linker; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Fc region</B>&#151;tuned for requisite effector function. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have built a library of proprietary small molecule linker-payloads and antigen binding domains that allows us to mix and match these components to strategically pair
and create new therapeutic agents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Our ImmunoTAC Platform Strategically Pairs Antigen Binding Domains with Linker-Payloads to
Modulate Pathways Underlying <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Difficult-to-Treat</FONT></FONT> Diseases </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g02k15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Development Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ImmunoTAC platform drives our pipeline of tissue targeted therapeutic candidates as summarized in the chart below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g09g06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Tumor-Localized Myeloid Cell Activation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Myeloid cells are a class of innate immune cells that develop from common monocyte-dendritic cell progenitor cells and are comprised of both
immunosuppressive and <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> subpopulations. Tumors are permeated with myeloid cells, which can comprise between 5% and 10% of the tumor. Activation of myeloid cells, either by reprogramming
immunosuppressive myeloid cells </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
towards a more <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> phenotype or stimulating other myeloid cells that have been silenced (e.g., dendritic cells), results in direct tumor
killing and recruitment of immune cells. Further, activated myeloid cells can prime and amplify T cell and natural killer (NK) cell responses, bridging the innate and adaptive immunity to elicit broad, durable anti-tumor responses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>SBT6050 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our lead product candidate, SBT6050, is
comprised of a TLR8 linker-payload conjugated to a HER2-directed monoclonal antibody and is designed to activate myeloid cells in tumors expressing moderate or high levels of HER2. TLR8 is expressed in myeloid cell types prevalent in human tumors
and TLR8 agonism can activate a broad spectrum of anti-tumor immune mechanisms. Therefore, we believe that TLR8 is the optimal target for activating human myeloid cell types in the TME. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">SBT6050 utilizes HER2 to localize and facilitate the delivery of the TLR8 agonist conjugate into myeloid cells in the TME. Therefore, unlike HER2
targeted therapies that have been approved by the U.S. Food and Drug Administration (FDA) such as Herceptin (trastuzumab), SBT6050 does not require HER2 to be an oncogenic driver to elicit anti-tumor activity. Furthermore, SBT6050 recognizes the
HER2 <FONT STYLE="white-space:nowrap">sub-domain</FONT> II, the pertuzumab epitope, and does not cross-block trastuzumab, allowing for potential combinations with trastuzumab-based agents, which are standard of care therapies in some HER2-expressing
cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently evaluating the safety and tolerability of SBT6050 in a Phase 1 dose-escalation trial in patients with advanced or
metastatic HER2-expressing solid tumors. Single agent pharmacological activity has been observed in the first dose-escalation cohort of this trial. We anticipate providing an update on interim data from the Phase 1 dose-escalation cohorts in the
second half of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>SBT6290 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">SBT6290 is our
second product candidate, expanding on the potential of a TLR8 agonist as a payload. The same TLR8 linker-payload used in SBT6050 is conjugated to a monoclonal antibody that targets Nectin4. Nectin4 is expressed in subsets of solid tumors including
bladder, triple negative breast, head and neck, and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancers, and has been clinically validated through the approval of the antibody-drug conjugate enfortumab vedotin (Padcev). We anticipate
submitting the IND for SBT6290 in the fourth quarter of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>SBT8230 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">SBT8230, an ASGR1-TLR8 ImmunoTAC therapeutic, is our third TLR8 program. SBT8230 is engineered to potently activate human myeloid cells in the liver for
the treatment of cHBV. Selgantolimod <FONT STYLE="white-space:nowrap">(GS-9688),</FONT> an existing untargeted, orally administered TLR8 agonist being developed by Gilead Sciences, generated anti-viral immune responses in a cHBV animal model. The
clinical development of this untargeted TLR8 agonist has shown promise, but we believe that toxicity prevented the use of a sufficient dose to elicit optimal clinical activity. We believe liver- localized TLR8 agonism could better realize the
potential for effective therapy and potentially lead to functional cures in patients suffering from cHBV. We anticipate selecting a development candidate for this program in the fourth quarter of 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Additional Immuno-Oncology Programs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to
SBT6050 and SBT6290, we are evaluating other solid tumor targets to leverage the TLR8 linker-payload paired with additional tumor directed antibodies. These targets are differentially expressed on tumors compared to normal tissue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>ASGR1-TGF&szlig; Receptor&#151;Fibrosis Program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">TGF&szlig; signaling is a key mediator of fibrosis across multiple organ systems, including the liver. In the liver, TGF&szlig; drives fibrosis
initiation and progression through multiple mechanisms, including hepatocyte apoptosis, hepatic stellate cell transdifferentiation to myofibroblasts, and <FONT STYLE="white-space:nowrap">pro-fibrotic</FONT> macrophage activation. Our <FONT
STYLE="white-space:nowrap">ASGR1-TGF&szlig;R1</FONT> antagonist conjugate pairs the ASGR1 antibody used in SBT8230 with a proprietary TGF&szlig;R1 antagonist to achieve liver-localized inhibition of TGF&szlig; signaling to treat fibrosis. Our
tissue-directed approach has been designed to prevent toxicities associated with untargeted systemically distributed TGF&szlig;R1 antagonist agents. Our <FONT STYLE="white-space:nowrap">ASGR1-TGF&szlig;R1</FONT> antagonist conjugates are currently
in preclinical testing and have demonstrated potent inhibition of TGF&szlig; signaling <I>in vitro</I>. We are currently evaluating conjugates <I>in vivo</I> in mouse disease models. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our goal is to transform the treatment of
cancer and other serious diseases with unmet need using our ImmunoTAC platform to deliver a new class of systemically delivered, tissue-directed, and locally active therapies. The key elements of our business strategy are to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Advance SBT6050 through development and seek expedited approval</I></B><B>. </B>We are pursuing clinical development
strategies that demonstrate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> early and capitalize on the potential for accelerated approval. We are evaluating activity broadly across HER2-expressing
cancer types, including cancers where no HER2-directed therapies are currently approved, and have identified several tumor types and lines of therapy that potentially present opportunities for accelerated approval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Advance SBT6050 into earlier lines of therapy. </I></B>Our long-term clinical development goal is to position SBT6050
in early-line standard of care regimens in key indications to benefit the greatest number of patients. We seek to accomplish this by evaluating combination therapy approaches with therapeutics approved as standard of care. We believe SBT6050 has the
potential to be an ideal combination therapy in early line settings. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Maximize the therapeutic potential of TLR8</I></B><B> </B><B><I>in oncology and other serious diseases</I></B><B>.
</B>We are adapting learnings from our SBT6050 program to expand the TLR8 agonist franchise by conjugating this payload to antibodies that target different tumor antigens that are prevalent in other cancer types. Additionally, the ability to drive
myeloid cell activation in the liver presents an opportunity to treat cHBV infections, which is our most advanced initiative outside of immuno-oncology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Leverage our ImmunoTAC platform for promising new antibody-linker-payload combinations</I></B><B>.</B> We are
strategically pairing our disease-modulating payloads with tissue targeted antibodies, such as our <FONT STYLE="white-space:nowrap">ASGR1-TGF&szlig;R1</FONT> antagonist conjugate, to create new therapeutic agents with the goal of providing benefits
to patients who suffer from cancer and other serious diseases. We plan to continue to leverage our ImmunoTAC platform, discovery of targeted binding proteins (including antibodies), and efficient therapeutic discovery infrastructure to discover and
develop novel small molecule therapeutics and ImmunoTAC conjugates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Evaluate opportunities to accelerate development timelines and/or enhance the commercial potential of our programs in
partnership with third parties</I></B>. We plan to selectively explore potential strategic partnerships on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis with biopharmaceutical partners
whose research, development, commercial, and/or geographic capabilities complement our own. We believe strategic partnerships can help mitigate clinical and commercial risk, accelerate timelines, and/or maximize global commercial potential.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Team and Investors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have assembled an accomplished management team with a proven track record of therapeutic development expertise and of generating meaningful
shareholder value. The members of our team have deep experience in discovering, developing, and commercializing therapeutics with a particular focus on cancer, having worked at companies such as Synthorx (acquired by Sanofi), Juno Therapeutics
(acquired by Celgene), Cascadian Therapeutics (acquired by Seattle Genetics), Acerta Pharma (acquired by AstraZeneca), Ignyta (acquired by Roche), Roche/Genentech, Seattle Genetics, SUGEN (acquired by Pharmacia), and Trubion Pharmaceuticals
(acquired by Emergent Biosolutions). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since our inception in 2016, we have raised over $215&nbsp;million in capital from leading investors including
OrbiMed Advisors, Alexandria Venture Investments, Boxer Capital of Tavistock Group, Celgene, Colt Ventures, EcoR1 Capital, Fidelity, Hunt Technology Ventures, Nantahala Capital Management, Nextech Invest, Pontifax, RA Capital, and U.S. Venture
Partners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Lead Product Candidate SBT6050: TLR8 Agonist Conjugated to a HER2 Antibody </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">SBT6050 is our lead product candidate, engineered using our ImmunoTAC platform. SBT6050 is comprised of a TLR8 agonist conjugated to a HER2-directed
monoclonal antibody and is designed for subcutaneous delivery with tumor-localized activation of myeloid cells. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Background and Our Approach in Addressing
Limitations with Current Immuno-oncology Therapies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Checkpoint inhibitors (CPIs) such as a programmed death
<FONT STYLE="white-space:nowrap">receptor-1</FONT> <FONT STYLE="white-space:nowrap">(PD-1)</FONT> and <FONT STYLE="white-space:nowrap">CTLA-4</FONT> blockers have emerged as important foundational immuno-oncology therapies because of their ability
to generate durable responses in some patients in previously intractable cancers improving the overall survival. Despite the significant benefit for patients with durable responses to CPIs, most patients unfortunately do not respond or have limited
benefit. One of the important reasons why patients do not respond to CPIs is the absence of a sufficient number of T cells within the tumor. To achieve an anti-tumor response with a CPI, a baseline level of T cells must already be present in the
tumor. Scientists and clinicians have termed tumors that lack the requisite T cell levels as &#147;immune cell deserts&#148; or &#147;cold tumors,&#148; but more accurately, these are &#147;T cell deserts.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Solid tumors, including those resistant to T cell targeted immunotherapy such as <FONT STYLE="white-space:nowrap">PD-1</FONT> and <FONT
STYLE="white-space:nowrap">CTLA-4</FONT> blockers, are permeated with myeloid cells, which can comprise between 5% and 10% of the tumor&#151;at least twice the number of T cells in the TME. Myeloid cells are a class of innate immune cells comprised
of both immunosuppressive and <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> subpopulations. Activation of myeloid cells, either by reprogramming immunosuppressive myeloid cells towards a more
<FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> phenotype or stimulating other myeloid cells that have been silenced (e.g., dendritic cells), results in direct tumor killing and recruitment of immune cells. Further, activated myeloid cells
can prime and amplify T cell and NK cell responses, bridging the innate and adaptive immunity to elicit broad, durable anti-tumor responses. Successful activation of myeloid cells can lead to anti-tumor immunity, even in tumors that are refractory
to immune checkpoint blockade, which we believe may bring substantial benefit to a larger fraction of patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We designed SBT6050 to potently
activate the myeloid cell compartment in the TME. We performed a thorough assessment of innate immune receptors with the goal of identifying a payload target that was well expressed in human myeloid cells. We believe TLR8 is unique in its breadth of
expression across human myeloid cell subpopulations and its restricted expression to the myeloid cell lineage. In consideration of internally generated data and emerging external research on human myeloid cell biology, we selected TLR8 as the best
payload target for activation of myeloid cells resulting in direct tumor killing and recruitment and activation of additional immune cells, such as T cells and NK cells, to further effect the anti-tumor response. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Activating the Myeloid Cell Compartment Through TLR8 Agonism </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Myeloid cells develop from common monocyte-dendritic cell progenitor cells and are critical mediators of innate immune responses. These cells are plastic
in nature and their function and phenotype are heavily influenced by environmental cues. In the TME and tumor draining lymph nodes, macrophages, conventional dendritic cells, myeloid derived suppressor cells, and monocytes are highly prevalent, but
also skewed towards inactive or immunosuppressive states. We believe TLR8 is the optimal target for activating these myeloid cell types due to its restricted expression and function within these cells. As shown in the figure below, TLR8 activation
of human myeloid cells elicits an anti-tumor response through a multi-pronged mechanism of action, including direct tumor cell killing, recruitment of immune cells, and the secondary activation of NK cells, T cells and B cells, thus driving both an
innate and adaptive immune response against the tumor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>TLR8 is Highly Expressed in Human Myeloid Cell Types That Drive Anti-Tumor Responses
When Activated </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g40t57.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a result of the broad immune activation triggered by a TLR8 agonist, systemically administered but untargeted TLR8
small molecule therapeutic candidates from other companies have resulted in an adverse event profile that we believe has limited achieving a dose level sufficient to produce the desired therapeutic benefit. For example, VentiRx licensed motolimod, a
TLR8 small molecule agonist originally developed by Array Biopharma. Motolimod was the first TLR8 specific agonist tested in the clinic for the treatment of solid tumors. Early trials of subcutaneously administered motolimod yielded adverse events
we believe to be consistent with broad myeloid cell activation in the periphery, including injection site reactions and symptoms associated with systemic cytokine release, which limited dose-escalation. As a result, we believe that sufficient drug
exposures in the TME were not reached to elicit meaningful anti-tumor activity. Similarly, Gilead Sciences is developing an orally administered TLR8 agonist for the treatment of cHBV. This therapeutic has resulted in adverse events consistent with
myeloid cell activation in the gastrointestinal tract, including diarrhea and nausea. We believe these two cases support our hypothesis that tissue directed, localized activation is critical to maximizing the therapeutic potential of a TLR8 agonist.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The selection of TLR8 as the optimal target to activate myeloid cells without activating other cell types outside of the hematopoietic lineage is
supported by both external research and internal data. TLR8 was selected after bioinformatic and functional assessments of several innate immune receptor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
targets. Intracellular localization and robust expression in myeloid cell compartments, with limited expression in <FONT STYLE="white-space:nowrap">non-immune</FONT> FcR positive cells, were also
key criteria in our payload selection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown in figure A below, unlike other intracellular innate immune receptors, TLR8 is highly expressed in
human myeloid cell types, including conventional dendritic cells and macrophages. Conversely, as shown in figure B below, TLR8 is not expressed in fibroblasts and endothelial cells and we believe this restricted expression will reduce the risk of
toxicities due to <FONT STYLE="white-space:nowrap">on-target,</FONT> <FONT STYLE="white-space:nowrap">off-cell</FONT> activation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>TLR8&#146;s
Expression is Restricted to Human Myeloid Cells </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g80a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the identification of TLR8 as the optimal receptor to activate myeloid cells in the TME, we designed and
created a library of TLR8 agonists. Our proprietary TLR8 agonists were evaluated in the format of HER2 antibody conjugates for their ability to activate myeloid cells <I>ex vivo</I>. Within this library, we identified a HER2 antibody-TLR8 conjugate
that activated myeloid cells in moderate and high HER2 settings as is found in HER2-expressing tumors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Tissue Directed and Localized Activation Through HER2 Expression </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many solid tumors, including those expressing HER2, are refractory to immunotherapy due to minimal T cell infiltrates. As shown in the figures below,
HER2-expressing tumors (stained in blue, left panel) frequently contain abundant populations of tumor-associated myeloid cells which express TLR8 (stained in yellow, right panel). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>HER2-Expressing Tumors and TLR8-Expressing Myeloid Cells are Adjacent in the Human TME </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g67046g81b11.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g67046g82c34.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">HER2 is an optimal marker to direct therapies like TLR8 agonist conjugates due to its differential expression between
tumors and healthy tissue. Furthermore, HER2 expression is prevalent in meaningfully large patient <FONT STYLE="white-space:nowrap">sub-populations</FONT> in a wide variety of tumor types including breast, gastric,
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung, colorectal, bladder, uterine, pancreatic, head and neck, ovarian, esophageal, and gallbladder cancers, providing the potential to address a large HER2-expressing tumor agnostic market
estimated to be more than 160,000 newly-diagnosed patients annually in the United States based in part on estimated prevalence rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown in
the figure below, the SBT6050 potential mechanism of action is outlined sequentially as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">SBT6050 is administered systemically through subcutaneous injection. Systemic dosing is essential to access myeloid cells
in both primary lesions and metastatic lesions, and in secondary lymphoid organs, to result in productive and durable anti-tumor responses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">SBT6050 is directed to tumors expressing HER2 and the TME, which is permeated with myeloid cells that express Fc<FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT> receptors on their cell surface, and TLR8 within endosomes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Upon <FONT STYLE="white-space:nowrap">co-engagement</FONT> of the HER2 protein on the tumor and Fc<FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT> receptors on the myeloid cell, SBT6050 is designed to be internalized by the myeloid cell into the endo-lysosomal compartment once there is a sufficient
increase in avidity, which is provided by HER2 binding on the tumor cell. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">SBT6050&#146;s TLR8 linker-payload engages TLR8 present in the endosomes of myeloid cells, which in turn drives
activation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Potential Mechanism of Action: SBT6050 is Designed to Localize TLR8 Activation of Myeloid Cells
in Tumors via a HER2-Directed Antibody </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g83q94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Preclinical Development of SBT6050 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our preclinical studies have shown the potential for SBT6050 to activate innate and adaptive anti-tumor responses in the TME and demonstrate anti-tumor
activity as a single agent and in combination with standard of care agents such as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and trastuzumab-based therapies in HER2-expressing solid tumors. Highlights
of our preclinical work using SBT6050 <I>in vitro </I>and <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> (our mouse surrogate) <I>in vivo </I>via subcutaneous delivery demonstrated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Potent activation of multiple anti-tumor immune mechanisms induced in the presence of HER2-expressing tumor cells.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Equipotent immune cell activation in settings of moderate and high HER2 expression. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Curative activity as a single agent in a xenograft model lacking T cells and B cells, and deficient in NK cells,
highlighting the potential of myeloid cell activation alone to mediate robust tumor cell killing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Potent single agent activity in tumor models with low tumor infiltrating lymphocytes, highlighting the potential for
clinical activity in tumors displaying immune evasive characteristics. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Anti-tumor responses upon tumor <FONT STYLE="white-space:nowrap">re-challenge</FONT> without additional dosing,
highlighting the potential for durable effects through the activation and expansion of tumor antigen-specific T memory cells. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Enhanced anti-tumor activity when used in combination with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy in a <FONT STYLE="white-space:nowrap">CPI-refractory</FONT> mouse tumor model. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Enhanced anti-tumor activity when used in combination with trastuzumab in a mouse tumor model. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Collectively, these data supported our decision to clinically evaluate the anti-tumor activity of SBT6050 as a single agent and in combination with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and trastuzumab-based therapeutics in relevant HER2-expressing tumor types. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>SBT6050 In Vitro Preclinical Data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In our <I>in vitro</I> studies, SBT6050 potently activated human myeloid cell types, including macrophages, dendritic cells, and monocytes. This
activation resulted in the induction of multiple myeloid cell effector functions, including the production of cytokines and chemokines that are critical to the generation of anti-tumor immune responses. In addition, SBT6050 activation of myeloid
cells <I>in vitro</I> resulted in the subsequent, indirect activation of NK cells and T cells. In our <I>in vitro</I> studies, SBT6050 also mediated antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity. Further, TLR8
agonism drove the downmodulation of SIRP<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>, highlighting the potential to block the CD47-SIRP<FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT> pathway. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In our <I>in vitro </I>studies, human peripheral blood mononuclear cells (PBMC) were <FONT
STYLE="white-space:nowrap">co-cultured</FONT> with HER2<SUP STYLE="font-size:85%; vertical-align:top">pos</SUP> or HER2<SUP STYLE="font-size:85%; vertical-align:top">neg</SUP> tumor cell lines in the presence of SBT6050. As shown in the figures
below, SBT6050 potently induced multiple anti-tumor immune activities, including general activation of myeloid cells as measured by <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokine and chemokine production (TNF<FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>), direct activation of dendritic cells <FONT STYLE="white-space:nowrap">(IL-12p40),</FONT> and inflammasome activation
<FONT STYLE="white-space:nowrap">(IL-18)</FONT> in the presence of HER2<SUP STYLE="font-size:85%; vertical-align:top">pos</SUP> tumor cells. No activation was seen when SBT6050 was <FONT STYLE="white-space:nowrap">co-cultured</FONT> with HER2<SUP
STYLE="font-size:85%; vertical-align:top">neg</SUP> cells. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>SBT6050 Activated Myeloid Cells in the Presence of HER2<SUP
STYLE="font-size:85%; vertical-align:top">pos</SUP> Tumors </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g11i22.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g22e33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Similar <I>in vitro </I>studies using PBMCs were conducted to compare SBT6050 with conjugates that contain a TLR7
agonist, resiquimod or a resiquimod variant payload that were designed to mimic competitor molecules. Of note, the EC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> of the free, unconjugated TLR7 small molecule agonist was 9 nM on a TLR7
reporter line and no activity was observed on a TLR8 reporter line. The EC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> of unconjugated resiquimod on TLR7 was ~700 nM and &gt;3 &micro;M on TLR8, demonstrating that resiquimod is a weak
TLR8 agonist. The resiquimod variant was of slightly better potency compared to resiquimod. As shown in the figures below, in these internal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> studies SBT6050
demonstrated a superior ability to induce TNF<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>, <FONT STYLE="white-space:nowrap">IL-12p40,</FONT> and <FONT STYLE="white-space:nowrap">IL-18</FONT> in the
presence of HER2<SUP STYLE="font-size:85%; vertical-align:top">pos</SUP> tumor cells. This highlights the potential for favorable activity of SBT6050, which we believe is due to efficient </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
engagement of TLR8 in conjugate form. SBT6050&#146;s functional profile was not replicated with conjugates comprised of TLR7-specific or resiquimod-derived agonists. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>SBT6050 Was Superior at Activating Human Myeloid Cells Compared to HER2 Antibody Conjugates that Use Either a Selective TLR7 Agonist or Resiquimod
</I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g11a18.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Robust activation of the myeloid cell compartment is also known to trigger an adaptive immune cell response. In an
additional <I>in vitro</I> study using a similar PBMC assay, SBT6050 induced indirect activation of mediators associated with NK cell and T cell responses
(IFN<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT> and granzyme B), as shown in the figures below. In a separate <I>in vitro </I>study, the induction of IFN<FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT> and granzyme B by SBT6050 was shown to be secondary to myeloid cell activation as blockade of <FONT STYLE="white-space:nowrap">IL-12</FONT> and/or <FONT STYLE="white-space:nowrap">IL-18</FONT>
abrogated the IFN<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT> and granzyme B response. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B></B><B><I>SBT6050 Indirectly Activated Mechanisms Associated with CTL/NK Cell Responses in the Presence of HER2</I></B><B></B><B><I><SUP
STYLE="font-size:85%; vertical-align:top">pos</SUP></I></B><B></B><B><I> Tumors</I></B><B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g11m85.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">HER2 expression in tumor cells varies and can be measured by protein expression using
immunohistochemistry (IHC) to understand the amount of HER2 in tumor cells. It is also common to determine the gene copy&nbsp;number using fluorescence in situ hybridization (FISH) or other methodologies as another way to understand if the HER2 gene
is amplified. Gene amplification typically results in overexpression of the protein usually at the IHC3+ level, but some HER2-amplified tumors express protein at the IHC2+ level. It has become standard practice among pathologists to characterize
protein expression using IHC1+, IHC2+ or IHC3+ and also to measure gene copy number because certain <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapies, such as Herceptin, are approved in the setting of high HER2 expression levels. High
HER2 expression tumors are categorized by either IHC3+ or IHC2+/FISH positive. Low HER2 expression in the industry is categorized as IHC2+/FISH negative and IHC1+. In our preclinical, studies we characterized IHC1+ HER2 tumor cells as expressing
less than 25,000 HER2 receptors per cell. SBT6050 has been tuned to work in settings of IHC2+/FISH negative (moderate expression) as well as IHC3+ (high expression) but not IHC1+ (low expression). Targeting tumors with moderate HER2 expression
allows us to address a patient population where most current HER2 targeted therapies are not effective. We believe that avoiding some normal tissues that express low levels of HER2 provides the opportunity for an improved safety and tolerability
profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown in the figures below, our <I>in vitro </I>studies demonstrated that SBT6050 stimulated myeloid cells in the presence of IHC 2+
and 3+, but not in the presence of IHC 1+/- tumor cell lines. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>SBT6050 Activated Myeloid Cells Only in the Presence of IHC 2+ and 3+ Tumor Cell
Lines </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g13k36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>SBT6050 In Vivo Preclinical Data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Background Regarding <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Because mice do not have a functional homologue of human TLR8, we designed <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> to enable preclinical mouse
studies with a molecule that in mice matches the myeloid cell activation profile of SBT6050. TLR7 expression in mouse myeloid cells mirrors that of TLR8 in human myeloid cells. RNA sequencing data published by third parties, as shown in the figures
below, highlight the differential expression of TLR8 and TLR7 across mouse and human myeloid cell sub populations. Activation of TLR7 in mouse myeloid cells results in a similar downstream functional profile as TLR8 activation does in human myeloid
cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>TLR7 Is Highly Expressed in Mouse Myeloid Cells and TLR8 Is Highly Expressed in Human Myeloid
Cells, Whereas TLR7 Is Expressed at Low Levels in Human Myeloid Cells </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g14r07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">SBT6050-S</FONT> is a proprietary conjugate that contains a selective TLR7
linker-payload and a mouse IgG2a Fc domain to promote uptake in mouse myeloid cells. Our preclinical data, as shown in the figure below, demonstrated similar <I>in vitro</I> functional results of SBT6050 in human and
<FONT STYLE="white-space:nowrap">SBT6050-S</FONT> in mice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Functional Results with TLR7 Conjugate,
<FONT STYLE="white-space:nowrap">SBT6050-S,</FONT> on Mouse Myeloid Cells Matched Those of SBT6050 on Human Myeloid Cells In Vitro </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g25o26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Our <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> Monotherapy In Vivo Data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Using <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> in preclinical studies, we have demonstrated that a systemically administered, HER2-directed
myeloid cell agonist activated a broad spectrum of anti-tumor mechanisms and led to curative single agent activity in both a human tumor xenograft model lacking T cells and B cells and with defective NK cells as well as a T cell-excluded syngeneic
mouse tumor model. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown in the figures below, <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> (at 10 mg/kg)
demonstrated curative effects as a monotherapy in a human tumor xenograft (NCI-N87) mouse model that has an absence of T cells along with defective NK cells. We believe that the activity of <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> in this
model is indicative of the potential of myeloid cells to drive tumor eradication. These data indicate that SBT6050 may have activity in tumors with low or no T cell infiltrate, which we believe has important implications regarding the substantial
potential benefit of SBT6050 for patients who do not respond to T cell-directed immunotherapy. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B></B><B><I><FONT STYLE="white-space:nowrap">SBT6050-S</FONT> Drove Robust, Curative Single Agent Activity in T Cell, NK Cell-Deficient Mouse
Strains</I></B><B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g86p72.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, in our preclinical studies, administration of <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> as
monotherapy resulted in durable curative effects in a HER2-expressing, T cell excluded EMT6 syngeneic mouse tumor model. EMT6 is a mouse tumor that we engineered to express human HER2. Expression of human HER2 in this model is moderate,
heterogenous, and may be lost over time, which is representative of certain HER2<SUP STYLE="font-size:85%; vertical-align:top">pos</SUP> tumor types such as gastric cancer. While conducted in immunocompetent mice, the EMT6 model is also known to be
resistant to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> treatment because T cells are excluded from tumor entry. The left panel in the figure below illustrates tumor cells that were demarcated by
H&amp;E staining. The central panel in the figure below illustrates that in the HER2-EMT6 model, CD8 T cells were sequestered on the periphery of the tumor. In contrast, the right panel below illustrates the presence of macrophage infiltrate within
this T cell-excluded mouse tumor model. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>IHC Staining in EMT6 Tumor Models, Depicting CD8 T Cells and Macrophages (F4/80) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g25x21.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown in the figures below, <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> (at 10 mg/kg) as
monotherapy resulted in a complete response (CR) rate of <FONT STYLE="white-space:nowrap">40-80%</FONT> in the HER2-EMT6 model, depending on the study. Approximately <FONT STYLE="white-space:nowrap">30-50%</FONT> of EMT6 tumor cells express human
HER2 at the time of dosing initiation. Given the lack of stability of HER2 expression in this model, we believe HER2 expression was lost in the tumors of the mice that did not respond to <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> in this
study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Treatment with <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> Monotherapy Resulted in CR Rate of
<FONT STYLE="white-space:nowrap">40-80%</FONT> in HER2-EMT6 Model </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g06o02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown in the figure on the left below, HER2-EMT6 tumor-bearing mice that were cured by <FONT
STYLE="white-space:nowrap">SBT6050-S</FONT> treatment were fully protected from an EMT6 tumor <FONT STYLE="white-space:nowrap">re-challenge,</FONT> indicative of the generation of immunological memory. As shown in the figure on the right below, mice
that were <FONT STYLE="white-space:nowrap">re-challenged</FONT> with EMT6 tumors that did not express HER2 were also shown to have complete protection, indicating SBT6050 engendered activation of an anti-tumor T cell response that was not restricted
to HER2. This is consistent with the expansion of T cells reactive to tumor neoantigens observed in the tumors of mice after treatment with <FONT STYLE="white-space:nowrap">SBT6050-S.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I><FONT STYLE="white-space:nowrap">SBT6050-S</FONT> Conferred HER2-Independent Protection in Preclinical Tumor
<FONT STYLE="white-space:nowrap">Re-Challenge</FONT> Studies </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g35v28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Preclinical Data Supporting the Potential for Combination of SBT6050 with Other Therapies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In our preclinical studies, <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> drove robust anti-tumor activity as a single agent and in combination with
standard of care agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown in the figures below, our preclinical data demonstrated that the single agent activity of <FONT
STYLE="white-space:nowrap">SBT6050-S</FONT> in the immune-competent, checkpoint resistant HER2-EMT6 tumor model was further enhanced when combined with an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1.</FONT></FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>The Combination of <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-1</FONT></FONT> Drove Robust, Durable Anti-Tumor Activity </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g51a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In a HER2<SUP STYLE="font-size:85%; vertical-align:top">pos</SUP> human xenograft mouse model, a combination of low
dose <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> with trastuzumab greatly enhanced the anti-tumor activity observed with either agent alone. As shown in the figures below, our preclinical data demonstrated the potential for enhanced clinical
activity with SBT6050 in combination with trastuzumab. In this study, a lower dose of <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> (1 mg/kg) was used to allow for the combinatorial benefit to be observed. A lower dose of <FONT
STYLE="white-space:nowrap">SBT6050-S</FONT> (1 mg/kg) was used as a monotherapy control. We believe that the potential to combine with trastuzumab-based therapies unlocks the possibility of accessing earlier lines of therapy in breast and gastric
cancer, where trastuzumab is a part of the standard of care. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>The Combination of <FONT STYLE="white-space:nowrap">SBT6050-S</FONT> and
Trastuzumab Drove Robust, Durable Anti-Tumor Activity </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g51b02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>SBT6050 Was Well Tolerated in <FONT STYLE="white-space:nowrap">Non-Human</FONT> Primates by the Subcutaneous Route of
Administration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">SBT6050 demonstrated a wide therapeutic window in safety and tolerability studies following repeat subcutaneous
administration including in the GLP toxicology study in <FONT STYLE="white-space:nowrap">non-human</FONT> primates (NHP) that determined our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> (FIH) dose.
Across the studies, there was no evidence of injection site reactions or cytokine release syndrome (CRS) in any animal. There were transient, dose-related hematological, clinical chemistry, and cytokine and chemokine changes reflective of the
potential mechanism of action of SBT6050. Because of the broad therapeutic window demonstrated in these studies, our FIH starting dose level of 0.3 mg/kg was selected because of its equivalency to the minimum pharmacologically active dose level in
NHP and the projection that this dose level may be pharmacologically active in patients. The FIH dose levels of immune activators, particularly those that are viewed as having a significant risk of CRS, are typically below the projected
pharmacologically active dose of the agent, resulting in lengthy dose-escalations to an active dose level. Notably, that is not the case with SBT6050. Based on the totality of our preclinical data, we believe that we have potential to reach the
recommended phase 2 dose (RP2D) for SBT6050 between the second and fourth dose levels. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Repeat administration of fully human or humanized proteins, such as that included in SBT6050, to
preclinical species, like a NHP, has been extensively evaluated by many organizations over the years and has been found to frequently lead to the generation of anti-drug antibodies (ADA), reflecting the development of immunogenic responses with
repetitive challenge of NHP with <FONT STYLE="white-space:nowrap">non-self</FONT> or foreign proteins. Importantly, the generation of ADA against human or humanized proteins in NHP, even when accompanied by
<FONT STYLE="white-space:nowrap">ADA-mediated</FONT> toxicities such as anaphylaxis, has not been predictive of immunogenicity in humans. ADA developed against SBT6050 in our NHP toxicology studies. The formation of ADA against SBT6050 in NHP was
expected given the inherent immunogenicity of humanized proteins in NHP and the potential mechanism of action of SBT6050, which includes the promotion of presentation of foreign antigens by dendritic cells, a mechanism critical to the formation of
immune responses to tumor neoantigens. The development of ADA in NHP resulted in decreased exposure following repeat dosing. As has been seen with other immune agonists administered in the presence of ADA in preclinical species, repeat intravenous
dosing with SBT6050 resulted in anaphylaxis but anaphylaxis was not seen in NPH studies using subcutaneous dosing of SBT6050. While no animal treated with SBT6050 subcutaneously showed signs of acute anaphylaxis, one animal in the highest dose group
was euthanized due to what is believed to be <FONT STYLE="white-space:nowrap">ADA-related</FONT> immune complex deposits in certain organs. Given the precedent data in the field, we do not believe that neutralizing ADA formation that affected
SBT6050 exposure in NHP will translate into the clinic. Nevertheless, a reduction in exposure following repeat dosing of SBT6050 in the Phase 1/1b clinical trial could present a risk for clinical development. Of note, in our ongoing Phase 1/1b
clinical trial, we have not observed reductions in SBT6050 exposure following repeat dosing of SBT6050 for the one patient where data is available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>SBT6050
Clinical Development Plan and Strategy </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">SBT6050 demonstrated a wide therapeutic window in our GLP toxicology study in NHP, enabling a FIH
starting dose of 0.3 mg/kg, which was projected to be pharmacologically active and within <FONT STYLE="white-space:nowrap">2-3</FONT> cohorts of where we could potentially achieve anti-tumor activity. In NHP, 0.5 mg/kg was defined as the minimum
pharmacologically active dose as determined by blood-based biomarkers, 6 mg/kg was determined to be the No Adverse Event Level and the highest dose level evaluated was 12 mg/kg. Our FIH starting dose of 0.3 mg/kg is the human equivalent of the
minimum pharmacologically active dose level in NHP and projected to be pharmacologically active in patients. Based on the totality of our preclinical data, we believe that the RP2D will be reached between the second and fourth dose levels in our
Phase 1 dose-escalation, particularly if 0.3 mg/kg demonstrates pharmacological activity as projected from our preclinical modeling. Additional dose levels may be explored in our Phase 1/1b clinical trial to further characterize safety and
tolerability. At the RP2D, we believe there is potential to demonstrate single agent anti-tumor activity in dose expansion cohorts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our IND for
SBT6050 was cleared in June 2020 with a starting dose of 0.3 mg/kg. In July 2020, we initiated a Phase 1/1b FIH, open-label, multicenter, dose-escalation and expansion clinical trial in patients with HER2-expressing solid tumors that have progressed
following standard therapies. The trial is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity of SBT6050 as a single agent and in combination with pembrolizumab, a <FONT
STYLE="white-space:nowrap">PD-1</FONT> inhibitor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In our Phase 1/1b clinical trial, we are monitoring key PD biomarkers in both the blood and the
tumor which have been associated with tumor regression in our preclinical mouse studies and was observed in our preclinical NHP studies. Key biomarkers in the blood include elevations in <FONT STYLE="white-space:nowrap">MCP-1,</FONT> <FONT
STYLE="white-space:nowrap">IP-10,</FONT> and <FONT STYLE="white-space:nowrap">C-reactive</FONT> protein and induction of additional PD markers indicative of on target mechanism of action such as IFN<FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>. We will be obtaining tumor biopsies at baseline and on treatment to measure biomarkers that correlate with the activation of myeloid cells, T cells and NK cells in cohorts 2 and later. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The trial consists of 4 parts: monotherapy dose-escalation and expansion (Part 1), monotherapy dose
expansion in tumor-specific cohorts (Part 2), pembrolizumab combination dose-escalation (Part 3), and a pembrolizumab combination dose expansion cohort (Part 4). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Part 1: SBT6050 Single Agent Dose-Escalation and Expansion </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Part 1, a standard 3 + 3 dose-escalation of SBT6050 is planned to study safety, tolerability, and PK of SBT6050, and to determine the maximum
tolerated dose (MTD) and the RP2D. The MTD is defined as the dose just below the dose level where 2 or more out of 6 patients (<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>33%) experience
dose-limiting toxicities (DLTs). The starting dose of the SBT6050 regimen is 0.3 mg/kg administered via subcutaneous injection once every 14 days. One or two dose levels may be expanded to 12 patients to obtain additional information to select the
RP2D. Eligible patients must have HER2-expressing (HER2 IHC 2/3+) or HER2-amplified cancer refractory to or relapsed after standard therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Part 2: SBT6050
Single Agent Dose Expansion in Tumor-Specific Cohorts </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Patients will be enrolled into parallel expansion cohorts based on tumor type and HER2
expression level. Patients enrolled in the expansion cohorts will receive SBT6050 at the recommended dose and schedule established in Part 1. The purpose of Part 2 is to confirm the safety and tolerability of the RP2D and evaluate the anti-tumor
activity and PD effects of SBT6050 as a single agent. Enrollment will follow a Simon <FONT STYLE="white-space:nowrap">2-stage</FONT> design. Planned expansion cohorts, which may also be informed by experience in the dose-escalation phase, include
the following tumor types: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Cohort A: HER2<SUP STYLE="font-size:85%; vertical-align:top">pos</SUP> breast cancer, n=40. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Cohort B: HER2 <FONT STYLE="white-space:nowrap">low-expressing</FONT> (IHC2+/amplification negative) breast cancer, n=30.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Cohort C: HER2<SUP STYLE="font-size:85%; vertical-align:top">pos</SUP> gastric cancer, n=40. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Cohort D: HER2-expressing (IHC 2/3+) or HER2-amplified <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer,
n=40. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Cohort E: HER2-expressing (IHC 2/3+) or HER2-amplified solid tumors, n=30. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Part 3: SBT6050 Plus Pembrolizumab Dose-Escalation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In Part
3, a standard 3 + 3 dose-escalation of SBT6050 plus pembrolizumab is planned to determine the MTD and RP2D of SBT6050 when given in combination with pembrolizumab. The MTD is defined as above. SBT6050 will be administered via subcutaneous injection
on Days 1, 15, and 29 of <FONT STYLE="white-space:nowrap">42-day</FONT> cycles in combination with 400 mg pembrolizumab administered via intravenous injection on Day 1 of each cycle. Eligible patients will have HER2-expressing or HER2-amplified
solid tumors. Part 3 of the study will open when changes in PD markers exceeds the <FONT STYLE="white-space:nowrap">pre-defined</FONT> criteria for pharmacological activity with demonstration of acceptable safety and tolerability in a cohort treated
with single agent SBT6050. The <FONT STYLE="white-space:nowrap">pre-defined</FONT> threshold is based on changes in peripheral PD markers in preclinical studies, and includes <FONT STYLE="white-space:nowrap">C-reactive</FONT> protein elevation to <FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT> 150 mg/L and 3-5 fold changes from baseline in certain cytokines and chemokines such as <FONT STYLE="white-space:nowrap">IP-10,</FONT> IFN<FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT> and/or <FONT STYLE="white-space:nowrap">MCP-1.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Part 4: SBT6050
Plus Pembrolizumab Dose Expansion Cohort </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The combination treatment expansion part of the trial will be initiated once the RP2D has been defined
by the safety monitoring committee from Part 3. The purpose of Part 4 is to confirm the safety and tolerability of the RP2D and evaluate the anti-tumor activity and PD effects of SBT6050 in combination with pembrolizumab. Approximately 30 patients
with HER2-expressing or HER2-amplified tumors of multiple histologies will be enrolled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>SBT6050 Preliminary Phase 1/1b Clinical Data </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently in Part 1 of our Phase 1/1b clinical trial and as of October&nbsp;1, 2020, four patients have been enrolled. These treated patients have
received between one and five doses, and no DLTs have been observed. Furthermore, pharmacological activity consistent with the potential mechanism of action has been observed in treated patients where data are available. Repeat dose PK is available
in one patient through three doses and exposure was consistent following the second and third subcutaneous doses compared to the first dose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
expect to initiate the Phase 1 SBT6050 combined with pembrolizumab in the first quarter of 2021. We anticipate providing an update on interim data from the Phase 1 single agent dose-escalation cohorts and the Phase 1 SBT6050 and pembrolizumab
combination in the first half of 2022. We anticipate providing a further update on interim data from the Phase 1 monotherapy and combination dose-escalation as well as a first update of the Phase 1b monotherapy in tumor-specific expansion cohorts
and the Phase 1b combination cohort the second half of 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>SBT6050 Addressable Market </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown in the figure below, HER2 IHC 2+ and 3+ overexpression, amplifications, and mutations are documented in at least 11 different tumor types with
varying frequencies. Most HER2 targeted therapies require the tumor cells to be dependent on HER2 signaling, often called an oncogenic driver. HER2 oncogenic-driven tumors are limited to subsets of breast and gastric cancer and hence the <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> therapies that require HER2 signaling are limited to these indications as noted in the figure. SBT6050 does not require the tumor cells to be dependent on HER2 signaling for its anti-tumor activity and
instead utilizes the HER2 protein to deliver the conjugate to adjacent myeloid cells. We believe that this expands the market opportunity beyond HER2-driven breast and gastric cancer in which targeted HER2 agents have been approved and are
established as standard of care. Because of the rationale to combine SBT6050 with CPI&#146;s, which is supported by our preclinical data, we have noted in the figure below those tumor types with an approved CPI. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Large Potential Market Opportunity for SBT6050 in Tumors That Express HER2 and in Combination With HER2 Targeted Agents and CPIs </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g55v08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">HER2 expression rates are well-understood in tumor types for which there is an
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> HER2 targeted therapy available. Breast and gastric cancer cases are routinely screened for HER2 expression as a part of the standard of care. HER2 overexpression has been reported in other tumor
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
types, but because of the lack of effective therapies targeting cancers outside of breast and gastric, screening is not readily performed. In calculating our potential addressable market for
these tumor types, the figure above shows a range of HER2 expression cited in the literature and the lower end of the range was utilized for market considerations. In the United States, we believe that more than 48,000 patients annually with solid
tumors that are refractory to standard of care treatments may benefit from SBT6050 as a single agent or combination therapy, if successfully developed and approved. In the future, if SBT6050 advances to earlier lines of treatment, more than 160,000
patients annually may benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In considering the market for combination treatment, SBT6050 was specifically designed to bind to the HER2 <FONT
STYLE="white-space:nowrap">sub-domain</FONT> II, the pertuzumab epitope, to enable combinations with trastuzumab-based therapies that bind to HER2 <FONT STYLE="white-space:nowrap">sub-domain</FONT> IV such as Herceptin (trastuzumab), Kadcyla <FONT
STYLE="white-space:nowrap">(trastuzumab-DM1),</FONT> and Enhertu <FONT STYLE="white-space:nowrap">(DS-8201),</FONT> all of which are <FONT STYLE="white-space:nowrap">FDA-approved</FONT> HER2 agents. Our preclinical data has demonstrated the
potential to use SBT6050 in combination with trastuzumab and CPI&#146;s. We believe that SBT6050 may also have the potential to be combined with tyrosine kinase inhibitors such as Tukysa (tucatinib), which is approved for combination with
trastuzumab and Xeloda (capecitabine) for the treatment of HER2<SUP STYLE="font-size:85%; vertical-align:top">pos</SUP> metastatic breast cancer. When considering the market potential for combination therapy, only combinations with trastuzumab and
CPI&#146;s was utilized in our calculations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">SBT6050 is also active in HER2 IHC 2+ / FISH negative tumors, expanding the market beyond the scope of
current approved HER2 targeted therapies indicated for IHC 3+ and IHC 2+ / FISH positive tumors as shown in the figure below. We considered this potential market extension in breast cancer and gastric cancer in calculating the potential addressable
market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>SBT6050 Addressable Market in Indications with an <FONT STYLE="white-space:nowrap">FDA-Approved</FONT> HER2 Targeted Therapy
</I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g56s00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>SBT6290: TLR8 Agonist Conjugated to a Nectin4 Antibody </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our second product candidate, SBT6290, is comprised of the same TLR8 linker-payload used in SBT6050 conjugated to a Nectin4-directed monoclonal antibody.
Nectin4 has been prioritized as our second target based on differential expression of extracellular proteins on tumor cells in comparison to healthy tissue, as well as the degree of myeloid cell infiltrate in the TME. Nectin4 is overexpressed in
cancers including bladder, triple negative breast, and head and neck, among others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Nectin4 is a target that has been clinically validated by
Seattle Genetics through the approval of the antibody-drug conjugate Padcev. In 2019, Padcev was approved under the FDA&#146;s accelerated approval program indicated for the treatment of adult patients with locally advanced or metastatic urothelial
cancer who have previously received a <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitor, and a platinum-containing chemotherapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Targeting Nectin4 to deliver a TLR8 agonist to adjacent myeloid cells presents a significant
therapeutic opportunity across different cancers. We are developing SBT6290 in Nectin4-expressing tumors, including bladder, triple negative breast, and head and neck cancers, which as shown in the figure below, represents over 80,000 patients
annually in early line settings and over 16,000 patients with relapsed or refractory cancer annually in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Nectin4
Overexpression Across Select Tumor Types </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g18o52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In our <I>in vitro </I>studies, human PBMCs were <FONT STYLE="white-space:nowrap">co-cultured</FONT> with Nectin4<SUP
STYLE="font-size:85%; vertical-align:top">pos</SUP> or Nectin4<SUP STYLE="font-size:85%; vertical-align:top">neg</SUP> tumor cell lines in the presence of SBT6290. SBT6290 potently activated myeloid cells with an EC<SUB
STYLE="font-size:85%; vertical-align:bottom">50</SUB> of ~200 pM, in the presence of Nectin4-expressing tumor cells. Not only did these data highlight the Nectin4-dependent activity of SBT6290, but also demonstrated that the TLR8 linker-payload used
in SBT6050 was transferable to antibodies directed to diverse antigens. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>SBT6290 Potently Activated Human Myeloid Cells </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g59a58.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g47h58.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We engineered a mouse surrogate of SBT6290 <FONT STYLE="white-space:nowrap">(SBT6290-S)</FONT> using a TLR7 agonist
conjugated to a Nectin4 monoclonal antibody to account for species differences in our <I>in vivo</I> studies, as was described for SBT6050. As shown in the figure below <FONT STYLE="white-space:nowrap">SBT6290-S</FONT> improved overall survival in
this Nectin4-expressing EMT6 mouse model. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Administration of <FONT STYLE="white-space:nowrap">SBT6290-S</FONT> as Monotherapy Resulted in
Improved Overall Survival in a Nectin4-Expressing EMT6 Preclinical Model </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g31n61.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In a single and repeat dose exploratory safety study, Nectin4-TLR8 conjugate was administered
subcutaneously to NHP at a dose level <FONT STYLE="white-space:nowrap">&gt;10-fold</FONT> of the anticipated, minimum pharmacologically active dose level, a dose that was also evaluated with SBT6050. The overall safety, tolerability, PK and PD
findings of the Nectin4-TLR8 conjugate were very similar to those observed with SBT6050 at this dose. Additional <FONT STYLE="white-space:nowrap">non-GLP</FONT> toxicity studies are currently underway, and GLP NHP toxicity studies are expected to
commence in first half of 2021. In parallel, we are in the process of creating a master cell bank for GMP production of SBT6290. We anticipate submitting the SBT6290 IND in the fourth quarter of 2021 and initiating a Phase 1 clinical trial in the
first quarter of 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>SBT8230: TLR8 Agonist Conjugated to an ASGR1 Antibody </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As our lead virology program, we have engineered SBT8230 to treat cHBV using our ImmunoTAC platform. SBT8230 is comprised of an ASGR1 monoclonal antibody
conjugated to the same TLR8 linker-payload as SBT6050 and SBT6290 and is designed to elicit an anti-viral immune response by targeting TLR8 activation to the liver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">cHBV infection remains a worldwide problem affecting approximately 257&nbsp;million people and contributing to an estimated 887,000 deaths in 2015. In
the United States alone, approximately 860,000 people suffer from cHBV. cHBV is estimated to be the cause of <FONT STYLE="white-space:nowrap">60-80%</FONT> of the world&#146;s primary liver cancers. There is a significant unmet need for therapies
that can elicit a functional cure for the disease, which is defined as sustained loss of hepatitis B surface antigen (HBsAg) in the blood. Many of the approved therapies for cHBV have low functional cure rates or lack durability over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical and preclinical evidence by third parties have demonstrated that
IFN<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>-mediated immune responses, including the activation of
IFN<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>+ T cell and IgG B cell anti-viral responses, can lead to a functional cure in cHBV patients and animal models of HBV. In HBV transgenic mice, <FONT
STYLE="white-space:nowrap">HBV-specific</FONT> CD4 and CD8 T cells have exhibited the ability to inhibit hepatocellular replication by a noncytopathic process that is mediated primarily by IFN<FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>. In acutely infected chimpanzees, viral replication was almost completely abolished soon after CD3 and IFN<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>
mRNA increased in the liver. Evidence by third parties has demonstrated that <FONT STYLE="white-space:nowrap">HBV-specific</FONT> IFN<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT> producing CD4 T
cells were associated with viral clearance in patients with cHBV infection. Additionally, these studies have demonstrated that TLR8 agonists were particularly effective in activation of myeloid cells and the induction of IFN<FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>. The figure below shows IFN<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT> production after human blood or
liver-derived mononuclear cells were stimulated with the indicated TLR agonist. TLR8 was unique in its ability to induce IFN<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B></B><B><I>TLR8 Drove IFN</I></B><B></B><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT><FONT STYLE="font-family:ARIAL"><B></B></FONT><B></B><B><I> Production from Liver Mononuclear Cells in Third Party Preclinical Studies</I></B><B> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g12v63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; margin-left:34%; font-size:8pt; font-family:ARIAL"><I>Figure source: Jo et al, PLOS Pathogens, 2014. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the figures below show concentrations of individual cytokines quantified in the supernatant of purified PBMC or isolated mononuclear cells
from the liver after stimulation with either a TLR8 or TLR7 agonist. TLR8 agonism, but not TLR7 agonism, induced IFN<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT> production, along with the production
of other cytokines important in the generation of anti-viral immunity such as TNF<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>, <FONT STYLE="white-space:nowrap">IL-1&szlig;,</FONT> and <FONT
STYLE="white-space:nowrap">IL-6,</FONT> from both liver and blood immune cells. We believe these data from third parties demonstrate that TLR8 is the agonist of choice for improving the outcome for patients with cHBV. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>TLR8 Agonism Drove Cytokine Production </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g28u96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><I>Figure source: Jo et al, PLOS Pathogens, 2014. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In a preclinical woodchuck model of cHBV conducted by a third party, oral administration of a TLR8 agonist small molecule, <FONT
STYLE="white-space:nowrap">GS-9688</FONT> (selgantolimod), was shown to drive seroconversion and reduce woodchuck hepatitis virus S antigen and woodchuck hepatitis B viral levels. Selgantolimod&#146;s effectiveness in cHBV patients has been limited,
however. We believe (i)&nbsp;this is due to not achieving necessary exposures because of dose limiting toxicities associated with activation of myeloid cells outside of the liver and (ii)&nbsp;that systemically delivered but liver localized TLR8
agonism could improve the potential for effective therapy and lead to functional cures in cHBV. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>SBT8230 is a Liver-Localized TLR8 Agonist Designed to Achieve
Functional Cure in cHBV </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown in the figure below, we designed SBT8230 to be comprised of an ASGR1 monoclonal antibody conjugated to a
TLR8 linker-payload with the goal of activating the myeloid cell compartment in liver tissue only. The conjugate is designed to be internalized in myeloid cells in an FcR-mediated manner when ASGR1 is present on adjacent liver cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Potential Mechanism of Action: SBT8230 is Designed to Localize TLR8 Activation of Myeloid Cells
in the Liver Via a Directed ASGR1 Antibody </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g37k46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As show in the figures below, in our preclinical studies utilizing human PBMCs <I>ex vivo</I>, ASGR1-TLR8 induced IFN<FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>-promoting activity through its activation of myeloid cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>ASGR1-TLR8 Potently Activated Human Myeloid Cells, Resulting in a Robust IFN</I></B><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT><FONT STYLE="font-family:ARIAL"><B><I></I></B></FONT><B><I>&nbsp;Response </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g43c67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Activation of human myeloid cells by TLR8 was mirrored in mouse myeloid cells by TLR7 as was demonstrated previously
in the SBT6050 and SBT6290 programs. Therefore, to evaluate the ability of a liver-targeted myeloid cell agonist conjugate to drive seroconversion in an <FONT STYLE="white-space:nowrap">AAV-HBV</FONT> mouse model, we engineered a surrogate for
SBT8230 comprised of an ASGR1 monoclonal antibody conjugated to a TLR7 agonist <FONT STYLE="white-space:nowrap">(ASGR1-S).</FONT> The antibody contained an IgG2a Fc domain to facilitate uptake into mouse myeloid cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown in the figures below, robust <I>in vivo</I> anti-viral activity and seroconversion was
demonstrated with <FONT STYLE="white-space:nowrap">ASGR1-S</FONT> in the <FONT STYLE="white-space:nowrap">AAV-HBV</FONT> model. A significant decrease in serum viral DNA and HbS antigen levels was obtained compared to control treatment and anti-HbS
seroconversion in the conjugate treated animals was achieved. Of note, paralleling their inability to drive seroconversion in cHBV patients, cHBV standard of care therapies and other agents that target the HBV life cycle such as capsid inhibitors,
have not resulted in seroconversion in this or similar models. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B></B><B><I><FONT STYLE="white-space:nowrap">ASGR1-S</FONT> Reduced HBsAg and Drove
Seroconversion in Mouse <FONT STYLE="white-space:nowrap">AAV-HBV</FONT> Model</I></B><B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g64a10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown in the figures below, <FONT STYLE="white-space:nowrap">ASGR1-S</FONT> treatment generated potent anti-viral
T cell and B cell immune responses and significantly increased <FONT STYLE="white-space:nowrap">anti-HBV</FONT> core and S antigen IFN<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>+ T cells and
anti-HBsAg+ B cells. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I><FONT STYLE="white-space:nowrap">ASGR1-S</FONT> Increased IFN</I></B><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT><FONT STYLE="font-family:ARIAL"><B><I></I></B></FONT><B><I>+ Anti-Viral T Cells </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g15l56.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I><FONT STYLE="white-space:nowrap">ASGR1-S</FONT> Increased B Cells Producing Anti-HbS Antigen
Antibodies </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g18k86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Importantly, as shown in the figures below, no changes in serum ALT, body weight or liver by histopathology were
noted as compared to controls, indicating that <FONT STYLE="white-space:nowrap">ASGR1-S</FONT> was well tolerated. In these studies, no histopathology findings or elevated liver enzymes were observed after treatment with the conjugate. Body weight
gain was also normal following treatment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I><FONT STYLE="white-space:nowrap">ASGR1-S</FONT> Was Well Tolerated in Mice </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g89m60.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Preclinical studies in mice and NHP for our ASGR1-TLR8 ImmunoTAC candidate are ongoing. We anticipate selecting a
development candidate for this program in the fourth quarter of 2020 and expect to initiate IND enabling toxicity studies in the first quarter of 2022. We plan to submit the IND in the second half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Additional Immuno-Oncology Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to HER2 and Nectin4, we have selected two undisclosed targets that may enable us to address a broad range of solid tumor indications shown in
the figure below. In these programs, the antibodies have been created and conjugated to the same TLR8 linker-payload utilized in SBT6050 and SBT6290. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>TLR8 Conjugate Pipeline Offers Broad Coverage of Solid Tumor Indications </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g90h45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Fibrosis Program: TGF&szlig;R1 Antagonist Conjugated to an ASGR1 Antibody </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We designed our ASGR1-TGF&szlig;R1 antagonist conjugate to achieve liver-localized inhibition of TGF&szlig;-signaling to treat fibrosis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Fibrosis is the overgrowth, hardening and scarring of tissue due to accumulation of extracellular matrix molecules, such as collagen, that is produced
by fibroblasts. Chronic fibrotic diseases often result in widespread distortion of normal tissue architecture and account for up to 45% of deaths in the United States. Fibrosis can occur in most major tissues, however idiopathic pulmonary fibrosis
and hepatic cirrhosis&nbsp;are among the more common fibrotic diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Hepatic cirrhosis and hepatocellular carcinoma (HCC) are leading causes of
morbidity and mortality worldwide. Patients with liver cirrhosis are at high risk of deadly hepatic failure and approximately 80%-90% of HCC develop on a cirrhotic background. HCC ranks as the sixth most common cancer and, with over 600,000 deaths
per annum, it constitutes a major global health problem. The most common causes of hepatic cirrhosis in the United States are hepatitis C, alcoholic liver disease, and nonalcoholic liver disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>TGF&szlig; Pathway and its Role in Fibrosis </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Progress has
been made to treat the underlying etiologies initiating liver fibrosis, yet significant needs remain for therapies that slow, halt, or reverse fibrosis and thereby prevent late stage liver failure and HCC. TGF&szlig; signaling is a key mediator of
liver fibrosis initiation and progression through multiple mechanisms, including hepatocyte apoptosis, hepatic stellate cell transdifferentiation to myofibroblasts, and <FONT STYLE="white-space:nowrap">pro-fibrotic</FONT> macrophage activation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">TGF&szlig; is secreted by many cell types and is implicated in a wide range of cell functions, critically regulating tissue homeostasis and repair,
immune and inflammatory responses, extracellular matrix deposition, and cell differentiation and growth. In healthy tissues, TGF&szlig; is expressed at a low level to enable homeostatic mechanisms and is also transiently upregulated in response to
tissue injury, which initiates a cascade that results in collagen production and, ultimately, healing of the tissue. In fibrotic tissue, TGF&szlig; production and signaling is dysregulated and perpetuated, leading to excess collagen deposition in
the absence of acute tissue injury. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While inhibiting the TGF&szlig; receptor kinase domains is the most direct way to down-regulate
TGF&szlig; signaling, systemic availability of TGF&szlig; receptor 1 (TGF&szlig;R1) antagonists is associated with DLTs due to the homeostatic functions of TGF&szlig; in multiple organ systems. Preventing TGF&szlig; activity with antibody blockade
of ligands or their activation machinery is challenging due to the presence of multiple ligands and activation mechanisms, and TGF&szlig;&#146;s sequestration in extracellular matrix. We believe a systemically delivered TGF&szlig;R1 antagonist with
liver-localized activity has the potential to ameliorate liver fibrosis while avoiding the toxicities associated with <FONT STYLE="white-space:nowrap">non-targeted</FONT> TGF&szlig; receptor inhibition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Using a similar strategy of liver localization that was employed in our cHBV program, as shown in the figure below, we engineered an <FONT
STYLE="white-space:nowrap">ASGR1-TGF&szlig;R1</FONT> antagonist ImmunoTAC intended to inhibit the TGF&szlig; pathway to treat liver fibrosis. ASGR1 is a scavenger receptor that is highly expressed exclusively on hepatocytes and internalizes and
recycles rapidly upon engagement. Thus, the <FONT STYLE="white-space:nowrap">ASGR1-TGF&szlig;R1</FONT> antagonist conjugate is designed for systemic administration with liver-localized inhibition of the TGF&szlig; receptor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I><FONT STYLE="white-space:nowrap">ASGR1-TGF&szlig;R1</FONT> ImmunoTAC Therapeutic is Designed for Liver-Localized TGF&szlig; Signaling Inhibition
for Anti-Fibrotic Effects </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g93m60.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As shown in the figure below, our initial preclinical studies with
<FONT STYLE="white-space:nowrap">ASGR1-TGF&szlig;R1</FONT> antagonist conjugates demonstrated potent inhibition of TGF&szlig; signaling <I>in vitro</I>. This activity was dependent on ASGR1 binding as no activity was observed on cells with low or no
ASGR1 expression. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I><FONT STYLE="white-space:nowrap">ASGR1-TGF&szlig;R1</FONT> ImmunoTAC Therapeutic: Potent and
Complete Inhibition of TGF&szlig; Signaling in pSMAD Reporter Assay </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g17x45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Preclinical studies in mouse disease models are ongoing for this program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The pharmaceutical industry is highly
competitive and dynamic, owing to rapidly advancing technologies. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, government
agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing treatments and new treatments that may become available in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We compete with other companies working to develop immunotherapies and targeted therapies for the treatment of cancer including divisions of large
pharmaceutical and biotechnology companies of various sizes. These companies are developing therapies of many different modalities including small molecules, monoclonal antibodies, antibody-drug conjugates,
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, cell therapies, oncolytic viruses and vaccines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Specifically, there are many
companies pursuing a variety of approaches to <FONT STYLE="white-space:nowrap">TLR-directed</FONT> therapies, including Apros Therapeutics, Ascendis, BioNTech, Bolt Biotherapeutics, Bristol Myers Squibb, Checkmate Pharmaceuticals, CureVac, Exicure,
Galaderma, Gilead, Idera, Mologen, Nektar, Novartis, Primmune Therapeutics, Roche, Seven&amp;Eight, Shanghai De Novo, Sumitomo Dainippon, TriSalus, and UroGen. Other companies using antibody-drug conjugates to target innate immune receptors include
Actym Therapeutics, Mersana, and Takeda Pharmaceuticals. Immunotherapy and validated pathway approaches are further being pursued by many smaller biotechnology companies as well as larger pharmaceutical companies. We also face competition from
validated pathway therapy treatments offered by companies such as AstraZeneca, Byondis, Daiichi Sankyo, Genentech, MacroGenics, Pieris, Puma, Seattle Genetics, Spectrum Pharmaceuticals, and Zymeworks. We also face competition from companies that
continue to invest in innovation in the antibody-drug conjugate field, including but not limited to AbbVie, ADC Therapeutics, Astellas, BioAtla, Celldex, CytomX, Eli Lilly and Company, GlaxoSmithKline, Genmab, ImmunoGen, Immunomedics, Millennium
Pharmaceuticals, MorphoSys AG, Novartis, Pfizer, Sanofi, Seattle Genetics, Sutro Biopharma, and VelosBio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many of our competitors, either alone or
with their collaboration partners, have significantly greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing, and marketing than we do. Future collaborations and mergers and
acquisitions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
may result in further resource concentration among a smaller number of competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large and established companies. These competitors will also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and subject registration for
clinical trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our commercial potential could
be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also
may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our
development more complicated. The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety and convenience. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our antibody-drug conjugate is produced by
chemical conjugation of a <FONT STYLE="white-space:nowrap">non-cytotoxic</FONT> linker-payload to a monoclonal antibody. We have significant internal expertise in engineering and humanization of antibodies and designing linker-payload to customize
the drug conjugate for a desired target profile. The small molecule linker-payload is chemically synthesized, and the antibody is produced by conventional biological process technology. The manufacturing process involves production of the
linker-payload and antibody process intermediates, the conjugation of the intermediates to produce bulk therapeutic substance and fill/finish of the therapeutic product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not own or operate, and currently have no plans to establish, any manufacturing facilities subject to compliance with current good manufacturing
practices (cGMP). We operate on an outsourced model and rely on contracts with third-party development and manufacturing organizations designed to comply with cGMPs to produce and test the intermediates, therapeutic substance and therapeutic product
to support clinical development, and commercialization, if any of our product candidates obtain marketing approval. We are working with these manufacturers to scale up our manufacturing capabilities to support our clinical plans. We also rely on
third parties to package, label, store and distribute our product candidates, as well as for our commercial products if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by
eliminating the need for us to invest on our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the design and development of our product candidates.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commercialization Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to retain significant
development and commercial rights to our product candidates and, if marketing approval is obtained, to commercialize our product candidates on our own, or potentially with a partner, in the United States and other regions. We currently have no
sales, marketing or commercial product distribution capabilities and have no experience as a company commercializing products. We intend to build the necessary infrastructure and capabilities over time for the United States, and potentially other
regions, following further advancement of our product candidates. Clinical data, the size of the addressable patient population, the size of the commercial infrastructure and manufacturing needs may all influence or alter our commercialization
plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>License Agreement with WuXi Biologics (Hong Kong) Limited </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2019, we entered into a cell line license agreement with WuXi Biologics (Hong Kong) Limited (WuXi Bio), pursuant to which we received a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, sublicensable license under certain of WuXi Bio&#146;s intellectual property rights, <FONT STYLE="white-space:nowrap">know-how</FONT> and biological materials (WuXi Bio Licensed
Technology), to make, use, sell, offer for sale and import a product developed through the use of the WuXi Bio Licensed Technology (WuXi Bio Licensed Product). The WuXi Bio Licensed Technology is used to manufacture a component of our lead product,
SBT6050. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2020, we paid a license fee in the low six figures to WuXi Bio. We may be required to pay an additional license fee in the mid
five figures if we manufacture one or more additional WuXi Bio Licensed Products. Additionally, if we do not engage WuXi Bio to manufacture the WuXi Bio Licensed Products for our clinical and commercial supplies, we are required to make milestone
payments to WuXi Bio upon the achievement of certain sales milestones. Under such scenarios, upon achieving certain thresholds for the aggregate annual net sales of a WuXi Bio Licensed Product, we would owe WuXi Bio aggregate milestone payments up
to the low eight figures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The WuXi Bio Agreement will continue indefinitely unless terminated in accordance with the agreement. The WuXi Bio
Agreement may be terminated (i)&nbsp;by us upon six months&#146; written notice provided we pay all amounts due to WuXi Bio through the effective date of termination, (ii)&nbsp;by either party for the other party&#146;s material breach that remains
uncured for 30 days after written notice, and (iii)&nbsp;by WuXi Bio after 45 days&#146; written notice if we fail to make a payment within 30 days after receiving notice of such failure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Master Services Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Master Services Agreement with CE3, Inc.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In January 2020, we entered into a master services agreement (MSA) with CE3, Inc. (CE3) pursuant to which CE3 will perform certain clinical
research and administrative services in connection with our lead product SBT6050, including trial management, site selection, site management, project management, data collection and analysis, and other related services, in support of certain
clinical research and trials. In addition to the fees for these services, we are obligated to pay the fees and expenses incurred in connection with the services provided by CE3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The CE3 MSA will expire in January 2025, unless earlier terminated in accordance with the MSA. The MSA can be terminated (i)&nbsp;by either party at any
time upon 30 days&#146; written notice provided any ongoing work order will continue until the termination date set forth in such work order; (ii)&nbsp;by either party for the other party&#146;s material breach that remains uncured for 60 days after
written notice; (iii)&nbsp;by either party if the other party becomes insolvent or bankrupt; or (iv)&nbsp;by us if either party is unable to obtain required ongoing review and/or approvals from regulatory agencies in connection with services to be
performed under the MSA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Master Laboratory Services Agreement with Q Squared Solutions LLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In May 2020, we entered into a Master Laboratory Services Agreement (MLSA) with Q Squared Solutions LLC (Q Squared) pursuant to which Q Squared will
perform certain project planning, laboratory design consultation, laboratory analysis, data management and other laboratory services in connection with our lead product SBT6050. In addition to the fees for these services, we are obligated to pay the
fees, expenses and pass-through costs incurred in connection with the services provided by Q Squared. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Q Squared MLSA will continue until May 2025, at which time it will automatically renew annually
unless either party elects not to renew by providing 30 days&#146; written notice prior to the date of an automatic renewal. Additionally, the MLSA can be terminated (i)&nbsp;by either party at any time upon 90 days&#146; written notice;
(ii)&nbsp;by either party for the other party&#146;s material breach that remains uncured for 30 days after written notice; (iii)&nbsp;by either party if the other party becomes insolvent or files for bankruptcy; or (iv)&nbsp;by Q Squared if its
continued performance of services would constitute a potential or actual violation of regulatory or scientific standards of integrity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our business,
including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We own the issued patents and patent applications relating to our lead product candidate SBT6050. Our policy includes seeking to
protect our proprietary position by, among other methods, filing patent applications, in the United States and in jurisdictions outside of the United States, directed to our proprietary technology, inventions, improvements, and product candidates
that are important to the development and implementation of our business. We also rely on trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to our proprietary technology and product candidates, continued innovation, and <FONT
STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop, strengthen and maintain our proprietary position in the field of immunotherapy. We also plan to rely on data exclusivity, market exclusivity, and patent term extensions when
available. Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, and improvements; to preserve the confidentiality of our trade secrets and <FONT
STYLE="white-space:nowrap">know-how;</FONT> to obtain and maintain licenses to use intellectual property owned by third parties; to defend and enforce our proprietary rights, including any patents that we may own in the future; and to operate
without infringing on the valid and enforceable patents and other proprietary rights of third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of September&nbsp;30, 2020, our licensed
and owned patent portfolio included four owned U.S. patents, 23&nbsp;owned U.S. provisional and <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, 10 owned patent applications filed under the Patent Cooperation Treaty
(PCT), 36 owned foreign patent applications, directed to TLR8 agonists and conjugates, including SBT6050, TGF&szlig;R1 antagonists and conjugates, TGF&szlig;R2 antagonists and conjugates, TLR7 agonists and conjugates, and various applications of our
proprietary antibody conjugates and antibodies, including antibodies specific for Nectin4 and ASGR, as well as certain of our other proprietary antibodies, compounds, conjugates, formulations, technology, inventions, improvements, and other product
candidates. Any patents that issue from these pending patent applications will expire between March 2038 and July 2041, absent any patent term adjustments or extensions. We also possess and/or <FONT STYLE="white-space:nowrap">in-license</FONT>
substantial <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets relating to the development and commercialization of our product candidates, including related manufacturing processes and technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Specifically, our patent portfolio includes the following families and/or groups of families: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>TLR8 Agonists and Conjugates. </B>We have four issued U.S. patents with composition of matter and method of treatment
claims directed to our lead product candidate, SBT6050, and composition of matter, method of treatment, and method of making claims to TLR8 agonist payloads, linker-payloads and conjugates, including conjugates to HER2-directed antibodies. The
issued U.S. patents expire in March 2038, absent any patent term extensions. We have three pending U.S. patent applications, four pending PCT applications, and 15&nbsp;pending patent applications outside of the United States, with composition of
matter claims directed to SBT6050, formulations of SBT6050, and other TLR8 agonists and conjugates, including capped and substituted TLR8 agonist variants and conjugates, as well as claims to methods of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
administering SBT6050, and other TLR8 agonists and conjugates, and to methods for treating oncology indications. Any patents that issue from these pending patent applications will expire between
March 2038 and August 2040, absent any patent term adjustments or extensions. We own all the issued U.S. patents and all the pending patent applications in these patent families. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">With respect to our product candidates and processes, we intend to develop and commercialize in the normal course of business, and we intend to pursue
patent protection directed to, when possible, compositions, methods of use, methods of making, dosing, and formulations. We may also pursue patent protection with respect to manufacturing, therapeutic development processes and technologies, and
therapeutic delivery technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Issued patents can provide protection for varying periods of time, depending upon the date of filing of the
patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. In general, patents issued for applications filed in the United States can provide exclusionary rights for 20&nbsp;years from
the earliest effective filing date. In addition, in certain instances, the term of an issued U.S. patent that is directed to or claims an FDA approved product can be extended to recapture a portion of the term effectively lost as a result of the FDA
regulatory review period, which is called patent term extension. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The term of
patents outside of the United States varies in accordance with the laws of the foreign jurisdiction, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-to-country,</FONT></FONT> and depends upon many factors, including the
type of patent, the scope of its claims, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the
scope of claims allowable in patents in the field of immunotherapy has emerged in the United States. The relevant patent laws and their interpretation outside of the United States is also uncertain. Changes in either the patent laws or their
interpretation in the United States and other countries may diminish our ability to protect our technology or product candidates and enforce the patent rights that we license, and could affect the value of such intellectual property. In particular,
our ability to stop third parties from making, using, selling, offering to sell, or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology,
inventions, and improvements. With respect to both licensed and company-owned intellectual property, we cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications
we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, even the issued patents
that we license do not guarantee us the right to practice our technology in relation to the commercialization of our products. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many
risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and the issued patents that we <FONT
STYLE="white-space:nowrap">in-license</FONT> and those that may issue in the future may be challenged, invalidated, or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent
protection that otherwise may exist for our product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology.
Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents that we own or exclusively <FONT STYLE="white-space:nowrap">in-license.</FONT> For these reasons,
we may face competition with respect to our product candidates. Moreover, because of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent
protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Government authorities in the United
States at the federal, state and local level and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling,
packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products, such as our investigational medicines and any future investigational
medicines. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved
by the regulatory authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Regulatory Approval in the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The FDCA, and other federal and state statutes and
regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post- approval monitoring and reporting, sampling, and import and export of
pharmaceutical products. Biological products used for the prevention, treatment or cure of a disease or condition of a human being are subject to regulation under the FDCA, except the section of the FDCA that governs the approval of new drug
applications, NDAs. Biological products, such as our ImmunoTAC product candidates, are approved for marketing under provisions of the Public Health Service Act (PHSA), via a BLA. However, the application process and requirements for approval of BLAs
are very similar to those for NDAs, and biologics are associated with similar approval risks and costs as drugs. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as
clinical hold, FDA refusal to approve pending NDAs or BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our investigational medicines and any future investigational medicines must be approved by the FDA pursuant to a BLA before they may be legally marketed
in the United States. The process generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">completion of extensive preclinical laboratory and animal studies in accordance with applicable regulations, including
studies conducted in accordance with GLP requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approval by an IRB or independent ethics committee at each clinical trial site before each clinical trial may be commenced;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, GCP
requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">submission to the FDA of a BLA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">payment of any user fees for FDA review of the BLA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a determination by the FDA within 60 days of its receipt of a BLA to accept the filing for review; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfactory completion of one or more FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections of the
manufacturing facility or facilities where the biologic, or components thereof, will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#146;s identity,
strength, quality and purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfactory completion of any potential FDA audits of the clinical trial sites that generated the data in support of the
BLA to assure compliance with GCPs and integrity of the clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">FDA review and approval of the BLA, including consideration of the views of any FDA advisory committee; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">compliance with any post-approval requirements, including REMS, where applicable, and post- approval studies required by
the FDA as a condition of approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The preclinical and clinical testing and approval process requires substantial time, effort
and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Preclinical
Studies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before testing any biological product candidates in humans, the product candidate must undergo rigorous preclinical testing. Preclinical
studies include laboratory evaluation of product candidates and formulations, as well as <I>in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of
preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical
data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become
effective before human clinical trials may begin. Some long-term preclinical testing may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or
questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND
may not result in the FDA allowing clinical trials to commence. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Trials </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of
qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control. Clinical trials must be conducted: (i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with GCPs, an international standard
meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; as well as (iii)&nbsp;under protocols detailing, among other things, the objectives of the trial, the parameters to
be used in monitoring safety and the effectiveness criteria to be evaluated in the trial. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. Furthermore, each clinical
trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated
benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There also are requirements governing the reporting of ongoing clinical trials and completed clinical
trial results to public registries. Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information related to the product,
patient population, phase of investigation, clinical trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Disclosure of the results of these clinical trials can be delayed in certain
circumstances for up to two years after the date of completion of the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A sponsor who wishes to conduct a clinical trial outside of the United
States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA
will accept a well- designed and well-conducted foreign clinical trial not conducted under an IND if the clinical trial was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if
deemed necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are
initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacokinetics, pharmacologic action, side effect tolerability, safety of the product
candidate, and, if possible, early evidence of effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 2 clinical trials generally involve studies in disease-affected patients to evaluate proof of concept and/or
determine the dosing regimen(s) for subsequent investigations. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation
of efficacy is conducted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data
necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product labeling. In most cases, the FDA
requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the biologic. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These Phases may
overlap or be combined. For example, a Phase 1/2 clinical trial may contain both a dose-escalation stage and a dose expansion stage, the latter of which may confirm tolerability at the recommended dose for expansion in future clinical trials (as in
traditional Phase 1 clinical trials) and provide insight into the anti-tumor effects of the investigational therapy in selected subpopulation(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Typically, during the development of oncology therapies, all subjects enrolled in Phase 1 clinical trials are disease-affected patients and, as a
result, considerably more information on clinical activity may be collected during such trials than during Phase 1 clinical trials for <FONT STYLE="white-space:nowrap">non-oncology</FONT> therapies. A single Phase 3 or Phase 2 trial with other
confirmatory evidence may be sufficient in rare instances to provide substantial evidence of effectiveness (generally subject to the requirement of additional post-approval studies). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB,
or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements or a finding that the patients are being exposed to an
unacceptable health risk. Similarly, an IRB can </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug or biologic has
been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee.
This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry
and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing
quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested, and
stability studies must be conducted to demonstrate that the investigational medicines do not undergo unacceptable deterioration over their shelf life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>FDA
Review Process </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following completion of the clinical trials, the results of preclinical studies and clinical trials are submitted to the FDA as
part of a BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the
safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic or drug may be marketed in the United States. The cost of preparing and submitting a BLA is substantial.
Under the PDUFA, each BLA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the
first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. The applicant
under an approved BLA is also subject to an annual program fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA reviews all submitted BLAs before it accepts them for filing and may
request additional information. The FDA must make a decision on accepting a BLA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an <FONT
STYLE="white-space:nowrap">in-depth</FONT> review of the BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of an original BLA for a new molecular
entity and respond to the applicant, and six months from the filing date of an original BLA designated for priority review. The review process for both standard and priority review may be extended by the FDA for three additional months to consider
certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process can be extended by FDA
requests for additional information or clarification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Before approving a BLA, the FDA will conduct a
<FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the
manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA also may audit data from clinical trials to ensure compliance with GCP requirements and the integrity of the data supporting safety and
efficacy. Additionally, the FDA may refer applications </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review,
evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it generally follows such recommendations when making decisions
on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After the FDA evaluates a BLA, it will issue either an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing
of the biologic with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete
Response Letter generally outlines the deficiencies in the BLA and may require additional clinical data, additional pivotal clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or
manufacturing in order for FDA to reconsider the application. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an
opportunity for a hearing. The FDA has committed to reviewing such resubmissions in two or six months, depending on the type of information included. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy
the criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a condition of BLA approval, the FDA may require a REMS to help ensure that the benefits of the biologic outweigh the
potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals and elements to assure a product&#146;s safe use (ETASU). An ETASU can include, but is not limited to, special training or
certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market
and profitability of the product. Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product&#146;s safety or efficacy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Orphan Drug Designation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Orphan Drug Act, the FDA
may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals
in the United States but for which there is no reasonable expectation that the cost of developing and making the product for this type of disease or condition will be recovered from sales of the product in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent
and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation on its own does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation,
the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years from the date of such approval, except in limited circumstances,
such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. Competitors, however, may
receive approval of either a different product for the same indication or the same product for a different indication. In the latter case, because healthcare </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
professionals are free to prescribe products for <FONT STYLE="white-space:nowrap">off-label</FONT> uses, the competitor&#146;s product could be used for the orphan indication despite another
product&#146;s orphan exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">FDA&#146;s determination of whether two ADCs are the same product for purposes of orphan drug exclusivity is
based on a determination of sameness of the monoclonal antibody element and the functional element of the conjugated molecule. Two ADCs are deemed to be the same product if the complementarity determining region sequences of the antibody and the
functional element of the conjugated molecule are the same. A difference in either of those two elements can result in a determination that the molecules are different. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Expedited Development and Review Programs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The FDA is
authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no
effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The
sponsor of a new biologic candidate can request the FDA to designate the candidate for a specific indication for fast track status concurrent with, or after, the submission of the IND for the candidate. The FDA must determine if the biologic
candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#146;s request. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track
product&#146;s BLA before the application is complete. This &#147;rolling review&#148; is available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The
sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. Any product submitted to the FDA for marketing, including under a fast track program, may
be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Breakthrough therapy designation may be granted for products that are intended, alone or in combination with one or more other products, to treat a
serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. Under the breakthrough
therapy program, the sponsor of a new biologic candidate may request that the FDA designate the candidate for a specific indication as a breakthrough therapy concurrent with, or after, the submission of the IND for the biologic candidate. The FDA
must determine if the biological product qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#146;s request. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with
the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and
taking other steps to design the clinical studies in an efficient manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Priority review may be granted for products that are intended to treat a
serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application
designated for priority review in an effort to facilitate the review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Accelerated approval may be granted for products that are intended to treat a
serious or life-threatening condition and that generally provide a meaningful therapeutic advantage to patients over </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
existing treatments. A product eligible for accelerated approval may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a
clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or
prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how
a patient feels, functions or survives. The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a product, even
if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is
generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large studies to demonstrate a clinical or survival benefit. The accelerated approval pathway is contingent on a
sponsor&#146;s agreement to conduct additional post-approval confirmatory studies to verify and describe the product&#146;s clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that
the trial be designed, initiated and/or fully enrolled prior to approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market
on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for
qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval, but may
expedite the development or approval process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Additional Controls for Biologics </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products
whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and
critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the
manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA
together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products,
such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biological products. As
with drugs, after approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pediatric Information </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Pediatric Research Equity Act (PREA), BLAs or supplements to BLAs must contain data to assess the safety and effectiveness of the biological
product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers,
or deferrals, for submission of data. Unless otherwise required by regulation, PREA generally does not apply to any biological product for an indication for which orphan designation has been granted. However, beginning in 2020, PREA will apply to
BLAs for orphan-designated biologics if the biologic is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that FDA has determined is substantially relevant to the growth or
progression of a pediatric cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Best Pharmaceuticals for Children Act (the BPCA) provides a
<FONT STYLE="white-space:nowrap">six-month</FONT> extension of any exclusivity&#151;patent or <FONT STYLE="white-space:nowrap">non-patent&#151;for</FONT> a biologic if certain conditions are met. Conditions for exclusivity include the FDA&#146;s
determination that information relating to the use of a new biologic in the pediatric population may produce health benefits in that population, FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting
on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Post-Approval Requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Once a BLA is approved, a product
will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, <FONT STYLE="white-space:nowrap">off-label</FONT> promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet.
Biologics may be marketed only for the approved indications and in a manner consistent with the provisions of the approved labeling. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Adverse event
reporting and submission of periodic safety summary reports is required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product,
or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, biological product manufacture, packaging and labeling procedures must continue to conform to cGMPs after
approval. Biologic manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA,
during which the agency inspects a biologic product&#146;s manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality-control to maintain
compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with required regulatory standards, if it encounters problems following initial marketing, or if previously
unrecognized problems are subsequently discovered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory
requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with
manufacturing processes or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks or imposition
of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the
product from the market or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fines, warning or other enforcement-related letters or holds on post-approval clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license
approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Patent Term Restoration and Marketing Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Depending
upon the timing, duration and specifics of FDA approval of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act, informally known as the
Hatch-Waxman Act. The Hatch Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. Patent term extension (PTE), however, cannot extend the remaining term of a
patent beyond a total of 14 years from the product&#146;s approval date. The PTE period is generally one half the time between the effective date of an IND and the submission date of a BLA, plus the time between the submission date of a BLA and the
approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for such an extension, only those claims
covering the approved drug, a method for using it, or a method for manufacturing it may be extended and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and
approves the application for any PTE or restoration. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, we or our licensors may apply for PTE for our
owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA. However, an extension might not be granted
because of, for example, our or our licensors&#146; failure to exercise due diligence during the testing phase or regulatory review process, failure to apply within applicable deadlines, failure to apply prior to expiration of relevant patents or
any other failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than requested. There is no guarantee that the applicable authorities, including the FDA in the
United States, will agree with our assessment of whether any extensions should be granted, and if granted, the length of such extensions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Biosimilars and
Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Biologics Price Competition and Innovation Act of 2009 (the BPCIA) created an abbreviated approval pathway for biological
products shown to be biosimilar to, or interchangeable with, an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Biosimilarity, which requires that the biological product be highly similar to the reference product
notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through
analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the
reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety
risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A reference biological product is granted 12 years of data exclusivity from the time of first
licensure of the product and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#147;First
licensure&#148; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological
product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest or other related entity) for a change (not
including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the
biological product that does not result in a change in safety, purity or potency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The BPCIA is complex and only recently implemented by the FDA.
Recent government proposals have sought to reduce the twelve-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a
result, the ultimate impact, implementation and meaning of the BPCIA is subject to significant uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Regulatory Approval in the European Union </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The EMA is a decentralized scientific agency of the European Union. It coordinates the evaluation and monitoring of centrally authorized medicinal
products. It is responsible for the scientific evaluation of applications for EU marketing authorizations, as well as the development of technical guidance and the provision of scientific advice to sponsors. The EMA decentralizes its scientific
assessment of medicines by working through a network of about 4,500 experts throughout the European Union, nominated by the member states. The EMA draws on resources of over 40 National Competent Authorities of European Union member states. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The process regarding approval of medicinal products in the European Union follows roughly the same lines as in the United States and likewise generally
involves satisfactorily completing each of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the applicable EU
Good Laboratory Practice regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">submission to the relevant national authorities of a clinical trial application (CTA) for each trial in humans, which must
be approved before the trial may begin in each country where patient enrollment is planned; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each
proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">submission to the relevant competent authorities of a MAA, which includes the data supporting safety and efficacy as well
as detailed information on the manufacture and composition of the product in clinical development and proposed labelling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfactory completion of an inspection by the relevant national authorities of the manufacturing facility or facilities,
including those of third parties, at which the product is produced to assess compliance with strictly enforced cGMP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potential audits of the <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical trial sites that generated the
data in support of the MAA; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">review and approval by the relevant competent authority of the MAA before any commercial marketing, sale or shipment of the
product. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Preclinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal
studies, in order to assess the quality and potential safety and efficacy of the product. The conduct of the preclinical tests and formulation of the compounds for testing must comply with the relevant international, EU and national legislation,
regulations and guidelines. The results of the preclinical tests, together with relevant manufacturing information and analytical data, are submitted as part of the CTA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical Trials </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the Clinical Trials Directive
2001/20/EC, as amended (the Clinical Trials Directive), a system for the approval of clinical trials in the European Union has been implemented through national legislation of the member states. Under this system, approval must be obtained from the
competent national authority of each European Union member state in which a clinical trial is planned to be conducted. To this end, a CTA is submitted, which must be supported by an investigational medicinal product dossier and further supporting
information prescribed by the Clinical Trials Directive and other applicable guidance documents including but not being limited to the clinical trial protocol. Furthermore, a clinical trial may only be started after a competent ethics committee has
issued a favorable opinion on the clinical trial application in that country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Directive 2001/20/EC will be replaced by Regulation (EU)
No.&nbsp;536/2014, which became effective on June&nbsp;16, 2014. The Regulation introduces an authorization procedure based on a single submission via a single EU portal, an assessment procedure leading to a single decision, as well as transparency
requirements (the proactive publication of clinical trial data in the EU database). Since October 2016, based on its Policy 0070, the EMA has been publishing clinical data submitted by pharmaceutical companies to support their MAA for human
medicines under this centralized procedure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Manufacturing and import into the EU of investigational medicinal products is subject to the holding of
appropriate authorizations and must be carried out in accordance with cGMP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Review and Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Authorization to market a product in the European Union member states proceeds under one of four procedures: a centralized authorization procedure, a
mutual recognition procedure, a decentralized procedure or a national procedure. Since our products by their virtue of being antibody-based biologics fall under the centralized procedure, only this procedure will be described here. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Certain drugs, including medicinal products developed by means of biotechnological processes, must be approved via the centralized authorization
procedure for marketing authorization. A successful application under the centralized authorization procedure results in a marketing authorization from the European Commission, which is automatically valid in all European Union member states. The
other European Economic Area member states (namely Norway, Iceland and Liechtenstein) are also obligated to recognize the European Commission decision. The EMA and the European Commission administer the centralized authorization procedure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the centralized authorization procedure, the Committee for Medicinal Products for Human Use (the CHMP), serves as the scientific committee that
renders opinions about the safety, efficacy and quality of human products on behalf of the EMA. The CHMP is composed of experts nominated by each member state&#146;s national drug authority, with one of them appointed to act as Rapporteur for the <FONT
STYLE="white-space:nowrap">co-ordination</FONT> of the evaluation with the possible assistance of a further member of the CHMP acting as a <FONT STYLE="white-space:nowrap">Co-Rapporteur.</FONT> After approval, the Rapporteur(s) continue to monitor
the product throughout its life </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
cycle. The CHMP is required to issue an opinion within 210 days of receipt of a valid application, though the clock is stopped if it is necessary to ask the applicant for clarification or further
supporting data. The process is complex and involves extensive consultation with the regulatory authorities of member states and a number of experts. Once the procedure is completed, a European Public Assessment Report is produced. If the CHMP
concludes that the quality, safety and efficacy of the medicinal product is sufficiently proven, it adopts a positive opinion. The CHMP&#146;s opinion is sent to the European Commission, which uses the opinion as the basis for its decision whether
or not to grant a marketing authorization. If the opinion is negative, information is given as to the grounds on which this conclusion was reached. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After a drug has been authorized and launched, it is a condition of maintaining the marketing authorization that all aspects relating to its quality,
safety and efficacy must be kept under review. Sanctions may be imposed for failure to adhere to the conditions of the marketing authorization. In extreme cases, the authorization may be revoked, resulting in withdrawal of the product from sale.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Conditional Approval and Accelerated Assessment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As per
Article 14(7) of Regulation (EC) 726/2004, a medicine that would fulfill an unmet medical need may, if its immediate availability is in the interest of public health, be granted a conditional marketing authorization on the basis of less complete
clinical data than are normally required, subject to specific obligations being imposed on the authorization holder. These specific obligations are to be reviewed annually by the EMA. The list of these obligations shall be made publicly accessible.
Such an authorization shall be valid for 12 months, on a renewable basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">When an application is submitted for a marketing authorization in respect
of a drug for human use which is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation, the applicant may request an accelerated assessment procedure pursuant to Article 14(9) of
Regulation (EC) 726/2004. Under the accelerated assessment procedure, the CHMP is required to issue an opinion within 150 days of receipt of a valid application, subject to clock stops. We believe that some of the disease indications in which our
product candidates are currently being or may be developed in the future qualify for this provision, and we will take advantage of this provision as appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Period of Authorization and Renewals </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A marketing
authorization is initially valid for five years and may then be renewed on the basis of a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To
this end, the marketing authorization holder shall provide the EMA or the competent authority with a version of the file in respect of quality, safety and efficacy, including all variants introduced since the marketing authorization was granted, at
least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization shall be valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds
relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member
state within three years after authorization shall cease to be valid (the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;sunset clause&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Without prejudice to the law on the protection of industrial and commercial property, marketing authorizations for new medicinal products benefit from
an 8+2+1 year period of regulatory protection. This regime consists of a regulatory data protection period of eight years plus a concurrent market exclusivity of 10 years plus an additional market exclusivity of one further year if, during the first
eight years of those 10 years, the marketing approval holder obtains an approval for one or more new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
therapeutic indications which, during the scientific evaluation prior to their approval, are determined to bring a significant clinical benefit in comparison with existing therapies. Under the
current rules, a third party may reference the preclinical and clinical data of the reference product beginning eight years after first approval, but the third party may market a generic version of the reference product after only 10 (or 11) years
have lapsed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Orphan Drug Designation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regulation (EC)
141/2000 states that a drug shall be designated as an orphan drug if its sponsor can establish (i)&nbsp;that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more
than five in 10,000 persons in the European Union when the application is made, or that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Union
and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment; and (ii)&nbsp;that there exists no satisfactory method of diagnosis, prevention or
treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regulation (EC) 847/2000 sets out criteria for the designation of orphan drugs. An application for designation as an orphan product can be made any time
prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a <FONT STYLE="white-space:nowrap">10-year</FONT> period of market exclusivity, which means that no similar medicinal
product can be authorized in the same indication. This period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because
the product is sufficiently profitable not to justify continued market exclusivity. In addition, derogation from market exclusivity may be granted on an individual basis in very selected cases, such as consent from the marketing authorization
holder, inability to supply sufficient quantities of the product or demonstration of &#147;clinically relevant superiority&#148; by a similar medicinal product. Medicinal products designated as orphan drugs pursuant to Regulation (EC) 141/2000 are
eligible for incentives made available by the European Union and by the member states to support research into, and the development and availability of, orphan drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the MAA of a medicinal product designated as an orphan drug pursuant to Regulation (EC) 141/2000 includes the results of all studies conducted in
compliance with an agreed PIP, and a corresponding statement is subsequently included in the marketing authorization granted, the <FONT STYLE="white-space:nowrap">10-year</FONT> period of market exclusivity will be extended to 12 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Data Privacy and Security Laws </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Numerous state, federal and
foreign laws govern the collection, dissemination, use, access to, confidentiality and security of health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws,
state health information privacy laws, and federal and state consumer protection laws and regulations (e.g., Section&nbsp;5 of the FTC Act), govern the collection, use, disclosure, and protection of health-related and other personal information
could apply to our operations or the operations of our partners. State laws may be more stringent, broader in scope or offer greater individual rights with respect to protected health information, (PHI) than HIPAA, and state laws may differ from
each other, which may complicate compliance efforts. Entities that are found to be in violation of HIPAA, as the result of a breach of unsecured PHI, a complaint about privacy practices, or an audit by HHS, may be subject to significant civil,
criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA
<FONT STYLE="white-space:nowrap">non-compliance.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even when HIPAA does not apply, according to the FTC, violating consumers&#146; privacy rights or
failing to take appropriate steps to keep consumers&#146; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&nbsp;5(a) of the FTC Act. The FTC expects a company&#146;s data security
measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually
identifiable health information is considered sensitive data that merits stronger safeguards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Certain states have also adopted comparable privacy
and security laws and regulations, some of which may be more stringent than HIPAA. For example, California enacted the CCPA, on June&nbsp;28, 2018, which went into effect on January&nbsp;1, 2020. The CCPA gives California residents expanded rights
to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a
private right of action for data breaches that is expected to increase data breach litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Further, the collection, transfer, processing and
other use of personal data, including health data of individuals within the EEA and the United Kingdom, is governed by the GDPR, which came into effect in May 2018. The GDPR imposes strict requirements on controllers and processors of personal data
of individuals within the EEA and the United Kingdom, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals
regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches and taking certain measures when engaging third-party processors. The GDPR prohibits
the transfer of personal data to countries outside the EEA, such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Failure to
comply with the requirements of the GDPR and the related national data protection laws of the EEA member states and the United Kingdom may result in substantial fines and other administrative penalties. The GDPR and related data protection laws may
impose additional responsibility and liability in relation to personal data that we collect and process and we may be required to put in place additional mechanisms ensuring compliance with such rules. This may be onerous and adversely affect our
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Marketing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Much like the Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the
prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of European Union
member states, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Payments made to
physicians in certain European Union member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#146;s employer, his or her competent professional
organization and/or the regulatory authorities of the individual European Union member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union member states.
Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>International Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to regulations in the United States and Europe, a variety of foreign regulations govern clinical trials, commercial sales and distribution of
product candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA or European Commission approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Healthcare Laws and Regulations and Legislative Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Healthcare and Privacy Laws and Regulations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Healthcare
providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our operations, including any arrangements with healthcare providers,
physicians, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws that may affect the business or financial arrangements and relationships through which we would market, sell and distribute
our products. Our current and future operations are subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to CMS, HHS (including the Office of Inspector General, Office for Civil
Rights and the Health Resources and Service Administration), the U.S. Department of Justice (DOJ) and individual U.S. Attorney offices within the DOJ, and state and local governments. The healthcare laws that may affect our ability to operate
include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully
soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service
reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. A person or entity does not need to have
actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the
one hand and prescribers, purchasers and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn
narrowly and require strict compliance in order to offer protection. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Federal civil and criminal false claims laws, such as the FCA, which can be enforced by private citizens through civil qui
tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of federal funds, and knowingly making,
using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted
under the FCA in connection with their alleged <FONT STYLE="white-space:nowrap">off-label</FONT> promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting
purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product. In addition, a claim including items or services resulting from a violation of the federal
Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any request or demand&#148; for money or property
presented to the U.S. government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">HIPAA, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any
healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal
laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same
to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to
have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their
respective implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or
disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of such individually identifiable health information. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The federal transparency requirements under the Physician Payments Sunshine Act, created under the Patient Protection and
Affordable Care Act (the Affordable Care Act), which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#146;s Health Insurance Program (with
certain exceptions) to report annually to CMS information related to payments and other transfers of value provided to physicians, as defined by such law, and teaching hospitals and physician ownership and investment interests, including such
ownership and investment interests held by a physician&#146;s immediate family members. Effective January&nbsp;1, 2022, these reporting obligations will extend to include transfers of value made during the previous year to certain <FONT
STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse practitioners. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate
and timely manner to government programs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that
potentially harm consumers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">State and foreign laws that are analogous to each of the above federal laws, such as anti-kickback and false claims laws,
that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, and state laws that require
manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the
pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare
providers; state laws that require the reporting of marketing expenditures or drug pricing, including information pertaining to and justifying price increases; state and local laws that require the registration of pharmaceutical sales
representatives; and state laws that prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals; state laws that require the posting of information relating to clinical trials and their outcomes.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Legislative Reform </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We operate in a highly regulated industry, and new laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and
decisions, related to healthcare availability, the method of delivery and payment for healthcare products and services could negatively affect our business, financial condition and prospects. There is significant interest in promoting healthcare
reforms, and it is likely that federal and state legislatures within the United States and the governments of other countries will continue to consider changes to existing healthcare legislation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In 2010, the
U.S. Congress enacted the Affordable Care Act, which included changes to the coverage and reimbursement of drug products under government healthcare programs such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">established a branded prescription drug fee that pharmaceutical manufacturers of certain branded prescription drugs must
pay to the federal government; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to
the program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased
to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible
beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">extended manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in
Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to
additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for
certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">established a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery models
to lower Medicare and Medicaid spending, potentially including prescription drug spending; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">created a licensure framework for <FONT STYLE="white-space:nowrap">follow-on</FONT> biologic products.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There remain judicial and congressional challenges to certain aspects of the Affordable Care Act as well as efforts by the
current U.S. Presidential Administration to repeal or replace certain aspects of the Affordable Care Act. For example, in 2017, the U.S. Congress enacted the Tax Act, which eliminated the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared
responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; On December&nbsp;14, 2018,
the U.S. District Court for the Northern </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
District of Texas held that the individual mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it was repealed by the Tax Act, the remaining
provisions of the Affordable Care Act are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the Fifth Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the
District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. On March&nbsp;2, 2020, the Supreme Court of the United States granted the petitions for writ of certiorari to review this case and has
allotted one hour for oral arguments, which are expected to occur in the fall. It is unclear how this litigation and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act. It is difficult to predict the
future legislative landscape in healthcare and the effect on our business, results of operations, financial condition and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition,
there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. In 2011, the U.S. Congress enacted the Budget Control Act, which included provisions intended to reduce
the federal deficit. The Budget Control Act resulted in the imposition of 2% reductions in Medicare payments to providers beginning in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the
exception of a temporary suspension from May&nbsp;1, 2020 through December&nbsp;31, 2020, absent additional congressional action. In addition, in 2012, the U.S. Congress enacted the American Taxpayer Relief Act, which, among other things, further
reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five
years. If government spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA, to continue to function at current levels, which may impact the ability of relevant agencies to
timely review and approve research and development, manufacturing and marketing activities, which may delay our ability to develop, market and sell any product candidates we may develop. Moreover, any significant spending reductions affecting
Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget
Control Act, could have an adverse impact on our anticipated product revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, there has been heightened governmental scrutiny over
the manner in which manufacturers set prices for their marketed products, which has resulted in several congressional inquiries and proposed legislation designed to, among other things, bring more transparency to product pricing, review the
relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, the U.S. Presidential Administration&#146;s budget proposal for fiscal year 2021
includes a $135&nbsp;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs for patients
and increase patient access to lower-cost generic and biosimilar drugs. On March&nbsp;10, 2020, the current U.S. Presidential Administration sent &#147;principles&#148; for drug pricing to Congress, calling for legislation that would, among other
things, cap Medicare Part D beneficiary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and place limits on pharmaceutical price increases. Further, the current U.S. Presidential Administration previously released a &#147;Blueprint&#148; to lower drug prices and reduce <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs,
incentivize manufacturers to lower the list price of their products, and reduce the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of drug products paid by consumers. HHS has solicited feedback on
some of these measures and has implemented others under its existing authority. For example, CMS issued a final rule in May 2019 to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January&nbsp;1, 2020. This
final rule codified CMS&#146;s policy change that was effective January 1, 2019. While some of these and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
measures may require additional authorization to become effective, Congress and the current U.S. Presidential Administration have each indicated that it will continue to seek new measures to
control drug costs. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare
authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. We expect that additional state
and federal healthcare reform measures will be adopted in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Environmental, Health and Safety Laws and Regulations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and our third-party contractors are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory
procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain
aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In particular, our product
candidates use PBDs, which are highly potent cytotoxins that require special handling by our and our contractors&#146; staff. In the event of contamination or injury, or failure to comply with environmental, health and safety laws and regulations,
we could be held liable for any resulting damages, fines and penalties associated with such liability could exceed our assets and resources. Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur
substantial costs in order to comply with current or future environmental, health and safety laws and regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pharmaceutical Coverage, Pricing and
Reimbursement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The availability and extent of coverage and adequate reimbursement by governmental and private third-party payors are essential
for most patients to be able to afford expensive medical treatments. In both domestic and foreign markets, sales of our product candidates will depend substantially on the extent to which the costs of our product candidates will be covered by
third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors decide which products will be covered and establish reimbursement levels for those products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination that use of
a product is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Obtaining coverage approval and reimbursement for a product from a government or other third-party payor is a time-consuming and costly process that
could require us to provide supporting scientific, clinical and cost- effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement at a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
satisfactory level. If coverage and adequate reimbursement of our future products, if any, are unavailable or limited in scope or amount, such as may result where alternative or generic
treatments are available, we may be unable to achieve or sustain profitability. Adverse coverage and reimbursement limitations may hinder our ability to recoup our investment in our product candidates, even if such product candidates obtain
regulatory approval. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such products. Additionally, separate
reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. There is no uniform policy for coverage
and reimbursement in the United States and, as a result, coverage and reimbursement can differ significantly from payor to payor. In the United States, private payors often, but not always, follow Medicare coverage and reimbursement policies with
respect to newly approved products. It is difficult to predict what third- party payors will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents
for these new products. Further, one payor&#146;s determination to provide coverage and adequate reimbursement for a product does not assure that other payors will also provide coverage and adequate reimbursement for that product. We may need to
conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our product candidates. There can be no assurance that our product candidates will be considered medically necessary or
cost-effective. In addition to third-party payors, professional organizations and patient advocacy groups such as the National Comprehensive Cancer Network and the American Society of Clinical Oncology can influence decisions about reimbursement for
new medicines by determining standards for care. Therefore, it is possible that any of our product candidates, even if approved, may not be covered by third-party payors or the reimbursement limit may be so restrictive that we cannot commercialize
the product candidates profitably. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Reimbursement agencies in Europe may be more restrictive than payors in the United States. For example, a number
of cancer products have been approved for reimbursement in the United States but not in certain European countries. In Europe, pricing and reimbursement schemes vary widely from country to country. For example, some countries provide that products
may be marketed only after an agreement on reimbursement price has been reached. Such pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. Political, economic and regulatory
developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Other countries require the completion of additional health technology assessments that compare the cost-
effectiveness of a particular product candidate to currently available therapies. In addition, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide
reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product, may adopt a system of direct or indirect controls on the profitability of the company placing the
product on the market or monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between <FONT
STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states, can further reduce prices. Furthermore, many countries in the European Union have increased the amount of discounts required on pharmaceutical products, and these efforts
could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, and
prescription products in particular, has become increasingly intense. As a result, there are increasingly higher barriers to entry for new products. There can be no assurance that any country that has reimbursement limitations for pharmaceutical
products will allow favorable reimbursement and pricing arrangements for any of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
our products, if approved in those countries. Accordingly, the reimbursement for any products in Europe may be reduced compared with the United States and may be insufficient to generate
commercially reasonable revenues and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Furthermore, the containment of healthcare costs has become a priority of foreign and domestic
governments as well as private third-party payors. The prices of drugs have been a focus in this effort. Governments and private third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular
medications, which could affect our ability to sell our product candidates profitably. We also expect to experience pricing pressures due to the trend towards managed healthcare, the increasing influence of health maintenance organizations and
additional legislative changes. These and other cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower-than-anticipated product revenues. In addition, the publication of discounts
by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if coverage and adequate reimbursement of
our products is unavailable or limited in scope or amount, our revenues and the potential profitability of our product candidates in those countries would be negatively affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time to time, we may become involved
in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on us because
of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our corporate headquarters are located in Seattle, Washington, where we lease approximately 19,829 square feet of office, laboratory and
storage space pursuant to a lease agreement which commenced on November&nbsp;1, 2016 and expires on October&nbsp;31, 2026. We believe that our existing facilities are adequate for the foreseeable future. As we expand, we believe that suitable
additional alternative spaces will be available in the future on commercially reasonable terms, if required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees and Human Capital Resources </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of September&nbsp;30, 2020, we had 52 full-time employees. Of these employees, 19 held Ph.D., Pharm.D. or M.D. degrees, and 41 were engaged in
research, development and technical operations. We have 49 employees based at our headquarters in Seattle, Washington. Our employees are not represented by labor unions or covered by collective bargaining agreements. We consider our relationship
with our employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and
integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and
cash-based performance bonus awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth information regarding our executive officers and directors as of September&nbsp;30, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Position(s)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I>Executive Officers:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laura Shawver, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director, Chief Executive Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valerie Odegard, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Naomi Hunder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Russ Hawkinson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President of Finance</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Peter Thompson, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vickie L. Capps<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Robert&nbsp;Hershberg,&nbsp;M.D.,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Saqib Islam, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Scott Platshon<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Jonathan Root, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Thilo Schroeder, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Member of our audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Member of our compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Member of our nominating and corporate governance committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Mr. Platshon has notified us of his resignation from our board of directors, effective upon the effectiveness of the
registration statement to which this prospectus relates. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Laura Shawver, Ph.D. </B>has served as our Chief Executive Officer and member of our board of directors since April 2020. Dr.&nbsp;Shawver has also
served as a member of the board of directors for Relay Therapeutics, Inc. since March 2017 and Nkarta, Inc. since March 2020. Previously, Dr.&nbsp;Shawver served as the President and Chief Executive Officer and as a member of the board of directors
of Synthorx, Inc. from November 2017 until its acquisition by Sanofi in January 2020. From September 2011 through April 2018 she served as Chief Executive Officer and as a member of the board of directors of Cleave Biosciences. From October 2010 to
August 2011, Dr.&nbsp;Shawver was Entrepreneur in Residence for 5AM Ventures, and she was previously at Phenomix, Inc, SUGEN, Inc. and Berlex Biosciences (formerly Triton Biosciences). Dr.&nbsp;Shawver holds a B.S in microbiology and a Ph.D. in
pharmacology, both from the University of Iowa. We believe Dr.&nbsp;Shawver is qualified to serve on our board of directors due to her experience as a director and executive officer of biopharmaceutical companies, her extensive background as a
scientist and her educational background. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Valerie Odegard, Ph.D. </B>joined Silverback in 2016 and has served as our President since September
2020 and as our Chief Scientific Officer since October 2018. Previously, Dr.&nbsp;Odegard served as Vice President of Research at Juno Therapeutics, Inc. from September 2014 to October 2016, where she was responsible for discovery, preclinical
development and translational research leading to the advancement of novel cancer immunotherapies into clinical development. Previously, Dr.&nbsp;Odegard held research leadership positions at Novo Nordisk and Trubion, where she oversaw the discovery
and preclinical development of therapeutics for oncology and inflammatory conditions. Dr.&nbsp;Odegard holds a B.S. in Biology from Wake Forest University and a Ph.D. in immunobiology from Yale University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Naomi Hunder, M.D. </B>has served as our Chief Medical Officer since September 2020, and served as our Senior Vice President of Clinical Research and
Development from January 2019 to September </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
2020. Previously, Dr. Hunder served as the Vice President, Clinical Development and Medical Affairs of Acerta Pharma B.V. from March 2017 to January 2019. From September 2010 to February 2017,
Dr.&nbsp;Hunder held various roles at Seattle Genetics, Inc., including Vice President, Clinical Development. Dr.&nbsp;Hunder holds a B.A. in Biology from Carleton College and a M.D. from Jefferson Medical College of Thomas Jefferson University.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Russ Hawkinson</B> has served as our Senior Vice President of Finance since April 2020, and previously served as a finance consultant from March
2016 to April 2020. Previously, Mr.&nbsp;Hawkinson served as the Chief Financial Officer of OncoResponse, Inc., from May 2015 to June 2018. From April 2007 to June 2018, Mr.&nbsp;Hawkinson was the Chief Financial Officer of Theraclone Sciences, Inc.
Mr.&nbsp;Hawkinson holds a B.A. from the University of Washington and was a Certified Public Accountant in the State of Washington for 17&nbsp;years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Peter Thompson</B>, M.D. is one of our co-founders and has served as Chairman of
our board of directors since April 2016. Dr.&nbsp;Thompson previously served as our Chief Executive Officer from April 2016 until April 2020. Dr.&nbsp;Thompson is a Partner at OrbiMed Advisors LLC, an investment firm. Dr.&nbsp;Thompson currently
serves on the board of directors of Prevail Therapeutics Inc. since August 2017, Alpine Immune Sciences Inc. since July 2017, Corvus Pharmaceuticals, Inc. since December 2014, and PMV&nbsp;Pharma, Inc. since November 2014, as well as several private
companies. Previously, Dr.&nbsp;Thompson served on the board of Synthorx Inc. until its acquisition by Sanofi in January 2020, Adaptimmune Therapeutics PLC until June 2018, Principia Biopharma Inc. until September 2018, and Sierra Oncology, Inc.
until December 2015. Dr.&nbsp;Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and Becton, Dickinson and Company. Dr.&nbsp;Thompson is an Affiliate Professor of Neurosurgery at the
University of Washington. In addition, Dr.&nbsp;Thompson holds numerous patents and is a board-certified internist and oncologist. Dr.&nbsp;Thompson holds a Sc.&nbsp;B. in Molecular Biology and Mathematics from Brown University and an M.D. from
Brown University Medical School. We believe Dr.&nbsp;Thompson&#146;s experience in management and venture capital in the biopharmaceutical industry provides him with the qualifications and skills to serve as a member of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Vickie L. Capps</B> has served as a member of our board of directors since June 2020. Ms.&nbsp;Capps has also served on the boards of NuVasive, Inc.
since June 2015, Amedisys, Inc. since November 2019, and Otonomy, Inc. since March 2014. Ms.&nbsp;Capps also serves on the board of private company, OmniGuide Holdings, Inc., and the San Diego State University Research Foundation. Previously,
Ms.&nbsp;Capps served on the boards of directors of Synthorx, Inc. from April 2018 until its acquisition by Sanofi in January 2020, and Connecture, Inc. from October 2014 until April 2018. From July 2002 to December 2013, Ms.&nbsp;Capps was the
Chief Financial Officer of DJO Global, Inc. Ms.&nbsp;Capps holds a B.S. in business administration and accounting from San Diego State University. Ms.&nbsp;Capps is also a California Certified Public Accountant. We believe Ms.&nbsp;Capps is
qualified to serve on our board of directors because of her exceptionally strong skill set consisting of corporate finance, accounting, operations, investor relations, capital markets and strategic business development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Robert Hershberg, M.D., Ph.D. </B>has served as a member of our board of directors since 2016. Dr.&nbsp;Hershberg has also served as a member of the
board of directors of Adaptive Biotechnologies Corporation since February 2013, NanoString Technologies, Inc. since March 2015, and Fate Therapeutics, Inc. since May 2020. Since 2020, Dr.&nbsp;Hershberg has served as a Venture Partner at Frazier
Healthcare Partners. Previously, Dr.&nbsp;Hershberg was the EVP/Head of Business Development and member of the Executive Committee at Celgene Corporation from 2016 up to the acquisition of Celgene by Bristol-Myers Squibb in 2019. Dr.&nbsp;Hershberg
holds a B.S. in molecular biology and M.D., both from UCLA, and a Ph.D. in biology from the Salk Institute for Biological Studies. We believe </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Dr.&nbsp;Hershberg is qualified to serve on our board of directors due to his extensive experience as a senior executive officer at multiple biotechnology companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I></I></B><B>Saqib Islam, J.D.</B><B><I> </I></B>has served as a member of our board of directors since July 2017. Mr.&nbsp;Islam has also served as
the Chief Executive Officer and a member of the board of directors of Springworks Therapeutics, Inc. since August 2018. In addition, Mr.&nbsp;Islam has also served on the board of directors of Passage Bio, Inc. since March 2019. From February 2016
to August 2017, Mr.&nbsp;Islam served as Chief Business Officer at Moderna Therapeutics, Inc. From February 2013 to February 2016, Mr.&nbsp;Islam was Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, Inc.
Prior to joining Alexion, Mr.&nbsp;Islam served in various Managing Director positions at Morgan Stanley and Credit Suisse. Mr.&nbsp;Islam holds a B.A. from McGill University where he was a Faculty and University Scholar, and a J.D. from Columbia
Law School, where he was a Harlan Fiske Scholar. We believe that Mr.&nbsp;Islam is qualified to serve on our board of directors based on his experience and expertise in operations management and executive leadership at various biopharmaceutical
companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Scott Platshon</B> has served as a member of our board of directors since September 2020. Mr.&nbsp;Platshon joined EcoR1 in October
2015 where he currently serves as a Principal and is responsible for due diligence and analysis of biotechnology companies for value-oriented investment opportunities. Mr.&nbsp;Platshon previously served as an analyst at Aquilo Partners, a boutique
life sciences investment bank, from September 2014 to September 2015. Mr.&nbsp;Platshon holds a B.S. in bioengineering from Stanford University. We believe that Mr.&nbsp;Platshon&#146;s educational background and his experience as an investor in
life sciences companies provide him with the qualifications and skills necessary to serve as a member of our board of directors. Mr.&nbsp;Platshon has notified us of his resignation from our board of directors, effective upon the effectiveness of
the registration statement to which this prospectus relates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Jonathan Root, M.D.</B> has served as a member of our board of directors since
March 2020. Dr.&nbsp;Root has also served as a member of the boards of directors of Inari Medical, Inc. since September 2011 and OncoMed Pharmaceuticals from August 2004 to April 2019. Previously, Dr.&nbsp;Root served as a board member for OncoMed
Pharmaceuticals, Inc., from August 2004 until its merger with Mereo BioPharma Group plc in April 2019. Dr.&nbsp;Root has served as a member of the board of directors for a number of privately held companies, including Cleave Therapeutics, Edgewise
Therapeutics, and eFFECTOR Therapeutics. In addition, Dr.&nbsp;Root has also served as the Managing Member of several U.S. Venture Partners&#146; funds since 1998. Dr.&nbsp;Root holds an A.B. from Dartmouth College, an M.D. from University of
Florida, College of Medicine and an M.B.A. from Columbia Business School. We believe Dr.&nbsp;Root&#146;s medical, management and directorship experience in the healthcare industry qualified him to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B><I></I></B><B>Thilo Schroeder, Ph.D.</B><B><I></I></B> has served as a member of our board of directors since March 2020. Dr.&nbsp;Schroeder has
served as a member of the board of directors of Revolution Medicines, Inc. since March 2018 and PMV Pharmaceuticals Inc. since November 2019. Dr.&nbsp;Schroeder has also served as a Partner at Nextech Invest Ltd., a venture capital fund focused on
investing in oncology companies, since 2012. Previously, Dr.&nbsp;Schroeder served as a member of the board of directors of Blueprint Medicines Corp., from January 2014 to May 2015 and IDEAYA Biosciences, Inc., from January 2018 to June 2020.
Dr.&nbsp;Schroeder holds a B.S. in Biology from the Technical University of Darmstadt in Germany, an M.S. in Biotechnology from the &Eacute;cole de Sup&eacute;rieure de Biotechnologie de Strasbourg in France, and a Ph.D. in Biochemistry from the
University of Zurich in Switzerland. We believe that Dr.&nbsp;Schroeder&#146;s educational background, his experience as a board member of biotechnology and pharmaceutical companies, and his experience as an investor in life sciences companies
provide him with the qualifications and skills necessary to serve as a member of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Family Relationships and Other Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to our amended and restated voting agreement, which will terminate upon the closing of this offering, the following directors were designated
as directors to our board of directors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Dr.&nbsp;Shawver was designated by the holders of a majority of shares of our common stock. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Dr.&nbsp;Thompson was designated by OrbiMed Private Investments VI, LP and elected by the holders of a majority of the
shares of our Series A redeemable convertible preferred stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Dr.&nbsp;Root was designated by U.S. Venture Partners XII, L.P. and elected by the holders of a majority of the shares of
our Series B redeemable convertible preferred stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Dr.&nbsp;Schroeder was designated by Nextech VI Oncology SCSp and elected by the holders of a majority of the shares of our
Series B redeemable convertible preferred stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Mr.&nbsp;Platshon was designated by EcoR1 Capital Fund, LP and elected by the holders of a majority of the shares of our
Series C redeemable convertible preferred stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Dr.&nbsp;Hershberg, Mr.&nbsp;Islam and Ms.&nbsp;Capps were designated by the other members of our board of directors and
elected by the holders of a majority of shares of our common stock and redeemable convertible preferred stock, voting together as a single class. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Composition </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors currently consists
of eight members with no vacancies. In accordance with our amended and restated certificate of incorporation, which will be effective immediately prior to the closing of this offering, our board of directors will be divided into three classes with
staggered three-year terms. At each annual meeting of stockholders, the successors to the directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our
directors will be divided among the three classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Class&nbsp;I directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at the annual meeting of stockholders to be held in 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Class&nbsp;II directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at the annual meeting
of stockholders to be held in 2022; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Class&nbsp;III directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at the annual meeting
of stockholders to be held in 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect that any additional directorships resulting from an increase in the number of
directors will be distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with
staggered three-year terms may delay or prevent a change of our management or a change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Nasdaq Stock Market LLC (Nasdaq),
Marketplace Rules (the Nasdaq Listing Rules), independent directors must comprise a majority of our board of directors as a public company within 12 months of listing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors has undertaken a review of its composition, the composition of its committees and the independence of each director. Based upon
information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that all of our directors other than Drs. Shawver and
Thompson are independent directors, as defined by Rule 5605(a)(2) of the Nasdaq Listing Rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Committees </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. Our board of
directors may establish other committees to facilitate the management of our business. The composition and functions of each committee are described below. Members serve on these committees until their resignation or until otherwise determined by
our board of directors. Each committee intends to adopt a written charter that satisfies the applicable rules and regulations of the SEC and Nasdaq Listing Rules, which we will post on our website at www.silverbacktx.com upon the closing of this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our audit committee
consists of&nbsp;Ms.&nbsp;Capps, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our board of
directors has determined that each of the members of our audit committee satisfies the Nasdaq Stock Market and SEC independence requirements. Ms.&nbsp;Capps serves as the chair of our audit committee. The functions of this committee include, among
other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluating the performance, independence and qualifications of our independent auditors and determining whether to retain
our existing independent auditors or engage new independent auditors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving the engagement of our independent auditors to perform audit services and any permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">monitoring the rotation of partners of our independent auditors on our engagement team as required by law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">prior to engagement of any independent auditor, and at least annually thereafter, reviewing relationships that may
reasonably be thought to bear on their independence, and assessing and otherwise taking the appropriate action to oversee the independence of our independent auditor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing our annual and quarterly financial statements and reports, including the disclosures contained under the caption
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and discussing the statements and reports with our independent auditors and management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing, with our independent auditors and management, significant issues that arise regarding accounting principles and
financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing with management and our independent auditors any earnings announcements and other public announcements regarding
material developments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing procedures for the receipt, retention and treatment of complaints received by us regarding financial controls,
accounting or auditing matters and other matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparing the report that the SEC requires in our annual proxy statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and providing oversight of any related-person transactions in accordance with our related person transaction
policy and reviewing and monitoring compliance with legal and regulatory responsibilities, including our code of business conduct and ethics; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk
assessment and risk management are implemented; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing on a periodic basis our investment policy; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and evaluating on an annual basis the performance of the audit committee and the audit committee charter.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors has determined that Ms.&nbsp;Capps qualifies as an audit committee financial expert within the meaning of
SEC regulations and meets the financial sophistication requirements of the Nasdaq Listing Rules. In making this determination, our board has considered&nbsp;Ms.&nbsp;Capps&#146; prior experience, business acumen and independence. Both our
independent registered public accounting firm and management periodically meet privately with our audit committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that the composition
and functioning of our audit committee complies with all applicable requirements of the Sarbanes-Oxley Act, and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to
us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our compensation
committee consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serves as the chair of our compensation committee. Our board of directors has determined that each of the members of our compensation committee satisfies
the Nasdaq Stock Market independence requirements. The functions of this committee include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full board of directors
regarding) our overall compensation strategy and policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) the
compensation and other terms of employment of our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving (or if it deems it appropriate, making recommendations to the full board of directors regarding)
performance goals and objectives relevant to the compensation of our executive officers and assessing their performance against these goals and objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving (or if it deems it appropriate, making recommendations to the full board of directors regarding)
the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluating risks associated with our compensation policies and practices and assessing whether risks arising from our
compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and making recommendations to the full board of directors regarding the type and amount of compensation to be
paid or awarded to our <FONT STYLE="white-space:nowrap">non-employee</FONT> board members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing policies with respect to votes by our stockholders to approve executive compensation as required by
Section&nbsp;14A of the Exchange Act and determining our recommendations regarding the frequency of advisory votes on executive compensation, to the extent required by law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as required by
Section&nbsp;10C of the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">administering our equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing policies with respect to equity compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing the competitiveness of our executive compensation programs and evaluating the effectiveness of our compensation
policy and strategy in achieving expected benefits to us; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and making recommendations to the full board of directors regarding the terms of any employment agreements,
severance arrangements, change in control protections and any other compensatory arrangements for our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing with management and approving our disclosures under the caption &#147;Compensation Discussion and Analysis&#148;
in our periodic reports or proxy statements to be filed with the SEC, to the extent such caption is included in any such report or proxy statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparing the report that the SEC requires in our annual proxy statement (if applicable); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and assessing on an annual basis the performance of the compensation committee and the compensation committee
charter. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that the composition and functioning of our compensation committee complies with all applicable requirements
of the Sarbanes-Oxley Act, and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Nominating and Corporate Governance Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
nominating and corporate governance committee consists
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our board of directors has determined that each of
the members of this committee satisfies the Nasdaq Stock Market independence requirements.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serves as the chair of our nominating and corporate governance
committee. The functions of this committee include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">identifying, reviewing and evaluating candidates to serve on our board of directors consistent with criteria approved by
our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">determining the minimum qualifications for service on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluating director performance on the board and applicable committees of the board and determining whether continued
service on our board is appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluating, nominating and recommending individuals for membership on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluating nominations by stockholders of candidates for election to our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">considering and assessing the independence of members of our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developing a set of corporate governance policies and principles, including a code of business conduct and ethics,
periodically reviewing and assessing these policies and principles and their application and recommending to our board of directors any changes to such policies and principles; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">considering questions of possible conflicts of interest of directors as such questions arise; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and assessing on an annual basis the performance of the nominating and corporate governance committee and the
nominating and corporate governance committee charter. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that the composition and functioning of our nominating and
corporate governance committee complies with all applicable requirements of the Sarbanes-Oxley Act, and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">None of the members of the compensation committee is currently, or has been at any time, one of our executive officers or employees. None of our
executive officers currently serves, or has served </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or on our
compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with this offering, we intend to adopt a written code of business conduct and ethics that applies to all of our directors, officers and
employees, including our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions, and agents and representatives. The full text of our code of business conduct
and ethics will be posted on our website at www.silverbacktx.com upon the closing of this offering. The nominating and corporate governance committee of our board of directors will be responsible for overseeing our code of business conduct and
ethics and any waivers applicable to any director, executive officer or employee. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics, or waivers of such provisions applicable to our directors,
officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, and agents and representatives, on our website identified above.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitation on Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation, which will become effective immediately prior to the closing of this offering, and our amended
and restated bylaws, which will become effective upon the closing of this offering, limits our directors&#146; liability, and may indemnify our directors and officers to the fullest extent permitted under Delaware General Corporation Law (DGCL). The
DGCL provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability for any: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">transaction from which the director derives an improper personal benefit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unlawful payment of dividends or redemption of shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">breach of a director&#146;s duty of loyalty to the corporation or its stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These limitations of liability do not apply to liabilities arising under federal securities laws and do not affect the availability of equitable
remedies such as injunctive relief or recession. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The DGCL and our amended and restated bylaws provide that we will, in certain situations,
indemnify our directors and officers and may indemnify other employees and other agents, to the fullest extent permitted by law. Any indemnified person is also entitled, subject to certain limitations, to advancement, direct payment or reimbursement
of reasonable expenses (including attorneys&#146; fees and disbursements) in advance of the final disposition of the proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we
have entered, and intend to continue to enter, into separate indemnification agreements with some of our directors and officers. These indemnification agreements, among other things, require us to indemnify our directors and officers for certain
expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of their services as a director or officer, or any other company or enterprise to which the
person provides services at our request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We maintain a directors&#146; and officers&#146; insurance policy pursuant to which our directors and
officers are insured against liability for actions taken in their capacities as directors and officers. We believe that these provisions in our amended and restated certificate of incorporation and amended and restated bylaws and these
indemnification agreements are necessary to attract and retain qualified persons as directors and officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Insofar as indemnification for
liabilities arising under the Securities Act, may be permitted to directors, officers or control persons, in the opinion of the SEC, such indemnification is against public policy, as expressed in the Securities Act and is therefore unenforceable.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_13"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our named executive officers for the
year ended December&nbsp;31, 2019, consisting of our former principal executive officer and the next two most highly compensated executive officers who were serving in such capacity as of December&nbsp;31, 2019, were: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Peter Thompson, M.D.&#042;, the Chairman of our board of directors and former President and Chief Executive Officer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Valerie Odegard, Ph.D., our President and Chief Scientific Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Naomi Hunder, M.D., our Chief Medical Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table presents all
of the compensation awarded to or earned by or paid to our named executive officers during the fiscal year ended December&nbsp;31, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive&nbsp;
Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Peter Thompson, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Former President and Chief Executive Officer and Current Chairman of the Board of Directors</I><I><SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valerie Odegard, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">415,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>President and Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Naomi Hunder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The amounts disclosed represent the aggregate grant date fair value of the stock options granted to our named executive
officers during fiscal year 2019 under our Prior Plan, computed in accordance with FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock options are set forth in Note&nbsp;10 to our audited financial
statements included elsewhere in this prospectus. This amount does not reflect the actual economic value that may be realized by the named executive officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The amounts disclosed represent performance bonuses earned in 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Dr.&nbsp;Thompson served as our President and Chief Executive Officer until April 2020. Dr.&nbsp;Thompson did not receive
any compensation in 2019 for his services to the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Annual Base Salary </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The 2019 annual base salaries for our named executive officers are set forth in the table below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019 Base<BR>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Peter Thompson, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><I> </I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valerie Odegard, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">319,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Naomi Hunder, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">328,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#042;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Dr.&nbsp;Thompson resigned as President and Chief Executive Officer in April 2020. Laura Shawver, Ph.D., joined as our
President and Chief Executive Officer in April 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Dr.&nbsp;Thompson did not receive a salary for serving as our President and Chief Executive Officer in 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Dr.&nbsp;Hunder began in her employment after January&nbsp;1, 2019 with a base salary of $340,000. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We seek to motivate and reward our executives for achievements relative to our corporate goals and expectations for each fiscal year. In 2019, each of
our named executive officers (other than Dr.&nbsp;Thompson) was eligible to receive an annual performance bonus based on the achievement of performance goals as determined by our board of directors or an authorized committee thereof. For 2019, these
goals included financing and clinical objectives. Each named executive officer (other than Dr.&nbsp;Thompson) was assigned a target bonus expressed as a percentage of her annual base salary. The target bonus amounts for Drs. Odegard and Hunder for
2019 were set at 30% and 30%, respectively. In December 2019, our board of directors determined that the 2019 corporate goals were achieved at 100% and, as a result, approved annual performance bonuses for Drs. Odegard and Hunder for 2019 in the
amount of $95,790 and $98,088, respectively, as reflected in the <FONT STYLE="white-space:nowrap">&#147;Non-Equity</FONT> Incentive Plan Compensation&#148; column of the Summary Compensation Table above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity-Based Incentive Awards </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our equity-based incentive
awards are designed to align our interests and those of our stockholders with those of our employees and consultants, including our executive officers. Our board of directors or an authorized committee thereof is responsible for approving equity
grants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Historically, we have generally used stock options as an incentive for long-term compensation to our executive officers because stock
options allow our executive officers to realize value from this form of equity compensation only if our stock price increases relative to the stock option&#146;s exercise price, which exercise price is set at the fair market value of our common
stock on the date of grant. Certain stock options that we have granted to our executive officers permit &#147;early exercise,&#148; whereby the executive officer can purchase shares subject to the stock option prior to vesting, subject to our right
of repurchase, lapsing in accordance with the vesting schedule of the stock option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may grant equity awards at such times as our board of
directors determines appropriate. Our executives generally are awarded an initial grant in the form of a stock option in connection with their commencement of employment with us. Additional grants may occur periodically in order to specifically
incentivize executives with respect to achieving certain corporate goals or to reward executives for exceptional performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this
offering, we granted stock options to each of our named executive officers pursuant to our Prior Plan, the terms of which are described below under the subsection titled &#147;&#151;Employee Benefit Plans&#151;2016 Equity Incentive Plan.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the completion of this offering, we may grant additional equity awards to our named executive officers pursuant to our 2020 Plan, the terms of
which are described below under the subsection titled &#147;&#151;Employee Benefit Plans&#151;2020 Equity Incentive Plan.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All stock options
are granted with an exercise price per share that is no less than the fair market value of our common stock on the date of grant of such award. Our stock option awards generally vest over a four-year period and may be subject to acceleration of
vesting and exercisability under certain termination and change in control events, as described in more detail under the subsections titled &#147;&#151;Potential Payments and Benefits upon Termination or Change in Control&#148; and
&#147;&#151;Equity Benefit Plans.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding Equity Awards as of December&nbsp;31, 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table presents the outstanding equity incentive plan awards held by each named executive officer as of December&nbsp;31, 2019. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Unexercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;Per<BR>Share</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Peter Thompson, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valerie Odegard, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/15/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,690</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/15/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/12/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,236</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/11/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,093</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/18/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Naomi Hunder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/8/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,336</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/8/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">All of the option awards were granted under the Prior Plan, the terms of which plan is described below under
&#147;&#151;Employee Benefit and Stock Plans&#151;2016 Equity Incentive Plan.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">All of the option awards were granted with a per share exercise price equal to the fair market value of one share of our
common stock on the date of grant, as determined in good faith by our board of directors or compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">This option vests over four years from October 24, 2016, with 1/4 vesting on the first anniversary of the vesting
commencement date, and the remainder vesting in 36 equal monthly installments, subject to continued service through each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">This option vests over four years from June 1, 2018, subject to continued service through each such vesting date.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">This option vests over four years from December 18, 2018, with 1/4 vesting on the one month anniversary of the vesting
commencement date, and the remainder vesting in 1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> equal monthly installments, subject to continued service through each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">This option vests over four years from January 14, 2019, with 1/4 vesting on the first anniversary of the vesting
commencement date, and the remainder vesting in 36 equal monthly installments, subject to continued service through each such vesting date. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Options held by our named executive officers are eligible for accelerated vesting under specified circumstances. Please see the subsection titled
&#147;&#151;Potential Payments Upon Termination or Change of Control&#148; below for a description of such potential acceleration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging Growth Company
Status </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act. As an emerging growth company we will be exempt from certain
requirements related to executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive Officer to the
median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Pension Benefits </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our named executive officers did not
participate in, or otherwise receive any benefits under, any pension or retirement plan sponsored by us during the fiscal year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nonqualified Deferred Compensation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our named executive
officers did not participate in, or earn any benefits under, a <FONT STYLE="white-space:nowrap">non-qualified</FONT> deferred compensation plan sponsored by us during the fiscal year ended December&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment, Severance and Change in Control Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Employment Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Below are descriptions of our
employment agreements with our named executive officers as well as a description of our employment agreement with Laura Shawver, who joined as our President and Chief Executive Officer in April 2020. For a discussion of the severance pay and other
benefits to be provided in connection with a termination of employment and/or a change in control under the arrangements with our named executive officers and Dr.&nbsp;Shawver, please see &#147;&#151;Potential Payments Upon Termination or Change in
Control&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Laura Shawver, Ph.D.</I> We entered into an employment agreement with Dr.&nbsp;Shawver in March 2020, which governs the
current terms of Dr.&nbsp;Shawver&#146;s employment with us. Pursuant to the agreement, Dr.&nbsp;Shawver is entitled to an initial annual base salary of $450,000, is eligible to receive an annual performance bonus of up to 50% of her annual base
salary, as determined by our board of directors, and was granted an option to purchase 2,899,124 shares of our common stock. Dr.&nbsp;Shawver&#146;s employment is at will. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Peter Thompson, M.D.</I> We entered into a consulting agreement with Dr.&nbsp;Thompson in September 2018, which governs the current terms of
Dr.&nbsp;Thompson&#146;s engagement with us. Pursuant to the agreement, Dr.&nbsp;Thompson provided services as the Company&#146;s President and Chief Executive Officer with no compensation. In March 2020, Dr.&nbsp;Thompson resigned as President and
Chief Executive Officer, effective April 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Valerie Odegard, Ph.D.</I> We entered into an employment agreement with Dr.&nbsp;Odegard in July
2016, which governed the initial terms of Dr.&nbsp;Odegard&#146;s employment with us. Pursuant to the agreement, Dr.&nbsp;Odegard was entitled to an initial annual base salary of $260,000, was eligible to receive an annual performance bonus of up to
25% of her annual base salary, and was granted an option to purchase 225,212 shares of our common stock. As mentioned above, as of January&nbsp;1, 2019, Dr.&nbsp;Odegard was entitled to an annual base salary of $319,300 and was eligible to receive
an annual performance bonus with a target achievement of 30%, which amounts are subject to annual review by and at the sole discretion of our board of directors. Dr.&nbsp;Odegard&#146;s employment is at will. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Naomi Hunder, M.D.</I> We entered into an employment agreement with Dr.&nbsp;Hunder in December 2018, which governed the initial terms of
Dr.&nbsp;Hunder&#146;s employment with us. Pursuant to the agreement, Dr.&nbsp;Hunder was entitled to an initial annual base salary of $340,000, was eligible to receive an annual performance bonus of up to 30% of her annual base salary, and was
granted an option to purchase 164,336 shares of our common stock. As mentioned above, as of January&nbsp;1, 2019, Dr.&nbsp;Hunder was entitled to an annual base salary of $340,000 and was eligible to receive an annual performance bonus with a target
achievement of 30%, which amounts are subject to annual review by and at the sole discretion of our board of directors. Dr.&nbsp;Hunder&#146;s employment is at will. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Potential Payments Upon Termination or Change of Control </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regardless of the manner in which a named executive officer&#146;s service terminates, our named executive officers are entitled to receive amounts
earned during his or her term of service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Stock options granted to our named executive officers include a &#147;double-trigger&#148; vesting
acceleration provision, which provides for acceleration of each named executive officer&#146;s stock options in the event of a &#147;change in control&#148; (as defined in the Prior Plan) and the named executive officer&#146;s termination without
&#147;cause&#148; (as defined in the Prior Plan), or resignation for &#147;good reason&#148; (as defined in the Prior Plan), within one month before or 12 months after a change in control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to Dr.&nbsp;Shawver&#146;s employment agreement, if Dr.&nbsp;Shawver&#146;s employment is
terminated by us without &#147;cause&#148; or Dr.&nbsp;Shawver resigns for &#147;good reason&#148; (each, as defined in Dr.&nbsp;Shawver&#146;s employment agreement), upon the date that a release and waiver of claims in favor of us is irrevocable by
Dr.&nbsp;Shawver, we will pay Dr.&nbsp;Shawver 12 months of her then-current base salary. In addition, in the event that we undergo a &#147;change in control&#148; (as defined in Dr.&nbsp;Shawver&#146;s employment agreement), then upon the date that
a release and waiver of claims in favor of us is irrevocable by Dr.&nbsp;Shawver, 100% of the option granted pursuant to the terms of Dr.&nbsp;Shawver&#146;s employment agreement will automatically vest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Compensation and Benefits </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of our named executive
officers (except for Dr.&nbsp;Thompson) are eligible to participate in our employee benefit plans, including our medical, dental, vision and life plans, in each case on the same basis as all of our other employees. We pay the premiums for the life,
disability, accidental death and dismemberment insurance for all of our employees, including our named executive officers (except for Dr.&nbsp;Thompson). We generally do not provide perquisites or personal benefits to our named executive officers.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employee Benefit Plans </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that our ability to
grant equity-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders. In addition, we believe that our
ability to grant options and other equity-based awards helps us to attract, retain and motivate employees, consultants and directors, and encourages them to devote their best efforts to our business and financial success. The principal features of
our equity incentive plans and our 401(k) plan are summarized below. These summaries are qualified in their entirety by reference to the actual text of the plans, which, other than the 401(k) plan, are filed as exhibits to the registration statement
of which this prospectus is a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2020 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors adopted our 2020 Plan on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and our
stockholders approved our 2020 Plan on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our 2020 Plan provides for the grant of incentive stock options (ISOs) to employees, including employees of any
parent or subsidiary, and for the grant of nonstatutory stock options (NSOs), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees, directors, and
consultants, including employees and consultants of our affiliates. Our 2020 Plan is a successor to and continuation of our Prior Plan, and will become effective on the execution of the underwriting agreement related to this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Authorized Shares</I>.&nbsp;&nbsp;&nbsp;&nbsp;Initially, the maximum number of shares of our common stock that may be issued under our 2020 Plan
after it becomes effective will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, which is the sum of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;new shares; plus
(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the number of shares that remain available for issuance under our Prior Plan at the time our 2020 Plan becomes effective; and (iii)&nbsp;any shares
subject to outstanding stock options or other stock awards that were granted under our Prior Plan that are forfeited, terminate, expire or are otherwise not issued. In addition, the number of shares of our common stock reserved for issuance under
our 2020 Plan will automatically increase on January&nbsp;1 of each calendar year, starting on January&nbsp;1, 2021 (assuming the 2020 Plan becomes effective in 2020) through January&nbsp;1, 2030, in an amount equal to % of the total number of
shares of our capital stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by our board of directors. The maximum number of shares of our common stock that may be
issued on the exercise of incentive stock options under our 2020 Plan is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Shares subject to stock awards granted under our 2020 Plan that expire or terminate without being
exercised in full, or that are paid out in cash rather than in shares, do not reduce the number of shares available for issuance under our 2020 Plan. Additionally, shares become available for future grant under our 2020 Plan if they were issued
under stock awards under our 2020 Plan if we repurchase them or they are forfeited. This includes shares used to pay the exercise price of a stock award or to satisfy the tax withholding obligations related to a stock award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Plan Administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors, or a duly authorized committee of our board of directors, will administer our
2020 Plan. Our board of directors may also delegate to one or more of our officers the authority to (i)&nbsp;designate employees (other than officers) to receive specified stock awards and (ii)&nbsp;determine the number of shares subject to such
stock awards. Under our 2020 Plan, our board of directors has the authority to determine and amend the terms of awards and underlying agreements, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recipients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the exercise, purchase or strike price of stock awards, if any; the number of shares subject to each stock award;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the vesting schedule applicable to the awards, together with any vesting acceleration; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the form of consideration, if any, payable on exercise or settlement of the award. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the 2020 Plan, the board of directors also generally has the authority to effect, with the consent of any adversely affected participant: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the reduction of the exercise, purchase, or strike price of any outstanding award; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cancellation of any outstanding award and the grant in substitution therefore of other awards, cash, or other
consideration; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any other action that is treated as a repricing under generally accepted accounting principles. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Stock Options.</I>&nbsp;&nbsp;&nbsp;&nbsp;ISOs and NSOs are granted under stock option agreements adopted by the plan administrator. The plan
administrator determines the exercise price for stock options, within the terms and conditions of the 2020 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on
the date of grant. Options granted under the 2020 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Tax Limitations on ISOs</I>.&nbsp;&nbsp;&nbsp;&nbsp;The aggregate fair market value, determined at the time of grant, of our common stock with
respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO
may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our affiliates unless (i)&nbsp;the option exercise price is at least 110% of the
fair market value of the stock subject to the option on the date of grant; and (ii)&nbsp;the option is not exercisable after the expiration of five years from the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Restricted Stock Unit Awards.&nbsp;&nbsp;&nbsp;&nbsp;</I>Restricted stock units are granted under restricted stock unit award agreements adopted by
the plan administrator. Restricted stock units may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. A restricted stock unit may be settled by cash,
delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit agreement. Additionally, dividend equivalents may be credited in respect
of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
shares covered by a restricted stock unit. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited once the
participant&#146;s continuous service ends for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Restricted Stock Awards.</I>&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock awards are
granted under restricted stock award agreements adopted by the plan administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us, or any other form of legal consideration
that may be acceptable to our board of directors and permissible under applicable law. The plan administrator determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#146;s service
relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase
right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Stock Appreciation Rights.</I>&nbsp;&nbsp;&nbsp;&nbsp;Stock appreciation rights are granted under stock appreciation grant agreements
adopted by the plan administrator. The plan administrator determines the purchase price or strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our common stock on the date of grant. A
stock appreciation right granted under the 2020 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Performance Awards.&nbsp;&nbsp;&nbsp;&nbsp;</I>The 2020 Plan permits the grant of performance-based stock and cash awards. The plan administrator may
structure awards so that the shares of our stock, cash, or other property will be issued or paid only following the achievement of certain <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals during a designated performance
period. The performance criteria that will be used to establish such performance goals may be based on any measure of performance selected by the plan administrator. The performance goals may be based on a company-wide basis, with respect to one or
more business units, divisions, affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise
(i)&nbsp;in the award agreement at the time the award is granted or (ii)&nbsp;in such other document setting forth the performance goals at the time the goals are established, we will appropriately make adjustments in the method of calculating the
attainment of performance goals as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of changes to generally accepted accounting principles;
(4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting
principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such
divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock based
compensation and the award of bonuses under our bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; (11)&nbsp;to
exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles; and (12)&nbsp;to exclude the effects of the timing of acceptance for review and/or approval of submissions
to the FDA or any other regulatory body. In addition, we retain the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of the goals. The performance goals may differ from participant to participant and from
award to award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Other Stock Awards.&nbsp;&nbsp;&nbsp;&nbsp;</I>The plan administrator may grant other awards based in whole or in part by
reference to our common stock. The plan administrator will set the number of shares under the stock award and all other terms and conditions of such awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation
Limit</I>.&nbsp;&nbsp;&nbsp;&nbsp;The aggregate value of all compensation granted or paid to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director with respect to any period commencing on the date of our annual meeting of stockholders
for a particular year and ending on the day immediately prior to the date of the meeting for the next subsequent year, including stock awards granted and cash fees paid by us to such <FONT STYLE="white-space:nowrap">non-employee</FONT> director,
will not exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in total value, or in the event such <FONT STYLE="white-space:nowrap">non-employee</FONT> director is first appointed or elected to the
board during such annual period, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in total value (in each case, calculating the value of any such stock awards based on the grant date fair value of
such stock awards for financial reporting purposes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Changes to Capital Structure.</I>&nbsp;&nbsp;&nbsp;&nbsp;In the event there is a specified
type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, appropriate adjustments will be made to (i)&nbsp;the class and maximum number of shares reserved for issuance under the 2020 Plan,
(ii)&nbsp;the class and maximum number of shares by which the share reserve may increase automatically each year, (iii)&nbsp;the class and maximum number of shares that may be issued on the exercise of incentive stock options, and (iv)&nbsp;the
class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Corporate
Transactions.&nbsp;&nbsp;&nbsp;&nbsp;</I>The following applies to stock awards under the 2020 Plan in the event of a corporate transaction, unless otherwise provided in a participant&#146;s stock award agreement or other written agreement with us or
one of our affiliates or unless otherwise expressly provided by the plan administrator at the time of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event of a corporate
transaction, any stock awards outstanding under the 2020 Plan may be assumed, continued or substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the
stock award may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then with respect to any such stock awards that
are held by participants whose continuous service has not terminated prior to the effective time of the transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full to a date
prior to the effective time of the transaction (contingent upon the effectiveness of the transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the transaction, and any reacquisition
or repurchase rights held by us with respect to such stock awards will lapse (contingent upon the effectiveness of the transaction). With respect to performance awards with multiple vesting levels depending on performance level, unless otherwise
provided by an award agreement or by the administrator, the award will accelerate at 100% of target. If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then&nbsp;with
respect to&nbsp;any such stock awards that are held by persons other than current participants, such awards will terminate if not exercised (if applicable) prior to the effective time of the transaction, except that any reacquisition or repurchase
rights held by us with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the transaction. The plan administrator is not obligated to treat all stock awards or portions of stock awards in the same manner
and is not obligated to take the same actions with respect to all participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event a stock award will terminate if not exercised prior to
the effective time of a transaction, the plan administrator may provide, in its sole discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to the excess (if any) of
(i)&nbsp;the value of the property the participant would have received upon the exercise of the stock award over (ii)&nbsp;any exercise price payable by such holder in connection with such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Change in Control.&nbsp;&nbsp;&nbsp;&nbsp;</I>In the event of a change in control, as defined under our 2020 Plan, awards granted under our 2020 Plan
will not receive automatic acceleration of vesting and exercisability, although this treatment may be provided for in an award agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under our 2020 Plan, a corporate transaction is defined to include: (i)&nbsp;a sale of all or
substantially all of our assets; (ii)&nbsp;the sale or disposition of more than 50% of our outstanding securities; (iii)&nbsp;the consummation of a merger or consolidation where we do not survive the transaction; and (iv)&nbsp;the consummation of a
merger or consolidation where we do survive the transaction but the shares of our common stock outstanding before such transaction are converted or exchanged into other property by virtue of the transaction, unless otherwise provided in an award
agreement or other written agreement between us and the award holder. Under the 2020 Plan, a change in control is defined to include (1)&nbsp;the acquisition by any person or company of more than 50% of the combined voting power of our then
outstanding stock; (2)&nbsp;a merger, consolidation or similar transaction in which our stockholders immediately before the transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the
parent of the surviving entity); (3) the approval by the stockholders or the board of directors of a plan of complete dissolution or liquidation of the company, or the occurrence of a complete dissolution or liquidation of the company, except for a
liquidation into a parent corporation; (4)&nbsp;a sale, lease, exclusive license or other disposition of all or substantially all of our assets other than to an entity more than 50% of the combined voting power of which is owned by our stockholders;
and (5)&nbsp;an unapproved change in the majority of the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Transferability.&nbsp;&nbsp;&nbsp;&nbsp;</I>A participant may not
transfer stock awards under our 2020 Plan other than by will, the laws of descent and distribution, or as otherwise provided under our 2020 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Plan Amendment or Termination.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has the authority to amend, suspend, or terminate our 2020 Plan,
provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require the approval of our stockholders. No incentive stock options may be
granted after the tenth anniversary of the date our board of directors adopted our 2020 Plan. No stock awards may be granted under our 2020 Plan while it is suspended or after it is terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2016 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our 2016 Equity Incentive
Plan (Prior Plan) was originally adopted by our board of directors and approved by our stockholders on April&nbsp;1, 2016 and was amended on May&nbsp;16, 2017, January&nbsp;23, 2018, February&nbsp;21, 2019, March&nbsp;2, 2020, August&nbsp;6, 2020
and September 22, 2020. Our Prior Plan allows for the grant of ISOs to employees, including employees of any parent or subsidiary, and for the grant of NSOs and restricted stock awards to employees, directors, officers, and consultants, including
employees and consultants of our affiliates. Once our 2020 Plan becomes effective, no further grants will be made under our Prior Plan. Any outstanding awards granted under our Prior Plan will remain subject to the terms of our Prior Plan and
applicable award agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Authorized Shares.</I>&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of shares of our common stock that may be issued
under our Prior Plan is 14,711,318 shares. Shares subject to stock awards granted under our Prior Plan that expire, are forfeited, or terminate without being exercised in full do not reduce the number of shares available for issuance under our Prior
Plan. Additionally, shares used to pay the exercise price of a stock award or to satisfy the tax withholding obligations related to a stock award become available for future grant under our Prior Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Plan Administration.</I><I></I>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors or a duly authorized committee of our board of directors (referred to
herein as the plan administrator) administers our Prior Plan and the stock awards granted under it. Under our Prior Plan, the plan administrator has the authority to: (i)&nbsp;determine the fair market value of our common stock; (ii)&nbsp;construe
and interpret the Prior Plan and any agreement thereunder; (iii)&nbsp;prescribe, amend and rescind rules and regulations relating to the Prior Plan; (iv)&nbsp;approve persons to receive awards; (v)&nbsp;determine the number of shares or other
consideration subject to awards; (vi)&nbsp;determine whether awards will be granted singly, in combination with other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
awards under the Prior Plan or any other incentive or compensation plan of the company or otherwise; (vii)&nbsp;grant waivers of any conditions or the Prior Plan or any award;
(viii)&nbsp;determine the form and terms of any awards granted under the Prior Plan and other related documents used under the Prior Plan, which terms and conditions include the exercise or purchase price, time of exercise (which may be based on
performance criteria), circumstances under which vesting will be accelerated or forfeiture restrictions waived, or any other restriction or limitation regarding any award; (ix)&nbsp;correct any defect or reconcile any inconsistency in the Prior
Plan, any award or any related documentation; (x)&nbsp;determine whether an award has been earned; (xi)&nbsp;determine whether and under what circumstances an award may be settled in cash; (xii)&nbsp;implement an option exchange program and
establish the terms and conditions thereof; (xiii)&nbsp;make all other determinations necessary or advisable for the administration of the Prior Plan; and (xiv)&nbsp;extend the vesting period beyond a participant&#146;s termination date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Prior Plan, the plan administrator also generally has the authority to amend, modify, extend or terminate any outstanding stock awards,
including, but not limited to, substituting the award, changing the date of exercise or settlement, and converting an incentive stock option to a nonstatutory stock option; the holder&#146;s consent is required unless the plan administrator
determines that the action would not impair any of a participant&#146;s rights under their award or the action is otherwise permitted by the Prior Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Stock Options.</I><I></I>&nbsp;&nbsp;&nbsp;&nbsp;ISOs and NSOs are granted pursuant to award agreements adopted by the plan administrator. The plan
administrator determines the exercise price for a stock option, within the terms and conditions of the Prior Plan, provided that the exercise price of a stock option generally cannot be less than 100% (or 110% in the case of ISOs granted to certain
stockholders) of the fair market value of our common stock on the date of grant. Options granted under the Prior Plan vest at the rate specified by the plan administrator. Payment for the purchase of common stock issued upon the exercise of a stock
option is made in cash (by check or wire transfer), however, the plan administrator may allow for alternative forms of consideration and may include (i)&nbsp;cancellation of indebtedness of the company owed to a participant, (ii)&nbsp;past services
rendered to the company, (iii)&nbsp;surrendering shares of common stock already owned by a participant, provided such shares are surrendered to the company in good form for transfer, clear of all liens and encumbrances, (iv)&nbsp;delivery of a
promissory note, (v)&nbsp;provided that a public market for the common stock exists, by the delivery of a direction to a securities broker approved by the company to sell shares and to deliver all or part of the sales proceeds to the company,
(vi)&nbsp;by a cashless &#147;net exercise&#148; arrangement, (vii)&nbsp;other good and valuable consideration allowed under applicable law, or (viii)&nbsp;any combination of the above. The plan administrator determines the term of stock options
granted under the Prior Plan, up to a maximum of 10&nbsp;years (or five years in the case of ISOs granted to certain stockholders). The plan administrator shall determine the effect on a stock award of the disability, death, retirement, authorized
leave of absence, or any other change or purported change in a holder&#146;s status. Unless the plan administrator provides otherwise, stock options generally are not transferable except by will, the laws of descent and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Corporate Transactions</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our Prior Plan provides that, in the event of certain significant corporate transactions
(including, but not limited to, a merger, reorganization or sale of all or substantially all of our assets), the plan administrator may take any of the following actions that it deems appropriate in order to (i)&nbsp;prevent dilution or enlargement
of the benefits or potential benefits intended by us to be made available under the Prior Plan or with respect to any stock award; (ii)&nbsp;to facilitate such transaction or event or (iii)&nbsp;give effect to such changes in applicable laws or
accounting principles: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide for the assumption of or substitution of the stock award by the successor or surviving corporation, or a parent or
subsidiary thereof, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide for the cancellation of any stock award in exchange for an amount of cash or other property with a value equal to
what could have been obtained on exercise or settlement of the vested portion of such equity award; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">if any award is not assumed, converted, replaced or substituted, provide for acceleration of vesting of any stock award
prior to its termination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make adjustments in the number and type of shares of common stock underlying stock awards and/or terms and conditions of
stock awards; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that a stock award shall terminate and cannot vest, be exercised or become payable after the applicable event.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The plan administrator may treat holders and stock awards (or portions thereof) differently. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Changes to Capital Structure.</I>&nbsp;&nbsp;&nbsp;&nbsp;In the event there is a specified type of change in our capital structure, such as a stock
dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in the capital structure of the Company, appropriate adjustments will be made to (i)&nbsp;the number of shares reserved for
issuance under the Prior Plan; (ii)&nbsp;the exercise prices of and number of shares subject to outstanding awards; and (iii)&nbsp;any repurchase price per share applicable to shares issued pursuant to any award under the Prior Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Transferability.&nbsp;&nbsp;&nbsp;&nbsp;</I>A participant may not transfer stock awards under our Prior Plan other than by will, the laws of descent
and distribution, or as otherwise provided under our Prior Plan or an award granted thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Plan Amendment or
Termination</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has the authority to amend, suspend, or terminate our Prior Plan; provided that no amendment of the Prior Plan shall materially and adversely affect any outstanding stock award without
the consent of the affected holder. Certain material amendments require the approval of our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2020 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors adopted, and our stockholders approved, our 2020 Employee Stock Purchase Plan (ESPP)
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. The ESPP will become effective on the execution of the underwriting agreement related to this offering. The purpose of the ESPP is to secure
the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward our success and that of our affiliates. The ESPP is intended to qualify as an &#147;employee
stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Code for U.S. employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Share
Reserve.</I>&nbsp;&nbsp;&nbsp;&nbsp;Following this offering, the ESPP authorizes the issuance of shares of our common stock under purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of
our common stock reserved for issuance will automatically increase on January&nbsp;1 of each calendar year, beginning on January&nbsp;1, 2021 (assuming the ESPP becomes effective in 2020) through January&nbsp;1, 2030, by the lesser of
(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of the automatic increase; and
(ii)&nbsp;shares; provided that before the date of any such increase, our board of directors may determine that such increase will be less than the amount set forth in clauses (i)&nbsp;and (ii). As of the date hereof, no shares of our common stock
have been purchased under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Administration.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has delegated its authority to administer
the ESPP to our compensation committee. The ESPP is implemented through a series of offerings under which eligible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
employees are granted purchase rights to purchase shares of our common stock on specified dates during such offerings. Under the ESPP, we may specify offerings with durations of not more than 27
months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. We currently intend to have <FONT
STYLE="white-space:nowrap">24-month</FONT> offerings with multiple purchase periods (of approximately six months in duration) per offering, except that the first purchase period under our first offering may be shorter or longer than six months,
depending on the date on which the underwriting agreement relating to this offering becomes effective. An offering under the ESPP may be terminated under certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Payroll Deductions.&nbsp;&nbsp;&nbsp;&nbsp;</I>Generally, all regular employees, including executive officers, employed by us or by any of our
designated affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, up to&nbsp;&nbsp;&nbsp;&nbsp;% of their earnings (as defined in the ESPP) for the purchase of our common stock under the ESPP. Unless
otherwise determined by our board of directors, common stock will be purchased for the accounts of employees participating in the ESPP at a price per share that is at least the lesser of (i) 85% of the fair market value of a share of our common
stock on the first date of an offering; or (ii) 85% of the fair market value of a share of our common stock on the date of purchase. For the initial offering, which we expect will commence on the execution and delivery of the underwriting agreement
relating to this offering, the fair market value on the first day of the offering period will be the price at which shares of common stock are first sold to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Limitations</I>.&nbsp;&nbsp;&nbsp;&nbsp;Employees may have to satisfy one or more of the following service requirements before participating in the
ESPP, as determined by our board of directors, including: (i)&nbsp;being customarily employed for more than 20 hours per week; (ii)&nbsp;being customarily employed for more than five months per calendar year; or (iii)&nbsp;continuous employment with
us or one of our affiliates for a period of time (not to exceed two years). No employee may purchase shares under the ESPP at a rate in excess of $25,000 worth of our common stock based on the fair market value per share of our common stock at the
beginning of an offering for each year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such employee has voting power over
5% or more of our outstanding capital stock measured by vote or value under Section&nbsp;424(d) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Changes to Capital
Structure.</I>&nbsp;&nbsp;&nbsp;&nbsp;In the event that there occurs a change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in
property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar transaction, the board of directors will make appropriate adjustments to:
(i)&nbsp;the number of shares reserved under the ESPP; (ii)&nbsp;the maximum number of shares by which the share reserve may increase automatically each year; (iii)&nbsp;the number of shares and purchase price of all outstanding purchase rights; and
(iv)&nbsp;the number of shares that are subject to purchase limits under ongoing offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Corporate
Transactions.</I>&nbsp;&nbsp;&nbsp;&nbsp;In the event of certain significant corporate transactions, including: (i)&nbsp;a sale of all or substantially all of our assets; (ii)&nbsp;the sale or disposition of 90% of our outstanding securities;
(iii)&nbsp;the consummation of a merger or consolidation where we do not survive the transaction; and (iv)&nbsp;the consummation of a merger or consolidation where we do survive the transaction but the shares of our common stock outstanding
immediately before such transaction are converted or exchanged into other property by virtue of the transaction, any then-outstanding rights to purchase our stock under the ESPP may be assumed, continued or substituted for by any surviving or
acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue, or substitute for such purchase rights, then the participants&#146; accumulated payroll contributions will be used
to purchase shares of our common stock within ten business days before such corporate transaction, and such purchase rights will terminate immediately. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>ESPP</I> Amendment or Termination. Our board of directors has the authority to amend or terminate
our ESPP, provided that except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#146;s consent. We will obtain stockholder approval of any amendment to our ESPP as
required by applicable law or listing requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>401(k) Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We maintain a 401(k) plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees
are able to defer eligible compensation up to certain Code limits, which are updated annually. We have the ability to make matching and discretionary contributions to the 401(k) plan. Currently, we do not make matching contributions or discretionary
contributions to the 401(k) plan. The 401(k) plan is intended to be qualified under Section&nbsp;401(a) of the Code, with the related trust intended to be tax exempt under Section&nbsp;501(a) of the Code. As
<FONT STYLE="white-space:nowrap">a&nbsp;tax-qualified&nbsp;retirement</FONT> plan, contributions to the 401(k) plan are deductible by us when made, and contributions and earnings on those amounts are not generally taxable to the employees until
withdrawn or distributed from the 401(k) plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In 2019, none of our directors received cash, equity or other <FONT STYLE="white-space:nowrap">non-equity</FONT> compensation for service on our board
of directors. Accordingly, the director compensation table required by SEC rules has been omitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have reimbursed and will continue to
reimburse all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in attending board of directors
and committee meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Peter Thompson, M.D., the Chairman of our board of directors, served as our Chief Executive Officer until April 2020. See
the section titled &#147;Executive Compensation&#148; for more information regarding his compensation. Dr.&nbsp;Thompson was also a director as of December&nbsp;31, 2019, but did not receive any additional compensation for his service as a director.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In May 2020, we granted options to purchase shares of our common stock to three of our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors at an exercise price of $0.34 per share, consisting of 129,125 shares to Robert Hershberg, M.D., Ph.D., 188,231 shares to Saqib Islam, J.D. and 193,274 shares to Vickie L. Capps. These options will vest in 36 equal monthly installments,
subject to each director&#146;s continued service through each vesting date and the achievement of certain financing milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of
directors adopted a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 that will become effective upon the
execution and delivery of the underwriting agreement related to this offering and will be applicable to all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. This compensation policy provides that each such <FONT
STYLE="white-space:nowrap">non-employee</FONT> director will receive the following compensation for service on our board of directors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an annual cash retainer of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an additional annual cash retainer of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for service as a member of the audit committee, compensation committee and the nominating and corporate governance committee, respectively;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an additional annual cash retainer of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for service as chair of the audit committee, compensation committee and the nominating and corporate governance committee, respectively;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an initial option grant to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock on the date of each such <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s appointment to our board of directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an annual option grant to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock on the date of each of our annual stockholder meetings. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each of the option grants described above will be granted
under our 2020 Plan, the terms of which are described in more detail below under the section titled &#147;Executive Compensation&#151;Employee Benefit Plans&#151;2020 Equity Incentive Plan.&#148; Each such option grant will vest and become
exercisable subject to the director&#146;s continuous service to us through the earlier of the first anniversary of the date of grant or the next annual stockholder meeting. The term of each option will be ten years, subject to earlier termination
as provided in the 2020 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following includes a summary of transactions since January&nbsp;1, 2017 and any currently proposed transactions, to which we were or are to be a
participant, in which (i)&nbsp;the amount involved exceeded or will exceed the lesser of $120,000 or one percent of the average of our total assets at <FONT STYLE="white-space:nowrap">year-end</FONT> for the last two completed fiscal years; and
(ii)&nbsp;any of our directors, executive officers or holders of more than 5% of our capital stock, or any affiliate or member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest, other than
compensation and other arrangements that are described under the section of this prospectus titled &#147;Executive and Director Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Financings
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series A Redeemable Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2016 and September 2018, we entered into a Series A preferred stock purchase agreement with various investors, pursuant to which, in four
separate tranches, we issued and sold an aggregate of 15,714,283 shares of our Series A redeemable convertible preferred stock at a price per share of $3.50 for gross proceeds of $55.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table below sets forth the number of shares of our Series A redeemable convertible preferred stock purchased by our executive officers, directors,
holders of more than 5% of our capital stock and their affiliated entities or immediate family members. Each share of Series A redeemable convertible preferred stock in the table below will convert into one share of our common stock upon the closing
of this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B><br><B>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Greater than 5% stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">OrbiMed Private Investments VI, LP<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,857,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,999,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">OrbiMed Capital GP VI LLC (OrbiMed GP), is the general partner of OrbiMed VI. OrbiMed Advisors LLC (OrbiMed Advisors) is
the managing member of OrbiMed GP. Peter Thompson, M.D., the chairman of our board of directors, is a managing partner at OrbiMed Advisors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Convertible Promissory Note Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October
2019, we issued convertible promissory notes in the aggregate principal amount of $10.0&nbsp;million with an annual interest rate of 3% per annum, pursuant to a note purchase agreement, with various investors, or the note financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table below sets forth the principal amount of convertible promissory notes purchased by our executive officers, directors, holders of more than 5%
of our capital stock and their affiliated entities or immediate family members. In March 2020, $10.1&nbsp;million of principal and accrued and unpaid interest were converted into approximately 4,673,388 shares of the Company&#146;s Series B
redeemable convertible preferred stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount of<BR>Notes<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Greater than 5% stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">OrbiMed Private Investments VI, LP<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">OrbiMed Capital GP VI LLC (OrbiMed GP), is the general partner of OrbiMed VI. OrbiMed Advisors is the managing member of
OrbiMed GP. Peter Thompson, M.D., the chairman of our board of directors, is a managing partner at OrbiMed Advisors. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series B Redeemable
Convertible Preferred Stock Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2020, we entered into a Series B preferred stock purchase agreement with various investors,
pursuant to which, in three separate tranches, we issued and sold an aggregate of 36,433,916 shares of our Series B redeemable convertible preferred stock. 4,673,388 shares were issued upon conversion of then outstanding convertible notes and
accrued interest and 31,760,528 were sold at a price per share of $2.16 for gross proceeds of $68.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table below sets forth the
number of shares of our Series B redeemable convertible preferred stock purchased by our executive officers, directors, holders of more than 5% of our capital stock and their affiliated entities or immediate family members. Each share of Series B
redeemable convertible preferred stock in the table below will convert into one share of our common stock upon the closing of this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Greater than 5% stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">OrbiMed Private Investments VI, LP<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,259,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">U.S. Venture Partners XII, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,944,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">OrbiMed Capital GP VI LLC (OrbiMed GP), is the general partner of OrbiMed VI. OrbiMed Advisors is the managing member of
OrbiMed GP. Peter Thompson, M.D., the chairman of our board of directors, is a managing partner at OrbiMed Advisors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes 6,609,027 shares of Series B redeemable convertible preferred stock purchased by U.S. Venture Partners XII, L.P.
and 335,417 shares of Series B redeemable convertible preferred stock purchased by U.S. Venture Partners <FONT STYLE="white-space:nowrap">XII-A,</FONT> L.P. Presidio Management Group XII, L.L.C. (PMG XII) is the general partner of U.S. Venture
Partners XII, L.P. and U.S. Venture Partners <FONT STYLE="white-space:nowrap">XII-A,</FONT> L.P. Jonathan Root, Ph.D., a member of our board of directors, is a managing member of PMG&nbsp;XII. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series C Redeemable Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September 2020, we entered into a Series C redeemable convertible preferred stock purchase agreement with various investors, pursuant to which we
issued and sold an aggregate of 24,926,685 shares of our Series C redeemable convertible preferred stock at a price per share of $3.41 for gross proceeds of $84.9&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The table below sets forth the number of shares of our Series C redeemable convertible preferred stock
purchased by our executive officers, directors, holders of more than 5% of our capital stock and their affiliated entities or immediate family members. Each share of Series C redeemable convertible preferred stock in the table below will convert
into one share of our common stock upon the closing of this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Greater than 5% stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">OrbiMed Private Investments VI, LP<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,918,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,361,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">U.S. Venture Partners XII, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,128,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,847,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">OrbiMed Capital GP VI LLC (OrbiMed GP), is the general partner of OrbiMed VI. OrbiMed Advisors is the managing member of
OrbiMed GP. Peter Thompson, M.D., the chairman of our board of directors, is a managing partner at OrbiMed Advisors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes 1,073,793 shares of Series C preferred stock purchased by U.S. Venture Partners XII, L.P. and 54,496 shares of
Series C preferred stock purchased by U.S. Venture Partners <FONT STYLE="white-space:nowrap">XII-A,</FONT> L.P. Presidio Management Group XII, L.L.C. (PMG&nbsp;XII) is the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners <FONT
STYLE="white-space:nowrap">XII-A,</FONT> L.P. Jonathan Root, Ph.D., a member of our board of directors, is a managing member of PMG&nbsp;XII. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investors&#146; Rights, Management Rights, Voting and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with our redeemable convertible preferred stock financings, we entered into investors&#146; rights, voting and right of first refusal and <FONT
STYLE="white-space:nowrap">co-sale</FONT> agreements containing registration rights, information rights, rights of first offer, voting rights and rights of first refusal, among other things, with certain holders of our capital stock. The holders of
more than 5% of our capital stock listed above are parties to these agreements. Our executive officers and directors who are parties to these agreements or who are related to parties to these agreements are Peter Thompson, M.D., Jonathan Root, M.D.,
Thilo Schroeder, Ph.D. and Scott Platshon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These stockholder agreements will terminate upon the closing of this offering, except for the
registration rights granted under our investors&#146; rights agreement, which will terminate upon the earliest of (i)&nbsp;the closing of a deemed liquidation event, as defined in our amended and restated certificate of incorporation, as currently
in effect; (ii)&nbsp;with respect to each stockholder, the date when such stockholder can sell all of its registrable shares without limitation during a three-month period without registration pursuant to Rule 144 of the Securities Act (Rule 144),
or another similar exemption under the Securities Act; and (iii)&nbsp;five years after the completion of this offering. For a description of the registration rights, see the section of this prospectus titled &#147;Description of Capital
Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Consulting Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September 2018, we entered into a consulting agreement with Peter Thompson, M.D. the Chairman of our board of directors. Pursuant to the consulting
agreement, Dr.&nbsp;Thompson provided business strategy and research and development consulting and served as our President and Chief Executive Officer and did not receive any consideration in connection therewith. Dr.&nbsp;Thompson&#146;s
consulting agreement was terminated in April 2020. Dr.&nbsp;Thompson does not receive any salary, commission or other fees for serving as the Chairman of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have entered into indemnification agreements with certain of our current directors and executive officers, and intend to enter into new
indemnification agreements with each of our current directors and executive officers before the completion of this offering. Our amended and restated certificate of incorporation and our amended and restated bylaws will provide that we will
indemnify our directors and officers to the fullest extent permitted by applicable law. See the section of this prospectus titled &#147;Management&#151;Limitation on Liability and Indemnification Matters.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Directed Share Program </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At our request, the underwriters
have reserved for sale, at the initial public offering price, up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the shares offered by this prospectus, excluding the additional shares that the underwriters have a 30-day option to purchase,
for sale to certain of our directors and officers and certain other parties related to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to adopt a written related-person transactions policy prior to the completion of this offering that sets forth our policies and procedures
regarding the identification, review, consideration and oversight of &#147;related-person transactions.&#148; For purposes of our policy only, a &#147;related-person transaction&#148; is a transaction, arrangement or relationship (or any series of
similar transactions, arrangements or relationships) in which we and any &#147;related person&#148; are participants involving an amount that exceeds $120,000. Transactions involving compensation for services provided to us as an employee,
consultant or director are not considered related-person transactions under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than five percent of our common stock, including any of
their immediate family members and affiliates, including entities owned or controlled by such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the policy, where a transaction has
been identified as a related-person transaction, management must present information regarding the proposed related-person transaction to our audit committee (or, where review by our audit committee would be inappropriate, to another independent
body of our board of directors) for review. The presentation must include a description of, among other things, all of the parties thereto, the direct and indirect interests of the related persons, the purpose of the transaction, the material facts,
the benefits of the transaction to us and whether any alternative transactions are available, an assessment of whether the terms are comparable to the terms available from unrelated third parties and management&#146;s recommendation. To identify
related-person transactions in advance, we rely on information supplied by our executive officers, directors and certain significant stockholders. In considering related-person transactions, our audit committee or another independent body of our
board of directors takes into account the relevant available facts and circumstances including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the risks, costs and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the impact on a director&#146;s independence in the event the related person is a director, immediate family member of a
director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the terms of the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth, as of September&nbsp;30, 2020, information regarding beneficial ownership of our capital stock by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">all of our current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The percentage ownership information under the column titled &#147;Before Offering&#148; is based
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding as of September&nbsp;30, 2020 (which includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares outstanding
that are subject to forfeiture or our right to repurchase as of such date) assuming the conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in connection with the closing of this offering. The percentage ownership information under the column titled &#147;After Offering&#148; is based on the
sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering. The percentage ownership information assumes no purchases of any shares of common stock in this offering by the beneficial owners
identified in the table below. The percentage ownership information does not reflect any potential purchases pursuant to the directed share program or otherwise of any shares of common stock in this offering by the beneficial owners identified in
the table below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of
a security if he, she or it possesses sole or shared voting or investment power of that security. In addition, the rules include shares of common stock issuable upon the exercise of stock options that are currently exercisable or exercisable within
60 days of September&nbsp;30, 2020. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding
for the purpose of computing the percentage ownership of any other person. The information contained in the following table does not necessarily indicate beneficial ownership for any other purpose. Unless otherwise indicated, the persons or entities
identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless otherwise noted below, the address for each beneficial owner listed in the table below is c/o
Silverback Therapeutics, Inc., 500 Fairview Ave N, Suite 600, Seattle, Washington 98109. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Greater than 5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">OrbiMed Private Investments VI, LP<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,034,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">U.S. Venture Partners XII, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,072,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Hunt Pacific, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,381,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nextech VI Oncology SCSp<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,207,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pontifax and its affiliated entities<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,655,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">EcoR1 Capital Fund Qualified, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,398,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Peter Thompson, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,034,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laura Shawver, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,899,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valerie Odegard, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">281,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Naomi Hunder, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vickie L. Capps<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Robert Hershberg, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Saqib Islam, J.D.<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Scott Platshon<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,398,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Jonathan Root, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,072,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Thilo Schroeder, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,207,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">All current executive officers and directors as a group (11&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(17)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,962,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">1,000,000 shares of common stock held by OPI VI - HoldCo LLC, 1,000,000 shares of common stock held by OrbiMed Private
Investments VI, LP (OrbiMed VI) and 26,034,680 shares of common stock issuable upon conversion of redeemable convertible preferred stock held by OrbiMed VI. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 7,682,820 shares of common stock issuable upon conversion of redeemable convertible preferred stock held by
U.S. Venture Partners XII, L.P. and 389,913 shares of common stock issuable upon conversion of redeemable convertible preferred stock held by U.S. Venture Partners <FONT STYLE="white-space:nowrap">XII-A,</FONT> L.P. Presidio Management Group XII,
L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners <FONT STYLE="white-space:nowrap">XII-A,</FONT> L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by
USVP XII. Jonathan Root, a member of our board of directors, is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The address for each of these entities is 1460 El Camino Real, Suite
100, Menlo Park, California 94025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 5,381,823 shares of common stock issuable upon conversion of redeemable convertible preferred stock held by
Hunt Pacific, L.P. The address for Hunt Pacific, L.P. is 4401 North Mesa, El Paso, Texas 79902. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 6,207,889 shares of common stock issuable upon conversion of redeemable convertible preferred stock held by
Nextech VI Oncology SCSp (Nextech VI). Nextech VI GP S.A R.L (Nextech GP), is the general partner of Nextech VI. Nextech Invest AG is the investment advisor of Nextech VI. Thilo Schroeder, Ph.D., a member of our board of directors, is a managing
partner at Nextech Invest AG and may therefore be deemed to be the beneficial owner of the common shares held by Nextech VI Oncology SCSp. The address of each of these entities is 8 Rue Lou Hemmer, 1748 Findel, Luxembourg. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 2,530,959 shares of common stock issuable upon conversion of redeemable convertible preferred stock held
by Pontifax (Israel) V, L.P.; (ii) 983,330 shares of common stock issuable upon conversion of redeemable convertible preferred stock held by Pontifax (China) V, L.P.; (iii) 676,034 shares of common stock issuable upon conversion of redeemable
convertible preferred stock held by Pontifax (Cayman) V, L.P. (together, the Pontifax Entities); and (iv)&nbsp;465,593 shares of common stock owned by Pontifax Late Stage Fund L.P. (Late Stage L.P.). Pontifax 5 G.P. L.P. (Pontifax 5 G.P.) is the
general partner of each of the Pontifax Entities and Pontifax Management 4 G.P. (2015) Ltd. (Pontifax Management) is the general partner of Pontifax 5 G.P. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a
result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP.
Pontifax Late Stage GP Ltd. is the general partner of Late Stage L.P. The address of each of the Pontifax Entities and Late Stage L.P. is c/o The Pontifax Group, 14 Shenkar Street, Herzelia,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Israel. and investment power with respect to the shares held by each of the Pontifax Entities. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement
with Pontifax 5 GP. Pontifax Late Stage GP Ltd. is the general partner of Late Stage L.P. The address of each of the Pontifax Entities and Late Stage L.P. is c/o The Pontifax Group, 14 Shenkar Street, Herzelia, Israel. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(6</SUP><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 493,619 shares of common stock issuable upon conversion of redeemable convertible preferred stock held by
EcoR1 Capital Fund, L.P., 2,470,707 shares of common stock issuable upon conversion of redeemable convertible preferred stock held by EcoR1 Capital Fund Qualified, L.P. and 1,434,501 shares of common stock issuable upon conversion of redeemable
convertible preferred stock held by EcoR1 Venture Opportunity Fund, L.P. (collectively, EcoR1). EcoR1 Capital, LLC is the general partner of EcoR1, Scott Platshon, a member of our board of directors, is an affiliate of EcoR1 Capital, LLC and EcoR1.
The address for EcoR1 is 357 Tehama Street, Suite 3, San Francisco, California 94103. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(7</SUP><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of the shares listed in footnote (1)&nbsp;above, which are held by OrbiMed. Dr.&nbsp;Thompson shares voting and
dispositive power with respect to the shares held by OrbiMed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of (a) 294,118 shares of common stock held by Dr. Shawver, 225,138 shares of which will be subject to a right of
repurchase by us as of November 29, 2020, and (b) 2,605,006 shares of common stock that Dr. Shawver has the right to acquire from us within 60 days of September 30, 2020 pursuant to the exercise of stock options, 2,605,006 of which will be unvested
but exercisable as of November 29, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 281,336 shares of common stock that Dr.&nbsp;Odegard has the right to acquire from us within 60 days of
September&nbsp;30, 2020 pursuant to the exercise of stock options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 78,980 shares of common stock that Dr.&nbsp;Hunder has the right to acquire from us within 60 days of
September&nbsp;30, 2020 pursuant to the exercise of stock options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 193,274 shares of common stock held by Ms.&nbsp;Capps, 167,274 shares of which were subject to a right of
repurchase by us as of November&nbsp;29, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 261,740 shares of common stock that Dr.&nbsp;Hershberg has the right to acquire from us within 60 days of
September&nbsp;30, 2020 pursuant to the exercise of stock options, 111,951 of which will be unvested but exercisable as of November 29, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of (a) 56,583 shares of common stock held by Mr. Islam, 9,431 shares of which will be subject to a right of
repurchase by us as of November 29, 2020, and (b) 188,231 shares of common stock that Mr. Islam has the right to acquire from us within 60 days of September 30, 2020 pursuant to the exercise of stock options, 159,478 of which will be unvested but
exercisable as of November 29, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of the shares listed in footnote (6) above, which are held by EcoR1. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(15</SUP><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of the shares listed in footnote (2)&nbsp;above, which are held by U.S. Venture Partners. Dr.&nbsp;Root is a
managing member at U.S. Venture Partners and shares voting and dispositive power with respect to the shares held by U.S. Venture Partners. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of the shares listed in footnote (4)&nbsp;above, which are held by Nextech VI. Dr.&nbsp;Schroeder shares voting
and dispositive power with respect to the shares held by Nextech VI. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(17)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of the shares described in note (8)&nbsp;through note (16)&nbsp;above and shares held or issuable upon exercise
of stock options by Mr.&nbsp;Hawkinson who is not named in the table above. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon filing and effectiveness of our amended and restated certificate of incorporation and the closing of this offering, our authorized capital stock
will consist of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, par value $0.0001 per share, and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock, par
value $0.0001 per share. All of our authorized preferred stock upon the closing of this offering will be undesignated. The following is a summary of the rights of our common and preferred stockholders and some of the provisions of our amended and
restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the closing of this offering, respectively, and of the Delaware General Corporation Law. This summary is not complete.
For more detailed information, please see our amended and restated certificate of incorporation and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant
provisions of the Delaware General Corporation Law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Outstanding Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of September&nbsp;30, 2020, we
had&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding (which includes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares outstanding that are subject to forfeiture or
our right to repurchase as of such date), held of record by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stockholders. This amount excludes our outstanding shares of redeemable convertible preferred
stock, which will convert into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the closing of this offering. Based on the number of shares of common stock outstanding as of
September&nbsp;30, 2020, and assuming (i)&nbsp;the conversion of all of our outstanding shares of redeemable convertible preferred stock and (ii)&nbsp;the issuance by us
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering, there will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding upon the
closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of September&nbsp;30, 2020, there were&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock subject to outstanding options under the Prior Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders. The affirmative vote of
holders of at least 66<SUP STYLE="font-size:85%; vertical-align:top"> 2</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be
required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified structure of our board of directors, the size of our board of
directors, removal of directors, director liability, vacancies on our board of directors, special meetings, stockholder notices, actions by written consent and exclusive jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to preferences that may apply to
any outstanding preferred stock, holders of our common stock are entitled to receive ratably any dividends that our board of directors may declare out of funds legally available for that purpose on a
<FONT STYLE="white-space:nowrap">non-cumulative</FONT> basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally
available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Rights and Preferences </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to
our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in
the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Fully Paid and Nonassessable </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of
our outstanding shares of common stock are, and the shares of common stock to be issued in this offering will be, fully paid and nonassessable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred Stock
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the closing of this offering, all of our currently outstanding shares of redeemable convertible preferred stock will convert into common
stock and we will not have any preferred stock outstanding. Immediately after the completion of this offering, our certificate of incorporation will be amended and restated to delete all references to such shares of redeemable convertible preferred
stock. Under the amended and restated certificate of incorporation, our board of directors will have the authority, without further action by the stockholders, to issue up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and
privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then
outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the
voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of
delaying, deferring or preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no
current plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Warrants </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2016, in connection with the entry into the loan and security agreement with Silicon Valley Bank (the Loan Agreement), we issued to the
lender the warrant to purchase an aggregate of 28,226 shares of our common stock with an exercise price equal to $0.62 per share. In December 2017, in connection with an amendment of the Loan Agreement, we issued to Silicon Valley Bank a warrant to
purchase an aggregate of 5,769 shares of common stock with an exercise price equal to $0.65 per share. These warrants expire ten years from the date of issuance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After the closing of this offering,
certain holders of shares of our common stock, including all of the current preferred stockholders, including certain holders of more than five percent of our capital stock and entities affiliated with certain of our directors, will be entitled to
certain rights with respect to registration of the shares of common stock issued upon conversion of our redeemable convertible preferred stock under the Securities Act. These shares are referred to as registrable securities. The holders of these
registrable securities possess registration rights pursuant to the terms of our amended </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and restated investors&#146; rights agreement and are described in additional detail below. The registration of shares of our common stock pursuant to the exercise of the registration rights
described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay the registration expenses, other than underwriting discounts,
selling commissions, stock transfer taxes and certain fees and disbursements of counsel for the selling holders, of the shares registered pursuant to the demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registrations described
below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Generally, in an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions and limitations, to
limit the number of shares the holders may include. The demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights described below will expire upon the earliest to occur of (i)&nbsp;the closing of our first registered
public offering of our common stock, with respect to any holder who then holds an amount of shares equal to less than one percent of our outstanding securities and may sell all such shares under Rule 144 during any three-month period; (ii)&nbsp;the
fourth anniversary after the closing this offering; or (iii)&nbsp;with respect to any particular holder, at such time that such holder can sell its shares under Rule 144 of the Securities Act or another similar exemption during any three-month
period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Demand Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The holders
of registrable securities will be entitled to certain demand registration rights. Beginning 180 days following the effectiveness of the registration statement of which this prospectus is a part, certain investors holding, collectively, at least 30%
of registrable securities then outstanding may, on not more than two occasions, request that we register all or a portion of their shares, subject to certain specified exceptions. If any of these holders exercises its demand registration rights,
then holders of all registrable securities will be entitled to register their shares, subject to specified conditions and limitations, in the corresponding offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Piggyback Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with this
offering, the holders of registrable securities are entitled to their rights to notice of this offering and to include their shares of registrable securities in this offering. The requisite percentage of these stockholders have waived all such
stockholders&#146; rights to notice of this offering and to include their shares of registrable securities in this offering. In the event that we propose to register any of our securities under the Securities Act in another offering, either for our
own account or for the account of other security holders, the holders of registrable securities will be entitled to certain &#147;piggyback&#148; registration rights allowing them to include their shares in such registration, subject to specified
conditions and limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the closing of this offering, the holders of registrable securities will initially be entitled to certain Form
<FONT STYLE="white-space:nowrap">S-3</FONT> registration rights. Certain investors may, on not more than two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> within any <FONT STYLE="white-space:nowrap">12-month</FONT> period,
request that we register all or a portion of their shares on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we are qualified to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> subject to specified exceptions.
Such request for registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> must cover securities with an aggregate offering price which equals at least $2.0&nbsp;million, net of selling expenses. The right to have such shares registered on
Form <FONT STYLE="white-space:nowrap">S-3</FONT> is further subject to other specified conditions and limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Anti-Takeover Provisions of
Delaware Law and Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Section&nbsp;203 of the Delaware General Corporation Law </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to Section&nbsp;203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested
stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the transaction
that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested
stockholder) those shares owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will
be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual or
special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Section&nbsp;203 defines a &#147;business combination&#148; to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested
stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of
the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any
class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial
benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, Section&nbsp;203 defines an &#147;interested stockholder&#148; as an entity
or person who, together with the person&#146;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the
corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts
to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Among other things, our amended and restated certificate of incorporation and amended and restated bylaws will: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">permit our board of directors to issue up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in control; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that the authorized number of directors may be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that our board of directors will be classified into three classes of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that, subject to the rights of any series of preferred stock to elect directors, directors may only be removed for
cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least 66 2/3% of the voting power of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by
the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of
stockholders and not be taken by written consent or electronic transmission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for
election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that special meetings of our stockholders may be called only by the chairman of our board of directors, our chief
executive officer or president or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors, and not by our stockholders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock
entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
amendment of any of these provisions would require approval by the holders of at least 66<SUP STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the voting power of all of our then-outstanding common stock
entitled to vote generally in the election of directors, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The combination of these provisions will make it more
difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to retain and discharge our officers,
these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue
preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These provisions are
intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our
vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying
changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions,
including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because
negotiation of takeover proposals could result in an improvement of their terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Choice of Forum </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation to be effective immediately prior to the closing of this offering will provide that the Court of
Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter
jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&nbsp;any
derivative action or proceeding brought on our behalf; (ii)&nbsp;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders;
(iii)&nbsp;any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of
incorporation or our bylaws; (iv)&nbsp;any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; (v)&nbsp;any action or proceeding as to which the Delaware General Corporation
Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi)&nbsp;any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine. This provision will not
apply to suits brought to enforce a duty or liability created by the Securities Act, Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our amended and restated certificate of incorporation to be effective immediately prior to the closing of this offering will provide that,
unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a
cause of action arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">While the Delaware courts have determined that such choice of forum provisions are facially
valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. We
note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and
consented to these provisions. Although we believe these provisions benefit us by providing increased consistency in the application of law for the specified types of actions and proceedings, the provisions may have the effect of discouraging
lawsuits against us or our directors and officers. Please also see the section titled &#147;Risk Factors&#151;Our amended and restated certificate of incorporation, which will become effective upon the closing of this offering designates the state
courts the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the feral court for the District of Delaware, and the federal district courts of the United States of America will be the exclusive forums for
certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against our company and our directors, officers and employees.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitation on Liability and Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">See the section
of this prospectus titled &#147;Management&#151;Limitation on Liability and Indemnification Matters.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have applied to list our common stock on the Nasdaq Global Market under the trading symbol &#147;SBTX.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the closing of this offering, the transfer agent and registrar for our common stock will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The transfer agent&#146;s address is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock, and a liquid trading market for our common stock may not develop or be
sustained after this offering. Future sales of our common stock, including shares issued upon the exercise of outstanding options, in the public market after the completion of this offering, or the perception that those sales may occur, could
adversely affect the prevailing market price for our common stock from time to time or impair our ability to raise equity capital in the future. As described below, only a limited number of shares of our common stock will be available for sale in
the public market for a period of several months after the completion of this offering due to contractual and legal restrictions on resale described below. Future sales of our common stock in the public market either before or after restrictions
lapse, or the perception that those sales may occur, could adversely affect the prevailing market price of our common stock at such time and our ability to raise equity capital at a time and price we deem appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sale of Restricted Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the number of shares of
our common stock outstanding as of September&nbsp;30, 2020, upon the closing of this offering and assuming (i)&nbsp;the conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the closing of this offering;&nbsp;(ii) no exercise of the underwriters&#146; option to purchase additional shares of common
stock; and (iii)&nbsp;no exercise of outstanding options or warrants, we will have outstanding an aggregate of approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock. Of these shares, all of the
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock to be sold in this offering will be freely tradable in the public market without restriction or further registration under the Securities Act, unless the
shares are held by any of our &#147;affiliates&#148; as such term is defined in Rule 144 or subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. All remaining shares of common stock held by existing stockholders immediately prior
to the consummation of this offering will be &#147;restricted securities,&#148; as such term is defined in Rule 144. These restricted securities were issued and sold by us in private transactions and are eligible for public sale only if registered
under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule 144 or Rule 701, which rules are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a result of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements referred to below and the provisions of Rule 144 and Rule 701 under the
Securities Act, based on the number of shares of our common stock outstanding (calculated as of September&nbsp;30, 2020 on the basis of the assumptions described above and assuming no exercise of the underwriter&#146;s option to purchase additional
shares, if any, and no exercise of outstanding options), the shares of our common stock (excluding the shares sold in this offering) that will be available for sale in the public market are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Approximate Number of Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>First Date Available For Sale Into Public Market</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">181 days after the date of this prospectus, upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements referred to below, subject in some cases to applicable volume, manner of sale and other limitations
under Rule 144 and Rule 701.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may issue shares of common stock from time to time as consideration for future acquisitions, investments or other
corporate purposes. In the event that any such acquisition, investment or other transaction is significant, the number of shares of common stock that we may issue may in turn be significant. We may also grant registration rights covering those
shares of common stock issued in connection with any such acquisition and investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the shares of common stock reserved for future
issuance under our 2020 Plan will become eligible for sale in the public market to the extent permitted by the provisions of various vesting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
schedules, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, a registration statement under the Securities Act or an exemption from registration, including Rule 144 and Rule 701.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 144 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, persons who have beneficially
owned restricted shares of our common stock for at least six months, and any affiliate of the company who owns shares of our common stock, are entitled to sell their securities without registration with the SEC under an exemption from registration
provided by Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under Rule 144, as currently in effect, once we have been subject to the public company reporting requirements of the
Exchange Act for at least 90 days, and we are current in our Exchange Act reporting at the time of sale, a person (or persons whose shares are required to be aggregated) who is not deemed to have been one of our &#147;affiliates&#148; for purposes
of Rule 144 at any time during the 90 days preceding a sale and who has beneficially owned restricted securities within the meaning of Rule 144 for at least six months, including the holding period of any prior owner other than one of our
&#147;affiliates,&#148; is entitled to sell those shares in the public market (subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to below, if applicable) without complying with the manner of sale, volume limitations
or notice provisions of Rule 144, but subject to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares proposed to be sold for at least 12 months, including the holding period of any
prior owner other than &#147;affiliates,&#148; then such person is entitled to sell such shares in the public market without complying with any of the requirements of Rule 144 (subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement
referred to above, if applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under Rule 144, as currently in effect, once we have been subject to the public company reporting
requirements of the Exchange Act for at least 90 days, our &#147;affiliates,&#148; as defined in Rule 144, who have beneficially owned the shares proposed to be sold for at least six months, are entitled to sell in the public market, upon expiration
of any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and within any three-month period, a number of those shares of our common stock that does not exceed the greater of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1% of the number of shares of common stock then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock immediately upon the closing of this offering (calculated as of September&nbsp;30, 2020 on the basis of the assumptions described above and assuming no
exercise of the underwriter&#146;s option to purchase additional shares, if any, and no exercise of outstanding options); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the average weekly trading volume of our common stock on Nasdaq during the four calendar weeks preceding the filing of a
notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Such sales under Rule 144 by our &#147;affiliates&#148; or persons selling shares
on behalf of our &#147;affiliates&#148; are also subject to certain manner of sale provisions, notice requirements and to the availability of current public information about us. Notwithstanding the availability of Rule 144, the holders of
substantially all of our restricted securities have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as referenced above and their restricted securities will become eligible for sale (subject to the above limitations under
Rule 144) upon the expiration of the restrictions set forth in those agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 701 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under Rule 701 as currently in effect, any of our employees, directors, officers, consultants or advisors who acquired common stock from us
in connection with a written compensatory stock or option plan or other written agreement in compliance with Rule 701 before the effective date of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the registration statement of which this prospectus is a part (to the extent such common stock is not subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement) and who are not our
&#147;affiliates&#148; as defined in Rule 144 during the immediately preceding 90 days, is entitled to rely on Rule 701 to resell such shares beginning 90 days after the date of this prospectus in reliance on Rule 144, but without complying with the
notice, manner of sale, public information requirements or volume limitation provisions of Rule 144. Persons who are our &#147;affiliates&#148; may resell those shares beginning 90 days after the date of this prospectus without compliance with
minimum holding period requirements under Rule 144 (subject to the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to below, if applicable). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with this offering, we, our directors, our executive officers and holders of substantially all of our other outstanding shares of common
stock or securities convertible into or exchangeable for shares of our common stock outstanding upon the closing of this offering, have agreed, subject to certain limited exceptions, with the underwriters not to directly or indirectly offer, sell,
contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of or hedge any shares of our common stock or any options to purchase shares of our common stock, or any securities convertible into or exchangeable for
shares of common stock during the period from the date of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement continuing through and including the date 180 days after the date of this prospectus, except with the prior written consent of
the representatives of the underwriters, and certain other limited exceptions. These agreements are described in the section of this prospectus titled &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition to the restrictions contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above, we have entered into
agreements with certain security holders, including the amended and restated investors&#146; rights agreement, our standard form of option agreement, our standard form of restricted stock agreement and our standard form of restricted stock purchase
agreement, that contain market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions or incorporate market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions from our equity incentive plan imposing restrictions on the ability of
such security holders to offer, sell or transfer our equity securities for a period of 180 days following the date of this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Upon the closing of this offering and assuming an initial public offering price of $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus), the holders of an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in
registration statements that we may file for ourselves or other stockholders. After registration pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act. See the section of this prospectus
titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information regarding these registration rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Incentive Plans
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to file with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act covering
the shares of common stock reserved for issuance under outstanding options under the Prior Plan and reserved for issuance under the 2020 Plan and the ESPP. The registration statement is expected to be filed and become effective as soon as
practicable after the completion of this offering. Accordingly, shares registered under the registration statement will be available for sale in the open market following its effective date, subject to Rule 144 volume limitations and the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described above, if applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following is a summary of the material U.S. federal income tax consequences to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) of the acquisition, ownership and disposition of our common stock issued pursuant to this offering. This discussion is not a complete analysis of all potential U.S. federal income
tax consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment income, and does not address any estate or gift tax consequences or any tax consequences arising under any state, local
or foreign tax laws, or any other U.S. federal tax laws. This discussion is based on the Internal Revenue Code of 1986, as amended (Code), and applicable Treasury Regulations promulgated thereunder, judicial decisions and published rulings and
administrative pronouncements of the Internal Revenue Service (IRS), all as in effect as of the date hereof. These authorities are subject to differing interpretations and may change, possibly retroactively, resulting in U.S. federal income tax
consequences different from those discussed below. We have not requested a ruling from the IRS with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree
with such statements and conclusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion is limited to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders who purchase our
common stock pursuant to this offering and who hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all of the U.S.
federal income tax consequences that may be relevant to a particular holder in light of such holder&#146;s circumstances. This discussion also does not consider any specific facts or circumstances that may be relevant to holders subject to special
rules under the U.S. federal income tax laws, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">partnerships or other pass-through entities (and investors therein); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;controlled foreign corporations;&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;passive foreign investment companies;&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">banks, financial institutions, investment funds, insurance companies, brokers, dealers or traders in securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations and governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons that own, or have owned, actually or constructively, more than 5% of our common stock at any time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">accrual-method taxpayers subject to special tax accounting rules under Section&nbsp;451(b) of the Code; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons holding our common stock as part of a hedging or conversion transaction, straddle, synthetic security, constructive
sale, or other risk reduction strategy or integrated investment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If an entity or arrangement that is classified as a partnership
for U.S. federal income tax purposes holds our common stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner, the activities of the partnership and certain determinations made
at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
partner level. Partnerships holding our common stock and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to
them of holding and disposing of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE
INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL OR FOREIGN TAX
LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Definition of <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is any beneficial owner of our common stock that is not a
&#147;U.S. person&#148; or a partnership (including any entity or arrangement treated as a partnership) for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under
the laws of the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a trust (i)&nbsp;whose administration is subject to the primary supervision of a U.S. court and which has one or more U.S.
persons who have the authority to control all substantial decisions of the trust or (ii)&nbsp;that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions on Our Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have never declared or
paid any cash dividends on our capital stock and we do not intend to pay cash dividends on our common stock for the foreseeable future. However, if we make cash or other property distributions on our common stock, such distributions will constitute
dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes
will constitute a return of capital and will first be applied against and reduce a holder&#146;s tax basis in our common stock, but not below zero. Any excess will be treated as gain realized on the sale or other disposition of our common stock and
will be treated as described under the section titled &#147;Gain on Disposition of Our Common Stock&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to the discussions below
regarding effectively connected income, backup withholding and Sections 1471 through 1474 of the Code (commonly referred to as FATCA), dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock generally will be
subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such lower rate specified by an applicable income tax treaty. To receive the benefit of a reduced treaty rate, a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must furnish us or our paying agent with a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or applicable successor form) and satisfy applicable certification and other requirements. This certification must be provided to us or our paying agent before
the payment of dividends and must be updated periodically. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds the stock through a financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to provide appropriate documentation to the agent, which then will be required to provide certification to us or our paying agent, either directly or
through other intermediaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that do not provide the required
certification on a timely basis, but that qualify for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock in connection with the conduct of a trade or business in the United
States, and dividends paid on our common stock are effectively connected with such holder&#146;s U.S. trade or business (and are attributable to such holder&#146;s permanent establishment in the United States if required by an applicable tax
treaty), the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be exempt from U.S. federal withholding tax. To claim the exemption, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must generally furnish a valid IRS Form <FONT
STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form) to the applicable withholding agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">However, any such effectively
connected dividends paid on our common stock generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected
earnings and profits for the taxable year, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Gain on Disposition of Our Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to the
discussions below regarding backup withholding and FATCA, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to U.S. federal income tax on any gain realized on the sale or other disposition of our common stock,
unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a
trade or business in the United States, and if required by an applicable income tax treaty, is attributable to a permanent establishment maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual present in the United States
for 183 days or more during the taxable year of the disposition, and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our common stock constitutes a &#147;United States real property interest&#148; by reason of our status as a United States
real property holding corporation (USRPHC) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period for
our common stock, and our common stock is not &#147;regularly traded&#148; on an established securities market (as defined by applicable Treasury Regulations). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Determining whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our other
trade or business assets and our foreign real property interests. We believe that we are not currently and do not anticipate becoming a USRPHC for U.S. federal income tax purposes, although there can be no assurance we will not in the future become
a USRPHC. If we are or become a USRPHC and the &#147;regularly traded&#148; exception noted above does not apply to the disposition, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will generally be taxed on any gain in the same manner as
gain that is effectively connected with the conduct of a U.S. trade or business, except that the branch profits tax generally will not apply. Prospective investors are encouraged to consult their own tax advisors regarding the possible consequences
to them if we are, or were to become, a USRPHC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Gain described in the first bullet point above generally will be subject to U.S. federal income tax
on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject
to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. Gain described in the second bullet point above will be subject to U.S.
federal income tax at a flat 30% rate (or such lower rate specified by an applicable income tax treaty), but may be offset by certain U.S.-source capital losses (even though the individual is not considered a resident of the United States), provided
that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income tax returns with respect to such losses. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding any
applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Annual reports are required to be filed with the IRS and provided to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder indicating
distributions on our common stock paid to such holder and the amount of any tax withheld with respect to those distributions. These information reporting requirements apply even if no withholding was required because the distributions were
effectively connected with the holder&#146;s conduct of a U.S. trade or business, or withholding was reduced or eliminated by an applicable income tax treaty. This information also may be made available under a specific treaty or agreement with the
tax authorities in the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is established. Backup withholding, currently at a 24% rate, generally will not apply to payments to a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of dividends on or the gross proceeds of a disposition of our common stock provided the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder furnishes the required certification for its <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by providing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> or certain
other requirements are met. Backup withholding may apply if the payor has actual knowledge, or reason to know, that the holder is a U.S. person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Backup withholding is not an additional tax. If any amount is withheld under the backup withholding rules, the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder should consult with a U.S. tax advisor regarding the possibility of and procedure for obtaining a refund or a credit against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s
U.S. federal income tax liability, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Withholding on Foreign Entities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">FATCA imposes a U.S. federal withholding tax of 30% on certain payments made to a &#147;foreign financial institution&#148; (as specially defined under
these rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities certain information regarding certain U.S. account holders of such
institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or an exemption applies. FATCA also generally imposes a U.S. federal withholding tax of
30% on certain payments made to a <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity unless such entity provides the withholding agent a certification identifying certain direct and indirect U.S. owners of the entity or an
exemption applies. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for
refunds or credits of such taxes. FATCA currently applies to dividends paid on our common stock. The U.S. Treasury released proposed Treasury Regulations which, if finalized in their present form, would eliminate the federal withholding tax of 30%
applicable to the gross proceeds of a sale or other disposition of our common stock. In its preamble to such proposed Treasury Regulations, the U.S. Treasury stated that taxpayers may generally rely on the proposed regulations until final
regulations are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prospective investors are encouraged to consult with their own tax advisors regarding the potential implications of FATCA
on their investment in our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to certain conditions,
each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs&nbsp;&amp; Co. LLC, SVB Leerink LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated are the representatives of the
underwriters. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">H.C. Wainwright&nbsp;&amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than the
shares covered by the option described below unless and until this option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters have an option to buy up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares from us to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above. They may exercise that option for
30 days. If any shares are purchased pursuant to this option, the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters by us. Such amounts are shown
assuming both no exercise and full exercise of the underwriters&#146; option to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Shares sold by the underwriters to the public will initially be offered at the initial public offering price set forth
on the cover of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from the initial public offering price.
After the initial offering of the shares, the representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#146; right
to reject any order in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and our officers, directors, and holders of substantially all of our common stock have agreed with the
underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus continuing through the
date 180 days after the date of this prospectus, except with the prior written consent of the representatives. This agreement does not apply to any existing employee benefit plans. See &#147;Shares Eligible for Future Sale&#148; for a discussion of
certain transfer restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At our request, the underwriters have reserved for sale, at the initial public offering price, up to % of the shares
offered by this prospectus, excluding the additional shares that the underwriters have a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase, for sale to certain of our directors and officers and certain other parties
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
related to us. If these persons purchase reserved shares, this will reduce the number of shares available for sale to the general public. Any reserved shares that are not so purchased will be
offered by the underwriters to the general public on the same terms as the other shares offered by this prospectus. If purchased by any of our officers or directors, these shares will be subject to the terms of
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. Other than the underwriting discount described on the front cover of this prospectus, the underwriters will not be entitled to any commission with respect to shares of our
common stock sold pursuant to the directed share program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prior to the offering, there has been no public market for the shares. The initial public
offering price has been negotiated among us and the representatives. Among the factors to be considered in determining the initial public offering price of the shares, in addition to prevailing market conditions, will be our historical performance,
estimates of the business potential and our earnings prospects, an assessment of our management and the consideration of the above factors in relation to market valuation of companies in related businesses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have applied to list our common stock on the Nasdaq Global Market under the symbol &#147;SBTX&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the offering, the underwriters may purchase and sell shares of common stock in the open market. These transactions may include short
sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering, and a short position
represents the amount of such sales that have not been covered by subsequent purchases. A &#147;covered short position&#148; is a short position that is not greater than the amount of additional shares for which the underwriters&#146; option
described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to cover the covered
short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares pursuant to the option described above.
&#147;Naked&#148; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must cover any such naked short position by
purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely
affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock made by the underwriters in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting
discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the
effect of preventing or retarding a decline in the market price of our stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the common stock. As a result, the price of the common
stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected on NYSE, NASDAQ NMS
or relevant exchange, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that our share of the total expenses of the offering, excluding underwriting discounts and
commissions, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We will reimburse the underwriters for certain of their expenses incurred in connection with this offering in an
amount up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have agreed to indemnify the
several underwriters against certain liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters and their respective affiliates
are full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making,
brokerage and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to
the issuer and to persons and entities with relationships with the issuer, for which they received or will receive customary fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans,
commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of
the issuer (directly, as collateral securing other obligations or otherwise) and/or persons and entities with relationships with the issuer. The underwriters and their respective affiliates may also communicate independent investment
recommendations, market color or trading ideas and/or publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short
positions in such assets, securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>European Economic Area and United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In relation
to each Member State of the European Economic Area and the United Kingdom (each a Relevant State), no common shares (the Shares) have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the
publication of a prospectus in relation to the Shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State,
all in accordance with the Prospectus Regulation), except that offers of Shares may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">To any legal entity which is a qualified investor as defined under the Prospectus Regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">To fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation),
subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">In any other circumstances falling within Article 1(4) of the Prospectus Regulation; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">provided that no such offer of Shares shall require the company or any representative to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or
supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to
the public&#148; in relation to any Shares in any Relevant State means the communication in any form and by any means of sufficient </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
information on the terms of the offer and any Shares to be offered so as to enable an investor to decide to purchase or subscribe for any Shares, and the expression &#147;Prospectus
Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This European Economic Area and UK selling restriction is in addition to any other selling
restrictions set out below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
the United Kingdom, this prospectus is only addressed to and directed at qualified investors who are (i)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
Order); or (ii)&nbsp;high net worth entities and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;). Any
investment or investment activity to which this prospectus relates is available only to relevant persons and will only be engaged with relevant persons. Any person who is not a relevant person should not act or relay on this prospectus or any of its
contents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Canada </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The securities may be sold in
Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the
Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the securities must be
made in accordance with an exemption form, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or
territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI
<FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares may not be
offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of
Hong Kong) (&#147;Companies (Winding Up and Miscellaneous Provisions) Ordinance&#148;) or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)
(&#147;Securities and Futures Ordinance&#148;); or (ii)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made thereunder; or (iii)&nbsp;in other circumstances which do not result in the
document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for
the purpose of issue (in each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the
securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; in Hong Kong as defined in the Securities and Futures
Ordinance and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or
purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor (as defined under Section&nbsp;4A of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;)) under
Section&nbsp;274 of the SFA; (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions
specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to conditions set forth in the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a corporation (which is not an accredited
investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, the securities (as defined in
Section&nbsp;239(1) of the SFA) of that corporation shall not be transferable for 6 months after that corporation has acquired the shares under Section&nbsp;275 of the SFA except: (i)&nbsp;to an institutional investor under Section&nbsp;274 of the
SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA); (ii)&nbsp;where such transfer arises from an offer in that corporation&#146;s securities pursuant to Section&nbsp;275(1A) of the SFA; (iii)&nbsp;where no consideration is or
will be given for the transfer; (iv)&nbsp;where the transfer is by operation of law; (v)&nbsp;as specified in Section&nbsp;276(7) of the SFA; or (vi)&nbsp;as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares
and Debentures) Regulations 2005 of Singapore (&#147;Regulation 32&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275 of
the SFA by a relevant person which is a trust (where the trustee is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the
beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferable for 6 months after that trust has acquired the shares under Section&nbsp;275 of the SFA except: (i)&nbsp;to an institutional investor under
Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA); (ii) where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than
S$200,000 (or its equivalent in a foreign currency) for each transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets); (iii) where no consideration is or will be given for the transfer; (iv)&nbsp;where
the transfer is by operation of law; (v)&nbsp;as specified in Section&nbsp;276(7) of the SFA; or (vi)&nbsp;as specified in Regulation 32. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Singapore
Securities and Futures Act Product Classification&#151;Solely for the purposes of its obligations pursuant to Sections 309B(1)(a) and 309B(1)(c) of the SFA, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A
of the SFA) that the common shares are &#147;prescribed capital markets products&#148; (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment
Products). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Japan </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The securities have not been
and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No.&nbsp;25 of 1948, as amended) (the FIEA). The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any
resident of Japan (including any person resident in Japan or any corporation or other entity organized under the laws of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of
Japan, except pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The validity of the issuance of our common stock offered in this prospectus will be passed upon for us by Cooley LLP, San Diego, California. Certain
legal matters in connection with this offering will be passed upon for the underwriters by Latham&nbsp;&amp; Watkins LLP, Menlo Park, California. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our financial statements as of December&nbsp;31, 2018 and
December&nbsp;31, 2019 and for each of the two years in the period ended December&nbsp;31, 2019, as set forth in their report. We have included our financial statements in the prospectus and elsewhere in the registration statement in reliance on
Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_22"></A>WHERE YOU CAN
FIND ADDITIONAL INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> including
exhibits and schedules, under the Securities Act, with respect to the shares of common stock being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the
registration statement and its exhibits. For further information with respect to us and the common stock offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the
contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is
qualified in all respects by this reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You may read our SEC filings, including this registration statement, over the Internet at the
SEC&#146;s website at www.sec.gov. Upon the closing of this offering, we will be subject to the information reporting requirements of the Exchange Act and we will file reports, proxy statements and other information with the SEC. These reports,
proxy statements and other information will be available for review on the web site of the SEC referred to above. We also maintain a website at www.silverbacktx.com, at which, following the completion of this offering, you may access these materials
free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on or accessible through our website is not a part of this prospectus or the registration statement of which
it forms a part, and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom67046_23"></A>INDEX TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Audited Financial Statements:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><A HREF="#fin67046_1">Report of Independent Registered Public Accounting Firm</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><A HREF="#fin67046_2">Balance Sheets</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><A HREF="#fin67046_3">Statements of Operations and Comprehensive Loss</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><A HREF="#fin67046_4">Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><A HREF="#fin67046_5">Statements of Cash Flows</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><A HREF="#fin67046_6">Notes to Financial Statements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin67046_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">To the Stockholders and Board of Directors of Silverback Therapeutics, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have audited the
accompanying balance sheets of Silverback Therapeutics, Inc. (the Company), as of December&nbsp;31, 2018 and 2019, the related statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#146; deficit and
cash flows for the years then ended, and the related notes to the financial statements (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the
financial position of the Company at December&nbsp;31, 2018 and 2019, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States
of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">/s/ Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have served as the Company&#146;s auditor since
2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Seattle, Washington </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">October 2, 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin67046_2"></A>Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(in
thousands, except share and par value data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Liabilities, redeemable convertible preferred stock, and stockholders&#146;&nbsp;deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Term loan payable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible notes, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current portion of lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liability, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Commitments and contingencies (Note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock, $0.0001 par value per share; 17,142,854 shares authorized,
15,714,283 shares issued and outstanding with aggregate liquidation preference of $55,000 at December&nbsp;31, 2018 and&nbsp;2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock, $0.0001 par value per share; 22,000,000 and 23,500,000 shares authorized, 2,475,365 and
2,489,504 shares issued, and 2,438,808 and 2,467,083 shares outstanding at December&nbsp;31, 2018 and&nbsp;2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,787</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total liabilities, redeemable convertible preferred stock, and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin67046_3"></A>Statements of Operations Data and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Loss from operations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of redeemable convertible preferred stock purchase option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,241,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,453,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares used in computing pro forma net loss per share attributable to common stockholders,
basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin67046_4"></A>Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(in thousands, except share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable&nbsp;Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series A redeemable convertible preferred stock for cash, net of $33 of issuance costs and
redeemable convertible preferred stock purchase option liability of $1,662</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,714,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Reclassification of redeemable convertible preferred stock purchase option liability to redeemable
convertible preferred stock upon settlement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Exercise of common stock options and vesting of early exercised common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">438,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,714,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,438,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39,820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Exercise of common stock options and vesting of early exercised common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,714,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,467,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,787</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(58,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SILVERBACK THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin67046_5"></A>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Amortization of debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of redeemable convertible preferred stock purchase option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of redeemable convertible preferred stock, net of $33 of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Payment of convertible notes issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Principal payments on term loan payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Change in cash, cash equivalents, and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,384</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash, cash equivalents, and restricted cash at beginning of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash, cash equivalents, and restricted cash at end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin67046_6"></A>Notes to Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31, 2018 and 2019 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. Nature of Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Silverback Therapeutics, Inc. (&#147;Silverback&#148; or &#147;the Company&#148;) is a clinical-stage biopharmaceutical company focused on leveraging our
proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The Company&#146;s platform enables us to strategically
pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed at specific disease sites. The Company was formed in Seattle, Washington and incorporated in the state of Delaware on January&nbsp;4,
2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Risks and Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is
subject to a number of inherent risks which include, but are not limited to, the need to obtain adequate additional funding, possible failure of clinical trials or other events demonstrating a lack of clinical safety or efficacy of its product
candidates, dependence on key personnel, reliance on third-party service providers for manufacturing drug product and conducting clinical trials, the ability to successfully secure its proprietary technology, and risks related to the regulatory
approval and commercialization of a product candidate. Additionally, the development and commercialization of new drug products is highly competitive. Products or technologies developed by competitors may diminish or render obsolete the
Company&#146;s existing products under development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Liquidity and Capital Resources </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net
operating losses since its inception and had an accumulated deficit of $63.8&nbsp;million as of December&nbsp;31, 2019. The Company had cash and cash equivalents of $10.0&nbsp;million as of December&nbsp;31, 2019 and has not generated positive cash
flows from operations. To date, the Company has been able to fund its operations primarily through the issuance of redeemable convertible preferred stock and convertible notes. During 2020, the Company has received an aggregate of $68.4&nbsp;million
in gross proceeds from the issuance of shares of its Series B redeemable convertible preferred stock and an aggregate of $84.9&nbsp;million in gross proceeds from the issuance of shares of its Series C redeemable convertible preferred stock. The
Company&#146;s currently available cash and cash equivalents as of December&nbsp;31, 2019, together with the proceeds received from its redeemable convertible preferred stock financings in 2020, are sufficient to meet its anticipated cash
requirements for the 12 months following the date the financial statements are issued. Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity&#146;s ability to continue as a going
concern for a period of at least 12 months from the date the financial statements are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Management expects operating losses to continue for
the foreseeable future. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that they will be sustained on a continuing basis. In addition, the manufacturing, clinical and preclinical
development activities as well as the commercialization of the Company&#146;s products, if approved, will require significant additional financing. The Company may be unable to secure such financing when needed, or if available, such financings may
be under terms that are unfavorable to the Company or the current stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely
affect its business and operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The financial statements have
been prepared in conformity with U.S. generally accepted accounting principles (&#147;U.S. GAAP&#148;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards
Codification (&#147;ASC&#148;), and Accounting Standards Update (&#147;ASU&#148;), of the Financial Accounting Standards Board (&#147;FASB&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Use of
Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The preparation of the Company&#146;s financial statements requires it to make estimates and assumptions that impact the reported
amounts of assets, liabilities and expenses in the Company&#146;s financial statements and accompanying notes. The most significant estimates in the Company&#146;s financial statements relate to accruals for research and development expenses,
valuation of equity awards, valuation of preferred stock purchase options, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be
reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may
differ materially and adversely from these estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The full extent to which the coronavirus <FONT STYLE="white-space:nowrap">(COVID-19)</FONT>
pandemic will directly or indirectly impact the Company&#146;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly
uncertain, including as a result of new information that may emerge concerning <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the actions taken to contain or treat <FONT STYLE="white-space:nowrap">COVID-19,</FONT> as well as the economic
impact on local, regional, national and international markets. The Company has considered potential impacts arising from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and is not presently aware of any events or circumstances that
would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Segments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing tissue targeted
therapeutics. The Company&#146;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Fair Value of Financial Instruments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Cash and cash
equivalents, restricted cash, and the liability for the Series A redeemable convertible preferred stock purchase option are carried at fair value. Financial instruments, including accounts receivable, accounts payable, and accrued expenses are
carried at cost, which approximates fair value given their short-term nature. Term loan payable is carried at cost, which approximates fair value as its effective interest rate approximates current market rates. Convertible notes are carried at
cost, which approximates fair value as their effective interest rate approximates current market rates and, in consideration of the value of the underlying shares into which they can convert, their short-term nature. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Cash equivalents are comprised of short-term, highly-liquid investments with maturities of 90 days or less at the date of purchase. As of
December&nbsp;31, 2018 and 2019, the Company&#146;s cash equivalents consisted of money market funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Restricted cash consists of a deposit securing a collateral letter of credit issued in connection with the Company&#146;s facility operating lease. The
Company had restricted cash of $0.8&nbsp;million and $0.6&nbsp;million as of December&nbsp;31, 2018 and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table
provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheets that sum to the amounts shown in the statements of cash flows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Concentrations of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is subject to credit risk from holding its cash and cash equivalents at one commercial bank. The Company limits its exposure to credit losses
by investing in money market funds through a U.S. bank with high credit ratings. Cash may consist of deposits held with banks that may at times exceed federally insured limits, however, exposure to credit risk in the event of default by the
financial institution is limited to the extent of amounts recorded on the balance sheets. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the
financial position of the depository institutions in which those deposits are held. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Prepaid Expenses and Other Current Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prepaid expenses consist primarily of operating expenses paid in advance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Property and Equipment, Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Property and equipment,
net consists of furniture and fixtures and laboratory equipment and is stated at cost, less accumulated depreciation. Furniture and fixtures and laboratory equipment are depreciated over the estimated useful lives of the assets (each three to five
years) using the straight-line method. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period
realized. Repairs and maintenance costs are charged to expense as incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Leases consist of the Company&#146;s operating lease. In accordance with ASC 842, <I>Leases</I>, the Company determines if an arrangement is a lease at
inception and evaluates each lease agreement to determine whether the lease is an operating or finance lease. For leases where the Company is the lessee, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
(&#147;ROU&#148;) assets represent the Company&#146;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at
the lease commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease
payments. The operating lease ROU asset also includes any prepaid lease payments, lease incentives received, and costs which will be incurred in exiting a lease. The Company&#146;s lease includes options to extend or terminate the lease. Periods
covered by an option to extend the lease are included in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate the lease are included in the lease term when it is
reasonably certain that the Company will not exercise that option. At the inception of the lease and as of December&nbsp;31, 2019, the Company was not reasonably certain that it will exercise its option to extend the lease and was not reasonably
certain that it will not exercise its option to terminate the lease, therefore, the periods covered by the options are not included within the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance
sheet. The Company does not have material short-term lease costs. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For real estate leases, the Company does not separate lease and <FONT
STYLE="white-space:nowrap">non-lease</FONT> components. The Company&#146;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Impairment of Long-Lived Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Long-lived assets
consist of property and equipment and ROU assets. These assets are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset or asset group may not be recoverable. An
impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not
recognized any impairment losses through December&nbsp;31, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All research and development costs are expensed in the period incurred. Research and development expenses consist primarily of direct and indirect costs
incurred in connection with the development of the Company&#146;s ImmunoTAC technology platform, discovery efforts, and preclinical study and clinical trial activities related to the Company&#146;s program pipeline, including the Company&#146;s lead
product candidate, SBT6050. Direct costs include expenses incurred under agreements with contract research organizations (&#147;CROs&#148;) and other vendors that conduct the Company&#146;s preclinical and clinical activities, expenses associated
with manufacturing the Company&#146;s product candidates including under agreements with contract development and manufacturing organizations (&#147;CDMOs&#148;) and other vendors, and consulting fees. Indirect costs include personnel-related
expenses, consisting of employee salaries, bonuses, benefits, and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities, facility and equipment related
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
expenses, consisting of indirect and allocated expenses for rent, depreciation, and equipment maintenance, and other unallocated research and development expenses incurred in connection with the
Company&#146;s research and development programs, including laboratory materials and supplies and license fees. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company&#146;s
research and development efforts and have no alternative future uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is obligated to make upfront payments upon execution of certain
research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized until such goods are delivered or the related
services are performed, or such time when the Company does not expect the goods to be delivered or services to be performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each
period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. Since inception, the Company has not experienced any material differences between accrued or prepaid
costs and actual costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">General and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses, benefits, and stock-based
compensation, and recruiting costs for personnel in executive, finance, and other administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters,
professional fees for accounting, tax and consulting services, insurance costs, travel expenses and facility related expenses. General and administrative costs are expensed as incurred.&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The cost of employee
services received in exchange for an award of an equity instrument is measured at the grant date based on the award&#146;s estimated fair value using the Black-Scholes option pricing model. The estimated fair value of the awards is recognized into
expense on a straight-line basis over the requisite service period. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the
outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized, and any previously recognized compensation expense is reversed. Management evaluates when the achievement of a performance
condition is probable based on the expected satisfaction of the performance condition at each reporting date. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. The option plan permits, but does not require,
the inclusion of early exercise provisions in individual awards. Proceeds from early option exercises are recorded as a liability until the underlying restricted shares vest. While the restricted shares have voting rights, they are not considered
outstanding for accounting purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the
expected future tax consequences of events </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax
basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that
includes the enactment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely
than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, <FONT
STYLE="white-space:nowrap">tax-planning</FONT> strategies, and results of recent operations. If management determines that the Company is more likely than not able to realize its deferred tax assets in the future in excess of their net recorded
amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes in the period in which the adjustment is made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company records uncertain tax positions on the basis of a <FONT STYLE="white-space:nowrap">two-step</FONT> process whereby (1)&nbsp;management
determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&nbsp;for those tax positions that meet the
<FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&nbsp;percent likely to be realized upon ultimate settlement with the related tax
authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. The Company did not have any uncertain tax
positions as of December&nbsp;31, 2018 and 2019.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from <FONT
STYLE="white-space:nowrap">non-owner</FONT> sources. The Company&#146;s comprehensive loss was equal to net loss for the years ended December&nbsp;31, 2018 and 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Net Loss Per Share Attributable to Common Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the
weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities.&nbsp;Diluted net loss per share attributable to common stockholders is the same as basic net loss per share
attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unaudited Pro
Forma Net Loss Per Share Attributable to Common Stockholders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The unaudited pro forma basic and diluted net loss per share attributable to
common stockholders has been computed to give effect to the conversion of all outstanding shares of the Company&#146;s redeemable convertible preferred stock into shares of its common stock upon the closing of a firm-commitment underwritten public
offering (&#147;IPO&#148;) for which the Company receives gross proceeds of at least $100.0&nbsp;million, prior to deductions for underwriting discounts, commissions and expenses, or the vote, written consent, or agreement of holders of a majority
of the Company&#146;s outstanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
redeemable convertible preferred stock. The unaudited pro forma net loss per share attributable to common stockholders does not include the shares to be sold in the proposed IPO. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Emerging Growth Company Status </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company is an
emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#147;JOBS Act&#148;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of
the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public
and private companies until the earlier of the date that it is (1)&nbsp;no longer an emerging growth company or (2)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial
statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recently
Adopted Accounting Pronouncements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In June 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-07,</FONT>
<I>Compensation&#151;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</I>, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the standard, most of
the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The Company adopted ASU <FONT STYLE="white-space:nowrap">2018-07</FONT> as of January&nbsp;1, 2019. The adoption of
the new standard did not have a material impact on its financial statements and related disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recently Issued Accounting Pronouncements Not Yet
Adopted </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> <I>Financial Instruments&#151;Credit Losses
(Topic 326): Measurement of Credit Losses on Financial Instruments</I>. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than temporary
impairments on investment securities are recorded. The guidance is effective for the Company beginning on January&nbsp;1, 2023, with early adoption permitted. The Company is currently evaluating the impact the standard may have on its financial
statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-13,</FONT> <I>Fair Value Measurement
(Topic 820): Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement</I>. The guidance is effective for fiscal years beginning after December&nbsp;15, 2019, including interim periods within those fiscal years.
Early adoption is permitted. The Company adopted ASU <FONT STYLE="white-space:nowrap">2018-13</FONT> on January&nbsp;1, 2020 and the standard did not have a material impact on its financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-12,</FONT> <I>Income Taxes (Topic 740): Simplifying the Accounting for
Income Taxes</I>, which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, <I>Income Taxes</I>, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. The
guidance is effective for fiscal years beginning after December&nbsp;15, 2021, with early adoption permitted. The Company adopted ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> on January&nbsp;1,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
2020 and the standard did not have a material impact on its financial statements and related disclosures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company follows authoritative
accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or
nonrecurring basis. Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Level 1:</I> Quoted prices in active markets for identical assets or liabilities. The Company&#146;s Level&nbsp;1 assets consist of
money market funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Level 2:</I> Observable inputs other than Level&nbsp;1 prices, such as quoted prices for similar assets or
liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Level 3:</I> Unobservable inputs that are supported by little or no market activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table identifies the Company&#146;s assets and liabilities that were measured at fair value on a recurring basis (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There were no transfers between the Level&nbsp;1 and Level&nbsp;2 categories or into or out of the Level&nbsp;3 category
during the years ended December&nbsp;31, 2018 and 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. Property and Equipment, Net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Property and equipment are summarized as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property and equipment, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(906</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,450</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Depreciation and amortization expense was $0.5&nbsp;million for each of the years ended
December&nbsp;31, 2018 and 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. Accrued Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Accrued expenses consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Employee compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Professional services and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company leases
an office and laboratory space in Seattle, Washington. The components of lease expense and related cash flows were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Variable lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating cash outflows from operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The remaining term on the Company&#146;s lease was 3.8 years and 2.8 years as of December&nbsp;31, 2018 and 2019,
respectively. To compute the present value of the lease liability, the Company used a discount rate of 8.5%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Future minimum commitments due under
the operating lease agreement as of December&nbsp;31, 2019 are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total undiscounted lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Present value adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(680</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total present value of lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. Convertible Notes and Other Debt </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Convertible Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2019, the Company issued
convertible promissory notes for proceeds of $10.0&nbsp;million. The notes were unsecured, bore an interest rate of 3% per year, and had a maturity date of March&nbsp;31, 2020. On March&nbsp;4, 2020, these notes and accrued interest of
$0.1&nbsp;million converted into 4,673,388 shares of the Company&#146;s Series B redeemable convertible preferred stock at the Series B redeemable convertible preferred stock issuance price of $2.16 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Term Loan Payable </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In November 2016, the Company
entered into a loan and security agreement with Silicon Valley Bank (SVB) that allowed borrowings up to $5.0&nbsp;million in two tranches. $3.5&nbsp;million was immediately drawn as a term loan by the Company. In conjunction with the term loan, SVB
received a warrant to purchase 28,226 shares of the Company&#146;s common stock with an exercise price of $0.62 per share. The warrant expires November&nbsp;21, 2026. The warrant was recorded as a discount to the loan and an increase in additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the terms of the agreement, the Company was able to draw an additional $1.5&nbsp;million
through a second tranche before December&nbsp;31, 2017 if it met certain financing milestones. SVB was eligible to receive an additional warrant contingent upon the Company&#146;s draw of this additional tranche. However, in December 2017, the
Company amended the loan and security agreement to extend the second tranche draw window to March&nbsp;31, 2018. This tranche expired undrawn. In exchange for the extension, SVB received an additional warrant to purchase 5,769 shares of the
Company&#146;s common stock with an exercise price of $0.65 per share and, because the tranche expired undrawn, an unused term loan fee. Neither the additional warrants to purchase common stock or the unused term loan fee were material to the
financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The outstanding principal amount of the term loan accrues interest at an annual rate of 1.75% per annum. At closing, the
Company incurred de minimis debt issuance costs and owed a final payment fee of $0.3&nbsp;million, both of which are amortized to interest expense over the remaining term of the debt under the effective interest method. The effective interest rate
of the Company&#146;s term loan is 5.14%. Interest expense under the term loan totaled $0.2&nbsp;million and $0.1&nbsp;million for the years ended December&nbsp;31, 2018 and 2019, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The term loan is collateralized by the Company&#146;s tangible and intangible assets, excluding intellectual property. The proceeds are to be used as
working capital and to fund general business requirements. The agreement includes customary nonfinancial covenants and events of default that include, among other things, <FONT STYLE="white-space:nowrap">non-payment,</FONT> inaccuracy of
representations and warranties, covenant breaches, cross default to material indebtedness or material agreements, bankruptcy and insolvency, material judgments, a change of control, or any material adverse event. The Company was in compliance with
all related covenants as of December&nbsp;31, 2018 and 2019. Given the existence of a subjective acceleration clause, all amounts due to SVB are classified as a current liability at December&nbsp;31, 2018 and 2019, though SVB has not accelerated any
amounts due under the debt agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The term loan&#146;s original maturity date was November&nbsp;1, 2020. However, in April 2020 the Company
amended the loan and security agreement to defer principal payments for six months and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
extend the maturity date to May&nbsp;1, 2021. There were no costs or additional warrant issuances in connection with this amendment. The Company accounted for the amendment as a debt modification
and is amortizing the remaining debt discount over the remaining term. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In April 2016, the Company entered into a Series A preferred stock purchase agreement under which the Company issued 2,857,143 shares of its Series A
redeemable convertible preferred stock for $3.50 per share in an initial closing, resulting in gross proceeds of $10.0&nbsp;million. In addition to the initial closing, investors agreed to buy, and the Company agreed to sell, future tranches of
additional shares of Series A redeemable convertible preferred stock at a purchase price of $3.50 per share in the event that certain agreed upon milestones were achieved. These preferred stock purchase rights met the definition of freestanding
instruments and the requirements for liability classification pursuant to ASC 480. The Company determined their issuance date fair value and recorded them on the balance sheet with the remainder of the proceeds raised allocated to redeemable
convertible preferred stock. They were revalued at each reporting period with changes in their fair value recorded in the statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In May 2017, the Company issued 7,142,857 shares of its Series A redeemable convertible preferred stock at a purchase price of $3.50 per share,
resulting in gross proceeds of $25.0&nbsp;million. The preferred stock purchase right related to this tranche was revalued at settlement and the resultant fair value reclassified to redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2017, the Company&#146;s board of directors cancelled the remaining $25.0&nbsp;million tranche available under the original Series A
redeemable convertible preferred stock purchase agreement. The preferred stock purchase right related to this tranche was revalued at cancellation and the resultant fair value was reclassified into additional
<FONT STYLE="white-space:nowrap">paid-in</FONT> capital as a deemed contribution due to the holder being a controlling stockholder of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September 2018, the Company entered into another Series A preferred stock purchase agreement under which the Company issued 3,571,427 shares of its
Series A redeemable convertible preferred stock at a purchase price of $3.50 per share in an initial closing, resulting in gross proceeds of $12.5&nbsp;million. In addition to the initial closing, certain investors received an option to buy up to
2,142,856 shares of additional Series A redeemable convertible preferred stock at a purchase price of $3.50 per share for a period of 180 days following the initial closing. These preferred stock purchase options met the definition of freestanding
instruments and met the requirements for liability classification pursuant to ASC 480. The Company determined their issuance date fair value (a Level&nbsp;3 estimate) using a Black-Scholes option pricing model. Assumptions used in the model included
the Company&#146;s then current Series A redeemable convertible preferred stock fair value, expected term, expected volatility, and risk-free rate. The options were recorded on the balance sheet at their fair value with the remainder of the proceeds
raised allocated to redeemable convertible preferred stock. They were revalued at each reporting period with changes in their fair value recorded in the statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In December 2018, the investors exercised their preferred stock purchase options and the Company issued 2,142,856 shares of its Series A redeemable
convertible preferred stock at a purchase price of $3.50 per share, resulting in gross proceeds of $7.5&nbsp;million. The preferred stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
purchase options were revalued as of the settlement date (a Level&nbsp;3 estimate) using a Black-Scholes option pricing model. Assumptions used in the model included the Company&#146;s then
current Series A redeemable convertible preferred stock fair value, expected term, expected volatility, and risk-free rate. At the settlement of the preferred stock purchase options, the final liability balance of $1.0&nbsp;million was reclassified
to redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table summarizes the preferred stock purchase option liability during the year ended
December&nbsp;31, 2018 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable<BR>Convertible<BR>Preferred<BR>Stock&nbsp;Purchase<BR>Option&nbsp;Liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Issuance of redeemable convertible preferred stock purchase option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in value of redeemable convertible preferred stock purchase option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Reclassification of liability to redeemable convertible preferred stock upon settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Gross proceeds related to Series A redeemable convertible preferred stock totaled $55.0&nbsp;million between April 2016
and December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In March 2020, the Company issued 14,701,054 shares of its Series B redeemable convertible preferred stock, including
4,673,388 shares issued upon conversion of then outstanding convertible notes and accrued interest, and 10,027,666 shares issued for cash at a purchase price of $2.16 per share, resulting in gross proceeds of $21.5&nbsp;million. The Series B
purchase agreement provides that the Company will issue, and the Series B holders will purchase, an additional 21,732,862 shares of the Company&#146;s Series B redeemable convertible preferred stock across two tranches for aggregate proceeds of
$46.9&nbsp;million in the event that certain agreed upon milestones are achieved or the preferred majority approves their closing. The future Series B tranches did not meet the definition of freestanding instruments or the definition of derivatives,
therefore, they were not accounted for separately or bifurcated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In July 2020, the Company issued 10,669,834 shares of its Series B redeemable
convertible preferred stock for cash at a purchase price of $2.16 per share, resulting in gross proceeds of $23.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In September 2020,
the Company issued 11,063,028 additional shares of its Series B redeemable convertible preferred stock for cash at a purchase price of $2.16 per share, resulting in gross proceeds of $23.9&nbsp;million, and 24,926,685 shares of its Series C
redeemable convertible preferred stock for cash at a purchase price of $3.41 per share, resulting in gross proceeds of $84.9&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The holders of the Company&#146;s Series A redeemable convertible preferred stock have the following
rights, preferences, and privileges: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each share of the Company&#146;s Series A redeemable convertible preferred stock was convertible, at the option of the holder thereof, at any time and
from time to time, and without the payment of additional consideration by the holder thereof, or automatically upon a qualified IPO (as described below), into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT>
shares of common stock as is determined by dividing the original issue price by the preferred stock&#146;s conversion price in effect at the time of conversion. The preferred stock&#146;s conversion price will initially be equal to the original
issue price for the redeemable convertible preferred stock. The conversion price, and the rate at which shares of redeemable convertible preferred stock may be converted into shares of common stock, is subject to adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The certificate of incorporation in effect for the Series A redeemable convertible preferred stock financings defined a qualified IPO as one with gross
proceeds of at least $50.0&nbsp;million, prior to deductions for underwriting discounts, commissions, and expenses, has a <FONT STYLE="white-space:nowrap">pre-offering</FONT> valuation of at least $200.0&nbsp;million, and a price per share of common
stock of at least three times the original issue price, or the vote, written consent, or agreement of holders of a majority of the Company&#146;s outstanding redeemable convertible preferred stock. The certificate of incorporation was amended in
connection with the Series C redeemable convertible preferred stock financing to define a qualified IPO as one with gross proceeds of at least $100.0&nbsp;million, prior to deductions for underwriting discounts, commissions and expenses, or the
vote, written consent, or agreement of holders of a majority of the Company&#146;s outstanding redeemable convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The holders of shares of the Company&#146;s Series A redeemable convertible preferred stock shall be entitled to receive noncumulative dividends, out of
any assets legally available therefor, prior and in preference to any declaration or payment of any dividend on the Company&#146;s common stock, at the rate of 8% of the original issue purchase price of $3.50 per share (as adjusted for any stock
splits, stock dividends, combinations, subdivisions, recapitalizations or the like) of each such share of Series A preferred stock per share per annum on each outstanding share of Series A preferred stock (as adjusted for any stock splits, stock
dividends, combinations, subdivisions, recapitalizations or the like). All such dividends are payable only when, as, and if, declared by the board of directors of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Liquidation Preference </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event of any
liquidation event, either voluntary or involuntary, the holders of shares of the Company&#146;s Series A redeemable convertible preferred stock then outstanding shall be entitled to be paid out of the proceeds of such liquidation event and the
assets of the Company available for distribution to its stockholders before any payment shall be made to the holders of the Company&#146;s common stock. The amount paid per share shall be equal to the sum of the original issue price of the Series A
preferred stock of $3.50 per share (as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations or the like), plus any declared but unpaid dividends on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
each such share. If, upon the occurrence of a liquidation event, the proceeds distributed among the holders of Series A redeemable convertible preferred stock are insufficient to permit the
payment to such holders of the full liquidation preferences, then the entire proceeds available for distribution shall be distributed ratably among the holders of Series A redeemable convertible preferred stock in proportion to the full amount that
each holder is otherwise entitled to receive. Upon completion of the distribution of the full liquidation preference, all of the remaining proceeds of the liquidation event shall be distributed among the holders of common stock and the holders of
Series A redeemable convertible preferred stock pro rata and on an as converted to common stock basis at the then effective conversion rate for the Series A redeemable convertible preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Voting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The holder of each share of the Company&#146;s
Series A redeemable convertible preferred stock shall have the right to one vote for each share of the Company&#146;s common stock into which the Series A redeemable convertible preferred stock could then be converted, and with respect to such vote,
such holder shall have full voting rights and powers equal to the voting rights and powers of the holders of common stock. As long as at least 20% of the shares of Series A redeemable convertible preferred stock originally issued are outstanding,
the holders of the outstanding shares of Series A redeemable convertible preferred stock shall be entitled to elect one director to the board of directors of the Company. The holders of outstanding common stock shall also be entitled to elect one
director to the board of directors of the Company. The holders of Series A redeemable convertible preferred stock and common stock, voting together as a single class and on an as converted to common stock basis, are entitled to elect any remaining
directors to the board of directors of the Company. The holders of Series A redeemable convertible preferred stock are also entitled to vote together as a single class on certain protective matters including, but not limited to, changes that would
alter the rights of the shares of preferred stock, payment of dividends, and issuance of debt or an additional class of stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Classification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has classified its Series A redeemable convertible preferred stock as mezzanine equity in the balance sheets as the shares are contingently
redeemable upon a deemed liquidation such as a change in control and in that event there is no guarantee that all stockholders would be entitled to receive the same form of consideration. Following the 2020 issuances of the Company&#146;s Series B
and Series C redeemable convertible preferred stock, the Series A redeemable convertible preferred stock continues to be contingently redeemable. No accretion to redemption value was recorded during the years ended December&nbsp;31, 2018 and 2019 as
a deemed liquidation event was not considered probable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Common stockholders of the Company are
entitled to one vote per share. Holders of common stock are entitled to receive dividends, when and if declared by the board of directors of the Company. The voting, dividend, and liquidation rights of the holders of the common stock are subject to,
and qualified by, the rights, privileges, and preferences of the holders of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has reserved shares of common stock for the following potential future issuances: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Conversion of Series A outstanding redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,714,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,714,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shares underlying outstanding equity awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,063,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shares available for future equity award grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,336,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,610,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shares underlying early exercised equity awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercise of common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,472,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,444,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The preceding table excludes 61,360,601 shares of the Company&#146;s common stock issuable upon the potential conversion
of 61,360,601 aggregate shares of its Series B and Series C redeemable convertible preferred stock issued in 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has established the 2016 equity incentive plan for the benefit of its employees and board members. The form of awards, term, exercise price,
and vesting schedule of the options are determined by the Company&#146;s board of directors at the time of grant. Awards may be made under the plan for 4,163,176 shares of common stock. The stock options generally vest over four years with a 25%
cliff vest at the first anniversary of the vesting start date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A summary of the Company&#146;s stock option activity under the 2016 equity
incentive plan and related information is as follows (in thousands, except share and per share data and years): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Available<BR>for Grant</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Options Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Subject to<BR>Options<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Life (Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,336,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shares authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(790,358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">790,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,935</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,610,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,063,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vested at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">812,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The total fair value of shares vested during the years ended December&nbsp;31, 2018 and 2019 was $0.3&nbsp;million and
$0.1&nbsp;million, respectively. The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company&#146;s common stock for all options
that were <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> at December&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The weighted-average grant date fair value per share of option grants for the years ended December&nbsp;31, 2018 and
2019 was $0.36 and $0.26, respectively. As of December&nbsp;31, 2019, the total unrecognized stock-based compensation expense was $0.3&nbsp;million, which is expected to be recognized over a remaining weighted-average period of approximately 2.7
years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The grant date fair value of stock options was estimated using a Black-Scholes option pricing model with the following weighted-average
assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.08</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below.
Each of these inputs is subjective and generally requires significant judgement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Fair Value of Common Stock.</I> The grant date
fair market value of the shares of common stock underlying stock options has historically been determined by the Company&#146;s board of directors. Because there has been no public market for the Company&#146;s common stock, the board of directors
exercises reasonable judgment and considers a number of objective and subjective factors to determine the best estimate of the fair market value, which include contemporaneous valuations performed by an independent third-party, the Company&#146;s
results of operations and financial position, including its levels of available capital resources, its stage of development and material risks related to the Company&#146;s business, progress of the Company&#146;s research and development
activities, the Company&#146;s business conditions and projections, the lack of marketability of the Company&#146;s common stock and preferred stock as a private company, the prices at which the Company sold shares of its redeemable convertible
preferred stock to outside investors in arms-length transactions, the rights, preferences and privileges of the Company&#146;s redeemable convertible preferred stock relative to those of its common stock, the analysis of IPOs and the market
performance of similar companies in the biopharmaceutical industry, the likelihood of achieving a liquidity event for the Company&#146;s securityholders, such as an IPO or a sale of the company, given prevailing market conditions, the hiring of key
personnel and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL">
experience of management, trends and developments in the Company&#146;s industry and external market conditions affecting the life sciences and biotechnology industry sectors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Expected Term. </I>The expected term represents the period that the options granted are expected to be outstanding. The expected term
of stock options issued is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term) as the Company has concluded that its stock option
exercise history does not provide a reasonable basis upon which to estimate expected term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Expected Volatility.</I> Given that
the Company&#146;s common stock is privately held, there is no active trading market for the Company&#146;s common stock. The Company derived the expected volatility from the average historical volatilities over a period approximately equal to the
expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Company has limited trading history for its common stock. The Company will continue to apply this
process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Risk-free Interest Rate.</I> The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected
term of the stock options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Expected Dividend Yield.</I> The Company has never paid dividends on its common stock and does not
anticipate paying any dividends in the foreseeable future. Therefore, the Company uses an expected dividend yield of zero. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company&#146;s effective tax rates for the years ended December&nbsp;31, 2018 and 2019 differ from the U.S. federal statutory rate as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Tax at the federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Benefit from R&amp;D tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(561</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of redeemable convertible preferred stock purchase option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other temporary and permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The significant components of the Company&#146;s deferred tax assets and liabilities were as follows
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">R&amp;D tax credit carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax liabilities&#151;Right of use asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,736</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2019, the Company had net operating loss carryforwards for income tax purposes of approximately
$59.9&nbsp;million. If not used, $18.2&nbsp;million of this carryforward will begin to expire in 2036 and $41.7&nbsp;million has no expiration. At December&nbsp;31, 2019, the Company also had research and development tax credits of approximately
$0.9&nbsp;million which will begin to expire in 2036 if left unused. The Company did not have any foreign tax provision and did not generate material net operating losses in any states with an income tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">FASB ASC 740 requires that the tax benefit of net operating losses, temporary differences, and credit carryforwards be recorded as an asset to the
extent that management assesses the realization is &#147;more likely than not.&#148; Realization of the future tax benefits from the net operating losses or credit carryforwards, if any, is dependent on the Company&#146;s ability to generate
sufficient taxable income within the applicable carryforward period. Because of the Company&#146;s recent history of operating losses, the Company maintains a full valuation allowance in the amount of $8.1&nbsp;million and $13.7&nbsp;million for the
years ended December&nbsp;31, 2018 and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company may have already experienced one or more ownership changes. Depending on the
timing of any future utilization of its carryforwards, the Company may be limited as to the amount that can be utilized each year as a result of such previous ownership changes. However, the Company does not believe such limitations will cause its
carryforwards to expire unutilized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Future changes in the Company&#146;s stock ownership as well as other changes that may be outside the
Company&#146;s control could potentially result in further limitations on the Company&#146;s ability to utilize its net operating loss and tax credit carryforwards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2018 and 2019, the Company did not have any liabilities for unrecognized income tax benefits associated with uncertain tax
positions, including any interest and penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12. Licensing Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>License Agreement with WuXi Biologics (Hong Kong) Limited </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In October 2019, the Company entered into a cell line license agreement with WuXi Biologics (Hong Kong) Limited (&#147;WuXi Bio&#148;). Under the license
agreement, WuXi Bio granted the Company a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, sublicensable, under certain of WuXi Bio&#146;s intellectual property rights, know-how and biological materials (&#147;WuXi Bio
Licensed Technology&#148;), to make, use, sell, offer for sale and import a product developed through the use of the WuXi Bio Licensed Technology (&#147;WuXi Bio Licensed Product&#148;). The WuXi Bio Licensed Technology is currently used to
manufacture a component of the Company&#146;s lead product, SBT6050. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In consideration for the license, the Company paid WuXi Bio a low six figures
license fee which was recorded as research and development expense in accordance with ASC 730. In the event the Company manufactures its commercial supplies of a product produced by the Licensed Cell Line using a manufacturer other than WuXi Bio or
its affiliates, the Company will become obligated to pay WuXi Bio aggregate milestone payments, upon achievement of certain sales milestones, of up to the low eight figures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company has the right to terminate the license by giving at least six months prior written notice to WuXi Bio and paying all amounts due to them
through the termination date. In the event the Company fails to pay all amounts due to WuXi Bio under the license agreement, and fails to pay the amounts within 30 days after receiving written notice of such failure, WuXi Bio may terminate the
license with 45 days written notice to the Company. In the event either party commits a material breach under the license and fails to cure the breach within 30 days after receiving written notice from the other party of such breach, either party
may terminate the license immediately upon written notice to the other party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Legal Proceedings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">From time to time, the Company may
have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably
estimated. Significant judgment is required to determine both probability and the estimated amount. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Indemnifications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the
Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification
will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits
or settle claims related to these indemnification provisions. The Company intends to enter into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that
may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#146; and officers&#146; insurance coverage that reduces its exposure and enables
the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to rapidly evolve, and management continue to monitor the situation
closely. The extent of the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on the Company&#146;s business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the
duration and spread of the outbreak and its impact on the Company&#146;s clinical trial enrollment, trial sites, CROs, third-party manufacturers, and other third parties with whom the Company does business, as well as its impact on regulatory
authorities and the Company&#146;s key scientific and management personnel. The ultimate impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or a similar health epidemic is highly uncertain and subject to change. To the extent
possible, management is conducting business as usual, with necessary or advisable modifications to employee travel and most of the Company&#146;s <FONT STYLE="white-space:nowrap">non-lab</FONT> based employees working remotely. Management will
continue to actively monitor the rapidly evolving situation related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> and may take further actions that alter Company operations, including those that may be required by federal, state or local
authorities, or that management determines are in the best interests of the Company&#146;s employees and other third parties with whom the Company does business. At this point, the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic may affect the Company&#146;s business, operations and clinical development timelines and plans, including the resulting impact on Company expenditures and capital needs, remains uncertain and is subject to change. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14. Related Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company reimburses
certain travel expenses incurred by one of its investors to support the business. Amounts due to the investor totaled less than $0.1&nbsp;million as of December&nbsp;31, 2018 and 2019. Reimbursable travel expenses incurred by the investor totaled
less than $0.1&nbsp;million during each of the years ended December&nbsp;31, 2018 and 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>15. Employee Benefit Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Company maintains a retirement plan, which is qualified under section&nbsp;401(k) of the Internal Revenue Code of 1986, as amended, for the
Company&#146;s U.S.&nbsp;employees. The plan allows eligible employees to defer, at the employee&#146;s discretion, pretax compensation up to the IRS annual limits. The Company does not match contributions made by employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>16. Net Loss Per Share Attributable to Common Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to
common stockholders for the periods presented because their effect would have been anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,714,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,714,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,063,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unvested common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total potentially dilutive shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,135,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,833,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>December 31,
2018 and 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>17. Unaudited Pro Forma Net Loss Per Share Attributable to Common Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pro forma basic and diluted net loss per share has been computed to give effect to the assumed conversion of all outstanding shares of the Company&#146;s
redeemable convertible preferred stock into shares of its common stock upon completion of a qualifying IPO of the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table
sets forth the computation of the unaudited pro forma basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss used in computing pro forma net loss per share attributable to common stockholders, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares of common stock used in computing net loss per share attributable to common
stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,453,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma adjustment to reflect conversion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares of common stock used in computing pro forma net loss per share attributable to
common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>18. Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For
purposes of the financial statements as of December&nbsp;31, 2019 and the year then ended, the Company evaluated subsequent events for recognition and measurement purposes through October&nbsp;2, 2020, the date the financial statements were issued.
Except for the issuance of Series B and Series C redeemable convertible preferred stock (Notes 1, 8, and 9), the conversion of the Company&#146;s convertible debt (Note 7), and term loan maturity extension (Note 7) described elsewhere in these
financial statements, the Company has concluded that no events or transactions have occurred that require disclosure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </P> <P STYLE="margin-top:50pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>Silverback Therapeutics, Inc. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Common Stock </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:16%">&nbsp;</P></center> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046g76j62.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:14pt">
<TD VALIGN="top"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>SVB&nbsp;Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Stifel</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>H.C.&nbsp;Wainwright&nbsp;&amp;&nbsp;Co. </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:120pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Through and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2020 (the 25th day after the
date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when
acting as an underwriter and with respect to an unsold allotment or subscription. </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;13. Other
Expenses of Issuance and Distribution. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the costs and expenses, other than the underwriting discounts and
commissions, payable by us in connection with the sale of our common stock being registered. All amounts are estimates except for the Securities and Exchange Commission (SEC) registration fee, the Financial Industry Regulatory Authority (FINRA)
filing fee and the Nasdaq Global Market (Nasdaq) listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Item</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount<BR>Paid or<BR>to&nbsp;Be&nbsp;Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transfer agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As
permitted by Section&nbsp;102 of the Delaware General Corporation Law, we have adopted provisions in our amended and restated certificate of incorporation and amended and restated bylaws that limit or eliminate the personal liability of our
directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably
available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our amended and restated
certificate of incorporation also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As permitted by Section&nbsp;145 of the Delaware General Corporation Law, our amended and restated bylaws provide that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may indemnify our directors, officers and employees to the fullest extent permitted by the Delaware General Corporation
Law, subject to limited exceptions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest
extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rights provided in our bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and our amended and restated bylaws provide for the indemnification provisions described above and
elsewhere herein. We have entered or will enter into, and intend to continue to enter into, separate indemnification agreements with our directors and officers that may be broader than the specific indemnification provisions contained in the
Delaware General Corporation Law. These indemnification agreements generally require us, among other things, to indemnify our officers and directors against certain liabilities that may arise by reason of their status or service as directors or
officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses incurred by the directors or officers as a result of any proceeding against them as to which they
could be indemnified. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities, including reimbursement of expenses incurred, arising under
the Securities Act of 1933, as amended (Securities Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have purchased and currently intend to maintain insurance on behalf of each and every
person who is one of our directors or officers against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The form of underwriting agreement for this initial public offering provides for indemnification by the underwriters of us and our officers and
directors who sign this registration statement for specified liabilities, including matters arising under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;15. Recent Sales of
Unregistered Securities. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Since January&nbsp;1, 2017, we have made the following sales of unregistered securities: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In December 2017, we issued a warrant to Silicon Valley Bank to purchase 5,769 shares of our common stock at an exercise
price of $0.65 per share in connection with the amendment of our loan and security agreement with Silicon Valley Bank. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In September 2018, we entered into a Series A preferred stock purchase agreement with various investors, pursuant to
which we issued and sold to such investors an aggregate of 15,714,283 shares of our Series A redeemable convertible preferred stock at a purchase price of $3.50 per share, and received aggregate gross proceeds of $55.5&nbsp;million.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In October 2019, we issued convertible promissory notes to certain accredited investors, pursuant to which we issued and
sold $10.0&nbsp;million aggregate principal amount of convertible promissory notes in exchange for $10.0&nbsp;million in gross proceeds. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In March 2020, we entered into a Series B preferred stock purchase agreement with various investors, pursuant to which we
issued and sold to such investors an aggregate of 19,929,286 shares of our Series B redeemable convertible preferred stock at a purchase price of $2.16 per share, and received aggregate gross proceeds of $43.0&nbsp;million, which included the
conversion of the convertible promissory notes described in paragraph (3)&nbsp;above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In September 2020, we issued and sold 11,063,028 additional shares of our Series B redeemable convertible preferred stock
at a purchase price of $2.16 per share, and received aggregate gross proceeds of $23.9&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In September 2020, we entered into a Series C preferred stock purchase agreement with various investors, pursuant to
which we issued and sold to such investors an aggregate of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
24,926,685 shares of our Series C redeemable convertible preferred stock at a purchase price of $3.41 per share, and received aggregate gross proceeds of $85.0&nbsp;million. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">From January&nbsp;1, 2017 to the effective date of this registration statement, we granted stock options under our 2016
Equity Incentive Plan, as amended (the Prior Plan), to purchase up to an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock to our employees, directors and
consultants, at a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. Through the effective date of this registration
statement,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock were issued upon the exercise of options granted to employees, directors and consultants and the payment of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to us was made. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The offers,
sales and issuances of the securities described in paragraphs (1)&nbsp;through (5) were deemed to be exempt from registration under the Securities Act in reliance on Section&nbsp;4(a)(2) (or Regulation D promulgated thereunder) in that the issuance
of securities to the accredited investors did not involve a public offering. The recipients of securities in each of these transactions acquired the securities for investment only and not with a view to or for sale in connection with any
distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions was an accredited investor under Rule 501 of Regulation D. No underwriters were
involved in these transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The offers, sales and issuances of the securities described in paragraph (6)&nbsp;were deemed to be exempt from
registration under the Securities Act in reliance on either Rule 701 in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under Rule 701 or Section&nbsp;4(a)(2) in that the issuance of
securities to the accredited investors did not involve a public offering. The recipients of such securities were our employees, directors or bona fide consultants and received the securities under the Prior Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions had adequate
access, through employment, business or other relationships, to information about us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(a) Exhibits. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The exhibits listed below are filed as
part of this registration statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Exhibit <BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Description of Document</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amended and Restated Certificate of Incorporation, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation to become effective immediately prior to the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws to become effective upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Common Stock Certificate of the registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Investors&#146; Rights Agreement, by and between the registrant and certain of its stockholders, dated September&nbsp;22, 2020.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrant to purchase stock issued to Silicon Valley Bank, dated November&nbsp;21, 2016.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrant to purchase stock issued to Silicon Valley Bank, dated December&nbsp;22, 2017.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Cooley LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1+&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnity Agreement, by and between the registrant and its directors and officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Silverback Therapeutics, Inc. 2016 Equity Incentive Plan, as amended, and Forms of Option Agreement, Notice of Exercise, Notice of Early Exercise, Restricted Stock Grant Notice and Restricted Stock Award Agreement
thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3+&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Silverback Therapeutics, Inc. 2020 Equity Incentive Plan, and Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4+&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Silverback Therapeutics, Inc. 2020 Employee Stock Purchase Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5+&yen;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement, by and between the registrant and Laura Shawver, Ph.D., dated March&nbsp;6, 2020, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6+&yen;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement, by and between the registrant and Valerie Odegard, Ph.D., dated July&nbsp;23, 2016.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7+&yen;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement, by and between the registrant and Naomi Hunder, M.D., dated December&nbsp;22, 2018.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8+&yen;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement, by and between the registrant and Russ Hawkinson, dated April&nbsp;17, 2020.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9&yen;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease, by and between the registrant and <FONT STYLE="white-space:nowrap">BMR-500</FONT> Fairview Avenue LLC, dated June&nbsp;8, 2016.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10&yen;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Master Laboratory Services Agreement, by and between the registrant and Q Squared Solutions LLC, dated May&nbsp;25, 2020.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11&yen;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Master Services Agreement, by and between the registrant and CE3, Inc., dated January&nbsp;21, 2020.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Exhibit <BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Description Of Document</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12&yen;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cell Line License Agreement, by and between the registrant and WuXi Biologics (Hong Kong) Limited, dated October&nbsp;11, 2019.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Loan and Security Agreement, by and between the registrant and Silicon Valley Bank, dated November&nbsp;21, 2016, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Ernst&nbsp;&amp; Young LLP, Independent Registered Public Accounting Firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Cooley LLP. Reference is made to Exhibit 5.1.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney. Reference is made to the signature page hereto.</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&yen;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Schedules have been omitted pursuant to Item 601(a)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> The
registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Certain portions of this exhibit are omitted because they are not material and would likely cause competitive harm to the
registrant if disclosed. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>(b) Financial Statement Schedules. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial
statements or notes thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;17. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such
denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC
such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The undersigned registrant hereby undertakes that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus
filed as part of this registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this
Registration Statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form
of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of Washington
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SILVERBACK THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Laura Shawver, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Chief Executive Officer</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Laura Shawver, Ph.D., and Russ Hawkinson, and each
of them, as her or his true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, each with the full power of substitution, for her or him and in her or his name, place or stead, in
any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to sign any registration statement for the same offering covered by this registration statement that is to be effective
upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and
necessary to be done in and about the premises, as fully to all intents and purposes as she or he might or could do in person, hereby ratifying and confirming all that said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, or their, her or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT>
has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Laura Shawver, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Director<BR><I>(Principal Executive Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Russ Hawkinson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Senior Vice President of Finance<BR><I>(Principal&nbsp;Financial&nbsp;and&nbsp;Accounting&nbsp;Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Peter Thompson, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Vickie L. Capps</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Robert Hershberg, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Saqib Islam, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Jonathan Root, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Thilo Schroeder, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Scott Platshon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">State of Delaware</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Secretary of State</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Division of Corporation</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Delivered 08:33 AM 09/21/2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">FILED 08:33 AM 09/21/2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">SR 20207369908 - File Number 5818437</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOURTH AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SILVERBACK
THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Pursuant to Sections 141(f) 228, 242, and 245 of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>General Corporation Law of the State of Delaware) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Silverback Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of
the State of Delaware (the &#147;<B><U>General Corporation Law</U></B>&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY:</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIRST:</B> That the name of this corporation is Silverback Therapeutics, Inc. and that this corporation was originally incorporated
pursuant to the General Corporation Law on January&nbsp;4, 2016 under the name Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SECOND:</B> That the
Board of Directors of this corporation duly adopted resolutions proposing to amend and restate the Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this
corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED,</B> that the Certificate of Incorporation of this corporation be amended and restated in its entirety as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of
this corporation is Silverback Therapeutics, Inc. (the &#147;<B><U>Corporation</U></B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the Corporation&#146;s registered office in the State of Delaware is to be located at 1013&nbsp;Centre Road, Suite <FONT
STYLE="white-space:nowrap">403-B,</FONT> in the City of Wilmington, County of New Castle, State of Delaware, 19805. The name of the Corporation&#146;s registered agent at such address is Vcorp Services, LLC. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The nature
of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> <B><U>Authorization of Stock</U></B>. The Corporation is authorized to issue two classes of stock to be designated, respectively,
common stock and preferred stock. The total number of shares that the Corporation is authorized to issue is 173,074,889. The total number of shares of common stock authorized to be issued is 96,000,000, par value $0.0001 per share (the
&#147;<B><U>Common Stock</U></B>&#148;). The total number of shares of preferred stock authorized to be issued is 77,074,889, par&nbsp;value $0.0001 per share (the &#147;<B><U>Preferred Stock</U></B>&#148;), 15,714,283 of which are designated as
&#147;<B><U>Series A Preferred Stock</U></B>&#148;, 36,433,916 of which are designated as &#147;<B><U>Series B Preferred Stock</U></B>&#148;, and 24,926,690 of which are designated as &#147;<B><U>Series C Preferred Stock</U></B>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> <B><U>Rights, Preferences and Restrictions of Preferred Stock</U></B>. The rights, preferences, privileges and restrictions granted
to and imposed on the Preferred Stock are as set forth below in this Article&nbsp;IV Section&nbsp;B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Dividend
Provisions</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The holders of shares of each series of Preferred Stock shall be entitled to receive, on a pari passu
basis, noncumulative dividends, out of any assets legally available therefor, prior and in preference to any declaration or payment of any dividend (payable other than in Common Stock to the holders of Common Stock) on the Common Stock of the
Corporation, at the rate of eight percent (8%) of the applicable Original Issue Price (as defined below) of each such share of Preferred Stock per annum on each outstanding share of Preferred Stock). As used in this Amended and Restated Certificate
of Incorporation, &#147;<B><U>Original </U></B><B>Issue Price</B>&#148; shall mean $3.50&nbsp;per share for each share of Series A Preferred Stock, $2.16&nbsp;per share for each share of Series B Preferred Stock, and $3.41&nbsp;per share for each
share of Series C Preferred Stock, in each case as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations or the like with respect to such applicable series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> All such dividends are payable only when, as, and if, declared by the Corporation&#146;s board of directors (the &#147;<B><U>Board
of Directors</U></B>&#148;). Such dividends shall be noncumulative. No dividends (other than those payable in Common Stock to holders of Common Stock) shall be paid on any Common Stock of the Corporation until all dividends on the Preferred Stock
shall have been paid. After payment of such dividends to the holders of Preferred Stock, any additional dividends shall be distributed among the holders of Preferred Stock and Common Stock on a pari passu basis and pro rata based on the number of
shares of Common Stock then held by each holder, including all shares of Common Stock into which such holder&#146;s shares of Preferred Stock could be converted at the then effective applicable Conversion Rates (as defined in
<U>Section</U><U></U><U>&nbsp;4(a)</U> below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Whenever a dividend or distribution shall be payable in property other than
cash, the value of such dividend or distribution shall be deemed to be the fair market value of such property as determined in good faith by the Board of Directors, including the consent of the Required Preferred Directors (as defined in
<U>Section</U><U></U><U>&nbsp;5(b)</U> below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>Liquidation Preference</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In the event of any Liquidation Event (as defined in <U>Section</U><U></U><U>&nbsp;2(c)</U> below), either voluntary or
involuntary, the holders of shares of Preferred Stock then outstanding shall be entitled to be paid on a pari passu basis out of the proceeds of such Liquidation Event and the assets of the Corporation available for distribution to its stockholders
(&#147;<B><U>Proceeds</U></B>&#148;) before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the sum of the applicable Original Issue Price for such share of Preferred Stock,
plus any declared but unpaid dividends on each such share (the &#147;<B>Liquidation Preference</B>&#148;). If, upon the occurrence of such event, the Proceeds thus distributed among the holders of Preferred Stock shall be insufficient to permit the
payment to such holders of the full Liquidation Preferences, then the entire Proceeds legally available for distribution shall be distributed ratably among the holders of Preferred Stock in proportion to the full preferential amount that each such
holder is otherwise entitled to receive under this <U>Section</U><U></U><U>&nbsp;2(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Subject to the provisions of
<U>Article&nbsp;IV</U>, <U>Section&nbsp;B.2(d)</U> below, upon completion of the distribution of the full Liquidation Preference, all of the remaining Proceeds shall be distributed pari passu among the holders of Common Stock and the holders of
Preferred Stock pro rata and on an as converted to Common Stock basis at the then effective applicable Conversion Rates for the Preferred Stock. The aggregate amount that a holder of a share of Preferred Stock is entitled to receive under
<U>Section</U><U></U><U>&nbsp;2(a)</U> and this <U>Section</U><U></U><U>&nbsp;2(b)</U> is hereinafter referred to as the &#147;<B><U>Preferred Liquidation Amount</U></B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>(i)</B> For purposes of this Section&nbsp;2, a &#147;<B><U>Liquidation Event</U></B>&#148; shall mean: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(A)</B> the closing of the sale, lease, transfer, exclusive license or other disposition, in one transaction or a series of related
transactions, of all or substantially all of the Corporation&#146;s and its subsidiaries&#146; assets, taken as a whole, or all or substantially all of the intellectual property assets of the Corporation and its subsidiaries, taken as a whole,
except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation for the benefit of the Corporation, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(B)</B> the consummation of the merger or consolidation of the Corporation with or into another entity, except any merger or consolidation
in which the holders of capital stock of the Corporation immediately prior to such merger or consolidation continue to hold immediately following such merger or consolidation a majority of the voting power of the capital stock of the Corporation or
the surviving or acquiring entity (or, if the surviving or acquiring entity is a wholly owned subsidiary of another party immediately following such merger or consolidation, the parent entity of such surviving or acquiring entity), </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(C)</B> the closing of the issuance, sale or transfer (whether by merger, consolidation or otherwise), in one transaction or a series of
related transactions, as a result of which the holders of capital stock of the Corporation immediately prior to such transaction hold immediately following such transaction less than a majority of the outstanding voting stock of the Corporation, or
the surviving or acquiring entity; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(D)</B> a liquidation, voluntary or involuntary dissolution or winding up of the
Corporation or a general assignment for the benefit of creditors; provided, however, that a transaction or series of transactions shall not constitute a Liquidation Event if: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(1) its sole purpose is to change the state of the Corporation&#146;s incorporation or to create a holding company that will be owned in
substantially the same proportions by the persons and entities who held the Corporation&#146;s securities immediately prior to such transaction; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(2) it is solely a transfer of securities to an underwriter of the Corporation&#146;s securities in connection with an initial underwritten
public offering pursuant to a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act of 1933, as amended (the &#147;<B><U>Securities Act</U></B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(3) it is solely for bona fide financing purposes in which cash is received by the Corporation, or indebtedness of the Corporation is
cancelled or converted or a combination thereof; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(4) the holders in the aggregate of a majority of the then outstanding shares of
Preferred Stock, voting together as a single class, on as converted to Common Stock basis (the &#147;<B><U>Preferred Majority</U></B>&#148;) elects in writing that such transaction or series of transactions, as applicable, is not a Liquidation
Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If Proceeds from any Liquidation Event to be distributed to the Corporation or its stockholders is other than cash,
the value of such Proceeds will be deemed to be the fair market value of such Proceeds. Any Proceeds that are securities shall be valued as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(A)</B> Securities not subject to investment letter or other similar restrictions on free marketability covered by (B)&nbsp;below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(1) If traded on a U.S. national securities exchange, the value shall be deemed to be the average of the daily VWAPs of the securities on
such exchange over the twenty <FONT STYLE="white-space:nowrap">(20)&nbsp;trading-day</FONT> period ending three (3)&nbsp;trading days prior to the occurrence of the Liquidation Event; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(2) If actively traded <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter,</FONT></FONT> the value shall be
deemed to be the average of the daily VWAPs (whichever is applicable) over the twenty <FONT STYLE="white-space:nowrap">(20)&nbsp;trading-day</FONT> period ending three (3)&nbsp;trading days prior to the occurrence of the Liquidation Event; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(3) If there is no active public market, the value shall be the fair market value thereof, as mutually determined by the Corporation and the
Preferred Majority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this <U>Section</U><U></U><U>&nbsp;2(c)(ii)</U>, &#147;<B><U>trading day</U></B>&#148; shall mean any day which
the exchange or system on which the securities to be distributed are traded is open and &#147;<U>daily VWAP</U>&#148; shall be the per share volume-weighted average price of the applicable securities as displayed under the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
heading &#147;Bloomberg VWAP&#148; on Bloomberg page &#147;[Ticker Symbol] &lt;equity&gt; AQR&#148; (or any successor thereto if such page it not available) in respect of the period from the
scheduled open of trading until the scheduled close of trading of the primary trading session on such trading day (or if such volume-weighted average price is unavailable on Bloomberg, the volume-weighted average trading price of one share of such
securities on such trading day, as determined in good faith by the Board of Directors using a reasonably similar method). The daily VWAP will be determined without regard to afterhours trading or any other trading outside of the regular trading
session trading hours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(B)</B> The method of valuation of securities subject to investment letter or other restrictions on free
marketability (other than restrictions arising solely by virtue of a stockholder&#146;s status as an affiliate or former affiliate) shall be to make an appropriate discount from the market value determined as above in (A) (1), (2) or (3)&nbsp;to
reflect the approximate fair market value thereof, as mutually determined by the Corporation and the Preferred Majority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(C)</B> The
foregoing methods for valuing <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration to be distributed in connection with a Liquidation Event shall, if definitive agreements governing such Liquidation Event have been approved by the
stockholders under the General Corporation Law and <U>Article IV Section B.5(c)</U> below, be superseded by the determination of such value set forth in such definitive agreements governing such Liquidation Event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> The Corporation shall not have the power to effect a Liquidation Event referred to in Section&nbsp;2(c)(i)(B) unless the
agreement or plan of merger or consolidation for such transaction (the &#147;<B><U>Merger Agreement</U></B>&#148;) provides that the consideration payable to the stockholders of the Corporation in such Liquidation Event shall be paid to the holders
of capital stock of the Corporation in accordance with this <U>Section</U><U></U><U>&nbsp;2</U>. In the event the requirements of this Section&nbsp;2 are not complied with, the Corporation shall forthwith either: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(A)</B> cause the closing of such Liquidation Event to be postponed until such time as the requirements of this
<U>Section</U><U></U><U>&nbsp;2</U> have been complied with; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(B)</B> cancel such transaction, in which event the rights,
preferences and privileges of the holders of the Preferred Stock shall revert to and be the same as such rights, preferences and privileges existing immediately prior to the date of the first notice referred to in
<U>Section</U><U></U><U>&nbsp;2(c)(iv)</U> below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> This Corporation shall give each holder of record of Preferred Stock
written notice of such impending Liquidation Event not later than twenty (20)&nbsp;days prior to the stockholders&#146; meeting called to approve such transaction, or twenty (20)&nbsp;days prior to the closing of such transaction, whichever is
earlier, and shall also notify such holders in writing of the final approval of such transaction. The first of such notices shall describe the material terms and conditions of the impending transaction and the provisions of this
<U>Section</U><U></U><U>&nbsp;2</U>, and the Corporation shall thereafter give such holders prompt notice of any material changes. The transaction shall in no event take place sooner than twenty (20)&nbsp;days after the Corporation has given the
first notice provided for herein or sooner than ten (10)&nbsp;days after the Corporation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
has given notice of any material changes provided for herein; provided, however, that subject to compliance with the General Corporation Law, such periods may be shortened or waived upon the
written consent of the Preferred Majority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> In the event that in connection with a Liquidation Event any portion of the
consideration payable to the Corporation or to the stockholders of the Corporation is placed into escrow and/or is payable to the Corporation or the stockholders of the Corporation subject to the satisfaction of contingencies (&#147;<B><U>Contingent
Consideration</U></B>&#148;), then (a)&nbsp;the portion of such consideration that is not placed in escrow and not subject to any contingencies (the &#147;<B><U>Initial Consideration</U></B>&#148;) shall be allocated among the holders of capital
stock of the Corporation in accordance with <U>Section</U><U></U><U>&nbsp;2(a)</U> and <U>Section</U><U></U><U>&nbsp;2(b)</U> above as if the Initial Consideration were the only consideration payable in connection with such Liquidation Event, and
(b)&nbsp;any Contingent Consideration which becomes payable to the Corporation or to the stockholders of the Corporation upon release from escrow or satisfaction of contingencies shall be allocated among the holders of capital stock of the
Corporation in accordance with <U>Section</U><U></U><U>&nbsp;2(a)</U> and <U>Section</U><U></U><U>&nbsp;2(b)</U> above after taking into account payment of the Initial Consideration as part of the same transaction. The Merger Agreement (or any
definitive agreement) for a Liquidation Event shall provide that all Proceeds, including but not limited to Contingent Consideration, are distributed in accordance with provisions of this <U>Article IV</U>, <U>Section B.2</U>, including but not
limited to this <U>Section</U><U></U><U>&nbsp;2(d)</U>. For purposes of this <U>Section</U><U></U><U>&nbsp;2(d)</U>, consideration placed into escrow or retained as a holdback to be available for satisfaction of indemnification or similar
obligations in connection with such Liquidation Event shall be deemed to be Contingent Consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> In the event of a
Liquidation Event referred to in <U>Section</U><U></U><U>&nbsp;2(c)(i) of Article IV, Section B</U>, if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within ninety (90)&nbsp;days after such
Liquidation Event, then (i)&nbsp;the Corporation shall send a written notice to each holder of Preferred Stock no later than the ninetieth (90th) day after the Liquidation Event advising such holders of their right (and the requirements to be met to
secure such right) pursuant to the terms of the following clause; (ii)&nbsp;to require the redemption of such shares of Preferred Stock, and (iii)&nbsp;unless the Preferred Majority requests otherwise in a written instrument delivered to the
Corporation not later than one hundred twenty (120)&nbsp;days after the Liquidation Event, the Corporation shall use the consideration received by the Corporation for such Liquidation Event (net of any retained liabilities associated with the assets
sold or technology licensed, as determined in good faith by the Board of Directors, including the Required Preferred Directors), together with any other assets of the Corporation available for distribution to its stockholders, all to the extent
permitted by Delaware law governing distributions to stockholders (the &#147;<B><U>Available Proceeds</U></B>&#148;), on the one hundred fiftieth (150th) day after such Liquidation Event, to redeem all outstanding shares of Preferred Stock of each
series at a price per share equal to the Preferred Liquidation Amount of the relevant series of Preferred Stock. Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not
sufficient to redeem all outstanding shares of Preferred Stock, then the Corporation, in accordance with the preferences and priorities set forth in this <U>Section</U><U></U><U>&nbsp;2</U>, shall redeem a pro rata portion of each holder&#146;s
shares of Series C Preferred Stock, Series B Preferred Stock and Series A Preferred Stock at the applicable Liquidation Preference to the fullest extent of such Available Proceeds, based on the respective amounts which would otherwise be payable in
respect of the shares to be redeemed if the Available Proceeds were sufficient to redeem all such shares, and shall redeem </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the remaining shares as soon as it may lawfully do so under General Corporation Law governing distributions to stockholders. Thereafter, any additional Available Proceeds shall be paid to the
holders of shares of Preferred Stock to be redeemed pursuant to this <U>Section</U><U></U><U>&nbsp;2(e)</U> in an amount up to the Liquidation Preference of such share of Preferred Stock as soon as it may lawfully do so under the Delaware law
governing distributions to stockholders. Prior to the distribution or redemption provided for in this <U>Section</U><U></U><U>&nbsp;2(e)</U>, the Corporation shall not expend or dissipate the consideration received for such Liquidation Event, except
to discharge expenses incurred in connection with such Liquidation Event or in the ordinary course of business. If the Corporation is required by the provisions this <U>Section</U><U></U><U>&nbsp;2(e)</U> to redeem shares, the redemption shall occur
in accordance with the provisions of this <U>Section</U><U></U><U>&nbsp;2</U>. The date upon which any such redemption is required to be effected pursuant to this <U>Section</U><U></U><U>&nbsp;2(e)</U> shall be the &#147;<B><U>Redemption
Date</U></B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(1) Not less than twenty (20)&nbsp;days prior to the Redemption Date, the Corporation shall send written notice of
any redemption pursuant to this <U>Section</U><U></U><U>&nbsp;2(e)</U> (the &#147;<B><U>Redemption Notice</U></B>&#148;) to each holder of record of Preferred Stock as required by <U>Section</U><U></U><U>&nbsp;2(e)</U>. Each Redemption Notice shall
state: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="31%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of shares held by the holder that the Corporation shall redeem on the Redemption Date specified in
the Redemption Notice (which number shall not be less than the number of shares the Corporation is then required to redeem); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="31%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Redemption Date and the redemption price; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="31%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the holder is to surrender to the Corporation, in the manner and at the place designated, his, her or its
certificate or certificates representing the shares of Preferred Stock to be redeemed. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(2) If the Corporation
receives, on or prior to the 10th day after the date of delivery of the Redemption Notice to a holder of Preferred Stock, written notice from such holder that such holder elects to be excluded from the redemption provided in this
<U>Section</U><U></U><U>&nbsp;2(e)</U>, then the shares of Preferred Stock registered on the books of the Corporation in the name of such holder at the time of the Corporation&#146;s receipt of such notice shall thereafter be &#147;<B><U>Excluded
Shares</U></B>.&#148; Excluded Shares shall not be redeemed or redeemable pursuant to this <U>Section</U><U></U><U>&nbsp;2(e)</U>, whether on such Redemption Date or thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(3) On or before the applicable Redemption Date, each holder of shares to be redeemed on such Redemption Date, shall surrender the
certificate or certificates representing such shares (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify
the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation, in the manner and at the place designated in the Redemption Notice, and thereupon the redemption price for such shares shall be payable to the order of the person whose name appears
on such certificate or certificates as the owner thereof. In the event less than all of the shares represented by a certificate are redeemed, a new certificate representing the unredeemed shares shall promptly be issued to such holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(4) If the Redemption Notice shall have been duly given, and if on the applicable Redemption Date the redemption price payable upon
redemption of the shares to be redeemed on such Redemption Date is paid or tendered for payment or deposited with an independent payment agent so as to be available therefor in a timely manner, then notwithstanding that the certificates evidencing
any of the shares so called for redemption shall not have been surrendered, dividends with respect to such shares shall cease to accrue after such Redemption Date and all rights with respect to such shares shall forthwith after the Redemption Date
terminate, except only the right of the holders to receive the redemption price without interest upon surrender of their certificate or certificates therefor. Any shares of Preferred Stock that are redeemed or otherwise acquired by the Corporation
or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the
holders of Preferred Stock following redemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><U>Redemption</U></B>. Other than as set forth in
<U>Section</U><U></U><U>&nbsp;2(e) of Article IV, Section B</U>, the Preferred Stock is not redeemable at the option of the holder thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U>Conversion</U></B>. The holders of the Preferred Stock shall have conversion rights as follows (the &#147;<B><U>Conversion
Rights</U></B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Right to Convert</U></B>. Each share of Preferred Stock shall be convertible, at the option of
the holder thereof, at any time after the date of issuance of such share, at the office of the Corporation or any transfer agent for such stock, into such number of fully paid and nonassessable shares of Common Stock as is determined by dividing the
applicable Original Issue Price for a series of Preferred Stock by the applicable Conversion Price for such series (the conversion rate for a series of Preferred Stock into Common Stock is referred to herein as the &#147;<B><U>Conversion
Rate</U></B>&#148; for such series), determined as hereafter provided, in effect on the date the certificate is surrendered for conversion. The initial Conversion Price per share for each series of Preferred Stock shall be the Original Issue Price
applicable to such series as of the date of the first issuance and sale of shares of such series of Preferred Stock; provided, however, that the Conversion Prices for the respective series of Preferred Stock shall be subject to adjustment as set
forth in <U>Section</U><U></U><U>&nbsp;4(d)</U> below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Automatic Conversion</U></B>. Each share of Preferred Stock
shall automatically be converted into shares of Common Stock at the applicable Conversion Rate at the time in effect for such series of Preferred Stock immediately upon the earlier of (i)&nbsp;the closing of the Corporation&#146;s sale of its Common
Stock (which shares are to be listed on a U.S. national securities exchange) in a firm commitment underwritten public offering pursuant to a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act pursuant
to which the Corporation receives gross proceeds of at least $100,000,000, prior to deductions for underwriting discounts, commissions and expenses (a &#147;<B><U>Qualified Public Offering</U></B>&#148;) or (ii)&nbsp;the date, or the occurrence of
an event, specified by vote or written consent or agreement of the Preferred Majority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><U>Mechanics of Conversion</U></B>. Before any holder of Preferred Stock
shall be entitled to voluntarily convert the same into shares of Common Stock, such holder shall surrender the certificate or certificates therefor, duly endorsed, at the office of the Corporation or of any transfer agent for the applicable series
of Preferred Stock, and shall give written notice to the Corporation at its principal corporate office, of the election to convert the same and shall state therein the name or names in which the certificate or certificates for shares of Common Stock
are to be issued. This Corporation shall, as soon as practicable thereafter, issue and deliver at such office to such holder of Preferred Stock, or to the nominee or nominees of such holder, (i)&nbsp;a certificate or certificates for the number of
shares of Common Stock to which such holder shall be entitled as aforesaid, and a certificate for the number (if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, (ii)&nbsp;a
payment in cash, if applicable, of such amount as provided in Section&nbsp;4(g) in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and (iii)&nbsp;a payment of all declared but unpaid dividends on the shares of
Preferred Stock so converted. Such conversion shall be deemed to have been made immediately prior to the close of business on the date of such surrender of the shares of Preferred Stock to be converted, and the persons or entities entitled to
receive the shares of Common Stock issuable upon such conversion shall be treated for all purposes as the record holder or holders of such shares of Common Stock as of such date. If the conversion is in connection with an underwritten offering of
securities registered pursuant to the Securities Act, the conversion may, at the option of any holder tendering Preferred Stock for conversion, be conditioned upon the closing with the underwriters of the sale of securities pursuant to such
offering, in which event the persons or entities entitled to receive the Common Stock upon conversion of the Preferred Stock shall not be deemed to have converted such Preferred Stock until immediately prior to the closing of such sale of
securities. If the conversion is in connection with Automatic Conversion provisions of <U>Section</U><U></U><U>&nbsp;4(b)(ii) above</U>, such conversion shall be deemed to have been made on the conversion date described in the stockholder consent
approving such conversion, and the persons or entities entitled to receive shares of Common Stock issuable upon such conversion shall be treated for all purposes as the record holders of such shares of Common Stock as of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><U>Conversion Price Adjustments of Preferred Stock for Certain Dilutive Issuances, Splits and Combinations</U></B>. The
Conversion Price for each series of Preferred Stock shall be subject to adjustment from time to time as follows </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>(A)</B> If
the Corporation shall issue, on or after the date that this Amended and Restated Certificate of Incorporation is filed with the Secretary of State of Delaware (the &#147;<B><U>Filing Date</U></B>&#148;), any Additional Stock (as defined
<U>Section</U><U></U><U>&nbsp;4(d)(ii)</U> below) without consideration or for a consideration per share less than the Conversion Price applicable to a series of Preferred Stock in effect immediately prior to the issuance of such Additional Stock,
the Conversion Price for such series in effect immediately prior to each such issuance shall forthwith (except as otherwise provided in this <U>clause (i)</U>) be adjusted to a price (calculated to the nearest
<FONT STYLE="white-space:nowrap">one-tenth</FONT> of a cent) determined by multiplying such Conversion Price by a fraction, the numerator of which shall be the number of shares of Common Stock Outstanding (as defined below) immediately prior to such
issuance plus the number of shares of Common Stock that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aggregate consideration received by the Corporation for such issuance would purchase at such Conversion Price; and the denominator of which shall be the number of shares of Common Stock
Outstanding immediately prior to such issuance plus the number of shares of such Additional Stock. For purposes of this <U>Section</U><U></U><U>&nbsp;4(d)(i)(A)</U>, the term &#147;<B><U>Common Stock Outstanding</U></B>&#148; shall mean and include
the following: (1)&nbsp;outstanding Common Stock, (2)&nbsp;Common Stock issuable upon conversion of outstanding Preferred Stock, (3)&nbsp;Common Stock issuable upon exercise of outstanding stock options and (4)&nbsp;Common Stock issuable upon
conversion, exercise or exchange of other securities directly or indirectly convertible into, or exercisable or exchangeable for, Common Stock. Shares described in (1)&nbsp;through (4) above shall be included whether vested or unvested, whether
contingent or <FONT STYLE="white-space:nowrap">non-contingent</FONT> and whether convertible, exercisable, or exchangeable or not yet convertible, exercisable or exchangeable. In the event that the Corporation issues or sells, or is deemed to have
issued or sold, shares of Additional Stock that result in an adjustment to a Conversion Price pursuant to the provisions of this <U>Section</U><U></U><U>&nbsp;4(d)</U> (the &#147;<B><U>First Dilutive Issuance</U></B>&#148;), and the Corporation then
issues or sells, or is deemed to have issued or sold, shares of Additional Stock in a subsequent issuance other than the First Dilutive Issuance that would result in further adjustment to a Conversion Price within 90 days of the First Dilutive
Issuance (a &#147;<B><U>Subsequent Dilutive Issuance</U></B>&#148;) pursuant to the same instruments as the First Dilutive Issuance, then and in each such case upon a Subsequent Dilutive Issuance the applicable Conversion Price for each series of
Preferred Stock shall be reduced to the applicable Conversion Price that would have been in effect had the First Dilutive Issuance and each Subsequent Dilutive Issuance all occurred on the closing date of the First Dilutive Issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(B)</B> No adjustment of the Conversion Price for the Preferred Stock shall be made in an amount less than
<FONT STYLE="white-space:nowrap">one-tenth</FONT> of one cent per share. Except to the limited extent provided for in <U>Sections 4(d)(i)(E)(3)</U> and <U>(E)(4)</U> below, no adjustment of such Conversion Price pursuant to this
<U>Section</U><U></U><U>&nbsp;4(d)(i)</U> shall have the effect of increasing the Conversion Price above the Conversion Price in effect immediately prior to such adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(C)</B> In the case of the issuance of Additional Stock for cash, the consideration shall be deemed to be the amount of cash paid therefor
before deducting any reasonable discounts, commissions or other expenses allowed, paid or incurred by the Corporation for any underwriting or otherwise in connection with the issuance and sale thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(D)</B> In the case of the issuance of the Additional Stock for a consideration in whole or in part other than cash, the consideration
other than cash shall be deemed to be the fair market value thereof as determined in good faith by the Board of Directors, including the Required Preferred Directors, irrespective of any accounting treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(E)</B> In the case of the issuance of options to purchase or rights to subscribe for Common Stock, securities by their terms convertible
into or exchangeable for Common Stock or options to purchase or rights to subscribe for such convertible or exchangeable securities, the following provisions shall apply for purposes of determining the number of shares of Additional Stock issued and
the consideration paid therefor: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(1) The aggregate maximum number of shares of Common Stock deliverable upon exercise (assuming the
satisfaction of any conditions to exercisability, including without limitation, the passage of time, but without taking into account </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potential antidilution adjustments) of such options to purchase or rights to subscribe for Common Stock shall be deemed to have been issued at the time such options or rights were issued and for
a consideration equal to the consideration (determined in the manner provided in <U>Sections 4(d)(i)(C) and (d)(i)(D) above</U>), if any, received by the Corporation upon the issuance of such options or rights plus the minimum exercise price
provided in such options or rights (without taking into account potential antidilution adjustments) for the Common Stock covered thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(2) The aggregate maximum number of shares of Common Stock deliverable upon conversion of, or in exchange (assuming the satisfaction of any
conditions to convertibility or exchangeability, including, without limitation, the passage of time, but without taking into account potential antidilution adjustments) for, any such convertible or exchangeable securities or upon the exercise of
options to purchase or rights to subscribe for such convertible or exchangeable securities and subsequent conversion or exchange thereof shall be deemed to have been issued at the time such securities were issued or such options or rights were
issued and for a consideration equal to the consideration, if any, received by the Corporation for any such securities and related options or rights (excluding any cash received on account of accrued interest or accrued dividends), plus the minimum
additional consideration, if arty, to be received by the Corporation (without taking into account potential antidilution adjustments) upon the conversion or exchange of such securities or the exercise of any related options or rights (the
consideration in each case to be determined in the manner provided in <U>Sections 4(d)(i)(C) and (d)(i)(D)</U> above). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(3) In the event
of any change in the number of shares of Common Stock deliverable or in the consideration payable to the Corporation upon exercise of such options or rights or upon conversion of or in exchange for such convertible or exchangeable securities, the
Conversion Prices of the Preferred Stock, to the extent in any way affected by or computed using such options, rights or securities, shall be recomputed to reflect such change, but no further adjustment shall be made for the actual issuance of
Common Stock or any payment of such consideration upon the exercise of any such options or rights or the conversion or exchange of such securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(4) Upon the expiration of any such options or rights, the termination of any such rights to convert or exchange or the expiration of any
options or rights related to such convertible or exchangeable securities, the Conversion Prices of the Preferred Stock, to the extent in any way affected by or computed using such options, rights or securities or options or rights related to such
securities, shall be recomputed to reflect the issuance of only the number of shares of Common Stock (and convertible or exchangeable securities that remain in effect) actually issued upon the exercise of such options or rights, upon the conversion
or exchange of such securities or upon the exercise of the options or rights related to such securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">(5) The number of shares of
Additional Stock deemed issued and the consideration deemed paid therefor pursuant to <U>Sections 4(d)(i)(E)(1) and (2)</U>&nbsp;above shall be appropriately adjusted to reflect any change, termination or expiration of the type described in either
Section&nbsp;4(d)(i)(E)(3) or (4)&nbsp;above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><U>Additional Stock</U></B>&#148; shall mean any shares of Common
Stock issued (or deemed to have been issued pursuant to Section&nbsp;4(d)(i)(E) above) by the Corporation on or after the Filing Date other than the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(A)</B> shares Common Stock issued by the Corporation up to a maximum amount of 14,711,318 shares (the &#147;<B><U>Authorized Plan
Amount</U></B>&#148;), and options issued by the Corporation to purchase such shares of Common Stock, to employees, independent contractors, officers, or directors of the Corporation pursuant to stock purchase agreements, equity incentive plans or
agreements, stock bonus awards, or other incentive stock arrangements approved by the Board of Directors (collectively, &#147;Incentive Equity&#148;) (which maximum amount of shares of Common Stock and options therefore includes Incentive Equity
outstanding as of the Filing Date); provided, however that any options for such shares that expire or terminate unexercised or any restricted stock repurchased by the Corporation at cost shall not be counted toward such maximum number unless and
until such shares are regranted as new stock grants (or as new options); provided, further that the Authorized Plan Amount may otherwise be increased if approved by the Board of Directors, including the approval of the Required Preferred Directors;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(B)</B> capital stock issued by the Corporation, and/or options or warrants issued by the Corporation for capital stock, and the
underlying capital stock issued pursuant to exercise, and if applicable, subsequent conversion, thereof to financial institutions, landlords or leasing companies in connection with equipment financing arrangements or lease agreements, if approved,
in each instance, by the Board of Directors, including the approval of the Required Preferred Directors; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(C)</B> capital stock issued
by the Corporation, and/or options or warrants issued by the Corporation for capital stock, and the underlying capital stock issued pursuant to exercise, and if applicable, subsequent conversion, thereof to other entities in connection with the
license of technology or other strategic transactions, if approved, in each instance, by the Board of Directors, including the approval of the Required Preferred Directors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(D)</B> capital stock issued pursuant to <U>Sections 4(d)(iii)</U> below; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(E)</B> Common Stock issued pursuant to a Qualified Public Offering; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(F)</B> Common Stock issued upon conversion of the Preferred Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(G)</B> Common Stock issued or deemed issued pursuant to <U>Section</U><U></U><U>&nbsp;4(d)(i)(E)</U> above as a result of a decrease in
the Conversion Price of any series of Preferred Stock resulting from the operation of <U>Section</U><U></U><U>&nbsp;4(d)</U> above; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(H)</B> Series C Preferred Stock issued pursuant to that certain Series C Preferred Stock Purchase Agreement entered into on or about the
Filing Date by and among the Company and the investors named therein (the &#147;<B><U>Purchase Agreement</U></B>&#148;); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman"><B>(I)</B> Capital stock issued pursuant to options, warrants or other exercisable or
convertible securities outstanding as of the Filing Date pursuant to their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Securities specified in
<U>Section</U><U></U><U>&nbsp;4(e)(ii)(A) through (I)</U>&nbsp;above shall be known herein as &#147;<B><U>Exempted Securities</U></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> In the event the Corporation should at any time or from time to time after the Filing Date fix a record date for the
effectuation of a split or subdivision of the outstanding shares of Common Stock or the determination of holders of Common Stock entitled to receive a dividend or other distribution payable in additional shares of Common Stock or other securities or
rights convertible into, or entitling the holder thereof to receive directly or indirectly, additional shares of Common Stock (hereinafter referred to as &#147;<B><U>Common Stock Equivalents</U></B>&#148;) without payment of any consideration by
such holder for the additional shares of Common Stock or the Common Stock Equivalents (including the additional shares of Common Stock issuable upon conversion or exercise thereof), then, as of such record date (or the date of such dividend
distribution, split or subdivision if no record date is fixed), the Conversion Prices of the Preferred Stock shall be appropriately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be
increased in proportion to such increase of the aggregate of shares of Common Stock outstanding and those issuable with respect to such Common Stock Equivalents with the number of shares issuable with respect to Common Stock Equivalents determined
from time to time in the manner provided for deemed issuances in <U>Section</U><U></U><U>&nbsp;4(d)(i)(E)</U> above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> If the
number of shares of Common Stock outstanding at any time after the Filing Date is decreased by a combination of the outstanding shares of Common Stock, then, following the record date of such combination, the Conversion Price for the Preferred Stock
shall be appropriately increased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in outstanding shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> If the outstanding shares of Preferred Stock or a series of Preferred Stock shall be subdivided (by stock split, by payment of a
stock dividend or otherwise), into a greater number of shares of Preferred Stock, the Original Issue Prices of the affected series of Preferred Stock in effect immediately prior to such subdivision shall, concurrently with the effectiveness of such
subdivision, be proportionately decreased. If the outstanding shares of Preferred Stock or a series of Preferred Stock shall be combined (by reclassification or otherwise) into a lesser number of shares of Preferred Stock, the Original Issue Prices
of the affected series of Preferred Stock in effect immediately prior to such combination shall, concurrently with the effectiveness of such combination, be proportionately increased. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><U>Other Distributions</U></B>. In the event the Corporation shall declare a distribution payable in securities of other
entities, evidences of indebtedness issued by the Corporation or other persons or entities, assets (excluding cash dividends) or options or rights not referred to in <U>Section</U><U></U><U>&nbsp;4(d)(iii)</U> above and the provisions of
<U>Section</U><U></U><U>&nbsp;1</U> do not apply to such a distribution, then, in each such case for the purpose of this <U>Section</U><U></U><U>&nbsp;4(e)</U>, the holders of the Preferred Stock shall be entitled to a proportionate share of any
such distribution as though they </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
were the holders of the number of shares of Common Stock of the Corporation into which their shares of Preferred Stock are convertible as of the record date fixed for the determination of the
holders of Common Stock of the Corporation entitled to receive such distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><U>Recapitalizations</U></B>. If at any
time or from time to time the Common Stock issuable upon conversion of the Preferred Stock shall be changed into the same or a different number of shares of any other class or classes of stock, whether by capital reorganization, recapitalization or
otherwise (other than a subdivision, combination or merger or sale of assets transaction provided for elsewhere in this <U>Section</U><U></U><U>&nbsp;4</U> or in <U>Section</U><U></U><U>&nbsp;2</U>) provision shall be made so that the holders of the
Preferred Stock shall thereafter be entitled to receive upon conversion of the Preferred Stock the number of shares of stock or other securities or property of the Corporation or otherwise, to which a holder of the Common Stock deliverable upon
conversion of such Preferred Stock would have been entitled on such reorganization or recapitalization. In any such case, appropriate adjustment shall be made in the application of the provisions of this <U>Section</U><U></U><U>&nbsp;4</U> with
respect to the rights of the holders of the Preferred Stock after the reorganization or recapitalization to the end that the provisions of this <U>Section</U><U></U><U>&nbsp;4</U> (including adjustment of the applicable Conversion Price then in
effect and the number of shares issuable upon conversion of the Preferred Stock) shall be applicable after that event as nearly equivalently as may be practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><U>No Fractional Shares and Certificate as to Adjustments</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> No fractional shares shall be issued upon the conversion of any share or shares of the Preferred Stock and the aggregate number of
shares of Common Stock to be issued to particular stockholders, shall be rounded down to the nearest whole share and the Corporation shall pay in cash the fair market value of any fractional shares as of the time when entitlement to receive such
fractions is determined. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Preferred Stock the holder is at the time converting into Common Stock and the number
of shares of Common Stock issuable upon such conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Upon the occurrence of each adjustment or readjustment of any
Conversion Price of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>, the Corporation, at its expense, shall promptly compute such adjustment or readjustment in accordance with the terms hereof and prepare and furnish to each
holder of Preferred Stock a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based. This Corporation shall, upon the written request at any time of any holder of
Preferred Stock, furnish or cause to be furnished to such holder a like certificate setting forth (A)&nbsp;such adjustment and readjustment, (B)&nbsp;the Conversion Price for such series of Preferred Stock at the time in effect, and (C)&nbsp;the
number of shares of Common Stock and the amount, if any, of other property that at the time would be received upon the conversion of a share of each series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><U>Notices of Record Date</U></B>. If the Corporation shall propose at any time (i)&nbsp;to declare any dividend or
distribution upon its Common Stock, whether in cash, property, stock or other securities, whether or not a regular cash dividend and whether or not out of earnings or earned surplus, (ii)&nbsp;to effect any reclassification or recapitalization of
its Common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock outstanding involving a change in the Common Stock; or (iii)&nbsp;to voluntarily liquidate or dissolve or to enter into any transaction deemed to be a Liquidation Event, the Corporation
shall mail to each holder of Preferred Stock, at least ten (10)&nbsp;days prior to the date on which the record shall be taken for a dividend or distribution, in the case of clause (i), or for a stockholder vote on such matter in the case of clause
(ii), and at least twenty (20)&nbsp;days prior to the date on which the record shall be taken for a stockholder vote on such matter in the case of clause (iii), a notice specifying the date on which any such record is to be taken, and the amount and
character of such dividend or distribution, in the case of clause (i), or a brief description of the action(s) to be taken, in the cases of clauses (ii)&nbsp;or (iii). Notwithstanding the foregoing, such notice period may be shortened or eliminated
upon the written consent of the Preferred Majority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><U>Reservation of Stock Issuable Upon Conversion</U></B>. This
Corporation shall at all times reserve and keep available out of its authorized but unissued shares of Common Stock, solely for the purpose of effecting the conversion of the shares of the Preferred Stock, such number of its shares of Common Stock
as shall from time to time be sufficient to effect the conversion of all outstanding shares of the Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of
all then outstanding shares of the Preferred Stock, in addition to such other remedies as shall be available to the holder of such Preferred Stock, the Corporation will take such corporate action as may, in the opinion of its counsel, be necessary
to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary
amendment to this Amended and Restated Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Voting Rights</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>General Voting Rights</U></B>. The holder of each share of Preferred Stock shall have the fight to one (1)&nbsp;vote for
each share of Common Stock into which such Preferred Stock could then be converted, and with respect to such vote, such holder shall have full voting rights and powers equal to the voting rights and powers of the holders of Common Stock, and shall
be entitled, notwithstanding any provision hereof, to notice of any stockholders&#146; meeting in accordance with the Bylaws of the Corporation, and except as provided by law or in <U>Section</U><U></U><U>&nbsp;5(b)</U> below with respect to the
election of directors by the separate class vote of the holders of Common Stock, shall be entitled to vote, together with holders of Common Stock, with respect to any question upon which holders of Common Stock have the right to vote. Any fractional
voting rights available on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis (after aggregating all shares into which shares of Preferred Stock held by each holder could be converted) shall be rounded to the nearest whole
number (with <FONT STYLE="white-space:nowrap">one-half</FONT> being rounded upward). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Voting for the Election of
Directors</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> As long as at least twenty percent (20%) of the shares of Series A Preferred Stock originally issued are
then outstanding, as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations or the like, the holders of the then outstanding shares of Series A Preferred Stock shall be entitled to elect one (1)&nbsp;director
of the Corporation at any election of directors (the &#147;<B><U>Series A Director</U></B>&#148;). As long as at least twenty </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
percent (20%) of the shares of Series B Preferred Stock originally issued are then outstanding, as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations or
the like, the holders of the then outstanding shares of Series B Preferred Stock shall be entitled to elect two (2)&nbsp;directors of the Corporation at any election of directors (the &#147;<B><U>Series B Directors</U></B>&#148;). As long as at
least twenty percent (20%) of the shares of Series C Preferred Stock originally issued are then outstanding, as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations or the like, the holders of the then
outstanding shares of Series C Preferred Stock shall be entitled to elect one (1)&nbsp;director of the Corporation at any election of directors (the &#147;<B><U>Series C Director</U></B>&#148; and collectively with the Series B Director and the
Series A Director, the &#147;<B><U>Preferred Directors</U></B>&#148;). As used herein &#147;<B><U>Required Preferred Directors</U></B>&#148; shall mean a majority of the Preferred Directors, including in all cases the Series A Director. The holders
of outstanding Common Stock, voting as a separate class, shall be entitled to elect one (1)&nbsp;director of the Corporation at any election of directors. The holders of Preferred Stock and the holders of Common Stock, voting together as a single
class and on an as converted to Common Stock basis, shall be entitled to elect any remaining directors of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>
Notwithstanding the provisions of Section&nbsp;223(a)(1) and 223(a)(2) of the General Corporation Law, any vacancy, including newly created directorships resulting from any increase in the authorized number of directors or amendment of this Amended
and Restated Certificate of Incorporation, and any vacancy created by removal or resignation of a director, may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so
chosen shall hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced; provided, however, that where such vacancy occurs among the directors elected by the holders of a class
or series of stock or different classes or series voting separately or together, the holders of shares of such class, series or different classes or series voting separately (or together, as the case may be), may override the Board of
Directors&#146; action to fill such vacancy by (i)&nbsp;voting for their own designee to fill such vacancy at a meeting of the Corporation&#146;s stockholders or (ii)&nbsp;written consent, if the consenting stockholders hold a sufficient number of
shares to elect their designee at a meeting of the stockholders, pursuant to the terms and conditions of that certain Amended and Restated Voting Agreement entered into as of or around the Filing Date by and among the Corporation and the
Stockholders named therein, as such may be amended in accordance therewith from time to time (the &#147;<B><U>Voting Agreement</U></B>&#148;); provided, however, for administrative convenience, the initial Series C Director may also be appointed by
the Board of Directors in connection with the approval of the initial issuance of Series C Preferred Stock without a separate action by the holders of Preferred Stock. Any director may be removed during his or her term of office, either with or
without cause, by, and only by, the affirmative vote of the holders of the shares of the class or series of stock (or the different classes or series voting separately, or together, as the case may be) entitled to elect such director or directors,
given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders, and any vacancy thereby created may be filled by the holders of that class or series of stock (or different classes
or series voting separately, or together as the case may be) represented at the meeting or pursuant to written consent, pursuant to the terms of the Voting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><U>Class Protective Provisions</U></B>. So long as at least ten percent (10%) of the shares of the Preferred Stock originally
issued remains outstanding, as adjusted for any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock splits, stock dividends, combinations, subdivisions, recapitalizations or the like, the Corporation shall not, by merger, amendment, recapitalization, reorganization, consolidation or
otherwise, without first obtaining the prior approval, by vote or written consent, as provided by law, of the Preferred Majority, and any such act or transaction entered into without such consent or vote shall be null and void <I>ab initio</I>, and
of no force or effect: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> amend, alter, repeal, or change the rights, preferences or privileges of the Preferred Stock,
including any series thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> increase or decrease (other than by redemption pursuant to <U>Section</U><U></U><U>&nbsp;2(e)
of Article IV, Section B</U> hereof or conversion) the total number of authorized or designated shares of Common Stock or Preferred Stock, or any series thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> create, authorize, designate or issue any new class or series of capital stock ranking on parity with or senior to the then
outstanding shares Preferred Stock in right of redemption, liquidation preference, voting or dividends, or create, authorize, designate or issue any options, warrants, other rights or equity securities exercisable, convertible and/or exchangeable
for such capital stock, or once authorized, designated or issued, increase the amount of such authorized, designated or issued amounts; provided that, for clarity, the issuance of any authorized but unissued shares of Series C Preferred Stock
pursuant to the terms the Purchase Agreement shall not be deemed an issuance of any new class or series of capital stock for purposes of this Amended and Restated Certificate of Incorporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> redeem, purchase or otherwise acquire (or pay into or set aside for a sinking fund for such purpose) any share or shares of
Common Stock; provided, however, that this restriction shall not apply to the repurchase of shares of Common Stock from employees, officers, directors, consultants or other persons performing services for the Corporation or any subsidiary pursuant
to agreements under which the Corporation has the option to repurchase such shares upon the occurrence of certain events, such as the termination of employment or service, or pursuant to a right of first refusal, at no greater than the original
purchase price thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> authorize or enter into an agreement for, nor consummate any transaction or series of transactions
that is a Liquidation Event; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> amend, alter, repeal, or change any provision of this Amended and Restated Certificate of
Incorporation, as may be amended from time to time pursuant to its terms, or of the Corporation&#146;s bylaws, as may be amended from time to time pursuant to its terms (the &#147;Bylaws&#148;) in any manner adverse to the Preferred Stock, or any
series thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> increase or decrease the authorized number of directors of the Corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> pay or declare any dividend on any shares of Common Stock or Preferred Stock, except as provided for in
<U>Section</U><U></U><U>&nbsp;1.(a)</U> above; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B> undertake any act or enter into any agreement that could result in the
Corporation&#146;s issuance of any debt instrument (or series of related debt instruments) in excess of $1,000,000 or in cumulative debt in excess of $4,000,000, unless provided for in the Corporation&#146;s budget as approved by the Board of
Directors; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> authorize, enter into or consummate any transaction in which any of the Corporation&#146;s directors or officers
or any of their respective relatives or affiliates is interested, unless such transaction has been approved by the Board of Directors, including the approval of a majority of the directors who are not interested in such transaction, and, if at least
one Preferred Director is disinterested, the approval of at least one such Preferred Director; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(xi)</B> undertake any act or enter
into any agreement that could result in the Corporation&#146;s issuing shares of its capital stock to acquire all or substantially all of the equity securities of another entity or all or substantially all of the assets of any other entity and the
number of shares of capital stock of the Corporation so issued or issuable would exceed ten percent (10%) of the shares of the Corporation&#146;s capital stock (including all outstanding securities of the Corporation on as exercised and as converted
to Common Stock basis, plus the amount of any unallocated shares of Common stock in any incentive plan of the Corporation) outstanding immediately prior to such issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><U>Series Protective Provisions</U></B>. So long as at least twenty percent (20%) of the originally issued shares of a series
of Preferred Stock remain outstanding, as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations or the like, this Corporation shall not, by merger, amendment, recapitalization, reorganization, consolidation or
otherwise, without first obtaining the prior approval, by vote or written consent, as provided by law, of the holders in the aggregate of a majority of the then outstanding shares of such series of Preferred Stock, and any such act or transaction
entered into without such consent or vote shall be null and void <I>ab initio</I>, and of no force or effect: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> amend, alter,
repeal, or change any provision of this Amended and Restated Certificate of Incorporation, as may be amended from time to time pursuant to its terms, in any manner that affects such series adversely, but shall not so affect the entire class of
Preferred Stock; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> increase or decrease the authorized number of shares of such series of Preferred Stock (other than
decreases resulting from the conversion of Preferred Stock to Common Stock). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B><U>Status of Converted Stock</U></B>. In the
event any shares of Preferred Stock shall be converted pursuant to <U>Section</U><U></U><U>&nbsp;4</U> hereof, the shares so converted shall be cancelled and shall not be issuable by this Corporation. The Amended and Restated Certificate of
Incorporation of this Corporation shall be appropriately amended to effect the corresponding reduction in this Corporation&#146;s authorized capital stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B><U>Notices</U></B>. Any notice required by the provisions of this Article IV(B)
to be given to the holders of shares of Preferred Stock shall be deemed given (i)&nbsp;if deposited in the United States mail, postage prepaid, and addressed to each holder of record at his, her or its address appearing on the books of this
Corporation, (ii)&nbsp;when such notice is provided by confirmed facsimile if sent during normal business hours of the recipient; or if not, then on the next business day, or (iii)&nbsp;if such notice is provided in another manner then permitted by
the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B> <B><U>Common Stock</U></B>. The rights, preferences, privileges and restrictions granted to and
imposed on the Common Stock are as set forth below in this <U>Article IV(C)</U> and are, in each case, subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Dividend Rights</U></B>. Subject to the prior rights of holders of all classes of stock at the time outstanding having prior
rights as to dividends, the holders of the Common Stock shall be entitled to receive, when, as and if declared by the Board of Directors, out of any assets of this Corporation legally available therefor, any dividends as may be declared from time to
time by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>Liquidation Rights</U></B>. Upon the liquidation, dissolution or winding up of this
Corporation, the assets of this Corporation shall be distributed as provided in <U>Section</U><U></U><U>&nbsp;2 of Article IV(B)</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><U>Redemption</U></B>. The Common Stock is not redeemable at the option of the holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U>Voting Rights</U></B>. The holder of each share of Common Stock shall have the right to one vote for each such share, and
shall be entitled to notice of any stockholders&#146; meeting in accordance with the Bylaws of this Corporation, and shall be entitled to vote upon such matters and in such manner as may be provided by law, provided, however, that, except as
otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Amended and Restated Certificate of Incorporation that relates solely to the terms of one or more outstanding series of Preferred
Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Amended and Restated Certificate of Incorporation or pursuant to the General
Corporation Law. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may
be required by the terms of this Amended and Restated Certificate of Incorporation) the affirmative vote of the holders of a majority of the stock of this Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the
General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Directors</U></B>. The holders of outstanding Common Stock shall be entitled to elect directors
as provided in <U>Section</U><U></U><U>&nbsp;5(b) of Article IV(B)</U> above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in this Amended and Restated Certificate of Incorporation, in furtherance and not in limitation of the powers
conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to
any additional vote required by this Amended and Restated Certificate of Incorporation, the number of directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Elections of
directors need not be by written ballot unless the Bylaws of the Corporation shall so provide. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws may provide. The books of the Corporation may be
kept (subject to any provision contained in the statutes) outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the Bylaws. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">To the
fullest extent permitted by the General Corporation Law, a director of this Corporation shall not be personally liable to this Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General
Corporation Law or any other law of the state of Delaware is amended after approval by the stockholders of this Article IX to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a
director of this Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of the foregoing provisions of this Article IX by the stockholders of this Corporation shall not
adversely affect any right or protection of a director of this Corporation existing at the time of, or increase the liability of any director of this Corporation with respect to any acts or omissions of such director occurring prior to, such
amendment, repeal or modification. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to any additional vote required by this Fourth Amended and Restated Certificate of Incorporation, this Corporation reserves the right
to amend, alter, change or repeal any provision contained in this Amended and Restated Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon stockholders herein are granted subject to this
reservation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Corporation shall have the power to indemnify (and advance expenses to), to the fullest extent permitted by the General Corporation Law,
as it presently exists or may hereafter be amended from time to time, any person or entity who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative (a &#147;<B><U>Proceeding</U></B>&#148;) by reason of the fact that he, she or it is or was a director, officer, employee or agent of this Corporation or is or was serving at the request of this Corporation as a
director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#146; fees), judgments, fines and
amounts paid in settlement actually and reasonably incurred by such person or entity in connection with any such Proceeding, including in excess of the indemnification and advancement otherwise permitted by Section&nbsp;145 of the General
Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of the foregoing provisions of this <U>Article XI</U>
shall not adversely affect any right or protection of a director, officer, employee, agent or other person or entity existing at the time of, or increase the liability of any such person or entity with respect to any acts or omissions of such person
occurring prior to, such amendment, repeal or modification. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Corporation renounces any interest or expectancy of this Corporation in, or in being offered an opportunity to participate in, an
Excluded Opportunity. An &#147;<B><U>Excluded Opportunity</U></B>&#148; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of, (i)&nbsp;any director of this
Corporation who is not an employee of this Corporation or any of its subsidiaries, or (ii)&nbsp;any holder of Preferred Stock or any partner, member, director, stockholder, employee or agent of any such holder, other than someone who is an employee
of this Corporation or any of its subsidiaries (collectively, &#147;<B><U>Covered Persons</U></B>&#148;), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a
Covered Person expressly and solely in such Covered Person&#146;s capacity as a director of this Corporation; provided, that nothing herein is intended to diminish the fiduciary duties of any director of this Corporation. Notwithstanding anything to
the contrary contained elsewhere in this Fourth Amended and Restated Certificate of Incorporation, the affirmative vote of the Preferred Majority will be required to amend or repeal, or to adopt any provisions inconsistent with this Article XII.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XIII </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless
this Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative action or proceeding brought on behalf of this Corporation, (ii)&nbsp;any action asserting a claim of breach of
fiduciary duty owed by any director, officer or other employee of this Corporation to this Corporation or this Corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim against this Corporation, its directors, officers or employees
arising pursuant to any provision of the General Corporation Law or this Corporation&#146;s Amended and Restated Certificate of Incorporation or Bylaws or (iv)&nbsp;any action asserting a claim against this Corporation, its directors, officers or
employees governed by the internal affairs doctrine, except for, as to each of (i)&nbsp;through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of
Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of
Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. If any provision or provisions of this <U>Article XIII</U> shall be held to be invalid, illegal or unenforceable as applied to any person or entity or
circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this <U>Article XIII</U> (including,
without limitation, each portion of any sentence of this <U>Article XIII</U> containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such
provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIRD:</B> The foregoing amendment and restatement was approved by the holders of the requisite number of shares of said corporation in
accordance with Section&nbsp;228 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FOURTH:</B> That said Amended Restated Certificate of Incorporation,
which restates and integrates and further amends the provisions of the Corporation&#146;s Certificate of Incorporation, has been duly adopted in accordance with Sections 141(f), 242 and 245 of the General Corporation Law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page follows.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Amended and Restated Certificate of Incorporation has been
executed by a duly authorized officer of the Corporation on this <U>18th</U> day of September. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Laura Shawver</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Laura Shawver</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Certificate of Incorporation </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SILVERBACK THERAPEUTICS, INC. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;I OFFICES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Registered Office</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Other Offices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;II CORPORATE SEAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Corporate Seal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE III STOCKHOLDERS&#146; MEETINGS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Place of Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Annual Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Special Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notice of Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Quorum</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Adjournment and Notice of Adjourned Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Voting Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Joint Owners of Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">List of Stockholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Action Without Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;14.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Organization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;IV DIRECTORS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;15.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Number and Term of Office</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;16.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Powers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;17.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Term of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;18.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vacancies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;19.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Resignation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;20.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Removal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;21.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Meetings of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;22.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Quorum and Voting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;23.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Action Without Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;24.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fees and Compensation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;25.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Committees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;26.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Organization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;V OFFICERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;27.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Election of Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;28.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Tenure and Duties of Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;29.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Delegation of Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;30.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Resignations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;31.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Removal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VI EXECUTION OF CORPORATE INSTRUMENTS AND VOTING OF SECURITIES OWNED BY THE
CORPORATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;32.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Execution of Corporate Instruments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;33.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Voting of Securities Owned by the Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;VII SHARES OF STOCK</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;34.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form and Execution of Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;35.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lost Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;36.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Transfers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;37.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fixing Record Dates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;38.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Registered Stockholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE&nbsp;VIII NOTICES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;39.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IX AMENDMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;40.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Amendments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE X MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;41.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Annual Report</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;42.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SILVERBACK
THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.</B> <B>Registered Office</B>. The registered office of the corporation in the State of Delaware shall be in
the City of Wilmington, County of New Castle.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B><B> </B><B>Other Offices</B>. The corporation
shall also have and maintain an office or principal place of business at such place as may be fixed by the Board of Directors, and may also have offices at such other places, both within and without the State of Delaware, as the Board of Directors
may from time to time determine or the business of the corporation may require. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE SEAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3. Corporate Seal.</B> The corporate seal, if adopted by the Board of Directors, shall consist of a die bearing the name of
the corporation and the inscription, &#147;Corporate Seal-Delaware.&#148; Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; MEETINGS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B> <B>Place of Meetings</B>. Meetings of the stockholders of the corporation shall be held at such place,
either within or without the State of Delaware, as may be designated from time to time by the Board of Directors, or, if not so designated, then at the principal office of the corporation required to be maintained pursuant to Section&nbsp;2
hereof.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.</B><B> </B><B>Annual Meeting</B>. The annual meeting of stockholders shall be held for
the election of directors each year at such place, date and time as shall be designated by the Board of Directors. Any other proper business may be transacted at the annual meeting. If no date for the annual meeting is established or said meeting is
not held on the date established as provided above, a special meeting in lieu thereof may be held or there may be action by written consent of the stockholders on matters to be voted on at the annual meeting, and such special meeting or written
consent shall have for the purposes of these By laws or otherwise all the force and effect of an annual meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.</B> <B>Special Meetings</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Special meetings of the stockholders of the corporation may be called, for any purpose or purposes, by (i)&nbsp;the Chairman of the
Board, (ii)&nbsp;the President or Chief Executive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Officer, (iii)&nbsp;the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not there exist any vacancies in previously
authorized directorships at the time any such resolution is presented to the Board of Directors for adoption) or (iv)&nbsp;by the holders of shares entitled to cast not less than twenty percent (20%) of the votes at the meeting and shall be held at
such place, on such date, and at such time as the Board of Directors shall fix. At any time or times that the corporation is subject to Section&nbsp;2115(b) of the California General Corporation Law (&#147;<B><U>CGCL</U></B>&#148;), stockholders
holding five percent (5%) or more of the outstanding shares shall have the right to call a special meeting of stockholders as set forth in Section&nbsp;18(c) herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If a special meeting is properly called by any person or persons other than the Board of Directors, the request shall be in
writing, specifying the general nature of the business proposed to be transacted, and shall be delivered personally or sent by registered mail or by telegraphic or other facsimile transmission to the Chairman of the Board, the President or Chief
Executive Officer, or the Secretary of the corporation. No business may be transacted at such special meeting otherwise than specified in such notice. The Board of Directors shall determine the time and place of such special meeting, which shall be
held not less than thirty-five (35)&nbsp;nor more than one hundred twenty (120)&nbsp;days after the date of the receipt of the request. Upon determination of the time and place of the meeting, the officer receiving the request shall cause notice to
be given to the stockholders entitled to vote, in accordance with the provisions of Section&nbsp;7 of these Bylaws. If the notice is not given within sixty (60)&nbsp;days after the receipt of the request, the person or persons properly requesting
the meeting may set the time and place of the meeting and give the notice. Nothing contained in this paragraph (b)&nbsp;shall be construed as limiting, fixing, or affecting the time when a meeting of stockholders called by action of the Board of
Directors may be held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.</B> <B>Notice of Meetings</B>. Except as otherwise provided by law or the
Certificate of Incorporation, written notice of each meeting of stockholders shall be given not less than ten (10)&nbsp;nor more than sixty (60)&nbsp;days before the date of the meeting to each stockholder entitled to vote at such meeting, such
notice to specify the place, date and hour and purpose or purposes of the meeting. Notice of the time, place and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, either before or after
such meeting, and will be waived by any stockholder by his attendance thereat in person or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any
business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8. Quorum.</B> At all meetings of stockholders, except where otherwise provided by statute or by the Certificate of
Incorporation, or by these Bylaws, the presence, in person or by proxy duly authorized, of the holders of a majority of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a
quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairman of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. The
stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by law, the Certificate of Incorporation or these Bylaws, all
action taken by the holders of a majority of the vote cast in all matters other than the election of directors, the affirmative vote of a majority of shares present in person or represented by proxy at the meeting and entitled to vote on the subject
matter shall be the act of the stockholders. Except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at
the meeting and entitled to vote on the election of directors. Where a separate vote by a class or classes or series is required, except where otherwise provided by the statute or by the Certificate of Incorporation or these Bylaws, a majority of
the outstanding shares of such class or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect to that vote on that matter and, except where otherwise provided by statute or by
the Certificate of Incorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of the votes cast by the holders of shares of such class or classes or series shall be the act of such class
or classes or series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.</B> <B>Adjournment and Notice of Adjourned Meetings</B>. Any meeting of
stockholders, whether annual or special, may be adjourned from time to time either by the chairman of the meeting or by the vote of a majority of the shares casting votes. When a meeting is adjourned to another time or place, notice need not be
given of the adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the corporation may transact any business which might have been transacted at the original
meeting. If the adjournment is for more than thirty (30)&nbsp;days or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at
the meeting.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.</B><B> </B><B>Voting Rights</B>. For the purpose of determining those stockholders
entitled to vote at any meeting of the stockholders, except as otherwise provided by law, only persons in whose names shares stand on the stock records of the corporation on the record date, as provided in Section&nbsp;12 of these Bylaws, shall be
entitled to vote at any meeting of stockholders. Every person entitled to vote or execute consents shall have the right to do so either in person or by an agent or agents authorized by a proxy granted in accordance with Delaware law. An agent so
appointed need not be a stockholder. No proxy shall be voted after three (3)&nbsp;years from its date of creation unless the proxy provides for a longer period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11. Joint Owners of Stock.</B> If shares or other securities having voting power stand of record in the names of two (2) or
more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two (2) or more persons have the same fiduciary relationship respecting the same shares, unless the Secretary
is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect to voting shall have the following effect: (i) if only
one (1) votes, his act binds all; (ii) if more than one (1) votes, the act of the majority so voting binds all; (iii) if more than one (1) votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question
proportionally, or may apply to the Delaware Court of Chancery for relief as provided in the Delaware General Corporation Law, Section 217(b). If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a
majority or even-split for the purpose of Section 11(c) shall be a majority or even-split in interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12.</B> <B>List of Stockholders</B>. The Secretary shall
prepare and make, at least ten (10)&nbsp;days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged in alphabetical order, showing the address of each stockholder and the number of
shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10)&nbsp;days prior to the
meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not specified, at the place where the meeting is to be held. The list shall be produced and kept at the
time and place of meeting during the whole time thereof and may be inspected by any stockholder who is present.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13.</B><B> </B><B>Action Without Meeting</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Unless otherwise provided in the Certificate of Incorporation, any action required by statute to be taken at any annual or special
meeting of the stockholders, or any action which may be taken at any annual or special meeting of the stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken,
shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Every written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be
effective to take the corporate action referred to therein unless, within sixty (60)&nbsp;days of the earliest dated consent delivered to the corporation in the manner herein required, written consents signed by a sufficient number of stockholders
to take action are delivered to the corporation by delivery to its registered office in the State of Delaware, its principal place of business or an officer or agent of the corporation having custody of the book in which proceedings of meetings of
stockholders are recorded. Delivery made to a corporation&#146;s registered office shall be by hand or by certified or registered mail, return receipt requested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to
those stockholders who have not consented in writing. If the action which is consented to is such as would have required the filing of a certificate under any section of the Delaware General Corporation Law if such action had been voted on by
stockholders at a meeting thereof, then the certificate filed under such section shall state, in lieu of any statement required by such section concerning any vote of stockholders, that written consent has been given in accordance with
Section&nbsp;228 of the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14.</B> <B>Organization</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> At every meeting of stockholders, the Chairman of the Board, or, if a Chairman has not been appointed or is absent, the President
or Chief Executive Officer, or, if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such officer is absent, a chairman of the meeting chosen by a majority in interest of the stockholders entitled to vote, present in person or by proxy, shall act as chairman. The Secretary, or,
in his absence, an Assistant Secretary directed to do so by the President or Chief Executive Officer, shall act as secretary of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board of Directors of the corporation shall be entitled to make such rules or regulations for the conduct of meetings of
stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairman of the meeting shall have the right and authority to prescribe such rules, regulations and
procedures and to do all such acts as, in the judgment of such chairman, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting,
rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the corporation and their duly authorized and constituted proxies and such other
persons as the chairman shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments by participants and regulation of the opening and closing of the
polls for balloting on matters which are to be voted on by ballot. Unless and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance with rules of
parliamentary procedure. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15.</B> <B>Number and Term of Office</B>. Except as otherwise provided by the Certificate of Incorporation, the
authorized number of directors of the corporation shall be fixed by the Board of Directors from time to time. Directors need not be stockholders unless so required by the Certificate of Incorporation. If for any cause, the directors shall not have
been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of the stockholders called for that purpose in the manner provided in these Bylaws.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16.</B><B> </B><B>Powers</B>. The powers of the corporation shall be exercised, its business conducted and its
property controlled by the Board of Directors, except as may be otherwise provided by statute or by the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17.</B> <B>Term of Directors</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances,
directors shall be elected at each annual meeting of stockholders for a term of one year. Each director shall serve until his successor is duly elected and qualified or until his death, resignation or removal. No decrease in the number of directors
constituting the Board of Directors shall shorten the term of any incumbent director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> No person entitled to vote at an
election for directors may cumulate votes to which such person is entitled, unless, at the time of such election, the corporation is subject to Section&nbsp;2115(b) of the CGCL. During such time or times that the corporation is subject to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;2115(b) of the CGCL, every stockholder entitled to vote at an election for directors may cumulate such stockholder&#146;s votes and give one candidate a number of votes equal to the
number of directors to be elected multiplied by the number of votes to which such stockholder&#146;s shares are otherwise entitled, or distribute the stockholder&#146;s votes on the same principle among as many candidates as such stockholder thinks
fit. No stockholder, however, shall be entitled to so cumulate such stockholder&#146;s votes unless (i)&nbsp;the names of such candidate or candidates have been placed in nomination prior to the voting and (ii)&nbsp;the stockholder has given notice
at the meeting, prior to the voting, of such stockholder&#146;s intention to cumulate such stockholder&#146;s votes. If any stockholder has given proper notice to cumulate votes, all stockholders may cumulate their votes for any candidates who have
been properly placed in nomination. Under cumulative voting, the candidates receiving the highest number of votes, up to the number of directors to be elected, are elected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;18. Vacancies.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Unless otherwise provided in the Certificate of Incorporation, any vacancies on the Board of Directors resulting from death,
resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created
directorships shall be filled by stockholders, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors. Any director elected in accordance with the preceding
sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#146;s successor shall have been elected and qualified. A vacancy in the Board of Directors shall be
deemed to exist under this Bylaw in the case of the death, removal or resignation of any director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If at the time of filling
any vacancy or any newly created directorship, the directors then in office shall constitute less than a majority of the whole board (as constituted immediately prior to any such increase), the Delaware Court of Chancery may, upon application of any
stockholder or stockholders holding at least ten percent (10%) of the total number of the shares at the time outstanding having the right to vote for such directors, summarily order an election to be held to fill any such vacancies or newly created
directorships, or to replace the directors chosen by the directors then in offices as aforesaid, which election shall be governed by Section&nbsp;211 of the Delaware General Corporation Law </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> At any time or times that the corporation is subject to &#167;2115(b) of the CGCL, if, after the filling of any vacancy, the
directors then in office who have been elected by stockholders shall constitute less than a majority of the directors then in office, then </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any holder or holders of an aggregate of five percent (5%) or more of the total number of shares at the time outstanding having
the right to vote for those directors may call a special meeting of stockholders; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the Superior Court of the proper county
shall, upon application of such stockholder or stockholders, summarily order a special meeting of the stockholders, to be held to elect the entire board, all in accordance with Section&nbsp;305(c) of the CGCL, the term ofoffice of any director shall
terminate upon that election of a successor. (CGCL &#167;305 (c)). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;19.</B> <B>Resignation</B>. Any director may resign at any
time by delivering hiswritten resignation to the Secretary, such resignation to specify whether it will be effective at a particular time, upon receipt by the Secretary or at the pleasure of the Board of Directors. If no such specification is made,
it shall be deemed effective at the pleasure of the Board of Directors. When one or more directors shall resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so
resigned, shall have powerto fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each Director so chosen shall hold office for theunexpired portion of the term of the
Director whose place shall be vacated and until hissuccessor shall have been duly elected and qualified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;20. Removal.</B>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Subject to any limitations imposed by applicable law and the Certificate of Incorporation (and assuming the corporation is not
subject to Section&nbsp;2115 of the CGCL), the Board of Directors or any director may be removed from office at any time (i)&nbsp;with cause by the affirmative vote of the holders of a majority of the voting power of all then-outstanding shares of
voting stock of the corporation entitled to vote at an election of directors or (ii)&nbsp;without cause by the affirmative vote of the holders of a majority of the voting power of all then-outstandingshares of voting stock of the corporation,
entitled to vote at an election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Subject to the rights of holders of any series of Preferred Stock to remove
directors, during such time or times that the corporation is subject to Section&nbsp;2115(b) of theCGCL, the Board of Directors or any individual director may be removed from office at any time without cause by the affirmative vote of the holders of
at least a majority of the outstandingshares entitled to vote on such removal; provided, however, that unless the entire Board is removed, no individual director may be removed when the votes cast against such director&#146;s removal, or not
consenting in writing to such removal, would be sufficient to elect that director if voted cumulatively at an election which the same total number of votes were cast (or, if suchaction is taken by written consent, all shares entitled to vote were
voted) and the entire numberof directors authorized at the time of such director&#146;s most recent election were then beingelected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;21. Meetings of the Board of Directors. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Annual Meetings</B>. The annual meeting of the Board of Directors shall be held immediately before or after the annual meeting
of stockholders and at the place where such meeting is held. No notice of an annual meeting of the Board of Directors shall be necessary and such meeting shall be held for the purpose of electing officers and transacting such otherbusiness as may
lawfully come before it. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Regular Meetings</B>. Unless otherwise restricted by the Certificate of Incorporation, regular
meetings of the Board of Directors may be held at any time or date and at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any place within or without the State of Delaware which has been designated by the Board of Directors and publicized among all directors. No formal notice shall be required for a regular meeting
of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Special Meetings</B>. Unless otherwise restricted by the Certificate of Incorporation, special
meetings of the Board of Directors may be held at any time and placewithin or without the State of Delaware whenever called by the Chairman of the Board, the President or Chief Executive Officer, or any two of the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Telephone Meetings</B>. Any member of the Board of Directors, or of any committee thereof, may participate in a meeting by means
of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in person at such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Notice of Meetings</B>. Notice of the time and place of all special meetingsof the Board of Directors shall be orally or in
writing, by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means, during normal business hours, at
least twenty-four (24)&nbsp;hours before the date and time of the meeting, or sent in writing to each director by first class mail, postage prepaid, at least three (3)&nbsp;days before the date of the meeting. Notice of any meeting may be waived in
writing at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of
anybusiness because the meeting is not lawfully called or convened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Waiver of Notice</B>. The transaction of all business
at any meeting of the Board of Directors, or any committee thereof, however called or noticed, or wherever held, shall be as valid as though had at a meeting duly held after regular call and notice, if a quorum bepresent and if, either before or
after the meeting, each of the directors not present shall sign a written waiver of notice. All such waivers shall be filed with the corporate records or made apart of the minutes of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;22.</B> <B>Quorum and Voting</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Unless the Certificate of Incorporation requires a greater number andexcept with respect to indemnification questions arising under
Section&nbsp;42 hereof, for which a quorum shall be <FONT STYLE="white-space:nowrap">one-third</FONT> of the exact number of directors fixed from time to time, a quorum of the Board of Directors shall consist of a majority of the exact number of
directors fixed fromtime to time by the Board of Directors in accordance with the Certificate of Incorporation; <I>provided, however, </I>at any meeting, whether a quorum be present or otherwise, a majority of the directors present may adjourn from
time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> At each meeting of the Board of Directors at which a quorum is present,all questions and business shall be determined by the
affirmative vote of a majority of the directors present, unless a different vote be required by law, the Certificate of Incorporation or these Bylaws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;23.</B> <B>Action Without Meeting</B>. Unless otherwise
restricted by the Certificateof Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if allmembers of the Board of Directors
or committee, as the case may be, consent thereto in writingor by electronic transmission, and such writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee.<B>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;24.</B><B> </B><B>Fees and Compensation</B>. Directors shall be entitled to suchcompensation for their
services as may be approved by the Board of Directors, including, if so approved, by resolution of the Board of Directors, a fixed sum and expenses of attendance, ifany, for attendance at each regular or special meeting of the Board of Directors and
at anymeeting of a committee of the Board of Directors. Nothing herein contained shall be construedto preclude any director from serving the corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation
therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;25. Committees.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Executive Committee</B>. The Board of Directors may appoint an Executive Committee to consist of one (1)&nbsp;or more members of
the Board of Directors. The Executive Committee, to the extent permitted by law and provided in the resolution of the Board ofDirectors shall have and may exercise all the powers and authority of the Board of Directors inthe management of the
business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it; but no such committee shall havethe power or authority in reference to (i)&nbsp;approving or adopting, or
recommending to the stockholders, any action or matter expressly required by the Delaware General Corporation Law to be submitted to stockholders for approval, or (ii)&nbsp;adopting, amending or repealing any Bylawof the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Other Committees</B>. The Board of Directors may, from time to time, appoint such other committees as may be permitted by law.
Such other committees appointed by the Board of Directors shall consist of one (1)&nbsp;or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution or resolutions creating such
committees, but in no event shall any such committee have the powers denied to the Executive Committee in these Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B>Term</B>. Each member of a committee of the Board of Directors shall servea term on the committee coexistent with such member&#146;s term on the Board of Directors. TheBoard of Directors, subject to any requirements of any outstanding series of
Preferred Stock, the provisions of subsections (a)&nbsp;or (b) of this Bylaw may at any time increase or decrease thenumber of members of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on
the date of his death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any time for anyreason remove any individual committee member and the Board of Directors may fill any committee vacancy
created by death, resignation, removal or increase in the number of members </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the committee. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the
committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously
appoint anothermember of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
<B>Meetings</B>. Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or any other committee appointed pursuant to this Section&nbsp;25 shall be held at such times and places as are determined by the
Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Special meetings of any such committee may be held at any
place which has been determined from time to time by such committee, and may be called by any director who is a member of such committee, upon written notice to the members of such committee of the time and place of such special meeting given in the
manner provided for the giving of written notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. Notice of any special meeting of any committee may be waived in writing at any time before or
after the meeting and will be waived by any director by attendance thereat, except when the director attends such special meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the
meeting is not lawfully called or convened. A majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of business, and the act of a majority of those present at any meeting at which a quorum
is present shall be the act of such committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;26.</B> <B>Organization</B>. At every meeting of the
directors, the Chairman of the Board, or, if a Chairman has not been appointed or is absent, the President or Chief Executive Officer, or if such officer is absent, the most senior Vice President, (if a director) or, in theabsence of any such
person, a chairman of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary, or in his absence, any Assistant Secretary directed to do so by the President or Chief Executive Officer, shall act as
secretary of themeeting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;27. Election of Officers.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Election and Qualifications</B>. The officers of the corporation shall include, if and when designated by the Board of
Directors, a Chief Executive Officer, a President, a Secretary, a Chief Financial Officer and such other officers, including, but not limited to, a Chairman of the Board, one or more Vice Presidents, a Treasurer, and Assistant Vice Presidents,
Assistant Secretaries and Assistant Treasurers. Any number of offices may be held by the same person. Any Vice President, Assistant Treasurer or Assistant Secretary, respectively, may exercise any of the powers of the President, the Chief Financial
Officer or the Secretary, respectively, as directed by the Board of Directors, and shall perform such other duties as are imposed upon him or her by theseBylaws or the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Term of Office and Compensation</B>. The term of office and salary of each of
said officers and the manner and time of the payment of such salaries shall be fixed and determined by the Board of Directors and may be altered by said Board of Directors from time to time at its pleasure, subject to the rights, if any, of any
officer under any contract of employment. Any officer may resign at any time upon written notice to the corporation, without prejudice to the rights, if any, of the corporation under any contract to which the officer is a party. If any vacancy
occurs in any office of the corporation, the Board of Directors may appoint a successor to fill such vacancy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;28. Tenure
and Duties of Officers.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>General</B>. All officers shall hold office at the pleasure of the Board of Directors and until
their successors shall have been duly elected and qualified, unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at anytime by the Board of Directors. If the office of any officer becomes vacant for any
reason, the vacancy may be filled by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Duties of Chairman of the Board</B>. The Chairman of the
Board, when present, shall preside at all meetings of the stockholders and the Board of Directors. TheChairman of the Board shall perform other duties commonly incident to his office and shall also perform such other duties and have such other
powers as the Board of Directors shall designate from time to time. If there is no President or Chief Executive Officer, then the Chairman of the Board shall also serve as the Chief Executive Officer of the corporation and shall have the powers and
duties prescribed in Section&nbsp;28(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Duties of Chief Executive Officer; President</B>. The Chief Executive Officer
and/or President shall preside at all meetings of the stockholders and at all meetings ofthe Board of Directors, unless the Chairman of the Board has been appointed and is present.Unless some other officer has been elected Chief Executive Officer of
the corporation, the President shall be the chief executive officer of the corporation and shall, subject to the controlof the Board of Directors, have general supervision, direction and control of the business and officers of the corporation. The
President shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Duties of Vice Presidents</B>. The Vice Presidents may assume and perform the duties of the President in the absence or
disability of the President or whenever the office of President is vacant if no other officer has been elected Chief Executive Officer. The Vice Presidents shall perform other duties commonly incident to their office and shall also performsuch other
duties and have such other powers as the Board of Directors or the President or Chief Executive Officer shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Duties of Secretary</B>. The Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall
record all acts and proceedings thereof in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the minute book of the corporation. The Secretary shall give notice in conformity with these Bylaws of all meetings of the stockholders and of all meetings of the Board of Directors and any
committee thereof requiring notice. The Secretary shall perform all other duties given him inthese Bylaws and other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors
shall designate from time to time.The President or Chief Executive Officer may direct any Assistant Secretary to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and eachAssistant Secretary shall perform
other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors or the President or Chief Executive Officer shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Duties of Chief Financial Officer</B>. The Chief Financial Officer shallkeep or cause to be kept the books of account of the
corporation in a thorough and propermanner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the President or Chief Executive Officer. TheChief Financial
Officer, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Chief Financial Officer shall perform otherduties commonly incident to his office and shall also perform such other
duties and have such other powers as the Board of Directors or the President or Chief Executive Officer shalldesignate from time to time. The President or Chief Executive Officer may direct the Treasureror any Assistant Treasurer, or the Controller
or any Assistant Controller to assume and perform the duties of the Chief Financial Officer in the absence or disability of the Chief FinancialOfficer, and each Treasurer and Assistant Treasurer and each Controller and Assistant Controller shall
perform other duties commonly incident to his office and shall also perform such otherduties and have such other powers as the Board of Directors or the President or Chief Executive Officer shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;29.</B> <B>Delegation of Authority</B>. The Board of Directors may from time to time delegate the powers or
duties of any officer to any other officer or agent, notwithstanding any provision hereof.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;30.</B><B> </B><B>Resignations</B>. Any officer may resign at any time by giving writtennotice to the Board of
Directors, to the President or Chief Executive Officer, or to the Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is given, unless a later time is specified therein, in which event the
resignation shallbecome effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective. Any resignation shall bewithout prejudice to the rights, if any, of
the corporation under any contract with the resigning officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;31.</B> <B>Removal</B>. Any officer may be
removed from office at any time, eitherwith or without cause, by the affirmative vote of a majority of the directors in office at the time, or by the unanimous written consent of the directors in office at the time, or by any committee or superior
officers upon whom such power of removal may have been conferred by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTION OF CORPORATE INSTRUMENTS AND VOTING </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF SECURITIES OWNED BY THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;32.</B> <B>Execution of Corporate Instruments</B>. The Board of Directors may, inits discretion, determine the
method and designate the signatory officer or officers, or otherperson or persons, to execute on behalf of the corporation any corporate instrument or document, or to sign on behalf of the corporation the corporate name without limitation, or to
enter into contracts on behalf of the corporation, except where otherwise provided by law or these Bylaws, and such execution or signature shall be binding upon the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All checks and drafts drawn on banks or other depositaries on funds to the credit of the corporation or in special accounts of the corporation
shall be signed by such person or persons as the Board of Directors shall authorize so to do. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless authorized or ratified by the Board
of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any
amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;33. Voting of Securities Owned by the Corporation.</B> All stock and other securities of other corporations owned
or held by the corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors, or, in the absence of
suchauthorization, by the Chairman of the Board, the Chief Executive Officer, the President, or any Vice President. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARES OF STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section 34. </B><B>Form and Execution of Certificates.</B> Certificates for the shares of stock of the corporation shall be in such form as
is consistent with the Certificate of Incorporation and applicable law. Every holder of stock in the corporation shall be entitled to have a certificate signed by or in the name of the corporation by the Chairman of the Board, or the President or
Chief Executive Officer or any Vice President and by the Treasurer or Assistant Treasurer or the Secretary or Assistant Secretary, certifying the number of shares owned by him in the corporation. Any or all of the signatures on the certificate may
be facsimiles. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it
may be issued with the same effect as if he were such officer, transfer agent, or registrar at the date of issue. Each certificate shall state upon the face or back thereof, in full or in summary, all of the powers, designations, preferences, and
rights, and the limitations or restrictions of the shares authorized to be issued or shall, except as otherwise required by law, set forth on the face or back a statement that the corporation will furnish without charge to each stockholder who so
requests the powers, designations, preferences and relative, participating, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
optional, or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Within a reasonable time after
the issuance or transfer of uncertificated stock, the corporation shall send to the registered owner thereof a written notice containing the information required to be set forth or stated oncertificates pursuant to this section or otherwise required
by law or with respect to this section a statement that the corporation will furnish without charge to each stockholder who so requeststhe powers, designations, preferences and relative participating, optional or other special rightsof each class of
stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Except as otherwise expressly provided by law, the rights and obligations of the holders of certificates representing stock of the same
class and series shall be identical. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;35.</B> <B>Lost Certificates</B>. A new certificate or certificates
shall be issuedin place of any certificate or certificates theretofore issued by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be
lost, stolen, or destroyed. The corporation may require, as a condition precedent to the issuance of a new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or his legal representative, to agree
to indemnify the corporation in such manner as it shall require or to give the corporation a surety bond in suchform and amount as it may direct as indemnity against any claim that may be made against the corporation with respect to the certificate
alleged to have been lost, stolen, or destroyed.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;36.</B><B> Transfers</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Transfers of record of shares of stock of the corporation shall be madeonly upon its books by the holders thereof, in person or by
attorney duly authorized, and uponthe surrender of a properly endorsed certificate or certificates for a like number of shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes
of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes owned by such stockholders in any manner not prohibited by the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;37.</B> <B>Fixing Record Dates</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any
adjournment thereof, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and whichrecord date shall, subject
to applicable law, not be more than sixty (60)&nbsp;nor less than ten (10)days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a
meeting ofstockholders shall be at the close of business on the day next preceding the day on which noticeis given, or if notice is waived, at the close of business on the day next preceding the day onwhich the meeting is held. A determination of
stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <I>provided, however, </I>that the Board of Directors may fix a new record date for the adjourned meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In order that the corporation may determine the stockholders entitled to consent
to corporate action in writing without a meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the recorddate is adopted by the Board of Directors, and which date shall
not be more than ten (10)&nbsp;daysafter the date upon which the resolution fixing the record date is adopted by the Board ofDirectors. Any stockholder of record seeking to have the stockholders authorize or takecorporate action by written consent
shall, by written notice to the Secretary, request the Board of Directors to fix a record date. The Board of Directors shall promptly, but in all events within ten (10)&nbsp;days after the date on which such a request is received, adopt a resolution
fixing the record date. If no record date has been fixed by the Board of Directors within ten (10)&nbsp;days of the dateon which such a request is received, the record date for determining stockholders entitled to consent to corporate action in
writing without a meeting, when no prior action by the Board of Directors is required by applicable law, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the corporation
by deliveryto its registered office in the State of Delaware, its principal place of business or an officer oragent of the corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the
corporation&#146;s registered office shall be by hand or by certified or registered mail, return receipt requested. If no record date has been fixed bythe Board of Directors and prior action by the Board of Directors is required by law, the record
date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> In order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or
allotment of any rights or thestockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which
record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than sixty (60)&nbsp;days prior to such action. If no record date is fixed, the record date for determining
stockholders for any suchpurpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;38. Registered Stockholders.</B> The corporation shall be entitled to recognizethe exclusive right of a person registered on
its books as the owner of shares to receivedividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person whether or not it shall have
express or other notice thereof, except as otherwise provided by the laws of Delaware. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;39. Notices.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Notice to Stockholders</B>. Whenever, under any provisions of these Bylaws, notice is required to be given to any stockholder,
it shall be given in writing, timely and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
duly deposited in the United States mail, postage prepaid, and addressed to his last known post office address as shown by the stock record of the corporation or its transfer agent, or facsimile,
telegraph or telex, or by electronic mail or other electronic means. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Notice to Directors</B>. Subject to
Section&nbsp;21(e), any notice required to be given to any director may be given by the method stated in Section&nbsp;39(a), or by overnightdelivery service, facsimile, telex or telegram, except that such notice other than one which is delivered
personally shall be sent to such address as such director shall have filed in writing with the Secretary, or, in the absence of such filing, to the last known post office address of such director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Affidavit of Mailing</B>. An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or
its transfer agent appointed withrespect to the class of stock affected, specifying the name and address or the names andaddresses of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given,
and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Time Notices Deemed Given</B>. All notices given by mail or by overnight delivery service, as above provided, shall be deemed to
have been given as at the time ofmailing, and all notices given by facsimile, telex or telegram shall be deemed to have been given as of the sending time recorded at time of transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Methods of Notice</B>. It shall not be necessary that the same method ofgiving notice be employed in respect of all directors,
but one permissible method may beemployed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Failure to Receive Notice</B>. The period or limitation of time within which any stockholder may exercise any option or right,
or enjoy any privilege or benefit, or berequired to act, or within which any director may exercise any power or right, or enjoy any privilege, pursuant to any notice sent him in the manner above provided, shall not be affected or extended in any
manner by the failure of such stockholder or such director to receive suchnotice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Notice to Person with Whom Communication
Is Unlawful</B>. Whenever notice is required to be given, under any provision of law or of the Certificate of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such notice to such person
shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with
whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the Delaware
General Corporation Law, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> Notice to Person with Undeliverable Address. Whenever notice isrequired to be
given, under any provision of law or the Certificate of Incorporation or Bylaws of the corporation, to any stockholder to whom (i)&nbsp;notice of two consecutive annual meetings, andall notices of meetings or of the taking of action by written
consent without a meeting to such person during the period between such two consecutive annual meetings, or (ii)&nbsp;all, and at least two, payments (if sent by first class mail) of dividends or interest on securities during a twelvemonth period,
have been mailed addressed to such person at his address as shown on the records of the corporation and have been returned undeliverable, the giving of such notice to such person shall not be required. Any action or meeting which shall be taken or
held without notice to such person shall have the same force and effect as if such notice had been duly given. If any such person shall deliver to the corporation a written notice setting forth his then current address, the requirement that notice
be given to such person shall be reinstated. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the Delaware General Corporation Law, the certificate need not state that
notice was not given to persons to whom notice was not required to be given pursuant to this paragraph. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;40.</B> <B>Amendments</B>. These Bylaws may be amended or repealed and newBylaws adopted by the stockholders
entitled to vote. The Board of Directors shall also have the power, if such power is conferred upon the Board of Directors by the Certificate ofIncorporation, to adopt, amend, or repeal Bylaws (including, without limitation, the amendment of any
Bylaw setting forth the number of Directors who shall constitute the whole Board of Directors). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;41.</B> <B>Annual Report</B>. Provided that this corporation has 100 or fewer stockholders, the making of annual
reports is dispensed with and the requirement that suchannual reports be made to stockholders is expressly waived, except as may be directed from time to time by the Board of Directors or the Chief Executive Officer or President.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;42.</B><B> </B><B>Indemnification</B>. Every person who was or is a party or is threatenedto be made a party to
or is involved in any action, suitor proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or a person of whom he is the legal representative is or was a director or officer of the corporation or is or
was serving at the request of the corporation or for its benefit as a director or officer of another corporation, or as its representative in a partnership, joint venture, trust or other enterprise, shall be indemnified and held harmless to the
fullest extent legally permissible under the General Corporation Law of the State of Delaware from time to time against all expenses, liability and loss (including attorneys&#146; fees, judgments, fines and amounts paid or to be paid in settlement)
reasonably incurred orsuffered by him in connection therewith. The expenses of officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the corporation as they
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are incurred and in advance of the final disposition of the action, suit or proceeding upon receipt of an undertaking by or on behalf of the director or officer to repay the amount if it is
ultimately determined by a court of competent jurisdiction that he is not entitled to be indemnified by the corporation. Such right of indemnification shall be a contract right which may be enforced in any manner desired by such person. Such right
of indemnification shall not be exclusive of any other right which such directors, officers or representatives may have or hereafter acquire and, without limiting the generality of such statement, they shall be entitled to their respective rights of
indemnification under any bylaw, agreement, vote of stockholders, provision of law or otherwise, as well as their rights under this Bylaw. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may cause the corporation to purchase and maintain insurance on behalf of any person who is or was a director or
officer of the corporation or is or was serving at the request of the corporation as a director or officer of another corporation, or as its representative in a partnership, joint venture, trust or other enterprise against any liability asserted
against such person and incurred in any such capacity or arising out of such status, whether or not the corporation would have the power to indemnify such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may from time to time adopt further Bylaws with respect to indemnification and may amend these and such Bylaws to
provide at all times the fullest indemnification permitted by the General Corporation Law of the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTION VERSION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SILVERBACK
THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED INVESTORS&#146; RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amended and Restated Investors&#146; Rights Agreement (this &#147;<B><U>Agreement</U></B>&#148;) is made as of September&nbsp;22, 2020
(the &#147;<B><U>Effective Date</U></B>&#148;), by and among Silverback Therapeutics, Inc., a Delaware corporation (the &#147;<B><U>Company</U></B>&#148;), the persons and entities listed on <U>Exhibit A</U> hereto (each, an
&#147;<B><U>Investor</U></B>&#148; and collectively, the &#147;<B><U>Investors</U></B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> The Company and certain of the Investors have entered into that certain Series C Preferred Stock Purchase Agreement of even date
herewith (as the same may be amended and restated from time to time, the &#147;<B><U>Series C Purchase Agreement</U></B>&#148;), which provides for, among other things, the purchase by the Investors of shares of the Company&#146;s Series C Preferred
Stock, par value $0.0001 per share (the &#147;<B><U>Series C Preferred Stock</U></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> A condition to the obligations of
such Investors under the Series C Purchase Agreement to purchase the Series C Preferred Stock is that the Company and the Investors enter into this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B> The Company and those Investors who own shares of the Company&#146;s Series B Preferred Stock, par value $0.0001 per share (the
&#147;<B><U>Series B Preferred Stock</U></B>&#148;) and, in certain cases also own shares of the Company&#146;s Series A Preferred Stock, par value $0.0001 per share (the &#147;<B><U>Series A Preferred Stock</U></B>&#148;), are party to that certain
Amended and Restated Investors&#146; Rights Agreement, dated as of March&nbsp;4, 2020 (the &#147;<B><U>Prior Agreement</U></B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D.</B> In order to further induce the Investors to purchase the Series C Preferred Stock, the undersigned Investors who own shares of the
Company&#146;s Series B Preferred Stock and Series A Preferred Stock and the Company desire to amend and restate in its entirety the Prior Agreement and to accept the rights and obligations created pursuant hereto in lieu of their rights and
obligations under the Prior Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, <B>THEREFORE</B>, in consideration of the mutual promises and covenants set forth
herein, and certain other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Definitions</U></B>. As used in this Agreement, the following terms shall have the meanings set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#147;<B><U>Affiliate</U></B>&#148; means, with respect to any specified person or entity, any other person or entity who, directly
or indirectly, controls, is controlled by, or is under common control with such person or entity, including without limitation any general partner, managing member, officer, principal, director or trustee of such party, or any venture capital fund,
registered investment company, investment fund, managed investment account or other fund now or hereafter existing that is controlled by one or more general partners, managing members or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investment advisers of, or shares the same management or advisory company (or stockholder or member thereof) or investment adviser with, such person or entity; provided that with respect to a
person or entity that is either an individual or an irrevocable or revocable trust established for such individual or for such individual and such individual&#146;s family, spouse or domestic partner, an &#147;Affiliate&#148; shall mean a family
member, spouse or domestic partner of such individual, and includes, in the case of a trust, such individual. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
&#147;<B><U>Board</U></B>&#148; means the Company&#146;s Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#147;<B><U>CFIUS</U></B>&#148; the Committee on
Foreign Investment in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> &#147;<B><U>CFIUS Investor</U></B>&#148; means any Investor to the extent that, in
connection with the exercise of such Investor&#146;s right of first refusal pursuant to <U>Section</U><U></U><U>&nbsp;4</U> below a notice or declaration is required to be filed with CFIUS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#147;<B><U>Commission</U></B>&#148; means the Securities and Exchange Commission or any other federal agency at the time
administering the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><U>Common Stock</U></B>&#148; means the Common Stock, par value $0.0001 per share,
of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><U>Election Period</U></B>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.4</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#147;<B><U>Excess Securities</U></B>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.4</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><U>Exchange Act</U></B>&#148; means the Securities Exchange Act of
1934, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#147;<B><U>Fund</U></B>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.3</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#147;<B><U>Holder</U></B>&#148; means any Investor who holds Registrable Securities and any other holder of Registrable Securities
to whom the registration rights conferred by this Agreement have been duly and validly transferred in accordance with <U>Section</U><U></U><U>&nbsp;2.12</U> of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#147;<B><U>Indemnified Party</U></B>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.6(c)</U> hereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#147;<B><U>Indemnifying Party</U></B>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.6(c)</U>
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#147;initial Public Offering&#148; means the closing of the Company&#146;s first bona fide, firm commitment
underwritten public offering of the Company&#146;s Common Stock registered under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#147;<B><U>Initiating
Holders</U></B>&#148; means any Holder or Holders who in the aggregate hold not less than thirty percent (30%) of the Registrable Securities then outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#147;<B><U>Liquidation Event</U></B>&#148; shall have the meaning set forth in
the Company&#146;s Restated Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#147;<B><U>Major Investor</U></B>&#148; means any Investor that holds not less than
2,900,000 shares of Series C Preferred Stock or not less than 1,500,000 shares of Series A Preferred Stock and Series B Preferred Stock, on a combined basis, as shall be adjusted for any stock splits, stock dividends, combinations, subdivisions,
recapitalizations or the like with respect to such applicable series of Preferred Stock. For clarity, at such time as any Investor who previously held the requisite number of shares of Preferred Stock set forth above in this subsection (q)&nbsp;no
longer holds at least such amount of Preferred Stock, such Investor shall lose its status as a Major Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#147;<B><U>New
Securities</U></B>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.2</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#147;<B><U>Other
Selling Stockholders</U></B>&#148; means persons other than Holders who, by virtue of agreements with the Company, are entitled to include their Other Shares in certain registrations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#147;<B><U>Other Shares</U></B>&#148; means shares of Common Stock, other than Registrable Securities with respect to which
registration rights have been granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#147;<B><U>Preferred Director</U></B>&#148; shall have the meaning set forth in the
Restated Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#147;<B><U>Preferred Majority</U></B>&#148; means the holders in the aggregate of a majority of the
then outstanding shares of Preferred Stock, voting together as a single class, on as converted to Common Stock basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B>
&#147;<B><U>Preferred Stock</U></B>&#148; means, collectively, all shares of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and any other shares of Preferred Stock of the Company whether or not authorized as of the
Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#147;<B><U>Pro Rata Amount</U></B>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.1</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> &#147;<B><U>Qualified Public Offering</U></B>&#148; shall have the meaning set
forth in the Restated Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#147;<B><U>Registrable Securities</U></B>&#148; means (i)&nbsp;shares of Common Stock
issued or issuable pursuant to the conversion of the Shares, (ii)&nbsp;any shares of Common Stock, or any shares of Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, in
each case, acquired by the Investors after the date hereof, and (iii)&nbsp;any shares of Common Stock issued as a dividend or other distribution with respect to or in exchange for or in replacement of the shares referenced in (i)&nbsp;or (ii) above;
<I>provided</I>, <I>however</I>, that Registrable Securities shall not include any shares of Common Stock described in clauses (i), (ii) or (iii)&nbsp;above which have been sold to the public either pursuant to a registration statement or Rule 144,
or which have been sold in a private transaction in which the transferor&#146;s rights under this Agreement are not validly assigned in accordance with this Agreement; and <I>provided</I>, <I>further</I>, <I>however</I>, that Registrable Securities
shall not include any shares of Common Stock described in clauses (i), (ii) or (iii)&nbsp;above as to which rights have terminated pursuant to <U>Section</U><U></U><U>&nbsp;2.14</U> hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#147;<B><U>Registrable Securities then outstanding</U></B>&#148; means the
number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible
securities that are Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> The terms &#147;<B><U>register</U></B>,&#148;
&#147;<B><U>registered</U></B>&#148; and &#147;<B><U>registration</U></B>&#148; refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder,
and the declaration or ordering of the effectiveness of such registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> &#147;<B><U>Registration
Expenses</U></B>&#148; means all expenses incurred in effecting any registration pursuant to this Agreement or an Initial Public Offering, including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow
fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one special counsel for the Holders (selected by the Holders of a majority of the Registrable Securities to be registered) (in each case, not to
exceed $35,000), blue sky fees and expenses, and expenses of any regular or special audits incident to or required by any such registration, but shall not include Selling Expenses, fees and disbursements of other counsel for the Holders and the
compensation of regular employees of the Company, which shall be paid in any event by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> &#147;<B><U>Restated
Certificate</U></B>&#148; means the Company&#146;s Amended and Restated Certificate of Incorporation (as may be amended or restated from time to time). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> &#147;<B><U>Restricted Securities</U></B>&#148; means any Registrable Securities required to bear the first legend set forth in
<U>Section</U><U></U><U>&nbsp;2.8(c)</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> &#147;<B><U>ROFR Holder</U></B>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.1</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> &#147;<B><U>Rule 144</U></B>&#148; means Rule 144 as promulgated by the
Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> &#147;<B><U>Rule 145</U></B>&#148; means Rule 145 as promulgated by the Commission under the Securities Act, as such Rule may be
amended from time to time, or any similar successor rule that may be promulgated by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><U>Rule
415</U></B>&#148; means Rule 415 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> &#147;<B><U>Securities Act</U></B>&#148; means the Securities Act of 1933, as
amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B> &#147;<B><U>Selling Expenses</U></B>&#148; means all underwriting discounts, selling commissions and stock transfer taxes
applicable to the sale of Registrable Securities and fees and disbursements of counsel for any Holder (other than the fees and disbursements of one special counsel to the Holders included in Registration Expenses). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B> &#147;<B><U>Series A Preferred Stock</U></B>&#148; shall have the meaning ascribed thereto in the Recitals hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B> &#147;<B><U>Series B Preferred Stock</U></B>&#148; shall have the meaning ascribed thereto in the Recitals hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> &#147;<B><U>Series C Purchase Agreement</U></B>&#148; shall have the meaning ascribed thereto in the Recitals hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B> &#147;<B><U>Shares</U></B>&#148; means the Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B> &#147;<B><U>Voting Agreement</U></B>&#148; means that certain Amended and Restated Voting Agreement entered into by and among the
Company and the Stockholders named therein as of even date herewith, as such may be amended or restated from time to time in accordance with the provisions thereof </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> &#147;<B><U>Withdrawn Registration</U></B>&#148; means a forfeited demand registration under <U>Section</U><U></U><U>&nbsp;2.1</U>
in accordance with the terms and conditions of <U>Section</U><U></U><U>&nbsp;2.4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>Registration Rights</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B><U>Requested Registration</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Registration</U></B>. Subject to the conditions set forth in this <U>Section</U><U></U><U>&nbsp;2.1</U>, if the Company shall
receive from Initiating Holders a written request signed by such Initiating Holders that the Company effect any registration with respect to all or a part of the Registrable Securities (such request shall state the number of shares of Registrable
Securities proposed to be disposed of by such Initiating Holders), the Company will: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) promptly give written notice of the proposed
registration to all other Holders; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) as soon as practicable, but in any event within ninety (90)&nbsp;days after the
Company&#146;s receipt of such written request, file and use its commercially reasonable efforts to effect such registration (including, without limitation, filing post-effective amendments, appropriate qualifications under applicable blue sky or
other state securities laws, and appropriate compliance with the Securities Act) and to permit or facilitate the sale and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders
joining in such request as are specified in a written request received by the Company within thirty (30)&nbsp;days after such written notice from the Company is mailed or delivered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Limitations on Requested Registration</U></B>. The Company shall not be obligated to effect, or to take any action to effect,
any such registration pursuant to this <U>Section</U><U></U><U>&nbsp;2.1</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Prior to the earlier of (A)&nbsp;the four
(4)&nbsp;year anniversary of the date of this Agreement or (B)&nbsp;six (6) months following the effective date of the first registration statement filed by the Company covering an underwritten offering of any of its securities to the general public
(or the subsequent date on which all market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreements applicable to the offering have terminated, not to exceed an additional thirty-four (34)&nbsp;days); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If the Company has not yet offered securities pursuant to a registration statement and the Initiating Holders propose to sell less than
20% of the Registrable Securities held by such Initiating Holders unless such lesser number of Registrable Securities proposed to be sold by the Initiating Holders is expected to result in aggregate proceeds of at least $20,000,000 (or if after the
Initial Public Offering, Registrable Securities with an anticipated aggregate offering price of at least $2,000,000); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) In any
particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such registration, qualification, or compliance, unless the Company is already subject to service in such jurisdiction and
except as may be required by the Securities Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) After the Company has initiated two (2)&nbsp;such registrations pursuant to this
<U>Section</U><U></U><U>&nbsp;2.1</U> (counting for these purposes only (x)&nbsp;registrations which have been declared or ordered effective and pursuant to which securities have been sold, and (y)&nbsp;Withdrawn Registrations); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) During the period that is thirty (30)&nbsp;days prior to the Company&#146;s good faith estimate of the date of filing of, and ending on a
date ninety (90)&nbsp;days (or one hundred eighty (180)&nbsp;days, in the case of an Initial Public Offering) after the effective date of a Company-initiated registration (or ending on the subsequent date on which all market <FONT
STYLE="white-space:nowrap">stand-off</FONT> agreements applicable to the offering have terminated, not to exceed an additional thirty-four (34)&nbsp;days); provided that the Company is actively employing in good faith commercially reasonable efforts
to cause such registration statement to become effective; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) If the Initiating Holders propose to dispose of shares of Registrable
Securities that may be registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> pursuant to a request made under <U>Section</U><U></U><U>&nbsp;2.3</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><U>Deferral</U></B>. If (i)&nbsp;in the good faith judgment of the Board, the filing of a registration statement covering the
Registrable Securities would (x)&nbsp;materially interfere with a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant acquisition, corporate reorganization, or other similar transaction involving the Company; (y)&nbsp;require premature disclosure of material information that the Company has a bona
fide business purpose for preserving as confidential; or (z)&nbsp;render the Company unable to comply with requirements under the Securities Act or Exchange Act, and the Board concludes, as a result, that it is in the best interests of the Company
to defer the filing of such registration statement at such time, and (ii)&nbsp;the Company shall furnish to such Holders a certificate signed by the President (or other comparable senior executive officer) of the Company stating that in the good
faith judgment of the Board, it would be materially detrimental to the Company for such registration statement to be filed in the near future and that it is, therefore, in the best interests of the Company to defer the filing of such registration
statement, then (in addition to the limitations set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)(v)</U> above) the Company shall have the right to defer such filing for a period of not more than one hundred (100)&nbsp;days after receipt of the
request of the Initiating Holders, and, <I>provided</I> <I>further</I>, that the Company shall not defer its obligation in this manner more than two (2)&nbsp;times in any twelve-month period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><U>Other Shares</U></B>. The registration statement filed pursuant to the request of the Initiating Holders may, subject to the
provisions of <U>Section</U><U></U><U>&nbsp;2.1(e)</U>, include Other Shares, and may include securities of the Company being sold for the account of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><U>Underwriting</U></B>. If the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as part of their request made pursuant to this <U>Section</U><U></U><U>&nbsp;2.1</U> and the Company shall include such information in the written notice given pursuant to
<U>Section</U><U></U><U>&nbsp;2.1(a)(i)</U>. In such event, the right of any Holder to include all or any portion of its Registrable Securities in a registration pursuant to this <U>Section</U><U></U><U>&nbsp;2.1</U> shall be conditioned upon such
Holder&#146;s participation in a underwriting. In such case, if the Company shall request inclusion in any registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> of securities being sold for its own account, or if other persons shall request
inclusion in any registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>, the Initiating Holders shall, on behalf of all Holders, offer to include such securities in the underwriting and such offer shall be conditioned upon the participation
of the Company or such other persons in such underwriting and the inclusion of the Company&#146;s and such person&#146;s other securities of the Company and their acceptance of the further applicable provisions of this
<U>Section</U><U></U><U>&nbsp;2</U> (including <U>Section</U><U></U><U>&nbsp;2.10</U>). The Company shall (together with all Holders and other persons proposing to distribute their securities through such underwriting) enter into an underwriting
agreement in customary form with the representative of the underwriter or underwriters selected for such underwriting by the Initiating Holders holding in the aggregate of a majority of the Registrable Securities held by the Initiating Holders,
which underwriters are reasonably acceptable to the Company; provided, however, that the liability of each holder as set forth therein shall be several and not joint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision of this <U>Section</U><U></U><U>&nbsp;2.1</U>, if the underwriters advise the Initiating Holders in
writing that marketing factors require a limitation on the number of shares to be underwritten, the number of Registrable Securities and Other Shares that may be so included shall be allocated as follows: (i)&nbsp;first, among all Holders requesting
to include Registrable Securities in such registration statement based on the pro rata percentage of Registrable Securities held by such Holders, assuming conversion (provided that if&#146;, by operation of this clause (i), the number of Registrable
Securities to be so included is reduced to less than </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
50% of the aggregate number of Registrable Securities so requested by all Holders to be included, then the Holders in the aggregate of a majority of the Registrable Securities; may withdraw the
request for such registration and, in such a case, (A)&nbsp;such registration shall not be counted as a registration &#147;initiated&#148; by the Company for purposes of <U>Section</U><U></U><U>&nbsp;2.1(b)(iv)</U> or &#147;effected&#148; by the
Company for purposes of <U>Section</U><U></U><U>&nbsp;2.3(b)(iii)</U> and (B)&nbsp;the Company shall bear the Registration Expenses of such registration notwithstanding any provision of <U>Section</U><U></U><U>&nbsp;2.4</U> to the contrary); (ii)
second, among all Other Selling Stockholders requesting to include Other Shares in such registration statement based on the pro rata percentage of Other Shares held by such Other Selling Stockholders, assuming conversion; and (iii)&nbsp;third, to
the Company, which the Company may allocate, at its discretion, for its own account, or for the account of other stockholders or employees of the Company. If a person who has requested inclusion in such registration as provided above does not agree
to the terms of any such underwriting, such person shall be excluded therefrom by written notice from the Company, the underwriter or, if applicable, the Initiating Holders. The securities so excluded shall also be withdrawn from registration. Any
Registrable Securities or other securities excluded or withdrawn from such underwriting shall also be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of shares to be included in such registration
was previously reduced as a result of marketing factors pursuant to this <U>Section</U><U></U><U>&nbsp;2.1(e)</U>, then the Company shall then offer to all Holders and Other Selling Stockholders who have retained rights to include securities in the
registration the right to include additional Registrable Securities or Other Shares in the registration in an aggregate amount equal to the number of shares so withdrawn, with such shares to be allocated among such Holders and Other Selling
Stockholders requesting additional inclusion, as set forth above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B><U>Company Registration</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Registration</U></B>. If the Company shall determine to register any of its securities either for its own account or the
account of a security holder or holders, other than a registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> or <U>Section</U><U></U><U>&nbsp;2.3</U>, a registration relating solely to employee benefit plans, a registration relating to the
offer and sale of debt securities only, or a registration relating to a corporate reorganization or other Rule 145 transaction, the Company will: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) promptly give written notice of the proposed registration to all Holders; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) use its commercially reasonable efforts include in such registration (and any related qualification under blue sky laws or other
compliance), except as set forth in <U>Section</U><U></U><U>&nbsp;2.2(b)</U> below, and in any underwriting involved therein, all of such Registrable Securities as are specified in a written request or requests made by any Holder or Holders received
by the Company within ten (10)&nbsp;days after such written notice from the Company is mailed or delivered. Such written request may specify all or a part of a Holder&#146;s Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Underwriting</U></B>. If the registration of which the Company gives notice is for a registered public offering involving an
underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to <U>Section</U><U></U><U>&nbsp;2.2(a)</U>(&icirc;). In such event, the right of any Holder to registration pursuant to this
<U>Section</U><U></U><U>&nbsp;2.2</U> shall be conditioned upon such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holder&#146;s participation in such underwriting and the inclusion of such Holder&#146;s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to
distribute their securities through such underwriting shall (together with the Company, the Other Selling Stockholders and other holders of securities of the Company with registration rights to participate therein distributing their securities
through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision of this <U>Section</U><U></U><U>&nbsp;2.2</U>, if the underwriters advise the Company in writing that
marketing factors require a limitation on the number of shares to be underwritten, the underwriters may (subject to the limitations set forth below) limit the number of Registrable Securities to be included in, the registration and underwriting, the
Company shall so advise all holders of securities requesting registration, and the number of shares of securities that are entitled to be included in the registration and underwriting shall be allocated, as follows: (i)&nbsp;first, to the Company
for securities being sold for its own account; (ii)&nbsp;second, to the Holders requesting to include Registrable Securities in such registration statement based on the pro rata percentage of Registrable Securities held by such Holders, assuming
conversion; and (iii)&nbsp;third, to the Other Selling Stockholders requesting to include Other Shares in such registration statement based on the pro rata percentage of Other Shares held by such Other Selling Stockholders, assuming conversion.
Notwithstanding the foregoing, no such reduction shall reduce the value of the Registrable Securities of the Holders included in such registration below twenty-five percent (25%) of the total value of securities included in such registration, unless
such offering is an Initial Public Offering and such registration does not include shares of any Other Selling Stockholder (excluding shares registered for the account of the Company), in which event any or all of the Registrable Securities of such
Holders may be excluded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If a person who has requested inclusion in such registration as provided above does not agree to the terms of
any such underwriting, such person shall also be excluded therefrom by written notice from the Company or the underwriter. The Registrable Securities or other securities so excluded shall also be withdrawn from such registration. Any Registrable
Securities or other securities excluded or withdrawn from such underwriting shall be withdrawn from such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B><U>Right to Terminate Registration</U></B>. The Company shall have the right to terminate or withdraw any registration initiated by it under this <U>Section</U><U></U><U>&nbsp;2.2</U> prior to the effectiveness of such registration whether or not
any Holder has elected to include securities in such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B><U>Registration on Form
<FONT STYLE="white-space:nowrap">S-3</FONT></U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Request for Form <FONT STYLE="white-space:nowrap">S-3</FONT>
Registration</U></B>. After its Initial Public Offering, the Company shall use its commercially reasonable efforts to qualify for registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> or any comparable or successor form or forms. After
the Company has qualified for the use of Form <FONT STYLE="white-space:nowrap">S-3,</FONT> in addition to the rights contained in the foregoing provisions of this <U>Section</U><U></U><U>&nbsp;2</U> and subject to the conditions set forth in this
<U>Section</U><U></U><U>&nbsp;2.3</U>, if the Company shall receive from a Holder or Holders of Registrable Securities a written request that the Company effect any registration on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Form <FONT STYLE="white-space:nowrap">S-3</FONT> or any similar short form registration statement with respect to all or part of the Registrable Securities (such request shall state the number of
shares of Registrable Securities to be disposed of and the intended methods of disposition of such shares by such Holder or Holders), the Company will take all such action with respect to such Registrable Securities as required by Sections
2.1(a)(&icirc;) and 2.1(a)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Limitations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration</U></B>.
The Company shall not be obligated to effect, or take any action to effect, any such registration pursuant to this <U>Section</U><U></U><U>&nbsp;2.3</U>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) In the circumstances described in any of Sections <U>2.1(b)(i)</U>, <U>2.1(b)(iii)</U> or <U>2.1(b)(v)</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) If the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to
sell Registrable Securities and such other securities (if any) on Form <FONT STYLE="white-space:nowrap">S-3</FONT> at an aggregate price to the public of less than $2,000,000; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) If, in a given twelve-month period, the Company has effected two (2)&nbsp;such registrations in such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><U>Deferral</U></B>. The provisions of <U>Section</U><U></U><U>&nbsp;2.1(c)</U> shall apply to any registration pursuant to this
<U>Section</U><U></U><U>&nbsp;2.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><U>Underwriting</U></B>. If the Holders of Registrable Securities requesting
registration under this <U>Section</U><U></U><U>&nbsp;2.3</U> intend to distribute the Registrable Securities covered by their request by means of an underwriting, the provisions of <U>Section</U><U></U><U>&nbsp;2.1(e)</U> shall apply to such
registration. Notwithstanding anything contained herein to the contrary, registrations effected pursuant to this <U>Section</U><U></U><U>&nbsp;2.3</U> shall not be counted as requests for registration or registrations effected pursuant to
<U>Section</U><U></U><U>&nbsp;2.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4</B> <B><U>Expenses of Registration</U></B>. All Registration Expenses incurred in
connection with registrations pursuant to <U>Sections 2.1</U>, <U>2.2</U> and <U>2.3</U> hereof shall be borne by the Company; <I>provided</I>, <I>however</I>, that, subject to <U>Section</U><U></U><U>&nbsp;2.1(e)</U>, the Company shall not be
required to pay for any Registration Expenses of any registration proceeding begun pursuant to <U>Sections 2.1</U> and <U>2.3</U> if the registration request is subsequently withdrawn at the request of the Holders in the aggregate of a majority of
the Registrable Securities; or because a sufficient number of Holders shall have withdrawn so that the minimum offering conditions set forth in <U>Section</U><U></U><U>&nbsp;2.1</U> and <U>2.3</U> are no longer satisfied (in which case all
participating Holders shall bear such expenses pro rata among each other based on the number of Registrable Securities requested to be so registered), unless the Holders in the aggregate of a majority of the Registrable Securities agree to forfeit
their right to a demand registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>; <I>provided</I>, <I>however</I>, in the event that a withdrawal by the Holders is based upon material adverse information relating to the Company that is
different from the information known or available (upon request from the Company or otherwise) to the Holders requesting registration at the time of their request for registration under <U>Sections 2.1</U> or <U>2.3</U>, such registration shall not
be treated as a counted registration for purposes of <U>Sections 2.1</U> or <U>2.3</U> hereof, and the Company shall bear the Registration Expenses for such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration. All Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the holders of securities included in such registration pro rata among each other
on the basis of the number of Registrable Securities so registered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5</B> <B><U>Registration Procedures</U></B>. In the case of each
registration effected by the Company pursuant to <U>Section</U><U></U><U>&nbsp;2</U>, the Company will keep each Holder advised in writing as to the initiation of each registration and as to the completion thereof. At its expense, the Company will
use its commercially reasonable efforts to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Keep such registration effective for a period of ending on the earlier of the date
which is sixty (60)&nbsp;days from the effective date of the registration statement or such time as the Holder or Holders have completed the distribution described in the registration statement relating thereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> To the extent the Company is a well-known seasoned issuer (as defined in Rule 405 under the Securities Act) (a
&#147;<B><U>WKSI</U></B>&#148;) at the time any request for registration is submitted to the Company in accordance with <U>Section</U><U></U><U>&nbsp;2.3</U>, (i) if so requested, file an automatic shelf registration statement (as defined in Rule
405 under the Securities Act) (an &#147;<B><U>automatic shelf registration statement</U></B>&#148;) to effect such registration, and (ii)&nbsp;remain a WKSI (and not become an ineligible issuer (as defined in Rule 405 under the Securities Act))
during the period during which such automatic shelf registration statement is required to remain effective in accordance with this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in
connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for the period set forth in subsection
(a)&nbsp;above; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Furnish such number of prospectuses, including any preliminary prospectuses, and other documents incident
thereto, including any amendment of or supplement to the prospectus, as a Holder from time to time may reasonably request; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>
Register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdiction as shall be reasonably requested by the Holders; provided, that the Company shall not be required in
connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Notify each seller of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto
is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing, and following such notification promptly prepare and furnish to such seller a
reasonable number of copies of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus shall not include an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> If at any time when the Company is required to <FONT STYLE="white-space:nowrap">re-evaluate</FONT> its WKSI status for purposes of
an automatic shelf registration statement used to effect a request for registration in accordance with Section&nbsp;2.3, (i) the Company determines that it is not a WKSI, (ii)&nbsp;the registration statement is required to be kept effective in
accordance with this Agreement, and (iii)&nbsp;the registration rights of the applicable Holders have not terminated, reasonably promptly amend the registration statement onto a form the Company is then eligible to use or file a new registration
statement on such form, and keep such registration statement effective in accordance with the requirements otherwise applicable under this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> If (i)&nbsp;a registration made pursuant to a shelf registration statement is required to be kept effective in accordance with this
Agreement after the third anniversary of the initial effective date of the shelf registration statement and (ii)&nbsp;the registration rights of the applicable Holders have not terminated, file a new registration statement with respect to any unsold
Registrable Securities subject to the original request for registration prior to the end of the three year period after the initial effective date of the shelf registration statement, and keep such registration statement effective in accordance with
the requirements otherwise applicable under this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Furnish, on the date that such Registrable Securities are
delivered to the underwriters for sale, if such securities are being sold through underwriters, (i)&nbsp;an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is
customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and (ii)&nbsp;a &#147;comfort&#148; letter dated as of such date, from the independent certified public accountants of the Company, in form
and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> Provide a transfer agent and registrar for all Registrable Securities registered pursuant to such registration statement and a
CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(k)</B>
Otherwise comply with all applicable rules and regulations of the Commission, and make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least twelve months, but not more than
eighteen months, beginning with the first month after the effective date of the Registration Statement, which earnings statement shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> Cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange on which similar
securities issued by the Company are then listed; <I>provided</I> that in the case of the Initial Public Offering, the Registrable Securities shall be listed on a national securities exchange; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> In connection with any underwritten offering pursuant to a registration statement
filed pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> hereof, enter into an underwriting agreement in form reasonably necessary to effect the offer and sale of Common Stock, <I>provided</I> such underwriting agreement contains reasonable and
customary provisions, and <I>provided</I> further, that each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6</B> <B><U>Indemnification</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> To the extent permitted by law, the Company will indemnify and hold harmless each Holder, each of its officers, directors and
partners, legal counsel and accountants and each person controlling such Holder within the meaning of Section&nbsp;15 of the Securities Act, with respect to which registration, qualification or compliance has been effected pursuant to this
<U>Section</U><U></U><U>&nbsp;2</U>, and each underwriter, if any, and each person who controls within the meaning of Section&nbsp;15 of the Securities Act any underwriter, against all expenses, claims, losses, damages and liabilities (or actions,
proceedings or settlements in respect thereof) arising out of or based on: (i)&nbsp;any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any registration statement, prospectus, offering
circular, issuer free writing prospectus (as defined in Rule 433 of the Securities Act), issuer information (as defined in Rule 433 of the Securities Act) filed or required to be filed pursuant to Rule 433(d) under the Securities Act or any other
document incident to any such registration or related qualification or compliance, (ii)&nbsp;any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not
misleading, or (iii)&nbsp;any violation (or alleged violation) by the Company of the Securities Act, any state securities laws or any rule or regulation thereunder applicable to the Company and relating to action or inaction required of the Company
in connection with any offering covered by such registration, qualification or compliance, and the Company will reimburse each such Holder, each of its officers, directors, partners, legal counsel and accountants and each person controlling such
Holder, each such underwriter and each person who controls any such underwriter, for any legal and any other expenses reasonably incurred in connection with investigating and defending or settling any such claim, loss, damage, liability or action;
<I>provided</I> that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability, or action arises out of or is based on any untrue statement or omission based upon written information furnished to the
Company by such Holder, any of such Holder&#146;s officers, directors, partners, legal counsel or accountants, any person controlling such Holder, such underwriter or any person who controls any such underwriter, and stated to be specifically for
use therein except to the extent such information was corrected in a subsequent writing prior to or concurrently with the sale of Registrable Securities to the person or entity asserting the claim; and <I>provided</I>, <I>further</I> that, the
indemnity agreement contained in this <U>Section</U><U></U><U>&nbsp;2.6(a)</U> shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company
(which consent shall not be unreasonably withheld). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> To the extent permitted by law, each Holder will, if Registrable Securities held
by such Holder are included in the securities as to which such registration, qualification or compliance is being effected, indemnify and hold harmless the Company, each of its directors, officers, partners, legal counsel and accountants and each
underwriter, if any, of the Company&#146;s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section&nbsp;15 of the Securities Act, each other such Holder, and each of
their officers, directors and partners, and each person controlling each other such Holder, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on (in each case only to the extent that such
claims, losses, damages and liabilities arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration except to the extent such information was corrected in a subsequent writing prior to or concurrently with the sale of Registrable Securities to the person or entity asserting the claim): (i) any untrue statement (or alleged untrue
statement) of a material fact contained or incorporated by reference in any prospectus, offering circular or other document (including any related registration statement, notification, or the like) incident to any such registration, qualification or
compliance, or (ii)&nbsp;any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and such Holders, directors,
officers, partners, legal counsel and accountants, persons, underwriters, or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action, in
each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon and
in conformity with written information furnished to the Company by such Holder and stated to be specifically for use therein; <I>provided</I>, <I>however</I>, that the obligations of such Holder hereunder shall not apply to amounts paid in
settlement of any such claims, losses, damages or liabilities (or actions in respect thereof) if such settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld); and <I>provided</I> that in no event
shall any indemnity under this <U>Section</U><U></U><U>&nbsp;2.6(b)</U> exceed the net proceeds from the offering received by such Holder, except in the case of fraud or willful misconduct by such Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Each party entitled to indemnification under this Section&nbsp;2.6 (the &#147;<B><U>Indemnified Party</U></B>&#148;) shall give
notice to the party required to provide indemnification (the &#147;<B><U>Indemnifying Party</U></B>&#148;) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying
Party to assume the defense of such claim or any litigation resulting therefrom; <I>provided</I> that counsel for the Indemnifying Party, who shall conduct the defense of such claim or any litigation resulting therefrom, shall be approved by the
Indemnified Party (whose approval shall not be unreasonably withheld), and the Indemnified Party may participate in such defense at such party&#146;s expense; and <I>provided further</I> that the failure of any Indemnified Party to give notice as
provided herein shall not relieve the Indemnifying Party of its obligations under this <U>Section</U><U></U><U>&nbsp;2.6</U>, to the extent such failure is not prejudicial. No Indemnifying Party, in the defense of any such claim or litigation,
shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a
release from all liability in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respect to such claim or litigation. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and
as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> If the
indemnification provided for in this <U>Section</U><U></U><U>&nbsp;2.6</U> is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage, or expense referred to herein, then
the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage, or expense in such proportion as is
appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as
any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the
omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties&#146; relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or
omission. No person or entity will be required under this <U>Section</U><U></U><U>&nbsp;2.6(d)</U> to contribute any amount in excess of the net proceeds from the offering received by such person or entity, except in the case of fraud or willful
misconduct by such person or entity. No person or entity guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) will be entitled to contribution from any person or entity who was not guilty of such
fraudulent misrepresentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into by the Investors in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control;
<I>provided</I> that the failure of the underwriting agreement to provide for or address a matter provided for or addressed in the foregoing provisions shall not be a conflict with the foregoing provisions and, in such event, the foregoing
provisions shall control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.7</B> <B><U>Information by Holder</U></B>. Each Holder of Registrable Securities shall furnish to the
Company such information regarding such Holder and the distribution proposed by such Holder as the Company may reasonably request in writing and as shall be reasonably required in connection with any registration, qualification, or compliance
referred to in this <U>Section</U><U></U><U>&nbsp;2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.8</B> <B><U>Restrictions on Transfer</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The holder of each certificate representing Registrable Securities by acceptance thereof agrees to comply in all respects with the
provisions of this Section&nbsp;2.8. Each Holder agrees not to make any sale, assignment, transfer, pledge or other disposition of all or any portion of the Restricted Securities, or any beneficial interest therein, unless and until: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) There is then in effect a registration statement under the Securities Act covering such
proposed disposition and the disposition is made in accordance with the registration statement; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) (x) the Holder shall have given
prior written notice to the Company of the Holder&#146;s intention to make such disposition and shall have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition, (y)&nbsp;if such transfer is
prior to the Company&#146;s Initial Public Offering, the transferee thereof shall have agreed in writing for the benefit of the Company to take and hold such Restricted Securities subject to, and to be bound by, the terms and conditions set forth in
this Agreement, including, without limitation, this <U>Section</U><U></U><U>&nbsp;2.8</U> and <U>Section</U><U></U><U>&nbsp;2.10</U>, and (z)&nbsp;if reasonably requested by the Company, the Holder shall have furnished the Company, at its expense,
with (1)&nbsp;an opinion of counsel reasonably satisfactory to the Company to the effect that such disposition will not require registration of such Restricted Securities under the Securities Act or (2)&nbsp;a &#147;no action&#148; letter from the
Commission to the effect that the transfer of such securities without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto, whereupon the holder of such Restricted Securities shall
be entitled to transfer such Restricted Securities in accordance with the terms of the notice delivered by the Holder to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Notwithstanding the provisions of <U>Section</U><U></U><U>&nbsp;2.8(a)</U>, no such registration statement, opinion of counsel or
&#147;no action&#148; letter shall be required for (i)&nbsp;a transfer not involving a change in beneficial ownership, (ii)&nbsp;a transfer under Rule 144, except in unusual circumstances, or (iii)&nbsp;transactions involving the transfer of
Restricted Securities by any Holder to (x)&nbsp;a parent, subsidiary or other Affiliate of the Holder; (y)&nbsp;any of the Holder&#146;s partners, members or other equity owners, or retired partners, retired members or other equity owners, or to the
estate of any of the Holder&#146;s partners, members or other equity owners or retired partners, retired members or other equity owners; or (z)&nbsp;any venture capital fund that is controlled by or under common control with one or more general
partners or managing members of, or shares the same management company with, the Holder; <I>provided</I>, in each case, that the Holder shall give written notice to the Company of the Holder&#146;s intention to effect such disposition and shall have
furnished the Company with a detailed description of the manner and circumstances of the proposed disposition and, if such transfer is prior to the Company&#146;s Initial Public Offering, the transferee thereof shall have agreed in writing for the
benefit of the Company to take and hold such Restricted Securities subject to, and to be bound by, the terms and conditions set forth in this Agreement, including, without limitation, this <U>Section</U><U></U><U>&nbsp;2.8</U> and
<U>Section</U><U></U><U>&nbsp;2.10</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Each certificate representing Registrable Securities shall (unless otherwise permitted
by the provisions of this Agreement) be stamped or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under applicable state securities laws): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">THE OFFER AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&#147;<B><U>ACT</U></B>&#148;), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO REGISTRATION OR AN
EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE
SECURITIES LAWS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A <FONT
STYLE="white-space:nowrap">LOCK-UP</FONT> PERIOD IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN AN INVESTORS&#146; RIGHTS AGREEMENT AMONG THE COMPANY AND THE ORIGINAL HOLDERS OF THESE SHARES, COPIES OF WHICH MAY BE OBTAINED AT THE PRINCIPAL
OFFICE OF THE COMPANY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holders consent to the Company making a notation on its records and giving instructions to any transfer agent
of the Restricted Securities in order to implement the restrictions on transfer established in this <U>Section</U><U></U><U>&nbsp;2.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The first legend referring to federal and state securities laws identified in <U>Section</U><U></U><U>&nbsp;2.8(b)</U> hereof
stamped on a certificate evidencing the Restricted Securities and the stock transfer instructions and record notations with respect to such Restricted Securities shall be removed and the Company shall issue a certificate without such legend to the
holder of such Restricted Securities if (i)&nbsp;such securities are registered under the Securities Act, or (ii)&nbsp;such holder provides the Company with an opinion of counsel reasonably acceptable to the Company to the effect that a sale or
transfer of the securities may be made without registration or qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Notwithstanding anything to the contrary in this
Agreement, (i)&nbsp;any or all of an Investor&#146;s rights hereunder may be exercised by, and any or all of an Investor&#146;s obligations hereunder may be discharged by, one or more Affiliates of such Investor designated by such Investor and
(ii)&nbsp;more specifically, (x)&nbsp;an Investor may cause any shares of capital stock of the Company (or any securities directly or indirectly exercisable for, or convertible into or exchangeable for, such shares) required or permitted to be
purchased or otherwise acquired hereunder by such Investor to be so purchased or acquired, in lieu of such Investor, by an Affiliate of such Investor (and such Affiliate shall then become an &#147;Investor&#148; hereunder), and (y)&nbsp;any Investor
holding securities directly or indirectly exercisable for, or convertible into or exchangeable for, shares of capital stock of the Company shall have the right to have any such shares (or other securities) issuable upon the conversion, exercise or
exchange of the securities held by such Investor issued in the name of one or more Affiliates of such Investor designated by such Investor (and each such Affiliate shall then become an &#147;Investor&#148; hereunder). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.9</B> <B><U>Rule 144 Reporting</U></B>. With a view to making available the benefits of
certain rules and regulations of the Commission that may permit the sale of the Restricted Securities to the public without registration, the Company agrees to use its commercially reasonable efforts to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Make and keep adequate current public information with respect to the Company available in accordance with Rule 144 under the
Securities Act, at all times from and after ninety (90)&nbsp;days following the effective date of the first registration under the Securities Act filed by the Company for an offering of its securities to the general public; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> File with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and
the Exchange Act at any time after it has become subject to such reporting requirements; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> So long as a Holder owns any
Restricted Securities, furnish to the Holder forthwith upon written request a written statement by the Company as to its compliance with the reporting requirements of Rule 144 (at any time from and after ninety (90)&nbsp;days following the effective
date of the first registration statement filed by the Company for an offering of its securities to the general public), and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), a copy
of the most recent annual or quarterly report of the Company, and such other reports and documents so filed as a Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such
securities without registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.10</B> <B><U>Market <FONT STYLE="white-space:nowrap">Stand-Off</FONT> Agreement</U></B>. Each
Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the Initial Public Offering and ending on the date specified by the
Company and the managing underwriter (such period not to exceed one hundred eighty (180)&nbsp;days, or such other period as may be reasonably requested by the underwriters to accommodate regulatory restrictions on (i)&nbsp;the publication or other
distribution of research reports and (ii)&nbsp;analyst recommendations and opinions)&nbsp;(a) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock held immediately prior to the effectiveness of the
Initial Public Offering, or (b)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause
(a)&nbsp;or (b) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise. The foregoing provisions of this <U>Section</U><U></U><U>&nbsp;2.10</U> shall apply only to the Initial Public Offering, shall not apply to
the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall only be applicable to the Holders if all officers, directors and greater than one percent (1%) stockholders of the Company enter into similar agreements. The
underwriters in connection with the Initial Public Offering are intended third-party beneficiaries of this <U>Section</U><U></U><U>&nbsp;2.10</U> and shall have the right, power and authority to enforce the provisions hereof as though they were a
party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in the Initial Public Offering that are consistent with this <U>Section</U><U></U><U>&nbsp;2.10</U> or that are necessary to give
further effect thereto. Any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Company stockholders that are subject to
such agreements, based on the number of shares subject to such agreements. For the avoidance of doubt, this <U>Section</U><U></U><U>&nbsp;2.10</U> shall not apply to shares of Common Stock acquired in the Initial Public Offering or in the open
market following the Initial Public Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to enforce the foregoing covenant, the Company may impose stop-transfer
instructions with respect to the Registrable Securities of each Holder (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.11</B> <B><U>Delay of Registration</U></B>. No Holder shall have any right to take any action to restrain, enjoin, or otherwise delay any
registration as the result of any controversy that might arise with respect to the interpretation or implementation of this <U>Section</U><U></U><U>&nbsp;2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.12</B> <B><U>Transfer or Assignment of Registration Rights</U></B>. The rights to cause the Company to register securities granted to a
Holder by the Company under this <U>Section</U><U></U><U>&nbsp;2</U> may be transferred or assigned by a Holder only to a transferee or assignee of not less than twenty percent (20%) of the Registrable Securities (as presently constituted and
subject to subsequent adjustments stock splits, stock dividends, combinations, subdivisions, recapitalizations or the like) then held by such Holder; <I>provided</I> that (i)&nbsp;such transfer or assignment of Registrable Securities is effected in
accordance with the terms of <U>Section</U><U></U><U>&nbsp;2.8</U> hereof and applicable securities laws, (ii)&nbsp;the Company is given written notice prior to said transfer or assignment, stating the name and address of the transferee or assignee
and identifying the securities with respect to which such registration rights are intended to be transferred or assigned and (iii)&nbsp;the transferee or assignee of such rights assumes in writing the obligations of such Holder under this Agreement,
including without limitation the obligations set forth in <U>Section</U><U></U><U>&nbsp;2.10</U>. The foregoing twenty percent (20%) threshold shall not be applicable to any transfers among Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.13</B> <B><U>Limitations on Subsequent Registration Rights</U></B>. From and after the date of this Agreement, the Company shall not,
without the prior written consent of the Holders in the aggregate of a majority of the Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the Company giving such holder or prospective holder
any registration rights the terms of which are senior to or on parity with the registration rights granted to the Holders hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.14</B> <B><U>Termination of Registration Rights</U></B>. The right of any Holder to request registration or inclusion in any registration
pursuant to <U>Sections 2.1</U>, <U>2.2</U> or <U>2.3</U> above shall terminate on the earlier of: (i)&nbsp;following the closing of the Company&#146;s first registered public offering of Common Stock, with respect to any Holder who then holds an
amount of Registrable Securities that is equal to less than one percent (1%) of the outstanding securities of the Company and may sell all such Registrable Securities under Rule 144 during any ninety (90)&nbsp;day period, and (ii)&nbsp;four (4)
years after the closing of a Qualified Public Offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><U>Certain Covenants</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby covenants and agrees, as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B><U>Basic Financial Information and Inspection Rights</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Basic Financial Information</U></B>. As long as at least twenty percent (20%) of the shares of Preferred Stock originally
issued remain outstanding, the Company will deliver to each Major Investor: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) as soon as practicable after the end of each fiscal year
of the Company, and in any event within 150 days after the end of each fiscal year of the Company a consolidated balance sheet of the Company and its subsidiaries, if any, as at the end of such fiscal year, and consolidated statements of income and
cash flows of the Company and its subsidiaries, if any, for such year, prepared in accordance with U.S. generally accepted accounting principles consistently applied, and audited and certified by independent public accountants of recognized national
standing selected by the Company, which audit may be waived by a vote of the Preferred Majority, in which case the Company shall deliver such unaudited statements within 60 days after the end of such fiscal year; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) as soon as practicable after the end of the first, second and third quarterly accounting periods in each fiscal year of the Company, and
in any event within 45 days after the end of the first, second, and third quarterly accounting periods in each fiscal year of the Company, an unaudited consolidated balance sheet of the Company and its subsidiaries, if any, as of the end of each
such quarterly period, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such period, prepared in accordance with U.S. generally accepted accounting principles consistently applied,
subject to changes resulting from normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments and such financial statements may not contain accompanying notes; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) as soon as practicable after the each month, and in any event within 30 days after the end of each such month, an unaudited
consolidated balance sheet of the Company and its subsidiaries, if any, as of the end of each such monthly period, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such period, prepared
in accordance with U.S. generally accepted accounting principles consistently applied, subject to changes resulting from normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments and such financial statements may not contain
accompanying notes, along with a comparison of such results to the Company&#146;s operating plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) at least 30 days prior to the
beginning of each of the Company&#146;s fiscal years an annual operating plan for such fiscal year (and as soon as available, any subsequent material revisions thereto); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) as soon as practicable after the end of each fiscal year, and in any event within 30 days thereafter, a report setting forth in detail
all equity and debt holders of the Company as of the end of such year; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) a capitalization table promptly upon the request of a Major Investor, but no more
frequently than once per calendar quarter; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) such other information relating to the financial condition or business of the
Company as any Major Investor may, from time to time, reasonably request related to monitoring its investment in the Company; <I><U>provided</U></I>, <I><U>however</U></I>, that the Company shall not be obligated under this <U>Subsection 3.1(a)</U>
to provide a complete set of materials prepared by or on behalf of the Company for the purpose of distribution to the Board or any information: (i)&nbsp;that the Company reasonably determines in good faith to be a trade secret or confidential
information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company, and is not a trade secret described in the next clause); (ii) that the Company reasonably determines in good faith to be a technology or
scientific trade secret; or (iii)&nbsp;the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything else set forth herein, the Company shall deliver to each Investor that is not a Major Investor and continues to hold
at least fifty percent (50%) of the shares of Preferred Stock originally purchased by such Investor the annual financial reports set forth in <U>Section</U><U></U><U>&nbsp;3.1(a)(i)</U> above and the quarterly financial reports set forth in
<U>Section</U><U></U><U>&nbsp;3.1(a)(ii)</U> above at the same time the Company delivers such reports to the Major Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything else in this Section&nbsp;3.1 to the contrary, the Company may cease providing the information set forth in this
Section&nbsp;3.1 during the period starting with the date 30 days before the Company&#146;s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to
such registration statement and related offering; provided that the Company&#146;s covenants under this Section&nbsp;3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause
such registration statement to become effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Inspection Rights</U></B>. The Company shall permit each Major Investor
to visit and inspect any of the properties of the Company or any of its subsidiaries during normal business hours or at such other reasonable times as may be requested, and to discuss the affairs, finances and accounts of the Company or any of its
subsidiaries with its officers, and to review such information as is reasonably requested all at such reasonable times and as often as may be reasonably requested; <I>provided</I>, <I>however</I>, that the Company shall not be obligated under this
<U>Section</U><U></U><U>&nbsp;3.1(b)</U> with respect to a competitor of the Company (as determined by the Board in good faith) or with respect to information which the Board determines in good faith is highly confidential or attorney-client
privileged and should not, therefore, be disclosed; <I>provided</I>, however that no Major Investor shall be deemed a competitor solely as a result of holding less than twenty percent (20%) of the outstanding equity of an entity or as a result of
maintaining a right to designate any members of the board of directors of a competitor. Each Major Investor may exercise its rights under this <U>Section</U><U></U><U>&nbsp;3.1(b)</U> only for purposes reasonably related to its interests as a
stockholder of the Company. The rights granted pursuant to this <U>Section</U><U></U><U>&nbsp;3.1(b)</U> may not be assigned or otherwise conveyed to any Holder or by any subsequent transferee of any such rights without the prior written consent of
the Company; <I>provided</I>, <I>however</I>, that a Major Investor shall be permitted to transfer rights granted pursuant to this <U>Section</U><U></U><U>&nbsp;3.1(b)</U> to Affiliates of such Major Investor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B><U>Confidentiality</U></B>. Each Holder agrees that such Holder will keep
confidential and will not use for any purpose (other than to monitor its investment) or disclose or divulge any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company&#146;s
intention to file a registration statement and the contents of any financial statements received), unless such confidential information (a)&nbsp;is known or becomes known to the public in general (other than as a result of a breach of this
<U>Section</U><U></U><U>&nbsp;3.2</U> by such Holder or as a result of a breach by a third party of any obligation of confidentiality such third party may have to the Company of which such Holder is aware), (b) is or has been independently developed
or conceived by Holder without use of or reference to the Company&#146;s confidential information, or (c)&nbsp;is or has been made known or disclosed to the Holder by a third party without a breach of any obligation of confidentiality such third
party may have to the Company; provided, however, that a Holder may disclose confidential information (i)&nbsp;to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with
monitoring its investment in the Company, provided such persons agree to hold such information confidentially as provided herein; (ii)&nbsp;to any prospective purchaser of any Registrable Securities from such Holder, if such prospective purchaser
agrees to be bound by the provisions of this <U>Section</U><U></U><U>&nbsp;3.2</U>; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Holder in the ordinary course of business, but only
on the condition that such Affiliate, partner, member, stockholder or wholly owned subsidiary of such Holder shall only use such confidential information in connection with monitoring such Holder&#146;s investment in the Company and not for any
other purpose, and provided that such Holder informs such person or entity that such information is confidential and directs such person or entity to maintain confidential treatment of such information; or (iv)&nbsp;as may otherwise be required by
law, provided that the Holder promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B><U>Right to Conduct Activities</U></B>. The Company hereby agrees and acknowledges that each of the Investors and their
respective Affiliates (each, a &#147;<B><U>Fund</U></B>&#148;) are investment funds or engage in corporate venture and other investment activities, and as such review the business plans and related proprietary information of many enterprises and
invest in numerous portfolio companies, may compete directly or indirectly with the Company&#146;s business (as currently conducted or as currently propose to be conducted). The Company hereby agrees that, to the extent permitted by applicable law,
no Fund nor its partners, employees, Affiliates, advisors or affiliated investment funds shall be liable to the Company for any claim arising out of, or based upon, (i)&nbsp;the investment by such Fund (or its Affiliates) in any entity, or
activities of such Affiliates, that may be competitive to the Company or (ii)&nbsp;actions taken by any partner, officer, advisor, employee or other representative of such Fund (or its Affiliates) in his, her or its capacity as such to assist any
such competitive company whether or not such action was taken as a member of the board of directors of such competitive company or otherwise; provided, however, that nothing herein shall relieve any Fund from liability associated with use or
disclosure of the Company&#146;s confidential information in breach of <U>Section</U><U></U><U>&nbsp;3.2</U> above or associated with a breach of any other obligation of confidentiality owed to the Company, nor
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liability associated with violating, breaching or misappropriating any proprietary right of the Company, nor shall relieve any director or officer of the Company from any liability associated
with his or her breach of a fiduciary duty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B><U>FCPA</U></B>. The Company covenants that it shall not (and shall not permit
any of its subsidiaries or Affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of
value to, directly or indirectly, to any third party, including any <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Official (as (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the
&#147;<B><U>FCPA</U></B>&#148;)), in each case, in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further covenants that it shall (and shall cause each of its subsidiaries and
Affiliates to) cease all of its or their respective activities, as well as remediate any actions taken by the Company, its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors,
representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) maintain
systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon
request, the Company agrees to provide responsive information and/or certifications concerning its compliance with applicable anti-corruption laws. The Company shall promptly notify each Fund if the Company becomes aware of any enforcement action
pursuant to such laws. The Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5</B> <B><U>Termination of Covenants</U></B>. The covenants set forth in <U>Section</U><U></U><U>&nbsp;3.1</U> and
<U>Section</U><U></U><U>&nbsp;3.4</U> shall terminate and be of no further force and effect after the earlier of: (a)&nbsp;the Initial Public Offering; and (b)&nbsp;the occurrence of a Liquidation Event, except that such covenants shall not
terminate upon the consummation of a sale of all or substantially all of the assets of the Company; provided, however, that this Agreement may be terminated after such sale of all or substantially all of the assets of the Company upon the consent of
the Preferred Majority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U>Right of First Refusal</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B><U>Grant of Rights</U></B>. Subject to the provisions of <U>Section</U><U></U><U>&nbsp;4.2</U> through
<U>Section</U><U></U><U>&nbsp;4.5</U> below, the Company hereby grants to each Investor that continues to hold at least 35% of the shares of Series B Preferred Stock or Series C Preferred Stock such Investor originally purchased (including through
the conversion of convertible promissory notes) who is an &#147;accredited investor&#148; within the meaning of applicable securities laws and regulations (a &#147;<B><U>ROFR Holder</U></B>&#148;), the right of first refusal to purchase its Pro Rata
Amount (as defined below) of New Securities which the Company may, from time to time, propose to sell and issue after the date of this Agreement. A ROFR Holder&#146;s &#147;<B><U>Pro Rata Amount</U></B>&#148;, for purposes of this right of first
refusal, is equal to the ratio of (a)&nbsp;the number of shares of Common Stock together with the number of shares of Preferred Stock (and warrants or other securities exercisable for Preferred Stock) calculated on an as exercised and as converted
to Common Stock basis held by such ROFR </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holder, to (b)&nbsp;the total of all outstanding shares of Common Stock and Preferred Stock and all other shares of other convertible securities, rights, options or warrants then outstanding, on
an as exercised and as converted to Common Stock basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B><U>New Securities</U></B>. As used herein, &#147;<B><U>New
Securities</U></B>&#148; shall mean any capital stock (including Common Stock and/or Preferred Stock) of the Company whether now authorized or not, and rights, convertible securities, options or warrants to purchase such capital stock, and
securities of any type whatsoever that are, or may become, exercisable or convertible into capital stock, including debt instruments convertible into capital stock; <I>provided</I> that the term &#147;New Securities&#148; does not include
(i)&nbsp;Exempted Securities, as defined in the Restated Certificate, (ii)&nbsp;any shares of Series C Preferred Stock issued pursuant to the Series C Purchase Agreement, or (iii)&nbsp;any shares of stock of the Company issued in the Initial Public
Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B><U>Notice</U></B>. In the event the Company proposes to undertake an issuance of New Securities, it shall give
each ROFR Holder written notice of its intention, describing the type of New Securities, and their price and the general terms upon which the Company proposes to issue the same. Each ROFR Holder shall have fifteen (15)&nbsp;days after any such
notice is mailed or delivered to agree to purchase such ROFR Holder&#146;s Pro Rata Amount (or such lesser amount as desired) of such New Securities for the price and upon the terms specified in the notice by giving written notice to the Company and
stating therein the quantity of New Securities to be purchased, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> <B><U>Election Period and Excess Securities</U></B>.
In the event the foregoing right of first refusal is not exercised in full by all of the ROFR Holders within the fifteen (15)&nbsp;day period described in <U>Section</U><U></U><U>&nbsp;4.3</U> above (the &#147;<B><U>Election Period</U></B>&#148;),
the Company shall promptly notify in writing the ROFR Holders who have elected to exercise their right of first refusal with respect to their full Pro Rata Amounts and shall offer such ROFR Holders the right to acquire such unsubscribed New
Securities. Each ROFR Holder shall have five (5)&nbsp;days after receipt of such notice to notify the Company of its election to purchase all or a portion thereof of its pro rata portion of the unsubscribed New Securities, indicate whether it
intends to purchase unsubscribed New Securities in excess of its pro rata share (&#147;<B><U>Excess Securities</U></B>&#148;) and, if so, the number of such unsubscribed New Securities it wishes to purchase. The Excess Securities, if any, shall be
allocated to participating ROFR Holders in a manner most consistent with the pro rata shares of such participating ROFR Holders as determined in good faith by the Board. If the ROFR Holders fail to exercise in full their rights of first refusal, the
Company shall have forty-five (45)&nbsp;days thereafter to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be closed, if at all, within twenty (20)&nbsp;days from the date of said agreement) to
sell that portion of the New Securities with respect to which the ROFR Holders&#146; right of first refusal option set forth in this <U>Section</U><U></U><U>&nbsp;4</U> was not exercised, at a price and upon terms no more favorable to the purchasers
thereof than specified in the Company&#146;s notice to ROFR Holders delivered pursuant to <U>Section</U><U></U><U>&nbsp;4.3</U>. In the event the Company enters into an agreement to sell such New Securities within such forty-five (45)&nbsp;day
period following the Election Period, or sells such New Securities within such twenty (20)&nbsp;day period following the date of said agreement, the Company shall not thereafter issue or sell any New Securities, without first again offering such
securities to the ROFR Holders in the manner provided in this <U>Section</U><U></U><U>&nbsp;4</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5</B> <B><U>Waiver, Termination, Transfer</U></B>. The rights of first refusal granted
under this <U>Section</U><U></U><U>&nbsp;4</U>, including notice with respect thereto, may be waived pursuant to <U>Section</U><U></U><U>&nbsp;7.6</U> of this Agreement. Notwithstanding the foregoing, if any of the waiving ROFR Holders purchase New
Securities covered by the waiver (any such purchase of New Securities, a &#147;<B><U>Waiver Purchase</U></B>&#148;), then each ROFR Holder shall have the right to purchase up to the same percentage of its Pro Rata Amount of the New Securities
purchased by the waiving ROFR Holder who purchased the highest percentage of its respective Pro Rata Amount of the New Securities (such right, a &#147;<B><U>ROFR Revival Right</U></B>&#148;). The rights of first refusal granted under this
<U>Section</U><U></U><U>&nbsp;4</U> shall terminate immediately prior to the earliest: of (i)&nbsp;an Initial Public Offering, (ii)&nbsp;the closing of a Liquidation Event, except that such covenants shall not terminate upon the consummation of a
sale of all or substantially all of the assets of the Company unless agreed to in writing by the Preferred Majority, (iii)&nbsp;as to any Investor at such time it, together with its Affiliates, is no longer a ROFR Holder. The rights of first refusal
of a ROFR Holder under this <U>Section</U><U></U><U>&nbsp;4</U> may be transferred subject to the same restrictions as any transfer of registration rights pursuant to <U>Section</U><U></U><U>&nbsp;2.12</U>. Notwithstanding anything else set forth
above, a ROFR Holder shall be permitted to transfer rights granted pursuant to this <U>Section</U><U></U><U>&nbsp;4</U> in any amount to its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Other Company Covenants</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B><U>Employee Agreements</U></B>. The Company shall require (i)&nbsp;all employees and consultants to execute and deliver a
nondisclosure and proprietary rights assignment agreement (in the case of employees, in substantially the form approved by the Board) and (ii)&nbsp;each executive-level employee (including, division director and vice president-level positions) as
well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Proprietary Rights (as defined in the Series C Purchase Agreement) to enter into a one (1)&nbsp;year noncompetition and nonsolicitation
agreement, substantially in the form approved by the Board (to the extent permitted under applicable law). In addition, the Company shall not materially amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the
above-referenced agreements or any restricted stock agreement between the Company and any employee, if such amendment would cause it to be inconsistent with this <U>Section</U><U></U><U>&nbsp;5.1</U> without the consent of the Board, including the
consent of a majority of the Preferred Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B><U>Equity Agreements</U></B>. Unless otherwise approved by the Board,
including the consent of a majority of the Preferred Directors, all employees of the Company who purchase, or receive options to purchase, shares of Common Stock following the date hereof shall be required to execute stock purchase or option
agreements providing for: (a)&nbsp;vesting of shares over a four (4)&nbsp;year period with the first twenty five percent (25%) of such shares vesting following twelve (12)&nbsp;months of continued employment or services, and the remaining shares
vesting in equal monthly installments over the following thirty six (36)&nbsp;months thereafter; and (b)&nbsp;a vesting commencement date no earlier than such employee&#146;s first date of employment with the Company. Without the prior approval by
the Board, including a majority of the Preferred Directors, the Company shall not amend, modify, terminate, waive or otherwise alter, in whole or in part, any stock purchase, stock restriction or option agreement with any existing employee or
service provider if such amendment would cause it to be inconsistent with this <U>Section</U><U></U><U>&nbsp;5.2</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B> <B><U>Successor Indemnification</U></B>. If the Company or any of its successors
or assignees consolidates with or merges into any other person or entity and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the
successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company&#146;s
bylaws, the Company&#146;s certificate of incorporation, or elsewhere, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4</B> <B><U>Expenses of Counsel</U></B>.
In the event of a transaction which is a Sale of the Company (as defined in the Voting Agreement), the reasonable fees and disbursements, not to exceed $50,000, of one counsel for the Major Investors as selected by holders of a majority of
Registerable Securities then held by the Major Investors (&#147;<B>Investor Counsel</B>&#148;), in their capacities as stockholders, shall be borne and paid by the Company. At the outset of considering a transaction which, if consummated would
constitute a Sale of the Company, the Company shall obtain the ability to share with the Investor Counsel (and such counsel&#146;s clients) and shall share the confidential information (including, without limitation, the drafts of memoranda of
understanding (but not necessarily all drafts thereof), letters of intent (but not necessarily all drafts thereof), and definitive transaction documents and related noncompete, employment, consulting and other compensation agreements and plans)
pertaining to and memorializing any of the transactions which, individually or when aggregated with others would constitute the Sale of the Company. The Company shall be obligated to share (and cause the Company&#146;s counsel and investment bankers
to share) copies of definitive agreements with respect to such transaction when distributed to the Company&#146;s executives and/or any one or more of the other parties to such transaction(s). In the event that Investor Counsel deems it appropriate,
in its reasonable discretion, to enter into a joint defense agreement or other arrangement to enhance the ability of the parties to protect their communications and other reviewed materials under the attorney client privilege, the Company shall, and
shall direct its counsel to, execute and deliver to Investor Counsel and its clients such an agreement in form and substance reasonably acceptable to Investor Counsel. In the event that one or more of the other party or parties to such transactions
require the clients of Investor Counsel to enter into a confidentiality agreement and/or joint defense agreement in order to receive such information, then the Company shall share whatever information can be shared without entry into such agreement
and shall, at the same time, in good faith work expeditiously to enable Investor Counsel and its clients to negotiate and enter into the appropriate agreement(s) without undue burden to the clients of Investor Counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5</B> <B><U>Observer Right</U></B>. The Company shall allow one representative of Nextech VI Oncology SCSP
(&#147;<B><U>Nextech</U></B>&#148;) for so long as Nextech and its Affiliates own not less than 25% of the shares of the Series B Preferred Stock purchased by Nextech under that certain Series B Preferred Stock Purchase Agreement dated as of
March&nbsp;4, 2020 by the Company and the investors named therein, as subsequently amended, to attend all meetings of the Board in a <FONT STYLE="white-space:nowrap">non-voting</FONT> observer capacity (the &#147;<B><U>Observer</U></B>&#148;) and
shall provide the Observer copies of all notices, minutes, consents, and other materials that it provides to the Board at the same time and in the same manner as provided to the Board. The Observer shall enter into a standard form of confidentiality
agreement with the Company pursuant to which such Observer shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided. The Company reserves the right to withhold any information and to
exclude the Observer from any meeting or portion thereof if the Board reasonably believes that access to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel, such information is a highly confidential trade secret or
would be a conflict of interest between such Observer and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6</B> <B><U>Qualified Small Business Stock</U></B>. The
Company shall use commercially reasonable efforts to cause the shares of Series B Preferred Stock issued in the First Tranche Closing and the Second Tranche Closing, as each is capitalized term is defined in that certain Series B Preferred Stock
Purchase Agreement entered into between the Company and the investors named therein as of March&nbsp;4, 2020, as subsequently amended, as well as any shares into which such shares are converted, within the meaning of Section&nbsp;1202(f) of the
Internal Revenue Code (the &#147;<B><U>Code</U></B>&#148;), to constitute &#147;qualified small business stock&#148; as defined in Section&nbsp;1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board of
Directors of the Company determines, in its good-faith business judgment, that such qualification is inconsistent with the best interests of the Company. The Company shall submit to its stockholders (including the Investors) and to the Internal
Revenue Service any reports that may be required under Section&nbsp;1202(d)(1)(C) of the Code and the regulations promulgated thereunder. In addition, within twenty (20)&nbsp;business days after any Investor&#146;s reasonable written request
therefor, the Company shall, at its option, either (i)&nbsp;deliver to such Investor a written statement indicating whether (and what portion of) such Investor&#146;s interest in the Company constitutes &#147;qualified small business stock&#148; as
defined in Section&nbsp;1202(c) of the Code or (ii)&nbsp;deliver to such Investor such factual information in the Company&#146;s possession as is reasonably necessary to enable such Investor to determine whether (and what portion of) such
Investor&#146;s interest in the Company constitutes &#147;qualified small business stock&#148; as defined in Section&nbsp;1202(c) of the Code. Nothing in this <U>Section</U><U></U><U>&nbsp;5.6</U> or in any written statement that is delivered
pursuant to this Section&nbsp;5.6 constitutes a representation, warranty or covenant that the Company has been, is or will be engaged in a &#147;qualified trade or business&#148; within the meaning of Code Section&nbsp;1202(e)(3) or has met, meets
or will meet the active business requirement of Code Section&nbsp;1202(e)(1)(A), and although the representation and warranty in this <U>Section</U><U></U><U>&nbsp;5.6</U> are undertaken in good faith, the Company shall not be liable for damages as
the result of any failure of any of its stock to qualify as &#147;qualified small business stock.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7</B> <B><U>Termination of
Covenants</U></B>. The covenants set forth in <U>Sections 5.1</U>, <U>5.2</U>, <U>5.3</U>, <U>5.4</U>, <U>5.5</U> and <U>5.6</U> above shall terminate and be of no further force or effect upon the consummation of the earlier to occur of (a)&nbsp;an
Initial Public Offering, and (b)&nbsp;a Liquidation Event, except that such covenants shall not terminate upon the consummation of a Liquidation Event that is the sale of all or substantially all of the assets of the Company unless approved in
writing by the Preferred Majority; provided further that the provisions of <U>Sections 5.3 and 5.4</U> hereof will continue after the closing of any Sale of the Company to the extent necessary to enforce the provisions thereof with respect to such
Sale of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B><U>CFIUS</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B> <B><U>Notice</U></B>. If any <FONT STYLE="white-space:nowrap">pre-existing</FONT> products or services provided by the Company are <FONT
STYLE="white-space:nowrap">re-categorized</FONT> by the U.S. government as critical technologies within the meaning of the Defense Production Act of 1950, as amended, including all implementing regulations thereof (the
&#147;<B><U>DPA</U></B>&#148;), or would reasonably be considered to constitute the design, fabrication, development, testing, production or manufacture of critical technologies after a <FONT STYLE="white-space:nowrap">re-categorization</FONT> of
selected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technologies by the U.S. government, the Company shall provide written notice to each CFIUS Investor reasonably soon after the Company becomes aware of such
<FONT STYLE="white-space:nowrap">re-categorization,</FONT> and in any event prior to the delivery of a notice pursuant to <U>Section</U><U></U><U>&nbsp;4.3</U> above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B> <B><U>Filing</U></B>. If and to the extent: (i)&nbsp;CFIUS requests or requires that any CFIUS Investor or the Company file a
notice or declaration with CFIUS pursuant to the DPA with respect to such CFIUS Investor&#146;s exercise of its right of first refusal set forth in this <U>Section</U><U></U><U>&nbsp;4</U> (a &#147;<B><U>Covered Transaction</U></B>&#148;) or
(ii)&nbsp;a CFIUS Investor and the Company mutually determine that a filing with CFIUS is required with respect to a Covered Transaction pursuant to 31 C.F.R. Part 801, then in either case: (x)&nbsp;the Company and such CFIUS Investor shall each,
and shall cause its Affiliates to, cooperate with the other parties hereto and shall promptly file a CFIUS filing in the requested form in accordance with the DPA; and (y)&nbsp;the Company and such CFIUS Investor shall each, and each shall cause its
Affiliates to, use commercially reasonable efforts to obtain applicable CFIUS clearances to enable such CFIUS to exercise its rights under <U>Section</U><U></U><U>&nbsp;4</U>. Notwithstanding anything to the contrary in this Agreement, under no
circumstances shall the Company have an obligation to issue or sell any of its securities to any Investor in violation of <U>Section</U><U></U><U>&nbsp;7</U>21 of the Defense Production Act of 1950, as amended, and all implementing rules and
regulations issued thereunder, including 31 C.F.R. Parts <FONT STYLE="white-space:nowrap">800-801</FONT> (&#147;<B><U>CFIUS Laws</U></B>&#148;) or other applicable laws, and no Investor shall have the right to retain any rights set forth herein that
are or become in violation of CFIUS Laws or other applicable laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B> <B><U>Termination</U></B>. The covenants set forth in this
<U>Section</U><U></U><U>&nbsp;6</U> shall terminate and be of no further force or effect upon the consummation of the earlier to occur of (a)&nbsp;an Initial Public Offering, and (b)&nbsp;a Liquidation Event, except that this Agreement shall not
terminate upon the consummation of all or substantially all of the assets of the Company unless approved in writing by the Preferred Majority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.</B>
<B><U>Miscellaneous</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B><U>Successors and Assigns</U></B>. The terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any
rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B> <B><U>Governing Law</U></B>. This Agreement will be construed and enforced in accordance with the substantive laws of the State of
Delaware without reference to principles of conflicts of law. EACH PARTY HERETO HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF ANY STATE OR FEDERAL COURT SITTING IN DELAWARE, IN ANY PROCEEDING ARISING OUT OF OR RELATING TO THIS
AGREEMENT AND TO THE RESPECTIVE COURT TO WHICH AN APPEAL OF THE DECISIONS OF ANY SUCH COURT MAY BE TAKEN, AND EACH PARTY AGREES NOT TO COMMENCE, OR COOPERATE IN OR ENCOURAGE THE COMMENCEMENT OF, ANY SUCH PROCEEDING, EXCEPT IN PROCEEDING WILL BE
CONCLUSIVE AND MAY BE ENFORCED IN ANY JURISDICTION BY SUIT IN SUCH A COURT. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT IT MAY DO SO, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE THEREIN OF SUCH A PROCEEDING. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B> <B><U>Counterparts</U></B>. This Agreement may be executed in any number of
counterparts and signatures may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method, each of which may be executed by
less than all parties, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4</B> <B><U>Titles and Subtitles</U></B>. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5</B> <B><U>Notices</U></B>. All notices required or permitted hereunder
shall be in writing and shall be deemed effectively given upon the earliest of: (a)&nbsp;upon personal delivery to the party to be notified, (b)&nbsp;when sent by confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> or confirmed facsimile if
sent during normal business hours of the recipient, if not, then on the next business day, or (c)&nbsp;one (1) business day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written identification of
receipt; provided that if the sender&#146;s and the recipient&#146;s addresses are not in the same country, two (2)&nbsp;business days after deposit with an internationally recognized overnight courier, specifying next day delivery, with written
identification of receipt. All communications shall be sent, if to the Company, at the address set forth on the signature page hereto, and if to an Investor, at its address as set forth on <U>Exhibit A</U> hereto, or at such other address or contact
information as such party may designate by ten (10)&nbsp;calendar days&#146; advance written notice to the other parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6</B> <B><U>Amendments and Waivers</U></B>. Except as expressly provided herein, any term of this Agreement may be amended, terminated or
waived only with the written consent of (a)&nbsp;the Company and (b)&nbsp;the Preferred Majority, or, following the Initial Public Offering of the Company, the holders of a majority of the Registrable Securities; provided that: (i)&nbsp;no
amendment, termination or waiver of any term under this Agreement shall adversely affect any Investor or group of Investors in a manner that is disproportionate to its holdings of stock relative to the other Investors of the same class or series
unless such amendment, termination or waiver is agreed to in writing by a majority in interest of the disproportionately affected Investor(s); (ii) neither this clause (ii)&nbsp;or <U>Section</U><U></U><U>&nbsp;5.5</U> may be amended, terminated or
waived without the written consent of Nextech for as long as Nextech has a right to have an Observer attend meetings of the Board pursuant to <U>Section</U><U></U><U>&nbsp;5.5</U>; (iii) if the second sentence of
<U>Section</U><U></U><U>&nbsp;4.5</U> is amended, terminated or waived pursuant to the provisions of this <U>Section</U><U></U><U>&nbsp;7.6</U>, and a ROFR Holder purchases New Securities in an offering that is made in connection such amendment,
termination or waiver which would constitute a Waiver Purchase (treating an amendment, waiver or termination of such sentence as if it were a Waiver Purchase for purposes of this sentence), then each ROFR Holder shall have a ROFR Revival Right; and
(iv)&nbsp;no amendment to Section&nbsp;1(q) shall cause an Investor that is a Major Investor to lose its status as a Major Investor without such Major Investor&#146;s written consent unless such amendment is in connection with the issuance of New
Securities, such Major Investor was offered a right to purchase its Pro Rata Amount of such New Securities (or was offered a right to purchase a lesser amount of such New Securities based on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Major Investor&#146;s relative holdings of Company equity as compared to the equity holdings of all other Major Investors) and fails to purchase the full amount of such New Securities
offered to it. For the avoidance of doubt, the addition to this Agreement of any new holder of shares of capital stock of the Company (&#147;<B><U>Capital Stock</U></B>&#148;) pursuant to the Company&#146;s issuance of such other Capital Stock
regardless of whether such Capital Stock has rights, preferences or privileges that are junior, pari passu or senior to the Capital Stock then held by then current Investors as long as such other or additional shares of Capital Stock have been
authorized and issued in accordance with the Company&#146;s then current Restated Certificate and applicable law, and as long as the addition of such new holder of Capital Stock of the Company (or inclusion of such new shares of Capital Stock) has
been approved as may be required pursuant to <U>Section</U><U></U><U>&nbsp;2.13</U> above shall not, in and of itself, be deemed to constitute an amendment or waiver that adversely affects one Investor in a manner that is disproportionate to any
other Investor. Any amendment or waiver effected in accordance with this <U>Section</U><U></U><U>&nbsp;7.6</U> shall be binding upon the Holders and each transferee of the Shares (or the Common Stock issuable upon conversion thereof), each future
holder of all such securities, and the Company. Each Holder acknowledges that by the operation of this Section (and pursuant to the terms of this Section), the Preferred Majority will have the right and power to diminish or eliminate all rights of
such Holder under this Agreement. The Company shall give prompt notice of any amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination, or
waiver. Notwithstanding anything to the contrary contained in this Agreement, if the Company issues additional shares of Series C Preferred Stock after the date hereof pursuant to the Series C Purchase Agreement, any purchaser of such shares of
Series C Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and thereafter shall be deemed an &#147;Investor&#148; for all purposes hereunder without the
consent of any party hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.7</B> <B><U>Severability</U></B>. Whenever possible, each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such
prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.8</B>
<B><U>Delays or Omissions</U></B>. No delay or omission to exercise any right, power or remedy accruing to any party upon any breach or default of any other party under this Agreement shall impair any such right, power or remedy of such party, nor
shall it be construed to be a waiver of any such breach or default or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other
breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions
or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing or as provided in this Agreement. All remedies, either under this Agreement or by law or otherwise afforded to any
party, shall be cumulative and not alternative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.9</B> <B><U>Entire Agreement</U></B>. This Agreement (including the exhibits hereto)
constitutes the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties are expressly
canceled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.10</B> <B><U>Further Assurances</U></B>. At any time or from time to time after the
date hereof, the parties hereto agree to cooperate with each other, and at the request of any such party hereto, to execute and deliver any further instruments or documents and to take all such further action as the other party may reasonably
request in order to evidence or effectuate the consummation of the transactions contemplated hereby and to otherwise carry out the intent of the parties hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.11</B> <B><U>Aggregation of Stock</U></B>. All shares of Company equity held or acquired by a Holder and/or its Affiliates shall be
aggregated together for the purpose of determining the availability of any rights and any obligations under this Agreement, and such affiliated persons may apportion such rights and obligations as among themselves in any manner they deem
appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.12</B> <B><U>WAIVER OF JURY TRIAL</U></B>. EACH PARTY HERETO AND ANY OTHER PERSON CLAIMING ANY RIGHTS HEREUNDER, HEREBY
IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION,
ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.13</B> <B><U>Amendment and Restatement of Prior Agreement</U></B>. The Prior
Agreement is hereby amended in its entirety and restated herein. Such amendment and restatement is effective upon the execution of this Agreement by the Company and the requisite Investors as set forth in the Prior Agreement. Upon such execution,
all provisions of, rights granted and covenants made in the Prior Agreement are hereby waived, released and superseded in their entirety and shall have no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[THIS SPACE LEFT BLANK INTENTIONALLY] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>COMPANY:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SILVERBACK THERAPEUTICS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Laura Shawver</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Laura Shawver</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">500 Fairview Ave N #600</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Seattle, WA 98109</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attention:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTORS:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ORBIMED PRIVATE INVESTMENTS VI, LP</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Capital GP VI LLC,</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">its General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Advisors LLC,</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">its Managing Member</P></TD></TR></TABLE></DIV>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Carl Gordon</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Carl Gordon</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Member</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTORS</B>:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>U.S. VENTURE PARTNERS XII, L.P.</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>U.S. VENTURE PARTNERS <FONT STYLE="white-space:nowrap">XII-A,</FONT>
L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Presidio Management Group XII, L.L.C.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The General Partner of Each</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Dale Holladay</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dale Holladay, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Attorney-In-Fact</FONT></FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTORS:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PRECISION ONCO LIMITED</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Yuan Sun</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Yuan Sun</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>PONTIFAX (ISRAEL)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>PONTIFAX (CHINA) V</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>LIMITED PARTNERSHIP</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>LIMITED PARTNERSHIP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Tamar Kariv</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Tamar Kar</I>iv</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Tamar Kariv</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Tamar Kariv</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>PONTIFAX (CAYMAN) V</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PONTIFAX LATE STAGE FUND</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>LIMITED PARTNERSHIP</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIMITED PARTNERSHIP</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Tamar Kariv</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Tamar Kariv</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Tamar Kariv</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Tamar Kariv</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Managing Partner</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTORS:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>HUNT PACIFIC, L.P.</B>, a Texas Limited Partnership</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">D.S. Hunt Corp., Its General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>/s/ David S. Hunt</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David S. Hunt, President</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTORS:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nextech VI GP S.&agrave;.r.l. as General Partner on behalf of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NEXTECH VI ONCOLOGY SCSP</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Dalia Bleyer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Philippe Detournay</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Dalia Bleyer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Philippe Detournay</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manager</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTORS:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF TRUSTEES OF THE LELAND</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>STANFORD JUNIOR UNIVERSITY (DAPER I)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Sabrina Liang</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sabrina Liang, Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF TRUSTEES OF THE LELAND</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>STANFORD JUNIOR UNIVERSITY (SBST)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Sabrina Liang</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sabrina Liang, Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="9"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTORS:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>EcoR1 Capital Fund, L.P.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>EcoR1 Capital Fund Qualified, L.P.</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">EcoR1 Capital, LLC, its General Partner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">EcoR1 Capital, LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Oleg Nodelman</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Oleg Nodelman</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Oleg Nodelman,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Oleg Nodelman,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Manager</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Manager</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>EcoR1 Venture Opportunity Fund, L.P.</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotech Opportunity GP, LLC, its General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Oleg Nodelman</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Oleg Nodelman,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Manager</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTORS:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>BOXER CAPITAL, LLC</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Aaron Davis</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Aaron Davis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>MVA INVESTORS, LLC</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Aaron Davis</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Aaron Davis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTORS: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RA Capital Healthcare Fund, L.P.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>RA Capital NEXUS Fund, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">RA Capital Healthcare Fund GP, LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">RA Capital Nexus Fund GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its General Partner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kolchinsky</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kolchinsky</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Peter Kolchinsky</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Peter Kolchinsky</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manager</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLACKWELL PARTNERS LLC &#150; SERIES A</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Abayomi A. Adigun</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Abayomi A. Adigun</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Investment Manager, DUMAC, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Jannine M. Lall</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jannine M. Lall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Head of Finance&nbsp;&amp; Controller, DUMAC, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTORS: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NANTAHALA CAPITAL PARTNERS II</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>LIMITED PARTNERSHIP</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NANTAHALA CAPITAL PARTNERS</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>LIMITED PARTNERSHIP</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Nantahala Capital Management, LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Nantahala Capital Management, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Its General Partner</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Its General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Wilmot Harkey</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Wilmot Harkey</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Wilmot Harkey</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Wilmot Harkey</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Manager</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Manager</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTORS: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLACKWELL PARTNERS LLC - SERIES A</B>, solely with respect to the portion of its assets for which Nantahala Capital Management, LLC acts as its Investment Manager</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"><B>SILVER CREEK CS SAV, L.L.C.</B>, solely with respect to the portion of its assets for which Nantahala Capital Management, LLC acts as its Investment Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Nantahala Capital Management, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Nantahala Capital Management, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Its Investment Manager</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">Its Investment Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Wilmot Harkey</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Wilmot Harkey</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Wilmot Harkey</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Wilmot Harkey</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manager</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5"><B>INVESTORS:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="5" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5"><B>NANTAHALA CAPITAL PARTERNS SI, LP</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"><B>NCP QR LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Nantahala Capital Management, LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Nantahala Capital Management, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Its Investment Manager</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">Its Investment Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Wilmot Harkey</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Wilmot Harkey</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Wilmot Harkey</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Wilmot Harkey</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manager</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>INVESTORS:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fidelity Select Portfolios: Biotechnology</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Portfolio</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fidelity Mt. Vernon Street Trust:</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Fidelity Series Growth Company Fund</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Chris Maher</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Chris Maher</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chris Maher</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chris Maher</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Authorized Signatory</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Authorized Signatory</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fidelity Growth Company Commingled Pool</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>By:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fidelity Management Trust Company,</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>as Trustee</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Chris Maher</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chris Maher</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Authorized Signatory</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTORS: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Fidelity Mt. Vernon Street Trust : Fidelity Growth Company K6 Fund</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Chris Maher</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chris Maher</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Authorized Signatory</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Fidelity Mt. Vernon Street Trust:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Fidelity Advisor Series VII: Fidelity</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Fidelity Growth Company Fund</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Advisor Biotechnology Fund</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Chris Maher</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Chris Maher</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chris Maher</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chris Maher</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Authorized Signatory</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Authorized Signatory</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to
Silverback Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated Investor&#146;s Rights Agreement (Series C) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE OF INVESTORS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>OrbiMed Private Investments VI, LP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue, 54th Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022-4629</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Celgene Corporation</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Bristol Myers Squibb Company</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">430 E. 29th St., 14th Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10016</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Corporate Secretary Office</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Alexandria Venture Investments, LLC</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">385 E. Colorado Blvd,
Suite 299</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pasadena, CA 91101</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Monica Beam</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Venture Partners XII, L.P.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1460 El Camino Real, Suite 100</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo Park, CA 94025</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Chief Financial Officer</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With copy (which shall not constitute notice) to:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilmer Cutler
Pickering Hale and Dorr</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">60 State Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02109</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Rosemary G. Reilly</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Venture Partners <FONT STYLE="white-space:nowrap">XII-A,</FONT> L.P.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1460 El Camino Real, Suite 100</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo Park, CA 94025</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Chief Financial Officer</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With copy (which shall not constitute notice) to:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilmer Cutler
Pickering Hale and Dorr</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">60 State Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02109</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Rosemary G. Reilly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Precision Onco Limited</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rm2865, 28F, AIA
Central, 1 Connaught Road</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Central, Central, Hong Kong</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Haige Lu, Michael Chuang</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pontifax (Israel) V Limited Partnership</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pontifax
(China) Limited Partnership</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pontifax (Cayman) Limited Partnership</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pontifax Late Stage Fund Limited</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Partnership</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address for all Pontifax entities:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14 Shenkar St. Herzelia,
Israel</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Ran Nussbaum</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Horn&nbsp;&amp; Co., Law Offices</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amot Investments Tower, 2
Weizmann St., 24<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tel-Aviv</FONT> 6423902, Israel</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Yuval Horn, Adv.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Meritz NS Global Bio Fund</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korean Partnership</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">203, 50, <FONT STYLE="white-space:nowrap">Seosomun-ro</FONT> <FONT STYLE="white-space:nowrap">11-gil,</FONT> Jung-gu, Seoul,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">04515 Rep. of Korea</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Kiel Kim, Ian Heo</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hunt Pacific, L.P.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2101 Cedar Springs Road, Suite 600</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dallas, Texas 75201</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: David S. Hunt</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Colt Silverback Partners, LLC</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2101 Cedar Springs Road,
Suite #1230</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dallas, TX 75201</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Darren
Blanton</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE OF INVESTORS (Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nextech VI Oncology SCSp</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8 rue Lou
Hemmer, <FONT STYLE="white-space:nowrap">L-1748</FONT> Senningerberg</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grand Duchy of Luxembourg</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact: Svitlana Dobrovolska</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Board of Trustees of the Leland Stanford</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Junior
University (DAPER I)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stanford Management Company</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">635
Knight Way</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stanford, CA 94305-7297</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Direct
Investments</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Board of Trustees of the Leland Stanford</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Junior University (SBST)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stanford Management Company</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">635 Knight Way</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stanford, CA 94305-7297</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Direct Investments</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EcoR1 Capital Fund, L.P.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">357 Tehama St #3</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94103</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Oleg Nodelman, Scott
Perlen</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EcoR1 Capital Fund Qualified, L.P.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">357 Tehama St # 3</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94103</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Oleg Nodelman, Scott Perlen</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EcoR1 Venture Opportunity Fund, L.P.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">357 Tehama St # 3</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94103</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Oleg Nodelman, Scott
Perlen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Boxer Capital, LLC</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11682 El Camino
Real</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 320, San Diego, CA 92130</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Aaron
Davis</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MVA Investors, LLC</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11682 El Camino Real</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 320, San Diego, CA 92130</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Aaron Davis</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nantahala Capital Partners II Limited</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Partnership</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Legal Entity Name and Address:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nantahala Capital Partners II Limited</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Partnership</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">130 Main St. 2nd Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Canaan, CT 06840</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notifications:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact: Operations Team</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nantahala Capital Partners Limited</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Partnership</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Legal Entity Name and Address:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nantahala Capital Partners II Limited</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Partnership</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">130 Main St. 2nd Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Canaan, CT 06840</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notifications:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Contact: Operations
Team</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE OF INVESTORS (Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Blackwell Partners LLC - Series A</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Legal
Entity Name and Address:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Blackwell Partners LLC - Series A</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">280 South Mangum Street, Suite 210</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durham, NC 27701</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notifications:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact: Operations Team; Jannine Lall</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copy to legal address above and investment</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">manager below for
physical.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Silver Creek CS SAV, L.L.C.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Legal Entity Name and Address:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Silver Creek CS SAV, L.L.C.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 5th Avenue, 40th Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seattle, WA 98101</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notifications:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact: Operations Team(s)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copy to legal address above and investment</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">manager below for
physical.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nantahala Capital Management, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">130 Main St. 2nd
Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Canaan, CT 06840</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nantahala Capital Partners SI, LPNCP QR</B> <B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Legal Entity Name and Address:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nantahala Capital Partners SI, LP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">130 Main St. 2nd Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Canaan, CT 06840</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notifications:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact: Operations Team</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copy to legal address for physical.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RA Capital Healthcare Fund, L.P.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 Berkeley St 18th floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02116</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RA Capital NEXUS Fund, L.P.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 Berkeley
St 18th floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02116</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BLACKWELL PARTNERS LLC -</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SERIES A</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Blackwell Partners LLC - Series A</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">280 S. Mangum Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 210</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durham, NC 27701</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Jannine Lall</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fidelity Select Portfolios: Biotechnology</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Portfolio</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mag&nbsp;&amp; Co.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Brown Brothers Harriman&nbsp;&amp; Co.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Corporate
Actions /Vault</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140 Broadway</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10005</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fidelity Mt. Vernon Street Trust:</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fidelity Series Growth Company Fund</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mag&nbsp;&amp; Co.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">do Brown Brothers Harriman&nbsp;&amp; Co.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Corporate Actions
/Vault</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140 Broadway</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10005</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fidelity Growth Company Commingled Pool</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mag&nbsp;&amp; Co.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">do Brown Brothers Harriman&nbsp;&amp; Co.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Corporate Actions /Vault</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140 Broadway</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">New York, NY 10005</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE OF INVESTORS (Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fidelity Mt. Vernon Street Trust: Fidelity</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Growth Company K6 Fund</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNY MELLON</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ONE BNY MELLON CENTER</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500 GRANT STREET AIM <FONT
STYLE="white-space:nowrap">151-2700</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PITTSBURGH, PA 15258</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fidelity Mt. Vernon Street Trust:</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fidelity Growth
Company Fund</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNY MELLON</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ONE BNY MELLON CENTER</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500 GRANT STREET AIM <FONT STYLE="white-space:nowrap">151-2700</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PITTSBURGH, PA 15258</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fidelity Advisor Series VII: Fidelity</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Advisor
Biotechnology Fund</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">State Street Bank&nbsp;&amp; Trust</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PO
Box 5756</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02206</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Bangle&nbsp;&amp;
Co fbo Fidelity</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Advisor Series VII:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fidelity Advisor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Biotechnology Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;<B><U>ACT</U></B>&#148;), OR
THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS&nbsp;5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE
COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="67%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Company:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SILVERBACK THERAPEUTICS, INC., a Delaware corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Number of Shares of Common Stock:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">That number of Shares of Common Stock which Holder is entitled to purchase pursuant to Section&nbsp;1.7.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Warrant Price:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$0.62 per share, which is based on the most recent 409A valuation report of the Company&#146;s Common Stock reviewed and accepted by the Board of Directors of the Company dated May&nbsp;31, 2016.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Issue Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">November&nbsp;21, 2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Expiration Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">November&nbsp;21, 2026<B> See also Section</B><B></B><B>&nbsp;5.1(b)</B>.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Credit Facility:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">This Warrant to Purchase Common Stock (as the same may from time to time be amended, modified, supplemented or restated, the &#147;<B><U>Warrant</U></B>&#148;) is issued in connection with that certain Loan and Security Agreement of
even date herewith between Silicon Valley Bank and the Company (as the same may from time to time be amended, modified, supplemented or restated, the &#147;<B><U>Loan Agreement</U></B>&#148;).</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS WARRANT CERTIFIES THAT, for good and valuable consideration, SILICON VALLEY BANK (together with any
successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, &#147;<B><U>Holder</U></B>&#148;) is entitled to purchase the number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT>
shares (the &#147;<B><U>Shares</U></B>&#148;) of the above-stated common stock (the &#147;<B><U>Common Stock</U></B>&#148;) of the above-named company (the &#147;<B><U>Company</U></B>&#148;) at the above-stated Warrant Price, all as set forth above
and as adjusted pursuant to Section&nbsp;2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. Reference is made to Section&nbsp;5.4 of this Warrant whereby Silicon Valley Bank shall transfer this
Warrant to its parent company, SVB Financial Group. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECTION&nbsp;1 <U>EXERCISE</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Method of Exercise</U>. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the
Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;1.2, a check, wire transfer of <FONT STYLE="white-space:nowrap">same-day</FONT> funds (to an account designated by the Company), or other form of payment acceptable to the Company in
the Company&#146;s reasonable discretion for the aggregate Warrant Price for the Shares being purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Cashless Exercise</U>. On
any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in Section&nbsp;1.1 above, but otherwise in accordance with the requirements of Section&nbsp;1.1, Holder may elect to receive Shares equal to
the value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue to the Holder such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> Shares as are computed
using the following formula: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">X = <FONT STYLE="white-space:nowrap">Y(A-B)/A</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">X&nbsp;=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the number of Shares to be issued to the Holder;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Y&nbsp;=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A&nbsp;=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Fair Market Value (as determined pursuant to Section&nbsp;1.3 below) of one Share; and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">B&nbsp;=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Warrant Price.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Fair Market Value</U>. If the Company&#146;s Common Stock is then traded or quoted on a nationally
recognized securities exchange, inter-dealer quotation system or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market (a &#147;<B><U>Trading Market</U></B>&#148;), the fair market value of a Share
shall be the closing price or last sale price of a share of Common Stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company&#146;s
Common Stock is not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 <U>Delivery of Certificate and New Warrant</U>. Within a reasonable time after Holder exercises this Warrant in the manner set forth in
Section&nbsp;1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor
representing the Shares not so acquired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 <U>Replacement of Warrant</U>. On receipt of evidence reasonably satisfactory to the Company
of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation,
on surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6 <U>Treatment of Warrant Upon Acquisition of Company</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Acquisition</U>. For the purpose of this Warrant, &#147;<B><U>Acquisition</U></B>&#148; means any transaction or series of related
transactions involving: (i)&nbsp;the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii)&nbsp;any merger or consolidation of the Company into or with another person or entity (other than
a merger or consolidation effected exclusively to change the Company&#146;s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or
reorganization, own less than a majority of the Company&#146;s (or the surviving or successor entity&#146;s) outstanding voting power immediately after such merger, consolidation or reorganization; or (iii)&nbsp;any sale or other transfer by the
stockholders of the Company of shares representing at least a majority of the Company&#146;s then-total outstanding combined voting power; provided that a transaction or series of related transactions shall not constitute an Acquisition if:
(x)&nbsp;its sole purpose is to change the state of the Company&#146;s incorporation; (y)&nbsp;it is solely a transfer of securities to an underwriter of the Company&#146;s securities in connection with an IPO; or (z)&nbsp;it is solely for bona fide
financing purposes in which cash is received by the Company, or indebtedness of the Company is cancelled or converted, or a combination thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Treatment of Warrant at Acquisition</U>. In the event of an Acquisition in which the consideration to be received by the Company&#146;s
stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a &#147;<B><U>Cash/Public Acquisition</U></B>&#148;), and the fair market value of one Share as determined in accordance with
Section&nbsp;1.3 above would be greater than the Warrant Price in effect on such date immediately prior to such Cash/Public Acquisition, and Holder has not exercised this Warrant pursuant to Section&nbsp;1.1 above as to all Shares, then this Warrant
shall automatically be deemed to be cashless exercised pursuant to Section&nbsp;1.2 above as to all Shares effective immediately prior to and contingent upon the consummation of a Cash/Public Acquisition. In connection with such cashless exercise,
Holder shall be deemed to have restated each of the representations and warranties in Section&nbsp;4 of the Warrant as the date thereof and the Company shall promptly notify the Holder of the number of Shares (or such other securities) issued upon
exercise. In the event of a Cash/Public Acquisition where the fair market value of one Share as determined in accordance with Section&nbsp;1.3 above would be less than the Warrant Price in effect immediately prior to such Cash/Public Acquisition,
then this Warrant will expire immediately prior to the consummation of such Cash/Public Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Upon the closing of any
Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property
as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance
with the provisions of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) As used in this Warrant, &#147;<B><U>Marketable Securities</U></B>&#148; means securities
meeting all of the following requirements: (i)&nbsp;the issuer thereof is then subject to the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(the &#147;<B><U>Exchange Act</U></B>&#148;), and is then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii)&nbsp;the class and series of
shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in Trading Market, and (iii)&nbsp;following the closing
of such Acquisition, Holder would not be restricted from publicly <FONT STYLE="white-space:nowrap">re-selling</FONT> all of the issuer&#146;s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise
or convert this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such restriction (x)&nbsp;arises solely under federal or state securities laws, rules or regulations, and (y)&nbsp;does not extend beyond
six (6)&nbsp;months from the closing of such Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7 <U>Number of Shares of Common Stock Granted to Holder</U>. On the initial
Funding Date of the initial Term Loan Advance, the number of Shares for which this Warrant shall be exercised shall be determined as follows: <FONT STYLE="white-space:nowrap">one-half</FONT> of one percent (0.50%) of the original principal amount of
such Term Loan Advance divided by the Warrant Price. In furtherance of the foregoing sentence, such number of Shares for which this Warrant shall be exercisable shall be increased for each successive Term Loan Advance in an amount equal to <FONT
STYLE="white-space:nowrap">one-half</FONT> of one percent (0.50%) of the original principal amount of such successive Term Loan Advance divided by the Warrant Price (which such number of Shares would be less any Shares for which this Warrant has
been previously exercised); provided that in no event shall the total amount of Shares for which this Warrant is exercisable exceeds $5,000,000 multiplied by <FONT STYLE="white-space:nowrap">one-half</FONT> of one percent (0.50%), divided by the
Warrant Price. For purposes of clarification only, if the aggregate original principal amount of Term Loan Advances advanced to the Company is $5,000,000, then the number of Shares for which this Warrant is exercisable shall be 40,322 Shares
(<I>i.e.</I>, 0.005 multiplied by $5,000,000, then divided by the Warrant Price). Capitalized terms used but not defined in this Section&nbsp;1.7 shall have the meanings given to them in the Loan Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECTION&nbsp;2 <U>ADJUSTMENTS TO THE SHARES AND WARRANT PRICE</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Stock Dividends, Splits, Etc</U>. If the Company declares or pays a dividend or distribution on the outstanding shares of the Common
Stock payable in securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which Holder would
have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Common Stock by reclassification or otherwise into a greater number of shares, the
number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Common Stock are combined or consolidated, by reclassification or otherwise, into a
lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Reclassification, Exchange, Combinations or Substitution</U>. Upon any event whereby all of the outstanding shares of the Common Stock
are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class
and series of Company securities that Holder would have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in accordance with the provisions of this
Warrant. The provisions of this Section&nbsp;2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Intentionally Omitted</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Intentionally Omitted</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>No Fractional Share</U>. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued
shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the
fractional interest by (i)&nbsp;the fair market value (as determined in accordance with Section&nbsp;1.3 above) of a full Share, less (ii)&nbsp;the then-effective Warrant Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <U>Notice/Certificate as to Adjustments</U>. Upon each adjustment of the Warrant Price, Common Stock and/or number of Shares, the Company,
at the Company&#146;s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written
request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, class and number of Shares in effect upon the date of such adjustment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECTION&nbsp;3 <U>REPRESENTATIONS AND COVENANTS OF THE COMPANY</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Representations and Warranties</U>. The Company represents and warrants to, and agrees with, the Holder as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which shares of Company
Common Stock or options to purchase shares of Company Common Stock were issued immediately prior to the Issue Date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All Shares
which may be issued upon the exercise of this Warrant shall, upon issuance, be duly authorized, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and free of any liens and encumbrances except for restrictions on
transfer provided for herein or under applicable federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of securities
as will be sufficient to permit the exercise in full of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company&#146;s capitalization table attached hereto as
Schedule 1 is true and complete, in all material respects, as of the Issue Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Notice of Certain Events</U>. If the Company proposes at any time to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) declare any dividend or distribution upon the outstanding shares of the Company&#146;s stock, whether in cash, property, stock, or other
securities and whether or not a regular cash dividend; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) offer for subscription or sale pro rata to the holders of the outstanding
shares any additional shares of any class or series of the Company&#146;s stock (other than pursuant to contractual <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the
Common Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) effect an Acquisition or to liquidate, dissolve or wind up; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) effect an initial, underwritten offering and sale of its securities to the public pursuant to an effective registration statement under
the Act (the &#147;<B>IPO</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, in connection with each such event, the Company shall give Holder: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) in the case of the matters referred to in (a)&nbsp;and (b) above, at least seven (7)&nbsp;Business Days prior written
notice of the earlier to occur of the effective date thereof or the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of outstanding shares of the Common Stock
will be entitled thereto) or for determining rights to vote, if any; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) in the case of the matters referred to in
(c)&nbsp;and (d) above at least seven (7)&nbsp;Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the Common Stock will be entitled to exchange their
shares for the securities or other property deliverable upon the occurrence of such event and such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such event giving rise to the
notice); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) with respect to the IPO, at least seven (7)&nbsp;Business Days prior written notice of the date on which
the Company proposes to file its registration statement in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company will also provide information reasonably requested by Holder
that is reasonably necessary to enable Holder to comply with Holder&#146;s accounting or reporting requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECTION&nbsp;4
<U>REPRESENTATIONS, WARRANTIES OF THE HOLDER</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holder represents and warrants to the Company as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Purchase for Own Account</U>. This Warrant and the Shares to be acquired upon exercise of this Warrant by Holder are being acquired for
investment for Holder&#146;s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this
Warrant or the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Disclosure of Information</U>. Holder is aware of the Company&#146;s business affairs
and financial condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities.
Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the
Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Investment Experience</U>. Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder&#146;s investment in this Warrant and its underlying securities and has such
knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the
Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>Accredited Investor Status</U>. Holder is an &#147;accredited investor&#148; within the meaning of Regulation D promulgated under the
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 <U>The Act</U>. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under
the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder&#146;s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued
upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is
aware of the provisions of Rule&nbsp;144 promulgated under the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6 <U>Market <FONT STYLE="white-space:nowrap">Stand-off</FONT>
Agreement</U>. The Holder agrees that the Shares shall be subject to the Market Standoff provisions in Section&nbsp;2.10 of the Investor Rights Agreement entered into between the Company and certain of the holders of the Company&#146;s securities as
of April&nbsp;1, 2016, as such may be amended from time to time pursuant to the terms thereof, or similar agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7 <U>No Voting
Rights</U>. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECTION&nbsp;5 <U>MISCELLANEOUS</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Term and Automatic Conversion Upon Expiration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Term</U>. Subject to the provisions of Section&nbsp;1.6 above, this Warrant is exercisable in whole or in part at any time and from
time to time on or before 6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Automatic Cashless Exercise
upon Expiration</U>. In the event that, upon the Expiration Date, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section&nbsp;1.3 above is greater than the Warrant Price in
effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section&nbsp;1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the
Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Legends</U>. The Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted
with a legend in substantially the following form: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE &#147;<B><U>ACT</U></B>&#148;), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE COMMON STOCK ISSUED BY THE ISSUER TO SILICON VALLEY BANK DATED NOVEMBER&nbsp;21, 2016, MAY
NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Compliance with Securities Laws on Transfer</U>. This Warrant and the Shares issuable upon exercise of this Warrant (and the securities
issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee (including,
without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the
transfer is to SVB Financial Group (Silicon Valley Bank&#146;s parent company) or any other affiliate of Holder, provided that any such transferee is an &#147;accredited investor&#148; as defined in Regulation D promulgated under the Act.
Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Transfer Procedure</U>. After receipt by Silicon Valley Bank of the executed Warrant,
Silicon Valley Bank will transfer all of this Warrant to its parent company, SVB Financial Group. By its acceptance of this Warrant, SVB Financial Group hereby makes to the Company each of the representations and warranties set forth in
Section&nbsp;4 hereof and agrees to be bound by all of the terms and conditions of this Warrant as if the original Holder hereof. Subject to the provisions of Section&nbsp;5.3 and upon providing the Company with written notice, SVB Financial Group
and any subsequent Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however,
in connection with any such transfer, SVB Financial Group or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder
will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable); and provided further, that any subsequent transferee other than SVB Financial Group shall agree in writing with the Company to be bound by all
of the terms and conditions of this Warrant. Notwithstanding any contrary provision herein, at all times prior to the IPO, Holder may not, without the Company&#146;s prior written consent, transfer this Warrant or any portion hereof, or any Shares
issued upon any exercise hereof, or any shares or other securities issued upon any conversion of any Shares issued upon any exercise hereof, to any person or entity who directly competes with the Company, except in connection with an Acquisition of
the Company by such a direct competitor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Notices</U>. All notices and other communications hereunder from the Company to the
Holder, or vice versa, shall be deemed delivered and effective (i)&nbsp;when given personally, (ii)&nbsp;on the third (3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP>) Business Day after being mailed by first-class registered or certified
mail, postage prepaid, (iii)&nbsp;upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed in writing by the recipient, or (iv)&nbsp;on the first Business Day following delivery to a reliable overnight courier
service, courier fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section&nbsp;5.5.
All notices to Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">SVB Financial Group </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn:
Treasury Department </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">3003 Tasman Drive, HC 215 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Santa Clara, California 95054 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice to the Company shall be addressed as follows until Holder receives notice of a change
in address: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Silverback Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn: Peter Thompson, Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">500 Fairview Ave N </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Seattle,
Washington 98109 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Telephone:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Facsimile:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6<U> Waiver</U>. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular
instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>Attorneys&#146; Fees</U>. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the
party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys&#146; fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <U>Counterparts; Facsimile/Electronic Signatures</U>. This Warrant may be executed in counterparts, all of which together shall constitute
one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 <U>Governing Law</U>. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without
giving effect to its principles regarding conflicts of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10 <U>Headings</U>. The headings in this Warrant are for purposes of
reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 <U>Business Days</U>.
&#147;<B>Business Day</B>&#148; is any day that is not a Saturday, Sunday or a day on which Silicon Valley Bank is closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of
page left blank intentionally] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Common Stock to be
executed by their duly authorized representatives effective as of the Issue Date written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;COMPANY&#148;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">SILVERBACK THERAPEUTICS, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Peter A. Thompson</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Peter A. Thompson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Acting President and Chief Financial Officer</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;HOLDER&#148;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">SILICON VALLEY BANK By:</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I><U></U>/s/ Jackie Spencer</I></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Jackie Spencer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Print)</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Silverback &#150; SVB Warrant to Purchase Common Stock] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">APPENDIX 1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>NOTICE OF EXERCISE </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
The undersigned Holder hereby exercises its right purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares of the Common Stock of Silverback Therapeutics, Inc.
(the &#147;<B>Company</B>&#148;) in accordance with the attached Warrant To Purchase Common Stock, and tenders payment of the aggregate Warrant Price for such shares as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">check in the amount of
$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U>payable to order of the Company enclosed herewith </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Wire transfer of immediately available funds to the Company&#146;s account </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cashless Exercise pursuant to Section&nbsp;1 .2 of the Warrant </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other [Describe] </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Please issue a certificate or certificates representing the Shares in the name specified below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Holder&#146;s Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Address)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. By its execution below and for the benefit of the Company, Holder hereby restates each of the
representations and warranties in Section&nbsp;4 of the Warrant to Purchase Common Stock as of the date hereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HOLDER:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Date):</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;<B><U>ACT</U></B>&#148;), OR
THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS&nbsp;5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE
COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="67%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Company:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SILVERBACK THERAPEUTICS, INC., a Delaware corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Number of Shares of Common Stock:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5,769 shares.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Warrant Price:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$0.65 per share, which is based on the most recent 409A valuation report of the Company&#146;s Common Stock reviewed and accepted by the Board of Directors of the Company dated May&nbsp;31, 2016.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Issue Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">December&nbsp;22, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Expiration Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">December&nbsp;22, 2027<B> See also Section</B><B></B><B>&nbsp;5.1(b)</B>.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Credit Facility:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">This Warrant to Purchase Common Stock (as the same may from time to time be amended, modified, supplemented or restated, the &#147;<B><U>Warrant</U></B>&#148;) is issued in connection with that certain First Amendment to Loan and
Security Agreement of even date herewith between Silicon Valley Bank and the Company (as the same may from time to time be amended, modified, supplemented or restated, the &#147;<B><U>Loan Agreement</U></B>&#148;).</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS WARRANT CERTIFIES THAT, for good and valuable consideration, SILICON VALLEY BANK (together with any
successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, &#147;<B><U>Holder</U></B>&#148;) is entitled to purchase the number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT>
shares (the &#147;<B><U>Shares</U></B>&#148;) of the above-stated common stock (the &#147;<B><U>Common Stock</U></B>&#148;) of the above-named company (the &#147;<B><U>Company</U></B>&#148;) at the above-stated Warrant Price, all as set forth above
and as adjusted pursuant to Section&nbsp;2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. Reference is made to Section&nbsp;5.4 of this Warrant whereby Silicon Valley Bank shall transfer this
Warrant to its parent company, SVB Financial Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECTION&nbsp;1 <U>EXERCISE</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Method of Exercise</U>. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the
Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in
Section&nbsp;1.2, a check, wire transfer of <FONT STYLE="white-space:nowrap">same-day</FONT> funds (to an account designated by the Company), or other form of payment acceptable to the Company in the Company&#146;s reasonable discretion for the
aggregate Warrant Price for the Shares being purchased. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Cashless Exercise</U>. On any exercise of this Warrant, in lieu of payment of the
aggregate Warrant Price in the manner as specified in Section&nbsp;1.1 above, but otherwise in accordance with the requirements of Section&nbsp;1.1, Holder may elect to receive Shares equal to the value of this Warrant, or portion hereof as to which
this Warrant is being exercised. Thereupon, the Company shall issue to the Holder such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> Shares as are computed using the following formula: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">X = <FONT STYLE="white-space:nowrap">Y(A-B)/A</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">X&nbsp;=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the number of Shares to be issued to the Holder;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Y&nbsp;=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A&nbsp;=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Fair Market Value (as determined pursuant to Section&nbsp;1.3 below) of one Share; and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">B&nbsp;=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Warrant Price.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Fair Market Value</U>. If the Company&#146;s Common Stock is then traded or quoted on a nationally
recognized securities exchange, inter-dealer quotation system or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market (a &#147;<B><U>Trading Market</U></B>&#148;), the fair market value of a Share
shall be the closing price or last sale price of a share of Common Stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company&#146;s
Common Stock is not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 <U>Delivery of Certificate and New Warrant</U>. Within a reasonable time after Holder exercises this Warrant in the manner set forth in
Section&nbsp;1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor
representing the Shares not so acquired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 <U>Replacement of Warrant</U>. On receipt of evidence reasonably satisfactory to the Company
of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation,
on surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6 <U>Treatment of Warrant Upon Acquisition of Company</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Acquisition</U>. For the purpose of this Warrant, &#147;<B><U>Acquisition</U></B>&#148; means any transaction or series of related
transactions involving: (i)&nbsp;the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii)&nbsp;any merger or consolidation of the Company into or with another person or entity (other than
a merger or consolidation effected exclusively to change the Company&#146;s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or
reorganization, own less than a majority of the Company&#146;s (or the surviving or successor entity&#146;s) outstanding voting power immediately after such merger, consolidation or reorganization; or (iii)&nbsp;any sale or other transfer by the
stockholders of the Company of shares representing at least a majority of the Company&#146;s then-total outstanding combined voting power; provided that a transaction or series of related transactions shall not constitute an Acquisition if:
(x)&nbsp;its sole purpose is to change the state of the Company&#146;s incorporation; (y)&nbsp;it is solely a transfer of securities to an underwriter of the Company&#146;s securities in connection with an IPO; or (z)&nbsp;it is solely for bona fide
financing purposes in which cash is received by the Company, or indebtedness of the Company is cancelled or converted, or a combination thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Treatment of Warrant at Acquisition</U>. In the event of an Acquisition in which the consideration to be received by the Company&#146;s
stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a &#147;<B><U>Cash/Public Acquisition</U></B>&#148;), and the fair market value of one Share as determined in accordance with
Section&nbsp;1.3 above would be greater than the Warrant Price in effect on such date immediately prior to such Cash/Public Acquisition, and Holder has not exercised this Warrant pursuant to Section&nbsp;1.1 above as to all Shares, then this Warrant
shall automatically be deemed to be cashless exercised pursuant to Section&nbsp;1.2 above as to all Shares effective immediately prior to and contingent upon the consummation of a Cash/Public Acquisition. In connection with such cashless exercise,
Holder shall be deemed to have restated each of the representations and warranties in Section&nbsp;4 of the Warrant as the date thereof and the Company shall promptly notify the Holder of the number of Shares (or such other securities) issued upon
exercise. In the event of a Cash/Public Acquisition where the fair market value of one Share as determined in accordance with Section&nbsp;1.3 above would be less than the Warrant Price in effect immediately prior to such Cash/Public Acquisition,
then this Warrant will expire immediately prior to the consummation of such Cash/Public Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Upon the closing of any
Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property
as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance
with the provisions of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) As used in this Warrant, &#147;<B><U>Marketable Securities</U></B>&#148; means securities
meeting all of the following requirements: (i)&nbsp;the issuer thereof is then subject to the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(the &#147;<B><U>Exchange Act</U></B>&#148;), and is then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii)&nbsp;the class and series of
shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in Trading Market, and (iii)&nbsp;following the closing
of such Acquisition, Holder would not be restricted from publicly <FONT STYLE="white-space:nowrap">re-selling</FONT> all of the issuer&#146;s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise
or convert this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such restriction (x)&nbsp;arises solely under federal or state securities laws, rules or regulations, and (y)&nbsp;does not extend beyond
six (6)&nbsp;months from the closing of such Acquisition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECTION&nbsp;2 <U>ADJUSTMENTS TO THE SHARES AND WARRANT PRICE</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Stock Dividends, Splits, Etc</U>. If the Company declares or pays a dividend or distribution on the outstanding shares of the Common
Stock payable in securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which Holder would
have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Common Stock by reclassification or otherwise into a greater number of shares, the
number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Common Stock are combined or consolidated, by reclassification or otherwise, into a
lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Reclassification, Exchange, Combinations or Substitution</U>. Upon any event whereby all of the outstanding shares of the Common Stock
are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class
and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in accordance with the provisions of this
Warrant. The provisions of this Section&nbsp;2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Intentionally Omitted</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Intentionally Omitted</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>No Fractional Share</U>. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued
shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the
fractional interest by (i)&nbsp;the fair market value (as determined in accordance with Section&nbsp;1.3 above) of a full Share, less (ii)&nbsp;the then-effective Warrant Price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <U>Notice/Certificate as to Adjustments</U>. Upon each adjustment of the Warrant Price,
Common Stock and/or number of Shares, the Company, at the Company&#146;s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, class and/or number of Shares and facts upon which such
adjustment is based. The Company shall, upon written request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, class and number of Shares in effect upon
the date of such adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECTION&nbsp;3 <U>REPRESENTATIONS AND COVENANTS OF THE COMPANY</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Representations and Warranties</U>. The Company represents and warrants to, and agrees with, the Holder as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which shares of Company
Common Stock or options to purchase shares of Company Common Stock were issued immediately prior to the Issue Date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All Shares
which may be issued upon the exercise of this Warrant shall, upon issuance, be duly authorized, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and free of any liens and encumbrances except for restrictions on
transfer provided for herein or under applicable federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of securities
as will be sufficient to permit the exercise in full of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company&#146;s capitalization table attached hereto as
Schedule 1 is true and complete, in all material respects, as of the Issue Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Notice of Certain Events</U>. If the Company
proposes at any time to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) declare any dividend or distribution upon the outstanding shares of the Company&#146;s stock, whether in
cash, property, stock, or other securities and whether or not a regular cash dividend; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) offer for subscription or sale pro rata to the
holders of the outstanding shares any additional shares of any class or series of the Company&#146;s stock (other than pursuant to contractual <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the
Common Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) effect an Acquisition or to liquidate, dissolve or wind up; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) effect an initial, underwritten offering and sale of its securities to the public pursuant to an effective registration statement under
the Act (the &#147;<B>IPO</B>&#148;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, in connection with each such event, the Company shall give Holder: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) in the case of the matters referred to in (a)&nbsp;and (b) above, at least seven (7)&nbsp;Business Days prior written
notice of the earlier to occur of the effective date thereof or the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of outstanding shares of the Common Stock
will be entitled thereto) or for determining rights to vote, if any; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) in the case of the matters referred to in
(c)&nbsp;and (d) above at least seven (7)&nbsp;Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the Common Stock will be entitled to exchange their
shares for the securities or other property deliverable upon the occurrence of such event and such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such event giving rise to the
notice); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) with respect to the IPO, at least seven (7)&nbsp;Business Days prior written notice of the date on which
the Company proposes to file its registration statement in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company will also provide information reasonably requested by Holder
that is reasonably necessary to enable Holder to comply with Holder&#146;s accounting or reporting requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECTION&nbsp;4
<U>REPRESENTATIONS, WARRANTIES OF THE HOLDER</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holder represents and warrants to the Company as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Purchase for Own Account</U>. This Warrant and the Shares to be acquired upon exercise of this Warrant by Holder are being acquired for
investment for Holder&#146;s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this
Warrant or the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Disclosure of Information</U>. Holder is aware of the Company&#146;s business affairs and financial
condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has
had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such
information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Investment Experience</U>. Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder&#146;s investment in this Warrant and its underlying securities and has such
knowledge and experience in financial or business matters that Holder is capable of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and certain of its
officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>Accredited Investor Status</U>. Holder is an &#147;accredited investor&#148; within the meaning of Regulation D promulgated under the
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 <U>The Act</U>. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under
the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder&#146;s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued
upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is
aware of the provisions of Rule&nbsp;144 promulgated under the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6 <U>Market <FONT STYLE="white-space:nowrap">Stand-off</FONT>
Agreement</U>. The Holder agrees that the Shares shall be subject to the Market Standoff provisions in Section&nbsp;2.10 of the Investor Rights Agreement entered into between the Company and certain of the holders of the Company&#146;s securities as
of April&nbsp;1, 2016, as such may be amended from time to time pursuant to the terms thereof, or similar agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7 <U>No Voting
Rights</U>. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this Warrant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECTION&nbsp;5
<U>MISCELLANEOUS</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Term and Automatic Conversion Upon Expiration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Term</U>. Subject to the provisions of Section&nbsp;1.6 above, this Warrant is exercisable in whole or in part at any time and from
time to time on or before 6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Automatic Cashless Exercise
upon Expiration</U>. In the event that, upon the Expiration Date, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section&nbsp;1.3 above is greater than the Warrant Price in
effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section&nbsp;1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the
Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Legends</U>. The Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted
with a legend in substantially the following form: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
1933, AS AMENDED (THE &#147;<B><U>ACT</U></B>&#148;), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE COMMON STOCK ISSUED BY THE ISSUER TO SILICON
VALLEY BANK DATED DECEMBER&nbsp;22, 2017, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER
IS EXEMPT FROM SUCH REGISTRATION. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Compliance with Securities Laws on Transfer</U>. This Warrant and the Shares issuable upon
exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance with applicable federal and state securities laws by
the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require
Holder to provide an opinion of counsel if the transfer is to SVB Financial Group (Silicon Valley Bank&#146;s parent company) or any other affiliate of Holder, provided that any such transferee is an &#147;accredited investor&#148; as defined in
Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Transfer Procedure</U>. After receipt by Silicon Valley Bank of the executed Warrant, Silicon Valley Bank will transfer all of this
Warrant to its parent company, SVB Financial Group. By its acceptance of this Warrant, SVB Financial Group hereby makes to the Company each of the representations and warranties set forth in Section&nbsp;4 hereof and agrees to be bound by all of the
terms and conditions of this Warrant as if the original Holder hereof. Subject to the provisions of Section&nbsp;5.3 and upon providing the Company with written notice, SVB Financial Group and any subsequent Holder may transfer all or part of this
Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however, in connection with any such transfer, SVB Financial Group
or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to
the transferee(s) (and Holder if applicable); and provided further, that any subsequent transferee other than SVB Financial Group shall agree in writing with the Company to be bound by all of the terms and conditions of this Warrant. Notwithstanding
any contrary provision herein, at all times prior to the IPO, Holder may not, without the Company&#146;s prior written consent, transfer this Warrant or any portion hereof, or any Shares issued upon any exercise hereof, or any shares or other
securities issued upon any conversion of any Shares issued upon any exercise hereof, to any person or entity who directly competes with the Company, except in connection with an Acquisition of the Company by such a direct competitor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Notices</U>. All notices and other communications hereunder from the Company to the
Holder, or vice versa, shall be deemed delivered and effective (i)&nbsp;when given personally, (ii)&nbsp;on the third (3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP>) Business Day after being mailed by first-class registered or certified
mail, postage prepaid, (iii)&nbsp;upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed in writing by the recipient, or (iv)&nbsp;on the first Business Day following delivery to a reliable overnight courier
service, courier fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section&nbsp;5.5.
All notices to Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">SVB Financial Group </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn:
Treasury Department </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">3003 Tasman Drive, HC 215 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Santa Clara, California 95054 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice to the Company shall be addressed as follows until Holder receives notice of a change in address: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Silverback Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn: Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn: Legal </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">500 Fairview Ave N
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Seattle, Washington 98109 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Waiver</U>. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular
instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>Attorneys&#146; Fees</U>. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the
party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys&#146; fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <U>Counterparts; Facsimile/Electronic Signatures</U>. This Warrant may be executed in counterparts, all of which together shall constitute
one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 <U>Governing Law</U>. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without
giving effect to its principles regarding conflicts of law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10 <U>Headings</U>. The headings in this Warrant are for purposes of reference only and
shall not limit or otherwise affect the meaning of any provision of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 <U>Business Days</U>. &#147;<B>Business
Day</B>&#148; is any day that is not a Saturday, Sunday or a day on which Silicon Valley Bank is closed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page left blank
intentionally] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Common Stock to be
executed by their duly authorized representatives effective as of the Issue Date written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="11">&#147;COMPANY&#148;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="11"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="11">SILVERBACK THERAPEUTICS, INC.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Russ Hawkinson</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Legal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Approved</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Russ Hawkinson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Acting CFO</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">&#147;HOLDER&#148;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="7"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7">SILICON VALLEY BANK By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Derek Scalf</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Finance</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Approved</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Derek Scalf</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Print)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Vice President</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Silverback &#150; SVB Warrant to Purchase Common Stock] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">APPENDIX 1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>NOTICE OF EXERCISE </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
The undersigned Holder hereby exercises its right purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares of the Common Stock of Silverback Therapeutics, Inc.
(the &#147;<B>Company</B>&#148;) in accordance with the attached Warrant To Purchase Common Stock, and tenders payment of the aggregate Warrant Price for such shares as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">check in the amount of
$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> payable to order of the Company enclosed herewith </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Wire transfer of immediately available funds to the Company&#146;s account </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cashless Exercise pursuant to Section&nbsp;1 .2 of the Warrant </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other [Describe] </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Please issue a certificate or certificates representing the Shares in the name specified below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Holder&#146;s Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Address)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. By its execution below and for the benefit of the Company, Holder hereby restates each of the
representations and warranties in Section&nbsp;4 of the Warrant to Purchase Common Stock as of the date hereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HOLDER:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Date):</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SILVERBACK THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2016 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As Adopted by the Board and Stockholders on April&nbsp;1, 2016, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as amended through September&nbsp;22, 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>PURPOSE</U></B>. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose
present and potential contributions are important to the success of the Company, its Parent and Subsidiaries, by offering them an opportunity to participate in the Company&#146;s future performance through Awards. Capitalized terms not defined in
the text are defined in Section&nbsp;23. Awards may be either Restricted Stock or Options. Options granted under the Plan may be ISOs (as defined in Section&nbsp;5 hereof) or NQSOs (as defined in Section&nbsp;5 hereof), as determined by the
Committee at the time of grant of an Option and subject to the applicable provisions of Section&nbsp;422 of the Code and the regulations promulgated thereunder. This Plan is intended to be a written compensatory benefit plan within the meaning of
Rule 701 promulgated under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2. <U>SHARES SUBJECT TO THE PLAN</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.1.</B> <B><U>Number of Shares Available</U></B>. Subject to Sections 2.2 and 16, the total number of Shares reserved and available for
grant and issuance pursuant to this Plan will be 14,711,318 Shares. Subject to Sections 2.2, 5.10 and 16, Shares subject to Awards previously granted will again be available for grant and issuance in connection with future Awards under this Plan to
the extent such Shares: (i)&nbsp;cease to be subject to issuance upon exercise of an Option, other than due to the exercise of such Option; or (ii)&nbsp;are issued upon exercise of an Award but are forfeited or repurchased by the Company. At all
times the Company will reserve and keep available a sufficient number of Shares as will be required to satisfy the requirements of all Awards granted and outstanding under this Plan. Notwithstanding the foregoing, in no event shall the total number
of Shares issued (counting each reissuance of a Share that was actually issued and then forfeited or repurchased by the Company as a separate issuance) under the Plan upon exercise of ISOs exceed 44,000,000 Shares (adjusted in accordance with
Sections 2.2 and 16 hereof) over the term of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2.</B> <B><U>Adjustment of Shares</U></B>. In the event that the number of
outstanding shares of the Company&#146;s Common Stock is changed by a stock dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in the capital structure of the Company without
consideration, consolidation, subdivision of the Shares, a rights offering, a reorganization, merger, <FONT STYLE="white-space:nowrap">spin-off,</FONT> or <FONT STYLE="white-space:nowrap">split-up,</FONT> then (i)&nbsp;the number of Shares reserved
for issuance under this Plan; (ii)&nbsp;the Exercise Prices of and number of Shares subject to outstanding Options and (iii)&nbsp;any repurchase price per Share applicable to Shares issued pursuant to any Award, will be proportionately adjusted,
subject to any required action by the Board or the stockholders of the Company and compliance with applicable securities laws; provided, however, that fractions of a Share will not be issued but will either be paid in cash at the Fair Market Value
of such fraction of a Share or will be rounded down to the nearest whole Share, as determined by the Committee and provided, further, that the Exercise Price of any Option may not be decreased to below the par value of the Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><U>ELIGIBILITY</U></B>. ISOs may be granted only to employees (including
officers and directors who are also employees) of the Company or of a Parent or Subsidiary of the Company. Restricted Stock or NQSO&#146;s may be granted to employees, officers, directors and consultants of the Company or any Parent or Subsidiary of
the Company. Consultants need not be individuals provided that the issuances to such consultant is in compliance with all Applicable Laws. A person may be granted more than one Award under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4. <U>ADMINISTRATION</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.1.</B> <B><U>Committee Authority</U></B>. This Plan will be administered by the Board, though the Board may appoint a Committee to which
it delegates such administration. If the Board has not appointed a Committee to administer the Plan, the Board itself shall serve as the Committee. The Plan may be administered by different administrative bodies with respect to different classes of
Participants. Subject to the general purposes, terms and conditions of this Plan, and to the direction of the Board, the Committee will have full power to implement and carry out this Plan. Without limitation, the Committee will have the authority
to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.1.</B> determine the Fair Market Value of the Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.2.</B> construe and interpret this Plan, any Option Agreement (as defined in Section&nbsp;5.1 hereof) or Restricted Stock Purchase
Agreement and any other agreement or document executed pursuant to this Plan, which constructions, interpretations and decisions shall be final and binding on all Participants; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.3.</B> prescribe, amend and rescind rules and regulations relating to this Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.4.</B> approve persons to receive Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.5.</B> determine the number of Shares or other consideration subject to Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.6.</B> determine whether Awards will be granted singly, in combination with, in tandem with, in replacement of, or as alternatives to,
other Awards under this Plan or awards under any other incentive or compensation plan of the Company or any Parent or Subsidiary of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.7.</B> grant waivers of any conditions of this Plan or any Award; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.8.</B> determine the form and terms, not inconsistent with the terms of the Plan, of any Awards granted hereunder and other related
documents used under the Plan, which terms and conditions include but are not limited to the exercise or purchase price, the time or times when Awards may be exercised (which may be based on performance criteria), the circumstances (if any) when
vesting will be accelerated or forfeiture restrictions will be waived, and any restriction or limitation regarding, any Award; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.9.</B> correct any defect, supply any omission, or reconcile any inconsistency in
this Plan, any Award, any Option Agreement, any Exercise Agreement, or any Restricted Stock Purchase Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.10.</B> determine
whether an Award has been earned; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.11.</B> determine whether and under what circumstances an Award may be settled in cash under
Section&nbsp;13 below instead of Common Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.12.</B> implement an Option Exchange Program and establish the terms and
conditions of such Option Exchange Program, provided that no amendment or adjustment to an Option that would materially and adversely affect the rights of any Participant shall be made without his or her consent; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.13.</B> make all other determinations necessary or advisable for the administration of this Plan; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1.14.</B> extend the vesting period beyond a Participant&#146;s Termination Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.2.</B> <B><U>Committee Discretion</U></B>. Unless in contravention of any express terms of this Plan or any Award, any determination made
by the Committee with respect to any Award will be made in its sole discretion either (i)&nbsp;at the time of grant of the Award, or (ii)&nbsp;subject to Section&nbsp;5.9 hereof, at any later time. Any such determination will be final and binding on
the Company and on all persons having an interest in any Award under this Plan. The Committee may delegate to one or more officers of the Company the authority to grant Awards under this Plan, provided such officer or officers are members of the
Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.3.</B> <B><U>Indemnification</U></B>. To the maximum extent permitted by Applicable Laws, each member of the Committee
(including officers of the Company, if applicable), or of the Board, as applicable, shall be indemnified and held harmless by the Company against and from (i)&nbsp;any loss, cost, liability, or expense that may be imposed upon or reasonably incurred
by him or her in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action taken or failure to act under the Plan or pursuant to the terms
and conditions of any Award except for actions taken in bad faith or failures to act in good faith, and (ii)&nbsp;any and all amounts paid by him or her in settlement thereof, with the Company&#146;s approval, or paid by him or her in satisfaction
of any judgment in any such claim, action, suit, or proceeding against him or her, provided that such member shall give the Company an opportunity, at its own expense, to handle and defend any such claim, action, suit, or proceeding before he or she
undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled under the Company&#146;s Articles of
Incorporation, Certificate of Incorporation or Bylaws, by contract, matter of law, or otherwise, or under any other power that the Company may have to indemnify or hold harmless each such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>OPTIONS</U></B>. The Committee may grant Options to eligible persons described in Section&nbsp;3 hereof and will determine
whether such Options will be Incentive Stock Options within the meaning of the Code (the &#147;<B><U>ISOs</U></B>&#148;) or Nonqualified Stock Options (the &#147;<B><U>NQSOs</U></B>&#148;), the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of Shares subject to the Option, the Exercise Price of the Option, the period during which the Option may be exercised, and all other terms and conditions of the Option, subject to the
following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.1.</B> <B><U>Form of Option Grant</U></B>. Each Option granted under this Plan will be evidenced by an Option Agreement
which will expressly identify the Option as an ISO or an NQSO, and will be in such form and contain such provisions (which need not be the same for each Participant) as the Committee may from time to time approve, and which will comply with and be
subject to the terms and conditions of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.2.</B> <B><U>Date of Grant</U></B>. The date of grant of an Option will be the
date on which the Committee makes the determination to grant such Option, unless a later date is otherwise specified by the Committee. The Option Agreement and a copy of this Plan will be delivered to the Participant within a reasonable time after
the granting of the Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.3.</B> <B><U>Exercise Period</U></B>. Options may be exercisable immediately but shares so exercised
prior to becoming Vested Shares shall be subject to repurchase pursuant to Section&nbsp;5.12 hereof or may be exercisable within the times or upon the events determined by the Committee as set forth in the Option Agreement governing such Option;
provided, however, that no Option will be exercisable after the expiration of ten (10)&nbsp;years from the date the Option is granted; and provided further that no ISO granted to a person who immediately prior to the grant of such ISO directly or by
attribution owns more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or of any Parent or Subsidiary of the Company (the &#147;<B><U>Ten Percent Stockholder</U></B>&#148;) will be exercisable after
the expiration of five (5)&nbsp;years from the date the ISO is granted. The Committee also may provide for Options to become exercisable at one time or from time to time, periodically or otherwise, in such number of Shares or percentage of Shares as
the Committee determines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.4.</B> <B><U>Exercise Price</U></B>. The Exercise Price of an Option will be determined by the Committee
when the Option is granted; provided that (i)&nbsp;the Exercise Price of an ISO will not be less than one hundred percent (100%) of the Fair Market Value of the Shares on the date of grant and (ii)&nbsp;the Exercise Price of any Option granted to a
Ten Percent Stockholder will not be less than one hundred ten percent (110%) of the Fair Market Value of the Shares on the date of grant. In the case of an NQSO, the per share exercise price shall be such price that is determined by the Committee,
provided that, if the per Share exercise price is less than 100% of the Fair Market Value on the date of grant, it shall otherwise comply with all Applicable Laws, including Section&nbsp;409A of the Code. Payment for the Shares purchased must be
made in accordance with Section&nbsp;7 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.5.</B> <B><U>Method of Exercise</U></B>. Options may be exercised only by delivery to
the Company of a written stock option exercise agreement (the &#147;<B><U>Exercise Agreement</U></B>&#148;) in a form approved by the Committee (which need not be the same for each Participant). The Exercise Agreement will state (i)&nbsp;the number
of Shares being purchased, (ii)&nbsp;such representations and agreements regarding Participant&#146;s investment intent and access to information and other matters, if any, as may be required or desirable by the Company to comply with applicable
securities laws, and (iii)&nbsp;any repurchase terms attributable to unvested Shares that have been exercised. Participant shall execute and deliver to the Company the Exercise Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
together with payment in full of the Exercise Price, and any applicable taxes, for the number of Shares being purchased. Options may not be exercised for a fraction of a share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.6.</B> <B><U>Terminatio</U></B><B><U>n</U></B>. Subject to earlier termination pursuant to Sections 16 or 17 hereof and notwithstanding
the exercise periods set forth in the Option Agreement, exercise of an Option will always be subject to the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>5.6.1.</B> If
the Participant (or other person entitled to exercise the Option) does not exercise the Option to the extent so entitled within the time specified below, the Option shall terminate and the Shares underlying the unexercised portion of the Option
shall revert to the Plan. In no event may any Option be exercised after the expiration of the Option term as set forth in the Option Agreement (and subject to Section&nbsp;5.3 above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>5.6.2.</B> If the Participant is Terminated for any reason other than death, Disability or for Cause, then the Participant may exercise
such Participant&#146;s Options only to the extent that such Options are exercisable upon the Termination Date or as otherwise determined by the Committee. Such Options must be exercised by the Participant, if at all, as to all or some of the Vested
Shares calculated as of the Termination Date or such other date determined by the Committee, within ninety (90)&nbsp;days after the Termination Date (or within such shorter time period, not less than thirty (30)&nbsp;days, or within such longer time
period, not exceeding five (5)&nbsp;years after the Termination Date as may be determined by the Committee, with any exercise beyond ninety (90)&nbsp;days after the Termination Date deemed to be an NQSO) but in any event, no later than the
expiration date of the Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>5.6.3.</B> If the Participant is Terminated because of Participant&#146;s death or Disability (or the
Participant dies within ninety (90)&nbsp;days after a Participant&#146;s Termination other than for Cause), then Participant&#146;s Options may be exercised, only to the extent that such Options are exercisable by Participant on the Termination Date
or as otherwise determined by the Committee. Such Options must be exercised by Participant (or Participant&#146;s legal representative or authorized assignee), if at all, as to all or some of the Vested Shares calculated as of the Termination Date
or such other date determined by the Committee, within twelve (12)&nbsp;months after the Termination Date (or within such shorter time period, not less than six (6)&nbsp;months, or within such longer time period not exceeding five (5)&nbsp;years
after the Termination Date as may be determined by the Committee, with any exercise beyond (i)&nbsp;ninety (90) days after the Termination Date when the Termination is for any reason other than the Participant&#146;s death or Disability, or
(ii)&nbsp;twelve (12) months after the Termination Date when the Termination is for Participant&#146;s Disability, deemed to be an NQSO) but in any event no later than the expiration date of the Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>5.6.4.</B> The Committee shall have the discretion to determine whether and to what extent the vesting of Options shall be tolled during
any unpaid leave of absence; provided, however, in the absence of such determination, such vesting shall be tolled during any such unpaid leave (unless otherwise required by Applicable Laws). Notwithstanding the foregoing, in the event of military
leave, vesting shall toll during any unpaid portion of such leave, provided that, upon a Participant&#146;s returning from military leave (under conditions that would entitle him or her to protection upon such return under the Uniform Services
Employment and Reemployment Rights Act), he or she shall be given vesting credit with respect to Options to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the same extent as would have applied had the Participant continued to provide services to the Company (or any Parent or Subsidiary, if applicable) throughout the leave on the same terms as he or
she was providing services immediately prior to such leave. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.7.</B> <B><U>Limitations on Exercis</U>e</B>. The Committee may specify
a reasonable minimum number of Shares that may be purchased on any exercise of an Option, provided that such minimum number will not prevent Participant from exercising the Option for the full number of Shares for which it is then exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.8.</B> <B><U>Limitations on ISOs</U></B>. The <U>aggregate</U> Fair Market Value (determined as of the date of grant) of Shares with
respect to which ISOs are exercisable for the first time by a Participant during any calendar year (under this Plan or under any other incentive stock option plan of the Company or any Parent or Subsidiary of the Company) will not exceed One Hundred
Thousand Dollars ($100,000). If the Fair Market Value of Shares on the date of grant with respect to which ISOs are exercisable for the first time by a Participant during any calendar year exceeds One Hundred Thousand Dollars ($100,000), then the
Options for the first One Hundred Thousand Dollars ($100,000) worth of Shares to become exercisable in such calendar year will be ISOs and the Options for the amount in excess of One Hundred Thousand Dollars ($100,000) that become exercisable in
that calendar year will be NQSOs. In the event that the Code or the regulations promulgated thereunder are amended after the Effective Date (as defined in Section&nbsp;17 hereof) to provide for a different limit on the Fair Market Value of Shares
permitted to be subject to ISOs, then such different limit will be automatically incorporated herein and will apply to any Options granted after the effective date of such amendment. For purposes of this Section&nbsp;5.8, ISOs shall be taken into
account in the order in which they were granted, and the Fair Market Value of the Shares subject to an ISO shall be determined as of the date of the grant of such Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.9.</B> <B><U>Modification, Extension or Renewal</U></B>. The Committee may modify, extend or renew outstanding Options and authorize the
grant of new Options in substitution therefor, provided that any such action may not, without the written consent of a Participant, impair any of such Participant&#146;s rights under any Option previously granted. Any outstanding ISO that is
modified, extended, renewed or otherwise altered will be treated in accordance with Section&nbsp;424(h) of the Code. Subject to Section&nbsp;5.10 hereof, the Committee may reduce the Exercise Price of outstanding Options without the consent of
Participants by a written notice to them; provided, however, that the Exercise Price may not be reduced below the minimum Exercise Price that would be permitted under Section&nbsp;5.4 hereof for Options granted on the date the action is taken to
reduce the Exercise Price; provided, further, that the Exercise Price will not be reduced below the par value of the Shares, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.10.</B> <B><U>No Disqualification</U></B>. Notwithstanding any other provision in this Plan, no term of this Plan relating to ISOs will
be interpreted, amended or altered, nor will any discretion or authority granted under this Plan be exercised, so as to disqualify this Plan under Section&nbsp;422 of the Code or, without the consent of the Participant, to disqualify any
Participant&#146;s ISO under Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.11.</B> <B><U>Right of First Refusal</U></B>. At the discretion of the
Committee, the Company may reserve to itself and/or its assignee(s) in the Option Agreement a right of first refusal to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase all Shares that a Participant (or a subsequent transferee) may propose to transfer to a third party, unless otherwise not permitted by Section&nbsp;25102(o) of the California
Corporations Code, including a right of purchase upon an involuntary transfer; provided, that such right of first refusal terminates upon the Company&#146;s initial public offering of Common Stock pursuant to an effective registration statement
filed under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.12.</B> <B><U>Early Exercise</U></B>. Any Option may, but need not, include a provision whereby the
Participant may elect at any time before the Termination of such Participant to exercise the Option as to any part or all of the Shares subject to the Option prior to the full vesting of such Shares. Any Unvested Shares so purchased shall be subject
to a repurchase option in favor of the Company or to any other restriction the Committee determines to be appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.
<U>RESTRICTED STOCK</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.1.</B> <B><U>Rights to Purchase</U>. </B>When a right to purchase Restricted Stock is granted under the
Plan, the Committee shall advise the recipient in writing of the terms, conditions and restrictions related to the offer, including the number of Shares that such person shall be entitled to purchase, the Purchase Price (which shall be determined by
the Committee, subject to Applicable Laws, including any applicable securities laws), and the time within which such person must accept such offer. The permissible consideration for Restricted Stock shall be determined by the Committee and shall be
made in accordance with Section&nbsp;7 below. The offer to purchase Shares shall be accepted by execution of a Restricted Stock Purchase Agreement in a form determined by the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.2. <U>Repurchase Option</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>6.2.1.</B> <B><U>General</U></B>. Unless the Committee determines otherwise, the Restricted Stock Purchase Agreement shall grant the
Company a repurchase option exercisable if the Participant is Terminated for any reason (including death or Disability). The purchase price for the Shares repurchased pursuant to the Restricted Stock Purchase Agreement shall be equal to or less than
the Purchase Price paid by the Participant and may be paid by cancellation of any indebtedness of the Participant to the Company. The repurchase option shall lapse at such rate as the Committee shall determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>6.2.2.</B> <B><U>Leave of Absence</U></B>. The Committee shall have the discretion to determine whether and to what extent the lapsing of
the Company&#146;s repurchase rights shall be tolled during any unpaid leave of absence; provided, however, in the absence of such determination, such lapsing shall be tolled during any such unpaid leave (unless otherwise required by Applicable
Laws). Notwithstanding the foregoing, in the event of military leave, the lapsing of the Company&#146;s repurchase rights shall toll during any unpaid portion of such leave, provided that, upon a Participant&#146;s returning from military leave
(under conditions that would entitle him or her to protection upon such return under the Uniform Services Employment and Reemployment Rights Act), he or she shall be given vesting credit with respect to Shares purchased pursuant to the Restricted
Stock Purchase Agreement to the same extent as would have applied had the Participant continued to provide services to the Company (or any Parent or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subsidiary, if applicable) throughout the leave on the same terms as he or she was providing services immediately prior to such leave. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>6.2.3.</B> The Participant shall have full stockholder rights with respect to any Shares issued to the Participant under a Restricted
Stock Award, whether or not the Participant&#146;s interest in those Shares is vested. Accordingly, the Participant shall have the right to vote such shares and to receive any regular cash dividends paid on such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>6.2.4.</B> Any new, substituted or additional securities or other property (including money paid other than as a regular cash dividend)
which the Participant may have the right to receive with respect to the Participant&#146;s Unvested Shares by reason of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares,
exchange of shares or other change affecting the outstanding Common Stock as a class without the Company&#146;s receipt of consideration shall be issued subject to (i)&nbsp;the same vesting requirements applicable to the Participant&#146;s Unvested
Shares and (ii)&nbsp;such escrow arrangements as the Committee shall deem appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.3.</B> <B><U>Right of First Refusal</U></B>.
At the discretion of the Committee, the Company may reserve to itself and/or its assignee(s) in the Restricted Stock Purchase Agreement a right of first refusal to purchase all Shares that a Participant (or a subsequent transferee) may propose to
transfer to a third party, unless otherwise not permitted by Section&nbsp;25102(o) of the California Corporations Code, including a right of purchase upon an involuntary transfer; provided, that such right of first refusal terminates upon the
Company&#146;s initial public offering of Common Stock pursuant to an effective registration statement filed under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7. <U>PAYMENT FOR SHARE PURCHASES</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1.</B> <U>Payment</U>. Payment for Shares purchased pursuant to this Plan whether by exercise of an Option or purchase under Restricted
Stock Purchase Agreement shall be made in cash (by check or wire transfer); provided, however, that where expressly provided in an Option Agreement or Restricted Stock Purchase Agreement or otherwise approved for the Participant by the Committee,
and where permitted by Applicable Law, payment may be made by one or more of the following methods: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>7.1.1.</B> by cancellation of
indebtedness of the Company owed to the Participant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>7.1.2.</B> for past services rendered to the Company, unless prohibited by
Applicable Law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>7.1.3.</B> by surrendering, or attesting to the ownership of, shares of Common Stock that are already owned by the
Participant, provided such shares shall be surrendered to the Company in good form for transfer, clear of all liens, claims, encumbrances or security interests, and shall be valued at their Fair Market Value as of the date of exercise or purchase;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>7.1.4.</B> by tender of a promissory note having such recourse, interest, security and redemption provisions as the Committee
determines, bearing interest at a rate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sufficient to avoid imputation of income under Sections 483 and 1274 of the Code; provided, however, that the portion of the Exercise Price or Purchase Price, as applicable, equal to the par
value of the Shares must be paid in cash or other legal consideration permitted by Applicable Law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>7.1.5.</B> provided that a public
market for the Common Stock exists, by the delivery (on a form prescribed by the Company) of an irrevocable direction to a securities broker approved by the Company to sell Shares and to deliver all or part of the sales proceeds to the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>7.1.6.</B> by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of Shares issued upon exercise
of an Option by the largest whole number of Shares having an aggregate Fair Market Value that does not exceed the aggregate Exercise Price or the sum of the aggregate Exercise Price plus all or a portion of the minimum amount required to be withheld
under applicable tax law (with the Company accepting from the Optionee payment of cash or cash equivalents to satisfy any remaining balance of the aggregate Exercise Price and, if applicable, any additional withholding obligation not satisfied
through such reduction in Shares); <I>provided </I>that to the extent Shares subject to an Option are withheld in this manner, the number of Shares subject to the Option following the net exercise will be reduced by the sum of the number of Shares
withheld and the number of Shares delivered to the Optionee as a result of the exercise; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>7.1.7.</B> by any other form permitted by
Applicable Law; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>7.1.8.</B> by any combination of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.2.</B> <B><U>Loan Guarantees</U></B>. The Committee may, in its sole discretion, elect to assist the Participant in paying for Shares
purchased under this Plan by authorizing a guarantee by the Company of a third-party loan to the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. <U>WITHHOLDING
TAXES</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.1.</B> <B><U>Withholding Generally</U></B>. As a condition of the grant, vesting and exercise of an Award granted
under this Plan, the Company may require the Participant (or in the case of the Participant&#146;s death or a permitted transferee, the person holding or exercising the Award) to remit to the Company an amount sufficient to satisfy federal, state
and local withholding tax requirements prior to the delivery of any certificate or certificates for such Shares. The Company shall not be required to issue any Shares under the Plan until such obligations are satisfied. Whenever, under this Plan,
payments in satisfaction of Awards are to be made in cash by the Company, such payment will be net of an amount sufficient to satisfy federal, state, and local withholding tax requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.2.</B> <B><U>Stock Withholding</U></B>. When, under applicable tax laws, a Participant (or in the case of Participant&#146;s death or a
permitted transferee, the person holding or exercising the Award) incurs tax liability in connection with the exercise or vesting of any Award that is subject to tax withholding and the Participant is obligated to pay the Company the amount required
to be withheld, the Committee may in its sole discretion allow the Participant to satisfy the minimum withholding tax obligation by electing to have the Company withhold from the Shares to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issued that number of Shares having a Fair Market Value equal to the minimum amount required to be withheld, determined on the date that the amount of tax to be withheld is to be determined. All
elections by a Participant to have Shares withheld for this purpose will be made in accordance with the requirements established by the Committee for such elections and be in writing in a form acceptable to the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9. <U>PRIVILEGES OF STOCK OWNERSHIP</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.1.</B> <B><U>Voting and Dividends</U></B>. No Participant will have any of the rights of a stockholder with respect to any Shares until
the Shares are issued to the Participant. After Shares are issued to the Participant, the Participant will be a stockholder and have all the rights of a stockholder with respect to such Shares, including the right to vote and receive all dividends
or other distributions made or paid with respect to such Shares; provided, that the Participant will have no right to retain such stock dividends or stock distributions with respect to Unvested Shares that are repurchased pursuant to Sections 5.12
or 6.2 hereof. The Company will comply with Section&nbsp;260.140.01 of Title 10 of the California Code of Regulations with respect to the voting rights of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.2.</B> <B><U>Financial Statements</U></B>. If required under Applicable Laws, the Company will provide financial statements to each
Participant annually during the period such Participant has Awards outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B><U>TRANSFERABILITY OF AWARDS</U></B>.
Unless otherwise provided in an Option Agreement or Restricted Stock Agreement, Awards granted under this Plan, and any interest therein, will not be pledged, assigned, hypothecated, transferred or disposed of by Participant, other than by will or
by the laws of descent and distribution and may not be made subject to execution, attachment or similar process. During the lifetime of the Participant, an Award will be exercisable only by the Participant or Participant&#146;s legal representative
and any elections with respect to an Award may be made only by the Participant or Participant&#146;s legal representative. The designation of a beneficiary by a Participant will not constitute a transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B><U>CERTIFICATES</U></B>. All certificates for Shares or other securities delivered under this Plan will be subject to such stock
transfer orders, legends and other restrictions as the Committee may deem necessary or advisable, including restrictions under any applicable federal, state or foreign securities law, or any rules, regulations and other requirements of the SEC or
any stock exchange or automated quotation system upon which the Shares may be listed or quoted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B><U>ESCROW; PLEDGE OF
SHARES</U></B>. To enforce any restrictions on a Participant&#146;s Shares set forth in Sections 5.12 or 6.2 hereof, the Committee may require the Participant to deposit all certificates representing Shares, together with stock powers or other
instruments of transfer approved by the Committee, appropriately endorsed in blank, with the Company or an agent designated by the Company to hold in escrow until such restrictions have lapsed or terminated. The Committee may cause a legend or
legends referencing such restrictions to be placed on the certificates. Any Participant who is permitted to execute a promissory note as partial or full consideration for the purchase of Shares under this Plan will be required to pledge and deposit
with the Company all or part of the Shares so purchased as collateral to secure the payment of Participant&#146;s obligation to the Company under the promissory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
note; provided, however, that the Committee may require or accept other or additional forms of collateral to secure the payment of such obligation and, in any event, the Company will have full
recourse against the Participant under the promissory note notwithstanding any pledge of the Participant&#146;s Shares or other collateral. In connection with any pledge of the Shares, Participant will be required to execute and deliver a written
pledge agreement in such form as the Committee will from time to time approve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B><U>EXCHANGE AND BUYOUT OF OPTIONS</U></B>.
The Committee may, at any time or from time to time, authorize the Company, with the consent of the respective Participants, to issue new Options in exchange for the surrender and cancellation of any or all outstanding Options. The Committee may at
any time buy from a Participant an Option previously granted with payment in cash, shares of Common Stock of the Company or other consideration, based on such terms and conditions as the Committee and the Participant may agree. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B><U>SECURITIES LAW AND OTHER REGULATORY COMPLIANCE</U></B>. This Plan is intended to comply with Section&nbsp;25102(o) of the
California Corporations Code. Any provision of this Plan which is inconsistent with Section&nbsp;25102(o) shall, without further act or amendment by the Company or the Board, be reformed to comply with the requirements of Section&nbsp;25102(o). An
Award will not be effective unless such Award is in compliance with all applicable foreign, federal and state securities laws, rules and regulations of any governmental body, and the requirements of any stock exchange or automated quotation system
upon which the Shares may then be listed or quoted, as they are in effect on the date of grant of the Award and also on the date of exercise or other issuance. Notwithstanding any other provision in this Plan, the Company will have no obligation to
issue or deliver certificates for Shares under this Plan prior to (i)&nbsp;obtaining any approvals from governmental agencies that the Company determines are necessary or advisable, and/or (ii)&nbsp;compliance with any exemption, completion of any
registration or other qualification of such Shares under any state, federal or foreign law or ruling of any governmental body that the Company determines to be necessary or advisable. The Company will be under no obligation to register the Shares
with the SEC or to effect compliance with the exemption, registration, qualification or listing requirements of any foreign or state securities laws, stock exchange or automated quotation system, and the Company will have no liability for any
inability or failure to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B><U>NO OBLIGATION TO EMPLOY</U></B>. Nothing in this Plan or any Award granted under this
Plan will confer or be deemed to confer on any Participant any right to continue in the employ of, or to continue any other relationship with, the Company or any Parent or Subsidiary of the Company, be deemed to modify any Participant&#146;s <FONT
STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> status with the Company, or limit in any way the right of the Company or any Parent or Subsidiary of the Company to terminate Participant&#146;s employment or other relationship at any time, with
or without cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16. <U>CORPORATE TRANSACTIONS</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>16.1.</B> <B><U>Dissolution or Liquidation</U></B>. In the event of the dissolution or liquidation of the Company, each Award will
terminate immediately prior to the consummation of such action, unless otherwise determined by the Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>16.2.</B><U> <B>Assumption or Replacement of Options by Successor or Acquiring
Company</B></U>. In the event of (i)&nbsp;a merger or consolidation in which the Company is not the surviving corporation, (ii)&nbsp;a merger in which the Company is the surviving corporation but after which the stockholders of the Company
immediately prior to such merger (other than any stockholder which merges with the Company in such merger, or which owns or controls another corporation which merges with the Company in such merger) cease to own their shares or other equity
interests in the Company, or (iii)&nbsp;the sale of all or substantially all of the assets of the Company, any or all outstanding Options may be assumed, converted or replaced by the successor or acquiring corporation (if any), which assumption,
conversion or replacement will be binding on all Participants. In the alternative, the successor or acquiring corporation may substitute equivalent Options or provide substantially similar consideration to Participants as was provided to
stockholders (after taking into account the existing provisions of the Options). The successor or acquiring corporation may also substitute by issuing, in place of outstanding Shares of the Company held by the Participant, substantially similar
shares or other property subject to repurchase restrictions and other provisions no less favorable to the Participant than those which applied to such outstanding Shares immediately prior to such transaction described in this Section&nbsp;16.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>16.3.</B> <B><U>Failure to Assume</U></B>. In the event such successor or acquiring corporation (if any) refuses to assume, convert,
replace or substitute Options, as provided above, pursuant to a transaction described in Section&nbsp;16.2, then notwithstanding any other provision in this Plan to the contrary, such Options will expire on such transaction at such time and on such
conditions as the Committee will determine. The Committee shall notify the Participant that the Option will terminate at least five (5)&nbsp;days prior to the date on which the Option terminates. If any outstanding Option held by a current
Participant is to be terminated (in whole or in part) pursuant to this paragraph, the Committee may, in its sole discretion, elect to accelerate the vesting and exercisability of each such Option such that the Option shall become vested and
exercisable in full or part prior to the consummation of such transaction at such time and on such conditions as the Committee shall determine in its sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>16.4.</B> <B><U>Other Treatment of Options</U></B>. Subject to any greater rights granted to Participants under the foregoing provisions of
this Section&nbsp;16 hereof, in the event of the occurrence of any transaction described in Section&nbsp;16.2 hereof, any outstanding Options will be treated as provided in the applicable agreement or plan of merger, consolidation, dissolution,
liquidation or sale of assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>16.5.</B> <B><U>Assumption of Options by the Company</U></B>. The Company, from time to time, also may
substitute or assume outstanding options granted by another company, whether in connection with an acquisition of such other company or otherwise, by either (i)&nbsp;granting an Option under this Plan in substitution of such other company&#146;s
option, or (ii)&nbsp;assuming such option as if it had been granted under this Plan if the terms of such assumed option could be applied to an Option granted under this Plan. Such substitution or assumption will be permissible if the holder of the
substituted or assumed option would have been eligible to be granted an Option under this Plan if the other company had applied the rules of this Plan to such grant. In the event the Company assumes an option granted by another company, the terms
and conditions of such option will remain unchanged (<U>except</U> that the exercise price and the number and nature of shares issuable upon exercise of any such option will be adjusted appropriately
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to Section&nbsp;424(a) of the Code). In the event the Company elects to grant a new Option rather than assuming an existing option, such new Option may be granted with a similarly
adjusted Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>16.6.</B> <B><U>Parachute Payments</U></B>. Notwithstanding anything in any Option Agreement or Restricted
Stock Agreement to the contrary, if any of such agreements provide for acceleration of the vesting of Shares or other actions with respect to the Shares underlying such agreement (which actions could be deemed a &#147;payment&#148; within the
meaning of 280G(b)(2) of the Internal Revenue Code of 1986, as amended (the &#147;<B><U>Code</U></B>&#148;)), together with any other payments that the Participant has the right to receive from the Company or any entity which is a member of an
&#147;affiliated group&#148; (as defined in Section&nbsp;1504(a) of the Code without regards to Section&nbsp;1504(b) of the Code) of which the Company is a member, would constitute a &#147;parachute payment&#148; (as defined in
Section&nbsp;280G(b)(2) of the Code), such deemed &#147;payments&#148; will be reduced to the largest amount as will result in no portion of such deemed &#147;payments&#148; being subject to the excise tax imposed by Section&nbsp;4999 of the Code;
provided, however, that such &#147;payments&#148; shall only be reduced if such reduction would result in Participant receiving a greater net benefit, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis (including after payment of any
excise tax imposed by Section&nbsp;4999 of the Code), than Participant would have received had such reduction not occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B>
<B><U>ADOPTION AND STOCKHOLDER APPROVAL</U></B>. This Plan will become effective on the date that it is adopted by the Board (the &#147;<B><U>Effective Date</U></B>&#148;). This Plan will be approved by the stockholders of the Company (excluding
Shares issued pursuant to this Plan), consistent with Applicable Laws, within twelve (12)&nbsp;months before or after the Effective Date. Upon the Effective Date, the Committee may grant Awards pursuant to this Plan; provided, however, that:
(i)&nbsp;no Option may be exercised or Restricted Stock purchased prior to initial stockholder approval of this Plan; (ii)&nbsp;no Option or Restricted Stock granted pursuant to an increase in the number of Shares approved by the Committee shall be
exercised or purchased, as applicable prior to the time such increase has been approved by the stockholders of the Company; (iii)&nbsp;in the event that initial stockholder approval is not obtained within the time period provided herein, all Awards
granted hereunder shall be canceled, any Shares issued pursuant to any Award, whether by exercise of an Option or purchase of Restricted Stock, shall be canceled and rescinded; and (iv)&nbsp;Options granted pursuant to an increase in the number of
Shares approved by the Board which increase is not timely approved by stockholders shall be canceled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B><U>TIME OF GRANTING
AWARDS</U></B>. The date of grant of an Award shall, for all purposes, be the date on which the Committee makes the determination granting such Award, or such other date as is determined by the Committee, provided that in the case of any ISO, the
grant date shall be the later of the date on which the Committee makes the determination granting such ISO or the date of commencement of the Participant&#146;s employment relationship with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B><U>TERM OF PLAN/GOVERNING LAW</U>. </B>Unless earlier terminated as provided herein, this Plan will terminate ten
(10)&nbsp;years from the Effective Date or, if earlier, the date of stockholder approval. This Plan and all agreements hereunder shall be governed by and construed in accordance with the laws of the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B><U>AMENDMENT OR TERMINATION OF PLAN</U></B>. Subject to Section&nbsp;5.9
hereof, the Board may at any time terminate or amend this Plan in any respect, including without limitation amendment of any form of Option Agreement, Restricted Stock Purchase Agreement or instrument to be executed pursuant to this Plan. No
amendment of the Plan shall be made that would materially and adversely affect the rights of any Participant under any outstanding Award, without his or her consent. The Board will not, without the approval of the stockholders of the Company, amend
this Plan in any manner that requires such stockholder approval pursuant to Section&nbsp;25102(o) of the California Corporations Code or the Code or the regulations promulgated thereunder as such provisions apply to ISO plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.</B> <B><U>NONEXCLUSIVITY OF THE PLAN</U></B>. Neither the adoption of this Plan by the Board, the submission of this Plan to the
stockholders of the Company for approval, nor any provision of this Plan will be construed as creating any limitations on the power of the Board to adopt such additional compensation arrangements as it may deem desirable, including, without
limitation, the granting of stock options and other equity awards otherwise than under this Plan, and such arrangements may be either generally applicable or applicable only in specific cases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B><U>BENEFICIARIES</U></B>. Unless stated otherwise in an Award agreement, a Participant may designate one or more beneficiaries
with respect to an Award by timely filing the prescribed form with the Company. A beneficiary designation may be changed by filing the prescribed form with the Company at any time before the Participant&#146;s death. If no beneficiary was designated
or if no designated beneficiary survives the Participant, then after a Participant&#146;s death and vested Awards shall be transferred or distributed to the Participant&#146;s estate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>23.</B> <B><U>DEFINITIONS</U>. </B>As used in this Plan, the following terms will have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Applicable Laws</U>&#148; </B>means all applicable laws, rules, regulations and requirements, including, but not limited to, all
applicable U.S. federal or state laws, any stock exchange rules or regulations, and the applicable laws, rules or regulations of any other country or jurisdiction where Awards are granted under the Plan or Participants reside or provide services, as
such laws, rules and regulations shall be in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Award</U>&#148; </B>means any award of an Option or
Restricted Stock under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Board</U>&#148; </B>means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Cause</U>&#148; </B>means, unless otherwise defined in an Option Agreement or Restricted Stock Purchase Agreement, (i)&nbsp;any
willful, material violation by Participant of any law or regulation applicable to the business of the Company (or any successor, subsidiary, parent or affiliate of the Company), (ii) Participant&#146;s conviction for, or guilty or <I>nolo contendere
</I>plea to, any felony or any willful perpetration by Participant of a common law fraud, (iii)&nbsp;Participant&#146;s commission of an act of personal dishonesty which involves personal profit in connection with the Company (or any successor,
subsidiary, parent or affiliate of the Company) or any other entity having a material business relationship with the Company, (iv)&nbsp;a repeated pattern of unexcused absences that causes substantial failure by Participant to perform the material
duties as a director, officer, employee or consultant of the Company, (v)&nbsp;any continued failure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or refusal by Participant to perform the material, lawful, duties required of Participant in his capacity as a director, officer, employee or consultant of the Company (or any successor,
subsidiary, parent or affiliate of the Company if Participant is then primarily employed by such entity) after written notice or (vi)&nbsp;a material breach of any applicable invention assignment and/or confidentiality agreement or similar agreement
that materially damages the Company (or any successor, subsidiary, parent or affiliate of the Company). The determination as to whether a Participant has been Terminated for Cause shall be made in good faith by the Committee and shall be final and
binding on the Participant. The foregoing definition does not in any way limit the Company&#146;s ability to terminate a Participant&#146;s employment or consulting relationship at any time and the term &#147;Company&#148; will be interpreted to
include any Subsidiary, Parent, Affiliate, or any successor thereto, if appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Change of Control</U>&#148; </B>means,
unless otherwise defined in an Option Agreement or Restricted Stock Purchase Agreement, (i)&nbsp;any merger or consolidation in which the Company shall not be the surviving entity (or survives only as a subsidiary of another entity whose
stockholders did not own all or substantially all of the stock of the Company in substantially the same proportions as immediately prior to such transaction), (ii) the sale of all or substantially all of the Company&#146;s assets to any other person
or entity (other than a sale to a wholly-owned subsidiary or a sale of one or more business lines of the Company such that the Company does not liquidate and continues to operate at least one business line after such sale), or (iii)&nbsp;the
acquisition of beneficial ownership of a controlling interest (including, without limitation, power to vote) the outstanding shares of stock of the Company by any person or entity (including a &#147;group&#148; as defined by or under
Section&nbsp;13(d)(3) of the Securities Exchange Act of 1934, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Code</U>&#148; </B>means the Internal Revenue Code
of 1986, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Committee</U>&#148; </B>means the committee created and appointed by the Board to administer this Plan,
or if no such committee is created and appointed, the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Company</U>&#148; </B>means Silverback Therapeutics, Inc., a
Delaware corporation, or any successor corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Common Stock</U>&#148; </B>means the Company&#146;s common stock, par
value $0.0001 per share, as adjusted pursuant to Sections 2 and 16 hereof, and any successor security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Disability</U>&#148;
</B>means disability, within the meaning of Section&nbsp;22(e)(3) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Effective Price</U>&#148; </B>is defined in
Section&nbsp;17 herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Exercise Agreement</U>&#148; </B>is defined in Section&nbsp;5.5 herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Exercise Price</U>&#148; </B>means the price at which a holder of an Option may purchase the Shares issuable upon exercise of the
Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Fair Market Value</U>&#148; </B>means, as of any date, the value of a share of Common Stock determined as follows:
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> if the Common Stock is publicly traded and listed on a national securities
exchange, its closing price on the date of determination on the principal national securities exchange on which the Common Stock is listed or admitted to trading, as reported in<U> The Wall Street Journal</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> if the Common Stock is publicly traded but is not listed or admitted to trading on a national securities exchange, the average of
the closing bid and asked prices on the date of determination as reported by <U>The Wall Street Journal</U> (or, if not so reported, as otherwise reported by any newspaper or other source as the Committee may determine); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> if none of the foregoing is applicable, by the Committee as applied consistently with respect to the Participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Good Reason</U>&#148; </B>means, unless otherwise defined in an Option Agreement or Restricted Stock Purchase Agreement,
(i)&nbsp;the assignment to Participant of duties, or limitation of Participant&#146;s responsibilities, materially inconsistent with his position, duties, responsibilities and status with the Company, <I>provided that </I>neither a mere change in
title alone nor reassignment following a Change in Control to a position that is substantially similar to the position held prior to the transaction shall constitute Good Reason, (ii)&nbsp;a material reduction by the Company of Participant&#146;s
annual base salary, unless such reduction affects all similarly situated employees, or (iii)&nbsp;the relocation of Participant&#146;s principal place of employment to a location that is more than fifty (50)&nbsp;miles further from
Participant&#146;s current principal place of employment; <I>provided however, </I>that in order for circumstances to provide Good Reason for Participant&#146;s resignation, the following additional conditions must be satisfied also:
(A)&nbsp;Participant resigns within six (6)&nbsp;months after the initial occurrence of the circumstance giving rise to Good Reason; (B)&nbsp;Participant provides notice to the Company of the circumstance giving rise to Good Reason within ninety
(90)&nbsp;days after the initial existence of such circumstance; and (C)&nbsp;the Company has a thirty (30)&nbsp;day period in which to cure such circumstance, if it is capable of being cured, and upon any such cure, Participant shall not be
considered to have Good Reason to resign. The determination as to whether a Participant has resigned for Good Reason shall be made in good faith by the Committee and shall be final and binding on the Participant. The term &#147;Company&#148; will be
interpreted to include any Subsidiary, Parent, Affiliate, or any successor thereto, if appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>ISO</U>&#148; </B>is
defined in Section&nbsp;5 above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>NQSO</U>&#148; </B>is defined in Section&nbsp;5 above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Option</U>&#148; </B>means an award of an option to purchase Shares pursuant to Section&nbsp;5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Option Agreement</U>&#148; </B>means a written document, the form(s) of which shall be approved from time to time by the
Committee, reflecting the terms of an Option granted under the Plan and includes any documents attached to such agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Option Exchange Program</U>&#148; </B>means a program approved by the Committee whereby outstanding Options (i)&nbsp;are exchanged
for Options with a lower exercise price or Restricted Stock or (ii)&nbsp;are amended to decrease the exercise price as a result of a decline in the Fair Market Value of the Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Parent</U>&#148; </B>means any corporation (other than the Company) in an
unbroken chain of corporations ending with the Company if, at the time of the grant of the Award, each of such corporations other than the Company owns stock representing fifty percent (50%) or more of the total combined voting power of all classes
of stock in one of the other corporations in such chain; provided, however, that the Committee shall have the discretion to determine that an entity otherwise meeting such definition is not a Parent for purposes of this Plan. A corporation that
attains the status of Parent on a date after the adoption of the Plan shall be considered a Parent commencing as of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Participant</U>&#148; </B>means a person who receives an Award under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Plan</U>&#148; </B>means this 2016 Equity Incentive Plan, as amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Purchase Price</U>&#148; </B>means the price at which Shares may be purchased pursuant to a Restricted Stock Purchase Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Restricted Stock</U>&#148; </B>means Shares acquired pursuant to a right to purchase Shares granted pursuant to
Section&nbsp;6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Restricted Stock Purchase Agreement</U>&#148; </B>means a written document, the form(s) of which shall be
approved from time to time by the Committee, reflecting the terms of Restricted Stock granted under the Plan and includes any documents attached to such agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>SEC</U>&#148; </B>means the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Securities Act</U>&#148; </B>means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Shares</U>&#148; </B>means the shares of Common Stock reserved for issuance under this Plan, as adjusted pursuant to Sections 2
and 16 hereof, and any successor security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Subsidiary</U>&#148; </B>means any corporation (other than the Company) in an
unbroken chain of corporations beginning with the Company if, at the time of the grant of the Award, each of the corporations other than the last corporation in the unbroken chain owns stock representing fifty percent (50%) or more of the total
combined voting power of all classes of stock in one of the other corporations in such chain. A corporation that attains the status of a Subsidiary on a date after the adoption of the Plan shall be considered a Subsidiary commencing as of such date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Termination</U>&#148; </B>or<B> &#147;<U>Terminated</U>&#148; </B>means, for purposes of this Plan with respect to a
Participant, that the Participant has for any reason ceased to provide services as an employee, officer, director or consultant to the Company or a Parent or Subsidiary of the Company, as determined in the sole discretion of the Committee. A
Participant will not be deemed to have ceased to provide services in the case of (i)&nbsp;sick leave, (ii)&nbsp;military leave, or (iii)&nbsp;any other leave of absence approved by the Committee, provided that such leave is for a period of not more
than ninety (90)&nbsp;days (a) unless reinstatement (or, in the case of an employee with an ISO, reemployment) upon the expiration of such leave is guaranteed by contract or statute, or (b)&nbsp;unless provided otherwise pursuant to formal policy
adopted from time to time by the Company&#146;s Board and issued and promulgated in writing. In the case of any Participant on (i)&nbsp;sick leave, (ii)&nbsp;military leave or (iii)&nbsp;an approved leave of absence, the Committee may make
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such provisions respecting suspension of vesting of the Award while on leave from the Company or a Parent or Subsidiary of the Company as it may deem appropriate, except that in no event may an
Award be exercised after the expiration of the term set forth in the Option Agreement or Restricted Stock Purchase Agreement, as applicable. The Committee will have sole discretion to determine when and whether a Participant has ceased to provide
services to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Termination Date</U>&#148; </B>means the date of Termination of a Participant. The Committee will
have sole discretion to determine the Termination Date of a Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Unvested Shares</U>&#148; </B>means shares that have
not vested pursuant to the vesting schedule set forth in a Option Agreement or for which the Company&#146;s repurchase option has not lapsed pursuant to a Restricted Stock Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;<U>Vested Shares</U>&#148; </B>means shares that have vested pursuant to the vesting schedule set forth in the Option Agreement or
for which the Company&#146;s repurchase option has lapsed pursuant to a Restricted Stock Purchase Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF STOCK OPTION GRANT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SILVERBACK THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2016 EQUITY INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Name)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Address)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Address)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Please note any corrections to the address above)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You (the &#147;<B><U>Optionee</U></B>&#148;) have been granted an option (the
&#147;<B><U>Option</U></B>&#148;) to purchase Common Stock of Silverback Therapeutics, Inc., a Delaware corporation (the &#147;<B><U>Company</U></B>&#148;), as follows. This Option is granted under and governed by the terms and conditions of the
Company&#146;s 2016 Equity Incentive Plan (the &#147;<B><U>Plan</U></B>&#148;) and the Stock Option Agreement, both of which are attached as <U>Annex I</U> and <U>Annex II</U> hereto, respectively, and made a part of this document. Unless otherwise
defined herein, any capitalized terms used herein shall have the meanings ascribed to such terms in the Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Approval Date:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of Grant (Later of Board Approval Date or Commencement of Employment/Consulting):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting Commencement Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Price per Share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">$</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Number of Shares Granted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">(the &#147;<B><U>Shares</U></B>&#148;)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Exercise Price:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Type of Option:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">X<SUP STYLE="font-size:85%; vertical-align:top">1</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Incentive Stock Option</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expiration Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Option shall be treated as an Incentive Stock Option to the maximum extent allowable under Internal
Revenue Code Section&nbsp;422 with any excess to be treated as a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="53%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vesting Schedule:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Option may be exercised, in whole or in part, as follows: (a)&nbsp;On the one year anniversary of the Vesting Commencement Date this
Option shall become vested and exercisable as to 1/4th of the Shares; and (b)&nbsp;thereafter, this Option shall become vested and exercisable as to an additional 1/48th of the Shares on each monthly anniversary of the Vesting Commencement Date so
that all the Shares become vested and exercisable within four years of the Vesting Commencement Date.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything set forth above, no Shares shall become exercisable or vested after Optionee&#146;s Termination from the Company. Optionee shall in no
event be entitled under this Option to purchase a number of shares of the Company&#146;s Common Stock greater than the &#147;Total Number of Shares Granted&#148; indicated above. If the application of this vesting schedule results in a fractional
share, such share shall be rounded down to the nearest whole share for each month except for the last month of the Vesting Schedule when the balance of all Shares shall become exercisable and vested.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">All references herein to numbers of shares and the exercise price set forth above shall
be subject to adjustment for any stock dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in the capital structure of the Company as set forth in Section&nbsp;2.2 of the
Plan.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Termination Period:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">To the extent this Option is vested and exercisable as of the Termination Date, this Option may be exercised for a period of up to 90 days after Optionee&#146;s Termination, except as set forth in Sections&nbsp;6 and 7 of the
Stock Option Agreement or as otherwise provided in the Plan (but in no event later than the Expiration Date set forth above).</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By your signature and the signature of the Company&#146;s representative below, you agree
that you have received a copy of the Plan and the Stock Option Agreement, and you and the Company agree that the Option described herein shall be subject to the terms of each of such document. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>OPTIONEE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>SILVERBACK THERAPEUTICS, INC.</B></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[Recipient Name]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">&nbsp;Name: Laura Shawver</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">&nbsp;Title:&nbsp;&nbsp;&nbsp;&nbsp;President and Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to Silverback Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notice of Stock Option Grant (Date of Grant) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ANNEX I TO NOTICE OF STOCK OPTION GRANT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SILVERBACK
THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Grant of Option</U></B>. Silverback Therapeutics, Inc. a Delaware
corporation (the &#147;<B><U>Compan</U></B><B>y</B>&#148;), hereby grants to [Recipient Name] (&#147;<B><U>Optionee</U></B>&#148;), an option (the &#147;<B><U>Option</U></B>&#148;) to purchase up to such number of shares of Common Stock (the
&#147;<B><U>Shares</U></B>&#148;) as is set forth in the Notice of Stock Option Grant, at the exercise price per share set forth in the Notice of Stock Option Grant (the &#147;<B><U>Exercise Price</U></B>&#148;), subject in all cases to the terms,
definitions and provisions of the Silverback Therapeutics, Inc. 2016 Equity Incentive Plan (the &#147;<B><U>Plan</U></B>&#148;) adopted by the Company, which is incorporated herein by reference. Unless otherwise defined herein, any capitalized terms
used herein shall have the meanings ascribed to such terms in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If designated an Incentive Stock Option, this Option is intended
to qualify as an Incentive Stock Option as defined in Section&nbsp;422 of the Internal Revenue Code (the &#147;<B><U>Code</U></B>&#148;), provided, however, to the extent not so designated or if this Option does not qualify as an Incentive Stock
Option, it is intended to be a Nonstatutory Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, in the event that the Shares subject to this Option
and any other Incentive Stock Option granted to the Optionee become exercisable for the first time by Optionee during any calendar year and have an aggregate fair market value (determined for each Share as of the date of grant of each option
covering such Share) in excess of $100,000, then the shares in excess of $100,000 shall be treated as subject to a Nonstatutory Stock Option in accordance with Section&nbsp;5.8 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>Exercise of Option</U></B>. This Option shall be exercisable prior to the Expiration Date set forth in the Notice of Stock
Option Grant in accordance with the Vesting Schedule set out in the Notice of Stock Option Grant and with the provisions of Section&nbsp;7 of the Plan as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Right to Exercise</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> This Option may not be exercised for a fraction of a share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> In the event of Optionee&#146;s death, Disability or other termination of employment, the exercisability of the Option is
governed by Sections&nbsp;5, 6 and 7 below, subject to the limitations contained in Section&nbsp;2(a)(iii) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> In no
event may this Option be exercised after the Expiration Date of this Option as set forth in the Notice of Stock Option Grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
<B><U>Method of Exercise</U></B>. This Option shall be exercisable by execution and delivery of the Exercise Notice attached hereto as <U>Exhibit A</U> (the &#147;<B><U>Exercise Notice</U></B>&#148;) or of any
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other form of written notice approved for such purpose by the Company, in its sole discretion, which shall state the election to exercise the Option, the number of Shares in respect of which the
Option is being exercised, and such other representations and agreements as to the holder&#146;s investment intent with respect to such shares of Common Stock as may be required by the Company pursuant to the provisions of the Plan. Such written
notice shall be signed by Optionee and shall be delivered in person or by certified mail to the Secretary of the Company. The written notice shall be accompanied by payment of the Exercise Price. This Option shall be deemed to be exercised upon
receipt by the Company of such written notice accompanied by the Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Shares will be issued pursuant to the exercise of an
Option unless such issuance and such exercise shall comply with all relevant provisions of applicable law and the requirements of any stock exchange upon which the Shares may then be listed. Assuming such compliance, for income tax purposes the
Shares shall be considered transferred to Optionee on the date on which the Option is exercised with respect to such Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B>
<B><U>Method of Payment</U></B>. Payment of the Exercise Price shall be by any of the following, or a combination thereof, at the election of Optionee by: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> cash or check; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> cancellation of indebtedness of the Company to Optionee; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> only with the approval of the Committee, which may be withheld in its sole discretion, by tender of a full recourse promissory note
having such terms as may be approved by the Committee and bearing interest at a rate sufficient to avoid imputation of income under Sections 483 and 1274 of the Code; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> only with the approval of the Committee, which may be withheld in its sole discretion, surrender of shares of Common Stock of the
Company that&nbsp;have a Fair Market Value on the date of surrender equal to the Exercise Price of the Shares as to which the Option is being exercised; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> if there is a public market for the Shares and they are registered under the Securities Exchange Act, of 1934, as amended, delivery
of a properly executed exercise notice together with irrevocable instructions to a broker to deliver promptly to the Company the amount of sale or loan proceeds required to pay the Exercise Price, such notice to be in a form approved by the
Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U>Restrictions on Exercise</U></B>. This Option may not be exercised until such time as the Plan has been
approved by the stockholders of the Company, or if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation of any applicable federal or state securities or other law or
regulation, including any rule under Part&nbsp;221 of Title&nbsp;12 of the Code of Federal Regulations as promulgated by the Federal Reserve Board. As a condition to the exercise of this Option, the Company may require Optionee to make any
representation and warranty to the Company as may be required by any applicable law or regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Termination of Relationship</U></B>. In the event of Termination of
Optionee, Optionee may, to the extent otherwise so entitled at the Termination Date, exercise this Option during the Termination Period set forth in the Notice of Stock Option Grant or otherwise provided for in the Plan. To the extent that Optionee
was not entitled to exercise this Option at such Termination Date, or if Optionee does not exercise this Option within such Termination Period, the Option shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B><U>Disability of Optionee</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Notwithstanding the provisions of Section&nbsp;5 above, in the event of Termination of Optionee as a result of Optionee&#146;s
total and permanent Disability, Optionee may, but only within twelve (12)&nbsp;months from the Termination Date (but in no event later than the Expiration Date set forth in<I> </I>the Notice of Stock Option Grant), exercise this Option to the extent
Optionee was entitled to exercise it as of such Termination Date. To the extent that Optionee was not entitled to exercise the Option as of the Termination Date, or if Optionee does not exercise such Option (to the extent so entitled) within the
time specified in this Section&nbsp;6(a), the Option shall terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Notwithstanding the provisions of Section&nbsp;5 above,
in the event of Termination of Optionee as a result of Disability not constituting a total and permanent Disability, Optionee may, but only within six (6)&nbsp;months from the Termination Date (but in no event later than the Expiration Date set
forth in the Notice of Stock Option Grant), exercise the Option to the extent Optionee was entitled to exercise it as of such Termination Date; provided, however, that if this is an Incentive Stock Option and Optionee fails to exercise this
Incentive Stock Option within three (3)&nbsp;months from the Termination Date, this Option will cease to qualify as an Incentive Stock Option (as defined in Section&nbsp;422 of the Code) and Optionee will be treated for federal income tax purposes
as having received ordinary income at the time of such exercise in an amount generally measured by the difference between the Exercise Price for the Shares and the Fair Market Value of the Shares on the date of exercise. To the extent that Optionee
was not entitled to exercise the Option at the Termination Date, or if Optionee does not exercise such Option to the extent so entitled within the time specified in this Section&nbsp;6(b), the Option shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B><U>Death of Optionee</U></B>. In<I> </I>the event of the death of Optionee (a)&nbsp;during the term of this Option and while an
employee or consultant of the Company and having been in continuous status as an employee or consultant since the date of grant of the Option, or (b)&nbsp;within thirty (30)&nbsp;days after Optionee&#146;s Termination Date, the Option may be
exercised at any time within six (6)&nbsp;months following the date of death (but in no event later than the Expiration Date set forth in the Notice of Stock Option Grant), by Optionee&#146;s estate or by a person who acquired the right to exercise
the Option by bequest or inheritance, but only to the extent of the right to exercise that had accrued at the Termination Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B>
<B><U><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Option</U></B>. This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of
Optionee only by him or her. The terms of this Option shall be binding upon the executors, administrators, heirs, successors and assigns of Optionee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B><U>Term of Option</U></B>. This Option may be exercised only prior to the
Expiration Date set forth in the Notice of Stock Option Grant, subject to the limitations set forth in Section&nbsp;5 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B><U>Tax Consequences</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Tax Advice</U></B>. OPTIONEE UNDERSTANDS THAT OPTIONEE MAY SUFFER ADVERSE TAX CONSEQUENCES AS A RESULT OF EXERCISE OF THIS
OPTION OR DISPOSITION OF THE SHARES EXERCISED. OPTIONEE REPRESENTS THAT OPTIONEE HAS CONSULTED WITH OR WILL CONSULT WITH ANY TAX CONSULTANT(S) OPTIONEE DEEMS ADVISABLE PRIOR TO THE EXERCISE OF THIS OPTION OR DISPOSITION OF THE EXERCISED SHARES.
OPTIONEE CONFIRMS THAT IT IS NOT RELYING ON THE COMPANY FOR ANY TAX ADVICE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Notice of Disqualifying Disposition of
Incentive Stock Option Shares</U></B>. If the Option granted to Optionee herein is an Incentive Stock Option, and if Optionee sells or otherwise disposes of any of the Shares acquired pursuant to the Incentive Stock Option on or before the later of
(i)&nbsp;the date two (2)&nbsp;years after the Date of Grant, or (ii)&nbsp;the date one (1)&nbsp;year after the date of exercise, Optionee shall immediately notify the Company in writing of such disposition. Optionee acknowledges and agrees that he
or she may be subject to income tax withholding by the Company on the compensation income recognized by Optionee from the early disposition by payment in cash or out of the current earnings paid to Optionee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B><U>Withholding Tax Obligations</U></B>. Prior to the issuance of the Shares upon exercise of this Option, Optionee must pay or
make adequate provision for any applicable federal or state withholding obligations of the Company. If Optionee is subject at the time of exercise of this Option to Section&nbsp;16(b) of the Exchange Act (an &#147;<B><U>Insider</U></B>&#148;),
Optionee may provide for payment of Optionee&#146;s minimum statutory withholding taxes upon exercise of the Option by requesting that the Company retain Shares with a Fair Market Value equal to the minimum amount of taxes required to be withheld,
all as set forth in Section&nbsp;8.2 of the Plan. In such case, the Company shall issue the net number of Shares to Optionee by deducting the Shares retained from the Shares exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B><U>Market Standoff Agreement</U></B>. Optionee agrees in connection with any registration of the Company&#146;s securities that,
upon the request of the Company or the underwriters managing any public offering of the Company&#146;s securities, Optionee will not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of
the Company (other than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may be, for such period of time after the effective date of such registration and subject to all
restrictions as the Company or the underwriters may specify for <FONT STYLE="white-space:nowrap">employee-shareholders</FONT> generally. Optionee agrees to execute an agreement reflecting the foregoing as may be requested by the underwriters at the
time of the Company&#146;s public offering. Optionee further agrees that the Company may impose <FONT STYLE="white-space:nowrap">stop-transfer</FONT> instructions with respect to securities subject to the foregoing restrictions until the end of such
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B><U>Limitations on Transfer of Exercised Shares</U></B>. In addition to any other limitation on transfer created by
applicable securities laws, following exercise of this Option, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Optionee shall not assign, encumber or dispose of any interest in the exercised Shares except in compliance with the provisions below and applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Right of First Refusal</U></B>.<B> </B>Before any Shares exercised by Optionee or held by any transferee of Optionee (either
being sometimes referred to herein as the &#147;<B><U>Holder</U></B>&#148;) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall have a right of first refusal to purchase such
Shares on the terms and conditions set forth in this Section&nbsp;13(a) (the &#147;<B><U>Right of First Refusal</U></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><U>Notice of Proposed Transfer</U></B>. The Holder of the Shares shall deliver to the Company a written notice (the
&#147;<B><U>Notice</U></B>&#148;) stating: (i)&nbsp;the Holder&#146;s bona fide intention to sell or otherwise transfer such Shares; (ii)&nbsp;the name of each proposed purchaser or other transferee (&#147;<B><U>Proposed Transferee</U></B>&#148;);
(iii)&nbsp;the number of Shares to be transferred to each Proposed Transferee; and (iv)&nbsp;the terms and conditions of each proposed sale or transfer. The Holder shall offer the Shares at the same price (the &#147;<B><U>Offered
Price</U></B>&#148;) and upon the same terms (or terms as similar as reasonably possible) to the Company or its assignee(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>
<B><U>Exercise of Right of First Refusal</U></B>. At any time within 30 days after receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares
proposed to be transferred to any one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection&nbsp;(iii) below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B><U>Purchase Price</U></B>. The purchase price (&#147;<B><U>Purchase Price</U></B>&#148;) for the Shares purchased by the
Company or its assignee(s) under this Section&nbsp;13(a) shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent value of the <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration shall
be determined by the Board of Directors of the Company in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B><U>Payment</U></B>. Payment of the Purchase Price
shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the assignee), or
by any combination thereof within 30 days after receipt of the Notice or in the manner and at the times set forth in the Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B><U>Holder&#146;s Right to Transfer</U></B>. If all of the Shares proposed in the Notice to be transferred to a given Proposed
Transferee are not purchased by the Company and/or its assignee(s) as provided in this Section&nbsp;13(a), then the Holder may sell or otherwise transfer such Shares to that Proposed Transferee at the Offered Price or at a higher price, provided
that such sale or other transfer is consummated within 60 days after the date of the Notice and provided further that any such sale or other transfer is effected in accordance with any applicable securities laws and the Proposed Transferee agrees in
writing that the provisions of this Section&nbsp;13 shall continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not transferred to the Proposed Transferee within such period, or if the
Holder proposes to change the price or other terms to make them more favorable to the Proposed Transferee, a new Notice shall be given to the Company, and the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and/or its assignees shall again be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> <B><U>Exception for Certain Family Transfers</U></B>. Anything to the contrary contained in this Section&nbsp;13(a)
notwithstanding, the transfer of any or all of the Shares during Optionee&#146;s lifetime or on Optionee&#146;s death by will or intestacy to Optionee&#146;s Immediate Family (as defined below) or a trust for the benefit of Optionee&#146;s Immediate
Family shall be exempt from the provisions of this Section&nbsp;13(a). &#147;<B><U>Immediate Family</U></B>&#148; as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister. In such case, the transferee or
other recipient shall receive and hold the Shares so transferred subject to the provisions of this Section, and there shall be no further transfer of such Shares except in accordance with the terms of this Section&nbsp;13. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Involuntary Transfer</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><U>Company&#146;s Right to Purchase upon Involuntary Transfer</U></B>.<B> </B>In the event, at any time after the date of this
Agreement, of any transfer by operation of law or other involuntary transfer (including divorce or death, but excluding, in the event of death, a transfer to Immediate Family as set forth in Section&nbsp;13(a)(vi) above) of all or a portion of the
Shares by the record holder thereof, the Company shall have the right to purchase all of the Shares transferred at the greater of the purchase price paid by Optionee pursuant to this Agreement or the Fair Market Value of the Shares on the date of
transfer (as determined below). Upon such a transfer, the person acquiring the Shares shall promptly notify the Secretary of the Company of such transfer. The right to purchase such Shares shall be provided to the Company for a period of 30 days
following receipt by the Company of written notice by the person acquiring the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B><U>Price for Involuntary
Transfer</U></B>. <B></B>With respect to any stock to be transferred pursuant to Section&nbsp;13(b)(i), &#147;<B><U>Fair Market Value</U></B>&#148; shall mean the price per Share determined by the Board of Directors of the Company that will reflect
the current value of the stock in terms of present earnings and future prospects of the Company. The Company shall notify Optionee or his or her executor of the price so determined within 30 days after receipt by it of written notice of the transfer
or proposed transfer of Shares. However, if Optionee does not agree with the valuation as determined by the Board of Directors of the Company, Optionee shall be entitled to have the valuation determined by an independent appraiser to be mutually
agreed upon by the Company and Optionee and whose fees shall be borne equally by the Company and Optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B><U>Assignment</U></B>. The right of the Company to purchase any part of the Shares may be assigned in whole or in part to any stockholder or stockholders of the Company or other persons or organizations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><U>Restrictions Binding on Transferees</U></B>.<B> </B>All transferees of Shares or any interest therein will receive and hold
such Shares or interest subject to the provisions of this Agreement. Any sale or transfer of the Shares shall be void unless the provisions of this Agreement are satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><U>Termination of Rights</U></B>. The Right of First Refusal and the
Company&#146;s right to repurchase the Shares in the event of an involuntary transfer pursuant to Section&nbsp;13(b) above shall terminate upon the first sale of Common Stock of the Company to the general public pursuant to a registration statement
filed with and declared effective by the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;<B><U>Securities Act</U></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B><U>Ancillary Agreements</U></B>.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Voting Agreement</U></B>. <B></B>As a condition to receipt of this Option, and concurrently with the execution of this
Option, Optionee hereby agrees that Optionee shall be deemed to be a &#147;Common Holder&#148; under, and shall be bound by the provisions of, the Amended and Restated Voting Agreement dated March&nbsp;4, 2020, by and among the Company and certain
equityholders of the Company party thereto, as such agreement may be amended, modified or superseded from time to time (the &#147;<B><U>Voting Agreement</U></B>&#148;), including without limitation the drag-along provisions under such agreement.
Optionee also agrees to execute a counterpart signature page to the Voting Agreement concurrently with the execution of this Option or at any other time if requested. A copy of the Voting Agreement is available from the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U><FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement</U></B>.<B> </B>In addition, Optionee hereby agrees that if
Optionee is at any time issued shares of the Company&#146;s Common Stock upon exercise of this Option and such issued shares constitute one percent (1%) or more of the Company&#146;s then outstanding Common Stock (taking into account this Option and
all other shares of Common Stock, options and other purchase rights held by such employee, director or consultant and treating for this purpose all shares of Common Stock issuable upon exercise of or conversion of outstanding options, warrants or
convertible securities held by Optionee and other parties, as if exercised or converted) or such person is an officer of the Company, as a condition to exercise of this Option, and concurrently with the exercise of this Option or at such time as
Optionee exceeds such ownership threshold, Optionee shall be deemed to be a &#147;Common Holder&#148; under, and shall be bound by the provisions of, the Amended and Restated Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT>
Agreement dated March&nbsp;4, 2020 by and among the Company and certain equityholders of the Company party thereto, as such agreement may be amended, modified or superseded from time to time (the
&#147;<B><U><FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement</U></B>&#148;), including without limitation the transfer restrictions under such agreement. In such case, Optionee also agrees to execute a counterpart signature page to the <FONT
STYLE="white-space:nowrap">Co-Sale</FONT> Agreement concurrently with the exercise of this Option or at any other time if requested. A copy of the <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement is available from the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B><U>Miscellaneous</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Governing Law</U></B>. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the
parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Entire Agreement; Enforcement of Rights</U></B>. The Plan and the Option Notice are hereby incorporated by reference in this
Agreement. This Agreement (including the Plan and the Option Notice) sets forth the entire agreement and understanding of the parties relating to the subject matter herein and merges all prior discussions between them. No
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the parties to this Agreement. The failure by
either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B><U>Severability</U></B>. If one or more provisions of this Agreement are held to be<U> </U>unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually
agreeable and enforceable replacement for such provision, then (i)&nbsp;such provision shall be excluded from this Agreement, (ii)&nbsp;the balance of the Agreement shall be interpreted as if such provision were so excluded and (iii)&nbsp;the
balance of the Agreement shall be enforceable in accordance with its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><U>Construction</U></B>. This Agreement is the
result of negotiations between and has been reviewed by each of the parties hereto and their respective counsel, if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be construed
in favor of or against any one of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><U>Notices</U></B>. Any notice required or permitted by this
Agreement shall be in writing and shall be deemed sufficient when delivered personally or sent by telegram or fax or 48 hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, and addressed to the party
to be notified at such party&#146;s address as set forth below or as subsequently modified by written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>
<B><U>Counterparts</U></B>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><U>Successors and Assigns</U></B>. The rights and benefits of this Agreement shall inure to the benefit of, and be enforceable
by the Company&#146;s successors and assigns. The rights and obligations of Optionee under this Agreement may only be assigned with the prior written consent of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><U>No Obligation to Continue Employment or Consultancy</U></B>. Nothing in this Agreement will confer or be deemed to confer on
Optionee any right to continue in the employ of, or to continue any other relationship with, the Company, be deemed to modify Optionee&#146;s <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> status with the Company, or limit in any way
the right of the Company to terminate Optionee&#146;s employment or other relationship at any time, with or without cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>
<B><U>Incorporation of Plan</U></B>. This Option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of this Option, and is further subject to all interpretations, amendments, rules and regulations, which may
from time to time be promulgated and adopted by the Committee pursuant to the Plan. In the event of any conflict between the provisions of this Option and those of the Plan, the provisions of the Plan shall control unless expressly provided in the
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original and all of which together shall constitute one document. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SILVERBACK THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Laura Shawver</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OPTIONEE ACKNOWLEDGES AND AGREES THAT THE VESTING OF ANY SHARES ISSUED PURSUANT TO THIS OPTION IS EARNED
ONLY BY CONTINUING EMPLOYMENT OR CONSULTANCY AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER). OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN
THE PLAN, WHICH IS INCORPORATED HEREIN BY REFERENCE, SHALL CONFER UPON OPTIONEE ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT OR CONSULTANCY BY THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH OPTIONEE&#146;S RIGHT OR THE COMPANY&#146;S
RIGHT TO TERMINATE OPTIONEE&#146;S EMPLOYMENT OR CONSULTANCY AT ANY TIME, WITH OR WITHOUT CAUSE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Optionee acknowledges receipt of a copy
of the Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Option subject to all of the terms and provisions thereof. Optionee has reviewed the Plan and this Option in their entirety, has had
an opportunity to obtain the advice of counsel prior to executing this Option and fully understands all provisions of the Option. Optionee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee
upon any questions arising under the Plan or this Option. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: ____________________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">_______________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[Recipient Name]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to Silverback Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stock Option Agreement (Date of Grant) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF STOCK OPTION GRANT </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SILVERBACK THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2016 EQUITY INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Name)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Address)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Address)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Please note any corrections to the address above)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You (the &#147;<B><U>Optionee</U></B>&#148;) have been granted an option (the
&#147;<B><U>Option</U></B>&#148;) to purchase Common Stock of Silverback Therapeutics, Inc., a Delaware corporation (the &#147;<B><U>Company</U></B>&#148;), as follows. This Option is granted under and governed by the terms and conditions of the
Company&#146;s 2016 Equity Incentive Plan (the &#147;<B><U>Plan</U></B>&#148;) and the Stock Option Agreement, both of which are attached as <U>Annex I</U> and <U>Annex II</U> hereto, respectively, and made a part of this document. Unless otherwise
defined herein, any capitalized terms used herein shall have the meanings ascribed to such terms in the Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Approval Date:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of Grant (Later of Board Approval Date or Commencement of Employment/Consulting):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting Commencement Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Price per Share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">$</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Number of Shares Granted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">(the &#147;<B><U>Shares</U></B>&#148;)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Exercise Price:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Type of Option:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">X<SUP STYLE="font-size:85%; vertical-align:top">1</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Incentive Stock Option</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option<B></B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expiration Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Option shall be treated as an Incentive Stock Option to the maximum extent allowable under Internal
Revenue Code Section&nbsp;422 with any excess to be treated as a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="53%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vesting Schedule:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Option may be exercised, in whole or in part, as follows: (a)&nbsp;On the one year anniversary of the Vesting Commencement Date this
Option shall become vested and exercisable as to 1/4th of the Shares; and (b)&nbsp;thereafter, this Option shall become vested and exercisable as to an additional 1/48th of the Shares on each monthly anniversary of the Vesting Commencement Date so
that all the Shares become vested and exercisable within four years of the Vesting Commencement Date.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything set forth above, no Shares shall become exercisable or vested after Optionee&#146;s Termination from the Company. Optionee shall in no
event be entitled under this Option to purchase a number of shares of the Company&#146;s Common Stock greater than the &#147;Total Number of Shares Granted&#148; indicated above. If the application of this vesting schedule results in a fractional
share, such share shall be rounded down to the nearest whole share for each month except for the last month of the Vesting Schedule when the balance of all Shares shall become exercisable and vested.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">All references herein to numbers of shares and the exercise price set forth above shall
be subject to adjustment for any stock dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in the capital structure of the Company as set forth in Section&nbsp;2.2 of the
Plan.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Accelerated Vesting:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">In the event that at any time while any of the Shares are not yet vested and Optionee has not been previously Terminated: (x)&nbsp;the Company undergoes a Change of Control (as such term is defined in the Plan), and (y)&nbsp;upon
or within the twelve (12)&nbsp;month period after such Change of Control, Optionee is Terminated without Cause (as such term is defined in the Plan) or Optionee has Terminated his or her services for Good Reason (as such term is defined in the
Plan), then upon the date that a release and waiver of claims in a form acceptable to the Company, or its successor, and signed by Optionee is no longer revocable by Optionee, automatically and without any further action on the part of the</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company or Optionee, one hundred percent (100%) of the then unvested shares underlying this Option shall be deemed to be exercisable and
no longer subject to vesting requirements.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><B>Section</B><B></B><B>&nbsp;280G</B></U>.&nbsp;If any payments and other benefits provided for in this Notice of Stock Option Grant or otherwise
constitute &#147;parachute payments&#148; within the meaning of Section&nbsp;280G of the Internal Revenue Code of 1986, as amended (the &#147;<B><U>Code</U></B>&#148;) and, but for the paragraphs herein regarding accelerated vesting of the Option,
would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then payments and other benefits will be payable to Optionee, at Optionee&#146;s election, either in full or in such lesser amounts as would result, after taking into
account the applicable federal, state and local income taxes and the excise tax imposed by Section&nbsp;4999, on Optionee&#146;s receipt on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis of the greatest amount of payments and other
benefits, by first reducing the cash payments and then reducing the equity grants, in each case, pro rata between amounts subject to Section&nbsp;409A (&#147;<B><U>&#167; 409A</U></B>&#148;) and amounts not subject to &#167; 409A.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U><B>Section</B><B></B><B>&nbsp;409A</B></U>.&nbsp;Notwithstanding any other term in
this Notice of Stock Option Grant, if, at the time of Optionee&#146;s separation of employment, Optionee is a &#147;specified employee,&#148; as defined in Treasury Regulation &#167; <FONT STYLE="white-space:nowrap">1.409A-1(i),</FONT> to the extent
delayed commencement of any portion of the payments or benefits to which Optionee is entitled under this Notice of Stock Option Grant is required in order to avoid a prohibited distribution under 26 U.S.C. &#167; 409A(a)(2)(B)(i), that portion of
Optionee&#146;s benefits shall not be provided to Optionee before the earlier of (a)&nbsp;six (6) months and one day after Optionee&#146;s separation, or (b)&nbsp;the date of Optionee&#146;s death, as applicable.&nbsp;All payments deferred pursuant
to this Notice of Stock Option Grant shall be paid in a lump sum to you on the date which is six months and one day after Optionee&#146;s separation or the date of Optionee&#146;s death, as applicable, and any remaining payments due under Notice of
Stock Option Grant shall be paid as required by this</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="53%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice of Stock Option Grant.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Each payment and benefit paid pursuant to this Notice of Stock Option Grant shall constitute a &#147;separate payment&#148; for purposes of Treasury Regulation
&#167; <FONT STYLE="white-space:nowrap">1.409A-2(b)(2).</FONT> This Notice of Stock Option Grant and the Stock Option Agreement attached hereto shall be construed in a manner that complies with &#167; 409A and the United States Treasury
Department&#146;s implementing regulations for &#167; 409A so that none of the payments and benefits provided under this Notice of Stock Option Grant will be subject to the additional tax imposed under &#167; 409A.&nbsp;All ambiguities herein shall
be interpreted to comply with &#167; 409A and the Treasury Department&#146;s implementing regulations for &#167; 409A. The Company and Optionee shall cooperate, in good faith, to take all reasonable actions, including amending this Notice of Stock
Option Grant, which are necessary to avoid imposition of any additional tax under &#167; 409A.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Early Exercise:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Notwithstanding the Section titled Vesting Schedule above, Optionee may elect at any time before the Termination of Participant to exercise the Option as to any part or all of the Shares subject to the Option prior to the full
vesting of such Shares. Any unvested Shares so purchased shall be subject to repurchase by the Company at the exercise price therefor and to all other terms or restrictions the Committee determines to be appropriate, and the Optionee shall be
required to execute an early exercise restricted stock purchase agreement in a form approved by the Committee in its sole discretion.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Termination Period:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">To the extent this Option is vested and exercisable as of the Termination Date, this Option may be exercised for a period of up to 90 days after Optionee&#146;s Termination, except as set forth in Sections&nbsp;6 and 7 of the Stock
Option Agreement or as otherwise provided in the Plan (but in no event later than the Expiration Date set forth above).</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By your signature and the signature of the Company&#146;s representative below, you agree
that you have received a copy of the Plan and the Stock Option Agreement, and you and the Company agree that the Option described herein shall be subject to the terms of each of such document. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>OPTIONEE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>SILVERBACK THERAPEUTICS, INC.</B></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[Recipient Name]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">&nbsp;Name: Laura Shawver</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">&nbsp;Title:&nbsp;&nbsp;&nbsp;&nbsp;President and Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to Silverback Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notice of Stock Option Grant (Date of Grant) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ANNEX I TO NOTICE OF STOCK OPTION GRANT </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SILVERBACK
THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Grant of Option</U></B>. Silverback Therapeutics, Inc. a Delaware
corporation (the &#147;<B><U>Compan</U></B><B>y</B>&#148;), hereby grants to [Recipient Name] (&#147;<B><U>Optionee</U></B>&#148;), an option (the &#147;<B><U>Option</U></B>&#148;) to purchase up to such number of shares of Common Stock (the
&#147;<B><U>Shares</U></B>&#148;) as is set forth in the Notice of Stock Option Grant, at the exercise price per share set forth in the Notice of Stock Option Grant (the &#147;<B><U>Exercise Price</U></B>&#148;), subject in all cases to the terms,
definitions and provisions of the Silverback Therapeutics, Inc. 2016 Equity Incentive Plan (the &#147;<B><U>Plan</U></B>&#148;) adopted by the Company, which is incorporated herein by reference. Unless otherwise defined herein, any capitalized terms
used herein shall have the meanings ascribed to such terms in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If designated an Incentive Stock Option, this Option is intended
to qualify as an Incentive Stock Option as defined in Section&nbsp;422 of the Internal Revenue Code (the &#147;<B><U>Code</U></B>&#148;), provided, however, to the extent not so designated or if this Option does not qualify as an Incentive Stock
Option, it is intended to be a Nonstatutory Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, in the event that the Shares subject to this Option
and any other Incentive Stock Option granted to the Optionee become exercisable for the first time by Optionee during any calendar year and have an aggregate fair market value (determined for each Share as of the date of grant of each option
covering such Share) in excess of $100,000, then the shares in excess of $100,000 shall be treated as subject to a Nonstatutory Stock Option in accordance with Section&nbsp;5.8 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>Exercise of Option</U></B>. This Option shall be exercisable prior to the Expiration Date set forth in the Notice of Stock
Option Grant in accordance with the Vesting Schedule set out in the Notice of Stock Option Grant and with the provisions of Section&nbsp;7 of the Plan as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Right to Exercise</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> This Option may not be exercised for a fraction of a share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> In the event of Optionee&#146;s death, Disability or other termination of employment, the exercisability of the Option is
governed by Sections&nbsp;5, 6 and 7 below, subject to the limitations contained in Section&nbsp;2(a)(iii) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> In no
event may this Option be exercised after the Expiration Date of this Option as set forth in the Notice of Stock Option Grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
<B><U>Method of Exercise</U></B>. This Option shall be exercisable by execution and delivery of the Exercise Notice attached hereto as <U>Exhibit A</U> (the &#147;<B><U>Exercise Notice</U></B>&#148;) or of any
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other form of written notice approved for such purpose by the Company, in its sole discretion, which shall state the election to exercise the Option, the number of Shares in respect of which the
Option is being exercised, and such other representations and agreements as to the holder&#146;s investment intent with respect to such shares of Common Stock as may be required by the Company pursuant to the provisions of the Plan. Such written
notice shall be signed by Optionee and shall be delivered in person or by certified mail to the Secretary of the Company. The written notice shall be accompanied by payment of the Exercise Price. This Option shall be deemed to be exercised upon
receipt by the Company of such written notice accompanied by the Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Shares will be issued pursuant to the exercise of an
Option unless such issuance and such exercise shall comply with all relevant provisions of applicable law and the requirements of any stock exchange upon which the Shares may then be listed. Assuming such compliance, for income tax purposes the
Shares shall be considered transferred to Optionee on the date on which the Option is exercised with respect to such Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B>
<B><U>Method of Payment</U></B>. Payment of the Exercise Price shall be by any of the following, or a combination thereof, at the election of Optionee by: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> cash or check; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> cancellation of indebtedness of the Company to Optionee; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> only with the approval of the Committee, which may be withheld in its sole discretion, by tender of a full recourse promissory note
having such terms as may be approved by the Committee and bearing interest at a rate sufficient to avoid imputation of income under Sections 483 and 1274 of the Code; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> only with the approval of the Committee, which may be withheld in its sole discretion, surrender of shares of Common Stock of the
Company that&nbsp;have a Fair Market Value on the date of surrender equal to the Exercise Price of the Shares as to which the Option is being exercised; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> if there is a public market for the Shares and they are registered under the Securities Exchange Act, of 1934, as amended, delivery
of a properly executed exercise notice together with irrevocable instructions to a broker to deliver promptly to the Company the amount of sale or loan proceeds required to pay the Exercise Price, such notice to be in a form approved by the
Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U>Restrictions on Exercise</U></B>. This Option may not be exercised until such time as the Plan has been
approved by the stockholders of the Company, or if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation of any applicable federal or state securities or other law or
regulation, including any rule under Part&nbsp;221 of Title&nbsp;12 of the Code of Federal Regulations as promulgated by the Federal Reserve Board. As a condition to the exercise of this Option, the Company may require Optionee to make any
representation and warranty to the Company as may be required by any applicable law or regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Termination of Relationship</U></B>. In the event of Termination of
Optionee, Optionee may, to the extent otherwise so entitled at the Termination Date, exercise this Option during the Termination Period set forth in the Notice of Stock Option Grant or otherwise provided for in the Plan. To the extent that Optionee
was not entitled to exercise this Option at such Termination Date, or if Optionee does not exercise this Option within such Termination Period, the Option shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B><U>Disability of Optionee</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Notwithstanding the provisions of Section&nbsp;5 above, in the event of Termination of Optionee as a result of Optionee&#146;s
total and permanent Disability, Optionee may, but only within twelve (12)&nbsp;months from the Termination Date (but in no event later than the Expiration Date set forth in<I> </I>the Notice of Stock Option Grant), exercise this Option to the extent
Optionee was entitled to exercise it as of such Termination Date. To the extent that Optionee was not entitled to exercise the Option as of the Termination Date, or if Optionee does not exercise such Option (to the extent so entitled) within the
time specified in this Section&nbsp;6(a), the Option shall terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Notwithstanding the provisions of Section&nbsp;5 above,
in the event of Termination of Optionee as a result of Disability not constituting a total and permanent Disability, Optionee may, but only within six (6)&nbsp;months from the Termination Date (but in no event later than the Expiration Date set
forth in the Notice of Stock Option Grant), exercise the Option to the extent Optionee was entitled to exercise it as of such Termination Date; provided, however, that if this is an Incentive Stock Option and Optionee fails to exercise this
Incentive Stock Option within three (3)&nbsp;months from the Termination Date, this Option will cease to qualify as an Incentive Stock Option (as defined in Section&nbsp;422 of the Code) and Optionee will be treated for federal income tax purposes
as having received ordinary income at the time of such exercise in an amount generally measured by the difference between the Exercise Price for the Shares and the Fair Market Value of the Shares on the date of exercise. To the extent that Optionee
was not entitled to exercise the Option at the Termination Date, or if Optionee does not exercise such Option to the extent so entitled within the time specified in this Section&nbsp;6(b), the Option shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B><U>Death of Optionee</U></B>. In<I> </I>the event of the death of Optionee (a)&nbsp;during the term of this Option and while an
employee or consultant of the Company and having been in continuous status as an employee or consultant since the date of grant of the Option, or (b)&nbsp;within thirty (30)&nbsp;days after Optionee&#146;s Termination Date, the Option may be
exercised at any time within six (6)&nbsp;months following the date of death (but in no event later than the Expiration Date set forth in the Notice of Stock Option Grant), by Optionee&#146;s estate or by a person who acquired the right to exercise
the Option by bequest or inheritance, but only to the extent of the right to exercise that had accrued at the Termination Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B>
<B><U><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Option</U></B>. This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of
Optionee only by him or her. The terms of this Option shall be binding upon the executors, administrators, heirs, successors and assigns of Optionee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B><U>Term of Option</U></B>. This Option may be exercised only prior to the
Expiration Date set forth in the Notice of Stock Option Grant, subject to the limitations set forth in Section&nbsp;5 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B><U>Tax Consequences</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Tax Advice</U></B>. OPTIONEE UNDERSTANDS THAT OPTIONEE MAY SUFFER ADVERSE TAX CONSEQUENCES AS A RESULT OF EXERCISE OF THIS
OPTION OR DISPOSITION OF THE SHARES EXERCISED. OPTIONEE REPRESENTS THAT OPTIONEE HAS CONSULTED WITH OR WILL CONSULT WITH ANY TAX CONSULTANT(S) OPTIONEE DEEMS ADVISABLE PRIOR TO THE EXERCISE OF THIS OPTION OR DISPOSITION OF THE EXERCISED SHARES.
OPTIONEE CONFIRMS THAT IT IS NOT RELYING ON THE COMPANY FOR ANY TAX ADVICE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Notice of Disqualifying Disposition of
Incentive Stock Option Shares</U></B>. If the Option granted to Optionee herein is an Incentive Stock Option, and if Optionee sells or otherwise disposes of any of the Shares acquired pursuant to the Incentive Stock Option on or before the later of
(i)&nbsp;the date two (2)&nbsp;years after the Date of Grant, or (ii)&nbsp;the date one (1)&nbsp;year after the date of exercise, Optionee shall immediately notify the Company in writing of such disposition. Optionee acknowledges and agrees that he
or she may be subject to income tax withholding by the Company on the compensation income recognized by Optionee from the early disposition by payment in cash or out of the current earnings paid to Optionee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B><U>Withholding Tax Obligations</U></B>. Prior to the issuance of the Shares upon exercise of this Option, Optionee must pay or
make adequate provision for any applicable federal or state withholding obligations of the Company. If Optionee is subject at the time of exercise of this Option to Section&nbsp;16(b) of the Exchange Act (an &#147;<B><U>Insider</U></B>&#148;),
Optionee may provide for payment of Optionee&#146;s minimum statutory withholding taxes upon exercise of the Option by requesting that the Company retain Shares with a Fair Market Value equal to the minimum amount of taxes required to be withheld,
all as set forth in Section&nbsp;8.2 of the Plan. In such case, the Company shall issue the net number of Shares to Optionee by deducting the Shares retained from the Shares exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B><U>Market Standoff Agreement</U></B>. Optionee agrees in connection with any registration of the Company&#146;s securities that,
upon the request of the Company or the underwriters managing any public offering of the Company&#146;s securities, Optionee will not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of
the Company (other than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may be, for such period of time after the effective date of such registration and subject to all
restrictions as the Company or the underwriters may specify for <FONT STYLE="white-space:nowrap">employee-shareholders</FONT> generally. Optionee agrees to execute an agreement reflecting the foregoing as may be requested by the underwriters at the
time of the Company&#146;s public offering. Optionee further agrees that the Company may impose <FONT STYLE="white-space:nowrap">stop-transfer</FONT> instructions with respect to securities subject to the foregoing restrictions until the end of such
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B><U>Limitations on Transfer of Exercised Shares</U></B>. In addition to any other limitation on transfer created by
applicable securities laws, following exercise of this Option, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Optionee shall not assign, encumber or dispose of any interest in the exercised Shares except in compliance with the provisions below and applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Right of First Refusal</U></B>.<B> </B>Before any Shares exercised by Optionee or held by any transferee of Optionee (either
being sometimes referred to herein as the &#147;<B><U>Holder</U></B>&#148;) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall have a right of first refusal to purchase such
Shares on the terms and conditions set forth in this Section&nbsp;13(a) (the &#147;<B><U>Right of First Refusal</U></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><U>Notice of Proposed Transfer</U></B>. The Holder of the Shares shall deliver to the Company a written notice (the
&#147;<B><U>Notice</U></B>&#148;) stating: (i)&nbsp;the Holder&#146;s bona fide intention to sell or otherwise transfer such Shares; (ii)&nbsp;the name of each proposed purchaser or other transferee (&#147;<B><U>Proposed Transferee</U></B>&#148;);
(iii)&nbsp;the number of Shares to be transferred to each Proposed Transferee; and (iv)&nbsp;the terms and conditions of each proposed sale or transfer. The Holder shall offer the Shares at the same price (the &#147;<B><U>Offered
Price</U></B>&#148;) and upon the same terms (or terms as similar as reasonably possible) to the Company or its assignee(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>
<B><U>Exercise of Right of First Refusal</U></B>. At any time within 30 days after receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares
proposed to be transferred to any one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection&nbsp;(iii) below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B><U>Purchase Price</U></B>. The purchase price (&#147;<B><U>Purchase Price</U></B>&#148;) for the Shares purchased by the
Company or its assignee(s) under this Section&nbsp;13(a) shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent value of the <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration shall
be determined by the Board of Directors of the Company in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B><U>Payment</U></B>. Payment of the Purchase Price
shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the assignee), or
by any combination thereof within 30 days after receipt of the Notice or in the manner and at the times set forth in the Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B><U>Holder&#146;s Right to Transfer</U></B>. If all of the Shares proposed in the Notice to be transferred to a given Proposed
Transferee are not purchased by the Company and/or its assignee(s) as provided in this Section&nbsp;13(a), then the Holder may sell or otherwise transfer such Shares to that Proposed Transferee at the Offered Price or at a higher price, provided
that such sale or other transfer is consummated within 60 days after the date of the Notice and provided further that any such sale or other transfer is effected in accordance with any applicable securities laws and the Proposed Transferee agrees in
writing that the provisions of this Section&nbsp;13 shall continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not transferred to the Proposed Transferee within such period, or if the
Holder proposes to change the price or other terms to make them more favorable to the Proposed Transferee, a new Notice shall be given to the Company, and the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and/or its assignees shall again be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> <B><U>Exception for Certain Family Transfers</U></B>. Anything to the contrary contained in this Section&nbsp;13(a)
notwithstanding, the transfer of any or all of the Shares during Optionee&#146;s lifetime or on Optionee&#146;s death by will or intestacy to Optionee&#146;s Immediate Family (as defined below) or a trust for the benefit of Optionee&#146;s Immediate
Family shall be exempt from the provisions of this Section&nbsp;13(a). &#147;<B><U>Immediate Family</U></B>&#148; as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister. In such case, the transferee or
other recipient shall receive and hold the Shares so transferred subject to the provisions of this Section, and there shall be no further transfer of such Shares except in accordance with the terms of this Section&nbsp;13. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Involuntary Transfer</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><U>Company&#146;s Right to Purchase upon Involuntary Transfer</U></B>.<B> </B>In the event, at any time after the date of this
Agreement, of any transfer by operation of law or other involuntary transfer (including divorce or death, but excluding, in the event of death, a transfer to Immediate Family as set forth in Section&nbsp;13(a)(vi) above) of all or a portion of the
Shares by the record holder thereof, the Company shall have the right to purchase all of the Shares transferred at the greater of the purchase price paid by Optionee pursuant to this Agreement or the Fair Market Value of the Shares on the date of
transfer (as determined below). Upon such a transfer, the person acquiring the Shares shall promptly notify the Secretary of the Company of such transfer. The right to purchase such Shares shall be provided to the Company for a period of 30 days
following receipt by the Company of written notice by the person acquiring the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B><U>Price for Involuntary
Transfer</U></B>. <B></B>With respect to any stock to be transferred pursuant to Section&nbsp;13(b)(i), &#147;<B><U>Fair Market Value</U></B>&#148; shall mean the price per Share determined by the Board of Directors of the Company that will reflect
the current value of the stock in terms of present earnings and future prospects of the Company. The Company shall notify Optionee or his or her executor of the price so determined within 30 days after receipt by it of written notice of the transfer
or proposed transfer of Shares. However, if Optionee does not agree with the valuation as determined by the Board of Directors of the Company, Optionee shall be entitled to have the valuation determined by an independent appraiser to be mutually
agreed upon by the Company and Optionee and whose fees shall be borne equally by the Company and Optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B><U>Assignment</U></B>. The right of the Company to purchase any part of the Shares may be assigned in whole or in part to any stockholder or stockholders of the Company or other persons or organizations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><U>Restrictions Binding on Transferees</U></B>.<B> </B>All transferees of Shares or any interest therein will receive and hold
such Shares or interest subject to the provisions of this Agreement. Any sale or transfer of the Shares shall be void unless the provisions of this Agreement are satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><U>Termination of Rights</U></B>. The Right of First Refusal and the
Company&#146;s right to repurchase the Shares in the event of an involuntary transfer pursuant to Section&nbsp;13(b) above shall terminate upon the first sale of Common Stock of the Company to the general public pursuant to a registration statement
filed with and declared effective by the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;<B><U>Securities Act</U></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B><U>Ancillary Agreements</U></B>.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Voting Agreement</U></B>. <B></B>As a condition to receipt of this Option, and concurrently with the execution of this
Option, Optionee hereby agrees that Optionee shall be deemed to be a &#147;Common Holder&#148; under, and shall be bound by the provisions of, the Amended and Restated Voting Agreement dated March&nbsp;4, 2020, by and among the Company and certain
equityholders of the Company party thereto, as such agreement may be amended, modified or superseded from time to time (the &#147;<B><U>Voting Agreement</U></B>&#148;), including without limitation the drag-along provisions under such agreement.
Optionee also agrees to execute a counterpart signature page to the Voting Agreement concurrently with the execution of this Option or at any other time if requested. A copy of the Voting Agreement is available from the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U><FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement</U></B>.<B> </B>In addition, Optionee hereby agrees that if
Optionee is at any time issued shares of the Company&#146;s Common Stock upon exercise of this Option and such issued shares constitute one percent (1%) or more of the Company&#146;s then outstanding Common Stock (taking into account this Option and
all other shares of Common Stock, options and other purchase rights held by such employee, director or consultant and treating for this purpose all shares of Common Stock issuable upon exercise of or conversion of outstanding options, warrants or
convertible securities held by Optionee and other parties, as if exercised or converted) or such person is an officer of the Company, as a condition to exercise of this Option, and concurrently with the exercise of this Option or at such time as
Optionee exceeds such ownership threshold, Optionee shall be deemed to be a &#147;Common Holder&#148; under, and shall be bound by the provisions of, the Amended and Restated Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT>
Agreement dated March&nbsp;4, 2020 by and among the Company and certain equityholders of the Company party thereto, as such agreement may be amended, modified or superseded from time to time (the
&#147;<B><U><FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement</U></B>&#148;), including without limitation the transfer restrictions under such agreement. In such case, Optionee also agrees to execute a counterpart signature page to the <FONT
STYLE="white-space:nowrap">Co-Sale</FONT> Agreement concurrently with the exercise of this Option or at any other time if requested. A copy of the <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement is available from the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B><U>Miscellaneous</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Governing Law</U></B>. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the
parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Entire Agreement; Enforcement of Rights</U></B>. The Plan and the Option Notice are hereby incorporated by reference in this
Agreement. This Agreement (including the Plan and the Option Notice) sets forth the entire agreement and understanding of the parties relating to the subject matter herein and merges all prior discussions between them. No
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the parties to this Agreement. The failure by
either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B><U>Severability</U></B>. If one or more provisions of this Agreement are held to be<U> </U>unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually
agreeable and enforceable replacement for such provision, then (i)&nbsp;such provision shall be excluded from this Agreement, (ii)&nbsp;the balance of the Agreement shall be interpreted as if such provision were so excluded and (iii)&nbsp;the
balance of the Agreement shall be enforceable in accordance with its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><U>Construction</U></B>. This Agreement is the
result of negotiations between and has been reviewed by each of the parties hereto and their respective counsel, if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be construed
in favor of or against any one of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><U>Notices</U></B>. Any notice required or permitted by this
Agreement shall be in writing and shall be deemed sufficient when delivered personally or sent by telegram or fax or 48 hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, and addressed to the party
to be notified at such party&#146;s address as set forth below or as subsequently modified by written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>
<B><U>Counterparts</U></B>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><U>Successors and Assigns</U></B>. The rights and benefits of this Agreement shall inure to the benefit of, and be enforceable
by the Company&#146;s successors and assigns. The rights and obligations of Optionee under this Agreement may only be assigned with the prior written consent of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><U>No Obligation to Continue Employment or Consultancy</U></B>. Nothing in this Agreement will confer or be deemed to confer on
Optionee any right to continue in the employ of, or to continue any other relationship with, the Company, be deemed to modify Optionee&#146;s <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> status with the Company, or limit in any way
the right of the Company to terminate Optionee&#146;s employment or other relationship at any time, with or without cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>
<B><U>Incorporation of Plan</U></B>. This Option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of this Option, and is further subject to all interpretations, amendments, rules and regulations, which may
from time to time be promulgated and adopted by the Committee pursuant to the Plan. In the event of any conflict between the provisions of this Option and those of the Plan, the provisions of the Plan shall control unless expressly provided in the
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original and all of which together shall constitute one document. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SILVERBACK THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Laura Shawver</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OPTIONEE ACKNOWLEDGES AND AGREES THAT THE VESTING OF ANY SHARES ISSUED PURSUANT TO THIS OPTION IS EARNED
ONLY BY CONTINUING EMPLOYMENT OR CONSULTANCY AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER). OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN
THE PLAN, WHICH IS INCORPORATED HEREIN BY REFERENCE, SHALL CONFER UPON OPTIONEE ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT OR CONSULTANCY BY THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH OPTIONEE&#146;S RIGHT OR THE COMPANY&#146;S
RIGHT TO TERMINATE OPTIONEE&#146;S EMPLOYMENT OR CONSULTANCY AT ANY TIME, WITH OR WITHOUT CAUSE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Optionee acknowledges receipt of a copy
of the Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Option subject to all of the terms and provisions thereof. Optionee has reviewed the Plan and this Option in their entirety, has had
an opportunity to obtain the advice of counsel prior to executing this Option and fully understands all provisions of the Option. Optionee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee
upon any questions arising under the Plan or this Option. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[Recipient Name]</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to Silverback Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stock Option Agreement (Date of Grant) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notice of Exercise </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Silverback Therapeutics, Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500 Fairview Ave N. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seattle, Washington
98109&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Date of Exercise: _______________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This constitutes notice
under my stock option identified below that I elect to purchase the number of shares of Common Stock of Silverback Therapeutics, Inc. (the &#147;<B><U>Company</U></B>&#148;) set forth below for the price set forth below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Type of option (check one):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Incentive &#9744;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Nonstatutory&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#9744;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option dated:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares as <BR>to which option is <BR>exercised:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificates to be <BR>issued in name of:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total exercise price:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">______________</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash payment delivered <BR>herewith:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">______________</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By this exercise, I agree (i)&nbsp;to provide such additional documents as the Company may require pursuant to
the terms of its 2016 Equity Incentive Plan, (ii)&nbsp;to provide for the payment by me to the Company (in the manner designated by the Company) of the Company&#146;s withholding obligation, if any, relating to the exercise of this option, and
(iii)&nbsp;if this exercise relates to an incentive stock option, to notify the Company in writing within fifteen (15)&nbsp;days after the date of any disposition of any of the shares of Common Stock issued upon exercise of this option that occurs
within two (2)&nbsp;years after the date of grant of this option or within one (1)&nbsp;year after such shares of Common Stock are issued upon exercise of this option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby make the following certifications and representations with respect to the number of shares of Common Stock of the Company listed
above (the &#147;<B><U>Shares</U></B>&#148;), which are being acquired by me for my own account upon exercise of the Option as set forth above: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I am aware of the Company&#146;s business affairs and financial condition and have acquired sufficient information about the Company to reach
an informed and knowledgeable decision to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquire the Shares. I am purchasing the Shares for investment for my own account only and not with a view to, or for resale in connection with, any &#147;distribution&#148; thereof within the
meaning of the Securities Act of 1933, as amended (the &#147;<B><U>Securities Act</U></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I understand that the Shares are
&#147;restricted securities&#148; under applicable U.S. federal and state securities laws and that, pursuant to these laws, I must hold the Shares indefinitely unless they are registered with the Securities and Exchange Commission and qualified by
state authorities, or an exemption from such registration and qualification requirements is available. I acknowledge that the Company has no obligation to register or qualify the Shares for resale. I further acknowledge that if an exemption from
registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Shares, and requirements relating to the Company which are outside of my
control, and which the Company is under no obligation to and may not be able to satisfy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I understand that I may suffer adverse tax
consequences as a result of my purchase or disposition of the Shares. I represent that I have consulted any tax consultants I deem advisable in connection with the purchase or disposition of the Shares and that I am not relying on the Company for
any tax advice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I understand that the Shares are subject to a right of first refusal in favor of the Company, which is applicable on both
voluntary and involuntary transfers of the Shares, as set forth in Section&nbsp;13 of the stock option agreement pursuant to which the Shares were issued. I understand that the Shares may be subject to other restrictions on transfer or restrictions
on voting. Any transferee of the Shares will be subject to all such restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further acknowledge that all certificates
representing any of the Shares subject to the provisions of the Option shall have endorsed thereon appropriate legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the Company&#146;s Certificate of
Incorporation, Bylaws and/or applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further agree that, if required by the Company (or a representative of the
underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell or otherwise transfer or dispose of any shares of Common Stock or other securities of the
Company during such period (not to exceed one hundred eighty (180)&nbsp;days, except that such period may be increased as reasonably deemed necessary by the managing underwriter(s) to comply with Conduct Rule 2711 of the National Association of
Securities Dealers or Rule 472 of the New York Stock Exchange or similar requirements) following the effective date of the registration statement of the Company filed under the Securities Act as may be requested by the Company or the representative
of the underwriters. I further agree that the Company may impose <FONT STYLE="white-space:nowrap">stop-transfer</FONT> instructions with respect to securities subject to the foregoing restrictions until the end of such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further agree that in connection with any registration of the Company&#146;s securities that, upon the request of the Company or the
underwriters managing any public offering of the Company&#146;s securities, I will not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of the Company (other than those included in
the registration) without the prior written consent of the Company or such underwriters, as the case </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be, for such period of time after the effective date of such registration and subject to all restrictions as the Company or the underwriters may specify for
<FONT STYLE="white-space:nowrap">employee-shareholders</FONT> generally. I agree to execute an agreement reflecting the foregoing as may be requested by the underwriters at the time of the Company&#146;s public offering. I further agree that the
Company may impose <FONT STYLE="white-space:nowrap">stop-transfer</FONT> instructions with respect to securities subject to the foregoing restrictions until the end of such period. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">[Recipient Name]</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g67046dsp49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;6, 2020 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Via
Email </U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laura Shawver </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Laura, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This will confirm the terms under which Silverback Therapeutics, Inc., a Delaware corporation (the &#147;<B><U>Company</U></B>&#148;) has made
you an offer of employment: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Position and Duties</U></B>. You will serve as President and Chief Executive Officer reporting
the Company&#146;s Board of Directors (the &#147;<B><U>Board</U></B>&#148;) and shall perform such duties as are ordinary, customary and necessary in such role. You will also occupy the Board seat reservedfor the Chief Executive Officer of the
Company. Your start date with the Company shall be April&nbsp;16, 2020. You shall devote on a full-time basis your time, skill and attention to the performance of your duties on behalf of the Company. You will devote your efforts to theinterests of
the Company as set forth in the preceding sentence and will not engage in other employment or in any activities detrimental to the interests of the Company without the prior written consent of the Company. Notwithstanding the foregoing, you may
serve on boards of directors of up to three (3)&nbsp;other entities, none of which may be a direct competitor of theCompany. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B>
<B><U>Proof of Right to Work; Assignment Agreement</U></B>. On your first day of work you will be required to prove your eligibility for employment under the Immigration and Reform Control Act of 1986, as well as to sign and comply with the
Company&#146;s standard proprietary information and invention assignment (&#147;<B><U>PIIA</U></B>&#148;) which requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company and <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> of proprietary information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><U>Compensation and Benefits</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>a)</B> <B><U>Salary</U></B>. The Company agrees to pay you an annualized salary of $450,000.00, less applicable tax withholdings, payable
as earned in accordance with the Company&#146;s customary payroll practices. Your salary shall be reviewed by the Board for possible increases annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>b)</B> <B><U>Stock Options</U></B>. Subject to approval of the Board, you will receive anoption to purchase 2,899,124 shares of the
Company&#146;s common stock (the &#147;<B><U>Option</U></B>&#148;) pursuant to the Company&#146;s 2016 Equity Incentive Plan (the &#147;<B><U>Equity Plan</U></B>&#148;). Such amount is 4.5% of the currently anticipated aggregate amount of all issued
equity of the Company on an as exercised,as converted basis, and the number of unallocated shares in reserve in the Equity Plan, as of the Third Tranche Closing, as defined in that certain Series B Preferred Stock Purchase Agreement
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entered into by the Company and the investors named therein as of March&nbsp;4, 2020, as such agreement may be amended from time to time as set forth therein (the &#147;<B><U>Series B
Agreement</U></B>&#148;). The Option will be presented to the Board for approval as soon as practical after the Company receives an updated third party valuation of the Company&#146;s common stock. The per share priceof the Option will be equal to
the per share fair market value of the common stock on the date of grant, as determined by the Board. The Option will be contingent upon your executing the Company&#146;s standard stock option agreement under the Equity Plan and will also be subject
to the terms set forth below. The Option will be an incentive stock option to the maximum extentunder applicable law, and the remaining amount will be a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option. TheOption will have an early
exercise feature, subject to the Company&#146;s right of repurchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <B><U>Vesting</U></B>. The vesting of the Option will occur in
three distinct tranches composed of the following amounts: 1,788,688 shares (&#147;<B><U>Tranche 1</U></B>&#148;), 545,176 shares (&#147;<B><U>Tranche 2</U></B>&#148;) and 565,260 shares (&#147;<B><U>Tranche 3</U></B>&#148;). Twenty-five percent
(25%) of the Tranche 1 shares will vest on the one year anniversary of the Start Date, with the remaining 75% of the Tranche 1 shares to vest ratably over the following 36 months (i.e., months 13 &#150; 48). If theSecond Tranche Closing, as defined
in the Series B Agreement, occurs, the Tranche 2 sharesshall vest ratably over 48 months commencing on the one month anniversary of the Second Tranche Closing date. If the Third Tranche Closing occurs, the Tranche 3 shares shall vestratably over 48
months commencing on the one month anniversary of the Third Tranche Closing date. Vesting will cease if your services to the Company terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <B><U>Accelerated Vesting</U></B>. Notwithstanding the vesting provisions set forth in Section&nbsp;3(b)(i) above, in the event that the
Company undergoes a Change of Control,then upon the date that a release and waiver of claims in favor of the Company in a form reasonably acceptable to the Company, or its successor, and signed by you (a &#147;<B><U>Release</U></B>&#148;) is
nolonger revocable by you, one hundred percent (100%) of the Option will automatically vest. As used herein, a &#147;<B><U>Change of Control</U></B>&#148; shall mean a Change of Control as defined in the EquityPlan, or any other transaction that is
a Liquidation Event, as defined in the Company&#146;s Amended and Restated Certificate of Incorporation, as may be amended from time to time as set forththerein, other than a liquidation, voluntary or involuntary dissolution or winding up of the
Corporation or a general assignment for the benefit of creditors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>c)</B> <B><U>Bonus Potential</U></B>. You will be eligible to earn a
cash bonus up to 50% of your annual base salary subject to performance milestones and other terms and conditions approved by the Board, including that you must be employed at the time the bonus payment is made, which payment shall occur at the same
time as other performance based bonuses for other officers of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>d)</B> <B><U>Relocation Expenses</U></B>. To assist with
your relocation to the Seattle, Washington area, the Company will reimburse some of the costs you incur in connection with selling your current home, moving expenses and closing costs for the purchase of a residence in the Seattle area in the amount
of $30,000 (&#147;<B><U>Relocation Reimbursement</U></B>&#148;). The Relocation Reimbursement will be paid to you on the Start Date, and if you are terminated for Cause or you resign without Good Reason, as each such term is defined below, at any
time prior to the two (2)&nbsp;year anniversary of your Start Date, you shall repay the Relocation Reimbursement to the Company in full within two (2)&nbsp;business days after such termination or resignation. In addition, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the Company will reimburse your actual travel and lodging expenses in the Seattle area that you incur prior
to your relocation for a peroid of up to six (6)&nbsp;months and up to a maximum of$40,000. All amounts set forth in this Section&nbsp;3(d) for which the Company is requried to make withholdings, shall have such amounts withheld, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>e)</B> <B><U>Severance</U></B>. If at any time you are terminated without Cause or you resign with Good Reason, upon the date that a
Release is no longer revocable by you, the Company will pay you twelve (12)&nbsp;months&#146; of your then current base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used
herein, &#147;<B><U>Cause</U></B>&#148; means: (i)&nbsp;any willful, material violation by you of any law or regulation applicable to the business of the Company (or any successor, subsidiary, parent or affiliate of the Company), (ii) your
conviction for, or guilty or nolo contendere plea to, anyfelony or any willful perpetration by you of a common law fraud, (iii)&nbsp;your commission of an act of personal dishonesty which involves personal profit in connection with the Company (or
any successor, subsidiary, parent or affiliate of the Company) or any other entity having a material business relationship with the Company, (iv)&nbsp;a repeated pattern of unexcused absences thatcauses substantial failure by you to perform the
material duties as a director, officer, employee or consultant of the Company, (v)&nbsp;any continued failure or refusal by you to perform the material, lawful, duties required of you in your capacity as a director, officer, employee or consultant
ofthe Company (or any successor, subsidiary, parent or affiliate of the Company if you are then primarily employed by such entity) or (vi)&nbsp;a material breach of any applicable invention assignment and/or confidentiality agreement or similar
agreement that materially damages the Company (or any successor, subsidiary, parent or affiliate of the Company); provided, however, that as to subsections (i), (iii), (iv), (v) and (vi), Cause shall not exist unless the Company hasfirst provided
you with written notice of the claimed grounds for Cause and a reasonable opportunity of not less than thirty (30)&nbsp;days to cure, if curable, the claimed grounds. Theforegoing definition shall not in any way preclude or restrict the right of the
Company or any successor or affiliate thereof to discharge or dismiss you for any acts of omissions, but such other acts or omissions shall not, for purpose of this Agreement, constitute grounds for termination for Cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used herein, &#147;<B><U>Good Reason</U></B>&#148; means (i)&nbsp;the assignment to you of duties, or limitationof your responsibilities,
materially and repeatedly inconsistent with your position, duties, responsibilities and status with the Company, (ii)&nbsp;a material reduction by the Company of your annual base salary, unless such reduction affects all officers of the Company, or
(iii)&nbsp;therelocation of your principal place of employment to a location that is more than fifty (50)&nbsp;miles from your then current principal place of employment (after your relocation to the Seattle area); provided however, that in order
for circumstances to provide Good Reason for your resignation, the following additional conditions must be satisfied also: (A)&nbsp;you resign within sixty (60)&nbsp;days after the initial occurrence of the circumstance giving rise to Good Reason;
(B)&nbsp;you providenotice to the Company of the circumstance giving rise to Good Reason within thirty (30)&nbsp;daysafter the initial existence of such circumstance; and (C)&nbsp;the Company has a thirty (30)&nbsp;day period in which to cure such
circumstance, if it is capable of being cured, and upon any such cure, you shall not be considered to have Good Reason to resign. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>f)</B> <B><U>Benefits</U></B>. You will be eligible to participate in regular health insurance, vacation, and other employee benefit plans
established by the Company for its employees from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time to time on substantially the same terms as are made available to employees of the Company generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment</U></B>. You will be an
<FONT STYLE="white-space:nowrap">at-will</FONT> employee of the Company, which means that the employment relationship can be terminated by either you or the Company for any reason or no reason, at any time, with or without prior notice and with or
without cause. Any statements or representations to the contrary should be regarded by you as ineffective. Any modification or change in the <FONT STYLE="white-space:nowrap">at-will</FONT> employment status may only occur by way of a written
employment agreement signed by you and an authorized member of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Other Agreements</U></B>. By signing this offer
letter, you represent and warrant to the Company that either (a)&nbsp;you are not bound by any other agreement or agreements (i.e., a <FONT STYLE="white-space:nowrap">non-solicitation</FONT> or <FONT STYLE="white-space:nowrap">non-compete</FONT>
agreement with a former employer) which would inhibit or limit in any way your ability to perform the duties required by this position or to contact, solicit, or hire any other individual or entity to work for or contract with the Company or
(b)&nbsp;you have provided copies of any such agreements to the Company prior to signing this offer letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B><U>Section
280G</U></B>. If any payments and other benefits provided for in this offer letter or otherwise constitute &#147;parachute payments&#148; within the meaning of Section&nbsp;280G of the Internal Revenue Code of 1986, as amended (the
&#147;<B><U>Code</U></B>&#148;) and, but for this Section&nbsp;6, would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then payments and other benefits will be payable to you, at your election, either in full or in such
lesser amounts as would result, aftertaking into account the applicable federal, state and local income taxes and the excise taximposed by Section&nbsp;4999, on your receipt on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis of the
greatest amount ofpayments and other benefits, by first reducing the cash payments and then reducing the equity grants, in each case, pro rata between amounts subject to Section&nbsp;409A of the Code and amounts not subject to Section&nbsp;409A of
the Code. Notwithstanding the foregoing, if any payment would be subject to excise tax imposed by Section&nbsp;4999 but for this section, but would not be subject to such excise tax if the stockholder approval requirements of Section&nbsp;280G(b)(5)
of the Code are satisfied, the Company shall use its reasonable best efforts to cause any such payment to be submitted for such approval prior to the event giving rise to such payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B><U>Section 409A</U></B>. Notwithstanding any other term in this letter agreement, if, at the time of your separation of
employment, you are a &#147;specified employee,&#148; as defined in Treasury Regulation &#167; <FONT STYLE="white-space:nowrap">1.409A-1(i),</FONT> to the extent delayed commencement of any portion of the paymentsor benefits to which you are
entitled under this letter agreement is required in order to avoid a prohibited distribution under Section&nbsp;409A(a)(2)(B)(i) of the Code, that portion of your benefits shall not be provided to you before the earlier of (a)&nbsp;six (6) months
and one day after your separation, or (b)&nbsp;the date of your death. All payments deferred pursuant to this Section&nbsp;7 shallbe paid in a lump sum to you on the date which is six months and one day after your separationor the date of your
death, as applicable, and any remaining payments due under this agreement shall be paid as required by this letter agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other term in this letter agreement: (i)&nbsp;no amount that constitutes &#147;deferred compensation&#148; under
Section&nbsp;409A shall be payable pursuant to Section&nbsp;3(e) above unless the termination of your employment constitutes a &#147;separation from service&#148; within the meaning of <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT>
of the Department of Treasury Regulations. Any installment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment paid pursuant to this letter agreement shall constitute a separate and distinct paymentfor purposes of Section&nbsp;409A. Additionally, to the extent that any reimbursement of expenses or
<FONT STYLE="white-space:nowrap">in-kind</FONT> benefits constitutes &#147;deferred compensation&#148; under Section&nbsp;409A, such reimbursementor benefit shall be provided no later than December 31st of the year following the year in which the
expense was incurred. The amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year. The amount of any <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided in one year shall
not affect the amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided in any other year. This letter shall be construed in a manner that complies with Section&nbsp;409A of the Code and the United States Treasury
Department&#146;s implementing regulations for Section&nbsp;409A of the Code so that none of the payments and benefits provided under this agreement will be subject to the additional tax imposed under Section&nbsp;409A of the Code. All ambiguities
in this agreement shall be interpreted to comply with Section&nbsp;409A of the Code and the Treasury Department&#146;s implementing regulations for Section&nbsp;409A of the Code. The Company and you shall cooperate, in good faith, to take all
reasonable actions, including amending this letter agreement </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B><U>Miscellaneous</U></B>. This offer letter constitutes the
entire agreement between you and the Company regarding the terms and conditions of your employment, and they supersede allprior negotiations, representations, or agreements between you and the Company. The provisions of this agreement may only be
modified by a document signed by you and the Company. This offer letter will be governed by the laws of the State of Washington. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B><U>Expiration</U></B>. This offer shall expire on March&nbsp;12, 2020, and is subject to you signing the Company&#146;s standard
PIIA, a copy of which is attached for your review as <U>Exhibit A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please indicate your acceptance to the foregoing terms by signing
this letter where indicated below and returning it to me. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I am delighted that you will be joining our team and I am looking forward to
working with you. If you have any questions, please give me a call. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Silverback
Therapeutics, Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Peter Thompson</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter Thompson</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President&nbsp;&amp;
CEO</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AGREED TO AND ACCEPTED BY: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Laura Shawver <U></U></I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laura Shawver</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: March 8, 2020</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enclosure: Proprietary Information and Invention Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SILVERBACK THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT TO OFFER LETTER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment to Offer Letter is entered into by Silverback Therapeutics, Inc. (the &#147;<B><U>Company</U></B>&#148;) and Laura Shawver
(&#147;<B><U>Shawver</U></B>&#148;) as of May&nbsp;11, 2020 and amends that certain employment offer letter agreement entered into by the Company and Shawver dated March&nbsp;6, 2020 (the &#147;<B><U>Offer Letter</U></B>&#148;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Offer Letter provides for the Company to reimburse Shawver&#146;s actual travel and lodging expenses in the Seattle area that she
incurs prior to her relocation for a period of up to six (6)&nbsp;months and up to a maximum of $40,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, various State and
county health orders with respect to the <FONT STYLE="white-space:nowrap">Covid-19</FONT> pandemic and related public health matters have resulted in unforeseen difficulties in connection with Shawver&#146;s near-term travel and temporary lodging in
the Seattle area. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in recognition of the foregoing, the parties hereto desire to eliminate the requirement that such travel and
lodging expenses be incurred within a specific number ofmonths prior to Shawver&#146;s relocation to the Seattle area. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE,
the parties hereto agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The penultimate sentence of Section&nbsp;3(d) of the Offer Letter shall be deleted and replaced in
its entirety as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company will reimburse your actual travel and lodging expenses in the Seattle area that you
incur prior to your relocation up to a maximum of $40,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Except as expressly set forth herein, all terms and conditions of the Offer
Letter shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties hereto have executed this Amendment as of the date first written above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SILVERBACK THERAPEUTICS, INC.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>LAURA SHAWVER</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Peter Thompson</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>/s/ Laura
Shawver</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Peter Thompson</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>9
<FILENAME>filename9.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SILVERBACK THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;23, 2016 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Valerie Odegard </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Re: This offer supersedes offer dated July&nbsp;19, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Valerie, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This will confirm the terms
under which Silverback Therapeutics, Inc., a Delaware corporation (the <U>&#147;</U><B><U>Company</U></B><U>&#148;</U>) has made you an offer of employment: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Position and Duties.</U></B> You will serve as Sr. Vice President, Translational Sciences such duties as are ordinary,
customary and necessary in such role (subject to the limitations set forth in the next paragraph). You will report Peter Thompson although such reporting is subjectto change from time to time. Your start date with the Company shall be
October&nbsp;24, 2016. You shall devote your full business time, skill and attention to the performance of your duties on behalfof the Company. You will devote your efforts to the interests of the Company as set forth in the preceding sentence and
will not engage in other employment or in any activities detrimental to the interests of the Company without the prior written consent of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>Proof of Right to Work; Assignment Agreement.</U></B> On your first day of work you will be required to prove your eligibility
for employment under the Immigration and Reform Control Act of 1986, as well as to sign and comply with the Company&#146;s standard proprietary information and invention assignment (<U>&#147;</U><B><U>PIIA</U></B><U>&#148;</U>) which requires, among
other provisions, the assignment of patent rights to any invention made during your employment at the Company and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> of proprietary information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. <U>Compensation and Benefits.</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>a)</B> <B><U>Salary.</U></B> The Company agrees to pay you an annualized salary of $260,000.00, payable as earned in accordance with the
Company&#146;s customary payroll practices <FONT STYLE="white-space:nowrap">(Bi-weekly).</FONT> Your salary shall be reviewed by the Board of Directors of the Company (the <U>&#147;</U><B><U>Board</U></B><U>&#148;</U>) for possible increases
annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>b)</B> <B><U>Stock Options.</U></B> Subject to approval of the Board, you will receive an option to purchase 225,212 shares
of the Company&#146;s common stock (the <U>&#147;</U><B><U>Option</U></B><U>&#148;</U>) pursuant to the Company&#146;s 2016 Equity Incentive Plan. The per share price of the Option will be equal to the per share fair market value of the common stock
on the date of grant, as determined by the Board. The Option will be contingent upon you executing the Company&#146;s standard stock option agreement. So long as you continue in service with the Company, the Option will vest and become exercisable
as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) with respect to 57,204 shares of Common Stock, 25% of such amount (14,301 shares) shall
become vested on the one year anniversary of your start date with the Company, with the remaining 42,903 shares becoming vested in equal monthly installments over 36 months following such one year anniversary; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) with respect 84,004 shares of Common Stock, 25% of such amount (21,001 shares) shall become vested, if at all, on the one year
anniversary of the Company&#146;s issuance of its Series A Preferred Stock in a Second Tranche Closing (as defined in the Company&#146;s Series A Preferred Stock Purchase Agreement), with the remaining 63,003 shares becoming vested in equal monthly
installments over 36 months following such one year anniversary; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) with respect to 84,004 shares of Common Stock, 25% of such
amount (21,001 shares) shall become vested, if at all, on the one year anniversary of the Company&#146;s issuance of its Series A Preferred Stock in a Third Tranche Closing (as defined in the Company&#146;s Series A Preferred Stock Purchase
Agreement), with the remaining 63,003 shares becoming vested in equal monthly installments over 36 months following such one year anniversary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For clarity, in the event that the Second Tranche Closing does not occur, no sharesof Common Stock set forth in subsection (ii)&nbsp;above
shall vest, and in the event that the Third Tranche Closing does not occur, no shares of Common Stock set forth in subsection (iii)&nbsp;shall vest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>c)</B> <B><U>Bonus Potential</U></B>. You will be eligible to receive a cash bonus up to 25%of your annual base salary subject to
performance milestones and other terms and conditions approved by the Board. The 2016 bonus will be prorated to reflected the equivalent of a <FONT STYLE="white-space:nowrap">six-month</FONT> period. The approved 2016 bonus payment will be paid
during the first quarter of 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>d)</B> <B><U>Benefits</U></B>. You will be eligible to participate in regular health insurance,
vacation, and other employee benefit plans established by the Company for its employees from time to time on substantially the same terms as are made available to employees of the Company generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>e)</B> <B><U>Expenses</U></B>. The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with
the Company&#146;s business, in accordance with any applicable policy established by the Board from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U><FONT
STYLE="white-space:nowrap">At-Will</FONT> Employment</U></B>. You will be an at will employee of the Company, which means that the employment relationship can be terminated by either you or the Company for any reason or no reason, at any time, with
or without prior notice and with or without cause. Any statements or representations to the contrary should be regarded by you as ineffective. Any modification or change in the <FONT STYLE="white-space:nowrap">at-will</FONT> employment status may
only occur by way of a written employment agreement signed by you and an authorized member of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Other
Agreements</U></B>. By signing this offer letter, you represent and warrant to the Company that either (a)&nbsp;you are not bound by any other agreement or agreements (i.e., a <FONT STYLE="white-space:nowrap">non-solicitation</FONT> or <FONT
STYLE="white-space:nowrap">non-compete</FONT> agreement with a former employer) which would inhibit or limit in any way your ability to perform the duties required by this position or to contact, solicit, or hire
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any other individual or entity to work for or contract with the Company or (b)&nbsp;you have provided copies of any such agreements to the Company prior to signing this offer letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B><U>Miscellaneous</U></B>. This offer letter constitutes the entire agreement between you and the Company regarding the terms and
conditions of your employment, and they supersede all prior negotiations, representations, or agreements between you and the Company. The provisions of this agreement may only be modified by a document signed by you and the Company. This offer
letter will be governed by the laws of the State of Washington. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B><U>Expiration</U></B>. This offer shall expire on
July&nbsp;29,2016. Please verbally reply to this offer by this date by calling me. It is understood that the written acceptance of this offer letter will coincide with your resignation from your current position anticipated to be within 30 days to
your start date above. At that time please sign the offer letter and return it with a signed copy of the Company&#146;s standard PIIA, a copy of which is attached for your review as <U>Exhibit A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I am delighted that you will be joining our team and I am looking forward to working with you. If you have any questions, please give me a
call. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Silverback Therapeutics, Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Peter Thompson</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter Thompson</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive
Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AGREED TO AND ACCEPTED BY: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>/s/ Valerie
Odegard&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Valerie Odegard </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: 10/22/16 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enclosure: Proprietary Information and Invention Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>10
<FILENAME>filename10.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g67046dsp59.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Silverback Therapeutics, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500 Fairview
Avenue North Suite 600</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Seattle, WA 98109</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;22, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Naomi
Hunder, MD </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Via email </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Naomi, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This will confirm the terms under which Silverback Therapeutics, Inc., a Delaware corporation (the &#147;<B><U>Company</U></B>&#148;) has made
you an offer of full-time employment: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Position and Duties</U></B>. You will serve as Sr. Vice President, Clinical Research
and Development and shall perform such duties as are ordinary, customary and necessary in such role (subject to the limitations set forth in the next paragraph). You will report to me. Your start date with the Company shall be January&nbsp;14, 2019.
You shall devote your full business time, skill and attention to the performance of your duties on behalf of the Company. You will devote your efforts to the interests of the Company as set forth in the preceding sentence and will not engage in
other employment or in any activities detrimental to the interests of the Company without the prior written consent of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>Proof of Right to Work; Assignment Agreement</U></B>. On your first day of work you will be required to prove your eligibility
for employment under the Immigration and Reform Control Act of 1986, as well as to sign and comply with the Company&#146;s standard proprietary information and invention assignment (&#147;<B><U>PIIA</U></B>&#148;) which requires, among other
provisions, the assignment of patent rights to any invention made during your employment at the Company and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> of proprietary information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><U>Compensation and Benefits</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>a)</B> <B><U>Salary</U></B>. The Company agrees to pay you annualized salary of $340,000, payable as earned in accordance with the
Company&#146;s customary payroll practices. Your salary shall be reviewed by&nbsp;the Board of Directors of the Company (the &#147;<B><U>Board</U></B>&#148;) for possible increases annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>b)</B> <B><U>Stock Options</U></B>. Subject to approval of the Board, you will receive an option to purchase 164,336 shares of the
Company&#146;s common stock (the &#147;<B><U>Option</U></B>&#148;) pursuant to the Company&#146;s 2016 Equity Incentive Plan. The per share price of the Option will be equal to the per share fair market value of the common stock on the date of
grant, as determined by the Board. The Option will be contingent upon you executing the Company&#146;s standard stock option agreement. The vesting schedule for this option will be detailed in the stock option agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>c)</B> <B><U>Bonus Potential</U></B>. You will be eligible to earn a cash bonus up to 30% of your annual base salary subject to performance
milestones and other terms and conditions approved by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>d)</B> <B><U>Benefits</U></B>. You will be eligible to participate in
regular health insurance, vacation, and other employee benefit plans established by the Company for its employees from time to time on substantially the same terms as are made available to employees of the Company generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment</U></B>. You will be an at will employee of the Company, which
means </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that the employment relationship can be terminated by either you or the Company for any reason or no reason, at any time, with or without prior notice and with or without cause. Any statements or
representations to the contrary should be regarded by you as ineffective. Any modification or change in <FONT STYLE="white-space:nowrap">the&nbsp;at-will</FONT> employment status may only occur by way of a written employment agreement signed by you
and an authorized member of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Other Agreements</U></B>. By signing this offer letter, you represent and warrant
to the Company that either (a)&nbsp;you are not bound by any other agreement or agreements (i.e., a <FONT STYLE="white-space:nowrap">non-solicitation</FONT> or <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement with a former employer)
which would inhibit or limit in any way your ability to perform the duties required by this position or to contact, solicit, or hire any other individual or entity to work for or contract with the Company or (b)&nbsp;you have provided copies of any
such agreements to the Company prior to signing this offer letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B><U>Miscellaneous</U></B>. This offer letter constitutes
the entire agreement between you and the Company regarding the terms and conditions of your employment, and they supersede all prior negotiations, representations, or agreements between you and the Company. The provisions of this agreement may only
be modified by a document signed by you and the Company. This offer letter will be governed by the laws of the State of Washington. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B><U>Expiration</U></B>. This offer shall expire on December&nbsp;28, 2018, and is subject to you signing the Company&#146;s
standard PIIA, a copy of which is attached for your review as <U>Exhibit A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please indicate your acceptance to the foregoing terms by
signing this letter where indicated below and returning it to Lindsay Blackner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I am delighted that you will be joining our team and I am
looking forward to working with you. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Silverback
Therapeutics, Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Peter A. Thompson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter A. Thompson, MD, FACP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President&nbsp;&amp; CEO</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AGREED TO AND ACCEPTED BY: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ Naomi
Hunder&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Naomi Hunder </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: <U>December&nbsp;23, 2018</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enclosure: Proprietary Information and Invention Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>11
<FILENAME>filename11.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g67046g31p63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Silverback Therapeutics | 500 Fairview Avenue N, Suite 600, Seattle, WA 98109 USA | Phone: 206-456-2900
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;17, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Russ Hawkinson </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Russ, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This will confirm the terms under
which Silverback Therapeutics, Inc., a Delaware corporation (the &#147;<B><U>Company</U></B>&#148;) has made you an offer of employment: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Position and Duties</U></B>. You will serve as Senior Vice President, Finance and shall perform such duties as are ordinary,
customary and necessary in such role (subject to the limitations set forth in the next paragraph). You will report to the Chief Executive Officer. Your start date with the Company shall be April&nbsp;20, 2020. You shall devote your full business
time, skill and attention to the performance of your duties on behalf of the Company. You will devote your efforts to the interests of the Company as set forth in the preceding sentence and will not engage in other employment or in any activities
detrimental to the interests of the Company without the prior written consent of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>Proof of Right to Work;
Assignment Agreement</U></B>. On your first day of work you will be required to prove your eligibility for employment under the Immigration and Reform Control Act of 1986, as well as to sign and comply with the Company&#146;s standard proprietary
information and invention assignment (&#147;<B><U>PIIA</U></B>&#148;) which requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company and
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> of proprietary information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><U>Compensation and Benefits</U></B>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>a)</B> <B><U>Salary</U></B>. The Company agrees to pay you an annualized salary of $275,000, payable as earned in accordance with the
Company&#146;s customary payroll practices. Your salary shall be reviewed by the Board of Directors of the Company (the &#147;<B><U>Board</U></B>&#148;) for possible increases annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>b)</B> <B><U>Stock Options</U></B>. Subject to approval of the Board, you will receive an option to purchase 347,895 shares of the
Company&#146;s common stock (the &#147;<B><U>Option</U></B>&#148;) pursuant to the Company&#146;s 2016 Equity Incentive Plan. The per share price of the Option will be equal to the per share fair market value of the common stock on the date of
grant, as determined by the Board. The Option will be contingent upon you executing the Company&#146;s standard stock option agreement. So long as you continue in service with the Company, the Option will vest and become exercisable as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) with respect to 214,643 shares of Common Stock, 25% of such amount (<U>53,652</U> shares) shall become vested on the one year anniversary
of your start date with the Company, with the remaining 160,991 shares becoming vested in equal monthly installments over 36 months following such one year anniversary; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) with respect 65,421 shares of Common Stock, 25% of such amount 16,344 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g67046g31p63.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares) shall become vested, if at all, on the one year anniversary of the Company&#146;s issuance of its Series B Preferred Stock in a Second Tranche Closing (as defined in the Company&#146;s
Series B Preferred Stock Purchase Agreement), with the remaining 49,077 shares becoming vested in equal monthly installments over 36 months following such one year anniversary; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) with respect to 67,831 shares of Common Stock, 25% of such amount (16,956 shares) shall become vested, if at all, on the one year
anniversary of the Company&#146;s issuance of its Series B Preferred Stock in a Third Tranche Closing (as defined in the Company&#146;s Series B Preferred Stock Purchase Agreement), with the remaining 50,875 shares becoming vested in equal monthly
installments over 36 months following such one year anniversary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For clarity, in the event that the Second Tranche Closing does not
occur, no shares of Common Stock set forth in subsection (ii)&nbsp;above shall vest, and in the event that the Third Tranche Closing does not occur, no shares of Common Stock set forth in subsection (iii)&nbsp;shall vest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>c)</B> <B><U>Bonus Potential</U></B>. You will be eligible to earn a cash bonus up to 25% of your annual base salary subject to performance
milestones and other terms and conditions approved by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>d)</B> <B><U>Benefits</U></B>. You will be eligible to participate in
regular health insurance, vacation, and other employee benefit plans established by the Company for its employees from time to time on substantially the same terms as are made available to employees of the Company generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment</U></B>. You will be an at will employee of the Company, which
means that the employment relationship can be terminated by either you or the Company for any reason or no reason, at any time, with or without prior notice and with or without cause. Any statements or representations to the contrary should be
regarded by you as ineffective. Any modification or change in the <FONT STYLE="white-space:nowrap">at-will</FONT> employment status may only occur by way of a written employment agreement signed by you and an authorized member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Other Agreements</U></B>. By signing this offer letter, you represent and warrant to the Company that either (a)&nbsp;you are
not bound by any other agreement or agreements (i.e., a <FONT STYLE="white-space:nowrap">non-solicitation</FONT> or <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement with a former employer) which would inhibit or limit in any way your
ability to perform the duties required by this position or to contact, solicit, or hire any other individual or entity to work for or contract with the Company or (b)&nbsp;you have provided copies of any such agreements to the Company prior to
signing this offer letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B><U>Miscellaneous</U></B>. This offer letter constitutes the entire agreement between you and the
Company regarding the terms and conditions of your employment, and they supersede all prior negotiations, representations, or agreements between you and the Company. The provisions of this agreement may only be modified by a document signed by you
and the Company. This offer letter will be governed by the laws of the State of Washington. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B><U>Expiration</U></B>. This
offer shall expire on April&nbsp;20, 2020 and is subject to you signing the Company&#146;s standard PIIA, a copy of which is attached for your review as <U>Exhibit A</U>. If the terms of this offer are acceptable to you please sign and return a copy
of this letter to Lindsay Blackner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g67046g31p63.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please contact Lindsay or me with any questions you may have. We are delighted with the
prospect of you joining our team. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Silverback
Therapeutics, Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><U></U><I>/s/ Laura Shawver</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laura Shawver</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">CEO</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AGREED TO AND ACCEPTED BY: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>/s/ Russ
Hawkinson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Russ Hawkinson </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:<U> 4/17/2020</U>&nbsp;&nbsp;&nbsp;&nbsp;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enclosure: Proprietary Information and Invention Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>12
<FILENAME>filename12.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LEASE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and between </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">BMR-500</FONT> FAIRVIEW AVENUE LLC, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware limited liability company </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SILVERBACK THERAPEUTICS,
INC., </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">500 Fairview Avenue North, Seattle, Washington </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease of Premises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic Lease Provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term: Early Termination Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Possession and Commencement Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Condition of Premises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rentable Area</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[Intentionally Omitted.]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes on Tenant&#146;s Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Security Deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rules and Regulations, CC&amp;Rs, Parking Facilities and Common Area</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Project Control by Landlord</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quiet Enjoyment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Utilities and Services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alterations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repairs and Maintenance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liens</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estoppel Certificate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hazardous Materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Odors and Exhaust</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance; Waiver of Subrogation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Damage or Destruction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eminent Domain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">26.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrender</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">27.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holding Over</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">28.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnification and Exculpation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">29.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assignment or Subletting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">30.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subordination and Attornment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">31.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defaults and Remedies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">32.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bankruptcy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">33.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brokers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">34.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Definition of Landlord</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">35.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Limitation of Landlord&#146;s Liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">36.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint and Several Obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">37.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">38.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Confidentiality</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">39.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">40.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">41.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rooftop Installation Area</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">42.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Option to Extend Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LEASE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS LEASE (this &#147;<U>Lease</U>&#148;) &#147;is entered into as of this 8<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of
June, 2016 (the &#147;<U>Execution Date</U>&#148;), by and between <FONT STYLE="white-space:nowrap">BMR-500</FONT> FAIRVIEW AVENUE LLC, a Delaware limited liability company (&#147;<U>Landlord</U>&#148;), and SILVERBACK THERAPEUTICS, INC., a Delaware
corporation (&#147;<U>Tenant</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. WHEREAS, pursuant to that certain Ground Lease dated January&nbsp;28, 2008 (as the same may have been amended, amended and restated,
supplemented or otherwise modified from time to time, the &#147;<U>Ground Lease</U>&#148;), Landlord (as ground lessee) leases from NELCHINA POINT LIMITED PARTNERSHIP, an Alaska limited partnership (&#147;<U>Ground Lessor</U>&#148;) certain real
property located at 500 Fairview Avenue North, Seattle, Washington 98109 (as more particularly described on <U>Exhibit <FONT STYLE="white-space:nowrap">A-1</FONT></U> attached hereto, the &#147;<U>Property</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. WHEREAS, Landlord wishes to lease to Tenant, and Tenant desires to lease from Landlord, certain premises located on the sixth (6<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) floor of the building located on the Property (the &#147;<U>Building</U>&#148;) and certain storage space (the &#147;<U>Storage Space</U>&#148;) located on the second (2<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP>) floor of the parking structure serving the Building (collectively, the &#147;<U>Premises</U>&#148;) pursuant to the terms and conditions of this Lease, as detailed below; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. WHEREAS, an affiliate of Landlord, <FONT STYLE="white-space:nowrap">BMR-530</FONT> Fairview Avenue LLC (&#147;<U>530 Landlord</U>&#148;),
owns certain real property located at 530 Fairview Avenue North, Seattle, Washington 98109 (the &#147;<U>Adjacent Property</U>&#148;), including the building located thereon (the &#147;<U>Adjacent Building</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AGREEMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Lease of Premises</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1
Effective on the Term Commencement Date (as defined below), Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, the Premises, as shown on <U>Exhibits <FONT STYLE="white-space:nowrap">A-2</FONT> and <FONT
STYLE="white-space:nowrap">A-3</FONT></U> attached hereto, including exclusive shafts, cable runs, mechanical spaces and rooftop areas, for use by Tenant in accordance with the Permitted Use (as defined below) and no other uses. The Property, the
Adjacent Property, and all landscaping, parking facilities, private drives and other improvements and appurtenances related thereto, including the Building, the Adjacent Building and any other buildings located on the Property or the Adjacent
Property, are hereinafter collectively referred to as the &#147;<U>Project</U>.&#148; All portions of the Building that are for the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> use of the tenants of the Building only, and not the tenants of
the Project generally, such as service corridors, stairways, elevators, public restrooms and public lobbies (all to the extent located in the Building), are hereinafter referred to as &#147;<U>Building Common Area</U>.&#148; All
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
portions of the Project that are from time to time designated by Landlord and 530 Landlord as being for the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> use of tenants of the Project
generally, including the fitness center, bike storage areas, conference rooms, driveways, sidewalks, parking areas, landscaped areas, service corridors, stairways, elevators, public restrooms and public lobbies (but excluding Building Common Area
and areas from time to time designated by 530 Landlord as being for the use of tenants of the Adjacent Property only), are hereinafter referred to as &#147;<U>Project Common Area</U>.&#148; The Building Common Area and Project Common Area are
collectively referred to herein as &#147;<U>Common Area</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Basic Lease Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 For convenience of the parties, certain basic provisions of this Lease are set forth herein. The provisions set forth herein are subject
to the remaining terms and conditions of this Lease and are to be interpreted in light of such remaining terms and conditions. This Lease shall take effect upon the Execution Date and, except as specifically otherwise provided within this Lease,
each of the provisions hereof shall be binding upon and inure to the benefit of Landlord and Tenant from the date of execution and delivery hereof by all parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 In the definitions below, each current Rentable Area (as defined below) is expressed in square feet. Rentable Area and
&#147;<U>Tenant&#146;s Pro Rata Shares</U>&#148; are all subject to adjustment as provided in this Lease. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Definition or Provision</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Means the Following (As of the Term</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Commencement Date)</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Approximate Rental Area of Premises*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19,370 square feet</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Approximate Rentable Area of Building</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>122,702 square feet</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Approximate Rentable Area of Project</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>223,820 square feet</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Tenant&#146;s Pro Rata Share of Building*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>15.79%</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Tenant&#146;s Pro Rata Share of Project*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>8.65%</B></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>*&nbsp;Note:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Subject to adjustment based upon the Rentable Area of the Premises (excluding the Storage Space) as of the
Term Commencement Date. </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 Monthly and annual installments of base rent (&#147;<U>Base Rent</U>&#148;) for the
Premises (excluding the Storage Space) as of the Term Commencement Date (as defined below), subject to adjustment under this Lease: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Dates</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Square<BR>Feet of</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Annual&nbsp;Base&nbsp;Rent<BR>per&nbsp;Square&nbsp;Foot&nbsp;of</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Monthly&nbsp;Base<BR>Rent*</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Annual&nbsp;Base<BR>Rent*</B></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Rentable<BR>Area*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Rentable Area</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term Commencement</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date &#150; Month 4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Abated&nbsp;in&nbsp;accordance<BR>with <U>Section&nbsp;7.1<BR></U>below</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">700,548.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 5 &#150; 12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$54.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,568.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 13 &#150; 24</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$55.88</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,199.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,082,395.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 25 &#150; 36</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$57.55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,895.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,114,743.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 37 &#150; 48</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$59.28</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">95,687.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,148,253.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 49 &#150; 60</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$61.06</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,561.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,182,732.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 61 &#150; 72</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$62.89</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">101,514.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,218,179.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 73 &#150; 84</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$64.78</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104,565.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,254,788.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 85 &#150; 96</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$66.72</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,697.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,292,366.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 97 &#150; 108</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$68.72</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">110,925.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,331,106.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 109 &#150; 120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$70.78</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">114,250.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,371,008.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>*&nbsp;Note:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Subject to adjustment based upon the Rentable Area of the Premises (excluding the Storage Space) as of the
Term Commencement Date. </I></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monthly and annual installments of Base Rent for the Storage Space as of the Term Commencement Date, subject
to adjustment under this Lease: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Dates</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Square<BR>Feet of<BR>Rentable<BR>Area</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual Base Rent<BR>per&nbsp;Square&nbsp;Foot&nbsp;of<BR>Rentable Area</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Monthly<BR>Base<BR>Rent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual<BR>Base Rent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term Commencement</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date &#150; Month 12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">18.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">688.50</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">8,262.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 13 &#150; 24</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">709.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,509.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 25 &#150; 36</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">730.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,766.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 37 &#150; 48</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">752.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,028.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 49 &#150; 60</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">774.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,299.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 61 &#150; 72</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">798.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,579.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 73 &#150; 84</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">822.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,863.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 85 &#150; 96</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">846.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,162.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 97 &#150; 108</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">872.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,465.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 109 &#150; 120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">898.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,781.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 Estimated Term Commencement Date: November&nbsp;1, 2016 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 Estimated Term Expiration Date: October&nbsp;31, 2026 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 Security Deposit: $950,000, subject to adjustment in accordance with the terms hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 Permitted Use: Office and laboratory use (except that the Storage Space shall be used solely for storage of equipment and personal
property, excluding any Hazardous Materials) in conformity with all federal, state, municipal and local laws, codes, ordinances, rules and regulations of Governmental Authorities (as defined below), committees, associations, or other regulatory
committees, agencies or governing bodies having jurisdiction over the Premises, the Building, the Property, the Project, Landlord or Tenant, including both statutory and common law and hazardous waste rules and regulations (&#147;<U>Applicable
Laws</U>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8 Address for Rent Payment: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BMR-500</FONT> FAIRVIEW AVENUE LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention Entity 251 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; text-indent:4%; font-size:10pt; font-family:Times New Roman">P.O. Box 511415 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Los Angeles, California 90051-7970 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9 Address for Notices to Landlord: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BMR-500</FONT> FAIRVIEW AVENUE LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; text-indent:4%; font-size:10pt; font-family:Times New Roman">17190 Bernardo Center Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; text-indent:4%; font-size:10pt; font-family:Times New Roman">San Diego, California 92128 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attn: Real Estate Legal Department </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10 Address for Notices to Tenant: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; text-indent:4%; font-size:10pt; font-family:Times New Roman">SILVERBACK THERAPEUTICS, INC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; text-indent:4%; font-size:10pt; font-family:Times New Roman">500 Yale Ave. N </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seattle, Washington 98109 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11 Address for Invoices to Tenant: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20%; text-indent:4%; font-size:10pt; font-family:Times New Roman">SILVERBACK THERAPEUTICS, INC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; text-indent:4%; font-size:10pt; font-family:Times New Roman">500 Yale Ave. N </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seattle, Washington 98109 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12 The following Exhibits are attached hereto and incorporated herein by reference: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;A-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Property</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;A-2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Premises</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;A-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Storage Space</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Work Letter</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit&nbsp;B-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tenant Work Insurance Schedule</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Acknowledgement of Term Commencement Date and Term Expiration Date</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Letter of Credit</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Rules and Regulations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit F</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tenant&#146;s Personal Property</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit G</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Estoppel Certificate</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit H</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Ground Lessor Recognition and Non-Disturbance Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit I</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Memorandum of Lease</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exhibit J</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Termination of Memorandum of Lease</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Term: Early Termination Option</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Term.</U> The actual term of this Lease (as the same may be extended pursuant to <U>Article 42</U> hereof, and as the same may be
earlier terminated in accordance with this Lease, the &#147;<U>Term</U>&#148;) shall commence on the Term Commencement Date (as defined in <U>Article 4</U>) and end on the date (the &#147;<U>Term Expiration Date</U>&#148;) that is the last day of
the one hundred twentieth (120th) month after the actual Term Commencement Date, subject to extension or earlier termination of this Lease as provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Early Termination Option</U>. Provided that, as of the date that Tenant exercises the Early Termination Option and as of the proposed
Early Termination Date, Tenant is not in Default of any monetary obligations or material <FONT STYLE="white-space:nowrap">non-monetary</FONT> obligations under this Lease, in either case that remains uncured, Tenant shall have the <FONT
STYLE="white-space:nowrap">one-time</FONT> right to terminate this Lease (the &#147;<U>Early Termination Option</U>&#148;), effective as of the date (which shall be the last day of a month) identified by Tenant in Tenant&#146;s Early Termination
Notice (the &#147;<U>Early Termination Date</U>&#148;), subject to Tenant&#146;s timely satisfaction of the following terms and conditions: (a)&nbsp;the Early Termination Date shall be no earlier than the last day of seventy-second (72nd) full
calendar </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
month of the initial Term, and no later than that the last day of the eighty-fourth (84th) full calendar month of the initial Term, (b)&nbsp;Tenant shall deliver written notice to Landlord of
Tenant&#146;s election to exercise the Early Termination Option (the &#147;<U>Early Termination Notice</U>&#148;) no later than the date that is twelve (12)&nbsp;months prior to the Early Termination Date (the &#147;<U>Early Termination
Deadline</U>&#148;), and (c)&nbsp;Tenant shall pay to Landlord an early termination fee, as provided in this Section (the &#147;<U>Early Termination Fee</U>&#148;). The Early Termination Fee shall be an amount that is equal to (i)&nbsp;One Million
Four Hundred Thousand Dollars ($1,400,000), in the event the Early Termination Date occurs during the time period commencing on the last day of the seventy-second (72nd) full month of the initial Term and ending on the last day of the eighty-third
(83<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP>) full month of the initial Term or (ii)&nbsp;One Million One Hundred Thousand Dollars ($1,100,000), in the event the Early Termination Date occurs during the time period commencing on the
first day of the eighty-fourth (84<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) full month of the initial Term and ending on the last day of the eighty-fourth (84<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) full month of the
initial Term; provided, in either case, the Early Termination Fee required to be paid by Tenant to effectuate the termination of the Lease as of the Early Termination Date shall be increased by the amount of any Rent that is due and payable by
Tenant, regardless of whether Tenant received notice from Landlord that such Rent is outstanding. The Early Termination Fee shall be due and payable on the Early Termination Date. Time shall be of the essence as to Tenant&#146;s exercise of the
Early Termination Option and Tenant&#146;s payment of the Early Termination Fee. The period of time within which Tenant may exercise the Early Termination Option and pay the Early Termination Fee shall not be extended or enlarged for any reason
whatsoever, including Force Majeure (as defined below). Tenant assumes full responsibility for maintaining a record of the deadline to exercise the Early Termination Option and pay the Early Termination Fee. Tenant acknowledges that it would be
inequitable to require Landlord to accept the exercise of the Early Termination Option after the Early Termination Deadline and/or the payment of the Early Termination Fee after the Early Termination Date. In the event Tenant does not timely
exercise the Early Termination Option, the Early Termination Option shall be null and void, in which event this Lease shall remain in full force and effect. In addition, Tenant&#146;s failure to timely pay the Early Termination Fee shall render the
Early Termination Notice null and void, in which event this Lease shall remain in full force and effect as if the Early Termination Notice had not been given. In the event that Tenant timely exercises the Early Termination Option and pays the Early
Termination Fee in accordance with the provisions of this Section, then all Rent shall be paid through and apportioned as of the Early Termination Date, the Term shall terminate as of the Early Termination Date, and Landlord and Tenant shall have no
further obligations under this Lease after the Early Termination Date, except with respect to those obligations which expressly survive the expiration or earlier termination of this Lease. The Early Termination Option shall be personal to and only
exercisable by the original Tenant (i.e., Silverback Therapeutics, Inc.) and, in the event of an Exempt Transfer, such Tenant&#146;s Affiliate (as such terms are defined in <U>Section</U><U></U><U>&nbsp;29.1</U>), and shall only apply to the extent
that the original Tenant (and not any assignee, or any sublessee or other transferee of the original Tenant&#146;s interest in this Lease, other than Tenant&#146;s Affiliate in the event of an Exempt Transfer) is the Tenant under this Lease at the
time the Early Termination Notice is given. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing, Tenant&#146;s Early Termination Option shall be expressly
conditioned and contingent upon Tenant negotiating exclusively and in good faith with Landlord for a period of six (6)&nbsp;months following the date that Landlord receives Tenant&#146;s Early Termination Notice (the &#147;<U>Alternate Lease
Negotiation Period</U>&#148;) regarding a lease for premises in existing improvements, or a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">build-to-suit</FONT></FONT> lease in improvements to be constructed, in either case upon
another property owned or leased by Landlord or an affiliate of Landlord (an &#147;<U>Alternate Lease</U>&#148;) and a design for such premises. In consideration of Landlord granting the Early Termination Option to Tenant, during the Alternate Lease
Negotiation Period, Tenant shall not actively solicit or negotiate with any other prospective landlord regarding a lease for other premises and shall negotiate exclusively with Landlord in good faith with the objective of executing a mutual
acceptable lease. In the event that during such Alternate Lease Negotiation Period, either (x)&nbsp;Landlord and Tenant agree in writing that a suitable premises cannot be provided by Landlord or an affiliate of Landlord or (y)&nbsp;Tenant and
Landlord or such affiliate of Landlord are unable to agree and therefore fail to execute and deliver an Alternate Lease, then Tenant shall have the right to seek space outside of the portfolio of properties owned or leased by Landlord and its
affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Possession and Commencement Date</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 The &#147;<U>Term Commencement Date</U>&#148; shall be the earlier of (a)&nbsp;the Estimated Term Commencement Date and (b)&nbsp;the day
the work described in the Work Letter (the &#147;<U>Tenant Improvements</U>&#148;) is Substantially Complete. Tenant shall execute and deliver to Landlord written acknowledgment of the actual Term Commencement Date and the Term Expiration Date
within ten (10)&nbsp;days after Tenant takes occupancy of the Premises, in the form attached as <U>Exhibit C </U>hereto. Failure to execute and deliver such acknowledgment, however, shall not affect the Term Commencement Date or Landlord&#146;s or
Tenant&#146;s liability hereunder. Failure by Tenant to obtain validation by any medical review board or other similar governmental licensing of the Premises required for the Permitted Use by Tenant shall not serve to extend the Term Commencement
Date. The term &#147;<U>Substantially Complete</U>&#148; or &#147;<U>Substantial Completion</U>&#148; means that the Tenant Improvements are substantially complete in accordance with the Approved Plans (as defined in the Work Letter), except for
minor punch list items, and a temporary or permanent certificate of occupancy has been issued with respect to the Tenant Improvements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 Tenant shall cause the Tenant Improvements to be constructed in the Premises pursuant to the Work Letter attached hereto as <U>Exhibit
B</U> (the &#147;<U>Work Letter</U>&#148;) at a cost to Landlord not to exceed Two Million Seven Hundred Eleven Thousand Eight Hundred Dollars ($2,711,800) (based upon One Hundred Forty Dollars ($140.00) per square foot of Rentable Area (as defined
below) of the Premises (the &#147;<U>TI Allowance</U>&#148;). The TI Allowance may be applied to the costs of (m)&nbsp;construction, (n) reimbursement of Landlord&#146;s actual,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses for project review and project management with respect to the Tenant Improvements (which costs shall not exceed Forty Thousand Dollars ($40,000)),
(o) commissioning of mechanical, electrical and plumbing systems by a licensed, qualified commissioning agent hired by Tenant, and review of such party&#146;s commissioning report by a licensed, qualified commissioning agent hired by Landlord,
(p)&nbsp;space planning, architect, engineering and other related services performed by third parties unaffiliated with Tenant, (q)&nbsp;building permits and other taxes, fees, charges and levies by </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Governmental Authorities (as defined below) for permits or for inspections of the Tenant Improvements, and (r)&nbsp;costs and expenses for labor, material, equipment and fixtures, provided that
no more than five percent (5%) of the TI Allowance may be applied towards the cost of the purchase and installation of cabling and telecom improvements within the Premises. In no event shall the TI Allowance be used for (v)&nbsp;the cost of work
that is not authorized by the Approved Plans (as defined in the Work Letter) or otherwise approved in writing by Landlord, (w)&nbsp;payments to Tenant or any affiliates of Tenant, (x)&nbsp;except as otherwise provided in this Section, the purchase
of any furniture, personal property or other <FONT STYLE="white-space:nowrap">non-building</FONT> system equipment, (y)&nbsp;costs resulting from any default by Tenant of its obligations under this Lease or (z)&nbsp;costs that are recoverable by
Tenant from a third party (e.g., insurers, warrantors, or tortfeasors). In addition to the TI Allowance, Landlord shall contribute up to Two Thousand Nine Hundred Five and 50/100 Dollars ($2,905.50) (based upon 15/100 Dollars ($0.15) per square foot
of Rentable Area of the Premises) to pay the cost of developing a test fit plan for the Premises (the &#147;<U>Test Fit Allowance</U>&#148;), which shall be disbursed by Landlord directly to Tenant&#146;s architect in accordance with the Work
Letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 Tenant shall have until the date that is twelve (12)&nbsp;months after the Term Commencement Date (the &#147;<U>TI
Deadline</U>&#148;), to expend the unused portion of the TI Allowance and the Test Fit Allowance, after which date Landlord&#146;s obligation to fund such costs shall expire. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 In no event shall any unused TI Allowance or Test Fit Allowance entitle Tenant to a credit against Rent payable under this Lease. Tenant
shall deliver to Landlord (a)&nbsp;a certificate of occupancy for the Premises suitable for the Permitted Use and (b)&nbsp;a Certificate of Substantial Completion in the form of the American Institute of Architects document G704, executed by the
project architect and the general contractor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 Prior to entering upon the Premises (or any portion thereof), Tenant shall furnish to
Landlord evidence satisfactory to Landlord that insurance coverages required of Tenant under the provisions of <U>Article 23</U> are in effect, and such entry shall be subject to all the terms and conditions of this Lease, except that prior to the
Term Commencement Date, Tenant shall not be obligated to pay Base Rent or Tenant&#146;s Adjusted Share of Operating Expenses (as defined below). For clarification, notwithstanding the foregoing, Tenant shall be obligated to pay all costs of
providing utilities to the Premises prior to the Term Commencement Date as set forth in <U>Section</U><U></U><U>&nbsp;4.7</U> below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6
Landlord and Tenant shall mutually agree upon the selection of the architect, engineer, general contractor and major subcontractors, and Landlord and Tenant shall each participate in the review of the competitive bid process. Landlord shall not
unreasonably withhold its consent, but may refuse to approve any architects, consultants, contractors, subcontractors or material suppliers that Landlord reasonably believes could cause labor disharmony or may not have sufficient experience, in
Landlord&#146;s reasonable opinion, to perform work in an occupied Class &#147;A&#148; laboratory research building. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7 At
Landlord&#146;s sole cost and expense, Landlord shall provide window sills and blinds in accordance with Building standard prior to the Estimated Term Commencement Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Condition of Premises.</U> Subject to Landlord&#146;s obligations under this Lease, Tenant
acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty with respect to the condition of the Premises, the Building or the Project, or with respect to the suitability of the Premises, the Building or the
Project for the conduct of Tenant&#146;s business. Tenant acknowledges that (a)&nbsp;it agrees to take the Premises in their condition &#147;as is&#148; as of the Execution Date and (b)&nbsp;Landlord shall have no obligation to alter, repair or
otherwise prepare the Premises for Tenant&#146;s occupancy or to pay for or construct any improvements to the Premises, except with respect to payment of the TI Allowance, the Test Fit Allowance and as otherwise expressly stated in this Lease.
Tenant&#146;s taking of possession of the Premises shall, except as otherwise agreed to in writing by Landlord and Tenant and subject to Landlord&#146;s obligations hereunder, conclusively establish that the Premises, the Building and the Project
were at such time in good, sanitary and satisfactory condition and repair. Notwithstanding anything to the contrary, Landlord shall deliver the Premises to Tenant on the Execution Date, free and clear of any Hazardous Materials in violation of
Applicable Laws to the extent in effect and as interpreted and applied as of the Execution Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>Rentable Area</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 The term &#147;<U>Rentable Area</U>&#148; shall reflect such areas as reasonably calculated by Landlord&#146;s architect, as the same may
be reasonably adjusted from time to time by Landlord in consultation with Landlord&#146;s architect to reflect changes to the Premises, the Building or the Project, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 The Rentable Area of the Building is generally determined by making separate calculations of Rentable Area applicable to each floor within
the Building and totaling the Rentable Area of all floors within the Building. The Rentable Area of a floor is computed by measuring to the outside finished surface of the permanent outer Building walls. The full area calculated as previously set
forth is included as Rentable Area, without deduction for columns and projections or vertical penetrations, including stairs, elevator shafts, flues, pipe shafts, vertical ducts and the like, as well as such items&#146; enclosing walls. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 The term &#147;<U>Rentable Area,</U>&#148; when applied to the Premises, is that area equal to the usable area of the Premises, plus an
equitable allocation of Rentable Area within the Building that is not then utilized or expected to be utilized as usable area, including that portion of the Building devoted to corridors, equipment rooms, restrooms, elevator lobby, atrium and
mailroom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 The Rentable Area of the Project is the total Rentable Area of all buildings within the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 Review of allocations of Rentable Areas as between tenants of the Building and the Project shall be made as frequently as Landlord
reasonably deems appropriate, including in order to facilitate an equitable apportionment of Operating Expenses (as defined below). If such review is by a licensed architect and allocations are certified by such licensed architect as being
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
correct, then Tenant shall be bound by such certifications, absent manifest error, so long as the calculations are commercially reasonable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>Rent</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 Tenant shall pay to
Landlord as Base Rent for the Premises, commencing on the Term Commencement Date, the sums set forth in <U>Section</U><U></U><U>&nbsp;2.3</U>. Base Rent shall be paid in equal monthly installments as set forth in
<U>Section</U><U></U><U>&nbsp;2.3</U> each in advance on the first day of each and every calendar month during the Term; provided that Base Rent for the Premises (excluding the Storage Area) shall be abated during the first four (4)&nbsp;months of
the Term (the &#147;<U>Base Rent Abatement Period</U>&#148;). In the event the Term Commencement Date occurs on a day other than the first day of a calendar month, then monthly Base Rent payable on or before the first day of the last month of the
Base Rent Abatement Period shall be a prorated amount based on the actual number of days in such calendar month following the expiration of the Base Rent Abatement Period. For purposes of clarity, Tenant shall be responsible for Base Rent for the
Storage Space and for all other Rent due pursuant to the terms of this Lease during the Base Rent Abatement Period, except as otherwise expressly provided in <U>Section</U><U></U><U>&nbsp;7.2</U> below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 In addition to Base Rent, Tenant shall pay to Landlord as additional rent (&#147;<U>Additional Rent</U>&#148;) at times hereinafter
specified in this Lease (a)&nbsp;Tenant&#146;s Adjusted Share (as defined below) of Operating Expenses (as defined below), (b) the Property Management Fee (as defined below), and (c)&nbsp;any other amounts that Tenant assumes or agrees to pay under
the provisions of this Lease that are owed to Landlord, including any and all other sums that may become due by reason of any default of Tenant or failure on Tenant&#146;s part to comply with the agreements, terms, covenants and conditions of this
Lease to be performed by Tenant, after notice and the lapse of any applicable cure periods. Notwithstanding the foregoing, Tenant&#146;s obligation to pay Tenant&#146;s Adjusted Share of Operating Expenses shall be abated during the first two
(2)&nbsp;months of the Term (the &#147;<U>Operating Expenses Abatement Period</U>&#148;). In the event the Term Commencement Date occurs on a day other than the first day of a calendar month, then Tenant&#146;s Adjusted Share of Operating Expenses
payable on or before the first day of the last month of the Operating Expenses Abatement Period shall be a prorated amount based on the actual number of days in such calendar month following the expiration of the Operating Expenses Abatement Period.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 Base Rent and Additional Rent shall together be denominated &#147;<U>Rent</U>.&#148; Except as otherwise expressly set forth in this
Lease, Rent shall be paid to Landlord, without abatement, deduction or offset, in lawful money of the United States of America to the address set forth in <U>Section</U><U></U><U>&nbsp;2.8</U> or to such other person or at such other place as
Landlord may from time designate in writing. In the event the Term commences on a day other than the first day of a calendar month or the Term ends on a day other than the last day of a calendar month, then the Rent for such fraction of a month
shall be prorated for such period on the basis of the number of days in the month and shall be paid at the then-current rate for such fractional month. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4 Tenant&#146;s obligation to pay Rent shall not be discharged or otherwise affected by (a)&nbsp;any Applicable Laws now or hereafter
applicable to the Premises, (b)&nbsp;any other restriction on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tenant&#146;s use, (c)&nbsp;except as expressly provided herein, any casualty or taking or (d)&nbsp;any other occurrence. Tenant&#146;s obligation to pay Rent with respect to any period or
obligations arising, existing or pertaining to the period prior to the date of the expiration or earlier termination of the Term or this Lease shall survive any such expiration or earlier termination; <U>provided</U>, however, that nothing in this
sentence shall in any way affect Tenant&#146;s obligations with respect to any other period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. [<U>Intentionally Omitted</U>.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <U>Operating Expenses</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1 As used
herein, the term &#147;<U>Operating Expenses</U>&#148; shall include: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Government impositions, including property tax costs consisting
of real and personal property taxes (including amounts due under any improvement bond upon the Building or the Project (including the parcel or parcels of real property upon which the Building, the other buildings in the Project and areas serving
the Building and the Project are located)) or assessments in lieu thereof imposed by any federal, state, regional, local or municipal governmental authority, agency or subdivision (each, a &#147;<U>Governmental Authority</U>&#148;); taxes on or
measured by gross rentals received from the rental of space in the Project; taxes based on the square footage of the Premises, the Building or the Project, as well as any parking charges, utilities surcharges or any other costs levied, assessed or
imposed by, or at the direction of, or resulting from Applicable Laws or interpretations thereof, promulgated by any Governmental Authority in connection with the use or occupancy of the Project or the parking facilities serving the Project; taxes
on this transaction or any document to which Tenant is a party creating or transferring an interest in the Premises; any fee for a business license to operate an office building; and any expenses, including the reasonable cost of attorneys or
experts, reasonably incurred by Landlord in seeking reduction by the taxing authority of the applicable taxes, less tax refunds obtained as a result of an application for review thereof; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All other costs of any kind paid or incurred by Landlord in connection with the operation or maintenance of the Building and the Project,
which shall include Project office rent at fair market rental for a commercially reasonable amount of space for Project management personnel, to the extent an office used for Project operations is maintained at the Project, plus customary expenses
for such office, and costs of repairs and replacements to improvements within the Project as reasonably appropriate to maintain the Project as required hereunder; costs of utilities furnished to the Common Area; sewer fees; cable television; trash
collection; cleaning, including windows; heating, ventilation and <FONT STYLE="white-space:nowrap">air-conditioning</FONT> (&#147;<U>HVAC</U>&#148;); maintenance of landscaping and grounds; maintenance of drives and parking areas; maintenance of the
roof; security services and devices; building supplies; maintenance or replacement of equipment utilized for operation and maintenance of the Project; license, permit and inspection fees; sales, use and excise taxes on goods and services purchased
by Landlord in connection with the operation, maintenance or repair of the Building or Project systems and equipment; telephone, postage, stationery supplies and other reasonable expenses incurred in connection with the operation, maintenance or
repair of the Project; accounting, legal and other professional fees </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and expenses reasonably incurred in connection with the Project; costs of furniture, draperies, carpeting, landscaping, snow removal and other customary and ordinary items of personal property
provided by Landlord for use in Common Area or in the Project office; capital expenditures incurred (i)&nbsp;in replacing obsolete equipment, (ii)&nbsp;for the primary purpose of reducing Operating Expenses, or (iii)&nbsp;required by any
Governmental Authority to comply with changes in Applicable Laws that take effect after the Execution Date or to ensure continued compliance with Applicable Laws in effect as of the Execution Date, in each case amortized over the useful life
thereof, as reasonably determined by Landlord, in accordance with generally accepted accounting principles; costs of complying with Applicable Laws (except to the extent such costs are incurred to remedy
<FONT STYLE="white-space:nowrap">non-compliance</FONT> as of the Execution Date with Applicable Laws, provided that such <FONT STYLE="white-space:nowrap">non-compliance</FONT> was not caused by Tenant or any Tenant Party); costs to keep the Project
in compliance with, or costs or fees otherwise required under, any CC&amp;Rs (as defined below), including condominium fees; insurance premiums, including premiums for commercial general liability, property casualty, earthquake, terrorism and
environmental coverages; portions of insured losses paid by Landlord as part of the deductible portion of a loss pursuant to the terms of insurance policies; service contracts; costs of services of independent contractors retained to do work of a
nature referenced above; and costs of compensation (including employment taxes and fringe benefits) of all persons who perform regular and recurring duties connected with the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operation and maintenance of the Project, its equipment, the adjacent walks, landscaped areas, drives and parking areas, including janitors, floor waxers,
window washers, watchmen, gardeners, sweepers, plow truck drivers, handymen, and engineering/maintenance/facilities personnel. Notwithstanding any of the foregoing, any insurance deductibles included in Operating Expenses shall be amortized over the
useful life of the repairs constituting capital improvements made with such deductibles, as reasonably determined by Landlord, in accordance with generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding the foregoing, Operating Expenses shall not include any net income, franchise, capital stock, estate or inheritance taxes,
or taxes that are the personal obligation of Tenant or of another tenant of the Project; any leasing commissions; expenses that relate to preparation of rental space for a tenant; expenses of initial development and construction, including grading,
paving, landscaping and decorating (as distinguished from maintenance, repair and replacement of the foregoing); legal expenses relating to other tenants; any costs or expenses relating solely to another tenant; costs of repairs to the extent
reimbursed by (i)&nbsp;a third party, including pursuant to a warranty (outside of any tenant&#146;s operating expense payments), or (ii)&nbsp;payment of insurance proceeds received by Landlord (or that would have been reimbursed had Landlord
carried insurance required by this Lease); interest upon loans to Landlord or secured by a mortgage or deed of trust covering the Project or a portion thereof (<U>provided</U> that interest upon a government assessment or improvement bond payable in
installments shall constitute an Operating Expense under <U>Subsection 9.1(a)</U>); salaries of employees of Landlord above those performing property management and facilities management duties at the Project; depreciation claimed by Landlord for
tax purposes (<U>provided</U> that this exclusion of depreciation is not intended to delete from Operating Expenses actual costs of repairs and replacements that are provided for in <U>Subsection 9.1(b)</U>); taxes that are excluded from Operating
Expenses by the last sentence of <U>Subsection 9.1(a)</U>; costs or expenses related to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
construction of any Building specialty areas, such as Building conference facilities, caf&eacute;, fitness center, loading dock(s) and outdoor meeting space/deck, except as expressly permitted by
<U>Section</U><U></U><U>&nbsp;9.1(b) above</U>; advertising and promotional expenses and other costs incurred in procuring tenants or in selling the Building or Project; legal fees incurred in connection with contract disputes with suppliers; costs
of renovating or otherwise improving or decorating space for any tenant or other occupant of the Building or Project, including Tenant, or relocating any tenant; financing costs, including interest and principal amortization of debts and the costs
of providing the same; rental on ground leases or other underlying leases and the costs of providing the same; wages, bonuses and other compensation of employees not performing property management or facilities management duties with respect to the
Building or the Project; any liabilities, costs or expenses associated with or incurred in connection with the removal, enclosure, encapsulation or other handling of asbestos or other hazardous or toxic materials or substances to the extent existing
as of the Term Commencement Date and not caused or exacerbated by Tenant or any Tenant Party, and the cost of defending against claims in regard to the existence or release of, Hazardous Materials to the extent existing at the Building or Project as
of the Term Commencement Date and not caused or exacerbated by Tenant or any Tenant Party (except with respect to those costs for which Tenant is otherwise responsible pursuant to the express terms of this Lease); costs of any items for which, and
to the extent, Landlord is paid or reimbursed by insurance; increased insurance or real estate taxes to the extent paid by any tenant of the Building or Project or for which Landlord is reimbursed from any other tenant; charges for electricity,
water, or other utilities, services or goods and applicable taxes for which Tenant or any other tenant, occupant, person or other party reimburses Landlord or pays to third parties; any violation of Applicable Laws to the extent that such violation
exists as of the Term Commencement Date and was not caused by Tenant or any Tenant Party; cost of any HVAC, janitorial or other services provided to tenants on an extra cost basis after regular Business Hours (as defined below) and for which such
tenants reimburse Landlord; any costs, expenses, bonds, assessments, entitlement or permit fees or subsidies or other fees associated with the initial construction of the Building or Project by Landlord; cost of any work or service performed on an
extra cost basis for any tenant in the Building or Project to a materially greater extent or in a materially more favorable manner than furnished generally to the tenants and other occupants; cost of any work or services performed for any facility
other than the Building or Project; any cost representing an amount paid to a person, firm, corporation or other entity related to Landlord that is in excess of the amount which would have been paid in the absence of such relationship; any cost of
painting or decorating any interior parts of the Building or Project other than Common Areas; any cost associated with operating an <FONT STYLE="white-space:nowrap">on-</FONT> or <FONT STYLE="white-space:nowrap">off-site</FONT> management office for
the Building or Project, other than as expressly provided in <U>Section</U><U></U><U>&nbsp;9.1(b</U>); Landlord&#146;s general overhead and any other expense not directly attributable to operation and management of the Building and Project (e.g.,
the activities of Landlord&#146;s officers and executives or professional development expenditures); cost of initial cleaning and rubbish removal from the Building or Project to be performed before final completion of the base building or tenant
space; cost of initial landscaping of the Building or Project; attorneys&#146; fees, accounting fees and other expenditures incurred in connection with negotiations, disputes and claims of other tenants or occupants of the Building or Project or
with other third parties, except as specifically otherwise provided in this Lease; cost of initial stock of tools and equipment for operation, repair and maintenance of the Building or Project; capital
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expenses (except as allowed under <U>Section</U><U></U><U>&nbsp;9.1(b)</U> above); late fees or charges incurred by Landlord due to late payment of expenses resulting from Landlord&#146;s
negligence or willful misconduct; cost of acquiring, securing, cleaning or maintaining sculptures, paintings and other works of art in excess of $25,000 in total; taxes on Landlord&#146;s business (such as income, excess profits, franchise, capital
stock, estate, inheritance, etc.); charitable or political contributions; costs and expenses incurred in connection with compliance with or the contesting or settlement of any claimed violation of law or requirements of law to the extent that such
violation existed as of the Term Commencement Date and was not caused by Tenant or any Tenant Party; direct costs or allocable costs associated with parking operations if there is a separate charge to Tenant, other tenants or the public for parking;
costs expressly excluded from Operating Expenses elsewhere in this Lease or that are charged to or paid by Tenant under other provisions of this Lease; professional fees and disbursements and other costs and expenses related to the ownership (as
opposed to the use, occupancy, operation, maintenance or repair) of the Project; and all other items to the extent that another party compensates or pays Landlord for such item so that Landlord shall not recover any item of cost more than once. To
the extent that Tenant uses more than Tenant&#146;s Pro Rata Share of any item of Operating Expenses, Tenant shall pay Landlord for such excess in addition to Tenant&#146;s obligation to pay Tenant&#146;s Pro Rata Share of Operating Expenses (such
excess, together with Tenant&#146;s Pro Rata Share, &#147;<U>Tenant&#146;s Adjusted Share</U>&#148;); provided Landlord shall reasonably endeavor to make such determination and apply such adjustments in a
<FONT STYLE="white-space:nowrap">non-discriminatory</FONT> manner with respect to the tenants of the Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2 Tenant shall pay to
Landlord on the first day of each calendar month of the Term, as Additional Rent, (a)&nbsp;the Property Management Fee (as defined below), and (b)&nbsp;Landlord&#146;s estimate of Tenant&#146;s Adjusted Share of Operating Expenses with respect to
the Building and the Project, as applicable, for such month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w) The &#147;<U>Property Management Fee</U>&#148; shall equal three percent
(3%) of Base Rent due from Tenant. Tenant shall pay the Property Management Fee in accordance with <U>Section</U><U></U><U>&nbsp;9.2</U> with respect to the entire Term, including any extensions thereof or any holdover periods, regardless of whether
Tenant is obligated to pay Base Rent, Operating Expenses or any other Rent with respect to any such period or portion thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) Within
ninety (90)&nbsp;days after the conclusion of each calendar year (or such longer period as may be reasonably required by Landlord), Landlord shall furnish to Tenant a statement showing in reasonable detail the actual Operating Expenses,
Tenant&#146;s Adjusted Share of Operating Expenses, and the cost of providing utilities to the Premises for the previous calendar year (&#147;<U>Landlord&#146;s Statement</U>&#148;). Any additional sum due from Tenant to Landlord shall be due and
payable within thirty (30)&nbsp;days after receipt of an invoice therefor. If the amounts paid by Tenant pursuant to this Section exceed Tenant&#146;s Adjusted Share of Operating Expenses for the previous calendar year, then Landlord shall credit
the difference against the Rent next due and owing from Tenant; <U>provided</U> that, if the Lease term has expired, Landlord shall accompany Landlord&#146;s Statement with payment for the amount of such difference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(y) Any amount due under this Section for any period that is less than a full month shall be
prorated for such fractional month on the basis of the number of days in themonth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3 Landlord may, from time to time, modify
Landlord&#146;s calculation and allocation procedures for Operating Expenses, so long as such modifications produce Dollar results substantially consistent with Landlord&#146;s then-current practice at the Project. Since the Project consists of
multiple buildings, certain Operating Expenses may pertain to a particular building(s) and other Operating Expenses to the Project as a whole. Landlord reserves the right in its reasonable discretion to allocate any such costs applicable to any
particular building within the Project solely to such building rather than the Project as a whole, and other such costs applicable to the Project as a whole among the buildings in the Project (which may include the Building), with the tenants in
each building being responsible for paying their respective shares of such building costs to the extent required under their leases. If Landlord allocates certain costs to the Building as well as other building(s) in the Project, said costs shall be
included in the Operating Expenses for the Project as a whole; if Landlord allocates certain Operating Expenses to the Building only, Tenant shall only be responsible for that amount of Operating Expenses equal to Tenant&#146;s Pro Rata Share of the
Building. Landlord shall allocate such costs among the buildings (including the Building) in a reasonable, <FONT STYLE="white-space:nowrap">non-discriminatory</FONT> manner, and such allocation shall be binding on Tenant. To the extent that Landlord
and affiliate(s) of Landlord currently own other property(ies) adjacent to the Project or its neighboring properties (collectively, &#147;<U>Neighboring Properties</U>&#148;) then in connection with Landlord performing services for the Project
pursuant to this Lease, similar services may be performed by the same vendor(s) for Neighboring Properties, as long as Tenant does not bear the additional cost of such services to Neighboring Properties in excess of the cost of such services if they
were provided solely to the Project. In such a case, Landlord shall reasonably allocate to the Building or Project (as applicable) the costs for such services based upon the ratio that the Rentable Area of the Building or Project (as applicable)
bears to the total Rentable Area of all of the Neighboring Properties or buildings on the Neighboring Properties (as applicable) for which the services are performed, unless the scope of the services performed for any building or property (including
the Building and the Project) is disproportionately more or less than for others, in which case Landlord shall equitably allocate the costs based on the scope of the services being performed for each building or property (including the Building and
the Project). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4 Landlord&#146;s Statement shall be final and binding upon Tenant unless Tenant, within ninety (90)&nbsp;days after
Tenant&#146;s receipt thereof, shall contest any item therein by giving written notice to Landlord, specifying each item contested and the reasons therefor. If, during such ninety <FONT STYLE="white-space:nowrap">(90)-day</FONT> period, Tenant
reasonably and in good faith questions or contests the correctness of Landlord&#146;s Statement, Landlord shall provide Tenant with reasonable access to review Landlord&#146;s books and records to the extent relevant to determination of Operating
Expenses, and such other information as Landlord reasonably determines to be responsive to Tenant&#146;s written inquiries regarding the same. In the event that, after Tenant&#146;s review of such information, Landlord and Tenant (both acting in
good faith) cannot agree upon the amount stated in Landlord&#146;s Statement, then Tenant shall have the right to have an independent public </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accounting firm hired by Tenant (and approved by Landlord, which approval Landlord shall not unreasonably withhold, condition or delay) on an hourly basis and not on a <FONT
STYLE="white-space:nowrap">contingent-fee</FONT> basis (at Tenant&#146;s sole cost and expense except as provided below), subject to a reasonable confidentiality agreement, audit and review such of Landlord&#146;s books and records for the year in
question as directly relate to the determination of Operating Expenses for such year (the &#147;<U>Independent Review</U>&#148;). Landlord shall make such books and records available at the location where Landlord maintains them in the ordinary
course of its business. Landlord need not provide copies of any books or records, provided that Tenant shall be entitled to make such copies at its expense. Tenant shall commence the Independent Review within thirty (30)&nbsp;days after the date
Landlord has given Tenant access to Landlord&#146;s books and records for the Independent Review. Tenant shall complete the Independent Review and notify Landlord in writing of Tenant&#146;s specific objections to Landlord&#146;s calculation of
Operating Expenses (including a written statement of the basis, nature and amount of each proposed adjustment) no later than ninety (90)&nbsp;days after Landlord has first given Tenant access to Landlord&#146;s books and records for the Independent
Review. Landlord shall review the results of any such Independent Review. The parties shall endeavor in good faith to agree promptly and reasonably upon Operating Expenses taking into account the results of such Independent Review. If, as of sixty
(60)&nbsp;days after Tenant has submitted the Independent Review to Landlord, the parties have not agreed on the appropriate adjustments to Operating Expenses, then the parties shall engage a mutually agreeable independent third party accountant
with at least ten (10)&nbsp;years&#146; experience in commercial real estate accounting in the Seattle, Washington area (the &#147;<U>Accountant</U>&#148;). If the parties cannot agree on the Accountant, each shall within ten (10)&nbsp;days after
such impasse appoint an Accountant (different from the accountant and accounting firm that conducted the Independent Review) and, within ten (10)&nbsp;days after the appointment of both such Accountants, those two Accountants shall select a third
(which cannot be the accountant and accounting firm that conducted the Independent Review). If either party fails to timely appoint an Accountant, then the Accountant the other party appoints shall be the sole Accountant. Within ten (10)&nbsp;days
after appointment of the Accountant(s), Landlord and Tenant shall each simultaneously give the Accountants (with a copy to the other party) its determination of Operating Expenses, with such supporting data or information as each submitting party
determines appropriate. Within ten (10)&nbsp;days after such submissions, the Accountants shall by majority vote select either Landlord&#146;s or Tenant&#146;s determination of Operating Expenses. The Accountants may not select or designate any
other determination of Operating Expenses. The determination of the Accountant(s) shall bind the parties. If the parties agree or the Accountant(s) determine that Tenant&#146;s Adjusted Share of Operating Expenses actually paid by Tenant for the
calendar year in question exceeded Tenant&#146;s obligations for such calendar year, then Landlord shall, at Tenant&#146;s option, either (a)&nbsp;credit the excess to the next succeeding installments of estimated Additional Rent or (b)&nbsp;pay the
excess to Tenant within thirty (30)&nbsp;days after delivery of such results. If the parties agree or the Accountant(s) determine that Tenant&#146;s payments of Tenant&#146;s Adjusted Share of Operating Expenses for such calendar year were less than
Tenant&#146;s obligation for the calendar year, then Tenant shall pay the deficiency to Landlord within thirty (30)&nbsp;days after delivery of such results. If it is finally agreed or determined that Landlord&#146;s Statement for any year
overcharges Tenant by five percent (5%) or more, then Landlord shall reimburse Tenant all reasonable costs of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
review (including without limitation the cost of third party auditors) within thirty (30)&nbsp;days of Landlord&#146;s receipt of an invoice therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5 Tenant shall not be responsible for Operating Expenses with respect to any time period prior to the Term Commencement Date;
<U>provided</U>, however, that if Landlord shall permit Tenant possession of the Premises prior to the Term Commencement Date for purposes other than construction of the Tenant Improvements and other <FONT STYLE="white-space:nowrap">move-in</FONT>
activities, Tenant shall be responsible for Operating Expenses with respect thereto from such earlier date of possession (the Term Commencement Date or such earlier date, as applicable, the &#147;<U>Expense Trigger Date</U>&#148;), subject to
Tenant&#146;s right to an abatement of Tenant&#146;s Adjusted Share of Operating Expenses under <U>Section</U><U></U><U>&nbsp;7.2</U>; and <U>provided</U>, further, that Landlord may annualize certain Operating Expenses incurred prior to the Expense
Trigger Date over the course of the budgeted year during which the Expense Trigger Date occurs, and Tenant shall be responsible for the annualized portion of such Operating Expenses corresponding to the number of days during such year, commencing
with the Expense Trigger Date, for which Tenant is otherwise liable for Operating Expenses pursuant to this Lease. Tenant&#146;s responsibility for Tenant&#146;s Adjusted Share of Operating Expenses shall continue to the latest of (a)&nbsp;the date
of termination of the Lease, (b)&nbsp;the date Tenant has fully vacated the Premises and (c)&nbsp;if termination of the Lease is due to a Default by Tenant, then the date of rental commencement of a replacement tenant (provided such date shall not
extend beyond the scheduled Term Expiration Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6 Operating Expenses for the calendar year in which Tenant&#146;s obligation to
share therein commences and for the calendar year in which such obligation ceases shall be prorated on a <FONT STYLE="white-space:nowrap">non-discriminatory</FONT> basis reasonably determined by Landlord. Expenses such as taxes, assessments and
insurance premiums that are incurred for an extended time period shall be prorated based upon the time periods to which they apply so that the amounts attributed to the Premises relate in a reasonable manner to the time period wherein Tenant has an
obligation to share in Operating Expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.7 Within thirty (30)&nbsp;days after the end of each calendar month, Tenant shall submit to
Landlord an invoice, or, in the event an invoice is not available, an itemized list, of all costs and expenses that (a)&nbsp;Tenant has incurred (either internally or by employing third parties) during the prior month and (b)&nbsp;for which Tenant
reasonably believes it is entitled to reimbursements from Landlord pursuant to the terms of this Lease or that Tenant reasonably believes is the responsibility of Landlord pursuant to this Lease or the Work Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.8 In the event that the Building or Project is less than fully occupied during a calendar year, Tenant acknowledges that Landlord may
extrapolate Operating Expenses that vary depending on the occupancy of the Building or Project, as applicable, to equal Landlord&#146;s reasonable estimate of what such Operating Expenses would have been had the Building or Project, as applicable,
been ninety-five percent (95%) occupied during such calendar year; <U>provided</U>, however, that Landlord shall not recover more than one hundred percent (100%) of any individual component of Operating Expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <U>Taxes on Tenant</U><U>&#146;</U><U>s Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 Tenant shall be solely responsible for the payment of any and all taxes levied upon (a)&nbsp;personal property and trade fixtures located
at the Premises and (b)&nbsp;any gross or net receipts of or sales by Tenant, and shall pay the same at least twenty (20)&nbsp;days prior to delinquency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2 If any such taxes on Tenant&#146;s personal property or trade fixtures are levied against Landlord or Landlord&#146;s property or, if the
assessed valuation of the Building, the Property or the Project is increased by inclusion therein of a value attributable to Tenant&#146;s personal property or trade fixtures, and if Landlord, after written notice to Tenant, pays the taxes based
upon any such increase in the assessed value of the Building, the Property or the Project, then Tenant shall, upon demand, repay to Landlord the taxes so paid by Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 If any improvements in or alterations to the Premises, whether owned by Landlord or Tenant and whether or not affixed to the real
property so as to become a part thereof, are assessed for real property tax purposes at a valuation higher than the valuation at which improvements conforming to Landlord&#146;s building standards (the &#147;<U>Building Standard</U>&#148;) in other
spaces in the Building are assessed, then the real property taxes and assessments levied against Landlord or the Building, the Property or the Project by reason of such excess assessed valuation shall be deemed to be taxes levied against personal
property of Tenant and shall be governed by the provisions of <U>Section</U><U></U><U>&nbsp;10.2</U>. Any such excess assessed valuation due to improvements in or alterations to space in the Project leased by other tenants at the Project shall not
be included in Operating Expenses. If the records of the applicable governmental assessor&#146;s office are available and sufficiently detailed to serve as a basis for determining whether such Tenant improvements or alterations are assessed at a
higher valuation than the Building Standard, then such records shall be binding on both Landlord and Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <U>Security Deposit</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1 Tenant shall deposit with Landlord on or before the Execution Date the sum set forth in <U>Section</U><U></U><U>&nbsp;2.6</U> (the
&#147;<U>Security Deposit</U>&#148;), which sum shall be held by Landlord as security for the faithful performance by Tenant of all of the terms, covenants and conditions of this Lease to be kept and performed by Tenant during the period commencing
on the Execution Date and ending upon the expiration or termination of Tenant&#146;s obligations under this Lease. If Tenant Defaults (as defined below) with respect to any provision of this Lease, including any provision relating to the payment of
Rent, then Landlord may (but shall not be required to) use, apply or retain all or any part of the Security Deposit for the payment of any Rent or any other sum in default, or to compensate Landlord for any other loss or damage that Landlord may
suffer by reason of Tenant&#146;s Default. If any portion of the Security Deposit is so used or applied, then Tenant shall, within ten (10)&nbsp;days following demand therefor, deposit cash with Landlord in an amount sufficient to restore the
Security Deposit to its original amount, and Tenant&#146;s failure to do so shall be a material breach of this Lease. The obligations of each party pursuant to this Article shall survive the expiration or earlier termination of this Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2 In the event of bankruptcy or other debtor-creditor proceedings against Tenant, the
Security Deposit shall be deemed to be applied first to the payment of Rent and other charges due Landlord for all periods prior to the filing of such proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3 Landlord may deliver to any purchaser of Landlord&#146;s interest in the Premises the funds deposited hereunder by Tenant, and thereupon,
Landlord shall be discharged from any further liability with respect to such deposit. This provision shall also apply to any subsequent transfers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.4 The Security Deposit, or any balance thereof remaining after application thereof in accordance with this <U>Article 11</U>, shall be
returned to Tenant (or, at Landlord&#146;s option, to the last assignee of Tenant&#146;s interest hereunder) within thirty (30)&nbsp;days after the expiration or earlier termination of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.5 If the Security Deposit shall be in cash, Landlord shall hold the Security Deposit in an account at a banking organization selected by
Landlord; <U>provided</U>, however, that Landlord shall not be required to maintain a separate account for the Security Deposit, but may intermingle it with other funds of Landlord. Landlord shall be entitled to all interest and/or dividends, if
any, accruing on the Security Deposit. Landlord shall not be required to credit Tenant with any interest for any period during which Landlord does not receive interest on the Security Deposit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.6 The Security Deposit may be in the form of cash, a letter of credit or any other security instrument acceptable to Landlord in its sole
discretion. Tenant may at any time, except when Tenant is in Default (as defined below), deliver a letter of credit (the &#147;<U>L/C Security</U>&#148;) as the entire Security Deposit, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If Tenant elects to deliver L/C Security, then Tenant shall provide Landlord, and maintain in full force and effect throughout the Term and
until the date that is six (6)&nbsp;months after the then-current Term Expiration Date, a letter of credit in the form of <U>Exhibit</U><U></U><U>&nbsp;D</U> issued by an issuer reasonably satisfactory to Landlord, in the amount of the Security
Deposit, with an initial term of at least one year. Landlord may require the L/C Security to be <FONT STYLE="white-space:nowrap">re-issued</FONT> by a different issuer at any time during the Term if Landlord reasonably believes that the issuing bank
of the L/C Security is or may soon become insolvent; provided, however, Landlord shall return the existing L/C Security to the existing issuer immediately upon receipt of the substitute L/C Security. If any issuer of the L/C Security shall become
insolvent or placed into FDIC receivership, then Tenant shall immediately deliver to Landlord (without the requirement of notice from Landlord) substitute L/C Security issued by an issuer reasonably satisfactory to Landlord, and otherwise conforming
to the requirements set forth in this Article. As used herein with respect to the issuer of the L/C Security, &#147;insolvent&#148; shall mean the determination of insolvency as made by such issuer&#146;s primary bank regulator <I>(i.e., </I>the
state bank supervisor for state chartered banks; the OCC or OTS, respectively, for federally chartered banks or thrifts; or the Federal Reserve for its member banks). If, at the Term Expiration Date, any Rent remains uncalculated or unpaid, then
(i)&nbsp;Landlord shall with reasonable diligence complete any necessary calculations, (ii)&nbsp;Tenant shall extend the expiry date of such L/C Security from time to time as Landlord reasonably requires and (iii)&nbsp;in such extended period,
Landlord shall not unreasonably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
refuse to consent to an appropriate reduction of the L/C Security. Tenant shall reimburse Landlord&#146;s legal costs (as estimated by Landlord&#146;s counsel) in handling Landlord&#146;s
acceptance of L/C Security or its replacement or extension. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If Tenant delivers to Landlord satisfactory L/C Security in place of the
entire Security Deposit, Landlord shall remit to Tenant any cash Security Deposit Landlord previously held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Landlord may draw upon
the L/C Security, and hold and apply the proceeds in the same manner and for the same purposes as the Security Deposit, if (i)&nbsp;an uncured Default (as defined below) exists, (ii)&nbsp;as of the date that is forty-five (45)&nbsp;days before any
L/C Security expires (even if such scheduled expiry date is after the Term Expiration Date) Tenant has not delivered to Landlord an amendment or replacement for such L/C Security, reasonably satisfactory to Landlord, extending the expiry date to the
earlier of (1)&nbsp;six (6) months after the then-current Term Expiration Date or (2)&nbsp;the date that is one year after the then-current expiry date of the L/C Security, (iii)&nbsp;the L/C Security provides for automatic renewals, Landlord asks
the issuer to confirm the current L/C Security expiry date, and the issuer fails to do so within ten (10)&nbsp;business days, (iv)&nbsp;Tenant fails to pay (when and as Landlord reasonably requires) any bank charges for Landlord&#146;s transfer of
the L/C Security or (v)&nbsp;the issuer of the L/C Security ceases, or announces that it will cease, to maintain an office in the city where Landlord may present drafts under the L/C Security (and fails to permit drawing upon the L/C Security by
overnight courier or facsimile). This Section does not limit any other provisions of this Lease allowing Landlord to draw the L/C Security under specified circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Tenant shall not seek to enjoin, prevent, or otherwise interfere with Landlord&#146;s draw under L/C Security, even if it violates this
Lease. Tenant acknowledges that the only effect of a wrongful draw would be to substitute a cash Security Deposit for L/C Security, causing Tenant no legally recognizable damage. Landlord shall hold the proceeds of any draw in the same manner and
for the same purposes as a cash Security Deposit. In the event of a wrongful draw, the parties shall cooperate to allow Tenant to post replacement L/C Security simultaneously with the return to Tenant of the wrongfully drawn sums, and Landlord shall
upon request confirm in writing to the issuer of the L/C Security that Landlord&#146;s draw was erroneous. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) If Landlord transfers its
interest in the Premises, then Tenant shall at Tenant&#146;s expense, within five (5)&nbsp;business days after receiving a request from Landlord, deliver (and, if the issuer requires, Landlord shall consent to) an amendment to the L/C Security
naming Landlord&#146;s grantee as substitute beneficiary. If the required Security Deposit changes while L/C Security is in force, then Tenant shall deliver (and, if the issuer requires, Landlord shall consent to) a corresponding amendment to the
L/C Security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.7 The Security Deposit shall be reduced on the following dates (each a &#147;<U>Reduction Date</U>&#148;) by the
following corresponding amounts: (a)&nbsp;on the first day of each of the third (3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP>), fourth (4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) and fifth (5<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) Lease Years (as defined below), by Two Hundred Thousand Dollars ($200,000) each; and (b)&nbsp;on the first day of the sixth (6th) Lease Year, by One Hundred Thousand Dollars ($100,000);
<U>provided</U> that (i)&nbsp;during the twelve (12)&nbsp;month period prior to the applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Reduction Date, there has not been a Default by Tenant, and (ii)&nbsp;no condition exists on the applicable Reduction Date that, with the passage of time or the giving of notice or both would
constitute a Default (provided that if such a condition exists, but such condition is subsequently cured such that no Default occurs, then the reduction of the Security Deposit shall take place on the date of completion of such cure).
Notwithstanding anything to the contrary, the Security Deposit shall not be reduced below Two Hundred Fifty Thousand Dollars ($250,000). For purposes of this Lease, the term &#147;<U>Lease Year</U>&#148; shall mean each consecutive twelve
(12)&nbsp;month period during the Term commencing as of the Term Commencement Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <U>Use</U>. Tenant shall use the Premises for the Permitted Use,
and shall not use the Premises, or permit or suffer the Premises to be used, for any other purpose without Landlord&#146;s prior written consent, which consent Landlord may withhold in its sole and absolute discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2 Tenant shall not use or occupy the Premises in violation of Applicable Laws; zoning ordinances; or the certificate of occupancy issued
for the Building or the Project, and shall, upon five (5)&nbsp;days&#146; written notice from Landlord, discontinue any use of the Premises that is declared or claimed by any Governmental Authority having jurisdiction to be a violation of any of the
above, or that in Landlord&#146;s reasonable opinion violates any of the above. Tenant shall comply with any direction of any Governmental Authority having jurisdiction that shall, by reason of the nature of Tenant&#146;s particular use or occupancy
of the Premises, impose any duty upon Tenant or Landlord with respect to the Premises or with respect to the use or occupation thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.3 Tenant shall not do or permit to be done anything that will invalidate or increase the cost of any fire, environmental, extended coverage
or any other insurance policy covering the Building or the Project, and shall comply with all rules, orders, regulations and requirements of the insurers of the Building and the Project, and Tenant shall promptly, upon demand, reimburse Landlord for
any additional premium charged for such policy by reason of Tenant&#146;s failure to comply with the provisions of this Article. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.4
Tenant shall keep all doors opening onto public corridors closed, except when in use for ingress and egress. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.5 No additional locks or
bolts of any kind shall be placed upon any of the doors or windows by Tenant, nor shall any changes be made to existing locks or the mechanisms thereof without Landlord&#146;s prior written consent. Tenant shall, upon termination of this Lease,
return to Landlord all keys to offices and restrooms either furnished to or otherwise procured by Tenant. In the event any key so furnished to Tenant is lost, Tenant shall pay to Landlord the cost of replacing the same or of changing the lock or
locks opened by such lost key if Landlord shall deem it necessary to make such change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.6 No awnings or other projections shall be
attached to any outside wall of the Building. No curtains, blinds, shades or screens shall be attached to or hung in, or used in connection with, any window or door of the Premises other than Landlord&#146;s standard window coverings. Neither the
interior nor exterior of any windows shall be coated or otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sunscreened without Landlord&#146;s prior written consent, nor shall any bottles, parcels or other articles be placed on the windowsills or items attached to windows that are visible from outside
the Premises. No equipment, furniture or other items of personal property shall be placed on any exterior balcony without Landlord&#146;s prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.7 No sign, advertisement or notice (&#147;<U>Signage</U>&#148;) shall be exhibited, painted or affixed by Tenant on any part of the
Premises or the Building without Landlord&#146;s prior written consent, which consent shall not be unreasonably withheld. Signage shall conform to Landlord&#146;s design criteria. At Landlord&#146;s sole cost and expense, Landlord shall provide
Tenant with lobby and directory signage in the Building substantially consistent with the Signage permitted for comparable tenants in the Project, as Landlord reasonably determines. Tenant shall have the right to install Tenant&#146;s proportionate
share of the Building exterior Signage, subject to all pre-existing rights of other tenants, Applicable Laws and Landlord&#146;s reasonable review and approval. For any other Signage, Tenant shall, at Tenant&#146;s own cost and expense,
(a)&nbsp;acquire all permits for such Signage in compliance with Applicable Laws and (b)&nbsp;design, fabricate, install and maintain such Signage in a first-class condition. Tenant shall be responsible for reimbursing Landlord for costs incurred by
Landlord in removing any of Tenant&#146;s Signage upon the expiration or earlier termination of the Lease, or at Landlord&#146;s option, Tenant shall remove such signage at its cost and shall repair any damage occasioned by such removal. Interior
signs on entry doors to the Premises and the directory tablet shall be inscribed, painted or affixed for Tenant by Landlord at Tenant&#146;s sole cost and expense, and shall be of a size, color and type and be located in a place acceptable to
Landlord. The directory tablet shall be provided exclusively for the display of the name and location of tenants only. Without the prior written consent of Landlord, which consent shall not be unreasonably delayed or withheld, Tenant shall not place
anything on the exterior of the corridor walls or corridor doors other than Landlord&#146;s standard lettering. At Landlord&#146;s option, Landlord may install any Tenant Signage, and Tenant shall pay all reasonable costs associated with such
installation within thirty (30)&nbsp;days after demand therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.8 Tenant may only place equipment within the Premises with floor
loading consistent with the Building&#146;s structural design unless Tenant obtains Landlord&#146;s prior written approval. Tenant may place such equipment only in a location designed to carry the weight of such equipment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.9 Tenant shall cause any equipment or machinery to be installed in the Premises so as to reasonably prevent sounds or vibrations therefrom
from extending into the Common Area or other offices in the Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.10 Tenant shall not (a)&nbsp;do or permit anything to be done in
or about the Premises that shall in any way obstruct or interfere with the rights of other tenants or occupants of the Project, or injure or annoy them, (b)&nbsp;use or allow the Premises to be used for unlawful purposes, (c)&nbsp;cause, maintain or
permit any nuisance or waste in, on or about the Project or (d)&nbsp;take any other action that would in Landlord&#146;s reasonable determination in any manner adversely affect other tenants&#146; quiet use and enjoyment of their space or adversely
impact their ability to conduct business in a professional and suitable work environment. Notwithstanding anything in this Lease to the contrary, Tenant may not install any security systems (including cameras) outside
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Premises or that record sounds or images outside the Premises without Landlord&#146;s prior written consent, which Landlord may withhold in its sole and absolute discretion. Landlord shall
provide an <FONT STYLE="white-space:nowrap">on-site</FONT> security guard at the Building, Monday through Friday between the hours of 6:00 a.m. and 10:00 p.m., (y) a roving security patrol service at or around the Building during <FONT
STYLE="white-space:nowrap">non-Business</FONT> Hours, and (z)&nbsp;once the Building is fully occupied, an additional <FONT STYLE="white-space:nowrap">on-site</FONT> security guard at the Building, Monday through Friday between the hours of 8:00
a.m. and 4:00 p.m.; <U>provided, however</U>, by providing such security, Landlord does not assume any liability or obligation to Tenant with respect to the safety or security of the Building, the Project or the Premises, except to the extent that
such liability arises directly from Landlord&#146;s gross negligence or willful misconduct. The Building will be accessible only via a security access card system or such other security system as Landlord hereafter may elect to install. The Building
shall be secured and accessible only via a security access card. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.11 Subject to Landlord&#146;s express obligations under this Lease,
Tenant shall be responsible for all liabilities, costs and expenses arising out of or in connection with the compliance of the Premises with the Americans with Disabilities Act, 42 U.S.C. &#167; 12101, et seq., and any state and local accessibility
laws, codes, ordinances and rules (collectively, and together with regulations promulgated pursuant thereto, the &#147;<U>ADA</U>&#148;), and Tenant shall indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to
Landlord) and hold Landlord and its affiliates, employees, agents and contractors; and any lender, mortgagee or beneficiary (each, a &#147;<U>Lender</U>&#148; and, collectively with Landlord and its affiliates, employees, agents and contractors, the
&#147;<U>Landlord Indemnitees</U>&#148;) harmless from and against any demands, claims, liabilities, losses, costs, expenses, actions, causes of action, damages, suits or judgments, and all reasonable expenses (including reasonable attorneys&#146;
fees, charges and disbursements, regardless of whether the applicable demand, claim, action, cause of action or suit is voluntarily withdrawn or dismissed) incurred in investigating or resisting the same (collectively, &#147;<U>Claims</U>&#148;)
arising out of any such failure of the Premises to comply with the ADA. Tenant&#146;s obligations pursuant to this Section shall survive the expiration or earlier termination of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.12 Except to the extent prevented from doing so by a failure of Landlord to comply with its obligations under
<U>Section</U><U></U><U>&nbsp;18.1</U> hereof. Tenant shall maintain temperature and humidity in the Premises in accordance with ASHRAE standards at all times. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.13 Tenant shall have unrestricted access to the Premises twenty-four (24)&nbsp;hours a day, seven (7)&nbsp;days a week, every day of the
year during the Term and any extension thereof, subject to such security systems and procedures as Landlord may implement from time to time. As of the Execution Date, the hours of operation of the Building (the &#147;<U>Business Hours</U>&#148;) are
7 a.m. to 6 p.m. Pacific time, Monday through Friday. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <U>Rules and Regulations, CC&amp;Rs, Parking Facilities and Common Area</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1 Tenant shall have the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right, in common with others, to use the Common Area in
conjunction with Tenant&#146;s use of the Premises for the Permitted Use, and such use of the Common Area and Tenant&#146;s use of the Premises shall be subject to the rules and regulations adopted by Landlord and attached hereto as <U>Exhibit
E</U>, together with such other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonable and nondiscriminatory rules and regulations as are hereafter promulgated by Landlord in its sole and absolute discretion (the &#147;<U>Rules and Regulations</U>&#148;). Tenant shall
faithfully observe and comply with, and shall ensure that its contractors, subcontractors, employees, subtenants and invitees faithfully observe and comply with, the Rules and Regulations; provided that to the extent any Rules and Regulations are in
direct conflict with any provision of this Lease, the terms of this Lease shall control. Landlord shall not be responsible to Tenant for the violation or <FONT STYLE="white-space:nowrap">non-performance</FONT> by any other tenant or any agent,
employee or invitee thereof of any of the Rules and Regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.2 This Lease is subject to any recorded covenants, conditions or
restrictions on the Project or Property, as the same may be amended, amended and restated, supplemented or otherwise modified from time to time (the &#147;<U>CC&amp;Rs</U>&#148;). Tenant shall, at its sole cost and expense, comply with the
CC&amp;Rs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.3 The Building has a two and <FONT STYLE="white-space:nowrap">one-half</FONT> (2.5) level secure <FONT
STYLE="white-space:nowrap">sub-grade</FONT> parkingstructure that accommodates approximately one hundred thirty (130)&nbsp;cars and can be accessed through the garage entry of the Adjacent Building. Tenant shall have a
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable license to use Tenant&#146;s Parking Share (as defined below) of the parking spaces in the parking structure serving the Building in common on an unreserved basis with other tenants
of the Building and the Project during the Term (including any extension thereof) at a cost equal to the prevailing market rate for parking (as of the Execution Date, the rate for such parking spaces shall be Two Hundred Seventy Five Dollars
($275.00) per parking space per month), which Tenant shall pay simultaneously with payments of Base Rent as Additional Rent; provided that Landlord shall not increase the rate that Landlord charges Tenant for such parking spaces more frequently than
one (1)&nbsp;time in any twelve (12)&nbsp;month period, and any such increase shall not be greater than five percent (5%) of the then-current rate for such parking spaces. For purposes of this Section, &#147;Tenant&#146;s Parking Share&#148; shall
equal one (1)&nbsp;space per one thousand (1,000) square feet of Rentable Area of the Premises, up to a total of nineteen (19)&nbsp;parking spaces. Tenant may increase or decrease the number of parking spaces licensed by Tenant pursuant to the terms
of this paragraph from time to time, upon at least ten (10)&nbsp;days prior written notice to Landlord (not to exceed Tenant&#146;s Parking Share of parking spaces unless otherwise agreed upon in writing by Landlord). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.4 Tenant agrees not to unreasonably overburden the parking facilities and agrees to cooperate with Landlord and other tenants in the use of
the parking facilities. Landlord reserves the right to determine that parking facilities are becoming overcrowded and to limit Tenant&#146;s use thereof, provided that Tenant shall always have the option to license at least Tenant&#146;s Parking
Share of parking spaces. Upon such determination, Landlord may reasonably allocate parking spaces among Tenant and other tenants of the Building or the Project. Nothing in this Section, however, is intended to create an affirmative duty on
Landlord&#146;s part to monitor parking; provided that Landlord shall not grant parking rights during Business Hours to a greater number of spaces than the total number of parking spaces actually available in the parking facility. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.5 Subject to the terms of this Lease including the Rules and Regulations and the rights
of other tenants of the Project, Tenant shall have the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right to access the freight loading dock serving the Building, at no additional cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <U>Project Control by Landlord</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.1
Landlord reserves full control over the Building and the Project to the extent not inconsistent with Tenant&#146;s enjoyment of the Premises as provided by this Lease. Thisreservation includes Landlord&#146;s right to subdivide the Project; convert
the Building and other buildings within the Project to condominium units; change the size of the Project by selling all or a portion of the Project or adding real property and any improvements thereon to the Project; grant easements and licenses to
third parties; maintain or establish ownership of the Building separate from fee title to the Property; make additions to or reconstruct portions of the Building and the Project; install, use, maintain, repair, replace and relocate for service to
the Premises and other parts of the Building or the Project pipes, ducts, conduits, wires and appurtenant fixtures, wherever located in the Premises, the Building or elsewhere at the Project; and alter or relocate any other Common Area or facility,
including private drives, lobbies, entrances and landscaping; <U>provided</U>, however, that such rights shall be exercised in a way that does not materially adversely affect Tenant&#146;s beneficial use and occupancy of the Premises, including the
Permitted Use and Tenant&#146;s access to the Premises. Tenant acknowledges that Landlord specifically reserves the right to allow the exclusive use of corridors and restroom facilities located on specific floors to one or more tenants occupying
such floors; <U>provided</U>, however, that Tenant shall not be deprived of the use of the corridors reasonably required to serve the Premises or of restroom facilities serving the floor upon which the Premises are located. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.2 Subject to the terms and conditions of this Lease, possession of areas of the Premises necessary for utilities, services, safety and
operation of the Building is reserved to Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.3 Tenant shall, at Landlord&#146;s request, promptly execute such further documents
as may be reasonably appropriate to assist Landlord in the performance of its obligations hereunder; <U>provided</U> that Tenant need not execute any document that creates additional liability for Tenant or that materially adversely affects
Tenant&#146;s quiet enjoyment and use of the Premises as provided for in this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.4 Landlord may, at any and all reasonable times
during <FONT STYLE="white-space:nowrap">non-business</FONT> hours (or during Business Hours, if (a)&nbsp;with respect to <U>Subsections 14.4(u)</U> through <U>14.4(y)</U>, Tenant so requests, and (b)&nbsp;with respect to <U>Subsection 14.4(z</U>),
if Landlord so requests), and upon twenty-four (24)&nbsp;hours&#146; prior notice (which may be oral or by email to the office manager or other Tenant-designated individual at the Premises; but <U>provided</U> that no time restrictions shall apply
or advance notice be required if an emergency necessitates immediate entry), enter the Premises to (u)&nbsp;inspect the same and to determine whether Tenant is in compliance with its obligations hereunder, (v)&nbsp;supply any service Landlord is
required to provide hereunder, (w)&nbsp;alter, improve or repair any portion of the Building other than the Premises for which access to the Premises is reasonably necessary, (x)&nbsp;post notices of nonresponsibility, (y)&nbsp;access the telephone
equipment, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
electrical substation and fire risers and (z)&nbsp;show the Premises to prospective tenants during the final year of the Term and current and prospective purchasers and lenders at any time. In
connection with any such alteration, improvement or repair as described in <U>Subsection 14.4(w</U>), Landlord may erect in the Premises or elsewhere in the Project scaffolding and other structures reasonably required for the alteration, improvement
or repair work to be performed. In no event shall Tenant&#146;s Rent abate as a result of Landlord&#146;s activities pursuant to this Section; <U>provided</U>, however, that all such activities shall be conducted in such a manner so as to cause as
little interference to Tenant as is reasonably possible and, except in an emergency, Landlord shall comply with Tenant&#146;s reasonable security and safety protocols. Landlord shall at all times retain a key with which to unlock all of the doors in
the Premises. If an emergency necessitates immediate access to the Premises, Landlord may use whatever force is necessary to enter the Premises, and any such entry to the Premises shall not constitute a forcible or unlawful entry to the Premises, a
detainer of the Premises, or an eviction of Tenant from the Premises or any portion thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <U>Quiet Enjoyment</U>. Landlord covenants that Tenant,
upon paying the Rent and performing its obligations contained in this Lease, may peacefully and quietly have, hold and enjoy the Premises, free from any claim by Landlord or persons claiming under Landlord, but subject to all of the terms and
provisions hereof, provisions of Applicable Laws and rights of record to which this Lease is or may become subordinate. This covenant is in lieu of any other quiet enjoyment covenant, either express or implied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16. <U>Utilities and Services</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.1
Subject to Force Majeure (as defined below) and the other provisions of this <U>Article 16</U>, Landlord shall provide, or cause to be provided, to the Premises during Business Hours water, gas, heat, light, power, HVAC, <FONT
STYLE="white-space:nowrap">de-ionized</FONT> water, and elevator service sufficient for the Permitted Use. Except as otherwise expressly provided in this Lease, Tenant shall pay for all water (including the cost to service, repair and replace
reverse osmosis, <FONT STYLE="white-space:nowrap">de-ionized</FONT> and other treated water), gas, heat, light, power, telephone, internet service, cable television, other telecommunications and other utilities supplied to the Premises, together
with any fees, surcharges and taxes thereon. Electric power and CFM/HVAC supplied to the Premises will be separately metered (with meters installed by Landlord at Landlord&#146;s sole cost, and Tenant shall pay the costs for such electric power and
CFM/HVAC supplied to the Premises as Additional Rent. If any other such utility is not separately metered to Tenant, Tenant shall pay Tenant&#146;s Adjusted Share of all charges of such utility jointly metered with other premises as Additional Rent
or, in the alternative, Landlord may, at Landlord&#146;s cost, install metering equipment to measure Tenant&#146;s consumption of such other utilities. Landlord may base its bills for utilities on reasonable estimates; <U>provided</U> that Landlord
adjusts such billings promptly thereafter or as part of the next Landlord&#146;s Statement to reflect the actual cost of providing utilities to the Premises. To the extent that Tenant uses more than Tenant&#146;s Pro Rata Share of any utilities,
then Tenant shall pay Landlord for Tenant&#146;s Adjusted Share of such utilities to reflect such excess. In the event that the Building or Project is less than fully occupied during a calendar year, Tenant acknowledges that Landlord may extrapolate
utility usage that varies depending on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
occupancy of the Building or Project (as applicable) to equal Landlord&#146;s reasonable estimate of what such utility usage would have been had the Building or Project, as applicable, been
ninety-five percent (95%) occupied during such calendar year; <U>provided</U>, however, that Landlord shall not recover more than one hundred percent (100%) of the cost of such utilities. Landlord will not provide any janitorial services to the
Premises. Tenant shall separately contract and pay for janitorial services for the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.2 Except as otherwise stated in the last
four sentences of this <U>Section</U><U></U><U>&nbsp;16.2</U>, Landlord shall not be liable for, nor shall any eviction of Tenant result from, the failure to furnish any utility or service, whether or not such failure is caused by accidents;
breakage; casualties (to the extent not caused by the party claiming Force Majeure); Severe Weather Conditions (as defined below); physical natural disasters (but excluding weather conditions that are not Severe Weather Conditions); strikes,
lockouts or other labor disturbances or labor disputes (other than labor disturbances and labor disputes resulting solely from the acts or omissions of the party claiming Force Majeure); acts of terrorism; riots or civil disturbances; wars or
insurrections; shortages of materials (which shortages are not unique to the party claiming Force Majeure); government regulations, moratoria or other governmental actions, inactions or delays; failures by third parties to deliver gas, oil or
another suitable fuel supply, or inability of the party claiming Force Majeure, by exercise of reasonable diligence, to obtain gas, oil or another suitable fuel; or other causes beyond the reasonable control of the party claiming that Force Majeure
has occurred (collectively, &#147;<U>Force Majeure</U>&#148;); or, to the extent permitted by Applicable Laws, Landlord&#146;s negligence. In the event of such failure, Tenant shall not be entitled to termination of this Lease or any abatement or
reduction of Rent, nor shall Tenant be relieved from the operation of any covenant or agreement of this Lease. &#147;<U>Severe Weather Conditions</U>&#148; means weather conditions that are materially worse than those that reasonably would be
anticipated for the Property at the applicable time based on historic meteorological records. Notwithstanding anything to the contrary in this Lease, if, for more than five (5)&nbsp;consecutive business days following written notice to Landlord and
as a direct result of Landlord&#146;s gross negligence or willful misconduct (and except to the extent that such failure is caused in whole or in part by the action or inaction of a Tenant Party (as defined below)), the provision of HVAC or other
utilities to all or a material portion of the Premises that Landlord must provide pursuant to this Lease is interrupted (a &#147;<U>Material Services Failure</U>&#148;), then Tenant&#146;s Base Rent and Operating Expenses (or, to the extent that
less than all of the Premises are affected, a proportionate amount (based on the Rentable Area of the Premises that is rendered unusable) of Base Rent and Operating Expenses) shall thereafter be abated until the Premises are again usable by Tenant
for the Permitted Use; <U>provided</U>, however, that, if Landlord is diligently pursuing the restoration of such HVAC and other utilities and Landlord provides substitute HVAC and other utilities reasonably suitable for Tenant&#146;s continued use
and occupancy of the Premises for the Permitted Use (e.g., supplying potable water or portable air conditioning equipment), then neither Base Rent nor Operating Expenses shall be abated. During any Material Services Failure, Tenant will cooperate
with Landlord to arrange for the provision of any interrupted utility services on an interim basis via temporary measures until final corrective measures can be accomplished, and Tenant will permit Landlord the necessary access to the Premises to
remedy such Material Service Failure. In the event of any interruption of HVAC or other utilities that Landlord must provide pursuant to this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Lease, regardless of the cause, Landlord shall diligently pursue the restoration of such HVAC and other utilities. Notwithstanding anything in this Lease to the contrary, but subject to
<U>Article</U><U></U><U>&nbsp;24</U> (which shall govern in the event of a casualty), the provisions of this Section shall be Tenant&#146;s sole recourse and remedy in the event of an interruption of HVAC or other utilities to the Premises,
including related to <U>Section</U><U></U><U>&nbsp;16.8.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.3 Tenant shall pay for, prior to delinquency of payment therefor, any
utilities and services that may be furnished to the Premises during or, if Tenant occupies the Premises after the expiration or earlier termination of the Term, after the Term, beyond those utilities provided by Landlord, including telephone,
internet service, cable television and other telecommunications, together with any fees, surcharges and taxes thereon. Upon Landlord&#146;s demand, utilities and services provided to the Premises that are separately metered shall be paid by Tenant
directly to the supplier of such utilities or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.4 Tenant shall not, without Landlord&#146;s prior written consent, use any
device in the Premises (including data processing machines) that will in any way (a)&nbsp;increase the amount of ventilation, air exchange, gas, steam, electricity or water required or consumed in the Premises based upon Tenant&#146;s Pro Rata Share
of the Building or Project (as applicable) beyond the existing capacity of the Building or the Project usually furnished or supplied for the Permitted Use or (b)&nbsp;exceed Tenant&#146;s Pro Rata Share of the Building&#146;s or Project&#146;s (as
applicable) capacity to provide such utilities or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.5 If Tenant shall require utilities or services in excess of those usually
furnished or supplied for tenants in similar spaces in the Building or the Project by reason of Tenant&#146;s equipment or extended hours of business operations outside of the Business Hours (as defined above), then Tenant shall first procure
Landlord&#146;s consent for the use thereof, which consent may not be unreasonably withheld, conditioned or delayed, but Landlord may condition such consent upon the availability of such excess utilities or services, and Tenant shall pay as
Additional Rent an amount equal to the cost of providing such excess utilities and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.6 Landlord shall provide water in Common
Area for lavatory and landscaping purposes only, which water shall be from the local municipal or similar source; <U>provided</U>, however, that if Landlord reasonably determines that Tenant requires, uses or consumes water provided to the Common
Area for any purpose other than ordinary lavatory purposes, Landlord may install, at Landlord&#146;s sole cost and expense, a water meter (&#147;<U>Tenant Water Meter</U>&#148;) and thereby measure Tenant&#146;s water consumption for all purposes.
If Tenant actually requires, uses or consumes water provided to the Common Area for any purpose other than ordinary lavatory purposes, Tenant shall pay Landlord for the costs of any Tenant Water Meter and the installation and maintenance thereof
during the Term. If Landlord installs a Tenant Water Meter, Tenant shall pay for water consumed, as shown on such meter, as and when bills are rendered. If Tenant fails to timely make such payments, Landlord may pay such charges and collect the same
from Tenant. Any such costs or expenses incurred or payments made by Landlord for any of the reasons or purposes stated in this Section shall be deemed to be Additional Rent payable by Tenant and collectible by Landlord as such. Notwithstanding
anything to the contrary in this Section, subject to Force Majeure, and subject to temporary interruptions in service for testing or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in connection with Landlord making necessary repairs or performing its maintenance obligations under this Lease or as otherwise reasonably required by Landlord in connection with the repair,
maintenance or upkeep of the Building or the Project, Landlord shall provide water in the Common Area for lavatory purposes twenty-four (24)&nbsp;hours a day, seven (7)&nbsp;days a week, every day of the year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.7 Landlord reserves the right to stop service of the elevator, plumbing, ventilation, air conditioning and utility systems, when Landlord
deems necessary or desirable, due to accident, emergency or the need to make repairs, alterations or improvements, until such repairs, alterations or improvements shall have been completed, and Landlord shall further have no responsibility or
liability for failure to supply elevator facilities, plumbing, ventilation, air conditioning or utility service when prevented from doing so by Force Majeure; provided that Landlord shall use reasonable efforts to provide one (1)&nbsp;business day
advance notice to Tenant (except in the event of an emergency, then Landlord shall provide prior notice to Tenant to the extent reasonable under the circumstances) of any scheduled stop in service, repair, alteration or improvement that Landlord in
good faith anticipates will materially and adversely impact Tenant, and Landlord further agrees to use reasonable efforts to perform such work outside of Business Hours (except in the event of an emergency) and in a manner that minimizes any
disruption to Tenant. Without limiting the foregoing, it is expressly understood and agreed that any covenants on Landlord&#146;s part to furnish any service pursuant to any of the terms, covenants, conditions, provisions or agreements of this
Lease, or to perform any act or thing for the benefit of Tenant, shall not be deemed breached if Landlord is unable to furnish or perform the same by virtue of Force Majeure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.8 Tenant shall be entitled to use its Pro Rata Share (after deducting any power required for the Common Area) of power from the <FONT
STYLE="white-space:nowrap">back-up</FONT> generator existing at the Building as of the Execution Date (the &#147;<U>Generator</U>&#148;) on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis with other tenants in the Building. The cost of
maintaining, repairing and replacing the Generator shall constitute Operating Expenses. Landlord expressly disclaims any warranties with regard to the Generator or the installation thereof, including any warranty of merchantability or fitness for a
particular purpose. Landlord shall maintain the Generator and any equipment connecting the Generator to Tenant&#146;s automatic transfer switch in good working condition, <U>provided</U>, <U>however</U>, that Tenant shall be solely responsible, at
Tenant&#146;s sole cost and expense, (and Landlord shall not be liable) for maintaining and operating Tenant&#146;s automatic transfer switch and the distribution of power from Tenant&#146;s automatic transfer switch throughout the Premises, and
provided further that Landlord shall not be liable for any failure to make any repairs or to perform any maintenance of the Generator that is an obligation of Landlord unless and except to the extent that Landlord negligently fails to make such
repairs or perform such maintenance and such failure persists for an unreasonable time after Tenant provides Landlord with written notice of the need for such repairs or maintenance. Upon receipt of such written notice, Landlord shall promptly
commence to cure such failure and shall diligently prosecute the same to completion in accordance with <U>Section</U><U></U><U>&nbsp;31.12</U> of this Lease. The provisions of <U>Section</U><U></U><U>&nbsp;16.2</U> of this Lease shall apply to the
Generator. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.9 For the Premises, Landlord shall (a)&nbsp;maintain and operate the HVAC systems used
for the Permitted Use only (&#147;<U>Base HVAC</U>&#148;) and (b)&nbsp;subject to <U>Subsection 16.9(a</U>), furnish HVAC as reasonably required (except as this Lease otherwise provides) for reasonably comfortable occupancy of the Premises during
Business Hours, subject to Force Majeure, casualty, eminent domain or as otherwise specified in this Article. Except as otherwise stated in the last four sentences of <U>Section</U><U></U><U>&nbsp;16.2</U> of this Lease, Landlord shall have no
liability, and Tenant shall have no right or remedy, on account of any interruption or impairment in HVAC services; <U>provided</U> that Landlord shall diligently endeavor to cure any such interruption or impairment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.10 For any utilities serving the Premises for which Tenant is billed directly by such utility provider, during the Term, Tenant agrees to
furnish to Landlord, but only to the extent necessary for Landlord to prepare an ENERGY STAR<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Statement of Performance (or similar comprehensive utility usage report) as described below
(a)&nbsp;any invoices or statements for such utilities within thirty (30)&nbsp;days after receipt of Landlord&#146;s written request therefor, however, Tenant shall not be obligated to provide such invoices or statements to Landlord if Tenant has
authorized Landlord to obtain copies of such invoices or statements from the utility provider, (b)&nbsp;within thirty (30)&nbsp;days after receipt of Landlord&#146;s written request, any other utility usage information reasonably requested by
Landlord, and (c)&nbsp;within thirty (30)&nbsp;days after each calendar year during the Term, authorization to allow Landlord to access Tenant&#146;s usage information necessary for Landlord to complete an ENERGY STAR<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Statement of Performance (or similar comprehensive utility usage report (e.g., related to Labs 21), if requested by Landlord) and any other information reasonably requested by Landlord for the
immediately preceding year; and Tenant shall comply with any other energy usage or consumption requirements required by Applicable Laws. Tenant shall retain records of utility usage at the Premises, including invoices and statements from the utility
provider, for at least sixty (60)&nbsp;months, or such other period of time as may be requested by Landlord. Tenant acknowledges that any utility information for the Premises, the Building and the Project may be shared with third parties, including
Landlord&#146;s consultants and Governmental Authorities. In the event that Tenant fails to comply with this Section, Tenant hereby authorizes Landlord to collect utility usage information directly from the applicable utility providers. In addition
to the foregoing, Tenant shall comply with all Applicable Laws related to the disclosure and tracking of energy consumption at the Premises. The obligations of each party pursuant to this Section shall survive the expiration or earlier termination
of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17. <U>Alterations</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.1 Tenant shall make no alterations, additions or improvements other than the Tenant Improvements in or to the Premises or engage in any
construction, demolition, reconstruction, renovation or other work (whether major or minor) of any kind in, at or serving the Premises (&#147;<U>Alterations</U>&#148;) without Landlord&#146;s prior written approval, which approval Landlord shall not
unreasonably withhold, condition or delay; <U>provided</U>, however, that, in the event any proposed Alteration adversely affects (a)&nbsp;any structural portions of the Building, including exterior walls, the roof, the foundation or slab,
foundation or slab systems (including barriers and subslab systems) or the core of the Building, (b)&nbsp;the exterior of the Building or (c)&nbsp;any Building systems, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including elevator, plumbing, HVAC, electrical, security, life safety and power, then Landlord may withhold its approval in its sole and absolute discretion. Tenant shall, in making any
Alterations, use only those architects, contractors, suppliers and mechanics of which Landlord has given prior written approval, which approval shall not be unreasonably withheld, conditioned or delayed. In seeking Landlord&#146;s approval, Tenant
shall provide Landlord, at least fifteen (15)&nbsp;days in advance of any proposed construction, with plans, specifications, bid proposals, certified stamped engineering drawings and calculations by Tenant&#146;s engineer of record or architect of
record (including connections to the Building&#146;s structural system, modifications to the Building&#146;s envelope, <FONT STYLE="white-space:nowrap">non-structural</FONT> penetrations in slabs or walls, and modifications or <FONT
STYLE="white-space:nowrap">tie-ins</FONT> to life safety systems), work contracts, requests for laydown areas and such other information concerning the nature and cost of the Alterations as Landlord may reasonably request. In no event shall Tenant
use or Landlord be required to approve any architects, consultants, contractors, subcontractors or material suppliers that Landlord reasonably believes could cause labor disharmony or may not have sufficient experience, in Landlord&#146;s reasonable
opinion, to perform work in an occupied Class &#147;A&#148; laboratory research building and in lab areas. Notwithstanding the foregoing, Tenant may make strictly cosmetic changes to the Premises that do not require any permits or more than three
(3)&nbsp;total contractors and subcontractors (&#147;<U>Cosmetic Alterations</U>&#148;) without Landlord&#146;s consent; <U>provided</U> that (y)&nbsp;the cost of any Cosmetic Alterations does not exceed Fifty Thousand Dollars ($50,000.00) in any
one instance or annually, (z)&nbsp;such Cosmetic Alterations do not (i)&nbsp;require any structural or other substantial modifications to the Premises, (ii)&nbsp;require any changes to or adversely affect the Building systems, (iii)&nbsp;affect the
exterior of the Building or (iv)&nbsp;trigger any requirement under Applicable Laws that would require Landlord to make any alteration or improvement to the Premises, the Building or the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.2 Tenant shall not construct or permit to be constructed partitions or other obstructions that might interfere with free access to
mechanical installation or service facilities of the Building or with other tenants&#146; components located within the Building, or interfere with the moving of Landlord&#146;s equipment to or from the enclosures containing such installations or
facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.3 Tenant shall accomplish any work performed on the Premises or the Building in such a manner as to permit any life safety
systems to remain fully operable at all times. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.4 Any work performed on the Premises, the Building or the Project by Tenant or
Tenant&#146;s contractors shall be done at such times and in such manner as Landlord may from time to time reasonably designate. Tenant covenants and agrees that all work done by Tenant or Tenant&#146;s contractors shall be performed in full
compliance with Applicable Laws. Within thirty (30)&nbsp;days after completion of any Alterations, Tenant shall provide Landlord with complete &#147;as built&#148; drawing print sets and electronic CADD files on disc (or files in such other current
format in common use as Landlord reasonably approves or requires) showing any changes in the Premises, as well as a commissioning report prepared by a licensed, qualified commissioning agent hired by Tenant and approved by Landlord for all new or
affected mechanical, electrical and plumbing systems. Any such &#147;as built&#148; plans shall show the applicable Alterations as an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
overlay on the Building <FONT STYLE="white-space:nowrap">as-built</FONT> plans; <U>provided</U> that Landlord provides the Building &#147;as built&#148; plans to Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.5 Before commencing any Alterations or Tenant Improvements, Tenant shall give Landlord at least fifteen (15)&nbsp;days&#146; prior written
notice of the proposed commencement of such work and shall, if required by Landlord, secure, at Tenant&#146;s own cost and expense, a completion and lien indemnity bond satisfactory to Landlord for such work. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.6 Tenant shall repair any damage to the Premises caused by Tenant&#146;s removal of any property from the Premises. During any such
restoration period, Tenant shall pay Rent to Landlord as provided herein as if such space were otherwise occupied by Tenant. Tenant&#146;s obligations pursuant to this Section shall survive the expiration or earlier termination of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.7 The Premises plus any Alterations; Signage; Tenant Improvements; attached equipment, decorations, fixtures and trade fixtures; movable
laboratory casework and related appliances; and other additions and improvements attached to or built into the Premises made by either of the parties (including all floor and wall coverings; paneling; sinks and related plumbing fixtures; laboratory
benches; exterior venting fume hoods; <FONT STYLE="white-space:nowrap">walk-in</FONT> freezers and refrigerators; ductwork; conduits; electrical panels and circuits; business and trade fixtures; attached machinery and equipment; and <FONT
STYLE="white-space:nowrap">built-in</FONT> furniture and cabinets, in each case, together with all additions and accessories thereto), shall (unless, prior to such construction or installation, Landlord elects otherwise in writing) at all times
remain the property of Landlord, shall remain in the Premises and shall (unless, prior to construction or installation thereof, Landlord elects otherwise in writing) be surrendered to Landlord upon the expiration or earlier termination of this
Lease. For the avoidance of doubt, the items listed on <U>Exhibit F</U> attached hereto (which <U>Exhibit F</U> may be updated by Tenant from and after the Term Commencement Date, subject to Landlord&#146;s written consent) constitute Tenant&#146;s
property and shall be removed by Tenant upon the expiration or earlier termination of the Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.8 Notwithstanding any other provision
of this Article to the contrary, in no event shall Tenant remove any improvement from the Premises as to which Landlord contributed payment, including the Tenant Improvements, without Landlord&#146;s prior written consent, which consent Landlord
shall not unreasonably withhold, condition or delay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.9 If Tenant shall fail to remove any of its property from the Premises prior to
the expiration or earlier termination of this Lease, then Landlord may, at its option, remove the same in any manner that Landlord shall choose and store such effects without liability to Tenant for loss thereof or damage thereto, and Tenant shall
pay Landlord, upon demand, any costs and expenses incurred due to such removal and storage or Landlord may, at its sole option and without notice to Tenant, sell such property or any portion thereof at private sale and without legal process for such
price as Landlord may obtain and apply the proceeds of such sale against any (a)&nbsp;amounts due by Tenant to Landlord under this Lease and (b)&nbsp;any expenses incident to the removal, storage and sale of such personal property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.10 Tenant shall pay to Landlord an amount equal to two percent (2%) of the cost to Tenant
of all Alterations (other than the Tenant Improvements) to cover Landlord&#146;s overhead and expenses for plan review, engineering review, coordination, scheduling and supervision thereof For purposes of payment of such sum, Tenant shall submit to
Landlord copies of all bills, invoices and statements covering the costs of such charges, accompanied by payment to Landlord of the fee set forth in this Section. Tenant shall reimburse Landlord for any extra expenses incurred by Landlord by reason
of faulty work done by Tenant or its contractors, or by reason of delays caused by such work, or by reason of inadequate <FONT STYLE="white-space:nowrap">clean-up.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.11 Within sixty (60)&nbsp;days after final completion of the Tenant Improvements or any Alterations performed by Tenant with respect to the
Premises, Tenant shall submit to Landlord documentation showing the amounts expended by Tenant with respect to such Tenant Improvements and Alterations, together with supporting documentation reasonably acceptable to Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.12 Tenant shall take, and shall cause its contractors to take, commercially reasonable steps to protect the Premises during the performance
of any Alterations or Tenant Improvements, including covering or temporarily removing any window coverings so as to guard against dust, debris or damage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.13 Tenant shall require its contractors and subcontractors performing work on the Premises to name Landlord and its affiliates and Lenders
as additional insureds on their respective insurance policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18. <U>Repairs and Maintenance</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.1 Landlord shall repair and maintain the structural and exterior portions and Common Area of the Building and the Project, including
roofing and covering materials; foundations (excluding any architectural slabs, but including any structural slabs); exterior walls; plumbing; fire sprinkler systems (if any); base Building HVAC systems (for purposes of clarity, any supplemental
HVAC serving the Premises and Tenant equipment shall not be part of the base Building HVAC and shall be Tenant&#146;s obligation to maintain and repair pursuant to <U>Section</U><U></U><U>&nbsp;18.2 </U>below); elevators; and base Building
electrical systems installed or furnished by Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.2 Except for services of Landlord, if any, required by
<U>Section</U><U></U><U>&nbsp;18.1</U>, and subject to Landlord&#146;s obligations under this Lease, Tenant shall at Tenant&#146;s sole cost and expense maintain and keep the Premises (including any supplemental HVAC serving the Premises, and any
other Tenant systems or equipment exclusively serving the Premises) and every part thereof in good condition and repair, damage thereto from ordinary wear and tear or from casualty and condemnation excepted (subject to the terms of <U>Sections
24</U> and <U>25</U> below), and shall, within ten (10)&nbsp;days after receipt of written notice from Landlord, provide to Landlord any maintenance records that Landlord reasonably requests. Tenant shall, upon the expiration or sooner termination
of the Term, surrender the Premises to Landlord in as good a condition as when received, ordinary wear and tear and damage by casualty and condemnation excepted (subject to the terms of <U>Sections 24</U> and 25 below) and with the Tenant
Improvements in substantially the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
same condition as existed on the Term Commencement Date; and shall, at Landlord&#146;s request and Tenant&#146;s sole cost and expense, remove all telephone and data systems, wiring and equipment
from the Premises (with respect to wiring, only to the extent installed by a Tenant Party (as defined below)), and repair any damage to the Premises caused thereby. Landlord shall have no obligation to alter, remodel, improve, repair, decorate or
paint the Premises or any part thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.3 Landlord shall not be liable for any failure to make any repairs or to perform any
maintenance that is Landlord&#146;s obligation pursuant to this Lease except to the extent that (a)&nbsp;such failure shall persist for an unreasonable time after Tenant provides Landlord with written notice of the need of such repairs or
maintenance, or (b)&nbsp;such failure arises from Landlord&#146;s gross negligence or willful misconduct. Tenant shall provide written notice to Landlord of any needed maintenance or repairs which Landlord is obligated to perform under this Lease,
and Landlord shall use reasonable good faith efforts to undertake such maintenance or repairs as soon as reasonably possible after receipt of such notice. Tenant waives its rights under Applicable Laws now or hereafter in effect to make repairs at
Landlord&#146;s expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.4 If any excavation shall be made upon land adjacent to or under the Building, or shall be authorized to be
made, Tenant shall afford to the person causing or authorized to cause such excavation, license to enter the Premises for the purpose of performing such work as such person shall deem necessary or desirable to preserve and protect the Building from
injury or damage and to support the same by proper foundations, without any claim for damages or liability against Landlord and without reducing or otherwise affecting Tenant&#146;s obligations under this Lease; subject to compliance with
Tenant&#146;s reasonable security procedures and so long as Landlord is using commercially reasonable efforts to minimize any material adverse interference with Tenant&#146;s use of the Premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.5 This Article relates to repairs and maintenance arising in the ordinary course of operation of the Building and the Project. In the event
of a casualty described in <U>Article 24</U>, <U>Article 24</U> shall apply in lieu of this Article. In the event of eminent domain, <U>Article 25</U> shall apply in lieu of this Article. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.6 Costs incurred by Landlord pursuant to this Article shall constitute Operating Expenses, subject to the exclusions set forth in
<U>Section</U><U></U><U>&nbsp;9.1(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.7 Notwithstanding anything to the contrary in this Lease, in the event of emergency that
results in an interruption in services to the Premises that has the reasonable potential to become a material interference to the operation of Tenant&#146;s equipment or the Premises with a material adverse effect on the conduct of Tenant&#146;s
business, if Landlord has not commenced restoring such services within forty-eight (48)&nbsp;hours after written notice from Tenant, and the failure to commence such restoration is not due to the unavailability of necessary equipment, parts,
materials or labor or other Force Majeure, then Tenant shall have the right, but not the obligation, to take such action and perform such work as is reasonably necessary to repair any portion or component of the Premises, Building or the Project to
the extent necessary to restore such services to the Premises; provided, however, that (a)&nbsp;Tenant shall give Landlord as much </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
advance written notice as reasonably practicable of the actions it is taking, (b)&nbsp;in no event shall Tenant be permitted access to, or to take any action that would reasonably be expected to
affect, any equipment or facilities that serve other tenants&#146; premises in the Building or the Project, and (c)&nbsp;in exercising its rights under this <U>Section</U><U></U><U>&nbsp;18.7</U>. Tenant shall be solely responsible for, and shall
reimburse, indemnify, defend and hold harmless and release Landlord and its affiliates and their respective directors, officers, shareholders, members, employees, contractors and agents for, from and against, any Claims suffered or incurred by
Landlord, any other tenant or any other person or entity caused by or arising from the actions taken by Tenant, including but not limited to any damage or injury to persons or property (subject to Landlord&#146;s obligations under the last sentence
of this paragraph). Tenant shall use commercially reasonable efforts to minimize interference with the rights of other tenants to use their respective premises in the Building, and all work done in accordance herewith must be performed at a
reasonable and competitive cost and expense. If the emergency situation resulting in the interruption of services to the Premises addressed by Tenant under this Section is due to the negligence or intentional misconduct of Landlord or its agents,
contractors or employees, or if the work performed by Tenant to remedy such interruption of services to the Premises is not Tenant&#146;s sole responsibility under the terms and conditions of this Lease, then Landlord agrees to reimburse Tenant for
the reasonable cost of work performed by Tenant pursuant to this Section within thirty (30)&nbsp;days of invoice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19. <U>Liens</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.1 Subject to the immediately succeeding sentence, Tenant shall keep the Premises, the Building and the Project free from any liens arising
out of work or services performed, materials furnished to or obligations incurred by Tenant. Tenant further covenants and agrees that any mechanic&#146;s or materialman&#146;s lien filed against the Premises, the Building or the Project for work or
services claimed to have been done for, or materials claimed to have been furnished to, or obligations incurred by Tenant shall be discharged or bonded by Tenant within ten (10)&nbsp;days after the filing thereof, at Tenant&#146;s sole cost and
expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.2 Should Tenant fail to discharge or bond against any lien of the nature described in <U>Section</U><U></U><U>&nbsp;19.1</U>,
Landlord may, at Landlord&#146;s election, pay such claim or post a statutory lien bond or otherwise provide security to eliminate the lien as a claim against title, and Tenant shall immediately reimburse Landlord for the costs thereof as Additional
Rent. Tenant shall indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to Landlord) and hold the Landlord Indemnitees harmless from and against any Claims arising from any such liens, including any
administrative, court or other legal proceedings related to such liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.3 In the event that Tenant leases or finances the acquisition
of office equipment, furnishings or other personal property of a removable nature utilized by Tenant in the operation of Tenant&#146;s business, Tenant warrants that any Uniform Commercial Code financing statement shall, upon its face or by exhibit
thereto, indicate that such financing statement is applicable only to removable personal property of Tenant located within the Premises. In no event shall the address of the Premises, the Building or the Project be furnished on a financing
statementwithout qualifying language as to applicability of the lien only to removable personal property </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
located in an identified suite leased by Tenant. Should any holder of a financing statement record or place of record a financing statement that appears to constitute a lien against any interest
of Landlord or against equipment that may be located other than within an identified suite leased by Tenant, Tenant shall, within ten (10)&nbsp;days after filing such financing statement, cause (a)&nbsp;a copy of the lender security agreement or
other documents to which the financing statement pertains to be furnished to Landlord to facilitate Landlord&#146;s ability to demonstrate that the lien of such financing statement is not applicable to Landlord&#146;s interest and
(b)&nbsp;Tenant&#146;s lender to amend such financing statement and any other documents of record to clarify that any liens imposed thereby are not applicable to any interest of Landlord in the Premises, the Building or the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20. <U>Estoppel Certificate</U>. Tenant shall, within ten (10)&nbsp;business days after receipt of written notice from Landlord, execute, acknowledge and
deliver a statement in writing substantially in the form attached to this Lease as Exhibit G or on any other form reasonably requested by a current or proposed Lender or encumbrancer or proposed purchaser, (a)&nbsp;certifying that this Lease is
unmodified and in full force and effect (or, if modified, stating the nature of such modification and certifying that this Lease as so modified is in full force and effect) and the dates to which rental and other charges are paid in advance, if any,
(b)&nbsp;acknowledging that there are not, to Tenant&#146;s knowledge, any uncured defaults on the part of Landlord hereunder, or specifying such defaults if any are claimed, and (c)&nbsp;setting forth such further information with respect to
thisLease or the Premises as may be requested thereon. Any such statements may be relied upon by any prospective purchaser or encumbrancer of all or any portion of the Property. Tenant&#146;s failure to deliver any such statement within such the
prescribed time shall, at Landlord&#146;s option, constitute a Default (as defined below) under this Lease, and, in any event, shall be binding upon Tenant that the Lease is in full force and effect and without modification except as may be
represented by Landlord in any certificate prepared by Landlord and delivered to Tenant for execution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">21. <U>Hazardous Materials</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.1 Tenant shall not cause or permit any Hazardous Materials (as defined below) to be brought upon, kept or used in or about the Premises,
the Building or the Project in violation of Applicable Laws by Tenant or any of its employees, agents, contractors or invitees (collectively with Tenant, each a &#147;<U>Tenant Party</U>&#148;). If (a)&nbsp;Tenant breaches such obligation,
(b)&nbsp;the presence of Hazardous Materials as a result of such a breach by Tenant results in contamination of theProject, any portion thereof, or any adjacent property, (c)&nbsp;contamination of the Premisesotherwise occurs during the Term or any
extension or renewal hereof or holding over hereunder as a result of acts or omissions of a Tenant Party or if a Tenant Party exacerbates any existing condition involving Hazardous Materials, or (d)&nbsp;contamination of the Project occurs as a
result of Hazardous Materials that are placed on or under or are released into the Project by a TenantParty, then Tenant shall indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to Landlord) and hold the
Landlord Indemnitees harmless from and against any and all Claims of any kind or nature, including (w)&nbsp;diminution in value of the Project or any portion thereof, (x)&nbsp;damages for the loss or restriction on use of rentable or usable space or
of any amenity of the Project, (y)&nbsp;damages arising from any adverse impact on marketing of space in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Project or any portion thereof and (z)&nbsp;sums paid in settlement of Claims that arise before, during or after the Term to the extent resulting from such breach or contamination. This
indemnification by Tenant includes costs incurred in connection with any investigation of site conditions or any <FONT STYLE="white-space:nowrap">clean-up,</FONT> remedial, removal or restoration work required by any Governmental Authority because
of Hazardous Materials present in the air, soil or groundwater above, on, under or about the Project. Without limiting the foregoing, if the presence of any Hazardous Materials in, on, under or about the Project, any portion thereof or any adjacent
property caused or permitted by any Tenant Party results in any contamination of the Project, any portion thereof or any adjacent property, then Tenant shall promptly take all actions at its sole cost and expense as are necessary to return the
Project, any portion thereof or any adjacent property to its respective condition existing prior to the time of such contamination; <U>provided</U> that Landlord&#146;s written approval of such action shall first be obtained, which approval Landlord
shall not unreasonably withhold; and <U>provided</U> further, that it shall be reasonable for Landlord to withhold its consent if such actions could have a material adverse long-term or short-term effect on the Project, any portion thereof or any
adjacent property. Tenant&#146;s obligations under this Section shall not be affected, reduced or limited by any limitation on the amount or type of damages, compensation or benefits payable by or for Tenant under workers&#146; compensation acts,
disability benefit acts, employee benefit acts or similar legislation. Notwithstanding the foregoing, Landlord shall indemnify, save, defend (at Tenant&#146;s option and with counsel reasonably acceptable to Tenant) and hold Tenant harmless from and
against any and all Claims resulting from the presence of Hazardous Materials at the Project in violation of Applicable Laws as of the date Landlord delivers the Premises to Tenant, unless placed at the Project by a Tenant Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.2 Landlord acknowledges that it is not the intent of this Article to prohibit Tenant from operating its business for the Permitted Use.
Tenant may operate its business according to the custom of Tenant&#146;s industry so long as the use or presence of Hazardous Materials is strictly and properly monitored in accordance with Applicable Laws. As a material inducement to Landlord to
allow Tenant to use Hazardous Materials in connection with its business, Tenant agrees to deliver to Landlord (a)&nbsp;a list identifying each type of Hazardous Material to be present at the Premises that is subject to regulation under any
environmental Applicable Laws in the form of a Tier II form pursuant to Section&nbsp;312 of the Emergency Planning and Community <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-to-Know</FONT></FONT> Act of 1986 (or any
successor statute) or any other form reasonably requested by Landlord, (b)&nbsp;a list of any and all approvals or permits from Governmental Authorities required in connection with the presence of such Hazardous Material at the Premises and
(c)&nbsp;correct and complete copies of (i)&nbsp;notices of violations of Applicable Laws related to Hazardous Materials and (ii)&nbsp;plans relating to the installation of any storage tanks to be installed in, on, under or about the Project
(<U>provided</U> that installation of storage tanks shall only be permitted after Landlord has given Tenant its written consent to do so, which consent Landlord may withhold in its sole and absolute discretion) and closure plans or any other
documents required by any and all Governmental Authorities for any storage tanks installed in, on, under or about the Project for the closure of any such storage tanks (collectively, &#147;Hazardous Materials Documents&#148;). Tenant shall deliver
to Landlord updated Hazardous Materials Documents, within fourteen (14)&nbsp;days after receipt of a written request therefor from Landlord, not more often than once per year, unless (m)&nbsp;there are any changes to the Hazardous Materials
Documents or (n)&nbsp;Tenant initiates any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Alterations or changes its business, in either case in a way that involves any material increase in the types or amounts of Hazardous Materials, in which case Tenant shall deliver updated
Hazardous Materials documents (without Landlord having to request them) before or, if not practicable to do so before, as soon as reasonably practicable after the occurrence of the events in <U>Subsection 21.2(m) or (n)</U>. For each type of
Hazardous Material listed, the Hazardous Materials Documents shall include (t)&nbsp;the chemical name, (u)&nbsp;the material state (e.g., solid, liquid, gas or cryogen), (v) the concentration, (w)&nbsp;the storage amount and storage condition (e.g.,
in cabinets or not in cabinets), (x) the use amount and use condition (e.g., open use or closed use), (y) the location (e.g., room number or other identification) and (z)&nbsp;if known, the chemical abstract service number. Notwithstanding anything
in this Section to the contrary, Tenant shall not be required to provide Landlord with any documents containing information of a proprietary nature, unless such documents contain a reference to Hazardous Materials or activities related to Hazardous
Materials. Landlord may, at Landlord&#146;s expense, cause the Hazardous Materials Documents to be reviewed by a person or firm qualified to analyze Hazardous Materials to confirm compliance with the provisions of this Lease and with Applicable
Laws. In the event that a review of the Hazardous Materials Documents indicates <FONT STYLE="white-space:nowrap">non-compliance</FONT> with this Lease or Applicable Laws, Tenant shall, at its expense, diligently take steps to bring its storage and
use of Hazardous Materials into compliance. Notwithstanding anything in this Lease to the contrary or Landlord&#146;s review into Tenant&#146;s Hazardous Materials Documents or use or disposal of hazardous materials, however, Landlord shall not have
and expressly disclaims any liability related to Tenant&#146;s or other tenants&#146; use or disposal of Hazardous Materials, it being acknowledged by Tenant that Tenant is best suited to evaluate the safety and efficacy of its Hazardous Materials
usage and procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.3 Tenant represents and warrants to Landlord that Tenant is not nor has it been, in connection with the use,
disposal or storage of Hazardous Materials, (a)&nbsp;subject to a material enforcement order issued by any Governmental Authority or (b)&nbsp;required to take any remedial action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.4 At any time, and from time to time, prior to the expiration of the Term, Landlord shall have the right to conduct appropriate tests of
the Project or any portion thereof to demonstrate that Hazardous Materials are present or that contamination has occurred due to the acts or negligent omissions of a Tenant Party. Tenant shall pay all reasonable costs of such tests if such tests
reveal that Hazardous Materials exist at the Project in violation of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.5 If underground or other storage tanks storing
Hazardous Materials installed or utilized by Tenant are located on the Premises, or are hereafter placed on the Premises by Tenant (or by any other party, if such storage tanks are utilized by Tenant), then Tenant shall monitor the storage tanks,
maintain appropriate records, implement reporting procedures, properly close any underground storage tanks, and take or cause to be taken all other steps necessary or required under the Applicable Laws. Tenant shall have no responsibility or
liability for underground or other storage tanks installed by anyone other than Tenant unless Tenant utilizes such tanks, in which case Tenant&#146;s responsibility for such tanks shall be as set forth in this Section. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.6 Tenant shall promptly report to Landlord if Tenant reasonably believes that mold or
water intrusion are present at the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.7 Tenant&#146;s obligations under this Article shall survive the expiration or earlier
termination of the Lease. During any period of time needed by Tenant or Landlord after the termination of this Lease to complete the removal from the Premises of any such Hazardous Materials, Tenant shall be deemed a holdover tenant and subject to
the provisions of <U>Article 27</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.8 As used herein, the term &#147;<U>Hazardous Material</U>&#148; means any toxic, explosive,
corrosive, flammable, infectious, radioactive, carcinogenic, mutagenic or otherwise hazardous substance, material or waste that is or becomes regulated by Applicable Laws or any Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.9 Notwithstanding anything to the contrary in this Lease, Landlord shall have sole control over the equitable allocation of fire control
areas (as defined in the Uniform Building Code as adopted by the city or municipality(ies) in which the Project is located (the &#147;<U>UBC</U>&#148;)) within the Project for the storage of Hazardous Materials. Notwithstanding anything to the
contrary in this Lease, the quantity of Hazardous Materials allowed by this Section is specific to Tenant and shall not run with the Lease in the event of a Transfer (as defined in <U>Article 29</U>). In the event of a Transfer, if the use of
Hazardous Materials by such new tenant (&#147;<U>New Tenant</U>&#148;) is such that New Tenant utilizes fire control areas in the Project in excess of New Tenant&#146;s Pro Rata Share of the Building or the Project, as applicable, then New Tenant
shall, at its sole cost and expense and upon Landlord&#146;s written request, establish and maintain a separate area of the Premises classified by the UBC as an &#147;H&#148; occupancy area for the use and storage of Hazardous Materials, or take
such other action as is necessary to ensure that its share of the fire control areas of the Building is not greater than New Tenant&#146;s Pro Rata Share of the Building. Notwithstanding anything in this Lease to the contrary, Landlord shall not
have and expressly disclaims any liability related to Tenant&#146;s or other tenants&#146; use or disposal of fire control areas, it being acknowledged by Tenant that Tenant and other tenants are best suited to evaluate the safety and efficacy of
its Hazardous Materials usage and procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">22. <U>Odors and Exhaust</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.1 Tenant acknowledges that Landlord would not enter into this Lease with Tenant unless Tenant assured Landlord that under no circumstances
will any other occupants of the Building or the Project (including persons legally present in any outdoor areas of the Project) be subjected to odors or fumes (whether or not noxious), and that the Building and the Project will not be damaged by any
exhaust, in each case from Tenant&#146;s operations. If any other tenant of the Building or the Project causes odors or fumes (whether or not noxious) to emanate from its premises, following written notice from Tenant, Landlord will use commercially
reasonable efforts to enforce Landlord&#146;s rights under other Leases of the Building or Project in order to resolve such issue. Landlord and Tenant therefore agree as follows: Tenant shall not cause or permit (or conduct any activities that would
cause) any release of any odors or fumes of any kind from the Premises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.2 If the Building has a ventilation system that, in Landlord&#146;s judgment, is
adequate, suitable, and appropriate to vent the Premises in a manner that does not release odors affecting any indoor or outdoor part of the Project, Tenant shall vent the Premises through such system. If Landlord at any time provides Tenant with
written notice that any existing ventilation system is inadequate, or if no ventilation system exists, Tenant shall in compliance with Applicable Laws vent all fumes and odors from the Premises (and remove odors from Tenant&#146;s exhaust stream) as
Landlord reasonably requires. The placement and configuration of all ventilation exhaust pipes, louvers and other equipment shall be subject to Landlord&#146;s approval. Tenant acknowledges Landlord&#146;s legitimate desire to maintain the Project
(indoor and outdoor areas) in an odor-free manner, and Landlord may reasonably require Tenant to abate and remove all odors in a manner that goes beyond the requirements of Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.3 Tenant shall, at Tenant&#146;s sole cost and expense, provide odor eliminators and other devices (such as filters, air cleaners,
scrubbers and whatever other equipment may in Landlord&#146;s reasonable judgment be necessary or appropriate from time to time) to completely remove, eliminate and abate any odors, fumes or other substances in Tenant&#146;s exhaust stream that, in
Landlord&#146;s reasonable judgment, emanate from Tenant&#146;s Premises. Any work Tenant performs under this Section shall constitute Alterations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.4 Tenant&#146;s responsibility to remove, eliminate and abate odors, fumes and exhaust shall continue throughout the Term. Landlord&#146;s
approval of the Tenant Improvements shall not preclude Landlord from requiring additional measures to eliminate odors, fumes and other adverse impacts of Tenant&#146;s exhaust stream (as Landlord may designate in Landlord&#146;s discretion). Tenant
shall install additional equipment as Landlord reasonably requires from time to time under the preceding sentence. Such installations shall constitute Alterations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.5 If Tenant fails to install satisfactory odor control equipment within ten (10)&nbsp;business days after Landlord&#146;s demand made at
any time, then Landlord may, without limiting Landlord&#146;s other rights and remedies, require Tenant to cease and suspend any operations in the Premises that, in Landlord&#146;s reasonable determination, cause odors, fumes or exhaust; <U>provided
</U>that if satisfactory odor control equipment cannot be installed within ten (10)&nbsp;business days, as long as Tenant commences such installation within ten (10)&nbsp;business days and thereafter diligently pursues such installation to
completion within forty five (45)&nbsp;days after Landlord&#146;s request, then Landlord may not require Tenant&#146;s operations to cease or suspend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">23. <U>Insurance; Waiver of Subrogation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.1 Landlord shall maintain insurance for the Building and the Project in amounts equal to full replacement cost (exclusive of the costs of
excavation, foundations and footings, engineering costs or such other costs to the extent the same are not incurred in the event of a rebuild and without reference to depreciation taken by Landlord upon its books or tax returns) or such lesser
coverage as Landlord may elect, <U>provided</U> that such coverage shall not be less than the amount of such insurance Landlord&#146;s Lender, if any, requires Landlord to maintain, providing protection against any peril generally included within
the classification &#147;Fire and Extended Coverage,&#148; together with insurance against sprinkler damage (if applicable), vandalism and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
malicious mischief. Landlord, subject to availability thereof, shall further insure, if Landlord deems it appropriate, coverage against flood, environmental hazard, earthquake, loss or failure of
building equipment, rental loss during the period of repairs or rebuilding, Workers&#146; Compensation insurance and fidelity bonds for employees employed to perform services. Notwithstanding the foregoing, Landlord may, but shall not be deemed
required to, provide insurance for any improvements installed by Tenant or that are in addition to the standard improvements customarily furnished by Landlord, without regard to whether or not such are made a part of or are affixed to the Building.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.2 In addition, Landlord shall carry Commercial General Liability insurance with limits of not less than One Million Dollars
($1,000,000) per occurrence/general aggregate for bodily injury (including death), or property damage with respect to the Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.3
Tenant shall, at its own cost and expense, procure and maintain during the Term the following insurance for the benefit of Tenant and Landlord (as their interests may appear) with insurers who have a minimum A.M. Best&#146;s rating of <FONT
STYLE="white-space:nowrap">A-VII</FONT> and lawfully authorized to do business in the state where the Premises are located: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Commercial
General Liability insurance on an occurrence coverage form, with coverages including but not limited to bodily injury (including death), property damage (including loss of use resulting therefrom), premises/operations, personal&nbsp;&amp;
advertising injury, and contractual liability with limits of liability of not less than $2,000,000 for bodily injury and property damage per occurrence, $2,000,000 general aggregate, which limits may be met by use of excess and/or umbrella liability
insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Commercial Automobile Liability insurance covering liability arising from the use or operation of any auto, including
those owned, hired or otherwise operated or used by or on behalf of the Tenant. The coverage shall be on a broad-based occurrence form with combined single limits of not less than $1,000,000 per accident for bodily injury and property damage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Commercial Property insurance covering property damage to the full replacement cost value and business interruption. Covered property
shall not include permanent improvements in the Premises installed by Tenant or furnished by Landlord which shall be insured by Landlord pursuant to <U>Section</U><U></U><U>&nbsp;23.1</U>, but shall include Tenant&#146;s Property including personal
property, furniture, fixtures, machinery, equipment, stock, inventory and improvements and betterments, which may be owned by Tenant and required to be insured hereunder, or which may be leased, rented, borrowed or in the care custody or control of
Tenant, or Tenant&#146;s agents, employees or subcontractors. Such insurance, with respect only to all Tenant Improvements, Alterations or other work performed on the Premises by Tenant (collectively, &#147;<U>Tenant Work</U>&#148;), shall name
Landlord and Landlord&#146;s current and future mortgagees as loss payees as their interests may appear. Such insurance shall be written on an &#147;all risk&#148; of physical loss or damage basis including the perils of fire, extended coverage,
electrical injury, mechanical breakdown, windstorm, vandalism, malicious mischief, sprinkler leakage, <FONT STYLE="white-space:nowrap">back-up</FONT> of sewers or drains, earthquake and such other risks Landlord may from time to time designate that
are generally </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required by landlords of similar properties in accordance with prudent business practices, for the full replacement cost value of the covered items with an agreed amount endorsement with no <FONT
STYLE="white-space:nowrap">co-insurance.</FONT> Business interruption coverage shall have limits sufficient to cover Tenant&#146;s lost profits and necessary continuing expenses, including rents due Landlord under the Lease. The minimum period of
indemnity for business interruption coverage shall be twelve (12)&nbsp;months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Workers&#146; Compensation insurance as is required by
statute or law, or as may be available on a voluntary basis and Employers&#146; Liability insurance with limits of not less than the following: each accident, Five Hundred Thousand Dollars ($500,000); disease ($500,000); disease (each employee),
Five Hundred Thousand Dollars ($500,000). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Landlord shall have the right to require that Tenant procure Pollution Legal Liability
insurance if there is any material change to the amounts or types of Hazardous Materials that Tenant stores, handles, generates or treats on or about the Premises. Such coverage shall include bodily injury, sickness, disease, death or mental anguish
or shock sustained by any person; property damage including physical injury to or destruction of tangible property including the resulting loss of use thereof, <FONT STYLE="white-space:nowrap">clean-up</FONT> costs, and the loss of use of tangible
property that has not been physically injured or destroyed; and defense costs, charges and expenses incurred in the investigation, adjustment or defense of claims for such compensatory damages. Coverage shall apply to both sudden and <FONT
STYLE="white-space:nowrap">non-sudden</FONT> pollution conditions including the discharge, dispersal, release or escape of smoke, vapors, soot, fumes, acids, alkalis, toxic chemicals, liquids or gases, waste materials or other irritants,
contaminants or pollutants into or upon land, the atmosphere or any watercourse or body of water. Claims-made coverage is permitted, provided the policy retroactive date is continuously maintained prior to the commencement date of this agreement,
and coverage is continuously maintained during all periods in which Tenant occupies the Premises. Coverage shall be maintained with limits of not less than $1,000,000 per incident with a $2,000,000 policy aggregate and for a period of two
(2)&nbsp;years thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(0 During all construction by Tenant at the Premises, with respect to tenant improvements being constructed
(including the Tenant Improvements and any Alterations, insurance required in <U>Exhibit <FONT STYLE="white-space:nowrap">B-1</FONT></U> must be in place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.4 The insurance required of Tenant by this Article shall be with companies at all times having a current rating of not less than <FONT
STYLE="white-space:nowrap">A-</FONT> and financial category rating of at least Class&nbsp;VII in &#147;A.M. Best&#146;s Insurance Guide&#148; current edition. Tenant shall obtain for Landlord from the insurance companies/broker or cause the
insurance companies/broker to furnish certificates of insurance evidencing all coverages required herein to Landlord. Landlord reserves the right to require complete copies of all required insurance policies including any endorsements. No such
policy shall be cancelled or reduced in coverage except after twenty (20)&nbsp;days&#146; prior written notice to Landlord from Tenant or its insurers (except in the event of <FONT STYLE="white-space:nowrap">non-payment</FONT> of premium, in which
case ten (10)&nbsp;days&#146; written notice shall be given). All such policies shall be written as primary policies, not contributing with and not in excess of the coverage that Landlord may carry. Tenant&#146;s required policies shall contain
severability of interests clauses stating that, except with respect to limits of insurance, coverage shall apply separately to each insured or additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
insured. Tenant shall furnish Landlord with renewal certificates of insurance or binders as soon as reasonably practicable, but in no event later than ten (10)&nbsp;days after such renewal.
Tenant agrees that if Tenant does not take out and maintain such insurance, Landlord may (but shall not be required to) procure such insurance on Tenant&#146;s behalf and at its cost to be paid by Tenant as Additional Rent. Commercial General
Liability, Commercial Automobile Liability, Umbrella Liability and Pollution Legal Liability insurance as required above shall name Ground Lessor, Landlord, BioMed Realty, L.P., and BRE Edison Parent L.P., and their respective officers, employees,
agents, general partners, members, subsidiaries, affiliates and Lenders (&#147;<U>Landlord Parties</U>&#148;) as additional insureds as respects liability arising from work or operations performed by or on behalf of Tenant, Tenant&#146;s use or
occupancy of Premises, and ownership, maintenance or use of vehicles by or on behalf of Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.5 In each instance where insurance is
to name Landlord Parties as additional insureds, Tenant shall, upon Landlord&#146;s written request, also designate and furnish certificates evidencing such Landlord Parties as additional insureds to (a)&nbsp;any Lender of Landlord holding a
security interest in the Building or the Project, (b)&nbsp;the landlord under any lease whereunder Landlord is a tenant of the real property upon which the Building is located if the interest of Landlord is or shall become that of a tenant under a
ground lease rather than that of a fee owner and (c)&nbsp;any management company retained by Landlord to manage the Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.6 Tenant
assumes the risk of damage to any fixtures, goods, inventory, merchandise, equipment and leasehold improvements, and Landlord shall not be liable for injury to Tenant&#146;s business or any loss of income therefrom, relative to such damage, all as
more particularly set forth within this Lease. Tenant shall, at Tenant&#146;s sole cost and expense, carry such insurance as Tenant desires for Tenant&#146;s protection with respect to personal property of Tenant or business interruption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.7 Landlord, Tenant and each of their respective insurers hereby waive any and all rights of recovery and/or subrogation against one another
or against the officers, directors, employees, agents and representatives of the other as respects any loss, damage, claims, suits or demands, howsoever caused, that are covered, or should have been covered, by valid and collectible insurance,
including any deductibles or self-insurance maintained thereunder. If necessary, each party agrees to endorse the required insurance policies to permit waivers of subrogation as required hereunder and hold harmless and indemnify the other party for
any loss or expense incurred as a result of a failure to obtain such waivers of subrogation from insurers. Landlord and Tenant, upon obtaining the policies of insurance required or permitted under this Lease, shall give notice to the insurance
carrier or carriers that the foregoing mutual waiver of subrogation is contained in this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.8 Landlord may require insurance
policy limits required under this Lease to be raised to conform with requirements of Landlord&#146;s Lender or to bring coverage limits to levels then being required of new tenants within the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.9 Any costs incurred by Landlord pursuant to this Article shall constitute a portion of Operating Expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.10 The obligations of each party pursuant to this Article shall survive the expiration or
earlier termination of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24. <U>Damage or Destruction</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.1 In the event of a partial destruction of (a)&nbsp;the Premises, (b)&nbsp;the Building, (c)&nbsp;the Common Area or (d)&nbsp;the Project
((a)-(d) collectively, the &#147;Affected Areas&#148;) by fire or other perils covered by extended coverage insurance not exceeding twenty-five percent (25%) of the full insurable value thereof, and provided that (x)&nbsp;the damage thereto is such
that the Affected Areas may be repaired, reconstructed or restored within a period of six (6)&nbsp;months from the date of the happening of such casualty, (y)&nbsp;Landlord shall receive insurance proceeds sufficient to cover the cost of such
repairs, reconstruction and restoration (except for any deductible amount provided by Landlord&#146;s policy, which deductible amount, if paid by Landlord, shall constitute an Operating Expense) and (z)&nbsp;such casualty was not intentionally
caused by a Tenant Party, then Landlord shall commence and proceed diligently with the work of repair, reconstruction and restoration of the Affected Areas and this Lease shall continue in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.2 In the event of any damage to or destruction of the Building or the Project other than as described in
<U>Section</U><U></U><U>&nbsp;24.1</U>, Landlord may elect to repair, reconstruct and restore the Building or the Project, as applicable, in which case this Lease shall continue in full force and effect. If Landlord elects not to repair, reconstruct
and restore the Building or the Project, as applicable, then this Lease shall terminate as of the date of such damage or destruction. In the event of any damage or destruction (regardless of whether such damage is governed by
<U>Section</U><U></U><U>&nbsp;24.1</U> or this Section), if (a)&nbsp;in Landlord&#146;s determination as set forth in the Damage Repair Estimate (as defined below), the Affected Areas cannot be repaired, reconstructed or restored within twelve
(12)&nbsp;months after the date of such casualty, (b)&nbsp;subject to <U>Section</U><U></U><U>&nbsp;24.6</U>, the Affected Areas are not actually repaired, reconstructed and restored within eighteen (18)&nbsp;months after the date of such casualty,
or (c)&nbsp;the damage and destruction occurs within the last twelve (12)&nbsp;months of the then-current Term, then Tenant shall have the right to terminate this Lease, effective as of the date of such damage or destruction, by delivering to
Landlord its written notice of termination (a &#147;<U>Termination Notice</U>&#148;) (y) with respect to <U>Subsections 24.2(a)</U> and <U>(c)</U>, no later than fifteen (15)&nbsp;days after Landlord delivers to Tenant Landlord&#146;s Damage Repair
Estimate and (z)&nbsp;with respect to <U>Subsection 24.2(b)</U>, no later than fifteen (15)&nbsp;days after such twelve (12)&nbsp;month period (as the same may be extended pursuant to <U>Section</U><U></U><U>&nbsp;24.6)</U> expires. If
Tenantprovides Landlord with a Termination Notice pursuant to <U>Subsection 24.2(z)</U>, Landlord shall have an additional thirty (30)&nbsp;days after receipt of such Termination Notice to complete the repair, reconstruction and restoration. If
Landlord does not complete such repair, reconstruction and restoration within such thirty (30)&nbsp;day period, then Tenant may terminate this Lease by giving Landlord written notice within two (2)&nbsp;business days after the expiration of such
thirty (30)&nbsp;day period. If Landlord does complete such repair, reconstruction and restoration within such thirty (30)&nbsp;day period, then this Lease shall continue in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.3 As soon as reasonably practicable, but in any event within sixty (60)&nbsp;days following the date of damage or destruction, Landlord
shall notify Tenant of Landlord&#146;s good faith estimate of the period of time in which the repairs, reconstruction and restoration will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
completed (the &#147;<U>Damage Repair Estimate</U>&#148;), which estimate shall be based upon the opinion of a contractor reasonably selected by Landlord and experienced in comparable repair,
reconstruction and restoration of similar buildings. Additionally, Landlord shall give written notice to Tenant within sixty (60)&nbsp;days following the date of damage or destruction of its election not to repair, reconstruct or restore the
Building or the Project, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.4 Upon any termination of this Lease under any of the provisions of this Article, the parties
shall be released thereby without further obligation to the other from the date possession of the Premises is surrendered to Landlord, except with regard to (a)&nbsp;obligations arising prior to the damage or destruction and (b)&nbsp;obligations
that, by their express terms, survive the expiration or earlier termination hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.5 In the event of repair, reconstruction and
restoration as provided in this Article, all Rent to be paid by Tenant under this Lease shall be abated proportionately based on the extent to which Tenant&#146;s use of the Premises is impaired from the date of the casualty until such repair,
reconstruction or restoration is completed, unless Landlord provides Tenant with other space during the period of repair, reconstruction and restoration that, in Tenant&#146;s reasonable opinion, is suitable for the temporary conduct of
Tenant&#146;s business; <U>provided</U>, however, that the amount of such abatement shall be reduced by the amount of Rent that is received by Tenant as part of the business interruption or loss of rental income with respect to the Premises from the
proceeds of business interruption or loss of rental income insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.6 Notwithstanding anything to the contrary contained in this
Article, should Landlord be delayed or prevented from completing the repair, reconstruction or restoration of the damage or destruction to the Premises after the occurrence of such damage or destruction by Force Majeure or delays caused by a Tenant
Party, then the time for Landlord to commence or complete repairs, reconstruction and restoration shall be extended on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-for-day</FONT></FONT> basis; <U>provided</U>, however,
that if such Force Majeure or delays caused by a Tenant Party will delay the completion of such repairs, reconstruction and restoration to a date that is more than six (6)&nbsp;months following the date of such casualty, at Landlord&#146;s election,
Landlord shall be relieved of its obligation to make such repairs, reconstruction and restoration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.7 If Landlord is obligated to or
elects to repair, reconstruct or restore as herein provided, then Landlord shall be obligated to make such repairs, reconstruction or restoration only with regard to (a)&nbsp;those portions of the Premises that were originally provided at
Landlord&#146;s expense (which includes the Tenant Improvements), and (b)&nbsp;the Common Area portion of the Affected Areas. The repairs, reconstruction or restoration of improvements not originally provided by Landlord or at Landlord&#146;s
expense shall be the obligation of Tenant. In the event Tenant has elected to upgrade certain improvements from the Building Standard, Landlord shall, upon the need for replacement due to an insured loss, provide only the Building Standard, unless
Tenant again elects to upgrade such improvements and pay any incremental costs related thereto, except to the extent that excess insurance proceeds, if received, are adequate to provide such upgrades, in addition to providing for basic repairs,
reconstruction and restoration of the Premises, the Building and the Project. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.8 Notwithstanding anything to the contrary contained in this Article or this Lease,
Landlord shall not have any obligation whatsoever to repair, reconstruct or restore the Premises if the damage resulting from any casualty covered under this Article occurs during the last eighteen (18)&nbsp;months of the Term or any extensions
thereof, or to the extent that insurance proceeds are not available therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.9 Landlord&#146;s obligation, should it elect or be
obligated to repair, reconstruct or restore, shall be limited to the Affected Areas, and shall be conditioned upon Landlord receiving any permits or authorizations required by Applicable Laws. Tenant shall, at its expense, replace or fully repair
all of Tenant&#146;s personal property and any Alterations (excepting the Tenant Improvements) installed by Tenant existing at the time of such damage or destruction. If Affected Areas are to be repaired, reconstructed or restored in accordance with
the foregoing, Landlord shall make available to Tenant any portion of insurance proceeds it receives that are allocable to the Alterations constructed by Tenant pursuant to this Lease; <U>provided</U> Tenant is not then in Default under this Lease,
and subject to the requirements of any Lender of Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.10 This Article sets forth the terms and conditions upon which this Lease
may terminate in the event of any damage or destruction. Accordingly, the parties hereby waive the provisions of any Applicable Laws (and any successor statutes) permitting the parties to terminate this Lease as a result of any damage or
destruction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">25. <U>Eminent Domain</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.1 In the event (a)&nbsp;the whole of all Affected Areas or (b)&nbsp;such part thereof as shall substantially interfere with Tenant&#146;s
use and occupancy of the Premises for the Permitted Use shall be taken for any public or quasi-public purpose by any lawful power or authority by exercise of the right of appropriation, condemnation or eminent domain, or sold to prevent such taking,
Tenant or Landlord may terminate this Lease effective as of the date possession is required to be surrendered to such authority, except with regard to (y)&nbsp;obligations arising prior to the taking and (z)&nbsp;obligations that, by their express
terms, survive the expiration or earlier termination hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.2 In the event of a partial taking of (a)&nbsp;the Building or the
Project or (b)&nbsp;drives, walkways or parking areas serving the Building or the Project for any public or quasi-public purpose by any lawful power or authority by exercise of right of appropriation, condemnation, or eminent domain, or sold to
prevent such taking, then, without regard to whether any portion of the Premises occupied by Tenant was so taken, Landlord may elect to terminate this Lease (except with regard to (y)&nbsp;obligations arising prior to the taking and
(z)&nbsp;obligations of this Lease that, by their express terms, survive the expiration or earlier termination hereof) as of such taking if such taking is, in Landlord&#146;s sole opinion, of a material nature such as to make it uneconomical to
continue use of the unappropriated portion for purposes of renting office or laboratory space. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.3 Tenant shall be entitled to any award
that is specifically awarded as compensation for (a)&nbsp;the taking of Tenant&#146;s personal property that was installed at Tenant&#146;s expense and (b)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
costs of Tenant moving to a new location. Except as set forth in the previous sentence, any award for such taking shall be the property of Landlord. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.4 If, upon any taking of the nature described in this Article, this Lease continues in effect, then Landlord shall promptly proceed to
restore the Affected Areas to substantially their same condition prior to such partial taking. To the extent such restoration is infeasible, as determined by Landlord in its sole and absolute discretion, the Rent shall be decreased proportionately
to reflect the loss of any portion of the Premises no longer available to Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.5 This Article sets forth the terms and conditions
upon which this Lease may terminate in the event of any taking. Accordingly, the parties hereby waive the provisions of any Applicable Laws (and any successor statutes) permitting the parties to terminate this Lease as a result of any damage or
destruction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">26. <U>Surrender</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26.1
At least thirty (30)&nbsp;days prior to Tenant&#146;s surrender of possession of any part of the Premises, Tenant shall provide Landlord with a facility decommissioning and Hazardous Materials closure plan for the Premises (&#147;Exit Survey&#148;)
prepared by an independent third party state-certified professional with appropriate expertise, which Exit Survey must be reasonably acceptable to Landlord. The Exit Survey shall comply with the American National Standards Institute&#146;s
Laboratory Decommissioning guidelines (ANSI/AIHA <FONT STYLE="white-space:nowrap">Z9.11-2008)</FONT> or any successor standards published by ANSI or any successor organization (or, if ANSI and its successors no longer exist, a similar entity
publishing similar standards). In addition, at least ten (10)&nbsp;days prior to Tenant&#146;s surrender of possession of any part of the Premises, Tenant shall (a)&nbsp;provide Landlord with written evidence of all appropriate governmental releases
obtained by Tenant in accordance with Applicable Laws, including laws pertaining to the surrender of the Premises, (b)&nbsp;place Laboratory Equipment Decontamination Forms on all decommissioned equipment to assure safe occupancy by future users and
(c)&nbsp;conduct a site inspection with Landlord. In addition, Tenant agrees to remain responsible after the surrender of the Premises for the remediation of any recognized environmental conditions set forth in the Exit Survey to the extent the
remediation thereof is otherwise required by the terms of this Lease and to comply with any recommendations set forth in the Exit Survey relating to the same. Tenant&#146;s obligations pursuant to this Section shall survive the expiration or earlier
termination of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26.2 No surrender of possession of any part of the Premises shall release Tenant from any of its obligations
hereunder, unless such surrender is accepted in writing by Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26.3 The voluntary or other surrender of this Lease by Tenant shall
not effect a merger with Landlord&#146;s fee title or leasehold interest in the Premises, the Building, the Property or the Project, unless Landlord consents in writing, and shall, at Landlord&#146;s option, operate as an assignment to Landlord of
any or all subleases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26.4 The voluntary or other surrender of any ground or other underlying lease that now exists or may hereafter be
executed affecting the Building or the Project, or a mutual cancellation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereof or of Landlord&#146;s interest therein by Landlord and its lessor shall not effect a merger with Landlord&#146;s fee title or leasehold interest in the Premises, the Building or the
Property and shall, at the option of the successor to Landlord&#146;s interest in the Building or the Project, as applicable, operate as an assignment of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">27. <U>Holding Over</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.1 If, with
Landlord&#146;s prior written consent, Tenant holds possession of all or any part of the Premises after the Term, Tenant shall become a tenant from month to month after the expiration or earlier termination of the Term, and in such case Tenant shall
continue to pay (a)&nbsp;Base Rent in accordance with Article 7 and (b)&nbsp;any amounts for which Tenant would otherwise be liable under this Lease if the Lease were still in effect, including payments for Tenant&#146;s Adjusted Share of Operating
Expenses and electricity and other utility costs. Any such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-to-month</FONT></FONT> tenancy shall be subject to every other term, covenant and agreement contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.2 Notwithstanding the foregoing, if Tenant remains in possession of the Premises after the expiration or earlier termination of the Term
without Landlord&#146;s prior written consent, (a)&nbsp;Tenant shall become a tenant at sufferance subject to the terms and conditions of this Lease, except that the monthly rent shall be equal to one hundred fifty percent (150%) of the Rent in
effect during the last thirty (30)&nbsp;days of the Term, and (b)&nbsp;Tenant shall be liable to Landlord for any and all damages suffered by Landlord as a result of such holdover, including any lost rent or consequential, special and indirect
damages (in each case, regardless of whether such damages are foreseeable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.3 Acceptance by Landlord of Rent after the expiration or
earlier termination of the Term shall not result in an extension, renewal or reinstatement of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.4 The foregoing provisions
of this Article are in addition to and do not affect Landlord&#146;s right of reentry or any other rights of Landlord hereunder or as otherwise provided by Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.5 Tenant&#146;s obligations pursuant to this Article shall survive the expiration or earlier termination of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">28. <U>Indemnification and Exculpation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28.1 Except to the extent caused by the negligence or willful misconduct of Landlord or any agent or employee of Landlord, Tenant agrees to
indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to Landlord) and hold the Landlord Indemnitees harmless from and against any and all Claims of any kind or nature, real or alleged, arising from injury to or
death of any person or damage to any property occurring within or about the Premises, the Building, the Property or the Project, to the extent arising directly or indirectly out of (a)&nbsp;the presence at or use or occupancy of the Premises or
Project by a Tenant Party, (b)&nbsp;an act or omission on the part of any Tenant Party, (c)&nbsp;a breach or default by Tenant in the performance of any of its obligations hereunder or (d)&nbsp;injury to or death of persons or damage to or loss of
any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property, real or alleged, arising from the serving of alcoholic beverages at the Premises or Project, including liability under any dram shop law, host liquor law or similar Applicable Law.
Tenant&#146;s obligations under this Section shall not be affected, reduced or limited by any limitation on the amount or type of damages, compensation or benefits payable by or for Tenant under workers&#146; compensation acts, disability benefit
acts, employee benefit acts or similar legislation. Tenant&#146;s obligations under this Section shall survive the expiration or earlier termination of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28.2 Notwithstanding anything in this Lease to the contrary, Landlord shall not be liable to Tenant for and Tenant assumes all risk of
(a)&nbsp;damage or losses caused by fire, electrical malfunction, gas explosion or water damage of any type (including broken water lines, malfunctioning fire sprinkler systems, roof leaks or stoppages of lines) or damage to personal property,
unless any such loss is due to Landlord&#146;s gross negligence, intentional misconduct or willful disregard of written notice by Tenant of need for a repair that Landlord is responsible to make for an unreasonable period of time, and
(b)&nbsp;damage to scientific research, including loss of records kept by Tenant within the Premises (in each case, regardless of whether such damages are foreseeable). Tenant further waives any claim for injury to Tenant&#146;s business or loss of
income relating to any such damage or destruction of personal property as described in this Section. Notwithstanding anything in the foregoing or this Lease to the contrary, except (x)&nbsp;as otherwise provided herein (including
<U>Section</U><U></U><U>&nbsp;27.2</U>), (y) as may be provided by Applicable Laws, or (z)&nbsp;in the event of Tenant&#146;s breach of <U>Article 21</U> or <U>Section</U><U></U><U>&nbsp;26.1</U>, in no event shall Landlord or Tenant be liable to
the other for any consequential, special or indirect damages arising out of this Lease, including lost profits (<U>provided</U> that this <U>Subsection 28.2(z)</U> shall not limit Tenant&#146;s liability for Base Rent or Additional Rent pursuant to
this Lease). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28.3 Landlord shall not be liable for any damages arising from any act, omission or neglect of any other tenant in the
Building or the Project, or of any other third party, unless otherwise expressly stated in this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28.4 Tenant acknowledges that
security devices and services, if any, while intended to deter crime, may not in given instances prevent theft or other criminal acts. Landlord shall not be liable for injuries or losses caused by criminal acts of third parties, and Tenant assumes
the risk that any security device or service may malfunction or otherwise be circumvented by a criminal. If Tenant desires protection against such criminal acts, then Tenant shall, at Tenant&#146;s sole cost and expense, obtain appropriate insurance
coverage. Tenant&#146;s security programs and equipment for the Premises shall be coordinated with Landlord and subject to Landlord&#146;s reasonable approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28.5 Tenant&#146;s obligations under this Article shall survive the expiration or earlier termination of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28.6 The indemnity from Tenant in this Article is intended to specifically cover actions brought by Tenant&#146;s own employees, with respect
to acts or omissions during the term of this Lease. In that regard, with respect to Landlord, Tenant waives any immunity it may have under Washington&#146;s Industrial Insurance Act, RCW Title 51, to the extent necessary to provide Landlord
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with a full and complete indemnity from claims made by Tenant and its employees, to the extent of their negligence. If losses, liabilities, damages, liens, costs and expenses covered by
Tenant&#146;s indemnity are caused by the sole negligence of Landlord or by the concurrent negligence of both Landlord and Tenant, or their respective employees, agents, contractors, invitees and licensees, then Tenant shall indemnify Landlord only
to the extent of any Tenant Parties&#146; negligence. LANDLORD AND TENANT ACKNOWLEDGE THAT THE INDEMNIFICATION PROVISIONS OF THIS ARTICLE WERE SPECIFICALLY NEGOTIATED AND AGREED UPON BY THEM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">29. <U>Assignment or Subletting</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.1
Except as hereinafter expressly permitted, none of the following (each, a &#147;<U>Transfer</U>&#148;) either voluntarily or by operation of Applicable Laws, shall be directly or indirectly performed without Landlord&#146;s prior written consent,
which consent shall not be unreasonably withheld, conditioned or delayed: (a)&nbsp;Tenant selling, hypothecating, assigning, pledging, encumbering or otherwise transferring this Lease or subletting the Premises or (b)&nbsp;a controlling interest in
Tenant being sold, assigned or otherwise transferred (other than as a result of shares in Tenant being sold on a public stock exchange). For purposes of the preceding sentence, &#147;control&#148; means (a)&nbsp;owning (directly or indirectly) more
than fifty percent (50%) of the stock or other equity interests of another person or (b)&nbsp;possessing, directly or indirectly, the power to direct or cause the direction of the management and policies of such person. Notwithstanding the
foregoing, Tenant shall have the right to Transfer, without Landlord&#146;s prior written consent, Tenant&#146;s interest in this Lease or the Premises or any part thereof to any person or entity that acquires all or substantially all of
Tenant&#146;s assets or all or substantially all of the equity interests in Tenant or that as of the date of determination and at all times thereafter directly, or indirectly through one or more intermediaries, controls, is controlled by or is under
common control with Tenant, or is the surviving entity in a merger with Tenant or an entity that acquires all or substantially all of the assets of Tenant (&#147;<U>Tenant&#146;s Affiliate</U>&#148;); provided that Tenant shall notify Landlord in
writing at least thirty (30)&nbsp;days prior to the effectiveness of such Transfer to Tenant&#146;s Affiliate (an &#147;<U>Exempt Transfer</U>&#148;) and otherwise comply with the requirements of this Lease regarding such Transfer; and provided,
further, that the person that will be the tenant under this Lease after the Exempt Transfer has a net worth (as of both the day immediately prior to and the day immediately after the Exempt Transfer) that is equal to or greater than the net worth
(as of both the Execution Date and the date of the Exempt Transfer) of the transferring Tenant. For purposes of the immediately preceding sentence (i)&nbsp;the determination of net worth (defined as total assets minus total liabilities) shall be
pursuant to a balance sheet prepared in accordance with GAAP, and (ii) &#147;control&#148; requires both (a)&nbsp;owning (directly or indirectly) more than fifty percent (50%) of the stock or other equity interests of another person and
(b)&nbsp;possessing, directly or indirectly, the power to direct or cause the direction of the management and policies of such person. Notwithstanding the foregoing, if Tenant is precluded by Applicable Law or by contract from giving Landlord prior
written notice of an Exempt Transfer, Tenant will provide Landlord with written notice of the Exempt Transfer as soon as Tenant may do so without violating Applicable Law or the terms of the applicable contract. Notwithstanding anything in this
Lease to the contrary, if (a)&nbsp;Tenant or any proposed transferee, assignee or sublessee of Tenant has been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required by any prior landlord, Lender or Governmental Authority to take material remedial action in connection with Hazardous Materials contaminating a property if the contamination resulted
from such party&#146;s action or negligent omission or use of the property in question or (b)&nbsp;Tenant or any proposed transferee, assignee or sublessee is subject to a material enforcement order issued by any Governmental Authority in connection
with the use, disposal or storage of Hazardous Materials, then it shall not be unreasonable for Landlord to withhold its consent to any proposed transfer, assignment or subletting (with respect to any such matter involving a proposed transferee,
assignee or sublessee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.2 In the event Tenant desires to effect a Transfer, then, at least thirty (30)&nbsp;but not more than ninety
(90)&nbsp;days prior to the date when Tenant desires the Transfer to be effective (the &#147;<U>Transfer Date</U>&#148;), Tenant shall provide written notice to Landlord (the &#147;<U>Transfer Notice</U>&#148;) containing information (including
references) concerning the character of the proposed transferee, assignee or sublessee; the Transfer Date; the most recent financial statements of Tenant and of the proposed transferee, assignee or sublessee satisfying the requirements of
<U>Section</U><U></U><U>&nbsp;40.2</U> (&#147;<U>Required Financials</U>&#148;); any ownership or commercial relationship between Tenant and the proposed transferee, assignee or sublessee; copies of Hazardous Materials Documents for the proposed
transferee, assignee or sublessee; and the consideration and all other material terms and conditions of the proposed Transfer, all in such detail as Landlord shall reasonably require. Within fifteen (15)&nbsp;business days of receipt of
Tenant&#146;s Transfer Notice, Landlord shall notify Tenant in writing that Landlord either consents to the Transfer, does not consent to the Transfer or needs additional information. Upon receipt of the additional information requested by Landlord,
Landlord shall have fifteen (15)&nbsp;business days to determine whether or not it consents to the Transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.3 Landlord, in
determining whether consent should be given to a proposed Transfer, may give consideration to (a)&nbsp;the financial strength of Tenant and of such transferee, assignee or sublessee (notwithstanding Tenant remaining liable for Tenant&#146;s
performance), (b) any change in use that such transferee, assignee or sublessee proposes to make in the use of the Premises and (c)&nbsp;Landlord&#146;s desire to exercise its rights under <U>Section</U><U></U><U>&nbsp;29.7</U> to cancel this Lease.
In no event shall Landlord be deemed to be unreasonable for declining to consent to a Transfer to a transferee, assignee or sublessee of poor reputation, lacking financial qualifications or seeking a change in the Permitted Use, or jeopardizing
directly or indirectly the status of Landlord or any of Landlord&#146;s affiliates as a Real Estate Investment Trust under the Internal Revenue Code of 1986 (as the same may be amended from time to time, the &#147;<U>Revenue Code</U>&#148;).
Notwithstanding anything contained in this Lease to the contrary, (w)&nbsp;no Transfer shall be consummated on any basis such that the rental or other amounts to be paid by the occupant, assignee, manager or other transferee thereunder would be
based, in whole or in part, on the income or profits derived by the business activities of such occupant, assignee, manager or other transferee; (x)&nbsp;Tenant shall not furnish or render any services to an occupant, assignee, manager or other
transferee with respect to whom transfer consideration is required to be paid, or manage or operate the Premises or any capital additions so transferred, with respect to which transfer consideration is being paid; and (y)&nbsp;Tenant shall not
consummate a Transfer with any person or in any manner that could cause any portion of the amounts received by Landlord pursuant to this Lease or any sublease, license or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other arrangement for the right to use, occupy or possess any portion of the Premises to fail to qualify as &#147;rents from real property&#148; within the meaning of Section&nbsp;856(d) of the
Revenue Code, or any similar or successor provision thereto or which could cause any other income of Landlord to fail to qualify as income described in Section&nbsp;856(c)(2) of the Revenue Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.4 The following are conditions precedent to a Transfer or to Landlord considering a request by Tenant to a Transfer: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Tenant shall remain fully liable under this Lease during the unexpired Term. Tenant agrees that it shall not be (and shall not be deemed to
be) a guarantor or surety of this Lease, however, and waives its right to claim that is it is a guarantor or surety or to raise in any legal proceeding any guarantor or surety defenses permitted by this Lease or by Applicable Laws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If Tenant or the proposed transferee, assignee or sublessee does not or cannot deliver the Required Financials, then Landlord may elect to
have either Tenant&#146;s ultimate parent company or the proposed transferee&#146;s, assignee&#146;s or sublessee&#146;s ultimate parent company provide a guaranty of the applicable entity&#146;s obligations under this Lease, in a commercially
reasonable form acceptable to Landlord, which guaranty shall be executed and delivered to Landlord by the applicable guarantor prior to the Transfer Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the case of an Exempt Transfer, Tenant shall provide Landlord with evidence reasonably satisfactory to Landlord that the Transfer
qualifies as an Exempt Transfer; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Tenant shall provide Landlord with evidence reasonably satisfactory to Landlord that the value of
Landlord&#146;s interest under this Lease shall not be diminished or reduced by the proposed Transfer. Such evidence shall include evidence respecting the relevant business experience and financial responsibility and status of the proposed
transferee, assignee or sublessee; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Tenant shall reimburse Landlord for Landlord&#146;s reasonable costs and expenses, including
reasonable attorneys&#146; fees, charges and disbursements incurred in connection with the review, processing and documentation of such request, up to a maximum reimbursement of $3,000.00; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except with respect to an Exempt Transfer, if Tenant&#146;s transfer of rights or sharing of the Premises provides for the receipt by, on
behalf of or on account of Tenant of any consideration of any kind whatsoever (including a premium rental for a sublease or lump sum payment for an assignment, but excluding Tenant&#146;s reasonable costs in marketing and subleasing the Premises and
excluding any consideration paid for Tenant&#146;s assets) in excess of the rental and other charges due to Landlord under this Lease, Tenant shall pay fifty percent (50%) of all of such excess to Landlord, after making deductions for any reasonable
marketing expenses, tenant improvement funds expended by Tenant, alterations, cash concessions, brokerage commissions, attorneys&#146; fees and free rent actually paid by Tenant. If such consideration consists of cash paid to Tenant, payment to
Landlord shall be made upon receipt by Tenant of such cash payment; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The proposed transferee, assignee or sublessee shall agree that, in the event Landlord
gives such proposed transferee, assignee or sublessee notice that Tenant is in default under this Lease, such proposed transferee, assignee or sublessee shall thereafter make all payments otherwise due Tenant directly to Landlord, which payments
shall be received by Landlord without any liability being incurred by Landlord, except to credit such payment against those due by Tenant under this Lease, and any such proposed transferee, assignee or sublessee shall agree to attorn to Landlord or
its successors and assigns should this Lease be terminated for any reason; <U>provided</U>, however, that in no event shall Landlord or its Lenders, successors or assigns be obligated to accept such attornment; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Landlord&#146;s consent to any such Transfer shall be effected on Landlord&#146;s forms; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Tenant shall not then be in Default of any of its monetary obligations or any of its material
<FONT STYLE="white-space:nowrap">non-monetary</FONT> obligations under this Lease; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Such proposed transferee, assignee or
sublessee&#146;s use of the Premises shall be the same as the Permitted Use; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Landlord shall not be bound by any provision of any
agreement pertaining to the Transfer, except for Landlord&#146;s written consent to the same; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Tenant shall pay all transfer and other
taxes (including interest and penalties) assessed or payable for any Transfer; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Landlord&#146;s consent (or waiver of its rights) for
any Transfer shall not waive Landlord&#146;s right to consent or refuse consent to any later Transfer; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) Tenant shall deliver to
Landlord one executed copy of any and all written instruments evidencing or relating to the Transfer; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) Tenant shall deliver to
Landlord a list of Hazardous Materials (as defined below), certified by the proposed transferee, assignee or sublessee to be true and correct, that the proposed transferee, assignee or sublessee intends to use or store in the Premises. Additionally,
Tenant shall deliver to Landlord, on or before the date any proposed transferee, assignee or sublessee takes occupancy of the Premises, all of the items relating to Hazardous Materials of such proposed transferee, assignee or sublessee as described
in <U>Section</U><U></U><U>&nbsp;21.2</U> and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) Tenant shall have paid to Landlord all outstanding Rent that is due and payable to
Landlord prior to any Transfer becoming effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.5 Any Transfer that is not in compliance with the provisions of this Article or
with respect to which Tenant does not fulfill its obligations pursuant to this Article shall be void and shall, at the option of Landlord, terminate this Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.6 Notwithstanding any Transfer, Tenant shall remain fully and primarily liable for the
payment of all Rent and other sums due or to become due hereunder, and for the full performance of all other terms, conditions and covenants to be kept and performed by Tenant. The acceptance of Rent or any other sum due hereunder, or the acceptance
of performance of any other term, covenant or condition thereof, from any person or entity other than Tenant shall not be deemed a waiver of any of the provisions of this Lease or a consent to any Transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.7 If Tenant delivers to Landlord a Transfer Notice indicating a desire to transfer this Lease to a proposed transferee, assignee or
sublessee other than pursuant to an Exempt Transfer, then Landlord shall have the option, exercisable by giving notice to Tenant at any time within ten (10)&nbsp;days after Landlord&#146;s receipt of such Transfer Notice, to terminate this Lease as
of the date specified in the Transfer Notice as the Transfer Date, except for those obligations that, by their express terms, survive the expiration or earlier termination hereof. If Landlord exercises such option, then Tenant shall have the right
to withdraw such Transfer Notice by delivering to Landlord written notice of such election within five (5)&nbsp;days after Landlord&#146;s delivery of notice electing to exercise Landlord&#146;s option to terminate this Lease. In the event Tenant
withdraws the Transfer Notice as provided in this Section, this Lease shall continue in full force and effect. No failure of Landlord to exercise its option to terminate this Lease shall be deemed to be Landlord&#146;s consent to a proposed
Transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.8 If Tenant sublets the Premises or any portion thereof, Tenant hereby immediately and irrevocably assigns to Landlord, as
security for Tenant&#146;s obligations under this Lease, all rent from any such subletting, and appoints Landlord as assignee and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for Tenant, and
Landlord (or a receiver for Tenant appointed on Landlord&#146;s application) may collect such rent and apply it toward Tenant&#146;s obligations under this Lease; <U>provided</U> that, until the occurrence of a Default (as defined below) by Tenant,
Tenant shall have the right to collect such rent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.9 In the event that Tenant enters into a sublease for the entire Premises in
accordance with this Article that expires within two (2)&nbsp;days of the Term Expiration Date, the term expiration date of such sublease shall, notwithstanding anything in this Lease, the sublease or any consent to the sublease to the contrary, be
deemed to be the date that is two (2)&nbsp;days prior to the Term Expiration Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29.10 Landlord shall execute a commercially reasonable
nondisclosure agreement acceptable to Landlord if so requested by Tenant or any proposed transferee, assignee or sublessee prior to receiving documents pursuant to this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30. <U>Subordination and Attornment</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30.1
This Lease shall be subject and subordinate to the lien of any mortgage, deed of trust, or lease in which Landlord is tenant now or hereafter in force against the Building or the Project and to all advances made or hereafter to be made upon the
security thereof without the necessity of the execution and delivery of any further instruments on the part of Tenant to effectuate such subordination; <U>provided</U> with respect to any future mortgage, deed of trust, or lease in which Landlord is
tenant, such subordination shall be subject to Tenant&#146;s receipt of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercially reasonable nondisturbance agreement. Landlord warrants to Tenant that there is not currently any financing encumbering the Project or Building. Not more than thirty (30)&nbsp;days
after the Execution Date, Landlord will obtain from the Ground Lessor under the Ground Lease a Ground Lessor Recognition and <FONT STYLE="white-space:nowrap">Non-Disturbance</FONT> Agreement in the form attached to this Lease as <U>Exhibit H</U>, or
such other form as is reasonably acceptable to Tenant and the Ground Lessor. Landlord shall be responsible for the cost of recording such Ground Lessor Recognition and <FONT STYLE="white-space:nowrap">Non-Disturbance</FONT> Agreement, including any
transfer or other taxes incurred in connection with such recordation. If Landlord has not obtained a Ground Lessor Recognition and <FONT STYLE="white-space:nowrap">Non-Disturbance</FONT> Agreement from the Ground Lessor within sixty (60)&nbsp;days
after the Execution Date, and Landlord does not obtain a Ground Lessor Recognition and <FONT STYLE="white-space:nowrap">Non-Disturbance</FONT> Agreement within ten (10)&nbsp;business days after receiving a written notice from Tenant (the
&#147;<U>NDA Notice</U>&#148;) that Tenant intends to terminate this Lease because Landlord fails to obtain a Ground Lessor Recognition and <FONT STYLE="white-space:nowrap">Non-Disturbance</FONT> Agreement from the Ground Lessor, then Tenant may
elect to terminate this Lease by giving written notice to Landlord at any time after the end of such ten (10)&nbsp;business day period, and prior to Landlord obtaining a Ground Lessor Recognition and
<FONT STYLE="white-space:nowrap">Non-Disturbance</FONT> Agreement from the Ground Lessor. The NDA Notice must include the following statement in capital letters and bold face print: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>IF LANDLORD FAILS TO OBTAIN A GROUND LESSOR RECOGNITION AND <FONT STYLE="white-space:nowrap">NON-DISTURBANCE</FONT> AGREEMENT FROM THE
GROUND LESSOR WITHIN TEN (10)&nbsp;BUSINESS DAYS FOLLOWING LANDLORD&#146;S RECEIPT OF THIS NOTICE, TENANT MAY ELECT TO TERMINATE THE LEASE. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30.2 Notwithstanding the foregoing, Tenant shall execute and deliver upon demand such further commercially reasonable instrument or
instruments evidencing such subordination of this Lease to the lien of any such mortgage or mortgages or deeds of trust or lease in which Landlord is tenant as may be required by Landlord, provided that such instrument includes a commercially
reasonable nondisturbance agreement. If any such mortgagee, beneficiary or landlord under a lease wherein Landlord is tenant (each, a &#147;<U>Mortgagee</U>&#148;) so elects, however, this Lease shall be deemed prior in lien to any such lease,
mortgage, or deed of trust upon or including the Premises regardless of date and Tenant shall execute a statement in writing to such effect at Landlord&#146;s request. If Tenant fails to execute any document required from Tenant under this Section
within ten (10)&nbsp;business days after written request therefor, Tenant shall be in Default hereunder. For the avoidance of doubt, &#147;Mortgagees&#148; shall also include historic tax credit investors and new market tax credit investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30.3 Upon written request of Landlord and opportunity for Tenant to review, Tenant agrees to execute any Lease amendments not materially
altering the terms of this Lease or materially adversely affecting Tenant&#146;s quiet enjoyment of the Premises, if required by a Mortgagee incident to the financing of the real property of which the Premises constitute a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30.4 In the event any proceedings are brought for foreclosure, or in the event of the exercise of the power of sale under any mortgage or deed
of trust made by Landlord covering the Premises, Tenant shall at the election of the purchaser at such foreclosure or sale attorn to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchaser upon any such foreclosure or sale and recognize such purchaser as Landlord under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">31. <U>Defaults and Remedies</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.1 Late
payment by Tenant to Landlord of Rent and other sums due shall cause Landlord to incur costs not contemplated by this Lease, the exact amount of which shall be extremely difficult and impracticable to ascertain. Such costs include processing and
accounting charges and late charges that may be imposed on Landlord by the terms of any mortgage or trust deed covering the Premises. Therefore, if any installment of Rent due from Tenant is not received by Landlord within three (3)&nbsp;days after
Landlord gives Tenant written notice that the payment is past due, Tenant shall pay to Landlord (a)&nbsp;an additional sum of five percent (5%) of the overdue Rent as a late charge plus (b)&nbsp;interest at an annual rate (the &#147;<U>Default
Rate</U>&#148;) equal to the lesser of (a)&nbsp;ten percent (10%) and (b)&nbsp;the highest rate permitted by Applicable Laws. The parties agree that this late charge represents a fair and reasonable estimate of the costs that Landlord shall incur by
reason of late payment by Tenant and shall be payable as Additional Rent to Landlord due with the next installment of Rent or within five (5)&nbsp;business days after Landlord&#146;s demand, whichever is earlier. Landlord&#146;s acceptance of any
Additional Rent (including a late charge or any other amount hereunder) shall not be deemed an extension of the date that Rent is due or prevent Landlord from pursuing any other rights or remedies under this Lease, at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.2 No payment by Tenant or receipt by Landlord of a lesser amount than the Rent payment herein stipulated shall be deemed to be other than
on account of the Rent, nor shall any endorsement or statement on any check or any letter accompanying any check or payment as Rent be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to
Landlord&#146;s right to recover the balance of such Rent or pursue any other remedy provided in this Lease or in equity or at law. If a dispute shall arise as to any amount or sum of money to be paid by Tenant to Landlord hereunder, Tenant shall
have the right to make payment &#147;under protest,&#148; such payment shall not be regarded as a voluntary payment, and there shall survive the right on the part of Tenant to institute suit for recovery of the payment paid under protest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.3 If Tenant fails to pay any sum of money required to be paid by it hereunder or perform any other act on its part to be performed
hereunder, in each case within the applicable cure period (if any) described in <U>Section</U><U></U><U>&nbsp;31.4</U>, then Landlord may (but shall not be obligated to), without waiving or releasing Tenant from any obligations of Tenant, make such
payment or perform such act; <U>provided</U> that such failure by Tenant unreasonably interfered with the use of the Building or the Project by any other tenant or with the efficient operation of the Building or the Project, or resulted or could
have resulted in a violation of Applicable Laws or the cancellation of an insurance policy maintained by Landlord. Notwithstanding the foregoing, in the event of an emergency, Landlord shall have the right to enter the Premises and act in accordance
with its rights as provided elsewhere in this Lease. In addition to the late charge described in <U>Section</U><U></U><U>&nbsp;31.1</U>, Tenant shall pay to Landlord as Additional Rent all sums so paid or incurred by Landlord,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
together with interest at the Default Rate, computed from the date such sums were paid or incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.4 The occurrence of any one or more of the following events shall constitute a &#147;<U>Default</U>&#148; hereunder by Tenant: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Tenant abandons the Premises or Landlord receives notice that Tenant intends to permanently cease business operations and permanently
vacate the Premises prior to the end of the Term; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Tenant fails to make any payment of Rent, as and when due, or to satisfy its
obligations under <U>Article 19</U>, where such failure shall continue for a period of three (3)&nbsp;days after written notice thereof from Landlord to Tenant; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Tenant fails to observe or perform any obligation or covenant contained herein (other than described in <U>Sections 31.4(a)</U> and
<U>31.4(b)</U>) to be performed by Tenant, where such failure continues for a period of thirty (30)&nbsp;days after written notice thereof from Landlord to Tenant; <U>provided</U> that, if the nature of Tenant&#146;s default is such that it
reasonably requires more than thirty (30)&nbsp;days to cure, Tenant shall not be deemed to be in Default if Tenant commences such cure within such thirty (30)&nbsp;day period and thereafter diligently prosecutes the same to completion; and
<U>provided</U>, further, that such cure is completed no later than ninety (90)&nbsp;days after Tenant&#146;s receipt of written notice from Landlord; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Tenant makes an assignment for the benefit of creditors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) A receiver, trustee or custodian is appointed to or does take title, possession or control of all or substantially all of Tenant&#146;s
assets; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Tenant files a voluntary petition under the United States Bankruptcy Code or any successor statute (as the same may be
amended from time to time, the &#147;<U>Bankruptcy Code</U>&#148;) or an order for relief is entered against Tenant pursuant to a voluntary or involuntary proceeding commenced under any chapter of the Bankruptcy Code; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Any involuntary petition is filed against Tenant under any chapter of the Bankruptcy Code and is not dismissed within one hundred twenty
(120)&nbsp;days; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Tenant fails to deliver an estoppel certificate in accordance with <U>Article 20</U>, and such failure is not cured
within two (2)&nbsp;business days following Tenant&#146;s receipt of written notice of such default; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Tenant&#146;s interest in
this Lease is attached, executed upon or otherwise judicially seized and such action is not released within one hundred twenty (120)&nbsp;days of the action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notices given under this Section shall specify the alleged default and shall demand that Tenant perform the provisions of this Lease or pay the Rent that is
in arrears, as the case may be, within </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the applicable period of time, or quit the Premises. No such notice shall be deemed a forfeiture or a termination of this Lease unless Landlord elects otherwise in such notice. The foregoing
notice and cure provisions shall be inclusive of and not in addition to the notices and cure periods provided for in RCW 59.12, as now or hereafter amended, or any legislation in lieu or substitution thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.5 In the event of a Default by Tenant, and at any time thereafter, with or without notice or demand and without limiting Landlord in the
exercise of any right or remedy that Landlord may have, Landlord has the right to do any or all of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Halt any Tenant
Improvements and Alterations and order Tenant&#146;s contractors, subcontractors, consultants, designers and material suppliers to stop work; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Terminate Tenant&#146;s right to possession of the Premises by written notice to Tenant or by any lawful means, in which case Tenant shall
immediately surrender possession of the Premises to Landlord. In such event, Landlord shall have the immediate right to <FONT STYLE="white-space:nowrap">re-enter</FONT> and remove all persons and property, and such property may be removed and stored
in a public warehouse or elsewhere at the cost and for the account of Tenant, all without service of notice or resort to legal process and without being deemed guilty of trespass or becoming liable for any loss or damage that may be occasioned
thereby; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Terminate this Lease, in which event Tenant shall immediately surrender possession of the Premises to Landlord. In such
event, Landlord shall have the immediate right to <FONT STYLE="white-space:nowrap">re-enter</FONT> and remove all persons and property, and such property may be removed and stored in a public warehouse or elsewhere at the cost and for the account of
Tenant, all without service of notice or resort to legal process and without being deemed guilty of trespass or becoming liable for any loss or damage that may be occasioned thereby. In the event that Landlord shall elect to so terminate this Lease,
then Landlord shall be entitled to recover from Tenant all damages incurred by Landlord by reason of Tenant&#146;s default, including: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The sum of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">A. The worth
at the time of award of any unpaid Rent that had accrued at the time of such termination; plus </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">B. The worth at the time of award of the
amount by which the unpaid Rent that would have accrued during the period commencing with termination of the Lease and ending at the time of award exceeds that portion of the loss of Landlord&#146;s rental income from the Premises that Tenant proves
to Landlord&#146;s reasonable satisfaction could have been reasonably avoided; plus </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">C. The worth at the time of award of the amount by
which the unpaid Rent for the balance of the Term after the time of award exceeds that portion of the loss of Landlord&#146;s rental income from the Premises that Tenant proves to Landlord&#146;s reasonable satisfaction could have been reasonably
avoided; plus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">D. Any other amount necessary to compensate Landlord for all the detriment caused by
Tenant&#146;s failure to perform its obligations under this Lease or that in the ordinary course of things would be likely to result therefrom, including the cost of restoring the Premises to the condition required under the terms of this Lease,
including any rent payments not otherwise chargeable to Tenant (e.g., during any &#147;free&#148; rent period or rent holiday); plus </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">E.
At Landlord&#146;s election, such other amounts in addition to or in lieu of the foregoing as may be permitted from time to time by Applicable Laws; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) At Landlord&#146;s election, as minimum liquidated damages inaddition to any (A)&nbsp;amounts paid or payable to Landlord pursuant to
<U>Section</U><U></U><U>&nbsp;31.5(c)(i)(A)</U> prior to such election and (B)&nbsp;costs of restoring the Premises to the condition required under the terms of this Lease, an amount (the &#147;<U>Election Amount</U>&#148;) equal to either
(Y)&nbsp;the positive difference (if any, and measured at the time of such termination) between (1)&nbsp;the then-present value of the total Rent and other benefits that would have accrued to Landlord under this Lease for the remainder of the Term
if Tenant had fully complied with the Lease minus (2)&nbsp;the then-present cash rental value of the Premises as determined by Landlord for what would be the then-unexpired Term if the Lease remained in effect, computed using the discount rate of
the Federal Reserve Bank of San Francisco at the time of the award plus one (1)&nbsp;percentage point (the &#147;<U>Discount Rate</U>&#148;) or (Z)&nbsp;twelve (12) months (or such lesser number of months as may then be remaining in the Term) of
Base Rent and Additional Rent at the rate last payable by Tenant pursuant to this Lease, in either case as Landlord specifies in such election. Landlord and Tenant agree that the Election Amount represents a reasonable forecast of the minimum
damages expected to occur in the event of a breach, taking into account the uncertainty, time and cost of determining elements relevant to actual damages, such as fair market rent, time and costs that may be required to <FONT
STYLE="white-space:nowrap">re-lease</FONT> the Premises, and other factors; and that the Election Amount is not a penalty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in <U>Sections
31.5(c)(i)(A)</U> and <U>(B)</U>, &#147;worth at the time of award&#148; shall be computed by allowing interest at the Default Rate. As used in <U>Section</U><U></U><U>&nbsp;31.5(c)(i)(C)</U>, the &#147;worth at the time of the award&#148; shall be
computed by taking the present value of such amount, using the DiscountRate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.6 In addition to any other remedies available to Landlord
at law or in equity and under this Lease, Landlord may continue this Lease in effect after Tenant&#146;s Default or abandonment and recover Rent as it becomes due. In addition, Landlord shall not be liable in any way whatsoever for its failure or
refusal to relet the Premises so long as Landlord is in compliance with any obligation Landlord has under Applicable Law to mitigate its damages. For purposes of this Section, the following acts by Landlord will not constitute the termination of
Tenant&#146;s right to possession of the Premises: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Acts of maintenance or preservation or efforts to relet the Premises, including
alterations, remodeling, redecorating, repairs, replacements or painting as Landlord shall consider advisable for the purpose of reletting the Premises or any part thereof; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The appointment of a receiver upon the initiative of Landlord to protect Landlord&#146;s
interest under this Lease or in the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the event of a Default by Tenant, Landlord may elect at any time to
terminate this Lease and to recover damages to which Landlord is entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.7 If Landlord does not elect to terminate this Lease as
provided in <U>Section</U><U></U><U>&nbsp;31.5</U> then Landlord may, from time to time, recover all Rent as it becomes due under this Lease. At any time thereafter, Landlord may elect to terminate this Lease and to recover damages to which Landlord
is entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.8 In the event Landlord elects to terminate this Lease and relet the Premises, Landlord may execute any new lease in its
own name. Tenant hereunder shall have no right or authority whatsoever to collect any Rent from such tenant. The proceeds of any such reletting shall be applied as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) First, to the payment of any indebtedness other than Rent due hereunder from Tenant to Landlord, including storage charges or brokerage
commissions owing from Tenant to Landlord as the result of such reletting; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Second, to the payment of the costs and expenses of
reletting the Premises, including (i)&nbsp;alterations and repairs that Landlord deems reasonably necessary and advisable and (ii)&nbsp;reasonable attorneys&#146; fees, charges and disbursements incurred by Landlord in connection with the retaking
of the Premises and such reletting; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Third, to the payment of Rent and other charges due and unpaid hereunder; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Fourth, to the payment of future Rent and other damages payable by Tenant under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.9 All of Landlord&#146;s rights, options and remedies hereunder shall be construed and held to be nonexclusive and cumulative. Landlord
shall have the right to pursue any one or all of such remedies, or any other remedy or relief that may be provided by Applicable Laws, whether or not stated in this Lease. No waiver of any default of Tenant hereunder shall be implied from any
acceptance by Landlord of any Rent or other payments due hereunder or any omission by Landlord to take any action on account of such default if such default persists or is repeated, and no express waiver shall affect defaults other than as specified
in such waiver. Notwithstanding any provision of this Lease to the contrary, in no event shall Landlord be required to mitigate its damages with respect to any default by Tenant, except as required by Applicable Laws. Anysuch obligation imposed by
Applicable Laws upon Landlord to relet the Premises after any termination of this Lease shall be subject to the reasonable requirements of Landlord to (a)&nbsp;lease to high quality tenants on such terms as Landlord may from time to time deem
appropriate in its discretion and (b)&nbsp;develop the Project in a harmonious manner with a mix of uses, tenants, floor areas, terms of tenancies, etc., as determined by Landlord. Landlord shall not be obligated to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relet the Premises to any party to whom Landlord or an affiliate of Landlord may desire to lease other available space in the Project or at another property owned by Landlord or an affiliate of
Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.10 Landlord&#146;s termination of (a)&nbsp;this Lease or (b)&nbsp;Tenant&#146;s right to possession of the Premises shall
not relieve Tenant of any liability to Landlord that has previously accrued or that shall arise based upon events that occurred prior to the later to occur of (y)&nbsp;the date of Lease termination and (z)&nbsp;the date Tenant surrenders possession
of the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.11 [Intentionally Omitted.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.12 Landlord shall not be in default or liable for damages under this Lease unless Landlord fails to perform obligations required of
Landlord within a reasonable time, but in no event shall such failure continue for more than thirty (30)&nbsp;days after written notice from Tenant specifying the nature of Landlord&#146;s failure; <U>provided</U>, however, that if the nature of
Landlord&#146;s obligation is such that more than thirty (30)&nbsp;days are required for its performance, then Landlord shall not be in default if Landlord commences performance within such thirty (30)&nbsp;day period and thereafter diligently
prosecutes the same to completion. Except as otherwise expressly set forth in this Lease, in no event shall Tenant have the right to terminate or cancel this Lease or to withhold or abate rent or to set off any Claims against Rent as a result of any
default or breach by Landlord of any of its covenants, obligations, representations, warranties or promises hereunder, except as may otherwise be expressly set forth in this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.13 In the event of any default by Landlord, Tenant shall give notice by registered or certified mail or overnight delivery with a reputable
international overnight delivery service, such as FedEx, to any (a)&nbsp;beneficiary of a deed of trust or (b)&nbsp;mortgagee under a mortgage covering the Premises, the Building or the Project and to any landlord of any lease of land upon or within
which the Premises, the Building or the Project is located, and shall offer such beneficiary, mortgagee or landlord a reasonable opportunity to cure the default, including time to obtain possession of the Building or the Project by power of sale or
a judicial action if such should prove necessary to effect a cure; <U>provided</U> that Landlord shall furnish to Tenant in writing, upon written request by Tenant, the names and addresses of all such persons who are to receive such notices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">32. <U>Bankruptcy </U>. In the event a debtor, trustee or debtor in possession under the Bankruptcy Code, or another person with similar rights, duties and
powers under any other Applicable Laws, proposes to cure any default under this Lease or to assume or assign this Lease and is obliged to provide adequate assurance to Landlord that (a)&nbsp;a default shall be cured, (b)&nbsp;Landlord shall be
compensated for its damages arising from any breach of this Lease and (c)&nbsp;future performance of Tenant&#146;s obligations under this Lease shall occur, then such adequate assurances shall include any or all of the following, as designated by
Landlord in its sole and absolute discretion: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">32.1 Those acts specified in the Bankruptcy Code or other Applicable Laws as included within
the meaning of &#147;adequate assurance,&#148; even if this Lease does not concern a shopping center or other facility described in such Applicable Laws; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">32.2 A prompt cash payment to compensate Landlord for any monetary defaults or actual
damages arising directly from a breach of this Lease; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">32.3 A cash deposit in an amount at least equal to the then-current amount of the
Security Deposit; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">32.4 The assumption or assignment of all of Tenant&#146;s interest and obligations under this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">33. <U>Brokers</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">33.1 Each party represents
and warrants to the other that it has had no dealings with any real estate broker or agent in connection with the negotiation of this Lease other than Cushman&nbsp;&amp; Wakefield (&#147;Broker&#148;), and that it knows of no other real estate
broker or agent that is or might be entitled to a commission in connection with this Lease. Landlord shall compensate Broker in relation to this Lease pursuant to a separate agreement between Landlord and Broker. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">33.2 Tenant represents and warrants that no broker or agent has made any representation or warranty relied upon by Tenant in Tenant&#146;s
decision to enter into this Lease, other than as contained in this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">33.3 Tenant acknowledges and agrees that the employment of
brokers by Landlord is for the purpose of solicitation of offers of leases from prospective tenants and that no authority is granted to any broker to furnish any representation (written or oral) or warranty from Landlord unless expressly contained
within this Lease. Landlord is executing this Lease in reliance upon Tenant&#146;s representations, warranties and agreements contained within <U>Sections 33.1</U> and <U>33.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">33.4 Each party agrees to indemnify, save, defend (at the other party&#146;s option and with counsel reasonably acceptable to the other party)
and hold the other party harmless from any and all cost or liability for compensation claimed by any broker or agent, other than Brokers, that was employed or engaged by the party, or claiming to have been employed or engaged as a result of the
party&#146;s own acts. The indemnifications in this Section shall survive the expiration or earlier termination of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">34. <U>Definition of
Landlord</U>. With regard to obligations imposed upon Landlord pursuant to this Lease, the term &#147;<U>Landlord</U> &#147; as used in this Lease, shall refer only to Landlord or Landlord&#146;s then-current <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successor-in-interest.</FONT></FONT> In the event of any transfer, assignment or conveyance of Landlord&#146;s interest in this Lease or in Landlord&#146;s fee title to or leasehold interest in the Property, as applicable,
Landlord herein named (and in case of any subsequent transfers or conveyances,the subsequent Landlord) shall be automatically freed and relieved, from and after the date ofsuch transfer, assignment or conveyance, from all liability for the
performance of any covenants or obligations contained in this Lease to be performed by Landlord first arising after the date of the transfer, and, without further agreement, the transferee, assignee or conveyee of Landlord&#146;s in this Lease or in
Landlord&#146;s fee title to or leasehold interest in the Property, as applicable, shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deemed to have assumed and agreed to observe and perform any and all covenants and obligations of Landlord hereunder during the tenure of its interest in the Lease or the Property. Landlord or
any subsequent Landlord may transfer its interest in the Premises or this Lease without Tenant&#146;s consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">35. <U>Limitation of
Landlord</U><U>&#146;</U><U>s Liability</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">35.1 If Landlord is in default under this Lease and, as a consequence, Tenant recovers a
monetary judgment against Landlord, the judgment shall be satisfied only out of (a)&nbsp;the proceeds of sale received on execution of the judgment and levy against the right, title and interest of Landlord in the Building and the Project,
(b)&nbsp;rent or other income from such real property receivable by Landlord or (c)&nbsp;the consideration received by Landlord from the sale, financing, refinancing or other disposition of all or any part of Landlord&#146;s right, title or interest
in the Building or the Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">35.2 Neither Landlord nor any of its affiliates, nor any of their respective partners, shareholders,
directors, officers, employees, members or agents shall be personally liable for Landlord&#146;s obligations or any deficiency under this Lease, and service of process shall not be made against any shareholder, director, officer, employee or agent
of Landlord or any of Landlord&#146;s affiliates. No partner, shareholder, director, officer, employee, member or agent of Landlord or any of its affiliates shall be sued or named as a party in any suit or action, and service of process shall not be
made against any partner or member of Landlord except as may be necessary to secure jurisdiction of the partnership, joint venture or limited liability company, as applicable. No partner, shareholder, director, officer, employee, member or agent of
Landlord or any of its affiliates shall be required to answer or otherwise plead to any service of process, and no judgment shall be taken or writ of execution levied against any partner, shareholder, director, officer, employee, member or agent of
Landlord or any of its affiliates. For the purpose of clarity, the foregoing paragraph is not intended to preclude any tort claim against any individual arising from the actions of such individual unrelated to this Lease in his or her personal
capacity and not in his or her capacity as a partner, shareholder, director, officer, employee, member or agent of Landlord or any of its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">35.3 Each of the covenants and agreements of this Article shall be applicable to any covenant or agreement either expressly contained in this
Lease or imposed by Applicable Laws and shall survive the expiration or earlier termination of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">36. <U>Joint and Several Obligations</U>. If
more than one person or entity executes this Lease as Tenant, then: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">36.1 Each of them is jointly and severally liable for the keeping,
observing and performing of all of the terms, covenants, conditions, provisions and agreements of this Lease to be kept, observed or performed by Tenant, and such terms, covenants, conditions, provisions and agreements shall be binding with the same
force and effect upon each and all of the persons executing this Agreement as Tenant; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">36.2 The term &#147;<U>Tenant</U>,&#148; as used in this Lease, shall mean and include each
of them, jointly and severally. The act of, notice from, notice to, refund to, or signature of any one or more of them with respect to the tenancy under this Lease, including any renewal, extension, expiration, termination or modification of this
Lease, shall be binding upon each and all of the persons executing this Lease as Tenant with the same force and effect as if each and all of them had so acted, so given or received such notice or refund, or so signed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">37. <U>Representations</U>. Tenant guarantees, warrants and represents that (a)&nbsp;Tenant is duly incorporated or otherwise established or formed and
validly existing under the laws of its state of incorporation, establishment or formation, (b)&nbsp;Tenant has and is duly qualified to do business in the state in which the Property is located, (c)&nbsp;Tenant has full corporate, partnership,
trust, association or other appropriate power and authority to enter into this Lease and to perform all Tenant&#146;s obligations hereunder, (d)&nbsp;each person (and all of the persons if more than one signs) signing this Lease on behalf of Tenant
is duly and validly authorized to do so and (e)&nbsp;neither (i) the execution, delivery or performance of this Lease nor (ii)&nbsp;the consummation of the transactions contemplated hereby will violate or conflict with any provision of documents or
instruments under which Tenant is constituted or to which Tenant is a party. In addition, Tenant guarantees, warrants and represents that none of (x)&nbsp;it, (y) its affiliates or partners nor (z)&nbsp;to the best of its knowledge, its members,
shareholders or other equity owners or any of their respective employees, officers, directors, representatives or agents is a person or entity with whom U.S. persons or entities are restricted from doing business under regulations of the Office of
Foreign Asset Control (&#147;<U>OFAC</U>&#148;) of the Department of the Treasury (including those named on OFAC&#146;s Specially Designated and Blocked Persons List) or under any statute, executive order (including the September&nbsp;24, 2001,
Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism) or other similar governmental action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">38. <U>Confidentiality</U>. Tenant shall keep the terms and conditions of this Lease and any information provided to Tenant or its employees, agents or
contractors pursuant to <U>Article 9 </U>confidential and shall not (a)&nbsp;disclose to any third party any terms or conditions of this Lease or any other Lease-related document (including subleases, assignments, work letters, construction
contracts, letters of credit, subordination agreements, <FONT STYLE="white-space:nowrap">non-disturbance</FONT> agreements, brokerage agreements or estoppels) or (b)&nbsp;provide to any third party an original or copy of this Lease (or any
Lease-related document). Landlord shall not release to any third party any <FONT STYLE="white-space:nowrap">non-public</FONT> financial information or <FONT STYLE="white-space:nowrap">non-public</FONT> information about Tenant&#146;s ownership
structure. In addition, all proprietary information of Tenant, including any information learned by or disclosed to Landlord with respect to Tenant&#146;s business or research, or information disclosed or discovered during an entry by Landlord into
the Premises, shall be kept strictly confidential by Landlord, Landlord&#146;s legal representatives, successors, assigns, employees, servants and agents and shall not be used (except for Landlord&#146;s confidential internal purposes) or disclosed
to others by Landlord (other than Landlord&#146;s and Landlord&#146;s affiliates&#146; respective employees, investors or prospective investors, accountants, attorneys, lenders or prospective lenders, consultants, advisors, purchasers or prospective
purchasers), or Landlord&#146;s servants, agents, employees, legal representatives, successors or assigns, without the express prior written consent of Tenant, which Tenant may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
withhold in its sole and absolute discretion. Notwithstanding the foregoing, confidential information under this Section may be released by Landlord or Tenant under the following circumstances:
(x)&nbsp;if required by Applicable Laws (including securities laws and regulations) or in any judicial proceeding; <U>provided</U> that the releasing party has given the other party reasonable notice of such requirement, if feasible, (y)&nbsp;to a
party&#146;s attorneys, accountants, brokers, lenders, potential lenders, investors, potential investors and other bona fide consultants or advisers (with respect to this Lease only); <U>provided</U> such third parties agree to be bound by this
Section or (z)&nbsp;to bona fide prospective assignees or subtenants of this Lease; <U>provided</U> they agree in writing to be bound by this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">39. <U>Notices </U>. Except as otherwise stated in this Lease, any notice, consent, demand, invoice, statement or other communication required or permitted to
be given hereunder shall be in writing and shall be given by (a)&nbsp;personal delivery, (b)&nbsp;overnight delivery with a reputable international overnight delivery service, such as FedEx, or (c)&nbsp;email transmission, so long as such
transmission is followed within one (1)&nbsp;business day by delivery utilizing one of the methods described in <U>Subsection 39(a)</U> or <U>(b)</U>. Any such notice, consent, demand, invoice, statement or other communication shall be deemed
delivered (x)&nbsp;upon receipt, if given in accordance with <U>Subsection</U><U></U><U>&nbsp;39(a)</U>; (y) one (1)&nbsp;business day after deposit with a reputable international overnight delivery service, if given if given in accordance with
<U>Subsection 39(b)</U>; or (z)&nbsp;upon transmission, if given in accordance with <U>Subsection 39(c)</U>. Except as otherwise stated in this Lease, anynotice, consent, demand, invoice, statement or other communication required or permitted to be
given pursuant to this Lease shall be addressed to Tenant at the Premises, or to Landlord orTenant at the addresses shown in <U>Sections 2.9</U> and <U>2.10</U> or <U>2.11</U>, respectively. Either party may, by notice to the other given pursuant to
this Section, specify additional or different addresses for notice purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">40. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.1 Landlord reserves the right to change the name of the Building or the Project in its sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.2 Tenant agrees that it shall furnish to Landlord, from time to time (but not more often than once per calendar year), within ten
(10)&nbsp;business days after receipt of Landlord&#146;s written request, the most recent <FONT STYLE="white-space:nowrap">year-end</FONT> unconsolidated financial statements reflecting Tenant&#146;s current financial condition audited by a
nationally recognized accounting firm. Tenant shall, within ninety (90)&nbsp;days after the end of Tenant&#146;s financial year, furnish Landlord with a certified copy of Tenant&#146;s <FONT STYLE="white-space:nowrap">year-end</FONT> unconsolidated
financial statements for the previous year audited by a nationally recognized accounting firm. Tenant represents and warrants that all financial statements, records and information furnished by Tenant to Landlord in connection with this Lease are
true, correct and complete in all material respects. If audited financials are not otherwise prepared, unaudited financials complying with generally accepted accounting principles and certified by the chief financial officer of Tenant as true,
correct and complete in all respects shall suffice for purposes of this Section. The provisions of this Section shall not apply at any time while Tenant is a corporation whose shares are traded on any nationally recognized stock exchange. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.3 Submission of this instrument for examination or signature by Tenant does not
constitute a reservation of or option for a lease, and shall not be effective as a lease or otherwise until execution by and delivery to both Landlord and Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.4 The terms of this Lease are intended by the parties as a final, complete and exclusive expression of their agreement with respect to the
terms that are included herein, and may not be contradicted or supplemented by evidence of any other prior or contemporaneous agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.5 Landlord shall record a memorandum of this Lease in the form of <U>Exhibit I</U>; provided Tenant executes and delivers to Landlord at
the time such memorandum is executed a termination of such memorandum in the form of <U>Exhibit J</U> attached which Landlord may record upon the expiration of the Term or the earlier termination of this Lease. Landlord shall be responsible for the
cost of recording the memorandum of this Lease or any termination of the memorandum. Neither party shall record this Lease. Upon the expiration or earlier termination of this Lease, Tenant shall provide Landlord with such additional documents as
Landlord may reasonably request confirming that this Lease is terminated so Landlord can remove the memorandum of this Lease from record title to the Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.6 Where applicable in this Lease, the singular includes the plural and the masculine or neuter includes the masculine, feminine and neuter.
The words &#147;include,&#148; &#147;includes,&#148; &#147;included&#148; and &#147;including&#148; mean &#147;&#145;include,&#146; etc., without limitation.&#148; The word &#147;shall&#148; is mandatory and the word &#147;may&#148; is permissive.
The section headings of this Lease are not a part of this Lease and shall have no effect upon the construction or interpretation of any part of this Lease. Landlord and Tenant have each participated in the drafting and negotiation of this Lease, and
the language in all parts of this Lease shall be in all cases construed as a whole according to its fair meaning and not strictly for or against either Landlord or Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.7 Except as otherwise expressly set forth in this Lease, each party shall pay its own costs and expenses incurred in connection with this
Lease and such party&#146;s performance under this Lease; <U>provided</U> that, if either party commences an action, proceeding, demand, claim, action, cause of action or suit against the other party arising out of or in connection with this Lease,
then the substantially prevailing party shall be reimbursed by the other party for all reasonable costs and expenses, including reasonable attorneys&#146; fees and expenses, incurred by the substantially prevailing party in such action, proceeding,
demand, claim, action, cause of action or suit, and in any appeal in connection therewith (regardless of whether the applicable action, proceeding, demand, claim, action, cause of action, suit or appeal is voluntarily withdrawn or dismissed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.8 Time is of the essence with respect to the performance of every provision of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.9 The covenants and conditions of the parties in this Lease are intended to be independent of each other covenant and condition of this
Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.10 Notwithstanding anything to the contrary contained in this Lease, Tenant&#146;s
obligations under this Lease are independent and shall not be conditioned upon performance by Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.11 Whenever consent or
approval of either party is required, that party shall not unreasonably withhold, condition or delay such consent or approval, except as may be expressly set forth to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.12 Any provision of this Lease that shall prove to be invalid, void or illegal shall in no way affect, impair or invalidate any other
provision hereof, and all other provisions of this Lease shall remain in full force and effect and shall be interpreted as if the invalid, void or illegal provision did not exist. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.13 Each of the covenants, conditions and agreements herein contained shall inure to the benefit of and shall apply to and be binding upon
the parties hereto and their respective heirs; legatees; devisees; executors; administrators; and permitted successors and assigns. This Lease is for the sole benefit of the parties and their respective heirs, legatees, devisees, executors,
administrators and permitted successors and assigns, and nothing in this Lease shall give or be construed to give any other person or entity any legal or equitable rights. Nothing in this Section shall in any way alter the provisions of this Lease
restricting assignment or subletting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.14 This Lease shall be governed by, construed and enforced in accordance with the laws of the
state in which the Premises are located, without regard to such state&#146;s conflict of law principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.15 Each party guarantees,
warrants and represents to the other that the individual or individuals signing this Lease have the power, authority and legal capacity to sign this Lease on behalf of and to bind all entities, corporations, partnerships, limited liability
companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed. Each party further guarantees, warrants and represents to the other that no third-party consent or approval is required in
connection with this Lease, or if such consent or approval is required, it has been obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.16 This Lease may be executed in one or
more counterparts, each of which, when taken together, shall constitute one and the same document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.17 No provision of this Lease may
be modified, amended or supplemented except by an agreement in writing signed by Landlord and Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.18 No waiver of any term,
covenant or condition of this Lease shall be binding unless executed in writing by the waiving party. The waiver by a party of any breach or default of any term, covenant or condition contained in this Lease shall not be deemed to be a waiver of any
preceding or subsequent breach or default of such term, covenant or condition or any other term, covenant or condition of this Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40.19 To the extent permitted by Applicable Laws, the parties waive trial by jury in any
action, proceeding or counterclaim brought by the other party hereto related to matters arising out of or in any way connected with this Lease; the relationship between Landlord and Tenant; Tenant&#146;s use or occupancy of the Premises; or any
claim of injury or damage related to this Lease or the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">41. <U>Rooftop Installation Area</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.1 Tenant may use those portions of the Building identified by Landlord in its sole discretion as a rooftop installation area as of the
Execution Date (the &#147;Rooftop Installation Area&#148;) solely to operate, maintain, repair and replace rooftop antennae, mechanical equipment, communications antennas and other equipment installed by Tenant in the Rooftop Installation Area in
accordance with this Article (&#147;Tenant&#146;s Rooftop Equipment&#148;). Tenant&#146;s Rooftop Equipment shall be only for Tenant&#146;s use of the Premises for the Permitted Use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.2 Tenant shall install Tenant&#146;s Rooftop Equipment at its sole cost and expense, at such times and in such manner as Landlord may
reasonably designate, and in accordance with this Article and the applicable provisions of this Lease regarding Alterations. Tenant&#146;s Rooftop Equipment and the installation thereof shall be subject to Landlord&#146;s prior written approval,
which approval shall not be unreasonably withheld. Among other reasons, Landlord may withhold approval if the installation or operation of Tenant&#146;s Rooftop Equipment could reasonably be expected to damage the structural integrity of the
Building or to transmit vibrations or noise or cause other adverse effects beyond the Premises to an extent not customary in first class laboratory buildings, unless Tenant implements measures that are acceptable to Landlord in its reasonable
discretion to avoid any such damage or transmission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.3 Tenant shall comply with any roof or roof-related warranties. Tenant shall
obtain a letter from Landlord&#146;s roofing contractor within thirty (30)&nbsp;days after completion of any Tenant work on the rooftop stating that such work did not affect any such warranties. Tenant, at its sole cost and expense, shall inspect
the Rooftop Installation Area at least annually, and correct any loose bolts, fittings or other appurtenances and repair any damage to the roof caused by the installation or operation of Tenant&#146;s Rooftop Equipment. Tenant shall not permit the
installation, maintenance or operation of Tenant&#146;s Rooftop Equipment to violate any Applicable Laws or constitute a nuisance. Tenant shall pay Landlord within thirty (30)&nbsp;days after demand (a)&nbsp;all applicable taxes, charges, fees or
impositions imposed on Landlord by Governmental Authorities as the result of Tenant&#146;s use of the Rooftop Installation Areas in excess of those for which Landlord would otherwise be responsible for the use or installation of Tenant&#146;s
Rooftop Equipment and (b)&nbsp;the amount of any increase in Landlord&#146;s insurance premiums as a result of the installation of Tenant&#146;s Rooftop Equipment. Upon Tenant&#146;s written request to Landlord, Landlord shall use commercially
reasonable efforts to cause other tenants to remedy any interference in the operation of Tenant&#146;s Rooftop Equipment caused by any such tenants&#146; equipment installed after the applicable piece of Tenant&#146;s Rooftop Equipment;
<U>provided</U>,<U> </U>however, that Landlord shall not be required to request that such tenants waive their rights under their respective leases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.4 If Tenant&#146;s Equipment (a)&nbsp;causes physical damage to the structural integrity
of the Building, (b)&nbsp;interferes with any telecommunications, mechanical or other systems located at or near or servicing the Building or the Project that were installed prior to the installation of Tenant&#146;s Rooftop Equipment,
(c)&nbsp;interferes with any other service provided to other tenants in the Building or the Project by rooftop or penthouse installations that were installed prior to the installation of Tenant&#146;s Rooftop Equipment or (d)&nbsp;interferes with
any other tenants&#146; business, in each case in excess of that permissible under Federal Communications Commission regulations, then Tenant shall cooperate with Landlord to determine the source of the damage or interference and promptly repair
such damage and eliminate such interference, in each case at Tenant&#146;s sole cost and expense, within ten (10)&nbsp;days after receipt of notice of such damage or interference (which notice may be oral; <U>provided</U> that Landlord also delivers
to Tenant written notice of such damage or interference within twenty-four (24)&nbsp;hours after providing oral notice). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41.5 Landlord
reserves the right to cause Tenant to relocate Tenant&#146;s Rooftop Equipment to comparably functional space on the roof or in the penthouse of the Building by giving Tenant prior written notice thereof. Landlord agrees to pay the reasonable costs
thereof. Tenant shall arrange for the relocation of Tenant&#146;s Rooftop Equipment within sixty (60)&nbsp;days after receipt of Landlord&#146;s notification of such relocation. In the event Tenant fails to arrange for relocation within such sixty
(60)-day period, Landlord shall have the right to arrange for the relocation of Tenant&#146;s Rooftop Equipment in a manner that does not unnecessarily interrupt or interfere with Tenant&#146;s use of the Premises for the Permitted Use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">42. <U>Option to Extend Term</U>. Tenant shall have one (1)&nbsp;option (&#147;<U>Option</U>&#148;) to extend the Term by five (5)&nbsp;years as to the entire
Premises (and no less than the entire Premises) upon thefollowing terms and conditions. Any extension of the Term pursuant to the Option shall be on all the same terms and conditions as this Lease, except as follows: Base Rent at the commencement of
the Option term shall equal the then-current fair market value for comparable office and laboratory space in the Seattle market of comparable age, quality, level of finish and proximity to amenities and public transit, and containing the systems and
improvements present in the Premises as of the date that Tenant gives Landlord written notice of Tenant&#146;s election to exercise the Option (&#147;<U>FMV</U>&#148;), and shall be further increased on each annual anniversary of the Option term
commencement date by three percent (3%). Tenant may, no more than fifteen (15)&nbsp;months prior to the date the Term is then scheduled to expire, request Landlord&#146;s estimate of the FMV for the Option term. Landlord shall, within fifteen
(15)&nbsp;days after receipt of such request, give Tenant a written proposal of such FMV. If Tenant subsequently gives written notice to exercise the Option, such notice shall specify whether Tenant accepts Landlord&#146;s proposed estimate of FMV.
If Tenant does not accept the FMV, then the parties shall endeavor to agree upon the FMV, taking into account all relevant factors, including (a)&nbsp;the size of the Premises, (b)&nbsp;the length of the Option term, (c)&nbsp;rent in comparable
buildings in the relevant market, including concessions offered to new tenants, such as free rent, tenant improvement allowances, leasing commissions and moving allowances, (d)&nbsp;Tenant&#146;s creditworthiness and (e)&nbsp;the quality and
location of the Building and the Project. In the event that the parties are unable to agree upon the FMV within thirty (30)&nbsp;days after Tenant notifies Landlord that Tenant is exercising the Option, then either party may request that the same be
determined as follows: a senior officer of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
nationally recognized leasing brokerage firm with local knowledge of the Seattle laboratory/research and development leasing market (the &#147;<U>Baseball Arbitrator</U>&#148;) shall be selected
and paid for jointly by Landlord and Tenant. If Landlord and Tenant are unable to agree upon the Baseball Arbitrator, then the same shall be designated by the local chapter of the Judicial Arbitration and Mediation Services or any successor
organization thereto (the &#147;<U>JAMS</U>&#148;). The Baseball Arbitrator selected by the parties or designated by JAMS shall (y)&nbsp;have at least ten (10)&nbsp;years&#146; experience in the leasing of laboratory/research and development space
in the Seattle market and (z)&nbsp;not have been employed or retained by either Landlord or Tenant or any affiliate of either for a period of at least ten (10)&nbsp;years prior to appointment pursuant hereto. Each of Landlord and Tenant shall submit
to the Baseball Arbitrator and to the other party its determination of the FMV. The Baseball Arbitrator shall grant to Landlord and Tenant a hearing and the right to submit evidence. The Baseball Arbitrator shall determine which of the two
(2)&nbsp;FMV determinations more closely represents the actual FMV. The arbitrator may not select any other FMV for the Premises other than one submitted by Landlord or Tenant. The FMV selected by the Baseball Arbitrator shall be binding upon
Landlord and Tenant and shall serve as the basis for determination of Base Rent payable for the Option term. If, as of the commencement date of the Option term, the amount of Base Rent payable during the Option term shall not have been determined,
then, pending such determination, Tenant shall pay Base Rent equal to the Base Rent payable with respect to the last year of the then-current Term. After the final determination of Base Rent payable for the Option term, the parties shall promptly
execute a written amendment to this Lease specifying the amount of Base Rent to be paid during the Option term. Any failure of the parties to execute such amendment shall not affect the validity of the FMV determined pursuant to this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">42.1 The Option is not assignable separate and apart from this Lease, except that is shall be assignable to and exercisable by a Tenant&#146;s
Affiliate that is the Tenant as a result of an Exempt Transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">42.2 The Option is conditional upon Tenant giving Landlord written notice
of its election to exercise the Option at least twelve (12)&nbsp;months prior to the end of the expiration of the then-current Term. Time shall be of the essence as to Tenant&#146;s exercise of the Option. Tenant assumes full responsibility for
maintaining a record of the deadlines to exercise the Option. Tenant acknowledges that it would be inequitable to require Landlord to accept any exercise of the Option after the date provided for in this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">42.3 Notwithstanding anything contained in this Article to the contrary, Tenant shall not have the right to exercise the Option: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) During the time commencing from the date Landlord delivers to Tenant a written notice that Tenant is actually in default under any
provisions of this Lease and continuing until Tenant has cured the specified default to Landlord&#146;s reasonable satisfaction; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
At any time after any Default as described in <U>Article 31</U> of the Lease (<U>provided</U>, however, that, for purposes of this <U>Section</U><U></U><U>&nbsp;42.4(b)</U>, Landlord shall not be required to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide Tenant with notice of such Default) and continuing until Tenant cures any such Default, if such Default is susceptible to being cured; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event that Tenant has defaulted (beyond applicable notice and cure periods) in the performance of either a material monetary
obligation or material <FONT STYLE="white-space:nowrap">non-monetary</FONT> obligation under this Lease two (2)&nbsp;or more times in the prior twenty-four (24)&nbsp;months, whether or not Tenant has cured such defaults. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">42.4 The period of time within which Tenant may exercise the Option shall not be extended or enlarged by reason of Tenant&#146;s inability to
exercise such Option because of the provisions of <U>Section</U><U></U><U>&nbsp;42.4.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">42.5 All of Tenant&#146;s rights under the
provisions of the Option shall terminate and be of no further force or effect even after Tenant&#146;s due and timely exercise of the Option if, after such exercise, but prior to the commencement date of the new term, (a)&nbsp;Tenant fails to pay to
Landlord a monetary obligation of Tenant for a period of twenty (20)&nbsp;days after written notice from Landlord to Tenant, (b)&nbsp;Tenant fails to commence to cure a material <FONT STYLE="white-space:nowrap">non-monetary</FONT> default within
thirty (30)&nbsp;days after the date Landlord gives notice to Tenant of such material <FONT STYLE="white-space:nowrap">non-monetary</FONT> default or (c)&nbsp;Tenant has defaulted (beyond any applicable notice and cure periods) with respect to
either a monetary obligation or material <FONT STYLE="white-space:nowrap">non-monetary</FONT> obligation under this Lease two (2)&nbsp;or more times. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Lease as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>LANDLORD</U>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BMR-500</FONT> FAIRVIEW AVENUE LLC,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Marie Lewis</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marie Lewis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">VP, Real Estate Legal</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>TENANT</U>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SILVERBACK THERAPEUTICS, INC.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">A Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Peter A. Thompson, MD<U> </U></I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Peter A. Thompson, MD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CEO</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A notary public or other officer completing this certificate verifies only the identity of the individual
who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">STATE OF
CALIFORNIA&nbsp;&nbsp;&nbsp;&nbsp;) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:19%; font-size:10pt; font-family:Times New Roman">&nbsp;) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COUNTY
OF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On <U>6/10/16</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U>,
2016, before me, <U>Fern M.
Kissel</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;
</U>, Notary Public, personally appeared <U>Marie
Lewis</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U>, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that <STRIKE>he/</STRIKE>she executed the same in
<STRIKE>his/</STRIKE>her authorized capacity, and that by <STRIKE>his/</STRIKE>her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WITNESS my hand and official seal. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g67046dsp139.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Fern M. Kissel</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Notary Public</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">STATE OF WASHINGTON&nbsp;&nbsp;&nbsp;&nbsp;) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:19%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;) ss. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COUNTY OF
<U>King</U><U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On this <U>9</U><U><SUP STYLE="font-size:85%; vertical-align:top">th</SUP></U><U> </U>day of
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>June</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;
&nbsp;</U>, 2016, before me, the undersigned, a Notary Public in and for the State of Washington, duly commissioned and sworn personally appeared <U>Peter A.
Thompson</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U>, known to me to be the
<U>CEO</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U> </U>of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
the corporation that executed the foregoing instrument, and acknowledged the said instrument to be the free and voluntary act and deed of said corporation, for the purposes therein mentioned, and on oath stated that he/she was authorized to execute
said instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I certify that I know or have satisfactory evidence that the person appearing before me and making this acknowledgment
is the person whose true signature appears on this document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WITNESS my hand and official seal hereto affixed the day and year in the
certificate above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="5"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g67046dsp140.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Sharen Bajema</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">S<SMALL>HAREN</SMALL> B<SMALL>AJEMA</SMALL></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Print Name</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">NOTARY PUBLIC in and for the State of</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Washington, residing at<U> </U><U>Kirkland&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">My commission expires<U> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">6-16-18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></U>.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">A-1</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PROPERTY </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ground lease estate in
the following described premises created by Lease dated as of January&nbsp;28, 2008 between Nelchina Point Limited Partnership, as ground lessor, and <FONT STYLE="white-space:nowrap">BMR-500</FONT> Fairview Avenue LLC, as ground lessee, as evidenced
by the Memorandum of Lease dated as of January&nbsp;28, 2008 recorded in the King County, Washington Land Records on January&nbsp;28, 2008 as Document Number 20080128000091: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lots 4, 5 and 6, Block 5, Sorenson&#146;s Addition to the City of Seattle, according to the plat thereof recorded in Volume 1 of plats, page(s) 218, in King
County, Washington. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">A-2</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PREMISES </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046dsp142.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">A-3</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STORAGE SPACE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g67046dsp143.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>WORK LETTER </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
Work Letter (this &#147;<U>Work Letter</U>&#148;) is made and entered into as of the 8<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of June, 2016, by and between <FONT STYLE="white-space:nowrap">BMR-500</FONT> FAIRVIEW AVENUE LLC, a
Delaware limited liability company (&#147;<U>Landlord</U>&#148;), and SILVERBACK THERAPEUTICS, INC., a Delaware corporation (&#147;<U>Tenant</U>&#148;), and is attached to and made a part of that certain Lease dated as of June 8<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>, 2016 (as the same may be amended, amended and restated, supplemented or otherwise modified from time to time, the &#147;<U>Lease</U>&#148;), by and between Landlord and Tenant for the Premises
located at 500 Fairview Avenue North, Seattle, Washington 98109. All capitalized terms used but not otherwise defined herein shall have the meanings given them in the Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>General Requirements</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1
<U>Authorized Representatives</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Landlord designates, as Landlord&#146;s authorized representative (&#147;<U>Landlord&#146;s
Authorized Representative</U>&#148;), (i) John Moshy as the person authorized to initial plans, drawings, approvals and to sign change orders pursuant to this Work Letter and (ii)&nbsp;an officer of Landlord as the person authorized to sign any
amendments to this Work Letter or the Lease. Tenant shall not be obligated to respond to or act upon any such item until such item has been initialed or signed (as applicable) by the appropriate Landlord&#146;s Authorized Representative. Landlord
may change either Landlord&#146;s Authorized Representative upon one (1)&nbsp;business day&#146;s prior written notice to Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
Tenant designates Russ Hawkinson (&#147;<U>Tenant&#146;s Authorized Representative</U>&#148;) as the person authorized to initial and sign all plans, drawings, change orders and approvals pursuant to this Work Letter. Landlord shall not be obligated
to respond to or act upon any such item until such item has been initialed or signed (as applicable) by Tenant&#146;s Authorized Representative. Tenant may change Tenant&#146;s Authorized Representative upon one (1)&nbsp;business day&#146;s prior
written notice to Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Schedule</U>. The schedule for design and development of the Tenant Improvements, including the time
periods for preparation and review of construction documents, approvals and performance, shall be in accordance with a schedule to be prepared by Tenant (the &#147;<U>Schedule</U>&#148;). Tenant shall prepare the Schedule so that it is a reasonable
schedule for the completion of the Tenant Improvements. The Schedule shall clearly identify all activities requiring Landlord participation, including specific dates and time periods when Tenant&#146;s contractor will require access to areas of the
Project outside of the Premises. As soon as the Schedule is completed, Tenant shall deliver the same to Landlord for Landlord&#146;s approval, which approval shall not be unreasonably withheld, conditioned or delayed. Such Schedule shall be approved
or disapproved by Landlord within ten (10)&nbsp;business days after delivery to Landlord. Landlord&#146;s failure to respond within such ten (10)&nbsp;business day period shall be deemed approval by Landlord. If Landlord disapproves the Schedule,
then Landlord shall notify Tenant in writing of its objections to such Schedule, and the parties shall confer and negotiate in good faith to reach agreement on </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the Schedule. The Schedule shall be subject to adjustment as mutually agreed upon in writing by the parties,
or as provided in this Work Letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Tenant&#146;s Architects, Contractors and Consultants</U>. The architect, engineering
consultants, design team, general contractor and subcontractors responsible for the construction of the Tenant Improvements shall be selected by Tenant and approved by Landlord, which approval Landlord shall not unreasonably withhold, condition or
delay. Landlord may refuse to use any architects, consultants, contractors, subcontractors or material suppliers that Landlord reasonably believes could cause labor disharmony or may not have sufficient experience, in Landlord&#146;s reasonable
opinion, to perform work in an occupied Class &#147;A&#148; laboratory research building and in lab areas. All Tenant contracts related to the Tenant Improvements shall provide that Tenant may assign such contracts and any warranties with respect to
the Tenant Improvements to Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Tenant Improvements</U>. All Tenant Improvements shall be performed by Tenant&#146;s contractor, at
Tenant&#146;s sole cost and expense (subject to Landlord&#146;s obligations with respect to any portion of the TI Allowance and the Test Fit Allowance) and in accordance with the Approved Plans (as defined below), the Lease and this Work Letter. To
the extent that the total projected cost of the Tenant Improvements (as projected by Landlord) exceeds the TI Allowance (such excess, the &#147;<U>Excess TI Costs</U>&#148;), Tenant shall pay the costs of the Tenant Improvements on a pari passu
basis with Landlord as such costs become due, in the same proportion that the Excess TI Costs payable by Tenant represent of the total cost of the Tenant Improvements. In other words, if the total cost of the Tenant Improvements is $100,000, and the
Excess TI Costs are $25,000, then the Excess TI Costs comprise 25% of the total cost of the Tenant Improvements, and therefore Tenant would pay 25% of the costs of the Tenant Improvements as they come due. If the cost of the Tenant Improvements (as
projected by Landlord) increases over Landlord&#146;s initial projection (the &#147;<U>Increased TI Costs</U>&#148;), then Landlord may notify Tenant and Tenant shall deposit with Landlord, within ten (10)&nbsp;days after receipt of an invoice
therefore, the portion of such Increased TI Costs that would have been required to be paid by Tenant had such Increased TI Costs been included in the initial determination of Excess Costs and Tenant had been required to pay the costs of the Tenant
Improvements in the proportion that the Excess TI Costs and the Increased TI Costs, in the aggregate, represent of the total cost of the Tenant Improvements. Thereafter, the remaining balance of such Increased TI Costs shall be included as part of
the Excess TI Costs to thereafter be paid by Tenant on a pad passu basis in accordance with this Section. In other words, if the Excess TI Costs originally comprised 25% of the total cost of the Tenant Improvements and subsequently Landlord notifies
Tenant of Increased TI Costs that when combined with the original Excess TI Costs comprise 30% of the total cost of the Tenant Improvements, then Tenant shall pay the difference (i.e. an additional five percent (5%) of the costs incurred to date) to
Landlord and thereafter be required to pay 30% of the costs of the Tenant Improvements as they become due. If Tenant fails to pay, or is late in paying, any sum due to Landlord under this Work Letter, then Landlord shall have all of the rights and
remedies set forth in the Lease for nonpayment of Rent (including the right to interest and the right to assess a late charge), and for purposes of any litigation instituted with regard to such amounts the same shall be considered Rent. All material
and equipment furnished by Tenant or its contractors as the Tenant Improvements shall be new or &#147;like new;&#148; the Tenant Improvements shall be performed in a first-class, workmanlike manner; and the quality of the Tenant
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Improvements shall be of a nature and character not less than the Building Standard. Tenant shall take, and shall require its contractors to take, commercially reasonable steps to protect the
Premises during the performance of any Tenant Improvements, including covering or temporarily removing any window coverings so as to guard against dust, debris or damage. All Tenant Improvements shall be performed in accordance with <U>Article
17</U> of the Lease; <U>provided</U> that, notwithstanding anything in the Lease or this Work Letter to the contrary, in the event of a conflict between this Work Letter and <U>Article 17</U> of the Lease, the terms of this Work Letter shall govern.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Work Plans</U>. Tenant shall prepare and submit to Landlord for approval schematics covering the Tenant Improvements prepared in
conformity with the applicable provisions of this Work Letter (the &#147;<U>Draft Schematic Plans</U>&#148;). The Draft Schematic Plans shall contain sufficient information and detail to accurately describe the proposed design to Landlord and such
other information as Landlord may reasonably request. Landlord shall notify Tenant in writing within ten (10)&nbsp;business days after receipt of the Draft Schematic Plans whether Landlord approves or objects to the Draft Schematic Plans and of the
manner, if any, in which the Draft Schematic Plans are unacceptable. Landlord&#146;s failure to respond within such ten (10)&nbsp;business day period shall be deemed approval by Landlord. If Landlord reasonably objects to the Draft Schematic Plans,
then Tenant shall revise the Draft Schematic Plans and cause Landlord&#146;s objections to be remedied in the revised Draft Schematic Plans. Tenant shall then resubmit the revised Draft Schematic Plans to Landlord for approval, such approval not to
be unreasonably withheld, conditioned or delayed. Landlord&#146;s approval of or objection to revised Draft Schematic Plans and Tenant&#146;s correction of the same shall be in accordance with this Section until Landlord has approved the Draft
Schematic Plans in writing or been deemed to have approved them. The iteration of the Draft Schematic Plans that is approved or deemed approved by Landlord without objection shall be referred to herein as the &#147;<U>Approved Schematic
Plans</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Construction Plans</U>. Tenant shall prepare final plans and specifications for the Tenant Improvements that
(a)&nbsp;are consistent with and are logical evolutions of the Approved Schematic Plans and (b)&nbsp;incorporate any other Tenant-requested (and Landlord-approved) Changes (as defined below). As soon as such final plans and specifications
(&#147;<U>Construction Plans</U>&#148;) are completed, Tenant shall deliver the same to Landlord for Landlord&#146;s approval, which approval shall not be unreasonably withheld, conditioned or delayed. All such Construction Plans shall be submitted
by Tenant to Landlord in electronic .pdf, CADD and <FONT STYLE="white-space:nowrap">full-size</FONT> hard copy formats, and shall be approved or disapproved by Landlord within ten (10)&nbsp;business days after delivery to Landlord. Landlord&#146;s
failure to respond within such ten (10)&nbsp;business day period shall be deemed approval by Landlord. If the Construction Plans are disapproved by Landlord, then Landlord shall notify Tenant in writing of its objections to such Construction Plans,
and the parties shall confer and negotiate in good faith to reach agreement on the Construction Plans. Promptly after the Construction Plans are approved by Landlord and Tenant, two (2)&nbsp;copies of such Construction Plans shall be initialed and
dated by Landlord and Tenant, and Tenant shall promptly submit such Construction Plans to all appropriate Governmental Authorities for approval. The Construction Plans so approved, and all change orders specifically permitted by this Work Letter,
are referred to herein as the &#147;<U>Approved Plans</U>.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Changes to the Tenant Improvements</U>. Any changes to the Approved Plans (each, a
&#147;<U>Change</U>&#148;) shall be requested and instituted in accordance with the provisions of this <U>Article 2 </U>and shall be subject to the written approval of the <FONT STYLE="white-space:nowrap">non-requesting</FONT> party in accordance
with this Work Letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Change Request</U>. Either Landlord or Tenant may request Changes after Landlord approves the Approved
Plans by notifying the other party thereof in writing in substantially the same form as the AIA standard change order form (a &#147;<U>Change Request</U>&#148;), which Change Request shall detail the nature and extent of any requested Changes,
including (a)&nbsp;the Change, (b)&nbsp;the party required to perform the Change and (c)&nbsp;any modification of the Approved Plans and the Schedule, as applicable, necessitated by the Change. If the nature of a Change requires revisions to the
Approved Plans, then the requesting party shall be solely responsible for the cost and expense of such revisions and any increases in the cost of the Tenant Improvements as a result of such Change, provided Tenant shall be required to pay the cost
and expense of any Change requested by Landlord to the extent such Change is (i)&nbsp;required to comply with Applicable Laws, (ii)&nbsp;made at the request of a Governmental Authority, or (iii)&nbsp;required to correct a defect or failure of the
Approved Plans to comply with this Work Letter. Change Requests shall be signed by the requesting party&#146;s Authorized Representative. In the event that any Change requested by Landlord would reasonably be expected to cause and actually does
cause a material delay in the construction of the Tenant Improvements such that the Tenant Improvements would have been Substantally Complete prior to the Estimated Term Commencement Date but for such Change requested by Landlord, and such Change
was not required for compliance with Applicable Laws or at the request of a Governmental Authority or to correct a defect or failure of the Approved Plans to comply with this Work Letter, then Tenant shall be entitled to a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-for-day</FONT></FONT> abatement of Base Rent for each day following the Estimated Term Commencement Date that Substantial Completion of the Tenant Improvements is actually delayed as a
result of such Change request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Approval of Changes</U>. All Change Requests that involve a material change to the shell and core
shall be subject to the other party&#146;s prior written approval, which approval shall not be unreasonably withheld, conditioned or delayed. The <FONT STYLE="white-space:nowrap">non-requesting</FONT> party shall have five (5)&nbsp;business days
after receipt of a Change Request to notify the requesting party in writing of the <FONT STYLE="white-space:nowrap">non-requesting</FONT> party&#146;s decision either to approve or object to the Change Request. The
<FONT STYLE="white-space:nowrap">non-requesting</FONT> party&#146;s failure to respond within such five (5)&nbsp;business day period shall be deemed approval by the <FONT STYLE="white-space:nowrap">non-requesting</FONT> party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Preparation of Estimates</U>. Tenant shall, before proceeding with any Change, using its best efforts, prepare as soon as is reasonably
practicable (but in no event more than five (5)&nbsp;business days after delivering a Change Request to Landlord or receipt of a Change Request) an estimate of the increased costs or savings that would result from such Change, as well as an estimate
of such Change&#146;s effects on the Schedule. Landlord shall have five (5)&nbsp;business days after receipt of such information from Tenant to (a)&nbsp;in the case of a Tenant-initiated Change Request, approve or reject such Change Request in
writing, or (b)&nbsp;in the case of a Landlord-initiated Change Request, notify Tenant in writing of Landlord&#146;s decision either to proceed with or abandon the Landlord-initiated Change Request. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>Quality Control Program; Coordination</U>. Tenant shall provide Landlord with
information regarding the following (together, the &#147;<U>QCP</U>&#148;): (a) Tenant&#146;s general contractor&#146;s quality control program and (b)&nbsp;evidence of subsequent monitoring and action plans. The QCP shall be subject to
Landlord&#146;s reasonable review and approval and shall specifically address the Tenant Improvements. Tenant shall ensure that the QCP is regularly implemented on a scheduled basis and shall provide Landlord with reasonable prior notice and access
to attend all inspections and meetings between Tenant and its general contractor. At the conclusion of the Tenant Improvements, Tenant shall deliver the quality control log to Landlord, which shall include all records of quality control meetings and
testing and of inspections held in the field, including inspections relating to concrete, steel roofing, piping pressure testing and system commissioning. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Completion of Tenant Improvements</U>. Tenant, at its sole cost and expense (except for the TI Allowance and the Test Fit Allowance), shall perform and
complete the Tenant Improvements in all respects (a)&nbsp;in substantial conformance with the Approved Plans, (b)&nbsp;otherwise incompliance with provisions of the Lease and this Work Letter and (c)&nbsp;in accordance with Applicable Laws, the
requirements of Tenant&#146;s insurance carriers, the requirements of Landlord&#146;s insurance carriers (to the extent Landlord provides its insurance carriers&#146; requirements to Tenant) and the board of fire underwriters having jurisdiction
over the Premises. The Tenant Improvements shall be deemed completed at such time as Tenant shall furnish to Landlord (t)&nbsp;evidence satisfactory to Landlord that (i)&nbsp;all Tenant Improvements have been completed and paid for in full (which
shall be evidenced by the architect&#146;s certificate of completion and the general contractor&#146;s and each subcontractor&#146;s and material supplier&#146;s final unconditional waivers and releases of liens, each in a form acceptable to
Landlord and complying with Applicable Laws, and a Certificate of Substantial Completion in the form of the American Institute of Architects document G704, executed by the project architect and the general contractor, together with a statutory
notice of substantial completion from the general contractor), (ii) any and all liensrelated to the Tenant Improvements have either been discharged of record (by payment, bond, order of a court of competent jurisdiction or otherwise) or waived by
the party filing such lienand (iii)&nbsp;no security interests relating to the Tenant Improvements are outstanding, (u)&nbsp;all certifications and approvals with respect to the Tenant Improvements that may be required from any Governmental
Authority and any board of fire underwriters or similar body for the use and occupancy of the Premises (including a certificate of occupancy for the Premises for thePermitted Use), (v) certificates of insurance required by the Lease to be purchased
andmaintained by Tenant, (w)&nbsp;an affidavit from Tenant&#146;s architect certifying that all work performed in, on or about the Premises is in accordance with the Approved Plans, (x)&nbsp;complete &#147;as built&#148; drawing print sets, project
specifications and shop drawings and electronic CADD files on disc (showing the Tenant Improvements as an overlay on the Building &#147;as built&#148; plans (<U>provided</U> that Landlord provides the Building
<FONT STYLE="white-space:nowrap">&#147;as-built&#148;</FONT> plans provided to Tenant) of all contract documents for work performed by their architect and engineers in relation to the Tenant Improvements, (y)&nbsp;a commissioning report prepared by
a licensed, qualified commissioning agent hired by Tenant and approved by Landlord for all new or affected mechanical, electrical and plumbing systems(which report Landlord may hire a licensed, qualified commissioning agent to peer review, and whose
reasonable recommendations Tenant&#146;s commissioning agent shall perform and incorporate into a revised report) and (z)&nbsp;such other &#147;close out&#148; materials as Landlord reasonably requests
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consistent with Landlord&#146;s own requirements for its contractors, such as copies of manufacturers&#146; warranties, operation and maintenance manuals and the like. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Insurance</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Property
Insurance</U>. At all times during the period beginning with commencement of construction of the Tenant Improvements and ending with final completion of the Tenant Improvements, Tenant shall maintain, or cause to be maintained (in addition to the
insurance required of Tenant pursuant to the Lease), property insurance insuring Landlord and the Landlord Parties, as their interests may appear. Such policy shall, on a completed values basis for the full insurable value at all times, insure
against loss or damage by fire, vandalism and malicious mischief and other such risks as are customarily covered by property insurance upon all Tenant Improvements and the general contractor&#146;s and any subcontractors&#146; machinery, tools and
equipment, all while each forms a part of, or is contained in, the Tenant Improvements or any temporary structures on the Premises, or is adjacent thereto; <U>provided</U> that, for the avoidance of doubt, insurance coverage with respect to the
general contractor&#146;s and any subcontractors&#146; machinery, tools and equipment shall be carried on a primary basis by such general contractor or the applicable subcontractor(s). Tenant agrees to pay any deductible, and Landlord is not
responsible for any deductible, for a claim under such insurance. Such property insurance shall contain an express waiver of any right of subrogation by the insurer against Landlord and the Landlord Parties, and shall name Landlord and its
affiliates as loss payees as their interests may appear. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Workers&#146; Compensation Insurance</U>. At all times during the period
of construction of the Tenant Improvements, Tenant shall, or shall cause its contractors or subcontractors to, maintain statutory workers&#146; compensation insurance as required by Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Liability</U>. As between Tenand and Landlord, Tenant assumes sole responsibility and liability for any and all injuries or the death of any persons,
including Tenant&#146;s contractors and subcontractors and their respective employees, agents and invitees, and for any and all damages to property, in each case to the extent caused by, resulting from or arising out of any act or omission on the
part of Tenant, Tenant&#146;s contractors or subcontractors, or their respective employees, agents and invitees in the prosecution of the Tenant Improvements. Tenant agrees to indemnify, save, defend (at Landlord&#146;s option and with counsel
reasonably acceptable to Landlord) and hold the Landlord Indemnitees harmless from and against all Claims due to, because of or arising out of any and all such injuries, death or damage, whether real or alleged, and Tenant and Tenant&#146;s
contractors and subcontractors shall assume and defend at their sole cost and expense all such Claims; <U>provided</U>, <U>however</U>, that nothing contained in this Work Letter shall be deemed to indemnify or otherwise hold Landlord harmless from
or against liability caused by Landlord&#146;s negligence or willful misconduct. Any deficiency in design or construction of the Tenant Improvements shall, as between Tenand and Landlord, be solely the responsibility of Tenant, notwithstanding the
fact that Landlord may have approved of the same in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>TI Allowance and Test Fit Allowance</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 Application of TI Allowance and Test Fit Allowance. Landlord shall contribute the Test
Fit Allowance towards the cost of a test fit plan for the Premises (which Landlord may elect to pay directly to Tenant&#146;s architect, in its sole discretion), and Landlord shall contribute the TI Allowance toward the costs and expenses incurred
in connection with the performance of the Tenant Improvements, all in accordance with <U>Article 4</U> of the Lease. If the entire Test Fit Allowance is not applied toward the cost of the test fit plan, or if the TI Allowance is not applied toward
or reserved for the costs of the Tenant Improvements, then Tenant shall not be entitled to a credit of such unused portion of the Test Fit Allowance or the TI Allowance. If the entire Excess TI Costs advanced by Tenant to Landlord are not applied
toward the costs of the Tenant Improvements, then Landlord shall promptly return such excess to Tenant following completion of the Tenant Improvements. Tenant may apply the Test Fit Allowance for the payment of the test fit plan costs and may apply
the TI Allowance for the payment of construction and other costs, all in accordance with the terms and provisions of the Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2
Approval of Budget for the Tenant Improvements. Notwithstanding anything to the contrary set forth elsewhere in this Work Letter or the Lease, Landlord shall not have any obligation to expend any portion of the TI Allowance until Landlord and Tenant
shall have approved in writing the budget for the Tenant Improvements (the &#147;<U>Approved Budget</U>&#148;). Prior to Landlord&#146;s approval of the Approved Budget, Tenant shall pay all of the costs and expenses incurred in connection with the
Tenant Improvements as they become due. Landlord shall not be obligated to reimburse Tenant for costs or expenses relating to the Tenant Improvements that exceed the amount of the TI Allowance. Landlord shall not unreasonably withhold, condition or
delay its approval of any budget for Tenant Improvements that is proposed by Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Fund Requests</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Test Fit Allowance</U>. Upon submission by Tenant to Landlord of an itemized invoice for the test fit plan costs, then Landlord shall,
within thirty (30)&nbsp;days following receipt of such invoice, pay to Tenant or, at Landlord&#146;s election in its sole discretion, to Tenant&#146;s architect, the amount of the test fit plan costs, up to the amount of the Test Fit Allowance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>TI Allowance</U>. Upon submission by Tenant to Landlord of (i)&nbsp;a statement (a &#147;<U>Fund Request</U>&#148;) setting forth the
total amount of the TI Allowance requested, (ii)&nbsp;a summary of the Tenant Improvements performed using AIA standard form Application for Payment (G 702) executed by the general contractor and by the architect, (iii)&nbsp;invoices from the
general contractor, the architect, and any subcontractors, material suppliers and other parties requesting payment with respect to the amount of the TI Allowance then being requested, (iv)&nbsp;unconditional lien releases from (A)&nbsp;the general
contractor, and (B)&nbsp;each subcontractor and material supplier performing work or providing materials or supplies, the total cost of which is $50,000 or more, in each case with respect to previous payments made by either Landlord or Tenant for
the Tenant Improvements in a form acceptable to Landlord and complying with Applicable Laws; and (v)&nbsp;conditional lien releases from the general contractor and each subcontractor and material supplier with respect to the Tenant Improvements
performed that correspond to the Fund Request, each in a form complying with Applicable Laws, then Landlord shall, within thirty (30)&nbsp;days following receipt by Landlord of a Fund Request and the accompanying materials required by this Section,
pay to (as elected by Landlord) the applicable contractors, subcontractors and material suppliers </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or Tenant (for reimbursement for payments made by Tenant to such contractors, subcontractors or material suppliers either prior to Landlord&#146;s approval of the Approved TI Budget or as a
result of Tenant&#146;s decision to pay for the Tenant Improvements itself and later seek reimbursement from Landlord in the form of one lump sum payment in accordance with the Lease and this Work Letter), the amount of Tenant Improvement costs set
forth in such Fund Request or Landlord&#146;s pari passu share thereof if Excess TI Costs exist based on the Approved Budget; <U>provided</U>, however, that Landlord shall not be obligated to make any payments under this Section until the budget for
the Tenant Improvements is approved in accordance with <U>Section</U><U></U><U>&nbsp;6.2</U> and any Fund Request under this Section shall be subject to the payment limits set forth in <U>Section</U><U></U><U>&nbsp;6.2</U> above and <U>Article 4</U>
of the Lease. Notwithstanding anything in this Section to the contrary, Tenant shall not submit a Fund Request more often than every thirty (30)&nbsp;days. Any additional Fund Requests submitted by Tenant shall be void and of no force or effect.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 <U>Accrual Information</U>. In addition to the other requirements of this <U>Section</U><U></U><U>&nbsp;6</U>, Tenant shall, no later
than the second (2nd) business day of each month until the Tenant Improvements are complete, provide Landlord with an estimate of (a)&nbsp;the percentage of design and other soft cost work that has been completed, (b)&nbsp;design and other soft
costs spent through the end of the previous month, both from commencement of the Tenant Improvements and solely for the previous month, (c)&nbsp;the percentage of construction and other hard cost work that has been completed, (d)&nbsp;construction
and other hard costs spent through the end of the previous month, both from commencement of the Tenant Improvements and solely for the previous month, and (e)&nbsp;the date of Substantial Completion of the Tenant Improvements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <U>Incorporation
of Lease Provisions</U>. <U>Sections 40.6</U> through <U>40.19</U> of the Lease are incorporated into this Work Letter by reference, and shall apply to this Work Letter in the same way that they apply to the Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <U>General</U>. Except as otherwise set forth in the Lease or this Work Letter, this Work Letter shall not apply to improvements performed
in any additional premises added to the Premises at any time or from time to time, whether by any options under the Lease or otherwise; or to any portion of the Premises or any additions to the Premises in the event of a renewal or extension of the
original Term, whether by any options under the Lease or otherwise, unless the Lease or any amendment or supplement to the Lease expressly provides that such additional premises are to be delivered to Tenant in the same condition as the initial
Premises. In the event of any conflict between the terms of the Lease and this Work Letter with respect to any matter contained in this Work Letter, this Work Letter shall govern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Landlord and Tenant have executed this Work Letter to be effective on
the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>LANDLORD</U>:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BMR-500</FONT> FAIRVIEW AVENUE LLC,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><U></U><I>/s/ Marie Lewis</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Marie Lewis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">VP, Real Estate Legal</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>TENANT</U>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SILVERBACK THERAPEUTICS, INC.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A
Delaware corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Peter A. Thompson, MD</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Peter A. Thompson, MD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">B-1</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TENANT WORK INSURANCE SCHEDULE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant shall be responsible for requiring all of Tenant contractors doing construction or renovation work to purchase and maintain such
insurance as shall protect it from the claims set forth below which may arise out of or result from any Tenant Work whether such Tenant Work is completed by Tenant or by any Tenant contractors or by any person directly or indirectly employed by
Tenant or any Tenant contractors, or by any person for whose acts Tenant or any Tenant contractors may be liable: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. Claims under workers&#146;
compensation, disability benefit and other similar employee benefit acts which are applicable to the Tenant Work to be performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Claims for damages
because of bodily injury, occupational sickness or disease, or death of employees under any applicable employer&#146;s liability law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Claims for
damages because of bodily injury, or death of any person other than Tenant&#146;s or any Tenant contractors&#146; employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. Claims for damages
insured by usual personal injury liability coverage which are sustained (a)&nbsp;by any person as a result of an offense directly or indirectly related to the employment of such person by Tenant or any Tenant contractors or (b)&nbsp;by any other
person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. Claims for damages, other than to the Tenant Work itself, because of injury to or destruction of tangible property, including loss of use
therefrom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. Claims for damages because of bodily injury or death of any person or property damage arising out of the ownership, maintenance or use of
any motor vehicle. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant contractors&#146; Commercial General Liability Insurance shall include premises/operations (including
explosion, collapse and underground coverage if such Tenant Work involves any underground work), elevators, independent contractors, products and completed operations, and blanket contractual liability on all written contracts, all including broad
form property damage coverage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant contractors&#146; Commercial General, Automobile, Employers and Umbrella Liability Insurance shall
be written for not less than limits of liability as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">a.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commercial General Liability:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Bodily Injury and Property Damage</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Commercially reasonable amounts, but in any event no less than $1,000,000 per occurrence and $2,000,000 general aggregate, with $2,000,000 products and completed operations aggregate.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">b.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commercial Automobile Liability:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Bodily Injury and Property Damage</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$1,000,000 per accident</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">c.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employer&#146;s Liability:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Each Accident</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Disease &#150; Policy Limit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Disease &#150; Each Employee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">$500,000</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">$500,000</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">$500,000</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">d.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Umbrella Liability:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Bodily
Injury and Property Damage</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Commercially reasonable amounts (excess of coverages a, b and c above), but in any event no less than $5,000,000 per occurrence / aggregate.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tenant shall require its contractors to cause all of their subcontractors to carry the same coverages and limits as specified
above, unless different limits are reasonably approved by Landlord. The foregoing policies shall contain a provision that coverages afforded under the policies shall not be canceled or not renewed until at least thirty (30)&nbsp;days&#146; prior
written notice has been given to the Landlord. Certificates of insurance including required endorsements showing such coverages to be in force shall be filed with Landlord prior to the commencement of any Tenant Work and prior to each renewal.
Coverage for completed operations must be maintained for the lesser of ten (10)&nbsp;years and the applicable statute of repose following completion of the Tenant Work, and certificates evidencing this coverage must be provided to Landlord. The
minimum A.M. Best&#146;s rating of each insurer shall be <FONT STYLE="white-space:nowrap">A-</FONT> VII. Landlord and its mortgagees shall be named as an additional insureds under Tenant contractors&#146; Commercial General Liability, Commercial
Automobile Liability and Umbrella Liability Insurance policies as respects liability arising from work or operations performed, or ownership, maintenance or use of autos, by or on behalf of such contractors. Each contractor and its insurers shall
provide waivers of subrogation with respect to any claims covered or that should have been covered by valid and collectible insurance, including any deductibles or self-insurance maintained thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any contractor&#146;s work involves the handling or removal of asbestos (as reasonably determined by Landlord), such contractor shall also carry Pollution
Legal Liability insurance. Such coverage shall include bodily injury, sickness, disease, death or mental anguish or shock sustained by any person; property damage, including physical injury to or destruction of tangible property
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(including the resulting loss of use thereof), <FONT STYLE="white-space:nowrap">clean-up</FONT> costs and the loss of use of tangible property that has not been physically injured or destroyed;
and defense costs, charges and expenses incurred in the investigation, adjustment or defense of claims for such damages. Coverage shall apply to both sudden and <FONT STYLE="white-space:nowrap">non-sudden</FONT> pollution conditions including the
discharge, dispersal, release or escape of smoke, vapors, soot, fumes, acids, alkalis, toxic chemicals, liquids or gases, waste materials or other irritants, contaminants or pollutants into or upon land, the atmosphere or any watercourse or body of
water. Claims-made coverage is permitted, <U>provided</U> the policy retroactive date is continuously maintained prior to the Term Commencement Date, and coverage is continuously maintained during all periods in which Tenant occupies the Premises.
Coverage shall be maintained with limits of not less than $1,000,000 per incident with a $2,000,000 policy aggregate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACKNOWLEDGEMENT OF TERM COMMENCEMENT DATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AND TERM EXPIRATION DATE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS ACKNOWLEDGEMENT OF TERM COMMENCEMENT DATE AND TERM EXPIRATION DATE is entered into as of [________], 20[___], with reference to that
certain Lease (the &#147;<U>Lease</U>&#148;) dated as of [________], 20[<U> ]</U>, by SILVERBACK THERAPEUTICS, INC., a Delaware corporation (&#147;<U>Tenant</U>&#148;), in favor of <FONT STYLE="white-space:nowrap">BMR-500</FONT> FAIRVIEW AVENUE LLC,
a Delaware limited liability company (&#147;<U>Landlord</U>&#148;). All capitalized terms used herein without definition shall have the meanings ascribed to them in the Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant hereby confirms the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.
Tenant accepted possession of the Premises for construction of improvements or the installation of personal or other property on [________], 20[___], and for use in accordance with the Permitted Use on [________], 20[__]. Tenant first occupied the
Premises for the Permitted Use on [________], 20[___]. Tenant accepted possession of the Storage Space for use in accordance with the Permitted Use on [________], 20[___]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. The Premises and the Storage Space are in good order, condition and repair. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. The Tenant Improvements are Substantially Complete. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. All
conditions of the Lease to be performed by Landlord as a condition to the full effectiveness of the Lease have been satisfied, and Landlord has fulfilled all of its duties in the nature of inducements offered to Tenant to lease the Premises and the
Storage Space. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. In accordance with the provisions of <U>Article 4</U> of the Lease, the Term Commencement Date is [______], 20[ ], and, unless the
Lease is terminated prior to the Term Expiration Date pursuant to its terms, the Term Expiration Date shall be [________], 20[__]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. The Lease is in
full force and effect, and the same represents the entire agreement between Landlord and Tenant concerning the Premises[, except [_________]]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. Tenant
has no existing defenses against the enforcement of the Lease by Landlord, and there exist no offsets or credits against Rent owed or to be owed by Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. The obligation to pay Rent is presently in effect and all Rent obligations on the part of Tenant under the Lease commenced to accrue on [________], 20[__],
with Base Rent payable on the dates and amounts set forth in the chart below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monthly and annual installments of Base Rent for the Premises (excluding
the Storage Space) as of the Term Commencement Date, subject to adjustment under the Lease: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Dates</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Square<BR>Feet of</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Annual Base Rent<BR>per Square Foot of</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Monthly Base</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Annual Base</B></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Rentable<BR>Area*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Rentable Area</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Rent*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Rent*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term Commencement<BR>Date &#150; Month 4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><U></U></TD>
<TD VALIGN="bottom" ALIGN="right">Abated&nbsp;in&nbsp;accordance<BR>with&nbsp;<U>Section&nbsp;7.1</U>&nbsp;below</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD ROWSPAN="2" VALIGN="bottom">$</TD>
<TD ROWSPAN="2" VALIGN="bottom" ALIGN="right">700,548.33</TD>
<TD ROWSPAN="2" NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months <FONT STYLE="white-space:nowrap">5-12</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,568.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months <FONT STYLE="white-space:nowrap">13-24</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,199.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,082,395.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months <FONT STYLE="white-space:nowrap">25&nbsp;-36</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,895.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,114,743.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 37 &#150; 48</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">95,687.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,148,253.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 49 &#150; 60</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,561.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,182,732.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 61 &#150; 72</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">101,514.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,218,179.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 73 &#150; 84</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104,565.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,254,788.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 85 &#150; 96</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,697.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,292,366.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 97 &#150; 108</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">68.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">110,925.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,331,106.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 109 &#150;120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">114,250.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,371,008.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Note: Subject to adjustment based upon the Rentable Area of the Premises (excluding the Storage Space) as of
the Term Commencement Date.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monthly and annual installments of Base Rent for the Storage Space as of the Term Commencement Date,
subject to adjustment under the Lease: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Dates</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Square<BR>Feet of<BR>Rentable<BR>Area</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual&nbsp;Base&nbsp;Rent<BR>per Square Foot<BR>of Rentable Area</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Monthly&nbsp;Base<BR>Rent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual&nbsp;Base<BR>Rent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term Commencement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date &#150; Month 12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">688.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,262.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 13&#150; 24</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">709.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,509.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 25 <FONT STYLE="white-space:nowrap">-36</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">730.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,766.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 37 &#150; 48</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">752.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,028.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 49 &#150; 60</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">774.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,299.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 61 &#150; 72</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">798.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,579.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 73 &#150; 84</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">822.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,863.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 85 &#150; 96</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">846.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,162.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 97 &#150; 108</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">872.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,465.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Months 109 &#150; 120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">898.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,781.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned Tenant has not made any prior assignment, transfer, hypothecation or pledge of the Lease or of the rents
thereunder or sublease of the Premises or any portion thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Tenant has executed this Acknowledgment of Term Commencement Date and
Term Expiration Date as of the date first written above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TENANT: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SILVERBACK THERAPEUTICS, INC., </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF LETTER OF CREDIT </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[On letterhead or L/C letterhead of Issuer] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LETTER OF CREDIT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: __________, 20__
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BMR-500</FONT> Fairview Avenue LLC (the &#147;<U>Beneficiary</U>&#148;) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17190<B> </B>Bernardo Center Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California 92128
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Real Estate Legal </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">L/C. No.: _________________
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Loan No. : ________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We establish in favor of Beneficiary our irrevocable and unconditional Letter of Credit numbered as identified above (the
&#147;<B><U>L/C</U></B>&#148;) for an aggregate amount of $________, expiring at __:00 p.m. on _________ or, if such day is not a Banking Day, then the next succeeding Banking Day (such date, as extended from time to time, the &#147;<U>Expiry
Date</U>&#148;). &#147;<U>Banking Day</U>&#148; means a weekday except a weekday when commercial banks in _______________ are authorized or required to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We authorize Beneficiary to draw on us (the &#147;<U>Issuer</U>&#148;) for the account of ________ (the &#147;<U>Account Party</U>&#148;),
under the terms and conditions of this L/C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Funds under this L/C are available by presenting the following documentation (the
&#147;<U>Drawing Documentation</U>&#148;): (a) the original L/C and (b)&nbsp;a sight draft substantially in the form of <U>Attachment 1</U>, with blanks filled in and bracketed items provided as appropriate. No other evidence of authority,
certificate, or documentation is required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drawing Documentation must be presented at Issuer&#146;s office at _____________ on or before
the Expiry Date by personal presentation, courier or messenger service, or fax. Presentation by fax shall be effective upon electronic confirmation of transmission as evidenced by a printed report from the sender&#146;s fax machine. After any fax
presentation, but not as a condition to its effectiveness, Beneficiary shall with reasonable promptness deliver the original Drawing Documentation by any other means. Issuer will on request issue a receipt for Drawing Documentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We agree, irrevocably, and irrespective of any claim by any other person, to honor drafts drawn under and in conformity with this L/C, within
the maximum amount of this L/C, presented </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to us on or before the Expiry Date, <U>provided</U> we also receive (on or before the Expiry Date) any other Drawing Documentation this L/C requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We shall pay this L/C only from our own funds by check or wire transfer, in compliance with the Drawing Documentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Beneficiary presents proper Drawing Documentation to us on or before the ExpiryDate, then we shall pay under this L/C at or before the
following time (the &#147;<U>Payment Deadline</U>&#148;): (a) if presentment is made at or before noon of any Banking Day, then the close of such Banking Day; and (b)&nbsp;otherwise, the close of the next Banking Day. We waive any right to delay
payment beyond the Payment Deadline. If we determine that Drawing Documentation is not proper, then we shall so advise Beneficiary in writing, specifying all grounds for our determination, within one Banking Day after the Payment Deadline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Partial drawings are permitted. This L/C shall, except to the extent reduced thereby, survive any partial drawings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We shall have no duty or right to inquire into the validity of or basis for any draw under this L/C or any Drawing Documentation. We waive any
defense based on fraud or any claim of fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Expiry Date shall automatically be extended by one year (but never beyond _______ (the
&#147;<U>Outside Date</U>&#148;)) unless, on or before the date 90 days before any Expiry Date, we have given Beneficiary notice that the Expiry Date shall not be so extended (a &#147;<U>Nonrenewal Notice</U>&#148;). We shall promptly upon request
confirm any extension of the Expiry Date under the preceding sentence by issuing an amendment to this L/C, but such an amendment is not required for the extension to be effective. We need not give any notice of the Outside Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficiary may from time to time without charge transfer this L/C, in whole but not in part, to any transferee (the
&#147;<U>Transferee</U>&#148;). Issuer shall look solely to Account Party for payment of any fee for any transfer of this L/C. Such payment is not a condition to any such transfer. Beneficiary or Transferee shall consummate such transfer by
delivering to Issuer the original of this L/C and a Transfer Notice substantially in the form of <U>Attachment 2</U>, purportedly signed by Beneficiary, and designating Transferee. Issuer shall promptly reissue or amend this L/C in favor of
Transferee as Beneficiary. Upon any transfer, all references to Beneficiary shall automatically refer to Transferee, who may then exercise all rights of Beneficiary. Issuer expressly consents to any transfers made from time to time in compliance
with this paragraph. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any notice to Beneficiary shall be in writing and delivered by hand with receipt acknowledged or by overnight
delivery service such as FedEx (with proof of delivery) at the above address, or such other address as Beneficiary may specify by written notice to Issuer. A copy of any such notice shall also be delivered, as a condition to the effectiveness of
such notice, to:&nbsp;____________ (or such replacement as Beneficiary designates from time to time by written notice). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No amendment that adversely affects Beneficiary shall be effective without
Beneficiary&#146;s written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This L/C is subject to and incorporates by reference: (a)&nbsp;the International StandbyPractices 98
(&#147;<U>ISP 98</U>&#148;); and (b)&nbsp;to the extent not inconsistent with ISP 98, Article 5 of the Uniform Commercial Code of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Issuer
Signature] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT 1 TO EXHIBIT D </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF SIGHT DRAFT </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[B<SMALL>ENEFICIARY</SMALL> L<SMALL>ETTERHEAD</SMALL>] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Name and Address of Issuer] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGHT DRAFT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AT SIGHT, pay to the Order
of __________________, the sum of _____________ United States Dollars ($___________). Drawn under [Issuer] Letter of Credit No. _______________ dated _____________. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Issuer is hereby directed to pay the proceeds of this Sight Draft solely to the following account: ______________________.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Name and signature block, with signature or purported signature of Beneficiary] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: _______________ </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT 2 TO EXHIBIT D </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF TRANSFER NOTICE </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[B<SMALL>ENEFICIARY</SMALL> L<SMALL>ETTERHEAD</SMALL>] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Name and Address of Issuer] (the
&#147;<U>Issuer</U>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSFER NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By signing below, the undersigned, Beneficiary (the &#147;<U>Beneficiary</U>&#148;) under Issuer&#146;s Letter of Credit No. _______________ dated
________________ (the &#147;<U>L/C</U>&#148;), transfers the L/C to the following transferee (the &#147;<U>Transferee</U>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Transferee Name and
Address] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The original L/C is enclosed. Beneficiary directs Issuer to reissue or amend the L/C in favor of Transferee as Beneficiary. Beneficiary
represents and warrants that Beneficiary has not transferred, assigned, or encumbered the L/C or any interest in the L/C, which transfer, assignment, or encumbrance remains in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Name and signature block, with signature or purported signature of Beneficiary] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: ________________] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-2-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT E </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RULES AND REGULATIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOTHING IN THESE RULES AND REGULATIONS (&#147;<U>RULES AND REGULATIONS</U>&#148;) SHALL SUPPLANT ANY PROVISION OF THE LEASE. IN THE EVENT OF A
CONFLICT OR INCONSISTENCY BETWEEN THESE RULES AND REGULATIONS AND THE LEASE, THE LEASE SHALL PREVAIL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. No Tenant Party shall encumber or obstruct the
common entrances, lobbies, elevators, sidewalks and stairways of the Building(s) or the Project or use them for any purposes other than ingress or egress to and from the Building(s) or the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Except as specifically provided in the Lease, no sign, placard, picture, advertisement, name or notice shall be installed or displayed on any part of the
outside of the Premises or the Building(s) without Landlord&#146;s prior written consent. Landlord shall have the right to remove, at Tenant&#146;s sole cost and expense and without notice, any sign installed or displayed in violation of this rule.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. If Landlord objects in writing to any curtains, blinds, shades, screens, hanging plants or other similar objects attached to or used in connection
with any window or door of the Premises or placed on any windowsill, and (a)&nbsp;such window, door or windowsill is visible from the exterior of the Premises and (b)&nbsp;such curtain, blind, shade, screen, hanging plant or other object is not
included in plans approved by Landlord, then Tenant shall promptly remove such curtains, blinds, shades, screens, hanging plants or other similar objects at its sole cost and expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. No deliveries shall be made that impede or interfere with other tenants in or the operation of the Project. Movement of furniture, office equipment or any
other large or bulky material(s) through the Common Area shall be restricted to such hours as Landlord may designate and shall be subject to reasonable restrictions that Landlord may impose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. Tenant shall not place a load upon any floor of the Premises that exceeds the load per square foot that (a)&nbsp;such floor was designed to carry or
(b)&nbsp;is allowed by Applicable Laws. Fixtures and equipment that cause noises or vibrations that may be transmitted to the structure of the Building(s) to such a degree as to be objectionable to other tenants shall be placed and maintained by
Tenant, at Tenant&#146;s sole cost and expense, on vibration eliminators or other devices sufficient to eliminate such noises and vibrations to levels reasonably acceptable to Landlord and the affected tenants of the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. Tenant shall not use any method of FIVAC other than that shown in the Tenant Improvement plans and present at the Project and serving the Premises as of
the Execution Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. Tenant shall not install any radio, television or other antennae; cell or other communications equipment; or other devices on the
roof or exterior walls of the Premises except </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in accordance with the Lease. Tenant shall not interfere with radio, television or other digital or
electronic communications at the Project or elsewhere. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. Canvassing, peddling, soliciting and distributing handbills or any other written material
within, on or around the Project (other than within the Premises) are prohibited. Tenant shall cooperate with Landlord to prevent such activities by any Tenant Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. Tenant shall store all of its trash, garbage and Hazardous Materials in receptacles within its Premises or in receptacles designated by Landlord outside of
the Premises. Tenant shall not place in any such receptacle any material that cannot be disposed of in the ordinary and customary manner of trash, garbage and Hazardous Materials disposal. Any Hazardous Materials transported through Common Area
shall be held in secondary containment devices. Tenant shall be responsible, at its sole cost and expense, for Tenant&#146;s removal of its trash, garbage and Hazardous Materials. Tenant is encouraged to participate in the waste removal and
recycling program in place at the Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. The Premises shall not be used for lodging or for any improper, immoral or objectionable purpose. No
cooking shall be done or permitted in the Premises; <U>provided</U>, however, that Tenant may use (a)&nbsp;equipment approved in accordance with the requirements of insurance policies that Landlord or Tenant is required to purchase and maintain
pursuant to the Lease for brewing coffee, tea, hot chocolate and similar beverages, (b)&nbsp;microwave ovens for employees&#146; use and (c)&nbsp;equipment shown on the Tenant Improvement plans approved by Landlord; <U>provided</U>, further, that
any such equipment and microwave ovens are used in accordance with Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. Tenant shall not, without Landlord&#146;s prior written consent,
use the name of the Project, if any, in connection with or in promoting or advertising Tenant&#146;s business except as Tenant&#146;s address. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. Tenant
shall comply with all safety, fire protection and evacuation procedures and regulations established by Landlord or any Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. Tenant
assumes any and all responsibility for protecting the Premises from theft, robbery and pilferage, which responsibility includes keeping doors locked and other means of entry to the Premises closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. Tenant shall not modify any locks to the Premises without Landlord&#146;s prior written consent, which consent Landlord shall not unreasonably withhold,
condition or delay. Tenant shall furnish Landlord with copies of keys, pass cards or similar devices for locks to the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. Tenant shall
cooperate and participate in all reasonable security programs affecting the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16. Tenant shall not permit any animals in the Project, other than
for service animals or for use in laboratory experiments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17. Bicycles shall not be taken into the Building(s) (including the elevators and stairways of the Building)
except into areas designated by Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18. The water and wash closets and other plumbing fixtures shall not be used for any purposes other than those
for which they were constructed, and no sweepings, rubbish, rags or other substances shall be deposited therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19. Discharge of industrial sewage shall
only be permitted if Tenant, at its sole expense, first obtains all necessary permits and licenses therefor from all applicable Governmental Authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20. Smoking is prohibited inside the Building and in any area that is within twenty-five (25)&nbsp;feet of any Building entrance, but is permitted in
designated outdoor areas of the Project (if any).] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">21. The Project&#146;s hours of operation are currently 7:00 am to 6:00 pm, Monday through Friday.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">22. Tenant shall comply with all orders, requirements and conditions now or hereafter imposed by Applicable Laws or Landlord (&#147;<U>Waste
Regulations</U>&#148;) regarding the collection, sorting, separation and recycling of waste products, garbage, refuse and trash generated by Tenant (collectively, &#147;<U>Waste Products</U>&#148;), including (without limitation) the separation of
Waste Products into receptacles reasonably approved by Landlord and the removal of such receptacles in accordance with any collection schedules prescribed by Waste Regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">23. Tenant, at Tenant&#146;s sole cost and expense, shall cause the Premises to be exterminated on a monthly basis to Landlord&#146;s reasonable satisfaction
and shall cause all portions of the Premises used for the storage, preparation, service or consumption of food or beverages to be cleaned daily in a manner reasonably satisfactory to Landlord, and to be treated against infestation by insects,
rodents and other vermin and pests whenever there is evidence of any infestation. Tenant shall not permit any person to enter the Premises or the Project for the purpose of providing such extermination services, unless such persons have been
approved by Landlord. If requested by Landlord, Tenant shall, at Tenant&#146;s sole cost and expense, store any refuse generated in the Premises by the consumption of food or beverages in a cold box or similar facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24. If Tenant desires to use any portion of the Common Area for a Tenant-related event, Tenant must notify Landlord in writing at least thirty (30)&nbsp;days
prior to such event on the form attached as <U>Attachment 1</U> to this Exhibit, which use shall be subject to Landlord&#146;s prior written consent, not to be unreasonably withheld, conditioned or delayed. Notwithstanding anything in this Lease or
the completed and executed Attachment to the contrary, Tenant shall be solely responsible for setting up and taking down any equipment or other materials required for the event, and shall promptly pick up any litter and report any property damage to
Landlord related to the event. Any use of the Common Area pursuant to this Section shall be subject to the provisions of <U>Article 28</U> of the Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Landlord may waive any one or more of these Rules and Regulations for the benefit of Tenant or any other tenant, but no such waiver by
Landlord shall be construed as a waiver of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Rules and Regulations in favor of Tenant or any other tenant, nor prevent Landlord from thereafter enforcing any such Rules and Regulations against any or all of the tenants of the Project,
including Tenant. These Rules and Regulations are in addition to, and shall not be construed to in any way modify or amend, in whole or in part, the terms covenants, agreements and conditions of the Lease. Landlord reserves the right to make such
other and reasonable additional rules and regulations as, in its judgment, may from time to time be needed for safety and security, the care and cleanliness of the Project, or the preservation of good order therein; <U>provided</U>, however, that
Tenant shall not be obligated to adhere to such additional rules or regulations until Landlord has provided Tenant with written notice thereof. Tenant agrees to abide by these Rules and Regulations and any such additional rules and regulations
issued or adopted by Landlord. Tenant shall be responsible for the observance of these Rules and Regulations by all Tenant Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT I TO EXHIBIT E </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>REQUEST FOR USE OF COMMON AREA </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>REQUEST FOR USE OF COMMON AREA </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date&nbsp;of&nbsp;Request:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Landlord/Owner:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant/Requestor:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property&nbsp;Location:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Event&nbsp;Description:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proposed&nbsp;Plan&nbsp;for&nbsp;Security&nbsp;&amp;&nbsp;Cleaning:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date&nbsp;of&nbsp;Event:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Hours&nbsp;of&nbsp;Event:&nbsp;(to&nbsp;include&nbsp;set-up&nbsp;and&nbsp;take&nbsp;
down):</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Location&nbsp;at&nbsp;Property&nbsp;(see&nbsp;attached&nbsp;map):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number&nbsp;of&nbsp;Attendees:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Open to the Public? &nbsp;&nbsp;&nbsp;&nbsp;[___] YES&nbsp;&nbsp;&nbsp;&nbsp; [___]
NO</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Food and/or Beverages?&nbsp;&nbsp;&nbsp;&nbsp; [___] YES &nbsp;&nbsp;&nbsp;&nbsp;[___]
NO</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">If YES:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Will food be prepared on site? &nbsp;&nbsp;&nbsp;&nbsp;[___] YES
&nbsp;&nbsp;&nbsp;&nbsp;[___] NO</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Please describe:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Will alcohol be served? &nbsp;&nbsp;&nbsp;&nbsp;[___] YES
&nbsp;&nbsp;&nbsp;&nbsp;[___] NO</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Please describe:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Will attendees be charged for alcohol?&nbsp;&nbsp;&nbsp;&nbsp;[___] YES&nbsp;&nbsp;&nbsp;&nbsp;[___] NO
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Is alcohol license or permit required?&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[___]
YES&nbsp;&nbsp;&nbsp;&nbsp;[___] NO </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Does caterer have alcohol license or permit:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[___]
YES&nbsp;&nbsp;&nbsp;&nbsp;[___] NO&nbsp;&nbsp;&nbsp;&nbsp;[___] N/A </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Other Amenities (tent, booths, band, food trucks, bounce house, etc.):
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Other&nbsp;Event&nbsp;Details&nbsp;or&nbsp;Special&nbsp;Circumstances:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned certifies that the foregoing is true, accurate and complete and he/she is duly authorized to sign and submit
this request on behalf of the Tenant/Requestor named above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[<I>INSERT NAME OF TENANT/REQUESTOR</I>]</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Name:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;</B></P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Title:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;</B></P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Date:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;</B></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT F </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TENANT&#146;S PROPERTY </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be attached] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT G </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF ESTOPPEL CERTIFICATE </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">To:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">BMR-500</FONT> FAIRVIEW AVENUE LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">17190 Bernardo Center Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">San
Diego, California 92128 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Vice President, Real Estate Legal </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">BioMed Realty, L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">17190
Bernardo Center Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">San Diego, California 92128 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Suite [__________] (the &#147;<U>Premises</U>&#148;) at 500 Fairview Avenue North, Seattle, Washington (the
&#147;<U>Property</U>&#148;) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned tenant (&#147;<U>Tenant</U>&#148;) hereby certifies to you as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. Tenant is a tenant at the Property under a lease (the &#147;<U>Lease</U>&#148;) for the Premises dated as of [_______], 20[__]. The Lease has not been
cancelled, modified, assigned, extended or amended [except as follows: [_______]], and there are no other agreements, written or oral, affecting or relating to Tenant&#146;s lease of the Premises or any other space at the Property. The lease term
expires on [_______], 20[__]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Tenant took possession of the Premises, currently consisting of [_______] square feet, on [_______], 20[__], and
commenced to pay rent with respect to the Premises on [________], 20[__]. Tenant has full possession of the Premises described above, has not assigned the Lease or sublet any part of the Premises, and does not hold the Premises under an assignment
or sublease[, except as follows: [________]]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. All base rent, rent escalations and additional rent under the Lease have been paid through [_______],
20[__]. There is no prepaid rent[, except $[_______]][, and the amount of security deposit is $[_______] [in cash][OR][in the form of a letter of credit]]. Tenant currently has no right to any future rent abatement under the Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. Base rent is currently payable in the amount of $[_______] per month. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. Tenant is currently paying estimated payments of additional rent of $[_______] per month on account of real estate taxes, insurance, management fees and
Common Area maintenance expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. All work to be performed for Tenant under the Lease has been performed as required under the Lease and has been
accepted by Tenant[, except [_______]], and all allowances to be paid to Tenant, including allowances for tenant improvements, moving expenses or other items, have been paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. The Lease is in full force and effect, free from default and free from any event that could become a
default under the Lease, and Tenant is not aware of any claims against the landlord or offsets or defenses against rent, and there are no disputes with the landlord. Tenant has received no notice of prior sale, transfer, assignment, hypothecation or
pledge of the Lease or of the rents payable thereunder[, except [_______]]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. [Tenant has the following expansion rights or options for leasing
additional space at the Property: [_______].][OR][Tenant has no rights or options to purchase the Property.] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. To Tenant&#146;s knowledge, no hazardous
wastes have been generated, treated, stored or disposed of by or on behalf of Tenant in, on or around the Premises or the Project in violation of any environmental laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. The undersigned has executed this Estoppel Certificate with the knowledge and understanding that [INSERT <FONT STYLE="white-space:nowrap">BMR-500</FONT>
FAIRVIEW AVENUE LLC, PURCHASER OR LENDER, AS APPROPRIATE] or its assignee is [acquiring the Property/making a loan secured by the Property] in reliance on this certificate and that the undersigned shall be bound by this certificate. The statements
contained herein may be relied upon by [INSERT NAME OF PURCHASER OR LENDER, AS APPROPRIATE], <FONT STYLE="white-space:nowrap">BMR-500</FONT> Fairview Avenue LLC, BioMed Realty, L.P., BioMed Realty Trust, Inc., and any [other] mortgagee of the
Property and their respective successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any capitalized terms not defined herein shall have the respective meanings given in the Lease.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated this [____] day of [_______], 20[__]. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SILVERBACK THERAPEUTICS, INC.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware corporation</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Name:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;</B></P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Title:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;</B></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT H </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF GROUND LESSOR RECOGNITION </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AND <FONT STYLE="white-space:nowrap">NON-DISTURBANCE</FONT> AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEN RECORDED RETURN TO: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Silverback Therapeutics, Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500 Yale Avenue N </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seattle, Washington 98109 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Document Title: Ground Lessor Recognition and <FONT STYLE="white-space:nowrap">Non-Disturbance</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Grantor:</B> Nelchina Point Limited Partnership, an Alaska limited partnership </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Grantee:</B> Silverback Therapeutics, Inc., a Delaware corporation </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Description: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abbreviated Legal Description:</B>
Lots 4, 5 &amp; 6, Block 5 Vol. 1 page 218 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Full Legal Description:</B> See <U>Exhibit A</U> attached </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assessor&#146;s Tax Parcel Nos.:</B> 786 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">350-0040-02</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Related Document No.: 20080128000091 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GROUND
LESSOR RECOGNITION AND <FONT STYLE="white-space:nowrap">NON-DISTURBANCE</FONT> AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Ground Lessor Recognition and <FONT
STYLE="white-space:nowrap">Non-Disturbance</FONT> Agreement (the &#147;<B>Agreement</B>&#148;) is made as of the ____ day of June, 2016 by and among <B>NELCHINA POINT LIMITED PARTNERSHIP</B>, an Alaska limited partnership
(&#147;<B>Landlord</B>&#148;), <B><FONT STYLE="white-space:nowrap">BMR-500</FONT> FAIRVIEW AVENUE LLC</B>, a Delaware limited liability company (&#147;<B>Tenant</B>&#148;), and <B>SILVERBACK THERAPEUTICS, INC.</B>, a Delaware corporation
(&#147;<B>Subtenant</B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Landlord and Tenant are parties to that certain Ground Lease dated January&nbsp;28, 2008 (the &#147;<B>Ground Lease</B>&#148;) which
demises certain real property located at 500 Fairview Avenue North, Seattle, Washington (the &#147;<B>Premises</B>&#148;) more particularly described on <U>Exhibit A</U> attached hereto and made a part hereof, together with all buildings and
improvements located thereon and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all easements, rights and appurtenances thereto. The Ground Lease term will expire on January&nbsp;31, 2088 and Tenant has the right to extend the term thereunder for two additional terms of
twenty (20)&nbsp;years each, by notice delivered to Landlord no later than twelve (12)&nbsp;months prior to the then effective expiration of the term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Pursuant to that certain Lease dated as of June ___, 2016 (the &#147;<B>Sublease</B>&#148;), Tenant has subleased a portion of the Premises
to Subtenant. Capitalized terms used in this Agreement and not otherwise defined shall have the meaning given to such terms in the Sublease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, it is agreed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Landlord represents and warrants that, to Landlord&#146;s knowledge, no event of default or condition that could become an event of default
with the passing of time, the giving of notice, or both, currently exists under the Ground Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Tenant and Subtenant have provided
Landlord with, and Landlord acknowledges receipt of, a true and complete copy of the Sublease, and Tenant and Subtenant certify to Landlord that the Sublease has not been modified or amended. Landlord acknowledges that Subtenant would not enter into
the Sublease but for the terms of this Agreement and in reliance on the recitals stated herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The parties acknowledge that the
Sublease is subordinate to the Ground Lease, but by this Agreement Landlord grants Subtenant cure rights and successor rights under the Ground Lease and <FONT STYLE="white-space:nowrap">non-disturbance</FONT> and recognition under the Sublease, all
as expressly set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Landlord agrees that in the event of a default under the Ground Lease by Tenant, Landlord
shall provide notice of such default to Subtenant in accordance with Section&nbsp;4A and 4B hereof at the same time as Landlord provides notice to Tenant of such default, and Subtenant shall have the same rights (but not the obligation) as Tenant
under the Ground Lease to cure any such default and shall be given the same notice and cure period to cure such default as provided to Tenant under the Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Provided that the Sublease shall be in full force and effect and Subtenant is not in default under the Sublease beyond the expiration of
any applicable notice and cure periods, Landlord shall not, whether in the exercise of any of the rights arising or which may arise out of the Ground Lease or of any instrument modifying or amending the same or entered into in substitution or
replacement thereof or otherwise (whether as a result of Tenant&#146;s default or otherwise), disturb, interfere with or deprive Subtenant in or of its possession or its rights to possession of the Premises or of any right or privilege granted to or
inuring to the benefit of Subtenant under the Sublease, nor shall Subtenant be made a party in any removal or eviction action or other legal proceeding (unless required by law to prosecute such removal or eviction action or other legal proceeding).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event of the termination of the Ground Lease by reentry, notice, conditional
limitation, surrender, summary proceeding or other action or proceeding, or otherwise (including, without limitation, in connection with any bankruptcy or similar proceeding), or if the Ground Lease shall terminate or expire for any such reason
before expiration or termination of the Sublease, (i)&nbsp;the Sublease shall be and remain in full force and effect, so long as Subtenant is not in default under the Sublease beyond the expiration of any applicable notice and cure periods,
(ii)&nbsp;Subtenant will not be required to pay or perform Tenant&#146;s obligations under the Ground Lease, (iii)&nbsp;Landlord agrees that the Sublease shall continue as a direct lease between Landlord and Subtenant, and in such event Landlord and
Subtenant shall be bound to each other under all of the terms, covenants and provisions of the Sublease for the remainder of the term thereof including extensions; <U>provided</U>, <U>however</U>, that Landlord is not bound by nor liable or
obligated to pay for the TI Allowance, the Test Fit Allowance or any other financial obligations owed by Tenant to Subtenant under the terms of the Sublease (including but not limited to the return of, or any reduction with respect to, the Security
Deposit or any L/C Security provided by Subtenant to Tenant and not transferred to and received by Landlord); and <U>provided</U>, <U>further</U>, <U>however</U> that Landlord shall recognize and be bound by Subtenant&#146;s termination rights under
the Sublease; <U>provided</U> <U>still further</U>, <U>however</U>, that if following termination of the Ground Lease, (a)&nbsp;Subtenant provides written notice to Landlord specifying the portion of the TI Allowance and/or Test Fit Allowance that
Tenant has not funded, and requesting that Landlord agree to fund such portion of the TI Allowance and/or Test Fit Allowance, as the case may be, and (b)&nbsp;Landlord does not, within twenty (20)&nbsp;business days after Tenant provides such
notice, commit in a notice (a &#147;<B>TI Commitment Notice</B>&#148;) to Subtenant to fund such portion of the TI Allowance and/or Test Fit Allowance as and to the extent the Sublease requires Tenant to fund such portion of the TI Allowance and/or
Test Fit Allowance, then Subtenant shall have the right to terminate the Sublease by providing notice of such termination to Landlord within ten (10)&nbsp;business days after the expiration of such twenty (20)&nbsp;business day period, and
(iv)&nbsp;subject to Subtenant&#146;s termination right as set forth in the preceding clause (iii), Subtenant agrees to attorn to and recognize Landlord as &#147;landlord&#148; under the Sublease and Landlord agrees to recognize Subtenant as
&#147;tenant&#148; under the Sublease. For avoidance of doubt, Landlord is not required to fund any portion of the TI Allowance, the Test Fit Allowance or any other financial obligation owed by Tenant to Subtenant under the terms of the Sublease
except to the extent Landlord commits to fund a portion of the TI Allowance and/or Test Fit Allowance or any such other amount in a TI Commitment Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any other provision of the Sublease or this Agreement, Landlord shall have no obligations under the Sublease that relate
to (i)&nbsp;the Adjacent Building or the Adjacent Property (and for clarification, Landlord&#146;s obligations with respect to the Project (as such term is defined in the Sublease) shall specifically exclude any obligations relating to the Adjacent
Building and the Adjacent Property), or (ii)&nbsp;the negotiation of an Alternate Lease in the event that Subtenant exercises its Early Termination Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. A. All notices, demands, requests, consents, approvals or other communications required
or permitted to be given under this Agreement shall be in writing and addressed as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to Landlord: Nelchina Point Limited
Partnership </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:14%; font-size:10pt; font-family:Times New Roman">c/o Wirum Properties LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:14%; font-size:10pt; font-family:Times New Roman">500 L Street, Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:14%; font-size:10pt; font-family:Times New Roman">Anchorage, AK 99501 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:14%; font-size:10pt; font-family:Times New Roman">Attn: John
Wirum </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy to: Miller Nash Graham&nbsp;&amp; Dunn LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:14%; font-size:10pt; font-family:Times New Roman">2801 Alaskan Way, Suite 300 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:14%; font-size:10pt; font-family:Times New Roman">Seattle, WA 98121 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:14%; font-size:10pt; font-family:Times New Roman">Attn: Maren
Gaylor, Esq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or such other address as Landlord may designate by notice to the other parties; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to <FONT STYLE="white-space:nowrap">Tenant:&nbsp;&nbsp;BMR-500</FONT> Fairview, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">17190 Bernardo Center Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92128 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn: Real
Estate Legal Department </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or such other address as Tenant may designate by notice to the other parties; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to Subtenant: Silverback Therapeutics, Inc. 500 Yale Avenue N </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:14%; font-size:10pt; font-family:Times New Roman">&nbsp;Seattle, Washington 98109 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:14%; font-size:10pt; font-family:Times New Roman">&nbsp;Attn: Russ Hawkinson </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or
such other address as Subtenant may designate by notice to the other parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notices may be given by a party&#146;s attorney on such
party&#146;s behalf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Any notice or other communication delivered or sent in accordance with the provisions of this Article shall be
deemed to have been properly given or served on the day of delivery (or first attempted delivery if refused), if delivered by hand, courier or overnight courier (e.g. FedEx). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. No modification, amendment, waiver or release of any provision of this Agreement or of any right, obligation, claim or cause of action
arising hereunder shall be valid or binding for any purpose whatsoever unless in writing and duly executed by the party against whom the same is sought to be asserted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. This Agreement shall be binding on and shall inure to the benefit of the parties hereto and their respective heirs, legal representatives,
successors, sublessees, and assigns. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. This Agreement may be recorded in the Official Records of King County, Washington. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Signatures on following pages] </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this instrument to be executed effective
as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>LANDLORD:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NELCHINA POINT LIMITED PARTNERSHIP</B>,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">an Alaska limited partnership</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">NP-GP,</FONT> LLC, an Alaska limited liability company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Wirum</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">STATE OF ALASKA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)ss.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">THIRD&nbsp;JUDICIAL&nbsp;DISTRICT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On this ________ day of _________________, 2016, before me, the undersigned, a Notary Public in and for the
State of Alaska, duly commissioned and sworn personally appeared JOHN WIRUM, known to me to be the Manager of <FONT STYLE="white-space:nowrap">NP-GP,</FONT> LLC, an Alaska limited liability company, which limited liability company is the General
Partner of<B> NELCHINA POINT LIMITED</B> PARTNERSHIP, the limited partnership that executed the foregoing instrument, and acknowledged the said instrument to be the free and voluntary act and deed of said limited partnership, for the purposes
therein mentioned, and on oath stated that he/she was authorized to execute said instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I certify that I know or have satisfactory
evidence that the person appearing before me and making this acknowledgment is the person whose true signature appears on this document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WITNESS my hand and official seal hereto affixed the day and year in the certificate above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Print Name </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">NOTARY PUBLIC in and for the State of Alaska, residing
at<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">My commission
expires<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TENANT</B>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">BMR-500</FONT> FAIRVIEW AVENUE LLC</B>,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">A notary public or other officer completing this certificate verifies only the identity of the
individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">STATE&nbsp;OF&nbsp;CALIFORNIA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COUNTY OF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On ____________, ___, 2016, before me,
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, Notary Public, personally appeared
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U>, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her authorized capacity, and that by his/her
signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I certify under
PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WITNESS my hand and
official seal. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Notary Public</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>SUBTENANT</B>: </P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SILVERBACK THERAPEUTICS, INC.</B>, a Delaware corporation</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">STATE&nbsp;OF&nbsp;________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">) ss.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COUNTY&nbsp;OF&nbsp;______________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On this ________ day of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2016 before me, the undersigned, a Notary Public in and for the State of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, duly commissioned and
sworn personally appeared
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U>, known to me to be the _____________________ of <B>SILVERBACK THERAPEUTICS, INC.</B>, the corporation that executed the foregoing instrument, and acknowledged the said instrument to be the free and voluntary act and deed of
said corporation, for the purposes therein mentioned, and on oath stated that he/she was authorized to execute said instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I certify
that I know or have satisfactory evidence that the person appearing before me and making this acknowledgment is the person whose true signature appears on this document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WITNESS my hand and official seal hereto affixed the day and year in the certificate above written. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Print Name</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">NOTARY PUBLIC in and for the State of Alaska, residing at
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">My commission expires
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Legal Description of Premises </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lots 4, 5
and 6, Block 5, Sorenson&#146;s Addition to the City of Seattle, according to the plat thereof recorded in Volume 1 of plats, page(s) 218, in King County, Washington. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tax Parcel No: <FONT STYLE="white-space:nowrap">7860350-0040-02</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT I </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF MEMORANDUM OF LEASE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEN RECORDED RETURN TO: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Silverback Therapeutics, Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500 Yale Ave N </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seattle, Washington 98109 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Document Title</B>: Memorandum of Lease </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Grantor</B>: <FONT
STYLE="white-space:nowrap">BMR-500</FONT> Fairview Avenue LLC, a Delaware limited liability company </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Grantee</B>: Silverback Therapeutics, Inc., a
Delaware corporation </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Description</B>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abbreviated Legal Description</B>: Lots 4, 5 &amp; 6, Block 5 Vol. 1 page 218 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Full Legal Description</B>: See <U>Exhibit A</U> attached </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assessor&#146;s Tax Parcel Nos</B>.: 786 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">350-0040-02</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Document No.</B>: Not applicable </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEMORANDUM OF LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a Lease dated as of June ___, 2016 (the &#147;<B>Lease</B>&#148;), between <B><FONT STYLE="white-space:nowrap">BMR-500</FONT>
FAIRVIEW AVENUE LLC</B>, a Delaware limited liability company (&#147;<B>Landlord</B>&#148;), and <B>SILVERBACK THERAPEUTICS, INC.</B>, a Delaware corporation (&#147;<B>Tenant</B>&#148;), Landlord has agreed to lease to Tenant certain premises (the
&#147;<B>Premises</B>&#148;) in the building located on the real property situated at 500 Fairview Avenue North, in Seattle, Washington, legally described on <U>Exhibit A</U> attached. Capitalized terms used in this Memorandum of Lease and not
defined shall have the meanings given to them in the Lease. The Lease is for a term of ten (10)&nbsp;years. The Estimated Term Commencement Date is November&nbsp;1, 2016. Pursuant and subject to the terms of the Lease, Tenant has an option to extend
the term of the Lease for one (1)&nbsp;five (5) year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of this Memorandum of Lease is to give record notice of the
Lease and of the rights created thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Signatures on following pages] </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Memorandum of Lease is made as of June ___, 2016. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LANDLORD:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><FONT STYLE="white-space:nowrap">BMR-500</FONT> FAIRVIEW AVENUE LLC</B>, a Delaware limited liability company</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">A notary public or other officer completing this certificate verifies only the identity of the
individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">STATE OF CALIFORNIA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COUNTY OF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On ____________, ___, 2016, before me,
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, Notary Public, personally appeared
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her authorized
capacity, and that by his/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WITNESS my hand and official seal. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Notary Public</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TENANT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SILVERBACK THERAPEUTICS, INC.</B>,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">STATE OF ________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">) ss.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COUNTY OF ______________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On this ________ day of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2016 before me, the undersigned, a Notary Public
in and for the State of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
duly commissioned and sworn personally appeared ____________________________, known to me to be the _____________________ of <B>SILVERBACK THERAPEUTICS, INC.</B>, the corporation that executed the foregoing instrument, and acknowledged the said
instrument to be the free and voluntary act and deed of said corporation, for the purposes therein mentioned, and on oath stated that he/she was authorized to execute said instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I certify that I know or have satisfactory evidence that the person appearing before me and making this acknowledgment is the person whose
true signature appears on this document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WITNESS my hand and official seal hereto affixed the day and year in the certificate above
written. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Print Name</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">NOTARY PUBLIC in and for the State of Alaska, residing at ___________________.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">My commission expires _______________.</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Legal Description </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ground lease estate in
the following described premises created by Lease dated as of January&nbsp;28, 2008 between Nelchina Point Limited Partnership, as ground lessor, and <FONT STYLE="white-space:nowrap">BMR-500</FONT> Fairview Avenue LLC, as ground lessee, as evidenced
by the Memorandum of Lease dated as of January&nbsp;28, 2008 recorded in the King County, Washington Land Records on January&nbsp;28, 2008 as Document Number 20080128000091: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lots 4, 5 and 6, Block 5, Sorenson&#146;s Addition to the City of Seattle, according to the plat thereof recorded in Volume 1 of plats, page(s) 218, in King
County, Washington. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT J </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF TERMINATION OF MEMORANDUM OF LEASE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEN RECORDED RETURN TO: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BIOMED REALTY, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17190 Bernardo Center Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California 92128 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Real Estate Legal </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Document Title</B>: Notice of
Lease Termination </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Grantor</B>: <FONT STYLE="white-space:nowrap">BMR-500</FONT> Fairview Avenue LLC, a Delaware limited liability company </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Grantee</B>: Silverback Therapeutics, Inc., a Delaware corporation </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Description</B>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abbreviated Legal Description</B>:
Lots 4, 5 &amp; 6, Block 5 Vol. 1 page 218 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Full Legal Description</B>: See <U>Exhibit A</U> attached </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assessor&#146;s Tax Parcel Nos.</B>: 786 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">350-0040-02</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Document No.</B>: Memorandum of Lease, Recording No. _________ </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF LEASE TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a Lease dated as of June ___, 2016 (the &#147;<B>Lease</B>&#148;), between <B><FONT STYLE="white-space:nowrap">BMR-500</FONT>
FAIRVIEW AVENUE LLC</B>, a Delaware limited liability company (&#147;<B>Landlord</B>&#148;), and <B>SILVERBACK THERAPEUTICS, INC.</B>, a Delaware corporation (&#147;<B>Tenant</B>&#148;), Landlord leased to Tenant certain premises (the
&#147;<B>Premises</B>&#148;) in the building located on the real property situated at 500 Fairview Avenue North, in Seattle, Washington, legally described on <U>Exhibit A</U> attached. A Memorandum of Lease was recorded on _____________ in the real
property records of King County, Washington under Recording No. _____________. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of this Notice of Lease Termination
(&#147;<B>Notice</B>&#148;) is to provide record notice that the term of the Lease has expired or the Lease has been terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
Notice shall be effective on the date this Notice is recorded in the real property records of King County, Washington. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Signatures
on following pages] </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LANDLORD:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">BMR-500</FONT> FAIRVIEW AVENUE LLC,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">A notary public or other officer completing this certificate verifies only the identity of the
individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">STATE OF CALIFORNIA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COUNTY OF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On ____________, ___, 2016, before me, _____________________________, Notary Public, personally appeared
____________________________, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her authorized capacity, and that by
his/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I certify
under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WITNESS my hand and
official seal. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Notary Public</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TENANT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SILVERBACK THERAPEUTICS, INC.,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">STATE OF ________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">) ss.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COUNTY OF ______________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On this ________ day of _________________, 2016 before me, the undersigned, a Notary Public in and for the
State of _____________________, duly commissioned and sworn personally appeared ____________________________, known to me to be the _____________________ of <B>SILVERBACK THERAPEUTICS, INC.</B>, the corporation that executed the foregoing
instrument, and acknowledged the said instrument to be the free and voluntary act and deed of said corporation, for the purposes therein mentioned, and on oath stated that he/she was authorized to execute said instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I certify that I know or have satisfactory evidence that the person appearing before me and making this acknowledgment is the person whose
true signature appears on this document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WITNESS my hand and official seal hereto affixed the day and year in the certificate above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Print Name</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">NOTARY PUBLIC in and for the State of Alaska, residing at ___________________.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">My commission expires _______________.</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Legal Description </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ground lease estate in
the following described premises created by Lease dated as of January&nbsp;28, 2008 between Nelchina Point Limited Partnership, as ground lessor, and <FONT STYLE="white-space:nowrap">BMR-500</FONT> Fairview Avenue LLC, as ground lessee, as evidenced
by the Memorandum of Lease dated as of January&nbsp;28, 2008 recorded in the King County, Washington Land Records on January&nbsp;28, 2008 as Document Number 20080128000091: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lots 4, 5 and 6, Block 5, Sorenson&#146;s Addition to the City of Seattle, according to the plat thereof recorded in Volume 1 of plats, page(s) 218, in King
County, Washington. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>13
<FILENAME>filename13.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I)&nbsp;NOT MATERIAL AND (II)&nbsp;WOULD
BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MASTER LABORATORY SERVICES AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Master Laboratory Services Agreement (&#147;Agreement&#148;), when signed by the parties, will set forth the terms and conditions between
Silverback Therapeutics, Inc., with its principal offices located at 500 Fairview Avenue North, Suite 600, Seattle, WA 98109, United States (&#147;Customer&#148;) and Q Squared Solutions LLC, with its principal offices located at 5827 South Miami
Blvd, Morrisville, NC 27560, USA (&#147;Q Squared&#148;), under which Q Squared agrees to provide laboratory services to Customer as set forth below. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Recitals: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Customer is
in the business of developing, manufacturing and/or distributing pharmaceutical products, medical devices and/or biotechnology products. Q Squared is in the business of providing central laboratory services for the pharmaceutical, medical device and
biotechnology industries and has made significant, <FONT STYLE="white-space:nowrap">up-front</FONT> investments in technologies related to those industries, building on important inventions and <FONT STYLE="white-space:nowrap">web-based</FONT>
technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Customer and Q Squared desire to enter into this Agreement to provide the terms and conditions upon which Customer may
engage Q Squared from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> to provide services for individual studies or projects by executing individual Work Orders (as defined below) specifying the details
of the services and the related terms and conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Customer and Q Squared agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <B>Services</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Description of
Services</U>. Q Squared shall provide project planning, consultation on laboratory design, laboratory analysis, other laboratory services, and/or data management services, as requested by Customer from time to time and agreed to by Q Squared during
the term of this Agreement (collectively the &#147;<B>Services</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Work Order</U>. The specific details of each assignment
or task (each a &#147;<B>Project</B>&#148;) will be specified in writing on terms acceptable to the parties and otherwise subject to the terms and conditions of this Agreement (each such writing, a &#147;<B>Work Order</B>&#148;) substantially in the
form of Attachment B to this Agreement. Each Work Order shall include Central Laboratory Services terms (including a Laboratory Services Document or Central Laboratory Worksheet) which shall describe the nature, scope and timelines for Services
being specifically performed for the applicable study. To the extent there is a conflict between the terms of this Agreement and a Work Order, this Agreement will control, except to the extent that the applicable Work Order expressly and
specifically states an intent to supersede this Agreement on a specific matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Affiliates</U>. &#147;Affiliate&#148; shall mean
all entities controlling, controlled by or under common control with Q Squared or Customer, as the case may be. The term &#147;control&#148; shall mean the ability to vote more than fifty percent (50%) of the voting securities of any entity or
otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-1-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
having the ability to direct the management and policies of an entity. Q Squared may utilize Affiliates to carry out its obligations under this Agreement or any Work Order and the Q Squared
entity that is the party to the Work Order shall remain responsible for all such Services. Any Affiliate of Q Squared or Customer may enter into a Work Order under this Agreement. The terms, conditions, and rights in this Agreement shall be
incorporated into each Work Order and such Affiliate, notwithstanding the foregoing, shall be solely responsible for the performance of the Services under such Work Order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Specimen Storage Limitations</U>. If requested by Customer and agreed by Q Squared, Q Squared will hold specimens in storage at the
conditions (including but not limited to temperature) agreed to between the parties for the time period defined by Customer in the study protocol or the Laboratory Specifications Document and/or Central Laboratory Worksheet, shall have the
obligation to hold specimens at such storage conditions, and shall notify Customer if Q Squared cannot hold specimens at, or if it becomes known to Q Squared that Q Squared is out of conformity with, such storage conditions, provided however, Q
Squared shall not be responsible, in the event that (i)&nbsp;the specimens or any specific analyte do not remain stable and/or suitable for testing, or (ii)&nbsp;stability data is not available during or after that storage time period. Customer
shall ensure it reviews the stability characteristics of the specimen or analyte with Q Squared&#146;s scientific affairs department prior to storage of any of the samples. If the stability is unknown, Customer shall define the specimen type,
storage duration, and testing interval of the specimen or analyte. Q Squared shall be responsible for the archiving and retention of all relevant documentation relating to the Services according to applicable law during the performance of Services,
subject to Section&nbsp;6 (d) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
<U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Research-Use-Only</FONT></FONT> Tests</U>. Customer may, from time to time, request that Q Squared performs
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">research-use-only</FONT></FONT> tests (&#147;RUO Tests&#148;) that have not been cleared or approved by the United States Food and Drug Administration, (or equivalent local regulatory
authority). If Customer requests Q Squared to perform RUO Tests, Customer represents and warrants that Customer and all of Customer&#146;s investigators shall use the results from RUO Tests for research purposes only, and will not use any test
results from RUO Tests for diagnostic or clinical purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Testing/Services Performed by Other Parties</U>. Unless determined to
have resulted directly from Q Squared&#146;s gross negligence or willful misconduct, Q Squared shall have no responsibility for or liability in connection with: (a)&nbsp;use of expired supplies by investigators, (b)&nbsp;incorrectly ordered and/or
incompatible supplies issued at Customer&#146;s direction, (c)&nbsp;testing or other services performed, at Customer&#146;s or an investigator&#146;s request, by a third party other than Q Squared, its Affiliates or its referral laboratories, or
(d)&nbsp;testing or procedures performed at any investigator site not pursuant to Q Squared&#146;s instructions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Conduct of
Services</U>. Q Squared shall engage adequately qualified personnel to perform the Services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <B>Payment of Fees and Expenses.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Budget</U>. Each Work Order shall contain a line item budget (&#147;Budget&#148;) for the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-2-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment of Q Squared &#145;s Services to be performed pursuant to such Work Order as well as additional terms and conditions related to the Budget. Customer will pay Q Squared for the fees,
expenses and pass-through costs in accordance with each Budget. Customer shall reimburse Q Squared for all reasonable and necessary travel, lodging and other expenses (including but not limited to investigator site special requests for supplies that
are not included in the bulk supply kit or other special requests) incurred in the performance of its Services that have been requested or approved by Customer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Budget Structure</U>. Customer agrees that the Budget will be structured in an effort to maintain cash neutrality for Q Squared (with
respect to the payment of professional fees, pass-through costs and otherwise). Unless otherwise agreed in the Work Order, Customer shall provide an <FONT STYLE="white-space:nowrap">up-front</FONT> payment which will be credited to Customer on the
final invoice. The <FONT STYLE="white-space:nowrap">up-front</FONT> payment will be outlined in each project Budget. Q Squared will draw from these funds in order to pay for Services and related costs and expenses consistent with the terms of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Invoicing</U>. Q Squared operates on a fee for service basis. Q Squared will invoice Customer monthly or as separately
agreed for Services rendered under any Work Order and Customer shall pay all amounts due within [***] days of receipt of the invoice date if an invoice is delivered electronically, or from the date of receipt if Customer requests a paper invoice. If
any portion of an invoice is disputed, then Customer shall pay the undisputed amounts within [***] days of receipt of the invoice, and the parties shall use good faith efforts to reconcile the disputed amounts as soon as practicable. Expenses and
pass-through costs will be supported by a detailed summary sheet. If the Project extends over more than [***], the Budget may be altered to include an annual cost adjustment. Q Squared reserves the right to impose, and Customer agrees to pay if
imposed by Q Squared, interest in an amount equal to [***] percent ([***]%) per month (or the maximum lesser amount permitted by law) of all undisputed amounts owing hereunder, which are outstanding [***] or more days from the due date of the
invoice . If Customer requires a purchase order (&#147;PO&#148;) related to a Q Squared invoice, then Customer will provide the PO prior to invoicing by Q Squared. If no PO is provided, Q Squared will invoice Customer without the PO. If <FONT
STYLE="white-space:nowrap">re-submission</FONT> of an invoice is required based on Customer&#146;s PO requirement or based upon Customer request, Q Squared&#146;s <FONT STYLE="white-space:nowrap">re-submission</FONT> of that invoice will not change
the due date for payment based on the original invoice. Any provisions contained within a PO that modify, conflict with or contradict any term or provision of this Agreement shall be deemed to be null and void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Taxes</U>. Customer shall pay all sales and use taxes, including all applicable goods and services tax, value added tax, local taxes,
applicable duties, electronic delivery taxes, excise taxes, levies and import fees (collectively, &#147;Taxes&#148;) that are imposed by legislation in connection with the provision of Services and that are not recoverable by Q Squared. All fees set
forth in a Work Order are exclusive of Taxes. Where Taxes are paid by Q Squared, Q Squared will provide an invoice, showing the Taxes included. Where any Taxes are paid directly to a tax authority or government by Customer, Customer shall not deduct
this amount from any amount due to Q Squared. The requirements of this provision shall not apply to any employment-related taxes, duties, income taxes or withholding and shall only apply Taxes applicable to the Services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-3-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Currency Exchange. The currency to be used for invoice and payment shall be the currency
stated in the Budget attached to a Work Order (the &#147;Contracted Currency&#148;). If a currency referenced within the Budget ceases to become legal tender, the applicable replacement currency will be substituted for such currency for the purposes
of this clause using the conversion rate established at www.oanda.com. Customer acknowledges that, due to fluctuations in currency exchange rates, Q Squared&#146;s actual fees and pass-through costs may be greater or lesser than the budgeted or
estimated amounts contained in a Work Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in a Work Order, if Q Squared incurs pass-through costs in a
currency other than the Contracted Currency, then Customer shall reimburse Q Squared for Q Squared&#146;s actual costs in the Contracted Currency based on the Oanda foreign currency exchange rate for the applicable currencies on the last business
day of the month immediately preceding the month in which such pass-through costs are submitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Work Order involves the performance
of Services by Q Squared or its Affiliates in any country that uses a currency other than the Contracted Currency, then the Budget for those Services will be based on the local rates in the currency used by Q Squared for pricing in that country, but
converted to and reflected in the Contracted Currency. If the fees for Services under a Work Order exceed the equivalent of [***] US dollars ($[***]) (based on the assumptions in the Budget), and the conversion rate between the local currencies and
the Contracted Currency has fluctuated more than [***]-percent ([***]%) plus or minus, since the budget was prepared, Q Squared may calculate a foreign currency exchange adjustment. The adjustment will be calculated every [***] after the contract
execution date, by comparing the foreign currency exchange rate stated in the Budget attached to the Work Order to the Oanda average rate (unless provided otherwise in a Work Order) over the preceding [***]. Any resulting decrease in costs will be
immediately credited to Customer and any resulting increase in costs will be invoiced to Customer, and shall be due for settlement without delay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Inflation</U>. If the Services are provided by Q Squared over multiple calendar years, the budget and payment schedule will incorporate the Inflation
Factor to Service fees for future year costs at the time the Work Order is executed by both parties, on a prospective basis only, and the Inflation Factor (defined below) shall remain fixed for the duration of the Work Order and subsequent Change
Orders to the Work Order. The Inflation Factor shall be calculated using a blend of [***] (&#147;Inflation Factor&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
<U>Information Requests</U>. To the extent not publicly available, and upon showing of good cause, at Q Squared&#146;s request, Customer shall promptly share financial details (such as audited financials) once per calendar year that demonstrate
Customer&#146;s continuing ability to meet its payment obligations under this Agreement and associated Work Orders (each, an &#147;Information Request&#148;). Additionally, Customer shall promptly notify Q Squared upon becoming insolvent or
commencing bankruptcy proceedings. Any information shared with Q Squared pursuant to an Information Request will be subject to Q Squared&#146;s obligations of confidentiality set forth in Section 5(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-4-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <B>Term and Termination.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) This Agreement shall commence on the date it has been signed by all parties (hereinafter &#147;Effective Date&#148;) and shall continue for
a period of five (5)&nbsp;years from the Effective Date, or until terminated by either party in accordance with this Section&nbsp;3. The Agreement will automatically renew each year thereafter for a period of one (1)&nbsp;year, unless either party
notifies the other party in writing at least thirty (30)&nbsp;days prior to the renewal date that the notifying party is electing not to renew the Agreement. If this Agreement is terminated but a Work Order issued under this Agreement is not
terminated, the terms of this Agreement will continue to apply to such Work Order as if the Agreement had not been terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) This
Agreement or any Work Order may be terminated with or without cause by Customer or by Q Squared at any time during the term of this Agreement on ninety (90)&nbsp;days prior written notice to Q Squared or Customer, as appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Either party may terminate this Agreement or any Work Order for material breach upon thirty (30)&nbsp;days written notice specifying the
nature of the breach, if such breach has not been substantially cured within the thirty (30)&nbsp;day period. In the event that Q Squared determines, in its sole discretion, that its continued performance of the Services contemplated by a Work Order
would constitute a potential or actual violation of regulatory or scientific standards of integrity, Q Squared may terminate this Agreement or the applicable Work Order by giving written notice stating the effective date of such termination (which
may be less than thirty (30)&nbsp;days from the notice date) of such termination, provided, however, in the event payment obligations are breached, Q Squared may at its discretion upon providing [***] notice thereof, cease extension of credit
privileges to Customer, suspend Services (including data transmission) and withhold payment of refunds to Customer until such undisputed amounts are paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Either party may terminate this Agreement or any Work Orders immediately upon provision of written notice if the other party becomes
insolvent or files for bankruptcy. Any written termination notice shall identify the specific Work Order or Work Orders that are being terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Termination of a Work Order shall constitute a termination of that particular Work Order only and shall not affect this Agreement or any
other Work Orders outstanding hereunder. Any written termination notice shall identify each specific Work Order that is being terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) In the event this Agreement is terminated, Customer shall pay to Q Squared: (i)&nbsp;any fees for services rendered then due and owing to
Q Squared because of any performance of Q Squared&#146;s obligations hereunder and all expenses reasonably incurred in performing those Services; (ii)&nbsp;all actual costs (including time spent by Q Squared personnel, which shall be billed at Q
Squared standard rates) to complete activities associated with the termination and close out of projects; and (iii)&nbsp;all kit destruction costs as noted in each Work Order. Upon the termination of this Agreement, Q Squared shall either:
(i)&nbsp;return to Customer, or (ii)&nbsp;dispose of at the direction and written request of Customer (or as more particularly specified in the Work Order), all data and materials provided by Customer to Q Squared for the conduct of Services under
this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-5-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Termination of this Agreement or any Work Order hereunder shall not constitute a release
or waiver of any right or remedy available to either party in connection herewith or therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Defective Services</U>. In the
event Q Squared fails to comply with the Work Order specifications and/or this Agreement in its performance of Services and such failure is not a direct result of any material act or omission by Customer or any other third party (&#147;<B>Defective
Services</B>&#148;), Customer may require Q Squared to <FONT STYLE="white-space:nowrap">re-perform</FONT> the Defective Services within an agreed time period after receipt of Customer&#146;s notice at Q Squared&#146;s cost (subject to <FONT
STYLE="white-space:nowrap">re-supply</FONT> by Customer of any materials, data or information at Customer&#146;s cost). If no such <FONT STYLE="white-space:nowrap">re-performance</FONT> is reasonably possible in the context of the Work Order and its
schedules and timelines, Q Squared shall reimburse Customer for the reasonable third party costs incurred to remedy such <FONT STYLE="white-space:nowrap">non-compliance</FONT> or reimburse Customer for the reasonable,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred to remedy the non-compliance, or only if such remediation is not reasonably possible, refund the portion of the fees paid to Q Squared
attributable to the Defective Services, subject in each case to Section&nbsp;10 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <B>Change Orders</B>. Any material change in the details of the
scope of Services set forth in a Work Order or the assumptions upon which the Work Order is based (including, but not limited to, changes in the expected number of investigators, number or schedule of visits, testing requirements, anticipated
commencement date, length of project or overall protocol specific database design) may require changes in the Budget and/or time lines, and shall require a written amendment to the Work Order (a &#147;Change Order&#148;). In such event or if the
Services are delayed for reasons beyond the control of the parties, the parties will cooperate with each other in good faith in reaching agreement with respect to any corresponding increase or decrease in the scope of the Work Order, Work Order
budget, and associated changes in the schedule of payments, timeline and/or schedule or other items associated with the Work Order. All Change Orders will be in writing and signed by duly authorized officers of each of the parties. [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <B>Confidentiality</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It is
understood that during the term of this Agreement and each Work Order issued hereunder, Q Squared and its employees may be exposed to data and information that is confidential and proprietary to Customer. All such data and information
(&#147;Customer Confidential Information&#148;) written or verbal, tangible or intangible, made available, disclosed or otherwise made known to Q Squared and its employees as a result of Services under this Agreement shall be considered confidential
and shall be considered the sole property of Customer . All information regarding Q Squared&#146;s and its Affiliate&#146;s operations, laboratory methods, pricing, and laboratory management and all Q Squared Property (as defined in Section&nbsp;6
below), disclosed by Q Squared or its Affiliates to Customer or its Affiliates in connection with this Agreement is proprietary, confidential information belonging to Q Squared (the &#147;Q Squared Confidential Information&#148;). Q Squared
Confidential Information together with the Customer Confidential Information, shall be the &#147;Confidential Information.&#148; The Confidential Information shall be used by the receiving party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-6-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and its employees only for purposes of performing the receiving party&#146;s obligations hereunder. Each party agrees that it will not reveal, publish or otherwise disclose the Confidential
Information of the other party to any third party without the prior written consent of the disclosing party, provided, however, that Q Squared may disclose limited Confidential Information as necessary in furtherance of a project hereunder, provided
that such third party [***] is not a competitor of Customer and is bound by confidentiality obligations substantially similar to those set forth herein, otherwise such disclosure to a third party requires Customer&#146;s written consent. Each party
agrees that the terms of this Agreement and any Work Order shall be considered Confidential Information, and each party agrees that it will not disclose the terms of this Agreement or any Work Order to any third party without the written consent of
the other party, which shall not unreasonably be withheld. These obligations of confidentiality and nondisclosure shall remain in effect for a period of [***] after the completion or termination of the applicable Work Order. For the avoidance of
doubt, the parties agree that the term Confidential Information shall include data and information disclosed in connection with potential services hereunder, even if the parties do not enter into a Work Order for such services, and if no Work Order
is executed such data and information shall be subject to this Agreement&#146;s confidentiality provisions for a period of [***] from the time of disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The foregoing obligations shall not apply to Confidential Information to the extent that it: (i)&nbsp;is or becomes generally available to
the public other than as a result of a disclosure by the receiving party; (ii)&nbsp;becomes available to the receiving party on a <FONT STYLE="white-space:nowrap">non-confidential</FONT> basis from a source which is not prohibited from disclosing
such information by a legal, contractual or fiduciary obligation to the disclosing party; (iii)&nbsp;was developed independently of any disclosure by the disclosing party or was known to the receiving party prior to its receipt from the disclosing
party, as shown by contemporaneous written evidence; or, (iv)&nbsp;is required by law or regulation to be disclosed; provided, however, that each party shall notify the other party in writing prior to making any disclosure pursuant to this
subsection &#147;(iv)&#148;, including but not limited to disclosures to the Securities Exchange Commission, FDA or any other governmental agency, unless prior notification is precluded by law or regulation or where enforcement action by applicable
authority precludes prior notification, in which case the party will notify the other party as soon as reasonably practicable. For the avoidance of doubt, any disclosures made under these subsections &#147;(i)&#148; to &#147;(iv)&#148; shall be
strictly limited to the information covered by the applicable subsection, and any Confidential Information not specifically covered by the exceptions in those subsections shall be redacted prior to disclosure of the relevant documents or materials.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <B>Property Ownership</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All
data and information necessary for Q Squared to conduct project assignments will be forwarded by Customer to Q Squared, and all such information received from Customer shall remain the property of Customer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All data and information generated or derived by Q Squared as the result of services performed by Q Squared under this Agreement and which
are provided by Q Squared to Customer as deliverables under this Agreement shall be and remain the property of Customer, excluding Q </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-7-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Squared Property (&#147;Customer Property&#148;). Any inventions that may evolve from the data and information delivered to Customer as the result of services performed by Q Squared under this
Agreement shall belong to Customer, and Q Squared hereby assigns its rights in any inventions and/or related patents to Customer, excluding that which relates to or constitutes Q Squared Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Q Squared and its affiliates own all right, title, and interest in and to the data, data models, databases, inventions, processes, <FONT
STYLE="white-space:nowrap">know-how,</FONT> copyrights, trade secrets, laboratory analysis, analytical and laboratory methods, procedures and techniques, technical expertise and conceptual expertise in area of laboratory services, manuals, personnel
data, pricing, financial information, technical expertise, software, and other intellectual property rights that (a)&nbsp;exist prior to the Effective Date or (b)&nbsp;are independently developed by or for Q Squared and its affiliates; and any
improvements, modifications and enhancements made to the foregoing during the term of this Agreement (collectively, &#147;Q Squared Property&#148;). Q Squared Property shall also include its proprietary systems, platforms and applications (&#147;Q
Squared Technology&#148;). If any Q Squared Property is included in any deliverable provided by Q Squared to Customer under this Agreement (&#147;Included Q Squared Property&#148;), Q Squared grants to Customer and/or its Affiliates a non-exclusive,
worldwide, royalty free license to use (but not to sell) such Included Q Squared Property, solely to the extent reasonably necessary for Customer to use or otherwise exploit the Customer Property for intended purposes, provided such Included Q
Squared Property is licensed to Customer &#147;AS IS&#148; without warranty of any kind, express or implied and that Q Squared has no liability to Customer of any kind, whether direct or indirect, arising out of or in connection with such Included Q
Squared Property. No proprietary IQVIA data assets or any Q Squared Technology shall constitute Included Q Squared Property, and Q Squared represents that, to the best of its knowledge, such IQVIA data assets or Q Squared Technology are not
necessary for Customer&#146;s use of the anticipated deliverables. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) At the completion of the services by Q Squared in the applicable
Work Order, all data and deliverables generated by Q Squared as a result of the services shall be provided to Customer by electronic means or as more particularly specified in the Work Order, subject to the payment obligations set forth in
Section&nbsp;2 herein; and any materials, equipment or information furnished by Customer for conduct of the services shall either be: (i)&nbsp;returned to Customer, or (ii)&nbsp;disposed of at the direction and written request of Customer (or as
more particularly specified in the Work Order). Q Squared, however, reserves the right to retain, at its own cost and subject to the confidentiality provisions herein, one (I)&nbsp;copy of all documents and materials relating to the Services, to be
used solely to satisfy regulatory requirements or to resolve disputes regarding the Services. All electronic and paper laboratory data required for internal business records shall be retained by Q Squared according to its Global Records Retention
Schedule. At the end of such period(s), Q Squared will destroy all paper laboratory data. Nothing in this Agreement shall be construed to transfer from Customer to Q Squared any FDA or regulatory record-keeping requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <B>Regulatory Compliance; Inspections.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In carrying out its responsibilities under this Agreement and each Work Order, Q </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-8-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Squared agrees that its Services will be conducted in compliance with all applicable laws, rules and regulations, including but not limited to the United States Food, Drug and Cosmetic Act and
the regulations promulgated pursuant thereto, ICH GCP Guideline, United Kingdom SI 2004 No.&nbsp;1031 Part 2 (and as amended), where applicable, and with the standard of care customary in the central laboratory industry. Q Squared&#146;s standard
operating procedures will be used in performance of the Services, unless otherwise specifically stated in the applicable Work Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
Customer warrants and represents that neither any assignment or task-requested by Customer, nor the conduct thereof, as provided in this Agreement or in any Work Order, shall violate any applicable law or regulation. Customer shall notify Q Squared
promptly in writing of any FDA or other governmental inspection or inquiry concerning any services that have been rendered or are being rendered by Q Squared, or any study or Project to which such Services relate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Q Squared certifies that it has not been debarred under the United States Generic Drug Enforcement Act, or any applicable law in any other
country, and that Q Squared will not knowingly employ any person or entity that has been so debarred to perform Services under this Agreement or any Work Order. Q Squared shall promptly notify Customer upon becoming aware of any inquiry concerning,
or the commencement of any proceeding or disqualification that is the subject of this Section&nbsp;7(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) In accordance with 21 CFR
&#167;50.25 and ICH GCP 4.8 (Informed Consent of Trial Subjects), Customer shall be responsible to ensure that all subjects (involved in clinical studies to which the Services of this Agreement and the applicable Work Order shall apply) shall
provide a valid consent pertaining to its Services performed hereunder, will understand the nature and purpose of the consent it provides to allow itself to be a participant in the clinical study including the removal and testing of its bodily fluid
samples and/or tissue samples as appropriate. Customer shall inform Q Squared immediately, in writing, if any such subject(s) are withdrawn from the clinical study. Q Squared shall promptly communicate to the Customer any serious breaches of the
Protocol and Good Clinical Practices, and Customer shall be responsible to promptly report such breaches to the Medicines and Healthcare products Regulatory Agency (&#147;MHRA&#148;), or to the equivalent local regulatory agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Each party acknowledges that the other party may respond independently to any regulatory correspondence or inquiry in which such party or
its Affiliates is named. Each party, however, shall notify the other party promptly of any FDA or other governmental or regulatory inspection or inquiry concerning any study or Project of Customer for which Q Squared is providing Services. During
any such inspection or inquiry, the parties agree to make reasonable efforts to disclose only the information required to be disclosed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) During the term of this Agreement and each Work Order, Q Squared will permit Customer&#146;s representative(s) (provided that such
representatives shall not be competitors of Q Squared), prior to any audit, Customer shall procure that its <FONT STYLE="white-space:nowrap">non-employee</FONT> representative enter into a confidentiality agreement with Q Squared on terms at least
as stringent as the confidentiality terms herein) to examine or audit the work performed hereunder and the specific facilities at which the work is conducted during regular business hours, upon reasonable advance written notice and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-9-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in a reasonable manner to determine that the project assignment is being conducted in accordance with the task in the applicable Work Order and that the facilities are adequate; provided however,
that all information disclosed or revealed to or ascertained by Customer in connection with any such audit or examination or in connection with any correspondence between Q Squared and any regulatory authorities (including any notice of violation or
potential violation of local law or regulations such as FDA Form 483 notices) shall be deemed to constitute Q Squared Confidential Information for the purposes of this Agreement. Unless the costs of governmental or Customer audits are specifically
included in the Budget, and except for [***], Customer shall, upon request, reimburse Q Squared&#146;s time and expenses (including reasonable attorney fees and the costs of responding to findings) associated with any inspection, audit or
investigations relating to the Services (&#147;Inspection&#148;) instigated by Customer or by a governmental authority, unless such Investigation finds that Q Squared breached this Agreement or any applicable law or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <B>Anti-Bribery</B>. Each party undertakes to the other party that: (i)&nbsp;it will not, and will procure that each of its employees,
directors, officers, affiliates, subcontractors and agents will not, (1)&nbsp;offer, promise or give an advantage to another person, or (2)&nbsp;request, agree to receive or accept a financial or other advantage in violation of any anticorruption
laws, rules, regulations and decrees applicable to the respective party (collectively, &#147;Legislation&#148;), including the United States Foreign Corrupt Practices Act, as amended (the &#147;FCPA&#148;), the United Kingdom Bribery Act 2010 (the
&#147;Bribery Act&#148;) and any implementing legislation under the OECD Convention Against the Bribery of Foreign Government Officials in International Business Transactions (&#147;OECD Convention&#148;). It is each party&#146;s responsibility to
be familiar with, and comply with, the provisions of the applicable Legislation; and (ii)&nbsp;from time to time, at the reasonable request of the other party, it will confirm in writing that it has complied with its undertakings under subsection
(i) above and will provide any information reasonably requested by the other party in support of such compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <B>Conflict of Agreements</B>. Q
Squared represents to Customer that Q Squared is not a party to any agreement which would prevent Q Squared from fulfilling its obligations under this Agreement, and that during the term of this Agreement, Q Squared will not enter into an agreement
to provide services which would prevent Q Squared from providing the Services contemplated to be provided by Q Squared under this Agreement or any Work Order. Customer agrees that it will not enter into an agreement with a third party that would
alter or affect the regulatory obligations delegated to Q Squared pursuant to any Work Order without the written consent of Q Squared, which will not be unreasonably withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <B>Indemnification</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Customer shall
defend, indemnify and hold harmless Q Squared, its Affiliates and its and their respective directors, officers, employees and agents (each, an &#147;Q Squared Indemnified Party&#148;), from and against any and all losses, claims, actions, fines
damages, liabilities, costs and expenses, (including reasonable attorney&#146;s fees and court costs) (collectively, &#147;Losses&#148;), resulting or arising from any third-party claims, actions, proceedings, investigations (including subpoenas
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-10-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or other legal process) or litigation relating to or arising from or in connection with this Agreement or any Work Order or the Services contemplated herein (including, without limitation, any
Losses arising from or in connection with any study, test, device, product or potential product to which this Agreement or any Work Order relates), except to the extent such Losses are determined to have resulted from the gross negligence or
intentional misconduct of the Q Squared Indemnified Party seeking indemnity hereunder or material breach by Q Squared of its obligations under this Agreement or a Work Order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Q Squared shall indemnify, defend and hold harmless Customer and its Affiliates, and its and their directors, officers and employees
(each, a &#147;Customer Indemnified Party&#148;), from and against any and all Losses, resulting or arising from any third-party claims, actions, proceedings, investigations or litigation relating to or arising from or in connection with this
Agreement or any Work Order or the Services contemplated herein, to the extent such Losses are determined to have resulted from the gross negligence or intentional misconduct of a Q Squared Indemnified Party hereunder or material breach by Q Squared
of its obligations under this Agreement or a Work Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The indemnified party shall: (i)&nbsp;give the indemnifying party prompt
notice of any such claim or law suit (including a copy thereof served upon indemnified party); (ii) cooperate with indemnifying party and its legal representatives in the investigation of any matter the subject of indemnification, and (iii)&nbsp;not
unreasonably withhold its approval of the settlement of any such claim, liability or action by indemnifying party that is the subject of Section&nbsp;9(a) or 9(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <B>Limitation of Liability.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except
for either party&#146;s indemnification obligations under Section&nbsp;9, neither Q Squared, nor Customer, nor any of their Affiliates, nor any of their respective directors, officers, employees, subcontractors or agents or representatives,
consultants, or shareholders shall have any liability of any type (including, but not limited to, contract, negligence and tort liability) for any loss of profits, opportunities or goodwill, or any type of special, incidental, indirect or
consequential damage or loss in connection with or arising out of this Agreement, or any Work Order, or the Services performed by Q Squared hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Except for either party&#146;s indemnification obligations under Section&nbsp;9, in no event shall the collective, aggregate liability
(including without limitation, contract, negligence and tort liability) of Q Squared or its Affiliates, directors, officers, employees, subcontractors or agents under this Agreement exceed the amount of fees actually received by Q Squared from
Customer under the applicable Work Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <B>Cooperation; Customer Delays; Disclosure of Hazards</B>. Customer shall forward to Q Squared in a timely
manner all documents, materials and information in Customer&#146;s possession or control necessary for Q Squared to conduct the Services. Q Squared shall not be liable to Customer nor be deemed to have breached this Agreement for errors, delays or
other consequences arising from Customer&#146;s failure to timely provide documents, materials or information or to otherwise cooperate with Q Squared in order for Q Squared to timely and properly perform
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-11-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its obligations, and any such failure by Customer shall automatically extend any timelines affected by a time period reasonably commensurate to take into account such failure, unless Customer
agrees to a Change Order to pay any additional costs that would be required to meet the original timeline. If Customer delays a project from its agreed starting date or suspends performance of the project, then the parties will either enter into a
Change Order to address : a) Customer payment of the standard daily rate of Q Squared&#146;s personnel assigned to the project, based on the percentage of their time allocated to the project, for the period of the delay, in order to keep the current
team members; or b) Q Squared may <FONT STYLE="white-space:nowrap">re-allocate</FONT> the personnel at its discretion. In addition, Customer will also pay all <FONT STYLE="white-space:nowrap">non-cancelable</FONT> costs and expenses incurred by Q
Squared due to the delay and will adjust all timelines to reflect additional time required due to the delay. Customer shall provide Q Squared with all information available to it regarding known or potential hazards associated with the use of any
substances supplied to Q Squared by Customer and Customer shall comply with all current legislation and regulations concerning the shipment of substances by land, sea or air. If Customer, or any third party acting on Customer&#146;s behalf or at the
direction of Customer, delivers, ships, or mails materials or documents to Q Squared, or if Q Squared delivers, ships, or mails materials or documents to Customer or to third parties, then the expense and risk of loss for all such deliveries,
shipments, and mailings shall be borne by Customer. Q Squared disclaims any liability for the actions or omissions of third-party delivery services or carriers, including loss or damage occurring during shipment, delivery or mailing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <B>Publication</B>. Project results may not be published or referred to, in whole or in part, by Q Squared without the prior express written consent of
Customer. Neither party may use the other party&#146;s name in connection with any publication or promotion without the other party&#146;s prior express written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <B>Independent Contractor Relationship</B>. Notwithstanding any provision herein to the contrary, the parties hereto are independent contractors, and
nothing contained in this Agreement or in any Work Order shall be construed to place them in the relationship of partners, principal and agent, employer and employee, or joint venturers. Each party agrees that it shall have no power or right to bind
or obligate the other, and neither party shall hold itself out as having such authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <B>Insurance</B>. Each party to this Agreement is
responsible for maintaining, at its own expense and throughout the term of this Agreement, programs of insurance or self-insurance as it deems appropriate and in compliance with statutory requirements to protect its liabilities and contractual
obligations; provided, however, failure of either party to have insurance coverage, inability to obtain insurance coverage, or any inadequacy of insurance coverage of such party shall not relieve such party of any part of its liabilities under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <B>Force Majeure and Related Matters</B>. In the event either party shall be delayed or hindered in or prevented from the performance of
any act required hereunder by reasons of strike, lockouts, labor troubles, inability to procure materials or services, failure of power or restrictive government or judicial orders, or decrees, riots, insurrection, acts of terrorism, war, Acts of
God, inclement weather or other reason or cause beyond that party&#146;s control, then performance of such act (except for the payment of money owed) shall be excused for the period of such delay. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-12-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16. <B>Notices and Deliveries</B>. Any notice required or permitted to be given hereunder by either party
hereunder shall be in writing and shall be deemed given on the date received if delivered personally, or by electronic mail, or by a reputable overnight delivery service, or three (3)&nbsp;days after the date postmarked if sent by regular,
registered or certified mail, return receipt requested, postage prepaid to the following addresses: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to Q Squared Solutions LLC:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Q Squared Solutions LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5827 South Miami Boulevard</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morrisville, NC 27560</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">USA</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Head of Laboratory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to Customer</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Silverback Therapeutics, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500 Fairview Ave. N, Suite 600</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seattle, WA 98109</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">USA</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Sue Hamke</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">With a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IQVIA Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of the General Counsel</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">P.O. Box 13979</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research Triangle Park, North Carolina</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">27709-3979 USA</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17. <B>Miscellaneous</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Governing Law</B>. This Agreement and each Work Order shall be construed, governed, interpreted, and applied in accordance with the laws
of the State of New York, exclusive of its conflicts of laws provisions. If any one or more provisions of this Agreement or any Work Order are found to be unenforceable on the grounds that they are overly broad or in conflict with applicable laws,
it is the intent of the parties that such provisions be replaced, reformed or narrowed so that their original business purpose can be accomplished to the extent permitted by law, and the remaining provisions shall not in any way be affected or
impaired thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Survival</B>. The rights and obligations of Customer and Q Squared, which by intent or meaning have validity
beyond such termination (including, but not limited to, rights with respect to inventions, confidentiality, discoveries and improvements, insurance, data protection, indemnification and liability limitations) shall survive the termination of this
Agreement or any Work Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Entire Agreement; Amendments; Counterparts</B>. This Agreement together with the applicable Work
Orders, contains the entire understanding of the parties with respect to the subject matter herein, and supersedes all previous agreements (oral and written), negotiations and discussions. Any modification to the provisions herein must be in writing
and signed by the parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-13-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement may be executed by electronic means (including .PDF) and in any number of counterparts, each
of which when executed and delivered, shall constitute an original, but all of which together shall constitute one (1)&nbsp;agreement binding on all parties, notwithstanding that all parties are not signatories to the same counterpart. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Binding Agreements and Assignment</B>. This Agreement shall be binding upon and inure to the benefit of Customer and Q Squared and
their respective successors and permitted assigns. Except as stated in this Section, neither party may assign any of its rights or obligations under this Agreement to any party without the express, written consent of the other party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Waiver</B>. The failure to enforce any right or provision herein shall not constitute a waiver of that right or provision. Any waiver
of a breach of a provision shall not constitute a waiver of any subsequent breach of that provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Headings</B>. The descriptive
headings of the sections of this Agreement are inserted for convenience only and shall not control or affect the meaning or construction of any provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <B>Incorporation by Reference</B>. All appendices attached hereto shall be deemed to be incorporated herein. In case of any conflict
between this Agreement and any such attachment or any Work Order, the terms of this Agreement shall prevail over the attachment or Work Order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <B>Data Protection</B>. Q Squared and Customer agree to comply with all applicable privacy laws and regulations, and this Agreement. In
addition, Q Squared shall at all times abide by its privacy policies and Customer&#146;s instructions- when processing personal data under this Agreement. If the services will involve the collection or processing of personal data (as defined by
applicable data protection legislation) within the European Union (&#147;EU&#146;&#146;), then Customer shall serve as the controller of such data, as defined by the General Data Protection Regulation (Regulation (EU) 2016/679 of the European
Parliament and the Council on the Protection of individuals with regard to the processing of personal data and on the free movement of such data) (&#147;GDPR&#148;), and Q Squared shall act only under the instructions of the Customer in regard to
such personal data. In addition, the parties will execute a Data Processing Agreement prior to any such processing and if Customer is not based in the EU, Customer must appoint a third party to act as its local data protection representative or
arrange for a <FONT STYLE="white-space:nowrap">co-controller</FONT> established in the EU for data protection purposes in order to comply with GDPR as Q Squared does not provide this service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Agreement has been executed by the parties hereto through their duly authorized officers and is effective as of the Effective
Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(signature page follows) </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-14-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Q Squared Solutions LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Silverback Therapeutics, Inc.</B></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dennis Golmitz</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey C. Pepe</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Print Name: Dennis Golmitz</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Print Name: Jeffrey C. Pepe</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director, C&amp;P</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">SVP, General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">May&nbsp;25, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">May&nbsp;22, 2020</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>List of Appendices</U>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;1:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sample Work Order</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix 2:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Q Squared Expression Analysis Laboratory Services Terms</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix 3:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Q Squared BioSciences Laboratory Services and Vaccine Services Terms</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-15-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Appendix&nbsp;1:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sample Work Order </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WORK ORDER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Work
Order (&#147;Work Order&#148;) is between [<I>insert Customer&#146;s full legal name</I>] having its principal place of business located at [<I>insert address</I>] (&#147;Customer&#148;) and [<I>insert Q Squared entity</I>], with a principal place
of business located at the [<I>insert address</I>] (&#147;Q Squared&#148;) and relates to the Master Laboratory Services Agreement dated _________________ (the &#147;Master Agreement&#148;), which is incorporated by reference herein. Pursuant to the
Master Agreement, Q Squared has agreed to perform certain services in accordance with written work orders, such as this one, entered into from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time.</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties hereby agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Work Order</U>. This document constitutes a Work Order under the Master Agreement and this Work Order and the services contemplated
herein are subject to the terms and provisions of the Master Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Budget</U>: Total fees and expenses hereunder not to exceed
$&#151; without a Change Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Services and Payment of Fees and Expenses. The specific services contemplated by this Work Order (the
&#147;Services&#148;) and the related payment terms and obligations are set forth on the following attachments, which are incorporated herein by reference: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Exhibit A: Central Laboratory Services </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Exhibit B: Laboratory Events Schedule </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Exhibit C: Laboratory Testing Requirements </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Exhibit D: Budget </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Exhibit E:
Data Processing Information Form </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Term</U>. The term of this Work Order shall commence on the date of execution and shall continue
until the Services described in this Work Order are completed, unless this Work Order is terminated in accordance with the Master Agreement. If the Master Agreement is terminated or expires, but this Work Order is not terminated or completed, then
the terms of the Master Agreement shall continue to apply to this Work Order until the Work Order is either terminated or completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.
<U>Amendments</U>. No modification, amendment, or waiver of this Work Order shall be effective unless in writing and duly executed and delivered by each party to the other. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-16-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ACKNOWLEDGED, ACCEPTED AND AGREED TO: </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><I>[insert Q Squared entity]</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B><I>Silverback Therapeutics, Inc.</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(signature)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(signature)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Print Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Print Name:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-17-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><U>Appendix&nbsp;2:</U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Q Squared Expression Analysis Laboratory Services Terms</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following terms shall apply specifically for any services provided by Q Squared Solutions Expression Analysis (&#147;Q Squared Expression Analysis&#148;)
Services as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Services</U>. Q Squared shall provide genomic, analytical and bioanalytical testing services, as requested by
Customer from time to time during the term of the applicable Work Order. Q Squared will use reasonable commercial efforts to perform the Services in accordance with the specifications and timelines set forth in the Work Order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Q Squared shall make and keep complete systematic records of all Services performed pursuant to a quotation for Services. Q Squared will
preserve all such paper records, on- site or at a secure location facility, for two (2)&nbsp;years after Services are completed. A retrieval fee may be imposed if Customer requires retrieval [***] or greater after data generation. Electronic data
generated during the course of the study will be retained according to the Quotation or project specific Work Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Genomic
Specimens: Materials: Quality Control. Each Work Order specifically for Q Squared Expression Analysis will become effective upon Q Squared&#146;s receipt of a Purchase Order from Customer or other writing from Customer authorizing Q Squared to
proceed with the Services (&#147;Purchase Order&#148;). Q Squared will not be obligated to perform Q Squared Expression Analysis Services until such Purchase Order and a Specimen Submission Form (&#147;SSF&#148;) per the instructions in the Work
Order is received by Q Squared from Customer. After a Work Order becomes effective, such Work Order shall be governed by and incorporated by reference all of the terms and conditions of this Agreement; any preprinted terms and conditions on a Work
Order or Purchase Order shall not apply unless expressly agreed in writing by both parties. In case of any conflict between this Agreement and any such Work Order, Purchase Order or similar writing, the terms of this Agreement shall prevail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Customer shall use reasonable efforts to provide to Q Squared the number of genomic specimens (&#147;Specimens&#148;) and, if applicable,
any reagents, microarrays and other materials (&#147;Consumables&#148;) in accordance with the timelines and specifications defined for delivery of such Specimens and/or Consumables in the quotation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Risk of loss of the Specimens and Consumables shall pass to Q Squared upon its receipt of such Specimens and Materials at Q Squared
designated place of receipt, (provided such designation is in writing and signed by Q Squared) and its determination that such Specimens are in acceptable condition. If at any time Q Squared becomes aware of any Specimens and/or Materials that do
not meet the requirements set forth in the Quotation or fail any portion of the laboratory protocol, Q Squared shall promptly inform Customer&#146;s designated project manager via electronic mail. Customer shall then elect to either:
(a)&nbsp;replace Specimens and/or Materials that donot meet applicable criteria, or (b)&nbsp;continue with the contracted service without replacing such Specimens and/or Materials, in which case, the Parties shall modify the affected Quotation to
reflect the reduced number of Specimens and/or Materials. If Customer elects to proceed with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-18-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contracted services, Customer shall pay Q Squared as mutually agreed for the Services performed of any such Specimens in accordance with the Quotation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Q Squared&#146;s standard quality assurance tests are intended to minimize errors that may occur during the preparation and processing of
Specimens. Specimens that yield data outside Q Squared quality metrics due to circumstances beyond the control of Q Squared are not the responsibility of Q Squared. Q Squared does not guarantee results. Customer will be notified promptly if a
Specimen does not pass Q Squared&#146;s quality metrics and Customer will be responsible for advising Q Squared on whether or not processing should continue. In the event the Customer requests Q Squared to process samples that do not meet quality
criteria Customer shall be responsible for any fees, expenses and/or costs incurred or associated with the process of such samples. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
Customer is not exempt from charges incurred due to failed experiments through no fault of Q Squared. Any Specimen deemed by Q Squared to be insufficient, invalid, or degraded to the point of being unusable may be returned at Customer request and Q
Squared may elect to charge a nominal fee for expenses related to Specimen preparation, quality testing and shipping fees for each returned Specimen. If replacement Specimens are submitted Customer will be responsible for charges incurred in the
processing of those replacement Specimens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event a Specimen is caused to be unusable due to a failure of a third party
Consumable, Q Squared will make a reasonable effort to obtain a replacement Consumable to re-perform the analysis, but in the event that a replacement cannot be obtained or the analysis cannot be <FONT STYLE="white-space:nowrap">re-performed,</FONT>
Q Squared accepts no responsibility for the Specimen loss or unfinished analysis. Additionally, in the event of subsequent preparation and testing, Q Squared reserves the right to recover appropriate fees and costs, including the cost of additional
Consumables for Services provided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Notices</U>. Any notice required or permitted to be given hereunder shall also be given to:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to Q Squared Solutions Expression Analysis LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Q
Squared Solutions Expression Analysis LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5927 S. Miami Blvd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morrisville, NC 27560, USA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Head of Laboratory </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Customer retains
all rights and title in and to Customer Specimens. Any and all Specimens supplied to Q Squared that are not utilized in the performance of the Services will, at Customer&#146;s request, be returned, destroyed or stored. Specimens that are returned
or stored on Customer&#146;s behalf will incur a fee as outlined in the Quotation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Each party acknowledges that the other party may
respond independently to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-19-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory correspondence or inquiry in which such party or its affiliates is named. Each party, however, shall notify the other party promptly of any FDA or other governmental or regulatory
inspection or inquiry concerning any study or Project of Customer for which Q Squared is providing Services. During any such inspection or inquiry, the parties agree to make reasonable efforts to disclose only the information required to be
disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Limited Warranty</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Other than as expressly set forth in this Agreement and attachments hereto, Q Squared makes no representations, warranties or guarantees
regarding the deliverables supplied by Q Squared to Customer, or the use of, or the results of the use of such deliverables, or the performance of the Services. Q SQUARED AND ITS AFFILIATES DISCLAIMS ALL OTHER WARRANTIES, WHETHER EXPRESSED OR
IMPLIED, INCLUDING, WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Customer&#146;s exclusive remedy under Q Squared&#146;s warranty is, at Q Squared&#146;s sole option, a credit for or <FONT
STYLE="white-space:nowrap">re-performance</FONT> of the Services in question. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-20-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><U>Appendix&nbsp;3:</U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Q Squared BioSciences Laboratory Services and Vaccine Services Terms</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following terms shall apply specifically for any Q Squared Biosciences Laboratory Services and/or Vaccine Services as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event it is necessary for Q Squared to assess and correct an immediate problem in connection with the Study, and
after reasonable efforts Q Squared is unable to contact Customer to notify Customer of such problem, Q Squared may proceed accordingly and use reasonable emergency measures in order to correct such problem for the purpose of maintaining the
integrity of the Study. Q Squared shall be entitled to recover any additional reasonable costs associated with such corrective emergency measures; provided, however, Q Squared agrees to promptly notify Customer of such emergency measures and use its
reasonable best efforts to minimize any additional costs to Customer for such emergency corrective measures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Test
Materials. (i)&nbsp;Test materials supplied to Q Squared by Customer for bioanalytical and biosciences services hereunder (&#147;Test Biosciences Materials&#148;) will be used by Q Squared solely for performance of authorized Studies. Q Squared
shall be strictly prohibited from conducting any structural analysis, modification or reverse engineering of the Test Biosciences Materials, unless specifically requested by Customer in writing. Test Biosciences Materials transferred to Q Squared
shall remain the property of Customer. (ii)&nbsp;Upon the written request of Customer, any remaining samples of the Test Biosciences Materials will be returned to Customer at Customer&#146;s expense. (iii)&nbsp;Customer shall provide Q Squared with
all information available to it regarding known or potential hazards associated with the use of any substances supplied to Q Squared by Customer and Customer shall comply with all current legislation and regulations concerning the shipment of
substances by land, sea or air. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For all Studies conducted under this Agreement, Q Squared will comply with all
applicable laws, rules, regulations and guidelines, including but not limited to Good Laboratory Practices set forth by the U.S. Food and Drug Administration (&#147;FDA&#148;), Good Clinical Practices, ICH GCP Guideline, Organisation for Economic <FONT
STYLE="white-space:nowrap">Co-operation</FONT> and Development (&#147;OECD&#148;), and Ministry of Health, Labour and Welfare (&#147;MHLW&#148;), and any other applicable laws, rules, regulations and guidelines relating to the provision of Services,
as stipulated in each applicable Protocol under this Agreement, and with the standard of care customary in the bioanalytical laboratory industry. Q Squared will perform this Agreement in accordance with professional and ethical practices and
industry standards and the employees it will provide or obtain for the provision of the Services will act with professionalism, competence and diligence. Q Squared&#146;s standard operating procedures will be used in performance of the Services.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Reporting. (i)&nbsp;Q Squared will maintain accurate and complete records in accordance with all applicable Good
Laboratory Practices, and if applicable Good Clinical Practices, and Q Squared will comply with all reporting requirements contained in each Protocol. Q Squared will keep Customer informed of the progress of Studies and will submit progress reports
as specified in the Protocols. (ii)&nbsp;Q Squared shall also provide Customer with a draft final and a final report for each Study either using Q Squared&#146;s report format or Customer&#146;s report format. If
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-21-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Customer requests the Customer format to be used, Customer must notify Q Squared prior to the analysis of study samples for a given study. If any changes to the draft report or final report
format has to be subsequently made due to the request of the Customer, or if additional copies of the final report are requested by Customer, then at Q Squared&#146;s option there may be an additional charge to Customer for preparation, handling and
dispatch of such reports. If such changes will be expected to affect the timing of the delivery of the final report(s), then Q Squared shall submit amended delivery dates for Customer&#146;s written approval. (iii)&nbsp;All reports submitted to
Customer and all data generated hereunder shall become the property of Customer and may be used by Customer for any purpose without further obligation or liability to Q Squared. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) All materials and documentation will be retained by Q Squared for a period of three (3)&nbsp;years (&#147;Retention
Period&#148;) following issuance of the Final Report. During the Retention Period, the materials and documentation shall be made available for inspection by Customer or any authorized agent designated by Customer. Q Squared may charge Customer a
reasonable fee for storage of records after three (3)&nbsp;years. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Unless otherwise required by law, Q Squared shall
not permit any inspections involving any Studies or the Confidential Information (as defined in the Agreement), until further instructions are received from Customer or until Customer and the inspecting agency have reached an appropriate agreement.
Unless otherwise required by law and subject to confidentiality obligations within the Agreement, no copies of Protocols or other Confidential Information maybe given by Q Squared to the Inspector. Any request for such information shall be
redirected to Customer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Q Squared does not warrant or represent that the results of the Study will be acceptable to
any regulatory or governmental agency to which they are presented nor that the results of the Study will enable Customer to market or otherwise exploit the Test Materials, or any product or Service. Customer acknowledges that it is responsible for
assessing and evaluating the reports, data, results, conclusions and other Work Product provided to Customer by Q Squared (&#147;Results&#148;), and the suitability of the Results for Customer&#146;s purposes. Q Squared shall have no responsibility
for the manner in which Customer uses the Results, and Customer&#146;s acceptance, reliance on, or use of such results shall be at the sole risk of Customer. EXCEPT AS EXPRESSLY SET FORTH IN THIS SECTION 2.(4)(g), Q SQUARED MAKES NO REPRESENTATIONS
OR WARRANTIES WITH RESPECT TO THIS AGREEMENT AND THE APPLICABLE WORK ORDER, THE SERVICES OR ANY STUDIES. Q SQUARED EXPRESSLY DISCLAIMS THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. Q SQUARED MAKES NO REPRESENTATIONS OR
WARRANTIES OF <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> WITH RESPECT TO ANY PATENT, TRADEMARK, TRADE SECRET, <FONT STYLE="white-space:nowrap">KNOW-HOW,</FONT> TANGIBLE RESEARCH PROPERTY. INFORMATION OR DATA PROVIDED TO CUSTOMER
HEREUNDER, AND HEREBY DISCLAIMS THE SAME. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-22-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Duplicate Study Samples</U>. Customer agrees to retain duplicate
study samples should the need for repeat analytical analysis be required and the original samples are unfit or unavailable for reanalysis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In addition to the indemnity provisions within the Agreement, Customer undertakes to defend, indemnify and hold harmless Q
Squared and its affiliates, and its and their directors, officers, employees and agents (each, a &#147;Q Squared Indemnified Party&#148;), from and against any and all claims, losses, damages, liabilities, fines, reasonable attorney fees, court
costs, and expenses joint or several, resulting or arising from any third-party claims, actions, proceedings, investigations or litigation relating to or arising from or in connection with (a)&nbsp;Customer&#146;s use of the Results, and
(b)&nbsp;any actual or alleged infringement of any patent or copyright, or wrongful use of proprietary information, arising from Q Squared&#146;s use of the Test Biosciences Materials as contemplated by this Agreement and/or the Work Order. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) All materials and documentation will be retained by Q Squared for a period of three (3)&nbsp;years (&#147;Retention
Period&#148;) following issuance of the Final Report. During the Retention Period, the materials and documentation shall be made available for inspection by the Customer or any authorized agent designated by the Customer. Q Squared may charge
Customer a reasonable fee for storage of records after three (3)&nbsp;years. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) In the event Customer requests Q Squared
to return any samples or Test Biosciences Materials to Customer or to a third party, Customer shall pay all associated courier/shipping charges incurred to return such sample and/or Test Biosciences Materials. If Customer requires Q Squared to use a
specific courier for such return and/or to bill the courier directly on its behalf Customer shall promptly provide in writing to Q Squared the courier account number and shall promptly pay any such costs in accordance with the payment terms in the
Agreement and/or the Work Order. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) In the event Customer requests (provided such request is in writing or by email) Q
Squared to store, destroy or dispose of any Test Biosciences Materials or samples supplied by Customer or used during the Study in any Work Order, and Q Squared agrees in writing, Q Squared shall store, destroy or dispose of any Test Biosciences
Materials or samples at Customer&#146;s option at a fee to be determined in the applicable Work Order. Notwithstanding the above, storage fees shall be at least [***] per sample, or Test Biosciences Materials, per month. At Q Squared sole discretion
it may provide discounts on storage of [***] samples at any one time or committed long-term storage. For the avoidance of doubt, if Customer fails to inform Q Squared of its decision to store, destroy or dispose of any sample and/or Test Biosciences
Materials within [***] Customer shall be charged the storage fees detailed in this Section&nbsp;2.(4)(1) for any such sample and/or Test Biosciences Materials and in accordance with the payment terms in the Agreement and/or the Work Order. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Upon written request of Customer, Q Squared shall remit to Customer all work products in its possession or under its
control, except that Q Squared may retain any work products which Q Squared is required to retain by applicable laws and archival copies of work product for its own records. Furthermore, subsequent to any retention period, Q Squared shall contact
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-23-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Customer to determine disposition of the records (return or extended storage) and upon Customer&#146;s decision, disposition will be taken by Q Squared and charged to Customer, at the rates in
effect at that time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Customer agrees that it will not enter into an agreement with a third party that would alter or
affect the regulatory obligations delegated to Q Squared in any Study or project without the written consent of Q Squared, which will not be unreasonably withheld. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) Indemnification and Limitation of Liability. Customer acknowledges that Q Squared has not participated in the manufacture
of any Test Biosciences Materials supplied by Customer and it acknowledges that Q Squared&#146;s sole mandate is to perform each Study in accordance with the terms of the Work Order for bioanalytical and bioscience services and the applicable
Protocol. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) Q Squared retains the right to use any general assay technique utilized on Customer projects as Q
Squared&#146;s own, royalty free. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) Notices. Any notice required or permitted to be given hereunder shall also be given
to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to Q Squared Solutions Biosciences LLC: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Q Squared Solutions BioSciences LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19 Brown Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ithaca, NY 14850
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">USA </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attn: Head of
Laboratory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Master Laboratory Services Agmt US</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Q
Squared Solutions LLC</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Version July 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">-24-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>14
<FILENAME>filename14.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I)&nbsp;NOT MATERIAL AND (II)&nbsp;WOULD
BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Silverback Therapeutics</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MASTER SERVICES AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS MASTER SERVICES AGREEMENT is made and entered into as of January&nbsp;21, 2020 (the &#147;<B>Effective Date</B>&#148;) by and between <B>CE3 INC.</B>
having a principal place of business at 246 Goose Lane, Suite 202, Guilford, CT, USA (&#147;<B>CE3</B>&#148;) and <B>Silverback Therapeutics, Inc.</B>, having a principal place of business at 500 Fairview Ave N, #600, Seattle WA 98109
(&#147;<B>Sponsor</B>&#148;). The term &#147;CE3&#148; includes CE3, Inc., its affiliates, and authorized agents. The term &#147;Sponsor&#148; includes <B>Silverback Therapeutics, Inc.</B> and its authorized agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties hereby agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>SERVICES</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CE3 will perform for Sponsor from time to time as mutually agreed upon by the parties in Project Specification
Orders (&#147;PSO&#148;), certain research and/or administrative services in connection with clinical trials sponsored by Sponsor (&#147;Study&#148; or &#147;Studies&#148;) and general clinical research activities including, without limitation,
trial management, site identification and selection, site monitoring/management, project management, data collection, statistical programming or analysis, quality assurance auditing, scientific and medical communications, regulatory affairs
consulting and submissions, strategic consulting and/or other related services (&#147;Services&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each PSO will set forth the terms and conditions of the particular Services, including a description of the
specific work to be performed, target completion dates, a budget and schedule of payments (&#147;Project&#148;), and will be separately executed by authorized representatives of CE3 and Sponsor. A sample PSO is attached hereto as Exhibit A. In the
event there is any material change in the scope of Services set forth in a PSO, or if the Project is delayed for reasons beyond the control of the parties, the parties will agree in writing to such changes and shall cooperate with each other in good
faith in reaching agreement with respect to any corresponding increase or decrease in the PSO budget, and associated changes in the schedule of payments, Project schedule or other items associated with the PSO. All such changes will be documented in
a Change Order, or series of Change Orders, to be numbered sequentially and each of which must be signed by duly authorized officers of both parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Services pursuant to this Agreement will commence until a PSO has been executed by both of the parties, or
otherwise agreed to in writing. The terms of this Agreement will be made a part of and incorporated by reference into each PSO and each PSO is hereby made a part of and incorporated into this Agreement. In the event of a conflict between the terms
of this Agreement and a PSO, the terms of this Agreement will govern, unless otherwise specifically agreed in the applicable PSO. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each PSO will, to the extent necessary, contain a statement of transfer of Sponsor obligations pursuant to 21
CFR 312.52. CE3 will use reasonable commercial efforts to perform all transferred obligations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event CE3 is required pursuant to a PSO to conduct or monitor a Study, CE3 will obtain any necessary
prior approval and ongoing review as required by: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any appropriate and necessary review authorities, including without limitation, any applicable institutional
review board that is properly constituted in accordance with applicable national, state and local laws and standards to act as a human subjects research review board (&#147;IRB&#148;); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all international, national, state and local laws and regulations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CE3 will collect documentation of training provided to investigators conducting studies on behalf of Sponsor
(the &#147;Investigators&#148;) related to each Investigator&#146;s performance of services and transferred obligations in conformance with Study protocols and with generally accepted standards of good clinical practice according to current Good
Clinical Practices, ICH Guidelines, and all other laws, rules, regulations or guidelines applicable to the performance of services. CE3 is not responsible for Investigator negligence or willful misconduct. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3-SBT.MSA.Final.200121</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 1 of 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Silverback Therapeutics</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to any contrary requirements in section 1.6 above, CE3 will use reasonable commercial efforts to
perform all Services and transferred obligations in accordance with the specifications and timelines set forth in PSOs, or in Project plans, templates and requirements documents referenced in PSOs, or in any modifications thereto or reasonable
additional requirements of which Sponsor may notify CE3. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the requirements of sections 1.6, and 1.7 above, and unless otherwise stipulated in the applicable
PSO, CE3 will provide Services in conformance with CE3&#146;s Standard Operating Procedures and with the Study protocol, all relevant regulations and rules of the FDA or other governmental requirements, and with current good clinical practice.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CE3 agrees to provide all reasonable personnel, facilities, and resources, as required, to accomplish its
responsibilities under any PSO. Sponsor may provide equipment to CE3, as more fully specified in the applicable PSO, including without limitation computer equipment and/or one or more software programs, for use in connection with a Study or Project
(&#147;Equipment&#148;). Upon completion or termination of any PSO (except to the extent otherwise authorized by Sponsor in writing), or upon written request of Sponsor, the Equipment, all associated peripheral equipment (including CDs and other
storage media), and all software and data will be promptly returned to Sponsor, at Sponsor&#146;s expense. No duplicates of any software provided to CE3 may be retained by CE3. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CE3 will not modify or alter a Study protocol without the specific written authorization and approval of
Sponsor or its designee. In the event CE3 is required pursuant to a PSO to perform and/or monitor a Study, CE3 will instruct Investigators and Study sites that Study protocols may not be modified or altered without the specific written authorization
and approval of Sponsor or its designee, will monitor to verify that such Investigators and Study sites do not so modify or alter the protocols, and will report immediately to Sponsor any such modification or alteration by Investigators and Study
sites. <B><U>PROVIDED HOWEVER, IN THE EVENT CE3 FINDS IT NECESSARY TO MAKE CHANGES TO THE STUDY PROTOCOL TO PROTECT AGAINST AN IMMEDIATE THREAT TO SAFETY OR HEALTH OF THE PATIENTS/VOLUNTEERS, CE3 MAY DO SO AND SHALL REPORT IMMEDIATELY TO SPONSOR ANY
SUCH MODIFICATION OR ALTERATION AND THE REASON(S) FOR MAKING SUCH MODIFICATION OR ALTERATION.</U></B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Materials and Study Drug</U>. Study drug and other materials provided to CE3 by or on behalf of Sponsor for
the conduct of a Project shall only be used in the conduct of the Project in accordance with the Study protocol and any unused study drug or materials shall, upon termination of a PSO and at Sponsor&#146;s sole cost and expense, be returned to
Sponsor or, at Sponsor&#146;s direction, destroyed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Clinical Trial Agreement and Informed Consent</U>. CE3 agrees to use a standard form of Clinical Trial
Agreements and Informed Consents approved by Sponsor in contracting with clinical sites and investigators to conduct each Project; provided that Sponsor and CE3 shall establish reasonable negotiation parameters which shall be used to support any
negotiation thereof. All material changes in the Clinical Trial Agreements and Informed Consents which fall outside of such negotiation parameters must be prior approved by Sponsor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>COMPENSATION</U><U></U><U>&nbsp;&amp; PAYMENT</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Compensation</U>. For performance of Services, Sponsor will pay CE3 fees (&#147;Service Fees&#148;), and
will reimburse CE3 for reasonable and customary expenses, in the amounts and upon the terms set forth in the applicable PSO. Any change in the Service Fees or expenses set forth in a PSO will approved in writing by the Sponsor and will require the
execution of a change order or amendment in accordance with the terms of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment Terms</U>. Sponsor will pay CE3 Service Fees and expenses authorized by PSOs within [***] of receipt
by Sponsor of a correct and undisputed invoice from CE3. Upon request from Sponsor and/or in accordance with Section&nbsp;12 of this Agreement, CE3 will make copies of receipts for expenses, or other documentation required by Sponsor available for
review. If CE3 incurs Service Fees and allowable expenses in any tradable currency other than U.S. dollars, CE3 will translate the foreign currency into U.S. dollars using the foreign exchange rate as published by The Wall Street Journal on the date
of the invoice. All payments will be made by Sponsor in U.S. dollars. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential Information Omitted</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3-SBT.MSA.Final.200121</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 2 of 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Silverback Therapeutics</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Start-Up</FONT> Payment</U>. Pursuant to a PSO and subject to section 8.4
of this Agreement, Sponsor may provide a <FONT STYLE="white-space:nowrap">start-up</FONT> payment to CE3, which is required to initiate the Study <FONT STYLE="white-space:nowrap">(&#147;Start-up</FONT> Payment&#148;) provided that such provision for
<FONT STYLE="white-space:nowrap">Start-up</FONT> Payment is specified in the applicable PSO. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Delays/Study Holds</U>. In the event of any delay or Study hold by Sponsor (other than a Force Majeure
event, as defined in section 14.7 herein), CE3 shall use commercially reasonable efforts to reassign to another project personnel or contractors who were assigned to perform the Services hereunder. A delay of the Study may include, but is not
limited to, delay in the provision of client materials or information, or delay in approval of documentation. In the event that such personnel or contractors cannot be reassigned to another project, Sponsor may elect to continue to pay all costs
attributable to maintaining the availability of such personnel or contractors for the applicable PSO, or such personnel or contractors may be terminated. If such personnel or contractors are reassigned or terminated, CE3 cannot guarantee
availability of such personnel or contractors for performance of the Services hereunder upon lifting of the delay or Study hold. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>CONFIDENTIALITY </U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the Mutual Confidentiality Agreement by and between the parties dated as of <B>September</B><B></B><B>&nbsp;18, 2019 </B>shall govern this
Agreement with respect to Confidential Information, as defined in such Mutual Confidentiality Agreement, and such terms are incorporated by reference herein. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>PERSONAL AND PROTECTED HEALTH INFORMATION</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Performance under this Agreement and/or each specific PSO may involve the exchange of certain information about individual persons including, without
limitation, individually identifiable health information, employment information, insurance information, and family information (collectively, &#147;Personal and Protected Health Information&#148;). Personal and Protected Health Information shall be
transmitted, handled, stored, maintained, used, and destroyed in a manner that will preserve its confidentiality. The parties will not use or disclose Personal and Protected Health Information received pursuant to this Agreement and/or to any PSO
for any purpose other than the performance of the Services under this Agreement and/or any PSO. The obligations and restrictions set forth in this Section will survive the termination or expiration of this Agreement and/or of any PSO. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>HANDLING</U><U></U><U>&nbsp;&amp; STORAGE OF DOCUMENTATION</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CE3 will take responsibility for the management and custody of all Materials and documentation related to a
Study or Project undertaken pursuant to a PSO (&#147;Documentation&#148;), so as to avoid loss, theft, or unauthorized disclosure thereof. All documentation is Confidential Information and/or Personal and Protected Health Information subject to the
terms and conditions of section 3 and (to the extent applicable) section 4 of this Agreement. CE3 will not disclose or transfer Documentation, or cause Documentation to be disclosed or transferred, to a third party without the prior written approval
of Sponsor including, without limitation, data or clinical specimens collected by CE3 in the course of performing Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CE3 will retain and, when required pursuant to a PSO to perform and/or monitor a Study, will instruct
Investigators and/or Study sites to retain the Documentation, related to a Study drug for which an IND has been filed, in conformance with applicable national and international regulations, but for no less than a period of up to [***] after
regulatory approval of the marketing application for the indication for which the Study drug was tested pursuant to any PSO, or if the application is not approved or Sponsor withdraws the application, for up to [***] after such <FONT
STYLE="white-space:nowrap">non-approval</FONT> or withdrawal, unless CE3 and Sponsor mutually agree to return the Documentation to Sponsor at the completion of a Project pursuant to the terms defined in a PSO (the &#147;Retention Period&#148;).
During the Retention Period, CE3 will make available and, when required pursuant to a PSO to perform and/or monitor a Study, will instruct Investigators and/or Study sites to make available the Documentation for inspection or copying by Sponsor or
any authorized agent designated by Sponsor upon request. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential Information Omitted</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3-SBT.MSA.Final.200121</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 3 of 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Silverback Therapeutics</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After the Retention Period, CE3 will contact Sponsor to determine the disposition of the Documentation
(disposal charges at Sponsor&#146;s expense). Sponsor&#146;s choice of disposition of the Documentation will be in writing. CE3 will not discard or destroy any Documentation without first receiving Sponsor&#146;s written consent to do so.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>INTELLECTUAL PROPERTY</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Inventions</U>. The investigational drug that is the subject of a Study (the &#147;Study Drug&#148;) is the
sole property of Sponsor. CE3 acknowledges and agrees that neither it nor its employees or agents will acquire rights of any kind whatsoever with respect to the Study Drug, including, but not limited to, methods of manufacturing the Study Drug,
methods of using the Study Drug, data or information relating to FDA approval and labeling of the Study Drug. CE3 will disclose exclusively to Sponsor and to no others, any and all inventions, ideas, discoveries, copyrights or work product and all <FONT
STYLE="white-space:nowrap">know-how</FONT> related to a Study Drug, including without limitation those which constitute a modification, improvement, or new use thereof, which CE3 makes or conceives of and/or reduces to practice during the course of
or as a result of performing Services hereunder (&#147;Inventions&#148;). CE3 hereby assigns all right, title and interest in and to such Inventions to Sponsor or its nominee and will, at Sponsor&#146;s expense, conduct all activities reasonably
requested by Sponsor to further effectuate or evidence such assignment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Patents</U>. CE3 acknowledges that Sponsor has the exclusive right to file patent applications in connection
with Inventions. CE3 will not prevent Sponsor in any way from filing patent applications, and that the prosecution and conduct of any patent application filed by Sponsor will be under the exclusive control of Sponsor. CE3 further agrees to use
reasonable efforts to assist Sponsor, at Sponsor&#146;s cost and expense, to file, prosecute, and maintain patent applications, and to enforce any resulting patent, on such Inventions in the name of Sponsor or its nominee, and to execute and have
executed any papers that Sponsor may consider necessary or helpful in such prosecution, or which may relate to any litigation or interference and/or controversy in connection therewith. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Ownership of Work Product</U>. All reports, data, documents, protocols, specimens, clinical supplies,
worksheets, technical information, product plans, regulatory plans, original works of authorship and all materials or documents created by CE3 related to any PSO (&#147;Work Product&#148;) will be reported to Sponsor and are its exclusive property.
Sponsor will have the unrestricted right to use such Work Product consistent with applicable law. For the avoidance of doubt, such Work Product shall also be deemed to be the Confidential Information of Sponsor. When appropriate, Sponsor will obtain
and maintain all appropriate third party software and hardware licenses necessary to use CE3 Work Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>CE3 Property</U>. Section&nbsp;6.3 notwithstanding, Sponsor acknowledges that CE3 has proprietary systems,
processes, tools, and other material (&#147;Tools&#148;) necessary to properly conduct clinical trials, consulting, and other related services. These Tools and any modification, improvement, or new use thereof are the exclusive property of CE3.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Trade Secrets</U>. In the performance of Services under this Agreement or any PSO, neither party will
disclose to nor use for the benefit of the other, any trade secrets of a third party without first obtaining the right to do so. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Right of Reference</U>. Pursuant to 21 U.S.C. Section&nbsp;355 (b), CE3 hereby grants to Sponsor, and
Sponsor hereby retains, the exclusive right of reference to and use of any clinical investigation, including data or results therefrom, in support of new drug applications submitted by or on behalf of Sponsor to the United States Food and Drug
Administration (&#147;FDA&#148;). Further, it is Sponsor&#146;s exclusive right to grant third parties authorization to reference or use any clinical investigation, including data or results therefrom. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>PUBLICATIONS</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CE3 will obtain the express written consent of Sponsor prior to any publication or presentation of results generated pursuant to any PSO hereunder including,
without limitation, articles or reports. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3-SBT.MSA.Final.200121</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 4 of 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Silverback Therapeutics</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>TERM OF AGREEMENT</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Term</U>. Subject to section 8.2. below, this Agreement will have a term of five (5)&nbsp;years from the
Effective Date unless extended by mutual agreement of the parties in accordance with the terms of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Either party may terminate this Agreement or any PSO at any time upon 30 days prior written notice to the other
party. Notwithstanding the foregoing, should any PSOs entered into during the period of this Agreement require CE3 to provide Services beyond the date on which this Agreement is terminated pursuant to the terms of this paragraph 8.2.1, then the
terms of this Agreement will remain in effect with respect to such PSOs, until the termination date set forth in such PSO or its earlier termination pursuant to this paragraph. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Either party may terminate this Agreement if the other party commits a material breach of this Agreement that
remains uncured for at least sixty (60)&nbsp;calendar days after written notice of the breach by <FONT STYLE="white-space:nowrap">non-breaching</FONT> party. In the event CE3 is in default of any material obligation set forth in this Agreement or
any PSO, which is not cured within a mutually agreed upon timeframe after receipt of written notice from Sponsor, Sponsor may, at its election, request that CE3 (i) repeat the related Services at CE3&#146;s cost, or (ii)&nbsp;refund to Sponsor
within sixty (60)&nbsp;days, amounts paid by Sponsor to CE3 for related Services; provided that such default was solely the result of CE3&#146;s gross negligence. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor may terminate PSO, in whole or in part, immediately upon written notice to CE3 if either CE3 or Sponsor
is unable to obtain the ongoing review and/or approvals in connection with a Study consistent with those set forth in section 1.5 of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor or CE3 may terminate this Agreement or any PSO immediately and without notice if the other party
becomes insolvent or bankrupt. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Transition Upon Termination</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Transfer of Work Product, Equipment and Documentation</U>. Upon the termination of this Agreement or any
PSO, Sponsor will have the right to assume full control of all Studies and Projects subject to the termination. In such event, CE3 will promptly submit to Sponsor all Work Product, Equipment, and Documentation in CE3&#146;s possession at the time of
such termination or subject to its oversight responsibility pursuant to applicable PSOs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Phase Down Plan</U>. Upon the termination of this Agreement or any PSO, CE3 will proceed in an orderly
fashion to terminate any outstanding commitments and to phase-down the work associated with the Services as soon as practicable, in accordance with a plan mutually agreed upon by Sponsor and CE3 (the &#147;Phase Down Plan&#148;).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payments Due Upon Termination.</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the termination of this Agreement and/or any PSO (excluding CE3&#146;s termination for convenience), and
in accordance with the applicable Phase-Down Plan, Sponsor will pay CE3 for all reimbursables expenses incurred (which may include <FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations committed before receipt of notice of termination)
and Services provided through the date of notice of termination (as well as Services completed as part of the Phase Down Plan) based upon the progress of the work performed and to the extent that such expenses and Services are authorized pursuant to
the PSO(s) that is(are) subject to the termination hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, upon termination of this Agreement and/or any PSO, Sponsor has made prior payments to CE3 that exceed the
amount owing to CE3 pursuant to any PSO that is subject to such termination, CE3 will refund the difference to Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any payment or refund hereunder will be made within sixty (60)&nbsp;days after the date of termination unless
otherwise agreed upon by the parties in the applicable Phase-Down Plan or other writing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3-SBT.MSA.Final.200121</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 5 of 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Silverback Therapeutics</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Survival of Legal Remedies</U>. Nothing in this section 8 will limit the legal remedies of either party in
the event that termination hereunder results from a breach of this Agreement by the other party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>REPRESENTATION AND WARRANTY </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Authorization</U>. Each party represents and warrants that it has the right to enter into this Agreement
with the other party. CE3 further represents and warrants that it is not a party to any agreement or under any condition which would prevent it from fulfilling its obligations under this Agreement and that during the term of this Agreement, it will
not enter into any agreement and/or arrangement which would in any way prevent it from providing Services pursuant to this Agreement or any PSO hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Compliance with Laws</U>. Each party shall comply with all laws and regulations applicable to the Services,
Study Drug and the Study, including, but not limited to, the applicable relations of the FDA, Good Clinical Practices, ICH Guidelines, and all other laws, rules, regulations or guidelines applicable to the performance of the Study and manufacture of
the Study Drug, as well as the prohibitions on kickbacks and referrals of the Social Security Act applicable to Medicare, Medicaid and certain other government healthcare programs, the False Claims Act and equivalent state laws.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Debarment</U>. CE3 warrants and certifies that all CE3 personnel performing Services under this Agreement
are not debarred under the Federal Food, Drug and Cosmetic Act, 21 U.S.C. 335(a) and (b)&nbsp;or any equivalent law or regulation of any other applicable jurisdiction. Further, CE3 will not employ any person to perform Services under this Agreement
if such person is debarred by such law or the FDA. CE3 agrees to immediately disclose in writing to Sponsor if any CE3 personnel performing services under this Agreement is debarred, or if any action or investigation is pending or, to the best of
CE3&#146;s knowledge, threatened, relating to the debarment of CE3 personnel performing Services related to this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>INDEMNIFICATION</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor will indemnify, defend and hold harmless CE3, and its directors, officers, employees, representatives,
associates, consultants, subcontractors and agents (&#147;CE3 Indemnities&#148;) against and from any liability, damage, loss, or expense (including, without limitation, reasonable attorney&#146;s fees and expenses of litigation) (collectively,
&#147;Loss&#148;) incurred by or imposed upon CE3 in connection with any Study related third party claims, suits, actions, demands or judgments (collectively, &#147;Claim&#148;). CE3 agrees to immediately notify Sponsor of any such Claim. Such
notice will set forth all information known to CE3 relating to the Claim and will be sent pursuant to the terms of this Agreement. The failure to so notify the Sponsor shall not relieve the Sponsor of its obligations hereunder, except to the extent
such failure shall have adversely prejudiced the Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor&#146;s obligation to indemnify CE3 will not apply to any Claim or Loss that arises to the extent
arising from any willful misconduct, negligent act or omission of CE3, including without limitation failure of CE3 comply with Sponsor&#146;s written instructions (provided such instructions comply with all relevant regulations and with generally
accepted standards of good clinical practice according to current Good Clinical Practices) or the Study protocol, or failure by CE3 to comply with relevant regulations and rules of the FDA or other governmental requirements, or failure to comply
with current good clinical practice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor will have the right to fully control the defense of any Claim to which its indemnity obligation
hereunder applies, including but not limited to the selection of counsel, compromise and settlement and proceedings. Sponsor will not be liable for any Claim where a compromise or settlement was made by CE3 without Sponsor&#146;s prior written
approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CE3 will cooperate fully with Sponsor in the defense and proceedings of any Claim, attend hearings and trials
and assist in securing and giving evidence and testimony, and obtaining the attendance of necessary and proper witnesses at such hearing and trials at Sponsor&#146;s expense. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3-SBT.MSA.Final.200121</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 6 of 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Silverback Therapeutics</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CE3 agrees to indemnify and hold harmless Sponsor, and its directors, officers, employees, representatives,
associates, consultants, subcontractors and agents (&#147;Sponsor Indemnitees&#148;) against and from any third- party Claim resulting from work performed by CE3 in accordance with a PSO to the extent such Claim arises solely and directly out of
(i)&nbsp;the negligence or willful misconduct of CE3, including without limitation failure of CE3 to comply with Sponsor&#146;s written instructions (provided such instructions comply with all relevant regulations and with generally accepted
standards of good clinical practice according to current Good Clinical Practices) or the Study protocol, (ii)&nbsp;any material breach of this Agreement by CE3, and (iii)&nbsp;CE3&#146;s failure to comply with relevant regulations and rules of the
FDA or other governmental requirements, or failure to comply with current good clinical practice, including, without limitation, amounts paid in settlement of such Claims, and agrees to bear all costs and expenses (including, without limitation,
reasonable attorney&#146;s fees), incurred in connection with the defense or settlement of any such Claim as such costs and expenses are incurred in advance of judgment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CE3&#146;s obligation to indemnify Sponsor will not apply to any Claim or Loss that arises from:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any willful misconduct, malpractice, negligent act or omission of Sponsor; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any injury caused by Sponsor&#146;s Study Drug(s) and/or devices, or Study procedures in connection with a PSO;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a failure by Sponsor to comply with all relevant regulations and rules of the FDA or other governmental
requirements, or failure to comply with current good clinical practice; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">negligence or willful misconduct by clinical study investigators. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EXCEPT AS SET FORTH IN THIS SECTION 10, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY IN ANY AMOUNT FOR
SPECIAL, INCIDENTAL, CONSEQUENTIAL, INDIRECT, EXEMPLARY OR PUNITIVE DAMAGES. FURTHER, ANY STUDY COMPOUNDS PROVIDED TO OR ON BEHALF OF SPONSOR ARE EXPERIMENTAL AND ARE PROVIDED WITHOUT WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF
MERCHANTABILITY, TITLE, USAGE OF TRADE OR COURSE OF DEALING OR FITNESS FOR A PARTICULAR PURPOSE. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>LIABILITY INSURANCE</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the term of this Agreement, each party shall, at its sole cost and expense, maintain such policies of
comprehensive general and professional liability insurance and other insurance as shall be adequate to insure against any Claim(s) for damages arising in connection with the performance hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Either party shall, at the other party&#146;s request, have its insurance carrier for such insurance furnish a
certificate that such insurance is in force, such certificate to indicate any deductible and/or self-insured retention and stipulate that such insurance will not be canceled while this Agreement is in effect without at least [***] prior written
notice to the other party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>SPONSOR&#146;S RIGHT TO AUDIT </U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Audits</U>. [***], Sponsor or its designee(s) will have the right during CE3&#146;s normal business hours,
without incurring any additional responsibilities under this Agreement, to audit, upon reasonable notice, CE3&#146;s facilities, records and documentation (including, without limitation, Study and/or Project records, Investigator and/or Study site
files, systems, operations, and standard operating procedures) related to CE3&#146;s performance under this Agreement or PSOs. Sponsor or its designee(s) may conduct such audits during the term of this Agreement and for a period of up to [***] after
completion of related Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Audit Findings</U><U></U><U>&nbsp;&amp; <FONT STYLE="white-space:nowrap">Follow-up</FONT></U>. If Sponsor
identifies any failure of CE3 in its performance of the Services in accordance with the applicable PSO, Sponsor will provide CE3 with written documentation of its findings </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential Information Omitted</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3-SBT.MSA.Final.200121</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 7 of 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Silverback Therapeutics</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
in connection with any such audit within [***] of the date on which the audit was completed. In the event that any such report includes findings alleging substantial deficiencies related to
quality assurance, CE3 will develop an action plan, subject to Sponsor&#146;s review and approval, to address all deficiencies at CE3&#146;s expense (the &#147;Action Plan&#148;), unless CE3 may dispute in good faith the audit findings and elect,
within [***] after such delivery, to hire a third party auditor (&#147;the &#147;Auditor&#148;) to review the audit results. In such event, CE3 and Sponsor will select an Auditor for such purpose only upon written approval of both parties, and will
equally divide the costs incurred in connection with the Auditor&#146;s review; provided, however, that if the Auditor determines that CE3 had no reasonable basis for disputing Sponsor&#146;s audit results, CE3 will pay all of the costs associated
with the Auditor&#146;s review. If the Auditor determines that Sponsor had no reasonable basis for the finding, Sponsor will pay all of the costs associated with the Auditor&#146;s review. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Adherence to Audit Findings</U><U></U><U>&nbsp;&amp; Action Plan</U>. Subject to section 12.2, CE3 will
comply with all provisions stipulated in the audit report and/or Action Plan, including any provisional requirements, pursuant to any service provided under a PSO. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>GOVERNMENTAL INSPECTION</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of section 13.2. below, during the term of this Agreement and/or the performance of
any PSO, CE3 agrees, at Sponsor&#146;s expense, including possible cost for CE3 personnel to prepare for audit, to permit representatives of the FDA and/or the duly authorized representative of a federal or international governmental, regulatory or
administrative department or agency (&#147;Regulatory Authority&#148;) to examine at any reasonable time during normal business hours (and where applicable make copies of)&nbsp;(i) the facilities where the Services and/or Study are being performed;
(ii)&nbsp;raw Study or Project data, including original subject records; and (iii)&nbsp;any other relevant information necessary to confirm that the Services are being performed in compliance with the Study protocol, this Agreement, and the
applicable PSO, and with applicable laws and regulations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor will be notified as soon practical in the event that CE3&#146;s facilities or designated facilities or
an IRB utilized in connection with any PSO are the subject of an inspection or the subject of an intended inspection by a Regulatory Authority which may involve the subject matter of this Agreement or any PSO. CE3 will provide Sponsor with the
following data: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">purpose of inspection; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">name and credential number of Regulatory Authority personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a copy of form(s) issued by the Regulatory Authority, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a copy of any communication to or from the Regulatory Authority. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition, unless otherwise required by law, CE3 will not permit any inspections involving a Study, Project,
Confidential Information or Personal and Protected Health Information until further instructions are received from Sponsor or until Sponsor and the inspecting Regulatory Authority have reached an appropriate agreement. Unless otherwise required by
law, no copies of a Study protocol, PSO other Confidential Information or Personal and Protected Health Information may be given by CE3 to the Regulatory Authority. CE3 shall use its best efforts to promptly notify Sponsor of any request for
information during a regulatory inspection to allow Sponsor the option to authorize CE3 to disclose the requested information during such inspection. Otherwise, any request for such information is to be redirected to Sponsor. Further CE3 will notify
Sponsor promptly of any governmental and/or regulatory action taken with respect to any aspect of a Study or Project. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>GENERAL</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Advertising</U>. Under no circumstances may one party use the name of the other party or the Study Drug, or
any of its personnel, for promotional literature or advertising without the prior permission and approval of the other party. Notwithstanding the foregoing, in the event that either party may be required to use the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential Information Omitted</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3-SBT.MSA.Final.200121</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 8 of 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Silverback Therapeutics</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
name of the other party in submissions to a Regulatory Authority, no prior consent for such use will be necessary. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Independent Contractors</U>. CE3 will perform the Services under this Agreement only as an independent
contractor and not as an agent, employee, joint venturer or partner of Sponsor, and nothing contained herein will be construed to be inconsistent with that relationship or status. This Agreement will not constitute, create, or in any way be
interpreted as, a joint venture, partnership, or business organization of any kind. CE3 Personnel performing Services pursuant to any PSO hereunder are not nor will they be deemed to be at any time during the term of this Agreement employees or
agents of Sponsor. CE3 will pay, when due, salaries, wages and other forms of compensation or reimbursement and all applicable federal, state and local withholding taxes and unemployment taxes, as well as social security, state disability insurance
and all other payroll charges payable to, or on behalf of, CE3&#146;s personnel working on any Project. No life, casualty, or disability insurance, or health, retirement or any other employment benefits will be paid by Sponsor to or for the benefit
of CE3 or its personnel. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notices</U>. Any notice or other communication pursuant to this Agreement in writing and will be deemed to
have been fully given when delivered by <FONT STYLE="white-space:nowrap">nationally-recognized</FONT> overnight courier service or three (3)&nbsp;days after being mailed by United States registered or certified mail, postage prepaid and return
receipt requested, to the following addresses or such other addresses as each party may provide in writing to the other party from time to time: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><U>If to CE3:</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">CE3 Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">246 Goose Lane, Suite 202 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Guilford, CT 06437 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><U>If to
Sponsor:</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Silverback Therapeutics </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">500 Fairview Ave N, #600 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Seattle, WA 98109 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Assignment</U>. This Agreement may not be signed or subcontracted, in whole or in part, by either party
without the prior written consent of other party; provided, however, that a party may assign this Agreement, without the prior written consent of the other party, to an entity who acquires all or substantially all of its business, whether through
merger, reorganization or otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Governing Law/Venue</U>. This Agreement in all respects be governed by, construed and enforced in accordance
with the laws of the State of Delaware, regardless of its choice of law rules. Each party hereby specifically consents to the personal jurisdiction of the courts in the State of Connecticut or the State of Washington; provided that, in the event of
a dispute concerning this Agreement, any suit, proceeding, arbitration or mediation will be brought: (a)&nbsp;by Sponsor only in a court or tribunal of competent jurisdiction in the State of Connecticut, or (b)&nbsp;by CE3 only in a court or
tribunal of competent jurisdiction in the State of Washington. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Conduct</U>. When interacting under this Agreement, neither CE3 nor Sponsor will commit any act of sexual
harassment nor discriminate on the basis of sex, race, religion, national origin, disability, marital status, Veteran&#146;s status and age. Each party will indemnify and hold harmless the other against and from any liability, losses, claims and
expenses (including but not limited to attorneys&#146; fees) arising from any breach of the foregoing obligations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Force Majeure</U>. Neither party will be liable for any delay or failure to perform as required by this
Agreement to the extent that such delay or failure to perform is caused by circumstances reasonably beyond the control of the party seeking relief under this section including, without limitation, labor disputes, accidents, any law, order or
requirement of any governmental agency or authority, civil disorders or commotions, acts of aggression or terror, fire or other casualty, strikes, acts of God, explosions, or material shortages. Performance time will be considered extended for a
period of time equivalent to the time lost </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3-SBT.MSA.Final.200121</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 9 of 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Silverback Therapeutics</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
because of any such delay or failure to perform; however, in any event, this extension of time will not exceed [***], at which time the <FONT STYLE="white-space:nowrap">non-affected</FONT> party
may terminate this Agreement or the applicable PSO, unless the parties agree otherwise in writing. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Headings/Counterparts</U>. The headings contained in this Agreement are for convenience of reference only
and are not intended to have any substantive significance in interpreting this Agreement. This Agreement may be executed in any number of counterparts, and each such counterpart will be deemed to be an original and all such counterparts together
will constitute one agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendments</U>. No alteration, modification or other change to this Agreement will be binding on the parties
except upon execution of a written amendment approved and signed by officers of CE3 and Sponsor. Any alteration, modification or other change to a PSO will require, to the extent required pursuant to such PSO, execution of either a change order (in
a form mutually agreed upon by Sponsor and CE3), an amendment, or other written authorization, in accordance with the terms and conditions set forth in each PSO. Change orders and/or amendments will be executed by authorized representatives of CE3
and Sponsor. Each change order or amendment executed in accordance with this section 14.9 will be deemed to be incorporated into the applicable PSO. Any amendment or change order will become effective only upon execution thereof, unless the
amendment or change order specifically sets forth a different effective date. Both parties agree to act in good faith to promptly identify, review and execute amendments and change orders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Invalidity/Waiver</U>. The terms of this Agreement will be severable so that if any term, clause, or
provision hereof is deemed invalid or unenforceable for any reason, such invalidity or unenforceability will not affect the remaining terms, clauses and provisions hereof, which will continue with full force and effect. The waiver by either party
hereto of any breach of the terms and conditions hereof will not be considered a modification of any provision, nor will such waiver act to bar the enforcement of any subsequent breach. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Entire Agreement</U>. This Agreement (including all PSOs and any other appendices, attachments, exhibits
and/or purchase orders) constitutes the entire agreement between the parties with respect to the subject matter contained herein, and this Agreement supercedes all prior or existing understandings or agreements, written and oral, between the parties
with respect to the subject matter contained herein. The parties intend for this Agreement to be a complete statement of the terms of their agreement, and no change or modification of any of the provisions of this Agreement will be effective unless
it is in writing and signed by duly authorized representatives of CE3 and Sponsor. In the event of a conflict between the terms of this Agreement and any PSO, appendix, attachment, exhibit or purchase order entered into between the parties, the
terms of the Agreement will govern, unless the PSO, appendix, attachment, exhibit or purchase order expressly states that it or a provision therein will govern notwithstanding a contrary provision contained in this Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Agreement to be duly executed as of the Effective Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CE3 Inc.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Silverback Therapeutics</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:8.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Digitally signed by Timothy Garrelts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:8.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: 2020.01.21 11:54:22 -05&#146;00&#146;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: <I>/s/ Timothy Garrelts</I> <B><I></I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Operating
Officer</I></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">By: <I><U>/s/ Jeffrey C.
Pepe&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Timothy Garrelts <B><I></I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name: Jeffrey C. Pepe</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: Chief Operating Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title:&nbsp;SVP, General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date<B>:</B>
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Date: January 21, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attachments: Exhibit A (Sample Project Specification Order)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential Information Omitted</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3-SBT.MSA.Final.200121</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 10 of 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Silverback Therapeutics</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT A </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Sample Project Specification Order) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PROJECT SPECIFICATION ORDER EFFECTIVE DATE XXX </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TO MASTER SERVICES AGREEMENT </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BETWEEN CE3, INC. AND SPONSOR NAME </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PROJECT NAME: XXX </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS Project Specification
Order (&#147;PSO&#148;) is made and entered into as of DATE by and between CE3 INC. (&#147;CE3&#148;) and Sponsor Name (&#147;Sponsor&#148;). Capitalized terms used herein and not defined will have the meanings ascribed to them in the Master
Services Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, CE3 and Sponsor have entered into a Master Services Agreement effective DATE (the &#147;Master
Agreement&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, pursuant to the Master Agreement, CE3 has agreed to perform certain Services in accordance with PSOs from time to
time entered into by the parties, as provided in the Master Agreement, and Sponsor and CE3 now desire to enter into such a PSO; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
Sponsor desires that CE3 provide certain certain Services related to the investigational drug referred to as <I>XXX</I>, in accordance with the Study Protocol # XXX entitled, &#147;STUDY TITLE&#148; (the &#147;Study&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the mutual covenants contained herein and intending to be legally bound, the parties hereby agree as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Project Description</U>. CE3 will perform services in accordance with the scope of services affixed hereto
and made a part here of as Exhibit A and any other documents attached to this PSO (the &#147;Project&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:5%; font-size:10pt; font-family:Times New Roman">CE3 and Sponsor Project Contacts: XXX </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Transfer of Obligations</U>. Pursuant to 21 CFR 312.52, Sponsor hereby transfers to CE3 all of the
obligations set forth in the Transfer of Obligations form attached hereto and made a part here of as Exhibit C. CE3 agrees to perform the transferred obligations. Any responsibilities not specifically set forth in Exhibit C as transferred to CE3
will remain the responsibility of Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Project Timeline/Duration</U>. It is anticipated that the Project duration will be approximately XX months.
The parties agree that any delay by Sponsor in taking any action or in delivering any documents, data, and/or records that the parties agree is required in order for CE3 to properly perform services hereunder will extend any affected dates or time
intervals set forth in the project timeline by the length of any such delay. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Compensation and Payment Schedule</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Project Budget</U>. For performance of the project in accordance with the Scope of Services, Sponsor will
pay CE3 Service Fees and Pass-Through costs (&#147;Total Project Cost&#148;) in accordance with the Project Budget affixed hereto and made part hereof as Exhibit B. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment Schedule for CE3 Services</U>. The amounts set forth in the Project Budget will be paid upon
Sponsor&#146;s receipt of an invoice from CE3 in a frequency no greater than one invoice per month. CE3 will invoice on a time and materials basis. Upon execution of this PSO, Sponsor will pay CE3 a Startup Payment in the amount of XXX (#) percent
(or $XXXX) of the Service fees as stated in the Project Budget. The Startup Payment will be reconciled against and subtracted from the final Project payment(s). Any change to the Project Assumptions, and/or Scope of Services, which will increase or
decrease the Project Budget will be handled in accordance with section 5 of this PSO. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3-SBT.MSA.Final.200121</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 11 of 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Silverback Therapeutics</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment Schedule for Pass-through Costs</U>. Upon execution of this PSO, Sponsor will pay CE3 an initial
payment of $XXXX to cover a portion of the pass-through costs stated in the Project Budget. Beginning [***] after this initial payment, CE3 will forecast the projected pass-through costs for the next two month period and invoice Sponsor if
insufficient funds remain from the previous (initial) payment. This process will be repeated <FONT STYLE="white-space:nowrap">bi-monthly</FONT> thereafter until study completion. CE3 will provide Sponsor with a final reconciliation of pass-through
costs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Changes to Project Budget</U>. Sponsor will not be liable for payment of any fees incurred by CE3 in excess
of the &#147;Total Project Cost&#148; as defined in Exhibit B except pursuant to an amendment or other written agreement executed by Sponsor and CE3 in accordance with the provision of section 5 of this PSO. CE3 will act in good faith to promptly
identify any changes in the Project, will track all changes, related costs and will notify Sponsor as soon as the change to the Project Budget is known. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Invoice and Payment Instructions</U>. If required for payment, Sponsor will provide CE3 with a purchase
order (&#147;PO&#148;) shortly following execution of this PSO. CE3 will submit invoices and supporting documentation to Sponsor, which will include the PO number (if applicable), invoice amounts and associated description of services. CE3 will
submit invoices to the following address, or such other address as Sponsor may subsequently designate by notice. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Sponsor Name </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">AP Address </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Attn: Accounts Payable </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">All
payments to CE3 will be sent to the following address or to such other address as CE3 may subsequently designate by notice: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">CE3 Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">246 Goose Lane, Suite 202 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Guilford, Ct 06437 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Attn:
Accounts Receivable </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Or Via ACH </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Project Changes</U>. No alteration, modification, amendment or change order to this PSO will be binding upon
the parties unless written approval is granted by Sponsor and/or CE3 in accordance with the provisions of section 1.2 of the Master Agreement. Upon completion of the Project, Sponsor and CE3 will review a final reconciliation and negotiate in good
faith any payments or reimbursements are due to either party before final payment will be made to CE3. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Term and Termination</U>. The term of this PSO will commence on the Effective Date and will continue until
the Project completion provided, however, Sponsor may terminate this PSO or CE3&#146;s participation in the Project in whole or in part prior to the completion of the Project upon 30 days written notice. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Incorporation by Reference; Conflict</U>. The provisions of the Master Agreement are incorporated by
reference into and made a part this PSO. In the event of a conflict between the terms and conditions of this PSO and those of the Master Agreement, the terms of the Master Agreement will take precedence and control over those of this PSO.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Certain Confidential Information Omitted</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3-SBT.MSA.Final.200121</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 12 of 13</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Silverback Therapeutics</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this PSO to be duly executed as of the Effective Date.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Sponsor Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>CE3, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">By:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>SAMPLE LIST OF EXHIBITS ATTACHED TO EACH PROJECT SPECIFICATION ORDER</U>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXHIBIT A: SCOPE OF SERVICES </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXHIBIT B: PROJECT BUDGET </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXHIBIT C: TRANSFER OF OBLIGATIONS FORM </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CE3-SBT.MSA.Final.200121</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 13 of 13</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>15
<FILENAME>filename15.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.12 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I)&nbsp;NOT MATERIAL AND (II)&nbsp;WOULD
BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CELL LINE LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Cell Line License Agreement (&#147;Agreement&#148;), effective as of 11&nbsp;October 2019 (&#147;EFFECTIVE DATE&#148;), is entered and made by and
between <B>WuXi Biologics (Hong Kong) Limited</B>, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (&#147;WuXi Biologics&#148;) and <B>Silverback Therapeutics, Inc.</B>, having its principal place of
business at 500Fairview Ave. N #600, Seattle, WA 98109 (&#147;Licensee&#148;). WuXi Biologics and Licensee may bereferred to herein individually as a &#147;Party&#148; and collectively as the &#147;Parties.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Definitions</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Affiliate</B>&#148; of a person means any other person that directly or indirectly Controls, is
Controlled by, or is under common Control with, the person. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Client Product</B>&#148; means [***] of interest to Licensee, which is designated by the Licensee to
be produced by the Licensed Cell Line.Each different Client Product covered under this Agreement shall be specified in Appendix I. An amendment to this Agreement is required for each new Client Product produced by the Licensed Cell Line.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Confidential Information</B>&#148; of a Party (the &#147;<B>Disclosing Party</B>&#148;) means all
information and materials disclosed by or on behalf of the Disclosing Party to the other Party (the &#147;<B>Receiving Party</B>&#148;) or its Related Persons (defined below) in connection with this Agreement. Confidential information shall be
identified as confidential in writing or, if disclosed verbally or by observation, summarized in writing and submitted to the Receiving Party within [***] of the oral or visual disclosure thereof; provided, however, information need not be labeled
or marked &#147;confidential&#148; to be deemed Confidential Information hereunder, if under the circumstances it is, or should be, understood to be confidential. The Confidential Information of both Parties includes the financial terms of this
Agreement, and the nature of any dispute and the outcome of any arbitration proceedings arising out of or in connection with this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Construct</B>&#148; means a [***] developed by WuXi Biologics that is used for delivering genetic code
and for transfecting </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 of 12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g67046dsp228.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and/or transforming the Host Cell Line for purposes of creating the Licensed Cell Line. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Control</B>&#148; over an entity means (a)&nbsp;owning 50% or more of the voting securities or other
ownership interests of such entity or (b)&nbsp;having the power to direct the management or policies of such entity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Drug Product</B>&#148; means the final dosage form which contains Client Product produced by the
Licensed Cell Line, in association with other active or inactive ingredients. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Drug Substance</B>&#148; means bulk Client Product produced by the Licensed Cell Line, which has not
yet been packaged into its final dosage form. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Host Cell Line</B>&#148; means the proprietary cell line developed by WuXi Biologics,and designated by
WuXi Biologics as the [***], that is used in the manufacture and production of Client Products for clinical trials and commercial purposes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Licensed Cell Line</B>&#148; means a transformed or transfected (using WuXi Biologics&#146;
Construct(s)) version of the Host Cell Line that produces the Client Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means any <FONT
STYLE="white-space:nowrap">know-how</FONT> and <FONT STYLE="white-space:nowrap">non-public</FONT> information owned or controlled by Wuxi Biologics that is used or incorporated in the Process, and that is necessary to operate the Process as
described m the Technology Transfer Package. The word &#147;control&#148; when used in connection with Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> includes both exclusively and <FONT STYLE="white-space:nowrap">non-exclusively</FONT>
licensed <FONT STYLE="white-space:nowrap">know-how</FONT> and <FONT STYLE="white-space:nowrap">non-public</FONT> information, as well a right of WuXi Biologics to transfer such <FONT STYLE="white-space:nowrap">know-how</FONT> and <FONT
STYLE="white-space:nowrap">non-public</FONT> information to Licensee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Materials</B>&#148; means the biological materials, including the Licensed Cell Line, provided to
Licensee pursuant to the license granted under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Media and Feeds</B>&#148; means any proprietary media and feeds used in the Process.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Process</B>&#148; means a process for manufacture of Client Product utilizing Licensed <FONT
STYLE="white-space:nowrap">Know-How,</FONT> Materials and Media and Feeds as described in the Technology Transfer Package. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2 of 12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g67046dsp228.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Regulatory Approval</B>&#148; means any and all approvals (including pricing and reimbursement
approvals), product and establishment licenses, registrations or authorizations of any kind of a Regulatory Authority necessary for the development, clinical testing, manufacture, quality testing, supply, use, storage, importation, export,
transport, marketing and sale of a Client Product (or any component thereof) for use in any country or other jurisdiction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Related Persons</B>&#148; means a Party&#146;s Affiliates and their respective directors, officers,
employees and agents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Research Cell Bank</B>&#148; is a [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Technology Transfer Package</B>&#148; means the information and data to be provided to Licensee
describing the Process and WuXi Biologics&#146;, Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> Materials and Media and Feeds for manufacture of Client Product using the Licensed Cell Line and/or the Process, . </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Third Party</B>&#148; means any person other than the Parties to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Third Party Manufacturer</B>&#148; means (i)&nbsp;a Third Party whose primary business is contract
manufacturing, or (ii)&nbsp;a Third Party who has a contractual arrangement with Licensee or with a sublicensee of Licensee that includes manufacturing of Client Product and/or Drug Product by such Third Party for Licensee or such sublicensee.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>License</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">WuXi Biologics hereby grants to Licensee and its Affiliate a
<FONT STYLE="white-space:nowrap">non-exclusive,worldwide</FONT> license, with the right to grant sublicenses as provided in Section&nbsp;2.3,to use: (a)&nbsp;Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> in relation to the Licensed Cell
Line, (b)&nbsp;to use the Licensed Cell Line, Materials, Media and Feeds, and (c)&nbsp;to operate the Process, including the following licensed activities: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to make, have made, import and use any listed Client Product; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to make, have made, use, sell, have sold, offer for sale, import, keep and otherwise deal in Drug Substance and
Drug Product for any and all purposes. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 of 12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g67046dsp228.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Licensee or its Affiliates may contract with a Third Party Manufacturer forthe limited purpose of
manufacturing Client Product on behalf of the Licensee orits Affiliates, provided that, such Third Party Manufactures are bound by thecontract to comply with the terms of this Agreement, and that the Licensee or its Affiliates will remain liable for
any Third Party Manufacturers&#146; breach of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, a Third Party Manufacturer cannotmanufacture Client Product, Drug Substance or Drug
Product utilizing the Licensed Cell Line and Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> without first being contracted with a Licensee, its Affiliates or sublicensee. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Third Party that has been granted a sublicense cannot grant, issue or transfer a sublicense to another Third
Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms and conditions of this Agreement, Licensee shall have theright to grant sublicenses to
Third Parties for the rights granted to Licenseeunder this Agreement. Each sublicense agreement shall be in writing and providethat the applicable sublicensee is bound by all applicable terms and conditions ofthis Agreement, and Licensee shall
remain liable for any sublicensee&#146;s breach ofthis Agreement. Licensee shall inform WuXi Biologics in writing any and all such sublicenses. [***]. Licensee shall provide WuXi Biologics at least [***] prior written notice if Licensee or its
Affiliates intend to grant sublicense to a Third Party under this agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as expressly provided in this Agreement, nothing in this Agreement shallbe deemed to have granted
Licensee (by implication, estoppel or otherwise) anyright, title, license or other interest in or with respect to any intellectual property, <FONT STYLE="white-space:nowrap">Know-How</FONT> or information owned or controlled by WuXi Biologics.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This license starts (the &#147;Commencement Date&#148;) from the date WuXi Biologics completes transfection of
the Host Cell Line to generate the Client Licensed Cell Line. Invoicing of License fees will commence from the date WuXi Biologics completes Research Cell Bank generation from the Licensed Cell Line. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Transfer of Materials and Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></U></B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">WuXi Biologics shall disclose and make available, and shall cause its Affiliates to discloseand make available, to
Licensee, its Affiliates, or any one or more of its Third Party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4 of 12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g67046dsp228.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Manufacturers designated by Licensee, all Materials, Confidential Information, andLicensed <FONT STYLE="white-space:nowrap">Know-How</FONT> owned or controlled by WuXi Biologics as of the
Commencement Date, that is necessary or reasonably useful for Licensee and Third Party Manufacturersto operate the Process as described in the Technology Transfer Package. The Partiesshall agree in writing to a schedule for such transfer of the
Materials and Licensed Know-How. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>License Fee</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As consideration for the license granted in Section&nbsp;2 of this Agreement, and therepresentation and warranty set forth in Section&nbsp;10
of this Agreement, Licensee agreesto pay WuXi Biologics as follows: (1)&nbsp;USD $[***] for a License to manufacture a singletype of protein for use in a single Product; and (2)&nbsp;an additional <FONT STYLE="white-space:nowrap">one-time</FONT>
payment ofUSD $[***] for any type of protein or proteins for use in any Client Product or Productsin the event that Licensee previously paid USD $[***] under subsection (1)&nbsp;above.The total amount to be paid under this section shall not exceed
USD $[***]. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Cell Line Milestones.</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If Client manufactures all of its commercial supplies of the Client Product by utilizing a manufacturer other than Provider or its Affiliates
(&#147;Third Party Manufacturer&#148;) utilizing the [***] License, Client shall pay to Provider the following Milestones: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">First commercial sale: USD $[***] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">First Calendar Year in which annual Net Sales of USD $[***] are achieved: USD $[***] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">First Calendar Year in which annual Net Sales of USD $[***] are achieved: USD $[***] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">First Calendar Year in which annual Net Sales of USD $[***] are achieved: USD $[***] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">First Calendar Year in which annual Net Sales of USD $[***] are achieved: USD $[***] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Payment Terms</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Licensee shall pay WuXi Biologics&#146; undisputed invoice(s) within [***] ofreceipt by Licensee. Such payments will be made by wire transfer
to the accountdesignated by WuXi Biologics. Invoices must be submitted, and payment must bemade, without <FONT STYLE="white-space:nowrap">set-off</FONT> or other deduction of any nature. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 of 12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g67046dsp228.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Bank Account Details</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Unless the Parties otherwise mutually agree in writing, and such mutual agreement isset forth in a particular invoice, Licensee shall pay each
invoice in USD by wire transferto the account designated by WuXi Biologics. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Restriction</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Licensee agrees that no attempt will be made by or on behalf of Licensee to modify orreverse engineer the Licensed Cell Line or attempt to
reverse engineer, recreate orassemble the Construct(s). Licensee shall only use the Licensed Cell Line in the way as permitted by this Agreement and shall not use or have used the Licensed Cell Line forany purpose other than operating the Process,
the manufacture of Client Product, Drug Substance and Drug Product, and for other purposes reasonably related to securing Regulatory Approval for the Client Product and/or Drug Product. Licensee shall nottransfer the Licensed Cell Line to any Third
Party except to a permitted sublicensee, as described in Section&nbsp;2 above. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Indemnity</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Licensee agrees to indemnify, hold harmless and defend WuXi Biologics, itsAffiliates, and their respective
directors, officers, employees and agentsharmless from and against any and all liabilities and damages (includingreasonable attorneys&#146; fees) resulting from any and all claims from any ThirdParty (&#147;Claims&#148;) to the extent arising from
the use of the Client Product, Drug Substance or Drug Product by Licensee; provided that Licensee shall have no obligation to indemnify any such Claims that arise from WuXi Biologics&#146; (i)negligence or intentional misconduct in connection with
the Licensed Cell Line(ii) material breach of this Agreement (including the representations andwarranties set forth in Section&nbsp;10); or (iii)&nbsp;Host Cell Line components of theLicensed Cell Line or any Media and Feeds. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">WuXi Biologics shall defend, indemnify and hold Client, any
<FONT STYLE="white-space:nowrap">sub-Licensees,Third</FONT> Party Manufacturers, and Client Related Persons harmless from andagainst Losses resulting from Claims arising out of or related to infringement ofany Intellectual Property rights in
connection with this License and that aresolely based on Licensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Representations and Warranties</U></B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6 of 12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g67046dsp228.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">10.1 WuXi Biologics represents and warrants that: (i)&nbsp;it is a corporation dulyorganized
validly existing and in good standing under the laws of the Hong Kong; (ii)&nbsp;the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of WuXi Biologics; (iii)&nbsp;the
performance of WuXi Biologics&#146; obligations under this Agreement will not conflict with its charter documentsor result in a material breach of any agreements, contracts or other arrangements towhich it is a party; (iv)&nbsp;WuXi Biologics will
not, before Termination of this Agreement, enter into any agreements, contracts or other arrangements that would be materiallyinconsistent with its obligations under this Agreement; (v)&nbsp;WuXi Biologics has sufficient facilities, experienced
personnel and other capabilities reasonably suited to enable it to perform its obligations under this Agreement; and (vi)&nbsp;WuXi Biologics has the right togrant the licenses or sublicenses, as the case may be, therefor granted under this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">10.2 Licensee represents and warrants that: (i)&nbsp;it is a corporation duly organizedvalidly existing and in good standing
under the laws of Delaware; (ii)&nbsp;the execution,delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Licensee; (iii)&nbsp;the performance of Licensee&#146;s obligationsunder this
Agreement will not conflict with its charter documents or result in a material breach of any agreements, contracts or other arrangements to which it is a party; (iv)&nbsp;Licensee has sufficient facilities, experienced personnel and other
capabilitiesreasonably suited to enable it to perform its obligations under this Agreement; and (v)&nbsp;Licensee will not, before Termination of this Agreement, enter into any agreements,contracts or other arrangements that would be materially
inconsistent with its obligations under this Agreement </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">10.3 Disclaimer of Warranties. THE LICENSED
<FONT STYLE="white-space:nowrap">KNOW-HOW,</FONT> AND LICENSED CELL LINES ARE PROVIDED AND LICENSED TO LICENSEE &#147;AS IS&#148;, AND WUXI BIOLOGICS AND ITS RESPECTIVE AFFILIATES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY
KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT THERETO OR TO THE PRODUCTS OR WUXI BIOLOGICS TECHNOLOGY, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF THE RIGHTS LICENSED HEREUNDER, OR
NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Confidentiality</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">11.1 Subject to the exceptions listed below, during the term of this Agreement andfor [***] thereafter, the Receiving Party shall, and shall
ensure that its Related Persons will, (a)&nbsp;maintain the Disclosing Party&#146;s Confidential Information in confidence,(b) not use such Confidential Information other than in connection with this Agreement,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7 of 12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g67046dsp228.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
and (c)&nbsp;not disclose such Confidential Information to any Third Party other than (i)&nbsp;thoseof its Related Persons that have a need to know such Confidential Information inconnection with
the Activities conducted pursuant to the Agreement and are obligatedto maintain such Confidential Information in confidence and (ii)&nbsp;to the extent requiredby applicable law or judicial order, or (iii)&nbsp;to the extent reasonably necessary
toprosecute or defend litigation or arbitration in relation to this Agreement, and, in eithercase, only after the Receiving Party gives the Disclosing Party prompt advance writtennotice of such requirement and reasonably cooperates with the
Disclosing Party&#146;s effortsto limit or avoid such disclosure, to seek a protective order or secure confidentialtreatment of the Confidential Information, and/or to seek any other remedies availableto the Disclosing Party at law or in equity.
Notwithstanding the foregoing, theexistence of this Agreement and its <FONT STYLE="white-space:nowrap">non-technical</FONT> terms may be disclosed confidentiallyin connection with a potential financing or acquisition or in discussion with a
potential acquirer of Client Product </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">11.2 The Receiving Party&#146;s obligations set forth in Section&nbsp;11.1 do not apply
toConfidential Information if (a)&nbsp;the information is public knowledge or becomes public knowledge after disclosure through no act or omission of the Receiving Party or any ofits Related Persons, (b)&nbsp;the information can be shown by the
Receiving Party to havebeen in its possession prior to disclosure, (c)&nbsp;the information was rightfully received ona <FONT STYLE="white-space:nowrap">non-confidential</FONT> basis from a Third Party that was not obligated to maintain the
information in confidence, or (d)&nbsp;the Receiving Party can show that equivalentinformation was developed independently by the Receiving Party without reference tothe Disclosing Party&#146; Confidential Information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">11.3 Licensee may disclose the Confidential Information of WuXi Biologics to aThird Party for the purpose of exercising Licensee&#146;s license
rights hereunder (including disclosure to potential Third Party sublicensees), provided that Licensee shall, prior tosuch disclosure, ensure that each Third Party to which disclosure is to be made is madeaware of the obligations contained in this
Agreement and agrees to be subject toobligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> no less onerous than those contained in this Agreement. Any breaches of the obligations of confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> contained inthis Agreement by such Third Party shall be treated as a breach of such obligations by Licensee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">11.4 Notwithstanding anything to the contrary in this Agreement, a Party maydisclose this Agreement and its terms, and material developments or
materialinformation generated under this Agreement, in securities filings with the U.S. Securitiesand Exchange Commission (or equivalent foreign agency) and any rules of stockexchanges where the Parties may be listed to the extent required by
applicable law after </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8 of 12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g67046dsp228.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
complying with the procedure set forth in this Section&nbsp;11.4. In such event, the Partyseeking such disclosure will prepare a draft confidential treatment request andproposed redacted version
of this Agreement to request confidential treatment for this Agreement, and the other Party will promptly give its input in a reasonable manner inorder to allow the Party seeking disclosure to file its request within the timelinesproscribed by
applicable laws and regulations. The Party seeking such disclosureshall exercise commercially reasonable efforts to obtain confidential treatment of this Agreement from the U.S. Securities and Exchange Commission (or equivalent foreignagency) as
represented by the redacted version reviewed by the other Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">11.5 The provisions of this Section&nbsp;11 shall survive termination or
expiry of this Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Termination</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">12.1. <U>Voluntary Termination by Licensee</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Licensee shall have the right to terminate this Agreement upon at least six (6)&nbsp;monthsprior written notice to WuXi Biologics, and upon
payment of all amounts due to WuXiBiologics through such termination effective date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">12.2 <U>Termination for Default</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Nonpayment</U>. In the event Licensee fails to pay any amounts rightfully due and payable to WuXi Biologics hereunder, and fails to make
such payments within thirty (30)days after receiving written notice of such failure, WuXi Biologics may terminate this Agreement upon written 45 days written notice to Licensee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Material Breach</U>. In the event a Party commits a material breach of itsobligation under this Agreement and fails to cure that breach
within thirty (30)&nbsp;daysafter receiving written notice thereof, a Party may terminate this Agreementimmediately upon written notice to the other Party. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Miscellaneous.</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">13.1 <U>Assignment</U>. This Agreement may not be assigned or otherwise transferredby either Party without the prior written consent of the
other Party, which consent shallnot be unreasonably withheld, conditioned or delayed; <I>provided, however</I>, that a Partymay, without such consent, assign this Agreement in its entirety (a)&nbsp;to an Affiliate, or (b)to a Third Party in
connection with a merger, acquisition, consolidation or a sale </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9 of 12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g67046dsp228.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
involving all or substantially all of the assets or business of such Party. Any attempted assignment or transfer in violation of this Section&nbsp;13.1 shall be void. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">13.2 <U>Regulatory Assistance</U>. WuXi Biologics will provide assistance to Licensee,and any sublicensee, in respect of Licensee&#146;s or
such sublicensee&#146;s regulatory filingactivities for the Client Product and/or Drug Product, subject to agreement ofreasonable commercial terms for provision of such assistance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">13.3 <U>Governing Law</U>. The laws of the state of New York, without giving effect toprinciples of conflict of laws, govern all matters
relating to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">13.4 <U>Arbitration</U>. The Parties shall engage in good faith consultation to resolveany dispute,
controversy, or claim arising out of, relating to, or in connection with this agreement, including with respect to its formation, applicability, breach, termination,validity or enforceability. Such consultation will begin immediately after one party
has delivered to the other party a request for consultation. If the dispute, controversy, orclaim cannot be resolved within [***] days following the date on which the requestfor consultation is delivered, then it will be finally settled by
arbitration in accordancewith this Section&nbsp;13. Any dispute arising or in connection with this Agreement shall be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Proceduresin effect at the time of applying for
arbitration in New York. Arbitral award is final andbinding upon both parties. The arbitration wilt be conducted in the English language bya single arbitrator and the arbitrator must be fluent in the English language. Thearbitration proceedings will
be confidential, and the arbitrator may issue appropriate protective orders in accordance with JAMS&#146;s arbitration rules then in effect to safeguardeach party&#146;s Confidential Information. During the course of arbitration, the Parties shall
continue to implement the terms of this Agreement. The arbitral award will be in writing,state the reasons for the award, and be final and binding upon the parties. Judgementupon the award may be entered by any court having jurisdiction thereof over
therelevant party or its assets. Notwithstanding the foregoing, each Party has the right to institute an action in a court of proper jurisdiction for injunctive or other equitable relief pending a final decision by the arbitrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">13.5 <U>Counterparts</U>. This Agreement may be executed in two (2)&nbsp;or morecounterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile, .pdf or other electronically transmitted signatures and such signatures shallbe deemed to bind each Party hereto as if they were the
original signatures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10 of 12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g67046dsp228.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties hereto have caused this AGREEMENT to be duly executed as of the Effective
Date set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>WuXi Biologics (Hong Kong) Limited</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Silverback Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Chris Chen</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Peter A. Thompson, MD, FACP</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Print&nbsp;Name:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chris Chen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Name:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Peter A. Thompson, MD, FACP</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g67046g20z22.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right">&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11 of 12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g67046dsp228.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Appendix I </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>List of Service Agreements for Licensee Products </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Licensee Product Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Contract (e.g., Master Service Agreements)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Effective Date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right"><B>***Certain Confidential Information Omitted</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12 of 12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g67046dsp228.jpg" ALT="LOGO">
</P></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>16
<FILENAME>filename16.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.13 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LOAN AND SECURITY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS LOAN AND SECURITY AGREEMENT (this &#147;<B>Agreement</B>&#148;) dated as of November&nbsp;21, 2016 (the &#147;<B>Effective
Date</B>&#148;) between SILICON VALLEY BANK, a California corporation (&#147;<B>Bank</B>&#148;), and SILVERBACK THERAPEUTICS, INC., a Delaware corporation (&#147;<B>Borrower</B>&#148;), provides the terms on which Bank shall lend to Borrower and
Borrower shallrepay Bank. The parties agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1. <U>ACCOUNTING AND OTHER TERMS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounting terms not defined in this Agreement shall be construed following GAAP. Calculations and determinations must be made following GAAP.
Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in Section&nbsp;13. All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such
terms are defined therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2. <U>LOAN AND TERMS OF PAYMENT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B>Promise to Pay</B>. Borrower hereby unconditionally promises to pay Bank the outstanding principal amount of all Credit
Extensions and accrued and unpaid interest thereon as and when due in accordance with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1.1</B> <B>Term Loan
Advances</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Availability</U>. Subject to the terms and conditions of this Agreement, Borrower may request that Bank make certain
term loan advances (each a &#147;<B>Term Loan Advance</B>&#148; and, collectively, the &#147;<B>Term Loan Advances</B>&#148;) from two (2)&nbsp;tranches, as described below, in multiple advances in an aggregate original principal amount not to
exceed the Term Loan Commitment, as follows: (i)&nbsp;the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) tranche shall be available to Borrower from the Effective Date through the Tranche One Commitment Termination Date in multiple
advances in the aggregate original principal amount not to exceed Three Million Five Hundred Thousand Dollars ($3,500,000) (each, a &#147;<B>Tranche One Term Loan Advance</B>&#148;), and (ii)&nbsp;provided that Borrower has achieved the Tranche Two
Milestone, the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) tranche shall be available to Borrower from the date on which Borrower achieves the Tranche Two Milestone through the Tranche Two Commitment Termination Date in the
aggregate original principal amount not to exceed One Million Five Hundred Thousand Dollars ($1,500,000) (each, a &#147;<B>Tranche Two Term Loan Advance</B>&#148;). Each Term Loan Advance, other than the final Term Loan Advance, must be in an amount
of not less than Five Hundred Thousand Dollars ($500,000). After repayment, no Term Loan Advance may be <FONT STYLE="white-space:nowrap">re-borrowed.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Repayment</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)
<U>Interest Only Payments</U>. For each Term Loan Advance, Borrower shall make monthly payments of interest-only commencing on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) calendar day of the first (1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP>) month following the month in which the Funding Date occurs with respect to such Term Loan Advance and continuing thereafter during the Interest-Only Period on the first (1st) calendar day of each
successive month. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Principal and Interest Payments. For each Term Loan Advance, commencing on the first
(1st) calendar day of the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) month following the Interest-Only Period (the &#147;<B>Conversion Date</B>&#148;) and continuing on the first
(1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) calendar day of each month thereafter, Borrower shall make thirty (30)&nbsp;consecutive equal monthly payments of principal each in an amount which would fully amortize the outstanding Term
Loan Advances, as of the Conversion Date, over the Term Loan Repayment Period, plus accrued interest (&#147;<B>Term Loan Scheduled Payment</B>&#148;). All unpaid principal and accrued and unpaid interest on the Term Loan Advances is due and payable
in full on the Term Loan Maturity Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Prepayment</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Mandatory Prepayment Upon an Acceleration</U>. If the Term Loan Advances are accelerated following the occurrence of an Event of
Default or otherwise, Borrower shall immediately pay to Bank an amount equal to the sum of (A)&nbsp;all accrued and unpaid interest with respect to the Term Loan Advances through the date the prepayment is made, plus (B)&nbsp;all unpaid principal
with respect to the Term Loan Advances, plus (C)&nbsp;the Final Payment, plus (D)&nbsp;the Make-Whole Premium, plus (E)&nbsp;all other sums, if any, that shall have become due and payable hereunder in connection with the Term Loan Advances,
including interest at the Default Rate with respect to any past due amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Permitted Prepayment</U>. So long as an Event of
Default has not occurred and is not continuing, Borrower shall have the option to prepay all, but not less than all, of the Term Loan Advances advanced by Bank under this Agreement, provided Borrower(A) delivers written notice to Bank of its
election to prepay the Term Loan Advances at least thirty (30)&nbsp;days prior to such prepayment, and (B)&nbsp;pays, on the date of such prepayment (1)&nbsp;all accrued and unpaid interest with respect to such Term Loan Advances through the date
the prepayment is made, plus (2)&nbsp;all unpaid principal with respect to such Term Loan Advances, plus (3)&nbsp;the Final Payment, plus (4)&nbsp;the Make-Whole Premium, plus (5)&nbsp;all other sums, if any, that shall have become due and payable
hereunder in connection with the Term Loan Advances, including interest at the Default Rate with respect to any past due amounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B>Payment of Interest on the Credit Extensions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Interest Rate</U>. Subject to Section&nbsp;2.2(b), the principal amount outstanding for each Term Loan Advance shall accrue interest at
a per annum rate equal to the greater of (i)(A) the Prime Rate fixed as of the Funding Date of the applicable Term Loan Advance, minus(B) one and three-quarters of one percent (1.75%) or (ii)&nbsp;one and three-quarters of one percent (1.75%). All
interest shall be payable monthly in accordance with Section&nbsp;2.2(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Default Rate</U>. Immediately upon the occurrence and
during the continuance of an Event of Default, Obligations shall bear interest at a rate per annum which is five percent (5.0%) above the rate that is otherwise applicable thereto (the &#147;<B>Default Rate</B>&#148;), Fees and expenses which are
required to be paid by Borrower pursuant to the Loan Documents (including, without limitation, Bank Expenses) but are not paid when due shall bear interest until paid at a rate equal to the highest rate applicable to the Obligations. Payment or
acceptance of the increased interest rate provided in this Section&nbsp;2.2(b) is not a permitted alternative to timely </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of Bank. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Payment; Interest Computation</U>. Interest is payable monthly on the first(1st) calendar day of each month and shall be computed on
the basis of a three hundred <FONT STYLE="white-space:nowrap">sixty(360)-day</FONT> year for the actual number of days elapsed. In computing interest, (i)&nbsp;all payments received after 12:00 p.m. Pacific time on any day shall be deemed received
at the opening of business on the next Business Day, and (ii)&nbsp;the date of the making of any Credit Extension shall be included and the date of payment shall be excluded; provided, however, that if any Credit Extension is repaid on the same day
on which it is made, such day shall be included in computing interest on such Credit Extension. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Fees</B>. Borrower shall
pay to Bank: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Good Faith Deposit</U>. Borrower has paid to Bank a deposit of Fifteen Thousand Dollars ($15,000) (the &#147;<B>Good
Faith Deposit</B>&#148;) to initiate Bank&#146;s due diligence review process. Any portion of the Good Faith Deposit not utilized to pay Bank Expenses on the Effective Date will be returned to the Borrower&#146;s Designated Deposit Account; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Final Payment</U>. The Final Payment due on the earlier of (i)&nbsp;the Term Loan Maturity Date, (ii)&nbsp;the final payment date of
each Term Loan Advance, or (iii)&nbsp;at the time of a prepayment pursuant to the terms of Sections 2.1.1(c)(i) and 2.1.1(c)(ii); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Make-Whole Premium</U>. The Make-Whole Premium when due pursuant to the terms of Sections 2.1.1(c)(i) and 2.1.1(c)(ii); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
<U>Bank Expenses</U>. All Bank Expenses (including reasonable attorneys&#146; fees and expenses for documentation and negotiation of this Agreement, which fees for documentation and negotiation of this Agreement will not exceed Fifteen Thousand
Dollars ($15,000) as of the Effective Date provided negotiations are not protracted) incurred through and after the Effective Date, when due (or, if there is no stated due date, upon demand by Bank). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Fees Fully Earned</U>. Unless otherwise provided in this Agreement or in a separate writing by Bank, Borrower shall not be entitled to
any credit, rebate, or repayment of any fees earned by Bank pursuant to this Agreement notwithstanding any termination of this Agreement or the suspension or termination of Bank&#146;s obligation to make loans and advances hereunder. Bank may deduct
amounts owing by Borrower under the clauses of this Section&nbsp;2.3 pursuant to the terms of Section&nbsp;2.3(d). Bank shall provide Borrower written notice of deductions made from the Designated Deposit Account pursuant to the terms of the clauses
of this Section&nbsp;2.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4</B> <B>Payments; Application of Payments; Debit of Accounts</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All payments to be made by Borrower under any Loan Document shall be made in immediately available funds in Dollars, without setoff or
counterclaim, before 12:00 p.m. Pacific time on the date when due. Payments of principal and/or interest received after 12:00 p.m. Pacific time are considered received at the opening of business on the next Business Day. When a payment is due on a
day that is not a Business Day, the payment shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
due the next Business Day, and additional fees or interest, as applicable, shall continue to accrue until paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Bank has the exclusive right to determine the order and manner in which all payments with respect to the Obligations may be applied.
Borrower shall have no right to specify the order or the accounts to which Bank shall allocate or apply any payments required to be made by Borrower to Bank or otherwise received by Bank under this Agreement when any such allocation or application
is not specified elsewhere in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Bank may debit any of Borrower&#146;s deposit accounts, including the Designated
Deposit Account, for principal and interest payments or any other amounts Borrower owes Bank when due. These debits shall not constitute a <FONT STYLE="white-space:nowrap">set-off.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5</B> <B>Withholding</B>. Payments received by Bank from Borrower under this Agreement will be made free and clear of and without
deduction for any and all present or future taxes, levies, imposts, duties, deductions, withholdings, assessments, fees or other charges imposed by any Governmental Authority (including any interest, additions to tax or penalties applicable
thereto). Specifically, however, if at any time any Governmental Authority, applicable law, regulation or international agreement requires Borrower to make any withholding or deduction from any such payment or other sum payable hereunder to Bank,
Borrower hereby covenants and agrees that the amount due from Borrower with respect to such payment or other sum payable hereunder will be increased to the extent necessary to ensure that, after the making of such required withholding or deduction,
Bank receives a net sum equal to the sum which it would have received had no withholding or deduction been required, and Borrower shall pay the full amount withheld or deducted to the relevant Governmental Authority. Borrower will, upon request,
furnish Bank with proof reasonably satisfactory to Bank indicating that Borrower has made such withholding payment; provided, however, that Borrower need not make any withholding payment if the amount or validity of such withholding payment is
contested in good faith by appropriate and timely proceedings and as to which payment in full is bonded or reserved against by Borrower. The agreements and obligations of Borrower contained in this Section&nbsp;2.5 shall survive the termination of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. <U>CONDITIONS OF LOANS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B>Conditions Precedent to Initial Credit Extension</B>. Bank&#146;s obligation to make the initial Credit Extension is subject to
the condition precedent that Bank shall have received, in form and substance reasonably satisfactory to Bank, such documents, and completion of such other matters, as Bank may reasonably deem necessary or appropriate, including, without limitation:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) duly executed original signatures to the Loan Documents; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) duly executed original signatures to the Warrant; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) duly executed original signatures to the Control Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) the Operating Documents and good standing certificates of Borrower certified by the Secretaries of State of the States of Delaware and
Washington and each other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jurisdiction in which Borrower is qualified to conduct business, each as of a date no earlier than thirty (30)&nbsp;days prior to the Effective Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) duly executed original signatures to the completed Borrowing Resolutions for Borrower; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) certified copies, dated as of a recent date, of financing statement searches, as Bank may request, accompanied by written evidence
(including any UCC termination statements) that the Liens indicated in any such financing statements either constitute Permitted Liens or have been or, in connection with the initial Credit Extension, will be terminated or released; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) the Perfection Certificate of Borrower, together with the duly executed original signature thereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) a bailee&#146;s waiver in favor of Bank for each location where Borrower maintains property with a third party, by each such third party,
together with the duly executed original signatures thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) a copy of Borrower&#146;s Registration Rights Agreement and/or
Investors&#146; Rights Agreement and any amendments thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) evidence satisfactory to Bank that the insurance policies and
endorsements required by Section&nbsp;6.5 hereof are in full force and effect, together with appropriate evidence showing lender loss payable and/or additional insured clauses or endorsements in favor of Bank; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) payment of the fees and Bank Expenses then due as specified in Section 2.3 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B>Conditions Precedent to all Credit Extensions</B>. Bank&#146;s obligations to make each Credit Extension, including the initial
Credit Extension, is subject to the following conditions precedent: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) timely receipt of an executed Payment/Advance Form; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the representations and warranties in this Agreement shall be true, accurate, and complete in all material respects on the date of the
Payment/Advance Form and on the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text
thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date, and no Event of Default shall have occurred and be
continuing or result from the Credit Extension. Each Credit Extension is Borrower&#146;s representation and warranty on that date that the representations and warranties in this Agreement remain true, accurate, and complete in all material respects;
provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Bank determines to its sole but reasonable satisfaction that there has not been a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B>Post-Closing Conditions</B>. Within ten (10)&nbsp;days after the Effective Date, Bank shall have received, in form and substance
satisfactory to Bank, a landlord&#146;s consent in favor of Bank for 500 Fairview Ave N, Seattle, Washington 98109 by the landlord thereof, together with the duly executed original signatures thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B>Covenant to Deliver</B>. Except as otherwise provided in Section&nbsp;3.3, Borrower agrees to deliver to Bank each item required
to be delivered to Bank under this Agreement as a condition precedent to any Credit Extension. Borrower expressly agrees that a Credit Extension made prior to the receipt by Bank of any such item shall not constitute a waiver by Bank of
Borrower&#146;s obligation to deliver such item, and the making of any Credit Extension in the absence of a required item shall be in Bank&#146;s sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5</B> <B>Procedures for Borrowing</B>. Subject to the prior satisfaction of all other applicable conditions to the making of a Term Loan
Advance set forth in this Agreement, to obtain a Term Loan Advance, Borrower shall notify Bank (which notice shall be irrevocable) by electronic mail, facsimile, or telephone by 12:00 p.m. Pacific time on the Funding Date of the Term Loan Advance.
Together with any such electronic or facsimile notification, Borrower shall deliver to Bank by electronic mail or facsimile a completed Payment/Advance Form executed by a Responsible Officer or his or her designee. Bank may rely on any telephone
notice given by a person whom Bank believes is a Responsible Officer or designee. Bank shall credit the Term Loan Advances to the Designated Deposit Account on the Funding Date of such Term Loan Advance. Bank may make Term Loan Advances under this
Agreement based on instructions from a Responsible Officer or his or her designee or without instructions if the Term Loan Advances are necessary to meet Obligations which have become due. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U>CREATION OF SECURITY INTEREST</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B>Grant of Security Interest</B>. Borrower hereby grants Bank, to secure the payment and performance in full of all of the
Obligations, a continuing security interest in, and pledges to Bank, the Collateral, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Borrower acknowledges that it previously has entered, and/or may in the future enter, into Bank Services Agreements with Bank. Regardless of
the terms of any Bank Services Agreement, Borrower agrees that any amounts Borrower owes Bank thereunder shall be deemed to be Obligations hereunder and that it is the intent of Borrower and Bank to have all such Obligations secured by the first
priority perfected security interest in the Collateral granted herein (subject only to Permitted Liens that are permitted pursuant to the terms of this Agreement to have superior priority to Bank&#146;s Lien in this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If this Agreement is terminated, Bank&#146;s Lien in the Collateral shall continue until the Obligations (other than inchoate indemnity
obligations) are repaid in full in cash. Upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment in full in cash of the Obligations (other than inchoate indemnity obligations) and at such time as Bank&#146;s obligation to make Credit Extensions has terminated, Bank shall, at the sole
cost and expense of Borrower, release its Liens in the Collateral and all rights therein shall revert to Borrower. In the event (x)&nbsp;all Obligations (other than inchoate indemnity obligations), except for Bank Services, are satisfied in full,
and (y)&nbsp;this Agreement is terminated, Bank shall terminate the security interest granted herein upon Borrower providing cash collateral acceptable to Bank in its good faith business judgment for Bank Services, if any. In the event such Bank
Services consist of outstanding Letters of Credit, Borrower shall provide to Bank cash collateral in an amount equal to (x)&nbsp;if such Letters of Credit are denominated in Dollars, then at least one hundred five percent (105%); and (y)&nbsp;if
such Letters of Credit are denominated in a Foreign Currency, then at least one hundred ten percent (110%), of the Dollar Equivalent of the face amount of all such Letters of Credit plus all interest, fees, and costs due or to become due in
connection therewith (as estimated by Bank in its reasonable business judgment), to secure all of the Obligations relating to such Letters of Credit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B>Priority of Security Interest</B>. Borrower represents, warrants, and covenants that the security interest granted herein is and
shall at all times continue to be a first priority perfected security interest in the Collateral (subject only to Permitted Liens that are permitted pursuant to the terms of this Agreement to have superior priority to Bank&#146;s Lien under this
Agreement). If Borrower shall acquire a commercial tort claim, Borrower shall promptly notify Bank in a writing signed by Borrower of the general details thereof and grant to Bank in such writing a security interest therein and in the proceeds
thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Bank. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B>
<B>Authorization to File Financing Statements</B>. Borrower hereby authorizes Bank to file financing statements, without notice to Borrower, with all appropriate jurisdictions to perfect or protect Bank&#146;s interest or rights hereunder, including
a notice that any disposition of the Collateral, by either Borrower or any other Person, shall be deemed to violate the rights of Bank under the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5. <U>REPRESENTATIONS AND WARRANTIES</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrower represents and warrants as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B>Due Organization, Authorization; Power and Authority</B>. Borrower is duly existing and in good standing as a Registered
Organization in its jurisdiction of formation and is qualified and licensed to do business and is in good standing in any jurisdiction in which the conduct of its business or its ownership of property requires that it be qualified except where the
failure to do so could not reasonably be expected to have a Material Adverse Change. In connection with this Agreement, Borrower has delivered to Bank a completed certificate signed by Borrower, entitled &#147;Perfection Certificate&#148;. Borrower
represents and warrants to Bank that(a) Borrower&#146;s exact legal name is that indicated on the Perfection Certificate and on the signature page hereof; (b)&nbsp;Borrower is an organization of the type and is organized in the jurisdiction set
forth in the Perfection Certificate; (c)&nbsp;the Perfection Certificate accurately sets forth Borrower&#146;s organizational identification number or accurately states that Borrower has none; (d)&nbsp;the Perfection Certificate accurately sets
forth Borrower&#146;s place of business, or, if more than one, its chief executive office as well as Borrower&#146;s mailing address (if different than its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
chief executive office); (e) Borrower (and each of its predecessors) has not, in the past five (5)&nbsp;years, changed its jurisdiction of formation, organizational structure or type, or any
organizational number assigned by its jurisdiction; and (f)&nbsp;all other information set forth on the Perfection Certificate pertaining to Borrower and each of its Subsidiaries is accurate and complete (it being understood and agreed that Borrower
may from time to time update certain information in the Perfection Certificate after the Effective Date to the extent permitted by one or more specific provisions in this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The execution, delivery and performance by Borrower of the Loan Documents to which it is a party have been duly authorized, and do not
(i)&nbsp;conflict with any of Borrower&#146;s organizational documents, (ii)&nbsp;contravene, conflict with, constitute a default under or violate any material Requirement of Law, (iii)&nbsp;contravene, conflict or violate any applicable order,
writ, judgment, injunction, decree, determination or award of any Governmental Authority by which Borrower or any of its Subsidiaries or any of their property or assets may be bound or affected, (iv)&nbsp;require any action by, filing, registration,
or qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental Approvals which have already been obtained and are in full force and effect (or are being obtained pursuant to Section&nbsp;6.1(b)) or
(v)&nbsp;conflict with, contravene, constitute a default or breach under, or result in or permit the termination or acceleration of, any material agreement by which Borrower is bound. Borrower is not in default under any agreement to which it is a
party or by which it is bound in which the default could reasonably be expected to have a Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B>
<B>Collateral</B>. Borrower has good title to, rights in, and the power to transfer each item of the Collateral upon which it purports to grant a Lien hereunder, free and clear of any and all Liens except Permitted Liens. Borrower has no Collateral
Accounts at or with any bank or financial institution other than Bank or Bank&#146;s Affiliates except for the Collateral Accounts described in the Perfection Certificate delivered to Bank in connection herewith and which Borrower has taken such
actions as are necessary to give Bank a perfected security interest there in, pursuant to the terms of Section&nbsp;6.6(b). The Accounts are bona fide, existing obligations of the Account Debtors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Collateral is not in the possession of any third party bailee (such as a warehouse) except as otherwise provided in the Perfection
Certificate. None of the components of the Collateral shall be maintained at locations other than as provided in the Perfection Certificate or as permitted pursuant to Section&nbsp;7.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Inventory is in all material respects of good and marketable quality, free from material defects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrower is the sole owner of the Intellectual Property which it owns or purports to own except for
<FONT STYLE="white-space:nowrap">(a)&nbsp;non-exclusive</FONT> licenses granted to its customers in the ordinary course of business, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(b)&nbsp;over-the-counter</FONT></FONT> software
that is commercially available to the public, and (c)&nbsp;material Intellectual Property licensed to Borrower and noted on the Perfection Certificate, provided that none of the foregoing shall be deemed to be a representation of <FONT
STYLE="white-space:nowrap">non-infringement</FONT> of Intellectual Property rights. To Borrower&#146;s knowledge, each Patent which it owns or purports to own and which is material to Borrower&#146;s business is valid and enforceable, and no part of
the Intellectual Property which Borrower owns or purports to own and which is material to Borrower&#146;s business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
has been judged invalid or unenforceable, in whole or in part. To the best of Borrower&#146;s knowledge, no claim has been made that any part of its Intellectual Property violates the rights of
any third party except to the extent such claim would not reasonably be expected to have a material adverse effect on Borrower&#146;s business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as noted on the Perfection Certificate, Borrower is not a party to, nor is it bound by, any Restricted License. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B> <B>Litigation</B>. There are no actions or proceedings pending or, to the knowledge of any Responsible Officer, threatened in
writing by or against Borrower or any of its Subsidiaries involving more than, individually or in the aggregate, One Hundred Thousand Dollars($100,000). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4</B> <B>Financial Statements; Financial Condition. </B>All consolidated financial statements for Borrower and any of its Subsidiaries
delivered to Bank fairly present in all material respects Borrower&#146;s consolidated financial condition and Borrower&#146;s consolidated results of operations. There has not been any material deterioration in Borrower&#146;s consolidated
financial condition since the date of the most recent financial statements submitted to Bank. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5</B> <B>Solvency</B>. The fair
salable value of Borrower&#146;s consolidated assets (including goodwill minus disposition costs) exceeds the fair value of Borrower&#146;s liabilities; Borrower is not left with unreasonably small capital after the transactions in this Agreement;
and Borrower is able to pay its debts (including trade debts) as they mature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6</B> <B>Regulatory Compliance</B>. Borrower is not an
&#147;investment company&#148; or a company &#147;controlled&#148; by an &#147;investment company&#148; under the Investment Company Act of 1940, as amended. Borrower is not engaged as one of its important activities in extending credit for margin
stock (under Regulations X, T and U of the Federal Reserve Board of Governors). Borrower (a)&nbsp;has complied in all material respects with all Requirements of Law, and (b)&nbsp;has not violated any Requirements of Law the violation of which could
reasonably be expected to have a Material Adverse Change. None of Borrower&#146;s or any of its Subsidiaries&#146; properties or assets has been used by Borrower or any Subsidiary or, to Borrower&#146;s knowledge, by previous Persons, in disposing,
producing, storing, treating, or transporting any hazardous substance other than in compliance with applicable laws. Borrower and each of its Subsidiaries have obtained all consents, approvals and authorizations of, made all declarations or filings
with, and given all notices to, all Government Authorities that are necessary to continue their respective businesses as currently conducted which, if not obtained, could result in a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7</B> <B>Subsidiaries; Investments</B>. Borrower does not own any stock, partnership, or other ownership interest or other equity
securities except for Permitted Investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8</B> <B>Tax Returns and Payments; Pension Contributions</B>. Borrower has timely filed
all required tax returns and reports, and Borrower has timely paid all foreign, federal, state and local taxes, assessments, deposits and contributions owed by Borrower except (a)&nbsp;to the extent such taxes are being contested in good faith by
appropriate proceedings promptly instituted and diligently conducted, so long as such reserve or other appropriate provision, if any, as shall be required in conformity with GAAP shall have been made therefor, or (b)&nbsp;if such taxes,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assessments, deposits and contributions do not, individually or in the aggregate, exceed Ten Thousand Dollars ($10,000). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent Borrower defers payment of any contested taxes, Borrower shall (i)&nbsp;notify Bank in writing of the commencement of, and any
material development in, the proceedings, and (ii)&nbsp;post bonds or take any other steps required to prevent the governmental authority levying such contested taxes from obtaining a Lien upon any of the Collateral that is other than a
&#147;Permitted Lien.&#148; Borrower is unaware of any claims or adjustments proposed for any of Borrower&#146;s prior tax years which could result in additional taxes becoming due and payable by Borrower. Borrower has paid all amounts necessary to
fund all present pension, profit sharing and deferred compensation plans in accordance with their terms, and Borrower has not withdrawn from participation in, and has not permitted partial or complete termination of, or permitted the occurrence of
any other event with respect to, any such plan which could reasonably be expected to result in any liability of Borrower, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.9</B> <B>Use of Proceeds</B>. Borrower shall use the proceeds of the Credit Extensions solely as working capital and to fund its general
business requirements and not for personal, family, household or agricultural purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.10</B> <B>Full Disclosure</B>. No written
representation, warranty or other statement of Borrower in any certificate or written statement given to Bank, as of the date such representation, warranty, or other statement was made, taken together with all such written certificates and written
statements given to Bank, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading (it being recognized by Bank that the
projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the projected
or forecasted results). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.11</B> <B>Definition of &#147;Knowledge.&#148;</B> For purposes of the Loan Documents, whenever a
representation or warranty is made to Borrower&#146;s knowledge or awareness, to the &#147;best of&#148; Borrower&#146;s knowledge, or with a similar qualification, knowledge or awareness means the actual knowledge, after reasonable investigation,
of any Responsible Officer, provided that in connection with any representation regarding Intellectual Property, &#147;knowledge&#148; shall specifically exclude any obligation of inquiry or investigation, including but not limited to any obligation
to obtain a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">freedom-to-operate</FONT></FONT> legal opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.
<U>AFFIRMATIVE COVENANTS</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrower shall do all of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B> <B>Government Compliance</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Maintain its and all its Subsidiaries&#146; legal existence and good standing in their respective jurisdictions of formation and maintain
qualification in each jurisdiction in which the failure to so qualify would reasonably be expected to have a Material Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Borrower shall comply, and have each Subsidiary comply, in all material respects, with all laws, ordinances and regulations to which it is subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Obtain all of the Governmental Approvals necessary for the performance by Borrower of its obligations under the Loan Documents to which it
is a party and the grant of a security interest to Bank in the Collateral. Borrower shall promptly provide copies of any such obtained Governmental Approvals to Bank. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B> <B>Financial Statements, Reports, Certificates</B>. Provide Bank with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Monthly Financial Statements</U>. As soon as available, but no later than thirty (30)&nbsp;days after the last day of each month, a
company-prepared consolidated balance sheet and income statement covering Borrower&#146;s consolidated operations for such month certified by a Responsible Officer and in a form acceptable to Bank (the &#147;<B>Monthly Financial
Statements</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Monthly Compliance Certificate</U>. Within thirty (30)&nbsp;days after the last day of each month and
together with the Monthly Financial Statements, a duly completed Compliance Certificate signed by a Responsible Officer, certifying that as of the end of such month, Borrower was in full compliance with all of the terms and conditions of this
Agreement, and setting forth calculations showing compliance with the financial covenants set forth in this Agreement (if any) and such other information as Bank may reasonably request; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Annual Operating Budget and Financial Projections</U>. Commencing with the 2017 fiscal year of Borrower, within ninety (90)&nbsp;days
after the last day of each fiscal year of Borrower (and more frequently as updated), (i) annual operating budgets (including income statements, balance sheets and cash flow statements, by quarter) for the upcoming fiscal year of Borrower, and
(ii)&nbsp;annual financial projections for the following fiscal year (on a quarterly basis) as approved by Borrower&#146;s board of directors, together with any related business forecasts used in the preparation of such annual financial projections;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Annual Financial Statements</U>. (A)&nbsp;at all times that Borrower&#146;s Board of Directors requires Borrower to prepare
audited financial statements, as soon as available, but no later than two hundred forty (240)&nbsp;days after the last day of Borrower&#146;s fiscal year, audited consolidated financial statements prepared under GAAP, consistently applied, together
with an unqualified opinion on the financial statements from an independent certified public accounting firm reasonably acceptable to Bank and (B)&nbsp;at all other times, as soon as available, but no later than sixty (60)&nbsp;days after the last
day of Borrower&#146;s fiscal year, a company-Prepared consolidated balance sheet and income statement covering Borrower&#146;s consolidated operations during such fiscal year certified by a Responsible Officer and in a form acceptable to Bank; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Other Statements</U>. Within five (5)&nbsp;days of delivery, copies of all statements, reports and notices made available to
Borrower&#146;s security holders, in their capacity as security holders, or to any holders of Subordinated Debt, in their capacity as holders of Subordinated Debt; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>SEC Filings</U>. In the event that Borrower becomes subject to the reporting requirements under the Exchange Act within five
(5)&nbsp;days of filing, copies of all periodic and other reports, proxy statements and other materials filed by Borrower with the SEC, any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Governmental Authority succeeding to any or all of the functions of the SEC or with any national securities exchange, or distributed to its shareholders, as the case may be. Documents required to
be delivered pursuant to the terms hereof (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which
Borrower posts such documents, or provides a link thereto, on Borrower&#146;s website on the Internet at Borrower&#146;s website address; provided, however, Borrower shall promptly notify Bank in writing (which may be by electronic mail) of the
posting of any such documents; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Legal Action Notice</U>. A prompt report of any legal actions pending or threatened in writing
against Borrower or any of its Subsidiaries that could result in damages or costs to Borrower or any of its Subsidiaries of, individually or in the aggregate, One Hundred Thousand Dollars ($100,000) or more; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Other Financial Information</U>. Other financial information reasonably requested by Bank. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B> <B>Reserved</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4</B> <B>Taxes; Pensions</B>. Timely file, and require each of its Subsidiaries to timely file, all required tax returns and reports and
timely pay, and require each of its Subsidiaries to timely pay, all foreign, federal, state and local taxes, assessments, deposits and contributions owed by Borrower and each of its Subsidiaries, except for deferred payment of any taxes contested
pursuant to the terms of Section&nbsp;5.8 hereof, and shall deliver to Bank, on demand, appropriate certificates attesting to such payments, and pay all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in
accordance with their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5</B> <B>Insurance</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Keep its business and the Collateral insured for risks and in amounts standard for companies in Borrower&#146;s industry, location and
stage of operations and as Bank may reasonably request. Insurance policies shall be in a form, with financially sound and reputable insurance companies that are not Affiliates of Borrower, and in amounts that are satisfactory to Bank. All property
policies shall have a lender&#146;s loss payable endorsement showing Bank as the sole lender loss payee. All liability policies shall show, or have endorsements showing, Bank as an additional insured. Bank shall be named as lender loss payee and/or
additional insured with respect to any such insurance providing coverage in respect of any Collateral. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Ensure that proceeds payable
under any property policy are, at Bank&#146;s option, payable to Bank on account of the Obligations. Notwithstanding the foregoing, (i)&nbsp;so long as no Event of Default has occurred and is continuing, Borrower shall have the option of applying
the proceeds of any casualty policy toward the replacement or repair of destroyed or damaged property in amounts: (x)&nbsp;up to Two Hundred Thousand Dollars ($200,000) with respect to any loss, but not exceeding Two Hundred Fifty Thousand Dollars
($250,000) in the aggregate for all losses under all casualty policies in any one year and (y)&nbsp;greater than Two Hundred Fifty Thousand Dollars ($250,000) with respect to any loss if there is no material impairment of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospect of repayment of any portion of the Obligations as determined by Bank in its sole discretion. In each of the foregoing cases, any such replaced or repaired property (1)&nbsp;shall be of
equal or like value as the replaced or repaired Collateral and (2)&nbsp;shall be deemed Collateral in which Bank has been granted a first priority security interest, and (ii)&nbsp;after the occurrence and during the continuance of an Event of
Default, all proceeds payable under such casualty policy shall, at the option of Bank, be payable to Bank on account of the Obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) At Bank&#146;s request, Borrower shall deliver certified copies of insurance policies and evidence of all premium payments. Each provider
of any such insurance required under this Section&nbsp;6.5 shall agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to Bank, that it will give Bank thirty (30)&nbsp;days prior written notice before
any such policy or policies shall be materially altered or canceled. If Borrower fails to obtain insurance as required under this Section&nbsp;6.5 or to pay any amount or furnish any required proof of payment to third persons and Bank, Bank may make
all or part of such payment or obtain such insurance policies required in this Section&nbsp;6.5, and take any action under the policies Bank deems prudent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.6</B> <B>Operating Accounts</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Maintain Borrower&#146;s primary banking relationship, including, without limitation, its operating and other deposit accounts, investment
management, Letters of Credit, and foreign exchange services, with Bank and Bank&#146;s Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Provide Bank five (5)&nbsp;days
prior written notice before establishing any Collateral Account at or with any bank or financial institution other than Bank or Bank&#146;s Affiliates. For each Collateral Account that Borrower at any time maintains, Borrower shall cause the
applicable bank or financial institution (other than Bank) at or with which any Collateral Account is maintained to execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect
Bank&#146;s Lien in such Collateral Account in accordance with the terms hereunder which Control Agreement may not be terminated without the prior written consent of Bank. The provisions of the previous sentence shall not apply to deposit accounts
exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrower&#146;s employees and identified to Bank by Borrower as such. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.7</B> <B>Reserved</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.8</B> <B>Protection of Intellectual Property Rights</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) (i) Protect, defend and maintain the validity and enforceability of its Intellectual Property to the extent that the failure to so
protect, defend or maintain would not reasonably be expected to result in a Material Adverse Change; (ii)&nbsp;promptly advise Bank in writing of material infringements of its Intellectual Property; and (iii)&nbsp;not allow any Intellectual Property
material to Borrower&#146;s business to be abandoned, forfeited or dedicated to the public without Bank&#146;s written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
Provide written notice to Bank within ten (10)&nbsp;days of entering or becoming bound by any Restricted License (other than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> software that is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercially available to the public). Borrower shall take such steps as Bank reasonably requests to obtain the consent of, or waiver by, any person whose consent or waiver is necessary for
(i)&nbsp;any Restricted License to be deemed &#147;<B>Collateral</B>&#148; and for Bank to have a security interest in it that might otherwise be restricted or prohibited by law or by the terms of any such Restricted License, whether now existing or
entered into in the future, and (ii)&nbsp;Bank to have the ability in the event of a liquidation of any Collateral to dispose of such Collateral in accordance with Bank&#146;s rights and remedies under this Agreement and the other Loan Documents. It
being understood that the Collateral does not include any Intellectual Property as described on <U>Exhibit A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.9</B>
<B>Litigation Cooperation</B>. From the date hereof and continuing through the termination of this Agreement, make available to Bank, without expense to Bank, Borrower and its officers, employees and agents and Borrower&#146;s books and records, to
the extent that Bank may deem them reasonably necessary to prosecute or defend any third-party suit or proceeding instituted by or against Bank with respect to any Collateral or relating to Borrower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.10</B> <B>Reserved</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.11</B> <B>Formation or Acquisition of Subsidiaries</B>. Notwithstanding and without limiting the negative covenants contained in Sections
7.3 and 7.7 hereof, at the time that Borrower forms any direct or indirect Subsidiary or acquires any direct or indirect Subsidiary after the Effective Date, Borrower shall, upon Bank&#146;s request in its sole and absolute discretion,
(a)&nbsp;cause such new Subsidiary to provide to Bank either a joinder to the Loan Agreement to cause such Subsidiary to become a <FONT STYLE="white-space:nowrap">co-borrower</FONT> hereunder or a Guaranty, together with such appropriate financing
statements and/or Control Agreements, all in form and substance satisfactory to Bank (including being sufficient to grant Bank a first priority Lien (subject to Permitted Liens) in and to the assets (other than Intellectual Property) of such newly
formed or acquired Subsidiary), (b) provide to Bank appropriate certificates and powers and financing statements, pledging all of the direct or beneficial ownership interest in such new Subsidiary (other than Intellectual Property of such
Subsidiary), in form and substance satisfactory to Bank, and (c)&nbsp;provide to Bank all other documentation in form and substance satisfactory to Bank, including one or more opinions of counsel satisfactory to Bank, which in its opinion is
appropriate with respect to the execution and delivery of the applicable documentation referred to above. Any document, agreement, or instrument executed or issued pursuant to this Section 6.11 shall be a Loan Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.12</B> <B>Further Assurances</B>. Execute any further instruments and take further action as Bank reasonably requests to perfect or
continue Bank&#146;s Lien in the Collateral or to effect the purposes of this Agreement. Deliver to Bank, within five (5)&nbsp;days after the same are sent or received, copies of all correspondence, reports, documents and other filings with any
Governmental Authority regarding compliance with or maintenance of Governmental Approvals or Requirements of Law or that could reasonably be expected to have a material effect on any of the Governmental Approvals or otherwise on the operations of
Borrower or any of its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7. <U>NEGATIVE COVENANTS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrower shall not do any of the following without Bank&#146;s prior written consent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B>Dispositions</B>. Convey, sell, lease, transfer, assign, or otherwise dispose of (collectively, &#147;<B>Transfer</B>&#148;), or
permit any of its Subsidiaries to Transfer, all or any part of its business or property, except for Transfers (a)&nbsp;of Inventory in the ordinary course of business; (b)&nbsp;of <FONT STYLE="white-space:nowrap">worn-out</FONT> or obsolete
Equipment that is, in the reasonable judgment of Borrower, no longer economically practicable to maintain or useful in the ordinary course of business of Borrower;(c) consisting of Permitted Liens or Permitted Investments; (d)&nbsp;consisting of the
sale or issuance of any stock of Borrower permitted under Section&nbsp;7.2 of this Agreement; and (e)&nbsp;consisting of Borrower&#146;s use or transfer of money or Cash Equivalents in the ordinary course of its business for the payment of ordinary
course business expenses in a manner that is not prohibited by the terms of this Agreement or the other Loan Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B>
<B>Changes in Business, Management, Control, or Business Locations</B>. (a) Engage in or permit any of its Subsidiaries to engage in any business other than the businesses currently engaged in by Borrower and such Subsidiary, as applicable, or
reasonably related thereto; (b)&nbsp;liquidate or dissolve; (c)&nbsp;fail to provide notice to Bank of Peter Thompson departing from or ceasing to be an officer of Borrower within five (5)&nbsp;days prior to his departure from Borrower; or
(d)&nbsp;permit or suffer any Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrower shall not, without at least thirty (30)&nbsp;days prior written notice to Bank:
(1)&nbsp;add any new offices or business locations, including warehouses (unless such new offices or business locations contain less than Twenty-Five Thousand Dollars ($25,000) in Borrower&#146;s assets or property) or deliver any portion of the
Collateral valued, individually or in the aggregate, in excess of Twenty-Five Thousand Dollars ($25,000) to a bailee at a location other than (i)&nbsp;to a bailee and at a location already disclosed in the Perfection Certificate, or
(ii)&nbsp;deliveries of chemical or biological materials (such as, but not limited to, reagents, gene sequences, nucleic acids, cell lines, compounds, proteins and vectors) pursuant to license agreements, collaboration agreements, and other similar
agreements in the ordinary course of Borrower&#146;s business, (2)&nbsp;change its jurisdiction of organization, (3)&nbsp;change its organizational structure or type, (4)&nbsp;change its legal name, or (5)&nbsp;change any organizational number (if
any) assigned by its jurisdiction of organization. If Borrower intends to deliver any portion of the Collateral valued, individually or in the aggregate, in excess of Twenty-Five Thousand Dollars ($25,000) to a bailee, and Bank and such bailee are
not already parties to a bailee agreement governing both the Collateral and the location to which Borrower intends to deliver the Collateral, then Borrower will first receive the written consent of Bank, and such bailee shall execute and deliver a
bailee agreement in form and substance satisfactory to Bank. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B> <B>Mergers or Acquisitions</B>. Merge or consolidate, or permit
any of its Subsidiaries to merge or consolidate, with any other Person, or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person (the &#147;<B>Target</B>&#148;) (including,
without limitation, by the formation of any Subsidiary) (an &#147;<B>Acquisition</B>&#148;) other than in connection with a Permitted Acquisition. A Subsidiary may merge or consolidate into another Subsidiary or into Borrower. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4</B> <B>Indebtedness</B>. Create, incur, assume, or be liable for any Indebtedness, or
permit any Subsidiary to do so, other than Permitted Indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5</B> <B>Encumbrance</B>. Create, incur, allow, or suffer any
Lien on any of its property, or assign or convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, permit any Collateral not to be subject to the first priority
security interest granted herein, or enter into any agreement, document, instrument or other arrangement (except with or in favor of Bank) with any Person which directly or indirectly prohibits or has the effect of prohibiting Borrower or any
Subsidiary from assigning, mortgaging, pledging, granting a security interest in or upon, or encumbering any of Borrower&#146;s or any Subsidiary&#146;s Intellectual Property, except as is otherwise permitted in Section 7.1 hereof and the definition
of &#147;<B>Permitted Liens</B>&#148; herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6</B> <B>Maintenance of Collateral Accounts</B>. Maintain any Collateral Account
except pursuant to the terms of Section&nbsp;6.6(b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.7</B> <B>Distributions; Investments</B>. (a)&nbsp;Pay any dividends or
make any distribution or payment or redeem, retire or purchase any capital stock, provided that (i)&nbsp;Borrower may convert any of its convertible securities into other securities pursuant to the terms of such convertible securities or otherwise
in exchange thereof, (ii)&nbsp;Borrower may pay dividends solely in common stock; and (iii)&nbsp;Borrower may repurchase the stock of former employees, consultants, or other holders of common stock pursuant to stock repurchase agreements so long as
an Event of Default does not exist at the time of such repurchase and would not exist after giving effect to such repurchase as a result of such repurchase, provided that the aggregate amount of all such repurchases does not exceed Two Hundred Fifty
Thousand Dollars ($250,000) per fiscal year or such great amounts with Bank&#146;s prior written consent; or (b)&nbsp;directly or indirectly make any Investment (including, without limitation, by the formation of any Subsidiary) other than Permitted
Investments, or permit any of its Subsidiaries to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.8</B> <B>Transactions with Affiliates</B>. Directly or indirectly enter
into or permit to exist any material transaction with any Affiliate of Borrower, except for (i)&nbsp;transactions that are in the ordinary course of Borrower&#146;s business, upon fair and reasonable terms that are no less favorable to Borrower than
would be obtained in an arm&#146;s length transaction with a <FONT STYLE="white-space:nowrap">non-affiliated</FONT> Person; (ii)&nbsp;investments made pursuant to the Series A Purchase Agreement; and (iii)&nbsp;any amendment modification or waiver
pursuant to the HoldCo License that would not reasonably be expected to have a Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.9</B> <B>Subordinated
Debt</B>. (a)&nbsp;Make or permit any payment on any Subordinated Debt, except under the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject, or (b)&nbsp;amend any provision in any
document relating to the Subordinated Debt which would increase the amount thereof, provide for earlier or greater principal, interest, or other payments thereon, or adversely affect the subordination thereof to Obligations owed to Bank. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.10</B> <B>Compliance</B>. Become an &#147;investment company&#148; or a company controlled by an &#147;investment company&#148;, under
the Investment Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Credit Extension for that purpose; fail to (a)&nbsp;meet the minimum funding requirements of
ERISA, (b)&nbsp;prevent a Reportable Event or Prohibited Transaction, as defined in ERISA from occurring, or (c)&nbsp;comply with the Federal Fair Labor Standards Act, the failure of any of the conditions described in clauses (a)&nbsp;through (c)
which could reasonably be expected to have a Material Adverse Change; or violate any other law or regulation, if the violation could reasonably be expected to have a Material Adverse Change or permit any of its Subsidiaries to do so; withdraw or
permit any Subsidiary to withdraw from participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred compensation plan which could
reasonably be expected to result in any liability of Borrower, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. <U>EVENTS OF DEFAULT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any one of the following shall constitute an event of default (an &#147;<B>Event of Default</B>&#148;) under this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B> <B>Payment Default</B>. Borrower fails to (a)&nbsp;make any payment of principal or interest on any Credit Extension when due, or
(b)&nbsp;pay any other Obligations within three (3)&nbsp;Business Days after such Obligations are due and payable (which three (3)&nbsp;Business Day cure period shall not apply to payments due on the Term Loan Maturity Date). During the cureperiod,
the failure to make or pay any payment specified under clause (b)&nbsp;hereunder is not an Event of Default (but no Credit Extension will be made during the cure period); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2</B> <B>Covenant Default</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Borrower fails or neglects to perform any obligation in Section&nbsp;3.3, 6.2,6.4, 6.5, 6.6, 6.7 (if applicable), 6.8(b), or violates any
covenant in Section&nbsp;7; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Borrower fails or neglects to perform, keep, or observe any other term, provision, condition, covenant
or agreement contained in this Agreement or any Loan Documents, and as to any default (other than those specified in this Section&nbsp;8) under such other term, provision, condition, covenant or agreement that can be cured, has failed to cure the
default within ten (10)&nbsp;days after the occurrence thereof; provided, however, that if the default cannot by its nature be cured within the ten (10)&nbsp;day period or cannot after diligent attempts by Borrower be cured within such ten
(10)&nbsp;day period, and such default is likely to be cured within areasonable time, then Borrower shall have an additional period (which shall not in any case exceed thirty (30)&nbsp;days) to attempt to cure such default, and within such
reasonable time period the failure to cure the default shall not be deemed an Event of Default (but no Credit Extensions shall be made during such cure period). Cure periods provided under this section shall not apply, among other things, to
financial covenants (if any) or any other covenants set forth in clause (a)&nbsp;above; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3</B> <B>Material Adverse Change</B>. A
Material Adverse Change occurs; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4</B> <B>Attachment; Levy; Restraint on Business</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) (i) The service of process seeking to attach, by trustee or similar process, any funds of Borrower or of any entity under the control of
Borrower (including a Subsidiary), or (ii)&nbsp;a notice of lien or levy is filed against any of Borrower&#146;s assets by any Governmental Authority, and the same under subclauses (i)&nbsp;and (ii) hereof are not, within ten (10)&nbsp;days after
the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise); provided, however, no Credit Extensions shall be made during any ten (10)&nbsp;day cure period; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) (i) any material portion of Borrower&#146;s assets is attached, seized, levied on, or comes into possession of a trustee or receiver, or
(ii)&nbsp;any court order enjoins, restrains, or prevents Borrower from conducting all or any material part of its business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.5</B>
<B>Insolvency</B>. (a)&nbsp;Borrower or any of its Subsidiaries is unable to pay its debts (including trade debts) as they become due or otherwise becomes insolvent; (b)&nbsp;Borrower or any of its Subsidiaries begins an Insolvency Proceeding; or
(c)&nbsp;an Insolvency Proceeding is begun against Borrower or any of its Subsidiaries and is not dismissed or stayed within thirty (30)&nbsp;days (but no Credit Extensions shall be made while any of the conditions described in clause (a)&nbsp;exist
and/or until any Insolvency Proceeding is dismissed); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.6</B> <B>Other Agreements</B>. There is, under any agreement to which Borrower
is a party with a third party or parties, (a)&nbsp;any default resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount individually or in the aggregate in excess of
One Hundred Thousand Dollars ($100,000); or (b)&nbsp;any breach or default by Borrower, the result of which could have a Material Adverse Change; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.7</B> <B>Judgments; Penalties</B>. One or more fines, penalties or final judgments, orders or decrees for the payment of money in an
amount, individually or in the aggregate, of at least One Hundred Thousand Dollars ($100,000) (not covered by independent third-party insurance as to which liability has been accepted by such insurance carrier) shall be rendered against Borrower by
any Governmental Authority, and the same are not, within ten (10)&nbsp;days after the entry, assessment or issuance thereof, discharged, satisfied, or paid, or after execution thereof, stayed or bonded pending appeal, or such judgments are not
discharged prior to the expiration of any such stay (provided that no Credit Extensions will be made prior to the satisfaction, payment, discharge, stay, or bonding of such fine, penalty, judgment, order or decree); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.8</B> <B>Misrepresentations</B>. Borrower or any Person acting for Borrower makes any representation, warranty, or other statement now or
later in this Agreement, any Loan Document or in any writing delivered to Bank or to induce Bank to enter this Agreement or any Loan Document, and such representation, warranty, or other statement is incorrect in any material respect when made; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.9</B> <B>Subordinated Debt</B>. Any document, instrument, or agreement evidencing the subordination of any Subordinated Debt shall for
any reason be revoked or invalidated or otherwise cease to be in full force and effect, any Person shall be in breach thereof or contest in any manner the validity or enforceability thereof or deny that it has any further liability or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligation thereunder, or the Obligations shall for any reason be subordinated or shall not have the priority contemplated by this Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.10</B> <B>Governmental Approvals</B>. Any Governmental Approval shall have been (a)&nbsp;revoked, rescinded, suspended, modified in an
adverse manner or not renewed in the ordinary course for a full term or (b)&nbsp;subject to any decision by a Governmental Authority that designatesa hearing with respect to any applications for renewal of any of such Governmental Approval or that
could result in the Governmental Authority taking any of the actions described in clause (a)&nbsp;above, and such decision or such revocation, rescission, suspension, modification or <FONT STYLE="white-space:nowrap">non-renewal</FONT>
(i)&nbsp;cause, or could reasonably be expected to cause, a Material Adverse Change, or (ii)&nbsp;adversely affects the legal qualifications of Borrower or any of its Subsidiaries to hold such Governmental Approval in any applicable jurisdiction and
such revocation, rescission, suspension, modification or <FONT STYLE="white-space:nowrap">non-renewal</FONT> could reasonably be expected to affect the status of or legal qualifications of Borrower or any of its Subsidiaries to hold any Governmental
Approval in any other jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9. <U>BANK&#146;S RIGHTS AND REMEDIES</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1</B> <B>Rights and Remedies</B>. Upon the occurrence and during the continuance of an Event of Default, Bank may, without notice or
demand, do any or all of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) declare all Obligations immediately due and payable (but if an Event of Default described in
Section&nbsp;8.5 occurs all Obligations are immediately due and payable without any action by Bank); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) stop advancing money or
extending credit for Borrower&#146;s benefit under this Agreement or under any other agreement between Borrower and Bank; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) for any
Letters of Credit other than the cash secured Letter of Credit described in the Perfection Certificate delivered to Bank on the Effective Date, demand that Borrower (i)&nbsp;deposit cash with Bank in an amount equal to (x)&nbsp;if such Letters of
Credit are denominated in Dollars, then at least one hundred five percent (105%); and (y)&nbsp;if such Letters of Credit are denominated in a Foreign Currency, then at least one hundred ten percent (110%) of the Dollar Equivalent of the aggregate
face amount of all of such Letters of Credit remaining undrawn (plus all interest, fees, and costs due or to become due in connection therewith (as estimated by Bank in its good faith business judgment)), to secure all of the Obligations relating to
such Letters of Credit, as collateral security for the repayment of any future drawings under such Letters of Credit, and Borrower shall forthwith deposit and pay such amounts, and (ii)&nbsp;pay in advance all letter of credit fees scheduled to be
paid or payable over the remaining term of any Letters of Credit; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) terminate any FX Contracts; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) verify the amount of, demand payment of and performance under, and collect any Accounts and General Intangibles, settle or adjust disputes
and claims directly with Account Debtors for amounts on terms and in any order that Bank considers advisable, and notify any Person owing Borrower money of Bank&#146;s security interest in such funds; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) make any payments and do any acts it considers necessary or reasonable to protect the
Collateral and/or its security interest in the Collateral. Borrower shall assemble the Collateral if Bank requests and make it available as Bank designates. Bank may enter premises where the Collateral is located, take and maintain possession of any
part of the Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred. Borrower grants Bank a license to enter and occupy any of its premises, without
charge, to exercise any of Bank&#146;s rights or remedies; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) apply to the Obligations any (i)&nbsp;balances and deposits of Borrower it
holds, or (ii)&nbsp;amount held by Bank owing to or for the credit or the account of Borrower; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) ship, reclaim, recover, store, finish,
maintain, repair, prepare for sale, advertise for sale, and sell the Collateral. Bank is hereby granted a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-free license or other right to use, without charge, Borrower&#146;s labels,
Patents, Copyrights, mask works, rights of use of any name, trade secrets, trade names, Trademarks, and advertising matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any
Collateral and, in connection with Bank&#146;s exercise of its rights under this Section, Borrower&#146;s rights under all licenses and all franchise agreements inure to Bank&#146;s benefit; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) place a &#147;hold&#148; on any account maintained with Bank and/or deliver a notice of exclusive control, any entitlement order, or other
directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) demand and
receive possession of Borrower&#146;s Books; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) exercise all rights and remedies available to Bank under the Loan Documents or at
law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2</B> <B>Power of Attorney</B>. Borrower hereby irrevocably appoints Bank as its lawful <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> exercisable upon the occurrence and during the continuance of an Event of Default, to: (a)&nbsp;endorse Borrower&#146;s name on any checks or other forms of payment or security;(b) sign
Borrower&#146;s name on any invoice or bill of lading for any Account or drafts against Account Debtors; (c)&nbsp;settle and adjust disputes and claims about the Accounts directly with Account Debtors, for amounts and on terms Bank determines
reasonable; (d)&nbsp;make, settle, and adjust all claims under Borrower&#146;s insurance policies; (e)&nbsp;pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the Collateral, or any judgment based
thereon, or otherwise take any action to terminate or discharge the same; and (f)&nbsp;transfer the Collateral into the name of Bank or a third party as the Code permits. Borrower hereby appoints Bank as its lawful <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to sign Borrower&#146;s name on any documents necessary to perfect or continue the perfection of Bank&#146;s security interest in the Collateral regardless of whether an Event of Default has
occurred until all Obligations have been satisfied in full and Bank is under no further obligation to make Credit Extensions hereunder. Bank&#146;s foregoing appointment as Borrower&#146;s attorney in fact, and all of Bank&#146;s rights and powers,
coupled with an interest, are irrevocable until all Obligations have been fully repaid and performed and Bank&#146;s obligation to provide Credit Extensions terminates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3</B> <B>Protective Payments</B>. If Borrower fails to obtain the insurance called for
by Section&nbsp;6.5 or fails to pay any premium thereon or fails to pay any other amount which Borrower is obligated to pay under this Agreement or any other Loan Document or which may be required to preserve the Collateral, Bank may obtain such
insurance or make such payment, and all amounts so paid by Bank are Bank Expenses and immediately due and payable, bearing interest at the then highest rate applicable to the Obligations, and secured by the Collateral. Bank will make reasonable
efforts to provide Borrower with notice of Bank obtaining such insurance at the time it is obtained or within a reasonable time thereafter. No payments by Bank are deemed an agreement to make similar payments in the future or Bank&#146;s waiver of
any Event of Default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.4</B> <B>Application of Payments and Proceeds Upon Default</B>. If an Event of Default has occurred and is
continuing, Bank shall have the right to apply in any order any funds in its possession, whether from Borrower account balances, payments, proceeds realized as the result of any collection of Accounts or other disposition of the Collateral, or
otherwise, to the Obligations. Bank shall pay any surplus to Borrower by credit to the Designated Deposit Account or to other Persons legally entitled thereto; Borrower shall remain liable to Bank for any deficiency. If Bank, directly or indirectly,
enters into a deferred payment or other credit transaction with any purchaser at any sale of Collateral, Bank shall have the option, exercisable at any time, of either reducing the Obligations by the principal amount of the purchase price or
deferring the reduction of the Obligations until the actual receipt by Bank of cash therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.5</B> <B>Bank&#146;s Liability for
Collateral</B>. So long as Bank complies with reasonable banking practices regarding the safekeeping of the Collateral in the possession or under the control of Bank, Bank shall not be liable or responsible for: (a)&nbsp;the safekeeping of the
Collateral; (b)&nbsp;any loss or damage to the Collateral; (c)&nbsp;any diminution in the value of the Collateral; or (d)&nbsp;any act or default of any carrier, warehouseman, bailee, or other Person. Borrower bears all risk of loss, damage or
destruction of the Collateral. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.6</B> <B>No Waiver; Remedies Cumulative</B>. Bank&#146;s failure, at any time or times, to require
strict performance by Borrower of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Bank thereafter to demand strict performance and compliance herewith or therewith. No waiver hereunder
shall be effective unless signed by the party granting the waiver and then is only effective for the specific instance and purpose for which it is given. Bank&#146;s rights and remedies under this Agreement and the other Loan Documents are
cumulative. Bank has all rights and remedies provided under the Code, by law, or in equity. Bank&#146;s exercise of one right or remedy is not an election and shall not preclude Bank from exercising any other remedy under this Agreement or other
remedy available at law or in equity, and Bank&#146;s waiver of any Event of Default is not a continuing waiver. Bank&#146;s delay in exercising any remedy is not a waiver, election, or acquiescence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.7</B> <B>Demand Waiver</B>. Borrower waives demand, notice of default or dishonor, notice of payment and nonpayment, notice of any
default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Bank on which Borrower is liable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10. <U>NOTICES</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All notices, consents, requests, approvals, demands, or other communication by any party to this Agreement or any other Loan Document must be
in writing and shall be deemed to have been validly served, given, or delivered: (a)&nbsp;upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt
requested, with proper postage prepaid; (b)&nbsp;upon transmission, when sent by electronic mail or facsimile transmission; (c)&nbsp;one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid; or (d)&nbsp;when
delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below. Bank or Borrower may change its mailing or electronic mail address or
facsimile number by giving the other party written notice thereof in accordance with the terms of this Section&nbsp;10. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If&nbsp;to&nbsp;Borrower:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Silverback Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">500 Fairview Ave N.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Seattle, Washington 98109</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Peter Thompson, Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fax:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Email:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If to Bank:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Silicon Valley Bank</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">555 Mission Street, Suite 900</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">San Francisco, California 94105</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Jackie Spencer, Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11. <U>CHOICE OF LAW, VENUE, JURY TRIAL WAIVER AND JUDICIAL REFERENCE</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise expressly provided in any of the Loan Documents, California law governs the Loan Documents without regard to principles of
conflicts of law. Borrower and Bank each submit to the exclusive jurisdiction of the State and Federal courts in Santa Clara County, California; provided, however, that nothing in this Agreement shall be deemed to operate to preclude Bank from
bringing suit or taking other legal action in any other jurisdiction to realize on the Collateral or any other security for the Obligations, or to enforce a judgment or other court order in favor of Bank. Borrower expressly submits and consents in
advance to such jurisdiction in any action or suit commenced in any such court, and Borrower hereby waives any objection that it may have based upon lack of personal jurisdiction, improper venue, or forum non conveniens and hereby consents to the
granting of such legal or equitable relief as is deemed appropriate by such court. Borrower hereby waives personal service of the summons, complaints, and other process issued in such action or suit and agrees that service of such summons,
complaints, and other process may be made by registered or certified mail addressed to Borrower at the address set forth in, or subsequently provided by Borrower in accordance with, Section&nbsp;10 of this Agreement and that service so made shall be
deemed completed upon the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
earlier to occur of Borrower&#146;s actual receipt thereof or three (3)&nbsp;days after deposit in the U.S. mails, proper postage prepaid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER AND BANK EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION
ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR BOTH PARTIES TO ENTER INTO THIS AGREEMENT. EACH
PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WITHOUT INTENDING IN ANY WAY TO LIMIT THE PARTIES&#146; AGREEMENT TO WAIVE THEIR
RESPECTIVE RIGHT TO A TRIAL BY JURY, if the above waiver of the right to a trial by jury is not enforceable, the parties hereto agree that any and all disputes or controversies of any nature between them arising at any time shall be decided by a
reference to a private judge, mutually selected by the parties (or, if they cannot agree, by the Presiding Judge of the Santa Clara County, California Superior Court) appointed in accordance with California Code of Civil Procedure Section&nbsp;638
(or pursuant to comparable provisions of federal law if the dispute falls within the exclusive jurisdiction of the federal courts), sitting without a jury, in Santa Clara County, California; and the parties hereby submit to the jurisdiction of such
court. The reference proceedings shall be conducted pursuant to and in accordance with the provisions of California Code of Civil Procedure &#167;&#167; 638 through 645.1, inclusive. The private judge shall have the power, among others, to grant
provisional relief, including without limitation, entering temporary restraining orders, issuing preliminary and permanent injunctions and appointing receivers. All such proceedings shall be closed to the public and confidential and all records
relating thereto shall be permanently sealed. If during the course of any dispute, a party desires to seek provisional relief, but a judge has not been appointed at that point pursuant to the judicial reference procedures, then such party may apply
to the Santa Clara County, California Superior Court for such relief. The proceeding before the private judge shall be conducted in the same manner as it would be before a court under the rules of evidence applicable to judicial proceedings. The
parties shall be entitled to discovery which shall be conducted in the same manner as it would be before a court under the rules of discovery applicable to judicial proceedings. The private judge shall oversee discovery and may enforce all discovery
rules and orders applicable to judicial proceedings in the same manner as a trial court judge. The parties agree that the selected or appointed private judge shall have the power to decide all issues in the action or proceeding, whether of fact or
of law, and shall report a statement of decision thereon pursuant to California Code of Civil Procedure &#167; 644(a). Nothing in this paragraph shall limit the right of any party at any time to exercise self-help remedies, foreclose against
collateral, or obtain provisional remedies. The private judge shall also determine all issues relating to the applicability, interpretation, and enforceability of this paragraph. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Section&nbsp;11 shall survive the termination of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12. <U>GENERAL PROVISIONS</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.1</B> <B>Termination Prior to Term Loan Maturity Date; Survival</B>. All covenants, representations and warranties made in this Agreement
shall continue in full force until this Agreement has terminated pursuant to its terms and all Obligations have been satisfied. So long as Borrower has satisfied the Obligations (other than inchoate indemnity obligations, any other obligations
which, by their terms, are to survive the termination of this Agreement, and any Obligations under Bank Services Agreements that are cash collateralized in accordance with Section&nbsp;4.1 of this Agreement), this Agreement may be terminated prior
to the Term Loan Maturity Date by Borrower pursuant to the terms and conditions set forth in Section&nbsp;2.1.1(c)(ii). Those obligations that are expressly specified in this Agreement as surviving this Agreement&#146;s termination shall continue to
survive notwithstanding this Agreement&#146;s termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.2</B> <B>Successors and Assigns</B>. This Agreement binds and is for the
benefit of the successors and permitted assigns of each party. Borrower may not assign this Agreement or any rights or obligations under it without Bank&#146;s prior written consent (which may be granted or withheld in Bank&#146;s discretion). Bank
has the right, without the consent of or notice to Borrower, to sell, transfer, assign, negotiate, or grant participation in all or any part of, or any interest in, Bank&#146;s obligations, rights, and benefits under this Agreement and the other
Loan Documents( other than the Warrant, as to which assignment, transfer and other such actions are governed by the terms thereof). Notwithstanding the foregoing, prior to the occurrence of an Event of Default, Bank shall not assign any interest in
the Loan Documents to an operating company which is a known direct competitor of Borrower (as determined by Bank). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.3</B>
<B>Indemnification</B>. Borrower agrees to indemnify, defend and hold Bank and its directors, officers, employees, agents, attorneys, or any other Person affiliated with or representing Bank (each, an &#147;<B>Indemnified Person</B>&#148;) harmless
against: (i)&nbsp;all obligations, demands, claims, and liabilities (collectively, &#147;<B>Claims</B>&#148;) claimed or asserted by any other partyin connection with the transactions contemplated by the Loan Documents; and (ii)&nbsp;all losses or
expenses (including Bank Expenses) in any way suffered, incurred, or paid by such Indemnified Person as a result of, following from, consequential to, or arising from transactions between Bank and Borrower (including reasonable attorneys&#146; fees
and expenses), except for Claims and/or losses directly caused by such Indemnified Person&#146;s gross negligence or willful misconduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Section&nbsp;12.3 shall survive until all statutes of limitation with respect to the Claims, losses, and expenses for which indemnity is
given shall have run. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.4</B> <B>Time of Essence</B>. Time is of the essence for the performance of all Obligations in this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.5</B> <B>Severability of Provisions</B>. Each provision of this Agreement is severable from every other provision in
determining the enforceability of any provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.6</B> <B>Correction of Loan Documents</B>. Bank may correct patent errors and fill
in any blanks in the Loan Documents consistent with the agreement of the parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.7</B> <B>Amendments in Writing; Waiver; Integration</B>. No purported amendment or
modification of any Loan Document, or waiver, discharge or termination of any obligation under any Loan Document, shall be enforceable or admissible unless, and only to the extent, expressly set forth in a writing signed by the party against which
enforcement or admission is sought. Without limiting the generality of the foregoing, no oral promise or statement, nor any action, inaction, delay, failure to require performance or course of conduct shall operate as, or evidence, an amendment,
supplement or waiver or have any other effect on any Loan Document. Any waiver granted shall be limited to the specific circumstance expressly described in it, and shall not apply to any subsequent or other circumstance, whether similar or
dissimilar, or give rise to, or evidence, any obligation or commitment to grant any further waiver. The Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements,
understandings, representations, warranties, and negotiations between the parties about the subject matter of the Loan Documents merge into the Loan Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.8</B> <B>Counterparts</B>. This Agreement may be executed in any number of counterparts and by different parties on separate
counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.9</B>
<B>Confidentiality</B>. In handling any confidential information, Bank shall exercise the same degree of care that it exercises for its own proprietary information, but disclosure of information may be made: (a)&nbsp;to Bank&#146;s Subsidiaries or
Affiliates (such Subsidiaries and Affiliates, together with Bank, collectively, &#147;<B>Bank Entities</B>&#148;); (b) to prospective transferees or purchasers of any interest in the Credit Extensions (provided, however, Bank shall use its best
efforts to obtain any prospective transferee&#146;s or purchaser&#146;s agreement to the terms of this provision); (c) as required by law, regulation, subpoena, or other order; (d)&nbsp;to Bank&#146;s regulators or as otherwise required in
connection with Bank&#146;s examination or audit; (e)&nbsp;as Bank considers appropriate in exercising remedies under the Loan Documents; and (f)&nbsp;to third-party service providers of Bank so long as such service providers have executed a
confidentiality agreement with Bank with terms no less restrictive than those contained herein. Confidential information does not include information that is either: (i)&nbsp;in the public domain or in Bank&#146;s possession when disclosed to Bank,
or becomes part of the public domain (other than as a result of its disclosure by Bank in violation of this Agreement) after disclosure to Bank; or (ii)&nbsp;disclosed to Bank by a third party, if Bank does not know that the third party is
prohibited from disclosing the information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bank Entities may use anonymous forms of confidential information for aggregate datasets, for
analyses or reporting, and for any other uses not expressly prohibited in writing by Borrower. The provisions of the immediately preceding sentence shall survive termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.10</B> <B>Attorneys&#146; Fees, Costs and Expenses</B>. In any action or proceeding between Borrower and Bank arising out of or relating
to the Loan Documents, the prevailing party shall be entitled to recover its reasonable attorneys&#146; fees and other costs and expenses incurred, in addition to any other relief to which it may be entitled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.11</B> <B>Electronic Execution of Documents</B>. The words &#147;execution,&#148;
&#147;signed,&#148; &#147;signature&#148; and words of like import in any Loan Document shall be deemed to includeelectronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity and
enforceability as a manually executed signature or the use of a paper-based recordkeeping systems, as the case may be, to the extent and as provided for in any applicable law, including, without limitation, any state law based on the Uniform
Electronic Transactions Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.12</B> <B>Captions</B>. The headings used in this Agreement are for convenience only and shall not
affect the interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.13</B> <B>Construction of Agreement</B>. The parties mutually acknowledge that they
and their attorneys have participated in the preparation and negotiation of this Agreement. In cases of uncertainty this Agreement shall be construed without regard to which of the parties caused the uncertainty to exist. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.14</B> <B>Relationship</B>. The relationship of the parties to this Agreement is determined solely by the provisions of this Agreement.
The parties do not intend to create any agency, partnership, joint venture, trust, fiduciary or other relationship with duties or incidents different from those of parties to an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> contract.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.15</B> <B>Third Parties</B>. Nothing in this Agreement, whether express or implied, is intended to: (a)&nbsp;confer any benefits,
rights or remedies under or by reason of this Agreement on any persons other than the express parties to it and their respective permitted successors and assigns; (b)&nbsp;relieve or discharge the obligation or liability of any person not an express
party to this Agreement; or (c)&nbsp;give any person not an express party to this Agreement any right of subrogation or action against any party to this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13. <U>DEFINITIONS</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.1</B> <B>Definitions</B>. As used in the Loan Documents, the word &#147;shall&#148; is mandatory, the word &#147;may&#148; is permissive,
the word &#147;or&#148; is not exclusive, the words &#147;includes&#148; and &#147;including&#148; are not limiting, the singular includes the plural, and numbers denoting amounts that are set off in brackets are negative. As used in this Agreement,
the following capitalized terms have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Account</B>&#148; is any &#147;account&#148; as defined in the Code
with such additions to such term as may hereafter be made, and includes, without limitation, all accounts receivable and other sums owing to Borrower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Account Debtor</B>&#148; is any &#147;account debtor&#148; as defined in the Code with such additions to such term as may hereafter
be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Acquisition</B>&#148; is defined in Section&nbsp;7.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; is, with respect to any Person, each other Person that owns or controls directly or indirectly the Person, any
Person that controls or is controlled by or is under common control with the Person, and each of that Person&#146;s senior executive officers, directors, partners and, for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any Person that is a limited liability company, that Person&#146;s managers and members and member, and for any Person that is a stockholder of Borrower, including, without limitation, any
general partner, managing member, officer or director of such stockholder, or any venture capital or private equity fund now or hereafter existing which is controlled by one or more general partners (or member thereof) or managing members of, or
shares the same management or advisory company (or stockholder or member thereof) with, stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148; is
defined in the preamble hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Bank</B>&#148; is defined in the preamble hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Bank Entities</B>&#148; is defined in Section&nbsp;12.9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Bank Expenses</B>&#148; are all audit fees and expenses, costs, and expenses (including reasonable attorneys&#146; fees and expenses)
for preparing, amending, negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred with respect to Borrower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Bank Services</B>&#148; are any products, credit services, and/or financial accommodations previously, now, or hereafter provided to
Borrower or any of its Subsidiaries by Bank or any Bank Affiliate, including, without limitation, any letters of credit, cash management services (including, without limitation, merchant services, direct deposit of payroll, business credit cards,
and check cashing services), interest rate swap arrangements, and foreign exchange services as any such products or services may be identified in Bank&#146;s various agreements related thereto(each, a &#147;<B>Bank Services Agreement</B>&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Borrower</B>&#148; is defined in the preamble hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Borrower&#146;s Books</B>&#148; are all Borrower&#146;s books and records including ledgers, federal and state tax returns, records
regarding Borrower&#146;s assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Borrowing Resolutions</B>&#148; are, with respect to any Person, those resolutions substantially in the form attached hereto as
<U>Exhibit D</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; is any day that is not a Saturday, Sunday or a day on which Bank is closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cash Equivalents</B>&#148; means (a)&nbsp;marketable direct obligations issued or unconditionally guaranteed by the United States or
any agency or any State thereof having maturities of not more than one (1)&nbsp;year from the date of acquisition; (b)&nbsp;commercial paper maturing no more than one (1)&nbsp;year after its creation and having the highest rating from either
Standard&nbsp;&amp; Poor&#146;s Ratings Group or Moody&#146;s Investors Service, Inc.; and (c)&nbsp;Bank&#146;s certificates of deposit issued maturing no more than one (1)&nbsp;year after issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change in Control</B>&#148; means (a)&nbsp;at any time, any &#147;person&#148; or
&#147;group&#148; (as such terms are used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;)), (other than OrbiMed Private Investments VI, LP, together with its Affiliates) shall
become, or obtain rights (whether by means or warrants, options or otherwise) to become, the &#147;beneficial owner&#148; (as defined in Rules <FONT STYLE="white-space:nowrap">13(d)-3</FONT> and <FONT STYLE="white-space:nowrap">13(d)-5</FONT> under
the Exchange Act),directly or indirectly, of forty-nine percent (49%) or more of the ordinary voting power for the election of directors of Borrower (determined on a fully diluted basis) other than by the sale of Borrower&#146;s equity securities in
a public offering or to venture capital or private equity investors so long as Borrower identifies to Bank the venture capital or private equity investors at least seven (7)&nbsp;Business Days prior to the closing of the transaction and provides to
Bank a description of the material terms of the transaction; (b)&nbsp;commencing when there are two or more members of the board of directors (or other equivalent governing body), during any period of twelve (12)&nbsp;consecutive months thereafter a
majority of the members of the board of directors (or other equivalent governing body) are composed of individuals that qualify under none of the following categories (i)&nbsp;individuals who were members of that board or equivalent governing body
on the first day of such period, (ii)&nbsp;individuals whose election or nomination to that board or equivalent governing body was approved by individuals referred to in clause (i)&nbsp;above, or such individuals&#146; respective Affiliates,
constituting at the time of such election or nomination at least a majority of that board or equivalent governing body or (iii)&nbsp;whose election or nomination to that board or other equivalent governing body was approved by individuals referred
to in clauses (i)&nbsp;and (ii) above, or such individuals&#146; respective Affiliates, constituting at the time of such election or nomination at least a majority of that board or equivalent governing body; (c)&nbsp;OrbiMed Private Investments VI,
LP, together with its Affiliates, ceases to own at least 20% of the voting securities of Borrower; or (d)&nbsp;at any time, Borrower shall cease to own and control, of record and beneficially, directly or indirectly, one hundred percent (100%) of
each class of outstanding capital stock of each subsidiary of Borrower free and clear of all Liens (except Liens created by this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Claims</B>&#148; is defined in Section&nbsp;12.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; is the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of
California; provided, that, to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently indifferent Articles or Divisions of the Code, the definition of such term contained in Article or
Division 9 shall govern; provided further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies with respect to, Bank&#146;s Lien on any Collateral is governed by the
Uniform Commercial Code in effect in a jurisdiction other than the State of California, the term &#147;<B>Code</B>&#148; shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions
thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Collateral</B>&#148; is any and all properties, rights and assets of Borrower described on Exhibit A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Collateral Account</B>&#148; is any Deposit Account, Securities Account, or Commodity Account. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Commodity Account</B>&#148; is any &#147;commodity account&#148; as defined in the
Code with such additions to such term as may hereafter be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Compliance Certificate</B>&#148; is that certain certificate in
the form attached hereto as Exhibit B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Contingent Obligation</B>&#148; is, for any Person, any direct or indirect liability,
contingent or not, of that Person for (a)&nbsp;any indebtedness, lease, dividend, letter of credit or other obligation of another such as an obligation, in each case, directly or indirectly guaranteed, endorsed,
<FONT STYLE="white-space:nowrap">co-made,</FONT> discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable; (b)&nbsp;any obligations for undrawn letters of credit for the account of that Person; and
(c)&nbsp;all obligations from any interest rate, currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange
rates or commodity prices; but &#147;Contingent Obligation&#148; does not include endorsements in the ordinary course of business. The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the
Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any guarantee or other support
arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Control Agreement</B>&#148; is any control agreement entered into among the depository institution at which
Borrower maintains a Deposit Account or the securities intermediary or commodity intermediary at which Borrower maintains a Securities Account or a Commodity Account, Borrower, and Bank pursuant to which Bank obtains control (within the meaning of
the Code) over such Deposit Account, Securities Account, or Commodity Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Conversion Date</B>&#148; is defined in
Section&nbsp;2.1.1(b)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Copyrights</B>&#148; are any and all copyright rights, copyright applications, copyright
registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Credit Extension</B>&#148; is any Term Loan Advance or any other extension of credit by Bank for Borrower&#146;s benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Default Rate</B>&#148; is defined in Section&nbsp;2.2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Deposit Account</B>&#148; is any &#147;deposit account&#148; as defined in the Code with such additions to such term as may hereafter
be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Designated Deposit Account</B>&#148; is the multicurrency account denominated in Dollars, account number *******___
(last 3 digits), maintained by Borrower with Bank. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dollar Equivalent</B>&#148; is, at any time, (a)&nbsp;with respect to any
amount denominated in Dollars, such amount, and (b)&nbsp;with respect to any amount denominated in a Foreign Currency,the equivalent amount therefor in Dollars as determined by Bank at such time on the basis of the then-prevailing rate of exchange
in San Francisco, California, for sales of the Foreign Currency for transfer to the country issuing such Foreign Currency. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dollars,</B>&#148; &#147;<B>dollars</B>&#148; or use of the sign
&#147;<B>$</B>&#148; means only lawful money of the United States and not any other currency, regardless of whether that currency uses the &#147;$&#148; sign to denote its currency or may be readily converted into lawful money of the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Date</B>&#148; is defined in the preamble hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Equipment</B>&#148; is all &#147;equipment&#148; as defined in the Code with such additions to such term as may hereafter be made,
and includes without limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>ERISA</B>&#148; is the Employee Retirement Income Security Act of 1974, and its regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Event of Default</B>&#148; is defined in Section&nbsp;8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; is the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Final Payment</B>&#148; is a payment (in addition to and not a substitution for the regular monthly payments of principal and accrued
interest) equal to (a)&nbsp;in connection with the Tranche One Term Loan Advances, the aggregate original principal amount of the Tranche One Term Loan Advances multiplied by seven and one half of one percent (7.50%) and (b)&nbsp;in connection with
the Tranche Two Term Loan Advances, the aggregate original principal amount of the Tranche Two Term Loan Advances multiplied by six and one half of one percent (6.50%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Financing</B>&#148; means a bona fide second tranche of private equity financing (including, but not limited to, a financing pursuant
to Second Tranche Put Right) with investors and on terms satisfactory to Bank in its reasonable business judgment; provided that the investors and terms set forth in the Series A Purchase Agreement shall be deemed to be satisfactory to the Bank.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Foreign Currency</B>&#148; means lawful money of a country other than the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Funding Date</B>&#148; is any date on which a Credit Extension is made to or for the account of Borrower which shall be a Business
Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>FX Contract</B>&#148; is any foreign exchange contract by and between Borrower and Bank under which Borrower commits to
purchase from or sell to Bank a specific amount of Foreign Currency on a specified date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>GAAP</B>&#148; is generally accepted
accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such
other statements by such other Person as may be approved by a significant segment of the accounting profession, which are applicable to the circumstances as of the date of determination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>General Intangibles</B>&#148; is all &#147;general intangibles&#148; as defined in the Code in effect on the date hereof with such
additions to such term as may hereafter be made, and includes without limitation, all Intellectual Property, claims, income and other tax refunds, security and other deposits, payment intangibles, contract rights, options to purchase or sell real or
personal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property, rights in all litigation presently or hereafter pending (whether in contract, tort or otherwise), insurance policies (including without limitation key man, property damage, and business
interruption insurance), payments of insurance and rights to payment of any kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Approval</B>&#148; is any
consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Authority</B>&#148; is any nation or government, any state or other political subdivision thereof, any agency,
authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any
self-regulatory organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Guaranty</B>&#148; is any guarantee of all or any part of the Obligations, as the same may from
time to time be amended, restated, modified or otherwise supplemented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>HoldCo License</B>&#148; is that certain Exclusive
License Agreement entered into as of March&nbsp;31, 2016 by and between Borrower and OPI VI &#150; IP HoldCo LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indebtedness</B>&#148; is (a)&nbsp;indebtedness for borrowed money or the deferred price of property or services, such as
reimbursement and other obligations for surety bonds and letters of credit,(b) obligations evidenced by notes, bonds, debentures or similar instruments, (c)&nbsp;capital lease obligations, and (d)&nbsp;Contingent Obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnified Person</B>&#148; is defined in Section&nbsp;12.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Insolvency Proceeding</B>&#148; is any proceeding by or against any Person under the United States Bankruptcy Code, or any other
bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Intellectual Property</B>&#148; means, with respect to any Person, all of such Person&#146;s right,title, and interest in and to the
following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) its Copyrights, Trademarks and Patents; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, <FONT
STYLE="white-space:nowrap">know-how,</FONT> operating manuals; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) any and all source code; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) any and all design rights which may be available to such Person; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) any and all claims for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the
obligation, to sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) all amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Interest-Only Period</B>&#148; means, for each Term Loan Advance, the period commencing on the first (1st) calendar day of the
first (1st) month following the month in which the Funding Date of such Term Loan Advance occurs and continuing through May&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Inventory</B>&#148; is all &#147;inventory&#148; as defined in the Code in effect on the date hereof with such additions to such term
as may hereafter be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such inventory as is temporarily out
ofBorrower&#146;s custody or possession or in transit and including any returned goods and any documents of title representing any of the above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Investment</B>&#148; is any beneficial ownership interest in any Person (including stock, partnership interest or other securities),
and any loan, advance or capital contribution to any Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Letter of Credit</B>&#148; is a standby or commercial letter of
credit issued by Bank upon request of Borrower based upon an application, guarantee, indemnity, or similar agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Lien</B>&#148; is a claim, mortgage, deed of trust, levy, charge, pledge, security interest or other encumbrance of any kind, whether
voluntarily incurred or arising by operation of law or otherwise against any property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Loan Documents</B>&#148; are,
collectively, this Agreement and any schedules, exhibits, certificates, notices, and any other documents related to this Agreement, the Warrant, any Bank Services Agreement, any subordination agreement, any note, or notes or guaranties executed by
Borrower or any guarantor, and any other present or future agreement by Borrower and/or any guarantor with or for the benefit of Bank in connection with this Agreement or Bank Services, all as amended, restated, or otherwise modified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Make-Whole Premium</B>&#148; is, for each Term Loan Advance, an amount equal to one percent (1%) of the aggregate outstanding
principal amount of each Term Loan Advance if the prepayment is made on or before the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) anniversary of the Effective Date. No Make-Whole Premium shall be charged if the Term Loan
Advances are replaced with a new facility from Bank. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Material Adverse Change</B>&#148; is (a)&nbsp;a material impairment in the
perfection or priority of Bank&#146;s Lien in the Collateral or in the value of such Collateral; (b)&nbsp;a material adverse change in the business, operations, or condition (financial or otherwise) of Borrower; or (c)&nbsp;a material impairment of
the prospect of repayment of any portion of the Obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Monthly Financial Statements</B>&#148; is defined in
Section&nbsp;6.2(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Net Proceeds</B>&#148; means the gross proceeds received by Borrower from the Financing, less reasonable
and customary closing costs (including, but not limited to, reasonable attorneys&#146; fees, brokers&#146; fees or commissions, investment bankers&#146; fees or commissions and similar items) owed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to any Person in an arm&#146;s length transaction that are actually incurred in connection with the Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Obligations</B>&#148; are Borrower&#146;s obligations to pay when due any debts, principal, interest, fees, Bank Expenses, and other
amounts Borrower owes Bank now or later, whether under this Agreement, the other Loan Documents (other than the Warrant), or otherwise, including, without limitation, all obligations relating to letters of credit (including reimbursement obligations
for drawn and undrawn letters of credit), cash management services, and foreign exchange contracts, if any, and including interest accruing after Insolvency Proceedings begin and debts, liabilities,or obligations of Borrower assigned to Bank, and to
perform Borrower&#146;s duties under the Loan Documents (other than the Warrant). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Operating Documents</B>&#148; are, for any
Person, such Person&#146;s formation documents, as certified by the Secretary of State (or equivalent agency) of such Person&#146;s jurisdiction of organization on a date that is no earlier than thirty (30)&nbsp;days prior to the Effective Date,
and,(a) if such Person is a corporation, its bylaws in current form, (b)&nbsp;if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c)&nbsp;if such Person is a partnership, its
partnership agreement (or similar agreement), each of the foregoing with all current amendments or modifications thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Patents</B>&#148; means all patents, patent applications and like protections including without limitation improvements, divisions,
continuations, renewals, reissues, extensions and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part</FONT></FONT> of the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Payment/Advance Form</B>&#148; is that certain form attached hereto as <U>Exhibit C</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Perfection Certificate</B>&#148; is defined in Section&nbsp;5.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted Acquisition</B>&#148; means any Acquisition, consisting of a single
transaction or a series of related transactions, by the Borrower or any Subsidiary in the form of Acquisitions ofany other Person if (a)&nbsp;total cash consideration paid by Borrower for all such Acquisitions does not in the aggregate exceed Five
Hundred Thousand Dollars ($500,000) in any fiscal year of Borrower, provided, that foregoing cash consideration shall not be applicable when consideration paid by Borrower in connection with a Permitted Acquisition is in the form of Borrower&#146;s
capital stock; (b)&nbsp;the Target shall be in a similar line of business as that of the Borrower; (c)&nbsp;the Target shall be a going concern (other than in respect of the formation of a Subsidiary formed to effect the Acquisition) in accordance
with the representations set forth in Section&nbsp;5.5, not involved in any material litigation that is not covered by reserves and/or insurance satisfactory to Bank; (d)no Event of Default has occurred and is continuing or would exist as a result
of such Acquisition, including, without limitation, Borrower&#146;s compliance with Section&nbsp;6.11; (e) if such Acquisition is in the form of a merger by the Borrower into another Person, the Borrower is the surviving legal entity; (f)&nbsp;if
such Acquisition is in the form of a merger by a Subsidiary into anotherPerson, one hundred percent (100%) of the outstanding and issued equity of the surviving legal entity shall be owned by the Borrower or a Subsidiary; and (g)&nbsp;no
Indebtedness shall be assumed by any Borrower in connection with such Acquisition other than Permitted Indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted
Indebtedness</B>&#148; is: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Borrower&#146;s Indebtedness to Bank under this Agreement and the other Loan Documents; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Indebtedness existing on the Effective Date and shown on the Perfection Certificate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Subordinated Debt; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
unsecured Indebtedness to trade creditors incurred in the ordinary course of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Indebtedness incurred as a result of endorsing
negotiable instruments received in the ordinary course of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Indebtedness secured by Liens permitted under clauses
(a)&nbsp;and (c) of the definition of &#147;<B>Permitted Liens</B>&#148; hereunder; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) extensions, refinancings, modifications,
amendments and restatements of any items of Permitted Indebtedness (a)&nbsp;through (f) above, provided that the principal amount thereof is not increased or the terms thereof are not modified to impose more burdensome terms upon Borrower or its
Subsidiary, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted Investments</B>&#148; are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Investments (including, without limitation, Subsidiaries) existing on the Effective Date and shown on the Perfection Certificate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Investments consisting of Cash Equivalents; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Investments consisting of the endorsement of negotiable instruments for deposit or
collection or similar transactions in the ordinary course of Borrower; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Investments consisting of deposit accounts in which Bank has a
perfected security interest; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Investments accepted in connection with Transfers permitted by Section&nbsp;7.1; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Investments (i)&nbsp;by Borrower in Subsidiaries not to exceed One Hundred Thousand Dollars ($100,000) in the aggregate in any fiscal year
and (ii)&nbsp;by Subsidiaries in other Subsidiaries not to exceed One Hundred Thousand Dollars ($100,000) in the aggregate in any fiscal year or in Borrower, provided, the foregoing limitations shall not apply to any Subsidiary that becomes a
Borrower under this Agreement pursuant to Section&nbsp;6.11; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Investments consisting of (i)&nbsp;travel advances and employee
relocation loans and other employee loans and advances in the ordinary course of business, and (ii)&nbsp;loans toemployees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee
stock purchase plans or agreements approved by Borrower&#146;s Board of Directors; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Investments (including debt obligations) received
in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not
Affiliates, in the ordinary course of business; provided that this paragraph (i)&nbsp;shall not apply to Investments of Borrower in any Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted Liens</B>&#148; are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Liens existing on the Effective Date and shown on the Perfection Certificate or arising under this Agreement and the other Loan Documents;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Liens for taxes, fees, assessments or other government charges or levies, either (i)&nbsp;not due and payable or (ii)&nbsp;being
contested in good faith and for which Borrower maintains adequate reserves on its Books, provided that no notice of any such Lien has been filed or recorded under the Internal Revenue Code of 1986, as amended, and the Treasury Regulations adopted
thereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) purchase money Liens (i)&nbsp;on Equipment acquired or held by Borrower incurred for financing the acquisition of the
Equipment securing no more than One Hundred Thousand Dollars ($100,000) in the aggregate amount outstanding, or (ii)&nbsp;existing on Equipment when acquired, if the Lien is confined to the property and improvements and the proceeds of the
Equipment; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Liens of carriers, warehousemen, suppliers, or other Persons that are possessory in nature arising in the ordinary course
of business so long as such Liens attach only to Inventory, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securing liabilities in the aggregate amount not to exceed One Hundred Thousand Dollars ($100,000) and which are not delinquent or remain payable without penalty or which are being contested in
good faith and by appropriate proceedings which proceedings have the effect of preventing the forfeiture or sale of the property subject thereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Liens to secure payment of workers&#146; compensation, employment insurance, <FONT STYLE="white-space:nowrap">old-age</FONT> pensions,
social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Liens
incurred in the extension, renewal or refinancing of the indebtedness secured by Liens described in (a)&nbsp;through (c), but any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the
principal amount of the indebtedness may not increase; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) leases or subleases of real property granted in the ordinary course of
Borrower&#146;s business (or, if referring to another Person, in the ordinary course of such Person&#146;s business), and leases, subleases, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses or sublicenses of personal property (other
than Intellectual Property) granted in the ordinary course of Borrower&#146;s business (or, if referring to another Person, in the ordinary course of such Person&#146;s business), if the leases, subleases,licenses and sublicenses do not prohibit
granting Bank a security interest therein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses of Intellectual Property
granted to third parties in the ordinary course of business and licenses of Intellectual Property that could not result in a legal transfer of title of the licensed property that may be exclusive in respects other than territory and that may be
exclusive as to territory only as to discreet geographical areas outside of the United States; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Liens arising from attachments or
judgments, orders, or decrees in circumstances not constituting an Event of Default under Sections 8.4 and 8.7; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Liens in favor of
other financial institutions arising in connection with Borrower&#146;s deposit and/or securities accounts held at such institutions, provided that Bank has a perfected security interest in the amounts held in such deposit and/or securities
accounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; is any individual, sole proprietorship, partnership, limited liability company, joint venture,
company, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Prime Rate</B>&#148; is the rate of interest per annum from time to time published in the money rates section of <I>The Wall Street
Journal</I> or any successor publication thereto as the &#147;prime rate&#148; then in effect; provided that, in the event such rate of interest is less than zero, such rate shall be deemed to be zero for purposes of this Agreement; and provided
further that if such rate ofinterest, as set forth from time to time in the money rates section of <I>The Wall Street Journal,</I> becomes unavailable for any reason as determined by Bank, the &#147;Prime Rate&#148; shall mean the rate of interest
per annum announced by Bank as its prime rate in effect at its principal office in the State of California (such Bank announced Prime Rate not being intended to be the lowest rate of interest charged by Bank in connection with extensions of credit
to debtors). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registered Organization</B>&#148; is any &#147;registered organization&#148; as
defined in the Code with such additions to such term as may hereafter be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Requirement of Law</B>&#148; is as to any Person,
the organizational or governing documents of such Person, and any law (statutory or common), treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such
Person or any of its property or to which such Person or any of its property is subject. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Responsible Officer</B>&#148; is any of
the Chief Executive Officer, President, Chief Financial Officer and Controller of Borrower. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Restricted License</B>&#148; is any
material license or other material agreement with respect to which Borrower is the licensee (a)&nbsp;that prohibits or otherwise restricts Borrower from granting a security interest in Borrower&#146;s interest in such license or agreement or any
other property, or(b) for which a default under or termination of could interfere with the Bank&#146;s right to sell any Collateral, other than the Restricted License itself due to the termination or expiration thereof according to its terms. It
being understood that the Restricted License constituting Collateral does not include any Intellectual Property as described on <U>Exhibit A</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC</B>&#148; shall mean the Securities and Exchange Commission, any successor thereto, and any analogous Governmental Authority.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Second Tranche Put Right</B>&#148; shall have the meaning set for in the Series A Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Account</B>&#148; is any &#147;securities account&#148; as defined in the Code with such additions to such term as may
hereafter be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Series A Purchase Agreement</B>&#148; is that certain Series A Preferred Stock Purchase Agreement entered
into as of April&nbsp;1, 2016 by Borrower and the investors named therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subordinated Debt</B>&#148; is indebtedness incurred
by Borrower subordinated to all of Borrower&#146;s now or hereafter indebtedness to Bank (pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Bank entered into between Bank and the other
creditor), on terms acceptable to Bank. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subsidiary</B>&#148; is, as to any Person, a corporation, partnership, limited liability
company or other entity of which shares of stock or other ownership interests having ordinary voting power (other than stock or such other ownership interests having such power only by reason of the happening of a contingency) to elect a majority of
the board of directors or other managers of such corporation, partnership or other entity are at the time owned, or the management of which is otherwise controlled, directly or indirectly through one or more intermediaries, or both, by such Person.
Unless the context otherwise requires, each reference to a Subsidiary herein shall be a reference to a Subsidiary of Borrower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Target</B>&#148; is defined in Section&nbsp;7.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Term Loan Advance</B>&#148; is defined in Section&nbsp;2.1.1(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Term Loan Commitment</B>&#148; is Five Million Dollars ($5,000,000). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Term Loan Maturity Date</B>&#148; is, for each Term Loan Advance, the date that the final Term Loan Scheduled Payment is due, but in
no event later than November&nbsp;1, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Term Loan Repayment Period</B>&#148; is a period of time equal to thirty
(30)&nbsp;consecutive months commencing on the Conversion Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Term Loan Scheduled Payment</B>&#148; is defined in
Section&nbsp;2.1.1(b)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trademarks</B>&#148; means any trademark and servicemark rights, whether registered or not,
applications to register and registrations of the same and like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tranche One Commitment Termination Date</B>&#148; is September&nbsp;30, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tranche One Term Loan Advance</B>&#148; is defined in Section&nbsp;2.1.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tranche Two Commitment Termination Date</B>&#148; is December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tranche Two Milestone</B>&#148; means Bank&#146;s receipt of evidence satisfactory to Bank that Borrower has received aggregate Net
Proceeds of at least Twenty-Five Million Dollars ($25,000,000) on or before December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tranche Two Term Loan
Advance</B>&#148; is defined in Section&nbsp;2.1.1(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer</B>&#148; is defined in Section&nbsp;7.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Warrant</B>&#148; is that certain Warrant to Purchase Common Stock dated as of the Effective Date executed by Borrower in favor of
Bank, as the same may be amended, modified, supplemented or restated from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed as
of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BORROWER: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SILVERBACK
THERAPEUTICS, INC. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Peter Thompson</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Peter Thompson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Acting President&nbsp;&amp; Chief Executive Officer </TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BANK: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SILICON VALLEY BANK</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Jackie Spencer</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Jackie Spencer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Loan and Security Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>COLLATERAL DESCRIPTION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Collateral consists of all of Borrower&#146;s right, title and interest in and to the following personal property: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All goods, Accounts (including health-care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license
agreements, franchise agreements, General Intangibles (except as provided below), commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts, fixtures,
letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Borrower&#146;s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all
substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Collateral does not include any Intellectual Property; provided, however, the Collateral shall include all
Accounts and all proceeds of Intellectual Property. If a judicial authority (including a U.S. Bankruptcy Court) would hold that a security interest in the underlying Intellectual Property is necessary to have a security interest in such Accounts and
such property that are proceeds of Intellectual Property, then the Collateral shall automatically, and effective as of the Effective Date, include the Intellectual Property to the extent necessary to permit perfection of Bank&#146;s security
interest in such Accounts and such other property of Borrower that are proceeds of the Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of a
certain negative pledge arrangement with Bank, Borrower has agreed not to encumber any of its Intellectual Property without Bank&#146;s prior written consent. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>COMPLIANCE CERTIFICATE </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SILICON VALLEY BANK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date: _____________________________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FROM:&nbsp;&nbsp;&nbsp;&nbsp;SILVERBACK THERAPEUTICS, INC.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned authorized officer of SILVERBACK THERAPEUTICS, INC., a Delaware corporation
(&#147;<B>Borrower</B>&#148;), certifies that under the terms and conditions of the Loan and Security Agreement between Borrower and Bank (the &#147;<B>Agreement</B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) Borrower is in complete compliance for the period ending &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with all required covenants
except as noted below; (2)&nbsp;there are no Events of Default; (3)&nbsp;all representations and warranties in the Agreement are true and correct in all material respects on this date except as noted below; provided, however, that such materiality
qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date
shall be true, accurate and complete in all material respects as of such date; (4)&nbsp;Borrower, and each of its Subsidiaries, has timely filed all required tax returns and reports, and Borrower has timely paid all foreign, federal, state and local
taxes, assessments, deposits and contributions owed by Borrower except as otherwise permitted pursuant to the terms of Section&nbsp;5.8 of the Agreement; and (5)&nbsp;no Liens have been levied or claims made against Borrower or any of its
Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Bank. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attached are the required documents supporting the certification. The undersigned certifies that these are prepared in accordance with GAAP
consistently applied from one period to the next except as explained in an accompanying letter or footnotes. The undersigned acknowledges that no borrowings may be requested at any time or date of determination that Borrower is not in compliance
with any of the terms of the Agreement, and that compliance is determined not just at the date this certificate is delivered. Capitalized terms used but not otherwise defined herein shall have the meanings given them in the Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Please indicate compliance status by circling Yes/No under &#147;Complies&#148; column. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Reporting Covenants</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Required</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Complies</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monthly financial statements +</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Compliance
Certificate (&#147;<B>CC</B>&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Monthly within 30 days</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annual financial statement + CC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(a) if Board requires audited financial statement, FYE within 240 days (CPA Audited) and (b)&nbsp;at all other times, FYE within 60 days (company-prepared)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annual budget and board-approved projections</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">FYE within 90 days*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">10-Q,</FONT> <FONT STYLE="white-space:nowrap">10-K</FONT> and <FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Within 5 days after filing with SEC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">commencing with 2017 fiscal year of Borrower. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Other Matters </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Have there been any amendments of or other changes to the capitalization table of Borrower and to the Operating Documents of Borrower or any of its Subsidiaries? If yes, provide copies of any such amendments or changes with this
Compliance Certificate.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following are the exceptions with respect to the certification above: (If no exceptions
exist, state &#147;No exceptions to note.&#148;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">__________________________________________________________________________________________________________ </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">__________________________________________________________________________________________________________ </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SILVERBACK THERAPEUTICS, INC.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By:&nbsp;__________________________________</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:&nbsp;_______________________________</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:&nbsp;________________________________</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BANK USE ONLY</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Received by:_________________________________</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AUTHORIZED SIGNER</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:_______________________________________</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Verified:____________________________________</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AUTHORIZED SIGNER</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:_______________________________________</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Compliance Status:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT C </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LOAN PAYMENT/ADVANCE REQUEST FORM </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>D<SMALL>EADLINE</SMALL> <SMALL>FOR</SMALL> <SMALL>SAME</SMALL> <SMALL>DAY</SMALL> <SMALL>PROCESSING</SMALL> <SMALL>IS</SMALL>
N<SMALL>OON</SMALL> E<SMALL>ASTERN</SMALL> T<SMALL>IME</SMALL> </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fax
To:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;Date: __________ </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>L<SMALL>OAN</SMALL> P<SMALL>AYMENT</SMALL>: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SILVERBACK THERAPEUTICS, INC. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From Account #________________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">To Account #___________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Deposit Account #)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Loan Account #)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Principal $____________________________________</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">and/or Interest $_________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Authorized Signature:_____________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Phone Number:_________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Name/Title:_____________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>L<SMALL>OAN</SMALL> A<SMALL>DVANCE</SMALL>: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Complete Outgoing Wire Request section below if all or a portion of the funds from this Credit Extension are for an outgoing wire. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From Account #________________________________&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To Account #
_______________________________________ </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Loan Account
#)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Deposit
Account #) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount of Credit Extension $__________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All Borrower&#146;s representations and warranties in the Loan and Security Agreement are true, correct and complete in all material respects on the date of
the request for a Credit Extension ; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further
that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Authorized
Signature:__________________&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Phone Number: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Print Name/Title: _______________________&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>O<SMALL>UTGOING</SMALL> W<SMALL>IRE</SMALL> R<SMALL>EQUEST</SMALL>: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Complete only if all or a portion of funds from the Credit Extension above is to be wired.</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deadline for same day processing is noon, Eastern Time </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficiary Name: _____________________________&nbsp;&nbsp;&nbsp;&nbsp;Amount of Wire: $ </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficiary Bank: ______________________________&nbsp;&nbsp;&nbsp;&nbsp;Account Number: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">City and State: &nbsp;&nbsp;&nbsp;&nbsp;________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficiary Bank Transit (ABA)
#:_________&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beneficiary Bank Code (Swift, Sort, Chip, etc.):_______ </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;<B>(For International Wire Only)</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intermediary
Bank:________________________&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transit (ABA) #:_________________________ </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Further Credit to:______________________________________________________&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Special Instruction: ________________________________________________________&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>By signing below,I (we) acknowledge and agree that my (our) funds transfer request shall be processed in accordance with and subject to the terms and
conditions set forth in the agreements(s) covering funds transfer service(s), which agreements(s) were previously received and executed by me (us). </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Authorized Signature: ___________________________&nbsp;&nbsp;&nbsp;&nbsp;2nd Signature (if required): </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">__________________________ </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Print Name/Title:
______________________________&nbsp;&nbsp;&nbsp;&nbsp;Print Name/Title: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">__________________________ </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone #: __________________________________&nbsp;&nbsp;&nbsp;&nbsp;<U></U>Telephone </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">#:________________________________________ </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT D </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF BORROWING RESOLUTIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[See Attached] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g67046dsp285.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE BORROWING CERTIFICATE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>B<SMALL>ORROWER</SMALL>:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>SILVERBACK THERAPEUTICS, INC. </B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>D<SMALL>ATE</SMALL>: November __, 2016</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>B<SMALL>ANK</SMALL>:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>SILICON VALLEY BANK</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby certify as follows, as of the date set forth above: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. I am the Secretary, Assistant Secretary or other officer of the Borrower. My title is as set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Borrower&#146;s exact legal name is set forth above. Borrower is a corporation existing under the laws of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Attached hereto are true, correct and complete copies of Borrower&#146;s Articles/Certificate of Incorporation (including amendments), as filed with the
Secretary of State of the state in which Borrower is incorporated as set forth above. Such Articles/Certificate of Incorporation have not been amended, annulled, rescinded, revoked or supplemented, and remain in full force and effect as of the date
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The following resolutions were duly and validly adopted by Borrower&#146;s Board of Directors at a duly held meeting of such directors (or
pursuant to a unanimous written consent or other authorized corporate action). Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and Silicon Valley
Bank (&#147;<B>Bank</B>&#148;) may rely on them until Bank receives written notice of revocation from Borrower. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>R<SMALL>ESOLVED</SMALL></B><SMALL></SMALL>, that <B>any one </B>of the following officers or employees of Borrower, whose names, titles and
signatures are below, may act on behalf of Borrower: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Title</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Signature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Authorized&nbsp;to&nbsp;Add<BR>or
Remove<BR>Signatories</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">_____________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">_____________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">_____________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">_____________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">_____________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">_____________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">_____________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">_____________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">_____________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">_____________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">_____________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">_____________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>R<SMALL>ESOLVED</SMALL> F<SMALL>URTHER</SMALL>, </B>that <B>any one</B> of the persons designated above with
a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>R<SMALL>ESOLVED</SMALL> F<SMALL>URTHER</SMALL></B><SMALL><B></B></SMALL><B>, </B>that such individuals may, on behalf of Borrower: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Borrow Money</B>. Borrow money from Bank. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- 1 -</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Execute Loan Documents</B>. Execute any loan documents Bank requires. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Grant Security</B>. Grant Bank a security interest in any of Borrower&#146;s assets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Negotiate Items</B>. Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an
interest and receive cash or otherwise use the proceeds. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Apply for Letters of Credit</B>. Apply for letters of credit from Bank. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Enter Derivative Transactions</B>. Execute spot or forward foreign exchange contracts, interestrate swap agreements, or other derivative
transactions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Issue Warrants</B>. Issue warrants for Borrower&#146;s capital stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Further Acts</B>. Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including
documents or agreement that waive Borrower&#146;s rightto a jury trial) they believe to be necessary to effect these resolutions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>R<SMALL>ESOLVED</SMALL> F<SMALL>URTHER</SMALL></B><SMALL><B></B></SMALL><B>,</B> that all acts authorized by the above resolutions and any
prior acts relating thereto are ratified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. The persons listed above are Borrower&#146;s officers or employees with their titles and signatures
shownnext to their names. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">*** <I>If the Secretary, Assistant Secretary or other certifying officer executing above is designated
by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, the __________________________ of Borrower, hereby certify as to paragraphs 1 through 5 above, as of the date set forth above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- 2 -</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LOAN AND SECURITY
AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this &#147;<B>Amendment</B>&#148;) is entered into this 22nd day of
December, 2017 by and between SILICON VALLEY BANK, a California corporation (&#147;<B>Bank</B>&#148;) and SILVERBACK THERAPEUTICS, INC., a Delaware corporation (&#147;<B>Borrower</B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Bank and Borrower have entered into that certain Loan and Security Agreement dated as of November&nbsp;21, 2016, (as the same may from time
to time be amended, modified, supplemented or restated, the &#147;<B>Loan Agreement</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Bank has extended credit to Borrower
for the purposes permitted in the Loan Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. Borrower has requested that Bank amend the Loan Agreement to extend the Tranche Two
Commitment Termination Date and make certain other revisions to the Loan Agreement as more fully set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. Bank has agreed to
so amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL></B><SMALL><B></B></SMALL><B>, </B><B>T<SMALL>HEREFORE</SMALL></B><SMALL><B></B></SMALL><B>,</B> in consideration of the
foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>Definitions</B>. Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>Amendments to Loan Agreement</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B>Section 2.3 (Fees)</B>. Section&nbsp;2.3 of the Loan Agreement is hereby amended by adding Section&nbsp;2.3(f) to the Loan
Agreement immediately after Section&nbsp;2.3(e) of the Loan Agreement as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Unused Term Loan Facility
Fee</U>. In the event that the Borrower does not request a Tranche Two Term Loan Advance on or prior to the Tranche Two Commitment Termination Date, Borrower shall pay to Bank a non-refundable facility fee of Thirty-Five Thousand and 00/100 Dollars
($35,000) (the &#147;<B>Unused Commitment Fee</B>&#148;). The Unused Commitment Fee shall be fully earned as of the Tranche Two Commitment Termination Date and payable by Borrower to Bank upon the earlier of (i)&nbsp;the Term Loan Maturity Date, or
(ii)&nbsp;at </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
the time of a prepayment pursuant to the terms of Sections 2.1.1(c)(i) and 2.1.1(c)(ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B>Section 13 (Definitions Amended)</B>. The following terms and their respective definitions set forth in Section&nbsp;13.1 are
amended in their entirety and replaced with the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tranche Two Commitment Termination Date</B>&#148; is March&nbsp;31,
2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Warrant</B>&#148; is, individually and collectively, the Original Warrant and the Additional Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Section 13 (Definitions Added)</B>. The following terms and their respective definitions are hereby added to Section&nbsp;13.1
in alphabetical order: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional Warrant</B>&#148; is that certain Warrant to Purchase Common Stock, dated as of
December&nbsp;22, 2017, executed by Borrower in favor of Bank, as the same may be amended, modified, supplemented or restated from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Original Warrant</B>&#148; is that certain Warrant to Purchase Common Stock dated as of the Effective Date executed by Borrower in
favor of Bank, as the same may be amended, modified, supplemented or restated from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Unused Commitment Fee</B>&#148;
is defined in Section&nbsp;2.3(f). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>Limitation of Amendments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> The amendments set forth in Section&nbsp;2, above, are effective for the purposes set forth herein and shall be limited precisely
as written and shall not be deemed to (a)&nbsp;be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b)&nbsp;otherwise prejudice any right or remedy which Bank may now have or may have in the
future under or in connection with any Loan Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> This Amendment shall be construed in connection with and as part of the
Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> In addition to those Events of Default specifically enumerated in the Loan Documents, the failure to comply with the terms of any
covenant or agreement contained herein shall constitute an Event of Default and shall entitle the Bank to exercise all rights and remedies provided to the Bank under the terms of any of the other Loan Documents as a result of the occurrence of the
same. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>Representations and Warranties</B>. To induce Bank to enter into this
Amendment, Borrower hereby represents and warrants to Bank as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> Immediately after giving effect to this Amendment
(a)&nbsp;the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which
case they are true and correct as of such date), and (b)&nbsp;no Event of Default has occurred and is continuing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> Borrower has
the power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> The organizational documents of Borrower delivered to Bank on the Effective Date remain true, accurate and complete and have not
been amended, supplemented or restated and are and continue to be in full force and effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> The execution and delivery by
Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.5</B> The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not and will not contravene (a)&nbsp;any law or regulation binding on or affecting Borrower, (b)&nbsp;any contractual restriction with a Person binding on Borrower, (c)&nbsp;any order, judgment or decree
of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d)&nbsp;the organizational documents of Borrower; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.6</B> The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision
thereof, binding on Borrower, except as already has been obtained or made; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.7</B> This Amendment has been duly executed and
delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other
similar laws of general application and equitable principles relating to or affecting creditors&#146; rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B>
<B>Integration</B>. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations
between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>Counterparts</B>. This Amendment may be executed in any number of counterparts
and all of such counterparts taken together shall be deemed to constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>Effectiveness</B>.
This Amendment shall be deemed effective upon (a)&nbsp;the due execution and delivery to Bank of this Amendment by each party hereto, (b)&nbsp;the due execution and delivery to Bank of the Additional Warrant by each party hereto, and
(c)&nbsp;payment of Bank&#146;s legal fees and expenses in connection with the negotiation and preparation of this Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature
page follows.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Amendment to be duly executed and delivered as of the date first written above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BORROWER: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SILVERBACK THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Russ Hawkinson</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Russ Hawkinson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Acting CFO</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BANK: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SILICON VALLEY BANK</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Derek Scalf</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Derek Scalf</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Vice President</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to First
Amendment to Loan and Security Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: DD4C21A0-3666-494F-96DD-069713BD1BC7 </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g67046dsp292.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Deferral Agreement</B></P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt"><B>Deferral Agreement Effective Date:</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;April
6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20 20&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><B>Loan Agreement Date </B><I>(use restated date if applicable):</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;November 21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20
16&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><B>Borrower:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;Silverback Therapeutics, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">If this box is checked, additional Borrowers (&#147;<B>Additional Borrowers</B>&#148;) are listed in the <B>Annex</B> attached hereto (Borrower and such
Additional Borrowers, collectively, &#147;<B>Borrower</B>&#148;).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><B>Loan Agreement:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">That certain Loan and Security Agreement, dated as of the Loan Agreement Date, between Borrower, Additional Borrowers, if any, and Silicon Valley Bank
(&#147;<B>Bank</B>&#148;), as amended, restated or otherwise modified and in effect from time to time.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Guarantor(s) or Pledgor(s):</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&#9744;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">If this box is checked, the obligations of Borrower are guaranteed or secured by a pledge of assets and the Consent and
Ratification attached hereto shall apply and must be completed for each Guarantor and/or Pledgor.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the Loan Agreement and the other terms defined herein. Borrower and Bank hereby agree to the Terms and
Conditions attached hereto and any applicable Annex and/or Consent and Ratification attached hereto, each of which is incorporated herein by reference (collectively, the &#147;<B>Deferral Agreement</B>&#148;). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BANK:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">BORROWER:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SILICON VALLEY BANK</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;Silverback Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Peter Sletteland</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Peter Thompson</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">&nbsp;&nbsp;Peter Sletteland</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">&nbsp;Peter Thompson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;Vice President</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="3"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="3"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">&copy; 2020 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley
Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Rev. March 30, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Deferral Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 1 of 6</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: DD4C21A0-3666-494F-96DD-069713BD1BC7 </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g67046dsp292.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Terms and Conditions</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Deferral Agreement</B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Definitions</U>. Capitalized terms used but notdefined herein shall have the meanings ascribed to such terms
in the Loan Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Interest Payments</U>. Borrower shall at all times continue to make regularly scheduled monthly payments of
accrued interest on each applicable payment date under the Loan Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Extension of Principal Payment Dates</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27">&nbsp;</TD>
<TD WIDTH="27" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The payment dates for all monthly paymentsof principal in respect of any term loans (butnot any other
facilities) which are due following the Deferral Agreement Effective Date shall each be extended by six (6)&nbsp;months. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27">&nbsp;</TD>
<TD WIDTH="27" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent that the Loan Agreement permits Borrower to extend the period during which Borrower is only
required to make payments of accrued interest (and no principal payments) (the &#147;<B>Interest Only Period</B>&#148;) upon achieving one or more milestones or other thresholds, which milestones or thresholds have not yet been achieved as of the
Deferral Agreement Effective Date, by execution of the Deferral Agreement, Borrower agrees that (a)&nbsp;the six (6)&nbsp;month extension of the Interest Only Period provided for by this Deferral Agreement shall supersede and replace any and all
extensions of the Interest Only Period set forth in the Loan Agreement, and (b)&nbsp;any and all extensions of the Interest Only Period set forth in the Loan Agreement as of the Deferral Agreement Effective Date are hereby void, and shall be of no
further force and effect. Nothing herein shall be construed asa modification or amendment of the existing terms and conditions in the Loan Agreement that provide for Bank to increase availability or to make additional advances or extensions of
credit to Borrower, including if such increase or additional advances or extensions of credit require Borrower to achieve the same milestone or threshold that would have previously extended the Interest Only Period prior to Borrower entering into
this Deferral Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27">&nbsp;</TD>
<TD WIDTH="27" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount of each monthly payment of principal following the extension shall be the same as the amount of the
scheduled monthly payment of principal prior to the Deferral Agreement Effective Date.
</P></TD></TR></TABLE></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27">&nbsp;</TD>
<TD WIDTH="27" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All deferred principal payments shall continue to be secured by all Collateral granted or pledged to Bank under
the Loan Documents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Extension of Maturity Date</U>. The maturity date(s) for all term loans (but not any other facilities) under
the Loan Agreement that occur after the Deferral Agreement Effective Date shall be extended by six (6)&nbsp;months, and the corresponding definitions of such maturity dates in the Loan Agreement shall be deemed to be amended accordingly.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Representations and Warranties</U>. Borrower hereby represents and warrants that (a)&nbsp;Borrower has the
power and authority to execute and deliver to Bank the Deferral Agreement, (b)&nbsp;the execution and delivery to Bank by Borrower of the Deferral Agreement and the performance of Borrower&#146;s obligations under the Loan Agreement, as amended by
the Deferral Agreement, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on
Borrower, except as already has been obtained or made and (c)&nbsp;the Deferral Agreement has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except
as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws and equitable principals relating to or affecting creditors rights. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Ratification</U>. Borrower hereby ratifies, confirms, and reaffirms all terms and conditions of all Loan
Documents and all security or other collateral granted to Bank, and confirms that the indebtedness secured thereby includes, without limitation, the Obligations and all deferred principal payments. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Release</U>. For good and valuable consideration, Borrower hereby forever relieves, releases, and discharges
Bank and its present or former employees, officers, directors, agents, representatives, attorneys, and each of them, from any and all claims, debts, liabilities, demands, obligations, promises, acts, agreements, costs and expenses, actions and
causes of action, of every type, kind, nature, description or character whatsoever, whether known or unknown, suspected or unsuspected, absolute or contingent, arising out of or in any manner whatsoever connected with or related to facts,
</P></TD></TR></TABLE></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">&copy; 2020 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley
Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Rev. March 30, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Deferral Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 2 of 6</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: DD4C21A0-3666-494F-96DD-069713BD1BC7 </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g67046dsp292.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Terms and Conditions </B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Deferral Agreement</B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
circumstances, issues, controversies or claims existing or arising from the beginning of time through and including the date of execution hereof (collectively &#147;<B>Released Claims</B>&#148;).
Without limiting the foregoing, the Released Claims shall include any and all liabilities or claims arising out of or in any manner whatsoever connected with or related to the Loan Documents, any instruments, agreements or documents executed in
connection with any of the foregoing or the origination, negotiation, administration, servicing or enforcement of any of the foregoing. Borrower expressly acknowledges and waives any and all rights under Section&nbsp;1542 of the California Civil
Code, which provides that: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:40pt; font-size:10pt; font-family:Times New Roman">&#147;A general release does not extend to claims that the creditor or releasing party does not
know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">By entering into this release, Borrower recognizes that no facts or representations are ever absolutely certain and it may hereafter discover
facts in addition to or different from those which it presently knows or believes to be true, but that it is the intention of Borrower hereby to fully, finally and forever settle and release all matters, disputes and differences, known or unknown,
suspected or unsuspected; accordingly, if Borrower should subsequently discover that any fact that it relied upon in entering into this release was untrue, or that any understanding of the facts was incorrect, Borrower shall not be entitled to set
aside this release by reason thereof, regardless of any claim of mistake of fact or law or any other circumstances whatsoever. Borrower acknowledges that it is not relying upon and has not relied upon any representation or statement made by Bank
with respect to the facts underlying this release or with regard to any of such party&#146;s rights or asserted rights. This release may be pleaded as a full and complete defense and/or as a cross-complaint or counterclaim against any action, suit,
or other proceeding that may be instituted, prosecuted or attempted in breach of this release. Borrower acknowledges that the release contained herein constitutes a material inducement to Bank to enter into the Deferral Agreement, and that Bank
would not have done so but for Bank&#146;s expectation that such release is
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">valid and enforceable in all events. Borrower hereby represents and warrants to Bank, and Bank
is relying thereon, that (a), except as expressly stated herein, neither Bank nor any agent, employee or representative of Bank has made any statement or representation to Borrower regarding any fact relied upon by Borrower in entering into the
Deferral Agreement, (b)&nbsp;Borrower has made such investigation of the facts pertaining hereto and all of the matters appertaining thereto, as it deems necessary; (c)&nbsp;the terms hereof are contractual and not a mere recital; (d)&nbsp;the
Deferral Agreement has been carefully read by Borrower, the contents hereof are known and understood by Borrower, and the Deferral Agreement is signed freely, and without duress, by Borrower and(e) Borrower represents and warrants that it is the
sole and lawful owner of all right, title and interest in and to every claim and every other matter which it releases herein, and that it has not heretofore assigned or transferred, or purported to assign or transfer, to any person, firm or entity
any claims or other matters herein released. Borrower shall indemnify Bank, defend and hold it harmless from and against all claims based upon or arising in connection with prior assignments or purported assignments or transfers of any claims or
matters released herein. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Full Force and Effect; Limitations of Deferral Agreement</U>. Other than as expressly provided in the
Deferral Agreement, the terms of the Loan Agreement remain in full force and effect. Bank&#146;s agreement to defer principal payments pursuant to the Deferral Agreement in no way shall constitute a waiver of or forbearance from any existing
defaults under any of the Loan Documents, nor shall it obligate Bank to defer any future payments or waive or forbear from any future defaults under any of the Loan Documents. Nothing in the Deferral Agreement shall constitute a satisfaction of the
Obligations. It is the intention of Bank and Borrower to retain as liable parties all makers of Loan Documents, unless the party is expressly released by Bank in writing. No maker will be released by virtue of the Deferral Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Miscellaneous</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27">&nbsp;</TD>
<TD WIDTH="27" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Deferral Agreement may be executed and delivered in any number of counterparts and all of such counterparts
taken together shall be deemed to constitute one and the same instrument. </P></TD></TR></TABLE></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">&copy; 2020 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley
Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Rev. March 30, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Deferral Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 3 of 6</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: DD4C21A0-3666-494F-96DD-069713BD1BC7 </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g67046dsp292.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Terms and Conditions</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Deferral Agreement</B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27">&nbsp;</TD>
<TD WIDTH="27" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The words &#147;execution,&#148; &#147;signed,&#148; &#147;signature&#148; and words of like import in any Loan
Document, including the Deferral Agreement, shall be deemed to include electronic signatures, including any Electronic Signature as defined in the Electronic Transactions Law (2003 Revision) of the Cayman Islands (the &#147;<B>Cayman Islands
Electronic Signature Law</B>&#148;), or the keeping of records in electronic form, including any Electronic Record, as defined in Cayman Islands Electronic Signature Law, each of which shall be of the same legal effect, validity and enforceability
as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including, without limitation, any state law based on the Uniform Electronic Transactions
Act or the Cayman Islands Electronic
</P></TD></TR></TABLE></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="53">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Signature Law; provided, however that sections 8 and 19(3) of the Cayman Islands Electronic Signature Law shall not apply to this Deferral Agreement or the execution or delivery thereof.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27">&nbsp;</TD>
<TD WIDTH="27" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Deferral Agreement shall be effective as of the Deferral Agreement Effective Date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27">&nbsp;</TD>
<TD WIDTH="27" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Deferral Agreement is a Loan Document and will be construed, interpreted, and applied in accordance with
the laws of the jurisdiction whose laws govern the Loan Agreement (excluding its body of law controlling conflicts of law). Each party to the Deferral Agreement submits to the jurisdiction of the same state and federal courts to which it submitted
under the Loan Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27">&nbsp;</TD>
<TD WIDTH="27" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of any action or proceeding to enforce the Deferral Agreement, Bank shall be entitled to recover
from Borrower its attorneys&#146; fees and expenses, disbursements and court costs. </P></TD></TR></TABLE></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[End of Terms and
Conditions &#150; Annex and Consent and Ratification Follow] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">&copy; 2020 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley
Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Rev. March 30, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Deferral Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 4 of 6</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: DD4C21A0-3666-494F-96DD-069713BD1BC7 </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g67046dsp292.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Annex</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Deferral Agreement</B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Additional Borrowers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferral Agreement Effective Date: April&nbsp;6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>
</U>&nbsp;&nbsp;&nbsp;&nbsp;, 2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Borrower: Silverback Therapeutics, Inc.&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Annex forms a part of the Deferral Agreement dated as of the date indicated above between Silicon Valley Bank and Borrower, as defined above. Capitalized
terms used but not defined in this Annex shall have the meanings ascribed to them in the Deferral Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the undersigned (collectively, the
&#147;<B>Additional Borrowers</B>&#148;) is a party to the Loan Agreement and hereby agrees to the terms and conditions set forth in the Deferral Agreement. Upon its execution hereof, each Additional Borrower shall be deemed to be a party to the
Deferral Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Name</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Name</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Name</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Name</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">&copy; 2020 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley
Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Rev. March 30, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Deferral Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 5 of 6</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: DD4C21A0-3666-494F-96DD-069713BD1BC7 </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g67046dsp292.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Consent and Ratification</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Deferral Agreement</B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This Consent and Ratification should be signed only to the extent that the Deferral Agreement to which it
is attached indicates that it is applicable. Otherwise, this Consent and Ratification is not applicable and void and the following signature blocks should be left blank. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the undersigned, in its capacity as a guarantor or pledgor of the Obligations under the Loan Agreement and the other Loan Documents, acknowledges
receipt of the Deferral Agreement. Each of the undersigned further: (i)&nbsp;consents to the Deferral Agreement and the transactions and agreements contemplated thereby; (ii)&nbsp;reaffirms and acknowledges its continuing obligations under the
guaranty, pledge agreement or other Loan Document(s) to which it is a party, and that such obligations remain in full force and effect; and (iii)&nbsp;acknowledges that Bank may, but shall be under no obligation to, obtain from the undersigned from
time to time further acknowledgment of its continuing obligation under such agreement(s) or with respect to any extension of the time for payment of the Obligations or of any amendment of the terms thereof, waiver of any default, or forbearance in
the exercise of any remedy afforded Bank by the terms of such Obligations or by law. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Name</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Name</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Name</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Name</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">&copy; 2020 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley
Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Rev. March 30, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Deferral Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 6 of 6</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g67046dsp139.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046dsp139.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MC@$GW% ,CO[A%!8CU('% %NVUG3+O2TU."_MWL74,)Q(-F/KVH K:/XIT+Q
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MJE3GD\=,T <#XYG23Q/-K6H)K[6,EVBK/,%M94544PE"0 H8K.1D \*2-PY
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M:R8"')P..<<^N: *T6O?"K39EG_MS4 /.AVR/:2[8A#*)TC&8NFX^YP<9 H
MTY?&7P]COKB634]31'5M\K64PC4FX,I7!CR#O<#IC&!G- &=I?B7X9:+;6*Z
M=XFU2">R%P(6^RR,X,SJS@AHBIYCP!C'7OS0!T&I?%3P1J$-O)'XAO[5[>7>
M&M["0D,5= IWQ,.[#ZCV- ',>*/$W@W4K'7_ +!XLOVU74K0VSQ7%K.(FVX4
M9"PY7:=W3N[9ZX !>E\3?#6X>2XN?$^ISSRI<PO,]G+DF=4C;_EC@$")0H
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C !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g67046dsp140.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046dsp140.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MY4GG@#=TH TI->N=7\4K?:1>/9VOC30V@LIVE8>3>Q;ALR.5VEB,@=6)!/-
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MVJ:=)!>W3C1/#^ED$,Z(< A<?*KL <@$*&QSD9 /6X3(88S,JK*5&]5.0#W
M/>@!] !0 4 4=9U6WT+1+W5;L.;>SA:9Q&,L0HS@#UH \"N/&NBZCXA?7].^
M*FLZ&\I+_8KJPDN8X\Y&S8"4X'/0CY@1R#@ ][T.VO[/1X(=3U/^T[M0=]UY
M A\S)R/D7@<<<>E 'A7B;P_K@^)6K7$GAA+V_N[V.2SUNY#_ &.S@"  L.$)
M4 #YL\KP"2,@&CX5L+S7OBW/<KXC@U*XTZ!)I=8L+:,)+G $#8)4Y5I!Q@_N
MP<DCY0#J/B!\2/[-MKBQ\.3K=7L#^3=26KH\EI("I"[&4AMP#KT.UL \T >=
MRZ#8:7X:3Q)XFTUI=.UJ[0MI]NVQR[(Y,C%MODX(8X5MI& >!P 9OC774\36
M4)UB>SABL#)]DBC655NHR!Y4H;G<66,CYRG3L<@@$EIX/U_Q)HVC:EIVF&*,
MR)8^:@.V;RPL:32H&(,>$3+*2,QM\IW9(!W*?"+Q#%%#J$.MVT>MV]^+N)B9
M&C8=2&)Z'<3T&"  <\8 *-Y\'O$7]GR7<MY;WFIS23WMXL,C(9IV(9$BW +'
MR"2_!Y Q@4 -CU?4OAA\(;"QALOL7B?5IY7CMQ&&,(! + '(<A!'@$DY8=<&
M@#,CU:=?#HU;Q06E02RZ=I]^ML!="XE@:)GF1@HD38BG/)QM!W$?* 6K>[UG
MX7>)+V&*V<Z-"OVF[=60^;;Q1)##@%B$9I,@\;CQV6@#TW6M T3XF^';473M
M#/;2B0/;RHTUG.!\T;$9&03AE]AZ T >.?$"[U!_'2VGBW5E,\:;XX+"-G2V
MBP[9B#$ S$+MW,/E)4C/!0 [KP-\2M.FO],\)>'_  GJD=E%^Z$DA0&% &R\
M@SQR#G)R><9. 0#I/'%I;:7<1>+_ .S;K5M3LHOLUC:H@>..1VXD(X(.< G/
M Q@9YH 3PG>KH^J+X6N;B;5-<F1[_4[N-MT44K$?)R?DX*A5 'R@' S0!V]
M!0 4 <?\1+Z\M-%MH]/\66'ANZEG \^\V8D3!!5=V><LIR.F.HH YKX9VFIW
MFJ37MSXQT?68;9%26#3[")0&89'[Q54X&./7';% 'JM %74M-LM8TZ;3]0MT
MN+2==LD3]&'6@#@O%U_H_P +_!PT[08;.QFO)&\F!YFBWC*B1ED/1@&!!)[#
M&>!0!YEHDL.E:-+XNU/9)=MF;1$U6^BG%W+E292Z$-YB'(.[&,JO!7( *<YN
M?&WC."ZL-%@;7KUO]+5YY?+C$95!(I#*ZQGHP^\OEX&.0P![1X(^&]GX4BEN
M+R87^I3JR2.4Q$B,P8HBDGC(!R<DD9XS0!T.I>*="T;4[;3M2U6WM+NY ,4<
MK[2X)P.>G48H XW6?B_::/XS'AI]"OGG-PENKDJA<L0 RJ3EEYX/>@#KX_%F
MAR^*I?#*7ZG68H_,>WV-PN ?O8V]&!QG/- %G6]!TSQ%8"RU6U%Q KB11N92
MCCHRLI!!&>H- 'C?COX>RZ --N8M9U2;PY!,5FCE?S!IT+$EY%YRV Q X)Z
MEA\I .?\,^*;?6[[2?"LOAZSD\,W5R8XK7[0SNC?*RNS%ANP68E%P.3\O3(!
MT6A:EJ?@+QH-(N6DN8I&8S1,?)0Q9W3:A(23W# *.-J'D?+D [OQYH%YXE\/
MQWOAJZ5KIU0J(951+R)BO#2CG:!\PP><=Z /,(=2\3Z!<S^%]'FT[P]J-M,\
M4=EINGM<->MY8D5C))O+#;CD[=N\;N!P >[:/'JG_"/6<>KW"'5# !<2PH%
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MOMMGXUFM)X8K:"Z@C:TFT\I;OY8<!Q/,RG8/O<@X&X$[OND HK,OBCP0\_\
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MS),YWGH1VH M^'?ACX1\*ZPVJ:3I8BNMNU&>1I/*X(.W<202#R?PH Z^@ H
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MLHI@>BG9DG!R>".WN" >A:GX_P#"NC:XVC:GK,-G?*@D*3*R+M/3YR-OX9H
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M-N9&4L><D;6Y)/WN_8 U]*T/3]%TZUL+. +;VA;R _S&(,2< GD#G'TH T:
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E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g67046dsp142.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046dsp142.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@!"0 23@#O0! E]9R#*74+#..) ><X_G0 YK
MNV3.ZXB&"5.7'!'4?J* $^V6H./M,73/WQZ9H 475N3@3QD^F\>F?Y$&@ ^U
MVP /VB+!Z'>/3/\ (T (]Y:QDA[F)<'!RX&#Z4 /^T0@X\Y,XS]X=,9_D#0
MJS1LI99%('4@].W]#0 BSPL@994*G@$,,'G'\Z  SPCK*@XS]X>N/YT .:1$
M7+.JC&<DXH 3S8]Y0.N\=5SSV_Q'YT *74*&+  ]#F@!&FC4$M(H )&2?09/
MZ4 .R-VW(SUQ0  @@$'(/0T "L'4,I!4C((Z&@ W+C.1C.* !6##*D$9QQ[4
M +0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ,,T0E$1D02'HNX9/X4
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MQK&H\,:<5C^Z&@#?Q!N<]3D#D]N.G% #?^%:>"_($!\-V)C ("F/ID@DCT/
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MN-1GMI=&O;6&/=MNI7A,<N#@;0LA?GJ,J.!S@\4 :% !0 4 % !0 4 % !0
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M%]I,MM<>5#;7327*[R/-C,,BA<#K\[(V#Q\N>H% &A0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &5
M?38U_280Z#=YK%3 S,<+C(DSA>OW2"6ZC[IH U: "@ H * "@ H * "@ H *
M "@ H Q_%G_(FZY_UX3_ /HMJ 'QI<?;=)!>2>%+=R[E%*%\(%;=]X-@OC P
M06SSM! +TUTEN',BRD* ?W<+OP>., YZ'ITXS0!5_M."=A;R0W<7FJ%W>4P
M))!7>O"L#WSWX)H @&HVUC!%!':W;M&1\D,$FQ02,D$@#8H8D#/12%!(Q0!?
M-U',GEHTT;R$HI\HA@<=<,.@]2,9P* 'D2"[4@_N]O/)Z\X&,8QR>>#P.N>
M":@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H H7BG^T]-8'@.X(^?^X>>#M[?Q ]>,4 7Z "@
MH * "@ H * "@ H * "@ H Q_%G_ ")NN?\ 7A/_ .BVH TK0,+. ,&5A&N0
MS%B#CN3R?J: )J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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ML*990P_><=N,@>YZ9Z>] $5OJ,=XLIME\PQ':P/RG()& #ST&02 &!4@D'-
M#KJ\-K) K1%A-((EV!F.3ZX'  !.2<<8H M4 % !0 4 % !0 4 % !0 4 %
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MUX]>OXT /H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MH C>%9((]R,6APR!C\X8#CG/U!YYR1TS0!*)$E2-HVWHX#JR'((XYSTQS^-
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MW2< ]%SC ! +A5_*92Y9]V0<8QSD=",@<?7% &=ICP+JVII$<O+*)6*QX!P
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M)>!I%/EV[('D,#C*G)V@ -\A)SN!_@R0#IJ "@ H * "@ H * "@ H * "@
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MG0F*WN(PJQ SRLIC@$0^9B<A<G)R3EC]YLMC!% %Z@ H 3'.: %H * "@ H
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M'(/.O[(H3T%JRGTZF0]\?G0!&L.N"8,U_9,IV@I]F8 8/)'SYR0>_3 Z\F@
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M' &,MD V+26::V22XMC;2G.8RP8KSQR..G- $U !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * (I[6WN1B>".48Q\Z!N,@XY]P#^ H K/HVFNA0V,(&,#" %1C VD?=ZGI
MCJ: )X;.W@=7B@6,HGEJ%& JYS@#H,\9QUP,]!0!/0 4 9.L7UEI\MI/?7"0
M(DJ[&D\O +'9D;N1RX4D=G]^ #3BECF0M%(LBABI*G(!!((^H((/N* 'T %
M!0 4 % !0 4 % !0 4 % &7XE$A\*ZN(CB0V<VTXS@[#CC(_F* %\.P/:^&]
M-@>W%NT=NB^4/X !P,8&..W0=!TH T74LH =D.0<KCL>G/KT_&@"K.EUY>;;
M_6$[OWK8'#+\N1TR 1P#Z_4 AU.*[?3=1%O*\<K0DQ,N200O3CGJ.W//!SC
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MD1'9%W= 7 )^8+P#UY8?F.N: ,7Q=937VGZ='! TKQZI9S';'N**DZ,S=1C
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M6=LY:ZNY_.82XNI%=H\J!M!'&,C/?DG'&  "]0 4 % !0 4 % !0 4 % !0
M4 5[YA'I]R[.$58F)8G&..M #-*##1[(.,.($W#GKM'KS^?- %N@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@#F?B$LA\ :V88%G?[)(OEF386#*5;:<'YMK'
MP<G [T :NC+?):*EVMNL:(BPB)V<E0HR68]\Y'&>!G/.  :- !0 4 % !0 4
M % !0 4 % !0!2U<R#1+\PEA+]GDV%"00=IQ@CH: 'Z;;K::;;6Z(J)'&%6-
M5"J@[* %4  <#@<"@"U0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!F:_8Q:GI
M,EA<@&VN"$F7R#*67N !T/N00/2@!^BWEI=Z5:-9/YEOY$;1R+"T:.I'!7/8
M@>IXQ0!H4 % !0 4 % !0 4 % !0 4 % %35-W]DWNUU1O(?#,<!?E/)- $M
MI;BTLX+8-N$,:H#@#.!CH.E $U !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 4=9@2YT2]@D@>XC>%@\"!29EQ
MRF&('S#Y>HZ]1U  MD]S*H=YX719)E8)$03AR%P=QQ@ @]<GD;>E %V@ H *
M "@ H * "@ H * "@ H KW_E_P!G70FQY7E-OW8QC!SG)'\Z +% !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MYY H ;=>,-*LK![JXD"[9(XQ$LL;NQD*A,!6/!W@\XXYZ4 7&U_35+ 7<#'
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M^V9);$26R36T@A:*.9'8,4#X8#HWWNO)P3CF@#6H * "@ H * "@ H * "@
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M8U\Q5?D#;A. !\IXZT =!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % #8XTBC6.-%1$ 5548  Z "@!=H#%@!N(P3W_SS0 Q
MX$DFCE;=NCSM^8@<\=.A_'WH DH * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@"-KB%#"K3(IF;;$"P&\X+8'J< GCL#0!!)J=E' 9OM"N@)7]U^\)
M(;80 N2<-P?0T 2RW4$ E,TJQ)$GF.[_ "JJ\\[CQ_"<^E "+>6SK"WG*OG
MF,,=K-@9/!YX[^E "_:[;=$OVB+,W^K&\?/QGCUXYH FH * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
< "@ H * "@ H * "@ H * "@ H * "@ H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g67046dsp143.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046dsp143.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( 2D!:0,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!L3^9$D@5EW*
M#M88(]B.QH =0 4 % !0 4 % !0!5^WPC5%T\AEG:)I5S@!E4J#CG)P7&<=,
M\XR,@%J@ H * "@ H * "@!"<8]Z %H * "@"*>Z@M?*\^58_-<1IN.-S'H/
MKQ0!+0 4 % !0 4 % !0 A.U2<$X]* %H * "@ H * "@ H * "@ H * "@
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MR*W&UBI8>QVDX/MUH MT % !0!7BO$EO)K8*P>+J3@9X!R!G./FZXQP: +%
M!0 4 4YM2@@U*"QD#B6?_5D $$X8\@<@80\D 9(&<G% %R@ H * (IKA('B1
MNLK;1\P'/XGG\,T 2T % !0!#+=10S11.X#R_=7(R>0.G4]1]* )J "@ H @
MN;N*T,0D)S*Q1 !DDA2Q_12?PH F5@ZAE(*D9!'0T +0 4 -D8I$[ $E03@$
M#/Y\4 .ZC(H * "@!JR(Y(5U)'4 ].2/Y@_E0 Z@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@!-HW!L#<!@'N/\XH 6@ H *
M&F-&=79%++G:2.1]* '4 % !0 A /!&: %H * "@!LD4<J[9$5UYX89'3'\B
M: '4 % !0 CHLB,CJ&1A@J1D$>E "1Q1PQK'$BHB@ *HP  , 4 .H * (4M+
M:.X:X2WB6=AM,@0!B,YQGKUH FH * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H @FAFD8&.Y:(<<!5/\Q_GC\0",VMSN&V_
ME"]P43/?V^E ""VO IQJ#%L<;HEQGGJ!SCIW'?GG@ L0I)'&%EE,K9/S%0/Y
M4 24 % !0 4 % !0 4 % !0 4 % #)8EFA>)BP5U*DHY5@#Z$8(/N.: ,_\
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M]10 R.21Y9E9%5$8!2'R6X!.1VZT 2T % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % %*4'^V[4A4VBWER2/F'S1]#Z>OX4 7: "@"M#IUE;W4E
MU#9P17$@P\J1@.W.>2.3SS0!9H * "@",V\#7"W!AC,ZKM$A4;@/3/7% $E
M!0 4 1R6\$LT4TD,;RPDF-V4$H2,'![<'% $E !0 4 5[BPM+N:&:XMXY)8#
MF)F&2AR#QZ<J/RH L4 % !0!5O\ 3K74X!#>1>9&"2!N(YP1V/H30!:H * "
M@ H KVMA:V7F?9X0AD8LQR23DD]3VR2<>YH DC!#RY.<MQ[<"@"2@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H IR$C6;9<\&"4XS_M1T 7*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H C1<22'
M!'S>_H* )* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"%D!O
M8GR^1&X&!\O)7J?7CC\: )J "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H 8@ 9\)M.[D_P![@<_T_"@!] !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 0->VB,ZM=0J8SA@9 -IQG!].* &?VE8;F47MON5BK#S5X
M(&X@\]0"#]* $DU33X91%+?6R2%=X5I5!*\<XSTY'YB@!SZC8QOL>\@1O1I
M#V/K[C\Q0 ]KNV2,2-<1*A. Q< 'C/7Z<T .2>&21HXY49T^\JL"1R1R/J#^
M1H DH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"
M%TGW$Q2QJ"<D,A;^HH C"W_F,#+;A,#!\MLD\YXW?3OW/IR -7^TS( WV4)W
M8;B1P.WUW=_3Z  M('"@.P+>JC H =0 4 % !0 4 % !0 4 % !0 4 % !0
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MG((_"@">@ H C6XA>5HDF1I%Y9 P)'U% $E !0 4 % !0 4 % !0 4 % !0
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * $(!!!&0>U "T % !0 R9'DB*QRF)^,, #CGT/;M_A0 VVB>"W2-YFF91
MR[8R?R_S]: ): "@"&[A>XLIX(YFA>2-D61>J$C (^E "6D4T$ 2>997& &5
M-@Q@#ID_Y- $] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0!'Y\._9YJ;]VS;N&=V-V/KCG'IS0 XR()%C+
MJ'8%@N>2!C)Q^(_,4 0Q7]G.\20W<,C31F6,)("70;<L/4?.G/\ M#U% $QD
M02+&74.P+!<\D#&3C\1^8H =0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 9FMZ[8Z!
M9?:+MG=VXBMX4,DT[?W8T'+'GMTZG YH T(9!-#'*%9 ZAMKKAAGL1V- #Z
M"@#$46$L<Q6.2-ENR^QBBM+*K'& 3_$1QG&0,C'6@"#4I[%;N*\EMKR>6SA>
MY40,#O(W?NPJM^\8'(  /)&3R,@"/86D>JP7<$=ZKF!C&T1C"(60\[3RSX3T
M/Y9H H:CX?TB^M6\.O/>L9-C;X7C5U2.0R(@; P R[0!R HZ#F@#?@U""VT>
M2;,\T=H"A/E O)MXR%4 '/&, #D4 22:O;HT(19)5EG-ON4 *C D')8CNIZ9
M[>HR /MM3M;KR%1RLD\;2)&X(;:I4'CMRZ_G0!7_ +=MDM8[B>.6&.21XP2
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M;:RMH5AD2RA@D2)8P$0 HH'" CL/3I0 0:9I]M;&V@L;>*W(4&)(E5?E "\
M8X"@#TP/2@!5T^R1D9;. ,A4J1&,J5!"X^@) ] : &QZ7I\+EXK"V1RRL66)
M0<JH4'IU 50/8 =J )9;.VGM3:RV\;VY4IY;*"NTC!&/3!(^AH ?Y,838(UV
MX(QCCGK0 UK:!Y [PQLXY#%03U!_FJ_D/2@"6@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M()5G_?-$V24 168 !N><[3CJ/7IT]0")+><S02O*5,6Y2H<L)%Y )X W?=/0
MXY'O0 0QW<%JX<K.^1@;R#C W<GOG<1T[#CK0!0U>V\02;?[(N[:+#IN%QDA
MUYWYP,@XQC!'.2: -N@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
&"@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g67046dsp228.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046dsp228.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g67046dsp285.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046dsp285.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M[^)_C1]8IKJ'U6MV'Q_#_P 7)-'(VB22!&!VNZ$''8\]*7MZ7<%AJR>Q+?\
M@CQIJ-Z]U<:/)YC8&%9%  &   >   *4:U**LF5/#UI.[17/P\\7'@Z/-_W\
M3_&J]O2[D?5:W87_ (5YXOX_XD\W'_31/\:/;TNX_JM;L)_PKSQ=_P! >;_O
MXG^-'MZ?</JM;L'_  KSQ=_T!YO^_B?XT?6*?</JM;L=9\./"&OZ+XNCN]1T
MUX+<0NI<LIY(XZ&L*]6$H6BSJPM"<*O-)'LU<!ZP4 % !0 4 &!Z4 % !0 4
< % !0 4 % !0 4 % !0 4 % !0 4 &* "@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g67046dsp292.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046dsp292.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( $$ V0,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /8O%6MRZ#I<5U%$)&:81X)QP03Z>U=6%H/$3<5V//S#%/"T
ME-=[?F<@OQ)O&X^QK_WV/\*]'^S'Y'B3SB:V;^Y"?\+)O?\ GS7_ +['^%4\
MK[6#^V)\N[^Y"?\ "R;T9)LU_P"^Q_A4O+4ET)6;U962?X(!\2;WG%F/^^Q_
MA0LMOM8?]KU8.TG^"+VE>/KJ^U&.V>U"A@>=_3 SZ5C6P#IQ;T.O#YG*K*U_
MP14N?B/>13R(+,!58J#O'/Z5I#+KQ39C/-9J;C=_<B&X^(^JVOEF;3BBR#*L
M6&,>O2LY82"ERHT68U8J\G^",Z7XOW\9_P"0<OM^]'_Q-*>#C#1FGU^I)7B_
MR.U\#^+)_%=K<SRVXA$3!0-V?7V%<%6*B]#UL/4<XW9U>:Q1TH=3 * "@ H
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M+OU%$:40E6J(K?\ "3ZX.FK77/\ M5JZ,;$1KU+A_P )1KO?5KD8_P!NE[&
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M:Q.H* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
)* "@ H * /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g67046dsp49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046dsp49.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 M !0 4 % !0 4 )0 4 % !0 4 <IXGUG -C;2D,/]85./PS31FW?0Y,$$
M $Y]<=JJV@XNW0<N,X SZ'.#6;L6]430320L)8I#&_JO%3;4RDV=AHGB!+YA
M:W!"W '!_O\ _P!>M'H-2OH;](T"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * %H * "@ H * "@!* "@
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M!(!PK=<#K4V<0Y6MCT/2KAKK3897&&*\_AQ5%*]M2Y0,* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H 15"YQW.3S0 M !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !2 *8!0 4 % !0 4 % !0 4 %
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MX&OZKOEO9R7C$AR5!_B/N:QG.WNH%$[VLV5L+0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 AH Y9_"L\VKW=_+/:1M,%7_1K<H9 LBN#)\QW, N ?]HT
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M<O"VT(X5<[@#Q2C*V@6ZG401)!"D48VHBA5'H!4[@<UKO@;3M<OFO6FE@G?
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MA32X-=;64$OVLN7R7^7)&#Q2N[6 -7\*Z1K5REQ=Q-YJC&Z-RI(]\=::DX[
M:MC9QV%E%:Q-(T<0PID8LV/<GK4,"Q0 4 % !0 4 % !0 4 % !0 4 % !0
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MVGW(!;SK>38,^I'2K4GL!=\(ZA<:IX:MKJZ??*2RE\8W@,0#^0J7H!N4@"@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
> % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g67046dsp59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046dsp59.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M' /.<8H /3US0!+!/);W"SPMAT8$=^: /387,D*.RE2R@[3VH ?0 4 % !0
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M<G'##'2@#8^(NOZ5X@^%^KRZ3?)<I#+"KM'G@^8AQS[4 <I\.M5NO KV::M
MJZ-K*+,E\J?+&VWHS?GQCCK0![I'(DT2RQ.'C<95E.01ZB@#%\57(ATGR1UF
M8+^ Y/\ +]: .'6)I"%0;F)  [F@#6O] EL-+2ZDP6S\ZXR%':@#)(&, 8P>
MU  DK0L^QMI9"I('8T -!!/J![4 =UX8L3:Z:)G7#SX;&.0O8?S/XT ;,K^7
M$[[6;:I.U1DGV% '&2'PS_;I=O"+'4RAG,G]GH7(SM+9_3UH W7ETC6]1FTV
MYLXKBXLTCE9)X0P3?G;C(Z_*>E !JT^CR1WD6IVL5REA +F420APJG<00".O
M[L\>PH I:)-H\4D<FF>'I;(7"@"5;(1 KU&2.W.?QH BAUS1=,FOY[+1;E0D
MKI<SVMB2&9"=V2HR<'/ZT :6H3Z%J&@#5+^*WNM-2/[0'FB#@#'4 C@X_&@"
MMH9\./IDFL:586]O&5=9"EN(WPI^96&,]1T- %&P\3>'M.TF*YM-,N++2Y@C
M+*MBR18; 4G X'3GM0 L\WAJVGO]#CT SJ/+>ZA@L-\9)Y7=@8)X_2@"?3[?
MPS8ZO9QVNB066H7D;S)BS$;X3"DD@<'YA^!H T94TG3-:CE%G$FHWX9?.2(;
MY-J[B"P&>@H QKS7M#N];MH[O0;R;4K=//@+Z>6DC7(^93CCG'2@#3OK+0M?
MD\K4],@N'@@67;<P@E$DW#'/3.PY% &5877AJ?3'M]+\/-/I4D@+-!8#R9&!
M^]C W8('.#TH MZC>:$XE\/2:0^HPP*OFVT5IYL48ZJ#QMST..O2@#;TI+6/
M3+=;&U%K;!?DA$7E[!Z;>,?2@#G/%UP&N[>V!QL0NV3ZG _]!- #O"=I')--
M<N"6CP%^ISS_ )]Z .HGA2>%H9 2C#!P<4 >:3)Y-Q+$&RJ,5!]<=Q0!$5&.
M1SCK0!H:';0S:S;13@%"3P>^ 3_2@#T7I0 4 8.U1X^W8^;^S<9]O,__ %4
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M]LUM;",VL1AA^8G8A() R?8?E0!)>Z59W\]O-<Q;Y+?=Y9#$8W*5;IUR#WH
MFL[2"PLH;2V39! @2-<DX4# &30!G7_AC2M2O#=W-N_GLH5GCGDC+ =,[2,T
M 2SZ!IUSI::=/ 9+>,AD#2,60CH0V=P//7- #=)\.Z;HKM):12&9UVM--,\L
MA7KC<Y)Q0!;.G6IU1=2,0^UK$81)D\(2#C'3J* 'K:Q)=R7(7]](BHS9/*J2
M0/S9OSH Q9/!>C-<B:-+BW&[<8K>ZDBB)]=BL!^E $]]X6TS4+MKF99UD<@O
MY5S)&'P,?,%8 T :=G9V]A9Q6EK"D4$*A41!@*!0!/0 4 % !0 4 % !0 4
?% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g67046g02k15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g02k15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1><4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %X"^8!8X0DE-! 0      $X< 5H  QLE1QP"   " '\< E  "')R,3<V
M,S8R' (% "U-:6-R;W-O9G0@5V]R9" M(%-T;W)M("T@1FEG=7)E<R!2:61E
M<B!T;R!3+3$X0DE-!"4      !"36DJ#V#D?VAR D-$IX9H;.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&4"%(         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             !BP
M!"0          0                         !              0D   !
MBP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
MBP    !29VAT;&]N9P  !"0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   8L     4F=H=&QO;F<
M  0D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MV9?9<ZG&  KCU;W_ $&D^[9#?=;;L]_I_N?3L3=-ZBW(+JG/;8]I(:]@(0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( .("7@,!$0 "$0$#$0'_Q  ?  $  00# 0$!
M        !P4&" D#! H! @O_Q !D$   !@(! 00$!0P-!P8-! ,! @,$!08
M!Q$("1(A,1,405$5%R*1T1894E-887&!DY75UA@R-71UDI:7H;&SM/ *(S0W
M0E?!)'>8MN'Q&B4F*#,V.%568W+3USE'@J*RQ=C_Q  = 0$   <! 0
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M0))04*&Q9'M_V^=X5,^NT]H=]TQ:?Y.T+]4\G_-'AW]&TOV[G_4J'8T?[/\
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MK!U02U"Z;[WLTNAM^Z]Z>XG3T#LRZ/)M_&S=GL[.P[?L$A#Q:\TB=^2/95N
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MMUU[>U29U>4N-UK<S -V-A@;&5W'Q\$Z9.EU%X&0?HMA3<J%3*DN9-10!$Y
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MT=$6'J'V;/O-A4>OS5XJ;:1M\C6J6+5+ZFGEEE7Y6L6T=LXY%FWBKE(6P,I
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M<+H$59*J$$S5RX2$%!(I([Y>.>?;Q]_SXYX\^/#S\L(OUA$PB>6$5-D'J3=
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M/DCX@/R@]WN$/'G[P 7PQCN,-HM<VFZ#K)F1.\:'N,#?<ZZQ"PLR^'.&AB(
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M37TP=X!#W_X^]A%IOWGI&B]!]BM_45K5A7*+T_[*N;^\]5A[1>WL'4-72*S
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M$--1K7,!\73J?%9_$VPPB(Y#QU,=_,03/B=]C\8?OM$QY\> Y#VAX!\_X?\
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MP ?$/,>>1$"]']'X,8JZ):19-/<1]))'?HZ>6VQD%8;&B(MP1K_.'?0@A@T
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ME!G7,]HC5<M],M9E/T?XNQQ =7N,*I4P3!<\8I:UG #G#*+SW@$C993!Y!^
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M7NB3S[QQ5Q+!K3+3=_..J=BRF]@<R'DYRW+J"W< :=!J5M-*TL[MXK/:!5(
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MAP?4-7(:UT]GU X,)%*FPG-D#G%S@TDQZIELI2D*!2AP    'L  #@ _Q_4
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M$R2>J)D$4;;>UNTVYKJR:\?2;B&:V1%@BM)-&Z3IPU!C+,)4HIH+'334%0[
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M  )6=1!:*@$@:$#-OY>WO]BSY_8T?Y0/_O&VE_TC]?\ ZZ9@?Y2]'G_!V?\
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M,;'BHY:(R<RV2,0 HN?.PCP)[_GV*H-/XK@C.O/9FG8'IEI'490J2KMJ_L=
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M:],>#*KVCW!2J0/+*")A$PB81,(F$4$=47_LV=0'_,IM/_J1-Y>8;_ZEA_\
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MNKF@CQ]3?DS\'89C&+8SQ%B-"G=.P'Z'2PZC6#:E*G>7@N'NNS2<"Q]6A3H
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MY;M[WNHFHQOBXT\HZ3*=-)U'W_/X+RF5]R#F*8.$C (&;)#SS_M 7P'D.!Y
M0Y]@_AST95@/>"#JZ1&G=L9]F\J]9JT0>HV.Q,Z&1&ZLO9<#;=S3%7U1 J.7
MLK)H3TDT;)%.NH*-4K4Q;'A2)^WEG"+@(\>T!Y[PADAK6^'6]:^J 4V-=3!=
M(;)JU64F23(WJ">L\MU0K;@;QU[H!\3]_@-.WK.0)(5"(5(<IN6Z0"!3"(!\
MD!$.?Z/Z\KUVD5''I)\QWQ$'J)52EJV")$=W4P.OME?=LRD]*U5"DQBRZ[NT
MR#*OQC%,QC&7?S;M&-9H))AR)U%7+E),A0 1$QP H<B #3HBG3+[I\-%&F^H
M][A(:U@+B[;N)[R-]84*Q@9=P>7(;_,<N6DA?T3:1!$K-1JM<3'Y%=K4%!D\
M/]B*BFC G]#?VB/'EGC:O4-:XKUB([6M5J0/^=[G?_ZC83$[0K;P5V921,(F
M$3")A$PBMNX56)O-4LU,GTU%X&VU^8K,R@BH9%5:+G(]Q&2":2Y/EHJG:.E2
MIJE^4F80.7Q#*E*H^C5IUF$!]*HRHPD2,U-P<V1I(D!1!@@]"#KMHO/P[_R=
M'1JCE<[+J'VLU9F64,V;N*Y47:Z" F$4DEG1"-".%"$X*=8K5 %# )@23*($
M+T%OI&Q$- =86;W#=V>L)/,AN8M;/=[28"N_ICR "UI(Y@Q[H[EUO_!S=+?=
M';0_DI5/_NY'_P"X]_\ HZS_ &ZJA]+/V!YGX)_X.;I;[H[:'\E*I_\ =Q_]
MQ[_]'6?[=5/I9^P/,_!/_!S=+?=';0_DI5/_ +N/_N/?_HZS_;JI]+/V!YGX
M+(SI>[(C771/LI?=%6V_=;M)FK,I4!A9^"@HYAZM//(M=5X#B..9P"[<T8F"
M9..X8%#][Q ,Q.-<776.68LJUG;46"LRL:E-U0OE@<T  G+!SZR#H%3JW!>S
M*6P"9T,[ GHMA&:^-AX*P.Y^?N3")A$PB81,(HFW52E;W09F$;!R[,B#AJ'@
M'+AL<%T?$?\ YA"@ ?AXS6>+^'J'%7#^*X#</[*GB-JZDVL!)H7#'-K6E>-0
M[L;JG1JEI'KM8YNDR*%Y:-OK.XM'G*:S"UCHG*\%KZ;H&KLE1H<0-2# 6GV5
MB9* >N(Z59+M';=4R:A%R&3$>#"'>)W@^641Y$HE\Q$> X\<^>W$/ 7%G#5]
M5LL1P6](8\MHW5K;5KFSNP28?;7%!E2D[M/K"BY[:S"2UU)CFN:.6W6&7UG5
M=2JV]4P3%1C34IN;R<VHV6N!&F\@@AP!!"DC46NIF^VV)2;,7/P8S?-W+]Z*
M9BH%204!04RJ"7NF%02 7@/'@1 0 H\YT7T5>BG'L8QW#L8QG#KK#<#PRZHW
MS_IM"I;U\0JVSA5H6]"WK,;6?;U*P:*]<L;1-$5&LJ%Q!&6P3 [FXN:5Q<T7
MT;6C4;4=VK<KJQ8<S6,IOASFN<!F<6Y2V1()"W&-D0;MT4 \DDB$Y]_=* >S
M\&>Z&3E$D$ZZ@ 3!B= !RY#N[UT5YEQG?F)G7W_>5SY,I4PB81,(F#L>:#<<
ME@IUEZFE[?'Q%L@6BKUW!IKHN6R)0.HHT6,4Z@D+P(F,F)0.4O'B &#QY\-(
MXRX?K8S:4G6H#KVT+GT&$Y!68X UJ8)(:'AK0ZG.A<"-R%W?T&^DJSX#QN\M
M\9<YF!8XRA2N[AC75'V%S;/J.M;H4V>N^D14JTKD,#G"FYM0-<693JT.Q>)J
MBW4:.2+E-W#)&04!0#@(AW1)W1, CQX!QSSX9Q5^%XE3J&DZPO!4#@ PVUQG
M,F! %(@F2.>TNV"]WT>+>%KBT%_1XCP*I9.:7BY&+6 HA@&KGN=7'9@'0YX(
MW( !*V"]&>H9MG/J[!FF2S)NDT5:1:;@ADU% 7[OIENX<H" &[A2D$1\@,/'
MB''5^".&KC##5Q&^IFE=5Z8H4J#M'T:1.=YJ _5J5"&0 /58T@EQ,#QQZ?O2
MKA?%8M.&.'*XO,+L+@WF(8BS-V-[>,;5HT*-LXF'V]NVM4#JS0T57Y0PN8PN
M?LQSI(VUT/3I\[^U>82(VU'(Q$ID5!,(F$3"+C5("B:B8^1R&*/_ /(!#_CD
MKA(CVGKW1X[3[E,V 9/SR/E,KPB=KWV9VX]3=0FQ-V:TI,_=M4[.L3^XNS5J
M-<3$E4[#..%GL\WDHU@1>0-%.I$SJ4;2J;91JU(Z.S>JHF;I*N.S<&\5V-Q8
M6^&WUQ3MKVSI,MVNN*C:=*YHT_5I/I5'D-SAN5KZ;BUV8$L#FC3!7MG5HUJE
M5C7/I5'=H7-!.0O,EKHD@AV8R0 00"2Z2=4.I.E?J"W=;XNEZ\U1=9:4DGJ#
M([I>ORD="Q8+J F+J9FGK5&.C6J0"90YW"Y5%"D.1NDLMW4S;??8YA.'4'W%
MU?VS*;&N=E;6IOJU,O\ 5I4FN-2H\D@-:QI))Z219LIUJI#&4JA<X@3E=E:#
M,.<Z &-$:O<0T=9T7]#+LY.E1+HZZ4M=Z95<$?3D>@\G+9)$*)22-IL+DTG-
M.$0$"F]52<J^HQ_?*"I8YHT*L)EBJ&/Y^QO%7XUBMUB):6,>]M.A3<-64*;0
MQ@=T<6S4<8@O>XB003LEO0%M092F7$%[R"(+SIIKJ! :(W#9C61G7F-4Z81,
M(F$3")A$PBEK7/\ H4E^^DO[$<M:_P!<?JC[RJE/G[/Q4C9151,(F$3")A$P
MB81,(F$3")A%K4[8F(G)OLQ.M=C ,G\D[^(NS/GT=%BL#Y_6XA9C+6]F@5 Q
M%E1=5-E-('03,4ZZ1SHE, J!R180]1FIME[LZTNB'9VA=3[?G:CK[;NDMIR,
MI.U+0L1TCR&LU=>OXZP[F8[,K+B,W_);9@JG-,:]4JE89J9K:SR#C"HT@8HA
M)!X16I0-=WG=/8[=I;4M35]_<W&[=K=HV&@:M!MR>M6*$LNTKS&5]A )K+)H
M+I3=D:S;J-.55-%<'Q!(8P& PD5Y;'T-U;4.1Z-8/8?[(GJ#T?!:YV$E?*_T
M?GB>FV\UC>#Z/U*UT\ZO[&G;3HB=DJ-1CHB^,E)B1L<A 'F'1'-Q@',>5D18
MBR7ZGM*]1^SNM[7%@H4SMB"U?2NCK:\U6UX?9%JJ6KE.JR+OE8=Z;3V1$5JP
M1S6W@R1/(OW4'/,Y2LS46U<LK"QE8H31ZQ%H(L3_ +1'IUZ=BN=X3W42RGMJ
M;?Z5M8V+55QMVT*".R]@1"VV;;MIS3MPH=6>W-DMX^Y1<3$1MTE-*ETC15HY
MM6WU6K+(&MAC0(LA.G.I=4%\U3J&]Z.NW4_O[2P](E*J^X;BSN^Q(._;!M5<
MZ]"R?5/0:&^O.Q@M$?M8=,,KY3:1-15R82+B*:1B=4M3%9S'"B17\SZ8.ON^
MN82&L!NLVHZ53UCVCMCU/57G4%>HS:%,:R$CJN0Z-J1N&X5+8:MAL5\:3#"X
M2]8CK%:[2^:PZB%?LTJ_:IRK!P3Y^?DKT9]-8[$'IXT9\;GPH&U?BBUT&R G
M 2"9"]!48@+3\+ @(H?"7PV#WU[T7^;]:]*)>>>1(JU=]<S]OD6KZ+W%M#7B
M+9F#52+HXZY^#GB@+*J^O.OJRUU<7_K@D4*@(MGS5KZ)%/\ Y*"OI%5"*R_B
M-N7W4/4+\^BO_P %X1<S?2=P0<(+GZF=_NB(K)*G:N1TAZLY*F<IS-W'J^D6
M[CT"P *:OH'""WHS&]$LD?NG*1=CJ2TS#]0VA=P:.GC)IQ^T-?V>G"[4+W@C
M7TQ%N$(F8( >/IX:5%C*MS  ]UPS3, #QP.0PG$*F%8I88E2G/975&X GZ[6
M5 :E,]SZ8<PZ@$.(3<1UY_/P7\]R-E9G5DS9]4[0CG%:ONNIN1JMGA) #).6
M$M$.%&KH@E.("HW6,3UAFY+RDZ:*H.4#G152.;V#1?2Q&A0OK-[*MO=TJ=>D
M]I#FEM1@< "1NTN((/K-@R&ZQ794ANNG=MTU@:]VFG/9;A^PRT"\WOU0WGJ5
MFX<76KM+U6:HL"Z?-_21D_L*_1RL9),F*ARBDZ-7:6XD#RY4Q 6Q['$=X>\N
M7.9^E7&F6.$VN"4:H%Y>UJ=U6:QWKT[6W<'L+H(+2^Y:,CG0X]D2  -:=0YG
M2'3'O^&D::=%K2WYJU]T7]2NWNG6U-W;")K=H?2>O9!\51-.P:XFW*SZH3#%
M=0"E>HA'G"*>+H"H1*7BY%F807;J$#=\ Q2GQ%@EAB5-S'5'TA3NV,+0:5W3
M:UM9CF@PPN=+V@@9FO!4U)^69]^@@QM\_C$Y]G%II_U>]=NG8M@P<O==Z2L,
M-N?8TJ1(ZT8T;TN21EZK"OG!2BB5Q9;4SC&2+,X@JY8H2RY"&29+F3Q/'6+L
MP+AF^!J-;=8BQUC:TP0'YJPRU:S!O%*BY[R[9KLG,@&%1X<0 >I[AKH/<>F\
M]Z]Y" >!A]G@ ?B ?^ AGEE4USX1,(F$3")A$PB81,(F$3")A%:%X_<!;]\M
M/[8,F;OY?O-4KMO/]UR@[+Y44PB81,(F$3"*U;'>J/4%&J-NN54JRKY-11DE
M8[#$0BCQ-$Q2+':IR;QL9P1,QR$4.D4Y"&.4IC (\93?48TPX$G?0#3P,J8-
M<1H=.DJUK)':DDHM>TV5S3@A&:J1'5AD).*0B6ZJRJ*"";F55<$9I**K.FR*
M157!3**N4$R )UB -$O9)(D: #3D)T^MRV\>@U53UN<'6? Z:[>/*8YGG5HF
M1UM7$J^TBIFHQI+67FK)(RT2D:RE J1^8  < ::#N+HGYCO6>2+(G_:JIB:(
M?3']4D:?U1TC:8TU \2-MX$//.(C8D#0F#ITTCI[3%_#Y^?/].7 (< 1L52(
M@D=%\R*)A$PB81=.1D8^(8NY.6?,XR-8(*.GTA(.D&3)FV2+WE7#ITX.F@W0
M2+R91590B9"@)C&  YR4O#9F=-]O=KJI@TG:/?[](5FEV9JZ1AI&83V%07L!
M'*MVDK*IVVO+Q+!=\82-&[]^60,R:*NS%$K9)PLF9P8!*D!Q 0"D:K#(()$1
ML)U[Y\Q]X4P:X;'J=]((@R(YB1/,2%:;J+T2,[&)NGVOBSTRR2F(AFK-0:<A
M+1SA)5=O*1K,SLJ[Y@J@@LNB\;)*MU$D55"*&*F82T\[)F#SY"2.6NNO+I^$
M^O.-N4QKN")U_'NYUJ#VSIAY6U+%7=GZR?5)E(DA%I^(NU6=UYK+J-$'R<2M
M+LY-2-1DE&+EL](P.X*Z.T<(.@2%%9-0\[:M-NS3XP)\#J(]FGM4KFN=N1X:
MP/G528BLDX2270537073(LBLB<JB2R2A0.FJDH03$434(8#D.0PE.40,41 0
M'*S7!PD: GPU5,@@P>7?.BY,F4$PB>>2N<&@N,P.G?HH@28"IPS$0 "/PK&\
M%DBPPCZ\UX"7,8I2Q8B*OA(F,<I08C_RH3& H)=X0#)>U:03K GIR]JFR.[E
M41\/P^/A[0X\/'W?]WO#("HQVH!D=0)^_P"=4R.VD0>\P?F%8B,SK?81W$0Q
MGJA;UT&*$FZ81DU$33EO&NI*8A6T@N@R<N%4&3B8K\_%(/#E(@K)0<NP34,Z
MBWR2$N9CC :=)(@ :SJ8Y'G._7NF#2W8C4ZZ>^="?!=$M6UE0_5Y1PVK59(]
ME(N&:/I%PQC474U.R3:(@XEJN]52(M*3,L\:1<2P1,9W(2+ILQ:)*NETDCO4
M DR2-XZ3$2?/?WIJ)R@ $:\CKUZ](UCP4D<  < '[7@. ]GASQ[O ./#S#D.
M0XR<5&D2 =>X>_52ECB23$G4F=SY>SV>"^@(#Y?X\>/Z_P"L/>&1SCO^?:F0
M]WS[%3&$U#2CJ98QDO&23VN22<-86;!^U>.H*76BHR=1BYENW546BY%:#FH>
M928OB(.CQ4M&2)4A:/VJRIM1KR0)D"=1RT^*E+2!)^=_@JGDZ@F$3")A$PBE
MK7/^A27[Z2_L1RUK_7'ZH^\JI3Y^S\5(V4543")A$PB81,(F$3")A$PB81=*
M1CH^78/8N68M).,DFCEA(QT@V1>,7[%XB=N[9/6C@BC=TT=-U%$'#==-1%9%
M0Z2A#$,8HD7!#0<+7(B,K]>B(R"@81@TBH:$AF+:+B(F+8($:L8V,C6*2#-@
MP9-DTV[1FU12;MD$TT44R)D*4"+I5>HU2CU^,J=*K,!4*M"HG;0];J\/'U^
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MFJ_U@VG;LA.7A&7M\?<-9T9] J1VRJ-%Z+8#9XV7M;N@W!@]JU#A*K+NS?\
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881,(F$3")A$PB81,(F$3")A$PB81?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g67046g06o02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g06o02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@44&AO=&]S:&]P(#,N,  X0DE-! 0
M    %_B^838X0DE-! 0      %4< 5H  QLE1QP"   "J  < E  "')R,3<V
M,S8R' (% #1-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52 #A"24T$)0      $!_&N<G0:<9D%J?:JKW5F1 X
M0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0
M<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT
M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P
M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q 9EQZX         IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M        /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      $K   $:          !                          $
M    !&@   $K                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   $K     %)G:'1L;VYG   $:     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !*P    !2
M9VAT;&]N9P  !&@    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     8X0DE-! P     #8,    !    H    "H   '@  !.P
M#6< &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( "H
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M<YSG*G=UNNK(%'V/,0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@ H0)= P$1  (1 0,1 ?_$ !\  0 " @(# 0$
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MZ1MG<'66CMDPP(;[2FSZG2;%%F5JE3[6[8A1RY$73.:^0#N@,^IT:0^[??\
M%] 7_P#76^?TGZ)U%L!>PJ#MAZX:^JYZ5LO5C3\?7-XFSA49V=9:9%E3RDN"
M *2\O28 ^80ERQ[2\0I3ZY##F> ;GX X X X X X X X X X X X X X X X
M X X X X!U0-M^7SM!JRJ>:&L,Z^[*["LW7S=6YZCUUW7K/1M3M.F^OP !K&
MM3:Y#V5:7'($5A==.2IEG)OV,+9I"0\^/)DN28ZVXK<\_P#'R[W!B>Z^^'>V
MR=D^H^I*+N#M6. ;#\66E^T-Y'=0NL.FNP&Q"VU[/:!0*P6RP5V]0($8!2)D
M<OEJ?-%36H@TXJO#H0I+15]UN@X#R?>2/M5UB[=;UU6#[B[<U(!T_P!.]$;
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MB+/K=W ,0QUD!E1!6(ZU+3 A.M2V9;'TWXR(LZ506 < < < < < < < < <
M< < < < < < < ],C*\,N9;4A"_@KX*<]_32K"<Y3ESXY3GX8SZROTI.?CC/
MZ\ ZIG7K?O=#1F^+YJCR"[R[9T[M'L?5/;BT:8"/-:@M?1O?,'7U*.78*4T
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MED1^U;4%A5NUW]^.%C#2UGME=&PAPP!:RAF$0?LP4; ACA9Q4^# CM1&&48
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MTW3)K9$-6CI"N*9EF?9"/"G3GI+V$S98^"^\SEV*RM &WS/CGZS6BP[JM%R
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M2\J-!A1,.+<;89C16D-,-JRZMT"5O ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M/FF1F9L61#D-I>C2F78\AE?OX.L/MJ:>;5\<XSZ6VI2<^LX_?]\?OP"N[3OB
M<Z"Z&M9B[ZTT#!&6HM3[30&3)R[;&NLFN4Z[07AMK 4K\ZV\^W2H1T=(D0)Z
MZNT)E.0WGHV)&&'G&E,=]_,'YZW>)OH3U-O]:VCI+1$4%?J2(* J)9+#>-BW
M^30A1N$X,,Q*/%OELL0^I?BHMYX;/D (4"2^/?D05/?:29#+H$H:1UGTOKK9
M6_=N5*D1!U^[03*;.WF8?(%23-\?H-3<I%6S.%$YTP1 :&UAYT4N.(@P8\YI
MQ3DYJ2_G+N (Y:$\6'0KK+<SU_TQUSJ=6LU@KUDJ#DB:4M-J'!:A<9#LFUU2
MH@[:<.A:;7;&X^ZDT'J\ 5!(,*S$D,KB8PSR87??7KY@XW2WB9\?77R3L&7J
MGK=6:\]LVAGM66?[NP76R):UE:9+\RPT"L)L]E+XI54+S)#LJ<)J/X*P^_EI
MU>,K88RS09+H7QE=(>M2]DOZGT,!@D-NU-R@;"+V\]<-EF;'K]YI]AVB2"NQ
MK!:9\6G.,2'6WZ[!D1ADM.6ONX[^8\?Z('(=5?&YTNZ562Q7#K;H\-KVTV8&
MS5I]@6?M]M+1*E&GY*1Z>!FW0_8'ZU5&2'QF?E\"L<,=D-1W7H[BHL;Z('U]
MI?'AU([GGZY9^Q>KY-X-U4"0J@N;!OVQJ5EVJEIJ"!.M%F*+;*W&-A)TM&'I
M$$NU,0KYN)3\4+4G($JZ!0J;JRD5/6^NZR'IE$HH 75:A4Z_":'A*]7@D1J
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M*DZ0:AC P45'B#18^(UC#4:%!C,1F&TI0TTA./7 +E> . . . . . . . .
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MEI:',(RA6,Y J;\67_I5\NW_ %J>T_\ X=>L? +=^ . . . . . . . . .
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MR3,'T]?R^R]=5R_&ZPNFKM$609' Y4Q4N:Q794R2Y6YI%2HL7$6<4 _AY27
MPAS$!R6J,I]Q;2O6.WJ2K4H590\-SS)1SE\C;Y&]%ARCAM=&S6X==5+VRH7=
M6B[=W$75C2DVY1HSE)T)3RH\LYT>2<X8]B4G%[%7'7FT5ZQ=N-M]C[2R1,2]
MA[5G:%T8.%0T2Y,V%68+$&QW!IEUR)B, "5@($23+XQC$1)0DTZAZ6_E"^+:
MSC.^KW=12DZE9VUM%).344E.:URH4X<N9>4GZ'PW!ZU&O]H.(\:KQJ3=YQ"?
M".%0A%R<Z="G"G7N4LI0HTZ=&//4>B52;SF33M-VMLT;J>J1K,1'3C"Y]FJ-
M2%!QBF$D"9FX6$=7AL:+]RXVTI2'I_W3N%+QG[>.\KW[3[QVJU948*;C*3E.
M$(P6.:4IR44EGR3<GY)-]#[F_OJ?#Z$:]2,ZG-7MK>%.GCGG5N:\*$%'+2>'
M/F?_ %BV;+3GY)QG./7O'OUS,;IYX X X X!#GOFF+9NK&]].C"=25LO=>DM
MP4/5%-LY.KQ'K[<"5$*0X@$*.M940-+S/KSXBW&UR<M04.(G2DY894E3]01@
M\?Y$QJQ+-$W,YV)U[:[/7:'6J16>U%MZ<N2;4= A3<LZ)U4SUS=CV&RSA4&&
M],/O6:([A8UF#.&MMKP7S@#G>W75/=^YNUNC=O:M$:AKP*DZ3W_J.W;2,6FP
MB=OC4[NK,JMC5U<0)HI*(2%Z\G-Q[:,B3+L&P4+ER;'TA2X3!&>QD%5%;\*G
M;1K5%$UW<K-U7L;8 3L_7XF(NO"Q2-+P]AUKJZ'9[#Z^+Z]T/K5FY;TKQO0M
MH-5^1::V(M8X=;@(%[<!&*"DKDS&5AZZ:^O?T!+WKGXJ=VZ_<W-!,[^D=?2%
MMK@VE#-T]32(R#NO;:QW8;;^\'-M[CE[%UD4K3&P2P;9,+7Y*+@;=97V#%E?
MC6YJ).#P1K':Z]<^FN?//4&2^%:AE-82_*+K\UL:];=*U7R=[.%3ME;,DA)E
M]N+[77GK0XHS:95<"5P$\4>PYAMU8P&,BY0TW\8J5?+*J"[W@#@#@#@#@#@#
M@#@#@#@#@#@#@#@#@#@%8OE>WJ:U9UI3K'7\M3>Y.T=K"]?=8QXZL_>(DWN;
M&%V<JVE'^F;;AUN5,'M36LI5"+&1+J587E'.WP&TC<7OCUEFVL*<[ROG&,4E
MS4XX:>6ZB3QMRQDWM@S4(<T\M9C!<\M<:)K]7IZX)U:4UF&TQJ36VIJ^VAL/
MKND5FGPO@GXX=0!$QA[DI6,?I]6:^R[+>5^ZWGG%9_K95SE7-:=S<U[B;;E7
MJSJO/G.3:7N2:BELDM$C%)\TFWU?^/DC:',)")?=D1U\;ZW[6V'V4TE4-^:W
MT_2+5M&?1;92:I=LROR>%EFUY"1;DPX&$EEI@I0P<E2A<01_RD0*0(,1^6P!
M!#Q>W7H]N*T7FR]=NH&F-&[%I=4!/VZVTB/K:W6*)(,[!W/KB13I&Q*F-_$O
MI,9U/*L(UK)3[(S5[:))08K<5U3DB=Y]_?NV^ NBQCUC_NQZ_P#9R@\\ < J
M&\2G_*?E-_ZW?MC_ .YND. 6\\ < < < < < < < < \*S\<>_\ C]> =.?S
M.7BU>3_N_HGQ<ZD)RDZ=HVZZT$W-8 SZ5MF=QNUR5;;UA*L*0S-$=9M%_F(O
M9/HON-CMK;&U[7RS+,]V"A<W>&M%Y^?R^OP\P6R=W]84(K-Z">*73E6!5'6F
MU]D0-B[7I]4&0QXH#U1ZDX#;"L$">,%,,1X,38FUEZHI2B$QG#)ATH?9S]S,
M7(<:>FW[>7T_L"[%IM+2$MH2E*$XPE*4)PE"4I3A*4I3C]$I3C&,)3C&,8QC
M&,8QC'*#V< K/\Q'85/6+QL=M-GQRS84^_JLSKVF3U/_ &RX]TVG]/7E;DL/
M?).6W1T^QI*_-*T+0W <6AQ"DX5@]GW_ '_)@H2_R?#K3/L/9BP;YMPU;3ND
MNN] CP(<QA*E56Z]B*74$:MJ\9[]?4W7G1O76AAQ)O/QF03FS;=&E*;DS)[&
M8NO?UZ[^Y;+9@[CO[<H' ' ,!V90=>;*I1^I;4HU6V31"4%U1ZF7*K"[G7S4
M6,C+^8\RMF81*"45[;]L1UPGEJ=PA+2,N93[>\%$_CBVUXW.P>Z:VWHWH;I/
M4>R8([9MDK5@AA-/V6Z42NT03UZ/@RJ4U>(4EZ[1;8&^8,',(43C,5RTTHU5
MI3DHBUC$*+#2^G:^6@.PKC'K]O\ C_O_ +^4'G@#@%0_6+_GC/*I_P#Q]\;_
M /\ U79[@%O' ' ' ' ' ' ' ' ' ' &<^L9S_+'O@$.-[N*W-L>G]:QSCJJ
MZEF%LG>DB.M7TVJ.-(_&K4>2XWGXHD7^P1%N2(R\H?\ R^!(+RVIB6G*M"YS
M<5:=HOP8C6N'OBFI/EIOHG4DL/KRY:TW^=XHGQ*\MN#0;\!*%[Q247_]+"7_
M (]K+#23O*T6YQW\&BWAJ2:RWMKM&/H[KMLFZL.MQ)L2MR -9:;PEO\ ^L1]
M& 8),=O'Q3\8<F6B:M*/7PBPW5)3G"/CGW?5U;6M:IIS*G)06<9E+V8I>NN<
M+HF;'V@OX\+X/?7>5&<*$Z5NMFZ]6+IT5%=6I24L=(QD]DR,WCRTU)@T"H[9
MLXQ8YQ5(B575H62C.' U/ER%&K1;G6E8Q\#.T[;(FV1UY>,OM5Q("!AS+2%I
MSJ\+MVJ5.O46'X:A136,0?M3JM?UUJCE-O?E:3SN<3[(<-<+.WOZ]-P_\96]
MA2E'E=*VD_$N+AK=SO[F4ZZE+VE0=)+";SOG<"OSGV*ZZ:S;3E^#6)-HWE9F
ML>EH;;JD!5<I2WD^LIQE5J..2X^5>LX=%Y<:SE32O6Q7?B75K1QE1<[B:\E!
M.%-OKK)OTTP]#J\0:N.,<'L<-PHNXXK623PON\/!MF_7[Q6YEC.7!K&C9+A'
M^JGW_+U_A_A_NYO=][GT!^N . . . 1K[=1-(IZ\[5M/874=6W=J_7='M6P[
M#KZUTFM7^&9AU(%/+26(=?MD64$61?BL/QH\J;]M&C8?6Y+F18GUWD 5V^,"
M^]&=LVZ\3.M7370G7J^5*D!CES/ZL#Z>,%(DDKMK?.H55(E==;A8[BF\HTH_
M9@3^23@ZPUFU1G13/V@YZ3+=_O\ 0%TV,>L8Q_+'K@#@#@%1'BR_]*OEV_ZU
M/:?_ ,.O6/@%N_ ' ' ' ' ' ' ' ' ' ' ' ' ' ' /&?VS_=G@%  XG*[K
M^8H"30Y@AICI%5K?( M_-3PHM=F)'Y2('V<_JRXZ_L:9*ACY$?VA_P#H?>6E
MQS"5(3]9**X9]G)+'+=\5G3YGM)46O$5/*>,*@E+#Q[5P^F<[6?#H-+\53&7
MZ/FS''HN7.7N_GV .?)FJ. 1*[[;%M>HNDG;3:=%(9%7/7?7;;]SJY/\M#KB
MB =KM$.%1LMZM&5H"%HT>5%;=E,',J"-QD.R##;PUF2TL",_C'HUXH57O8^S
M4^QTH2434S8P61L?34Z"E$Y\,FLT2"HZAT^HCD./^H*99&V1Y&2;"8*@N6FV
M9J<@>OL_VSL&FN[FH-3O[GQ4=8W+K=V"MMNK<73A*Y2:Q;J@+&%J!=Y5B&BR
MA$PN5#B75P70Q3PG)5=4F1I22DHH,;C3]^G?K\P520O(CWD,TC6YBA[ILEW3
M9+%NHOJR0OK *G7/==C#[:T %TOU@W;"K-#9J.K[79-4W?9=]/3J2FJDQHN$
M.S(MC4N@WE$QKIY?7\O+XY\@2:ZG]X/(I;A.\;&K1-P[>6^O5;4A2?HI0FB=
M3GM*[FL^R]QU_:6BP.T=G"JG5+\,UO0*WKNU2Y)8C8[-G\9CS?QZ5!N("+'H
M-M>$"R7:XTKR*6K9.MY>GK]8/*?V:*V_5DZU5R\3: >ET72#I&KRKA47I-9L
MCPJ1E<99@'(>&S5(R]%<6TI*L@7<< < < < < < < < < @'Y)>W[_3GK*<M
MU.A,63?>S+#7M'=8=?9RVN;?]_[/GHKM%%QHCB5XEP +K\JZ61&4X1BM5HJG
M"\2'([3H%5?A$ZF#PVS-W=C"!A^^0=62+9U=UUL8@K[E_;&W9=IB7;O;V*^X
M=PXJ<YLW?T.#KNKFD.J>;H6HQXGZSD=3B$SKZ[?J":G1QY/9;NSWD[POJQ.J
M51.B^@_7>9ZPJ,NAZ*G/6G=]H$.XSEMZ'=MYV>:$=EMJ4I]G5H]M:OC'0RR_
MQ\F\]]06^<H' .IGY_-P5SL;VDZ5>+J4=S"U@]9/\[;NB3BY=4BN:1U<)L]D
M:@3I41*G(CSM.J.R;#*B?4Q)97FFD,-?"7#6N=5\_P##_/??7<%NWAQUH5JW
M3(+N.W!5 -B=Q+W>>W-R$+:;8_!(&XBN)VJ:K'CMXPF' IFCQ^LZI"'_ *8@
M-B51T(:0E+39>_.[^8+5N4#@#@'P%7G(XPC(9RXEYB#*>:RU%7.=PZTPXMO+
M<%I2')B_FG'PB-K0N2KTRE:5+PK %#'AYE;@O#83?%_ 6&(O>.KW+O;;<R[T
MB!U:\V8D8A2XA9^C:'J G= $DMN1/D,AK\?,+J;SQ('99,TZVB6N+.-=^]?B
M":O?+LO9^N^QNDD8)LEFH5O:'9052-IUA.NG[?+M&M9E<.?B9)5D;@%OR6,K
M]C758TR3$A12<^2?'_0,P8,(C'G4%3ES\AG9^7-W4K7G:*ROZD@=CH=%A;2_
MS2XA'9^G0 G3/8D[(:_H[BT J.?U=M3?E'U9J/6MAO(@]?EQG;%(($8CM]UZ
M79CST^NFO[O"_)[ W3T\[H^179V[U ]F4LB2NZ=3;/+["ZG&M:.:CJ6JS%8J
M6A"&D[2QO^;3"C[,K>1NV[)1*"&BUQCPV(4J,$!CG]=VC[IW[N_GKY;#:?02
MR;1M?E8\I!?<.L1&H;JYHOQY,2*6#V)%VC CCV1W9E, @FVQ:Q4FWG9S65..
M0?P=&87K#>7W_?RQ07D< < < < < < < < < QJX6^O4.LG+?:R<<-7JZ-DE
M"Q*4O"&8T2*WEQ><?K\G'G,_%J/';PIZ3(6W'CH<><0C/B<X4X2G.2C&*RV]
MDN^AAN+BC:T:MQ<5(TJ-&#G4J2>%&*W][>R2RY-I)-M(C4/W#V'V)&C3=:=?
MF*H )QH\D;:=Y74?77'XLMI+K$K-'IC5NLC25,N(<3%*OA92L*PEUJ.O"O6H
MJ]U5UHVO)%K,9W,U!-=)<E/Q)K*PTI*,M\I;'&CQ'B]Y%2LN$JA2G&,H5^)W
M,*+<9:J7W6V\>LO9PTIRIMMX?*TS8VD=2D]<Q;@>N!F!:=E[)L\FU7FRCX<B
M% =<0T@=7ZZ&C3'Y,N/7:L"CQ18F.^_E>5IESG$H?G/)QEMZ#I*<JDE4K59\
M]2:6%G11A'.O)!:1V\\)LV^&6$[.%Q5N:L*][>UY7%W6C&48:+DHT*2FY2C0
MMJ*C2I1;V4I-)S:*X^[UI_IT[3=>>H8UU,ROQK,&M^RXT=_/Q=R]B1.4+F(0
MM.4.C:9!)$L(]I^HFP1O2L*PVK')XE/[S>VMBL2@IQJ5DGOEZ1EIIB";TS^-
M/=:?&_:BX7%>.\'^SL'STHW-*YOHQEAK/--1EAK\%M&I+'7Q5G6.EPT2+%'Q
M(L*%'8B0X<=F)$BQFD,QXT:.TEIB.PTWA+;3++2$MM-H3A"$)2E*<8QC'.\D
MDDDL))));)+1+X'Z)&,81C&,5&,8J,8I)*,4L**2T22222T26A%+36<7;L)V
M0V:OT]"KA.MZ'K+N<X7\8M(&-V6X?35^N$I7<;5*A.X1GTI8E.%Y^;64HTK?
M^)<W=;I&<+:/GBE!2GCT=2HU[X/*V9P>&YNN+\:O6GRT*E#A-NV\KEMJ<:]S
MRI:).YKN+ZMT]<81+?F\?0#@#@#@#@$9.Z-VLVM>H_9G85*GRQEOI&AML6NL
M$8-='6V7 .@:0:)"YC-:,.-"#2HTR.RZJ 67@6\A*L$$KB_50H"$/BAJ-LJM
M5N<@Z"_+H^U5_7UJ1$'[3ZJ; K\\^6@E)!DP/@=9]3:R0+>F)7#^9*TK,I*Q
M416A.8WV,U3X&8]INUECTOW@ZRZHSMQ-5UELC4.^"]^JC.II]L>&'Z^#7*UK
M=)ML@C"<[+4XK"-0!5.%O!%D'Z\022?)H+#&H+OOO] 5*M>1;NV9UM6+%KO?
M-CN\8]>>Q1'4QG/5.#,ONU#-5D=>T==^K>ZJX U^W5]8V7:L"W[9M3Y"MQZY
M9!U0:KD4C:1EGI%\:7/K_CK]?+HL FITU[==]]E6G?."M&>W<;K@$<0):@N-
M?:ZTA-";6<WSMVF$=*!MKR]=$$;!BP].UNE;!60(0[@6>=F0RZ#\4!?J[&B/
M[^GGCOK^0,W\.16Y'+!Y4B^PJ?!H%T(>4#9\BQTT9:6KM KY%77CK/AP?%M;
M @ R=:;0EM6)S88<AS*\IQ'3\/DJ@NGX X X X X X X X X X X X X X X
M!%+N3O*?H[2YJ93\-DMR; ?CZRT-5$84\0M&V[FI0FL-1(2$K7(A5]QYVUV%
MW*4QX5>"$I,EYA"<*SO<.M5=7,54]FUH_P >\J_RTK>#]MREG1S>(0VS.263
MW3CS26?PK63Z)=,OU>BU6Y#;Q':2#TG6>T=K#GUE6-DWQZGU&PRE*<EG]=::
M7/ID"RN+7E>4+O-]SL._2OIJ<1+=LB)*GG_;2T]/[0W<ZU>WMY)1="BJM6G'
M\-.O=)5)073%*DJ-*.-E!K3.#)7FW)1T]G5XQNU'JM\12]$\I::NW;GSQ@'
M(^=I'ZD_H;:E>MTES ^S46T!OPN$)H5D.G<213[<@97:GL[#E&M19YI>4Q@=
MGC20LY:DLDF51G%>P*WO%-0BU(O_ &92'I$^M:?FCM.(H!:U:LZLZBOA2PQH
MU[S>QQ:N=:8S*2( 4IVN/5\W;VARUO$RPX-#DH@SB#[OR!='G&,_OC&?]G '
MK'\L?X8X ]8_EC_#' *A_$I_RGY3/^MV[88_V8IND/6/[L?PQ_#@%O/ ' '
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M#B0 6$P.#@QD .)'QD81'@C!D5J% A1T8_U&(L5AIAI&/T2VVG'\.4')\ <
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M7CGMN[N,9_\ %MY>UC:M76,1ZITZ>=5UGOHM?FIXX[?.GI+A'#:V:KQS1O\
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M7@H^.G*WYI0P5D18$&,VG'M3TF0VC'Z8]_KC' *H=L>>#QGZJKDJU_TV679
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MFG15Q><CC;RG4E*O7\"%6JU&I*5=9EGBNNF^Z9H#!3KLL:SN'8L(AB37+/I
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M*D,)K&CM8+#,D6U#]&ZO<)VB;KP(4P0Q@H.?NMA;DX&BU-Y8?:E/RXL):;=
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MD2%JBT#W"!041AE!^Z=V03M6CAH.SQ4*NT<]%V"T6I51R(W3M<1,JM:F#09
M9>SD.?"D-*AXB3"QCIWW] ;DU=T#ZFZ8V#.V5KC5$6OG95>*U>((59+<5HE?
M$6$=21-H15-<F3Q"BU:9;!VN*/&M!(#7X! ]BN1'",E]Z00<F4$/.IH8."\P
M'E1' Q(P- ;T!XY'40A4&*.B)=>%]G5.N8CQ&F6?J.9QC*U_#Y*SC]<YX!<3
MP!P!P!P!P#QG.,>O>?W_ &_MX!IK>.]M?=?Z3+NU]*_;L)RJ,&"PDIE'[.74
MVM44*!'84ER7-DK2E&5JRW$AH5F3-D1XZ%.8U[FYI6M-U*LL):1BM93ETC&.
M[;.=Q3BEIPBUE=7<\+\-*G'6K7J8]FG2CNY-XRWB,4\R:17>#H/;;N;-79MC
M6>Y]=M-E)?W,&F@B"0]A)5W.,?9P(L&-&CEES)K7R>+6:W3TPW<O_;B*.F*A
MN<OEQIWM_+GJSJ6MNWI3BW&4H=--)/F6DI-\O]$6O:?R%*T^T'VDDZU]6NN#
M<,J-\MK2FJ5Q.CM",>1>)S3CB<Z]>?)[3A2M>7^(6+:GT7JS2(- ?751&@LJ
M1C! OE&9EA-/9^.')1L_,^L4)/.*Q]17W$C++:LJQ'98;^*$]6C;4;>*C2IJ
M.F'+5SEZRD\R;UZOW:'V%APNQX915*RMX4EO*?XJU66F95:TLSG*367S/"VB
MDL)5W;R+V#M1VT%Z#U_/E1*CIX7+>V#:X2\X9KQ:P-)@V2; ?3\FEV6+77\T
MFMX5_I8)"R6DFVAM8+#O.7<.5Y?*VIR:IVZ;JR6,0E/V9-/&.?D?)!/9SJ/^
M4^/XI4J\>^T$.$VLI1M^&TY.[KQ;2I5*ZC&M.$D_^94)_=Z&JE&=2O/.*9)#
MLE7=34W4U7UH#"RA]W;ECV^O];UW&BHO$2^ VFD!C0)*\MML0!>/@NVER[B!
M2@CDUHM(=7*;;<VKN-&G0A1C%^)E.VITUBIXD$VI+&&DFVYR>F&\ZMY[/&:/
M#[;A]"QHTG"YC*'^CT;.,5=1NJ2_A5:*Y>50IK6O5GF'AN:J-R:SC&C^HA4B
M9+;F[3OQKSMZV%X9<A4([_U=9UIVO,Y$UER&#;6N&<(PA+278\DNJ9$%.SI*
M!T-F9F80F>+>QDY.O>-5:]1J3@M*4&DHQQ'JU'\3>5G/*M3!PO[/5)U*G$N/
M2C=\1N)PG.WC)RL:+HPC3HM4M(5IPA'FC.:Y:;G/DBI-R)TV$Z%IU?+6,U+8
M% J^*FE2<QW*6XT$:,BN29+ROV2EMAAI2L(1C&583A"<9SG&.=*<HTX2G)\L
M(1;;QLDO)>G1'U-:K3MZ56O5DH4J-.52I)X2C"G%RD_@EM\O6,W6^O%[D3L_
M96\PGHECVLQ&BT(+,1E,BDZ:'NK=J ?Z2LK^V)VA+F;C94H5C.9Y*-#6E'X>
MEM&I:QE4E.[FL2K+%*+_ /703]A:K253'B32T3QU.+P:C5N*EQQJZBXU[]0C
M:4I9S:<-@W]WIX:S"I</-S<):<\XQV@FY<?MS=.^. . . . . 1K[8TJU;!T
MT=J]65UZ8Q-?979"'9^@3MHZF#U2/'ENERY6BP[/2FC\Z#\8SD.,2MM>%MMY
ME2)9%&&4-.@: Z&]!1?2YS91V%NR][*F;=_+LXA3T1@E+T!0W KAF0AS2.G0
M*)L+7L8U^.+P<5FS6%\NR.#J>E?4BJ<? GG;:J O55LM)M8UHS5K@ ,U:R"'
MW'VF"H"P#I(DP-><C.L26V9PZ7)BN+CO,OH0[E33K;F$K2!7R.\2'0\8.%C6
MM3V24@:9(%I,PIN3<Y4K98A4+KBMD*E="I"_2)]RU_+ ZAUF)?H%D?)5!R%3
M1+2PZLJFJEAW^W?YF^=.]).LVB#%[-ZXULS#E[$4EL['L5AM%X%01;=LM5\;
MK52"W4T?$TBIM76[VVT-5>I0PP-HP<DR&X*4L06X@$*O%) @B]D^6X>,A1!T
M")Y3]IM184&,S$B1FL==NLF<-L1HZ&V648SG.<(;0E.,YSGU^O +@N . . .
M . . . . . . . >B3(:BL/29#K3###:WGGWEI:99::0I;CKKJ\I0VVVA*EK
M<7G"4)QE2LXQC.<,9:2W;PDNK>B7Q>V.H*[R?8_;W:&9-IW2J)!#T)N2Z-L_
M;Z\A'IE&@?1=RP0B:/ILI425MFQ1LX6AJQSECM<P'V\+Q/L?RQ%SUXV="Q4:
MG$WSU7B4.'4IXJRB]8NZJ+*H4Y+>$6Z[65RT])&90C!9JYYNE-:/5;R\E[GE
MFX*!I/2?4*DW_:18B4,V*/7R=NW#O;8Y'\Q['M<,!!D$R) X>?;91#&Q8T=Q
M8^L (PBNCFT-1QPIGU[7K5[JZXC4I4(QC&'/&E;6E"*A1@Y22A&$,RS)MI.I
M-RG)MN39X<I3:73916R6=L+YF&]"J79,ZTLO8#8XYP=M7M3;I&Y[*/E8SF;5
MZF2BLPM4Z^6M:<.HCTJ@,B8JHJ\Y^B6FF'<_Z60[G.7BM2GX\+2@T[>PIQMJ
M<HXY:DXOFKUENLU*SEKUC&.-$CU5?M*"V@N7/F\Y;^.GR)T\YAB' ' ' (@^
M0(0L_P!'>VP1O74_;BRO7G;4#&LACAMJ?><2:48:56XN:RQ)LRW2:5*8Q'K4
M=VQ2L*S&!(_%G8></J""_B6+V_!W?]-);]/]K:95A>H9%7WVW*[!Q*'(*F8=
MT19=8AJWOO:&X)4>T4/(H7+LQ>MW5W[J)9P JSAQ1T,MR?%^6GIIY:OW/U0+
MIN4&KE[QTHWD1AS<&K6\V"YSM< <+V!4T9-[#&2%125#$847QDE<QTI"XTZK
MP_K'(DA*F9$%MQ.4X R.L[ H5UF60=3;O4;:0IA=0"X0:S90QZ95#R$?46$L
MD45-EO@BZ&\9<4-*(BS$HQ\LLX3^O *M/$I_RGY3/^MW[8?^YND. 6\\ < <
M >\?SX!!KM7Y%>K/3ZQ5+7VT;L0,[EV(RZK6FA-8ULOLG=6Q)27V(L:#6:'6
M&)<_#Q&4_P#0'2CCH85+5&GJ01PV.G+C@5F=K^RW=@UJ23M3>YLKXX=!6$D/
MI^OM%Z<_+NX?)'V9M]H<^RJVKJ4;>CDM<:6N5TD.L1(PRH5W8UPK25S"4VV@
MHP^1-8CSAXWZ JGW5OKM=XGM%$DZZNW5G5?9S9HV)L^Q]8M?:&O_ &;[*18]
MH+L00%A[>=NMJ=AS$@U9,RRHVM,'9%#>AW"_D&ZIJ>EM"Y4./$:]I^?GKT^N
M&]&#=T#6]\VQJ&.]Y4_/_=.M&]KB,R5OW6G2NZ^OW7^#IJ87^G)AT*T01$9F
MQS2@H3)@QK$(D8'I8GO2X*I)%M#DV8^/DOC]-7E Y/QZ:QZG]&K_ +C@^*XW
M>O*WVZWG%!B+!N>S680G2NAZ.RYF7ZVWV% !9 &"-+G41;$2J]::LFP+DL&(
M'P!HYH;@APL=_7Z[^H+K=1^.]ZR7X'V&[\[*3W ["!7_ ,2I8(@#_+O6#0<E
MU/R2QH_1$B64#X/0\J^WSM38DBW[)GXCQI$0N!3\X7*#?W:7N_UYZA00\#9-
MFDEMD7#YQ-8:)UV+EWG=^U2R$YPP)H>M:^W*L!3#CV$L/%WXT*NC,JPLJ6AM
M_P!;@%)EU9[.+OM4V-=8@Z-Y8^^PP[K7J]K)Q35CJGC)Z<QUQYNR]BR(K:LQ
MGKN'#R(\W8-\<^TDWK;!>G:Y!_3K0$E"G3OK]?W_ %P"Q<7X?]!?EP.'M6_O
M('<B,(8.BECA?R"=NHKM@*Q(C+,T[*$C-N1 L"42E(=G.1!<"(/ANOJ9@1H\
M=MMM%!L;77BLZAZUV9KC;L"%OBYWC4AV1:-?2MO=KNS6Y@5<L\D"5K+EBAT[
M:.U[74,&VPQPK%BD5 \R(69CCL-<=U+:T1+'U?S!8UR@< < < < XTTG*PY5
M&(BY^5C9R,0&G<,.3<KC.IQ$;?S^C*Y.<_12[G]&U+PO/^KP#KB>'K!RI[:I
M]$&V$\7JLOKW;#MDT@,-=P80;HQ:!=NHD<3H/8(7?6Y]CZ\L-F(13YP?7I@"
MF:J/"<4"R3@E773C[+ .=?V_-Z_H#LF\H-8G]V:9JC5J?M.W-8UMFBD 8B[/
M'[[50[5.*V=M#M;&6IPB6C(KQ"PM.-N X1?,.26;<0N U(2I.<@<V-V-KTU:
MRE##WRF%KR#%#SANF#;0#GVL.$+)0H48*5V+.=,#Q1)+B%#R$N&S$F)6C,9Y
MS"L9R!5UUB_YXSRJ?V]??'!Z_M]"NSWO_?C_ !QP"WC@#@#@#@'C.<8_?.,>
M_P!O>?7O@$,>RO<2KZ1=C4BIB7MG[ML#\096-< %K>?:)%<90-=LDB,EY8V.
M]GV_'@I3DF1:1E3#<>)AXE%Y]WQ"%NU2IKQKF34848ZOF>W/C\*6[SAX/F^-
M?:*APN4+2WIN^XI7E&G0LJ.9-3J?@E7E'_CCC,N3\<TO9PGS'OTIUS)+)Q-R
M=C9,/8V]I[6)4=<IO#]1U7%?RAYJKZ\!.K?&CE#\XPW,L26W2\^0VM:9WP4Z
M[*6UHVU<7>*UR]=5F%'*_!2B\\F,X<MWU9ZX;P>?B1XEQJ<+WBU1<R3BG:\/
MBWE6]E2>8Q\/*4KB6:U1ZN?5S&PG"<8QC_9[S_9Z_P!N?7\_>?\ #'KH'T1H
M_L-MQK3>L3=GCL8(VB>Y%JVOZ^WC#DNS; L;OX?50D1CW\G\O3W,2I:$_P!9
ML;#FOY]8:SS6NJZMZ,I[S?L48+\52K+V802WUDUKLEKL<OB_$%PRQJW"CXE>
M<H6]G1RD[B\KOP[>C'?+E-\TM-(1DTG@C5KZM#>E>CVY$Z([?=^[<L+<LC#C
M+^H;V1MZS(?E-!8SV/FZU7J_]24Y+F9SB+ &QRII[#<@@XAW4I0C86ZRO$NK
MB69=9UJ\LOEZOEIZY>O+&+;.-:4(_9GA:=3-YQ;B%=2J*+3JW_$J^9*G&6,^
M#36>:3RH4X3JMKF9N+7NN@^I(!W=6[K8,,;0*"T2;UL0[(8'@JF);Q]=--I3
M,O*&*W3!3KBVF6&,XGG9>5$BTB5,?988V*5.-",KBYG%UFLU:DFE"FNL*6?P
MP3Z9<I/=[1CTK2SI</A4XGQ2XIU+^=).[O:LE"C;PT;M[52?+;VL'A**;E5D
MN>I.I-IK+-?]F=([,G_A%4V &=.JQA;%>,8DUNP2X[F,.1IL -8&1I A FQU
M-RX4V#'D1I,9Q#K;N4YSZR4[JWJO$*L>;;EEF,GURE+#:PGJDT]T\;Y[7C7#
M+R?AT+NDZKRU1J9HUI1RTI0I55&=2,L9C*":DO:6C1JK<#[V]MKA.NP[*G:%
M56PVP-^SHRU9:E0L2LS*/K!UU&?CARTSX&#=ABYSAS-9ALMY]-E,?+!</[S6
M5HM:=/EJW+P]L\U.FFMG)KF?7E2VRLZ'$&^*<0I<'IO-K;JG><7DGI**DI6M
MB\;.XG'QJJW\""7_ +"9###3#;;;*$MMM-I:;;0A*&VVT8QA"$(2E.$(2G&$
MI3C&,)3C&,8QZYO[;'T22222226$EHDELDNB1[N"C@#@#@#@#@$9.Z0B8?ZC
M]F @_7SVV9I;16TQT76,>08BO7Y^73"[#53;>KSK!_V;6M,#+0)YDS(P]E@4
M\U/<CKP!6IX@TVH):-WT5W:UZ[ Z^KFM]!SZ[ML[&[8UNKA+297LJ%;-*"JC
MV?VUMS.#NOH8"M%"QFHF1Q&./M8>NWD;@J*@3)@GS[QW\]B\;@IJV3O+2D/$
M;,S<&K8N)MZDZOAYD[ J;&)>RX;B&I>NXWU2Z?KWJ*ZZVW)J37S/L..(0Z/2
MI:<9 R2N[ H5P)V<)4KO4;09I!- 2Z"*[90QLG43+C7UVQ%G@#)LJ6 )N,8R
M\B 5:B2U-8^HEK*/UX!5MXLO_2KY=O\ K4]I_P#PZ]8^ 6[\ < < < < < <
M < < 9SC'[YQC^_@'CY)_GC_ !QP"F;R,]H'3<PGU:U]@N8@?<UX3N_-,FKC
M6^V%KEA+U"ZO:]F,8<7&OFV6?D0NQ=G#BJ'JI@N;D,K?GQFD_1\&L7%1OZW)
M!^W*T=59ITX4M*U_63:S2MVG&DDFZERX0CK')L4H8]MZ864VFTEEIS:TREJD
MLK,NN$\2$HE6\D%/IU5"07>B X>%K@8;#I0.A[MK ZLQX8R%':K8^=&O]A@2
M8@;+3H]B;'%#X\B.PP^R/BX7F.C3J5."U*DY-<7<YSG)UI5K2IXC;;=2<?!I
MR3GG+3G)YZO&7X;I/+_BY\VXOXXPNO3.W4X+:6J.['8X0"TYN8'UUK6ES]UJ
MD_<177%UV'.M%GU]6S&+"3HPT(?I\2*PQ<90L2&,S%GT+9#2BK*&W\/?25ZH
M7'"[.<KBVG>SNHTJL+:-:E25.G5J1<(U74A4S)TXMRCB*Q-)X>%FITHKFBYN
M6-%)+&7HWH]--OW++6&T,M(:;0EIMI*6VVT)PA#;:$X0A"$X]82E*<82E.,8
MPG&/CC'K'.,O7=Y;SKJWEZ]=3#ON>[.<8_?.,?W\ Q&[WRF:VK1.Y7ZU5^FU
M0*QF26L5F+0@H> SC*4I5)GSWF([:G%J2VRC*_J/.J0TTE;BTIS[ITJM><:=
M"G.K4F\1A3A*<I>Z,=?5O9%2<GA)M^2W-=Z-W[4>P8DY9J"'N[5.&DVAX*X6
MBHE*H"OL9R/A]1ZB*-)C$3M;0OW&;-+'PHLMY.5P?NHJFY"\MS:U;24:=:5+
MQ914I4H5(U)T<[1K<CE&$VM>3+<5H]2R@X8RXZIZ)Y:]_EUTW]QO+FN>2&7D
M7M]DH'0CN3=J:=/U>VU7K3N4[6+'5C$:OV(&?&T(Y*$E0QN2V[@7/@3FV)+,
MR,VHDUEOV(Q@K]GG $.O$I8J-81^VWJ=O#2FY7D1=?N%EZA[Y=O.Z;H-R1'L
M:V56*'VKMUID:O<)*P_F%$JB1[IQ426T>0\H(-2P!:MM.J'[WK/85)JMW*ZS
ML]OI-HK%>V,"@PR9RAFCP6:+&7$,/(^H$TK6IDIDP/C3<_:NRX;*'_\ 1Y5P
M#KJ0/!QNZNB&:3!W-H>V4J=+VW3,O']7F:X8U=KS9FP^N&P4;$U-"#R#$9&[
MH+NAY<"0\9)L1'Y-CBFW+=)?&3H1B8_;TSO\7Y_OD2*ZV^)G;^K@>S )KLP2
MTD0,Z^U+J*H[4ZA-0JGMRV5O5.SMR;(7L+;QC9E.MU?([&NZMKX V./" %V(
MT462FP[(\X?Q&$N\_MC'Y@RCPB4LAKFG^1FB%;Y=-H$JEY5.SH";L38LL3.O
M=SD#J+H]ARPVR8!$5\+).DE8S((.BP@J$M]:U,06$9PC%^.?E^B0+GCU@!58
M1/L%F,BJZ!%1G)A0V<(PQ(@;$:]?4E$"4]Z/#AQT>\?-^0\VTCWCY*QP"M^S
M^7/I<P<(4S3ELNO;?8@]:X[M!ZA:WM^_R:9J<_'$&=9Z:.>UP!?^27,.*LMV
M#,1\-._<.M91ZR!P[79WR7[*;<G:I\<]0UE7G5)P.G=K^TE<I]KFM9_7,F50
M=+4S<SP1./TPB*3L[<Y6?>78\=/KY 1#[H[E\F^MM-R;/O7:W7?K)5#I@=2Z
MS4NF ^Z[G[<;NV':W\"J7I/39C=%4&4&JV.YD7L1GKJBAV(E58*)!]AB T.>
MFLSKT_7W=_($'D=*>@'0'IIL![R'[,?(]]>U)0=LJ0?J5X/[4[=UG;\(ADSI
MNF=:BTP@8V87LNMCRAD1%P==;%W>TI*2K3/_ "G,B"H#3O5^6?W!$G1MX[Q[
MA[(6'9/E8[44;QX[-T)H^F$Z?8]F5"M#=O ](6T=D%9[WULJ=I9+Z/IFT-E&
MH[XS;^R7!NP=KU@]*A4:HU"C"8T:!*?3;U^6VNK7KI[@<[3Z6KLCVW":FZ(U
M&UCV!11G9VN]L[YB6JX[!FV67&P&LOE$[63MFX>M=O+ X$\K4.B^G[@W!%$K
M3/<V5"J("KC(C4EZ?KK\]P=K/KYT#ZI]:M=5ZC5'4=*L$X.T_+L.R[_6 %QV
MEL"TDI*REEO5^O9P;+.6&TV4T]),%)TJ7AAN0\F./C0A\6)$CT&E[MY+^I^M
M+:;TCH,'<>T6ZJ_*7"(Z0Z?Z\7L.< )^FVU,76VB\"=3:\3&5A"23UTNX5Z"
MTVO*XRU-8:X>G[ C%V#["=\D4*5L[L+MOKOXC.O+LJ-!_$)L@5V>[;&I$]?V
M\&OU]IR&K2P.UETN9^Q"UJN;CL#4GXIAM./-N+3'[\>??0&O>L6_N@'7-5AN
M/6CKKWX[9[TN492]A]@9'5#L1L7=FSY>$_5RZ?W%M^I4X,, 2I/P5&K-8*UZ
MB"$X9_#J]"9:3GC/Q[[UV!./Q^]=]H#R>RNZO:X2W"[<]H/P])"K./)G-===
M" I#\O5G6RNO(=?BL9KJ9<JT[&GC_IJLVPS)!^>[,:#BG6KW[@6;< < < <
M< < < XPT\J.&+/H6\VMD;.=2N.Y&9?0IN*ZM*F'IN%0VGDYQC+3LM*HK:\)
M7(3EK"\9 ZX7A-V8,V6>JM@/]B]8;3VP=TD0-7:J-^03MUOC>$$K(.5_)>;L
M+K/M"USM!:])CYBT0K$4UQ6!, "6?;&TIN'63#C"YIV^^_>#LG+PK*%82KX*
MRE6$K]85\%9QG&%?'/Z*^.?6?6?TSZ]9_3E!UMB_A;[%A[9>+D*[!Z5WI.LN
MRA&S)(??.I) ,1L&T&-1=H=4WFT[252\G%$[8*5V(CV:D2X<.1 5FK,5E,.J
M"F0;XF?'OX8[PP;EZE^(W8G7G9 AT_N&N2Z-1]>[>JM8VUK^.>J_:2UD=TU7
M0U;(1+A;9L>8$%UK6J=-+70&8,NPR'FIU:3)C!UU9W)IKW]=\_GM[@9+T+UQ
M_17Y7?*74OSYLC9'T-%>.V=^9]K6C%OMSWWPWLVY]H^9Q '87!B?3PB$Q]JG
MZ#><IRM?[\H+OUK2VA2UJ2E"<94I2LX2E*<?KE2E9_3"<8_7.?X8_LX&VYZ(
M\V)*0AR-*C2$+Q[2MA]MU"O[4J0I6%8]XS^N."*49;-/W-,^A2L)2I6<XQA.
M,YSG.?6,8QCWGWG^'!=MS0MU[,Z7HI!0(C=(!FV*SEN-2*<W)N5SFR<9]8BL
M5NMLDB*'5J_J?*6S%CMJ_5]YM&%*3JU+RWIRY'-2GTITTYU&_)1BGK[VOAIG
ME77&N&VD_"J74)UV\1MK=2NKF3Z)4;=5*BSYS44GNT1TW%NW=$BFRCC@177.
MD3G6!<,K87!]HWW;99!W#,.O:WUT*<( Q=K.J5B ,58"A"4.D/?>/BV$QUNM
MZU>XN'3<N7[K3SCFE[=S+*:C&C2BI)5)O2/,Y8U>%@Y'$.)\3E;2K>$N#VLY
M*G"I7<*W%;F4VHPI65G#FI0KU7[-/QIRG%R4G37*T^5ZH]5X>OI#NV+X%98V
M4<;DO" \H@[8)-#%%?3LQLD?F./2K-L,[\OJW:XR7'7'GU+! U0JW$C0U>K*
MS5/%:I'%62>(Y;\--Y]K+;E5DGFI-O?1)+)[X#P&%G.5_=4__-JI^'"<G5E:
MTIXE)5*LLNO>5'EW-RVVW_"I<E&*B2\NVQ:-K8.Z>OELK]1#L)SE<^P%8@QE
M>4XSGX,?<NH7)>5ZSAMB.AUYQ6<)0VK/Z9W:M6G1CSU9QIQVYIM)9PWC5K+T
M>$M7T/H+J\M;*DZUW<4;>DMYUIQ@LZX2RTY2>'B,4V\/">"NK:/E+T\"64$:
MQ@/W<J/9RM9DXN55:NTO*'%(5&C/09EO/YQ\/DIL77$1OIJ2\Z2C,*^OCE5>
M-6ZYXT$ZDHK+E-.G!9VT:YY>Y17JT?'7WVZX;3\6G81=U4IYYJM5RMZ"QU@N
M5W%?&N52I8QJYI:D?:I<>T.U+$#[=[5IU7<U-J038+!1PMR+N:PK$2>2BH9S
M<AHAL9<K"=1"@IS'#2R^794PG(@O ?IK2]%5JPJ7E:<;^O3AX%O3G*G&H_"B
MI-:U4DY2<5'*BY)RYL-8T:Y-O<\=OZ]+[1<0M:'W#AT*U2TI755\/I1G42B[
MI04+FK4BH:4Y5(\\JK7AI)<I)K7HKMG?[M#[&&]:ZJ:G&*TP.UG4[G>[3 >U
MA42:?NB*VQ8RDS&UVBWNHARRQ>4\V28%HB!4QQ[+<J(K;I1OJLU=RI4$Y02H
MTZE6HW1@\-OEC2Q*<]'*2:?*^5O"P=NSA]H;JZCQFK8</3J6ZIV5O<WEQ"5C
M;SQ*?\.-G./C7#49U*C?/R*%-*"31(*O=?SUW.0[YV3/#KX=%SL3JIK@*B4Q
MJ*B.-YPJ/(C!I:6G[K86_P#7_,=O:E9BN?'(<:+PA.<[D;:522J74U5DGF%*
M.50IZ8_"_P#DDOZIYQT2W.O1X35N:L;OC56%W6ISY[>SI*4>'6DEM*-*3YKF
MLFWFM<\V/_73@TF;MO6I];[-&I$7ZE5NV06T_&.@R)B2GX.<?ZK@V:IO$X8^
MG]?A('R8TA'O/Q=QC/KF>I0HU4E5IPJ8VYXQ;7N>,KX8.G=6%E?4_"N[6A<0
MZ*K3C)PQLZ<FN:FUT<'%K7#U/AU5IR@:7$%@E %2AL(V;?L!1TB8+V E,(/1
MHL%"I)D_.)%I+,2!!AP8+,B:ZW$B1FVF<)Q\OE*%O2MU*-*/*IRYI9E*3;PH
MK63;PDDDFWA'BQX=:\.IU*5I"4(U:LJTW.K5K5)3DHQS*K6G.I)1C&,()R:C
M%**2Z[-R\SC.$Y=:PK.?6,9<3C.<Y_;&,9S[SG/\N9LKS-W*6C:R]EG<]G!1
MP#PK/Q3E7\L>_P##_#_C^? ,+$[$I)ZT&J6%M(,M::W'BRK #'$(\P@&8F.N
M,1E$F8ZW,Q%NNMK3AE[*'L?'VIO&%)SG'&K3G.5.,XRG##E%/+CG;/?YHUZ=
MW;5:U2WIUZ4Z]**G5I0FISIQD\)S4<\K;36&\F:\R&P. 14[T6<]2NF?:FWU
M4N<K]GK/7S;QRO':R5@@["'-#:*;EC"84R1:>B#",*:TS(BS%-+=8=;2N,G,
MK#/ *]O#W:Z;:H&S)E<WMI?<Q5=0U7+L+>K.^G<'N,5!RYK%D=4_;*OVEMUE
MC:B>)RL2TQF*;&&2C,F&0'GD.-UP4VP!<-?Z^:ME&N-7K=LGT.PV*KGP8*\"
MX,(F3IQ<L*EP!UH'#B6%#Y\X#+D-%(D.<E4.1(BMM24J96M.0.M[#\&&\:U7
MBE%'[NT3>ZF;+[QK3<BZZP-!RU"I.[0762 3VU1HXB4:0[V$%$- SIR9QDHJ
M,5)V%JR3[ADHX8C3IC\FOGCKW] 3'ZG^+O8&FCNT%W;<+%4A&*9"UG4+OUNG
M&J%MN[ H6_-O;V_/^Z;07%28TW8<QW9R*C*:%,EXBX$2PDL&<?F=(P-0>_P\
M53\CV;RKU'\R6NX?@'E#V>/_ #->3'X_;C/T^N_697WIXS]O$_$9Z_G\7)/V
MS/R2E&/ACU[R!=%P!P!P#QE2<*PG*L84K&<X3G./EG&/7O.,?OG&/>/><?M[
MQ[_?@'G@#@'Y^:<IRI.<*QCWC],XSCWC]\?IG]\?QQ^_^W@&*KO5-;:L;Z[9
M64L4]3B;:\H\+PW5U,QDS'46%7W7H*MN&M$I>".8^4QUI>5C#:DJSZ5.IF"\
M.>:C_AXA+V\O"Y-/:R]/9SEY2U1<-XPF\Z+3=^2\R%1?R0Z-8'6"QTZG;YVS
M0ZTJ9@GM'6&G;,?U:E QIQTK)B["GI#U:</%_36B64B$G1F5I5B-+D?%7KIQ
MX-=N4(5*EI;5:F.6WN+JG3N'S?A_@IRJ)M/*3CGS4=S(J,WORI^4I)/Y=Z_'
M$/[YWO[)=HA%11U!ZY]F:EI6TI=?LV_T4"AYOTT<R_EIT9J*OW2X,4YEV9]%
M]A5]-S2T2%C+N!09V>PT_GH4^%V-BZO^I7EC.ZII>%9^/5='+2;=S.C1E/"R
MOX4)0;U4I+*,JI0IY=2=-R6?8R]'_P!M-\;+#3ZG%YV'LZJ)=R?['>4C324?
M+.7=I]1=-;9!I5E3F5-M'Z'HZY176484A.'5E6WTHQ\ON$?-I:/3I4*KQ"RX
M#<IO:AQ*ZH-Z924:UW3DM7_2].KPQB+>D*+3:_G:QOZZ>J^AMGQY]3L1I;/9
M78HRRYERG;),T8$V*RE-]@P+G*7(N^^-F1OI--XW)O*5A!-YMUM;E#UYBNT(
M7F%%B2XC>MQ>_4D["BX**Y%=2HR_@N5**C2M*#VE;6L<0YHO%6MXE667),\5
M)_RQTT2EC;"VA'TB\ZK\3>66]XQZQC'\N<$P&M-E;EU1IP7^-[5V11]=B<_+
MZ<ZYV<1767LH3A2TQLDY4=4E:<9Q[1'0XO'R3^F<YQA66C;W%Q)QH4*M:2Z4
MJ<ZC^/+%X],O4JC*6D4W[D1<QY!]0V?"F](4?>?8Z1E7TT/Z>U)9Y=9^2O\
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MLU-55;4>=:J7(MWZ:I=.CWT\S3_V_P #5?[RN$V"K:^U]VI8RWG/)R^'S?\
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MKI''79Y1AG-5-0LDW%QH>89'+L-*7TH^LH#?G].GFJ_Z/KIC_/\ ]>JV_O\
MS_\ 5LX&%Y'G^G3S5?\ 1]=,?^W5;?\ PV< 9WKYJO6??C\Z98QZ_7/^?7;<
M>L?S]_YMG\. 3JZ@;T(=F^K>@.PI:M1:84W/J>D;((5*"6<.PZY,M@*&7D!H
MIEZ +>*1Q[LE<9J>Z-@N2D-X>5%9RO*,._($C^ 1M[+=5-1=LP^LZUN@.[9*
MMK':PK;T"M*<;2(/6$-4;I3X,"Q,+9<<F!D0KP2G*C1GH;ZB,,<[]UAIIUEX
M#E]+]7] ==G[!*TGJJIZVD6ID;'L3M:B/1EEV1"YC@UN9EY][YIAK(35,X3\
M?69+F595[QZ WWP#\+SZ3G]?7ZXQC/\ ;G./]_\ _P!]XX!0?UJ[">3ZR3]\
MRANO2FYKH("#9,G5_8JO3^K6MM9[6<[#;>K9/7FK]HQ--*G[$J,30@C7]O9-
ML1=C0YTET&5_.#2KNIMIWW@?4J.Z^]<>VW9GLAWWVQ</'=U;W?;ZUW"OE!N-
M=N?=2_T6HT6Y)HFM[:5!@8M=TQ(7?F$0+<*D-7DLH2Z\E] =JMP_P3) EUK?
MC?$;2TIV=K5C0ITY2ESPIP\6?/)R:G4DFVLO&$EIH\K0RQK3A'EB^59;RMWG
MSS\MO>2HN_C>[,749@>GQ!=*Z8^A7R9+T/R+[< %&\X3A.,*4K0\R#)1G&/6
M6YT"4WCWE2487A*L9Z7VDXS3ES.[=58QRU:5*<>NN.1-/W2UZK&_I7%:/\[?
MH\8^F#[JSXZ^RE8&_AJ/#?T9.^_CEPA:/(IN<Z3=6GUE2\RY6DO;/SSCY*1&
M0RUC.<I2VE&?CCS/[1<9G)R^^RAEOV:=*C"*7HE3Z;;D=>J_YFO<DC%+YT*W
MW4JM9KR:\.G2Z"*J%>,VDJH#Y'MZQ9B1E=%R2D_[-F-I^/AV0J)$=RVSEQK#
MSWQ2IQ/OY8L?M)QF*TO&_+FHT'C?;-)X]<+IKD>/5_K?T_MC_".*Z====\7>
MFZ:[@:/\/_3*4'VEKRL;,UZK9??S;5HQ% W>OPC ::1I-PTG9JY#.M#YS2OD
MN/,?&2U+<BR<2$)>QCN./\7N:4J-2\FJ<FN94XPI2DDV\.=*,)XV>,XSIL)5
MZLEART]-'A>OE\=]295JT7W>NBW'['X6O%]/EN95E<]KLY^&$E?+*<Y]E!75
MF$0]9SCWZ^Y]8_;^.<\UJ?%>)TEB'$+R*\G7J3COG:;DM.F$CSXM3^MO"QKK
MHMM\FG+1T;[<6\>H48\1O3- U3N'LCAGDIWT,'MNI4I2'68,/4#,-I:,JS\,
MM,-_#"E81\<?OLT^/\6I2<HW>9/>4Z-"I)KR<I4W)KT;P55ZBZI^^*T]VGJ1
M,VGT3VGIAJB2;GXD.LSC6R]LT33]92/\F_8.=ENW;&)*$5UF8E.IHGVP?[Q"
MOO9[F9CT9O/RRV]CUA&;_<_&_P#\N.?/P*"]-O#\M]==?<_7WFK_ %+;&RV-
MK%_%EV+*(PEGQ*]40Z\)^*7Q/D\WNT[C_6_7Z<S2DZ*I6<JQG*EQU*_J(Q[S
MC'/4?M1QN+UNXR76+H44G[\03]-UYIIHOWFM_5E^J[QKY:>6#$POBD[PU68^
M1IO2:@4V>ZA;;<JL^4JZ"7V$JQGTE$B+U.;E+0G.<_U'7UX5C.?EG.<YSGW+
M[4\3FL5(6=2+QE5*',FT_)R:VSKZM:9R'<U'NJ;75."?RSHOEJ:HN?A^\H)T
MA,.5W0FH1]@D)RE@A?.[\;:Z&,JRK*G%?F3JE$)J>3\O;;S)>,\A?]=+B5_U
MN;-+[6W5-*,K*TY5TH^+0E\XSE'SW@\?-%5RU_ZX:[Z8_+?777.OIH0KK?C9
M\G8GMI_FO!Z;I@%O>H:3KO:".; [^*#H8VD']B6/6@Z8+MT:A1R+%E;M%5)J
MS!9CLXCP<1IB9N5._1;W/]XQFI1K<-A.,TE./C\T9KRG&=-J2T_F3SY&3[VL
M/--MXQK+/HM<)DA+GX5_,M>3TVSVJNZ*N5B(82B=8+EV@L!TY,;1E.$8DEB.
MN9\YQ3:$X2VI3ZE(3[1C/PSE/(OM?3I0\.WX9"G!;056$(I>D84,);:))?(G
MWI+&*:]V=,=$L>6W]C&X_@E\LBU(3-U;UC0RE:EY^U[#D%OJPI7O*5NN:O9R
MK],JQC/Z9PGXXQZ]<]1^VDM>:PBE_P!+AI_6DD]?/8OWO.]->Y/OOKMB3%)\
M-'=H(&>'6[ICU7M\]R-AI)^9VMVW$)1WL8Q[DLL )%;#+=]XSGXR1+[.,+SC
MZ.?CC.4OM;"I)2;OJ"ZPI*RK1>BT;KT>?&5G\3],!72_[KT2IM+XM<V>N^^V
M%MI'K5T:[L[A=W*2T5UZZP*AZ1W]L_KI;@VUB&N[K!:V+J,C#&VMH9,N.O;$
M9)@$RYK'X83=(,IG-)5ET:WC"TN6I]J+&K'VH<3YTL*5.O&W;:U3;HUE&.?-
M0RLIXRBNZ@VW_%>F-U'7IL_/73;IM@W^>\:WF/*.(;']7?&2"BH4A7U!(#34
M>6]]/*<I^NJ9U^)XRE:D^WF6W$,N84I"F\HSA&-%?:2E&3Q;\0G%IKV^,WO-
MKI_(XI?)^F#']XCY5/\ _;?^/>;)A]$O,/) (K%PZB>+VW!VTX^BW(!ZTK4Z
M&O'K'U1A?7>H:,5%R,8QCXS!\R-*]I3[<S[5[\KC]LI^)&EQ2E/&KCQ:M56F
M,>S7C4BTM?QQEZ8U(J\4\I5.N?XC:>?1IDF*/:?++X[NO>Y+T7Z@];[QKC7%
M-MVXK/&?[L[9=55JSKNGDK!8!5#KMOIFS_I-.BA$N3$%#3%?@R)^6V<Q$X^+
MZ.1Q2\H7M6E5HPJ1<:;C5E5A;QG.;FWERH4X>)IA<\US/RZF.K-5)*236F'G
M'Z?V1V.*X54>KP$XMA,99D*+*JCI7EU,=1&"Q,4PES*49<2UE[+>%Y0C*\)^
M64ISGUCF&(YG@#@#@#@'S2Y,>%$DS)2DMQH<=Z5(<RG.<-L1VU/.KSA.,JSA
M"$J5Z3C.?T_3&<\ KOZ(]R-:=G"VT!=(T,;T3+DUO5O9:-DM'H#2MO:\['2=
MAB*)N&<JADR/V]JLSVF+'&LHNV*Q:QK, '^(OR42&DQHM=5UU]_Z@L9Y0. :
M@WU:2U,U'>+()UO VSD<%D++T0M9ZK3Q!BLN8^E:%F#]V4FKQ1,  LA/)M%\
MYC3(,9^(I*LO8QP#$^HVT8.ZNLND-JA]4SM(5V\Z[KQVI:J(-AV'J;3)$-**
M:.8B &8P@>.>J[8F>(&PXL1 T5+A05PX;L=R,T!(O@#@%=NW>[NJ]?;%W]2]
MOZI/1(_5RBZFW-6;$931CN-DV+:1^ST'7(O4@AHP1)C;R7NX]_7];<L*:P5F
M'SC;49ID+-;*3 )(=5M_">TG7W5F_@@&95A^SZM&L:*P0*BC9"NOKD28DP+/
M)A'I(F9-'RHSL>0] ?=C+6CVTI2?ZV0)!< XXO+DCQ9&=#'2S$N'!ERHHB [
M!8G%I$>.X\P,A/$Y< :S+G.H1%C.D)\*"AYU"I<N,QAQY %5=/[^5$L4INR"
M?4:X5.\[ [8P.@]GO2"NES^01.+)8("9,G9=7M!"1?*+!L!HJ&6(ISE@AUV_
M!+R$*?A<\0Y*(OSV!;$CW\<>\^\_K^^<9_L_A_N_Q]9]XP!^^ 1S[5[Y(]:-
M)W#<\+6Q?:,6D0)1HX $6ZBTEV(!'0)I$D7?.; /  _Q:1"0.@#(3I T8.%!
M R -<3)D2H8$,NMWD$U9L#M68ZC4CKA<=0%2E4=W0:,%H.OJBIZT6S7NIMPV
MIVVT,.5_,K%@F)W.(#FK+*BSIA:] K?%(X2R-9+3YYZ?OW\_H"UG'[8_X_[_
M /?GE X!6SV@[QTS4F_ZAU6NF@[#M3^E#75YOE>4.(ZZL$<\2UK1[SM!FO)U
MH1+R+A.5/<ULX$"&L5YQE5X)5R"-BS?<P@- W)TD[:B^YNFU[8@T@WK$B.MY
MZD6;6]KE.KN5+L(!D?)E!;B)EB 12MV!N,4AR) $P*ASXS#\:3\78TJ,^X!,
M+@#@#@#@'CUCUZ]8]?R]8]?K^_\ CP"N?27<C66R>WFQ-2!-$&:6<.,[B !=
M]RH]"2SNN5T_N=$UYM&ORDA",B]PX>N[)N41#IZKE%:A%8<RQRPC<)II:)T\
M_?\ IWO_ &!8SC/O'O\ GR@< X"UD38>LV K6JZY;K"-#$IP.JM%( -RQEHL
M1YX>$;,E,I&BEE)2&H:2,]6(</+V)$G.&FU\ BGT9W0-W?J"PGP6@V.O%?JN
MWMJZ\@5,62I)>L6 M3K;.'7JY5,E0&F:X2#%-C9M\%\Q%:]&SPLT81(GL362
M$J+W8[SWC/O!,OE X!"S>7:+76NMS@-![DH+\?7%OT?N#>1S;=ODTJ3J<76M
M$KK!2ZBS8285G61R2"'6 78I9 C6H0!B,EA0XF2GL3HXMY>O]F_T!RG2WM[7
M.Z&LK)LZM4VQ4*+7MEV[7;M=MD\)+L./RXD9+@%R,8%-(1PZSH@O )8!RY'X
MH'4ZZ.*-M3H[[38$O^ >%9])SGWZ_3]_VX!4OLSR 5ZFD>SEWNW3>_%+9T71
M5'&K/',:,LLMJG;LDFQY(C7;O&N<Q-%+X!TL18]AZU3.S?44^SZRGD*Y-_'X
ML,?$]^].C^. 6RM^\XSG.<Y_;^/[?IC/KU^^/7O^/Z_[/6<T'LX!A.Q[.9IE
M(LEHKU0GWTR$&/3A]1&&JU7)AM]O*<?;)/W$L"K(>.TA2I4TB8*Q8T6%'D.I
M^N\EJ,\!43JGRJ:CLN[>NE0$=5[M0;MW:KU5MIVX3']5"R"W\GMEZTJDPN0'
M&_Q/;0@<+U%+)B+6*D3HN-:V"C$ZXB?%+?AD("ZM/[8]Y]_I^_\ /_?_ -_\
M^ >> 0C[N=TPW2BL:ZN-FUV?O5>O6P05 F2@=KH5;= R[ 4%BH&685RL(>;9
MBLQ9)Z7!"@H[Z50@Q>05)AD-0\SP/UU+[*5_<%EWIIT%I2P:(B=9[NG7 6M'
MP^*M&L]0B$[*!KUZH]90""1(VMCOY2G9J10,HF"(Q6G(\.<F1 FQ&0)M< <
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M2W5$W<\BS6XA*/6BVG[&88'QA,!XM9KH;L5CF1 XB'%$@13I3(FOBF&AH2#
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MNLVT*X1VL2IH_8M<-RC4*X:9C7C?1;KZ L9<(K7JH,BK%K2'E& 4ZYG-9E;
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M.J $_>\[00B[.!Y&N4L$*;8K(-F%JT4O9'4TPX/C3!<(8JT#R(*),]_''S]
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M:U9L\JZMT1R P,;C+JN+A.G6I013>8+EBF2S+C*B,EZ0L#/JKJ+5M&MU]O\
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( X X X!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g67046g09g06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g09g06.jpg
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M 1$  A$! Q$!_\0 'P !  (" @,! 0            4&!P@#"0($"@$+_\0
M8A   00" 0$#! @/"P@) @4%!0,$!@<! @ ($1,4"1(5%A<9(523EM/4&#$U
M4U976'62E9?5UM?A"AHB,S=1<WBRM+4C-#9!4G%TN"0E)CAAE)BSM[&V)S*%
MP=)%9&9R=O_$ !L! 0$!  ,! 0             ! @,$!08'_\0 4Q$  @ #
M @<*"P8% P,# P4!  $" Q$A,00%$D%189$3%#)2<8&4H;'P%A<B4U5RP='2
MU.$&%6*2D],S0E2R\2,DH@>"LS1#PF1S="5$8X2D\O_:  P# 0 "$0,1 #\
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M&<9QVXSCW<9QGZ6<9_UXSR < < < < < < _?]6/]^?_ *:\ _. . . . .
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M=[>PZMNBLJTK-=E,U*.M+U=>8XCW4-UT6U.>EX)/H).ZS'>OU'GYB,BW3_>
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MTVSKG;3.<8SG3;.FV^F=M<^YG.F^VN<XSYNVV.S.>(AY< < < < < < < <
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M]O0C7W.!S\IS#]"./%3/]-RN@1_-#<]?5]1[>A&ON<#GY3F'Z$<>*F?Z;E=
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M$/:#>M7[+>GOX\3?]67'C$Q%YG&71\'^;&^I?%CV0_$/:#>M7[+>GOX\3?\
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M@N9<K[(3:?@@X X X!&AOJ2-_P"!:_\ LZ<S!P(?5A[$:CX<7K1=K)+FC(X
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MF5PW;E2K9-$BY$?N[/895X X X!8T/XA'^B3_L:\ @5_X];^E4_M[< XN .
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M8<T*T+7I>?DHEOOSS3B(PU]1BWWL?_W57F8^!%ZL78S4'#A]:'M1)\T9' '
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M"#G4!>T292/5N=ZJ5GPYG- S:1'H P:#+5H$@R%Q 6F)).J/;1=TR&B-!9C
M55-=N9:J5V/ZVGNP7I<NX'*&4@GER6+,QX^\=K.,B4;REN6$OC8:+=0:$?#A
MXF+AU<H0_+Z66-5[\[7AN?3JO7H^MH\P\<U9Q1@W-!54YJ7+2L]^:^QVTN9D
MFM7DA(]6<W(2T(SC4J?='73 \DT<'F,2%A'Y"ZLKJ77-!&)_#$7@XS%$MW+!
ML8P-'8)HM]'N&+3O_#I@[EROV&XO!!P!P!P"-#?4D;_P+7_V=.9@X$/JP]B-
M1\.+UHNUDES1D< < C'_ /G(;[YJ?X25YF*^#UG_ &1%5T7)[42?-$' ' '
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M[:-%]EF""#5,*^[JH0QOIRJ*12*<2DN"/.2]CXCRDPU2L*QF0@B0B/J_M$9
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ME-H5:-6K-^UQ_D'+-JV:*I[-VZ*6@5>EE^A-?P6M0F(W7D.C,'C^'*CWT+%
M@X",R\520;J.MF0QNV0V7RV:M6N%=M,[ZM6C5KKMJW;()IB'PV?NL%^^8]7'
M31ED\=L\J].3K"F6KA9OE3&EF2[S,;Y2WT\_&OG;>;YW;YOG;=G9VY[?O?L4
MDX,8U2?E8+>D\V$:3T<!2:F52=L-_(SIIAW3LA-(CTK0R/ [*+3?JA!M)(YO
M+63G7$%K%ZMU&2VE]XLE#!$>=)2/#(-$V.[]B^D8R3%IW/XN-"JLF"(UG-/I
MH\)W./#)D;DPR\$B<"P?(AW2:E@T$_+W1Q+)K%&Z-0."&7+C<5N4X.RXJ.8W
MDT@JLG)M?D*.M7IJ\U*)NKO5FB_0X&D0YE)'74G/H]&)8!B)FO\ 4Q3ZR<T<
M[2:']2,L70L2))7%NU@2#-/IFE'HUR'D<^7D 67P*2,6*0XN_P!!6(\/<#<.
M])444$4R&;DSDY:R(\%@3E1[A68WON"JB@EJ&*"; W6%94<RUK<X6TVHK52J
M<*L>35\)9E1IK634CZ*@#:F&IH#:MANI?LC==F1V6NH*40B\KK*+=$?3'UG1
M6,6&JA9)(;4<P;Q"R9B"&)A=+(2E$_(-X^H63CS!K)4,PX=$Y[ABD2MSK(E1
M0*9#EP38\887@$<<I;DG.@RY4$3RMRR):<63E-PA1^51PPT\E-554W,CENEB
M<2JDW6E%;?8?M@=!+QK/I/#(;;4N)35&;R!8;6H&(;.V:-<-^N>6]$3' *:2
MBV!'I>:ZS$*+/CXY)&H "YC;YPH<LH2]'[[O;+Q@G+AF1R)<,O<X:S8HZ-S7
MB^##WE2X),63+R(G XH7%%E)9,J).R*8J*L*X*J]>YJ9<H;%2J;S/-2Z0+=#
M48A35DV(6Y8TKE9(TQ7$(>@03>!NH+*>DIEU&1Y\:D,*MV78&RANZ?KBD=(V
M:F,5,)C6SIH97:O7&K>+#XYC;4B3!+4,64\J)S%,@PQX+$H8)DB"L%%5Y<,N
M.'*=8:I5;I7^2%*G/53,BYPJ^E<S*4>Z'48B/DYN5]04Z&!:TTG["SG+>JUW
M#O:1UZ&J@R12I]N]M@4RM2($TK4')B9D2*5YC=-,01>A&0F4B7_-P8?EN&&#
M!9;BFN6Y2<U4R9D4Z%;NU);DS%N+<4M0S:6I1.*")&E&G2D$+KDTM5T65PO)
ML?DNRW:J$-5O0K-K1ON_:"97FP"F^GVUR\#E$B*-3.@!2%Q\I8T5-6JZ5V,(
MJA@+.>1JN85H.=8766+V_'=<ODMQZB!#4W#Y4K!L&PEX.XH<)DPS((8<EQY<
M<,J.&2ED^5$Y<<V8VJ)0R([+;)%,A4,,61510US5K8\FZUT;?_;KJK.2Z.0D
M-J&W#=B639#.P:HCUCJNA4/C:A)^TM"#I=!2$JK*<B3TW%)L&5<23JEF<'D)
M()JD71+Q$M)G*+U@,9Q)[A8:XYTF&5*DN5.BE4BF1))RICQAD39<4,MU<V#!
M()D*BK#2-0)IMQIEUB5(8<EN&^G!;F*JHL^0G:VJ.EEZ]FU.E6OX]U@UI!(9
M84Y+TU97738G2\3 O&SV-22$;5U;-<Q^2@@AQQ*YIO*1+:(6M&FT?G15,,7)
MEF9C<G$FB35JZ*I.%S(\"FS)DJ7#/E8OE86HE2.&9NLF;%!%%"H(%!$XY,;B
MEPN*%0N&D;JTBCK+B;AARH9:CK8T\J%M645+4ZJU:S(D:H+IKF.[G,%$6W;Q
M!W<72K2,K 5+:4E>-*\DMU.^K-68.H!(S]:)+S'(J*5#4IINM)8Z]CXR2GIO
M'?2YP6S&G4^*/",*ETW1R)"4G#)\,4^3 G-@D+ E ID,,VDO*CGSX:01Y3@A
MEQ4AB;A,Y427E9,/DQQ+*AA\K)R*52>=N)*C551T3-5ZOHX20L*U(-)9,5LI
MLQH[J6GM:2FJ+5 O630O3M76+-XP;FX ,WF!1%I(7D-'H(PXB1AQC5(NF[4?
M.DV_@'O<G3VI<F9!!#*KA&"2YL$Z3$FX9\Z5+BAEQQ."%N%1MN-*9#92B;JM
MN*R!J%*L4">5#2JB:5FV^W,LYH_K(#^FVN^APOKMKG&VNVI)[KMKMKGMQMKG
M"^,XSC.,9QG&<9QG';CG?R(.+#^5>XY:+0MB/M^\A3Y=?2T=(AT6]:<OU3LY
M/5E&Z.O*1O<::63IIC1J*KNQ2KK?&NEA:ZX29Q65/%<:SS&$0QE;$WPS>33X
M#[1?9W<LO#\ E_Z5L>$X/ OX6=S94*_]J]QP+^'PH5N=5+\["<&R:S):\F^*
M%9M:U=A](?3_ /RP]<G]9B$_\F72=SX@Z3NAY/:S:C@@X X!&&OJ,6^]C_\
MNJO,Q\"+U8NQFH.'#ZT/:B3YHR. . . 1BOU98?>PM_>@O,/^)#ZDS^Z6:7
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M\SJ^$6%.DH[7B\[DY:*QQIF5>E@,J=)RV0QZ&%81(2H:*.9*%L\&%9SF"JY
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M_P#SD-]\U/\ "2O,Q7P>L_[(BJZ+D]J)/FB#@#@#@&J_3_\ RP]<G]9B$_\
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M*")'+(Q&@2?12DZKTLXKALU,9IKJ"D,\M#9X@#7FVT2%"HT0;.H3%85/]A&
MR >&++D6XU9ML%;;=?6J9^V_3:6J\J/GU@7)8,J"4NDT'-P57A<FQ1:O&C3J
M)AX^W:%L>VHK8^SR2LCQ @]@E9%:?K6+2P A"6PXQ/\ UFF"("QL- 0J=E&U
M1YK;'1I/1GS6W%2BE"V/&S81T8Z;ADA;0ZK[QQ'T1TFK-!.6-[+-V(5@G2]/
MI&3-IF1U35; RT>KD:&'QN908G+'3&3I8"A:]8KRD+--+5IV\M[O5.<VVH"
M3B!4E7<28-F%>EQTG.G9?&Y3&!)ABR$R6;2:62.'P$5 +.< (-'FKD[Z+JI+
M$FFK*"P9B# E )ETS4U0$=K[^VG.8+E73=:FE@=1-H1#$1]:+%NRI9#"7#V.
M0A8VR@<-K>B@IAQM,"0IV?;90D\'E3@7'5G.&S%VF@?%:-W[_5QD*W:%?KM>
MO0^ME4D]-]6+E@RC^TPM&6BQX7IXDYHSBP8Q%I0_F$$N*HYG:4<AI()(0HLL
MG,XHRM9);UIC-?#0Y'0!&&,DDD(/LQE:A57\ME-5G7RY\]_O=1/1[.K@FG4=
M.1A<:)>2*BI'!JJT&M!S.2GY-)*+MJKG &43!^X>Z-*V;E+"92?U-7 Y'O9T
M!BLR>D%M8YH-<"IJS5?MK5:Z65T6',7@76VQET7$ )?(U(2"*VSA>8>L$+.2
M<I$3R]T(PP>3'2%^#"+2F--G],/HF0+1B6IEG THTDQJ%HA2FUDB64>G-?JM
M[:]6JQ4[$>L=O:]?E;0DA!A7(N,JMB4>&Z@#C0CA!"RQ^6T[(%;4-'@\I-.W
MM:S+'JZSM],&L&W@S6TE1&DD.S,'3-WUW<VN^B,9V#1MX/3MBE8' K  :)=9
M96\XP]!V37(F3'(X<Z*S] N"\<*FY+)$Q&<6YJC)'X20) UDH!(&WHQHJ0;D
MX<P%KV)<MJ>KG[3)MV5CU.34Q4K))[M)10'/31)3V $FCL0A.+%JZ[H[85N&
M)H+*"7,C-"9*#CT;S6+:-,G6T?+A3VQ9HT0)H-R@B:T:>M-+F6?/=H,11BLN
MN1!PSF<J=RPL='PR_HS&XNVL@*+:B'LXB/3H2B+V4-=9R79R3 R:1"^&D9(Y
MESPRR>R.$837KN+/7JD$"RE.2KV^QK1<9/E$8ZV=J!JX%'2>REQ#I5,'4ED.
MQD(W<M0S"32!Q6:!YDI+$AA=FXB>00Z5JK2>?K-B*>N"4?L)5X^D(H'3LL[;
MM>CJ*C-*FZU'@Z8C])O+9, EQIXL1"C)E 0YYL,(O^K8:-&Q4F3!-1X./"6Q
MSI%)2)@X675)1J&S%'5G)Y$1DH6:!9S\^K7R^ZXMMA0+K('CZ)C5'D1,7UA=
M2!P)\P0*C2,9S+T(.?CKUI(PCHFUW6'B36D,+AG[",3Q4QA TCKO!/16F\Z!
M4S[.=>RJV<V#773MU6$U2R&J$]0BL]N4#81</(;.K8A*4'47&=&@D68M,P/:
MKL)*%;QZH;M## <15(/$WQ>'KOV^[M9K+H2+9JN>G2Z)=3J_H3[+I]ZO(^UT
M6BQ!NSF2$6CQ$ 1)'(>[KN%3$5TEWM5J*$0BK@:1:Q LC<!RO31,C&XAJ'(1
M\J_RLH69;R6.JA565MTZ;UGY*\]=)E /7G6(H8$G$9E, L9#3&+DXQ!9=,84
M4D&L.7N6O\S,':AP..D+23$]*D3M/T&H+/&$1[<['&NS\O,0 PRQ$LZGMMIG
MY-FWGZ;ZSZH4K##3V_\ =-3T/$[TC09NZ-BB94"RL8?T<%V(;+@>>DVY-CO8
M-97:_9DUS.RB89:/YP&B+)\-AD>!TI1=Z.+DS-9C!]6]$-YU!$:=(Q&9^A[&
MBU)2C22M8>H"BD.8VJ0&]'P9K$FP)WK(T"D7DJ5'2Z1V(;V(>(F4U=OSCU=B
MTD*(AL*VFW?2NJZKZ[;#*0*+=<^)3@D7?/T@V]W1 ZWC.Q^./(^A"U7!(=/4
MRD@2G:4L5C ]AEA(8HV&B^YD3]#4(4IF%I&5BL2$5*6W]Z4]M>9YB3 U7U)G
MNC:\*ZO)S(;/MN;Q(L!&B-5X?%D%9&2@($*_6CY\=9A)FZ@)&P=#,MTTD;^'
M.\!'A0"E7 (!Z'A>H65LNKKT[;+K.LF^I>N+_M.OZZC$)'204&(UY(A,[B*$
ML@X1^QGB[ZL5H@[F;]=P:8'86*C8NV AX5%"Y9P^/R.)NVC;?5GI*HH%G?GU
MK5WL>-UJYZV2,\2EY5P>5$QFWR$IB\+'6:*"#%V!.K^H:)J:%"F3!W8W DI:
M6HTIAH0!BG#(:G(BH>HV9AFX%%0LIK^JNLY??F-NNF 3=(2MW;"]'KI[*<3"
M2N0FQ!8>X*M8:]<(O 0\JL/E,X34>C]EGK3/?3*3.-6Z3?38LNEJEHF(;%<
ML:'\0C_1)_V-> 6;>)C=]]M\JO.W?;;;/8JCV=NV<YSV=K?.>SMS[GNYX!X^
MJ(SZZ]^%1^;\ >J(SZZ]^%1^;\ >J(SZZ]^%1^;\ >J(SZZ]^%1^;\ >J(SZ
MZ]^%1^;\ >J(SZZ]^%1^;\ >J(SZZ]^%1^;\ >J(SZZ]^%1^;\ >J(SZZ]^%
M1^;\ >J(SZZ]^%1^;\ >J(SZZ]^%1^;\ >J(SZZ]^%1^;\ >J(SZZ]^%1^;\
M >J(SZZ]^%1^;\ >J(SZZ]^%1^;\ >J(SZZ]^%1^;\ >J(SZZ]^%1^;\ U1C
MT5'9ZX[>1[UYYNO2CTYJXSWB/G><I;W5-IG&<]QV=F,)Z]F.S&>W.>W.?<Q@
M7,N5]D)M=ZHC/KKWX5'YOP0>J(SZZ]^%1^;\ >J(SZZ]^%1^;\ >J(SZZ]^%
M1^;\ A8Y%ARX ,MNJ\QNJ,9;[8U41QKC.S=/.<8QEOG.,>[[G;G.?_'/,P<"
M'U8>Q&H^'%ZT7:R:]41GUU[\*C\WYHR/5$9]=>_"H_-^ /5$9]=>_"H_-^ 0
MA:+#DWL<UU5>9PL;52W[5$>W&N !Q7MU[$,=F?.2UQVY[<>;G..SMSC.,17R
M]<;_ /'&S2NC]7_Y0DWZHC/KKWX5'YOS9D>J(SZZ]^%1^;\ >J(SZZ]^%1^;
M\ >J(SZZ]^%1^;\ U/Z>8L.4N;KNTV5>=B'4]!T].Q1'MSKMT4](ZV?.[4,]
MN?.5VQC.,8QYN,8[.W&<Y%=T/)[6;8>J(SZZ]^%1^;\$'JB,^NO?A4?F_ 'J
MB,^NO?A4?F_ (22Q8<A'#Z^BKS.Z(0JKKC91'.N=DV*^^N-L80QG..W&.W&,
MXSV?2SCZ?,3+)<;_  1=C-0<.'UH>U$WZHC/KKWX5'YOS9D>J(SZZ]^%1^;\
M >J(SZZ]^%1^;\ >J(SZZ]^%1^;\ A5XJ.Q(A:.%7GF*!3ZNV>\1\[SDGT;T
MUQC/<=G9G"V_G8SC.<YQKV9QV9[<OAPO\,?6X/<:7 B]:'LC)KU1&?77OPJ/
MS?FC(]41GUU[\*C\WX ]41GUU[\*C\WX ]41GUU[\*C\WX!"2*+#D0[M315Y
MG;7+;L\Y1'./X3M#7/;C#?&?I9S_ *_I\S'P7S=J-0<)<_8R;]41GUU[\*C\
MWYHR/5$9]=>_"H_-^ /5$9]=>_"H_-^ /5$9]=>_"H_-^ /5$9]=>_"H_-^
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MVSIOV>=IG.,9SKMYN=M?.U[>S/F[;8[<9[,YQ[O!D\N . . . . . . . .
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MTQ?E8_>M/E6OL;HG\LH_\R\>%N*.-A'Z#^(;\DZ8ORL?O6GRK7V-T3^64?\
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MCY9ZNNN].>..N552#]PKL)6O?G-B. . . . . . . . . . . . . . . .
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MASGF)G\.9ZD7]K-0<.'UH>U$_P V9' ' ' (%Q_I.'^\,C_Q"*\R^'#ZL7;
M:7 B]:'LC)[FC(X X X! 2CZAO?][3^^MN9CX+YNU&H.$N?L9/\ -&1P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#%RTA,:JJZZO
M,XQJIOKC'<-O<QC;.,8_B?\ 5C' ./UC,^_<_ -OD> /6,S[]S\ V^1X ]8S
M/OW/P#;Y'@#UC,^_<_ -OD> /6,S[]S\ V^1X ]8S/OW/P#;Y'@#UC,^_<_
M-OD> /6,S[]S\ V^1X ]8S/OW/P#;Y'@#UC,^_<_ -OD> /6,S[]S\ V^1X
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MG;3;+?MQW+?';V.D=L>[A'&?IXQGZ?\ O]SF8^"^;M1J#A+G[&2WK&9]^Y^
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M&#SD6Q#]]G=57W+G3[^.+&_/W'@7@7]7A6R5\ WC!YR+8CN%\DW^Z X+UW6
M\H3J"BL2HB\3+SO*HP%+D%H'9C;N-,K15B[/KJO15@-E=%W \4Y=KM90SW[@
M1ND6:8'/_#QU]FIF+I2PG!8X\)P>%?ZV5"MUDNO#:A244IW.)).!VQ5A=5P3
M\%<I94+<4/\ -9;#KLS:\V<^BI__ )R&^^:G^$E>?)Q7P>L_[(CJJZ+D]J)/
MFB#@#@#@&J_3_P#RP]<G]9B$_P#)ETG<%=T/)[6;4<$' ' (PU]1BWWL?_W5
M7F8^!%ZL78S4'#A]:'M1)\T9' ' ' (Q7ZLL/O86_O07F'_$A]29_=+-+@1>
MM#V1DGS9D< < < J\V2-+Q*0H1MZ/'2)84Z2 $"S%8F*8&E-,Z"WI,:V>#W!
M >U?;(+O&+=^Q6=MDU$$GC;=35;3,?!?-VHU!PEWS,PZJ/ZDQ?36S#O#D'FG
M4UK"@X8W+(XQWA,,<R]ZHS'2.7QL0<]8DVN0C)P0D (*7SD>;+#68Q]L%'DE
M=F&B65T+1?S5]O4==@-;J>AL#@I2TA74ZWL*-Q[IH;PE>.R&QK(C3 8(LK9A
M>SZZF4,>$6DXD+F'86,3)Q8D?/EGT0?"=*P66FXP\Y9BV6VK/F2LS4JK*Z%U
M7FPG4<G;!*W3B=8,;^#- U?"TY8^CI6R5(G8H<U+X6XE@*M&C8IO7\0G,2JX
M+.EV$L%I1FR2<ZD<;"Q4JXRB6QD%=6QVW65NVM5=U&K##QICU(K VPF#->I4
M)8@FONK0Y!9*?/V28C\K!'2'44,Z5:MD3"0&B,(&6&'!EJVG9RPK>3%V*$>Q
M>MX48+'W\DFJ<8"R^RCI72KJO3I5FO0C=&B4[/%0R4[#@TC*1]Y;I!2M1M[3
M6<#YT*J!P.CR9%T;,2@)/Y\^*)3!.:DHD FV6Q-2,O (U\8 ,V[5!L)WL]UG
M/MM->+=$=3B]JVTO2^;3;6'O,4%ZP*'#Y_'3PTK+'30+9N&QR/FB^U<N7KF\
M-'^&.H0 XL9M*=F!,DLWKW!U5454LK=GTUK[GR/EM607!F?1#IG.F*3 WYI/
M&AF.*KA[MWL">608(IHQO67"P*TLQ9Z@GT@DB["CS#"/DJG923<B:'-F<3=+
MR]J)>\RZDN^WG,/2:7]>)HQ+2HN"(8)P.S;0*5W \)G!8PLP#UYU.#*@0DLE
MU$QR(2"(3S76D",F8#I]/% ,X*K+/B41SAG&HX+Y/9VPM^W533:<YF8];4BK
M^;A6JTH"20C25H.Z>D$1K%QDG([.R.LI(0'L0E/X7 4J^+1/(^N7,2)K0*'
MYP3/$=&R1=$;G7(EEEFBM>;1S\UR+2\FW5B,F^6\6 3$E$#4TC#V,F#T(?.W
M$T:N(UTU-"[.?,RSUGK2<?U#E;L/.LAP<39M)G'%FR;#0\SVB%E@J9^_?OI6
MP/328Z@R0E;V?&Z."9""5-+T%4HXSC> DLED<?+6)7NC=D0?Z/$(.:',D]'K
MK;9^JN8=:JN5FNK)NS!TS:[=-MAL_P $' ' ' ' ' ' ' ' ' ' ' ' ' '
M' +&A_$(_P!$G_8UX! K_P >M_2J?V]N =5%Q>3!!V_8-JV"^M1 "I9,QKJ8
MKP\56 A&!%2E=RO$E'%[4BS22#V-IS/9BFWA2$Z4]5I G"D=1)54ZY\PAH*G
M2FJO+;HT:M=66,IY-6)O:G]B=&VYLL/TZ3*RZ2\%9"-%GG9&)5G.U9LB\D"6
MBHOTD-E""RL+D,<8+AM]8:NX8!3HDCEJ5:"J)K\V41E?>3HD-=$:PW']0[F0
M1RH*:L>J*[ATPJP8? P9Q9[F6O)#)(8DI,$%1O=H'(W"AK,[O*# VIX0QKX=
M*6FDDF9N0"-UK8K>_?37DI7ZO\E7&ZTD%>EV]V2HD*CLGB4MF<3UBH=D!D3^
ML^HFU.I^J04(PL2)D*SA<*LVWI/IO']'TL=FHP@+"JFF:K=<@Z%<3>J^ZF=)
M.O*E;2EK>FAVQ<&1P#3KJ3ZI<T1/J9BC<2T*CI8;2*6@1782![B&UBO*8E7'
MI_#P(U<#HZZ:RFPA4Q7*S%1I'EJ\K>U$VRNQQJ.4;BI6/O;;[GU7F%4^KRVU
M9 M6!%K!HI:V2D\./6SV FI($!0>,AV9V)!XE@3<@\9=\GLH&[=RB*FA4UK3
M=*)Q*?OY%7T?.1-U&5@HJ5ONN?TS777N\_*[ZR[.LJU["AL:"P=W$&E5$YO6
MTI+1R4Q=D8?#ZAZ7+*1=.7Z\L,NY"B[VZ@B2Q*(-HQ$BL:% @*3J2DG!MV]&
M TJ5Y.MQ>Y&]U23![854UE/B39HR(S>OH9+R#-AWO@6CZ2QP:9=M6?B%%E_"
MMW#U1)OA=95;"6FG>J;[^=MD0R%P##]^V.5J.H)M8P0-I(2L68,GC('OV9R4
M4<%QP_9DEC9Z-3RY63>;ZM.^(,V_BNY\0X20[S? J573ZFLL;ZW'A&R-*S*T
MI9FLA?V>6BF@X5'MBCZ'PU@5J>,ZRF;N(Z_E4>;9:F[01-&UTS[(0*A @@25
M>9D&!$</BTL3LNT\ONVV<E=$^4=@Q&(QF5NJXE@[:2M:SE#<$B5!20PG6UH!
M8H9%3/.L16/LT=P>DP#M96-*.Q(T X=C='LDTVD<5T."9+K3E7/;I>>G;2M#
MEBO6G/I"9@HM:J!+5_+IE$(L2!8E"6=8Z*D5A=1<)7E6DKSG9(RY3VH]#_LC
MM%0ZC-<@JKB2E,/$F0H*9\UO53WZ^8F1'6D[-4/:]B-(BHSEM<]*8;J)!:R,
M<\CX2Q=2]+-[,R1 !DBIO9.(,#SM.(&$QLXDA0&;9E Y5ZWSH",2(*6I:72S
MEIJM]E-)GCIOM:4VI%YGF="V8::U]9<FKR1CF@=:/;I[CF861 7;P%F4SUB*
M=%HC)XZ9\(*G\S9>%(-EEBK FL1C8(&J<_O?)V(^+G]UE_\ >WZ9/ZN;S_Y,
MEG/OOL3P,9>M@G9A!Z& W3.6'LB/E+Y]T=\< < < < < < ]M@_?"GS(H+>N
MQI,:[;/QQ%@Y69OF#YFMHX:/63MONFX:NVKA--=LY0436063T52WUWUUVQ&D
MTTTFFFFFJIIV--.QIJQIWB^\_H5^0,\JO:W7;!'](7S%Y0?M2AV MPXOIH(<
M+12?1IVQ)"P[*>%TD\,1%L:]VJKC7;;7$[$CRA]-% D(-;O?R_[3XFDXNG2<
M(P:."&3A,V);V<24<J-01Q-RE6L4G_Q1.&&KABA2\O"9$,IN*%I0Q+@MVIUA
MK19X;>:YWH^DKGS!TQP!P!P#5?I__EAZY/ZS$)_Y,ND[@KNAY/:S:C@@X X!
M&&OJ,6^]C_\ NJO,Q\"+U8NQFH.'#ZT/:B3YHR. . . 1BOU98?>PM_>@O,/
M^)#ZDS^Z6:7 B]:'LC)/FS(X X X!5YL2<!HE(2[002D#H4*=$FP$-AIDN;<
M,=,ND1 K!!TP89)$E$M63'#U\S:9=+)8<NFZ/GK:9CX+YNU&H.$N^9E(AD^F
M4_I$#8Z5=F*KG,G@[>1:5M;6$6IF$FWK#Q&H2;)1IV4TPX%K9[7S0>\U<+:Z
M>%45%NE%<M-$N>FCS9^3_!IL)ZQK*.@(C-&P^M1@II"NC203.%$&1YQ+YN3Z
MKBX@.MBN">DJ9-(X,C;@JJSB6#$>G"T^E <Y$EG,4]';'E16DJWYZ<VGVW45
MMMQDR^^H6QJNG[T%$=J]DX-** U3;1Z#D"1"I3$WGL)KV#3*P9.UF&HLE&2I
M.22 SF#MH]%SKR+P>3'6TS1;#'&NHBIKS]2Y.O-H(&'=1]JR<[#Q'I>G]M\$
MNHN/VBDG&I*Q2A02D)O=U;B+]?FG5C+C0$"F4TKB("6%9%DGDA>IGIN1!6.5
M&5K(GB(45'>M%>:SVUY+%5&=*>MJ0GZFC\ZL=@HX>R"6R$(#)5_7D]68RB,9
MF1L17T]3A3/>>R6& IE$V@:5*[R R^8@V)5!V9,#DU_#-0:M^OM[VF(YQUBJ
M5U8%KQ$O7I*2CJ[*'B*I&-OQ+)8;7D)JWI\GTUD)A(\4;9)EFCJ[]FP40#2P
MH21%MVRV&FV[@EJ%+G6EG75T5G(4A'KB(LI%(&LEC@<-"8MI&R3^>.%6K/5Z
M/,3SJ6BA-J[ OI8DVB30.TZ?7CK,Q?2<VS4\]T]=QL<W>(M184NUNFRG;4X=
M?*#)85R_7IR5H 68B0L2J65"FLO0L<;>\-H<-%V4,<QEI)G8<N?G<=*N"Z@9
MJ<&BWJN<Q1R\9Y9.0I[\UUNMVV79L[+5='5?8$2KB)RN$5XW"R>95=:TJ91:
MW6$@"N@<N@Q:" 0PR0,V.[(L@#=D96[<O5?!H%7(E$>[;-F"ZRK7 655;K*F
M$'GE +".)V.;B@"O8J*J2*7U+Y;&;!:'7)]8QT_UKT@2*84XYD F4"QD7FC6
MP[_L&NW\L1 S04U?PP,H/BIK5PY5>BY-UM[76W[C;>1]5X$19D&K 16=PR,U
M*WV$#*R-:3<,A$AV9G%8(M('FYR.L6Q&-CC$L;DR<K:/-(=K%PYXF*DA<DB'
M!FQ$K^^E^Q\]##0/RB$0*1F$R$C6,R N)H:K35".+OPQH\RA%J"*:*@IVLC%
MU#;/08'VO6#C99@B\%BP951<;Z>=OR<1:R<*7ZJ]5;.>EACG7R@<N]10!,A#
MQ(.2M8R5F\J=ZMFDJ!E(AO4'5?+8^0C0L5.ACH>9VFW3*5:E(P?/MW*4==,T
MUR8PR7<IQD5*O?6NJC[Y\A2WRB$>B3&4*N:>GKLH-D>H"'AFI&//'D]WW*=2
MH9MJ+1$.BSQF6-$^EBP&4;!JL7+HFZD-?(O51&QB1>J0B5='>E=E;>1F7)YU
M-'(%:D@KMW6GI-LRAG3Z0CY-K+AK-<I/;]L^?UF(BI)(@S1:"08AW"MR3V3:
MNWCA5'95@.!$S+T(+(A3V]2J>O3W61#KDG/J %B$G%&M:B9W.IL2>Q=5KF,O
M]@#!L.:NF!QRV(R#4^2+CWK0>NX8"Q V/2XH291NS:U?2@&FE76USKOS\S*/
M#^N'UE.Z)D*O(Q^-^AZ01([OCVK:81B>W/U(FNG1*%R>)%Q 9X->1,LQ9F9'
MLHIJNUUR]9-&Y#3<4^(A3;;U*M^TQW+O*&X=B!DDKJ(80B;=M-W$DDDCW"'5
M]G4<Z4)EU)L1L;B8J:QXH80RQT@*BDAR3:1\AJYD<:P1#DM!QG86EK6S:EL,
MKB.N$,:RY?HU%:(Z((VB&KS6?GX^5"PS0:3DMC1!W+7I9R)SAN.$2"N%!Y/=
MLD^!"59U7:4CDP!T7D#:*B4Y.39[^IJ^PWGX(. . . . . . . 6-#^(1_HD
M_P"QKP#KGZC.F\K*K#M.SX+7<9(2XK2; $!/,48J(FA&?#Y?MEUHU/$E1:[,
MF]@+=",)&R)@>U4%90 .B2 M/=-(57JMU?\ )@&V>FKJ$GTZNJV@$;?!<6JV
MDT4&0QT:@(NP $<-]/M*1QF5.2$5*2\;EX0'-(18H\=29*58@A::R0++"Q@>
M (R<JD+6[2E[6^[5J[+\8Z<NH&6=(]?=/(QVQKXL2G%@D9S(U2B 9[%8:WE=
MC32K5 K& &R3".R=*4.:I-*PR!%7=<1%B&/P, ZQ"V@9FX"J3;I6RQ9LU^FE
MJUWWVF+HW,>N2<6I88R0AKABJS$;"%WT.B(>)#X3Z$9$*%VM +7%H3=,/'<3
M=3=S9#: D'"ZK*71Q[.G"<PCI6+1(FF%E%=GJZOE5FCFU.ADM[5_7.6A;[0_
M-/6$Z6#JQ9Y$3"M6/8DL"==/&V?2Y1IZJ-VKZ:>SVS$M##M-;6.+-=C+L)'V
M$9)*:9"S137;9;V4U&0ZO@_4TE=D,EUE%+"?PH"4ZC8]LDI)H$-;E TT3IF0
MUC)9U!0$E,A_1@!U&K,AH;$:+%Y"@^<QJ3*1F&@I5)8_%A'2EEMWMKHU=T;\
M<$(EZ!!DL%,$0HE_@V*U FL/1S-U@N#T\?Y@8IWZ*GI 5IZ5*>:.=]ZSU])/
M^Q''C''> 4U>FJ@<@"<4<U56SB+&CJDH,QI>#1A4 6DRN^BBLB)AE!>PY^=4
M43344+NFRI#?=/3;9QG;77. )HC7\#+LG0TM"8B4'/M5=7K C&PSUD\U7%,P
M2^KIJY9*H.-5@@X>'5PJGOA04Q9C]\;-&R*.@$N!  8L(8Q^,!!$< BT<MQ@
M0"-9B! Y#*FZN4&(T>BW9-$<JJ**93;HIZ94WWW\WSMMLY E^ >J]8LB355D
M19M7[)?&N%VCUNBZ:K8TWU5TPJW7T424QHIIHIKC?3/F[Z:[X[-M<9P!7",!
M@A<B+,%H5$BA8(94D84H1C@9Z1$2%5)HBJ>%O7+-1R/,J(L&**A1JJB^W29-
M$]E\Z-D<: ::P&7]%4;AU4PB-0&#QR$,H;'['"HRF.1(8SKMEZCV,JV.S)_,
MG^A1.?LH[1=B"Y2[35D,X9[0D^\E"^@P47+-1JVWG5F>U:,SK70ZF9=9ITE*
M B1S0U1"D>*2!N6*$-<PG8>5E;/T19; @[VPGE,E)4U9>"G(UQOA<MN[DPJ0
M,=MW1AJZ<"6O2]'?FZC*P&$5CJQ($HS#H,D.G $.R+O0T< HM9;&6H? T"R*
M+,V6FAP(T +:CA31[ERR;"%,,VJ:;/;NLB$_&XO&8:':QZ(1T%%0#'*V60.-
MB!X,.SRX6W<.,M1@MNU9-\KN%55ULI(:9564W5W\[??;;('PH?NLO_O;],G]
M7-Y_\F2SGWWV)X&,O6P3LP@]' ;IG+#V1'RE\^Z.^. . . . . . =B'DW?)
MNW?Y2.[FU:UJV4CT!CRK C;UODF"SF,UQ&7*V^-=MM<;M]#4O-:-W3>)1%NZ
M1=F7:*[ITX&1\8;-B_,QKC7!\58.YLUJ*;$FI$A.D<V-+GR8(6TXXVJ0JQ**
M)PPOBG3H9,.5%:W9#"KXG[$L[S:VTG_3$Z5>D:D.B2FJ^H6A(NG'HA'GZCDD
M1<]RYDTUDSD&^3,32:&$T$-S4F-;MTLN7.4D6C%HBR#!F0P$,&#&?Y'A^'81
MC#"=\X3'E1Q1-0I602X%#'DRY</\L,-;KVVXHFXFV_(CF13(HHXG5M6+,EE*
MB6A+K=6ZMMFUG.L<8X X X!JOT__ ,L/7)_68A/_ "9=)W!7=#R>UFU'!!P!
MP",-?48M]['_ /=5>9CX$7JQ=C-0<.'UH>U$GS1D< < < C%?JRP^]A;^]!>
M8?\ $A]29_=+-+@1>M#V1DGS9D< < < KTK)C@L<,&3#]D*$"62A,J4).D&0
MX:.89U=/G[]ZYW2;M&3-LDJX=.G"B:#=!-157?1/3;;&8^"^;M1J#A+OF93L
MS2O+.J3$XBJ0:]*UFD7T*!&\.WC<U!V.!+):X:MPRCU^E%#+$MJIJEA4D3;!
M=-,J*$GK1JBX62T9::L:H]#-34K'Z&YZ(B04K65?><R:U0&B$1D%:0UJ<C?L
MY6B5KJ/"HL.PDHH-R/L0*45DCR(K;C1F[+UF8$7[?=J04%MK7/:ZUU5=O)>9
M!M*?=/L-L\PSL*D]7T^.PW+4)+7-:PLP\M<86D]75(Y@4?D3EWL4=;N93=]:
M09TQF>8W%7>TI52T*N0P*4N@H4;[\K]C*\,F_31(B4$5:].>CI\5AL_AD%?K
M5# =W31[7#*9"; H ;C+K<F(-@6XB;1Y^(3;MJV<+X)@6TJ=+E-&CP+=E']>
MS:;!T03K<S7#$A5<)9UU%])!-@3J&M(R#B>T?EL+F9Z#3D4]$1K=<!L0&3"-
M&AKHD&>DQ);=G@D**DQKEH^7$*T,L^G)7/[-B"X(6B0ATD$UU+I+(1\1;BS4
MRFH&'ND(3KAR35D[PF8!/(4BDD; ,!DH9MQB$>>GVX;?#$6VSLMS5^MVLH8V
M^>C4W))MH[D5*BR\"8#DWAZ1.*^8IEH-)H9!K@:RJ.&%GBJKZO'[*X13U0JM
MNR8N#[TXZP@LAO@H^"CT=[5[&13RW^A@?#') 6]H&0P>%BY,/-(1)I6YEA!X
MT9B4TD\L0=1YGOAXD//"*FEC$S'0(LB6-/XD3'.P;KU:-Y$!1Z].>WO7KUDQ
M9_4'TR4M!(6:D EBX@#ZO%I5"]8? D3XMO <SZEJY4T!A1;+*R+->17)7&Z8
M44/V4=,$G3E)FJJ(2;[@DVZ(K4@O[I;<21,J0KEO*$H<;DDK,68UKN+'@U=.
M!DP:5V6L=\9V75/MQ[PR 88=S.,#2^&4="-9'(W8J.B<$&H+NM/?MI0W",P^
M)2,B +R&+1P\6BCW<E%R9D(,*$8V14[GO'X!Z^:KN0[U3P[?SW0Y5LOOW"/G
M*9[K3S1"*=5E6[[(?9[7T(>;1YRQ>@,NHH!<9!O!C!L*&NP^56&^1CD>+9LQ
MK%=EW"K1@U;,T-TVZ"2>@'XRK&MAJ!!J.KV#CVQ9\Y)E6[*)@6J!,D\$+1]V
M0((H,$TWKYT!<N CEVYU477$+K#55-F2NZ.P5>GO?VVE*M/IRI>YP;6.6%!F
M9,2S)J%T4@Y(W#W6SU87,@Z^7!*&DP!)XV6'V'-]%&+MVLRRYDY8EAO@FOAY
MH+5]^;W(NA.L*W.-$6)V PT\T0C/J8FB>C0<UCU1RY'/-XQOL49N]U0*KT.)
M>K"E=MV2[T8P=K([N&B"J8A+,X?$AV^J@^+1QBIHW49Z*,P@QMOHT6&!PJK7
M7=!KIMJW5#1V/B5$,9PEN,!!V&VN6HQDD@!6_8<J+(IN"S5=<>A&@4G&V@;U
M'C'HIK'39)L9,@6X[T7X1 *7,,V98F+21U8OR31L^=(*ND$E= /<Q5E8X=IO
M\5S \/D@6(ND]Q$(_AVG&M6Y!IK'4W.!_?: M6A8JUP)UWPPPW)D$<-^[>.=
M5 .+:I:KW(N"^]9U]N6=R9E-79/:&1S8BZF0WQ/HZ6N'N1N7*TF8>,>>"/**
M[%6OBG/<.T^_5\X#(' ' ' ' ' ' ' ' +&A_$(_T2?]C7@$"O\ QZW]*I_;
MVX!Q< < < < < < < < < < < < < U +]$5*F1=@"'.\P2:V//[/L,SL@=;
M9<#R5MUA9U72P*!7<BG.XZ+:M;DLJ8B FWB4AD[EI8TDKNS<JB=A:OOJ=5WY
MKB3G'2) )[,I=,2DGF;?US</216*X:5N?A>D@*02%UH4D28";UW*TWKY]":^
MBH78<<7+QIIL/5*# +$R_?D7(5NU;>3KY=9L5#XTUAD2BT/9$#19E$XX$C30
MK)"C@W(B;4$,:BVY ^:=?]*+FGJ371R5*.?^D$'RB[M;_*+;<$+%P#KVG?3O
M0%_=:T]1O:C:?NE*+=+=%*1A*V:TAEBIQU0S;/4EJ74!:2\*8U$;E=1@W4CN
M/PWV?:CV.'.5<-$,)]B1A>%8-E;VPB?(RZ9>XS8Y>5DUR<K(B5:5=*UI5TO-
MJ**%>3%%#5NM&U6B5*T+_P"US^3Y^X4Z.?\ TRTK^A/.?[UQGZ0PWI4[XQND
MSSD?YHO>/:Y_)\_<*='/_IEI7]">/O7&?I##>E3OC&Z3/.1_FB]X]KG\GS]P
MIT<_^F6E?T)X^]<9^D,-Z5.^,;I,\Y'^:+WCVN?R?/W"G1S_ .F6E?T)X^]<
M9^D,-Z5.^,;I,\Y'^:+WD>)\G5Y/M06/W4Z%^CM3?=FVVWWWZ9Z7WWWVV2US
MMMMMM"L[;;9SG.<YSG.<Y^GGF8,:XSR8?_U'#GY*OPJ>W=I<=344R8HHJ1Q\
M)_S1:7K)#VN?R?/W"G1S_P"F6E?T)YK[UQGZ0PWI4[XS.Z3/.1_FB]X]KG\G
MS]PIT<_^F6E?T)X^]<9^D,-Z5.^,;I,\Y'^:+WFP%6TQ3U&Q]S$Z4JFMJ?BK
MPFN:>1JKH-&(  =&7*#9JX+.0\4%B1RY-PU9LVRS]5ONZ50:-D=U=DT$M=.M
M.PB?A$2CPB=-GQI9*BFS(YD2A56H4XVVE5MT5E6WG,N**)UB;B=U6VW31:7=
M_P#YR&^^:G^$E>=>*^#UG_9$%=%R>U$GS1!P!P!P#5?I_P#Y8>N3^LQ"?^3+
MI.X*[H>3VLVHX(. . 1AKZC%OO8__NJO,Q\"+U8NQFH.'#ZT/:B3YHR. . .
M 1BOU98?>PM_>@O,/^)#ZDS^Z6:7 B]:'LC)/FS(X X X!"2-HU?@R+%\V;O
M63U##1XS=HIN6KMJY4T1<-G+=;7=%=NNCONDLBKINFJGOMIOKMKMG&<Q\%]\
MZ-0<)=\S*>>JN//ZJ(4_$'1*H8JXB^T/#+5"F%A9*% ]F^&>C>#82#/0\9W:
ML<;-!RK$/C(I/?"PS#-VBV<H:,YZW\N?E,2#^D&J&N1#I_Z4-F@3>AV8F0.A
MD##$!;#ISGCVP*Y&AV</A,9 1\8F_>Y"&1T>"B63^-MVX]!!DXPL^6%J^_)3
MVO:>S,NET!.9K.)L8LFS]'<RTKE1D);*UVJ+@)*I91&)W 2<#<DZZ(R(=@+/
M8LVFKH 9/'H?(3Y$KO)HV8'J,A[$*OOGK6_F=*Z"$%](0("3>E@%Q76%>O:^
MFT#RX9$:VW=CG5D&Y!+Y[8,=)OJQ>%XI8,OG\A4G\B*Q<@'#%Y($B2+X O&X
ME'X^/"O?3_C-HM,NPREH9%(#!*\)MD; %5L]'$X>_G$<@JY$.5"+N5(\78M8
MS$HQ'1QJ/I.=VHLX* L#&NF-G;M\[*.7K]T(8UG/2A$K L!]9YB=V(SFNK8$
MSB)D-I6S%> ,P,WBE@H- >VU<+[RALK(H@/W20M;>Q4P3$A(F,3UCR$C,8=B
MULIW[TLLYRBA^@:H0[(*%UE-H$(Q'6T&4#Q<D=C2PQG):_JJO*4#S?QB$/;2
M%Q)'=;5L& %4'1Q>+N-R)TJUC;(N\;/F(-UO[WOM9;"?1A3AAX7=D-Y:MDX^
MF+XBWP;;(H*[SDSU(G#J.G<BTUTD-G?5-9J;3NU]5F[=&,Z=\HJ*=+$PKV4Y
ME2G87&1]-\,F&U6N96<EYXI4X<*'"F'+L R>&M0EIT;<"+Z1M@\<&AUWKN7=
M/L%P]U#BPK#84XD#%LQ:[D&K@<)]>LQ%'>@6FHB+UC$9D%DAH&X;2@*>K] [
M'W,;D\)E%A$+%4KDJY(11Y*6,'#O2*L9$B8S)(^YV@Z2,6,$"[#ON^%KMLMY
M/?>]9N_P0< < < < < < < < < < < < < < < < L:'\0C_ $2?]C7@'20W
MG%ZO13L^UE=J.P;%3NWYMN8E;@4S5SYN<Z/"2:^[1NIGO-,YU66TVSY^N>S^
M%CM\S=)U*Y4=--M-MQ^.0X?CN*7%.APO&<4F!TCFPSL*<N!V613%$X87:K&U
M>M)ZJEBW.BRV)+3BQDF&CS0=N\4D<BT;ZO\ =OXO1GLKL\QIJYW:X\1JCG.-
M]D?\IC&=/=XW2=2N7'2M+\]*TV&7C''"@<QX=C!0*/<W$\)PA)1N'*4+;CX3
MA\JE]+2/]ENT_MD3KXUG/GW)NLWCQ;3'WMC3TCAW2I_QDOK.[QW$;R#26VCN
M!36\.H;U,RG80FX\_1/N-R6'&66BWGJ::=ULMC?S]]-?-[=L8S=TG4KE1TTV
MTT7W7V'+O_'3E.>L,QFY*>2YV[X3N2BNR7,RLA.K5E:D1[+=I_;(G7QK.?/N
M3=9O'BVG%][8T](X=TJ?\8]ENT_MD3KXUG/GW&ZS>/%M'WMC3TCAW2I_QCV6
M[3^V1.OC6<^?<;K-X\6T?>V-/2.'=*G_ !CV6[3^V1.OC6<^?<;K-X\6T?>V
M-/2.'=*G_&/9;M/[9$Z^-9SY]QNLWCQ;1][8T](X=TJ?\8]ENT_MD3KXUG/G
MW&ZS>/%M'WMC3TCAW2I_QCV6[3^V1.OC6<^?<;K-X\6T?>V-/2.'=*G_ !CV
M6[3^V1.OC6<^?<;K-X\6T?>V-/2.'=*G_&/9;M/[9$Z^-9SY]QNLWCQ;1][8
MT](X=TJ?\8]ENT_MD3KXUG/GW&ZS>/%M'WMC3TCAW2I_QCV6[3^V1.OC6<^?
M<;K-X\6T?>V-/2.'=*G_ !CV6[3^V1.OC6<^?<;K-X\6T?>V-/2.'=*G_&/9
M;M/[9$Z^-9SY]QNLWCQ;1][8T](X=TJ?\8]ENT_MD3KXUG/GW&ZS>/%M'WMC
M3TCAW2I_QD2G/)NB=>2A*82=*2D1(T _D"9TGH9>@PSPJ1$!W9/5SAXX&"WY
MTV]'L55MVS-V7)N&Z2:KYSNHW6;QXMH^]L:>DL.Z5/\ CU$M[+=I_;(G7QK.
M?/N-UF\>+:/O;&GI'#NE3_C'LMVG]LB=?&LY\^XW6;QXMH^]L:>D<.Z5/^,>
MRW:?VR)U\:SGS[C=9O'BVC[VQIZ1P[I4_P",>RW:?VR)U\:SGS[C=9O'BVC[
MVQIZ1P[I4_XSQTMBT$]-4T[%G":>FN-=--)2;UTTUUQV:ZZZZO<:ZZXQC&,8
MQC&,8]S&.%-F)44<5%8K0\;XU;;>,L.J[7_NI_QGE[+=I_;(G7QK.?/N-UF\
M>+:/O;&GI'#NE3_C'LMVG]LB=?&LY\^XW6;QXMH^]L:>D<.Z5/\ C'LMVG]L
MB=?&LY\^XW6;QXMH^]L:>D<.Z5/^,\=K7M#?.FV]BSC;9/;.Z>=I2;VRGOG3
M=/.^F<O<YTVRFIOIG;7LSYF^^O;YNV<9;K,L\N*RU6ZFNQL?>V-/26'6_P#U
M4_XSR]ENT_MD3KXUG/GW&ZS>/%M'WMC3TCAW2I_QCV6[3^V1.OC6<^?<;K-X
M\6T?>V-/2.'=*G_&/9;M/[9$Z^-9SY]QNLWCQ;1][8T](X=TJ?\ &/9;M/[9
M$Z^-9SY]QNLWCQ;1][8T](X=TJ?\9$CIY-P[T^2$S"3C"$J*('),^8'2;1W(
M334('C+8L;<(.4U2A)O'8^! HO7NZSE(.%%#=%,,V#5%)NLWCQ;1][8T])8=
M9_\ 53_C);V6[3^V1.OC6<^?<;K-X\6T?>V-/2.'=*G_ !CV6[3^V1.OC6<^
M?<;K-X\6T?>V-/2.'=*G_&/9;M/[9$Z^-9SY]QNLWCQ;1][8T](X=TJ?\9X[
MVO:"NFZ:EBSA1-37;11/>4F]]-]-\9UWTWUV>YUVUVUSG7;7;&<;8SG&<9QG
MAS9C33CBH[':%C?&J=5C+#JJU?[J?\9Y>RW:?VR)U\:SGS[C=9O'BVC[VQIZ
M1P[I4_XQ[+=I_;(G7QK.?/N-UF\>+:/O;&GI'#NE3_C'LMVG]LB=?&LY\^XW
M6;QXMH^]L:>D<.Z5/^,>RW:?VR)U\:SGS[C=9O'BVC[VQIZ1P[I4_P",\<VO
M:&=]5,V+.,J::[Z:*9E)O.^NBF=-E--=O&^=KKOLDGMOKC.,;93TSMC.=->R
M;K,K7+BJDU6N9TKMHM@^]\:TI]Y8=2__ -5/S5I_/K9Y>RW:?VR)U\:SGS[E
MW6;QXMH^]L:>D<.Z5/\ C'LMVG]LB=?&LY\^XW6;QXMH^]L:>D<.Z5/^,>RW
M:?VR)U\:SGS[C=9O'BVC[VQIZ1P[I4_XQ[+=I_;(G7QK.?/N-UF\>+:/O;&G
MI'#NE3_C/'>U[04USHI8LX4TSV=NF\I-[:Y[,XSCMUV>YQGLSC&<=N/<SC&<
M>[CC=9G'BVA8WQJG58RP[I4_XSR]ENT_MD3KXUG/GW&ZS>/%M'WMC3TCAW2I
M_P 8]ENT_MD3KXUG/GW&ZS>/%M'WMC3TCAW2I_QCV6[3^V1.OC6<^?<;K-X\
M6T?>V-/2.'=*G_&/9;M/[9$Z^-9SY]QNLWCQ;1][8T](X=TJ?\8]ENT_MD3K
MXUG/GW&ZS>/%M'WMC3TCAW2I_P 8]ENT_MD3KXUG/GW&ZS>/%M'WMC3TCAW2
MI_QCV6[3^V1.OC6<^?<;K-X\6T?>V-/2.'=*G_&/9;M/[9$Z^-9SY]QNLWCQ
M;1][8T](X=TJ?\8]ENT_MD3KXUG/GW&ZS>/%M'WMC3TCAW2I_P 8]ENT_MD3
MKXUG/GW&ZS>/%M'WMC3TCAW2I_QCV6[3^V1.OC6<^?<;K-X\6T?>V-/2.'=*
MG_&/9;M/[9$Z^-9SY]QNLWCQ;1][8T](X=TJ?\8]ENT_MD3KXUG/GW&ZS>/%
MM'WMC3TCAW2I_P 8]ENT_MD3KXUG/GW&ZS>/%M'WMC3TCAW2I_QCV6[3^V1.
MOC6<^?<;K-X\6T?>V-/2.'=*G_&/9;M/[9$Z^-9SY]QNLWCQ;1][8T](X=TJ
M?\8]ENT_MD3KXUG/GW&ZS>/%M'WMC3TCAW2I_P 8]ENT_MD3KXUG/GW&ZS>/
M%M'WMC3TCAW2I_QCV6[3^V1.OC6<^?<;K-X\6T?>V-/2.'=*G_&/9;M/[9$Z
M^-9SY]QNLWCQ;1][8T](X=TJ?\8]ENT_MD3KXUG/GW&ZS>/%M'WMC3TCAW2I
M_P 8]ENT_MD3KXUG/GW&ZS>/%M'WMC3TCAW2I_QCV6[3^V1.OC6<^?<;K-X\
M6T?>V-/2.'=*G_&/9;M/[9$Z^-9SY]QNLWCQ;1][8T](X=TJ?\8]ENT_MD3K
MXUG/GW&ZS>/%M'WMC3TCAW2I_P 8]ENT_MD3KXUG/GW&ZS>/%M'WMC3TCAW2
MI_QCV6[3^V1.OC6<^?<;K-X\6T?>V-/2.'=*G_&<F+@MC&,8Q9L_QC&.S&,3
M"08QC&/I8QC!#LQC'^K&/<QQNLWCQ;1][8T](X=TJ?\ &9$C=JQ<1&XMLXWD
MR9^'0BP(8WC;1BP5B<B4FV\GRD:*D%3*+EKEKI)=<$F&0!+)'((5HF\;Z;YR
MRW#,AAAAOK##'#DWPQ956FVW9?;8[E2P[<C&,B5(P;*<]3L%P7#<%4B&"!X-
M/WWOBDV9&YL,4.2I])D&XS,MR9=(H4WD7$S?D2+;&M'0]^3927=1P49OHC$]
M,-MMJP)19LT9JX>K[XW8RM9@52+MO1K[=DAJIYFBK-NS4TYT#=J;3=6LF&Q9
M#5.:*VMCI=<CM3<<X--W5103)D$]Q13(8\&P:D+>+YF#P0PM1MU@PEP3%-A4
MN/(5:)PPP.)D-QU\JT=>K,38CW>861#!-5X0 RH#+/B$#43T6?.S9=L69L6(
M"1^ )X"#R+1X6W=:(;K%WNX^.;!3R5;D1)5@5C;AI_,TTJ.EEC>MG'/QI@3A
MBWO@T$$6](Y4K*P2363-CCP.QQQ39D,V&&"3/R9NXP3(8ICB2;FQN"LQBY&4
M:AT1BB(9-QEL3,)RX@Z;+.5EHP5D49-N!(9KL93#N-G^@'NGVY</LX2[$TA[
MYNFX<J<S#-4,,"HG>HFTZT<2=%:E:EG6JJJ=?!\:0X/@N#8,I2BR9DU83'%"
MXFY$R?@\Z*7)AW52HG&I-(W-E.)42@CA443=O%VK6Q;5PS/!&K;<Q(""#EMO
M"HHW!J#R$@ ;1\X^+#]M207$/C@YPPV#!P[QN]URIGQ&^2A393:F0-.JI6)V
M9,*3K$LF)Q*U9*LHMMIVI>,< FJ*&=*AAW6?,44+P3!U*R(Y\ER9T<R7_J2M
M[2)<4#E2I<:CM=6YDRL[.K'KH6;49L]19@>3)5\NX<QZ)0AP^$Q8&9GBLJ#Y
M>+K&P:I\J@3C[M@Y';*M%Q6K428V8K,'+5:Q1RT[ZJL#\F&&J2<64JVJKJL]
MR2=MARX7AV 2YK@@4N9+F1X$XHI&#8(XY>#R9N&/"9>6W.DN=-4<B."*"L,4
MM02YN3%!%"XQQ=M:(/EG V))K8>(M$2:S^"0Y;Q^6D&D07O,-7[XOAOW\G<Q
MTLOYCG*CE$<JNZ4573U:N)NT&4G1M65K##;2&)557QFGF=%;4Q%C; (8G%+P
M5/*4*F./ \%BRW#@D^5E*"9'-4.5A$4B;%Y58E W$V_)BI,PL>!R.)2,>T"*
ML3Q5U$R3-9G%P(G7)5I&8@,EC@H2:$U\;C'Q80>(B1@T*/5:NRBCY1_A$H1$
MI9CF010Q)+RGDM4A25:0J*U9JIM*BOOI8=7"L/P.?@T^"&4X)TR+!HX'!@\F
M4MTAD8++PAS)D,QU@CF2IT<N7+DP.&.-QN.DR.6M?><!X@X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X!W'
M?0'4E[\G6?\ ]>&__L!YZ&]I7XMOT/T[P/Q5Q\,_6E_L#Z ^DO?DZ_'PW\P\
M;VE?BV_0>!^*N/AGZTO]@?0'TE[\G7X^&_F'C>TK\6WZ#P/Q5Q\,_6E_L#Z
M^DO?DZ_'PW\P\;VE?BV_0>!^*N/AGZTO]@?0'TE[\G7X^&_F'C>TK\6WZ#P/
MQ5Q\,_6E_L#Z ^DO?DZ_'PW\P\;VE?BV_0>!^*N/AGZTO]@?0'TE[\G7X^&_
MF'C>TK\6WZ#P/Q5Q\,_6E_L#Z ^DO?DZ_'PW\P\;VE?BV_0>!^*N/AGZTO\
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MOO\ [XG2U_5I>_\ RC,.???8G@8R];!.S"#TL!X$SUEV'R.\^Z.\. . . .
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M6A[(R>YHR. . . 0$:^ISG[_ ,K_ /NDQS$O@OUYG_DB-17KU8/[(2?YLR.
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MI<#V3_WB;^F<2#_E[Q^](^@W[J7JA_\ .U)^K3CPSQA_2X'LG_O#?TSB0?\
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M8GW^W_#_ &< >FQ/O]O^'^S@#TV)]_M_P_V< >FQ/O\ ;_A_LX ]-B??[?\
M#_9P!Z;$^_V_X?[. /38GW^W_#_9P!Z;$^_V_P"'^S@#TV)]_M_P_P!G 'IL
M3[_;_A_LX ]-B??[?\/]G 'IL3[_ &_X?[. <V"3#;&-L.DLXSC&<9QM[F<9
MQVXSCW/]>. 8B7_CUOZ53^WMP#$MQ6JA3D0TF;V&3&;,,'8^!=,85O#<$V*T
MF+-0 EZXTFLPAC!1BL=(BQ:N61!V]06(H.E&6!J!!\R Q$<ZOX/'AMBGB4+L
M%*-U7$K#DTPD&%*VPS0)51%'$JL*&B&"MCI2"2'8MX-Y&BAR/AB5<(3!D^C^
MT\\4Q>;("TN55:Z9\^>ZXII[KDB4;EH $:@QX8)*BW) D26D$1*D0^[6MKEM
M#=-/2(%I5!S26P*G73)# JQ5BCPO)Q35B(=HC)&Y$A2QNJL^GOY+[;J[ TA=
M\4OJ)OI;$F)D:V%'W$:)L#>T?=.&I1 4'-^8W+Q"02N)&F^XL\+6W=QZ2EV[
M%\H\ %5&$C#&PXX3VF8^ . . . . . . . . 8);=1=;*IQYP]?. ;*36+8M
M6#7IU8*.3VF%;VTXI)\Q\,H9V(NDI!8"*(R-+#&3_*R) <N93"9=:I:BT?57
MFI7L.!UU2]/3+!'=U;$31;B6.2#]_LZ<9%HI:K"$MF^A;5ML,<$\(R"/DLAF
MSM8OZ"/@I#X'T$9&D70E'H[]TS.3!\V)L61)GLKLT(-&SYKLLW<-%MFSM'1=
M#95H\20=M5<I*:Y4;ND$7"&^<IKI)JZ[:8 ]O@'Q>?NDSJVZE^E;J]HYQTYW
M98--+SCIN9(RY6!G5PF\A2CUG6!N#3*90QGQ.HO<T6V9XV_BLD'/9_&9Y]G]
MD\!P/#8</>%8/*GN7%@R@W2'*R<I3\JFBN3#7D1WL#EP3%'EPJ*CAI7-5.NV
MB/G=]MY\IQ]W!U"_'M__ /QY]A]QXH]'X-^G]3N;WD^;AZ_>/;>?*<?=P=0O
MQ[?_ /\ 'C[CQ1Z/P;]/ZC>\GS</7[SWQ?EB?*?""8XJWZV;V<KC'[,@BV*R
MO8N,<*LG";E- B))-G0XFP5W2U3>#G[9PR>M]E&SI!5!51/:/$6*&FON_!U5
M-54%&JJEC333T---.U-,;WD^;AZS[PO)$^5VK+RE-98"&\AX%U2P(.W5M"KD
MG&4F9UFEE%IO8];Z.UE79&&D7:B.I,9NJZ*P@JZ2#F%G;%V D$@_.\=XDFXJ
MFY<&5,P.9$]QG4JX&ZO<IM+%&EP8K(9D*RH:-10P^;/D128M,#?DQ>QZ'VG<
M$&^I(W_@6O\ [.G/GX.!#ZL/8CACX<7K1=K)+FC(X X!&/\ _.0WWS4_PDKS
M,5\'K/\ LB*KHN3VHD^:(. . . :K]/_ /+#UR?UF(3_ ,F72=P5W0\GM9M1
MP0< < C#7U&+?>Q__=5>9CX$7JQ=C-0<.'UH>U$GS1D< < < C%?JRP^]A;^
M]!>8?\2'U)G]TLTN!%ZT/9&2?-F1P!P!P",$_P":J_?,U_C+_F8;GZT?]\1J
M*]>K!_9"2?-&1P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P"QH?Q"/]$G_8UX!5RKYD,0)$B3QJ/'#TGCY^_?.$FC)BR::*.'3QXZ<;
MIH-FK9!-19PX64T212TW44WUTUVVP!3)E%8Q9\0]"F'.SR-$G47D:3P4_233
M<^KI\/, CMN_2PLBHR5?AV"^ZB>=DG3+*FNBF-5<*8 U]FG1A4%ADI2\-D)@
MI')DE9CMW"618-K%6$@N2O)'65ARV/KJQ]S*!3^3167R-1Z$:R?,$7D9A],E
M(BI*W*QE06K[ZG5=^:X]"9='$/L><S0I,"Y!"NC[" I":VBJ8@"';EH6 L$*
MD:(N4@>Y?5=LI/5B AD'+CA>'PUJN88E$N\:J!6S;UTS<W>AG*KZ\KRJ-I3#
M($L@PU($Q\[)0],BTWTCOIT0SC"1 8!;ZH[ 0TL(P8R=<;ZMM&IV;*S@WJJL
M1=E,)!HV=^3LH943536TPHBIHJGMG;&-T]]=],YUVSIMC&VN<ZYSKOKMKMC&
M?<VQG7/9G&<<$//@&DG5!>=HUE/:L85S&3YV)1Q9"QNH%\(C+0ZU&U8XE(&#
M*LB+IVZ:O!6$0)JQ[::/(J@5D*[VCV\:78:!Y6\W5%6?3F[]7/J-8M^IZV6V
M3$?DMJ/1H4/,)_ZSWS%?8F5K?)9H*8%:TIZ$3&1U>YC%:O#3)<XI,A5SQF9S
M"'2>+M:]3FLA(SR)2%<+.RQUN:M>G0[.6E+IJ&=1'4$;LJS'4GD1BM:@=528
M+0<Y9$4A;1&,2@?1G2A8+5NZ;MH\!6%3!L2L^U71I"82N0Q@F]%Y&Q\"T;PH
MTS="V45EKI9;I=G/8L]VWL&H:9N[%I*I)T2),BY>5UQ#39X@/PUU:KR)]'V"
MLBUT198PU:J-S>7[9PR1U3U8N45F>4DMT-D]!FXRQP!P"JR&=P>(D(\)E<RB
MD8*RY_D5$QDAD(@*0DY3"K1#(V/,R3QLY-/\+/V*.68U-RX[UXT3[OSW".-P
M-8AO391-AB9DT'3L[.XT9*6H03:!YL"?L8$7ZB5-K5EKN)%HT.0*B"1=2>";
M#B3TF7*/P:!&+GHTX:L%!RJPM78^2G-=[N8]L9T/T"$-."X6/+B]7(VN6"K)
MNB 54PM50FO([#2#>3/0#J=L]V49JR$QYV'92UO%G[$6J\=1_<X0(%G(5;[\
MOO9M<.*#"[=1V)(L2C5%\4%JN1SMN];I$PA-V%-#E%FRBJ>CX08'OQ)1IMMA
MP/)LG;!VFBZ;+):"'O< ^#/]UE_][?ID_JYO/_DR6<^^^Q/ QEZV"=F$'HX#
M=,Y8>R(^4OGW1WQP!P#8;I.*]1H7J-J%_P!)*DRTZB])D-2JM.!IY7D+J0KY
MW2RRPUWUW8.PKMAN\0D[0WIO&W$;W*IR738#L1QSK8;#@L6"SUANY[UW-[MN
MCI"H--;U$G1P.'RU'DY'E4,3% X(MTID4\JN9=M=%+:W6G]9Z@UK6<4G52]Y
MLHD.N)6!QG>RF,#<OGD.;3+84VR<2CS@CIH\W&X>][E'57*V$LYV11=O44TW
M:_XI.4A38U@KF18.HGN+G*%37+_D<:A\G*I?2G(KEXLRFZ1TNRHJ5Y69<YQF
M!P!P",?_ .<AOOFI_A)7F8KX/6?]D15=%R>U$GS1!P!P!P#5?I__ )8>N3^L
MQ"?^3+I.X*[H>3VLVHX(. . 1AKZC%OO8_\ [JKS,? B]6+L9J#AP^M#VHD^
M:,C@#@#@$8K]66'WL+?WH+S#_B0^I,_NEFEP(O6A[(R3YLR. . . 1@G_-5?
MOF:_QE_S,-S]:/\ OB-17KU8/[(23YHR. . . . . . . . . . . . . .
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MS9D< < < C!/^:J_?,U_C+_F8;GZT?\ ?$:BO7JP?V0DGS1D< < < < < <
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M7 'JF*_G=?#:_)< >J8K^=U\-K\EP!ZIB_\ :=?#:?)< _/5(7_MN_A4_D>
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M1>N(1N*F\6D/5:\/OSPW6T 8V'TW*8@14*&XS'$YW:PXA7M.$'T,B:9,\F7
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MA)3+]FGC9PSPGOEPFGYFW8!-< < < < < < < < < < < < < < < < < <
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M1IY$G(<='%7<L,2K4*V-47+GS=^<W6X(. . . . . . . . . . . . . .
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M7>FNS;CFN*$Z\:R/@(6TM\^M780E%8%FR=5HE:DZD<"C;PQ.!1Z0A[8DH=J
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M02%DKZMF1F6EDMBK\9(K.KZPI[=HV1XD$YAOI",0OJG95RI"-F!PGO'ZH*J
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MB:CUWJP:L6.KIUMKE=QJR9,VF%=]\-FK='S$M!#V> . . . . . . . . .
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MM9[("\%KV*V+:Q\>'VTD#YK/X1B1EF((>](,!I)/5JKH5]78JNE_,R]R&_\
MK"0%"3+: H-34<F\R$SFN8]T[WC)<FQ, IFWCNBL4LLJ_!ABP>X[%B,/Q6QT
M9&,)Q%A*H[&IDJ6F)!:,NA**WDLM5]5I2NK;R.TM@VV>KAG7%^;&H#A:0P6
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:@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g67046g11a18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g11a18.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1F<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &8"^92@X0DE-! 0      $X< 5H  QLE1QP"   " '\< E  "')R,3<V
M,S8R' (% "U-:6-R;W-O9G0@5V]R9" M(%-T;W)M("T@1FEG=7)E<R!2:61E
M<B!T;R!3+3$X0DE-!"4      !"36DJ#V#D?VAR D-$IX9H;.$))300Z
M  #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O
M9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O
M;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R
M;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T
M3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--
M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&\DH^         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             "0
M!B,          0                         !              8C   "
M0                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M0     !29VAT;&]N9P  !B,    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   D      4F=H=&QO;F<
M  8C     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MK(+6M#ZV1[?:U(=#8&O;]MS#O(.MY):0'-_1[IV[O4_\]JWT_P#H&-_Q3/\
MJ0C/>RMCK'D-8P%SG'0 #4DI*<W]@LTVYV:T-#0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,T)YH=4T.%)65Y>8LKC!T0HF*35&676W\?_$ !P! 0 " P$! 0
M   #! $"!08'"/_$ $T1  (" 0," P0&!@8%"0D    ! @,1!!(A!3$305$&
M(F%Q!Q0R@9'P(T)2H;'!%3-38M'3%A<D-'(E0X*2DY2RX?$U-F-TA[.TP]+_
MV@ , P$  A$#$0 _ /OXX X X X X!1QV^[^;KZR>2#6]/*6"H#>DM>U1ILU
MV(26 0\&ZM+WYLG;VHZELK%Q6XW(%5ZL[ K^MAM@BN^L!L.>)3W<)4QEUL#0
M/5ORX;PQL+:UN[3 @<?KS;]P]:8NMBL"%#J,GKSI[M97MQ6#2UAV,^]$>=M3
M-C9JNM!]A*3IXI-?)WA$AM3T-K,3 &V1/G%A&K=J.LP>INT"#-ZJVF[]=W@Q
MK)8[1*-V(NAP#I\X+K<:JY?MCLVG#ANRKI$D3:PU5JZ7^CA3;"2'S&4@::Z[
M^6?:E ZX 8!74MZ[6;*HNKNR?:3?=N([(IU$<J'7^A=G=N:X&2 \BS(4Y=[5
M"'TZ9#%U2%'&1VA(.&T^::>FQ&,@;OB>4VP2+ILZ@Z@UCL[>VP-@;TNE>U94
M[+>=6:]$U#7%!ZIZ3WE<#H0V]5@6(+ V)LP6Z'IULGW"QE[02+K>N@L RQ$%
M@=,#[L]AJ5XF/'=LH+;@);L+VQ/=7]'2=R;?AR;(!J5AW/+?CFMGVT;"(@\V
M":.A#I>1PYXE B3CDN!F:X[&2]%D 9SOKR.;)Z 6*I]?-HAK%WAW-.I-DWA9
MK3KVF"]/R1>F8%D'U:"/'TX(J\Q+=LE9APO]O$PU5420&Q8N9A(=-?8Q. U7
MUT[3;ROG>BB4TGLZZS==V'N]Y(*8NHE7?IXJJ#K/1^D;)K*JSARV$O1X5,)V
M0O/'0',I<A$"$Q3^7'<J5P#D=K/+82T?Y--<]?!]^HPS2%+N.C-1;XIY4"[*
MN1^X=C!=WEP[?7[0EM<<, TPM[2<JSQ')49PA'V 8PZP]D0UC@'<;S\L'9M[
M2Q?=W6CJ*(*ZMQV:JNBJ-L_96WJI 1>6X'8J+H&]9D:X'839JB^<MC<@'3RA
M&?/8&P9OZN/P6D#V:\7 RZ/Y48^EMF[:@;\JMQ$4P;O39>L+$>-W6D%ZSIR]
M:XZ::X[)1=<53].:_JTTW7KLAS8 4&2L1L\=>N G#C$MT/8APFO =9_=F+3_
M $EZHU))ZJ8A7+<E1!,5\8UO.IF"M6W+;NO+N^ZWK38H@=759I4=36&*F5)'
MYX^QQ)+J;&Q2I5:?A$);G\_G]W[P:4TWY>]GQM+: [(=I*&=KCUEZ6=ANQ1&
MC:@L-+GT'9T:B7S1E.J)=(:P5N9<:E9CIW8CP0(-7LV,$K,%)0C:63^)H]X*
M!(&1Y?=CL7R%U_:Z46.;VH3M6[:F/:BB;NU]FLBRE9T>)W^*L,3:;\%D(1KQ
M>BDGU3T+&0CH4B-?@I#$G)4/+H$T.O\ V8N_=+4=<N^NJ=8-(TW;G7>J['H^
MWYAF@VTY5-AVDK9 AVF9UV0;G((2J$H+$)M6(S <J=G013%8CX=B2FL 4^ ^
MZ_D#J^D>I^W\;@3O2P[>[&=EQETUHYIS60)\UJ+J''W\<NM*I3U4#B)Z+GL6
MDZF=F!Y[KK\F+=F!(V"C DC/BO@9]3/(#V0W?M[K.$H&R;Q,UMMF_>0,FZ3T
M9I/6&QRAW76B>V]!UCIF0:_5[*&J[1(VM+8\S:K<(=4?=DOCR+R),Q2G$ 61
M]=_(#![&;=IFNJKJV8-JUXU?NC;8J\$+<RN;!JNJMZ.Z%$1SE/S7HT@>=OUA
M&6(Z,'H-2F!M?#+6].FE$E1H8"Q?@#@#@#@#@#@#@#@%3?:[M[VDUGV)V[K?
M28[04NG:(Z2Q>W]G&;2KM^>LU]7$O>Q@)ND ;Q6M@A@=!0\ H[;PHX6H%W0P
M8E.9G1'(*\)C =!!\V'4N86MH1L-M"3-I.K[AL@ZX*'T$DC,G7^G8F[[A1XH
M=.Q6;K"L(RHORX44Y::A6M>%[.*(5X9=9!),=E\#UW_Y70%0T]MQS6^E]V?\
M("K:J["707KVRU?7LAVAQ]-:BU]M%O8^RL0]M-!'=>+&;FU$3>%U.S'M@/QK
M0\+<J4$P'.Q!8!WR=%9U;HS-4U9<YU@$[GZX:1VK:2M1J:Z'9[MN/5E.V<1I
MVJEJW95SD0\\(NP94"S6<2Y4JZ[]5',,$5XB8D :^T[Y@)-FJNEMA;=U"?H@
MW;G7>+L<+K6M"*_:[O<MDV;L9K[0&O@E M36V6JV@);SE\A#X(R]!:K-C3<2
M#=BLM8##<QR8$Q>P':?;=;?ZHZ[U3K\31-P]L-B62GP&.P41HJ*U('HE#M&P
M+B4ME<U??\LW,_\ ;JXT.KM?JFR8HLI(*((.6IF#"<P^!I+9WE+UWI[8!_JQ
M=G5'>T55J#42QV"B@A+&HANTCVL#6QZ>-S5[!LB5MY $P+@C),\D-KEJJ]7?
M-C0=BOD:<^I[ 'Z]&N]MTV_K;L;M#?TFHAJSHO6_778TTG7A$D0S!#7[IGJK
ML-LB80Q**D?G8AV&UV-P0A"F,P@[<* \N4ZPJ6[A<I/U2!K+JQY9#UUUK/;[
M#ZM9=['S-UZXUO2=(]>,#"1.UAM\:@9WQJ)QJ3LG88>NC"@RAQ+H,V$6/W8&
M C6375F0/1'4] %*R#G2/*;L3%BW!"G==K;41.H.ZE%ZV?33(%/N-JOP&QZ&
MB;B(@! D/N<$S6=LJ<E,1Q\DD\9HL8<5K\=YXD=E6*!4P,^L7F6ZK ]=G]I0
MPFQC]-KH33AB438FZ7JJ9TG<^G9&]A-7!JV5N6C1SESJNO/LQ"XU47(DEX\V
MT 8-=CV1:BC@L#7H7RPEKG8-@O!=62Z=JRI=E.IFK:[L^UP@I^!;]=]CZ-1;
MXLI+ !MHAK'4;/D%<$&1$Z6,+!PH!V"\=$3[,V3J,0#;L#RSZ5("Z]/:TYV-
M9FW\)HZW:@ R:IKA!C<E#[$W>3KW5]XI.$;8<&C Y2S,QV"@K89*C7 !#*#)
MY>L18LA;C0$J^O7:8'V3#!++3-9[5 5<N%NLB99+H+IX\57+KKO:%CU)=-3G
M/LMXL$Y5^!6BIG'W7 D(S2)P6*@@+NDY<AB,Z!"KI7Y#=B]A-@5P#M,/JVFU
M*;U#M78JPG0[)T.D,9K7:3:VE'T/D[#;"8V!4(U,H, X05-9S+8,NDYRS#(K
M+(Z(!O>Y=L[6UVOZ;:WUD5TS?>OO9^N[[>=NP.>2M%C4?T[3G;*W(K-F 6+%
M)37W9CL(9.2L?8ITA]DJPET0[%94^!'6C^1_8]1OW8VJ;MIE=W%6]7;_ -'=
M;]<WCJG5B ^/:]T[=#S)9_3Y ;M3:,@3+L6JBWV$5<+;!N H3'<LD-!6NUV5
M!*QX8&$7/S%5TM?.KT/3 01FI7F[6>L=D*GM,>X.VUK61%"]BH]>JP--:NLN
MG1;DQ=^L.RA%D4]/N0?(Y=7E"G%Q[,-)K D'T1[E[I[ W<E1=VUS6(Z>?ZQ=
M=.V]"GZL@VJ#"$47L)*O\&/KRWYL]BLGWFVT^52$*=MH=T"+LC!1:FJD"4.S
MB6!:!P!P!P!P!P!P!P!P!P"BR]=T>R&N^\/9G35%EU.Y1K%V8Z::(U:#VC(,
M-4O6$;:G4O8>TK8?AM51I@Y.5*M-.C$9HQV3G!'#TB&S.$Y>;GQ (6E.V_9[
ML)>(F^I=^?UI44Z5\8YD3K'7-OV.)%!#V].]Q?7&TWWH[-EAUZTXM+.NK$"E
M3[)7)1!NB/UD&-P-D_JV380)&U7S'[8OMNOM/HNO]/6!QR]]<*[JFPRR=C#"
M7!6^NR5BZ\ON7@/&.'[A#D5^0(BV2*\4K]"-$FES(KU'@Q,CBLX#V3Y:>T02
M!'9M>G] OG[0 O6*.U7[1L1L0NSZB[R:MZ7W5RTR"(UR9  VJ9L1^ZUAD7&)
M$*Q%%-#BLBSORU98 &/+CV%UW))Q-JZ\T) CN6CM9J>O'*I.V$0:=V5U@WSK
M?3#ILJ',R13,:J[ >V&VL0#<LL)0"<,CR['?((4I.E5P#D4?S*['*C=)66VZ
MHH$:NW@=V $'HU-._K&T6W9VF[AN6L ZE2 -;MQ\E5!M\@:E>. +>3@; H9&
M=*+5AFZQW@T8R7 [6D^5/L7?B^MZ#5*GU=M=RVU9.M<8#=JE;KW8-5TZ#V-T
MQV V>JE7)V!EXM(V9K%_2X]PQ!@3(,>S5^UC)*QU,?FLNQ@,%1YE.Q O7];.
M6C1NI,6?;&M.K&QM;JJUF.RZK21O83:FP-5DG-HDKJ3H4"0T&F4-LF)<8L--
M&2"MJ#4Z:=1EK-IF 6F=6>Q^S=Y5ZMF-A0])T8V8THQ<S.L*ALD7?MBAK.QL
M"\TV7:&WJP9/U23J2P0JS E5<G$+$"<.P+-ULS)7-$O82!73XV^Z&R+A:HT;
M>>V3-W=F=!.NNT@5.EO"9-JN6Q#>V>TPRXSJ;78C4(I:+:< TRI#'!@IN0X_
M@6+;;C-NNY6Z'Y_$D'MKM 1 =WNIK36W+MKZ@[1Z[=H;-;=$7H6""SAAJ@0*
M7*H9TCKU8B-L9RTSWR5A^W!99J:DXW :BU\:Q)Q-5) T;X5.SN\M\R]RA]Z;
M3L&P2X_6'6[9(&.3L-!OXS,+9H"X225Y@6S7XX3$H\J]S@R)$OK\<AO%M3H%
M1TME",8[E;0%]G ' ' ' ' ' ' ' ' ' (Y;8ZD==-Y2]A3=L:JKMXD;6U@'
MTUL)9E952;-K2O6:?<P=7EM1B,9F/'%6DI..P9\%N*6CD'4/-S\?!'PT!H#M
MCXZM0=CM"]@M,U>%7=4%.R5=T[2]@WEBL/6QURHZ7*C,T^#!KDP^*%PR->K,
M8B#JA&$[$^QS)D4P_&*NCVXK@&P[=X_.G5]O&K]E7'0M).WW38*F5G7UG>:)
M0IH@%KR6R0I N:R*(P(%A@U0BRF?7X=CAEHPF7ZO06F%J5G(&(7#Q>=!+^(H
M@&Y]8-<V(3K1VRKID0DV<=P-CW"W3;[9A,QU)EN0>KIBXD9U@EUFPNE:]DA*
M?6V,;0XIO(&3['\=_2S;K!F-LCKS0K8P?V<C<A5LBP43B1L;%.!:^>/HS%)Q
ME1&YU*K0.ME </,>NEA@YEDF)EY]ZU@;%*]2.MQ[KU!ZI'=/4TYUY%UX55AF
MJS$)\G6QX0$\S("1H7UTE\C%DAY4=B6*)L3D%!TQEJ7#FLR6D.X CU*\3OCP
MFUJGU*7U;H$@-1"ATQ6OFEVQ1:/,LSD!VP()6/\ 4GZBL XPL4-S.#V$J5$/
M8@1$*@_&PA& )#USJ;U[J-\@[-K>L00F]#;ULG9<&Q1I!CZJ+>=O@@=:V586
M67":X6)5L!UH&/G,9C?0L-#F5P(L1Y3KBP/R.]1^NMFH6Y-8G]7 RM'[!7,I
ML/<827*-+_75V+K KE60D22406B$F?TO6TBW!4\>@&T"$LA6X#,",AL#4!+Q
ME=$2\O<DR?UKH#KW8!C#.W?CR>C-6[.;,(NCLE4:*:9C R,JX  MIG%*VR'(
MS[ ,B%ILJ1.:P_P#O[+X\NF5PU[9-4V70=.-:\MUZIVS+#5Y[]@>A$;W0*I7
MJ-4;&I[)G$V--$5&J@J_A,24Q&FCH:V2$>5F;/5* YDWH#T](;^C=HY6AZ:K
M?<0V,LD?8S6348FT?#UO-0@&4C8I9D!]S16?C"R)N1.7YT&/$9G+D8B1<L@=
M'4/&[T>H88A7*KUPU^,KA2K[2I1"NJ;,$0,JI;JEU6;LZO+#E"LT:D5:)%)J
MJW8B(J6QJ0L1H-@:SAU#@'=ZOZ ]/=+HH*=7:(IU-7K&S7:YTR8,<.+)#[7L
M:IYHMUL,\I,+RB%A+'J?[*[(F6227=CBV(D:"J+B'&RT!L#4/570&A2 XKJ+
M6H6D$!6MJ_J ?)&RC,AR-K:K'[!: %41@D3FH5!&GK58"33[B5SW7B3J)$MU
MIMEML#+ >B-+UENC-5[5E#"M:R/W"U:\;&5@3#12;)L%JP,7D[6$L148#%;:
MS;+,U89L'#+Y5L^61,6ZF?(PX!P*#UST)JN37IFM=.:VH4JI0+T*J[U2IX,"
MNO#-G60;<=ACPV1L./@;#NMJ#BK#98T3#31<N.ASIB'7X[2T@<FO: T?4[B]
ML.L:DUX O3[Y:2Y;A%2"P+%\IZ88(F\MEH\-N8R@N2L)\F299=0S-)G3)&0V
MY-*3GWP-O< < < < < < < < A_NOHEUH[#[#?V?MJG62P6<AKT?J>P1QNU=
MLU&J7/6@RPE[5%H]_HU-O%?I=]K>3AXK+E"K>!-19R):H<UN1!2B,D#T-=#>
ML9XGM8A+I=CB0MW K( V;40>U-LUS7%D9MU-;U_9"ZM8 +N.UZ,M9:GLLA9%
MQ$5J!:4M,MR6BR)V,2L =-M'QU=1=ROEY5_UF3GS; Y8DG9X796TZ<0,C;=K
M:@:EM-:+3Z==04LC3;'1=6Z_&'*9,>>JQ295AIR8(>._4$GP,Q&]*NMXB!'&
M#]?K9@Q-OZ]WPPPJV75[V;3U92JMKRBV53LBQ.NN(#5&F5P8L*XM8 FN N<6
M%S2$R;*D :R8\973*/6\5)&KC#@*-5I],"1I.U=ORY-1KLW9]=W+'@T4I)OC
MI2B.5_9E4KUKI\VHS \ZF3AC+-7DB83DB*\!MR\]0-%;(UU0-970#:30759Z
M+:]=6-S:.TXNU*A;(C)*.BU!=T0;G&VW&L<B,8*PR!K-T60)P2,R"1?E1'U,
M\ Q!CH1UJBV29;8U<OC!PU6!E2MKK>\MZ8A;"'!:],J@>?L\3G8^1.S;.+KT
MZ0,A6^^0K#:&(^(V$EO?!A+C@<P+T/ZNU[6.U-.A]=2(FNMV5FC4S9U>_6M^
M>Q:*OKG6]7U%5 KQ)^T.%H$.)KNF@*T00+G0E'HL:3(/*)321*5+ Q:Q^-CI
M783TVT1M'AJ+8)N*$[@KJ _<-*2AI364ZW3J190:]26&EX V\'B^7 :FX!DP
M+-. V A7B166$=Q 2!EHWHMUH$W&1?(5)-IL4O86LMLRG)&R=GSA4G9NH:7C
M7E'O4FOSKE) R+1&IK<4$>,NCE3;E&'"G;>Z<DC(#\<#5C/BLZ,0M>-:N$:;
MEURGL;%V%M-F/4]G;;J9IJV[6K<BF;#2FV5N]B[5BLVJG25U$G2?O/Z-566H
M@)D"R,A18K(&<C/'IU-$3(\P?K8A';CR]'$?M.=B;.>K<@MUQ$"Z]J$W,K#]
MR<KTXY6P 0.$FF9@Q\E:1(R$/M<DW&9PWD#A4CQQ]0->?09K&L232@QO5IFN
M+,;+VK9UU&/I.U2KMJFI4Q=FNQ==.US2;/.EE0^M*UD904N2'&'ZX_&]K*0-
MQ:KZQZ?TJ648UN$.UYY4.]0\CE7R_%Z[Z;*VI8]T72=^EC=F(UO[R7V);3Y=
M!W[5@T.'S<5D9/AUB-%$,@:DJWCSZMT:VZZNU)JEWIY_5M:=I=7<J^Z]V AL
MNG2-CV#;,JJ7,$,V#&!;%K<N^VD\:F!+\.L@V6V06(D1G S3$!H#.-@].=&;
M.V[JW>5I&WQK8FEH\Z+K.55-Q[?H=9K+)=4C!W#5"I-Y 4:<Y9(TA0VT/$Z[
M-=L@=F('-KG"X4.&P!%JP>)CKFC653U!K,UMG7=! ;MUMN0@ E[NW[?HC[U!
MMY:Z3!E.7:=O.S-7G+0:-SIQ&]T66*L*"*FB,C[A(CQ_A WA \<_2D:+T^*8
MZ\T%_P#H)L[5QUP9)Q)IBVP[&VS<$+(V2Z%ILVV7WZF9?;2=G1+T9L<*?:"+
M=IFQW["/&DH@&QNOG4?0G5Q%A1I6FS:VJS0JT&(2"]RO-YF1JQ2V24>F4L%.
MOEDLLRM42GLF2Z*M2*^^-JP#!0@H6)BJF/Y6!)+@#@#@#@#@#@#@#@#@'2.5
MFMNSUE7:^$<*.389%PDL5 7/<(#X;H^!/<F*8S(7,@P'WX,.4IS+\:&\[&96
MAEQ:,@<9NG5!EO#+-5KC3.&1<?#30,8VWB.$(/%0S&$(BX3AD04DR"0QKT]D
M">^],BI:D.N.* _)BC4F-(DRHU/JT>5,GLE9<EBOB69$HI'FX)QR4EYN(EQ^
M>P13@@S,=4J0W-QB4AQ+^/DX!^JZ;4',MY75*VO+.9.6LK!BU9:S,+L'Y>6\
MYBY]F91Z+%-R<I]/G+QF"3ONF,MO) ])5(I<YMYF;4:Q,:D?=_J&I0 5(;?_
M % ^W)/_ #-O1%H=^^266I!CWX5]S>:;=F_.MM"L (5)I@V2/FCJC6($P2B<
MV*EP@ J+*&-E'5ODVQ\AB(V["01?<<>G)C+:3+=6MR1AQ:E9R![P:;4!:&VA
ME4K8YMDNZ?:;@@Q<1#1Y]I]A\VVB/%;2@N\Q)DLNDDXQ,<:D/MK>4AUS"@/1
M5)IJX;PY=2K*Q\@2R!D0%@12H;X*.Z\_'"O151,L.B6'I#[S(U:%0VG7WG&V
M4J<7E0'80J^!&N-O#@@@>ZT-C!VG80V%%<;$0W'7H@IM;#+:D#8KK[[L:"G.
M(K#CSJVFDJ<7G('2)UUKY!$.711:<@M7H[40 436 N"(.*RX^ZS&$3<0OJ1K
M#3LJ2XVS"=9;0Y(?6E.%.N94!R)]%I!0]#M1.G54C9QV(^!]CGUX1+/0<1%N
M.1<0R\B&X0BXC./.N1_@D(^%;KBF_:I:LY [ +6Z[6FI3%= !0#,Z6[/FLA1
M4$4U+G2,XR_-E-P6&$2);V<8R[)=PMYS.,96M7IP#NN . . . . . >,JQC]
M_P"/[?C_ '_[> >OR)_GZ?GT_.,X_P#]_P!7\_\ /Z ><+3G.,8_?/\ #@'M
MP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P"%=_P#(1U2U?LS8
MFI;UL(D!MVK*T8LUQR[1+W* 1D@:;6-AEJZ*LT*N205BNL2E72HV'%- SB-C
ME1+$,8A#Y$]Y<1L#K@GD<ZDGSVN:S#V <CG-EDI(,? *ZZV&(74;$Q>+'K)F
MM[3=)5B-'U58"NQJA:*."%7YX!*.V,"1@"$3,LX<6!M_KYVFTMVA#'CNG+$4
M.0*Y+#,D$FJG:J;.<'6<'$LU0LPT;;PX2>4J%RKDZ,;J=I'QY 4\/6XY F.K
MC26V0)">[&5>WU_/IZ_[_P"_IP#VX X X X X X X X X X X X X X X X
MX X X X!X5GTQG/ *L+SY1*W4Q?8F7$T-MQ\CH+>^L-#Y#GQ,X+.N$_90R,:
M:V!&&A MQL@778D(J<?P7E5V61+ (;)2&';9(P\+ S36'D>USL7:$&E+K:15
M#(")J8F[XEUK9K6TNX M!ZX[*68/#E)^W$5U,=JK9, K V!+APAQ2:#/PWA8
MMI@?*( ;]U/W8Z?[XMJ*%I3L]H?;%V<'3"Z*EKO:E+N%C4*'?#]>2P' F9T_
M,&%]1'^JE?!\+'S-?(M/O3Z@2?X X X X X X X X X X X X X X X X X
MX X X X X!45Y=M(=D=VZXT[ T((M=N&5FYWPO>*+39-2:)GSLO4=S%:7(EX
MUSL-6$RJ=7]M2ZV]:Y4,TQ9*N/FXO%4Q%LE7%FPP$'W.JW;%RY[B-;,T)L^\
M "YR\D-_@:SL4(1']H Q_M!2[SU^"ZN9,[1&2%0]$Z;@EP1EJU+I<B*(COU2
M+FRNS,-2P.^ZQ=5O(C2MK5LM8VCU?W*+T@6$%NPE^M\38&KIXN1TXZ\Z[UCJ
MLW7H%XFG+47H'::I;/V)8_6OPX4EAX_98%@E2-C.96!+[I]LGOU6.ZFP.K?=
M#;6C-N1(O5VK;\J)?36L"^O$#9!S:]BUX\-+9,&"<B>I+59E2L8;0TRG$MGV
MJRMMS&0+>> . . . . . . . . . . . . . . . . >/7'\\?V\?R!YX X
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ML\%O3QM2FXII./GE)R_5_P#7MV^1>%4Y8"?6*[-JTIF;6I8(/*K\R.\Y)8E
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MP>,KX%1K#:RGAM979X\U\&=QS4P. . . 4U;H_QYO23_ $&NU7^W>M^ 7*\
M< < < < < < < < Z2RL )5=/1K4@:Y5Y 8FQ8VS68^ ZP3L)]LN@MF7G$7
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MNN0[&!EV!H5'..@HQ@>^9;"RW/BB&'!C4A<U N4[Z-QR"F<1'W,^QIU2O3'
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M"TRB-PNP-U![DNV_:C8-CQA=%'8#KJ&U-@V,^'&:S50P[L-P<"+0"0@7"BM
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M3*L\\S=JM3J'F_477/UMMG/_ ,4F57.<OM2D_G)_X_'L15[Y:F[$[;$Z.@Z
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M1Y4*2P^QB-5X*!;2TB_EFYB?6/@3(X X!35NC_'F])/]!KM5_MWK?@%RO '
M' ' ' ' &<^F,Y_EP#Y[M?\ 3V3VZ\DFQ.^-;MD*O:NTUOT!4J^-FBR11_:9
MK3U5"UBX&0A>,;AL# T&V#W1PZ0A@B/(NP);;D3X6I#4GUUO4ET_HM72;*G9
M?J=%.R4E)1^KPU5CMKC*#BW*4JGN?,7[T7E\8N.QUT1J:3E.,G_PJ3RO5//'
MICR?F?0CSR)3' ' ,$V=KFH[=U[<=8WP4R;I]YKY*M6 8]^,2!Q-A3#JFEX_
MK,2XZE(E0I;64OPYC+$IA:'F6UIEINLT]U=],MMM4U.$O1I_P:RFO--I]S,9
M.,E)=T\HI>LW8KLAHCJ;OW4K.R!=:[)=') 69^HK14(5M3O+KO/<<&:UMT.&
M1G0F8<LI%GCQ%C.,9,.C+!49D.:RJ2<4MCTE>CTFLZAI-1X,K-'U7<ME=CK^
MJ:U>]?4Y1BVTG%SK@U'="V+3]U%G9"5D);<PM6<)M;9<[DN_9IX[K#^XN%UT
M2/UG3]7,[AO@,\='52,7NU_4)@T2OR%+C9(RBKHM9*;  08L5Q"'_>3=8;2P
MM];J$KRE/G;E">ILCIZIPA*UQIIW2MFEG$8[L*4Y-^>U=\8XR5WAR]U-)OA9
MR_Q(,%^R^[.W18C0>CS+52U@Q(>&VSNC<P:IU284PZN.1&:'IQ%IC.S#J%)^
M)%JGN1J8.<2][5D%KAOYZD=%I>GJ-O56[+VE*OIE4MMO*RGJ[8M^!'S\..;9
M)K[*RR90A7S;R_*N+6>V<R?ZJ[<8>>?D0XOVF^G_ %D[V]%*L7L-?L.RYAK;
M%MVK>MM'F+1LRX6^QU8:-U19K<3+^]3<F?<X<F)0H<)B$-'%XZT XK$O#KKG
M2IU/4M=TKJ]BC*%"CIJ]/3IH>'155"4GJ84QB\J*K:=S;<I0:WMQ21+&5EE5
MSQ[N(J,8I)))^]A?)IM]VL_(^@7GDBD/WX!ZX2G&?7&/S_GS_P#7_+QCS_F_
MX=@>W ' /G&[;]@6^DV[;K1=":C[!:H="L56TT[.L+27.Z!VLDX]5)UJKTG2
MEPUK?==TF0[@[9XE?>U8]3C]PM%2,!YUBJZ,9() O?VAO73>BZZ'LVZ]HT35
M ,U,0+&%=@V@/4X4\G@?(*/PHSYB9%:>D1!D*<3GI:6M, ;!FD):V8421(;
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M0>O:-D.R<6^K9T[5^Q#6PB=L74H\@!71>D;&JY'W<5\@W%D1X :/(=F&H>$
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MY:;GG;]I)MI3SOBJW3!9BN-[??U>/CY=BZS_ '_W_;GFBJ. . . . . . .
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MIO*,93G&/9G*<>GIC]N<VW/BV9SGQ)YSWSN><YYR1O.7GOEYSWSGDRSD9@<
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M[8\L=K"&7T?2=';+B[:U\   A=)AUVUJ1=(4,A9RMVA&R5D;B1F9#\=+><J
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M C-=VUB;=[^Y7K\&B5G-/&PK#3L6A-1EI# ,YB@'L!$2 $G_ (T#/02O^&\
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MB*Z>Z346]D6]J[=V\OXOXOXX+&.<8A' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M?@1,/^26S!=AG:O"T99+- &F2X<;7P<"SS=GE'H.934:,BFC A8A@IEQA*B
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MPTTPRVAIEEM#333:$MMMM-IPAMMMM&$H0A",82A"4X2E.,)3C&,8QS8C/TX
MX _?@&M(NG=2C-EE=UP]<4:%MHP#17#.SF*P%8O!*OLI@(0)(6E$-)B2/0T*
M%M9CO3%-9CBQS"L99@1$,@06I5-ZF=M.WP'MGIW>U8V&>T+5+)K:YZWIDP(5
MKA"PV:>/EUG8-OB^B23IT#% RXFO[0F.^-G#'I[@,G)CMK6F176J#K5EB@\Y
M@IR46GG*<4\8>7E=GEY[@LSQCTQZ?RY&#T>:;?:<8>0AUEY"FG6W$X6AQM:<
MI6VM"L92I"TYRE258SA2<YQG&<9X[=@:JUUH;2NH9QXGJS5.O]=D;2]F18YU
M,J82N2SCV7<O?(4?%0HKDU7S9R[CYU+QAS.5XQ[OSR:W4:B]15U]MJA]E663
MFHY[[5)M+/GC!ER;QEMX6%GR1WVSZB.V)KJ^:Y*$G!,+8-.LM&E$(_PJEPV+
M:%G 7I,-N1_>79C+4YQV*RYC*'7D(2I*DYSC,)@CUHSI;J+475[2/5BQB1VX
M*;HREA:;72NP@ :=.(-AF<,ME9$)+#D*%.D)2CY_HDMMJPE*?3*<?G>%EE;;
MKLG6VL/9)QRO1X:RO@_\02N#AA->%P @(;"#AQ<9J$-%C8S,.! B,)PAF-$B
MQT-LL,-(QA*&VT)2G&/3&.:RDY-RDW*3>6V\MM^;;!V7, UE,TQJ:?>(^RYN
MN:;*V!$6T[&N3U>&.6-EZ.E"6'FRJHV9>'V$MMI9>^3+K:6T80O&$)])%=:H
M>&K;/#PULWRV8?+]W..?/CGS'K\>YKVS]>@%M[1ZA[0.V0I'L.G-4[CU&.J\
M>/#6'*P-Q&]7GRI(E)6G,^.0#N:Q&-#V6%)8>9*3%2<94W'Y&"09 ?!+0)HL
MI#C$!I&*_"GP)K#<F)-ARFE,R8LJ.\E;3\=]E:VGF74*;<;4I"TY3G..93<6
MI1;33RFFTTUV::Y37J@850M4:SU:R1CZXH=4I#)A]$DJW6 @\/@B^U\GQ.S,
MPF&<R%-?,[\6',J2U\KGQX3[U>NT[;+&G99.QK.'.4I-9PWRV^^$#8/- :=W
MOJ6C;MUG:-=7Q@<D?90I<(-,S(D"5.K!HV,E!QMBKZYZ<HC6$4_.3+#OM*0]
MB:TRE"O7/-X63K;<)S@VL-PDXMKT;365\ </K9I>%UTT+J?1@^SF[M%U920E
M-1<;+\.;%:G!$5#$BPGE,94TX8,2/EGDG4*5\TM]YU2E*6I6=92E-N4FY2?+
M<FVW\V^0;NY@&LK)I?4MQM VZVK7%,L-N#_#]KLABO#)YF#]-GUCXCSY,9R0
MC$=6,*8Q[\_"K'N;]N?SR2-UL(N$;)Q@\YBI-1>5A\)XY7<&S,YQC'KG\8QR
M,$<C.B*[9>T>O>S>+-.39-7:;VMI!BJQD07A,H=MFV:GNI$J3?QZSHI06[JT
M3'@1DY2P]%,2GWTY6W&SP#856TQJ:D60I<*AKFF5JTFL.)*GPM>%CBT]+RL+
M>3(FQ8S;ZTO+QA;V/?C#JL84YA6?SR25MLXJ$K;)06&HRG)Q37":BVUPN%QP
M#9G(P. . . . <(F/BEQT\5-2M<,G"E0):&W76'%QIC"X[Z4/L+:?96IIQ>$
MNLN-NMYSA;:T+2E6 *P^C_0:]].]L7*?"V/4"&EG-;B-<5>LUJIRZM9[JFLE
MH;E#OFYXD.4U1B6UJ)2VI>MYVQ*@##$MJ@7!!6[0V"U=A?.!:3P!P#1G9;>(
MWK9HO8^\C%>)V@7KH&@U.#"GF8CKK#I"$-5-GD9*'8X:OB,SL%[0?D,OL5^M
MP2IIZ/);@*8< KO*CZ/WTM-)VM5']V];.Y6@U6S7U6,PF8=NK^E[ 4'5#9$M
M=WQ6YTK7NUM-[KJ[=;0$)+/*K>R:C,>8K<VMW89F4  MZAIDHB1D376GYB&&
MDRWV&5QF'I*6TX?=9C./RG([+CN%+:87*DK:0I+:I#V4Y<4!R> . :HWEIBD
M=A]4772VR8TZ;0]@C&@MJ@#IF1\HB'3/B3I0WZQ#;CC$8BF)B#.RSA#ZX,B2
MTP]'=6A]L#&.N.H+7HNA2-:'MI']L5ROGIK.KS%SC+?OE>UNN-!R"I-TMKA&
M6]L(I5Y?W,>-NDV$+,D:RD%$L*"Y^ 3LAD#?W ' -#=EB?8$/IZP3NKM=I-J
MW<@O2&:H$V/.DC:-)'RKW6HUT=LA"#+BD84*'17;++:EC,3B4>8S%>A"#+Z$
MBY8%7/2'JKL")ON!V8K>7]+TM)[=<79NH+K1"H/?'ZGO!DF9MFF;U=ADF/0=
MYZIHVUR4S8^D-T8@DK-%K\]^JB3A*OF9SL4"[_@#@&EMX[\U?UZK(6S[6N(6
MCB+3<0&NJZ:LCTF$ >O%O5)C5427+LQI$8##*SX_T:S11487#6M&94MG*V_<
M!\UR0/:#OYV-)@3Q;35&[45#1\6)8)CU$V#33?6BS:]O_P!9!R.DL6.XVBB[
M.H%]V2]:=/;.J=BGZ@[KZ1GV:M6D&$335D8@'U7#V9,>!"8FR?K9C,5AJ7,^
M%,;ZN2VTE+\KZ="EH8^H=PIWX4*4AKW_ !I5E*<9X!S. . . . . . 1O[9]
M>8/:71-OTS-L"ZL^;EU:P SRPHVT#!]JH=K"WFJ.66H&T+"72HN6*O#6+;33
M"<#[/7720=UZ*J6W+C@:HZ": VYUPU1:J%M.;18L27LHW8]=Z^UD<N-EU]JB
MED@5:8D4JE%;V.%V.#4I-UA6ZX5JF2(\N#KL/:8E$#F"H@!!?P!.?@#@$5NU
M?:.%U>!:YGJUQ;MIG]I[&8UG4*E4"=1"3R-@<J-MNWT:"UX/5NOX*$1-,*#:
MJ"4323MMLF!:P(:7.*-K; B'JZCZTWWOV%W;ZF[2VG3;YM"#KX]N"-=:)<)&
MHMA:FK[TK4AS2ECKQ"/61-9W#K0UKNRR&,,''MC:POL@HW:1Y&C6E5>D@6R\
M < < T'V6ZYT/M5J@GIG9<RT0J<9L%(L)-=..OUBP.OT.Y@[P*C0[#";R5"I
M?+ (*'R(.0-.16?>Z)*C9J69;0'9:!HVSM;:Y@4;:NSU;B-5J>2%@MASPJ M
MK/TJ-)4BI.7_ !&DNBS%^C",,Q+590T$&+L9%E1AD"*=EOQL ;JX X!HOLH<
MWM7=,6XMUHJE5N^[F9%6CT>LWF7*'T^>Z2N-?&G7K&0@S8$Z *%UB8:+2IL%
MV1-BH@_/$&&9#;8F:!3_ -1NM.SK!VC:[/:[8B:=$-;HVV3[)4V\0;+7M]!+
M/=A9DWLGK=:) D+G7?9#43&S;-6]IZ'W1-*QC-'K.5!JK..UPND=" OSQZ^F
M/7]_3'K_ )_X\ \\ P+:&S:+IG7UOVGLVQP:AK^A@IMDM]H)8D9'@00]'R32
M<S$1B3(Q'C-^JW5-,.*0C&5Y3[<9S@#YO>ZFX=J=G^Q]&Z_68)UO/UW^FOUZ
M_:VNT*SRHVU=?;!UJ8'T3;<XK!L!F+M/4FQ@Q*TP%;5T>, ;%ZF[1#5NP$1U
MGK;1240 OSZE:^VOJKKOK'7F[K@F][*JH>:,-V3[S/LSSH])LF[5A,VVE1
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MZ-)7(DYDO0[9M"PBJKK\).AP$2YD&7:SQL5 $YEQV6'<S$25NMPT.R&P-F\
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M(Y(*;%R89<*3C120N;$G1F'VP-= ,];.H%)I.LDVRA::JQ,Z3&TL=?\ 8T2
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M&T[YM'JY>NY[TU>)28+<?7CVF-IOZ]=9;9;.0MU66(.60EO8^G N:\<HLNV
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M ' ' &<8SCTS^<?RX _;@'C.,9_?'KP!A.$^OICT]?WX!YX X X X X X X
MX X X X X X X X X X X X X X X X X X X X!7CVI\EW7_J>0NM7N4#81
MV]5 %#+H  J2>6'*/E83$P3"Q='(7Z:@ID)DL8E2GYBDPO5Q*VG9",1U]C0=
M$U?4(UV52IA59-Q<IVPWQ46U*7A)^(\8>$ESZI/)-73*S:UA)O&6UE<X;QE9
M_/*-$=7O,UU[[!#Z_ L%0V)KR_GK;#I[5;B5DY>P.)Q67#BB9?ZQ!!V1T:))
M7.:3)P4CCGX.6WG7F\Q?BDN6M=[-ZS1N<HV474PK=N]V0JFU%-R7A3DY-I1S
M[KDFFL/.4;V::<&\-26&\Y2?'P;_ #Z(L=[%[.L^E]%;7VO3-<FMNVO7U'/6
MD!K2O..LF;F2%0UR(X2"['@DY2%R%)]SJH8PE-Q';=^B'S97PQ7?.E8I"VKY
MP+IKFB=:;D'TKJ/8BMN4O;]UV,W3]L;(EA*0QJ3;E%UL6!134G1\6;7SL8?=
MDG+5_3  UH'HQ$3/K]B+1GL1IDD"4&TO(MO+26U^XD/8&D]2S=%=1]#1>QI*
MXU#;5G(;!N=!N;>T&]7#Q57(ZX@5J)9#,[6ZF;2A^UK$ 8Y9F4.)'$L+1D#2
MLGS&["F:DK1ZC:2U1L'<7VOLK>=BT2!M?9E1K='H/5NL4VW7\2^5V'H:J75&
MTR S8-3:K]7,4$0"E-DFS2[+@6XU[@,XF^7>76=F=F1U\U4"J>L]):#N^_\
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MQBUT)6M;-5B 4;2QU;15K#559:-_; PZPE"CLDW+/.%)+LK(%D? ' ' ' '
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M212[6'%FK86UC@5F@3G1A:"_ 6J/D"157\=72&E U5NJ=:]:@@:KY3]G?;X
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MREX#,1_E1& P_;?EIZJZ:V+?-8685OHQ8]<F+17['*I.B-@7"N8.TFHBM@W
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M(D]4B(!LQ!<^HALE8$M^^KDI;>2S8%_!F*^CUEY#\_G\_B:G#>&6.)K$!/\
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M("LMPEW^R"JF&LQXF'JD&PW"8L\98 08")\]MAQ[&?C]% 3"X X X X X X
BX X X X X X X X X X X X X X X X X X X X X!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g67046g11i22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g11i22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2!L4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (%"^@G(X0DE-! 0      %H< 5H  QLE1QP"   "03X< E  "')R,3DU
M-C<V' (% #E-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52+F1O8W@X0DE-!"4      !!*(AO,67Y-JX&8@6+2
M3VS..$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           !%0   ^@          0                         !
M          /H   !%0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !%0    !29VAT;&]N9P   ^@    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   14
M    4F=H=&QO;F<   /H     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,     !78     0   *     L   !X
M4H   !6\ !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT
M<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M          $  /;6  $     TRU(4" @
M                                   18W!R=    5     S9&5S8P
M 80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA9
M6@   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(
M=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P
M   D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P
M!#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K
M87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M           2<U)'0B!)14,V,3DV-BTR+C$
M                                         %A96B        #S40 !
M     1;,6%E:(                     !865H@        ;Z(  #CU   #
MD%A96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@
M                        9&5S8P         N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                         &1E<V,         +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E
M<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                          !V:65W       3I/X %%\N !#/%  #[<P
M!!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                      */     G-I9R      0U)4(&-U<G8        $
M      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H
M &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4
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M'0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        _^%
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M@:'P)$)28K$*&%-45I?!T1DE8W*"DI2BLM+4UO_$ !T! 0 !!0$! 0
M       ! @,$!08'" G_Q !'$0 ! P($ @8(! 0% @0'   !  (#!!$%$B$Q
M05$&$V%QD:$'(E*!L='2\!0R0L$C<H+A"!4S0V(D\9*BLM,6-%15<Y.4_]H
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MHPZD'^V7<RYSB3YC3]]5(%M@+$W-P";[:$[#L MOS7<SNUO8' [>RS/(>/\
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MP?[JRX6<1R)6<:*E-$31%02DBVBF#N0>*%2;-$%%U3F'@ (F43&_P#@/Q$>
M 1\!@Z*0+FW-06L]A=6B:=S#L.D5C=FV1_ZLS2,?W=#GXF IS**"/FLHH)0
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M1%=LSN<:(!]XY)BC2%EBNS+R(J/$U" *J:8AWWHSQEV#=+\,=>T.(O&%U(U
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M0C) [5\[CI)H@NP<9N'T\-54]5.^2.+J*AY?&T.>UT<3GM<&NL' %MW,!!<
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M;VU/$K340IVTA/J\CRF_1:AY< 1)FBJ'''/F+DW/X^?&N@:;S2]D<('==[O
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M<E/GS\M:8:^?D;*V-0#S7(?W_'R_S_'4'<=XTTU'$:[Z74$7MMN#_P!NU6"
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M RAC#7>_#32VEK]H\-U&4MT(L;[:_OOKQTOR6%JTN5Q_;K777SDSN/67:2L
MY5 >V/'JHF:J(*G-XK*-3M4B=H(B<R9T^L3' QS;?"Y2#)&YUP&,$8.X#,WJ
MDDW(]8DDWL!L=5=:XY3<:-L.^^UA[K+$;]!R<Q'IFATVZC]OVP)D==78'(ND
M=%0JI  P*%%,YA JA3)B<""J15,IDC3T@P+#NDN$5V!XO2P5V%XE ^DKZ.IA
MCF@JZ69KF3T\S)&N#HY&.RO;LYA>VP<YKV95+4ST51#5TLCH:FGD;+#,PELD
M<C3=KVN:0X.8=6V-@[4@K!<>T.>C90)*808QB*'!TH^,%P"2C@R1$UEG G6,
M18G403M043[1N"BA>L>LW5P'HP]"WH[]$,.(Q=!.CM'@W^;3MGKY8@]\TSV-
MZM@,LKGN9&U@L(HBR+.<W5C(U;K'^E..=)GP28U7RUAIFED#7FS8VNL38  $
MW) <07@"V<C1;XUZPN>7F/O0@9)Q:4'PD4%J[AR-&Z@ 82@=!5PH)0'R P]N
M(\!^ B'CSK>83*TLEI[V?FZUK=+N!;D<1?E87Y#7M5QA%G-V=<$&VXY7X]HY
M77C_ #V,I9U9DWQ!< 5-7D"AU])O$//CS#_AXCP/ !K-=$20=;CAL!]\?*]M
M*[:@_8^^RWOX3XVTU>4"WU-L@145D)!LZ,8H'-V2;?A0YC"'D'W>GQXY$WQ'
M5-=*(:.5KCZTK#&S:]R1?0\ "2=@!L==(=8!USOH-=3W;=ITOIV:#V]3 2ID
M*;S A0']H  #\ ^/Y:YCW6[E9V7T(@4!,8>"@ F,;Q#I  $1'P_  _+CSY#C
M5+CE!=P;ZQ[FZF_990;Z6/'Q&MPL.JSU L(YF'"I$FKY_(2)55#% H-G+M51
MN(B B')DCI@ %_2$0 H>(<V&.;!3M?*<H:TN<3Q<\AS@ 3N'D@<.VUK5$6N>
M1L>RW/?MXGBHV[Y\,9$REM;M$M5ZK,SLF,Y4PK-;CVY323EFG8XY>3EU4%C)
M  %8$64 AC =%J4WZ2BADRL#Q.)F.P555*VGI8HZIK#)F+69Z>1C22T.]=SW
M91<6]:RI:\9N3;6)/$VX]AUL#R6G=OUWG,;5"Q0EHQME=D_DLEY%M#5)"@S;
MTAXFRV9[+1:HJM$54B*J-'"9E6YC L@H)DU2$. AKH*RNPN:1CFXA26;#$P7
M>X:L8&G3J]K@\M."2%I((+3PX^[;L^'!;S_IY;_]@LN_]VUE_P#YM8GXC#/_
M +A1_P#[#_[2M:?\?_.ODFX&&*_B&$C6LC0??4JRA6+V=HL_%QG>,BL"#)!=
M^Y;%0;]NN8J1#JF*7K.4HB F#5V$T=0\QT]7332!KGY(WW<6L:7.(#F-N !K
MRN%( .V3Q<#YD*_N[9<;Q:$L5XC(F\N[U-$TY8E40>0N-XIUT]$O*IF*=N]G
MG")Q6KU<5'AX8I9"4[*(2X=VZR2"@B$TXS%P/4TX);).X?J)%C' S=\H%W7#
M8R3>T@ >L[30V;KJ;7!.NQOK_=2R<X/BL)42J1\8JY>JC(/7-FFI!47,G-SL
M[PK(SDN].':.Y&0?D3.X<*<> I((D2;HH(I<FRMEGKFU-0X%SSD( #8XV$ -
M9&QOJLC80,C0-  3J2C7$NU-[Z=@Y <@.0T^*L?''^?[O_#6_58-[]ALFBE6
MF>C@EH>1C1'@'C19#YA1+^7X_B'X::@@@V(N?> ;>=E!VVOL;'C8WM[UX99L
MQ+(,):2AI-JHD9-=4&YSIG!-PW$Y^S43$?NF Q?TB%,(E$/$.!YUTM/6153&
M@N:R9HRR1N<T.+M!G;>UP\EQ'$AVPLKX.:Q)L>(TW-M=>'"_;P6E*7B0L/($
M.DC]\ZH"5-,AC'.<3?=*!0 3'$WAP!2B(B(>'/&KY$<#<\CV,:T$FY&FMS86
MN2>#0";7N."DV&]M_/GW]IUXKVMVO4)_4*BL\DD#M7$PHFN5!4#%4(B5,"I=
M91\C"'(B'PZN!USU;5?BIRX7$;!DCN+$MN3FU)-W;D&]CQX*TYV8@\ T-&O
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M4Y3 (<\E.03$,'X&*82F#Q*(@(#K-8X/8UXN ]H<,S2TV(XM< 0>!N%1\R/
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M>#O9.4?J]2SQXZ4Y,JJ<P%* $10(DW2113QJJJGK9WSU#L[W6Y!K6C\K(V
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ML#0R*&%N5C0.)))<][MWR/<Y[W$N>YSB2O/ZBHGJI7SU$KYI7DETDANXW[@
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M.FFG9W[C]N"U5(DN->5,C9*/.-^S$0,[B4PEF8@ \=8=F"+H $>?N^[G-Y
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M(FB)HB:(FB)HB:(N!'@!'\ $=$5F9F]ZE'SP 'L44TXU$?,IU$3&7>*%'R$
M543:F >#%5:J@/@ :CC?2VP_>_O"<+=WE?YJY.FJ+Q!1LX+UI*E$AR\F*/ \
M" E,42G(<H@!B'(8IR' IR& Q0$)3[TT5I;O56!R,Y4P%$P]#:1-P1NZ+U@1
M(BYQ J;=^(&*!T3 1)R;[[01$5&[>F]MR.%B=+_M>^PO=3W>'R%[J^\@/D(?
MQU4H7.B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(N!$ _S_AHBL:[]5\8[.+'J'GH<R)0ZVS0O7T*)H* !DW+_@#E
M*B3J2;&X4>&)PFBXCN]]P=NS[T3[W^_[JZM6R31NDV0)T)(EZ"%ZC''CD1$Q
MCG$QU#G,(G44.8RBAS&.<QCF,(RBJ-$76HDFL0R:I"J)G+TG(<I3D,4>0$#%
M, @8! 1 0$! 0'Q#0B^A16SN9NF  T</F !^B1JZ-V! _!-HX*X9D /@!6X
M'PX#D-1:VWS^-]TO?X+GNUUZY*?)@_HVI1.[77KDI\B#^C:(G=KKUR4^1!_1
MM$3NUUZY*?(@_HVB)W:Z]<E/D0?T;1$[M=>N2GR(/Z-HB=VNO7)3Y$']&T1.
M[77KDI\B#^C:(G=KKUR4^1!_1M$3NUUZY*?(@_HVB)W:Z]<E/D0?T;1$[M=>
MN2GR(/Z-HB=VNO7)3Y$']&T1.[77KDI\B#^C:(G=KKUR4^1!_1M$3NUUZY*?
M(@_HVB)W:Z]<E/D0?T;1$[M=>N2GR(/Z-HB=VNO7)3Y$']&T1.[77KDI\B#^
MC:(G=KKUR4^1!_1M$3NUUZY*?(@_HVB)W:Z]<E/D0?T;1$[M=>N2GR(/Z-HB
M=VNO7)3Y$']&T1.[77KDI\B#^C:(G=KKUR4^1!_1M$3NUUZY*?(@_HVB)W:Z
M]<E/D0?T;1$[M=>N2GR(/Z-HB=VNO7)3Y$']&T1.[77KDI\B#^C:(G=KKUR4
M^1!_1M$3NUUZY*?(@_HVB)W:Z]<E/D0?T;1$[M=>N2GR(/Z-HB=VNO7)3Y$'
M]&T1.[77KDI\B#^C:(G=KKUR4^1!_1M$3NUUZY*?(@_HVB)W:Z]<E/D0?T;1
M$[M=>N2GR(/Z-HB=VNO7)3Y$']&T1.[77KDI\B#^C:(G=KKUR4^1!_1M$3NU
MUZY*?(@_HVB)W:Z]<E/D0?T;1$[M=>N2GR(/Z-HB=VNO7)3Y$']&T1.[77KD
MI\B#^C:(G=KKUR4^1!_1M$3NUUZY*?(@_HVB)W:Z]<E/D0?T;1$[M=>N2GR8
M/Z-HBX&%;*@(/'#Y^!@X,1VZ,*!P_P!D[1 $&AR_[IFXA^7@'"WW<H-/[@?+
H3W*YI))HIE22(5-,@ 4A"% I"%   "E*4  H  >    'PT1=FB+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g67046g11m85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g11m85.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %_"^82@X0DE-! 0      $X< 5H  QLE1QP"   " '\< E  "')R,3<V
M,S8R' (% "U-:6-R;W-O9G0@5V]R9" M(%-T;W)M("T@1FEG=7)E<R!2:61E
M<B!T;R!3+3$X0DE-!"4      !"36DJ#V#D?VAR D-$IX9H;.$))300Z
M  #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O
M9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O
M;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R
M;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T
M3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--
M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&$5@0         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             !>
M UX          0                         !              ->   !
M>                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
M>     !29VAT;&]N9P   UX    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   7@     4F=H=&QO;F<
M  ->     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M4X>HK/5NN=,Z
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $( EX# 1$
M A$! Q$!_\0 'P !  (" @,! 0            @)!@<! @,%"@0+_\0 61
M  8" 0(#! 4&" H' PT  @,$!08'  $("1$2(3$3%!51"A9!<9$787:!N/ B
M-SDZ>:&QM1@C,E)3593!T=,9)$*3TN'Q)28X,S5#1$5(5WB$EI>CU?_$ !L!
M 0 " P$!               %!@$#! ('_\0 3!$  @$# P$& P0&!P0'"0$
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MZPH"![WUMZ!GM'7E9''!<RJI91-WQ&I'YHOLF4UO%')ID-FQFOMSEMDK2SR
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M7/(%EK6+QM?^3#4C:>MN^]09<M3/RH6PT0OD\G7IDY"_4=+4#GNFEW(*$PB
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MVUG9&U$T-+<D* 0D;VQN3%(T"%(07H)9*9(E)*((* '02RBPA#K6M8![3 &
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MO7^K]_\ =O .V , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MS?/%SHS\I'& <N8?R*-?[/"7#T8X6V22.P8AL&D=RY,N2S.2.+B?HQ"G$>H
MG=6/3?N&Q>/%U1"W[PO/AG/;WYMSCEZH(X/7J=$9% 6E\@C'7K548[&*B)*=
M[C#BE8BIQ+6M P)&]7-U!"Q.J."WB.4@1CX)U[:W%SK7W+Q(<N9/,SD[4J#I
MWH;D;F_E9?DEMXULG#]>D!CYSFW-R@MIC*(]$TIU*%N<$[ %W)2NKLE$Y&)U
MII. ?2?@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P"E_Z0Q_(Z<TOT=J?]H&I< MJK3^+BO\ ]"8I_<2# ,VP!@#
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MJX0U-5%<5@A&B-3U]!XM#O>FYL3,R1>9'F9(V*7$IL1A"E1:<U"<Y>8F*\0
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M(;5@^?Z@Z#O;IVZ2H]]/N\8VXSSMQQMW;MN.-N,<8)29'G&, 8 P!@# & ,
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MB?)/J"3I <5,N<]TOLK81N -#7H*@KQR>8G7S04,8AF)D*4?QE*E3!]F$2!
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M8O&.*<$UF+)'7KA5K^5*GE4;2*MJ<>,)P^_PNC4\QQQC;AK*+;LK9"C & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & 4A]5JWGZI++XH1.&/J*N@7DX70*>S
M.#</B.8UZ*BZRBD.7Q<N-U8FC<A<%L2)->5B&:R4+>N51XU3#RDQ9"%:N-(
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MY<I/UY^;Y?F_S97FVVVWEYZY;S[Y?)Y<R8& , 8 P!@# & , 8 P!@# & ,
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M7GOMOOOOKOOU[>GR[ZSY(O@ESEI>_//J_5E#/)F0, 8 P!@# & , 8 P!@#
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M%84HQ?AE)\N3?7+>,MX6,%OX=>'6M=][[?;OU_7^?\^5LACG & , 8 P!@#
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M/:UMY3BGG"D7SEZ\/EVWKMKMW[=M=M>6M?+R\_L^?IZ;IQ73RX P!@# & ,
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M -X"IPZ\/?OO7\$6^_?8O/S[=_/0%M=:?Q<5_P#H3%/[B08!FV , 8 P!@#
M& ?A<%2="F/6*C0$)4J<]2I/,V$)1!"<L1IQQ@A;UH("BPB$,0MZ#H/?>]Z[
M8Y;45RWCC&6\O"277+?3&?WHS%.3BDLN4E%)=6WT7GUP40](=M4\C[SYN]3!
M^+&H)Y V>=4=)+#P;UI+2=1'$1Y-MJ":#QID#RJ9&,*[V.P%+'2/GG'E 6A4
MB'<>T\E86FCZ!&2W65#O[R,7E?:KG-1;L-IN.ZHX^:[QM/#BE8-9E]EMK#3(
M-9HTE7KI/AU:F5XN6I-;IR2\MV4L-,OLRG%>& , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8!0? ?YRA=_]$S$_VCX=@%^& , 8 P!@# &
M, QF9RR/0.(R6;2UU3,<7B3&YR.0O"P>P)6QF9DAK@XKCQ!"(6RTR0@TT0
M&89X? 6 8Q!#O92IU*U6G1I1<ZM6<*=."67*<Y*,8^7632ZI>K2Y/=.G.M.%
M*FFYU)1A%+AMR:2YZ+KU?"ZOA%)?2%A\AY#37D9U2K0:CD4IY1R=;"Z/;70
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M=W=Q</\ WM24HKT@O#!+T2@HI+.$EA$E\X3D& , 8 P!@# & , 8 P!@# &
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MYD0ZS[ <HBYH)4(=N;D%-Q^9IRY/(#$)CNV21)6NS_<%I*+8%H/&/ASRD?\
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M>$9+UJR7CRLN.)149\)/=.:SC"5X^M=M:U\M=LJ1 C & , 8 P!@# & , 8
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M/$8I9X*]=7$[JXK7%3[]:I*H_;<WB*Z\16(KV1N+.4T# & , 8 P!@# & ,
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M7-Q6KR;;JU)3YYPFWMCSSX8I)9\DO/)M_.8T# & , 8 P!@# & , 8 P!@#
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M^"QCU7J63A=FL6M;TY(.V^__ -<3_9OM_I/_ #^>0I[.?BK7_K)!_MB?_F8
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MLE1-!TC87",//MXG)7:).Y:UB= %N+<,IX95Q04ZTHA3[, !FD$BWLO0&_,
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MB!#HD8- 8N9U=>$ 3*N/13N9O+1:#'#9+N2,U56$NC=9M-C3==6D'.N9V"P
M)K Z1V$U/$-1H9($A<0]M#D!Q3(TB;WTP#;E4]0OC-<]^/W'&#/\O4SUH.L1
M*UNCM7DQ8X!.EU0OR.+VLWUY/71I3QR7+*^D"Y.V2 IN6;ULSVREK&Y($RE6
M2!-[6^^M;^>N^ , 8 P!@# & <;]-_=O]_+ *7T74)D)G,YLCN^-]?IJ6E7+
M.6]/-NOPN7"_+6JMZ#UB[6NX_$HD7#/9@JTYRC+PPMY8ID8=I8E02 \@LI2)
M$G N>+_R==NW;OOMO7V^>_/>OLWO??OY[W]N_/OK0'? /SJ51",@Y4J, 0F3
MDF*%"@T8"R2""0[,.--&/>@@+*+T(P8][\(0!%L6]:U@$/\ CCSZXJ<M);,8
M+0]EJ)=)X4U$2)Q0.$'L&&EO$35OCE&DLTA:^;Q:.ML\ABE_9G1H(E,.5O3*
M8K2=PK/=U: ]6!A=;\^."R^QK8I^O+#C[1*:Z26;/;  AKJ91.(.7Y,59".X
MW]DFZB'MD(L1V@Z\12.=#B;[(7AO5ISBUX![1*!$ 22X^\A:GY1U6P7524C/
MEM;R=7(4+(_GL3_&S%:F+2%SBKX ;/)VQF>TGNCXSN"37OC<GV<$CW@G0R#"
MC!@;JP!@$)X)SEX>\A;BF_%6*3U'-;%8T\V2/L0>8!-$\2E">OGM'&;'1QB5
M2>*(Z^L4N%/S@A9Y:EBSZ_!;5BH!*H'8"C9(&Q6?D[Q^(Y#ZX:,DL2%WBPUD
M=8YE=-<;?B&]AK]F/BS6$P;X2SEP] :E#+XMM-'"G<#L4V.B%6!L+0#)-$!)
M/7GKY?FWZ_KP!@# (M7/R#XU5E:=!53<#PS@M"XIIMJHQC6PUVE*]1+$Z50?
MMQ1NB%B=4$+& E,H*(?'AP9"CC0#2)59I@#"P 2B+]-_;Y_=]FN_EZ^O?U^_
MTWK .^ , Q">3R)UE#I)/IR\$QZ(Q)I5O3^\J"52DM W(P>(XW21 0J7JSA;
MV$I,C0I5*U8H,*3(R#U!I90@('2CJ$<!(;6-0<O)!+D0(Y>[*]ZJJ;ME+V%(
MK,E,5C"=4ME:HN-Q^!NMGM<8BR!*>ODRAW9FYI8THB3'(1 UB4LT"Q-L7I'5
MN0.B [2E"Y(DJ]$H" PL)Z182!2F.T T(#0:-), /030 ,#XNPPA%K>M ?MP
M!@$.#N>W$OWWDJUK+80)"^)38D<N02]PCTL2LT(1N!3@(D '14PEH)6>,38M
M1"1Q Y_/$YE_" %C<A:28!H=FZF_3JKJF$UD1N:[A\#66#((']3(U05M,L\2
MSQACY<JE"-PI1GK8FQ6\UJAY9$I=WI=#R&T$>VE<S'$2<])[0"Q" 3V(VE!X
M=95?OJ*4P6P(NQ32&R5L$8)O?XM)FM(],+RBV<62=[JY-BU*L)"<44>$LT(3
MB2C="+"!E^ 1YN_E31/'-_J&*V_-]1:17O/&ZM:K:2V*1OBJ42YS7-;:0BU]
M7VET+:412U[:$ZQY>S&YG1F.2,!ZX S@AP#2<XYU\'7&XW[BC85@QQQG#2<N
M(DC#+J_E3E6:1_C,6_*.XQ5VL-TBBBI@39CAY )DHBBB4"D")J 2OT@ 9X Z
M PJ+=5[@"ZUE+K CMP*2(C6SK7D46LHJEMQCE:M;: 5)%1H('6SA 4,TFR*Q
M0-JPF!J(5'7EM>P(%84!_L42@1 $RJ/O6K>1U91JX::DX)A7TL+7":'C38\L
M2L*AJ<%30[MCJP21O9Y"PO+0[(EK8ZLSVUM[HW+DIR=6D*&'M@&W< 8 P!@#
M & 1YY(\6Z<Y70YHA5Q,[\M0QR2HIA%GN'S.6UU-8G)4*5:W@>(M.(*\L$JC
MZQ0UN;DT+C&MU3>_M3BM;U>C4JDPL0&PJFJB 4;6\+J.K8ZEB=?U^PHXW%8^
MC,4'%-S8B!O0=&*E9JA8M6*31&JW!P6J%"UQ7'J%JT\Y4>::,#8F <"]-_=O
MY?[_ "_' *D.>'3TMCE-9#[*:ON*$UQ&[AX\H^+=\MLQ@KM+WD^LD%EGV.G?
M*P7-DB9$3)-]"=9$RFF2-,]LQB9P1*Q(=*6T&C@/'REX/<G;L>(A*ZYN"D*_
MDM?QCD30T8*D-<S25L9W&R^XU!X_K;TG)FC2N,N.)F0I.N3O:%8FA[KL\U,K
M8BB]>+0'K&'@1R+K?DUPFG]7V=21-#\-.-*3BRQQ:6PZ=++,DM?/##4[',W9
M:_-LF2QTJ3^&I6@43.TV@0(0+EY;RD=!^R,) N$!Z>FM=]]_+[M?O]OYM[UV
MWL#O@%<O.CB/<]^R6K++X^6C7U:V/ (A=-8.6[2A+U.8B[U]>L411J3')4$=
MD<8<T4KCY[6V/$?5&+SFL\XDU&Z)#DIHP# P6?\ ##D,+@E9G!.J+%I9LA;S
MQQ8.,M=RJ:PZ;KGUMA3W5:JMK<?9<6SRE.B6R5P^(+G6OOA*9*W,>]IB9 F?
M=%FB/ FOQ>@=E5=055UO;C["I+.X'$&N'NCU7K4],D3<$4=*TTL2AO;)"YO#
MLG4#8TC?ISVH7C*-=-+3491",9!!0&_< 8!BLU+EQT5D1,!4QU'-S&9P#$U<
MN1N*^+IW_:8WX6:_HFA8WNBQI JT6)<G0+4BLPC0PD*"S1!& "$?3;XRWAQ%
MX^!I&ZIU5M@'LDUG,DBKW649E4:*TVS^7/D\>$CZGD[X\C4+4D@DCBG;C4'N
M9);04E*4%J503E)@%@V , \1FN_;RUO?;?A[Z[]M^6N_;[==N^]Z[;[Z_/V[
M@4I7OTX^1W(B_.84DF5NTLRT7RKXR./%\;''8/-Q6E%HLU@E+M!I%IX72DV+
MK7Y-*I+LZ5:"U 0N;(F"E:T[:N%M9@$L^%/%>V*2EO(6Z.05B0*Q;QY&OM:J
M98KJN'O$'KQG8:CKEHK>(H65DD,AE#WMQ6M[<<YOZQ6[C3FKE "D"1(02+1H
M$_\  & 5W=1_C)?W*^K(%6]%SNI("-CMJO;2DSE:D7ETF"N-JJ8,$\B;8QEQ
M5^9-I"UC^Q (D.UWO E329LIO-0JPZ5! BG)>EO;MDWBO?['NJO3*#F5\Q_E
MG/H3&(%(T5D;OMHHE+3ZENB$R72I4SM]7"=4*28)$#S'W:3%^ YE-=#4PRU!
M0&VN"? &V>-=E(K#N:W()8YE:\98'P]I1# (,\PS2&FZ_F#_ "QN?;!.>9'(
M/C5ANHW5 W.9[(!ICY*9F*.1MP%*Q888!;"'TUY=O7Y^O???U\_O[^??UP#U
MCZ!W,978M@&W%/HVU<!E-=R%"II*=1)3=-YCHG2')U9[>!7LD2TE*>2H-3:,
M+(-+-$ 80*&H/TR>:$<KYDTNOGC>&W:QYJ37F;4SNVU=8ZF!'O\ ;+;8;39<
M*L%D73K3VK8]I;"5&0];'75N<FL]M2_$U#D TX(P,09^B;9L/C":KHKR'@^J
MLN&,T2V<N0.];/1\QDS[1G)*PN3R-TH]<FEA35!D<GF]H2QJ<4$L12X2!B"U
MA2'"5$&&C#Z^OK\D2EXT=."T:7Y*1:R)G;\&EE+T:]<H7KCQ#&*#/;'82!5R
MEFFY1(06;+%LE<&.0$P]N4N4?81,,>9S'$"T#BZ"VI3@*$!<$'_)U]W[^N][
M_'??Y^> =L 8 P!@# & -^F_]_I^O ((-73LXUM?)<_E*E;YT*<&3YWMQ'#C
M[!DAM/M%P2"&A@+];+/5^U?U:06 ]1;:EM<'\! C#C7!T7ED%.+DM5&@3M#K
M6M:UK^O6];WO[=[[^??>_/O@'; ,:E\?(ED8D455'G)DLD8'AA4J4^@^\)R'
MAN4MYQY&S B+]L24H&87XP[#XP@\6A:[!V!37Q+X'<PN.\FC$]DLPXX2^54G
MQJK+AS2;8S[LQE8G^H(U:I,GE<[L]6>TK%J*Q%,(V8C88]'43G'=2=$4<M>B
MF]R4C3 ?DH_IT\G:@N)FG*J<T1*HEQO:>:SKQ1;3$\];)'*ISRUF*R:I4E_*
MB6]4UM45AQBY5&U9\)3/[H[I# /@$B=<5[@("573(XY<@^*''(=)<@5]/.[F
MRV#8<HBSO3[K,G- L:+'F\@L-R)?]3*,QD],X-K])W!M0@;TZE,<T)D:@\\M
M6,TO0%C6 , H]I'IY\I*9N1CG8)Q0LDB?&YOYB&\4VHTNP6N02EZY63U+- _
ME\7D-JIO:FZ')2#F00H.E>SG@U9\6]W0B2$(]@;UD''+F [=2:J^6J8SC<13
M,'H60T0],NW^R V:M;+"=*ZF\U?D"($+W&#G-HF<&$U1<A2_)TZV**@JW;:-
MT#M* "TS7IK[M?OY8!S@# *Q^>7'3E9>=D<2)5Q]4<?$K#QVN1NNU_#<+Y83
M4]/;\T-3W'4+ T@AD1D:3X*>TR-P6*U2M2C6%N25(645M,8:, %F9.S-E V;
MX?:;#K9G@[^#0]ZUL>@;WK6]AT+OK7?6M_9O7?6 >7 & :WME)/G"N)J@JY-
M#E=A+6%P21(BP5CP@A9CPH)V4F^L2Q@;G9Y3MH/&,1AC:V+%.C %Z 2+6MB"
M!0_$^F7SHBO'GB?#V^<<52+AXP5QRGX_I3%2FUW6MI54'*5GB"9[DIY^HLT2
M5+8T1=8@D4M;46AU'G)O,/1J7),:I">F ^@*%1\,2AL3BH3/;!C,:8H^$[0C
M!:."S-:5M";H1PQF[T8%-H>MFC$9OQ?PQ;%WW@&38 P"ARX.GCS&O"VN?;S(
M)9QOB%=\KJ^KR+5^O8%]D/<TBCQ1#[\6JEQEK"Y1%L8%*"2^(S\H9#8_*#4!
MFP? 1K0^TU@&+.73,YEG3)[Y1MT_XS$<K9_;5NRR=114FLXZA$,)M/CY!./@
M6Z-.NFW<Z4RF.--<Q^3 7K6= W/"Y8\-AQ*(H\A:2!<3Q3HXOC/QKHCCZ!Z%
M(Q4[5<)KY1(=D"2EOKA&F%$VN;N2C,,/&A3.3@0I6I4&SCO<4YY*,)HM$>+8
M$@\ K,ZDG'#E#R3;..C5QO4T*A#4E_PB_P"4*+K>I^T&K7BJ79L=X5'8_J#Q
M23:-:GPQ1( 2L]PVA4(_=F(;9I5LQ9[ /KZ^O\H;6KTGKUNN?V-$IG:%4-G&
MJP+\M?E8:I8$,N-NUGMBVN,BWCVNA:/2I,GAY]?QY6YK):WOBD\;^XE#3,ZM
MG3!3Z., Q!FZ4W+_ &K9KIDEH\<]\CJG7\*&^H61B061JF'R'<,4MB(6XBQ%
MRQ#J6()#9!%DO W)6P-3@EB1S>V:;@/.@JQJ +8.#/'&2<7*"1U].W]BE=A/
M\^M"UK!<XDE<D40!,[9G;W.GQNB*5Z,,=BHVT'NX6QL&XB+6*BDNUB@@@U0(
M@H"9> , 8 P!@# & , 8 P!@# & , Z:&'>^WGW\_LWK6^W?6_/?W>6]]M;U
MVWK?;>M[ [:WK?GK]_\ =O[]=]?GP#G & , Z>,/KW^?ZNWGY_+O_P"O; .V
MMZWW[?9OM_5K?]F];_7@''BUYZ[^>N_VZ^SS[>OKO[-??@'.MZWW[?9\];UO
M\-^?XX!SZ8!ZI:^LK:L;&]Q=FU O>U)R-E0K%R5,L=U2=.8K4IFM*>: ]P/3
MI"C51Y*0LXTI.68>,&B@"%H#V?C#W[=_/U\O/O\ =K7?> /&'^SR]?/>^VM>
M7EW\]>7?OKOK>^VL ]8WOK([&N)#4[MKF>SKAM;L0WKDRTYK<RBRS36YR*3&
MFF(5Y11I1AB-4$I0 LTL8B]!&'>P/:X P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , XWOMV]?/?;R\_W^7_EWW@'&QAUKOO?_E]_R[?;_P < [>N
M , 8!QL6@]N_V[[?V[_W?9_9WW@'7V@>^M>>M[^SM]OR_/OMY^7?TWV]-X!V
MWO0=;WO?;6O7>_LP#KXP^7KY_/R_?7KZ=_3?RP#O@'&Q:UZ_+>_S]M=M?[_W
MW@'7V@?P[_+[//S\_+OKSUW[=^W;U\L Y\8?GW^[MO\ L_??;R^SN!QLP.NV
M^_EO7?O_ ,?MUZ^G;O\ +[< Y"+0N_;[/7^O_A^^];[ =L 8 P!@# & , 8
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MC?7]/V3?UM1H<B7SGDE,H_-+&=9"YIG#PGQ.)-D)C#!'RD[>A"U1IB86HDM
MVF"6'Z5JW%:J7*#E0]Z D'@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P#C>M;]=:W]^N^ 1;M/A/Q,NJT8K=EK<>:JG]LP@QM.B\_DD3;5\F:S&
M92!6T;TXF%:&LTU*0 /;2W#2H"(8=^[!+T(6M@>M9N!W#>.3ZQ+48.--/L]C
M6RTR=CL68-L,:TCY*6J:)5*&6HUZPDLL19<F1K5B=^$CTG-=2U2C2PP[VH_$
M!D2[A_QC=&GX$Z4773HS?D<1\?/A;FP)E[>*E&YP1.[?6HDJO1Y&XPB=&QM<
M$B39>Q)UJ%*I*- >G*'H#54CZ9O .7UQ"*CDG$:D':N:V-=#X)%54*;M(8N<
M^'!4O(VHXG1:XKXJH !2XZ&J'I8> HU1[0PH RP-O+>)G'!Q;9<T+Z9@ZMLG
MCU5TBF*(UJ#LF1/E)GLBJJ'-S!H?8]3 U$;9#8Z9O?=$)L2;UH?@[; ]-OA5
MQ2W.)19?Y *V!/9O8U<V_+Y41'TR=XD%GU(ZB>ZVG#FI($#2F0P]X&8Z-"X6
MO$4X&FJ3?:FFG&# _&_<&^(DGO%'R7?^.M6.=_-[K'GU);1\71:FQ+U%-)PQ
MUVT\E^ \;BT%HDA*5</0E/NR=.E,&-.4 D('Z8IPHXHP9]-E$.X_5G&7\^U5
MMX&N;+'4J!4.VG%E<8ZNGN_8" 5I_4L;LYMAJ@(-%B3N"SL7XCAB&!C$:Z>/
M""'%6V3%.*]+QPJ]X\\12W0,T*:D'UYC$@T+3Y'G<28HL869U\>]K6M%M&C4
M&!+&84(1)(P 2!C5/5I#Y@^6!&(4QL<SDL:BD,?Y&@2:)='6*P0I83#V-6?H
M>]FM\>)<5Q;81H.@D@4G:\_%KL!'JF>#=05(O>51J J:D)N1]G\F*H(DK8BV
M;2LSMY-O4V0PE8DV68)$X.KA)W8M0M )6 <H<DY@SBM$C !GS1Q!XS,!*).S
M4? $"9NCMI1)$02REZ+3QN[I .56RS +&,8=M\^D!ACM)"#/%I8L&(S7A\6P
M8!KCD+P0IB]ZKLVLT#4EJLZW*[KVFIK,80THB)*NIJO7XIS;:V2G&#+)0LOP
MHYYCZ 9&@&LJ5Z4J$.MFDE P"9S<A3MJ-(WHR"TJ%O2IT*)*2'0"4Z5*4 @@
M@D.M:\)11)0"P!]-!#K6M=M=]@?NP!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , XWO6O7>M??OM@#OKOV[Z[_ "[^> <[WK7KO6OOP!@# & , 8 P!@''
M?7SU\O7[?E_7K\< =]?/7XZP!WU\]?CK .< 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M")R@KP:YLRM9\#?#SEA2$PC1@BUX5R-"!.S & , 8 P!@# & , 8 P!@# &
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MV52DA#6[OD'=HDZ7-;+^QV>N>CG\IDD$EC<'BD?C"ILC9;LL>7A2^NSBG&P
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E@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g67046g12v63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g12v63.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1PP4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '!2^<8@X0DE-! 0      &(< 5H  QLE1QP!6@ #&R5'' (   +.(!P"
M4  (<G(Q-3$Q.#$< @4 .4UI8W)O<V]F="!7;W)D("T@4U1/4DT@+2!&54Q,
M($)54TE.15-3(%-%0U1)3TX@4DE$15(N9&]C>#A"24T$)0      $%E0^KZR
ME+5V??$H% ' QJ0X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 8'SMH         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             !R@   0<
M         0                         !              $'   !R@
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !R@
M  !29VAT;&]N9P   0<    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    )
M.$))300,     !%^     0   %P   "@   !%   K(   !%B !@  ?_8_^T
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MPGZ3TKO36G]KROV-]LV5?:_LWJ^GZ@]+U=F_9]H^CZ/J>WUOW%;V,#R_:-Y
M!=&L"2&S_:3H*?_1]522224I))))2/(_H]O]1WY%\]4_S+/ZH_(OH6_^8L_J
MN_(OGFFX^DSV,^B.Q_\ )*7%D$+N]:V4E_,?\!_U35!3;:2RR6,T [']YO\
M*4/5_D,^X_\ DD\YX]BJGTC_ !<T6Y'U/ZI102VZS)N%+@XL(L]''])WJ,][
M/TFU=!D],ZP]SJJ+7UU57>K4XW.,L]&MC:6NW>HUWVAEO\]ZM7O]7T[_ *"Q
M/\6.71C?5C/RL@BNFK,L=8YK7$!HJQO<6MWN_K+K3UKI;:V6.O#6/>*P2'
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MX=(_(M)N-P-Q'Y:C\1UY2IJQ298&1?E2,$M+A)N$!68)"L0#(M.=P;<XAW
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M<\Y-XB&G I<,(TO,@<+]>5?R^?(:PSE+/32Q5/"7:(,ZTW=/B3*KTT:+14Y
M0*D1SSB F)J0<V>6.I&:;&KY#J@<9SW&5\RQ9.,:;K.8G&,HN2C\:6!M.RU.
M8>BPD7.IIR*;):K.V;)^1XD45'OIATR]D=,=!QQ0PW\>+VT<"/#AQ:^1^R5(
MO5:Y2.(_%'$)PB3$H94_QDPS<[')NIF*8.3 5%96"D9)LJ\:(% R$LM/IE*8
MK93DC/CMXRQ!)9XE,8V3@GGV'E1I'-62)$JK%KC_ "'CIQ9G;G$L5A6PXZ^
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M6Z#7L&C9'T9L0I&[?LT$R=@@4@B0J*0%!-(I!$I2%* = #3 'WZ : : : :
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M,Z:S2\'58&)E+"=0JIIN0CXQLU>2AE2ALH9\X24<"??Y0J"(]1U(+VT T T
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M<X,'.W+)(LVJ;ODV%4B"13!\G?4E)Q$[X3^'9_=YO)#O$%+7O-C7>.IVRFC
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M=#Y,<C;)I[1<-OG6NT28W.G2O-RE!S:2XDDZM-MNM]UV0\XY>2==;>6YK68
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MTQ^MUJIQVX4VODG&H+5:W6GT)$E>LXX<$]BOIEV[AQCS0+<*'$.03E#?$UO
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M1$VE5+Y2:-B5*)T4ZBI=LNKF^O8;5&O1;1<H?G4VK3KC##G7%)+.E%@2H.%
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MNY= 7>WX/,)(N<9*NJXK,M\6XP?8?BXZ;6;RT58:"_+"\T)<HUXR5:V(C5S
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MNI;3*3T+7!KDH$U+5=U+,K''QWHJGI3N%=P)3S+>212YCM58PIGI%0*9 .T
M- 02N/Z0K,37,*FI4W:+!53Y/XNDX2;N;V>D+7),1O%/%%U./K.1*?</SB @
MJK*$!T.P<X;;;^GHNR.US9D"A47,@Y]&JX.E-F/9K)5+ZNB_KL>=/ERQ47NS
M'<4RS)=L;Y<2X3V 1,(B/)N/41W[MA\=O7MKU[5H:.59ITSF0UERXYG.I@H;
MVEG5K=2XI@CYT:5U$J*Y7O*[C6]GIG<+7Z6G G7;^=#CWK_\+QGNW]WB/@.M
M5)(*WG)DA5&/E(Y$LT[G4G:F&<9'!..CFKE $@:2($'M5I)J?F'KS%%/8! =
MA'71.2_+67H'1BL$RQ3+1$ITR;YR"9#!#28ZTHTVVL]]U,Y\TYJPK2OQ?;Q3
M68!@G\??W?:P[MMX9AO\_P#FS]>XZV)^4Z1^#+1T6F%>PCT>/)42_%RW-=UY
M7X=Q_P!1]/M>P>/P/'CO]$R.GOFR/P9:/\2O >CQZN[QXR+PH,[1369MZ.^L
MYE"Q\\H4JD0P*0W9P$F<Y3'"6,8OY6!MMBB FVWU#\H4NW12;++T?-@BFSY$
M*CCM%4OGTN*K257=!2[61%(<,$5<8DE#AM=][N[F5^.-##H#FR].@",9'_-_
MID&MS>F;5E9X&LJSHJ].:Z[L%0Q?-8.D5:+!NCHNBM=]X"WT01_JJSC[HJ.#
M_I/1:9M-;[-+>ZT3*_M$J6_B/N[XS5\;J+_=-G_Q7&_QGJKW8M'WK#^OC_F)
M\V_B/])?S$X'S8:1BY/A3S:O$&>J-29I*B)G[=!NL"H5>+.8 *@NN42[& =Q
M. >SKKCG+ZTQVK3,J9,@4#ALDN!+G5OYT<=SQ:I,2JVVVGL+DI<U-7UYS?76
M['%4I=CK9)HUI!=&@&@&@&@&@-)PW*(=WM]N_3O$/'0& R996FI\1V7VV5X?
MC8BW[_*DE8J%E#"66F5HKKJB2:T>O!0\WB9I97#B BX;9=@ A4S).(Q!)RX5
M]+57T&XSULQ S5N8#*' R*8@98-E3 )>@J%';E.(#N<-@V,(] [M ?5H!H!H
M"WK9)R4+6IN6AX!W:I2.C73MA7&#EFS>S;I!,3HQK5U(*HLD%W1P!)-5TJF@
M0Q@%4Y2 (Z @.^5IL\Q*-\23T_5Y"CS$KF;B^6D*I*/(]^_@G)[I3S'CW;R+
M6<Q[A5+D 3*-%U$3 8.4P["&MXY#63TNWVR&E7#8XHE?1>O"L,ZUOKE=?5HM
MS$^:VJ46O7?3-7/L,(]FFS+0$L0%-A49F( [_P"N,4!#8=NNVP;^'JUOFEM&
M12=%:1F)44-CGQ.M]_-NI<\Z;*;:E$N)*9#A@[ZUOQ2KC2M^W*AZH'"R']#7
M@4!V';$./1[NX?BQ&]?N;>[?7"R^0'/.= #^28O@[@#"6,1W]7YFDA[A]>XC
M[]7)>?1[3)D*Z+''6]1'@,4#!L(  !TYNFXCMW@ =-N_KX>'3?5PNM]"KF\:
MURZNCI1H*4.10O<8-]Q'U=X>OP#1UR>KY>.W,F^^FSLQ6JN*ZK]5[8X#:U-!
M]<39@V\.M:E^H^WH _@UGZ*YWNC8FW7Z*D[O6NNZ\:EN:O@WN[G+H7R7FUB8
M0W .[<=@V#Q'W>.NUQ<UQ1/FPXN^C3[&8:P6Y%.80[M@^8/P:BYXPI]?B25Y
MS>OZ@_!J*0_$AZGXDU>M];)YOFJX;\(&<Q\0S@(A[QJD3O\ ,.P;ZY?RT^N<
MO\W@[EQ>6X<8]_B9P\D<<N(<69/9XAL\%EQ:Z2JL@C!-H/%EGFH^Q#$LH]_+
M+0$FQ;J-91M%MY-F9\L@?D;G5Y%! Q1 -/*SERO<0V-;17<HVJ+E'I8C#4E/
M1&0CNXMXU=0<A681O8)IL9HJ3MG"C*-<I*F! IN903(EW.4=@.$J9Y0?AQN\
M+:IUC-6N%:U+&$EF9VA:Z/8:Z_E<9Q+<'+^UUIM(-$_C P;)G1YPCU%5BF<-
MP,F';$$5?9V@YMPEGVHYYCI"7J$+?HF/8(QC@JUWI,S3@D6\L@HY9N8D)=)(
M9% R*?.LHAS%2[1$#<HJ &@.<M - 6O=;?7J#5)ZYVR13B*W7(Y>4F9-5-95
M-DQ; !EG!TVZ:JYRIE^48$TSFVW';8!T!'ZR908,V2<W5RC8TJ>5L_6C*LW=
ML5\1E'S'5HBW8\F)J28/(:)R;#2UDC++%,*$ FC%HF-BIN*F(!LV2(Q%PZ73
M(XXXN!(@C2N21[(CPY5'96J!72A/SBC@$R@L<G_BG4 QB^P0Z!H#[= - - ;
M%9Y=> K\Q--H:4L2\6P</48*$306EY91 @G*PCDG*[5NH[<B )H$6<(IB<P
M90@;B 'G[^64L#JR,\0V%U7YRHNY7-_%\[7KEB1;-YR(.I<Z@ LY-%FY=MDW
M27]F1!RL0-R[*&Z@'5O)1)AFZ5TBXFES;##FZT\_*;N6706+3$X9<-/MH^;C
M?7FMK9KQ=->36"&8<JC&.P,8# *0 (>LO:%V]OOV\-QWZ:ZYRCLL$&@M,-4^
MMUH=]+J]V-,FJZ[G8E5\Y!SDZ)M-O)XTNW.EV-,FSUB>%KIPV8%#O_G18^Z[
M>NL1P[#[N[WC[=?)IG$!SSG4-_*9/R]V^$<8!OOX^C26P?/J[+SU57&LR).$
M63K15VY=--^HCPB.W> ;;E !]_3ZAZ>&VJS(NXV>!0X /3;<1\/6&PAWZIC3
M:5,4T^.-]Q#[VJ=_92OC@7MCH!&V-@ !V+$V7J/B 5J8W'U_CX!KTM%?7"Q?
MG4G]HMS;X.E8\9\4-F,("(B'=KM47K1?C/JK<84-:*I35)4- 3T/-5OTH&<_
M#^?AW^K^96)UR_EI]<Y?YO!W0E$.,>_VLS8YPIEIG.,+@VN$1 R3^LTR*X@4
MK3--FYSQT&I/UZEMH4DBX* %0-)+LG:;0#" J'05 H;E$=:>5G4JM25IJH^4
M'PY)XHS :PYDR5FJ=Q_.Q^/Y=Y2IR-LV-&#"%<)VM$!CDA>/FZK0A5!W*Y J
M0AS&T(;IKZ..XXAPQPR6W%3:O)9TKN9\V8^R3P*N\<2+4K(LC=,.O6<?"_'C
M&,"TAFT1Z(C=XUQO$E53<S(2E<39IO! VR@J>.6N[;ET';[@@:7]IE?+J$ 3
M.+7A=9T?'$?CJ/X@6;YE:VN0F2DTVM:=62FT$;"%31@TH)%<LIN@$L4PQHF1
M,L81''@9-- - ?'(D<*,'J;3T;TH[5<K87B8JM 7,F8$1<I%$#*-P4$HK$*(
M&,F!@ 0$0'0& :2K6;LHCD*GY3P/P"<1V8HJ_P!G1AK%!9@A(*Z4UP$YSUQ:
MRUAQ7FEF;1<*T41/Z)\:#V86Q4TE6QW0@ @9^(TBB<>S36*D59-LBFJ5 3&0
M*J1,I%"HB?Y8I%. @F)OE"4 $0WWT!]N@&@&@-)Q I1,(@ !U$1VV#8?'?N#
MV^'?H" #Y;_Y<WCH=BF <\\89@V$-OT9T[Q[N\=A$!W$/;UUV'R.0*/3&DZX
M>YZU5OGRM_R[;S&M444$N&*&ETR&O5%W^QD?V7(48U[_ &( D7IMU'\M3 >O
MK#O[OF'P[/RGLT"Y.Z;<3:3T=:*I4KA55='E=MV-F+*GQ139<.'SUN^]-8W7
M[,<>T]8GA;';AKP+]J+'W[UXS\1'7QI+;<$+>-_8VO8>F0&/.=!*;RF3W<#
M'V$L8!N'02CZ+)=?QZ^L-9$O-W977[=749$C![U6_"[5MI3N(\)MQ#E ##L(
M#S;!L/7?U_7M\VJZPYQ);,_#M+]*IK77M*AN'0.8 $=Q\3!](" =V^VWSZAQ
M0PM4:BUX\7= N5%7KHKMF"[R^L<[A;&X_*-O$V4-Q   .:M2X!X%W[^H  CX
M=X@&O0T4U%I*Q4HOHB4\;O66+;N*)C^"J?&A[[NC:;)R]W0V^P?V/3[N_P!6
M_LWZ:[5$_A.]-5=ZYSZJ0-/H9@ITHJPK!7NCZ53'85 @^/3Z]0Z91)_W8U_
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M'J80$P]1U(/M$0 -QZ &@- J$ -]_HW$=_=[=] .T)Z]^NW3<?N?1[Q /$-
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M^<8_&QQE2&;<(Q5 =TE?'5)K2:MDN'P')C)P3=VF^(9D$4] $0,L0$E>V_+
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MM - - - - - - - - - 4$ ';<-]N[YPV^YH!L'J#Z- -@[]NO7KX]1W'Z]
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$0'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g67046g13k36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g13k36.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1,>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $P*^2&8X0DE-! 0      %H< 5H  QLE1QP"   "7:4< E  "%)2,3$W
M-3<R' (% #E-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52+F1O8W@X0DE-!"4      !!P1XQ$ CUH^O_);1\_
MA X%.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            X@  !#T          0                         !
M          0]    X@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    X@    !29VAT;&]N9P  !#T    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   .(
M    4F=H=&QO;F<   0]     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      B*     0   *     A   !X
M/>    AN !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
MA  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,
M# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1
M"  A * # 2(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M              #_X4 6:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \
M/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z
M:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X
M.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P
M,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS
M.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O
M,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL
M97(@,3 N,2XQ-B H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^4%-C
M<FEP=#4N9&QL(%9E<G-I;VX@-2XR+C(\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C M,#DM,S!4,30Z-3(Z,S K,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^
M,C R,"TP.2TS,%0Q-#HR,#HS,BLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @
M(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C M,#DM,S!4,30Z-3(Z,S K
M,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S
M+S$N,2\B/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U
M;'0B/DUI8W)O<V]F="!7;W)D("T@4U1/4DT@+2!&54Q,($)54TE.15-3(%-%
M0U1)3TX@4DE$15(N9&]C>#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!
M;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A=&]R
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:3Y24C$Q-S4W,CPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G
M92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM
M+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @
M>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX
M;7 N:6ED.C<R,3$R0S<W1D4P,D5",3%!,38R.34W0C,Y,3 T0C1%/"]X;7!-
M33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N
M9&ED.D1&0C-$-35%1D(P,D5",3%!,38R.34W0C,Y,3 T0C1%/"]X;7!-33I$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/GAM<"YD:60Z1$9",T0U-45&0C R14(Q,4$Q-C(Y-3=",SDQ,#1"-$4\+WAM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O
M<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D1&0C-$-35%
M1D(P,D5",3%!,38R.34W0C,Y,3 T0C1%/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 Y+3,P5#$T.C4R
M.C(V*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z-S$Q,3)#-S=&13 R14(Q,4$Q-C(Y-3="
M,SDQ,#1"-$4\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C M,#DM,S!4,30Z-3(Z,S K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S
M/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G
M92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R
M:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O
M8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C<R,3$R0S<W
M1D4P,D5",3%!,38R.34W0C,Y,3 T0C1%/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 Y+3,P5#$T.C4R
M.C,P*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C<Q,3$R0S<W1D4P,D5",3%!,38R.34W0C,Y,3 T
M0C1%/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C
M=6UE;G1)1#YX;7 N9&ED.D1&0C-$-35%1D(P,D5",3%!,38R.34W0C,Y,3 T
M0C1%/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z1$9",T0U-45&0C R14(Q,4$Q-C(Y
M-3=",SDQ,#1"-$4\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @
M(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P
M:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E
M/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MTNUPD8-K4\P->;!228,FEUB9S/4TJ>A</R5A=9D&&@.ZO ' ' ' ' ' ' '
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M,H0TRTA#;:4H3C& /KX X X X X!7*L?]7&[_P#QRZL_ZF=Q. 6-X X X X
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M5:$+:M*M&I3E.3E*$G%J6$DX))97B>5Z4*3BH2U)IM[IX>?(Z=\XA0. . .
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ML.N*6XE*49SGEM&C5N*L*-&#J5:DM,(+&9/GC=I+9-Y;2/8Q<FHQ66]DEU(
MJG>SIS=:F7>(#LCJ5=8"E"84B2EK;'UI:9,04(T@9N/LJXB3(RV+(!N_*.$Z
MPO#WM0ZI;;J4:ZG"N)4ZBI3LKC6XJ24:;FM+;2>J&J*W36&T_+=$W1JIX<)9
MQGET^&Q%TYY1>D$60J/AMR*V)+Y7EH:'U31MA;*+->QGV_ (54*M*1*WLJ]$
MI0Y)->Y6?1.<^F?2^/ N*26J5MV,<9<KBK1H)+Q:J5(RQZ19)4*O6.E=7)J*
M7KEY_0YXVCS,;D,[<16A]1=4IFTU2>EJO%5V,OXDYJG;$X].5P&4>PZ);"Q*
M[6FWCR7G(DF=0TT]")&,(0V^3AI'8I_1NV7#W=W-_&G.,:DIRHN%Q;P49RBM
MZ:<YM)+4H[J64N1>K6*I:Y5$FE)O&)1V;2PUEM;;XZY+YJG_ "D['RIR&U_U
M2ZV0[N,)2F\W"Z[LO(^%*]/G0%3HNL4W+B6\95EAZ8<2T\I"?D*;PO/.5HX#
M1VE6XA?2\:5*E:TGZ]K*I5]-EE<\,IQ;QZU*C\DH+YMM^6<>>-]H_P!L^/?L
M1V)UI;*'O/O]LF7;M8*1G8.BZKH5%UPRI)8Q;8\U68QW-@MD:.L?'QB%W&*P
M\XE@DCW/,_SVV_&+.SKTZMKPBA'LWG55KUJM?DTW"I+N4Y/+W5*6$VET:]C6
MA"47"C%:>KDW)^>>2SZ/'3SGKH%TL$Z*Z:EM1";%(V8B5N\K<U3Y-6;J*V5R
M<=$1_P".3&-3]CPM+&(K#OVLGIRYE_*/KMX;PI>3BW$GQ6YC<.BJ&FE&DH*I
MVFT92EJU:(<W)[:=L<R%:KVT]>G3W4L9SR;WY+Q+Q\Y94. >?'L-+;(LOD(
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M^B_YN2C.<4XQG*,9<U&32>V-TGA[;;]#U-I-)M)\TF\/U,[R)X. . . . .
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MT)=G9TLX=S=236/'LJ,6Y59+JE!/4\%])=FG6E]UM4U[T\<^?*/-\UT-_P!
M>,KICUVAC8JL::J]T*,F79O]1[9@Z[L6SA.N!1X6 8R7FX13D=%L_C\%#ABM
MMX:,,/?PYG).4IIN^-\2O))SN:E)**CV=O.=&F\.3S*,9]Z7>PV\[**Z'DZ]
M6H\N36V,1S%=>>/4N["5FMUH? E<K\)7Q<)2G T)% 10^$IQZ)3AD =AO"4X
M_9./;Z8Q^V,8YRY3G-YG.4WXRDY/YMLJ;;YMOU>3ZUQ,6X:F1<C8]<@C*<I/
M6&,HU.4)]B,I*4WE].4H_D3G"\>U/\N/3'[<:I8TZI:?=R\?+D>9?+.W@9#D
M0. . . . >>'>=FC.NO8RW;X[2LZ>W+=-7P>OK'L:\=<NY-YZI[#JVNJ]--"
M:UFMI].-H[W!U-<(!J9N3,1F<SM4@:P2EB%CF*@]F<;C!0.\TC;BW];'7RF0
M;]K.>HY5NJ=;;*'#)LI;D"N9@H-!F%$BBOS+RA0$E860.PX3AW"G6T^J@.5T
M=WB[P2&$+_P670%A=8:EL.2^J]K@FMRRZ$/-DQ9,8*Y*--/@S;DB8H,:5/>.
M:@E:Z (>O5B@270+9Z$N-KNW8S;<Q<M=V'7,X]U;Z;E'1DZ]!.,%'RMK[82\
MI^'9C9V3FQ 8B3.+@'Q[A%5>P)D(PO*X7Z613B@+K< < < < < < < < < <
M < < < < < < < < < < U6\UHVXU"Q5>-N%IU](3L45' W>D+@6[;5BGT>C
M$W7\VB!M%;5)@.82\,W.UR<B75)^(^+-&6XPL#S\:G[%:^T'V7KZ02.M>_9^
MZ=@7-#W3:KO52\=;.UU5D+5LR=U?.W^XW>C:[M^I]O5!^]56?KYMZC8W2E)F
MI\!JMG6!JR(=;? [>]DB-Y"Z<LY'7&-C9C;C1U15 QLG)0<.@R'_ %G7\79H
M"3LP,G7 IS]#9L:H!^=CRXM,TD'!;#C6<IR!0^M&^5I=LKZK-#U)FHKGXO\
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M*9&?E9/Z!+"T/"??,^!;?V'?<!@.NW] 6#^^G:'_ ',;;X!.G ' ' ' ' '
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MO3>'TB_9[.0?')>N=FWB]UXUA>]LWU;+OT4_K&^VHI<0IUUD)(\>.X(!VLX
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M#@#@#@#@%<JQ_P!7&[__ !RZL_ZF=Q. 6-X X X X X X X X X X X X X
MX X X X X X X X X X X!!6F?ZC[#?WU+_TJU1P"=> . . . . <P]E8;[:
M=XJ5IIC.3],],L0NYMMY0K+D;8]\SZ",:CHQB,XRP1BE0[)UYDFO<YC!,A'A
ME,ISA.<]RCGA_"ZER]KGB>NVM_>A:0Q^TUEU7:R<:,7X1DT7Q^SI.7WZC<8^
M4$N\_BVDO1G3SG#*!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P""
M^NW] 6#^^G:'_<QMO@$Z< < < < TV_[$H>JJK(WG9=QK="IL0L)N4M%MF 8
M&!CW)$T>- 09*2+PX@ZC9 L8(9+KJ<O%$,L-X4XXE.;*5&K7J*E0ISJU)9TT
MZ<7.;TIR>(Q3;PDV]MDFSV,92>(IMODDLLYT]9SA.Y/9F\]R'#1YC3.FW)_1
M?5<9IY)4=*'MNLIV[N1E&<*:P]8C&@:K63&<X4NOQQ2UXPMU"L]F]4N&V-+A
MN'&YN=%W?MIJ45O^S6WI".:M1>_)>&%?4S2@J7*4L3J>*RN['S26[SE9Z;'4
MCG",XX X X X X X X X X X X X X!IVP;S"ZUIEAO-A0<[$UP')A(T8PV3
M)&N./-"AQ\>P\^*.X=(G$# B8*+$$200VHLL49+I#8%(ZMVMZTM=F-GV>6WQ
MJ.KQ=FZT=428G%QV'4ZB<MPBV]H;0J-*C;#+QQP,R%7[?5I63ABV&9*-"L,,
M^<,PU)A*> GO'<KJ IYP9/:SK:HAIIE]T?&\]89>:9(6^V.\XUBT?(AI]8Q*
M&7%)PAU8[Z495EIS"0/G_P :O3;XTN_XM>LOQ+9?)0Y_'G5GQK'%<;:)?2O]
M5>U3([KS+;[N,Y0TXZVAQ25.)QD"MN]?+=T;T/(U^-DMO0^RWK -)DI>TE*U
MG:@D-B*.Q&O,6(FLV$E$,6\8DID48OVN/KCY!*<86(\E/4X?PB\XG&K*U5-J
ME*$9]I44-YJ36-GG:+R^FWB74Z%2JFX);-)Y>.9+(WD8Z+DC#DX[4:58P0PT
M_ADF\0[)#.'6TN?$^THCW-/-^[V.MY_="\*3G]\</@O%DVOJ^Z>&UE49M/'5
M/&Z\&>=A6_#G^5GY%>2#H@)G&'NUNELYRG*\89N4>3G.,>O[>HZG$X5G./3"
M59QG/_;'I^_//J;BO[ONEZTI+^.!V%;\.>WD5\TYYGNB>W9"< (V%(:IQ"B"
MEH.VZ%&U,"9^T\ZSD:%?'F9;)90WQX>*9<;8^-EUM>%+SE24Z[GZ-\4MXPDJ
M4;C6VFK=RJ.&$GWDXQPGG"?5EDK6M''=4L^Z\X]<I%C4>13HLXA#B>UND/:M
M*5I]UZB$*]JL8SCU0MY*TY],_NE2<*QG]LXQG]N9/J;BW[ON_A1F_P"17V%;
M\.?Y60WN'R\=$=/#P)#VXH_8_P">>D&4LZEP'>7XG\>@1>79QL(]C,:R9]O"
M %N95@I8Y:48Q\"O71;_ $=XM<:_\-*AHT_\3FCJU9]C,7JQCO8Y97B2C;5I
M9[CCCWN[\L\R4H/R2]%IR%B)I/9[446F7C 9-,9-7"(CIB.P<*T5@&5CW"5.
M R0F'?@.$6I2QB6W659SE&<\IEP3BT92C^P7,M,I1U0I2E"6EM9C)+$HO&4U
MS6Y%T*R;79SV\(O!D7/(IT7;;6YGM7I%6$(4O*47N&6M6$IRKVH1A_U4O/IZ
M)3C]U9SC&/\ GR/U+Q;]WW:\W1GA>NP["M^'/\K(*U%YBNB&W9.:C&MJ9UTJ
M%#8,4;M<06DQLGAXA0_UH<PN1(;D"VLX^9YAO&,H'SAWURG/-5Q]'.+4(QE^
MS]OJ;6+=NM*.%G,DHIQ3Y)OF]B<K6M''=U9]WO?/'(GC_B(]&/\ \K='_P#]
MY#?_ .CF7ZEXM^[KO_TS_H0["M^'/\K(7W#Y>NB.GFH!U[<(.R/S[DDVEK4B
M1+T[$?C4@J4N=0$>Q^,;-^\E,<IW*OMJ%-PC&/K+]=%O]'>+7&O_  TJ&C3O
M<YHJ6K/L9B]6,=['+*\24;:M+/<<<>]W<^F25H;R2=%YF'BIA/:#4$8F5C09
M+$;,7*( EH_!PS1. I0%9*EAR N'?@-%4I2AR6W&LJSE&<YIEP3BT92C^P7,
MM,I1U1I2E%Z6UF,DL.+QE-<UN>.A63:[.;P\947A^GD?01Y'>B(OM^;M=I3^
M?U]OQ72.(_Y>GKZ_74[[?^>/3W>GK_V]?3/(_4W%?W?=+UI27\4AV%9_Y<_B
ML?Q(2TOY@.DNZ;U9J0%L+^'::S&2LN[<=NG5'7E%E1(J2'CW,0UCFK4E@M\I
M)&)$,=;3#KT8R06I+>&5IQ;?\$O.'6].YN'2T5)1AIA.3G&4HN24DXI;*+3P
MWAH]J6]2E%2EIPWC9[KURD6I<[K=-F5NMN]M>LK3C/N^9#F^=6(6U[$B+7\J
M56O&6_8D\%2O=C'M2:)G/I@EG*^.4$F:UW;IC<X\F7I[;FL-L"PB@TS).M;]
M5+V/$*D,F) 3)O5>6E6P%'*CI!(>"E-9)R"9AGWY%?\ 8!)W ' ' ' ' ('W
MSO!&CP]:EKJ4C;,;%VS3M78P"8D!J#5:UFXQ-%/J".P0MGZ?U8V)P@94S*EA
M1J#PE/X?2!"VM]^T^LS^Z'IJF=BA6;-MLNPP3K74GM2<U(0WZ!U_!8.;<C]-
M%(;;5*P4H,AM_+3ZTBX)2UD4@9]X"15]N=2MMRCSM=[(,LPREID7G^FG<%EI
MG#8 \FXXVX[HM""F&PRFEK($4^PEW#PJG,%#$LM :YCO1U^4L9O#6_<K+#I<
M@,G_  >]O?5X+8LG(0U((1_\&?NW8Y2*D0H_.?3*GA'<.X:3A*L@<X.P?G!I
M^J-[T[5&NM%W;:=>L\3K^2<G9:,V'J*YK>OCR"0@('6VS]:5N;FG2($Z%DH(
MQ1 ,7-DRK<>V>.Z,6MGZ/AG %Q&QJWCNU0=.=6&F5+,%V<(SU3J:TXQ[V[4)
M-)-X9II6_:P<]:6,[->"SG.>7P):O7DM[&Q)Z@Z?XR^USP?M;PB;O%7M88J7
M'GT,-)?"U=1-MD)1E3C:EK8>(^-.75K2EMG+BLOU?PVGM7XS1U>[:VUQ<+X3
M<:</FUY9(]G27M5X^D(RE^K27S_0K+V*[A>0F[ZEV#!0]%B]$2LE0K'8(T2J
M:0[_ ,CN(6+K1$*N=D*U=VNOU6I<&5%IE8]HF5)*82T@[&&<.9<Q[=-J_H];
MW%*52I>W2C):G5MZ,;;&-W.DW4JSBF_92;VY'L/V>,UESDD^;C'2UYQRW_\
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M41+3$',""&P);AK('3?@#@#@#@#@#@#@#@#@#@#@#@%5NV?7*8[%U+735/V
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M45(LU.NQT T>2I:EKR08B/20]E2U*RXXK*E*SZYR!OW ' ' ' ' ' ' ' '
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M,G"S6O@C[+#]IZ/0*3M.ORHL?K@2"&B'<:RIUB@T04/#F1D[&N+483'F%@/
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JT6$D&0Q'6ILZ=E*UL._6.>+DS)^6B)E24()L&7P0.H? ' ' ' ' /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g67046g14r07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g14r07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1>(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %VR^698X0DE-! 0      $X< 5H  QLE1QP"   "]^<< E  "')R,3<V
M,S8R' (% "U-:6-R;W-O9G0@5V]R9" M(%-T;W)M("T@1FEG=7)E<R!2:61E
M<B!T;R!3+3$X0DE-!"4      ! :[2HEM5K,IP=I=>CE>37S.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&?WC4         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             !X0
M!+D          0                         !              2Y   !
MX0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
MX0    !29VAT;&]N9P  !+D    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   >$     4F=H=&QO;F<
M  2Y     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M^B&^H0)W3$_V5'FYK#AE"&27#+(:@*E+B_Q?[R^&*<P3
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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ML8 2T/H_1T;OM!<C%-# _5Z@DLX20=ZM'B/#E%-=?1-;C?319377C?8,GP&
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MD47@$]3EDZ(**-)+MSR%H6!!W6+T:^O7J.J;V" 8$XX# 8# 8# 8# 8# 8#
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M7+:/^^R%?1A]=,:B[.2JOEZLL)I')#7Z=H'B+1LV( "4^%*_)11L>?,(>I'
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M(0A"'8A"$.U!:H]N/ECRLWSA?# 8# 8# U.[A]R:HZ15P M&X!TT)1R1S9A
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M;]58]]D,\]*^COP?Y%\SLL>Q+%US9@V^QOC?$NFUF59F*T& P& P& P& P&
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MT!I;M+5G;WLE+K^J&)@GMO=:NL!.Q[DBMFEIL%L.\P%Q]S#TD;Q],E6,,4^
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MR2:[& P/1#\.+T#^IOJ.@GV0CD><Q[?8MPZX]>*UU>ZS[Z+=7+*XS 8# 8#
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M5\SNOY)6D3L"HHC#"X.R;D"WK)GL^CD[EDE9_>KD Q5^\@]*!!<MD":$4)/
MG!DX99E&T"B:HI\J9"RG @[K%Z-?7KU'5-[! ,"<<!@0]V!\RUD?5A[_ )IY
MHS9,> /2MYH8CRTV;:-]W65^-K?^)2!GGJ3Z,!@7;==/,C7/T#Q^VN\]!>Q;
M\7W19YM2=.O$"=)F[W,_&4W,TDU9OU@I@,!@,!@:O]P?,<<^F([]JH9#_9S^
M+SC_ !]E;VO1;:T);O[#@.)]$G4_YT;IK& P+]H+\R(;]58]]D,\]*^COP?Y
M%\SLL>Q+%US9@V^QOC?$NFUF59F*T& P& P&!H]WJ^8,-^M^_P!BD,Z\_JBW
M@VR)Y\3^P<3;^V/FZ+'.)9>G6RL#.H-+(P.1#_[6%_2++]I2RYX+MSA/&=AT
MJDI;[O*\X+<<S.[!^>G5ULF P& P&!3-VM"]L9AVV.#^O#B439$35;>*O&,?
MO_>KHW1NUIUO;L;%2R<0!\Z'-9.Y4F^T4L,+,(RPF\M090I]&VHT%L@R^4(6
M3WDNH)I<WR3%3.5/&[(&BJO7E=!;/EK(JF_'\(R\)7AUB682!Q'R*:<@U8)A
MC3U#5G\('B7SMNBCL&N?ANP><5_0<I#3B+2".J$[]O*8QHG,HTA!)S/HO.IV
M0E[6PIM7#)7D=7,@D90T7XYB UD$:,Q;,8^XC<<7(KA&(;&]A?F$ ]>/6+^)
M2IL#[[,^C?V!]2-K^P9[*W#=L;#AMKS]-^I/AR[Z7E@\U7))KL8# ]$/PXO0
M/ZF^HZ"?9".1YS'M]BW#KCUXK75[K/OHMU<LKC,!@,!@,"J;QL?ZMR^/I.HO
MWR0+,JR5NDL-[>="N'/;=UAY)N1T0,WLN)@,#TW*L\V%<?4.(>SP[(S77?-Q
M^OK<Y,M$W;CY8\K/,X'PP& P& P*#/NB7T-ZH_Q,Q;]UEOYGNCS;F[XLJ]*L
MU3:]TFWD?6E=-K-QJ\P)-I3SRU)ZS8%[5"LI;[O*\X+<<S.^3=J/DCR/3+R-
M*T& P& P& P*M?%$:1@U&.O<6G@B.IU_);A*M)=8)3K)OVL.5LV'5C-S0<G&
M:\5B<U&!W$BD(X5%2,S)QLTB(9EN&*0WWTMP5$!EWADVQ#YI0'%>@8XUB9FJ
M)78H5\)"]>IUUSC)6)KVW8[*MK '0:41<$"%%K/A@4;8$H 1=\4T!')$ZT(H
M!]WC8>F%CF P(.ZQ>C7UZ]1U3>P0# G' 8$/=@?,M9'U8>_YIYHS9,> /2MY
MH8CRTV;:-]W65^-K?^)2!GGJ3Z,!@7;==/,C7/T#Q^VN\]!>Q;\7W19YM2=.
MO$"=)F[W,_&4W,TDU9OU@I@,!@,!@:O]P?,<<^F([]JH9#_9S^+SC_'V5O:]
M%MK0EN_L. XGT2=3_G1NFL8# OV@OS(AOU5CWV0SSTKZ._!_D7S.RQ[$L77-
MF#;[&^-\2Z;695F8K08# 8# 8&CW>KY@PWZW[_8I#.O/ZHMX-LB>?$_L'$V_
MMCYNBQSB67IULK SJ#2R,#D0_P#M87](LOVE++G@NW.$\9V'2J2EON\KS@MQ
MS,[L'YZ=76R8# 8# 8'6_P#$VG%+QKLW:DDGA#J3$YE4E UO+XY'KF2LMU9G
M9)!T3G[W6O(T=AEKP8;#&@ET'^*A/',;E9)N9E'$D,,]8_LCPN%_%1V?7EQ5
M['+ JR5QN:0DTTV3%'HF;92($JJ-64'$&30P/6<-'NXL@U<CG*B2V_'#EJKK
MSS[K7G DC @[L+\P@'KQZQ?Q*5-@??9GT;^P/J1M?V#/96X;MC8<-M>?IOU)
M\.7?2\L'FJY)-=C 8'HA^'%Z!_4WU'03[(1R/.8]OL6X=<>O%:ZO=9]]%NKE
ME<9@,!@,!@53>-C_ %;E\?2=1?OD@695DK=)8;V\Z%<.>V[K#R3<CH@9O9<3
M 8'IN59YL*X^H<0]GAV1FNN^;C]?6YR9:)NW'RQY6>9P/A@,!@,!@4&?=$OH
M;U1_B9BW[K+?S/='FW-WQ95Z59JFU[I-O(^M*Z;6;C5Y@2;2GGEJ3UFP+VJ%
M92WW>5YP6XYF=\F[4?)'D>F7D:5H,!@,!@,!@5X]SM9!;&\:KBE^Q8OKA:4#
MM"NFI^VMW,F=G8(K:3=Z-A4< USKPRKVW2EI.]?DTC&[&?.XF$26WDO YU)A
M0%'@);Z3-G@KK\'C)B1MYC)X1.+;@,VEZ$OGTWVE4[@UIS"+321.C5E(I2IN
M0,R442?D([RJ0 Q)ZNO%XB7+Q40&).@RZJ.T-27).9A6L2<S09.H2"!RTI&;
M K*Q:P*D(7)2AP(!FT::V%&(VI*(B3+QHV-0/@>'[#1XQV0<*([K-N%@V%P(
M.ZQ>C7UZ]1U3>P0# G' 8$/=@?,M9'U8>_YIYHS9,> /2MYH8CRTV;:-]W65
M^-K?^)2!GGJ3Z,!@7;==/,C7/T#Q^VN\]!>Q;\7W19YM2=.O$"=)F[W,_&4W
M,TDU9OU@I@,!@,!@:O\ <'S''/IB._:J&0_V<_B\X_Q]E;VO1;:T);O[#@.)
M]$G4_P"=&Z:Q@,"_:"_,B&_56/?9#//2OH[\'^1?,[+'L2Q=<V8-OL;XWQ+I
MM9E69BM!@,!@,!@:/=ZOF##?K?O]BD,Z\_JBW@VR)Y\3^P<3;^V/FZ+'.)9>
MG6RL#.H-+(P.1#_[6%_2++]I2RYX+MSA/&=ATJDI;[O*\X+<<S.[!^>G5ULF
M P& P&!3KVK>=B)W,I#9?77LI%H/U]&5,ZF=E1S6Y!PP];L2K>0.6=CO:O,.
M*_E#CKCO#VK=W'Y/:0YX72D1%XU#JAX83:-)^T"TX]8$'KZ <S^=2L%"X0)#
MC'Q.3RP^R8AQK1YJU;L]R!X@YT:J;N7#ILU17W<;;OW:Z6B/*JSA/7</[UY9
M%?VW$14^J^:1BP82;X=?%$KAYL?(0!'9B[78/DVI08NY:*JLGS9RR>(ZJ^^M
M7;=9LOHFLEOIJ&!]A?F$ ]>/6+^)2IL#[[,^C?V!]2-K^P9[*W#=L;#AMKS]
M-^I/AR[Z7E@\U7))KL8# ]$/PXO0/ZF^HZ"?9".1YS'M]BW#KCUXK75[K/OH
MMU<LKC,!@,!@,"J;QL?ZMR^/I.HOWR0+,JR5NDL-[>="N'/;=UAY)N1T0,WL
MN)@,#TW*L\V%<?4.(>SP[(S77?-Q^OK<Y,M$W;CY8\K/,X'PP& P& P*#/NB
M7T-ZH_Q,Q;]UEOYGNCS;F[XLJ]*LU3:]TFWD?6E=-K-QJ\P)-I3SRU)ZS8%[
M5"LI;[O*\X+<<S.^3=J/DCR/3+R-*T& P& P& P*T^XG7;I[I(];V[$77:%)
MJRJ35@,1=Q?L%/JKCD@G=;*E#E;/6T<C)9JU(RV,Z)%##4BW9J.V \8Z*.]T
MF(QPY1#;7KA6]7U16'$,J*1F9?%F<[M=^3D<CFY*Q9$3L(O9\N)6KS(9<8>/
MR9(^TLMS*QYM%ZYV<"RC1V)6T149;(Z!K9U'@/8]&WKDNGM)541C=FV8+%1]
MA)X?:Z$XC<3K&#R XYK>FXA'MHB (LV ].5R693&9DW:A&83LV47W'BX^VBD
M?C86%8$'=8O1KZ]>HZIO8(!@3C@,"'NP/F6LCZL/?\T\T9LF/ 'I6\T,1Y:;
M-M&^[K*_&UO_ !*0,\]2?1@,"[;KIYD:Y^@>/VUWGH+V+?B^Z+/-J3IUX@3I
M,W>YGXRFYFDFK-^L%,!@,!@,#5_N#YCCGTQ'?M5#(?[.?Q><?X^RM[7HMM:$
MMW]AP'$^B3J?\Z-TUC 8%^T%^9$-^JL>^R&>>E?1WX/\B^9V6/8EBZYLP;?8
MWQOB73:S*LS%:# 8# 8# T>[U?,&&_6_?[%(9UY_5%O!MD3SXG]@XFW]L?-T
M6.<2R].ME8&=0:61@<B'_P!K"_I%E^TI9<\%VYPGC.PZ524M]WE><%N.9G=@
M_/3JZV3 8# 8# INFG0GKQ'Y._KJ0=_NPU?/IE55T1EG4[FRNK E1.BK'D3B
M:6T"##)'U]=RW:$?&2:BSN2.RCXP%9L]M-).APDX4V"Q:]I;+Z?HF0R*JJ@/
MWY-(H&#M(/6 1X&:$9&73=#QH=P\)F%V;)D,#*;)'3A!MHX)(#1[Q8,-?D^&
M;%8(NZ(09U J'V8FXW/8[-Y-8MCV/9JEA1H1#R,@LRS).\G<W/ (T%D,G9AX
M2H;/N!408JEER+<*);)%%'9'5R0>A+?87YA /7CUB_B4J; ^^S/HW]@?4C:_
ML&>RMPW;&PX;:\_3?J3X<N^EY8/-5R2:[& P/1#\.+T#^IOJ.@GV0CD><Q[?
M8MPZX]>*UU>ZS[Z+=7+*XS 8# 8# JF\;'^K<OCZ3J+]\D"S*LE;I+#>WG0K
MASVW=8>2;D=$#-[+B8# ]-RK/-A7'U#B'L\.R,UUWS<?KZW.3+1-VX^6/*SS
M.!\,!@,!@,"@S[HE]#>J/\3,6_=9;^9[H\VYN^+*O2K-4VO=)MY'UI73:S<:
MO,"3:4\\M2>LV!>U0K*6^[RO."W',SODW:CY(\CTR\C2M!@,!@,!@,"L;Q.8
MB/L."5=7 AI=SNW+'DM@0:L$:,;TXH>=M3E03CFR1TA6OTU'*Q0C;J!M"B^W
M+H\,D_!IF&<QQ?;5J4TY#:+J)#ST(HJ/"9;&K'BTR)22QYC-&-M%JL,SXA,9
M[8TJFLGD1MU2AJ05>V1DAH\]-A0\2);,  %Z,"*-F;L>X:I!LO@,"#NL7HU]
M>O4=4WL$ P)QP&!#W8'S+61]6'O^:>:,V3'@#TK>:&(\M-FVC?=UE?C:W_B4
M@9YZD^C 8%VW73S(US] \?MKO/07L6_%]T6>;4G3KQ G29N]S/QE-S-)-6;]
M8*8# 8# 8&K_ '!\QQSZ8COVJAD/]G/XO./\?96]KT6VM"6[^PX#B?1)U/\
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M)+OH:37AU@630EVTE=H\S)PX\@,(*0V4&JND+9ZGP^W/"24R4DS?X>_:NFI
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MA"4N#+EDF&<CNE=IUM">E?WGY=4.]@=3NO<GZ]NQ=D0J0$JPE(N>1FK1<DF
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M=N.>=-O+KQQSMISKMSKSMISS[C?;7D)NP& P& P& P& P&!")_;GCLA5&O\
M1\G-(=@MN>>==>=O+K/.LW''DWYX]WKKSQMS[K77;C7?GC7G;CGG33G4)NP&
M P& P& P& P&!"(#;GGLA:^O]'R<4AU]VXY]SKQMY=IYV9XY\N_''N]M>.->
M/<Z[;<ZZ<\[<Z\<<[[\[!-V P& P(/ZR>C;U[]1]3^P0# G# 8# 8# 8# 8#
M 8# 8# _&1W()#WZ@AJR>E4V3K<8R(OEQ8]V0T04V9-7Y-L.,.1S)PYX22=/
MFXDHNT0W4<)#GJB>K94*PF'>GL*&C7869V=UIIF/QOKY;43I$MS!.TLWGAN1
M3J5R*E!Z#@<-D'4VMF#2)- 5P\%%C#DUN84+1[D'I&N&97Y0#@Y;N'X@YCJO
M:3J!L:PKF:BP%+@[I/J2>^U*TL>3L35B&("E!*.K?FIIHTMFQUE1'+H3&GDW
M@G!E^0& VSS1R\3<<!+$M[%WU#^RM,4JZH^HRL*NV0S/4'*@W82:KVC'*X@4
M/5D<GLR6U(^ZTCXN/&"CCV'0=V-9701VUDL_BJ"!!SHY=?!0W;P& P& P& P
M& P& P& P&!!]L?/WK)Z\#_\-O83 G# 8# 8# @_L)\P@'KPZR?Q)5/@3A@5
MX5GWW<2XW7:\VH:75Y5MRVW8E)U;;FDQA\L O; @$FL"--P\Z ,G R3P;Y;.
M*VD?,1?)C9('6>ZL1)DF&?$1VKL)IT[N]2]X_+I9M?U<MXQ!=HYO)Y"\-<,0
MS ?+Y'S$(M(&Y%XD@T+1(_*-50 F8AE2$5>E&[MF@8W5:.M40QN8]_.IL3J]
M*T^;M@+L(5TGS:,H+F5ASDN=K9LHI,0Y!HL/5*Q?6,.O@;.6E)")9,(ER2'+
M'=VFC]EPY#'U^_M)MH"#*.))#F=M$Z>KBXB=.$9>HR>1H%8H,(>8_'LJYCRK
M(8/U:E7"8HR2%L$I"X&KMV+1-SPN@U#E1'>BI95,)[!HJ@6X.U=V4B?6B:[3
MAJ^@0I22R@#'9!H7A9@@.?L)<DBA)$&+(%[\'-E'P]^XT;-@*X(X;"<:G["4
MK>J,C<U#8\;G[2)N&R!Q]'W*KA@W3?;$=!Y%H_4119EP9)0063&2$.N_!$E1
M1))B1<*,'6J01ZR[M]42@(])15XPHN%CT@$19T[#KORVY0^?4.) 1\29CF#E
M].MS>\7D_ A>%-I U):QF1[LEU] );9H$.V!X@$1C9XLV@T:$VA$$(9U'FT>
MG4?GC=,/*!G:GL8;H%#ECPVCA=%).%?$_,JV6X?.-SZJRD<6;QY9KN5W#;JM
MKEK*X$S[BM)8RE[.-$]Q!0D+;$N!&SQ-=XUVV$&'3)N+D3#X4/?M=2T>=E!6
M[EFZ;Z/=ED%--0QVV/G[UD]>!_\ AM["8$X8%<L \22LIM5W;&R'<'F4<=]4
M[*L6NB$(=K"'\GLWF*3^657!ST!2:.>$'+2W[)A$H@D)9/\ =L\VE04B*=\:
M[-N5MPE6M.\5%36N*!FTLDPVKSG8*$5],H[!Y.0T=D0FUDJMQL6$R V,;J@A
M2IN2K;12-OR[L4RE<B2W$1_9Z2\K/4.9+=Y.HX)*<.2]^U\Q95R=:1B8D52:
MW(L7(7DH^1&@= JFUW'&'[>:_P#P<2;@W1+<3*O_ (=*<,S'_8\#G%NW_69M
M-8I73JYX6SFTU;1)S'X\\?+LWBRD_8Z$H(+)[.6R3:/2&:L5-'$2C,B7%2*1
MZ[<:AQ;Q3^A@0C/_ !(NL@JD[VMBH[(@EV%Z2H^<7JM"04MX";2>,05GOL74
M82%P')-]1XPSLRC<K+#!QWY$'"#,7)6+,HX;CU@EAKW;ZI$(<_GHR\(86BPR
M4JPMZ^#JD2[Q*2)1Q"9[,= @T>Z.N$=H4Z;3=(DW&*BEX2X0F"#U2-K)E-@Y
M21]P.M$5DD#B)6WXNM(+-;P5W!F(+XSE6AYE9ZSU"MW^CZ+CS ]B/GNPLLI#
MGY1VQ9R-L(,.Q"SMJ)(K-@_@U[E=7'S29OF=W09RT@*+1Q(G")!91/=L0E'$
M&'.HWMJVY^6[4C.=TH./<PKY0(/IHNVB311:0NFXU4)\C$E#3&/B)3'72CT&
M=8H$ACI9D_&K+-'&OND]EAY1LR),EN/RZJM7S1L[04XV27034UVTX"+#_I)5
M/ZC^PGM[UDP)PP-6^X_9]AT_HPM=I"OY7:*8V6UW$F\(A*PY*3F7UA3D#"6?
M G@JL@R<.FBYS5[HQW624(;-^&**J2KC170,+E_>2M@-[]4:/C(<M8'/:H41
MD@B>1QV/XBD&BSBNYE8E?')'NYWU=NDK385_-&\-;CD]MUTXI(B#K=%$=HFZ
M#(F_?+INZ:3$BEV.JS@7 6C4G*#*\C0;!&01W,1U>ZR1D:<Z(BCL4;3DN+BA
M.5@'A.-ASK]J.+%&3A;33D.7W[I=6=*[96KS=D.VA)*9D*Y'/TUGZQ9_8 IJ
M[(%(0SB:3'>7.98.$,'Q]_'T06Y5I&FCB2KM4P*.Y'4/V(=P^L#PU"8\,N^!
M&R]BQ,-.88UCQ;Y1:&XC)=">T6/Z.P:1!DR'RU0*8:Q%0DX9[2L@))C8]H2(
M,'39((^M7Q!.KU2-J8=EIP\EB-];5X^KW[W  K.57D-M'E]Q#;&>MP:"Z[>$
M%^1SOA@^03=%"^Z#E("'+*LG^C4)/<]L>MC&432&D+H@0X]7@B8')FD2-)#A
M@$=78U$Q8F[F0O=4(\L[KT4X1)3T8S*.2<+9*:N9,S%H\^[P)3@4_BEFQEG+
MX61<% #]5V@V=.A!H"YY68N%&KG185(1PHNUYT62V]Q\*8H\+)<IN$.5&ZJ2
MNX9E@0> ])*V/4?U[]O>S>!.& P& P(9ZY,7HOKU0XPFS=#B0ZF:O8D![YNL
MT>L7K2$ V[MF\:.-$UVKIJNFH@X;KIZ+(K:;IJ::[Z[:\!,V P& P& P& P&
M P& P& P-*I[TR#S*L^RM>L;!.1]SV+N8!=R\CT"BRBT+D\:YJ986R'"W*B+
M4P+U=U()7<)/UDEE]";Y#WW3C1'?@,&GG0(;<[B42>[[/<3BSS=+L*GCMCA8
M!&X:7K@W&;'D%G0&UH @@Z,;QZ=PJ2%A3D>Y;/N&[Q:.L5GFFVCATWV#9B.4
M:S%WG(;^/R8C*Y@3JJ'5" :O&3-D)AD: EB\EE2P!NALHHF1LB3D1Y26.5%/
M*NVB4.%Z<;-P#=3<)VP& P& P& P& P& P& P&!#-H,7KN;]<G#1FZ=("[F.
M/B:[=NLLB.9*=>KX&)O'RB>FVC1KN2(CQ^CAQLFCL]?,VFN_*[I!/<)FP& P
M& P(2[ )J*P0#JDGNIMQ=O6A3G5/3;?;A-'L=5*RRG/&O'//&B26FZJF_/'N
M=$]-]]N>-=>>> FW K)@?0*>L6\!@MK7]&IQ1U37!:=V0& P>E2E:2Y[+["D
MUG2,)Q9-BE[HLMM*6$ 6M,PY!HP^$5HH_/"@)DFJJV9*AW 8%6/A7#Z]KH-7
M2MEQ GI#>>N@6%3=K6-@:3_2 ]>[>@]HL8I,2,O[$3R.%EY2E 0PM\\@<5J\
M .,*NY(A$73;X''&89G+_#YGRMH65;=6=B <%E-J/[_%2%*64DK8P@=6W82.
M4.+D(&.CT;9A/#&<1\[0P:0@YP05+1]?0\5$FZX*::)O=PYW\7JE]ZZZ:W^^
MSS[NX:BZOU4H=X@6O&P#7K;'4 *9OXO^6//);67\H[O.!6Q ?Q'>5MD-2!OG
MRK[!R<MZ)EY?,;0=OK>'(5U8_:>K^UFL4;5N_3F0:50JNH=6DIC&U@)V6F-(
M1^5!(& > EV\!$EX<44+K.GLM0>,6PL)AZXT#8M/TNVH:Q[7BMG06)U]&ZEK
M5>)52_J>1A*^C$;7B;/29$M[0L%A+9DZ":"4GDCC8BN@VKL:H[8Q!EL^W30#
M5!QX<MCEZ8H&G)+V'A1L?U(/0E?K@0:T=.(DDQBD/J6P:.W"7.WA79B/&+'.
ME*[G6B7,EK^2T@Q920 T+\19R+)%H\Z#)M_#?&:L=V8RP8[%$'$/ZM1U83$:
MU+LXVV*==.T$I[.&3(IC(+3DYU%"R34K?@U&)B4'B<<6Y5D3V0RYRZ4'ZA/O
M6'K1)>OQZV2A*Q(\8CMC$@A*/U77,'EM<5)7#UB]E9"0FHI#)?;]R\A)!/74
ME:J3%.'E(9!WJT;$DF,#'GWDB,G DZUDU-YWUHVT3WWU1NT\HMMIIMMJDGSU
MQ[ (\**<\<<\::<JJI)<;[<\:\J*)Z<<^ZWUXY";<"KL'X98$38U13Q>W"SE
MA K'["6%8$-:1%JP W.I9O8ZSNSU'C97RI(7Z[+?K+95H%S$4(-OA?,G*I;D
MW+0 DYT'- P.0^%S,S,4Z_0!+M&\^0=(5]UUAVT9+0"<N1KTY05E(6&ZG$0!
MQ[L!$X5'3EG(LA,6EFT^A]ON!@<"%WBQ ,ND1^- F"+]&+!"0.&4R3OF*EZ:
MJ:^*RN:IPK>D7PV?C&%=7PWNW6)6!.UKB*AIT\>:H?)$?+ \!@;ABCMQ(3@B
M5E_???PY"P>CDGF-E6*4'W,)$4K<-YTQV.L^LW55J&+#)651S&KFD<80VXN;
M'&"HA!#N]+5VK(@)&J)8<TV0DO,<ET>5D.BPH-0*9\,F[9IU9BU:]CK:C\6.
M".G5Z=8()#8[5@Y8C4^O8DC$'LV,V#+15P2$!<Y  E 8X/BK6*M:P#Z"UBGQ
M^I)#RS,^-#:>]^A,TM:Q;%GD1[$.X /LR4Q [)H"O$IT\B)@?%:>)54B/D.]
M<7E3LCD+ML\=,9D W>'DXN.)C6[<_#):JV$$0X:2L.D':BINP=*AX?&U[6I>
MK8CT/K[<D83A\=K"8\=:XVC$#ENRM-AV:B5B0B<PMJ0D<I@L70HGL*/>R)A#
MT2LM*BDQ[&NPV4JWPMF%4UJ:K1C*J7G+)C6PBH:S/VG2MO34_'H$*G,-EJ;2
M:K;]MAK(\=23@45=C#U4,J&V$V!'H_8+9CLH#81],+%*)KJ15)4<%KB66*>M
MF11,-\6E+!DVQ/<Q(E]GCIUHHMN</RR0;M1Z#A(2+WDDMELFW%,&6TCE<F.<
MOSC\.,/)J<]CJI6X3WY2TI+L GNKQIMRGHHK.^M&R2>^_''N==U-45MD].>>
M-M]4E.=>.>--N> FW @Z_:7TO.+PJ-*2+Y-:1"[J(N3EUR'X-ZD^*4MJ(VCS
M&MFW),5PUUD_$6Y [%O?G/Q/P_\ C/XL*_!?B]R&E=1^&1':G+PXDA;1J1I0
M7L:8M2,(%(NBW<QZC!](W;2-/=7(X09R/143#:8$W=(2T;DZB3Y\^<[ED%0C
M%4YP^&!AC3POI81B%1P&==C <BBO6ZL8;2W7Q(#16L3,!:WC-T]<+4?ZVN1W
MMF0,[*FA8)U@KZ$-I!&!%4QP=L]D<I>0<V0>L60X)ID_2*:)6Q([XJN[8]$;
M4=]A97=L5VG=0D+(KX*$GG6RI>N\O@AZ'A[9K8W('3C2IV,X!S0)-X4\#DRC
MD*Z#&1.Y;@X'X^M?1B<=4Y>F1K&]P)"%3,5#E;VC\WIM0Q+)O-8R[ES\I)JV
MF0*T8L%J<1*7DM7^&PXK ;/'AVS)/2./13QX_?N @*G_  Z+$#1BSWNDT:5G
M/A'< =.>M3F<Q0=:8& ]:Z#LJ>EZ'J<S%839$,6+011.R;7D418,K$C$IC4;
MG\68R9%E(HX;CVX2C&?#6$Q.96J;1D533>,SF3]G9U%X_;U06/8CV,2KM20G
MYF?CI'QOV4"5O,:]5?6C.0;V,B:I@DF/P$HE%"<^Y>_&TC,AN!UAI234%5^M
M?RFS'MH/$Y/)3@\BJSE(\+%@9HARY$0.',)U85L35A#XLTXT:!F,ELF7.67"
MCAJ+=BHZB%C@4-A\"$@*:G'8ZUEN4]^$MZ2Z_IZ*\Z;<)[J)3OLOLJGIOSQ[
MG;=/59'933CGG;355/G;CCC?7GD)MP& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
4& P& P& P& P& P& P& P&!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g67046g15l56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g15l56.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1>\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %Z"^8$@X0DE-! 0      $X< 5H  QLE1QP"   "C@\< E  "')R,3<V
M,S8R' (% "U-:6-R;W-O9G0@5V]R9" M(%-T;W)M("T@1FEG=7)E<R!2:61E
M<B!T;R!3+3$X0DE-!"4      !#'++%2'7I,&GK;I?JM\$MH.$))300Z
M  $9    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    ; $@ 4  @ $P 80!S &4
M<@!* &4 =  @ $T -@ P #8 ( !5 %  1  @ %  0P!, "  -@      #W!R
M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M       _@   .$))300-       $    >#A"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          CA"24T#
M]       $@ U     0 M    !@       3A"24T#]P      '   ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #-0    8
M 60   +I          $                          0             "
MZ0   60                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   60     4F=H=&QO;F<   +I    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   "Z0    -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     (_\        #A"24T$$0       0$ .$))3004
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
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M[6#;336;7/\ 2QJ&_P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M65M$,#*U1MC9XZQHR&YE86Q RM#<F#<M,@:VM*4A0(DX+^8"4R0@DDH/GX0
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M=[WOY6ZM;Y>?G\[>=O#>U[W[].]6O9+Z*-HWL7NVX[;.&0,@PJ(S"97R!D_
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MIQRJ<'G)LQQ@L--3Y04B>WE:XRR3N)S'8E&K2)52ITM&0+VQF3@0V,3U$/\
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MM;OSOZ>0K=]^GK;JN=*4I2E<;B#;ON]K=>O?E_G_ )?;:J6&&_75_7OKRO\
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M5B9HAK0A(5*$:<9DJD*]M8D"^Y]V\IP6%IU*@LZX2A_AUKY8\';)2HQ4P/\
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M,ZYR;/ML/Y 1'X^GA(XS'U[RLA<C3KDB\V/NP5;>>W&*#$2PNP+ 6DDFDF
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C[]6^RW=K7Z^VUK_*O(5^3?[[?^T->6E*4I2E*4I2E*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g67046g17x45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g17x45.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1L^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &R*^:48X0DE-! 0      $X< 5H  QLE1QP"   "C@\< E  "')R,3<V
M,S8R' (% "U-:6-R;W-O9G0@5V]R9" M(%-T;W)M("T@1FEG=7)E<R!2:61E
M<B!T;R!3+3$X0DE-!"4      !#'++%2'7I,&GK;I?JM\$MH.$))300Z
M  $9    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    ; $@ 4  @ $P 80!S &4
M<@!* &4 =  @ $T -@ P #8 ( !5 %  1  @ %  0P!, "  -@      #W!R
M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M       _@   .$))300-       $    >#A"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          CA"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M     =,   +#          $                          0
M   "PP   =,                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   =,     4F=H=&QO;F<   +#    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   '3     %)G
M:'1L;VYG   "PP    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M[KFV>K/M+6;_ $/2]
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M8!N8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & 14=M?\ :W-Y_C+H+^(G5. 2IH_8DOP9
M/W0P#<P"@B >?R_[8!0IRF\ ]G_M_P!?VXW]>@-6 , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MVU1-W%G""1NG7NJ*D(;H(B'7H8P#TZ@/CTZ8!OE,4Q0,40,4P )3 (" @/B
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M<^N2S&RQ5-AV4RSDG0+N0</FS]%=%RKZPMWU2'-Z0_7J(&1N , 8 P!@# &
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M1CMMJ*WXBGJ.WK7DF4G)1W*3U%16WO27I&._2*]R26MLGI^H#]$7??W\!_\
M0"X?\X@,_/G\/G_H?G2_'YO]1]0'Z(N^_OX$?Z 6_P#I&//P7S?Z#2_'YO\
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MO-TV>B6&+UOL8*PUCBU.ZNH]=.OV!V:'9"LNE&R)DG"I#M7A52$$JC98OQ!
M\]_8T]F]RDF]B\CK5R1Y"P<I5]0;)VOQF9R>F6R]!V2KL_6-BKJ;VTA8&$#'
MIO*:_9NG8H1CP?6!?$;+K-2^A < ]").(N^ZN*8ZWYP[@8)) 4I6.QJ]6-EM
MU4B ;N(J.7A8=Z7H(@/I_2J+B4H%.8_41$/YZ^O4VQK':.4_O#%[,X][613
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M!(=@# & .H>\, BH[:_[6YO/\9=!?Q$ZIP"5-'[$E^#)^Z& ;F , 8 P!@#
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M0W#UWM&JL/?C]B<>MH-DRE[B,_4Y^H22X@;J/I#PZRC A3% H"(* )1$1
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M;1^Q<).F3ULB[:.D%"JH.6SA,JJ"Z*A?BJ)+)'(HF<HB4Q3 8HB @. ?3@#
M& , 8 P!@# & 8;\G:9PCV_*UC1/+*IZ1NLOL:(LTK2JGMF$@74A,Q]3+'-[
M*]JDO,-B.(^0ATY^.%52(EF,L@@^%=J HIN3I =D<:-':AXZZGA-5:*%\GK&
M$D)MW6V#RZ3=\1ATY:2<R#F'BIRPR\W(IPL<Y64;141\(*-8AHF5BU3101(0
M ,@, 8!00 0$! ! ? 0$.H"'N$!\\ IW2] +W2]T.G0O0.@=WITZ!TZ!TZ!T
M]W0.F 15=M?]K<WG^,N@OXB=4X!*FC]B2_!D_=# -S & , 8 P!@# & , 8
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M?G\!#S^01^?W=/+Q\,  H41$/'J'0/(?;T]OE[< V$'S-SZ;U9R@X]77.V<
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M203C6_JP$.8#.+ & , 8!%1VU_VMS>?XRZ"_B)U3@$J:/V)+\&3]T, W, 8
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M/W3*)$5 [J:K(NFZ3A%0%&[A))=!4AOBJ(JD!0ARF]I3D$IP'H'4# (^(CU
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M .X7_A#RZ>77PP"O0.G3IX>[\O7 *=TOAX!X>[P_9@#NE]P>SY_#R\?/P]F
M?&PBXV*; SBX]C&LP6<N :1[5!DV!=ZX5=O%P0;)I)>F=.UUG3E7N=]=PLJN
MJ8RJAS"!]G=+[O?Y=0\_/R]_M]^ .Z7W!_?[?[]P8 [I?=[.GY, =PH>P/\
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MQC)->I1<I@6\9R.7@7+4\:Z=?I_%#>ZIKW:G6XS7X21W+E>? , 8 P!@# &
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M , 8 P!@$5';7_:W-Y_C+H+^(G5. 2IH_8DOP9/W0P#<P!@# & , 8 P!@#
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M[NY7>UR%LL]A@(#5L_9*14Z7*S$P[)3ZG$2:GP#!-6;-UZ1T55RY D4P!@#
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MHXBZ;)J1T"(.B-FY7(-@,#<%RI$*L"'?^/Z$% -Z(#?&!/N@/C@'VX P!@#
M& , 8 P!@# & , 8!I$I1\PZ_E'_ *X [I?#P\OGP#5@# & , 8!00 ?, '
M   =>GM^4?[Z^\?,?;@%< 8 P /D/]_\A_8. 8AWSDY:(/=]GT7K[1MHVM8Z
M5JBG;>LSF(M]*K!"P-XL-ZKD+$0:%KDHY.5GU7>OIHPMW+V*CR^G8%6DD2K*
MJMP-VM<X^*]BKM3GW&Y*;6U+A3&E^8UZU2K:#M,;6W,A,0JSV?@W*GKD,2.L
M-?GJY(JO0(V;3L,_C?6#.$0*8#MFU[^TG1OAXMOVE2:\I5Y2 A)]O*3S%NZC
M)BTQ19VNQ3AH9470R,S"&^%V#--)1PXC"J/RI^JI*JD ^22Y!ZC;:3FN0T3=
MX&UZEAJS+6PEQJ<BSGX>8BX?UE-88-^Q65:2BKIXV/',0;+G3<OC)HD4^/WL
M X32_(&,W'9-LU)*J6*GV#3<U1:];8ZQ&C3JDEKSK&I[/0:(FC73Q(5(AA;F
ML/*"*GHPE63SU51PU]$Y4 YIAR0T#)K7-!AN37#E37K"2E;J)+;#%2KD7#.C
M,9F4D5SNRH$C8B0(:.E7Z:BC2-D0"/>K(/!*@('+:YWCI_;T?8I76&QZC>F%
M0?EBK6XK<RUDBUJ5/%M9OX+GB('%2)DBQ+YI(*L'Y$'2+5RBHJB0#A@&,^U^
MT4XO:\T3L3?U6O\ #[MK6LXFB6":@].3$%;;-(06P[G TFO2\ S^$VC258N9
M6>2(F[0? T56:/(XKD)!([8 +CL/-75T5=N,M @(^Q6^<Y6UZ=M&N5X9NP2B
MHR%BJ.ZN[%S;WSYZW-"*61NS<1<"V!!TX=2+*8,HFBUA9-=N!W]J#:E<W3KJ
ML;(JQ7S>+L;1P*T9*MP:35>FHQZYB+'5I]F!S@SL-6L#"2K\ZS*=0K65CG:)
M%%"$!0P'9> , 8 P#2)2CYA\OF/_ %_OQ]XX!7NA[O(>OY?[#\N 5P!@# &
M, H)2B/40Z^7^WEX>7_7V^6    \O;\_S?L\, K@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@ ?(>GGT\/[#Q_-@&!-LH'(:F<O-D;WUCKBB;
M%K=^X[ZDU8Q0L>TGFOW41:M>7K<5D=KRB"% N)UH-XSV%$ F\8&6>IJ,WZ81
MR@^@,</K^J_MOY:]^S"V+[,#9$%1=[4QO/4:5D]A<-->Z?K]G<JR4<57;\7N
MW>N\+N1RA\$RK^ U_)6/94,SC7+=:8DRL$51<1RJ\>@+M]?H#@]CZWW?I[D*
MVYD;/I^NF:\UMJLNH;532T[#N-=-')<5GFFIE[8;]6M)3I*Q88F68*2U:=2%
M/+"2<;(OJW\,-9>0:J+ 7_KK1NU9KL@HS73FF.J_LL\<.U&NO(Y)_&+KA!;\
M+O&.I3)G*1<7)M$;)"12,$UCY6&C7Y6LJDTD(MFOZ9FF!D=J2K;RJ>ZN1FSJ
MUK6O6G5_**Y:JV'79Y[L-S3K;5(-CI2@T&5;SE+D:.]7)-L'=?>OTF/PLBH8
MID6KD6CDJ@ ^/X_HE_8& 6T>#N\X+1.I(JZ--8UB X5:=<5*!LM-=WF[R'()
MTPV3J&S1XW6G5W6KJQ4ZI6./U@5WL!HQ)LJ10FK(\DVS2390:KF2 R\X'M+Y
ML"Q=H#MB=H$70(G>6ZJPM0D(QQ8'4%.,JWQHU+0)2;CY.Q4FA2DJW"TP\K%R
M$P2L-V#B8C)1*-<RK5J20=OR!C2[[,W=Q=+<?-<1B>LFCS67"KCOQ_M+=.7?
M-HIU>=8<H./6XK6JP%*NB+V"<UC6MN+'R#E!NY=S#IDV79-47[IVV [+TQP,
MW+J;8&KKS<K#2Y2O:2Y"761JIV3Z2._A.)]?UKNJ(U#6>X>&*H[M4//;?F@F
M(LBHL$&9!=LW[E<PMC 9N\&J98*II%Y,V6-E()]MC;F[MY,JU,H+-):L5[<>
MT;1?JO!RS!P1)>,F6U<FHM:=BU4B*1LXXD62@&41.<0,QL 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M-I;[&;YA_=' -0_Y2_-__@< )_Y"_-@%3_Y#?_B;]@X!M(?Y?R$_<# -_ -I
L;_(/SA@&LG^4/R_M' -6 , 8 P!@# & , 8 P!@# & , 8 P!@# & , _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g67046g18k86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g18k86.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1;04&AO=&]S:&]P(#,N,  X0DE-! 0
M    %K2^6!(X0DE-! 0      $X< 5H  QLE1QP"   "C@\< E  "')R,3<V
M,S8R' (% "U-:6-R;W-O9G0@5V]R9" M(%-T;W)M("T@1FEG=7)E<R!2:61E
M<B!T;R!3+3$X0DE-!"4      !#'++%2'7I,&GK;I?JM\$MH.$))300Z
M  $9    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    ; $@ 4  @ $P 80!S &4
M<@!* &4 =  @ $T -@ P #8 ( !5 %  1  @ %  0P!, "  -@      #W!R
M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M       _@   .$))300-       $    >#A"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          CA"24T#
M]       $@ U     0 M    !@       3A"24T#]P      '   ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #-0    8
M /0   '#          $                          0             !
MPP   /0                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   /0     4F=H=&QO;F<   '#    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   !PP    -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     (_\        #A"24T$$0       0$ .$))3004
M   $     CA"24T$#      ,G0    $   "@    5P   >   *,@   ,@0 8
M  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(
M# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,
M# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ 5P"@ P$B
M  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*
M"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4#
M##,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q
M8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75
MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
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M22E)+(Z5]9<+JO5.I=+HJOKOZ2]K+W6LVL=OW[75.P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^$]:VAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0$! 0$! 0'_P  +" #R ;\! 1$ _\0 'P !  $#!0$!
M  D'" H! @,$!@4+_\0 21    8" @$" @4+ 08$ PD  0(#! 4&  <($0D2
M(1,Q"A0B05$5%AHZ66%Q>)FTUI$7(S)2@? S0J&Q&27!&"0X0TAB<M'Q_]H
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M+/-RE$DV[R>BIRU(.6"3=)VT=)@57X+=QEWH"<?5Z^NQ](]@'11'W PE  Z
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M).,%)HE;6LY4YQT5C#,9-^YBX^-16RLT1$0'V$  0  $H%$O0>GTB >WV0*
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MN2E6L4K7&MO3*8I14&=:1J+ATX](?69 KQQ["H(!*6(@'S$ ^_W$ ]OQS4!
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M*IS23ADNC"PI#KLW23I9M*NXBNW#[R*W"Y\6-H[]\A6BGGCRE=$7ZSZ\V?\
M[5; DTUM)_FPY:Q1+IK>URZ$:>>JLW-O#04$JQ)*-Y>4;@E7YRR)/X]12J&M
M_*IX]-QZ6VER$UARMU=<]0Z0B%Y[;%EA%ILTGK^#0(HJ:5L=/<12-W8QZZ:*
MYV+X:V9%^HT<%8?7%$5")^=UIY=_&ONBW2>O]1\P]/[!O$;K]WLM6M5Z4D7#
MUQ4VE="W/W+-4(TC%[)14(8[R=KD4Y<6B%40=MYF'8NX]X@G8EPK^D9<%>1^
MI=W[<W-LZB<>6>IMU6"E,X63<WBT%6U<I-P57UGLR6EV]&9-FH;$FY-P5&/:
M,BJ02 HHRY$@07D#W]2_EU\;4)HIKR7E^7VI&6D).[36NH:^JOY7ZG8+I6?A
MC/059B AEK#9G,4DLF[=*UZ)E&Q62J3TBYVAP7RV#F1Y?Z3K?3?$_>7#F<T]
MR2U[R)Y+T?1SVT-YN1DXN%C[*]:-I5= (23BY&(M421V03Q%@;$6:^M/Z_%$
M]9?5. D @0 $>Q['W 0$!['L1#T@ ==]@ =!\O< '.3&,8QC.LJ?TB81ZZ*)
M0^XI@[ 1$0/[B!3"*9#>Q1('J,(@ @8,935WGGO]]\KBW$>2T[2XCA79^0FR
M^(NK^2Q75D+8YSD=J^CPLE-TF046E5:X"LE>),M9B&2$8BLZ;*MGZ:RBJ;G+
MD?)EY2-_<:^4_'GA#Q%TQI[8O(/?%1N5_:S7(78K_76MFD-3B%.E6(I2+.UE
M++=K,)'#2$8,GZ*J$H:/;IQ\F#[U)>8E?-E<*EP&UOR%O?#O8U:YA;5W2\XM
MZ_X<29Y:NRMRW^S=F24:P%FGX)NL?7*L20UF):#1#QDJS:OHUBY?+MB/W/=T
MSSM\OE-Y,Z0TUS:\<5(;ZOWZ]6BV.YN)=QM5_B-)O$FQG/HW2G.%>,VK= OH
M2?2C)W$Q(&35/$NIM846)K<ZSY-_,9R'VOS&B>)/&'@S:=5<2-QS^K9!_M?8
M>UZG>+ 6#CCS('1182+NO \=L$E2_6E#Q;1%SZ"F*FW*94:CLOI".OX_QGPO
M-6]Z-NK#=5IM.WM1U;CQ1(V>V&%AW'IENL:XJ,K+!Q@H--;PK<GY=E;-)JLA
M)"MG8LG#EP5,YI1O&1RRM7.3@WH'E3=JS7JA:-Q4]&QRM;JQWZM>BW"CI9$&
MD>>4=R,@=(")%_WCIPLKV(B8W?MEAWDE\I'(KCYR^TSP.X<Z3TULG?VT=1V3
M=_Y2Y!;'?:YI;RNP$H\B$Z11ACU8Y_9-CS+A@Z/%1C9^"2H&,F=F9)H_<MY!
M_'URKN/,WB]1]W[%T==N.^Q91U8*Y>M2WN,EXZ1KEIJ<R[@I<8M2<C(I](5N
M7=,3OJ]+*1R?U^'70<G$WK*<U\I>_2'?L/7^G_H7_P!@_AFN,8QC&,8QC&,8
MQC&,8QC&,8QG J4PF*/N(#T4  #=![^H_K](]&*8H (@8/2/H%,!]:I>L8*[
M7+<GB,\H_//DY:^(G*+E)Q2\BD%QWN$#L/B3JX^Y;=J#:>AJ/.T%YKC8U*:S
M,5)0\-90G).5AK:93\DF2?UF'9G?JM[$E#VY^0V4\A7DV\=U&WG<O&ILN@5/
MC[Y#->;V#A[.R$A(\@^4/#S7C*X-GZ=LT:XJQG4+;GZMFAW3C63YU.KSJL+-
M/(:%=I,:H:RV2\E-.[7YM6[R4\X>+G [DKQ1X_O_ !D67CF6F;-T8]U5MGDM
MN!>07E&:=7TK7G$G*3J%<8$CVJMFCRS*+MU4V$(+HZHQ9&M[9^&+BE[D^C;2
M6N.,3VKI5CCU(,]]S=;U%(1B55LEDTGK!]-MMP2;2!(:!D)*YN[(M(M;HO'.
MUID\R18@.@>>B)BU:2V^AX\.8'"5YP5Y5,-NPGE8/N)W8EN,MS#7UWTG<.0-
M(:PS.G6YE%F>VY@A#QDC87+-G$G@&-74++(2BB!7/PYS_*#H-UQAY_\  CFB
MAPCOW*/A/H?6VT=;VW37'#4L5M&QZRNEM:1Z-4V(VU(DDV1?,XM-@B=:P?&:
MD:JMD4%I9 QDQ&'.6X@<GYYA(<DZSP^W3H/1W)CRT:*W-I?C.^UM8&]_UKK.
MLMD8^Q;$OFO(ABY_V9,)^1.I,&1?H)-CI.7+QPM\%%NN[_0L;CVD >_V1$/<
M0$WX_:$/L^H>^Q OM[AUU\@Y\8QC&,M/YR;DM/'WB1R%W%1Z79=CWNC:LN$O
M0J%3X.4L=DMMT+"N4:S7XN)A&$E*.%I695:M%#M6+DS5NHLZ.)$TC]82-A\.
MOE8UIXJ].;K9<B(*U3>D[I6_(W7.+L)QAD6?(UENJQ)M[78&SW8R#]UL"9V6
MT@91RTEJV\K#EVXFV*=<%@DY8(. DO\ *W9X'E+"\.;US'\5G('D)Q*VAH-C
M<VNQ>+VMMGR'-;B;R#LD$UDY.BSD)$V"O.X*IA)':0ZS.>:DB7LQ"G6=EF7"
M$+'/K0=*\3?)S_\ #_XK\H)#3O);9MXX$^0N9Y#<>>,/(IT@UY1WGB P9_FW
M7JK*Q[LQ7T?=XJ-?N)6+J[M#ZS(C'RC.O0*;*6KSA?WUMWWY%>;/D!T7>>#=
M<\U6G*!+[=JL[R3U?RIUZSX[<4=6ZVAVK=&QUFK/I"P$5G)]9\V.>4@WKIPX
MDVZCG\G1:[PY$DZ-$\&=FYM#Y=-G)L-VZ?Y)QW*FRS7']W+O+Y2-;;=@&<,,
MI^;\C7'1H:*M%?MJJ)X9.T1**RK9PNBB$RFU,J)9CN)TVMM;P5[=UO%\,[3Q
M4VSK'1>X-3V3CR35ELK;D-C,*Y)1;VQ:^;2$<>1NC&^."_E!G+0KB:>2SU15
M)1VL4[<5>GXYN/'D!=>'+@;KKC=O*/X0;AJ-- NR";PXX)[(F7<8H=8&D [I
M%U=UI[69!JY SOXSE '1R*E*"0I@!AM=\P.M)B:MO'G77DBX$;EYZZ68:/=I
MM>;G /5=O3Y)T/D8@Z!%_&O:54+G$Q-;H4XD0)B*C)PDA6@D'C--LQL3Q&5+
M$23?1^ZGS J7 &!C.7D=NZ"FPOUT-J*N\CCO/]M<!I4TLJ%$C=@,9-)M-Q$B
MA' 06L-,I-G4:R^$W*RCDP1;)SF%[ H>H  >@[ #"8._W&, "/\ $0 <W8QC
M&,8QC&,8QC&,8QC&,8QC&,XCE*90A3 !BBFIV4P (#T=$0[ >P'H?<,Z+@QB
MHJ&*80,4CX2F 1 2B#@@ ("'N @ B "'N "(?(<XSG.+@Y!,82_6TB>D3")?
M08$0,7H1Z])@$>R]=#V/8>XYSM_M?6/5]KX8J GW[^@/6L7HG?\ PAZ0 O1>
MOL@ ?(.LY *4"EZ*4.T ,/0 '9@^& "/M[B >P"/N 9P']E$"![$%0 $@>Q1
M QS]@)?D(#]X=>_WYO;&,8BOJ,)O2!A+ZA$?2(&. "7OY=   '7R^[.1B8QF
MQ!,(F'LWN(B(_/\ $<[F,8QC&=)<1!0G0B'^] /F/RZ0'K^'?OU^/OG"?W!
M!]P,<WJ ?<#=MW'?8??WT'??SZ#OY83^T81-]H047* C[B!2+D]( (_("_\
ME#Y%^[K-Z?NF<1]Q AP ?O .TQZ ?F =^_0>W?OG&X,9,R0)F$@&;JF,!!$O
MJ,!0$##UUV8!$1 1]P[S<O[&3Z]NT#F'KV[, %Z$>OF(?<(^^<Z)2F,("4HA
MZ1]A !#WZ ?8?;W 1 ?W"(??F],  $^@ ._6(]  =B @ "/XB >P#\P#VSK>
KHWJ3^T/_ .9]X_=\3K_3[OP^[.ZE_P"&3_\ B&<F,8QC&,8QC&,8QG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g67046g18o52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g18o52.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5A2:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(P+3$P+3 Q5#$W.C P.C(U*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(P+3$P+3 Q5#$W.C P.C(V*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,"TQ,"TP,50Q-SHP,#HR-BLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$R-#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%F045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T9867$W1EA9<3=&
M6%EQ-R8C>$$[1EA9<7=,.#!026YM:GI5,6HK:6179W,W93%I=D5K<W)I1C)2
M-4QQ,&QT;&TU;S,R:T5V1E%524A*;2M+9U5Q<$)Q4#5896(W+W=!="8C>$$[
M-DQO4WI7=&TR:W-Z>#-Y>D8O4DUT,%I683-#5SA+;5<S9VE72F8S8V%%4TY2
M5D,X4W%I9DMF-5<V-7!0;75Y,6E73%1R5S!H65-#,"8C>$$[<S5*1RMQ2W-&
M>D,Y=&$X;TEU559Z2F-R4$M4>"M.96IF0U9697 T<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3A0+U!(>C$U<S!$>EIA5V5J-FQ*6C(P;&A(33A3
M0D-$23 P>6QV:54Y:R8C>$$[1UHR;7A2;$=Y3W))0C4S+T%-<F,O368O04MV
M:S,O07AF.#!::V5"1'545$E024@U;65E.5(X-39063-U<GEZ,FQX8W!(3D5Y
M>#!:5"8C>$$[,4)O;T]6-6--0D5K0F%F4VUA,6<W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-R8C>$$[
M1EA9<3=&6%EQ-T9867$K8V8K8VHO=T1L3TQ(+T%,6FM8+U524&UX,&XP+T9L
M1C56;55Y6E(K5T@O:W=D0B\U:30X<GIF455&.60U<28C>$$[1T1S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER-7@O-28C>$$[>5 X02M5-'-F*S):1B\Q150U
M<V1*.5!X6E)E5EIL36U59FQH+W=#5$(P2"]!2FDT.')Z9E%51CED-7%'1'-6
M9&ER<U9D:7%183$U;"8C>$$[=CE0,2]43DMT.4XK=DIQ161W-U!(3VE42C9%
M5%-!:49H46]75EDR9&Y52WIO3C9M:7)(9%HO3FXY1V58=$8Q='1+36M'<%=)
M,4<W:"8C>$$[17@Y4T-%>3)S2$=)0TIV6&8Q3#50:"M(64AV4E-Q<F57+WI0
M;#%F6&),4UIT35,R:W5)-5)C4U(S6')I3V5/93AH0TM04VHU>&MA8B8C>$$[
M23-Q9D1U5DA(<E)6;F5+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMV;D@O;DDO+VQ/3"8C>$$[2"]T;5)F.$%5
M4E!M>#!N,"]&;$8U5FU5>5I2*U=(+VMW9$(O-6DT.')Z9E%51CED-7%'1'-6
M9&ER<U9D:7)!9D]0;G8X=79,,VUI,R8C>$$[8E<W15-A.6%W:')7+U<Q:FQM
M:6EL-41J2$UF:E=T5W%!92M847=3:TQ#44=09CA!2S%V>5@U>$]D3#5'0GA,
M8CAR2TYH139X<D-':28C>$$[1$5I4#DS1W$O0E196E X04MZ6&A45'EP*UEF
M-58S=75A9' K:#9A=')Q2$)R4W=D3$M+2#!O:51+,%--;39)5T)9<4YQ-4=7
M;FQ%5R8C>$$[5G V6&Q#2%EQ-T9867$W1E9'83AS-$I9;UIP-#1P<"M8;U)U
M-G%Z.$8U3G="3E<T<4MM;F)&54TK=C9%9W-Y*W!7<6I545<P.&UA328C>$$[
M9E=&5F5B1T@T=C-G0R]%94YD=#A65S)8;51Y-V9Y=U$R3W%7;#%,9%%M-71O
M-$HT<$=L9U9U1%-X:%=*6D%W-&QH=%AB1E5X>%8R2R8C>$$[=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C@T+S@U2"\X<'A9+SES>4PO<4EN>EDV5#9F
M:7EI.'%Z2UI-;R],1"]!36U$;U X028C>$$[>D9X-5AM*V=O3#97.#=E5F)R
M6#$P-7)3-2MQ6$9L3&--2BMB:FET>%IZ,B]*55@T5V1:2E598W5G0F]D.3E1
M=UE:8R]L;#5M=69,,28C>$$[=F]S54=N-F1(0G%!,4=/2S-L9')A,TUL=$QB
M2#9T5T)7.5-#47)D25=J0W1)>$<Q3U=&5DAY=BM56&U,4W16<V)U-$]N0T\S
M;71:028C>$$[.$UK<&MT:F%X4DI03&)H;T9R2G%2:F(V>E9L<%AQ-7%31F5V
M67$W1EAZ4B]Z:THO>6XT+S5G;V8Q=FUY,&XP36<X>GI*6DUV+TM0+R8C>$$[
M04UM4&]F.$%X;6(O04I.4&Q79C9#9W9Q<E5T5C!V4S=5,V5P,VM&:F%H;%$S
M1GI):TUF2FI25C5U5E=P4%1.4W=53E(X>"M8=$YL828C>$$[2%5D571,2UI)
M5&-V2&-4>%)-24$S07EK3WEN:'E02&PP<FEQ<%DV-6]M;UA%,71986AB6&1X
M8G)'.#A-13!C:GAP2T]58D]Q16Q1-B8C>$$[-W%4,3=9<6IC5F1I<D<O361J
M-5IU.5DP=34Q2S=S;W Y3F5:;FAU4%-,>7<S1G1,8G1#,TYG46IE<GE);U%A
M9$UK26MR5$1,+W=!:R8C>$$[-DIQ1VYA4G!D>C5P<V\W2%(W4G1/47=L0DQ.
M07DR>CAU4FTO8WE#93%R.%!)1D1X-C<T.$HW;'!(95902G5L,DAM1W<Q065:
M8E,O=28C>$$[255L.5,Q9U-/4#%,:5-A.&TU4FA:<$-K64=O>40P+VDV2S-,
M63%413EY,'HO53E7,')3<DYR,U9,>4-W<S!)1#-.,4EK35-L:E)16"8C>$$[
M8W%O<61H=FM643$U-7 X<U=5:GA8;7(R5G1,2$%,=#0U<FE+3FQT>5%O;4E:
M9U)(>4E(3'!I<719-C5O;6]813%T66%H8EAD>&)R1R8C>$$[.#A-13!C:GAP
M2T]58D]Q16Q1-C=Q5#$W67%J8U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<C5X
M+S5Y4#A!*U4T<V8K,EI&+S%%5#5S9"8C>$$[2CE0>%I2959:;$UM569L:"]W
M0U1",$@O04II-#AR>F91548Y0RME-W4W:#%+,U='85-*5$15:$=+:79*=D$U
M<&DT3V]K45=.9G!0528C>$$[=BM7=6(O:UDS.6-$4GAN=E)';F%J<41A:&%Q
M,3%+5DUS64E-:D5%1F@W-'-O>4YJ9#9N:S-93WA6.#!F.#5#9CAP*U K64M(
M.6(U<R8C>$$[=$HY1$E033AY5U1,+W=!;R]W1'E9*V@O.%IM+S5.4&Q79C9#
M9W9P:GIN-65U=DU/9UA';%<Q-&QK.7=#:GI01SAO.4YL2U-,4TM7,B8C>$$[
M:TA*5TEQ<V<K:U9",4Q":D=S+VQF<3)R-G1:-G10<E5C9#=90S!A0W1S6D9E
M8E1B:5=7,6QL-'EW,58P;F(Q;VA11G%-<%=M2V\W>28C>$$[2"M7-3AP>5)+
M3E(K=3(Q<&)083)31T5X4T%43VMS-U-Y96\T:W)*2"LW059E0R]$=FER3F-6
M9&ER-6<O4'8X03AM3F1F.'<Y=B]X1"8C>$$[3FYP9F]::#4S;5%L;"\U4B]W
M1&MX.40O04]->F8X;6YY<E Y0E%8,'HU>#!,53EC,%9R1%1B*U!43&@S56TW
M:W1Z8VQ5;U$V;T)*028C>$$[>4TV;FIZ5BM10E!':&]2<5=$1DQZ.'$Y4W9,
M;4,U+U-L<F%.6C-6=&978T5.<$DP4UA&:GAI='582S16;6<K<G=O2&AR.75R
M0BMM2R8C>$$[<&HU1"],8RM5-4EL1V\O6&)A,'1N=&)*1$-9<$%*;E-79'!:
M4%5C4U9K:B]!2%E#<G=8-&0X5EIR:7)S5F1I<G-69&ER<U9D:7)S5B8C>$$[
M9&EQ=WEX06M'44%J<4MJ1E='*V-V>7<X<"MB=%1I,4Q63&TT5S1H9U<S55%3
M>&]V0EA:>%5-:C<Q:T]863@U9TM#455H+S9&.2],,R8C>$$[+VQR=F8K4CA8
M+U9,2B]M-6538E(R:"]K<C5(,&)6-U168E,V=7IC,F-G;&E%:S!25&MV4V]%
M62]89VQQ6D5585)B3&17,$A39%5N4R8C>$$[835M64]I.$)W9%%+5DHW9RM/
M67AA<#1H3&UG9CA%*UAV.2]Y+W=$27A0.$%M;D=G=R],>%AW950Y06AM:FU3
M951N1W=D87E*4W%M;R8C>$$[+UIX<$EW4D-F*W1$+W8Q9G9'1G5D-C!0*R]6
M*SA9<7=R>F0K5EAL2'I6<3,V53%/-75&=6945T=K17-A2GA1:VI::V)F-'9(
M3'-E;R8C>$$[;$5516=P3"]!3D,K+VPW+T%-=&0W+WE0:2\V<%I0.$%.>3AK
M,FU(;"]W1$IN>51O3W,R=7(R5C%D3F17:D8T:$Q.1WE62VQD=TDQ4"8C>$$[
M42M/4FYQ6E-&1D9S<3%B44Y),5,T5S1U6FU%:6])>'=D44M!:SEW9C5S>'DQ
M5'A#4G-O3"]"4&PW+V8X=B])>% K86-A1$0X=D95="8C>$$[=DM/9S(Y>$9C
M4GIY97!#-GE*5U)#2W%A:79W*S).2D=#24YP.38P4"LO5BLX65<U,W)1+S<Y
M6#=X:7)#4$YF-51E5"]!1%!R1#9T<28C>$$[3GIC<F1326E-25I9,5-I0V<R
M2TXK=DQO86E54E%4850O=T11=G8U92]W1$Q892\X:C1V*W%75"]!1&-V2DYP
M:#5F.$%Y6CAK-D1R3B8C>$$[<G$Y;&185%A6;WAE25-Z4G-L4W!88T-.5#!0
M:FM:-FU5:%)28DPY43!U>G9P;&QE.6UI2W%%-'=Y:$8R2DYA538W-6IT8W-D
M;V(O1"8C>$$[;&@O,6-B=B]!2U-0-TUA62M%3SAR-$Y"<UE:;S52<49Y>&I9
M3T9A97%N:6$P27!U355J1EA5<'5*23).0DE#5#!!27=T:2]&6%EQ-R8C>$$[
M1EA9<3=&6%EQ-T9867%X9E8O.$%J;WIF368X0452:T-Z0T1W2SAV+T%$8C@V
M-CDU9C%7,&<P-BME,%=45#=M-&AJ55=F1U<V:6UH5R8C>$$[3EI0<E$U=6Y"
M,G)(8B]V5"MY1&A#;U-$.#9B;E1)-V4Q,4=Z3W!8:S,V5&Q,>'5)<&%7,7IE
M<D)':TEI-'5/1FU%3$)Q9VM60DHS3B8C>$$[271+<FHX-G1F9S R2GI(1DY)
M,G!'57I14TI*-C%K3E1E1#9R67(V249Y4D9(>$UN=TAI>70Y;S0P='-W+TPS
M.#%:4$]M<'DR='1P:28C>$$[45=T=&)R4&-8;G)Y<W!A4U(P4EE6:W0T5$EV
M-W8T;5!':'%!1%-U06A,,$1!<7)B9C-W*U1F.$%%5&EQ;&ER<U932'HU8S9H
M8654="8C>$$[6G8X051R>5-X=DQ#>G5,=4-A2EEN2F5#2G!&5FQM4U93<D9F
M:3)R-$595F5A*UEF4%!N-U)D8W0W0T<V:W4W1C$P84]A-FQH="]64R8C>$$[
M92]U2D=C<TDT;S$T4U)X4$A53'-1=%!I2D]':TE0>3<K6FYM4RMS;U!R=793
M5S%H2TQ!-FAR:VM6:$TQ;S@Q<&-Y5$%F5FME,VI6-28C>$$[-%EK5EHQ.5)E
M6'A!16I';&5Y*U@W;5<V,$]W=5I:>F-Y5%<X8G9C=$,Q<UI#>6<X>D%X3%(X
M=79(=&M5;R]&6%EQ<3-8*SE5,RMU,R8C>$$[-GIH2W9+9E!N-6<K6DY!,3=5
M;S=A0S1U3D]S,C!6>C9%9'4S0T\U=5IL=4EZ>DEL6G)H67=I8U9A:$@W2C-+
M07%72"]!2GE.<R]Q,28C>$$[=%!(;WAU4%99;SAC3GA*>F-L=VEF5E9L=#1J
M4'5A3CEN:6%J9EEK,&DP85!Z1#AX6&YK1'I0<FM&>$1(9#(R<'A7,FY35W)X
M5'=1=R8C>$$[4U(R:D5E=DI&2$=6+V9/5VQK46AA-S%!<&=P2TDQ2'HO=T-9
M:C5&.'!A-7!)935V8GDY:F@Q4S-E1TY*3&E/0S-U2'5O,6IQ-&ID,B8C>$$[
M='E5;U%1861.>&I3<&8U8B]/>3=B5$ER8E5B1G)N56].4',W<35V;EEW47,Q
M>6)D9E=N6EE42$1$+W!.4S8X<6-(*T5F1'E.3&%E*R8C>$$[469Z0S%(6%!-
M;7%A6&5W<6M823-.:$M81D)&.5AT5SE#2&I'=G$X1VY,=3=%16,Q,DE0=V=H
M6' R:R\X9$=(-6XY4GA#;&1Q4&XO428C>$$[9$UK=#0Y4W5B97EK=3)+5W%8
M3GA(13!R06=&67<O2&MF:4A4>'<R>'!&5&5B3$]&;VMM5EDR;F8P;T9E4E9,
M=GA,.$5"*S S1D=.0B8C>$$[,D)X-&LP<68T:E0O04AW9BM#+W-X-&QP5'50
M3FQN8E(K<F-+<TU82E4U>5-+:3AP1T-)=%115EIM0V=D>6%9.%,P;W=E9#E*
M=4IZ8B8C>$$[=U-24WIJ,4%9:VU2;G)!-&IL*T5B+W4S64LS9U11-#)I;&%F
M>EI:,C9Q.7=Q=W$W<$5J4U-+;TQY34520514-&U99T%D>FIX2G!P=B8C>$$[
M3FQM;'A(8DUQ<F-Y<7IX46U243=+:$%D;%AQ479.86YT55DX4S!Q+S1J5"]!
M2'=F*T,O<W@T;'!F2F$R5GEW=4A2=55Q<7AO,VEO>"8C>$$[4F$S.4=A9B]!
M0TXO=U=.3&)V,%IP+SA!23,O0EDP='4O4FUN+W=!:F8X1FI3,C<Y1V%F+T%#
M3B]W5TY,8G8P6G O.$%),R]"63!T=28C>$$[+U)M;B]W06IF.$9J4S)U:C V
M=U8V<6I6,R]A.7-A5S%V-DTP+W=$:V(O9W-A5S-F;WI4+T%/4G8K0WAP8F0K
M:DY0.$$U1R\T3$=L="8C>$$[,S9-,"]W1&MB+V=S85<S9F]Z5"]!3U)V*T-X
M<&)D*VI.4#A!-4<O-$Q';'0S-DTP+W=$:V(O9W-A5S-F;WI4+T%/4G8K0WAP
M8EA3828C>$$[9%E.23=-:F-I4U0X6&-N1VQT8BMJ3E O04I'+S1,1VQT,S9-
M,"\X06MB+V=S85<S9F]Z5"]W0U)V*T-X<&)D*VI.4"]!2D<O-$Q';"8C>$$[
M=#,V33 O.$%K8B]G<V%7,V9O>E0O=T-2=BM#>'!B5F)7=W-O-3!E3D=$<C!*
M879B1%,R.',X-S966E1A,V]M<E0V.6(V3DIP:5A40B8C>$$[3&@U27A.13=1
M4$ME559Z6FUK9F]R>35C,"M,-&Q/4D1*25DO>7DQ>E0W964O=790=#58-G9+
M:W5O>CAK-%)&3&YG>&8Q=W9'3G)O4R8C>$$[5F)U9W!X2%)T5EA69GEO.#!8
M,6I.6DHU-3%#2S-L=4QI44MW:VLO,&5D56I7,UIM;C5/23!29T-X3E-X86Y,
M9D<Q<%5F.'$Y9FUM2"8C>$$[,7)Z9F0S3FM,-D,Y1FA,1WI22VQU.&-I>$PK
M*S5B3D8X4$ES;T)R>$PO2&IA,&QM<F9L4$1:83%E87AA96,U=DPY,V5T93-S
M-5AG9R8C>$$[.4]7.%,V;5EC-49O:4M)-#5#3FI24S(Q5EIT55IQ=FM(53E1
M85A6;U!0<SEV2&8X;SE0=E5*;W$S;'A"2D=S5'!/:4AL-E%I55)H5B8C>$$[
M64556&Q6;6)63V1$+TQM9E1F3D5(;4<T,38Y,4=A0T<V=%9G=65,;TE*-5)*
M16EU,TM4.3).:5=9;'1V<V=53&%S,'=+>4M$+V5E2"8C>$$[+VI';B]%4FMM
M2W!H5E%V<C(P<TQ+-'9R>5998E,Q:F5E-&UB-TM2>'%79&HW0E)81E5P<R]0
M2&QE.&MK:F=V9FII=%=V<&A*1DY&=R8C>$$[9VHT*V]8.5)&-'-N3F532#1L
M<4MJ1VQ3+W=$-5=V-4)$0E<Q37AT-F)3<W-L=F-O5E-/5#!P0S1A26-05&)E
M44Y49W9X=%)D.&%6:R8C>$$[=6Y8.7)Q3FAB6#EO>&4Q=31K;F=D:V%-=$A)
M;UI356-+-C%"-D56>%9%67$R;C)V=B]6:7)72W5X5D0S*V\V9G Q;SDU<48Q
M1EHR:R8C>$$[6E536$9W-GA2<5A9279*,TE58VU9064K2W!D6BMC9DQ&,T1F
M>G<V:D-,9E1*1$9E,T5H355334=+5CE344EJ3'I6:S5+4W9)1F$Q0B8C>$$[
M>%9!+SAR3#AJ,4I'<6\P661)>&-+:W)1<UI)-5I%36-W47AU:%<S:RM.5TLQ
M2$=V2V=X<%=3>'5(4EA7;T1!14)G5DY$=G5R54DK4B8C>$$[>%9D:7)S5F)F
M-V)F331Q,6EQ1S%(54Q,5&)#-3%#*VQ70WIT23-M=4IM<E))-'=76FI49EE$
M1E5V:#@T*U=:5S%%9E@T-&PP;TLR;R8C>$$[5%1H;TEO,5ES;V(Q6E%K8D%.
M1WEK<7A!26]D.%915&9M5C5(5C-8.4MX:TI):U)L5DI7:5EY4GEY;WE3:$1'
M-D9B950T,5ER>55R6"8C>$$[;'1J4W-K:F-/:75T44=!241!<6%(9F17;U(X
M:FEQ-T96.% Y-G5+=D90>E@O3#=44$]-,FMX,V5U<F\P.7%L>DAB2E)#,'AU
M;6=I228C>$$[05HT>5%'-'!19%,T2&A724Q*2SE3.&IN6&IE861$-2]-<T8O
M13@V-F%S:&M68E-:5T-30T]/-E%S:6AG<2\W<4MJ9$=E<C1B43=3=B8C>$$[
M22MQ-G9P=# R;&9M8F0V:WAD55,K='!F5U=%:5(U;5%I1S0T1FU%:61D=T9P
M.6AU3T,P<V@X<RM13F(P6%4W-C5F>E1E6$YL9'@S0R8C>$$[=S)(0E)(8GDS
M13=Z*W1&-G!N6&MN<55(2E18.7%O;V]B5E$X-"]L,V(V>EEX1%9V34YY0D1B
M6&1K;#5C1T]&:2MO=$%K9E V<CE3:B8C>$$[9%9A24M),E5H>3%$,GA"5DEB
M<CAT4%!E;S9L8S9D9&59<G1.3&AT3%0V;G%R=3!R3F57-S)R<DUS2'(O04%U
M2'1P1'E)0G$Y96(Q;R8C>$$[:'1$,6E.5U=.5EIU8DM!1V,W5DE(6$EP6%EQ
M>4M$+V5E2"]J1VXO15)K;4MP:%9"83%P3G!R1VHS,FLS;DPV<'%&=DQA,TA!
M.%<Y3R8C>$$[6D-J8U1V43!B8D972W K569L>%,S2S<Q03AR5U<Q25<T.45F
M=C0Q:6MK<$%S44I-8U-,-EIR14%Q,%%5>'1#;"]W07%9.&].6FUY;B8C>$$[
M.5=E,$YV3F)#0F\W4E563&DU4S9L2T-/0D]"3'AQ1D,P5D(Y9TLS>%DR;&QM
M9S91=6HV5&(V870S8S-Y,C190S9V6E!7;EE--6(T,R8C>$$[;W1E4$QI=3-1
M05EQ;4=+=' Y<C<O=T)72W19<3=&57$X>F588DAZ1F\X=6Q8>$LR.'A2;5I5
M:&M)2TU'2'=816,P4C-(-U-(-SA64R8C>$$[3S$O2R]23%I.4U9,-U5E97!2
M3D)*2W1X-DQ):E)Y>$0K-5=)5$UI5&M).7@V:D-I-R]#36)6<B]!2E92-54K
M=#9J8SA*03)P5#(Y>28C>$$[-D%19U)35W9Q96PV3$-)3W106%E63$4X9F="
M0V9$:F%S<#!Y>2MO86)A5U!R>EA8,5='3T0V,6-V-FLX=G!Q1CE35C9$:S=5
M<7AP=28C>$$[8U923TMU>%9T+W1T.'II<E=+;TQ7=$ES.5HP:3@P<3E"83%V
M;UAG;7!4:T9K57)Y6&M'2$IE<6UN6$973"\X04MP9DQ"8E4S36QY6"8C>$$[
M,5=14S-(>%)C0WEY4U-,-FM8<"MJ8VA7;6%G=6ML;T%O2#)24G163WDO2C=Y
M;F%X>E)H-VU:6D1A1U Q5VE9=R]5;&-296=21U!43"8C>$$[1UHR8W)U,TEJ
M-TI)3&%'66%:6F953DYT3$@Q-7)R-G)$2$(Y8758.5-E6# Q0RMP2SE">61Q
M5EDP,T]+551I<2M(*SE81EAM=FTO."8C>$$[=5HO370W<#%X3$IC5WE71WI*
M16MI=31.,V%84C1Y;S!B>&XO045,:4=5,4A,:T]M.%=36&564'EM,41Y.%5J
M:G4R=4Q264)'-DY9;R8C>$$[2E1..59H=$,T;4I::U1H8G%E0R]T5G%X1W=+
M16YL+TM8>C=P9FQN-G)P3W0S:S%Z65=5,$9L87=F6&)C5%-F5B]39TIA83AN
M4TYK628C>$$[0FQ#0EEX+TM0:$MQ<&Q:+VQ4-7ET-W5Z=40U=#%A5#9V9'!C
M5'=L6E=I;&=33E4K<D9:2EI+3'E$2&M34V58>#AM05E+;UA4=GEG."8C>$$[
M*S)T-6)4>F5D.5AU;V](1%!"2D4O1U)28TQ.>% W,W5I;$17=7@R;W9W-'%M
M96@O;' U=3 W5F)E*W5F375P6#AC1$M8=$I5;#E*,"8C>$$[0WI",5I7;&-6
M9'!58VMJ67!207%%2W%R3G9Q3C<O>7IY9CA!04XO5$)38F0Y4G9F*U=E5"]G
M1R]P:E,R;C!%56=G:4)19VA%0D9$,28C>$$[0VI*358O<'EF>6XW<U9D-F-N
M.' K-T9896Y*+TMF=7A6,W!Y9GEN-W-69#9C;CAP*S=&6&5N2B]+9G5X5G15
M9FPY:R]D:7)8<'EF>28C>$$[;C=S5F0V8VXX<"LW1EAE;DHO2V9U>%8S<'EF
M>6XW<U9D-F-N.' K-T9896Y*+TMF=7A6,W!Y9GEN-W-69#9C;CAP*S=&5S)2
M*U(K128C>$$[.50R>%9R,#50-50Y,DMU.4]4*U4O9&ER=E1K+VQ0,UEQ-S U
M4#54.3)+=3E/5"M5+V1I<G94:R]L4#-9<75I4GA)<$MK1#59<6ES2R8C>$$[
M2%EQ-T9867$W1EA9<3=&6%EQ>&8X>G)Y-W,O25=S,U9N4$IB6$U504U5.$Q.
M1S9N;6]Q<DM14FQU15A-5VM02%!Y53@P*UHY4C@K,B8C>$$[,7)Q1W(S=#5B
M3D)/5V=U3&U75D-1;%%3<G-2=&U:<5E214YG:W929D]E;2]M1S-M;3=V9$$K
M=&96=C!F0VQI.&-Q3D-T>7!U4%8O8R8C>$$[5%AT=D1Y2W9(=DIB4T$W8G)3
M;S%Z1FIU:V%2*V9N,3(R839V<G$Q:6MH5G(Y,FPP,C1!;F9507I*1W)+>6A9
M-T]:.3%287-O2%%+328C>$$[2W1Y4B]W1$]1<D0Q1U-:-7)D241#<51A6D9(
M23=75GEL=U-!<&]235EE26-/=E T<6-0:%962#9D62]N1&-4;30Q43-Y4$9A
M>'8X028C>$$[5B]R1VYR0S!Q6&QR35E9:F%M171+.$55<4\P;T-686DP5FII
M<4IV=% O375:=$QV3&%#.6EN='13=G)I5S!K=6]J13ET3F5*3F)2>B8C>$$[
M96QD>"]#='974#A!,V%%*TI21W=+=&=612MA8F8X,35037!V=DQB4U<R;71:
M5VIF535N=$=2<FQB;CDW1$ER;5AH*S1K8FTP4D93;R8C>$$[;WAO3599,7)D
M:"]Z:T$U:6LP>5<V8VTR5F=*<$Y/:&8V,41E4$I%='=S56AI-&5G85 V3D]F
M=T)H5&M-2V]U,E0O;DE"-$I*<FPU;R8C>$$[1$LY>D=L=$8K:4IP65EL84DR
M:VES>7=X>5-'<V=L<5%V14AI<71X>%9-8E-4.#9Z;VUP:2]H:U<O5SE8-G%B
M4U146&YE,G!*>DYS2B8C>$$[;&IG4U!L-F1&=4MY0F58>$9U3T)6>39&*V%A
M8499>DIE>78U9UA68C(O=EDU3&A48DY!64HP9W1105)30U$K;49&0U59.#96
M6$973B8C>$$[,D9N+T%--4A35V(V9F5.3&)23%EY45$S56-U;E-Y4&166DEM
M95%L6E54,&%664TX;G)F1EAG4V]64E8U<$@U+U!P;6\R,6ID4T%44"8C>$$[
M9&DR5S=U3%-/6DE23$1.8G-K.$-3=C8P;TUS6E5S159E;D-I-%94;GI"<#,U
M;7(U:S$R.#!:3&US=W1H;VMN<F\Q;D=W:6A75#%)-28C>$$[8C%9>$AZ16YQ
M9C9#6D-T4VHX=5!%2VMM:S,S-39A:TY3=6)75S0K<E=Q6&M6=$9C2%-5:VMV
M24HR9SE(;$A%-%AH1T]18VII6E905R8C>$$[3V=9<6U7;4XK9D101V(Y0VE'
M+S T=D=',#1K5UAO>4QE<5A10W!$.$=D,55%=#A-87%V>%E&53E!=&9Z>E-B
M5%DW,F%D3&$Q4S,K=28C>$$[<DTR;7E#6C%U,%=6038X-6I(.5-*67-Z0U%Y
M0G0O<S%+<G)Y,3@Y86XU:#%E4WA/<$),965A1S0Y1SE33T%O<VEE;F)1=W1.
M15E:2B8C>$$[3$QJ2C9W5#=B<E)G3UI:5E,Q=GDS*V)0-D=68DLT=F)M+VMT
M3D]6;WAF2D%)-W1,2S9H;EE33$EH-'@S1%<X>C$U*W%W<%%R.6M+.28C>$$[
M03AI,TXU8RM5.5!M=35';61L9C!R:'E785<S16I#,VQ:;4I,1U-%27A*2G)8
M<6-65#=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1B8C>$$[54QQ;#9B2%0U
M-W-*>DU+.&=H3DLW*T],1V-Q1G!*;U!M-EA63E%7,&$R5TE&5V)M1THK>5!#
M9W=!=%=03GA'<5%0;5 X>%<P4%@W<B8C>$$[5#5.3&QU<DMX<S1B>31U8F-4
M>5-N,3)M5EDP4EE$8F<Q9R\S8F-2,7)T56EH3&5K1F@K9G5K6&1Z0D-U:#,X
M:3-K6'(R6F=A,6Q,>"8C>$$[1RM.:7)T5V%.1D13;4]L1V(W6&=/4E966"]0
M,WET4EI%<V)V-G5Q=W9C>7E.87@K;4QM,6YU25%16FI2;4YS52M09W4T8FQW
M;WA65"8C>$$[0W<O3EID5V%984YO;'IC<6UN>C9H03!S,75G=41B4U)*2D1$
M-DPS1E<O9F)-,T9344M%<6515E-M>B\U>4@X;WE7:S%X8S)S.$)J6B8C>$$[
M,FEJ5U<Q679!1F562D<U>E)'1FI%9TIJ;$-N:V5#97 Q2W%:*U4O>FLP8GI(
M<E57;%(V8F4R8VPV-DA46&Y%2D4P1#)2=E1/=VIK9B8C>$$[,#%694MN<6%Y
M4CDR25966%@X>35P9$1M,4LR,&MY>E)796U883)O;5EK='%5>GA'3#DS1DI)
M5VA%9DMI4G-Z.497=$MQ<CEC+TU7-B8C>$$[<TY',#=63%!466)Y3S<P;34Q
M=356-V]W:4\S=$EO<%A73G92:SE2>C8T0SAU03(S27A623E5+S5Y23AL5U=N
M6&0U2$)C,T17=VQ+>"8C>$$[0C=2969P<W%+82MU865O.&=P2%0Q44MK>&=$
M1E5W<V9Z;3!U6%9).4QV9$EV<D\V;796<V]P1#E8940Y-6-Y5VE33DM*5C1J
M,5E3<"8C>$$[6&I8;'-V36(T<7$R4#5X*UAT4CAZ=#59<TQ3-F9723=T-T]A
M3U95:FI2;UI!<W@U<3!L94M,238P1D<Y3FA59&-64VUX+S5Y0CAV328C>$$[
M8F1.5'-*<D-A94LS;&%%>5)&:T9W,'!6=C-H:$5I96Q':VDK;GED=61!;%9A
M:7%V6B]N;' Y,W%Z,F-79V%I25!Q;'1E5S!J=&)*3"8C>$$[8T,X;FEH9SE+
M3G!G;D9X8TDS2C5&4&)J6$96.% U,V%0<4U'<E1A1F$O<$)D3FLP=49+>4U$
M2S)P>4-)+W4T27)M6E1!>&]Y:4US5R8C>$$[0D%(46Q61V%H*V(K;#9B9719
M6&UL6#=8<T9Q;#5E:3-717!&13%Q.3)8<&-35S%W445H;$A%=V@V<%%O3U-C
M;%5V4"]!1&M$-5!62"8C>$$[3#)/;TI*2$@V>E%L8E1M275-36YQ34)C2&=N
M<%A58CAN;TM%:C=3<T%Q<3)V-34K6')N54PR,6HP,BM+,D-Q,7<Q3&-/:6-M
M16MR4B8C>$$[;555:E9E1$1C=7=B-TAI859.25!Z3G1B-U)R82]W0D\P*U0Q
M-W%D<F1,5SEL:'0K0E=W8E51.&MS8EA%65)O074T2G!Y,W!1,$-P6"8C>$$[
M669N0F-837!I:S!*;S)%,7)#4W1X54%816QQ:E-S2&EI64I454EM:BM(:S0O
M6EAE:%9(951V>E)I.'AE6DHY0V94+W%K.&-%='ER<B8C>$$[35IA3$A*1VYP
M>6=X>&-*=C-T5U%&=4Y/<'=+>G)&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%G
M=&(K<2]O<34K=#@O<3-$.3<V9$]62R8C>$$[.7$T;&A/<4YS8SAS+W=#1W8P
M<78V4#A!<E Q;F<Q4%8T.&%5,S9:14Y/3&=V83!6-6<O-59P*VQ$+VE(.4,O
M<%@V=CA8-E$K<2]74"8C>$$[<71(-BMT.&9P53E4,BLQ-S5*>59+=R\U5E8Y
M6E0V:"MG=G)00U P+U$K<#@O5#E74# V8TXK4')E;G@O>75.3C99<6AM+S55
M>E=4;"8C>$$[+VAY=D905W(Y4G)X.4-4:'DY=G$O<3!R*WAY-U9X5D@K6"\K
M5F$O<$-8+T0S-D<O4T@Q6E!8+U(O=T)6.6(V<#A01&XV4'AE;#EM;"8C>$$[
M9F@V67%L,3$O=T%Q5C1Z9E=V.$%$9DAJ1CE9.5@V:%1H-E(Y2&YY-V5J6&A8
M.6YP=&EQ<%IF-$@O=T%B-F(K:G92*W4O;S(U+U(O,28C>$$[5#9T.58Y3W1P
M-C%04R]E970V4#%F:EAB,'9S-U9X5D5T+WEQ+W="0SDU9F]4,$]5=C92<CE5
M-&,K8V9R970R<C9N<&,K6#=81W4Y328C>$$[5E<S=B]+<79Q1VUF6&8P1CE1
M-7EF;V(Q=G%F;S@V+W9F<79,-&569G1C4'!X5D-8;B]+;$MY+UA0.$YC=G)%
M;G(K=#E1<CE:-4PV;B8C>$$[4&PO=7IL>#56,W)3=4MO,E O;%8S<C)(<"]O
M5#$O5FHO4FY(-G!Z.6(Q6E!4.4-M+U Q9E4T.&0K6$MM.6-64FQT+V=B.4Y.
M.58O4B8C>$$[;C9C.59U6'!F5B]R9G)C6F5695 W>FYX.6%V96Y0,WA60C-V
M+TMR=E5S=G(S-D0Y5# W8CE(978Y57(V9%I0<6YO8W8R95AQ*VQX+R8C>$$[
M>7509D963%1V*U93+UA"*VIF,$(Y8S1,5#9V.50Y6# O<DDT+UDK3&HY87!4
M+VEZ+TMX5D<S+R]!0W(W.49Y9E@O,%0K:792=%!6.28C>$$[9C9T.5@K<CAJ
M.5,U8R]G.5!N6#!E,69S-'%X=E<O.$%L5$@V5#!$-GHK:4]F,70O<6YP9E5F
M4C4O54YV6'(K>#E8.4QH5'8V6&)J:28C>$$[<5HS9B]+;D]4+U<O.$\X=E)H
M-2MR.5)R-D9%.4-V3#EI;G X3S,R861S5E=N+VQ3+W%I=BM(4%8K='!3=C%(
M;#ED<3-$,SEA=DQJ*R8C>$$[,3%X5G98=BM69"]53DXY9C9N*VDO<G9W*V@Y
M5RMQ8W8P8DQZ*W1C=C-0<&9O+VQ8;"MX>#0O<S1Q:G1-+W=#5F(X6F8P6BMH
M=4Y,8B8C>$$[,79Q,S%7;%!52#%8;'<O-',T*VQ8.7%N2&9&55!P2"M"=CA!
M1G%F;U0V=CED*W(S=DPV:#E8*W(X+U=T+W)N<2MJ.%@Q:FPV3F5F8B8C>$$[
M<"LQ:7),8U9D:7(O05 O6CPO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @
M/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @
M(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3 N,#$\
M+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @
M(" @(" @(#QD8SIF;W)M870^87!P;&EC871I;VXO<&]S='-C<FEP=#PO9&,Z
M9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U
M;'0B/C$R-RTQ/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @
M(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F1E<V-R:7!T:6]N/@H@
M(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X
M;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@3F%M93H@(" @(" @(" @(" @("!G
M.3ET-C8N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @<G(Q.34V-S8F
M(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#,P+5-E<"TR,#(P(#$U.C4P
M.C$X)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#,P+5-E<"TR,#(P(# V
M.C(P.C$X)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL
M;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E
M.B @(" @(" @("!"87(@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H
M="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE
M8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H
M92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT
M.B8C>$$[(" @(" @(" @($%R:6%L350M0F]L9"8C>$$[(" @(" @(" @($%R
M:6%L350F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E
M;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@
M(" @(" @(" @0TU92R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @
M(" @(" @(" @(" Q,C<M,2YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @
M("!R<C,V,# S,B8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,#$M3V-T
M+3(P,C @,3<Z,# Z,3(F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,#$M
M3V-T+3(P,C @,#<Z,S Z,3(F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @
M(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'
M<F%P:&EC('1Y<&4Z(" @(" @(" @($)A<B!#:&%R="8C>$$[)B-X03LJ*BI4
M:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E
M(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF
M(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86Q-5"U";VQD)B-X03L@
M(" @(" @(" @07)I86Q-5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R
M<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @
M0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID
M97-C<FEP=&EO;CX*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/G)R,3DU-C<V/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC
M<F5A=&]R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @
M(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @
M(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.
M4&%G97,^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC
M>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @
M(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z
M2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI-87A086=E
M4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS
M=$1I;3IW/C(Q-2XY,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I
M;3IH/C(W.2XT,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU
M;FET/DUI;&QI;65T97)S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%10
M9SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @
M(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M
M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F5G=6QA
M<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#<N,# \+W-T
M1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC
M;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;"YT=&8\+W-T1FYT.F9O
M;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86Q-5"U";VQD/"]S
M=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M86UI;'D^07)I86P@350\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO<W1&
M;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N
M4W1R:6YG/C P,2XP,#,\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O
M<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YA
M<FEA8E]?+E!&0CL@87)I86)?7RY01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A
M9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z
M4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y9
M96QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP
M5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG
M<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP
M/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H
M1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @
M(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(CX*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HX.$4V
M0T$U,T0Y,#-%0C$Q049#1$-"14%"-T5"-3%$0CPO>&UP34TZ1&]C=6UE;G1)
M1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HX.$4V0T$U
M,T0Y,#-%0C$Q049#1$-"14%"-T5"-3%$0CPO>&UP34TZ26YS=&%N8V5)1#X*
M(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C9"
M0S=$.#@P,#8P,T5",3%"-S9#0S!",S9#1#E%.49%/"]X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD
M969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HX-T4V0T$U,T0Y,#-%
M0C$Q049#1$-"14%"-T5"-3%$0CPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HX-T4V0T$U,T0Y,#-%
M0C$Q049#1$-"14%"-T5"-3%$0CPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C9"0S=$
M.#@P,#8P,T5",3%"-S9#0S!",S9#1#E%.49%/"]S=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD
M969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-
M33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C9"0S=$.#@P,#8P,T5",3%"
M-S9#0S!",S9#1#E%.49%/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 Y+3,P5#$U.C4P.C S*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#HX.$4V0T$U,T0Y,#-%0C$Q049#1$-"14%"-T5"-3%$
M0CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C R,"TQ,"TP,50Q-SHP,#HR-BLP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MCXBS>H!+Z<97,WI[P;!<$& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# /G,>)9]WWVW
M_KQF_P"<M\^B_@Q^#_@C\RL>QG:67S5'DH@]G>FP8 P!@'TG^BGW$73C^RMU
MZ_1'$,^;/#OW\\,_I7PC^]VQU5I\Y:>75^TR5.=48# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P#YS'B6?=]]M_P"O&;_G+?/HOX,?@_X(
M_,K'L9VEE\U1Y*(/9WIL& , 8!])_HI]Q%TX_LK=>OT1Q#/FSP[]_/#/Z5\(
M_O=L=5:?.6GEU?M,E3G5& P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MWW*EX?V@W7Z.('GC7])'WVX%^CJ?WGA)P>%?+I\GUL]$.>>'%& , 8 P!@#
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M\DX8)>R8L9=Q^!Q+DP7YB<# +#(=&>2I+D$#'\OG7*H-MY^^KZ7M>;,^X(,
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M-FFX430&+E"A$J>+ERKT&YC!*%&'G>V=?=$A,$& , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8!\YCQ+/N^^V_]>,W_.6^?1?P8_!_P1^96/8SM++YJCR4
M0>SO38, 8 P#Z3_13[B+IQ_96Z]?HCB&?-GAW[^>&?TKX1_>[8ZJT^<M/+J_
M:9"/OQ_IH#?U>!/S[*,_-\*^<I\A?M5'E_PQ^^ME^96/^MP@A)G&/R@P!@#
M-JWA[?YFV'_287^:MLYW!?D5>5ZD>B? O^R<-_.*/],V%9RC]H, 8 P#R&?L
MD_\ TS]9OZL)G_U6SSU[^C;^Q>$_SJQ_T6<[@OR*O*]2/-5GI1RA@# & >R?
M]C??<J7A_:#=?HX@>>-?TD??;@7Z.I_>>$G!X5\NGR?6S<?VDMB44Y7@N4Q)
M(2L2>2X<#5U,-%WC7ADZ$'7RNVB3=VRWU7X6&M^-%.5=M>-.5->4^>=N-M?-
M[:MV=%ZE)N4L9C&=&C\Q\(/"7"/!? K/A'!E9NTJX318M6M-55-RJSMJW"IJ
MH<S9TPYB)P("?9XW;^!03W$3_P ?SB\:M.31U5>T?CONP\*\C@?U-I_SC[/&
M[?P*">XB?^/XXU:<FCJJ]H?=AX5Y' _J;3_G'V>-V_@4$]Q$_P#'\<:M.31U
M5>T/NP\*\C@?U-I_SC[/&[?P*">XB?\ C^.-6G)HZJO:'W8>%>1P/ZFT_P"<
MSCUU[6V=:EJ!89)FL52$$&)IPON*%/6KWA0>+<O$.$UERSM/77E9'3A3CE#;
MG;3RZ\<Z\\^7C996]=I6J6J4FGDG."YVSM? GPCX?X0\(V/!;>G@RLK2FU=3
ML[.NFN:+*NNF&[6I9TJ<'A.69L<SEG[D8 P!@&L_QB?_ "V>T7]'81^E6!Y^
MF^!WX2^"_P#V6_[IP@VV'SM'2^QGSY\^@CLQ@# & ;:/ \_\RRA?]DW!^AJ>
M9^3^''X,^$/*X'^_<'-'"?FGTT]I[UWCCAFT=.]M>=]6K9=QSIQSQQSOP@EL
MKSKQSSQSQQSMQKY..>>.>..>?+Y,\#.MJ=VFJK.ZFXZ%)KU_;#(S_)J=]_C_
M *AG$XVN0^M=Q^*^[7@_]QMOKJ/8'[89&?Y-3OO\?]0QQM<A]:[A]VO!_P"X
MVWUU'L#]L,C/\FIWW^/^H8XVN0^M=P^[7@_]QMOKJ/8'[89&?Y-3OO\ '_4,
M<;7(?6NX?=KP?^XVWUU'L#]L,C/\FIWW^/\ J&.-KD/K7</NUX/_ '&V^NH]
M@V##7FI$<P(:I\I:OV35YJEMMQMLGJZ037X3VVXXXXVYTXWXUYVXXXXYYX\O
M''&<I.4GJI/V=G6K2BBM*%7136D\TJDG#Z).[E,Q@# & , 8 P!@# & , 8
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MXX3\G''''VN../M<<939ED?WT</_  %G_=D/U, >CA_X"S_NR'ZF =S & ,
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M3U3=NDV)-PS6<J+.6NK=!9-JCAG,88O"9C'*<)C*<]<3-3"G,R7@HP!@# &
M7M/?XX'_ -%8A_TV,RO\7R+/]BDU6/R'Y=?[3+)R&TU.^-!9<[J7I8I-*ZE,
MZB4B97;2+7E]7)TM'I60%O)PR2* &+P,1%NW&AQKQN/5&[O4FA'A;5JZ\J.^
MWDRH2JJ2:3459J5\EXXZ&%>7G]3(O'^],TL?Q*^DC)[6G<'J[5HFLNV)ZQ(3
M?<=VK:/V4WCM3/Y"P-I1*-3J4B)IK"=Q2KK5P8:\.0K]XQW&:[+.-E$ZJ?B5
M-W75-*48M9[843HB7FZEA52HR<+7'!LO+JUXS@OL!=-+08Y!ZFCT,[*%YP#J
M]"'7Z"G]UP E%&Y)]'F]_54S!,-H3Q8S$8LH 5%FBR8@@NQ&E>5='/)!%50Z
M55F[N+^*U3#Y-3<.-N"VO855RUAFWDYB-5GC[X8NKUIXM4F,=J:VH*S:VHL$
M'M4Y:H)#2J>RT?NZQZ?7K4$<D37>YAD&CSV LG4H&@U-T@\9G90B#Y76T(Z[
MNQJS)<Z/BNI-N(SH=*:?);>,:Q#V8.0J\5*4.<$Y:C<YV)8^N-%K=]^TG8N-
M>'K<D=K%S0W7"[_$NZ^Q>#3*)W@8YL6;0)A.IM$"T*N*"AP )@G&++2&DC/H
M="32()PG&-AAX>]T=@RKNW$E:)Q4Z;.IXTJ%5":=+EXTS#<+'+:C%U-I.(4X
M0\<)7-G[S@S9IXKMKG*MZ26FC ;*D%9W/92L=K"BWD,8FB4^EEHR0VS<#(!
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M +9%_P#/(9:<UTKM,:_D5>35V,V/YSSJ1@# & , 8 P!@# & , 8 P!@# &
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M<E_H[Q^>16;+/.KR?]U)Q^$94>4_V69LS8<<8 P!@# & , 8 P!@# & , 8
MP"I./XK'?S@C_N9Y=BZ7V4F*^55_E["FY#(8 P!@# & , 8 P!@# & , 8 P
M!@%2*_PA'^8C_P#DT<KS\U/8B++SU=K*;D*, 8 P!@# & , 8 P!@# & , [
M#3^%M?YPC_Q-<M.:Z5VDJR?0^PS!F\T&L?.O.X//T8\7VW #GQ 8J2K2M][
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M;,*?BM?6Q0;A_,K>G\>LHAVJM5P+/%(-5@BO(L+/ BE0G@Y\&*86),Y.]>L
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MVYW5:H<\<:YBW,<R2ZE!FE$\[;ZR160HP!@&9*9_C.2_T=X_/(K-EGG5Y/\
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M>AX0%D-AS:V#T<AJ#$.,>(""UAV%*)&XVD3^2%F_#D<!'%&48 @@@X"1. ,
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M%635ZC%4THZ8AU*)48PU..*R#H3<SG$X)S&S'#;IZHX>?#$%..V2G:5U<BK
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MJ#)T)3'QLL*<)QAWJ5SZEG&^TS_HOUC=]@[7K_MF2J<5:VHBW%>TEA54;O6
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MB2#,B=C[O8BA$8>@>T+HQ&-:"@EPE.2:6L/-3G&?6]69NK.KX54$9>1" "E
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M7#!F]D! >V<O>6S==QPU05W7\P@LMYOS:>^VH0WDI.2"V17=H"'$@K.>PNQ
M+0BL'=&X+*0<N$-BS=LT>.!;@D ?$&:)%!F_8.UF2BVKE)L]:+[I:I.4=]P+
MTP!@# & 4P*:#R00+D$>+##P X/9E@IP*_:E!!@41;INQY,628JKLB ]\U52
M<LWK1=9LY;JIK(*[I[Z[<@5/ *<^,"!CD0R)%1H]Y("*@@ T?/FK1R<+(BB1
MU46(0<*IJDB*00*8,*,F6B[G04))$-DN&C!TLD!:4>M:KI</DI:*63 9.*A;
MAXUF)./3&.FA\3=#D57!!M)7HTBY; G#%NBLN\1**-5&J*2JJ^NFB>^W L/1
ME3 3R#2N*ISN+S.*22#K-'C]&9 )$',155@.V7U(/4Y".>.1&[1ALV<ZO'.K
MSE%KLW7X7WTY24XU$.H>LNN8KI%U)//X3'-)N];#87N>E0(/I+R+U-)9F/B^
MQ!^WX/O7:2R*K9J)Y=KKIJI;I)[ZJ:<\A#T+E8F!!1P6:#"@XBZ $=0YULQ?
M-G;@*7W&#C6@LLBW544&D=PY@06U8O-47.PPH.?\)<M7S954"HX P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & ><"7?YUR?^D)K\Y.<ZFOY=7E5=K/
M#N%?VGA'_OMO]2HS-U0^Z#K;_:);_ILUFS@_SU'^;]FH[3X.??K@/EVO[O:F
M]G.R/73S2TU<%20CL+VJ$3SN-X6=1*H>(!>3PG5G9>L8^7[)O!:TX%J*;AYP
M6[<5EZ*X/MM5$H.\<5"7;AG6R;K9"3)I;-5!M:<+XM;^*L4W=RVJZYY\>HKE
MA=A[5DMU=FJ+,=@9%8*=BL^]=>1R+4[-X"\)UT%@U;67(X='[:ZRS*F(E<U'
M<PD?$Q\4CU[1Z46E!+Q/R:(&_2/(2X8+J(&.2324X/;GADYASM6#6*C"2@4S
M<5@F_F)K.G.R!I*$3@AX;5;.K4@J52R*5DH?,NN7:<Y8H!K,N(46%.W:1ZOQ
M@%F]=,GY"%.@.R(SEB31)_&@A1,8N]ACL:V3L4F0(]V#["T]&(G;LN[)WA9@
MG:V?%?I$_%GD*JV8N/F_Z3;=K$*FD<9A\>A4)>RRXT=.NX$B0>/I(S2GYB1F
MPI/AD*<B$PH-++FH?6J9E^?S=<Q8G'8BPK8J?M;7\C[+D)95X6A.H=]\RL1?
M5.7<0B9A+LZV864:.V#7E*PFN80GQ$6T?E,VKL,8G\6@;1@!D#,Q'1!YRQ(A
M$).[#O1#37:^[&9E1$GXMVV[+F.V.X!A?%>JNF_;T;4\/I([=05X:L3K'RR8
M<A):+Z_P[J](IJ=YLBM-EKY"=BV]SC*^:&'FB9J21FM!!N)-@A1.,1GLGI;U
MPA+)KI*CTWM52W^V?0J9R_LZ:N"^#W3WM-).Q=*E-H+IIUON \6ZO[36ODXM
M%HT&DE5\1F4LI!73>$3T@5)OVE?I%T-UC*$M/2 *E">$*5&>*APYR<YRH3G#
M""1O=FAUB':BA@4*FQ:O(?XAIHQUM[@@ +=1-6RH-3=06+>X R()M7X]Q$YT
M<A59R_KK*I>TT=E2=265PW049FZ^@A$2(G*::F[+7-+2ZI<QKTLAW3W;OL2
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M^AU?FNKU/3^M)C8,;Z$59W1JB8V[:/:J+U^<.>@6R]=/#S1[7I+5\E5U0HS
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) , 8 P!@'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g67046g20z22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g20z22.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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1 * "@ H * "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g67046g22e33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g22e33.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1?>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %\*^8((X0DE-! 0      %H< 5H  QLE1QP"   "03X< E  "')R,3DU
M-C<V' (% #E-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52+F1O8W@X0DE-!"4      !!*(AO,67Y-JX&8@6+2
M3VS..$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           !?@  !+8          0                         !
M          2V   !?@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !?@    !29VAT;&]N9P  !+8    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   7X
M    4F=H=&QO;F<   2V     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    '.$))300,      U)     0   *     S   !X
M7Z    TM !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M1) *:I^K=Q(/[8ZB-K=K1ZK(_K?S/O\ ^N;U.WZN>@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^% %FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( , "70,!$0 "$0$#$0'_Q  >  $  @(" P$             " D&!P$%
M @0* __$ $P0  $$ @(! 08"!0<(" 4%  4#! 8' 0( " D1$A,4%2$Q%E$*
M%T%QD2(C.6%WN/ 8)3-2@:&QM20R.'-YLL'1&28G8N$I0D9RU?_$ !L! 0 "
M P$!               $!0(#!@$'_\0 1!$  @(" 0,!!@0#!@((!@,  0(
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MC^..(G/$1Q$<1'$35-ZSN2U=2MM63#861L>70&MYM,8O7PA)XN5F\@C<;)&
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M_O!UUQ$OZXB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB)TDAD0** RTFDAD6
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M S>H.]>#BWY3UKWNM%;6=J^.YBH( WP-GD@@>#)&/BY.6S)C4V7,H[F%:EB
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MI&B8_(Y+;EJ02 "XG'G,K._B.1C&)%H ;;>[V((AMG&2[_5=S[#%BBP8NG!
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MCALZQ36GE30C,&5M@7B?]&=-:PC69U6MDJ_S4X&P7?GP<D_*N^0BAD/K+?\
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MQKS)*[+72JI2]ECJB( 2S.Q[550.268@#\YDB-8ZUHI9W8*JJ-EF8@!1]R2
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M<<-'L6J6Z[ET[>.E$D&Z**2>ZFZBF^,:ZZYSZ9YDB/:ZUU(UECGM1$!9F;P
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M!6J6@T (:,T2,7@I^OB&Z"9_.@@?_-C/$2V7B(XB.(CB(XB5!>;T_9:'1@Q
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MSQ$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1*??-1_V>NLG_ (E7CO\
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M=G(YTNSPHW_A4:5?H )N'D6:(XB.(CB(XB.(CB(XB/7&/OGTXB:9MN_ZIHY
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MSG/LZ=@J\VVSZ8_9KKKMMMG]F,9SGZ8YDJL[!45G8\!5!9B?H  2?Y">@$D
M DDZ  ))/V V3+5Y1W?Z9PO5?:5=L.N0+=OC;*S=_=-=)/=/8QZ[_P#0,2+9
M[MG7'IZXT0VSCUUQZ>NVOK/KZ1U6[7NNFY[]W@KB7]I\?XNSM]1Z^HDM>GY[
MZ[<+*._!^'M /Y,4 U]]ZD=#GF(\9H%=5JOW%J<JY1VWU4:Q):03EWC.F/7V
M=6D+!'W*N<_;3W:>WO<X]$_;SC..3D]EO:%]:Z5DJ/4VA*5_\UKHH/V)WYDI
M>A]68Z&%:. VW-:+HZY+.ZJ////'KKG4#N[?Z1!UFH*HV\OZX@95V'FA22L
M#%F<K^WJDK\8V<,WSYT6)S*<UV&1(J:I,-F[ &$T7(/U5]W6%46#)PMFYZ3[
M#=1S,@IGO7@4(C,S)=BY5S$:"JM=.0P +,"S,> "O;W%1)^![-9>181DL,>H
M*?F1J[V+ ]H 6IV  ))+,0OR]H(+">]UA>WCYM:DB][WZ<4H7I,>=$AS#JK4
M$ED.LGO5_%RCB/R=W>=O9'1DQO6JLB&%4!%=P)L,:F6.J.90?=N6.$UL.HC#
M]D<JS#P4&7U=55FZGE)7[O"6W;5KA8X:Q1DBL@M?:Q*LWR+VF>Y?PO0+FHQ4
M&3U  /\ &7JA7&#:9!31\P]X!IB]G(VI T>T7O0* P:KHD @-<Q2/0:%Q8:@
M(CL3BPID# !!K?'HDS'"AZ*#-HCKG&=MM4DM<[J[;J*9V54WWVXZVZW(M>^^
MVR^ZT]]EUC,[V,?+,[$DD[]3XX' G.6667.UMKM98Y+,[L69B?J3_0> -
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MWF<9QG&?8QZ?6H'LIFD#>#E*>>!U+HQ\?<W_ )>GVD0]%ZKQJFGG_P#)Q?\
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M;I%=-311%9JN@FZ16T4151T4TSKSTXV0'-?N;"ZD!E5&;1/CE000?0^#Z1W
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M \[U^X]PR;-&N@E/W^5W.X_=;XE==TJHXWU69N38[.;74L22%=M#?&ASX
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M[?M1QHY.<7B9ON9,<V&K&/PP:)P)C'VT1AHL)+UG,^<#PTC4DF1KQC"E'2C
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MT[7#S>FU8ME=E'82'[JRIN-I((73GY@-< $C7!UQ,&2PL"'&A]>-??0'^_\
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MDYH$R4<HIN-\[(FC6WD+V);^,0F@$KB.B>^91F"L !*["U:6)4,F/=3Y9V(
MQ,;'-&*+<N6:R0*"KZ1_.7PEZP)2J,,V@-X0DS'X5$M Q]L>OW],>OI]O_7_
M (\1.>(D+81VD=R#O=??3\JC7;5I6%!4-=<2?AYFH3GIS%J26WHY*!,KB:[-
MEI'5HJI7(0DV:L%36RL?F,;.$'[7$A8C&B)-+B(XB4U=D?)M+:7N6^J4&A^O
MNAB 23JX @\@F-K$1X00SOO]9>LAE-UIM12#J)LHDX@#%BS%BOB4W3V:1!%_
M(&BAQ!-%$LIZVVTZOGK_ $K=;Z.;Q%Y;%602Q',84<[O,@7$OC8XXL*T>JH-
M%7J#-1[E)L\4:-MW+?5-?=!'93*6B)NSB)2-V;\J4RH^V.Q5/B@G73YW5<KI
MP3#SDUMLF+ (@IY3U[VO)"-J*-0^CJ-&$'5+-80 #C$G370[8,6V(%W*RZ8Y
MRB9MT.\FLO[BW6M7Q:JHQ @!6II98HP(UE),K:U</X"<J2.$@=TQQT+8,HY^
M/G-I*G:S4:[)K$HY%23I9%SLOONP1+@\?;'K^7$2CGLYY7IC1L_[(UL,C_75
M4Y3MD12-QDE+;>)#P:D8?]=;1OHLXL)9H&T=Q^9%7=8*UQ&8^P;.&*$JE(5%
MV5)+)[L72)&TCYS[-V6()#JGH2,_/MYHYC>\_MD\+Q42%;+7/J7C/9/#>/Z_
MA*=67K3JR=3"!N44B+J3CDG67N&F=GZ)]#U7312QZSKJPU0SR.*SV"Q&:*1X
MAG.S\"I*(^/.;AGVV4T<Y>"]GV6+G.4DLY60WSE/3_JX1,ZXB.(FDNRD+L2Q
M^O5XU]44L_ =J3>I;#B=<S7+Y^+_  I-Y!$RPJ+R#YH*2<%!7RHTZ9/,E!B"
MY$=A+XUBBJ[013V1,+ZE5A8]45L?C]E%,.'I6U;4E\2C:<E)S)"N*[E<T*&8
M37#:4F&[4@91C(9RCI[:J6&HQ1TH"$[K"!3!7=$E#Q$K<[%6?V\AO:&"#*UB
M,K,T0V$4\9-(QJNTI<+E31[*KOT[*-I+($ I,S'#U>UW'Z8.5*%$F(V^G4ME
MI4&S9391-02*1(H6]>/DL;,NQIJOHY88G0&A,W]<AM.N:DO7;J,;X!#*4!UZ
MV:1A<E*5K+Z^[F97:I0ZK-4*ZE">0ZS>$D=FPK1$O%'.]"#%F^3T<I)/&C9T
MFF]8O!KS31PCHMIHZ'$$&K]@YTUWQJNS>MF[MLI[2+A!%9-1/5$UC?A:S0-'
M7$<I4,WD5P!JOGI2K #M))=L:L-A%RCJ&"UVZ[ED@Y3?R%(>UV;+/62+C"ON
ME7;9/;9;1$K)EEX=WQ_4*[WT=$V^O?<9G*I6CY ^ZT$SDML2I-YH(%#&<@@X
MB#BH\!F[Y-O,$'C5Q#V#P5"VL?E#\*V<'F9/=$N(9.DGS-H]1U<Z(O&R#I+1
MXR>#G>B3A+19/5T/((-7[!SKIOC"[)\V;O&JN-D'*"*VFZ>J)[/$2&_:Z;WA
M"I+U<4J'\3N@![L5&8_=@J,U*8LA1>H" <XF<)E30H0;Q A0<O@&JN7^&;/W
MGQ6N&A!JT8%-5D28^/MC]V/\?7B)SQ$ACV]G-ZP9[UO=4LE)GS$OV*A *WP\
M:J<Q9*CZH2*9%&4O2A42(-9@@D1OE@Z<G,-&Y!QG=--@0:IMWNJZ)A70^<]M
M)NQL%QV@!GA.6P^LEP7XFA(Z"OQT^)QTBXN:%@&0\6)U/UY"Y&F&8PF8+X.J
M2!!X2W3E\F0:I/$T2P/B)"KN!.[[@A7K.YI-*3/QAGL3$P-RAHS49JR5'M1$
M!Q?0^0*F10DWB!AP[_ I5V7U:-B+S=PC\ 39M6)1)RB5D1>\O+F]'1M0M YH
M@Y(1F($%-GE,@6BV_81U&.O#B=TH?0Q$T\ ^N@232*_V06X_<LG+]K#Q&R%N
MEM,LG)]$^@S'VQ^SZ<1(F]G)I=<.+4FK3K,J9R7F<_%RZ,L:W.3 8<0WHRT5
MJZTE,N$LGB%:1E.Z4:T;%3[U04DX2(?]+.BX\PD.RR)4_';U\N[A]G#& S8Z
MCK(*3VJ[2;TQ'H>WLAJ9"=9W': 3<ZZ,5"J5:+JHM(.R36GB?_TZ4G?X2 IH
MG['13'NY0B65=#9CV;FM>STCV5821N^:S6&MZX)S:#L*XF1N,ONO5'G[$R=A
MX\''$QR$9['FKS@L8=+!&2Y2(14 _P!',C9K,YC)$2='$1Q$<1'$1Q$<1'$1
MQ$<1'$33$7[$T;-;/FU,1*U(3(K2KA#9Q.X.'.M'YZ*Z);#]'&IILAOOJS<,
MMBXK4BTW4^*&[$V&'Z+;+QOA1$W%A='.V=,+)YWQC.V=,;ZYVQKC&N<[>SC/
MKZ8QOIG.?3TQC;7US]<<1&'"&<8SA9+.-M,*XSA33ZIY]/13'U^NF?7'IM_U
M?KCZ_7'$3H\2V*[2)6(XD@+,J0"-9*O&\%F&3J,=>OW0MF=5$^_^.T#NB3%Z
M/;D=D,-%GK1RV36V614TU1.#DMB\:3'*2"1@@>A<T-C@K<N58C]24@,;;:"0
M;#+I=+#LN3WUVU8#F^5';O.,X014].(B-2N/2\"(DT<+-"H$Z-2+B23?;;5!
M\-7QC9%ZEA;5)7"&^NV,XVW3TSCUQ[6,>N,91.EG=F0FM1X I,CJ(AI*9O#*
MYCV<-WI!8M,K D3&+14*S:#&SQTHH^,$$,.G/N<,A(Y)\:+N6 <:0?MD3J9[
M=E35:5KD'8E@Q6&E[<FC6NJS8'RS8<O-IV_8N23&)Q_"V^-7QQZR:.%VC+3;
M"KG&FJ:.NZJJ6FR)A<%[6]>+,L0M55?VU$9G.P,BM:'' D<>*E?DLSH]Q7;:
MV(:6(M45!0^6PC>UX#N8C;MZD9T;'M7:#-=LP**L420W$1Q$<1'$1Q$<1'$1
MQ$<1'$1Q$XSCU_;G'[N(G/VXB.(F*+P2$.BSL^YA\7<'7ZH==\:7CXE4L]6C
MKM-_'U79%1IL\<* GR23P,HLMON,=)IN&6R"VFN^$3I-Z>J93Y/A2L:^WQ'C
M#N0@,;PR-[8!'R#MN_?G WJ,S\L,/G[1J]>$V7N'KIVV;N5U]UD4M]438OTQ
MC&/MC[8XB=-((]'I6+<@I2$#R,(\V1R\#'AK(N+=[-UDW+?XD>01<-%_<.$D
MG"/O4=O=+))JZ>SOIKMA$QM[5M8$B(XR1KR"/RX8QM(1!5[$H^Z(B3^V!N-C
M@U\N/4=,2^=0X?&Q-LJD]SJ+&^J_HQ:^Z1,\QMK],8SC[8]/K^ST^GW^_P!,
M?^_$3GVM?M[6/7\O7'KQ$Q)"!P5I*WT[:P^*M9P3:Z,"4S0CXA&5OV*:+1NF
MR?2)-IJ7=--&[!@WT;.'BB&J+%FCC3&C9'71$RSVM<?3VL?3'[<X_K_]L\1.
M?:U_UL?QQ_7_ .V?7\N(FO']2U25(GBY.MH 1*RENDTDY-_#XZ\(21J@HU51
M;'GKD:HX,-T56+)5) @HX2349M=]--=D$LZHF?(HH-DDT4-$D4$4]$D4DM=$
MTDD4M<:)II)Z8UT33TTUQKKIKC&NNNN,8QC&/3B)^W$373VH*G)$39@C65?/
MRTEV:[R,F]AD<=$#^[)PV=LMC3U8;NY*Y9NV;-TUR_5<>X<-6RZ7LJH);:HF
M3CHM&1!8J>%1X&-.'=&:9LRP$L&94PF.2]P/T*$&[=-V0T8H?S+/5VLMALE_
M-(83T_D\1.^XB:[=5#5#Y^:*/*RKYT3D;IH]D)%S#(XN^//6#C5XQ>&G:HW=
MP4=,G>FCIFX?*+JMG.FBZ&^BNN-\(GMO*QK@C\[^80&%OOQ,]'DI)\9%@3G\
M0$A&VNPH@;]^PW^:OAFVFFP]V_\ B'#+;37+91+.N,X1,XUUQKKC77&,:ZXQ
MKC&,8QC&,8],8QC'TQC&/IC&/IQ$YXB.(CB(XB.(CB(XB.(FJR]YTR M".TF
M;M2OQ-P2X<L7C%8D)8$:SL\+02(KJ/Q<76>Z&'C7W @NLFLDTVT62%$U$<J:
MCW>443:?M:_ZV/XXXB<>UK_K8_CC]N?3_P!,\1.O(&0XC<<F5*C1FY@DB&$Z
M$'S5EN4+N$7#EN*':N54\O22[=F[718ML*N546KA71+;1%3;5$]Y19%%-199
M5)))'39555135--)/37.^ZBF^V<:Z:::XSMMOMG&NNN,[9SC&,YXB8R!G4+E
M+QR/C4JC\@>- L>DCA$*68D\IQ^6:$%(P;]MFLLGN*D"8HDH(?I[[MB";)RH
MV44T2VSA$RGVM?K]<?3[_7B)A,-L>$V!&5IG#I(./11 I+ VY]GLKH.^80>1
MF(E*D=%W":.JJ0:0@# QP[2QNS55'K+-EUVV=%MT35B?;GK$YC5>S ??-6%H
MY;8:9R"JR868"#B=EAZ[$OCDY>0% 0Y>.YCB*BQKYV:0CR!!RRU:K)JHX6U]
MWE$WE'I %E@ '*8V39FX[)0XT^!,CUM7# N%,,D"(LFQ7U_DK,W[%R@Z;*Z_
MR5$5=-\?3;'$3N.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(E04X\<UPR
M& 732HR[ZO<4K/NP1KL?&8G+:9DY R^D,NNL9=,PK6X3\>MV-M[!JDL1UD '
M<<,#Q@T]"DPK<N0?HQQ5L=1(R(>#4\S8/%&':,J/F;B()U\UGK2,2;4H)@+G
MIO-^M9B""6F]BJ+M8@YG,AC%EM1N3.Y)$=!8^#6.N#3)C*&B)Z,@\'TYD%@2
MB:)=CX_#A$JH$A3*%=UQ )=$H- /F(AT+6'05HYLL_(4J]PZ<8DZ,2?R79)G
M,?;D(_9FX38HLD3-7_A%CVTC,N!<Y@K6)G1RL/V#+UR;W.QZK6?=)UVE"UK%
M9.UG;-47&=XD9,5,;8+LG:3@>B)?#_@&:"XG=$Z?7PE&U+FN&TC%UUY*@4T[
M"TW>E=UG(*.22AD&WJ*R9W(QXTFRCTQ"[2(VI7UA%:^;2I11 K[#!J2?JO6S
MI46V1,?.^#JP#(;<5IVG8LR.E GZC93M*!3'%CCG1CK=.^OR4:92!.UTQ+>E
M=3,S3O!["DXU@^XM$,U(I2A#U1<-42::71245+6]2P2IW(J01RL_(#GLA'H7
MLEJ$&PVGI[)IB//P\#L7*ND5EJR#V6;F@[7XION9<@E!XIDD^>L6^R)$0/X,
M_DT$CD+'WSJ-5BP:OY.!.,HB47=B>R-<4G+8$ OQFD1EKST-ZV4[KNS7 [97
M35TG7S6/*NO8>Z/FB)N[J]XSY;U;O^L#HF7:3>"#)I<-XSB;.FS0&>?V3*NI
MG4CJYN)+B\$GCL\4M*2UA:5[261-$&HL<559AG*.SQPT>.D2Z+'VQ^SZ8XB<
M\1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$\-\>N/3T]?7_=],_[/ZOK]/K]
M?IQ$H 3#=ZZP'7,<BE8=JENQ$D['3[6T[G;26"W) 2_6XI;5CEZ:<]7*2L>\
M!=8,9#&ZZ_53$C YY 8B0CX%::.Y$I*)*W8/'2)[X^P?-PU4F)TQ XD](YKI
MP$"5R.AU>[1X78J'1BC[#<S0)*U)LU?'=<]P7UOU>#C)@XE'723+X1Z:4":"
MI*V1/67LSS,KW XCX"$/M*3<=<3KF*SR>U[50NQ'UI9B)UR$+R^%P\O)8O'K
M#;3=(,R6 :3-I!"$9]_G6&,"Q%-R+1^_W^_UGXH9\P+><.W2TDG^SR116FJP
M9$=:XI-_6@!,!Y$Y96MK7>0C"AALX'6*4Z6%HS<[ 2-;+1<RF\,M%F[=S"XY
M'FZ)U3R4^8V87M:HD_&K*@-"U[VUIAY6,A@PJCB4PL&D&-H6?$;%;*LG"8-D
M[A)B"[U;8#X>7=&)"P9J%O9..'N'D5 HG6L)AYF(7'&4<AU7FM%P%%6>]!"2
MD<K6510K*4*IO8W&7TCL"3V>1L?%KHWDSI6,Q2#Z"7D',P4N5?GR&=U%W8%$
MD58Q/M7IT^FH[M0X=/'T:[L=:!+^:AXZ'AR\MZVNK\ZZ').<( XF1(,AT>&_
M.IK$9,XQNBJK!X\2>&]5--B!1TB15MB#>8.]HJ+B,A?RJ,F&=K5?<<'E4+0C
M=8:0PK%W?=07FO)8ZB$EU7FU=[;P7JG*I>RD"3],YM:)!ENR5$I[" :)^]0P
M[ND%NV#6CV*'V!&9_P!@N\W7FT857I::;RJ,5?&#=!]B=+IJ2.-1Q)^*%@:V
MJ9,0 E>S1LT"GK"&H'T7!%Z\2?;HGT@X^V/W8XB<\1'$1Q$<1'$1Q$<1'$1Q
M$<1'$1Q$<1'$2L:WNF%Y22V.U,JJBW:^A$5[;UB+B\I-FH1)W]Q57,HC44IJ
MZ)F:KE\?EX!LU![+E@LD>-'R+<H'?(2K< _2>RG0@'1(?Q?Q"7 ,>P"0O;_%
M@BE=3!E.H-$H43NA" 5F6T[$T!9A05#FTCL0V8-!2M95?9L-<HS!V0;IF;ED
M>S$8Q Y48[HG5O\ Q"]C71>@B;?M6F)Q4'8.2VW,EXV0M(87N3YU(:V+M+ E
M[Z72BQF(^U=!T(+ R@Z*"(_#'8R5$F3#86T=F$"R)D$=\.DH!E*V.$[3CDY>
M0>T^O]RDQTY6M(Z'/6#5DQOO:6R9OHXF>[@(2.5M;$/C8%,?E(8T>5J):D6"
MH?=%-!$Z#;PW6[H:Z?:M>QPY"(TC%BXR]QB[2<$C5WFYH]D3&RW2APK)7SYL
M$FD-.,8]L"PX%M1> *&-=7S1TQ2 (G1*>&:[VM10ZL@=Y5T,#Q&L:5KA6!MV
MMU"JU..JMA_92(NINZ2C-E )<SD&YFZXG; 5JS/8&Z6! T4G2:(W0*X%(DUN
MK_CWG/7SL1M>AB\"]A/"PVW8_-=S1&8N'\S!2UO2.:YT?C"4@(1<>]A1:NY\
M;<*BAC;W[^QR6[57U<DMG")&:G/%]="+FDYY++#4@TPI,?!:]8 DCTF>CRL;
MK:T>SVDWD^S".RK>*/\ '8. 6I"2VR9T:\-@\L5F)KW!!+9%)$Q2D?#=..N)
M.DYLSM 59[?JZ!$*5/5S6/?)TV2CWJU/Z^O>-1$F7*MV++>^;^D@:R\.#KA!
MB$'"T!#UUG3719JB7%=0*NDE(=5.ME.3%9%>65;1-50"3*-5-5F>I^)P@($,
M-V*R>V^BK!J09.&S!37;;&[1)';&<XV]<HDC>(CB(XB.(CB(XB.(CB(XB.(C
MB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB
M.(CB(XB.(CB(XB.(CB(XB.(CB(XB>.VN-O3U_9_C/\>(GEQ$XSKC;Z9_?Q$Y
MQ],8Q^7$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$
M<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$
M1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<
M1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1
MQ$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1
M'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1-96[<=8T37\KM&VIL"@<#A A8[)Y$==>
MY:#!B.VJ?O<HI:K/'2R[C=)HR9,6SE\0>K(,63==TNDEM(Q<7)S;ZL;%I>ZZ
MY^RNM!RS:)Y)TJ@ $EF(55'<2!S-U&/=DVI316UEEC!5"CR3SR20HT.220 .
M20)I#J9WLZK]WHB8FO6FW ]BAXZ83 R!#88>BL@"E%T\KLTB46EXH#(FC<DA
MKNJ+?*#?@"6$7.C%RNHT=:)2NI='ZETFQ*NH8K4M8A=&#);6Z@Z)6RIK$.C^
M(=W<HT2-$&;\SIV9@.J9-+(74LI!5T8#7<0]99?EV-@D$ @D &20FDZB-=A$
MY'-CS&. U34:CB9(CMOHWW.3&0C(I&!N,IZ*;?$F9$9%B&>N=<:[.WJ.N^VF
MN<[8K9"FJYUVDHNN9NC6<HFRF+%<)BUF\#CD6F4WF#A R-DI@<Y;QN$QZ0F%
MFJXJ'2<ANZ39[-VK4*\5=J(:ZZ9W1,>?]R^NHEZ38F9N7!J1\:#,RY<]6UI
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M1.&D21F$1Y\D6M6'[/'("! %@;30^X$N5%$L($\.?MP?S_VT8_\ ?^GZ_O\
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D<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g67046g25o26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g25o26.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1_Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ']Z^@5@X0DE-! 0      &(< 5H  QLE1QP!6@ #&R5'' (   )=I1P"
M4  (4E(Q,3<U-S(< @4 .4UI8W)O<V]F="!7;W)D("T@4U1/4DT@+2!&54Q,
M($)54TE.15-3(%-%0U1)3TX@4DE$15(N9&]C>#A"24T$)0      $+H<V!I\
M-0""T2_R-<C]?W@X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q :&            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             "90   Q0
M         0                         !              ,4   "90
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "90
M  !29VAT;&]N9P   Q0    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    (
M.$))300,     !5(     0   *    !\   !X   Z(   !4L !@  ?_8_^T
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M?LM?[SOP_N2&+7(]SN?+^Y6OL]GE]_\ L2^SV>7W_P"Q*P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                        _^% %FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR
M95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM
M971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U
M-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$
M1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F
M+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,"TP
M.2TS,%0Q-#HT-3HT-RLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @
M(#QX;7 Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E
M/C(P,C M,#DM,S!4,30Z-#DZ,C,K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@
M(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(P+3 Y+3,P5#$T.C0Y.C(S
M*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q
M+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!8W)O8F%T($1I<W1I;&QE
M<B Q,"XQ+C$V("A7:6YD;W=S*3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @
M(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N
M9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"
M55-)3D534R!314-424].(%))1$52+F1O8W@\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \
M9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^4E(Q,3<U-S(\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIF
M;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @
M(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @(" @(" @/'AM<$U-.DEN
M<W1A;F-E240^>&UP+FEI9#I$14(S1#4U149",#)%0C$Q03$V,CDU-T(S.3$P
M-$(T13PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M
M96YT240^>&UP+F1I9#I$.4(S1#4U149",#)%0C$Q03$V,CDU-T(S.3$P-$(T
M13PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#YX;7 N9&ED.D0Y0C-$-35%1D(P,D5",3%!,38R.34W0C,Y
M,3 T0C1%/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#I$.4(S1#4U149",#)%0C$Q03$V,CDU-T(S.3$P-$(T13PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP
M.2TS,%0Q-#HT-RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D1$0C-$-35%1D(P,D5",3%!
M,38R.34W0C,Y,3 T0C1%/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 Y+3,P5#$T.C0Y.C(S*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @
M=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO
M=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I$
M14(S1#4U149",#)%0C$Q03$V,CDU-T(S.3$P-$(T13PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP.2TS
M,%0Q-#HT.3HR,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&
M<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T
M4F5F.FEN<W1A;F-E240^>&UP+FEI9#I$1$(S1#4U149",#)%0C$Q03$V,CDU
M-T(S.3$P-$(T13PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T
M4F5F.F1O8W5M96YT240^>&UP+F1I9#I$.4(S1#4U149",#)%0C$Q03$V,CDU
M-T(S.3$P-$(T13PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.D0Y0C-$-35%1D(P,D5"
M,3%!,38R.34W0C,Y,3 T0C1%/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O
M;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_
M/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_  !$( 2X!A ,!$0 "$0$#$0'_Q  >  $   8# 0
M 04&!P@) P0* O_$ &D0   & 0,!!0,$"0H/"PH' 0$" P0%!@< "!$A"1(3
M,4$4%5$687&!(SE357B1H;'P&2(D)3(SDI3!T0H7&"8T-39#1%16M]/A\2A"
M14988V5T@X654F)D=9.CI;/#U#A(<H*$LK35_\0 ' $! 0 # 0$! 0
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MN5FKVNZR%^@9"\QDJU3DVKF9<6F-&#;+UAY"*.Y,'6J72N/QV%C4Q/2LZ5+
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M4G3CT8MI/7JJU24EG[M.-GK;&2G*,J;7NTDWIG;)1MVWLFM>_5:3=RJ2,AL
MV93<HJ)I^-RYNKJL&94AC++TU"WP<J*)7!N3>Q1D\\<HMDBB5(AG:R291\ _
M'W/15X^T73-."_ARP/1-6HTW95W1G&[6CE.DHYZI065F=$+JI46ZU-][2:O:
M_9;3QXZRO+\G0/I#TX#J//7@.0^;D-?5FX<"/=ZCU_(/4>?G$..@AY_$ 'J
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M?[;/0'KY!^_^0@(?$0X$.HZG5T_@6_=SP\<@?7ROM?']T\\/_>S\0'XA^_\
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M.1'X^OU\@''0>OI\!TYY]0:T-TLIAZM[M<.3VZ$M.2P2;;=GN$K4AE!E&/\
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M%8G0#%LIUY*01Y-K,/8MFKEMYR6U[SG2[W%[&TN%KW;MX]C,EL%(9ZM^1,.
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MC_IUZ:;<>*^]'\Q"?V"N6%0\2*4',' D#%IG[L8].!5"(CWR&[J(]TY1$>\
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MY20_OV09#)L(4)=B,L]C@*8POVD=[1[8Y9 4AC"Z11.@!2F$5."CILP[//\
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M(/G%F1DF#]R_+"QKE.2*FX,JV9V'VM-W//:#TR_I^3YOS>GKK< ''KS]7Y=
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M'OS\D2[W-+_>N0_B;C_1ZSNN*\T4>YY?[UR'\3<?Z/2ZXKS0(^YI;[UR'/\
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M!1JAVY#MX")=2JK"!C!$Y(R&:Q\:FH=%FD($XI))K+BT"XH0LH'0(AZ'ZT"
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M5Q<ME"L_*13#&6J?G+')O>DO&>X,G4,ST]6L8A$OF02/NP\@Z,$9)^V13H5
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M_=?+-Y6SS/0?KY$Y1H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H#
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M.2CPB9&1%9B@H+Z0B@91H1CUV)O:'4>$<P!FNHHV!DU!/P$Z"=: : : : :
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MO=VX:F2.N,P&@&@&@&@&@&@&@&@&@&@&@("(% 3&$ * "(B(@   !R(B(]
M ZB(] #0&*]IWT;*:18C5"Y;N=M%6M2;@[12N3^<<:1,TDZ3-W%&RT:]LJ+M
M%PF<>XHBJD10AOUIB@/30&1E:M%9N<(PLM/L4%:Z[*(@XC)^MRS"<A9% W[E
M9C*1CATQ=I#Z*(+J$'XZ GN@&@&@&@,!NU5^UD=H3^!9N:_S-W'0DM'W/Y%L
MNQ/^U/;"_P 'FG_G>:!:+N1LKLM<A;?7YBKV)BE)P<]'.HN48K=X$W+-VD9)
M8G>(8JB9P W?262.19!4I%D3D4(0P90G*G.-2#V9PDI1>MI)W3MH[-;RZF),
M'LGIL?)0"<]D+)MVHM0DT9:J8TM%@!Y48EVU.<S,%&9$4R/&S,#F(@V!-LD*
M1E6ZX+M5W+=;NETC5:FX4J%.K4BXSK0A:I)2^UG>RO;.RTNM]S%1M:U\KV6[
MY7,T   #@/YOT_DUYUDM$D9&#^^#9="[U(W;A V6:@V-:P=NGQ1N)L5;LM/:
MW:#R/"XY]]DD,=2<4_?M(]%E9V\R=LY>OFTNT10(H1>'>D5$@4&!>5>Q<BK-
M1MW5)Q9D3&6,X;<=NSVZ[HJ?4#X(C)7&&.S8"C*(W#'TQCV+M=<B+?7+G)T]
MR]G$6YJZU5;33MDX8NC*KN50*VR)V1T%N4A=GM9W:R.!,@TO;.^W)C9L7XLV
M^%P_BN]1><Z4I5:XE6:@UOMB)CJ;Q[)>RV]"?CWLFZ?V9JE+1Z<'(%3=)@6I
MR%V2^ZZYX=V68.5WKX\M>.=GC54@47+&W26MU!S/*U&<<A@FP98K%?S+3#VQ
MWB&F(5V*9PDU*252L%LASW69K[EZNW9LA'NY]+^6MGF;UJHULC&K5IE<I:,G
M[>T@(=K:IV%B58"&FK(A'-DIR6B8)Q(S"\+&2,F1T\81*\M*+1K59)FK(OCH
MF<JBD_T T T T T T T T!J [0%R7/&ZK9#LL; +Z$E;ZXW%Y?8DY.D-'Q<B
M[5@(^2 ![I6,]*(S+)0B@?KUB,P Q#&3!7Z'HG_9<!TKTD\IJC^Q8:]U>KB,
MIRB\KNG'8ED]&SHI+9A4J<%LQTS;>=FUW:<6;?@            #@  .@  !
MT  #R#7SUK<^!SD= - - - - - - - 6WREA_%N;:NYI>6\?U/(E8==XQHBV
M0K*7;MUS$$@/(]1TD=Q%R*11$6\E&K-'[8W!V[E(X 8-U#$8C"SZS#5JE"HO
MYZ<G%V>J=LI1>^,DT]Z*I.+O%M/BCQKY@[&+>#$;E;#1,5XS/)XLE[L^=43)
M*4]&(U:%I3Z45<Q*L^\>2AYJ/D*[&&2;R3)5LXDW3EF=2,3D07;JK?H^&]I>
MC7@X5<174:\:48U:#I2VYU+6FJ:C#8M4DFTTTDG[ULST8XBFX7E)*6RMJ+U;
M25[7UN\V[YW5['M5K,8[A*W7X9_(K2[Z(A(J,>RS@ !Q*.V#!!HXD5P#H"SU
M9([E4 \CJFU^:2DIRE)145*4I**TBFVU'PT\#SGFW;)7=D3O6)!H!H!H!H!H
M!H!H!H!H!H#J2#!G*L'L9(MDGD?(M'+!^S<$!1!VS>(G;NFRQ!Z'2704.DH0
M>AB', ^>@//'FFRXOQKAG.6(-M'8E99JUY0HV4*AA^S,]H&V ^-G.1$(&;AZ
M#<'82%O<#.U<UE"(FG#F8@Y!R_B#"H_CG*BRK0X<>?KSN-R^T_"=#P1@^EU>
MCXIHV&W$Y#05RO\ 3L>U* H]>+DR<K4&2Z2(5NKM&-?CWSJ29>$[3BF;=F M
MB%13 A0$0,D- - - - 8#=JK]K([0G\"S<U_F;N.@]2V78G_ &I[87^#S3_S
MO-"+1=RYW?)&T;0HT T T T T T T T T T T T T T T!IXV)\[A]Y^]G>.
M[_9U<A;(RVP8:>G'QFY:O0017M[Z*4'D@-IB60B)$JK<0(<\B_( F[RAU?H>
ME5^Q]&]%]'+*I*$L?B5I_$K/9IJ2UVH14XI.]ME-9.[WU/<ITZ:>OOR7:UEZ
M/NRW[MP^OGC0- - - - - - - - - - - - - - - - - - - - - - - >6
MCM",9,LO=J+DF#GL5[2,K1E<VFX&DHR)WP;F<@83KT2YF+UEY!])X,B:.UE$
M))N]+'-F61E92+]K;2[2 4;/T6[[V=P)^''RX?+Y'IMHC1./I%.8(M(6/28U
M6O,TV%;?+2E=8D;1#-$C.!DG":+B0A6Q2 C%OETDEG;$B#A5,AU#% 5<WY^>
M?$UU9&[0&X8BWD9NP'D3#D9%8AQ-L1R-O5A,C15V]^7:]16,KA5JO/0XTY.'
M:1E7;+K3,PVBRNYZ3DG;B%2?.4F#21301$]-?#G7/U,2XSM=LZHV;&^&+9MP
MQM%Y\W$P>T.Y8"8165[!*8V;U+=D&0G)295L*U$93L=/8FC\:3Z]A1JT++LK
M>NXCFU?79 HJL2;]WX\Z#/QYYR?B40KVWF2W=-R[:8;;;3?'V=X[MN0]Y4;*
MY/F408MZ5N,ON )2#P4Z:4AP6V/WZ&+[CD&.?6TE=9IQP0]<<IFE'B[MK1S?
M+GT\>&RG=GNUR=B>YX0Q#@+&].R'E;-5%SGE5@&2K9+4NFPE$P+4ZW/3J+M]
M!0%ADW-CM,W=ZA6*^W2:),& /92;E7/LL61H]%-9_:.]K9LUENRJM#?).11Q
M/EC?SV<V0[S@[$LK6;W9I25?Y7Q#-0\36E+15:A)U-DNVMLJ6M&DIZ4@6:JB
M/O-0&L<?QB"/1[LGX?B9U]B?]J>V%_@\T_\ .\T"T5^"-HVA1H!H!H!H!H!H
M!H!H!H!H!H!H!H!H#%/?!G-+;AM3S9EPKDK>8K]*D6-3YX$ZUTL?<KE113((
M")Q^4$HP54*4IA!!)4_=$"B&N[HS"O&X_"X:UXU*L74M;*E#WJCSR^RFN]HS
MIQVYQCN;S[EF_3>4[V?&"U-NNT#">-Y!N*%E+54;7=1.'[(4N5U54L\^5V?D
M14<,74G[J%0QC&,G'I@)AX#6SI?%_MO26*KIIP=1TZ=M.JI>Y"RNTKQ2D[9-
MMLRK2VZDGN3LNY97\=3,[7FFH: : : : : : : : : : : : : : : : : :
M : : : : D-JC)>:K%CAZ_8G-0GI:!EXV$MC-A'RKRKR[Z/<-8VQ-(N71<Q,
MDYA7JJ,DA'RC=>.>JMBMWJ*K915,P&B_*>W[<1 69Q<=V&PW9-VL:,+&1\7)
M98QOCC&N-=W;*KQXNG#,LSB'-H3F-[F=LV4='C(RG9FI9WS@[A.)JJ1U"I+Q
M]U]WAO'/+?XFW?;9F.FYUQ!6+[0Z/D/&==,#VN-\?Y3QO-8HNE06JKM2"7@9
M&ES39N+%LP,R!&,=1"C^O2$>5NZ@Y-]'J(K#1KVF/5\[/RE9+W1V+=!<\PYB
MF'=KP5:MLL]B)0N*DL5/\$799G)VG'BB:.+R7XK26LS%O:E)TE[+:F\H!V32
M=;UXXPNA+;]_X?CSWEFX?L@, 14/&'7RIN"F\E4T^ 6^(\W3=NISS)F&H';"
M%@3PO5J,=.@-Z<Z@:ZVMMH;3:5TJ%M?7@D\_5N;Z<<@V7;BG1<]C-M9/$IP3
M"UYLAXFSTYY0\^M&-PKZQMT-9E<O3F=9QIFQW)T]^\7=SN2K3:I24EL?+T&3
M4B+++U=NZ;5U5O'-@+NY$[.2CY%?)6%WGW<U WN+OV=[54<@Q.0H"1L]"I6X
MR$BJ[DC!M)"W4RS0D#AT8N"A J<"A#&FZ4_B6$I6K''R*(NC@68[1W:SMZQ]
MV3>Z*FP6(:"ZCMO79]YJHF'9*Q5>&L]GHE>H>#[$SK"4%:IYD_GV3V/&.:O?
M>2$@F^6E"&E%5S/E#KB(\D^YV[,MW K+L3_M3VPO\'FG_G>:!:+N1M&T*- -
M - - - - - - - - - - - - :>.T5$=P&Y+91L?9"+F)MF0E<^YA:D 3)DQ
MOBU)TNQ8/^![I6UB=ISS1#Q0[HOV3$!#DZ9%?HNA[83!=*=)O*=.A^R85M:U
M\1DVF]\%LR=GH\SHH^[&K4X1V5P;E]++S-PP !0 "@  '0      .@  !T\M
M?.G.1T T T T T T T T T T T T T T T T T T T T T T T T!Y#^V1J\
M1C_>U?+[1=U."L)Y5R_M_JL)/O[S>=V-=L^+ZPK3,PX7<2=K:80HV0L01F.+
M@VOT?9$K9F%K!.8BQ8T:HP*[8CXT_'@;NNRGVN9 VF[>[;0[O7<64.*L>6YR
M[XZQGA6[VG(6,J+1GU1I,"D6L62W1,)**(7RRUVR95=L"1Z32.?7QPV3$RQ7
M % V;: : : : P&[57[61VA/X%FYO_,W<="2T?<RV78G_:GMA?X/-/\ SO-
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M,TU'8BU\4KZ/BK)]QN%U\\<XT T T T T T T T T T T T T T T T T T
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M0G\"S<U_F;N.A'H^YELNQ/\ M3VPO\'FG_G>:!:+N1M&T*- - - - - - -
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M 4FM3]PM4HS@ZU5H>1GY^8D%BH,HN'B6BKZ1?NEC="(M6J"JR@]1[I."@)A
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M9-ZU*C7VIO=>ZA'W8[VXHVS>;>K^G!%[-<YD- - - - - - - - - - - -
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M+I:M(GJ*R3A)-=!5-=!9,BJ*R)RJ)*I*% Q%$U""8ATSE$#$.41*8H@("("
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M3-RS!.,O-M7RU#J6*#<I7A%LC9W,@_?,6KGG</U/1KH4: : : : : : : :
M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M: : : : : : Q WZ[MX78OM-RYN@G*L]NZ>.(^O-XBH,GZ<2:QVR[V^ Q_3(
MEW,*MW:<)$O+9:(9.:FCLWGNB(%[(E9NS-BMU0+!(;OMQ&W& JA]^..,8.+[
MFW(50QGMTQMLS=WC)%MNM\FZW<K79:7-M\FLZ3 1JE3AJN5W\MEK3&U60:!*
MO) E=2:-2O0*=5[8;;6NG4&==QSN2N-RMAMQ;1QC6M8MCEKW3IO:H[AVV;("
M[,)2X141#2-:+-MG#5RC-OX.923\**EW3U[$-)("Y^.NTPP-F:Y8OI>%*CFK
M+SS)>(<-YW>2U)H+8\)C'%>>9)Y%8XM&3G-@L, \B/>3J.D5I&(K["T3<+%Q
MTE-24<WAXY\^;A?GS^ACM4.W?V#WIAD27K-@OTG$4+"V9\^M'S."J[]6]8[P
M&4ALC.:S"QMU>V2 EFI5$U(&(RG#8X=6IDH65KH2,0!I HE_Q\==/GO[.)T,
MM]LQ4:C68:3QSMBW#7&S.,S;3,>R]+MT'4L<S1:3N[5G5<99!@ F+DNWDQL3
M.L3;"!@)1>"?I69%"+N0T]H=:21%Y^?/X(RE9]HMBZ1NFY"E1V*,^O'&U K!
MMFRPDJ%/;U&M6"6HU5R!%U)M/O,@MF\M/NH*V- 7]@(K#0Z\?(N)^8B8E2)D
MY0.>>XQ+>]MEC&V.L((X!P3EG,ILB;NW.TG($;%2F)DY*A6UOB1]EE$828B\
MG36.KZ^EX,&#V'&OWU2M#&,+666LT3/Q,9 S0E]?QRYMO9=2L]IK38B\Y,QM
M8F=]S/DQWO+SCMLPQBC#6'T8BYO$\(XTHV0KI%OW]JRDM49Q&GQ-B<R\KDJ8
ML.-XJ60?-(IA4F[QAXTH*=1YVS6UHT7!R-8HFXZ^K2F$\J;@)>%J.*6RDY1\
M=X/R1,XJRRO>&$]:H$(*8I%LK\NW?Q8+.SR:+5(E>5F)"0C6#L.?J72WA;M)
MZL[=MM=[V[3C-M.;OL\;5\58KN<Q!I/V<16,[V"*L<I:G4#+(F1,[)BIA9E8
MME(H""<XYCDG!4S%,)1/*V5L];\Y:W.BP[4W;P\S1_275J.<8]4-UDILI')L
MACUFCBD^XR/@WMC:49&R(V1>4=>_(>,DW<9+-*ZM%MP8G3G7$*HY8$=BFN_!
MO;D76VX?W&SN6,.4N!S9%2,@&S+&E/EYYRWW(-IW<E>MG6/H1RK(J.WK"Q(;
MB:4C"7X8TPIPU/L\+:4F"+7Q^)POKSD2_P [<VONS\M"\VV#M&,_Y?L/9D73
M)D/2*O4-[##>9B/(E!IC-=]$U3-^WNV6IQ2+56+',G/:E8&>JV,+K#R<8^5<
MLP?2T6]\)N9#Q1I3>GH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H"T>>,%XMW,8@OV",UU5K=<7Y+@EJ[;JXZ
M</&8/6"BR+I!9K(1R[61C)..?MFDG$RL<Z;/XR39M'S-=)PW3.4# 17LAL"2
M-!94BRYUWLW23K%VI&0,5Y/N&ZC($WE7!UCQ]#6>N5U7#MK5%-*FM1K]QL4-
M,-BQCXL^R>HEF3/E8^-59AGX^7U+@8U[+K:UB9QC9_46^1?>V-:CN(JB,]/7
MR0LUANSS=.ZB'V9;MD6=G6[Z5M5ZL4A"M'J$ZJ[:I,%1.@@P]B3:M6X%/5#L
MG=M..K/M]MV-[=N'QQ-;?,88GPTV/0,V62GLLOXTPE.EL>.:GG>,@4F,?D2,
MAI4SPRZ9FT2,HPDY*'DA<P[H6!1-]N*;X:67;SQ*9J/8Y;4*)5,VX[K5FW#L
M\2YKQ9EC#Z^'%\US\EBS&=-S,L9Q=4L2TZ2:NF-7D!44<>XWLB>>&!2=O6\:
MDBW>.4U0\>>W]+<"YV4^S(VWY=KUV@9^0RM"N+I#;7(TEHIM^5K%PI[_ &?O
M;)(85M-'GV$9[3 6J*=6F6/+28E>)2/>0\)HS,D(G!:W\-,\KKG^EII/=FYM
MTM..=V>,+&ODN8@-Z$W4;+F>0=WQX%G6L-'I=$I-=FZW8D&:,C%R3=ICJM3#
MMP]4EADI])Z\?@X:/UX\12R$1V,NU>#H*M*CK[N=;S)]RE:W9HY:)G2<3S.R
MS56L<CBM.>99"2CTY)!A+4Q5W&RL2*)VP@^6]V#&(H1R#$3>NU^MM?)-%;7O
MLH-LUX<ST\UL>=\=Y#E-RF2=U4-ES%.6Y?'V4:+E#+U*@L?9';TJU0;)(\?3
M[94J^QB96N2327172,N(N!,9,4A2:4WLK-IU CVT74HV_1;)':GE/9^N"EV=
M2KN4QKF>[NLCY%L4S*33.1E9;)5AN<A)SKFVO7RI <R+E/W69#P$T1-/%_A^
MAV]TFSB0LVUS;UB7!,E"Q-CVBY2VL9'PTOD>3D?=#QKMTL%>C3PEJFH2 F)$
MB]CQHE9( \LQKSDQ9>30="T01[YT8]+\,_(<]RX96*B4[.C;NM*MIL_R[!ZT
MWRF[0D@%L[<4?ZH(U8EJF<!*,.!C488N:?&"M]XKCVL45O>H)IB@:E+?U+LD
M]G-0L^U2XLZW;).P[.+UG?(6'I";LB+PXSNX*]3^2[<E;RHQ+0MCC*]>["YL
MM":']D/5Y-HR<)KNS \]L$S[.;=F?IN7:4M4NSL9XSW";%T,=RK)KMMV55_=
MC?H2'LT_*3>3;%FK<M/.TDU%DT*Y'UT*=6(JZ9(>I2"TN,P61D8&,0A3-63J
J55!<.&??>_K=,VNZ%&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g67046g25x21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g25x21.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %QJ^610X0DE-! 0      %H< 5H  QLE1QP"   "7:4< E  "%)2,3$W
M-3<R' (% #E-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52+F1O8W@X0DE-!"4      !!P1XQ$ CUH^O_);1\_
MA X%.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           ! P   _           0                         !
M          /P   ! P                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   ! P    !29VAT;&]N9P   _     &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   0,
M    4F=H=&QO;F<   /P     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      RB     0   *     I   !X
M3.    R& !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M8WU?3_-J-/\ X(J#,>ETN#60 -IAO8Q/'YWM1+++#<Y[W;G..P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( )P"70,!$0 "$0$#$0'_Q  >   " @(# 0$
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MA>E6Q4W\<L^G_ICTE<D8&2(LJ:2U:4/*D<4E>WL ,#,6/M5'^026"D$T>O\
MT\^%4M&O56?C?/T,V-1EJ#]*GM]%;3[!-&(KMKAB7L^ 6N[>?1?F72$X-<O%
MXK"E"?=B+TW#:,ND)D4(SV6=!;50)M2:YOP#?'\;!_2WH<,W9R?3XE=9(XV"
M2Y!Y="4Y6<@%I-5;@ #;W @ D-OZ9?3/#0LFJ<J'M)8MV0E43:&R*6CK*61
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M !8@W8''DG@;=<-A]N/T*V%KBHXCQUF=#2ZHUM3)L L/)) Q?1[^^V]8V)-
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MJRFO= (5W"C4,.+(H$4/"CD5ST075[IG;"F_CEXAT;*ENO5JVTFWL@I4'(I
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M<Z!;Z160]:2%)0O^ZRZ)QD;$K%KDR<CPV1GR>I*(\A3AB-E[)T9Y'E8Z1]J
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M5=F_'7/&QJ+1E:U89E7U3.A2L_T,DOQPM[8AL8$&C=_F7)CJ51'$NU9+<'&
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M0[0R JQ9=[Y50#\-Y) X'-^/438X]1QIHLF2.%W9,R(!A'&X11J*8^UF8%I
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M-_4/<=@=DV5=U((V(YL<'@TGEC?&DE4]UGC$98@^V@.*\T*-'^?]O;#Z</\
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M3:8X>).,$,#DABZ;G?EGR/-.;-QH@55,@^IM,9,)R%02,\W<02J*!:-3KK5
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M>\\%^C+\?C_^)+Z2._W_ +?CO-'>?W_^O>?_ .O^O?QFR?8WXH]>8B_S$_\
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MTQFE".5S 0!G-P7MY 1(Q.(4D=UEB$F+'$TG>D=(9HU5#&40KL8RSQB]@2Q
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M+=)I,VK8I9*TJ4=/<;"E[745,PKP4%%8OK$8I2'C%FI9719%TG&?G WT0X_
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M/(:@+2L8  / '85$\3K$?=SL11?6.3+=8\ED?'Q(HP!.8L65UFB9K#+;,J2
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MY'% >V/TX?\ +QX&_P"S'B[_ -#T7TGUB=>3'UA7-]G?N_>ON[SS%?UM*O\
M17$E19VPZE2\"WX*M%.(G)-1J9QA(:#\@K\&?OZL)\)R$2<Z)FQ^XD60^G>5
MQ&ZHS,C*58<!@.2 MGCG\D#I_"21A*Z*6$84N 1]I-'@_%U=>1P:'/5K\JY4
MRG86-E7(U.AI8I56A7 -=EM(K,H,(5LW%(]D=:<G)G6%"7Q<FT0W(\E*??K)
M8,*Y+(6.C,#3E2$V*GC;BB2+-62?!?*DU2Z%U#<-R!9]MJ 0."=>/)_-=,FJ
MSWZJQ:XU_8V]E86=U:5YKDR;Q5/FG*:Z(!+@5"2IS_6H KUY0D8<(!B9@Q>>
M[LDD24QD(JA534K1+,JZF0DDZLQ-V* /CCJ*&57+$D-8-\Z@\:DC\U5?S=<\
M)OS949#4UTX?P[]Y=5^+O:&CND:EN_IDF'+JII+1(M&LT +MAUZ &2#_ !$B
M]<HU$;0X=F.8Y(UD:/A#(DT<J[ND<G";]V-W4JJA"1R"&<A2#?3N+(\0D5&9
M$>-A*J@E2."B:1ZL7-#@&P+)X%](^QQK4O-]/;X<V)1HDJ;-K:,R&@<0U^K!
M5@)_!]KA*L#0775N ="[4,Q-&V4_7#*,?UQ][6='QX-E]\H/T]3*85AEFR-C
MK*P]QDA8D:D&)@*.K =.PR1RHRRF0(-I@L:[J8XH:LQ7M2R"R6!Y)'N(/1/7
M3PE[95U,8;MC*U_8[I=#94U53-B9KW+&I2RMD:*9%KRQ'9'(NRG)KC:T7AE+
M'LG?[7R)$BEC^B"03+)(TN5@R"5T?&[?<D9T'M3WT6.P>JL>>A(D^DKY+2R*
M(T[6-E=Q$:/(MT"C8?>!L%X*UX!KIN$H-!14K\VK*IG.WWE+6Z=YVK^)6[PJ
MP3AM$?:4Q0!OK!$ 4(=A.:*E4!F7X^29"?191!%CI)"<A!$IG=UE3NK*'#NU
MUS$S$NXJRQ !'%+0LTD_;E"-M$\4<9#:EJU1;!YU!('S8'N(-]%/D*C7\?>,
M1N9)]JF4H&$WZ^SS'4*\ <_$!9LU=F87R=L* PYR77@L']D3+4/X^$23Z3I<
M::&!7?)"S))%([AWV>;(G8=N2*S8F9F"U[@-?<=:Z"T<N7DA$ 29B$ "?8D0
M]X<*H.J@%C\^!?/5;*WR-RKS>[=CC[ME5!Z@V^:N]_8M10:N+O0G5B*QMA<Z
M5.MSX8]@_7@K^2SM9T=?PK1>S)#N+-CP-D1F:;Z:$9 RYJ1XV41;38V(06#2
M1N"J,IJ5[90/'34^+-.^.0N.9Y^VN/!"K)(@0A89<D,HXF^XW6HH'FR*R:IC
M-,^6O*-UIZ.9,;H<IE[328U*EL^U.@2SM<(C-73].99/07;4C#16/8C$TI7D
MD0Y>0YWO%XEBDR']1G[CKE>F.GIV+',?JLI4A[K23Q\MC1)& $.J^_9+O4#6
MVFCP(,& J)\?U!'RLI]>QC-+*8U$<A%R,S[!QL?:%/ OI^9:P>N3Y=G-6.;2
MP^KIJ<;8#5I[J\S6MRG#H?T!.P%-><IP6774L)]JN148Y"0O<.'?=GQ8\\GI
M^&N%B*LH!R,^:=>XPQP$?'C<, JE@I0-&0P=V- V3>::&+*S?JYF<JRPX:8[
M]E7:9M9LA:O8H=9%#5&:/FAUR9S(:FWTS=/<M?UBQY U[,-NEILK9J2\8I5B
MEDPFI5P^99OC]\J#K5-?E5B D%9$/\@FPQYO^FPK@8\V;E9)67-AD.#!V(2\
M@E $N)+)M<F-C$:/&2K%7]P)LC(S\I,F2.#'QUBCP GU,\4[%'9"$3(17"B.
M5Q[M0678D _'1;Y+\8XX4ZGR\I:7%G:LYOE;ERV=IUM3*0RU:^M8W<LN4!>V
M#75YEB"O9ZRYSG11B,7NXO\ 0^]C1S1#,=3&I23LX<=I4;#:.&9=DA5ULRLH
M+$ J+NC6'ZF2.:&&.R=T=YG +]]OV]P0+(XHF[;DBAT98!VF)DJ3R,2\M[<V
M>Q#J$=-*=-9OM:03;1)T-N=I6%VO<I!; \C0A&( 0=$*7"='V$A^I9N)+E3O
M# /H8)!DK)CB0QQ1LD8: P.!)N:II?:6) %$<VQL7*1%A=T3(G)AD@F!794-
MK/&X.A2T9-"&!LMK[@>J^>);[".'>6T5GO[$V]TW]2+.97FF?7KKD1YKM&V9
MH1$"HNBM]+\R$HJA6[&?9"C^8SD(>I8OI,@Q_3,0M!.AR6SY,59__P!X=C&V
M]2.4KMEE#,#]QZ?RL+,]143YF1$DN*/IEP_J(X@%Q0"9(%#$Z.*?P 03QY'5
MD;G-X;8N:+2;]!<N+4A YJ,]>T5/C&?FNPGK7'/@#9*-\*M*9DE2'7D,L9')
MWGOC'OU4.9V$C5Y)B&B,K1M%*"QXC!-2!8[(#K7#50-D)+'D87= ?MJS))0E
M5T((/D+[7L'P;!Y)NB 2!V![GI[]O!)V>,ML^*IHWX<$N>SSKC8I]3)4M\
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MJU["HC^>WNCTJ@/:EQV:W&OX1+XVIN$3DR^8)>=B/U.!@TB:;O5"213KJO\
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M44T3?/C8CD$$"_/3$Q2>7$E#PXS02N),8H#,T@MHE5[U]T5\4;W/ XZ[I_\
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MEV/TCDR.L0",I5-'*QIVW$0%M:^?:O#AKJ2AX-&L*+W2LR2!GYVWL,Q4@,I
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M@$ QI3)"GU>*@BQMBG;*RZF>8I?;D.MHVNS(2A(#$CL<K,&4(9&25BTK*I!
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M$(1QE LQ1+R2(-[IAI(X*#WA@ K-;[J3:$WKM1/VD<69BYLI#WCQ&2(,9-$
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M9H-8 L4&PDU/:O\ RRH+;[$ZCDV I!OQP1==3&FJ(51F"M5$ L:MQ*KJ[%)
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M)'CC ^1Z[R#?^:&C5NQ5JZU-^QS'+U2K6K'5#3H^R2:DPM665;R !V#M583
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MHCIK-!6[39>KZ6L=5:BF8<>D8@MSXXWHA2L:*=-1*TBI:J0P1HQ1]RCB0\D
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M,(Y//^\L8=;$+D.QGP<Y^Z7TL@RLJ!)8DC99\B5_VE+-&D2+%VY$9B40!&<
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M9=!!=8$^2E,W>]04@* -K'D,* 8WL!\ZT1\WM='XZT6 I&2VV%L/)V!((_T
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M:5B%020A?L<7)&H(,[(S+':?YS$CMJ>.18!'/Q_O=]>@]!D+PB$ *=G19BQ
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MRC[7Y[R%J@%V=,G0V%W"%<.=T5D"5JCFFLQ9*%LOEXO%N_<L) 2[#J9Y$(K
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MW-J63<-R6H?/- D\\_Z73WI\S2Y*PM&R8["6..<AH)64)N7=[ :0LJ[,E!?
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M*RW(W>(#FV2LY\G10[T/"BA%B,80&,<)0XAE5%(_[;-IVW3% +&58Z 0R\L
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M= W6TP=I6RRSHKT/!WQ+)OJAK/\ 0&E\+M=66\S"55&('"PGR4I!57<@GL.
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MY$XPM&/ 2E#\KRS(C=H:=QY/L 9N!5%G)90-=AP >;OXZYC3PO(88'9Y#"K
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M/2VK5&^&.C40=$V5>$1S[U,WP]D,#/R=%TX>RX6$.2A.,)]^D>W)'H[H\8E
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MM3CX9Q7[L+K84F0KLV/.T>Q%LD@^& H=1\9<S'WPG<OB1QSSF8+&4  ;MQ*
MHD 8A2R^3]UL;$=Y+H]!X8\KX'5X'=F2\* =M3V^; &RN];M]>5L\24M?T[Q
M(FIDY\["E17K6$.CF<!2]]L"\M%F2P"6$+"F+,BNTTV,V08BH#=F$Q,"D\R@
MNQE9_!U4 ZF+!#FQ$R+*WJ"$+&(YX\>-8SXGGW!V1&H.RD$W0 ^![9Z?0^3,
MK89S5;.IR^5T+KK!+&_\<V >T](3O ]7U.G7Y'/T-M3&6-RKK$A0L+!_L03"
M,'8SEW.R,?#QA/C%\>;([42Y;*8\?'#D%5[3ALB23)HQ-LH5"RE-;'1,'&+Y
M2K-!]0N-'(\F)#.DLV2P6B\94+&(DHO;'A;# ^0+9JXT&)#@3 >IRX!N_&E0
M>1&;>QM%]LZP^.KJ=1H$BS O4DZM#]OB[OM0%)$@6O:<H>2-C?J#"@].&-D.
M0'@3&ARM^T\3JT@>&3?&8F5Y#[=6;90@JC8KD>C9&5F3S0IM*KKDSX:P@_LQ
MG<F,QSG9"MF2@H7XH"A=O&7UW6X!VNT]RWI6<S:.(V=I76:M=5^0V+-F8I7)
M+M<W#@IE$VAJ#17^.8&%I<'*4@]A%?'FQY\A1BY,C%3J[RQ!F!CA#@%8U53[
MK%T ;Y'QTGE0RQ@O)CI$LP9HTC,A,8-D@!V<\<@@DD63SU$;KP]8VNRJ=-0/
MI.>/7LEQ2PHNZ4':M.J%%F<&,])_G5U)JV!E[6PN>E*RQ\)EO;V/!0Z=,K($
MC2'U"2&<98E^F2&(IDQ-['6:M9CH#LL0(L@"C\448W8[1PDD_;"KDEW5X95(
M>U !0JP'.P("L2*-7%4SNWU?BC1U3F.!MY^/W*]/%$6U+%>79MIQ8XT^!Y*8
M6SKUBT@A4YP(.6DOD_ ^1CR?UU1E8N;)'CRPX[3.563,CVA"R+M1U[A4&F4$
M@E"U-R1U9AAO'"TPEU*!IEQB))(]3HJE3J0 "23R:KQ72HJ<D]E_-&5\HNXA
MR7DG,4=E2V5[:<;B-O/Z:GZM_%1&4\JURTI[,5*)RQ3C$G\0A[6?R?AR]1@2
M5IYLEQCXN/DR?2946-/(=2@#R9B)(J, S"@5&K%N?/6AD31'"3#266=HD,^.
M\L2HPMAK"6C=B05/]5-Y-"S1Y;;8]U39'.^+4RW<Y7.OU5IH46*;E#/;O+O!
M[6KV+[0R&47-,KMDJFF](P(P4C+W?B4-*#/QO4!ZEI.J1)A+B8F9,D@ >.4:
M]N&-6:5@5.Q!0?R>.L]L"7 ;#?*A][S)++AJ2TAA862\_(BVOVA^;/!')Z3&
M7K_4!NDM1EUXMF6IF,SK<A8.7I%;M3LGB?RRZ5B\JJC$]JT2P7%7,V+74TUE
M8"7_ #SI.K+//VL<1P^E3[G(Q,G/1,C'63E0,AHA'M%H@ *K&#LVS%CR7Y5P
M(YI)6ESXBK),F(RQRJ:V]A*R'9:9=;:R QI3=L;8AH=Z7,YOR:6CK'A-TX6K
M<$5([J5M7%E_%5,XUK1!1(4D3!AVKYP8%H0,4QBF[WBT605@DP4D>26,@HK3
MH^/(-K#H)>RSD+[0Q!?Y*W8%='21?4(X]89$922DFR6.30[@6C\>!X!  /1S
M>>/I:+7(7F6W&YPO])3$"51=B6& F:2C,1NXNO4/[3U!(]BG^\T Q/V!<G,T
M?S.79DXT,PQ5>*-"TGWXLZ13NP%!,@OLJ@-3%(@H=11V!(ZIBYK0+D@JD\;)
MHO?1V2/8[!XZ",[: @=S95)XXY =8^-\70#M/)DZZ^V%6ZY**+FQO"63&?LF
M)2-:VCE+";)*Q&N &'4!0>D?YO;'L5HPY")(?1&R/4)'R\V2:=(PZ8LP3LE(
M0&@5 BK%(=C[BZM8%\FJZ_K<B8D6-C8\&)$6]^1CH_?+,2']^Q=;%;*I -\@
M@]5%\,6]#=^L/U;N4!%NKP\:^E)9T2EE86<EK0 /.47%WCV?O**PA_IR:66E
M),$I1@O+O/=SC\+9(4C)3'CD#L!' 4[:(*"J-:!(HAC5V#?6!ZB(AD*8FE=6
MAB<MD J[,VUD!U)*FK4_@CHL]"N3FUA?(U_F<MF"ZXWJT]4U:WL;6M5D_644
MO,-Y\RRIQ0B^\:0_VN %(_Q+=-_84XSESEGD +QR2R", 2=M#PQ/')^!Q\$>
M >;XWO1<A4]/>.>:5,<O*W9C:0]R8*K(S $HB@K_ %*5NSP>3V!;;28G"MB:
MT.F#^WO+P%?0@O9SDNOU3HEXU-&="M-Q/Y#G@.0&S>YAQF4^2Y#A(\#!'-."
M(D8I$I9]"/<"207MEV(% <<B_/6AAKD3]N-80@Q(@Y,0"ER6V626W +A11<
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M)#EVA9D$9D-(/W H8AM&LJ]"R=OBSX_ZUE.5G:#&A1XF,D,\JH"7D2RU'RT
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MA^>Y.1"^=C33I%!D0K+0:!]_W=B'D>+MRR2L6LGD+Y'MZ[&L@AEB1WDC9QN
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M>XG1"'NVVC$ AS;>TE6))*4"0HH$'[J\D$]%R!@:#)E)>8U%!IW(5C:-T9)
M0+CD74E]00P]HI:Z4UAF:O)5EB^?E,#3Y7.00V%H4"MX=[JK+<UJJA76&LQ;
M5MD#O.6+BJT.)P@R)4DAP)+Z*&9=2@*AGN()[:NN6'/N_ Y_@GQU1JF,LDBE
MY%B"/[0TLL&.C3%I "KQAZ<LT?O ^6YK=<S=4IJ&-3=Z?+V% 6DK7[;Q_:>0
MK*--==31 P*M<0KEJU.2DOG@*MI)?O-0KID&9F;4>\^@L2$"ZND^Y*S"'D;
M<@N"I''S7!'/P:1F!WF;*$HQ[$:,\DR1A7C+0F&.16#]D5$I<4P>R.NYO_9I
ME'E/6EZZ1/J"KCR\)^$&(UBY)&6K5F=?MF5453SC$C"X%RCB$Q?<68^Q^679
M1EWZ\]ZF#]4UDM[8K8A1L=7#$:V*)_%5XL\]?)OUS&T?K80DTN%BJH;4LJA2
M*.JJ#M5D@ "ZKY/:I_M 7#=]/GI ^ ZZQN_<9]*/ L-_C]9<O\]?>PS'YE#G
MPCE^)$_RCSL>=_,H\Y^?K,>M&VLBC= D_P"@')_L.O(Q_>O]^ECB=3F-&:]S
MU9;N7C^*LAYR\L75"K3E9?%-D1 E*/\ 7>_6&;@2,*]G'DX>TLND[^/K/EQY
MH4B>1.VF0ADB&RDE-BMD DJ;'@T1?(''6KM9:OBB:\7\$?']CQR?SR9/0FR]
MLS39O9.UAG?Y%:WIJTG7!-<LJ67[2K\3BF* )K=[PO!E+ 4H2]A.3AWL>41)
MV1YH@:B\N"H OV@$$DLIL*U#D&N!?7=PAK@]Q: NN#S8\\@<C\_%BB5]JTQV
M.2JT]7MP5&M:L6&J334B1DEUBIR:LEDS3G%P(:P]>M']OKW>)6)03["'Y]D.
M&4"22,PPRB&.6*66+N"Y60?:X)NMBQ 6[4A2/SV,F+<>QS)$\2EUYC20 6*
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M\7?'DW^.M#S.!>YI+#,1R[)X6MH?%N;JTX0-RBA6UA6ZS7!,N<#I:NM:M#I
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M@4C5OW&* @/*P(#$!3M8>1E?+ZX*5C*(I7^8U.:RY*7.Y@J*5LY36,@3MA6
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MKJ=A<:.9*^QN%K?G3=7J^F$6X[!<2B"XN?KJ2!R/?K"$TN%Z%+'AI(TV<_\
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M_I8\Y[ICC\OY_/>=JVS$L>6"D"^:UL@5X ^#0%"_CJZ2BBB_:QHA0O-_Z?)
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M$ZU9'2N\@^.?&^PS56+=^;$<[5V-4'8[:IS]H]4Z#;6=>4-B=RBNX%*=R:#
M%(!_B1<8[,7L:F4!/\<OZ#$EQ()E:6%Y)MS*)U9,D/1.,5D ]X-!9D!-$@D
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M5963"'#AY<5RZX%Y&KI'XK*(VUY=**?(<943M)'$Q5@88VD8"E1E0*Q5OZ7
M4>_D_%7QU[''?&/IR93!GR\<RX@,;JJS<JO<*D!Y(2ULRDA0+M30Z^6:G$:!
ML&<O<U4J>0.9=&U&IGIOH+L9OLYD3KM XG!2*C5Q/\6XH EP2A.B4)&)9SC(
MAEEB'<LF&,DO(5&X)L,54FY-30]ML2?M NNXZ8^5/)#V8H\QU 6"!GB5X+0@
M-)[45B_(0FO%_CH.N,E&QC0:_+NU2/D'^M JCK[&V$C6KHHUSE98.UPW &AJ
M5JX2XORB5R3@"S(: Y#C'L;1Y"DA2MQTY%BG(D!-A0#H39K:JNSXZIGX>2,B
M)X21*)49\AYP,=# K0]M 3W)G6,*QU!4@WTQDP;G,TG;^[MD-.^5J4;/M543
M=RDZ@HQ0HWN(DL:]CMXPW-N30@0"M% 79S+QCX9?7"T<K;1C1H_#. LM\G4<
M<CY!X\\>>KLN? -,AHYXI87<&*,RI*05 9D,BLK1EK5E(']1!)KJ"W>5RNWT
M-5GM2IGPYZFJ4>Y<^0Y;*VK[]C+Y>"N&E20%R?+ QQ@ZV5ZR$8D!-O1$",OH
MD;LBR3$G9V.P86H50/M_#4;'^O'R%I<6.4#&E65XV;N*'=Q,TLHU]S1,VB!C
M05CYU-<,1MI[W.K6-;E+#9+^/,YCLQ(A+!>MM+:>VT2C;(NT5N,\FH6D@EZ-
M1(-FWU41(\?(:1"\ER"(F/ND23EY+"DJ!&C4 5Y]I &_(Y)-\<]"R<EH)NPD
M:%H(HHDD5J(=#[V;NCWZ"[4L68CVFM>BI>AQ%O)?6T=+H\[P;X;-BCOR633=
ME=.C5Y>W\GI]K8JU)N"E%.M$S%8XA2"M+W%E*=@^1'M&Y!3E0RZ\*#1!*EF+
M?^;R?_<BPJ\;Y '<R&=I=PKPHC2 +[-VV;6KOD$@@<=":>F\D(6MLSX9B/QU
M>;&Y<Q;N6S>4J,/6NU$$)$#9ZW7"MNOD*.QY(J(U_P 080E*7>'//W1J\,>J
M]_\ =C"B4&3:18WJET0 -LNUBK_MY Q$QF$U%(9&64$I,I>2-TY82.S;!.1H
MX8K5VNVI&A5_LUFQK+C-MI>8M51Z>N6OL$C,HT%>UM2>L, I;9FN&W2_O%/*
M4EFO>6781&8I>]GSKE'A"JDD ()6=O8&X\@#W*Q-T". /GQUIM&3)D3!FR>X
MFDL& RO+C\6LB;#4*IJVU;D7J3=RV[%C+C;3UEGD]/B;&Q/H/W&I(/.QS+;-
MD,IW:Y\)[.GJ057(?(@J;]U\"'0?J1+*7._4B[D<>@:.4ZA[4 %R1R&)HLQ-
MFQ?^_11'BL8$>#(62/'E6Y-FGU8)I-ML8%:1U)8%5.S$A: '6]L YJ3;MIXU
MTF5#1Y4,'C>3+&SURVIWM/;+L2N6 )Z9:M#6C@TJ%'L[ @XL&!+B'5QG##M(
MI3[/J492]GLE0A@YH[N"P8M\%;/)'\=(1B?(@[T<*XD: B4S.&:))/(*F@^S
MA:=; )H $]0&"\BX_:9;73NKZF\?VV:(3891A=XY7*^X2X18FMU4;2;EZ/.%
M'^5&@5!I=,OTDF127^(G.9$\:N/W8C:EW5X]=8APQ(Y9B ./!/!_MQ,B-T+?
M40P?2*2\>1D2+*57;::.,TJ(2#_21J+\D=3GCWFH\X1V3C.XQ]6"]YELM3;9
MFS19HZ5BJLR7J][F+-Q(-S54EBZY%A!,O&"$$VP*,NP]L8U62"-1*IDD4JTC
M!"P#QE-E&C<DD'VBQQ0JZZKOBRP9.2A4EDBD@[#*TDC2<ED=EHPR#[4-&O%U
M?4558*_\<67D.HW.KQ&BNJ.HV0Z/346A3=L@JW1X--E77"%NT7,^-@\USV/0
MS&R+B87!Q&-?IB\<X3MM(=W#&)@4% $D'90/P#XN^+^.8<SH"-5>5$)$ZA6F
MQL=^2L1?W"U!&VH8'@$=#1:P/<G9:>AK7[\S&DSA/'[RO)!=6Z,<5)Q\@ENG
MCCBO\(Q3K^#7FPZ5F F1KQ)/OT5V8R:'7A6:0$CVJ2=.RPH!AP#P=?//(Z;5
M1-4\ 7MM*L<9?NC(76K,V[:,&% D:\:T.:Z=.PU6H\PFM-KZA39DG,#GBTM#
MRAOD\U=YQ//+-6%:HY2,)/UR%W=LE;B8I%&#L#*MU;D>0'^$(T^D=8<='*Y#
MF20@[@%QY9R237(! 'QQ0ZIB8&)!AYTT+00M%,)(TR&FDDE9WIVC4$(KA06H
ML:4>T%ATA*B\7T^-I[%M+."SS%Z"OR*WY#J[.W@JR&8.LGM(<8IGQJPX0Z'Y
M4);QZ:7"*J\#'IFLO["20"&-%6!HUY!XY_B_:?%CIJ.3ZF"&2:14C,H7$$'N
M,SRLOO -L-*-H2MK?@#KOQ_V<2SH+/UU^O;F8I%**E0\,>"4E%TP\"-J7]1:
MUME^??VFYF,=IL\2'(;Y"2%WDQPY'D?KS'J2R+E-W"2VD=$U]M4OR;L+9_O5
M\=?(/UH(QZW(L0;5(85;?YD(+,R"S2$L2 . ?QUV;_[0@B.S]-_I)KC1(0+W
MW$O2LF6 9>PLQLW6@#/@I?\ 0GMGWD.]_MR7>=^LUZU.VM$$'878JZ\C\'S?
M^_7EXB5D1AY# C\?/\'H;KQIKJ1I[%;VBB'BOPO!B<,QK^P8Q&[V)!S*2'(S
MC#\RCW^_?Q[H][]9)#*0Z$ J692IY4^21^!6W/%5QP>M,^[Y^X@GQ7GD$V0.
M:H<CCD]=.'EWUE>:_('DCS'X!]">(T/E76>-M)RQ\C>:M9L,_F,/AW.$$-O!
M8]B\0ZATBH4BHJ#C",NS@^?G6XP(27<%FS,23U(0K!Z6Q;&@R-V&1GS,=C+!
M#N>Y&2LA'VDA Y54DB9F<F7&P<N+"F#9.>(1D3XL8 BQ8N2%R)N2LK+IP%-R
M.8@Q>.15G?,GW /-OAG"^#M5HO2R:7D#R_Y$JO%5'A]?Y,1J&E]6LLV!JZ#:
M5%38TY,[>&.J:EM_<KQM-HK# 5A@@*1HH1/ZM@^E8,S3S>H>GY&=M*HA?&&-
M)%%]/D1EF"S@.97U)55"B]F*J*60P>E9WJ.7$83@Y^/B*L!$T.1%DP39 GBF
M!!**J)$%* ]P2706RPP?<%\@^,/*..\/>LWTW/\ @!SRTY*I\9;G/;JM\G>/
M+/1KR$'N?N[:G"JS7LLG,F'@@)GCWY^S+(8XR)]$P<?']1R9,#%R#_B,4+91
MQ98709,*D<XCDZO(@#EPP #*B7M-':F5-D8./]?D0(?3Q*D$D\4HD;&ED5F7
MZF, :*RQN5UVM5+54;TL_47Z_?)#6\\R^(/3%Z9:CRY<>FX-);^4MILKNBJ*
MK+NQF.V?'CJ2Q@5ZS=733:4@\2:_53@F<(&8Q%\V,9Y,CT[)]9=OIO3,?/.#
M]0T)RI9)())8F988Z"HZP3/&=MM$V9;-=:T(&+ZKA>E.K3Y>9Z>V?]/%+])$
M()A"80^40X9V^I@)0+K<BIM[7*''I)VK?EZCT_JV\+Q_I;%^=L]K+LF&U]T%
MR_0\P4R?\3>4]0DT/J0J"=@%NRA9UIR<*:PYPJR_9Q'!_P!0]/S<%W@AR8VQ
M<G'7.AD<:F*7-QPL+$L#VS%)18+LKGA+ VZF#ZI@^HPP196-*,WTZ<8&1VU!
MO%QR)V"LK>YWBU()HJHMRI-=+/S/M/%?CNX\7U=QVKK_ #QL,]1^,]EK]-:3
MNQM^/K;8'3:IAV79<G_-A:)&(ZQ16/P%53 4_(!Z2*,<X]*GQ])B?5",=I)D
MB=I2S1N&?4MIJ7T*R<;#R!UZ".";U+'S':$)Z.DLTN/#:Q+NKH4B9ALQ)C#G
M4^"?GJN2./\ (E_Y%3].6T;-MTZ$9';?8[-5.Q8H#Y_1S<J@KI!F>J!9W8U*
MM<_+0A75:N4AP7C[N$FOCQ9^7E30R9#RP)$^9ERO4V2)-BQCQS;I$Y'"MVRV
MMQT;L:<^3Z9AX<>=# ()9G7$@QHF:*-PZE-YV54D=$+?T. 2 Q/W W%P'DQ&
MQI4JQ%8V@?I;>-)HJ7MC73[3LR(7]J,TUN08,5ED4V*>,I2CP/9FD4(QRC]>
MIP7Q?5.^HRXI?IKQ5GE#+/+&/\EI48L@L<;  ,0: KCR>?!D^GM$QA[(G"YB
M)'LT09T(94D:V)57!:-@39'N((/1]L<UH1:JYM*^ZS]5B[*IXKP4K7C[0GA*
M+G@T_22$51:RC'\(C#)GOR"[ O\ E(D8_6U%-"(X8RT\F3"TC(!"B1D48R@D
M"[L*(:T'P:(X/6.GN#GM@!S3D.-J#!N!X78K5DCSY!'4@DH)#+N6*0JU6ZW3
MPU%2Y51JOJUV)J?HBM-:N-WDFS]9$,++4 C(#A.PC#@^?F*;&*6>&-)U^IA1
MI=\TEUDFB!"-%$=798U)*(6MJ#&N!TQW)5V+1O\ 3(X72-QND<C!F4R $ N0
M+/(OCK,PG:UR<^;RW"RP^FI!R2XY]4@:'!E:C^T#\\]P9BXXR8DBP"D,'^\=
M_'U<,LT$=,,N9 JY)"".V2Z8P.66);-J"K-9/N((JLGME810M!"QV@5W$K:U
M[U#CA[X)(\B^#?4C&])>VF1)<H'>;%H; F6N5?E/72IQRZ A+'IB017@_ @/
MUA"FVQ\("S@2,B>W@W@G5LD)DX\<:K'++'VQ,[**<1)(ZL$D!H.T155/ \=$
M!A5(ZCE9W&A);ME9""-PH))3R:?4F^1^">&U\DUQ=9GUNUZ(*NZ"J\_&F4@-
MO.L5<S=74C-IB80E=E"/+8<._%$1923E.4/P&+$D;(AGG=3ARR2-!"K$Y!"J
MB$/P/#;,/=5MY YZDLF,,?5 _P!28OW26';1]V#$<53(I-$\$@7QT(U&]@&W
M1LTPD<K'/VDKB<;#B=55N) $LNVS4V"Z]T59DQQE5GTHUG)]E(7>='+GTS-]
M+/#/B[Z3XLZK],?;ER!^0NQ9HFA"D%B 2"6 -\"J0SQ&.:14$<\)=9:,D2A/
M*[!:$I L)7@CFB.N&XU;P?(-=9$MMPK547">ZCS <_W 7Q6%Q ;_ )7LN28-
MQ7OY8DR5L1U2\+'\$ESD>+SX<>D4LA 3&1C&1/,':60C2.6&RQ=*';HB*AL2
M.BX\QTDCC$#OD.+)BIU1/$L4C&E!!(?:FNUU-=?<:?*P4[;YQ2LK6KFXX=%3
M14GZA7K>)"?,1 :S CV''1"')([\8)P]G?D_/YC^'\7*RLQ>W)#E8RC83.I&
MQ (42R;]P,M$!@A!U)-<=*Y$(QV4&2+(_;)C 8Z+L0=+_I(/D$$_D@'DKFO!
M/MZ9+2+ ?O':JYV"<]2G^QG)?J0[7UZ$51,'0Y:]!Q1NN/!84X$+-5B$(2GQ
M-YT;7&1(9I,<M"I90H".6.T\8"ER"2R; ,;'GCHJH:[SB6**50Z%0P,KH &5
M'.P*D^W\CY^1T@$_-=+?><8>/M3X^)522FVR?1$=%9U]HC_%\._55\IB.BJ!
M?I%56Y-.E_W@LX*<Y*$H_6=_B&7C^H_X> L&..PV/,T$Y;/EU5@V,.RL<3*W
MM>1FCHU7MYZUO\*@?TGZ]9>]-(727&22-#A)N5'U&SAI&*D.H0$$#D@BNGM6
MT.U2\;6JU7=9(,F[-Y_-"6A\BPZ%UGG3"-"15 QM0]D?V^PZR?Y['WQ_$93E
MMSYV'+GX\K)/?:TG]YLS1&E1&4.:W 4GW$KL.";& D+I"Z +2NI%C@(WDT>1
M[1X!N_P.OIBFT/Z<Q/4J=DOG:\?*@8G@W!M#2GZ+AU^24<1KZNT]PH&2.L3V
MUW!EF-B4R<[U6)NW*Y23MO-(Q+2($$+L774%XWD9-.'  5P?@@DE/;=(^#JB
MA#2V6JS=>36WD>?P*Z&L8C<6+E)6)7-MEJW-2/S^&L:X-TP2DNK"<V4F[NT7
M8FP^Z*,T4153WN43EWI>GF6,N.9I[$0D98<DS>Z7)$DBEI$!4)'&'%1W^X2Z
M%>*KYZK&PD+5L#SHE'93Y#EN!XL>TWQST74V@V3Z6R%;TX>)L[#LLYVUB6EN
MZRJ@2 OXVN(^9BOJ:%-.M"$PA1@PR5AR<.>TO.P#D+C0OBB.42.<1N[K;HTS
M?,I0J;!(4#X)!/ KJ*&8,=:T/!!]Q!8"P"#?!-BQQ8Y'BL'KN93S_H4]06?(
M1UD1_%]^X&SXPM9=5;LK&M/&H=<X/HB+&Y/D:\%>O J0!%ZT[+W]EW/1,N5I
M)78 @ M"C./8H]S>Z@%440H^2:!/5LEH!&ZHO)CX8I5E39O^>0";OD?WZ]C_
M *</^7CP-_V8\7?^AZ+Z)UC=><39 *;[R'W+^0$(D/Z)]%/R>_\ '9\_/AP_
MM[#G?[?V_$N]_/Y[S\<[SG?S_9#-K:$<<[C^:.OCX/S0_/\ ?I_":A)\^Y;_
M + $G_7D5YYX\]4)I/7MZD?+OJ*\XX+P+Z3\QNR^G;2/^.+>XT'GJOPH+(+]
M@:"KQJ>VH^B.X8M:>8>+G8*I#W0(27OY^$O3"V9Z#@^L3*D&+ZA-)&EKW&2>
M#MM(GD-J$EB;;4 ES7]73V>?H_5LGTE 99\:-9G_ *04*QAF!/M*AVT4W9'-
M ]6W]87JX<](_@W,^5-%E VGDG3QIZ&I\-5%CQYB_P!N\B)NPJD](JJUWE5F
MA0<9;MUJLT6%P#]L82.*,@YCB/U&'#P9&R4D:>0R.@QPGI^)'W,WU"8,28HH
M 41=N2\B;E$.PO@IW<'(R<R,8\D4:!51Q,'S,B1X<+#BU $DF1(%+!>4C[K!
M3VR#K^CCUD:KU4> \?YIL?&A<OS=[2VQ]/04E@?5?QT:0UD!ZXO+ BU=^JA.
M=;( &" %"3#"T)>V)8R^MC/]-7#&+V\A3W?3X?4)'G(A6-)'>@@+,9O8A-B@
M038!!'6?BY:SR9:RQ%?I,LXY6+WE]8TE 8E=5+;ZV Q ]RW\4]PGKUTU?Y'^
MX+Y]TMEPWI5]-K%=CLGEJ3.Y\%GKO)(B+5]D_*\$D&W=?.W.O3+-VW(@H)R,
MH\$ /)0R()^W^EL;U?*0SYWK'KGTGH\8+1M#@&4Q(TBDA3 _U,$C3?<J0R:H
M\@5>G<B%Y?U*GI&-((<?TST9\OU@D+(KSB$S2=LG8EXF@G4Q(4)8(& 5B024
MWW(/*EA?^"L/YY]-I/"^*]9-:Q0>%?)]#Y'H]FZ&RTZB"]%8Z?/ 55_A!\_G
MJQD\2.'(ITT?? HA&)#2B]-67.SO1,B;3U+$],;U&:%5?Z=X8X<B:2-<CCWL
ML!5#7#,C, I)&</4C'@1>N0PM)Z:,Y<<R&EE4=PQ]UH&(;1:DD8+;,J.$4L8
MPRS\G?<#\G,<\GF\*>G?OE+Q%Z1W$,;YO\EDV]?0LZ48Z4-#NZRFR9TF):%Q
M Q)-+O0,8%9T'[)%9!YTG ^F2PKZ9C9^?'+B^E9TSX.(8SW,E6BF#KG0QAP(
M\=K0JSLI*%E+*UZZ&:S#U:7T[&[65G1PQY;@J1 &GMH\0R:U),:91&OE@=>*
M8V8]/.XP_GKP?W2^-]+Y=OO'.@I:*_S(_(.KKDMY3:SQF1)ZSA2*J+HR84LR
M3$"ZOR=<0>Z-CGO3 -<<3>H8Y].8P9#/-F2_Y(9))!/@Y,?[>7"9&+6 XE"L
M_<5U*?'4]/R3FE)UC@A6,LN2J%42*<'WPS GC=&7Q8U=&Y:QT9Z+REY+W.7+
M1^/%JX!25)UG\7WM8@A95FH4G&"5-?3G^.:FE9C9S7XV00+,Y^."#,08^Y+U
MO!R(FP5QYA.9W1)&R0TL:10!>]// I8D4ZA4+K14AB*(&MZ3)A#ZULV)HC!$
M)8C#22=YMC"JV3LC$"RML37%\G5].V8\>HX.J7/<6VD%E=-?:0-E.QG9,C?(
MZVAT;T5^1_-O5Q&PF'@I3'6'@245^Q- TGFP9_3(),?'S&D@R:21V:,I"&YE
M7&9CK#"[@$@@D56YY'2N1G'/RA--AB":)5545&0OJ1H90++O7!- M?/MOJ,R
MWC7QZG4[TWC8B*.:\@6![UKRA*P@C:9G-V[W[5Y0K15A&W4WZ\92@L>RC,LF
M;)8G[!>1FI]#S699\%XJ,JPQXDOI\TC-COVD*+-!I4<B3 VK;5Q=UT2"4O'-
M%E6@B=YED2)682V&1)-Q:QQDDN%\J]55'K0P/I^K<[6O^*<9OM!C\F75DLM'
MB+[4\H]!Y R9ERQ1KBVZ_P#[W7<L2FXY=NP(O_)0B, 1JD[,O5,WT^9O3L6
MQ+*(Y9I=Q).[M&Q&L$DRM0$7MT7@ +R2 "&D]4C^LGS&6G:&*.-DBA[4<P N
M5('7DE;53Y7;P1Y+]",^6\D3J/'F.K5JBHJ*_-+;*:FCN24_SK#KN9[-52<@
M*\JEU9C@[9F<*S![CS['2F($G!8L&%-DX\[PJRXN.T8[)$15HW&ZO+D$F5R5
MO]NZ/M)()/4DR,A<.=&R'VGE[@BFMPT;AB)%6,7$;(!%*-=J '1UH?%?BW+5
M(-!G*KQ#CMO0V4+W07#%4R_8EFS&%<@*G4+^#34NC_[PX#^_>'Y,X_\ /A"R
M8R,K!VR6+S>UX<J7Z2.,931*Z(SS.$O55/;#IJQ%\\ =+8R^HLT$;!LB)DDQ
M8TEF=<86"Z(@9@ -FWU)L, ?D *KR[YK4H*ZBU]SC=+J:_86];BUW:$_2YFJ
MVK8A551H6TU7HDL<PTV04[!0PHMA'PPDB<-SG.-1)#"SS8"Q9<RE,F9;998(
M:-]V24#5@A.Q7;8<7=="$4TH:&>8X@2.1(F"V)"U-(@UO8["T)*@5YYXGZFO
M\Q5WD@V6\A:X]EI$:^Q/4OX7/5KND8HG(*6$%<F6V0 R!8H^Q1M>@@.4_P!<
M4?\ 4-[R3RL;(RWQ_48,L$;Y8:&/$E6%'CE#E97+AB_8L* 0H1CQY'6ADQ>F
MCZ&?"C1HQCKWFSU,FLT=+(NJE=2[64J[%_/6CXTN-!K*CS-0>;Z_<45%H[%^
M.)M#L*Y%M7.YGLOXY-2M$<[M"[9? 7MJX29>L$*>#!1CG"':>C)E-'F9OJ W
M1)NSVLQP8Y(5&JR0PQLH[8]K:G=C);D&P.B^M?21/Z=!Z3VV<0B5FQD>21)9
M&)9))'&I>R5 "J5%"_D O@C366N\HJ^,=ABM#'Q]EDR:7Q[I+IT#UJMVF#"L
M6J:M@,?@1K9A$,_2_"/I@_LF,67YA.".&,ILF>7Z-<G ;)EVGD1)4Q&4ZI#$
M[$!5(+-&R*=A5FQR_P"IKCQ8<13-3'SS#%&\$#.GU2R[.T\B*Q8LNI1U8C5P
MW@<].JXPM#;^H!S1)-[%J-.E6/OW8=Q7MY6RKQKM5[:%G7?ISBKRF_9 6L$K
M^6C<0BQR<@$)\NM-Z+AF+$]3FD=9XUFQX(@TD)C;82"6U([WWE"=5"UP:KK&
M@]8S$QY_3XHX'BE822NT*LQ"KRH=B&16JV\DGD@\CJ-O\\^#9+6^._C19KQW
MQP<.QE07EA;R94#R%?8I6%<"QK?V@M,M2#GR!:$,P;"T9CV7Q\7Q(,894DLN
M5#&D+"!_J(Y,F1O#[_5E_P!@"_<I(V7@^:Z-D3R_2I']+-++E Y"F$K!"I6T
M*]FO^(-65) HG5/Y&+>V\)Z+P[G=MGGM;BO&>UU-]8/^.LQPS-GM]34Q.L?E
MR\!P=C64]:\";)!%=65?C_NQXDZ;@OK;FP']0.3CP#'RX8L=5>;$B6-7!-H8
MR@02N074;*S%C9/D]9D&5+B2Q]\R#)5QVFRI&9H!8N^X6I?M]HX4"E !Y*<W
M@]!:T- -O(Y9K*78XIUM+\U?G6Z^GM;.,7;"@<69(R=YQ,*CUJ H9V0V0L\4
M; *48D2CQDQ'^EA5\''50T@90N3#*L>I21XE4*TK@$4^JHWN]UJ&ILHSLV1+
M,^5E+(45U*R8\H)V 1'6P8[H6M&@?!L[[>SQ!9>5L%XRW62S0\ND0&P;2II:
M'4V&F9$/@*Q.[LF%ZARS6J>+\KJVO;8L$B?#%L,(S^+H4RL)HY.VPE(",3!.
MQ"1J]2)(M&1PS@@DLT8-G[>!&Q,[NXTN1%*#(7$8D$: VC:NM!574G8; $FJ
MVN^@%NA\8HUE5<^/%]QCM96VJ+\M9L:PI;;5/D/7$MG*G)MR(9T![,_/Y*84
ME$TFN_BN7*O&4@Z.#G>H9T61CPF6/'+AVQ#'##%)[6K9FC;M1LJ$B4#W%>-;
M%@R((L22)LIL?(9XV"20.TC0N3[-VC:,/(.=DNE\-8/2QINOR]<WJPB^L8#H
MO#7H]$U)@?1$:,-/SK$CWP$*60(MDY,T!=+/V1ESGYYS\<^BXBZQD4H&[:ZL
M6I;L D@61=70O\#K"SBIGM2Q]JV64+S7P!X'X%FOS=]+[T<OZ[GCGS'35N0:
MT> M/4'ZO^;5J!QKF4MQ>9;;^&2J!F'+KC-BE,W&OU^3DE^LLWWL)"_M=A%L
M6,HCG1XC"EFG!:G+55 #D\\T1\WU[#].#&^EQ>]/'#.,R3Z<O[OVRJES(@JD
MW %L;-GQ\4I^X+3FP/J*^W/E,)L5/$3.=U.C>J?)#G9[X.)LG[3(M2L+E+2,
MQC=-4DXP9>G8.#6:X2/>R",78\IZ.LN3^I_59(Y=99/TO*A00(_=B6+UQWB5
M%-)'D(Y@4GF$N9+8ACT3]51OD>B_IZXV<9'ZKD[3.52BK^A!)_;PR0']V.'C
MN:&,D[$A([_OE^D]<'HRV/FGS;_X_N'O=&Y0=3Q>9KGD:="34Z8O5<;=7*]F
M70@DE=)(3=&^JD8 #1";W0@_Z"D:_J3.Q5Q_W_\ [6S'[_<*!A)C>L*N/VW^
MTPR*Y:8\%W( J(6A^J,3U"/T_P#3HE]0!BD_4F%'$AQHL18'^K],[THE1F,D
M;JR1@%0"(RP'NOI=^7O&6U]:ODCU7^5?*/E_Q?@//OIKL*[+9/PQ95R.'HO(
M62SA2%LAS;T-Z!LZ-Q#][B*AV+.1>%ZFV0:;0BAQ\)H,/TJ+U]84R3E^JL_J
MF',0RQ08B0"(211'N22(RQQDF)3*8'"S-*$$8O5F;U#U^;T*5Y<:/%]( ])S
M(F"-D39#-+*LN0[(="DCM:RCM+*K)&524//^F[U:;OU)><J?.5NA6\)>*?'?
MAU&FAXFK-*I5^-E+]6P20M;'*9\7%.,H6+LU"IU"O'K9[L@*%9=A$A^^@02Y
M2>N>I+W7.3E8+8D#EY)L/!$+GM1@*O;9 A0,(@+DW8!K U/T9G>DX7K&#AYL
M44$>'Z=FX\6/![QZOZSOV8)'=E>)V!9LAY)9"2R J3LH&IZ%Z'&.>5/+/C[;
M^IOS#AHF]0]F053A?+&9QE%I6Z&Y.T77;K.7]2<;522*WY:N VX_R0D4^H$[
MR#':>D2:^A_I[U2$PEHHY,@^G9#A\>)4$';A6(,) LVY2139EHZD!6/2&3Z6
M,KU7]8"7U-_398)95[Z.,;(R#,9MA$W)[T+M:K0"CB[:A;SU-9I+RU;^:?*U
M':6.BP?C#=65\?66]BK;=K=';5@9/7N3/1'7DQF5%%P5V4<9_5,U:G0.Q @A
M=/+:PG&-'APNO9E>+5%U*ED )02D@D2,".XHH^X@D'KWN%+&?3,:#*W?M0B3
M'=2H#U( IC # M! S,QNB[>:L]4KH^YS5I9=C.GMSV-%7W%-GV+(2]@[?\M[
M,YZBI(O\48W#KD&'W[BXX(@$E)CC\P3KM&[J7ILK:G;0L%(4*Q]Q:R>(_&H-
MUQ?Q>KCF #N+)^U!'-&';2,2;D=N( 6))6]S/(G/@:]'](G?0SMULZ85M/2=
M1!D(<<*A8TZN@7)^QTS5KUN*UQ5UR8QEDZT8L_W^Q",DQ#Y#ZXQ#/'$[J%#;
M &P=065B/ VVJCSQ_?K2@1D5I<:.43:(J([)*K2.Y=&9U:VCC0@D, P8+1*@
MV9)Y6S13GKBV5;<2=:3L;1FHRRNACA]9,:E?;,5J76>\[!ZGY[K$-7,,^3F5
MD,I\X</1!XQ*J(G!#?N.P!D4L;#$\;5PMT*  /ST6?'G.'DL9D?(AD22)2G<
MUFI5EDA53[870L'4<[@G\]?.<IWKG-Q%>/\ CA.OVQ[N+M4CI$K717%.G-7H
M+ENH$V/J8BULTK<<&%2'3[#HN_&:7M^K2NBR=P*^R%2"$+*2WV+M1#%CP/PW
MD_E;TV:+,_\ T]T]ZF:28^V6)EHDN)&8"(.5+LIY5O:M]!UHBKC*5&/C:RLK
MQQALK-?=N,=2M85]>UUFQ D"[&UUOMEV$1K0$I$4JZ!3+CE_;O3Q[Y#GO@Q(
MI]T:T0I/%D@GBB01Y%\CJ9*IAX17T]V>>8\9.P5WC2]@#*5>P:U0BV"L0.+Z
MTM!B;%-3,KK]+?Z;5#J[*GN:U.6BG!2?[## V%UQPK*^-=Q?JXX-K F96 N3
MC$OO_%HI?<R@=N)"P;@DFP M$$G4UL/FJX\TO.L/T\+/(V3F,T%2[6FM%R2@
M4AM:[;-Q;@@GYZ;V5R"UOB=0YYCMK6OU.%BF]7:\$A6V'KVFB3G7?R]4.=<<
M<N)]"$BX"%4#,G1]*,T(SXO)D=J8=M%97+*RT5DM3RR\4+!OYYH6+(-V.1DP
MXT#R0PS(\DCG(?10JDF/5FI&.K$]L^2!7GHD6\E)T^4UD*+,9?6+RQ,U]"H0
MMX6Q:@<TP6->$Y^-5&D;II-QL:VM2L:UI;Y!_(O(0I]E"3-)&S2F)>XA4@1J
M$902-J.WCBB->>>>>LYL*<JCR*'U:27]N19YY(XF5G7OQD*"5 5HB9'4,!0N
MNAW4;:>RQM(3R"QXD1KEJW- [H_$..J<WY"0_BIBZ2JNQ/OSE.].N>-;=\]W
M 5S4H'3C\HRP)1(])2JR9$KLTDA$^\D1VNB@6,^VS7'@'BN0#8.*T>'/-'ER
M)E'=5$C)L '5PC(S#12 3PP8!N1=]!?FCR5C/!F%\B6&+\Q5GDQNLR=(WAOV
M\PQV*]Q?2Z!C/Z96<15MC8U*DB=+I(,6(FG(#&2OK^<[T@,F::+':9\<XS[,
M LC4I*$ZF%2 0I- +0(Y'/PID^N9^%Z3E9&9CP+/ A34R*4?;VX[::L7!:B:
M8 #S0Y/6U;Z/*>7YU6GTOE+52M%LS1U&PQF="^MF(LZ)LY#5M&\O-B2*JJ?/
MF>'RKLPAN9RYV$$8D^-$/C9JK-)-('CC6.2&-7 9R?Z=5)J^2*YX^ "?)3YD
M?JTL>3D9^688\."/.Q/35G2".2<%NW&421:.IV!#4_-@*1U;:D\1Y2*^8OV)
M#\DN#JM?C]19^/-)0["TW&';I0AI,Q:/9B^$'-:  +'@G.?J ?MV5Y3[!D0"
MAFQ$F%DZLLTL\B*8B\JMH01JT<M*#HOA3YNV-CK0QL?!SF3,>3(RS!CY.#D2
M=I@,B$H1"D[Q<1RKL [6K2437/4[?9PB\%?&K_A/)Y3"(2KPYBFN?+!;#1-@
M/2D9K!6ER*EF.LNJE-#DKA=8=>ND:<>'C'XA_(QCG)0?N1PJBVJZQR&XQP#S
M8_%&QQ_ KK3QUS&$'ITWIV+!"B+C1E<L.)87C/T[IO$S0.E;[,Y&U>#]VE>[
MM'Q+JVF*+P]LJFF9R:M)8;+%W]=:B"-R)G UXS6=-95.DXZ>!AV#EV%1@D83
M."(O@A*9)\@_MJREP="0"-B220U D@@6/^7W?!\$S)Y?3&:%<*61](TD]0T6
M0!$#,B1H:5B36S Q@5L5(NF-J]QDZ_Q_G:6\M-#FV;"MSNBM\,'#6-18L*+F
M'?(,*5*3M>+MO9@* ;&CM9LK6 8\-7*<7A$7*)EQB:XH<B0KO153(B;C5BPT
MH:@$VMF_YOKC^KXS111E\II9#')*BX\O9B*N2'0I(BAG^V1 W_G-*>N:BHMU
MY-EG-JLG3-UU>A:FI9-%E6KV=JZNZ!(UZNL@10U@DJ;@X=L'8?YPXN. 9]GS
MKKM&B,;=-]1L%-J =B H!/\ \?!NNMC$5IC&0()?;).BO*>VTC; K+ \C2,5
M! &M*#Q_/0+'1736I0%:8K+Y^KSM4TJ$#5@E75M)9A6.+C:"781KIZ)LP_W@
M]*"])&?(>SHP?Z?(\86)G$LCL_@A&_<%'D@ G4?(XMJLGGJJO,,Q>[A(BHQ*
M('2(0/H::$RZJ)#;%0.ZQ%_CKOZ_V;&U1M_6IZW#H+S6@MZ?O3TBQPA!$(9U
M:\U8VSD( "P)S(7DNRD(412ES\PY[>\Y]>4]2V.3;FV[<8/M*\T:X/(X'/Q9
MXZ^5_KIXW]><Q.73Z3%!+:@A]+96U 4L"P!(%$^/CKM3^_O_ /N']&G_ /DD
M])7_ -/ZAO?^O_\ SZS)/L;^W7D8_O7^_0^'O.,V4XDA[>-1_'._\.=@'\2G
MWO/^O._VC+O]N>R?/SSV]^L+(1I<>:*-VBDEAEC20?=&SHP#UQ]I]W^GSSUJ
MJ>5)H!2K$>* *V*_L+/\5?YZ\ZGVFME1>"?*/KB\#><]GFO'F\!Y7/L$:WR!
M8HT3-^JP=M8ERHW=E6!9UOZ)(3F+]LT&0VZ[ (]ATD^OX$B9?Z-]%2!%5_2Y
MLB#*B5@TN*TD&%CO$T8M@RS8LL9(!IP-J##J>I%,?]5^K3R%P/4U27&D"L$R
M((I<N=6$I_;7VSHZAB+"NJG9& E_N6[_  -E'[=YLMO*[;YFI]5<!,^0$[A2
MRH>%I;1=*R3->0Z.OAVB,>(/;(W1+*A['YB0#(G;^@U_]Z>D9\BQQ13>B>J-
M%[6A6:)Y,9%G"R4P61HF5F;4,XY N@'UB5)_TGZSC1.99$]6P8Y 27[4GTF4
M_:D=055M)4<*395K-@]$OW;O,'CGS/JO2MZ>/$NII?(GE8?J&QVT;AB&1:KN
M2S5=#BY[NPL:2;J2 #_R8"$]K4.Q"N<IHCXM+L*?I['F?]6>D9@#18_IV-D3
M9F2PU1$=L5Q [$4RE(6D/!6UC#>Y@.K>J311?IWU5&D22?-6/&PL:[=I"\M3
MQJ0!P5:'A@:F)%H6/5*?/GCWGJI]6WKHT.7\QY#T=3\39QS";!$^I=S>@\_R
MJD#RE;ZFJ;O:=1VFNSU2RINU*AS<7:0.<=B2$V"YV'(B_I3U'UG2.7'S_59<
MJ'].HEXT)Q<GO,N2J]V09TCF0I2:C+[J%(M7,K31E?7?2/1IG:/*PO28(!ZY
MMK-4V-!CZQ.]#(PHHY"I<.';',;#9!&L;^]%^HL_61X#\ >'?&F*S.!T/@O2
MYO5;)5L.ASV&G@:S020;T. MQ,3:>NK9VEK;%R)&#?L,N.0F<\IDB+8_4TCY
MS8Z1/-BR9.)AYTV--"ZC&CC4_38T)%JN*J[-CQAK2%E4LQ4L;?I=/\(BR\C(
MC3*ABRLKTV#*BDBDERY)(S)DY,L;<"38Z%]%V8$Z('"BTGK+],OAC;^H_P .
M[/RAY U/CKL=S44&=HB 1K\.X:K6%HYWZLFN1>;([;$&"V> P"$&SPC$<R<G
M$GELQX(\V&;-S,99\O'UC+!BZ_3O'&L+$#6'93L&D !KR*KKU/I$N8_I>3!@
M84\\6'()YS&X D,NX1RC@]PQ ::Q$M0)HW?01X<VOBKQMK?4=3>.MVQOO(1M
M^7?/PL:>5Q3@I]*G!!WBEPS^M^)*,&!QJO>(-]9L?8C(4)(QAJ^AQX!GS<;%
M,SNL61W<A9"L;NBM*F/$% $K; )W&/N )4<7T#UH>HRX_ITN5##CP,L*QQ,O
M[BDE5:24-11"MD!064_<5H ;_IYJ\#FG%+CQMC++CGD^WT=G>6=N5GJJNM!)
MDB7>!.8MGVN*61A,.<A%>O!(HX1Y GYX;T%AAP,8<2::!WK.SU=3+#LQ[+"!
MN65;*&B:JS=FN?J 2Y<Q3+SH4EQ4!Q, 1L!*G;C64-*#0;4*0*-W1 XNX&2U
M/P$JCOHYBRK;G;6F>T[I%%V$OWQ(L2G<A,/O!) 5N0_Q8??!L\S?'"7(1A+L
M-[&F@S$>-,R>;)@C<0R6(R@20KH8V%LVI&P0A;!(!(Z\SEPRXK;&"*&-HXRT
M;';B11KSL31!W7B_D^>A9IW84.E3"NG35V3;=T$I:$<A.?$CT<^591K!(-8I
M^NRG(?OB24ICZ*0O\I3Z6;&@SQ--++)B9D"Q011N>,B-:$K1N1^P2!8+ ZDL
MUT0!>+(&,B1*BY,4BM*ZZE3')=(OR75K ( /!X')/1$>+R]P]7DN#W):9"J2
MT"5Q5G$IHV"_$/MJC!*85@S//YQ6A>+M0*&<5QPAR$9$3CA:)(TQQCF&629<
MEG=!G3B2()&LL[NJ5JQ:,A5V #"KOHCSQR@F194E41G&[5C&QD239CVRA9U
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M:PH[%A/*UMLA:.0A,4QC6YR1EN\B:-?U2O;R/2/T]AB&''PF]/\ 1DR.9,?
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M9$L@*MM[7:[LGI[*_5&-E_31S>EB6#$G&5C033QNF-E+)#(F1%IB1TZMC0$
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MTMA*K&)FE;ZG*$7.?,42\%WSZI+++#/D!YI(1("2R R/* &D9@A(;8;'R!\
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MTCRXMS@/S\?^/U.IU!+>,O&Z21JU/Q_B5*]BJ/1,(+9:C F>D99DXS3&6$C
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-IU.OKZG4ZSZG4Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g67046g28u96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g28u96.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[17,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %;"^55(X0DE-! 0      %H< 5H  QLE1QP"   "SB < E  "')R,34Q
M,3@Q' (% #E-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52+F1O8W@X0DE-!"4      !#S4(YJ1M"O6!PZX0U4
M6>-[.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/T       2 #4    ! "T    &       !.$))30/W       <  #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      ,U    !@
M       "^0  !V4          0                         !
M      =E   "^0                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   "^0    !29VAT;&]N9P  !V4    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   OD
M4F=H=&QO;F<   =E     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    ".$))300,      O"     0   *    !    !X   >
M  NF !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ,
M" @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,
M# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,
M#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !
M * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%
M!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%
M!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<E
MDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D
M]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'
M!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q
M)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75
MY?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U*JJNFME5
M3&UUUM#6,: &M:!M:QC6^UK6M4UDV] Q,Q_VFZVX/L&XM:_:T$@3M9M_ZK_O
M[T3&Z?3B658M;[C6&6O]UKY)+V.]Q:YN[Z?TOI_Z3](DITDD'[+5^]9_V[9_
MY-41C9%>8Q]MMGHWV/K91ZCS V;JW[V>[_M,ZSWO_P"U-O\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                             /_A0!-H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H
M:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V
M+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D
M9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R
M+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P
M,C M,#DM,S!4,30Z,S@K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @
M(" \>&UP.D-R96%T;W)4;V]L/E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR
M/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR
M,#(P+3 Y+3,P5#$T.C4V.C W*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @
M(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,"TP.2TS,%0Q-#HU-CHP-RLP
M-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS
M+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@
M,3 N,2XQ-B H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O
M96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @
M(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<]
M(G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!35$]232 M($953$P@0E53
M24Y%4U,@4T5#5$E/3B!2241%4BYD;V-X/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C
M.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/G)R,34Q,3@Q/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z9F]R
M;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @
M(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-33I);G-T
M86YC94E$/GAM<"YI:60Z-T8T,T9$,T%&13 R14(Q,3@V1#)".$5&-3<W-T(Y
M,$$\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N
M=$E$/GAM<"YD:60Z-T0T,T9$,T%&13 R14(Q,3@V1#)".$5&-3<W-T(Y,$$\
M+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^>&UP+F1I9#HW1#0S1D0S049%,#)%0C$Q.#9$,D(X148U-S<W
M0CDP03PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP
M34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M-T0T,T9$,T%&13 R14(Q,3@V1#)".$5&-3<W-T(Y,$$\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#DM
M,S!4,30Z-38Z,#,K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HW130S1D0S049%,#)%0C$Q
M.#9$,D(X148U-S<W0CDP03PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,"TP.2TS,%0Q-#HU-CHP-RLP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A
M<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P
M('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N
M+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R
M86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M-T8T,T9$,T%&13 R14(Q,3@V1#)".$5&-3<W-T(Y,$$\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#DM
M,S!4,30Z-38Z,#<K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @
M(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D
M1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS
M=%)E9CII;G-T86YC94E$/GAM<"YI:60Z-T4T,T9$,T%&13 R14(Q,3@V1#)"
M.$5&-3<W-T(Y,$$\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS
M=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-T0T,T9$,T%&13 R14(Q,3@V1#)"
M.$5&-3<W-T(Y,$$\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HW1#0S1D0S049%,#)%
M0C$Q.#9$,D(X148U-S<W0CDP03PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O
M8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO<#I#
M;VQO<DUO9&4^,3PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B
M/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  +" #T EX! 1$ _\0 'P !
M  (!!0$! 0            @)!P$%!@H+! ,"_\0 =!    4$  ($!0H-"A )
M" L  @,$!08  0<("1$2$R$Q%!5!47$6&#@Y87=X@9&X"A<E-525H;&UMK?!
M\!DD)U58=7F8T=4B(R8H,C="14A697:"A>'Q&BDT-D9'EI>E.D139FB2E-=2
M9'*&AXBFI\72U/_:  @! 0  /P#O\4I2E*4I2E*4I2E*4OVVO75UXP4IXG6K
M68\"S+"?$A<H;B_<+<K%&ML1Q 7K+A=Y)PFSY!;KHE+\3,Y 0Z/<\$WN#2K<
MPMSF2S'*O&=TMW1,6E+$.0B+,6ZNNG$GX:&D65MJ#M@F#*^$]IY?G"7J<1X]
MQR=DU_B0GEZ@*T31'T;@;%;Q%!9M:"R(Z]I$KN!"-8Z$'G+#0AP'Q/MR\_X_
MXF\;UG9>)3$N'1@>VCBO/"F;S7&^&YRSO^36[)C]'2(\"V2DJ9U6+WQB)L>G
M9F!Y.<#P1\^S8RJ5*A0;:&S_ ,6?B&O/#;T5S_E>?NFMD$RQM5.,0[';KX_P
M4UR1X;L*,E[(L:Y79<82MI6Q^.(<D.HG5 K>RF.Y(#(V%4P-UC'$IH7W/<#+
M9/9?:363*&0\^9 /S/"D&Q638AK/GEXAC+CR69KP5&%"%M99S)(A'FYJ:$)Q
M[T6\(TBQ.WHSU@$YQ2LBYJ+PA3=;2E*4I2E*4I2E*4I2E*4I2E*4I76DXN[_
M ,1S73-NMLHP9Q%9#CS&6X.X^'-963$9&N.$I$DPVUSUG,1NDG02Z3-KI()H
MJ*<V96[@:W?Q< P3J)$%Q3IT1'3R+%LT;K:_<631/0O*^UZ[8J$Y U0S]E/*
MLG=,18UQRNGLM;9;/E,+7F-\4;#CH_:(LK4RL!"=C>$J-U*0&KG1(<K7'"#$
MWB6;Z[%8]XL+KJLEXE48X>&O#5IVUYD13*68KQ!/&EVR:%^<4I<:Z<_; /"I
M=)$%C#DS>UO!RD1;$82V-!RE2:.L^ZIY!XF7$'X;6 ]DW;=!/H3-XX?F-RR5
MD%+K5 YFSYQQ?'7/P>%Y1.C615C21CYO\2LKN[C,:"B&]Y(4C="TZ1ONC+ME
M/Z'VS_NGM5KKF;/VUN:7/-4$E6:7N+ZQR-\QM",:/3MC. C5L;M-5#1!VIN1
M62S"0&"3IT2M2[FM:N-N))#D>0?85[^*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
MJG.*AI)ES=$[1B^*'&&MUM;]X\,[&ST4Q=')LLK@4!&["?4D=\6LSQ=?(S+*
MR+(&]79O2*+B%<UQ(L"]ZPAQ#M0-[YIOMIYN_I2T:ZREXUQQ;F&!.T5V F$T
MBK6O5Y.+LWA5)@PZ/.:M42C;%"HP(_&*,0%I10#"#B1WN+@SKPP\R[<;IP[9
MKB 8SUJD4*?N'9*M8<O8VACB_2Y$S9?>LN.TB0ON,Q2^- 6HD""$+"3&^9W>
M$$E:)"H6$(4X" A4F0*)X/?$N@N)=,H@\*]==N(WH!L1F%;C+7[,.098BQYF
MC $P2MOTJW2>K%L04M2'(^)EMWTIA:7=FDK*VM2MO3(52E,W7:EUMO!ZT3S3
MIE&MHI+FA#C3'+GLYL$\9I8-;L)N[F]X@U]9UR "$,7BCDXMK,2J7N8[6/>C
M6AI;V<)*%I)1DVN2: NY.E*4I2E*4I2E*4I2E*4I2E*4I2JM>)IIIE?;YUT/
M68O<(@@)UKWIPSL?/[2QS<FT:N P$+SX[2QP+>SN]G"1&76I[(&]9=M2'](=
MS7$CH?T47]^M-M^Y%Q)M9M_-*&;6V6*\)ZZ3K"[I$M@IE.(JC4N4S?9,H4.)
M!<-CKBH5)2&E_+NE,LZ)QA7$&@4)!DW+,'C-3PGLV;3<0 &V6^<"UFD>/<A<
M/=5KAE?',0<'^6D1[,R^4#4#><>%S"* 5)&QJ83#%#)-+/".2-KH::6E)*#>
MQX]B;>'KQ067@[S/AL(\DX86Y'43=TPO#<R.,ZF Q$:8N[^%>>:XF7@YC@1D
M!)&SG"!I(X6%0A*BJ@DM._IU2),&]]6N>"X3K-@G$V ,<( -T)Q'!([!H^G"
M"P!F)6)N(1FKU/*XKC7.RLM0ZN)PA"&>O6*3C!"&8*]\TTI2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M5^ E28!Y:89Y0%!H1C*($,(330%]&Y@BP7O80PEV$&YEPVO8%A!Z5[<[5\Q;
MJV&K#FXI>C,<$Y99QZ$"DD:P@DV]K%'')0CN>449>_(!AA80#OV!O>M4SHVK
M#%121>C5&H3;D+BTZDDX:,^P;#N0K"6,5TYW1%875'6 /HWM?ERO:]_S(>FA
M4C,<4SHWJ$!/6V-7$+$YJ0JY'2L?8Q2 P1)=R;A%8[ICMU5PWL/H\KU]:16E
M7IB5B)00K2* 6,(4IC2SR#BQ=H3"CBA#+, *W:$8!"#>W=>OHI2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*ZXN9W'!^,^/S
MJK*S=@"'*;3O VS4<F\:FN:&U<SX\>_$N(&[%N-8W!U3LF;(".2&.+L^M+(%
ML*D4T>G]Q<AJ78/@):*A_&DW/8H#JSM!@J:N;EQ5<F9=XIQ>U*ANEC@^Y2<6
MN#8MSLO;&&>PQ2M6>+XK W)@Q2H@K:JCZ1N;G$Q'9I(NH4#*%Q5V?H5AW7(F
M6:-9 = 2++?!"7Y+WBD,%G+K(W]7D-]SSB-DDV1\D*O&CFL8<J%M\ERXV6<!
MA;GU&UIU"2P$S>D!<K/V5VW7O&N:<[:[:ZRQ"S\+29[4<)N,Y_30F>KUV'D:
M7(C#-'#)[6LG!#PMNT(IV6RXS4Y/,)?T851JRXWD\DQ4<$=SW"<!E)IQMO\
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M1R)N88ZK &R8J_3C+B_6)X)1S;5':&8;\L.1G3=*7Y6''\/:C0"9X]G"URV
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M7]=5A_YE^N'Z?R=U64TI2E*K7XQOM5G$!^"KF#\4U]>.[WA[_P"Y[_B\O?\
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MV#>_+E:]5Y:5RB,DY6XBESI$Q%65;P*#DUS'=O!905?5W6(JQI%Q*+6.+N:
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M*843<'4W,!M>UK6OVWM:UKW[^=_/SO3I![.VW;W=MNWT5K2]^5KWOY+<_DK
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MK>[/7M?7_*=N=N?J:#S[>7]]F[O[>5_CY6[O+:N-_1CO+UT6E_G];I*OD^F
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ME%GC\PR5*I'F^1@?7N6NC V"=53H79 1<E4$X'@XR.I*NGL2$FX B+J0>N'
M1TPU =9.^:P3_;+![O-&]O:I6X0+8-^;%+\W-2D]8W(W 9S6JZPA(J4GGDA#
M8'1,-%>][VY6M83@#4>&:^3+(>0VS(>:\H3C)S%"8S)93FS(RW(CP&/8\52U
M;%F=J4JT:(+<A1+)Q)%)A998Q*#5_2&.UB@6K)N9\1 S/%D\6,R3EG%P4[ND
M=_5%AJ:J(#+#KI"%A%FP]\3)%AIC,H\+ZY6WW)L!0H3(S;CMU%K"A?'>&)!(
MD\S:0QK:?>IE?,D2!'*YXZH-E'DE9*I&WQEBAJ)Y=S/$0O"%R:+1B/L11EK
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M'G;I"Y!YVY\Z@/KUQ+==]F9)KA%\<I,A$N.TF!Y]L7C,4CC*)L3DX_QO-6J
MR(F3FD/B^[5(AOSNG$VMB8#DG5("SU)B].,)9)O(\;\0O7?+.X&2=)X(=.'3
M+V*8$NR!+797"G5EQZ)N:98CA3PU,$L>+(;RAU:)"M @<#F!N<(^2I(7H0/I
MCDWK$1/V80WRP]GG(<:Q[%&B<-8\APK(&1\12F1-C*GC&6X+BR<-N.YY(X@8
MV2!V>T"=ED[RS *1S1DBCD[M#JB>V=&N0"/,3S9I5<^SG% UNU,D>=HOE-)D
M<UQUXPMBS/,_'&(NA>$QD&R_DY?B6*%L!A[\W#<WTN5-YPW=O/+0D(FH92PE
M:L-N-*#GFS>^&+=8[XG8UL(R_F7*.<B7A;BO"&!X/:=95E31'&E&]2>1A9U3
MHPLS-&(R@<&_QV_O[\UMZ=6X(4!!BE:H 14I\<S.^1(+%)Q>+2^$7E3$V/OJ
M0G[-:/3:-W<DI:F[+*F.RE:%J?6X0Q)7)"!6J+(4E& +4'%V"8+FM5I2GBL:
MQ1'(V8,7NB/)@Y+A'9C7[5"9C21-"<W&92V5;@.>.3F94-^*&OBQ*<0@R1W-
M(2*FLT%PIFQQ"( QY)V4XA6O6J^9=?,"Y+,G:S)&RD[BT @;?$H2Z/K,UN,Q
M=EC&PN<UE [H8W'&I<Z-Z],F(&Z*I"LLA7J4#"K1H%B@C ^RW%QP_J9E9!BW
M+>N&YB1*_92AN'8EE5DP>B6X>G,[G@48H\UPR8K)FVFR(9PE)Q)X$+0-6 ]K
M=0%)3PH[C'EJ1<2O6J+[RQ/A\NRN9!SI+F!([HW8B.%FXQ;GASC<DF;/ 7J9
M>,@7;L@/<.BKK)FJ.C:AW6-5T9Q:OK%9956!=]1IV&VKQCK*\Z_,F2"I*8KV
M4SO$]=<="CK22Z$E9"F38_.S..1#.7H;M<?LFCJX"MS("N.(/,3!LA, 8885
MP6 ;X8"R+@7,&R")1+VG%V$,AY6QE-U+O$G!7(+R;#TG/A\G P1B,WD;Q("5
M[X2%-&2FU,<Z/-U*8 6U.H,N0'!R+BU:R.NGV+]RV!@S(^PO-N25&&\.8N:\
M?74YSR/E,N722%(X+'8"!WNG ]+W2)/BHOQJ^MJ) TI!+'=6W&!,3@E)J5ME
MC'<K%!F6<7HY>QI&N8R[',RA60XZ;$\@X\R) W4;-+H--HZ8H6 ;) R+@ Z\
MM*O7HCDRA*J2K#BCPWM)VE1RVCVAQMJ+C-+EC*I,D/BZR?8XQN2"*M9#PZ^J
M+*4S:(+&A"1J%[:79N+>GM(8Z*;*;F)$ 3SRDZDT $YD4(?Q4L1Y V"RKK["
M<$;92@["63YCB'*69&7#B==@6&36"Q\4D?T;UD$N5V-0IRVZZ6R0U4R$G*3W
M)MM9. E:4=?A.$>-7I5L)A_'N9<>*\E&M&0MG,?:F)HJ]PQ.TSN+95RFW&O,
M%4R]A->S26Z%R!A"6^()2W.#NE5MQUO R%*M.M2);; GE7YVZP'3#8/3!85K
MB!<5N=K"MWVYVYW#SY<[=MJK$4\6/7QGW!ANF<PQSLACR99-E\HQ[B?*.0,,
MO45PAE><PP)@I''<?S9P5A7/O@ER[%)GL,?)CCB<:G"A=SP*4QA]H-5+Y1XR
MNK6+3<PH%,.SY-)!AC;&(Z6O42Q[CA%)93*LXSB.*Y-'6N!M5Y.AN_M"U&A4
M(P+CCFY:8Z6*2)VPZQY!IGU./&$U?B65=6,-9@A6?<!Y#VV2O2K'K+FW&!,)
M-B0FN:+8 U)<IC,D2Z\)43.3)2$4-&,+@E<[.[*8J4MUG(FU31UWVBQGLX1F
M)1C@N1D%X/SMD37>9VDC62U#-G^,#VY-)364)*Y=X?'[F.:6S<Y&W2G*K7,N
M8B3W#:PI&!$$5N8;V%;NYVOS[;=]J"ORM>_+GR\GZ6O]ZJD4O%_QFJV62ZGW
MU%WZ2Y:5B\8E)UFNZ4AE! K3N^.Q9<-7>KH2P&*02*W1%,+-HD]D?]/\'ZRW
M4U_,!XU>E62<2;,YAC*W(YC7J9E%@Q3EN*KH@B0SLMRE.16[%D<E$:8S7_P=
M[A+Q,%JA"E?;N2,8 LCT%2B(5(RDJC*$+XF6-,B;13C5B#8$VNE;UC+*=\.Y
M$S Q8@3N& H5- 1=KEYB>29%(E-S&M&6S/32:,]2Q%G6&XI+>"]4>4:.R&ML
M>G5,Q,[J]K>L\"9VY:ZK.I#TSO!&],:K4W*+YVZPWJ21] OI!Z8N0>D'GSM7
MYK7Q/M;MJ9O@Z 8Q1Y')?]@M;Y3M- O5-%T32C*QC$,F7Q.[%/ZE.^N/BZ3B
ME01C2-)!:Y,<U \,&XDF""F%S+'O$(U^RAN)DG2*(!R JR]BG';ADJ6/#A!W
M5CQV-F:):WPAV0QV5O5T I4XM<B<+-ZY5'FUQCA*I$YH OYCDVK41/T81WSQ
M%G6?PB QZ/Y!CAN6<>3++.%I)+F=E0QW+^.X!)66*RB1Q,37(GEY:_ 7"1,*
MXEHG+-$GQP87=&\H&Y0FLJ\&FY2JXM@.*-K3K;)=HHKD-/D8UTU$Q;B++^6/
M4]%4CFG.B6:Y6*'0TN)G'/:*SR[E._5B>T2JS64A1G /(5K!!-)+R!L[O=BO
M5\.)VE=",NYCR?G6SL;BC".!X0"=Y8E[9&6A,^RN0%,:AT8VEIC,3;%Z Q]?
MG]^:T"52X(4!)JE8K)(%+6$R>TTB$:EUF&11:TE8VI\]3<O;/$LK8+.J$A=9
MGDK1URCQ6^MMC[(W9OLH/LC7DGI['&V+Z8N456+DKBT:L8IE^4X3*4^31/6(
M-I,"ZA2V[9$$JQ&/+&QL>+D^/CF@\;Z0);$R6L8[R)Y-*2J6U22,E*VN-A%#
M,RQL)Q \ :VYUP)KE/;3URR;L7-8O!H4DBD%>7J-LSA,ECTWQQ=.)F:6ABD;
M1NBV//!2)O&[JY,N+;5RQ"P*4"-4J)P=G?BRXJUPS*QX<R?K5N@WVEF8XA@J
M%9408-2J<.3G($Y.*(CJ*&S-1,D9T@3*^DJ-$-$SC5A(:W0X"(P",=[Y><>(
M]K8U;U,G#R5N,JMGM]A09@E6%L !X[)5FL;G*DL%5RV[@&Y&0%T09W"6(8X)
MMO=0PDV5!56--+(%/6HU;$[58RUC<L"->1RI(:JV.SS#-<\=VCK44Z%@R'.T
MCRL8S) ,U<BNV1X)3&L"N<R0K3TY@B+ 0G!&,1>,,:\0C7O*.L$YVZ9C9NWX
MAQ]+<DPE\NXPMU7S%1(,73A=CQ[1LD.BMI(\OISK*$/@<92M9*E>[ 6(Q"1I
M33#22<.I>+AK(Z:D86V]CD:S7*(YL9D)1B?!>(8_C].X9WR9D9.^REA'%&&#
M%2#P A8 4,D#HJ5NTC;FQM9T7A+HM1'F%I12HU(VUQ7N?B:^7,4%2IJ0MTNE
M>/)C#9\PBB^0,=Y$@KH-FE\%G$=NI7 :9&QK@!\((3KUR0](H1KD:Q0E5%&7
MD]2E*4JK3C":Z9?VCT\38MPA%K3"< V#UIFPV>[LT,MK1F YHB,JE;A=<]K4
M"'DV,3:L7W36474J@D7)2E''B 4*.^H_#FG$-VKW_P!G<F..:(@]Y VRR]-,
M)0I@S6XH\,Y%QS,,6QF.M<JF&*&-V/C3D]F.IKVE3JI0D3/2,QI;#Q$%E(41
M@JCH-P=MX\4,'"UDF.H V-MBW;5AMXAF*/55$R#&1\UFS:9/L=9G3J0O%FF0
MOK/!E[K!GHR/K7%P.9P-:4*1:9:QJ*=(L>9E;H?KTR3'$&S#EFJ$[92;*6^>
M083$9HN4Y/Q1',R2>706/LTE))2-F:X[+)'?#"R.12!.3B;!,51V4H5K=&T3
M>Y1ISY2GBF].6^*_'L\[)Z*S][P-@J3.^-M/EL>S#AKZ76*F65*366;;49 8
M5$I%+Y9D.01ZQ1#1'VYF*!#HZ.Z%"4O?@7<1=C'MZ/N]'T=O+XN7YJZH>TG"
M^VPS8_YO;$./Y BC&2..)@C:4J013(\>B4K3:TL.&6:$3')T:?DCZ0ZQY]C[
MGX6%K3I;DRY*N2%N+8VFV)*,%+'9_A)*\U92Q3AXE1D66X 8-$-J\-_3NRMD
M=5D?)L-S5/<O8=R;A^1J9)(W0<W>'F,2*+*WYC=4H+E-*"-IV42U(2)*2=#/
M3?2C<C7?56=S?909&(-Y\M[S3^/P^6H<B)EC8[MVU[)&,0O<M:D$>?UD;5K#
MY*N-RP6A7HS) >''C>(M.@N2E"3VJ,>PACQK!8?CZ-%J"H_"HTR19F L6*G!
M9XM8FY.V(Q+%ZTT]8N5C(3 &J6*SSE*I0(P\\T9I@A7YA55;AKEF!1QFF?:D
MJ*"O@I'P]'+"1\T\;,]@AR8?GDJ9%1VS+=;9\%<4>")?XP"W7;;!Y$75V4?T
MJNOMF/@P;NFZ>87<<08Y;T6QQN7\YXKV.QR=,(DD(GFKL\W/?]CL:R,QZ$]E
ML"QTQX_M[#*FU*)P\;DMDJ=T5RA&(C6R]T>H_#ME\7WWW>VSRJ[9JA(9+L^U
MS;"4;BF:W1LQ!DR#CP'!(:N?IWBJ/NIS(_KD<B(?F],9+42=S*&TMR@@CP=&
MB.'=U7'I<A5.D4DS8B+ZY8XQ]X0I"ND$'6*5;>H((+Z8[V #IFF!#TAWL$//
MF*]K6O>W5@UNUDW\TG4<,#)#;I;+,[O6 M%\\Z^9;@4.RQB"+.L/F^1,WL<X
M8[G.\KDY+.[([,+-<TX;,<M+L8K+ )0682874Q8PR[HN'&B%LR\Z-SN+8!<]
M7R]25.1E>6\-KTK7=%E%=E&V5CF!LDQ\@41M86,IB"Q)V\4@LN/\..*"18PL
M.->%VR2YY0\.B:XIADR;TD<Q!L=#-G)E*XK($<(<,=.$M=W'%K5!)*_)KL#C
M(EV26QI=.KQRK$I''V][%.>I&0T)K]D6E=9CBN:";8;%Y%XA4BPUBT4Q;<SZ
M(:GXEQD8&41-H%*,BXPVHD.2IC&B@/3TA&WFMD/4IW,"YT"C;58SRTB16>KL
M,D.-ML]=-Q-O,E:];'S[AQYALSXEPQF?6QZP"Q;:P?'.3#W:5MD'DF/,SH)U
MCO)$99UT%22=G7LKY%5\A&X)5:%$_78W8*=OL5?1P^,59SP?I9KCB;968FS[
M.<%QFS,F1I0>]JI*>L?"AJ#@H3Y(MYJY$<PMYR*/F/RB]S7@;6)Q$,?A/3%,
MBNJ+L?H3NP#,V_F8H#K^NR0EG?$MX>^T.)HXU3O'[(YY)QOKY#!$Y!.0*7Z0
M)$C L0NH2FLI/(_ %!YIHE*5,J3%#'6<^(,MX@FT"#0>40OAH900.^"]L('M
M-D"++,[:_#7H&_%3E,V B!>, RTI >_2UL<D,F;G1*-2U-R)6%"OO9> \LJ6
M&2];<\;<\2;5'*V8L;.$$U/T[Q /-,39G631EXO,MR,AEV:26]:SLCDL.,38
M/C%SQIGY8F3HU4I&8-D,/;E(CCJD<G<,7BISARRIO&RR6",F95&^S1N5!M2%
M<1C"S)*U-B1]*Q-C:,@V/M/;,C0VN.OZ90,V'&-MX^.SFI0+E)+@K$-)V^D!
MYZI$D4JDIB%0>F(./1'#*,.1G&% &:E-,(&:0,U.,0BC!D&F$B$"]RQC#R%>
ML+B4:[9>S[,^'&Z8JBWJD0X(XA6'<X914"=6AL#&\9Q:+9 0/DAL!T6HS'*Z
M-6\-I%FUK L<SQ*@B(2&%@-$"'FBPMY]08=M'AE^X?.19PVJ\^[;9^Q_D!ES
M1@]O9LC$9'R6NDD(B+2TN4GN[LKN\MK@$X*]^+1H4-TYEEEB3+@+J#N =->(
M%&-*](F9]T^D3-EKAX;['[)?2O<,N8G&HV!QSD*29B?)05!7=#(U,=89-"$>
M06M,G13%T;"7=8G7&(CPEC+ *Z?A2ZY9=P)B+/,HSE$B<<Y(VDV[SWM4\8P+
MDC9+U&-6[*;PU$1J'.DE8^DQNSVACT=;ECR<SFGMY2]P.2E'G"(&.]HU*K,X
ML> ,K[)ZKM&.L-1>\NF"78G6.<GM-G1J:+@C&/\ -T,EDL<O"WE:@1B\5L#6
MN7W3!/NJ4A(N2D)/4" 4.&.I'#.R'$MC.(OL?E%?FR&2/(VW>?9U@:#1K.;B
MWX9R;CF>XP;(ZPRB<8KC[R=&79V4.B]X3DFR],F=T1C4SFGIBBFM$.]=3?P>
M-OH"\\(/(>,H&W,]HP'3U'Q#,;AD<72V99EJZJ-4PG,/6@>0MDE?&6*OLI@#
MRHCQCJY*VQ*QIRBEI8PJ$4KT6-LY-\=UJ:,EXEV7>\P0#:*:Y6WZR-CN.30P
M.6H+'\IRN58?CD?>DI:1)F6-2>7*,+N3(P0M>K*QSBN*RQHD*>+M9#FQ+N6-
M\)W;ROQ7FC8G9O0S(4JQ'A>4*,8::.[+F#"Q.-\'0V3GE-D^V7FL=.E@Y=,<
MF2IO  9+6C:BRHC&DY+2T)W-]+*="NQW74CS+PK=MLJY.V<*4X^DC-!LO<;#
M 6SB"5PO)T=B,O(UNCL =X_,<F1A^;G\E[C+XP*7,L+<2G"GE:=:796V-YPD
M]C+2EV8X.:O-N=(IBPQ3DJ4Z[M_#LSEAAJSQE+):G)64H7L$_P"Q<*S%BY]/
MD4F=#9RZND7<VH;PSN195T2-E9[1L:PA.8!.=&C5'3'<77C5=^G^Q;H7A[>_
M+V\T\B,;?TF24"R.R-AVK3MN*WM_0M;,_FL*]2I?791FTAJ-2F21R78IBH#$
MS>4D (GM/8]A3/C>"0['\?NKNQPJ,L<6:1."L]>X&-["VIFQ(:O7JA&*EJTT
ME, Q6K4F&'J5 C#C1B&.]ZYA59ZK .5A\7Y!L\"+\\)$\.X[!QDQLYM7(.3A
M;%F3H,;\3>&>.[\XQ>SEXQLW^+.5_!O"[*N9-NNQE+@[[V-&NN/Y)A3&+23F
MB<9GS9BO:3&JJ61!'>8ZT23=M3LYAS(Y3OX_3,:V28^<F1*I2D'+E#Z1')HN
M:[) A2*40;G--^'9+(CN]NWM?EAWS;!U4GV\=I[A:)Q?-KNVX<R/CMQPC (G
M:3SC%$==C6!]<RW\N1H212M$0ZE#96DVZ:Z9 @,'=W7%IRW+'>%2]H;R>O7N
ML7?VU"3TP%V-6+FE6F3%W,,$$LNPSC0 N,8K!#TND*]K6O>W5#U1U9XA&B\Y
MX?&7TFD<MSLJQ#PY<FZQ9.A$-RYAN,.T1R%+=FW7*"$*AQE,I+;')$"+D(#[
MG-!BT@1SF GP@)R144&;Z!LW74\9$.SCAHE/&/ Z_5%%I^NGYF7L,*DC5TLQ
M*LK+<M',J:2^/U,92I%@V@QB2MHY">M)&I)*,)&"U^/<."/R-\'PU9]B:%3U
MNLP:VY$A>T4OE43DC?!EN.5K&S*<9-L)DLH37CKA(7#(K#'W5,7BM69X1'DD
M@/GPB%!+8FOV)Z5UB>(]P_-MLXY,XMDGQ7BSU5-6R&H>G&.<+F E42:S9I-L
M3Y;O*9PQ%E.SRB&SFM+*1=0%8^!;T"P1A)2)2H-%U=8OW(U1W&V_R-KSM)*-
M LQE_2XP3G'5Y^UQ:]LX7CG(#6]2%LC<BQ5GEIG^.\@QQD5Q$<P*6-,LC"I^
M4N*<IA:'4^.O 4Z,)78<T<QIF+#>H.N>+-@I>9/<UP/$T0C>3)<:[K) :\RQ
MN:R2G(TQ_< @7/@TH^B@$\*@]>Y7276F7$([I7E574OW1X>.[4HGV[N2<9X'
M49$!,>*9H/M;C*/()W 6-RR%BS .)+M$^6-RE_?TB-E6)9#U3*0C?1(5APS#
M%J=(I1$&&WE)O5)N(!L65H?)X;PR,J)G/"6U$!VLR!'%6>-?[+6U/C!3E*'%
M8YNNO*R42M_DK2],TP;WA&-4SH&YS"VK+V="%)9<I<A:^Y\V>XF6M.6LI8T7
MP[5/33##OE2"HG:11AVO/-O\HI"6"X!LK.[+3PE87A9SFG0/BY*F2F2I4H4,
MZA0A4!-%3G(N&GQ7Y"^O?$&\8PA+G5/OTS[BL>FYD5A9N33F*%NML*Q^$!V3
M!/"8^E8U.N5C[FPL*0MF.L>(D]2![-%<'<+1FFGI$QQZ<Q(<<02::E.$6(Y,
M:86$9B<T1(S"A&$BO<L8BC!E"$&]RQB!>U[U@<2S7;+N?Y/P[G#%46]4J/!G
M$,P;G#)QUW9H:_4[C*(-,U32&16 Z+$@W.Z YU0 \6M@53F?X1:Z=(:$!EPP
M0X>2??7337_,FNDLX=>1I@:S9)VARU#9PRYLP4E8\C'9*S([R:*15D;EDH-<
MF5S5L4E&X>,WT*1 G\3J23A%'J4Q=1+UFU.XA^,=1>'VC>-+)&1DWAS[A2C+
M#KC)7F#$-G#.^-LPH<U)Y(Y8\<DTF/CS/(,?6R$RE^*YDZM07<T"T]M4" 7<
MJ]V'"MU_S/@[#>;I'GR*-V.\D;+;8YTV>7XP0/3=)3<:-&3G5K(C<.>)&S''
MLKT_HV./H7!Z5-!IC>2O<CD)!IMD@C1V=4I2E*4I6G*W/GRMS\_+M\WWJUI2
ME<'F^-X-D;U(WF\:;9)>!S9CR+$/&10C;,$WC85A;%)4 ;""$#FU!<%ET9H[
M&!*&=<RP.F$ @\W#W6]%OO5K2E*4I7Y'E@-).*':]P&%# .UKW#>X1!N$5K"
M#>P@WO:][=(-["MWAO:]K7KAN-\<P;$<&C.-L:1AIAD$AS:4SQB+,:>R5I9&
MTD9@RTB$CF*Y9?3-,,%<0Q#&8888,0AC$*_-Z4I2E*4I2E*4I2E*5IRMV=EN
MR_.WN7]RM:4I6/)]B['^3#X(=/(LUR<W'$]9<FP<QS+&8*-3Z.)'1&QREMZ!
M@+ =&Q,\.924PVQI9=EAHNJN/H"#D.E*4I2E?BH)+4$&IS@V&4> 1)H+\^0R
MS+= 8;WMRO;I!O>W.U[7[>RN)8\Q]"\4PB+XXQS&VN'P6&-"1@BL792+)6EB
G9D .J1MK>GYBZE,G+MT2P=(5^^XA"%>][\SI2E*4I2E*4I2E?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g67046g31n61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g31n61.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[27Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )=Z^EI0X0DE-! 0      $X< 5H  QLE1QP"   "]^<< E  "')R,3<V
M,S8R' (% "U-:6-R;W-O9G0@5V]R9" M(%-T;W)M("T@1FEG=7)E<R!2:61E
M<B!T;R!3+3$X0DE-!"4      ! :[2HEM5K,IP=I=>CE>37S.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&/W=,         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             !JP
M E<          0                         !              )7   !
MJP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
MJP    !29VAT;&]N9P   E<    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   :L     4F=H=&QO;F<
M  )7     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   &.$))300,     !MQ     0   *    !R   !X   U<   !M5 !@  ?_8
M_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X
M @ )  8 ,0  86-S<$U31E0     245#('-21T(               $  /;6
M  $     TRU(4" @
M                   18W!R=    5     S9&5S8P   80   !L=W1P=
M ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA9
M6@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&
M=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M   ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M  !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD
M &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U)'
M0B!)14,V,3DV-BTR+C$
M                         %A96B        #S40 !     1;,6%E:(
M                  !865H@        ;Z(  #CU   #D%A96B        !B
MF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@
M        9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M         &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M          !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %8
M65H@      !,"58 4    %<?YVUE87,          0
M      */     G-I9R      0U)4(&-U<G8        $      4 "@ / !0
M&0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"&
M (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8
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MQ1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY
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MX78^=IMV^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MYP7]%6TJ6L:U4B&8B4JVE2:8@4J$AAB4XY.,Q.,90@"V&S7 8# 8# 8# 8#
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M<ZMJ(IRB8V8B-^4Q,Y[\HPJFF9_%B8C+@F<YS[NYFG.9B8# 8# 8# 8# 8%
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MK"J:U<&KG?7H;RXA*G+0M9@,!@,!@,!@,!@,!@,!@,!@,!@,"@?K![^O@+
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M5QO6]?UQ:M@],TQ"*ZMX)YE83"5SQB8&6=$I=!VM4QI2YJTWTFD;P#+,<E9
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MOM,Z/.D1+;IV<2.C[<*6N>FY,,Q.WZ7J0&JM(B#!DI?-\@H8@%A%L-EF P&
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M4Y+G#Y4TO01=V-*^=F"3MQBI 9IS;BEB (U 0V#X# 8# 8# 8% _6#W]? 6
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M&^4*K A"E[4,[F*(+)6SI NK<0G=5J9K1N38)8%GT]XA=L70W2]ECG%LT37
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MH(+.,0J]IC3TVU*08Q$'[3GG$;-+'Y1IA?HC$'-P& P& P& P& P& P& P&
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M/.%I0J,T(XW?RC$%]8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8% _6#W]?
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MI2]+H1=\*CD44K-F,;&XU\@=5K:C\HL.DZEP,3B,5&:-T8/S1"WOT1Z#\O\
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6& P& P& P& P& P& P& P& P&!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g67046g31p63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g31p63.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MEMO*C<#N8 XS2L@&:=?2W<F7,*=<Q#.]/K0,U:0!0 4 % !0 4 % !0 4 %
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A 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g67046g35v28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g35v28.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1B<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &("^8G(X0DE-! 0      %4< 5H  QLE1QP"   "J  < E  "')R,3<V
M,S8R' (% #1-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52 #A"24T$)0      $!_&N<G0:<9D%J?:JKW5F1 X
M0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0
M<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT
M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P
M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q 90ARP         IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M        /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      &)   $)0         !                          $
M    !"4   &)                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   &)     %)G:'1L;VYG   $)0    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !B0    !2
M9VAT;&]N9P  !"4    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     <X0DE-! P     #@L    !    H    #L   '@  !NH
M#>\ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( #L
MH ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&
M!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'
M!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R62
M4_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&
M!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E
M!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /54EB%]S/K-
M7CWVV6"ZIUU&U[ZV,:S]'Z!QF'T<C=O]1UU__6UJMRL9Y#&7,<]WT6M<"3IO
M]H!_<]R2G,ZE;]96YFWI]-3L(FJ;"0;0"X_:MC'V5UNV4_0W_GH&-D_7%N\Y
M.)2]S*LA[&M+6LLL_1NZ?CBWUGV5/_I#,FQ]'H_S7_&JYT&[-MZ/TRQ\6BS$
MH=;<][C87FMCG./L=OW?\8BLNZT'[;,:@M#B-[;7"6EWM=L-3_<VKZ7N_G$E
M-$]2^M'VEN..E5B9)N-OZ,-_1-]3<!]+>^[]!]-]5*9V?];36/\ )53;'-GV
MWM<&F;O:=VS?]#'_ .W_ .0M(6=5-M4TTMK)_3>\N('\CVL_ZE7$E/.GJGUH
MMLNQ1TX8]M;*7MM!]1C@^YC<IM5C_1H]6C#]1VQUG\\E5;]=7O/JTX]36/&V
M(.]LVV>_]*?1]CL;']OJ>^J^_P#PM=;.B224U.EOSW]/H=U*
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                             /_A/7)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H
M:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V
M+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D
M9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R
M+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O
M8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!8W)O
M8F%T($1I<W1I;&QE<B Q,"XQ+C$V("A7:6YD;W=S*3PO<&1F.E!R;V1U8V5R
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A
M=&]R5&]O;#Y04V-R:7!T-2YD;&P@5F5R<VEO;B U+C(N,CPO>&UP.D-R96%T
M;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,"TP.2TS,%0Q
M-#HT-3HP,2LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z
M0W)E871E1&%T93XR,#(P+3 Y+3,P5#$T.C(Q.C0X*S U.C,P/"]X;7 Z0W)E
M871E1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,"TP.2TS
M,%0Q-#HT-3HP,2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @
M(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA
M;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!35$]232 M($953$P@
M0E5324Y%4U,@4T5#5$E/3B!2241%4CPO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC
M<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:3YR<C$W-C,V,CPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA
M=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @
M(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N
M8V5)1#YX;7 N:6ED.C1&-# W0S9"1D0P,D5",3$Y.$0T.41&0S0V0C%#130T
M/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)
M1#YX;7 N9&ED.C0P145!,3DQ1D,P,D5",3$Y.$0T.41&0S0V0C%#130T/"]X
M;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U
M;65N=$E$/GAM<"YD:60Z-#!%14$Q.3%&0S R14(Q,3DX1#0Y1$9#-#9",4-%
M-#0\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C0P
M145!,3DQ1D,P,D5",3$Y.$0T.41&0S0V0C%#130T/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 Y+3,P
M5#$T.C0U.C Q*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP
M87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#HT1C0P-T,V0D9$,#)%0C$Q.3A$-#E$1D,T-D(Q0T4T-#PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP
M.2TS,%0Q-#HT-3HP,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV
M961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HT,$5%03$Y,49#,#)%0C$Q.3A$
M-#E$1D,T-D(Q0T4T-#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HT,$5%03$Y,49#,#)%0C$Q.3A$
M-#E$1D,T-D(Q0T4T-#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @
M/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C0P145!,3DQ1D,P
M,D5",3$Y.$0T.41&0S0V0C%#130T/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P
M.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB
M=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_  !$( . "70,!$0 "$0$#$0'_Q  >  $   8# 0
M     08'" D* @,%!/_$ %H0   & @$!! 0(" D* @@' 0$" P0%!@<( !$)
M$A,A%!4Q419!4G&1DM+A"B(S86*QP? 7,C8Y0G*!H;48(S=3='9YN-'Q)&,G
M0U9S=8*7UR4F*#55:;.V_\0 &@$!  ,! 0$               $" P0%!O_$
M $01  (" 0($ @<%!0<"!04    ! A$#(3$$$D%1!6$3(C)Q@9'P!A2AL=$C
M0E+!\146)#-B@N%#DC1$4W)S8X.BLK/_V@ , P$  A$#$0 _ -_3N]X1'O'#
MH/3H4W0/+\WGY\ >'^FI];[N /#_ $U/K?=P!X?Z:GUONX \/]-3ZWW< >'^
MFI];[N /#_34^M]W 'A_IJ?6^[@#P_\ S%/K?=P"'<#_ %I_KA_TX  @#[%#
MC\Q^O[. .Z _^M/]?\_3W>_@#N!_K#_7#_IP!W Z]/$/U\A_C^_V?%\? (^'
M^FI];[N /#_34^M]W 'A_IJ?6^[@#P_TU/K?=P!X?Z:GUONX \/]-3ZWW< >
M'^FI];[N /#_ /,4^M]W (=TOE_G3^?L_'#S^;RX!'P_TU/K?=P!X?Z:GUON
MX!#N!UZ>(?K[N_Y^_P!WNX!$2 'M44#YS_=P" $ ?8HH/_S_ '< "4H>U4X?
M.< _9^?@#N!TZ^(IT]_?\O/V?%\?Q>_@#NE_UI_KA[NOZO/YN  ( ^Q10?\
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M0&SN&D7JTB4S9PF^!KX[L#:$2'J7V]?(!Z^SS'KUZ!Y^7N_-TX!V\ < < <
M< < < < < < < < < < < < < ^1\H9%F[7)T[Z#5PJ3J'4.^FD8Y>H>74.I
M0Z@ @(AY=0X!K1:H=M@I?>SBV?S5G3.^N%7VTQM*[-L,9T%Y*UVJOI<,?1+A
MQBY-;'S^RA+32TI*%*R &ADO7H)E10*"XJ*&#X_7_!37-7:O[@Q>M'8SW* R
MY@?"%LWZ;22.<LO9*QTWFL?4<S>/KRR-A;P;NX5MG$1#-62<J/$59Y IP,D
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M-P#F7^E_6']G .7 ' ' ' ' ' ' *<YA@I2TXDRC681N#N:L6.[K!1#054D
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M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#XY AU6+Q%,.\HLU<)$ 1 H"=1$Y"
M(CY!U,(!U'R#X^ :Q&F_9%62E=EWMGB+.NK>'7VV]_EMK7F+92?B,76NU]+Q
M!N4,6*L\AE]9E@U/69_%8&6FV1H-0_I"OH9A,H(%(,Q]G!N8AK3V'<1'ZJUS
M8*QZ,I2;W8G!<YD'%\9$R158ZN)IUIQ*6R0=U:;:R"C!TFLJS1G&:8HE,LB8
MBA#< N(WFU0VBW3[-,F"\?\ 9_TO5"\Q&W>+;>WP+ Y&PP_K4UCRO@WD;/D$
M9.HEKM-:JO7<J]BG<$X*>;=A#&="1P@Z;D*!7&DZ/9LTU[4L<WZ@X>K3/3G9
M+7EW ['8[J<_6*%5J1GO'\3+N*)=HBBBYCV0FMZL;7*X^D*S$.#HN+);YR53
M[RIE'P%D>J>).U K&Z5]WHV[[.A_G?8>ZR1:9C>RMMGL'PN/M8<+.#C'&K6+
M:>Z>3+SUF6*=R)9VPE>-I.<2>2I?!0>V">>2@&4KMMM6LV;C:+R6%L U5O<,
M@N,Q87M:<.ZGH.NHF@ZI=6LI/NO65@?1T<46; JCCP#.0<+@0R;=-53H40*,
M[&:$YPS9VH\'FAG$)P^!)OLJ,K:BV3)2,W"&?5S)U_LN12-VK>M^L$K ]!E#
MVF/DTY)NQ&,[Y1;B](LFH4@&-;1/LDLHX3L>N>-L^]EY0KG9L(Y6K<Y*;CLM
MX[5\!56%0MQ['!9/K6"DG_IREICDD&";&J*P$/'/G+<JTD6.1=/(],#&7'Y2
MH\-;]L-E,Y47-&8-**SVEU_RO8*=A[:[%V,L26BX0>08-K3;.^U3NK&.R[:9
MJ*<DCEY9)M-,&EN.T17,"$>R573 RY=HUI_VG>W6:=B92BQ65<P:LYYU\K,7
MJQ7:ON 76K'6%WUFQLDQN9\Y8<2BRR66)*6F7[^1-#OS.8V2C'257EI)1BX4
M1KH?7R_4J1D'0O=JD:]=A?><9X8@<HYD[-]JW3S#@IUDRIT][*?"*@U"O2I8
M2]2+AU5ECP#ZK+-USMUGH.#2+5PT3<-VSH0 NOKVC^8LB]J5M3L#FC&$?&:Y
M;(]GS1]?9PA;97ITRMLE6\6SR!1A9-')99RA&LCR[(LZK#M8R0(DDX;*=%RI
M 'U]?7_%CG91]E;N7C+8%>6W8B8^.QQJ3KEDC5C3&P1MJKUC=RU?RCDG(,O-
MY!38Q4W)OX.58TJP)5MHE+IL%TX%[$1*"*9HMZ  6Z:G=C-E?!QJ)@C/'9CX
M]V*6IN8FLB3;EKN]:Z70'M!/>O7[:Z.\()/TY/X45*'65%I76E=9DF73)J@[
M73%9Q(.A%=?KZ1L6]K!@7)VSW9U[38"PO )6;)V2,?L(6G0+F5C(1*2D6ENK
M<RHV/*S3MC&,Q%C&NC$4>/$$S*$*EXGB*% 1)CFUVU[V)-I)L#K-+=F/CS5S
M)$GH;=,*1.8JSD7!4O+9OR0XQHK36$+-C2&C&7CD['-JC8%I*T2[B-:N0 SY
MR*P^D 'U]46'[)]C3N[>M5>S)A,)MTL>9TJ>MAM'-UTV-MJ2*C37>]NHJ2L*
M"TDI)FCK)$U=Y\*C/8JON))]*&G6PQY#@W5[X&7["6D>1L.=K;.9TK-(:P^K
M$'V=6+]9:!.I3D.HLC9*'=8U9M6!@@?'L"9&=;C4EC2KB/*P<& "^EG<G%,
M/OU-U,SEB[M7^TOV=NM4;1>&MAJGKS&8ILR<]!OE["\H]<<Q]F25A63]>8B1
MCW0D3[TJR9D<^(4S4RQ.H@!B:R]V8V]M*-VF^LV(-5<&9OQCVAV8Y')-!VBM
MN3JC4Y+!C"Z2II.:C[E596!D[K,.Z.NH+JOGJQ%2F?%6E&)7#EV9@B!M(ZZ8
MJ4P7@7#&%E9UQ:%<38MH6.5;([(9-S.JTVL1M?4EEB'.H=,[\[ SKPS**&3!
M4""<X@)A K-P!P!P!P#J)^55^9/]1N <R_TOZP_LX!RX X X X X X X X X
M X Z![@_<>OZ_/Y^ .@>X. .@>X. . . >1/0439X.8K<]'M9:"L$7(0DW%/
MDP692<1*M%F$C'.T1\E6KQFX6;+I#T Z2ARC[> 23AW#>+]?\;5?$&&:1 XY
MQI2VSQI5J96FHM(6$;R$F]F7Q&2!SJG+Z9*R+Z0<'.H=15T[75.8QCB/ *F=
M ]P>SI[/B]WS< CT#W![.G]GN^;@#@#H'N#@$.@>X/HX!\KYDUD6CE@];-WC
M)Z@LT>M'21%VSMHX3,BX;.$%2G27072,9)9%0AB*)F,4P"41 0+&,9]E]V>N
M',GM,S8PTYP!2<G1LCZWA;=!X^AF[^N2O4Q@E*NW.@I'5:23$Y_!>UYE&N40
M.<$E2 <P"!?B4.@ 'N]G]_[_ +1]O (] ]P< AT#W!]'[^\> 1X Z![@X Z!
M[N . . . . . . . . . . . . . . . . . . . .@![  . . . .@>X. .
M@![  . .@>[\_P#;[^ 0Z![@^C@$>@>[]_;^OSX!9*_[-S0:5RJIG"2TYUQ?
MY96F@LJ]Z=XFISB<<67TH'PV1RLI$&0<6(7H \&?704EO2@!SZ7XP ?@%[!2
M@4I2 4 *4 *!0#H4  .@  =    /(  .@!Y!Y< Y= ]W[A[/HX X Z![OS?V
M>[@$.@>X/H_?W!P"/0/<'[_]@^C@$.@>X/HX!'H >P. . .@>X//V_GX X X
M X X X X!U$_*J_,G^HW (@;H!_> C\0]/S>?3X^ 8X\][%[\Q66+!C+5S1>
MM9,KU?;0JBN:\Q['UC$U"DW,O&I/UT:_68.M7Z_R9(997U<_7>P\*@L\2<%8
MJN4T!.8"FL+LYVK-.L$"WS1V<>+[53)*7BV$W:M;-KXBU3E882#Y%H[F%J/D
MZAX\=3+6&;JGD'J<7."[601429-%UC$ 0,M(=>@=?,>@=1]X_P!GEP"/ ' '
M ,57:M[G9=TNJ.FDWB!K37;W/F_FO^LUW"YPTA,H(X[R=&7]W8W$"2.FH4S"
MRIJUF.]62;H\@S;$,Y*M&.A5(9(#*H'7IY^W]_W\_/W^? (\ < < < < < <
M < < < < < < < < < < < < < < < < @(@'M'@ # /D \ CP!P!P!P!P!P
M" B >W@%FFWF5]DJ)!T2'U2J^NUMR3?+DO4_%V+S$^Q?3J^5*'=R2:S-A7*]
M9+;?9URNV!JG5:VU;2":)U))98K5JH40+3UH_MU(Y,TPUL?9EVA<I#'"DN8?
M8RL,SFZ /HY+JDO.N@$!*)4UU*N &\3O*$(!.A@,CV"+!F6SXMK,QL#CRKXM
MRXN$FA;Z72KJ?(54CW+&6?,F+V M:L-7W,A&S<8W9S3=%Y$,WT<60]6O"'<M
M%53@5>X X X!X-J?.8RL6.29* D\CX&8?-%1(10$W+2/<.$%!34*9,X$53(8
M2*%,0W3NF*)1$! QH=BOLUF3<7LTM<MB\_V9M<<M9!6S(2U6)G7X"K-I M1S
MUE"C0()P57C8F#8^B5JM0[(_H4>@+E1L=VY\5VX764#Z9E-X X $>@"/N\^
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M0!$+X\<LLXXX*Y2NDVELFWJ]-DPW6OY)O\%J66VKM%L!UYW"-X_X6V5*3>>
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MG/!1VRR3F24DCP1'PQ3598(LKHHLB@9@2")B@(^WW>[Y_P _T?,' .7 ' '
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M&MVZ6KSV&K]TAY %3,YRIN) $74G#NB)>.S?*LVB;]BNSDV .HM\S>K@54X
MX X X X X X X X X! Q@*'4?W]H_LX!)-0L4#-N;0UAYF+E'$78WS:31CI!
MH]6CG/AH@#=\DV64.U6'N* ":X$.(IG#N]2&Z6G&2<)-22E!*-Q:35MVF]UY
M[;:Z@G?E0. . . . . . >7-J*HP\HL@Z18K)1[Q1)ZY#JW9JIME3INEPZ#W
MD6YP*LJ42F 4R& 0$. ::NB>8<99=1Q'=\V[,=N'D_.TOF1VSLEMPW-;+N=*
M[M8(K+;Z(BI6JIU*OACQO@N::LXQ1]'NPC6S&MK/V4^RCA1=(I@;G1/,G3XQ
MZ_, _P!_]OM\^O ,/F1MV<]X4WLV.Q-?D\>6/!>+>SIR1NI3Z]4:]+QEY,[Q
M_D#U E#6&V2\^[923N6B8^2,JG'0D-',G+MBFD9P9HL\> 6A$[2#=6%9:P8I
ML4UA1[F7?(FG=NQ-D&)QG.MZ5@&K[00F9K+9ZW9*>XR$=_E.1Q[$X8=HUN;"
M>J);1(V-,):,B6L<55<"G3/M6-WK\QSQ1J4M@FL9,T<Q'MEE/.UIG,?66;JN
M>'FLNPEJPS&5:CP#>]1SW&+"[05.D;+,SCF4MKJ(EG[2)BXUPR25> !>-L5V
MY>F& *Y4*9FPF6X+(>5]=:)E]M"U'%EENT)&1F7::>7AV"MDBTP8G<LU55FK
MP@]TZ)4R+*%*10.@'1^#<?S,.GOYU]AQ]@A[=ILVB'D( /Q\ SE< < "/0!'
MW< M3H>W-&O=\94=.HWZMI3M@SK6*E;[$UJA*K:YC7.]R6/LGH,#PUMF9Z*3
MCIF)D7<:YM,% -Y6*:G<MU07.DU4 N*KENJUQCO6]1L<%:8D'"[092N2\=-Q
MP.FP]UPV]-C7+EMZ0@80(LCXOB)&, *%+P"AV2=H<5XXE*#'N[)7Y9&YY8)B
M68DHVTUP66/YL:5=KLJ\NBRDD5.(;-V=(?,UT'1D7:3EVW.9+PDUA*!60E\I
M"[NO1:-QJRTE;6)Y2J,$[%$*/+/&(H@[5D:\V([%>;8)M>CE1Y&)NFY4!\4R
MH$ZFX!:CKUO'C//<2^L!V#O&L''8APQF%[,7R:@(Z):Q&:7=[:0D4YD/3BM&
M\C&+T-XD]466(U74DF1&AU%/&*4"Z5SDW'+-Y"QSR^TQH_LB44O76+FTP2#R
M>0G57*$(M#-57Y%Y1*869/$HM1BFX+(*-')&@JF05 @'2&5<9#896HAD.CC;
M(*.=3$Y5PMM?&Q0T2Q*D=[)RT*$B,E'1[,BZ!W3UXV1;-R+HG65(50HB!ZC*
M]4J1K*ETC[=67].1:NGRML93\2ZK23)CW_37BDZ@\4BR-6?A*>E+F= DAX9P
M5.3NFZ ?37[;5[8Q4E*K8H.S1J+QS'*R-?EH^98IOV1@*\9*.XURY;D=M#&
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M-,-+Q6I=YC-.S0T@Z/*H W3:#-M'U>?13V00<LG7C%,@!QPSD#9+ 5DDI7M
M]Z=+K11YZ/90-$@Z70"X/L!KS(2[)!D)7]HRI:36,CQLHO'MX&-C"OE7KENL
M182I&24 R562+D)JNS4/%3\E59.4BGT>PLT.A%N9:OO';51!O,QK:;82D,N^
MCE3E=M4I2,D(]1=(A';)P@)TC 8KJ5V2-"I&*XC&K/8K8!Y(TC8I[M1B/(RA
M\4Q]UQ1F.PO;P]O,Q73Q>-6L'-0U]-D*RH62LW*&L4&9JY1;1C*-2;(E(!SL
M?8\Z]V$B,:.0<W157M&/,<8VV J\7:J^C&[-P^+KK)9$K\EEURO5G$M\()*W
MSM@D+5*TJ0J:MC8S<A"/@"'5*R(!4O%W9EX5Q3FN'RY$6S)LS TG(^:,N8EP
MI.S%?7Q1B/(^P8OC95L].CV=<9610TT$Q84HJ(G;++PE:3LDZ6#CVAGWB$ Q
MK]O1BG%U%I/9FRU(QM0:=*N>UWT^CG,G5:=7:](.(]6)RPY58K/(B.:.56:C
MEHU<*-5%3('7;-U3$%1%,Q0-D?@#@#@%OFT^)9K.>";KBRONFC*4M"]1!)T]
MDY.%12:PMWK=ADA)+0J:LK'NS1D2\)'NV!2.47YFQTW#40])1 Q^6O0;,Y99
M6+KE@JMJQA"Y;S=;86M7>WJ/[7;X+.%.IADK'D&UY!Q/FA&<R'B>WLKM2:5-
M3<78Y]'#\S#H1=RA'T&6NOP+D\FZP9'FL<8>JT-=%,F1^+;-B28F,39CG8\]
M(R'!8_K#RMRD%9[Q"XZ7M=AD'4B[8Y!1D;M#6F*F[K5X<\C!Q"+L7L.!39_I
M1:I"_6C*#"LXAI=M?91TRMU+&MNWZZN/JA@UY76^5J=7Y]*FUY\UBIZK)6BL
MP\?'L(J-LL7)F8SS*$9.U$$ *-UO17:1W=)&UWZP88;IO<ZZ[96-"T5^\BZU
MW\70>=(?(4Y'5R,Q;4&T3-6WX>T8K!"3<VV?>L8 R5JR#*+Q<>JJ!,>&]"<P
MT2Q8?5N-@K5AB:/4M96@3,%;FL/8L?2N#:?"0ECK%.=RF%+!;)"D7";B)&3?
ML83(F-VEGC;K;X.T0X-7"JLR(5]?K1?SLHGE'3')>#=;*Z,*%19SD?BO#N,L
ML2%0:6:62M%G)N'AB[O+C<&$34'\A<J5 8^0R WMCV=A)A0:Y*S<3+04A59"
M82X).O%FF=\R91(CX-0T?#4!FKL#0WD<_F(S'XJV*\YRFLF/M@<*NI?7&R25
M7CYH\ZI"U16%JF.+;4F5(JC>M6BP0+=A/J@7];2:GS6?;M49H$:?+0%8USV=
MQB1G<%'+ERED'+;+&+:@V9DB$3(-D_42M0FG#V>*HA,Q"KEHO$(.EEE10 ]1
M+5"Y2BK20L6<+X0SRB,*O/UIA8[PYKQGXX_;TZ6>-6RUY:PCD%I KB<(LXJ:
M(N'ARN7+8'IU'' )3TGU=RCKR:*9V]W58>NUC .(\*I5NE7FYW&(O%LQDI/-
MI/-<NSM4#7F]7L%JAGD-&'BF*<[(D:,",I6S23.(A$T ,A? ' ' ' ' ' '
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M6>I.-G>8K&\V&K=U:/\ %E=9XM:J-OAPA894B\4_A%W\8BHP<N7(231PV;J
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M]Q2%MN;V>D5_I76O-Z_*G1>V'D ![N><7' ' ' ' ' ' .HGY57YD_U&X!R
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M7FA)^:<Y4["E?.]FGA)"TR+==*FTEAXKJQ6V9[ATV$;'1K-)T]\!P^,@V<2
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MKUEVBGL0X<1MTC.4A_4+E"LZ=",26.#H\1"JW"2G$)F464+X *@9?;GN)O\
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MH   '0  /+@&&'\&W_F8=/?]HV)_YI\V\ SE< < < < < < < < < < < <
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M+@6*$5BX5-\N&/*Z@JY>:7M2=N3;;W[:VC!1;D]9/=U3+]@]@?,'/.+D> .
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M@'ES;9L]B)-F\6]'9NV#QL[<>(5(4&R[95)=8%3B!4Q23,93Q#?BD[O>-T*
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M2DJ4>5TJWM/;35.N@^MO=U^OQ)YY4#@#@#@#@#@#@#@#@#@'43\JK\R?ZC<
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M X X!XMC HP,R!VA'Q1BY #,E%003>%%FL!FJBXB4$4W "*)U1,4$RG$PF
MZ@!J7]E!ES/L=@+ %5@.T:[./"5":Y#L4,UU"MU5A)O-V/(,^8; BXPFE9)7
M,E7L$C9$$5%H*L3+RJ2KUT1U$/4WUI(9)^_ VYT_,O7\_M]_Y_B_5TX!SX X
M X!*UY_D3</]UK!_A+O@&%[\&W_F8=/?]HV)_P":?-O ,Y7 ' ' ' ' ' '
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M.TUVGQ3F=M4W$UV%9BD5S*S<BUC&"!ECE21(HZ=JI(E.LJ<B2)!/WU5#D33
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M>K]!.LVCYPT^[2/X17$E*0E$@!7,4QB)+2]PD(Q=,3@41(*<8L*P"7T<J_?
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M5UJWUT>GG];] 1 P#[_H_P"G7Z/;\?3IY\D 3  @ _']W_4/W$. <N =8J%
M>G7W^[SZ>WIY^?(O6NOP_FP<P$! !#V#R01X X!U$_*J_,G^HW .9?Z7]8>
M4]3Q+C=+*;C-J=0B"Y7=T9'&CB\@FKZ[6H;></9$:N=45A0&,3G3GDRD! %/
M23"(JB3\7@?7U\RH8@ ^T.O (^S@#@$!\@'K[AX!J>:H0K][NIKLM"U^?;[K
M0.[7:32.Z$\]@+*TF_\ )[DS9.;8B+DB?,S182&,9)PI@@,3M2O%(-PBP2^"
M!2BV<G$"IV]4=N<C4]="=IK.Z134(.WF(%-83ZV0.<ZR[:[0)0M\+CT+*?)%
MHF$7HKL5)[U B1).#(^27&?$YCQ0<]'PY<"WF^^Z+D3QN3E%>UZU<C_S*I13
MN+3E>Q2?/R^I2E?7HM>]]:\R\++VM_:U9-CS$@L]8*KI7)5 -&2UNR+%HMTU
M>\()J-Z!C9@R7,0# 7NN7,H4@@9+TA<@@<>_'QW@W#V\?A^;--;2G+'%/IO.
M/$2I>4(?A9=1C2YY3;>ZCRQ6^RENKZ[]NYBXOW8J=KI>7YW#G:G4U-JHJ91>
M//)YT0:.B'-WA1<FK])KCQ8ANHE,HH\.MT,;NJ% 1YL_M-/&ZX?P[@\:_BR+
M)F:\U>2*7?2*UU2-5+%#6&&%K:61O([Z/55:W^=.WKWTCL.]_J<L1V^KG9+W
MY\0W>!YD%MOM-"=3S RB[./RO#QCCKU'_-KL5$>H]02$0+W<<OVG\8RJH\3Z
M&/2.+'C27NYHR:^#6FC6B)>?*U2DDJK1)?RM?"B\BDZ/=JWCD4#TC%?8*5Q=
ML!? >,=;]FAD$A)[#ED5[@L_!41\SJ^D"J<W4QSF,(CSS<OB7B&?_-X[BLGE
M+/D:]U<U5Y;%'DF]YR_[G^I)^\.QW;AZ#ZGY5VDOZ_9.6J@XI0IIINI47%FU
M(3TFG<L@U/'D>2-;3648B%,#24MK%\[!V];E!@U<BCXBX(HJ<3;;MMM]VVWV
MW92WO>O<NAJ*W;_VVJ5BU1UU[(9HPLU>A; R:N<;;@E<MFLS&-I%!NX*AD91
M$%D47)$U024.F!RCW#F* &&._GOY^\'N%KWX0,0YU27?L?"J*]WQ%"XUW$ Z
MG<#H3Q#!D/O'[H?BE PCW0\@Z!Y<5WU[6W2]RV7P!V^I?P@O_P!O.Q__ /IO
MN+_]P^12\_F_U!\_P:_" O2/2_AIV//I?A^#Z5_!GN%Z1X/7O>%XW\(7B GW
MOQO#[W<Z^?3KR?G\W[NX+==N<R]NMJ;K?F#9:^RG9*VVJ8;I[RYSL!7,7[8+
MV&58,EVJ"C6)+,Y-8QHNS&<$,0'CUNCT(/50! H"U[M>YM?DP=^,*_VT6RF'
M,49H-"=BJZ@,P8SH>3H>)N>"-G)66C8B^U6&M<;'2P&O4BR&18LY%HV>@U<N
M6P.6X^ NLD1)0=89\^/_ "\V6%N_5R3CK\)(MSR_BE\WUU)48=GCVGD9=YG(
MC3#_ &#06N?9MV,FY<8 VM>Q1D&Q2$(9E5WM\<5:*<J$3(5T^BH9D]? 0GIC
MA?NATZWXKXD\,<'W[BEC@[BEFG&5W>N2+622MVE*;2Z(GTN2JYY5[_Y[E4&.
MK';#Q@(EC:)V#<<#<PF;@QUHV/: @81,(F2!O:$_#,(F,(F)T$1,81'J(]<'
MQG&--/B^*:>Z?$9FODYLCGG_ !2_[G^I+]TTO[6K(HM!N^-^P<LAV#9^T8JR
M>N>SBZK-O)I>"^3;*A<"J(@X(  8R9@,0P HF)5  W+X_$..PZXN,XF#W]7-
MD5U_N_/0*<X[2:^)8HZ['[M0<*SERSQ0\VZ?8$:UVM3UFDZYK!9MJZ85PW@X
MYU,N6S%.^N[X9?TDC/P4(U[*)1!% 2'PT2%'N^YPWVDGE<,/BW#8./X>XJ<Y
MX,?IHQMIR6G)-I:M<L9/?G;9M'.WID2FKW:2:6W2K7O[O<KMV?5B[8[9/5#&
M.P&%-HL1V/&N1#6U]4_X:X]]-7LR-8N]CI\DUFY-Y1I"0%NK/5R6(R*ZDW:R
M,:+8$5$$02;)[<1Q?V4R9)-<%Q:5).?#KT<&WNX8GE25?^R/FJ=EI2X9OV9)
M>6GPJ^G=5KW*V2];_""FF:ZN1M<\(2L(%:D#.)-@A5VN&2JF%X)V]I8+P#2^
M'L@*"U"/6BXY5KYLQ37!L6:[ME/[(/ALC]%Q<9>D51DYOB7&HZP<<KP\NZ:D
M^9]MA_A>5Z2WM?Q/R5NJ]^OXE;"Q';X!T,-IT@-T'KW!;64 -T'R W2N%,!1
M_I=TQ3=.O00'ISFYOLFV_P!GXFE;V<-%TT<G^+_0I_AK_P"LE_M:_4H[E<?P
M@A&V8N1AEL *-75B,E(KXH:Q"M403[S8PGR@>_M33*%>31\<R:E7(#DQ?22
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MACZS[+O#]2CU 3'?6]R=0W7S,90QC'$1$PFZCSEGXMXG-5+Q#C&NRXC+'_\
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M[:L&KE\^<MV3)F@JZ=O':R;9JU;($,JNX<N%C$20013*91554Y4TR%,<Y@*
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M3GRHY4L$3CFYJIR%OR)4,:PV#J_9KU'U1W!G+,MF*L9%.5Y=6*KJ17)Y=:+
M5Q,!0/LY:%MI3.UDR->]G-;[M2\GYMTVD[+FC(SBZXVM5&&P.-D;@^I#6MR-
M-M=@;A7:OC^,H^'*O506/<FD=3T;98HAE%RP2*H&SGP!P#B;^*/3]77X_=[O
M?\7O\N :X7;%SF \F;$ZY:OVNEI4.UR5DQ#F[+6X"F([G8;!C7#^*,C25@K>
M,,67:F4RQ37\)>0K.UFHY%F@^:0E1K<E,S<\1<TLS;' J!CBXX3KW;YY+7I$
M2\@VU]T)KV,Y^>CL:7J-A;3L:TV)OF1;3&S%I5JR$-(V8,;A7I1S/NY,\:O&
MH1T0WE57;1*.2 S_ / ' (&_BF^8?U< UV^W1E<*9!0Q!J;;Z*TAKMG9S"O+
M3M7(XGMMT-K9A&D7B,L5ADJ=8JA4++/$RA;)".=PM#KD*NR(5\HXFK.Z8Q";
M51T!9 \JL_)=K3$7& Q]=[#!/M_L*VB.QY-8AN2N89FCHX K-32VY@-H'>/2
M1E=U:@".A?3V 9.P XDYFHV#QIIB_F/@Z(&X&7^*7V^P/;[?9\?Y_?P"/ '
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MP;U7&N0&1ZW;XFKX-L6(:3"*SK*Q>)$*3Y8ZPQLG#>B)1#&;=BR]/3A4&CA
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M3C)<T4TE,AV>9B$DWL.^D8TZ"T:_;.DB-G1RID7 #E34[Z90,J' ' ' ' '
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MGVN .\/R#?23[7 '>'Y!OI)]K@#O#\@WTD^UP!WA^0;Z2?:X [P_(-])/M<
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..$.OXH#U]@B'Q^_@'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g67046g37k46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g37k46.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1UN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '5*^=08X0DE-! 0      %H< 5H  QLE1QP"   "SB < E  "')R,34Q
M,3@Q' (% #E-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52+F1O8W@X0DE-!"4      !#S4(YJ1M"O6!PZX0U4
M6>-[.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
M  !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R
M8F]O;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O
M=6) ;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M            0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M                4G-L=%5N=$8C4'AL0&54DX         *=F5C=&]R1&%T
M86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT
M1B-2;'0               !4;W @56YT1B-2;'0               !38VP@
M56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .
M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           "40  !#0          0                         !
M          0T   "40                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   "40    !29VAT;&]N9P  !#0    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   E$
M    4F=H=&QO;F<   0T     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,     !+9     0   *    !8   !X
MI0   !*] !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M[]&Q D#4FDB).P<<.S[KW.K?UFEKF[GL<QH:'SCXS=EQKM=Z;&?I+*ZZ+?\
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MO;:]F2_9?[:G^C_,_3_X5#@R?NG_ )H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M658YB-7(N\JO:;&Z>*.9-I>VD*JKF 3PGU)DYYAA"EJ(0A)6"M:DH1W*4!H
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M0D;ES^ "5=/ZSR?0>D5WO4!MA3ULR:K-:2:(S;A6U2257K[?I\!86Q4(FNM
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M&ZP_%>;;=0\RXD'7TGX4\<Z7XJM1I>J-LV]^\"'&E@;'E"/;9C*5DR3!!!&
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MD^WC\(]<:N29W!1B<G Z8DQGX=((K?1:D\I,0!GTZ8DQ[\^Z:H;MTXHE/(\
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M?^X?ST@]S]/TIY:?V@T^V1_S#_W?^^D'N?I^E/+3^T&GVP/^8?\ N'\](/\
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M=Q9TJCMK!F^A^A*=7",21T BR4A$$I/63U..WYQ/6(%<CS]1:4I)#BD[B0$
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M;>5ZL;%\<A--4N+073W,5["I<M3]K.L9DN3>(=:MO!/A\BW2'-5NDK2TG!6
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MW<B9F!,^_P##4UL=(8MPQ96K%LP% 9 "<3!(''7*LGJ23%1]MEU.XON?C/\
M2>M<E5<55C+KDQ;!R.9)<AE"%K_W9]UL(62?33W]_P!T_<&LE_:&S?2PIQ*D
MA.X@*3S'4C$F??@XFNG?::NR>#*BA7LA<IS$\B1T,CF<Q%2&-W*( _\ S5@\
M@JX]0'[J3P3[D<)Y')^7SUSPL+R%)Y/5((CGK/3WQ\:Y^PJ E/>%0<01/ C&
M.OUJGY/OY@^"XH<SR:5<2ZI5]!QUEB@;A.RQ/L(DV:TXY\;+BLI82U 65=JU
M.DK"DH*0>.[HND'5B^/, #*-Q)5@=O0D<QDQ$C-7MVM]>7:6;%# +3"WW?.0
M22E!2-O&)"I':/05)-?OW.VXO0N@RB17J]*-)$5;B3&E1I49J2EJ=#4X8LA)
M8>2'DE*D@A12KP%' FZN](NW&F7U+\M6WRDJ.V#@*6G((S@$*![5R;G1[/6&
ME(OK5"W2%H<<3 4TMM905M.'"5 ICT(X!,5*3[VW7457S;G;.16X]N]"BKFW
M.#!]J-69>MMLO2)F-H)]%FP> 6Z8B2GO7X*".'!V'&=/UQOS;,HMM10-SK0(
M2AQ29)<;VS*ED$$)@&)CO&Q<ZIX7N&K>^4J_T9:PVQ=J2I3EH@G!>GVB$C!,
M])SBL1'\V-=-E5UG'?B3H4AR+,ARFRT_'D,J*'6WD+X4A;:@H'D#GCW/OJ,O
M-K:6M+GL*0HA943N)3R5?,<G$XFITTXW<-AYDI4RL)4TI)E)29,B#&>T$SSG
MC]?T]AJ'@ \_V?O CCP/[WC\A\]82($A70$QC\1P?63/-7E,"9]#@C)['KP<
MXK\_T[B?1/C_ *O_ ,]6E1$R2(,')P?V:MV^_P"9Z\=<?&N!GD0_)/\ W$?X
MK_$:!1.03\S0ICOF8]HD8YR#TZU^CG<4>Z1[@?VC[GV_X]5E7<_,U3;/$_-7
MZUQ_3R)SQPGGZ=__ .?U/'YZ;CG)QSD]>*KM]_,94>>W//?L,FG]/(GT3_W_
M $__ &]-Q_S'YTVYCVI[2J?SI_3N(?8)^G]H_+G_ *_P.FX]SR1R>1R/A0H(
MYG/J?UY].:?T[B?1/_=]//\ ?U3<?\QSQGFFPXYSQD^OKZ&N1GD+GSV@<?W_
M /\ /]?IXYU7<9B3.1$GD1(]^1BJ;>.<R!DYB)Z^H^=<*SN'[A0X^G=^GNKZ
M^_/'&J@F8DGT!/SQ/Z5< C$A4^]72)_F]14<R,ZB9MD(C(4',2QB:A<TA8#-
M_DL52'6(921VR*W'W"B1)/EMZX## [S7OI.9!#2 K$J"A,3DR (GI,SB3':M
M5;9N'"D3M21R,P,\S!GIQ[HBI&&>Q?8?E_:*?'R]E#@<#\>#\_.L!24G)DJ*
MCW]3B. .>D?&MHH P ( $P,<>O,3^XFN1GL4>Y\$<<=X /L3XY]_KXY'/OY.
MA4,'\,Y&>GI,=>U4V<'D^DG\P1$]1V,&ASV*?/)'/_W.0>.?/'/S^OS_ !U0
M$8ZCWX//4?OIUIY<D$CI S$3Z#/'/ISBN!GL4\^QY)Y/=QR?GS]X<_\ Z_/G
M0D!1_E(Z3QQGU]_UYJI01(@GC())P!UY&([33^G<3Z)_[_\ \]5!4>"3[C\>
M_:J!,\;L3.5= 2>O0 GX4&>1?D!X_P"L_P#G^/\ EJA,\F>G,Y[>_P!*;)Y!
MQG)."/CZS]:^;V;P7VUMNA!0L<*!5R/P/]HD%)\I(X*3Y!''(W-/O[G3;QJ]
MLW U<LKE+@@1D;@2( !2"(./=6K>V-O?VKEK=)"F74[#NDA.Z85ST.?3/NKN
MXEE]MC.14N;8/9?9N68K.$^FG*2%ME2T%J966+([1)I;R%ZM7<Q#QZT-]3K#
MC$^-"FQ?J_1=6LO'6@^9O_YM#0"VY&YB\0F"I$DGR5D*.>9[Q7SEX@T*X\/W
MSEN\9:6X5L/$R%L*DH3N_P P!3(Y!P(XKT#[(;P8_OAMS19[1-K@.3D.P[['
MI3K3EEBV2U[BHUSCUEZ1[%/09:%F),0!%MZQV!=5RGJVQAONPJX8=M7W+=Y.
MQUI:D*3,B1U2>%)(@@C!!KC'Y>^I<UAI32E-*4TI32E-*4TI32E"0!R? &A,
M<TKI2'TI'//  ^H^?X?N'L?KSK6=<$$S$#OQZ^D_['J+T(*B('7^^1SQZ9QW
MJUI\SE1/<" / 'L /H#[\_0GZG\=1K4+X(2KVB#D"#[XX_IS[ZZ33)D#H(CC
MG^WOXC(JQK2V*04H4..//UY\C@<<>WS^GUUY_J.HY62M4'@"< S[^9/<GUC/
M;M;:2)&.?01WGY9ZF>\6'-GE2E$J]CX'/N/_ -?Q \_/4(U#4%+4K:O!G,Y)
M]P/]?[]IECC@=<CW2.WQ[=A5OO2"KDD\ >1]3^?O^\^?D/GJ/N7"E$R3W [S
MUZ@=?7WXKH(2E R,Y,D2".>G..3&.8YKH+>4OVY _'R?'Y_K_A]3IE:E'!$2
M,">,2>?W'>JJ5/J,8[>_N?3CT)X^.@$=2??5E-5I7V9_M?Z^AU4<_!7Y&KT<
M_$?DJNXD<DC\/\QJY')]W]154_C5\?S%89=;=8U+V[KWW8[4M##>516XD@*6
MQ*F3,<EF$UZ:CZ1D(D1T/1W5)*V2A:F%(<!Y[VG.#R'F9_&I*H]T_">#QT]U
M2?PNLB_=;2"5.)0E)$#;M4%*DQ(!!QGGX5"?3E>"?B5.S)0$R$5L9"RH$E+J
M6P.5<GCD\$CQR1P?!\ZDVBNIV-I.4H!'<843GO\ TGW3UO$;*D7"U1A<*/$S
MF?<!&/<9)DBNAU2T G[9[L746+6V+\;;:QJ_1LX<J7";9<=#KZ4*B<AJ0^X8
MRGE);>=?:C!@F.GAS7JWV76Z5_:7X5=;,>7?  D3CRW%=N92,SP8B0*\H^TJ
MX=:^SKQ(@*<:4+53I=1!W)#B!L()X_RB.01,\:"\+9;K,?%4ME++55+LFFT=
MCJ$MQUS9#\9H)DCUT(;9=;0AIX%QEI*&BISL#BOTYMD*:;V+*"0M9,*F?>,0
M>XZ>^OSBU4N7=XV^RLG[TEL+23*M[8VSM$(!,'"0 3,0>8XM[-NSW%PJ$RPR
MY&@2,CGR'5@%F(ZFJ?:BRU )7P8K_I/)[P4I4$K*>4\ZX.K.%Z]L&2G<VE=P
MZX<@);99W*W3C=),#TD<5-+"U>M=!U!]#B@^H6;+8_F6O[R#M21&520().8S
M7K$VSBSHFW& Q;)Q]RPC85BS,Y<IQQR0J6U1P42"^MU2WEO%T+*UNJ4M2NY2
MU*6I2C\T:@MM6H7BFT@(5=/;,9@NJCZ$>@'?BOI/24N#3+3S%'S!:,!T'!4H
M-)3/$RG;[4@29 CI>NM:MROT%$?D/EYX_P >3_'C5NT?/GC/OQCWB/?-5GO!
M@0)_?R[=*[+3ZD<<C\CSXX/\.>/;GZ?EQ84'ID>^#[I_K58XZ _*.8!/7T/;
MDR*KT*P*.WR![<'GY?7R3Y^7[_'S&L2D ] #[NO&?K/^U53 ()(^G8S/,>[$
MSZ14A4M^6UI"E< D#S['@#WY^?/M^?DZY[UN<D)]/3/T^&<3UYR[@8R.@!_V
MYY'>!'2IKH;]"@VE:^4>#[^4G@_J.>.1\A^'MQWV29( D](Z=?AWZ&<=JJ/U
M_>3&.>GPP1*=?."TI(/*%<#GS[CQY^?S_?\ +V&N<M&W,1W[9Z_[4.<<GOW_
M #GT,\5<K#O=X4KGGR#SR/;GW)\#C]3^'&L54KM:4II2FE*:4II2FE*:4II2
MFE*:4H3P"3\AS^FE*H%M:PZN%*L;.7&@0(3#DF9,F/-QHL6.R.YUY]]Y;;33
M3: 5+6XL)2 22.#JJ0I:DH0DK4L@)2D22?2.:J!,GH/V/G6CSJ<ZEZC/9\O/
MD7;<#;''H<Z#@$N2LHARZITN0[[<]80A+JE980JHQ(*1(=1A\1NVKG6_Z:V,
M-N7V)LO#.E7OB#6%H81:,N/*+AW)#38)"&R4D;UK2H>R23(CK66UMKC4+MBR
MM$E3[SJ4  '()]J(QA,F(CH<\ZAI>]-=FF4QZZFRFGES[RW@T])6Q6[QZ3(>
ML+.PJX<=EE%05K=4J''>4E')6BSA\<K]5*/D#Q-]J+WBO7'WQ:/K;>>#5DP
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MNHOM.63B2BU<>05I*8*5)"H!@1M,8$R1G KI>%="M]=U&YM7WD&W8L+BX)W
M@+(2$@$=1OS.!B:NBDWLP:KJ8-?%S?&H;,6,VW\.ERY60YVU2I"W'/LHE]U;
MUI(<=?6I2GG(%@ZI17V%?!OO%Z6[RY:1I]RIM#[J$E*H3"7%H!2"@DX1(SG$
M"")C;C2+9QQA+[<,K<:G PA9$&>8ZD\&<XI;[I*S.,S0X)N-0Q,AFV%>AE]M
MN]><;BIN)T6<I+#5(XXM'P]8)2R$DIB3XJP2OU4MYM*\7I7?)2K2KIX!FX4
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MJ "VYX<:R3,#)'0R8'O\^=PN)3Q;-:;"7+>D(2VQ&E/%]R)VH[2A+SH,ET*
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M *VU6Y4*3N@0929VOM?L:.FWA'98WI+90IONBU_<5MM6#(+G"0'06[26MQ)
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M=IJUJNSO$-K*?-87)VJ@?RDA23&".LFO/WU2XAOUT>;UX WM)'LI-98W%4C
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MK.H/J>;*7+!=TZJV2E:TD;6MP1 2D)@@C &8FMN>9X3C&?4$G',LI(%[3S$
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MA+TJ2Z'PX' [(><![G%\NL]8B>L=I[5LF]O"WY)NKDM1M\HONEO;CV=A5MC
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MFQNWO"^[YR73M2N4PHI4"/9@&1' ^?OJ[<7Z<^KU[:3-V:"FW?P[,=H>A_\
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M;C2'D_VFF'G4>PY4VVI21Y!Y'<.#R#^FNA9-!RX80H^RKVE9D2E9 ) ../?
M/>:QDA:A'"B!@CY?[=NU:N]QYD6?NW4!LAQ_^B<R?+"OO%N%/N7(M4EPCGRI
MNME.I2KP2IY1_MJ.IE>["_;IS*4 $)R(!!!,].PP,=.LYT@*:TJY3!3O?:*#
MG(2DA41D[5$28/NBK=ZQVVFND'?OX- 0'=L[,H#2PCM7WPAQW#M]+G@\J'(
M\ ^3KV#['I3]HOA/R]I+E^A,JP$CR7%$DGW#@C(@5YI]HSCBO".NA2MP-JZ
M1RW_ !$*"^\**4C!CJ8Z^7G;*;.9R&EAK<=,<K?LI@[EN)2&(,A,=OXA1\E;
MY;?[$A0)6S]X*'G]%FV6M5UJZU1&]:=%#MA8@J):7>NQ]_>))VD )\I!&84X
M!CGY+\07#OAKP';: RA*+WQ8]:ZWJ:B0739L/J386R?9"MKWMW2XQ*4;I,5Z
M/NA"UF(R_J&Q=9XJ8]KM5EU9&<=Y,=[)=L*"%/=ALJ)4FNG1J*IGI<; CFQ>
MLFQP\RZ3XSX]MVT/6URG<2ZY>)=5SE#ZH1N&82"8&,&3@YD/V</DV"[<1"$H
M=@1&Y82%D ]4D!*@,&">LUL<UYZ"G@'UZ^_K\Z]'4E1]HB03R"#GL8Z],\TT
MW)'7^OY53:H]/Z?G35U6U@S^TNPS+]PNAKJ!P[ L7O<URVZQFH138OC5>]:W
MMN]$R_'+!V-65[ ]:5($:)(>#3?"BEE9'R4-'4&U.6CJ4)*SSM2))]K,#N!-
M94Q GI)G\X]W42,Y@X-8?]0&X&7]0,_IOOK#8'K0B=,. Y%FM/U#[9UN#9GM
MYN5E%[88)5)VIR!K%\5R>ORK-]NJ*^:NFKANILD,PKJ152IL-]F*%-Z#JW'?
MNZ@U<AMMM3:VPE0*C  40(Q/Y$\556P\!/&(SP.9/'ID5CYB6V_4O3,=+0ZQ
ML ZL-U.GZ!MKNQ&K\$VQO\UR/<?"]P[+=I=CL^[U!1<(RNHRC)9E/LLNOHX%
MK.N+R'09 Q8MV79*4X^JU#=RDL&Y#BK<)5"$%7F)422G?!"C@B(D \D&B=LY
MZJ!]XQ/J)(D#WUW(^/=6=[UWR<RB;6;T8)AEIE'5=@.X--&QW<J;M]?;=+V>
MRS_8OD=YGV0;DWN)Y8[F&35M/.I:#$]N\<K<$MG(U.NR=F2V67+%"X6XJ&G0
MWYCL2#E!;AO<#UD"3DYS$D&\CT)Y@'![^Z<XSD],U;&#X-U%;3[*T\7*NF[J
M(W/J:3]F1L!@./[/XI(W'QQA?4-!WBLY*(-FK"[BFMZ65BL)4"]SC[+<1;.8
MM$5 =;?1+0P==33R-L-+,,,@B,[P94<'F8,@YP)/%5B< SZ#]QT$]SQ/7ORM
MCNI&'M+TY8ABC76Q(V=K\+WCK]U[G*]I]_\ )]R(W5-E4W'+&MW%C[6X=OI@
M6X,/":3'GQ2[+WTN^R;',:M*.Q=MZ--K83;<\Y]EV$R#UW3@@D^O3GJ>Q'>F
M?ET[=X!S[_K5\];_ $X=6VX6W_5!M_NMMIUM=4&Z^4].?3%5=)VXNWR,QIMJ
M6JO%L7H'=\V=T,#K<^;QN@W"R'+H%M<9EB^45V67.22IE-%IW9KD)I]G3*2G
M!Y]T3^_V!5*WF?M)]K>H'J.R7HPZ<]G\1J'<6D[HS=\]X,YW'Q3(,EV=IJ;9
M7%G7L0P7/(-#9T4RP?S3.<FJIU52IMX*Y*\3>EK]=B&\A5*5JPVSV&ZE=GV>
MDO:'K*VJZJ]X^EKIYP'?W8VOH.ED[DQ*]>\N)=160-[*[F9;BN%Y9CF8WVV-
MGTX?T4A[=V\RQN*C&K)N9&LF69 ?F*4JH9ETM[N[;97^T_@;0['=2M%N3NGU
MC=)V[^V.=X[(W&DXMF.Q]QG'3U99Y$H[YK)ID!_(J6]J<_?S2K<C-7%-C,:3
M ?DHQJ/'@LTXGK^?[[4J=*[ISZTXW5?NYL9(1O*>E?86\ZG.K/9_<9.39-Z&
MYF0[^[6X_6;5;#0[%%HJ7;?[&=RKG>6\12R)$B%%87AGH1(I;BA-:5!?3IT1
MYO9[][&6O4/M?U)T5QO?^R0P?9R[WNCW6Y"$;8=0-% RFIS$[H7C&41CAM[7
MX9)JY%2+YA4"5DJ6[&(A.1.RIR7Y_OK\*5FQ^Q.G;_;V5^Z74EU Y'<7$K%<
M=V^Z*-O'F\HG7N(YQ%Z7F;+']U]]:1293M-;KW?W0E6+[6216W9$J%C;;*I\
MION 3'QQ2M]I6A/NH#_7^ORU0$&8/!@^AI6/>Y^]#M);)V]VZK$YKNA8LE3%
M2RX/LG&H[G@7&6SVRI%="CA2741E<2I'"4!+2'&W%]*RT\.H%U>N%BR2=Q61
M[;T?_#83C<L\'D#L33]Q5!V^VD:Q6RE9MF5J<WW0M6S]IY9-:5Z58RL$&HQ>
M(ZE0J*QA"UL LI9>D- I6AEI?H#/>7YN FWMFQ:6#<;+=))4XH?_ !GE?SN$
MY,\8B8!JLQ)^N!'/>8/QG!@U$?5QG4C%-JY]3627HEUN'8,X%5S8SQB2:YFX
MB6$S(K9A]LAUF54XA6Y!/KG6NUS[48KVO5C!P26<NG6JKN[88$$+4/,/,-IR
ML_$#;W]K ,&D@))Z\<]^N,CMVS\*LKH-VY:>?R3<^5 ;88: Q3%6@V$-18L9
M#1F*ACCM:::91'@M!D]H0EY X'(/:\7W@!M],;PEB5. 8$2?*Q SM()YZ$P1
M6%H'VEGE1ZG/Q^F>>:V#9"_Z4=U7C@(7\B>>X'CZ^W'/TX]SJ%M@%21ZC'H
M3S_3K682..X[>\9/J/=WJGXC8Q8>)R+*4^W'B05VDF9(>6E#3#,5;KS[KJU>
M$-MM)*E*/ 2D<GV.K[C#A]R?RJJC)/IBL/:C]H5M=>UT"SK\<ROX2SI[*;7F
M4JCBNV5S$RE&+0L3J@JS<8GW\]V17W#\=N2E%516D"QG+0VZL-8:MKYO?M!\
M!9R7,,21AF4VUWA&$G-;UG&I^,WK#,>.Y!:LH2)35JPRI58N<EJ9+4I,=$AB
M3&1ZCS0"U*D>PZM\7K]PW\$7C%U+B(./,1\JK[&AGU$J7D%1E%RB&B.S.5.9
MD048C=1)OKMH[)33+8"@X5(4_>.W4QCB?V:P6W3W^VTZ\8&V6RV/1\OPJXRW
M+'KJEN+2OI;K'5.XS'?>6Q;PV+7BT@K;6\T\E!#<2R90P"^Z"@<O5].7J=DN
MU1<N6@6M)6\RLH6-N0D[2"0J2#T_.N?J=BN]MTH0Z&U;B9S(''3O'/O'/&*>
M);F1MQ<MB]'!E.5H9S'+L/B[DJMI;V23*:D^#Q6M18P7'$)>^+N($F6]5%_X
M-=-VQ4K]1"SJ=W?@Q2_"BU.73K8<L4,!38)<.V5[PK!]E"DDJ)&)VDF153IY
M^Z-6Z7C*1M*C*B9R9Q/O /H1$5O>Z>=GF]C=L*3 %7CN0NUS]A+?LG(R83:Y
M%C+<F/,0H3:W$PJ]A;I:AQ$K4&(Z$-@D)\0G3;-5A9L6JKARY\EI#0==,J4$
M"!U5'NFLEE;&TMTL%6_:5&<_S0>N> /3TJ6[;(Z"A57HN[JKJ56T]JKJTV,Z
M/#58V3R''&8$$2'&S*F.MM.K;CL!;JT-K4E)2DD;];=?.ZRK&L;:B/Y#?T]&
MQ/FLUT%ZVL8E>W+GR.?0A1ERW6DO2GN"6V&RIU0!(20"0I5;"DK'W5 ^1['^
M1^G.E*QMWD7#>RG&H$IIF5&E5<YN5$D-)>COLKDM)+;[+H4VX@\$$+24GYCC
MP>A:-@LO**0I)6EI04)24K2HJ&<<#/? G!K*E"7&UI4 08!!B#!D9]/V*U%=
M&\&1D/[1/>^GO?L"SQ6FA[E.U=,M'Q,6([7Y7B+5:W'KI+/P<=UE(C6D949/
M+)"W4%'*.97XB:L_^&=,VVR-Z5VP!*$PD(;7 3@D;3$'$&"*QJ0@A*5(00VJ
M1*4G.0($&8'&8'P%;$/VBF8X1A731D$W,[B[K6WK.M;HH&/R Q.O+V'ZEC#K
MGRI"^VM;3$7,GO=A,1J,)(4A;25"'6&A/>(;M&GM7+MJDK0\X^TYL*$-D$@J
MD84<%(R>T"M6ZMDW38;+CC8"TJELD$QB/9R09[>N:P;O-L-\.L/:7 5(J+W$
MMEA53,^B3Q?..9=96=.JZC+A1*]J3 ARH^9.($V 9T-]AN!;!U+P<80A[I-O
MWVC>)C9A%D[9!I5K<W+A\QSS'(2DH,*&U ,D@D@>N*UWW;VS(+3"7K>W;6M9
M4X5.N[$E6T0F961 Z9QBLD>BO"NFC-*+)JNDQ&3,R*AIVL*R*%F]E&O)]GB[
MTDI9E/P$-L0FX\ZPI2'4MQEHC2:]EE+Q4PD(E'BRY\1:7_AUN[?MJMD1=69L
M@&@RX4_AWIA1*4J("I!(),&H;X>L]!U]S4]17I#S+]PI5M=MWP6MMY 7.$*3
ML,E(/!B!M,54-T^@"NK=Q*;>GIS7 Q#<:/*36V<7(7S.H&<<GQQ$LY- W)AS
MIE/<M(:84RN))908Z[",R8QG.N&#:KKNO:A:,VB;E@@7*%ON7*2XZID$^8 J
M2=VTG;,2<D]:F2K0VUNS;Z<E%NRVM +24[4!"3,)&0F.AQ^D6]$VZ]3,ZI]\
M]OL]Q.3B&[\5":]#YFV*JJQ@4#5:B9 BHL7$H>F/AQB\A*8:47*>2VMI19:[
MM;^J>&[.UM;37;1Y3JKEM"+H%2E)3(A"BC(22?9./Q#!@UN-VK3:W'DQYK@A
M2LY .!';&.)/KSN'2X E([N>1QS\P>?;CY^"//M[<^_GA[I!VY(@D<0/68CB
M*R=IQ/ ,9[?L=ZU:_M8:MR)T[U^48^NII\GC[BXE!5D4DJA3VJQV->)6?M&(
MRJ?\/6.+%TIA"^Q'P!>">]I)U)/"(8_QI*W&$N*+"TDE"5*@$<R"8$D0"<*-
M$I0E9<"$;R(*BD;H[3$QZ<?G65_1S&C_ /PT[+VJV8#=E;[?8U/MI,*.AI<F
M4NM:!3*>2A#LF1&3Q%<<?*G"62GGP>>;JZ&TZKJ'EH#:?O3T)2-HC>>0/G_6
M@2A)44I2G<9,) G]^^H1_:7H5"Z7<POZIZLKLDC66*P(602DK8EUL:;D=>B0
MJ//CMJG168PXG._#K [(RE]JE)2%=#PLE@ZW;J>:#L-7 @I!4!Y:C[),$20!
M@Y,<Q50@*4#MW*Z$ %0'6#RGWR.]4WH1V@J)W3)M9EDV_P LA9-E6/JLLBD8
M]EEK7M*D)M+(1H#QC.,K<-0R4P0ETJ[%M+">.>=:>NAD:SJ*FF0QO= 4?*"%
M* 2(*U;020>_I&*!"&W%+2TA*E_C.V%*(Q)@SF#UP/>:G[>'IN@;M[<RMKY6
M>YQ7XY<7E?9Y$_*MUY!:64&L8E%FECR;P3&8<%VR57SI*?AGTO?!]OII4L.)
MY"2D  *QG)B?Z?49Q\0!Z2?K'[^/]!C?_P# YGT=R585>]+55<R+%QYEZ'CT
MYN%"^UX-0SF&40F1>>O7YKE=A2P[.=,AOM5*E.6D<URTW$];E92<;H)XCGD3
MGIT_*F9X]YQCX3)/[FKMVGZ'(>UMEC%A#S=^7,QS-LLS1N[^S$#)4/YCMA+P
M"SKX5K,>EF-!C3)"+NNC+;=C1&H<:N^'<;9:<:KUX(^&",]?KTS21QB1\_C5
M-W&Z+<ARRVS]RGS.E@5FZ-5N1198_,K9+=U'A9[4[7U;=A!?@%N-,N(?^SE3
MSSDAMEEQ=RM381\. Y23TB3T5/$=!@_TD3WI'6,=_P!3\<9ZU]^EOHRR#I\W
M4O,ZGYK5Y#52L*5B%?#C5\N).4WWXFAF7-#KRXB)H9Q8O64^/WNW,FT0VXS!
M8J(R7V[I*0K&)G^@/Z\TZ@03,YZ"._I$UL,0LJ4/O CY@#CW'CGY_E\C^[0'
M,& >TY_+^M(/:OOJZE?AS^PKY>#Y^GX^Q]O?V_3WU0\'$^G[BE:F^O[;!B'?
MT6X3$)AVORF&K'<BCN,(<C/6,-IPQG);2TJ:=185:U1'$.)4EQ$ I6E041J>
M^$+OSFG]-<S/M("C,MKPXB,@@D9S/M2,C.)SV5)7_P#*?<>.>V9C.9Z5E1T1
M;DO9]L32U]M.5-R3;B9)V\O'I$IR7.D1Z-MA[%;.>\^Z[*?FVN&3,?FV4M]1
M^)MUV12MSL*M1+5+0V-_<6_\J5E3>(EM?MH)$X.T@$=P>D5E['H1(K+_ -]:
M%*X("O!Y_<2/\/\ 7[N=*5&5GLWM5<[H8[O3;X'BMGNOA^.6V)XKG]A40Y>4
M8UCEY):DW-516DA#C]5'LWF&_CE0BR]*;"H[KJH[CC2W[%*DH-I /'/!]O/M
M^7'T]A]  /EI2OUVCC@?E\O'X\<<<^?!X^0^7NI5*M3Z3">TD=RSSY\\<$D?
M+YGD_@/IR#H:BK9;DS&?Z'G]\UF8$N#KZ"?Z5&ES*X2OSR?8#S^9YYY_A['Y
M^3KS'6;P[E@$"$F/4@$=21UXZU([1F2DB!T)QZSCCOSTBHQL)!(<)5R3R #Q
M\^ .!R/;P?P'D>1KS'4;HRJ#R2.(!'K$2 <B9[U)F$;4QW2 >8SQV/'U';%6
MR\Y[^?))Y/GDE7'/GGD\^Q)\_CJ-%4C."">#MCF>"#!$\DR.G-;@ VP03 D9
M( [#D3,$GN.]=8<J5X Y//@#@?/D>/D/H/IYYU:  <1$9 )!)P024D'H"#,T
M!)/&?>KCWSQ7V1'6HCCCQX/@J/'_ %<@\_3@GSYY!)\WA!7 $F  .5<# ZC
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MA\[D'DIY]_'\?]'6L01!'PQR-RCT]P..E5A0)@'!['H1S]*J \#@#QR/UX)
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M2K?RK%<?S7&K_#\KK(MWC&44]EC^0TT]'J0;:EMX;U?9ULQ *%+C3(<AZ.\
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M@T$X"DI0#*B"%2F1[!.<0DFLD3M2%I*\E1(( '*!*LR9CC)]*](&693D.69
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MR1+@)1)9DA#@<3Z%M6A33JTM,H=41W2$*[S7@_POY+G_ "-ZZ9*FG5/+!6A
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M@)Y)QQZQ).<R%':]9L,M^@VR0$@".R ?8$) ; Y')' ]O;P!QK="0?9 ]D8
MP/>9Y^A(/>9K6*RB5E97G\1)GG@P9P<">@ R>;BK\6CI3PLJ!7SPEM+;8X^J
MNQ"03X)X/)Y\^=;"+8*&0(D\QR8^0'2>!(K4<OCNP9 '$\=X@B3Z=>IKHY/M
M6IZJEV[RD>A%BON?$(CL.2H[:@"2A+J/1<*A]Q7KA32$DNJ!+?(GOV;62&/&
MWA^Y*PE%O=N..*./8%J^%)DX *)'/IF8KS_[1]4??\%:U:633C]XXVTVQ;M)
M+BW'%W3 1M:(*5A*@F>H23',U@1N5:HDY=95N-6$:S"DQS=,7,FP@0GE(AMO
M)7"@09$*.*Y45MM?,CXB09#:U27FRXE _1[PR];7'AVUN[9U5O;7'F?='6@A
M1;;+B@  Y(49!.TXB ! -? ?C71M<L/'NIV6NZ4U=ZO9FWN;NW(5A#EE;+V^
M8TH*:(1M"MI&PB#F)^BJ;!\EQUAIQI=G=0T!BVIL)N;69\-&2GENP9A/.(6E
M:/ DI;<DL*\+8;66GN-2_NO%&BI=NK9EO6;5N7O)>:8M;MY$;E!"D^7;J5 )
M0DC>5 "22)W-%9\ >(KAFRNGKWP9=72A;M7Y+^I:&BY*MC8?2XEV[2A2X"W&
MU%I"5%1,!1JR*W$\6KI*?L(YNIRP6I%9;563.QDU3[:?7*[9H*6VS'0RAY;D
M@)0TR&7''%%M!5K;\/>+-,\56K[ELXRU<6:PSJ6EWK2FK^S=5,LNVZP"D2"E
MMQ)4A<B"217*\>^"/%GV=ZE:VNJV=I<:;J+1N]&US3W?/T_5[4%(-Q97;)*
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M@P03F._(P?>>M2/B'5-N; JMQMP]SY=!!V_VHQR;=Y*(,& P]/LGJQ,W&:>
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M8+:QW#S1VY?=U,:R7W$:AL*0^THM%0DD H;(:)S&[82>Y,5(ON[:G_/*/X@
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M_2ZP",H4>1^/B #71L]5ULW[ML[I:;:S#KB4:BJX8<2I"I&]3*-RBG:0(/M
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M^6MAIR4*E1WR#N7E2R4-W=?/4.X(//97Q'Z_V[EJE_%!)<C\C2;<O(4/\80
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M94"!PXX/U;/XCVX\Z@?BLD:<#_\ S,COBI+I_P#U^),?KCXU UH\?47YX(\
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MZD\C3KHW(0V_*[Q]DM+;<=,W*MB0%(4I?.Z1))C@GG::FX6T;B_MK>UO7'G
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M#/RBOOFEJ8S]AD,9F310H\R5;1I"4KCO040W_79>2L*0I#R"6R%H4D=W)22
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MN3*A7=M/#VYR'T+>=X>N5!1"B<$^V93UB"2)P(&<7-Z/VA479AQ=;D^+Y/\
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MUZ53WP6238"@R#0Y]<M1%%EM)33Y$L3&4)X3REH28\=Q"? 292CP"I1UZR4
MH)2<%K>", G>D <B2$D<B.A,FO/!)7;+R$W5DT72, O;3)7T*BV0"?Q8&1$5
MZX=D?&SVV)"@KNP?'%!7CC@US"@$@>/ *1^''Y\?)?BC&OZQP/\ G7DCO^*%
M9Z@@^[I[_I3P=_\ VOH@S[5JHJG$PZZ ,Y,8F/C,FI/\D_B=<2?9!YXGYY_K
M4B(A<*P)D^[D\>F:C/=[<^CV?P&]SN^#KT>I80W!K8H[Y]U<S'$1:BDKF>X*
M=GVE@ZQ%CH0.4E:G%'L0K6Q:6SMZ^TRTI"$E1+SCN VT 2IPD82E,&2<8CJ*
MW;"S7>W#+"9""ZLW*CC8P/Y@3C@CKQ!Y!(N_IUZ>,DVHV^R[J.W25$E=3VYF
M.KM[1+R3)_V;XIZ8L*G:[$FW>T5R(49,=G(7V3ZMI9I6AUQYJ.A;L)\<^)$/
M-/:?IKA1IFGJ*;9((#EV\#M7<O!)&X%25*;)PE @9(J8L%N\O;72K9"O\.ME
M!EE<0EQV0D..GJ"J=N0<E49$6-?;F8/NGB-C$N+!=PSE=>_4LVZK7U;IF9.A
MJ:1$I*UI?<Q9,3%!L-!H!*6EK><0VA2AXB_=+NDJ4M9)(+<[I]KB$YZ'@#M.
M3!KTVPT15@I&T)"F5A;B$<&")23G''!(Y@"K7P':S<^-ALZ)D&[^'T\RH;2F
MH?<QY^VOHD,E+C(L'E2TP8L]^*!ZSD5J8F.M?JM(6I/)U;9GRK=:7[YH+0?9
M\YLE7& 3_,<QWQG, ]F[U%I-VVMG2'[AI8AUQM9#23!"U%L# '.!TF>#5KV^
M3;84,FTQ[>7#L&B2ZNI;R&1D=FW$NK&\8A\-&75W<KOMA+5*")+27"S(8+C"
M6$J4G1#]PC.YKRR  M("21$$P,QSZXZFMYNQNE^6]I=R\ZVX5*=8!4RTTDD3
M*9*58)"L0<YS)J&+5>X>X#<"?,SO%L'P=1>MDTF00Y=CD670VI(-"N_37R8T
M:/$C0BQZL%MU:I,@I>F NI6DU3Y7F2[<HM;?E#BTE2GUG^0IXZSTQ//36O?N
M]L5"WL5W]TKV;B%%(M_\RDK)&U4XG(Y( D5-+-ON-,LIU=D=M!C4E2L(AY#2
MEP5LEMYCAZNJ*B2E#\FRB-*2VIMQW[)B+<2_,E+>0BO?EVDZ/)3?ZH^IVV1[
M=G86ZBE3ZDJ)274$[4,R9@2%@S@"H1JNIVK85;:.P3?.@"[?7"S:J5A2EK!A
MP#:8GVDA$ 9-9L[!5-1C6(,1:>FBT,:>X[/>=>>+ME</'[HL+&5Z?J2I#B$@
M!9#+#*>68D=F.EMO4C3J"KM<K"6D).QM#4I;;1/X$@8GUYS,G!KS35;):7%+
MW^:\3N<6#N2I:C)V2?9'H![N],D@KVKR%O,*0%&%9%-;9RNK;^\Q2VDE26XU
M_#0 E#,24M7H6"$=J6U!MP#[R W([=TZ@W]W69?92?)5 "G$Q);)Y*DC\),@
MGW&>9_U4E#F%)R%'!/0#X8S$1R:G^JGM2F6WD+2I#@!2I/'!Y3X/CQP0?)'/
M/@^?<<YQ)!,B"#M(/,@<]OE6DH$&"#N$@S.8ZY_V[5WW!]]7CP23_/6.K:Z:
MO8_D?\-7)Y^7_P!R:S]1[C^::I\I7:V?P')_+_0UFYK#C'U/[[5JQZ\)BU9!
MM#!"E!LL[D6I;! "G(+6%U[3A'>DGTTW;K:>$+ ,CRILJ'?*_"[97J.[HTRZ
MJ.P*D)'T.,>_BJ/$)00.\3[D@Y[F:QXQ6 HT<1:1R7"XOGM]^7% 'D_E[\\\
M\_(#4Y>4"XN2(DP">D^OR]P%<^(G$=2/EGXS[^]7%\"]]/\ #^>L/L?]OTI3
MX%T^%#Q^ Y_P/(_U]=5!2.-OTJHB1/$YKYNUI*0"CD<?>YX/C\3[ CGY'\/'
MOJ[S.((] (_?K[ZRJ*,@ 1T@C$>^,9QUF>.#9=WBS4II0+14."1P!SS\@3[G
MCY>?;Z:O#L3T$9[2(R)X]_>,C)K,A0B9ZX&#Z^OZ36/66;;EPK4A@<>3P$D_
M7W''///[QSR?;G6TA[!ZDXF.@/4'!X(&.!'%;*75)$#(_,8]/2OS@N\&_6R/
M,;!LUM&*0*/?C=JE%SC[R.?O-JK+%+T=MMSD=X8#"B.?)/!&C>:587RM]RU+
M@@!UL>4L1B2I!D]Y.169):<_$,_23/(F9@\]^.E3)'ZVQ.'_ .\OIQVSRJ40
M ]:4;<O%ICY_XENHCHE-%9'/E)2.?/ Y.N9_P^^U'W/5KI .4H<VN!(/2%*S
M Q/8<5=]W09A1Y.8F!R!,?.(Z<\5WU]8FQ*$%<;I/0J7R%)$C-IRHI5QR24I
MB*7QSY  YX\$CY/\)UQ0"5:TH)!QM92%1F9@CDD]2,SQ5/NP[Q\#]93^9.(J
MA3^NO-(B5L[4[,[8[;.*'8U:HJ%Y%=,C@A*FY=BAIE#@\'N+#O*B#P.#JX>'
M2Y'W[4KNZ');*_*;C&-J25'K(P#,2*N1;H'XYZQ, '^OZ9[Q6-^9Y9N_O-:"
MQW)S#(,J=#@4Q&G27!70QR#VPJQCLKHB0/NI]&.@I'()/(UV+2QL-/0$6K"4
MP9+A "Y/.Y0.XYXY(X&3-7$H0" ($=8Z=B/A[^\ U>F(;;%/H+7&( ".24D#
MP$^22!R1P/'[OEK,MS=F<CT@1Z#C'K\ZTUN*5(G'2,'K@9QR>WK4W*Q1N)6.
M\-I!2@GG@D'@#P!P?)]@?W_AJQM<K D1,X[>ISU),>LP*PA8)V\'./=S6'ML
MA*=Z-NHSQ]-HY7 =[O5L8Y[XOJR&^UZHB3[)M7JMM]BHL1YT+[3V]H41(PG;
MIMVI.26I&$F1P<+*4$ 1^)4'NG-;"" #UX2M)!V^65"3C.Z 8(X@=:Q9K:$Y
MQL=NA(DMF;/SGJ1CP\@DRVGGY#T*+$M[5#,B;)IH<E9=EOEU0>FJ=<4CU7H#
M*P5#O;S;:C8I;(;#.CI4$).T%2RVE9"0N)*! E,"8"LQ6YK:$+78M.MI<"+9
M)94I(44>6K>B9!$C!@$QC/\ EH-IL=<[)6V/YEMGD$2GAR'68L^OG/B.R94U
M;2767VUH4W.J$+9$I3(;5+8]2>['<[W$D:;UR;QUTND@ !*(F$E(,0.D\^_D
M5PMJ$J7Y<@ C?("23!), 0?0Q/<C$S5?[C;K80Y$G7^$0\KJ\AG26Z=%,9[:
MH3$!OU)+BI+5;*3*C2$N,?#K?+;_ *GJGT2TG@<EQ_R5A 4"3P29^8GWQCW3
M0+@;4J(&">/6.<_+$8XXR!Q?)ZUP2I=[C\_%F4P84F%,2U,?7+5,=#)BC_<H
M_IO-+6RLEQ;04E7=VH+9[<:[CVD#S1N.8!) Q)'0F,B,U@<\MQ.U]M#K60$J
M )(.1]<GGW'FK'R?=[$F;J?C.(5-YD^81VW)!@? +BM*88]%<Q]<IQ;KY3'9
M?0H%,9:74GN;4IM)6+4W25++:E*P>\SUP)R8.3_M54J)1!0EM*<("8$ <"!'
M;//(/6*QWW'A[I[U98U@2*96,X0TW$DVHF*:+Y3(:'9/?>:]0O*0VM]V'6I+
M([S&=DJ#@[$=%I7E$.-*R.YR/Z<G..1WJZ4@&0"8."8GTYR(],'WB*D=DZ';
M;:7J!HJI#ZJF-A./74)U8>6INQB9/%2X^I+,"Q2A;C;SK*2Z8H2V2T)C;:BE
M76&I.NOZ0@;07;YP.DF%J2MG; .X$@;)*1*03^'J+=%T33K;7&M4:8VW-XII
M+Y"E.(*4D[OX2P$()0HCS$^T()$D"ILQ6PD6[VS4^0\J1,G;/X;\8MV5.DN]
M\(S8+/J";4U26.&([?8S&3+92@!7Q3BEGCD.M^6-193(0W?W 4=J0""$DQM<
M6222"20DG)VB!7=NPENY?"<I4M0*223DS.Z "1[NL]:V'XM"6:R/P..&4>!X
M!\#R.0?!\>.0>??41NB-Q&<*,$Y(D]<P<'@]/C7*6VI2C$<GD@8DQ^?)]_6K
MF,%PD?=\?/G@\?76'<D]1^7YUC4G8H).,"8(//.1C]YI\ L\@I/[@GV'/'/X
MCD\?3Y:H5'^58 CN/[]A5)COV&0#'J8/8?[5U9M(Q8Q94"?$8FP9K#L69#E,
MH>CR8S[9:>8?9=2IIUIULEMQM25)4@E*@02-)!ZB>9D3/<\35)(ZY/OGK\/Z
M_,U]T5A:0E#;:4(0E*4(2D!*$I 2E(]@$I2.T)2.    !JH4($J!]<9]>GRZ
M4/O&3,9D?$C^M?KX%[Z?X?SU3V?^WZ52GP+WT_P_GI['_;]*4^!>^G^'\]/8
M_P"WZ4I\"]]/\/YZ>Q_V_2E/@7OI_A_/3V/^WZ4I\"]]/\/YZ>Q_V_2E/@7O
MI_A_/3V/^WZ4JV,O@N)I775C@-/,*Y\@#E?:?(Y_O>W@G\N=9K=20Z(@GL([
M<_#.>AJX=9,1QR,_#/0CXBLR_P!F_:I7+WRQT]JA#<VUR8#A0'.0QLTI"KGN
M()/]# DCL24A"?OK24H9\^\8M^7JP5F'+=LQDP4%2",3Q $\'U@D[B#*$D"!
M$#_?$Q[JVD:BE75^>Q///:.3SR?STI6/74KTX;>=4.V=QMCN)!<5"EJ1/HKV
M#Z3=WB611FUBOR.BDK2KT)T-3BD/,JYC6,)R36SFWH4M]I?0TK5+K1KQ-[9J
MA:0 XT5$-OMR"IMP#E*H'200",BKDJ@@]I@_EZ<]P><UY9-]OV<O5OLY<VN(
MQ<<K<YPRY>=@5>XM-E>.4>/RZ]Y7:U,RFGN;F'=8])C-.^M8M? V<4.(6FJG
M62TI1KV:U\=^&KAA-W?7!L%I9<^],K8=4IEPI2 BV<0DI6E<")5,*]L)$&L5
MQ=-V[?F.D)1N&3&X'$D9F,"> ?>*WO[;;5=%NYC>%3,IP7:C.=Y,<QC':>VW
M*3C=4C);7)*>JB09.3&S3'$N5;?&,*F0K6=\18QG"EQ+Z5GMUXNKQ9>'[PS9
M:A>-V#ETZMNW4["2VI4)(296 H<I!"2.,FM9C4[.Z5M9>"B21!$''.#'OQQC
MC%9"XE?R</M,FVYR1RZR5K%EUR\?MJZFL;N>Y36,8R(\6T:JX\E;!B,JCMQG
MG@EMQ0D1HZEM14<1S5=&9U%"'AY2/,"E*W[I*E&3@&>@B1Z=*Z]O=%HE))(B
M0.8!YQUX,YCOS74OIBMR,NKMO(CUOCN+LU#N2Y4[+K9M):VD9B6TPW61F9K4
M:2U#6XM@N25-KCN*4ZH=[]>AM=FEZ/;Z2S][4EIQP*(:*<E"@H*W [MT2  "
M "8B.:N?NE/%(W* ')F)$=>?49CH1$@C'_<'!NB;"[3-9F+X#M#@F].28[?U
M51N+'Q:E_I!1Y):TTNN@Y*Q+^'7(B6S,MQB9+M(?HVDU;1>>DO/J!/?9\6Z@
ME5C;WU_<.:>T^A:;0O**?(2L*6E24?Q/*5E*IE/*0 8%<-_4[-AP(WYD@E)$
M!7$SD\P.G6*T<[1?L_.L[=)=+MY8X_7X!M[1RA'L,^MLIQRWQ9B(5!,BTQRE
MHKF7=9-*ELM^M :^!@LK<<0BTG5@[^SV'5OM"\(:?9G46+UB]>>MB$VK#3J%
M(<4@)@J(@)"NY)C@P:Z-N4W*4EDAP*(43@F(&"0(Z9./C.?1%LALCMQTP;85
MVU^VL-U,2,XJ=?W\X-N7^7Y"^TTW8Y)?RVVT)=FS TA#,9KMAUL)N/70FVHD
M=I&OD/Q[X[O]?OEW5Z[M4@+:MVFU!26V-T ;3.WN0<S)SQ4MTRQVPI2!DS$9
MZ_*)GY5<$Z8IUQ0))YY[1SX Y_>#QXX^H\^->'7UXIYTD3LW'@#!DQD# /OC
M-2I"$H3@" ,B #C Z".(Q,D=<U3"23RH\GZ_NX_PUIQ,$_OB)Z]!^55))/O
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M9E<.KL?]G[J6,T;H+%50J/>R<>>6&YT.M6_+4?O18[XYXO3J+2U*2%'<@$&
M2"0"3C@B,S_3-9LCK'&0>_6,]_7MDXKOPJ'#<BQ2FSFKMH!Q/(*Z':U-W.5]
MDQ)4">@.0WC]J)@NQC(0I/:S+:8>2LAMQL+Y2-Q%XA32'"H 'J0!/7KVC/\
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M!JFU,$ *<[7?8<I [OGS_P!/CV\#^Z-=_4G-B%%)$&1D @>[UZ3R>>3C#I2
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MN5%O82<<QPO*F77;#?G2%=C<=EX@.I2KM"E?=)!4!X \DE23J/!P)0D[2A6
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M-NN==95"J\:6^6G GO3*F90AD*!D-<A)B/%)[/\ B([B  (WXU/_ #=K(/\
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M-:>XA>W< 2%*O'8$$*(VX ,$037FGAK4]+LO$X;8M7&Q?*CSE7B"E'WI"E(
M2EAO<?,;ZJC(QT&^)^RQ(-J[L7L 0">#DI! [02#_P#)^?((XX^0]AXUX0&[
MV82\T53QY*H/,$DN'CW8Z=Z]S"=R2DQ"MR>0,$YZ R9DQF2<GBH,Z';]C'.F
MW?-\1GG&,9ZI]\F[2(U*2W-C>I+I[",4O.*9^(484II+@(;4L)Y".00.%]IY
M4+[3EJC:O1-.="T#:2Z@*;(B2()DD3,8R.)\EL/ZG9)$!2[*S2"2 "AO>E4]
M<>SQU.>E8MY]M-F/7!:2<K@.TVV6&44FQB0IEL7!DF?R(@<"JZ4Y!>:$*E7Z
M;C"'9#CZR29#;'8WR?$G6FW'G7EAL/&842<C@$SZ#B8SD]O;++4;?PW:M(6V
MY=7%R$[DHE3EJE8$$Q $22/=.,@=^]L< 8VTR7IXKL0HL:L9]1(QV9B-+3LR
M,P;NVX7:S)[66NZ7 <FEB8FX=D-PGZ]:E//M]ZTCDW#[Z@;<N;D'A'#IZ@!P
MR4H .<"<=ZW[:W4[>)U1UY[G>EP..)8"")VE"EE(61!!V$2#@U%$;;FOVJR7
M:+='=?;B\P*5AF481-GVM-%AW^..H9NH89EH-/,=5'G(6LNQV9L94AI]M*(Z
M2O\ K#W-*U_6]-0WIR+_ %!C3;U;7WNUMUH^ZO- @$N$E:T)*0=X04 @01R*
MXVO:;I.MVNJW%M;V3VI,VMP&5O@IN0LG<O:4H2E:CD2  0<UV<&Q[<W#';ZO
MFQL"K%5I@U+6/6%S<Q7)CE.A41O)XUG#BEFQBY97J@6$>0W'$29"5$D,O.>H
MMS7ISOV;^&KDV=P[KCJW;]*70I5L%-2L@[4[5"5()"5!0R0!DUYD/M5O;>W-
MFK3T-JM$^2DK=2'$E$A22%H4!N(R#*03.1BOUL7-WLW ZN9F8IEX^,2VMPZ[
MAYU$HF["16HFSJ:YJ<5QUF<ZZM$J[L+.V4\N*$L%%)"GR?AP&DDYO$7@+1_"
MXL;VTU.\>U!Q*T*9>\MMG[OM_AE+2 E1./Q>8 ,@C!FH\=/^(=$N=-O-*2DO
M+:78+;,*<?#J5/J63M2$[$F"$!.Z 2G=%;C'=KX^18N53\ED2+<P6Y,.LKTL
M0Z9R06_5:2]W-O2'0M '*UO@)621VZA3;;(;6X@?QH4H'JM14N%'T [Y@^@K
M1^^NLW "64A("$DJ/M)A 28C'(,YYXZU4Z>'@SE5&QYR!!KYL<-ATM/,PK6#
M9QCPHN.N'DK\D\N>HAY*R.%)/&MI%C>W-LETVBU(P5NB 0H=L@$#/ /KSC3=
MU!";I7\:5R4I2L^R0<P8QDX'RY$5>D*R:J+FK@0,A7/;6H)F,+^#=E(:[?ZM
M0>88;*1W>#W'E2?*0 -966W4JA(<]?9(_/&#.0?=D5KW :<MW%K4A)SM2DB
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MJ:E[%V\!C<H* QE*@">/7M'/ Q6ND9X!$<QV '7M'6.I]*D/X$?W/_2G7/\
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M!<JM2IR;$=\<N )D,@^1(/( \:USP+XAT]Q1MV%:C9J4"EZW&XH2HF-S9/F
M# D"",R>DJL=<L[E 0\M+3O!"C&!UW83TR/6*I)ELI)2ZI;#G/"FY##[#B2.
M>0I#R$*"@?=)X4#X(!U"7;2[864NLNI6F04K9=3DF.=L'CUGD5U4KMU@%%PT
M?>M'6.A//]N]7!54=G>PK"32Q_M!ZN4R78B5!EYUMY*U)5'4]VM.J'IK'9WH
M/CD%1*4J[NE>$]7UFUN7[)L*7;D M%12M0/M>R%J!)V]!F9$5H76IV5F\VTZ
ML*W_ (EMD$)GTR.?[>EM(GMB4Y ELR*^Q9/#M?/9<C2D'R.2TXE*E(/_  N(
M[VU =R20>1Q+NTN]/?5;WELZT\%*(;4A220#C)[C)R<>D5T&G&'DAUAU"VR9
M $%>,< [L$3B,=JQAZS\O.+;#9)"8<+<_-)-=AD1*%<.+8MG_4N$I '/9]BQ
M9[:U#^SZJ0>.X'6ND$DXR0,&?9X)!Z2,GB<GO4K\(6?WK663$M,O!XF,0/Q!
M6>!@CU))[U@MMI';J\53V\(' 400D<D)(!YX^G'/@_/GVU+=-&RWZRH'YDC^
MF>!G J=ZNKS+U4=%D)@R E/ GIR/C5;V3Q]>Y74'BT)YLNU&,OR<QN. 2E+-
M&6U5K9^1#M^_4LE//E"E>X\'E7;GG.G& <'J )CI(^LF<8FM76KC_#O#UV"!
MYE_Y=NW,^R%Y<4.T 'J8@]9(D#KAB"%O%A%HD#FQPUMA:@."I4&[LDI/S)(1
M)3SY'GY>>-:R<*0KDDA([&#D]P3Q,Q/&:U_ OM:7J2=TD7*4Q_F"FPLGD8'
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MF-UE6Y;EENEA)EH(+[\5"4M\*(4CA24\J4$D@D$#VXY\<Y'G-B0E_9O5NB
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M=,@^>HEY"3_E7F0!&%D^D#G/>>';2Z/F,J+#IDF =LG. 3'(Y'7GO5W1NM;
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M_P!I[UD@'P3Q['@#4RTT2$&>$I.">8YCMZ]@8GFLFL**2L03N4HX/ )P,>D
M \]R>,I\#P.ZLZV$]D[D>*F2SZLJ+%6LRBMQQQQH$EH(C=K"FVU-A;RDE!"B
M5'C4MMU[1)Y.9]_I!G@28]034&N8!(&>Q/'$1GN<CWY];EWQQ;$CL5G=%9XM
M4WV/C''$/4%E6Q+.%.2V^P6TOQ)C3[,ISU2EP_$(6EQ8"GU=I5J;>"&&;WQ7
MHUN^0AA;ER'%*!(0G[NX5.E."?+C= $QNVX)J'>+'UM:!>J;2MQ1=L6VF6_^
MHXXJ^MT):2H$*EY1#2#PDN3%>>GJVW,K+"1M[A.49;,Q&ND,2K6-<54)P2J*
ME-T[6Q&?LF$XRR]4Q6XBXR8$5^'VI:/I>H$M\_37@3P;I=K<&^9OFM5O+]Z^
MTUIUMORFTM^2_=LC8LK45!VW0 Y!(2I68)%/M)\7>)4L75A>^#;KP^SH6C:#
MKNGVUR\T]</7J=3T[2G74W2"VIMA5G=7+A0L$!9;42" 1K-R>Y8M7^698FOM
MR?O60C-LFP0EM/ISTO!*)04M;:W$,2$][*'&PI/>WW:^@_#;6Y"5K:<;?MRN
MU6HNNJ0XAHPVI+95Y:(3R4#VL=Z^7/%;X05H:6RIF[::O2GR6@^RN[;*G$+N
M$!1=W*,I]M:DC!R:SPZ;<OGS@N9*?A,2854Y6//R'EID3$2J^P@-N1VD*27)
M;SKK:1[I;<'J$'N.NOJ;1""D29(68D_A(5GD8B"<9X%>07S2 HDRI1*C*C@>
M@DX$"8 [5ZAL!@BJP?#JY([1"QFDC$$>Q:KHR%CCP!Y/!' !'=X U\GZR[YN
MJW[HR57CI ) X4=N<SW]2?G]0^%V4M>'=+:YFQ0J0<0L&0?7W\=L37GNZU<)
M..]5^70'VGF:+*X:K\HC\-EY5TPW*CNI[VG$%J'?EN:^I:0 B,I'*.\K1[MH
M89UGP39_> 5+L'FG$+C>II=M(+B0/:WED.)3M@RH1@DUYFQ?N>'O'&I)9*6F
M-04]9NHD(0\-005,M+*H3Y"KDM)<W2V@02(2*PO;QR'63'I1L6\AFU\M#60U
ML2)(@M*IW?1CN68F6;#*6K2.[Z2I \-_%0V[7XI+Q>+<\LKQJ]MDAIQ*VWV]
MS#@4%)4EL>R$Y/M'"5C*DJ44D$XJ :]IU]87EVS<VSM@LW"0D/*!=MKE*@H,
MDX\QEU04IM:!L<:44#<!GTH]%&ZR-S]D**/-E>OD&%@8O:+<4"Y*BPP31V*P
M%+5_O-:$,N$GA,R)*;[E=H4?G/[0=(5I.O/7"4)#%^0^V1(2G<2ET#$;@L[H
M' 5F",^T_9SK"=4T,VZSMN--<++R2J5AC 9@3OV*,[#_ #  Y@5]=^)%WM%F
MNVG5)B%;(M+'9^PF1,YHX07\3E.T.3)9A9M4)0T>9$BK;2Q>UJ'.4,R(C[X^
M_P <QNW9:U.QO='N%#9>H0;=:LAB\:,LN1_E4"4*]_6:]ET.X0M%SISR@EJZ
M+;C"SD,OM82L)D"58!C,3G)K9-E"\?W5VX@V^"S*>[P3<#'X5A2V2F&Y&.?8
MUS%]5N<XUV$27RR^I2H24J>7);+#ZVE!QQKP+6[!^S>?M+A 8N&%N(N$*01L
M*5[4A.!(*1))')$8 )E&@WWW*\0IPNBZ:5M2@+" IP$[04$@A*A[60#!D<UJ
MPMNFK#-L\NPBLN-S,VS';*5=6%-(P*5;+H\=38.QYEE'9$"N>C-2JHOM+C?9
MC[KC/+K3:BL=R3#GU;%)*@DH08(2-A5UDS@CD8GH 8 KVBSUJYO+-X(M&+2\
M* G[RD;W!_[20?:DD@]Q)Z$_;()\:+O3#K]A=OMO-JJRBPYE5A;-P31JOF;&
M4ZRXMQJJB--MFIEP_0#SAD27RX\'7&6GFDCTKPWX+T;Q3H*M6>U*]L[NUN7&
M/(9+?EMH1!0I2U20MY,E) $)]3(\PU_QIK/AIW_"[UMS5+>\E;:[M1=*4R4K
M4A!"D (7_P!N"-N2*B[>W=3,^G.SA;RY?N+%S"!?+AXS<H:IXS3\6)\1*5$E
MT(8!E/*JYDY[[LUR4I]CU.]2%-I*9#KO@7PO;>%-0U'3O/M-0L;7S?OBKQ:T
M7;Z2!Y3P,C<1) 01[1VGO7)\*>,=9UCQ#::)<M(-A<NAME/DE*F!*]QA!2-I
M 2)4C$#F:Z^4_M J:%2T&98QD%Y>Y"]+I$L/C&K&/$KZ=,EMRQ3.5(;2B;&,
M4N<1G7%M?$I;>9"'0E8\9TO4=0L$E+A7J=JZV/,9NEA92")W,C)000  "%?2
MO8;WP-8:IYK10Q8+1[;;K;OENK=C^<;5&%09$QZ8K87MEUD;;[]X0J%BEFB3
MG5<\U\1"8+[+L=\__0L*U$CB4I"X_P#]:&D..-O>JTE4F.D/F:-VZ;NS%W8)
M<=2E.Y^W60;FW()!"PDPMN<I6D =%<BO)=1T.\T34E6NI!+3*H\FX0?X3P(
M20I0!+A)!6DDJ]H1,5D#C>$YQG\*!.L,H$-MM2E1@D%$IM0'"@5-A'8I24]B
M@HD^.>T\)XNL7'VW"6E^6D H69))<(D) X((!DQ*3Z5RM0>T]"7&7F2KJ%)V
MB?7/K$Q$SQ$S*EJ^YM5A2G$2')N6W!-10QG5(<=DVTA*FDR1SPI46$@F4^OG
ML2E"$J*2M('>TRV>O'D&Z,^4HK=5!VI;!.$DY)6( ![D=ZBRRA4)MT;6@<\?
M &#!.".G4P>:JFUF*_8=3 C*)<<:2IR2^KDJD3'U+=DOK*ARHN/+6KDGD@CG
MV UT;VX#CKBDX0#L2F,!($"/4=8)$D]36F^0M8*2# VGK$0)R3\,\_"IT2@(
M0D?,@D_GX_C]=<LF23W,U@,3@0*^;@/''U[_ .)\:I5Z.OP_K5(F@J94![D$
M>W/R_P!?E[ZV$?R_#^E6 <]('NZ@'\ZP#ZSJI$K:]-DI*U*H<PQ*:V6T@EK[
M6N6<1DOJ)4GL98AY+)>DNDCTXK3RSR$GCMZ6X&[RV6>$W#<G/X5_PR)Z8<)/
M<<]#57 53@D1CMQ//O\ 6L>.F>Q]1O)J=:OO]T&R;1X^8=COE(]SY#(/@#D@
M<@G4WUE.6'I!E"4*,8) GG D&09,X.#6JV,F1!S(DC.<'Z<9CD$&:RM]+Y<*
M_?X_Q&N)N3W'SJ\R.=W^K^U<^B?Q_4:IO3W^A_2J;O\ W?ZO[4]$_C^HTWI[
M_0_I3=_[O]7]J>B>0!SS\O;_ !'M_B/H?8BH$'/IZ_+]^\54%7("C[U2/E _
M?NK7ID^Y?1XMO=)^;C=TF;TV[A(JKMS'HEG0W4S+]T\H9CRV<3MZV]IUWE/E
M&=RUU-Z)]E#QQ60P9C=KV-P \C2\UI15 RS$3 ! P!ZB)Y!F!Q60$YW$#T.<
M=.^0)R.@,=JL[(=N.G2XW8HY\38+=:VS&VPG,']P]I*&CQF8Q04&ZMI%:?N\
M[=E[AQ\3QB3:VE#*O:Z+A=[+MKB4)=^(CLIHOBP^6I>Z!)Z"(_*!\NO6JX /
M Z3W]!^\ 1C@UW$[;I JLFN<0K-B\MIG,>F;C.0[^3B1O8>67FVUOCV29ZS1
M.5&29'EEO>1;FLHK1:KFGA/W,NO0Y$=F]G"R7&4D\=0>.0<@P 9]1Z>^K?9Y
M)'NGN#GMU]\<15\Y) Z;I&QE]O[#V@S+.=N]R*-G/,AQ_%XKK-D8)6,BD9;_
M $.OLQQJGQ^[@R8#5G865,[#R$3V67T+?DIY&1:VDHW0-JN9['F3&>GR@3%7
M2B-H.!W4#@3B<G/Q'>17[VRR;IPE[?9+3U.T.3X1CNVM/3=1EIB.64=6FT"L
MA3>9-4Y>W]G93DC%GD-JNCLK5Y4RV,EZ0\TY/6F0^L(HA;!1@8'3!//.1P0<
M$=<#TL(,RF8B 0<2#QGIZ#CM41XWNMT7XJQ(NV-E<SQ3)#9XQD3.*V6*Q;#)
MXM=&HIV\E!D&/M5V7WU#4XC4U4.RS U-1=1$Q)S$A(Q]=NMJ,]8E^W4J(R,
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MR!'FE7*?*+3B0M(2AQ*VPM/L@)(&!B<"?D3D9[U*7W"Z7GGE!:B"RZI!RHJ
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MQN62"1$^T"(SCUJ9Z.068F)@]#U!CN/3CXU^'N?45S\P!Q]#SR?Y:\56 5K
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MGVCSB.*]<O2[N#$W*V2PF^9?2]*AUR*.R2""I$RJ CI[^!X6]'##H"N20KD
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M5]G&MLN&=$NB!$EEA2T<22DH*P1Z@B8XK?\ \3UX'>BSOBX0(5[3B1& !"E
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M0@H'.]J:HM/NZ"=P$A8,@B($*!)P!\0/:DXJ&N>%[IO7E:@R4FW4E)V>T$I
M F))3))&<YB(Q$PXCM]E6 S%Y!C4X6,RS::B3&JNN'VA':BQY#T0IL\EFV$A
M4&59_!JLZ]I;4=#+1=8(>2V1Y=XJ:UA^S;;T=M!>\QL.)604;1&Y1QUC(!"O
MB:DVH+N?X";, J"OXLP1L@B,#O@\R)XS4A;C97N;C5C39)/3&3%E?9]4S/7$
M;5CC$6R:A,S(-_,"NV%+J;827FYL\*9FU;G>'NQI3+>YIZ AEE%T$MW#3*"]
MLP/,*<AO),<\&#/? V[82T$/*ATI@@C@QQP.G;/&#4ZX!9T&;Q?3C&)"R**]
M*A6U F1'?<:L:XE-@JN<8D/IFP>[_>(RT*]14-QMWM4T?5.PJ[2@B2=HB7%8
MQ/!'0Q(.""?7%8EH6A1V@K!(P!R".AGT]X[Q4KJP.8TV7%P)#:$@%15'<2D
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MX9<B+#C(D36F4!"&TI4)Z8B(ENXI:U*2FFB)+/ 8D*+W;KTK1;EVY6ZVXZ\
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M^LJ,T^XAEQ]*"TEY:6ROO4$FOM<A4CW1F)@".V:M+8Z1_J_L?S]X%=P,I/\
MPJ]N?_;\^//'R'G5-RO\P^7O/4#F,539^]W_ .- RD^R5'QS[@?XD:2KJ8]X
M_M_;UR);/3_ZO_QIZ _N+_4?STW'_,/D?_&FS][O_P :>B!_P+_4?STE1QN!
MG''?WIIL]/K_ /C6)/5?EJ*S'*G#XKH$J]E"QGHY!4FL@*/H!2>0>R1-\CG[
MJOA5 CP=27PY;%Q]5RH2EOV$GLI4^X"!UG^;X&F8@ R3F<^DG QGGI&,UV_V
M>.%,9'EFX6Z,B"[\)@S*-L<8G.=B6I%[=H@Y)N \A)"E/B%6L8%709;7IH8<
ME9)#*WW5.M1./XPNO,O6;0*D,-^8X >'70(2>Y2@3)XW$#DSGVA"$('&5'O)
M)P?W\JVT?GJ'U;32E-*5^5DA*B#P0#P> ?X'@'2E8;9?UX]-N"YEU 8'D^<R
M*W(>F3;ZLW,W;9_H[>2(U7C-I"C6"$4DN-!?9R>Z@Q;.@7;4=&9EC5JR?&43
M6&#=P^]2N%];&UZI>#43>)[S2\YSO'W\PC[:P=ILIG9_BN$MY O%V\USRBAQ
MWD8ABT^Y9<C4ME;3&OM\,R7Z)JR:AS%Q[%@D8$Q/LYS\J50T=>?3C+D[G11D
M&3P_]D]3N+=Y*\_@&9N-6--M+FT?;K<:TQ,0:::]D\7#\SEPZ.X75-/.1WI<
M:6655[AE#5<;6!N2V@',0XH+P.1&X1TR)](FKTF#)S\)$G]]LU4MY.J7;G:+
M;K"=TKZ!GEYA.X<G#H>.6V%8/D&6N+E;B3Z*JP9B?"K8ZY-:_E5ODM)45"92
M&W)%G.:AA ="TB)ZDQ</%Y#:4E925*\YQ7X9!&R0,\21@ $](KJ,*0D!49[
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M.WK7IW@-@AO4[P#*6PVA0Y*HS$B,B(/K/6H;38(H<1=D*4E'9%6!SQPHAL
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MP9 _"9'7\/H>8@BM;8$*)$[5'UX,2,&?<..PYG;$(S2P%)[%)4 I/N000"%
M@CD$$<?@0>3SJ ^T)2HY!@3^GP/R/:KY4G.1/8_[Q[JY^$1_=3^XK'^"M5JO
MFJ[G_P"G_P :?"(^B?U7_P"6E/-5W/\ ]/\ XT^$1]$_JO\ \M*>:KN?_I_\
M:?"(^B?U7_Y:4\U7<_\ T_\ C72LG&*NNG6;L9^0U B2)KK$".N5->;C-*><
M;C1DJ"WWE)00VTDA2U\)!Y.J;@#^*#Q_O5I658*E=^9X]P'U,5C.OJ[V/CXI
M#S*;/R6OJ)UK25"&9N)7;-HS)R"FEY#6N/UOH&2W&=IX4B<MX(5VMH"/36ZM
M#:JETCK/,1QT]/7&/E3<< $G,3WGCF?7Z5*VUNZV![QU][:X'/DV$/';^7C=
MFN772ZXMV<()4ZEI$I#:W&E)4E22 EQ'/:^TPZE3>K=X/)^AGXXY^?OH%*[G
MH!@=>/F)GW<]Y/\ A$<<=J>.>>#WGS_W:NYJOFJF9,Q'\O'^FL6NI:%&524;
MDPX\B)&R6"7W<LK95OC[")C<FO0[/K("VIDI/J2DI9;96%>LILJY2%:DGAU2
M_.?" ^I:F5@"V<2V\=L+ 2I<H @&28$#!G!PN^UM/)*P%$CN4@2.?601G&<5
MYY.F6E8E[H;\X>B!3V,NRPC<6!!;JML;>[2MZ,MYT&HA/V415$RH-%2'[ *+
M 2D%M9;('M&M.J1IFCW!6I(0_;+<4N\0R<J3&X[' Y[1DH!!40,C@W7"4E+?
M)$#@J^.)$8'XOB1&*K&SM$U&9C]S(#OW4D'@%/GM((*1VE)3QX/(X4.?/FZ^
M>)5((,I$&)G=[1[B)CGGWF*O<1N2 "=B4&!N(]K!Y!DCF#/;BL]<3I$.M,N%
M ([0$\$_='(Y]A\_;]_Y:BMRX<C<1"I(&)(@\@@@3)Y'%<\J*.#!43[6)C@>
M\R,\29!D34ZT^%L7$656RX295991),"?#=2I3,R',97'DQWT#@J:>9<6DJ!"
MT<A2%)5P1QKE\$;EG((,SG' GT,=(YGM5!)5,YY))/U[_O@35HX!T:0,6W;C
M[C6N12++&ZEFMFX] 4]-KKZ-=5LI"HR+F1&4(%]6LUZI->M]]MJ=-CJBQY"/
M3CK<D</5/$MM:VC@?<8MT;3YBW"#*4S( G<%'I&>@F:W'%+6V4@^VGVA_F!
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M_P"Q2%23[,GW]*Y#7'R3_'Q[>WCQ[<>/(\\<$\ZK/[^?ZTVJSP9[S\/3X17
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MO ^G_P#UD>&=+1XBT_QSX=&W0O&%AIM\@-.$V[-Z]8M/J\II,)0BZMG6;H;
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M*E*\2UFX#KRBDR$G: #A($I GI &!/;TJUH)2D9/J .9&<SC.([]JR&#7('
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M@B<R>L@$<5Z1<%LX%]35UM7+]2-+9#@!3PXVKA)4R\GG[CC:CVJ2?;@J'*%
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M!2$WMHK[S;^8 I/F(]IL%! G($S ]]8K^Q9U&TN+)\[F;EI;:^ XD*! 4VJ
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MDO#G\;V6I8KBE_[Y<Y'9-I4 DI:EVSZ4I ''"?ZHE/CSW<\$*Y,9<TUP P#
M).X"!$SD8/,Y[1R*B?BS4!<ZO<K'M*(9W>A*0DR?= )F(&:GJ_#M?36\Q !5
M#J["4GGY+CQ'W4^WC^TD'S\P.#P>#J&V<0LDC F#&8$\]S(^$5QV%H4\TD1)
M>81&#RK(XXCZ#X5H<VVK'!)Y4%$DA7D< E7<H^ !QR>21P/S\#6WI[)4O@X)
M)/'IZ<R3C F8%>Z:F]#+:(PEEL"3$0D)(^&T1Z?"LWL(@J"$$I]DI'M_'_\
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M[Y]RX5 -J4\X?:("1@X  5$5I:J+O564O+9%NP]>M%BV992Q96[95MV6]NF
MVI:DJ6J![04#GI7*+IZD2<.A)5!6XY%?F+C\M<A*K5$VN[.WM_\ YSCL<^"
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MB1 $R"<=)U;:Q0E5X @0APJ2".LP3F)P?R(]-D>R^Q[.$0\/S*F0 J0ONM6
MDD1YJ9CX6ZV5)!;:DQ"F.XE 0$J;Y2GM6 /.M5U<7*[ZS<R%$J09$*!$B<F5
M DQS(Z3SWF6%?PEB#&V3!S&.?6((S!/2MBL*/VA(3QP0%$_4'CCC]Q_#WX_*
M!'DCL3^G]*Z9Y(S@]:JZ4A(X'@:I5*YTI32E-*4TI32E-*4TI32E-*4TI7"A
MR"/T_/2E4B4U_: \GZ@>2?X\<@_KSSH#&1508/Y^HJQ[RO3(0X.W@CQR0"".
M003XX'''OY(]M;#2\P<<YG&1&1[OUQ%.3@=..>1SC]@UC3G>S=;N9,K**7+D
MTL]FP784.25[+#T^@N68<I$><PT^"Q*CNH=>@VM8^4QKBHESJR4H,RE*3O?>
M5LLJ4V86DA2<YW)P .TSF._!(K-NA!!3F-N1$8 )SSZ=9XQQKCS?$LNVGSNP
M+++F.99A\Z'+L(U>MQ3##<M3BZO*,?>5VO3<-R ,RTPGWD!V',C6./V2&["L
MF(1.](U1C6+55I=9(3M4E<'D;1$Y.(SV$^[56A6'$D0#) ].9 ^)XYQS-;+.
MG_J I]W:EJLL5,5N<5T9'VE7=X0BR0TD!=G6)5VE;*^.7XR>]<5PD$J1V$Q+
M6='=TUY2D_Q+9:CL6 ?9DX2K)SV/!XHE25G=.U0Y3CMT]>_;,>F2BBH<<#]0
M?\/?ZZX=7U^>Y?\ =_@=*4[E_P!W^!TI3N7_ '?X'2E.Y?\ =_@=*4[E_P!W
M^!TI7QD16Y+*FW$A14#Y(!(*O?CV_P 1JY*BE04.09[#Z15")!'RG.<]3)ZU
MC%NCM-&NV'W&&$EQ7/@('D\*(*>1Y)YY'^/.I-I>K*8("E&,0>3'Z?4<QTK5
M6V.??C!(^&,GX3,^E:[LTVLNL>DV;E:J=6N3X,VJGOUSCD1R;5S06Y5?,4RI
M DPY* D/1G@MIP#A0XXUZ!:ZC;W26_-"7=JD.)W\)6CV@M(_S)Z$9Q%:ZDJ$
MJ),9B"09!S_\OIZ9SQBIN)L9M/N;;-S-PL 9I[65=XRFRS';UEFFGP,/HJUF
M!(H:O&UMKK'7[!V.B1-FN2$./!UT);"TMIUWK/4=2L6R+&]4\TAEU;5O=DN!
M=RZX5I<6^96 U.U*0.",F*O1=N( "D@[8R8P.H,Q)G_;(K%VRZ+H+)39X7O$
MS6R(U+EV4.5>44\^KE1;:!/7!QC%XDZ*[)BR[.PI71Z\IAMU 0%!MM840CM-
M^)W0?+O-.\Q!<MK=OR5)*/+6C<^\H&"$I<PD&"?6LZ;ILJ27$ RH @Y!!)P"
M0>1',\F>,HG3-NWC,F56R=[L+,22Q@>+5DZ/G$U,6-+L'6+*)8^6VU1X6+(^
M)A/R4%TQW91866TNJXAWC#7M,6?#BO\ "GVU#Q$R^K=; NN);+Z%-F25>VE0
M6"1D$$1R9IX54RY:>)4M,!Q7^#NI4$HW>T7&_*2H $[CG:#!5TF *Z=7T72K
ME+3V6[[XTEF4C<ZN)Q]FRRE<*;5V!70I]6,N,TNJR>0EU^,\.(Y<(6E("@H3
M!'BEM3078Z:MT)-H4NE33*'-X\MXH&4ERV&]*T@R",F*B3Q5;/+MG+4VRF@%
M*04*0L3$%:% %().%>XGFL@L#Z;MF\,5!L:[%KK,LF93@U[$N,T<8;KJ7*Z-
MQ#F0QTX[%2N/=T=HE'I)3*EM+[7%<GM;3W<ZZU75;LEMQ]NTM]URTI%L5!UQ
MAPD,*\XQY;B"=QVR! CFM1=V>$I !B)R0>8SB.1T)[S67F/X+<Y6J!$DQT-T
M]?-L)U+0PH@CT&/+MI@F3F*&LX6BNC+> "6FUJ*> ._SJ/O75O:)61_$>4$(
M>>6=SKWE)VH6XLY60,YY,QSG!M+D%1F9)S$8GB<3(,'/O,D9[[3;-M5R8\B2
MQP>U!Y*#SW$#QYY\^.//^/&H-JNLEP* 5D@R4GC.)YZ<8,?#&REDI )/6/3,
M_"#]>L\UF/75S=:PAIEM*0$\<)!^7S/XG].>?GJ'..%PR23F<Y/['%;*2I)
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M$:UG0'K)2W[<%VU/M!0DE((!.(RD&1W'_MS50J<$@*&#VGDQGMUF./=68!2
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M9->%20[2X=76.8VK"B0 +)-%'EPZ-KE2>Z9?S:V&UW)4_*:2I)."Y\0V-L"
MZAL@0EL0HD]]J?:^0CJ3&ZLZ;)+9!=>VF)A)!(Z9SP<#![=*R\V\Z+-T;QR+
M)NJ>GV]KE+2X_,S>3&RO)@$+/<W$PG#[8T#:)3?F//L=POB814E4S')*D+CF
M+WOBM;DIMFU*GE;I/Q"0(5':3GW1%X\AO+:-RHY4 /GT/Q!YR9K.+;WI,VJP
MIZ+974:?N/?PI")D&TSH5TV!42DA/:[CV*5U?68E2N,J3_NT]BE<O4-D)D7,
MI?<XJ,7-]=79/GNJ4DD^P#"0.F.I]35JG5KY4>(@8'RXK)Q"$-@)0D) '  ]
M@/D /8 >P'R&M3OZ_3W5CK]Z4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2J;9T]7<PI-9;U\*UK9B"U+K[*)'G0931/*FI$24VZP^V3QRAUM:>
M0"03YTI)'!BL<+_H[Z=;D23#P-G"WY2RZ^]MW;7.!(=?4DI,A^NQ>=6T\I\\
MA2W9E;(6XI(]0J3W)5L-W=TS_P!.X=1V 68'N'QJX+6(A1QQG]:A._Z!:21Z
MBL:W@S. . 66,GH,/RF&T>])#;OV;58E9R64H!;3ZEI\4H%*WICJT*+G0;US
M4$1+B5@=%)&?B(SUDR9YX$7^<J<A)]Z1Q_3X5%MAT$[E1^\0LWVPR$@J#;DK
M'<HPOO2!]WO;:M,\[.5'M7VO.$<=X'<HH3T6O%5VW&YI)X!*7%)D#T*5BJ^8
MD_C;21V$CZR,>Z*L2?T,]0J%D0*O8N6TE/(6_NKN!6NJX"R0&&MB[%M)Y#8
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'FE*:4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g67046g40t57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g40t57.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1O<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &\"^<00X0DE-! 0      %H< 5H  QLE1QP"   "+KP< E  "')R,CDS
M-S0X' (% #E-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52+F1O8W@X0DE-!"4      !#W*0@_A6IAZCVRR*L8
M^V]B.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           "+@  !,4          0                         !
M          3%   "+@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   "+@    !29VAT;&]N9P  !,4    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   BX
M    4F=H=&QO;F<   3%     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,     !%'     0   *    !)   !X
MB.   !$K !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MM)(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?<?V>Z&_T#/YUI_[TV=+[.?HG]FV\IQ_A,2OQ8Z<_P!7W']GNAO] S^=:?\
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M'0(7T&K#$-X$5L()TN69';!%(> EI>%0I4].8CY%%.WO)";*VWJDOKF5MBH
MGI'0CI3U<ASAKUSC(D[%ZG[*D;&*D2$L0V#.0*#='&X86*3!DHEQ$MOR"K$*
M/,A14/D7KZ6\EYN/KI?-+[CU K1D>YUR'V-K>T->[0V7V#W342,#L,2U$0*;
M"#;.V&R5V'9MA#E:DAQRD T*K 2QAS,L,B<#=9D&B)%XFS/):=E#E*V=4-?;
M TW6["OO%N/M[U[W1BQ[1!7[4I'>"CCQI\I6Q=>)4^X/UILW-K4[7]@09INT
M*O.F1S!.G/Y1C)%GQ',28L&''FR\3IC$2,S*FX81%Q+DM,H;?E8C-J4W'Q(=
M2IW#"%*0SA?HTYRE.,Y(N[PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB@?M%MQ[077#>^[HPW!B5J34.Q]D1!.7TQ<$Y-)IYBR1X&9*V)2(^)C
MHU$;+ZXTA+6'<N*8=PG*%$6+'56KO*Q;5UEK[9H[RB=;&PM@4NLW.*,?ZD:>
ME.#F;,&AF6H#DA)&-ZPJ(B9AA3^&FO2Y;])Z-'G93@BD#'7/RN2<9\/*-TY7
MC]I74#5&?B^+["PM_=\/=[_Z.$6[ZG?RN>/B\HG1<_XW3[6.?^;;D?\ U]OA
M%KCK]Y71&?=Y0W7BO#^[Z?:YSC/W<(O#?]/Q?Q<(MV-#>5Y3\7E =8N>&?=E
M?3RB^_P_Q-AIQ]'^;A%K^P9Y7Q/OQWWU.O\ QNGM0]WWFRTYQC^+'T_%PB8T
MGY7_ !GW=[M.+]V,>"^G];^YGQPC:2?C_P"OXN$QPY^B?L,>6#3GZWO)I!>?
MD5U!#8Q__9MM&?B^UCPQC\A%IG3WEB,>Y/=O0KGA]I?4(?C./#[?UFXD9\?Z
M<_'G^+P(M,ZC\L8C/N[H=>UY]_N7U$;]_P#'GS-U)^3W^'"*GK;2O+$U"K6&
MT2.X'7.7'KH4F:=CYZD.M*?;&0GICC*5IW?G"%.)94E*O,5C&5>.4J^+)%$/
M5>U>6#[/]=--]@PW:'K57QVWM>UJ^10$OJK/(O!VK&,CD4CG)[6[H29:HOIL
MLYD)C1L.X1Y_H4>.,8(I_P#V-?+-)^+MEU97X8S^Z=2S?CG[N4[^3CW_ &_M
M?%\G"+9^Q[Y9Y.?K>U'4U7A\7I.IME\<?@^PJ?\ -GP^3W<(M?@)Y:%./#ZI
MWJ"OXO>OJ?<,>/A[O_([&IQ\6/'Q\/'^+'$Q_0GP1,T?RTN,>*>RO3M6/#PQ
ME75.[X\?D\<X['_TY^7/"+C^!GEJL8SX=C^FRO#X\9ZJ7K'CC^/P['>&??GY
M??\ 'PB? _RUB<>[L/TQSC[7G=6+_C^+[78[W^[[?O\ 'QY$G<>7Y1:9JGEK
MT_\ [0/2W/R95U<V$GQ^CL=]ODHM/@UY:U/N_9YZ4*\,?'GK#L?'T>;V/^+/
MN_\ K'"+AEB/+4P8DB6]O+I.MN,RX^YX=9-EX5E+:%+SX8QV.S[\XQ]K'^;Q
MX10)U1W/Y9+M3U]UEO\ K^S^EM<$;+ ^W8@.;UUV40DC4XFRX2H[LYGL+";D
MJPJ(I?I4Q6,9POP\S'F^.2*XC ?RU*<_[L?2%>,>'V76W::<Y]_O]Z>QV?''
MW/?]OQX1;L#/+4X^/;'1U?Q_'UVVPG&?_P#(I7N_B^3A%N]1\M0G_P#$[HTO
MY/'K]MU'W/#">PBL^&<8_)X<*)TND^]\@8]IZBM<1_+4)QC_ +X71=SQ\?LM
M$;A1X>__ (_\XS_1]SPX5IX#G^5KYGEJ$X]]WZ*.9_CTCN1'Q?<WTKX_E\,8
MX4+=ASRTR<>^U=$U_P#]&]SI\?O=YJ_Z_'Y/D(F)7EI<>/\ M_T17X?W6HMV
M(\?N8QNY6?\ K^/.<<<O?OU1;O7O+38\? KT-7_&K5F\4X^G&Y\X_P _R_'Q
M[]^S^1/#ND_GWV+7!3RTN/=ZUT*<\/C\=:;U1XX^WX^&XE8QC'V_=[^$5N&>
MUWE?D=KD]3<A>BBK<K1:M[>WLT7>;8OV(B\HHN1&8J=L9D>O9FKQ+Q(PYZ'T
M'[7YGG^"L$5Q^;!Y:9/OS"Z!*\/EI&_D>/RX\<;5SCP^W\>?Z?=PB*L_EI4I
MSGV-T!7G"<YQC%1[ -^=[OBQ_P!\Q>/'/C\>,_1X>XGOWN5$]<-%]_Z?L;N?
MVKV1&ZZY[%[NINF*-KNHU\;L2%J.%$TRN]X@D[([..$KB\\<:OI'$F,-E(1%
M<'0UM.N)DOH9>_?OT*^+15A[M$:1L>3V%K/7T9?H\12M6Q=7/[$^#,J9@9,R
MA-U5:EO%$1\E_9V%>Q,Y=P.S,SA/K.&,\>_<HNCUHLG>PH?LK7:NJ]<@U<8$
MMJJSVE).RG2[YO$E&'T&4WA;D3 U4+*\L+A9Q*Q*PG"T^B\<Y(O+TU:?* S]
MO3H&]:=UE&:5;P?Q )ZXG;1=V"M:'<_!O+[-G;37<MN-8Q[8RA>%)<\[U+Q3
MC&,D6L:U]_%=@E"I='ZU)ZW?"J2VDXP6V?G;7P,\UWU-[,5R%\#_ (1X5F/F
M0UZ;V;YOI4M.>/F*X1>=NZY>4/%;0E#]":[ZOG-4>C$>H%=EV':D"Z9>7&9]
MN>N1*P'EA$M-R\R/9OH7W%KBX:5)PEW*TX(JN['6[NR"D4S/6*AZ$M$26-EJ
MO/[+Q_8 B1!*^=#Q ;KV:<()-/PO,S/S,42PT^E2(V&$*\YW*2>_?O 8K3=-
MR[H ]1Z]-:8H.B#VW)$>$YM('?;%?H%)&N^Q/2E<4HA7PDLY/0V>QEF!DW"A
M*<%9P\_A$OQ9416V=4>V/;WLST$#;VK^N]+.=EIFQ-NTV;4BA*Z =3XCZSWU
M?=:/N1YT./8+8E[%:JC#S3CD=29QKTKSK0^&_P"KQR*YZA7#N5/T)=#FPM=:
M-%]AHKY;X"56L6R]R]7DXZ(<!015E.E:U'M,!YZ?DFV2P-#3VV8K<)R*IYUU
M]MHBX] 73N6?K>Q)/8?6>CZC9H$.*O6D+6-QO1\69FYB%<S6;;(M-5"RA;")
MS85N*Z(:)NN1GR2W6FG8\9M\B\WKC?.\-FM9^)V:U1H2CU&*#== D=37R_6D
MW-L6)L1+<4A#MM*K,&.'4.S-=S*8EOR_6TQ&_5?0N.NM$7F:GV'WO,;E?![?
MTUU]K6E6Y5A2U;*7LG81R^+B,HE?!EU5>-Z^"@</35XAI,H]N^9"2Y(5"<FY
M:;2X1']C=[&^POP9CZ3T"[US59XT?%\7LZ_M;/34E,M*E$LU!.NG*NHZV[EY
M+([X5(@N-I:6LDA2E)01:[GV-WL [=@A-*:/T'<M//* XF6R][4O]8N<?+[B
M46'+5=!:SLH5:8:%+4*RL\C,Q:4XEIAX5G.'OWBB]?LEL7NE4#U;C=9=*Z4V
M57Y@AR199^T]I7:A$AIG,G*68@R#5M:W>/.@9AXPZ]+DRX;[<CSF41%M)P[P
MB[NT-@]P06E==6'6&E=.VW=Y+(3&S*/9]I7"MT*N9="2W;!FI6\9K2PGK#B'
M84PH(I):J ,SA#LB?+5!F,-#Y!%RN;"[>(ZU_#)K2NH7.S&'VT_L7*VG;D:N
MS&S8TQW',;%QK/-G]*FJJ420VK7^4*.XP*R[B%G)5)%MUML3MZ:TA>[-LG2>
MHJKO$9@PK7U!K6U;=8*'8LLBV'02;-=".L@1P!B<6S*BDLC:@=]1@-L3(^)S
M[JXC1%"G3WN#OW>=_P"T.HMT::UCK;9G7).O67!.O]E6V]"#!#8E2G6\4Q.*
M6+6M%=@LI@)&84Z/A%EX7)F8=:;]69]9(I(ZX[6[P7.[FQ79'KSI+5M(AAI;
MP>Q:TW3==BFR!]N;%1%@R0ECU!08448_!5.?=(-F)$EJ2S%CI'N-R''X[WU<
M"BZ6N-M=ZS6]5U38_6_2%4T6DM9F<;%K6\;K8[SD/$9(*JDQ-&):8KX3,XM(
M0+;-0\W/T AF5,=B32V8;*)9%R'-N]X8G81FF@^N&EB77M5K!PGMHSMY7*!L
M%NHR&X*CQI.NV=,3@2S8]:R*!H7-]1#))C1,R# _,IW$8BY=[[=[NU'9XZO:
M)ZVZ9V5K.0/#N3KC>]Z6^@6.,2D27TF(S58"Z7O(]V%!BXCNPI:K(V[.><?9
M>BPDLH>=(O;[*[6[?T,M4V.MO7W5.X!!(=-=M<S8VY+1K"<$(I>82/BBX=>U
M)LIDM%D1U/N2Y4J6+<C.MMM,QI275.MD7/N?:7;>J:OUO8=/:!U;L/9IN,-7
MLRF6S<EFI=:J$IX(U(*,UBU"]2V\C:F8A[+P^*\1K%77+&I02<9B259'((O7
ME;*[0M];F+U'T=KJ1V.7%CN2=0N;8L+&O&Y*S^8TAAG:&-7N'W6VJWCVJTZK
M6K67"W^U"D-Q_P#;7CK1>;J/:?:^S:>V':-J]?\ 7%$VX$49SKO7]9W%8+?5
M;=B,$CR0F3]V(ZJJI.KY)6!4H;.]3I]B]GC66BC69[[RAK)%KUKVSVKV NZ9
M[&]?->:;9#Q1;M/50-PGMI.620]DEDRP6;-:JULD&B"ED5F [&69415-F8>:
M@>H-9F$Y#'/AV:Z80K6J7WT[.!>SV@NO79CJC1=6C^Q1'8X&D7;7^]RNR%PC
MNNZ"8V+,;,@S.G]?82-("04J"Q,AE9#[4^1%4N&J/AUU!%EKX1.$3A$X1.$3
MA$X1.$3A$X1.$5CWE+_[7MW9_P"2MOW_ -UMIX125TR_WI?6O_B,U5_H."X1
M7+\(G")PB<(G")PB<(G")PBBW=_^XYM'_P! ;9_["G<(K*_(_P#]K+Z1_P#)
MSUC_ *-0.$62;A$X1.$3A$X1.$3A$X1>%9__ !?,?^;IGYASA%C9\C#_ &L_
MJC_Q?.?Z0&N0W(=0\$64/DHG")PB<(G")PB<(G")PBQ%._V[QK_U<3__ ,14
M?D:GJ'BY%ETQ\6/N8Y*+7A$X1.$3A$X1.$3A$X1=:6IM$9];J<*;;9<4M.?B
MRC"<Y4G^+QQCP^Y[OBSPBM#Z*=@ G9SKZ/VV"HT;7<2=L3=].56(L]!1EI[5
MNZ]@ZN=*XFH'BTK79%4SX2/,>I)S">++A*?F*CJF2"*\7A$X1/#'R?Q?T?)P
MB<(G")X8^3A$X1/#&?CQX\(G")X8^3A%9KI*AZ* =H^WEOU]<\F]RW$AIM6^
MZKD@N3BH3!&O&X6N6T0%1&4#L&J;Z,BKT<J:F2K]MSF.O"F<$5Y7ACY.$3PQ
M\G")X8\?'PQX_+]OA%IX8^/PQX_+X<(F4IS\>,9^[C&?R\(M<XQGX\8S]WA%
MIX8^+PQX?)X<(GACY,?1PB8QC'Q8QC[F,8_)PBLWWN1ZZP^RG3@;M$5)F;H/
MVW;,?KB28@RWXP.PC=2V,IL%^9+CRV(X])#7D8R.9<G1YC4E]Y$9E#,EQIY)
M%>3PB<(G")PB<(G")PB<(G")PB<(K'O*7_VO;NS_ ,E;?O\ [K;3PBDKIE_O
M2^M?_$9JK_0<%PBN7X1.$3A$X1.$3A$X1.$3A%%N[_\ <<VC_P"@-L_]A3N$
M5E?D?_[67TC_ .3GK'_1J!PBR3<(G")PB<(G")PB<(G"+PK/_P"+YC_S=,_,
M.<(L;/D8?[6?U1_XOG/](#7(;D.H>"+*'R43A$X1.$3A$X1.$3A$X18BG?[=
MXU_ZN)__ .(J/R-3U#Q<BRZ)^+'W,?DY*+7A$X1.$3A$X1.$3A$X1=>7AO,9
M_P!-CQ:]$YZ3W^&?,PA7G^'RY\WQ]W"*T3HM?]';.Z_#[CUXHR]<:TE;$W:%
MC51P($KRH]HJ&ZM@4_8!?(NNR9@IO%JO@&R6M,QN1F852;P5+-1R\V<PV17A
M\(G")PB<(G")PB<(G")PB<(K,](:$K>O>TG;[<@K8$2QV'>1#3<FW4EB0-<D
MZ^>H.O&ZN!9ELQ93Q!C-E$>C,M)*1HF5M*\^%Z>.KTG"*\SA$X1.$3A$X1.$
M3A$X1.$5FN^J-H:P]D^G%FV3;U@]O4^V[9E=>ZXF<_'Q;SY+4UB'[ B+B-17
MF2'LO7CQHLAN5)A)CJC8DM./NM)CK(KRL8\,8Q\F/#A$X1.$3A$X1.$3A$X1
M.$3A$X16/>4O_M>W=G_DK;]_]UMIX125TR_WI?6O_B,U5_H."X17+\(G")PB
M<(G")PB<(G")PBBW=_\ N.;1_P#0&V?^PIW"*ROR/_\ :R^D?_)SUC_HU X1
M9)N$3A$X1.$3A$X1.$3A%X5G_P#%\Q_YNF?F'.$6-GR,/]K/ZH_\7SG^D!KD
M#(=0190^2B<(G")PB<(G")PB<(G"+$4[_;O&O_5Q/_\ Q%1^1J>H>+D671/Q
M8^YC\G)1:\(G")PB<(G")PB<(G"+KRVVW8LAMU7F-K9<2M?]RA2<X5G^C'OX
M16@]$X'7*!U\&M]5)<N9IM6Q-X9@.S4VA$C%U3NW836V4Y3<LY/^CQMAJ[>K
MY?\ ]KEQ\M+KW_<^H9QDBO&X1.$3A$X1.$3A$X1.$3A$X161Z)ZY6[67;+N=
MO@N='D:[V0):3FUP-&;DHG@4:NULW1YZ"CSJLL2%$)2<S(?JV/-9CY\QWQ<Q
MX8(KW.$3A$X1.$3A$X1.$3A$X168;]T16=C]E^FFV"^Q8%6L.B+9MHW3:5)?
M&MR]DS+KJ:Q4LX.@-2YD>>^NN 2DRQO)$QISS<>"MR6AB$EZ0@BO/QCPQC'R
M8\.$3A$X1.$3A$X1.$3A$X1.$3A%8]Y2_P#M>W=G_DK;]_\ =;:>$4E=,O\
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M=<REMME"$Y6MQ:L)2C&5*SC&,^%A)(: 2XY  DG3 #$F=!BI:USB&M!<XF
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MX1>;+EQH:7I,N0Q%CM8\77Y+J&66TXQCZY;KBD(1CW?&I6,8^7E' F&@$DG
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M CE8\Z .S(0S/FUTVZ<)C3"AB<N.->?&>A%?5\IB3DL/M3>0^F7M+FN<3=)
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MZ^6\?2.X%PD,XL9=E,>2E7KX&2N.K$7&4?0_@KHMK:=;IBM3!+7/H6-KY,N
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MG2QJN36!X^&Y'4*0/7)S/]HR5-L#OEW3G0O_ (7I.K9VN<ZSNNUK)-[&D\"
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M^D[![8.!D&1.$@2OG#WYU=C;K;@BCDA_66^=42",2KVB4.:G8B>MLKCD*W:
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MK0,^D"I%BB/";),]C%;79:!.1S[2JWOF+HSS'8-8ZO!5A,\M\*9+;,KT'1X
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MQSQDB=^[7M4L$?+GL&:Y5+)J+JC=MI1[]*,Q*3$"F-G'B)XCKC2.N=M;OKF
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M20)^V0/95J-AGP(& Z++V89G(ZP$H*V)IF#_ +$)/R8V,-8ASY!$=N<>"EK
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M_)GA4J?0>MO_ *@NQ,_?4C^57^7A776X1.$3A$X1.$3A$X1.$3A%VHGV;O\
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M3[-)LX;9L2HQC\8MAI@_(N,0'?XX(=)8)/6)46T-QE$9>9K\!Q)&&!$Y'/\
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M<I]PI0RD!Z\-O%)MVOCLX)#B,FWZW=XGJ=@8R3FQYSLEZ2A,9Q+A%$YOTD&
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M*=OM[9B6/3)N\36*@C9I0 4$8]&,/UV49JUJLUB@3(HIV)%KE)QG%O:(RI8
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M"Y;[M/8I=L.6ZDA97P8Q#KTNX;0A;DN\)4QBO-%#4.Q[!'0RC2C4V9+K\%G
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M]R;A':=);6JT>/0 [53M\;:=CIVN&7S&GMX "0$36DFXHB;<)-_-:T-Q+8-
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MN(TY7#8,66-10HL0'OBK(4CR+MV+H%4B>L*4_!D3&Y6D*Y;#4J- 2W.%[,A
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M?7W<746SK[>*)4LFYN-? KE8+';%.5-5:A1:):<TT[&GQH=LEW&N373;!3V
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MAYP5)8V=L.$2&+<5!+#;G8Q92/,&E)45R-H=PX>]>2FXWCWC\+=)ZO=?9IB
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MZ;."ZI40+'K1H^43*@3$#A<7Q2J7.?9BNXC16\Y>DNX2PRE;RT(417L:O%$
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MZ)2]H:WH5XK.X]N6RJV.VLJIM[V)L'6="VUV%\^3/9U9.C62R$2O7;3&QC!
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E<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g67046g43c67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g43c67.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1K$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &JB^:"0X0DE-! 0      %H< 5H  QLE1QP"   "SB < E  "')R,34Q
M,3@Q' (% #E-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52+F1O8W@X0DE-!"4      !#S4(YJ1M"O6!PZX0U4
M6>-[.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           ",   !+L          0                         !
M          2[   ",                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   ",     !29VAT;&]N9P  !+L    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   C
M    4F=H=&QO;F<   2[     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,     ! P     0   *    !*   !X
MBL   ! 4 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MIH=*ZI]L:*K@_P"T %SG#'R*:R)TVG+K9[OY'J?\(M%)))2DDDDE,&V,<YS
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M8#CX5GYU74,,L/@775T/_P ZJZQB().AUM+_ /_0]55+K%U]'3;[L<D6
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,C,WM[C!T24H4EA9<GB5E[+A)B<U8F=VU]CQI/_$ !L! 0 " P$!
M       #! $"!0<&_\0 4!$  @$" @0&# L( 0,$ @,   $" Q$$(042,4$&
M$U%A<? 4(C(S<H&1H;&RL\$'%S0U0E)C=)+1TB,V5%5UD]/A\14D)4-38H(6
M9'.BU/_:  P# 0 "$0,1 #\ [_' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MB]@ZWM%-U/3]F=;Z5+;AGMHW'7=&KE6IP$O/5R^[!*@=GR8S.(^RPLWLZA[
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ME1EVM]KBXMK,KUZ?%SMNEFGN?1?/KSV6R+GSI". . . . . . . . . . .
M4QW=T8T_OW<U-WE=I6\CVVCLZY8B(Z$E8$:N$-ZPV*7LVO\ RD#(UB5.(R38
M"W!Y7U,F-Z^+2V.)["4G)JP("U]X2N@M:IJ$;7ME;X>J%-MN@=@@T26L6NSZ
MU(7_ *ZJUZU3KA*O?N7LV=V0FHG6%3@;9&!V0&LEQHQ3\'!5^9,=E> 098O
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M5+$Q56A0H*/(DR1Q@QR)%\0!ETU\<,1ATI;KC0S"%);2!F/ ' ' ' ' ' '
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M+C<--1LHML _+F #EH!)?4D,WU+WLA6<89)]4[ZE:_5K]$#). . . . . .
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MSY?D]W]&<X^C.> >> . . . . . . . . . . . . . . . . . . . . .
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M;#+;>7RGWGW/1])UQ:\Y5D"^7 ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MDP[$U&B$KBW;'&$$J*;^4A#@S(P4"UN"Q\YPG#J,YSY8QC"V_BI&7$I_XO\
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MX1RA!ZK6M*4C=RU4XPE962=LM=WS;SW;K[K;D;)TX0K&,XQC./?Y>[^;./\
MO^GX\XY$<<'!PL<42;'Q$8":8I2C"PP!1B2E+5A:U$OLM(=?4M>,+7EQ2LJ5
MC"E9SG'GS+E)I)R;2V)MM+;L3V;7Y7R@Y3F . . . . . 8K=&+F16Y1K7\E
M6HFVJ9:Q#GV^(E)ZNCO8?;R^J2B86<KDD6A0N'D,I%F0E-DJ9><4ZTVMAS:'
M%JI%UE4E23[=4IJ$VO\ XN49P3OMO!Y;,[&5:^>PU\=,*IXD\'<-E$=M]@ZN
MGJ.1<RWZS'@PR)"??A<LR6&GJ?)5V3A@ZM *?5%K:B[?%6:9RPR2SY1KRLEE
M=?2=30LZ=!:.HXF%6-)*HY3<8:_:WXR,XS=225\Z<H1N[MRS2EJ.BTN+4D[+
M:U:^QWR;W99\^5R4-[.=L69V^"Z,CIY#4NUK ROVK!.LY>*B0(Q=C%O<1!UF
M]7"+2W9S7RJ\<^N2AQ(,^"9D<#V(>P,QS*>,0D"6"&\1"Y2TY"SK$A$TI>RZ
MH5 OUB:TS'23]?A[A59"2S,'8=Q,BZ_,@HF=-3'Q;O[I6)23"@BCY6$0:0H"
M8;UGNHJPSB:2[.-AKO$O\@K\](*J#==08"JIX>3+BN7=527!IE$WWUJLWW[[
M%1V*@MNMY*=0!&43,=\X0],-(O&WNX1=6C)N1'2UKV*&.:M&NHD=T)HQ@&OZ
M]:=J^['; D9.7/OG<H-<R\IR?R6PF<;]GC]P(KINP/$*VU%6<*!<N$%)-[DM
M%5L#\W%ZGK493Z&VL*&CBJR453XR;D6B079ZQB.-GSUPK$]&00<JJ;B)M/J,
M>/\ YY^J!;WK !VUB[%, [\F)4^F@4>E@5;Y;%UJ9*$SXL% CS<A*62DRJ)8
MRQOR[5A<L#)\$NOE>OC"X"4:P@L5_(+O\ < < < < < @=/SG'?J)9^W[W )
MXX!!/9[YO&Z_JMO?V:DN6\!\NP7WO#>V@;0[N/A1]*.O7]SK?OB[1?R+K#]N
MN//1/A%[G173BO4PQ<QGT?"E[CM%<\P*(X X X X X!1+PQOF"=6/JLC/VZ0
MX!>W@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'HY_P FY_ZBO_ESP"H?0KYI
MFG_Y,L/VTLG.CI;YPQ/33]C3)*O?)>+U46_YSB,< < < < T:>/]\S>B?7_5
M/L-L;GW' 'YYK_T^M[?#%O!]\?0O619?P@/F :,_B=J^VUDYQ.%_[PZ1\.E[
M&F1XCODNE>I V:<X1 . . . . . 1ENB:!KVI=CS,D-)& @TJRN$BQ LT9)$
M-KAS&?5"M5T4R;0M67,>F5'#./@M8<-\VT#K=0!J0\$G[Z#=9;LGKO!VT.U2
M5VK0)D^?986RT*=BX:#+8A(^B/PQLN@1VI!D?>Y-BO3DO@:/$JX0BHL(,>"B
MP-WG ' *,^&O\R;1_P#$[Q_TFW3@PMGCEZ67FX,C@#@$ =IMJTC2/7_9VTMB
MYG_O1J%?P=)(JRSV[ \00>''Q(\6[&FQI3)!$P8 QZ_Y0#&9;<6X:0T&E]6+
M>!P];%XNAAJ&IQM6>K'C-74M9N6MK*2[A2R<7=V25[&].+G.,8[6\O3Z"GG1
MH@?M;5-;]I;%\J.4BMA2$'HBAV&2/FS8*5C%DUR[[4N)DD9(9DK_ &.8%F *
M]ALTX&I5)?J8XC)\S)J:Z&E%+1]6OH^&JJLY*>,JPC&"E&252EAZ2BHJ%&$)
M1E.R3G4RE>,8VDJKBY2II]M]-\MUDEOM:W)R6-H&4(S\4XYPTDMG7HY-NX@/
M;F0. . . . . . . 8U;['FIUZ2GDP-BLZP&FW$P54CVI2?/RZ^TQZ$>"\4$
MT0XWZW+[J5%->BPTZO&5*3A"@*3]6^[Y'9&U76KKT5M"C)JEH*@,3LB$T;!B
MMC-&NH1:BW$QKE>G%J!4RY$#L3&&WWV6_;/15ZS(&0;U[:8TK8[/ 9KT;8I:
M#:ILQ%U5F88 MEIK<O 7^:LLE""&+0V0S KI.!EFH0N/$40[F2>9REK"@,9-
M[V0<>B39D*5&P\K"O_),K'6+9=7KZ0YUFT6"KFD8>D1VW'*6*36S6\77(:!7
MY<N+@FXWV\U660Z];&+L>(E NAQ<S(:PM-:B)%[VQG$V;')/57&V=B-'2LFV
MEQ@:M.1)^OI!X]@QZ2]"*7@EY0GDXM@#@I_Q/];Q#>QY,:EF25;UG"A2,C-M
M3^,(ECY(6$F(F*A$!U^3CCL3T#,.GP)K<NI!)D86'*,Q ;\?*F ?<%XB(X;V
M8BT:N?\ EQO.Q3B5U^UAO0D9#578VS*1!E3<C-1T6W%JP+KQN2OJGUYS3FK+
M G,CS4:68_%@<V#WBL(E(U9.&ZJQ;9O9"[>0XJJVF)"@(<.,W,'J>O88DC&S
M4S39S\["GDR0.<"KC!Y64#:6K(4:0!%4QXFRT38),31V Z3)R-6,@96X.R=1
M;GZ]BFS4EL81JV3(H].3-U>W*K5?"Q%G3#1A!!8#S227Q'4NO7KY+ VN5^8;
ML$'#SK(Q0;,U%1TLR(<UZ@T5J1#9,;',8SG*F2F4/8:(9SG.6WD+1Y^[@',<
M < < < @=/SG'?J)9^W[W )XX!!/9[YO&Z_JMO?V:DN6\!\NP7WO#>V@;0[N
M/A1]*.O7]SK?OB[1?R+K#]NN//1/A%[G173BO4PQ<QGT?"E[CL$=GINX5[3\
M])TO=FK>NTD@N)&-W'M^$$L-2I<2:<T&8>U$2=KI<(78'U/L!U],].MPJ9,A
ME1P4FWC !'F!1->/52\;9,[)AZYK7B=T_NS #TA[8NRZN;J;2[HT+729AZM!
M_>=L;15CA<U6QMSOLK[-=N-<M01T%@M;9@Y:6R< ;/KWN[3VK)JE5K96T:#0
M[%L>937=?P=OMD'7I>[3RW&&DQ%5C94X8R>D,NDC->RQK)+WK21V\I]-]I*P
M(O*[N].08.Q68SM+U^%KM1N+&O;1.D;=H;437KV3A_(]/F#USJ18^QOI%*6U
M$$N-FN(%*6AG*1G\M@<](=M.KL3,WZNRG8C2L?/:JK8]QV7#&[,IPTE0JH6@
M-8MCMP;LPA^OPKZ)&.RU(RB!A7/E '"7<Y,'PX!*])OM)V54X*^:\ME>O-)L
MX")2N6VI3$?8*Y.QSJU-MG1,S%D% 'BJ<0MO#PS[B,.(6WG.%H4G %/_  Q_
MF"]6/JLC/VZ0X!>W@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'XOK2VTXI><
M8QAM><YS[L8QA.<YSG.?AC&/?G/Y,>_/NXWVZ]6"HG0=:'.I>H,H6E>,1MBQ
MG*585CSQ=++YX\\9S_1GW\Z.EDUI'$IIK.D\U;;1IM<^QI^,DJ]VWRV?_P#5
M%P><XC' ' ' ' -&GC_?,WHGU_U3[#;&Y]QP!^>:_P#3ZWM\,6\'WQ]"]9%E
M_" ^8!HS^)VK[;63G$X7_O#I'PZ7L:9'B.^2Z5ZD#9ISA$ X X X X X!&NY
M+O&:UU3L6_S-EAZ;&4^F6.P%6RPN)9@:XF-BBB&YJ:><:?:9BHUY#9<@^\PZ
MPR(T\Z^A3*%\ IWX9NV[WO3KJ5M'8&UZGN"5M&P; \!8Z<=KQ^*CX@.%JX#<
M(J-U?LK;=4KA:)$:2F78)J]2)[3,TQ('Q=7=D<5>( V%Y6G&<XSGX>?G[OAY
M?E]W]7Y?X. ><+3G/EC/O\O/_/\ 3C^GW>? *-^&O\R;1_\ $[Q_TFW3@PMG
MCEZ67FX,C@#@%(^Z+<OLB$I/5ZK#1\C-[[F2,VD22->CP ]-Z^5'V/9!<B<+
M&S) 0<^\Y6==)(;BRW$E7EE;3:5-9=:Z6C;49U<=-N,,)%*FXQ4F\363A02C
M)QC)Q_:5GVR6K2:VM$M/M6YOZ*R\)Y+QV;?)EF60T]3GM?ZTI%)>@*O6<U.O
M1T"F&ICV7JV*W&C(%2Y&95"5W+;9?J_:W6?D@;#3[[B/2?RGVARGB*BK5ZM5
M3J3XR;GK54E.\G=IVG45HWU8]L^U2V;%I)WDW=N[O=[7SDF<A-1P!P!P!P!P
M!P!P!P#"=B[(UUJ*GS.P]L7NG:SH-;98?L%WO]EAZ?48)@HM@ 5V7L=@-CX>
M-04>4*",HPQG!!A(XK65OO--J H+U&\7'P]>Z]ZMNLNO_8"HRNP:Y9C:^'3K
M,XBD638:PQ9 U^P:OAK&X!);%KZ08>0-(DJV,<]' BI.E10 R0GR0+7VK>M1
MK-OL<%*5:VF1=*#KK=NNL7$1LU$0TK=%H;K%1'@@90C8EDL%A<>C&A8ZG4FP
M,*(E8P9XALAUUL<",2^[G6YTZ%C8LZX6,N>L,!6$-Q6HMDJ:'+L&80M2SBY*
MI !J;@,6*$?MH Q!4O6'I)MF9C!#FR&&0..ENT_6ZRS.I9>)&G;1/3]HJ$50
M'Y*@[#J 3"]M&0E75+#GV^K0L ]*MUFZL33T*0\JSKJ4J2<$$U'2;Q+PSZ.K
ML?LYLOJ-2MA6'8;PDE&7&<D)BI3=M7KC;9<$\[#S53I4X2U)?>P33 HA5CA:
M=5)"X1[@T/+3<-#P[TT<9&-#LC!E4)VWZ[65."PK 8T%\E/3#94U0;G!%8'>
MK]NLYC3L)/5J/L@3SM3I$U8,>W1 S,I#YCG8]XY4H"V^ZH&,S_>SJY PTK*9
MLT\6F')M,8''CZNV*(389FI4T?89D+4GYBIQ<3-DR-:)!DJ^6%)9AYY18Z8N
M3(<PO+8$FZD[%Z+WA,SU2H%@9E;13HR'E;159"MS4+*UIN=:PXP*>--1((Z9
M$5[S#F 0WB2(>1;4%)(&*QAO(%B,8QCX8QC]&/+@'G@#@#@#@$#I^<X[]1+/
MV_>X!/' ()[/?-XW7]5M[^S4ERW@/EV"^]X;VT#:'=Q\*/I1UZ_N=;]\7:+^
M1=8?MUQYZ)\(O<Z*Z<5ZF&+F,^CX4O<=E'9%&I.QZ7.5#8E.JM^J4F,E<G5;
MI6(JY5R26"Z@\+)];FARHV3R(<,.8,R0SGT2F&7&EMO(0XGS HG7D\" /9DG
M;]M[ NM/K%9AKC0X4Z"75:AX?%&BW,.VF0<P*)5NJH8F\ZXP.+AM.*_O5*GH
MA:%@D*<L0Y;J@-A/<?H%LGL9V5TUO[7.]9'4;M%J8=!LJ(Z6V/'2K5;%V5$;
M"DBJX'3+O6*O92K8$ =2;!7MGP]HJ?R8:!.CQRI:$$:==?("CPG@R;ZBD0D]
M'[TT<1<:+K8+KW3A9+55L<IDQIP;6VY-:N6^\1[-R3(&;G4%N(Z8P;&D,UY1
M,-\G+_V,X4<"!S7^IAVC%JBXN"WMK@FO:AEI&[Z->G]<3A-CL=RF]F=;MGR,
M1O@P:T(#GJ6'(=<P(&*361PY1N*LZ2%I0Y61!)("^^K_  \J@#I>B4#<5SV7
M*6VN6#;5SEI'0N^.QW6NH+L.Y]FV+:5FC0:_I[;E-<F(*#E; N'K1%P=FI86
M,$RZTZ"N2.&RZ]>OY R7PNA&@/#XZF@L*?4P%J.%$84442:2ID8DYEI1)IKQ
M!A;^4(3EXHM]\DASTGGW7'5J7D"^W ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MBW@^^/H7K(LOX0'S -&?Q.U?;:R<XG"_]X=(^'2]C3(\1WR72O4@;-.<(@'
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MGF-<5]N3K;%68@'O0+4Q#YI2XE58*CP%%* %DXI$!!C-RS0J90@"'C(XPP@
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M ' ' ' -&GC_ 'S-Z)]?]4^PVQN?<< ?GFO_ $^M[?#%O!]\?0O619?P@/F
M:,_B=J^VUDYQ.%_[PZ1\.E[&F1XCODNE>I V:<X1 . . . . . >%)2K'DK&
M,X_+C/PS^3WX_+C^#/NX \L8SG.,8\\_'/E[_P"G^;@'G@#@%&?#7^9-H_\
MB=X_Z3;IP86SQR]++S<&1P"N?:6^SU*U/(1=(?2SL[9DM#ZGU?G*?34/=K\5
MB&#G,MX][@E-C7)2[2V,>6&XBN'N*4G"?/ES TH5<0G5[Q0C+$XCGI44I2@G
ML4JLG"E&_P!*:R9O3C>7-%.3SME%-^=JWC)6UM0X#5^OZ7KJKL*8K]'K,/6(
MA#F?3?6'#@LA-D%._%\TOU.2CB5Y4X46\^0ZI;CJU9KU:LZ]6K6J.\ZM2=2=
MMFM*3;2Y(KN8K=%);C63UI-O>_\ CR(S;D9@< < < < < < < < < < < <
M< < < < < < < < < < < @=/SG'?J)9^W[W )XX!!/9[YO&Z_JMO?V:DN6\
M!\NP7WO#>V@;0[N/A1]*.O7]SK?OB[1?R+K#]NN//1/A%[G173BO4PQ<QGT?
M"E[CL]2JFTQQN7FFWV\"D>F.]G_9/HPRYE3+GXCF<MNIQE#F,-KSZ&5?B*^&
M?,"B=./PPI[KM8.Y4 -MNLV2IW*8(J-FT]$Z]-\0!RGP-]A):QPL-I;:0>YB
M;!K&S"ZWKD16I&JVJ)7 4B,1%00,,U@0 -AH#N5I]^,>>/+W?#'PX!YX X X
M!1+PQOF"=6/JLC/VZ0X!>W@#@#@#@#@#@#@#@#@%3>]7S0]__5W*?UOB?E^'
M.CHEVTE@O_YX^:Y)2[[#PD6ACEI1&1_I9\L8 $SG/Y,8PPCWYS\,8]V<^><^
M6,?'R]W.?)]LUSOQYFCS;Z7Z2LUW[:Z]AY\RAZUCK%OC: :O4E434H@\]F$)
MSGT4XNMN??%I5''PO./79LD^$;A&%*'CREXPVJ[3P%:4%5K2AA*#5U5Q-X:R
M^RI).K5=MBA!KE:1O&FWG+M8[V\O(O0:"^Y'AL>(9V=[61.\V1Z;6Q+,[6G(
MWY.V@J2;T>%!H&&9!<)(C8(T\H10ZYUYRJQI0Y$F60RP\XK&'U?6:,TWH? :
M/EA'QM1T^,UG*BH/%.=W?)S26:C^T:>K%9+?:IUJ,(.#S23^B^V>:SZ;YWW)
M=!O C=@]O=41T?';*T=![KBHP(80F[:%N(X]G-0(TAE<A(ZTV0N!6HPK",OO
MLP=UF5J>4XEEC/FVGGRTJ.CZTI.ABYX9R;:I8RGVD6Y/M8UZ"G'55U;C*<$E
M;.R;59JG)WC+4O>ZDLER6:\]]G.9I5NY_7Z?EF:U.VXO5ER(6AE%*W/ 3.J;
M$X0K\7U 3-T$B@9E65XRA*X,^38<7CR:=<QE.5:5-&XNG!U(TU7I9OC<-*->
M"5][I.4H/-9347S7-73FDW:Z65XYJ^Y>/KO*#57N_IL/MKVV@=/2@&Y=JWI[
M2=2U90ZKDA3%KM51J5FB[.MZQJ%^1XZKU M?M-LL&2W1PHX<AT))Y&66'>I/
M1>*_Z?H^>)B\-0I=E5,15J63A"K5A*#5.ZG*<U90BHW;R=LR5TI\73<HM1CK
M.3=K)-Y;6DV^8V(:(T250"9S9&RIEF^[[O[(RKS>5,J:!C065*?!H5"!=4XJ
MO4&NK<4U'Q[:L$RI6'9N:=*DREK;Y.+Q4:RC1HPXG"4G^RI;7*5K.M5?TZT]
MK>R*>K!);8YSO:,<H*]EO?.^5O?[EDK(.?\ )N?^HK_Y<\ID94/H5\TS3_\
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MU4G.Z>;^BU=\F?EY[9'8XY\>4C\GEI0VOTL^7FA7OS\/AGXY_)YY]V/_ />
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MFMTQJ$/&IP"A?E,+[[+)DJ7(9?8'; V < < < < < < < < < < < < < <
M@=/SG'?J)9^W[W )XX!!/9[YO&Z_JMO?V:DN6\!\NP7WO#>V@;0[N/A1]*.O
M7]SK?OB[1?R+K#]NN//1/A%[G173BO4PQ<QGT?"E[C=%XD5QG-?]/]D7"ON:
M@47 SFK) ^-WQ8-?U75UBK8VV*2[;JI8[)M$&2H\&Y:*LB8@8>5F 2%Q\V?'
M%QB,2S(*D^8%$HYX0_98'=<WM6M&ZCZ54NV03<S8W;;U6WQUYVA*R=1G[[-/
MTNHV>L:6K<,?$!4^MOQ4+]\TT4^/9)6/?.]F&,+<;2!97O3TMV7VIV=UUL=,
MGJ/38C4FP*?=YJU2\C:GK*VW5;>'8R(H:B#!F4._,208N1Z^];GXHR@6%U=K
M@2WS_5-- :VA?!@[#QK,/,CVOK/)V"GZX!T/$5F6A;BJD7BD#:QW9KA>Y;_E
M$(Z8K=./W8,3B8\>/D8QQ<*7'YM;>9C!X &0+\&+=D<\$!&;&TI,Q.KY(ZVZ
MZF['!67[Z-P34OM#K#LHJE=@%,!$CM4:)3UV=K$.1"E6@O$=9H\AR(;Q7EA2
MN'GU_-- V*:>Z&V&LZ,H.O+;O3:VNK-7['M^XS@G6*_2.M:$J3W%M*S;/+@
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M -&?Q.U?;:R<XG"_]X=(^'2]C3(\1WR72O4@;-.<(@' ' ' ' ' ' ' ' '
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MMS.7&VGE+0A><K2G"LYSP#/. . . . 42\,;Y@G5CZK(S]ND. 7MX X X X
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M;;VNY5;;;;S;S9RV<8SY>?Y/X<_]G-;+G\K7H9@8QC&/+'_;G^WF0>> . .
M. . . . . . . . . . :-/'^^9O1/K_ *I]AMC<^XX _/-?^GUO;X8MX/OC
MZ%ZR++^$!\P#1G\3M7VVLG.)PO\ WATCX=+V-,CQ'?)=*]2!LTYPB < < <
M< < < < 9SY8SG/PQ[\\ A#4W9#2.]#YV,U/L")NAU9@Z]9)T:.'E&%QT):[
M'L&HUZ0>S( !H4U)V/5>P(IE#2G'4$5DU3[;3+@CA $?6OO+U1I,#M.SV/<U
M>$@=)[!7JS:DD*!8I=BF7T> 3:3Z]*)AH8]U3T/7<NS$\8&V3&P  <D_,F H
MC)#(P=>O26<AYN'L$>'+0<F#+QAXHAP1\>2T6(4&>*R<$2R^RI;:V2@B!RF%
MX5Y.#O-.I\T.)SD#E. . . . . . >N4ISGSSCSSC_/^?T< \YQYXSC/Y?\
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MLO) ]G(8=< _73FX]?;XH,)LS6,^W8J?84&+C#_92XXE6 )(Z))25&2+ LB
MXDZ.*;0V8,RMU#>'FTJ9<;6H"4> . . . . 0,C'EV<=QCS_ .8IK/OSY^_-
M_=\_[,?H_IX!/&,8QG.<?'/Q]^?[/AP""NSWS>-U_5;>_LU)<MX#Y=@OO>&]
MM VAW<?"CZ4=>O[G6_?%VB_D76'[=<>>B?"+W.BNG%>IABYC/H^%+W':*YY@
M41P!P!P!P!P"B7AC?,$ZL?59&?MTAP"]O ' ' ' ' &<^7OSP#7AWU'&[ 4:
M8Z14IO,QLK=D1&DS1;#ZT16I:!%6&.E"-DW9YA*U($6?$MQE8KG^R.N4NI80
MBF 0Y22!Z^BGV'5CI6J]7#X64E%.*<L56=.5L/1O;MM63E.:RHQ:E+-Q3FI7
M@^-R48WV[W:UER\]O>53\&[HX'ULJFR=KFW5ZUV6^V6TZZR&+'KBHB*A]5W^
MT5=96&EF%.&G3<E%.R.%N8:3'B+9#;]<XLA]?0X2:4>-J4*$:7%TJ5.E63E+
M6FYUZ-.;B\K1C!2U;)V;3EL:2DQ-37DE:R237_VBGXO.O&G?=WSY@JC@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@&C3Q_OF;T3Z_ZI]AMC<^XX _/-?^GUO;X8MX
M/OCZ%ZR++^$!\P#1G\3M7VVLG.)PO_>'2/ATO8TR/$=\ETKU(&S3G"(!P!P!
MP!P!P!P#U]-/GY9SC&?X?=]/_=G@'HXO'HYQC/OSYX^&??Y^[W9^'G_3Y^_]
M. -1^D/#'M^E+):T0O:&9'USL;65(H.P8NGT.>UYMMT_6FW]^[>IT]0=RU[;
MZTT<1V0WU*5^W015 MB[+!0J1QYF#3+E-C >NS/#V[)7M7;H**[?:TKU;[;[
M>I%VM=<)ZM6>791K*GZ^C-6&:8LTM']J:W+66*N](J=$C+I9X R@R4DX#<\
M@1L;=6(JL@7_ -&:C+U&)>$R4I29(^\6R.MACE%UP/K2(8+%H%(I1#2XMNR6
MDB16Z[4%& GR$H\9'PA4567'36H!F3. G;TT_3C\G]?PX![8SY^_' ' ' '
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MXZJA0I.+M"[;E)-NRBDLTY1D[I-9)9M/)));$O'T<[+<<H$8X X X X X X
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MPQ\A>KS?&HL=JQOX35W7JXA1<BAXIQJ"<S$-./+;C\(%0TA($X< < < < <
M< < < < B7?L%9K3HG=59I31+]RL>I=CP528#-:C3'K-+TZ9CX%H61?)#8 )
M<E2!$,&O%BM"NY2^X2PAM3J0-8W2&G]X]3![!UK<-3RH#<CL#75T-V-M*]5R
MPU::UXWHS4U*N50UJ_2-ES5ZC-G@6^LV0H5-JJE?HSSCC\HW927SDJ4!4L72
M7:N1UCK"@2_43N-%%0/>3:NTQ]@!]BM22NP];Z6-W"#LZHJ%;+[>MQ]UE;7
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M.OVDYBEOSVU-JR0=MW]LEH5=XL0N',P]7AQ5K?A]8T%DCTG8RCU7+SB&\8]
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M]X=(^'2]C3(\1WR72O4@;-.<(@' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' /&<XQGRSG&,_'@#&<9\_+.,^6?+/E]/ // ' ' ' ' ' ' ' /5*<)
M\_+S]_Q]^<__ .?ES[N >W ' ' ' ' ' ' ('3\YQWZB6?M^]P">. 03V>^;
MQNOZK;W]FI+EO ?+L%][PWMH&T.[CX4?2CKU_<ZW[XNT7\BZP_;KCST3X1>Y
MT5TXKU,,7,9]'PI>X[17/,"B. . . 5![U:3NO8/K=9]:4$*KS=@(M^I[6JG
MW>3*AJ;L*$U[M6FWRR:YM,H'%SC@4)>X"N2-9,>>A9<'RDDHDXTR.64PL"H6
MM_#UW@QU[U!KS_2VW9U)FJ5+;CG)6C]5)K7$A11 MI;2L&P*[26Y/:&H[$5(
M1FKH27%I]>(A8NJQJA&2LLPK0GL+0P$7=">F6UY[ISUZEVN\';[739^O(YY-
M(KYNJ1(:N8]I,1F/CQI_5<G,,L8RC+WH2!Y+^%NJSEST<I2F]'&4$DO^FX.5
MEW3GC$V][:6(23>UV27(2*:7_ITWTJ7NDBW7^@YMO_TBO=;_ -ZZ2_\ X=YG
MLVA_*\%_<QO_ /H'&+_VZ?DG^LU#=\?!Z[?;?W'4;50-SSV_X1^"C8"0M>\;
M=6XFW4E0AY+KN%,P,!7XH^N)29D\9,#$.S."4FMDC$+4*\[]-H;A!H[!86K2
MK8=X>;E.:IX>$ZE.LG%*,7*<YSUKJSXQNG9K-62+5'$4X0:E'5=FK13M)-/)
MYW2V<^V]]IMDJ_1;=D/5J_"%>(AVW9*C(2*CB?DS.EEQ[9 (# KR8WY:U)*2
MR0L.-*]DS)21Y^&,-Y+-))PX\OYRKI&G*=24=&8&*E.4HZT:TFE*3:34:NJV
MKV:45'D5BM*HFVU3II7OW/IS*W;NZL]AZAM7K#0X/Q"NZ)D%NC95SIMPD?E/
M6"3*]$P.F=AW\"0C28O6 8PI!-@J<5&O.2[1P:Q#7V1V&SG1R&M%I#>L!HY-
MJV>&D^:_;5+/+FZ&K&%4LU^SI_A_V:Y= >#!W1IG<P6UV2_)I6MJE;IJRB]A
M:C<X(O8=H%(P?D%V#KAD?(F1UIF,EI;L:K/#M0H27Y-01$UGV5+WT6-X34<5
MHMX2.&G&M4IQI5%+45""44G*"B[MY+53244[+>W8J8F,Z>IJN[5K/)1M:S5M
MNS+=R[[[W\=--G?D[Y=O,?P8F-3X\OZ=5JSG]/GGGQN?*O(_S*9&NX.B&X;C
MK2ZUB%[K=CK)*S4"6$%!7V8HGWFS3R\)5B+L2JUK^'FD1AR4*&?< .;6UZQ*
MW6RA\/"/L]]O);WL%7.E?AK=CM71]U*O.^+]H9V:*CF@H/2MDJLB],(CO:L9
MD[$3.5VR1*$>1"6XYH!ID["%$9-<2G+3&,F%?>[DS=<M';YVY%[<-MO=?M9!
MO4/L/N?4\"W'FZW#1)537EM(@J]-E)DM;&*(/E06DDF%AK9CB759<"%'9SA&
M,9[FO)?WHR8!W-\./L+LZC0(U'[';1WC(0TTLUZF[IL-0!CL-OCY'Q(P1E?J
MM9 ;DA_24EY$RIYM8KB\B/,/(4V3DPU=;;>1^DEOKOT"W50-0U&K6/N'OR@R
M\>,4LNG:OFJ.NE5]1AKY>(^(=L]#G9-[+:7\9+=P:D-9BG\A#M#^AZ6'?=;Q
MJ_O1DFS/339WEG_Q\NWG_OC4W_\ %7&?*O(_S!IM[Z])MUT3=&I+T?MF[;3K
M6U-J:FTM!;$M9+$I?ZE;[G+)BH=R9!KD3$B#UV,=8(D4S42 .-'LMX2>E!BT
MNE9!N*%Z9;10PTVOOAVX2MMIMM6&I;5:&O20G&,^JP_K AW#?GC\3#C[KF,?
M\HXXOS6K&>YKR?[0/HSTTV?Y9\N^7;OS\O=Z4QJ?*?/_ /-A.K$JSCZ<84G.
M<?!6,^_#/E7D?Y@UFZ#\++M#3>Q$O;;#MZ4U]6@2+"\QM?7UECW]@VO$K[2E
MI8P,O&RK 3YZGD/SOWQ /M(_VR DEOJ9+:R8SY>O7_@V9?Z&NSO_ #\^WG_O
MC4_E_P!%?P_G_GYC/E7D_P!F36G':,[4]E[)XAV@C.T>ZIF-T+L?6U#U;'7D
MF !K&R8>R:IH^RY?%X.B:B 28XW.3$C$@&UUR-CA4C!-2H)N6S5/Y&[KUL^G
MW&0]7O"T[/U>GS;=D[@[VZIFR$T@ANI];[!K*2&F66!U,8D[:5?->W^-R;C/
MHHC6Z[[ XV,I[,L^8M0C$>ZOW LY_JV]^_\ I;_$1_7^LG_]=> /]6WOW_TM
M_B(_K_63_P#KKP"%.P74SL[UPURSN2L>)KWJV9*U+9.D6E4*YN:".JUIB+-N
MO7U0LD5.B5G14'/.1SU=GY53ZHV6 ?9PC#RB$M(<PH96W/9OZ#>7CX8_1C@P
M>> :-/'^^9O1/K_JGV&V-S[C@#\\U_Z?6]OABW@^^/H7K(LOX0'S -&?Q.U?
M;:R<XG"_]X=(^'2]C3(\1WR72O4@;-.<(@-3=N[S=HH.\V^L0W4RQ2]>@MIP
M](BKJFO;$*BI6C369O,SMUA,17CV#:[JI<;"B6V' /<E+.[<(O,(Y#&PUAB0
M@/TU7WC[7W>]46M6CI;<:?&6:?M4?-DDAV]ER ;@?4-#Q#DO,UZ'KC,H\.XF
MRIG9@^*JDI%%L0T,>5,!R3HP%O\ K;V1D-]G[CKMCTW?M&WC1][A:%<Z7L":
MUM83_;[%KNF[/AI*-F=5W>_5@R.,K-YA\YQB;2:.8DH8D1I37FH"T/ ' ' '
M ' ' ' ' ' ' ' ' ' ' ' ' ' *8]G+KVCK-HJ\;H"CYM$%)TJR/V:5S Q4
MGFOV :[ZT8C7Q79*VP.#3\4$S:$C&0&0EBR4Y%0@Y4FPDE(I %2;+V1\3C4O
M7K9.X+/UETU<K3KF+(N-LJ-BV@[JF&BJ=5J_LJPW@RGS\!#;9>N3P\-7]<%1
M8DB# ^OFK7;8W,EAFN#-J VKT*R.W*C4VWO"(CW;55:]9%@MO9(0&J<B Y-0
MB2%-LJ?2.HK+*7LLM9=2C#F6V\J]' &6\ < < < < < < < < < \>DG_P K
M'Q\OCCX_1^GB_FS!YX X X X! Z?G.._42S]OWN 3QP"">SWS>-U_5;>_LU)
M<MX#Y=@OO>&]M VAW<?"CZ4=>O[G6_?%VB_D76'[=<>>B?"+W.BNG%>IABYC
M/H^%+W':*YY@41P!P!P#U7G*4YSCR\_R>?O_ "^_W>[SSY>?EP#7%H;Q!PMT
M[:ONOY'5,G2ZG$U3<M[UM?%VJ.GG;[5=!;C-T;L8J8JXT>"92I)-R$:,K<6Z
M?.YF*^6@LDF,.9>CD@0#">+7+2.GKSM0GK!.A9J8?6:]!PK>TJP8T;I7M5.D
M0NO+[)2F8@9V-L0+H9:;%0@(R;?!*6"T/.E!O%2 0==ON-S+2_6-H<\O+TTX
M5Y?1Y^_@'Z< QJZ6F.HU/M5UF,/JB*?7)NT2J1F\.DYC8"-)E3\#M94C#K^1
M1'?4MY6G"W/13E6//SX!2'J=W8L/9NJ;1DS-'25#NU KVN[G"T=N_5VS8N-4
MV]K*.VCK=YBR9%@HN%G3H>21&62)D&E!P$NR[AF8E@,M&K G?J7O]/:/KOK#
M?6*H[15;%A2I1RI$3#$\[!OAS$E#OA*F!PP&)#T7HY:\$-!CH7A>,81[O/(%
MC. . ?D0M;;#SC;*R%MM.+0PTIM#CZT(RI++:W5MM)6XK&$)4ZXAO"E8RM:4
M^:L 5@ZD]C"^S.OKA<9+7Y6LI:F;GVWIR6JAECC[2^U):IN!U2,D/E:*%%CW
M$R3H62L#B>U,"Y7EELXQ"</K M)P!P!GS\L^7OSY>[]/ -;N_/$"SH39^\->
M3^F9F3QJG2.MMMU&8%N,$UC9LAM#:2M/U^L, X')S4A&[FX**=/3A3CC(?M9
M^(58[(ZC +(]6-^G=BM:25PFZ.YKFUU;8FQM57:G9GQ;6'$7'65LDJE.XB+,
M&%&-3L(83'X.BY%<5%D.BDH05'BD-N-) LCP!P"J_8KLD=H.Y];:WG79MJA-
M_P"Z(_31MM8L47%#422EJU9+'&'D1#[)4K8,F-5D]G P+(HXZ$*=)D6G5##$
M@:]8?Q>)RSG1-<J/5R2D+CM-VM377J*DMMUZ*B]AZ_GR=T^MM%SF\UPO]S65
MCXO15ME%UC,?;'2?E. "9D\$/R.(T#:GU_W##=@]':@WK7(Z0B*_N/6='V="
MQ,MZCY5BXR\UN.L@<;)9&<=&4<"Q(MC%*'=<86\VM3+BV\I5D"7^ 05V<W')
M]>^OVX-XQ5&*V.1J77EKV(130IV+K1$O&4^&+GYA*9F7PX(&@:* ,+<4D8TM
MU#&6 0##'61W -:NZ/&$K>EBCYR?T39)75M6J%)+NUTB;E#?+</LK8G6JU]H
M:O18FG%QS+LY#KHM7;C)2ZJF8YD&P3L<,U"E"BR90@'$RWB_S5;(L=;L/5R5
M&OVGY.ZE=BZ]';9KLC$Z\H5(,ZWI*M%*L3E="3LR7DHGM!0I,"L?)M2RA4/;
M@"Y@=\.(<F3Z^_R W:8SYXQGZ<8S_3P#1KX_WS-Z)]?]4^PVQN?<< ?GFO\
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M\XI2W7KT PQ?AI=)<ZZM&IV-),QU!NEBK=HL\%#7[:,&N5D*:EQ-/!<F(:[
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M;;$N])NN#5$UI0[_ +:L:=T]B":PV#8=PS\C.660"$4MU#=:II-I_P!XK,$
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M;+7(1V\>V$]99NA$U^2;KT"?0Y&,A^O->AU2J,2)5="E[ "P/&^B)%YER5&
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MMPW^T1K%W&VALN;VM#U^9"?%;U[:[SIJ+TCM%V#D0))EPX7854B_*29,%0L
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M6,N.N(;1C*UIQD#Z?/'T_P"?C_9[^ >//'TX^CX_E^C@'GSQ].. . . . .
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ML?(\5#1P &RO1N/1TKJ#'TZOH&?AY?&IQ/ )2X X S\,_P"?^[^W' *9M_\
MWX=J72%)]IUWU5%4$QZ2,+"F-^WF%0X:\G.<J0\YK;74DP,A6$9]1+7\M.%8
M)C<^KZ-^QM'K8JND.V?+'!TI-+/Z/'5XMOEC26YDMM6FOK5'Y(K?ERNZL_<B
MY24X3CRQ_9Y?V<YQ$>W ' ' ' ' ' ' ' ' ' ('3\YQWZB6?M^]P">. 03V
M>^;QNOZK;W]FI+EO ?+L%][PWMH&T.[CX4?2CKU_<ZW[XNT7\BZP_;KCST3X
M1>YT5TXKU,,7,9]'PI>X[17/,"B. . . . . . . . . 1!N"E;-NL*$%K#<
M1>G)0<@ATZ7$I%8NZI09T53+(2Q+.A;(.&2,I)P4'C!"LI]7G/H9Y8P]6A2F
MY5\,L5%I6@ZLZ-FG=O6AF[K*SRWFT7%/MHZW-=KRVS\ECK;]0O#/\1;7'="?
MV19-AE:SC&C+61.[S9EZQ?7=CLR_M>&6F:;(R1;\IF7)<&.)8MD8 Q$9:P\Q
MYG#"IS]GI#3FAJ^BZ=&%%5Y2C34<-J2HNBX99U(4XZFKNE3FW4^DDKEVI6HN
MG&*2DTK*-K))6WK/+<UM6?+?L_4Z'L,%58>'M=K=O%C!"PQ+6U^&C:^[.EX6
MM2C5PL.E,9'Y4C*&_9PTX9QA&%8QZ2E>?P]24)5)RIPXJ#=X4U*4]2-EVNO*
M\I<MY9YE%M-MI66Y7;MXV:XY6'[-UB@VFFZTIEQ@90OMUM"\V^9#:K;CU@T=
M=]DWRQ,O44_-NCG\3!BY:GF2K""X.Q"5A-E;BG$V!H,=W0QUZO\ Y,4L3GB*
M#3>M86H1]EDY.$I9D;9]AV)W6\=3[M)GZ.V(7&REAHX-@,8J4I#[FQK^/E6X
MW[YS)!8Y1X$G%5(TZ*? RC4=([.0=1[CVB(B=FQ>U+U2M?YU));AE-62,_(7
MVO:>S$2;@2ZP7*UT>/#O*B,1K=K1[)[8ZO#;&*FF.'9 ^R_"=LG106=8A;]%
M83KCRUZ[9)C4BCXW=.+DQ@PK=BWYDAV4U^JM*86"(!F5;^2LVY/L;5B12/5@
M1W>5]HZ%496P;.LT\5"VNS7^*-B[8[KZ7@8Z7?[KZYB>N<75HEH!9*2I[2\Q
M/-C#)^4C"\"1[\YEFS @*2!A^[-J]W-= @/R45<(2#$F?O"DIN4M6I:M"WF;
MM_;VM,UEFMVXB8.(J^)#KSF5B1K1,Q<.]!(DFT"L.7(5IID#[Z-:>W>Q:YUM
M9UVO:%KJ*\PD-M/;TA9JH@*TBO3VS:KMQI^/7*@R SE6/CJ\_7+S!N6-%G!>
MAIK7OR3%MRSQ[KUL#F]04;O+6HSK-3"I?9-<K=0U/I2(N,C87JUL>8)V;7KD
M6/O1%^D978K)LM 6FFBQ@-/E4$3S$8 =*S42*/9AHP=YUZ]?&#<-P!P!P!P!
MP!P!P!P!P!P#1IX_WS-Z)]?]4^P^Q<?VYQC^?GW' 'YYK_T^M[?#%O!]\?0O
M2BR_A ?, T9_$[5]MK)SB<+_ -X=(>'3]C3(\1WR72O4@2=3>@^K*5VQM';\
M&Q6,[8-H<L3K\(=6M2-0<<[98YB+.<CYR+UM';'RX@-E33:S[T;EY#[K)OM8
M^4LIX1 6TQKRB8]K]&F5-/MZI)9WE6X;'MBYEQAZ847_ +G_ +QF6>%&>DLO
M>GDYT9APK+JV6U) ^]FHU@8IHX:O00YS!A,@P:Q#Q[1;)YH[89AK1+8Z7VS"
MA&FQ224N8>(';;8>6MI"48 IOU>]W:/Q)<?1V'TI_P!2WK?P"]? ' ' (7W=
MN&+U!56I!V.-LMLL<DU6-=4.&4W]\-\N9[3JHZ!B4N9]6.TE+;A\U,$XQ'P$
M(*?,R+C8@;F<V,-AY8FHXJ4:=."UZU67<4:2MK3EO;S2C%7E.3C&*;:1M&.L
M^1+.3W);W_K::_?#,Z<;%ZSV'?\ >=KV.X3EWW)-0DK(HG$1CT2U[*J3EB7
MI=FRV"6FS4RT_)@K/D1X7#P(0A:0$.FN,C=;36DZ..A@Z.'ITH4<+"<5J74K
MRU8VE#BZ:C=4XSMV[3<DY62):U55%%15HQO;*SZ'FT\K;#;5S@D X X X X
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MY[N-KQ7.Y4Z4GZ/'XBYC-D'RMOT>3FYK/?8[3W/+"B. . . . . . . . .
M>%9\L9S[O=].?+^OW\ XD2>A3I V)#EHLJ4CL)S(1HT@(^>#A?O1DP-IU1(V
M%^:?1R\TCTO/'H^EC/G@#EE9\DYSCW^6//'E^7@' (M5<<R)A,]"J]NFBJT'
MZ,J"KVNQ@8.4? "YP_G!$T$F+DE%Q;7I'#)CSE/,(P&1AL#(. //'Q\_=]/
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MJ/CC1I1W=&S=LVW(Z_?9]*\R2]*-DO.$0C@#@%%.K_SH_$F_]H?2G_4MZW\
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MY80GM4D2V<(.Z=ZG:Y_56;Y5VV2W;'MN7QYRR(< < < < < < < < < < <
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MYI()9J""!/-AQM60)AX X X X X X X!U8_NA#:2)N^]?-%13J238&&L5_F
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M*O2QY^7E_GZ<?'@'MP!P#QG'GC./IQG']/ -?F_MQ]9:5(;SZWWNJ2M?#O\
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M=?\ GD!!K^S>XLQ/!UFERMZ)HA%HLC0>V;#HP: N1D?&]=C+LB./JLW5H:)
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MH-PE(*Q09185ML&I$UD36C]BF#[++2CK\! B7> 5(NX,?*:NK!QC)CM:$8.
MV9Z0I<OKC4&L=?S\DU+S=)H-2JLO*#N$/"G24%!A1II KQ:4%.#+?'7D=9*&
MWUL>K4ZTVXI2$@2GP!P!P!P!P!P!P!P!P#QG&,X\LXQG'T9^' *@]GNE.C^T
M]=?A]C50 H[#;GR=.CM)%FHM]>,^1 $DSA)([F,^6582YZI[&/0?;=1YHS?T
M?I/':+K*O@<1.C*ZUXJTJ51+=4IR3C);KV4EN:R-HSE!WB[/RKQK>CKB;O\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g67046g47h58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g47h58.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1DT4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585    !L 2 !0 "
M3 !A ', 90!R $H 90!T "  30 V #  -@ @ %4 4 !$ "  4 !# $P (  V
M       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E
M '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I
M;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
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M8VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M   .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L
M;VYG       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F
M   .             #^    X0DE-! T       0   !X.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      ,U
M!@             !C    SL          0                         !
M              ,[   !C                      !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !C     !29VAT;&]N9P   SL    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M 8P     4F=H=&QO;F<   ,[     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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MP  1" !- * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M<8+?I?1:C*-3/3K:R9CD^)_.=_:4TP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M.4)VN-'Q,S925Y;4*#4W5F)H<G/A=(*%LM7_Q  < 0$  04! 0
M    !@$$!0<( P+_Q !&$0 " @$"! ,%!08"" 4% 0   0(#! 41!A(A,0=!
M\!,B46%Q%(&1H;$(%3+!T>$C0B0E)C1#4F+Q%C-3<I(71&.4TW3_V@ , P$
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M$0+T B(@'?IZ_?[8!RX P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MF+^/7M[@(>_?7H(?B A^H=8!J @/L. !,4O0"/0C[!]_\, U >P[_'UP!@#
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MS'3+YVHF[23D#NVR9D%2H)*D5 EH7U !]/4 ]O;V^WY?A@&N , 8 P!@# &
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M ]6:IB8PD;J+F2((B)2 (C@'01HE(;P\E7F].JR$!,N'#J7@T:_%)0\JZ=J
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MU]!QNMVO-?V_J/7K8Y/?*@VF,! [-[91O;U_4&T%2"'?8]>_M^8AZ?CWT/\
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M0VZ=>&&/,V,L"ZGQA$52J%0.F7L0$P#Z8!-@OL'Z!_E@&N , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@'C3T_%5N)DYJ8=)LXZ(9+R#YPH8"E2;MT
MC*G-ZB F,(%\I"% 3G.)2% 3&* XO6]9T[AW2-2US5\F&)IFDX>1GYN38THU
MX^-5*VQK=KFFU'EK@NMEDHUQWE)(N\#!RM3S<73\*J5^7F75T44P6\IV6S4(
MK;R6[WE)](I-MI)LC]HN'D;1+3N\+4U6;S5S*=A5HYT7L\#1VJI/IZ"7F /A
MJ2AD2/5SIE#XQ#)JB8174#- ^!^C:CQ1JFN^.'%&/93J_&2G@<*Z?D1?-H/!
M&/<I:?32II>REJGLJ\VYPBO:Q<+FW*^PV+Q[GXNDXFG< Z1;"W"T)J_5\JE[
M0U+7;8/[19/9^_#%4G37&;?LY<\8[**;DUG21J\8 P!@&$2(\;+7"W*W>'&^
MR:3LU=A=)-.0SF7OJ%]J,]9?)QN@F5@MTI:=/L4TK?0:G:VDBR3UM;)YTI&W
M!R[9IM2-RNVZB@'GP?C0/GT!)P$]P]OU8Y)R]NXUU[4/'MSL^F/UMFP_+""L
M=EU+:'>Q&D<$'26J$+4+(K?6,G%2*]1>,6[--69%ZBJ '3N/C?5Z"UA3=AUC
MC#?;D]C]8[3W%R9J2%_J$3(<:Z)I#89M7;1</Y!RU<,MC34);&<X2*AZV#$T
MW%P;E_\ -1YW+5HH!=GQ?]CTBP^'3L8D?:H SVSV+B98(6'/,1R<T_BY;E!H
MN68KHQ*C@KY1-=@H#HIB(C_J2'4#S$(<Q0,O9#"8!$?L(A^'M_7Y]^_?V #?
M@# & , 8 P!@# & <:O]C[>_W#O[#]O\/PZ]_P ,>O7Z@^%*<_X23R^9\OW;
MME1:XKH&.V([K!]&%KI3W>0K#:54A@3&S"F,NA>UA '9$DDOIZ4J'TDS-1IV
M8-MQX%TJ6F\KLM^URIC8\QV/V<9\BDY<G2#HW;Z;.:BDW+H3Y<-X*QH0<IQO
M=>[RE.4U[1P3Z5Q:7LT^OE[O?=KKGW#Q:^0\PD4:7X0?B"2BAD1,D-OI#+7S
M<YR'*)P^-)I2(@B+<?BHJBGYUU/]21$"]JEB$>&L*.WMN)]#BFVMZKU<X_\
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M%AUYM^LQ==NYHUI&6F/0F8^XHS:#MRDNC'(1?D.\=@96"]B4/-[_ '_K^@_
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M_$.:5E$=7T_@+0[7[T8:?PUC0CJ3HFMXNK-U"-.5-)]+%U4=]C:'&BEI'"?
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MK8RYE[*/N^QC/=;IO9-175<^[?,DOHA  #V  _0.LA1&37 & , 8 P!@# &
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MYD%V\<Y'R-FCL2'0.91=+SH@(&6\.^@[]^@[_7[X!K@# & , 8 P!@# & ,
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MNN"\]HPBDEVV2[>>MK;;+[;;K9N=EUMEMDWWE.R;E-OYN3;>_7<[V7!YC &
M05Y!\3=M[*V IM+17-??O&"YN86/@Y&$KL7K?:NGY5.,.M\I+N]3[6JT]',[
M"5)8S9Q*U^8@ROFY4_J#1TL3Y@CUZ_$'3X\\5=JT2_$VGNWG)O;E-;H:.EJX
MTK\M'ZRU9IZ'6D"$(^>*:JU-6(5D^LZ* @BW>62;F/IJ2GF8L&K@0<"!/,G0
M%  ] #L/7OOW'OOO[_C^?8=![8!OP!@# ,77C-?]'3NC_MWQ=_[V>C< RBX
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M>G7H'M^7O^@9T>EMMTV2W271;)[/;9=.^^W7HME]-8/NVWNWY]7O^)RY] 8
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M)M_!%4G*2C%-N3V27F]TDOJV^GQ\B-''@HV![L_9J@&,:\79VA'G,'\00E:
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MO]=O]OJ5^VW+2HT04>D8J"WE&*2224Y3Z)))[]#*AD=,., 8 P!@# & , 8
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M%Y3?+'()38!-PO\ 9+^@?C^'Y^O]_K@&N , 8 P!@# & , 8 P!@# & , 8
MP!@# & , C'OT?VFLNH=8I#YRV>Y)3\RGZ&+^SU1(1^](I[@0':BR:*1C 8H
MG(8.O0>N:O'IOB3B'PC\,JFYPXGXSJUS6JX-[KA_A2$<_,A;W4(9<YQJJFU)
M.RJ46NNYM'P]VTO3.-.*I[K]UZ%+3,)].NI:VYX]$HOOO3"$YSVV>TH]>I)H
MI2@ >4 *'7L'L'?V#\LZ422222222273HELE]$NQJ[N]_-F[*@8 P!@&#:QT
M7G6\\4#EQ8N,5HTW0*E(Z#XM,)&9WSK'8EU@K!*1Y]H>9K3'E2N5-9(.HDK@
MHV BBD@J/S<<4Q&_1?.!E%X[0_*"&KD\CREN>E[K:UIP%JX^TG2;=1X-G7OD
M6Q#-)=A;[7;7CR6&2*[5!XU>-6WR9VZ(M?BD.H8"0F < .4#*'2*H0RR92G.
MB4Y!5(0X]$.9,#><I3B @4PE H]#T/H. ; >M!247!PB**(JE65!5,4T3("(
M+%54 WD3,D8# H4P@)!*(" 8!N,Z;$!(3KI%!82E1$RA !4QR^8A$A$>E#'+
M_$4I/,)@ 1#TP#&!XS1N_#JW. !W_P _.+OJ(]>G^EEHT>P]^_MZ>@^O?VP#
M*/@# & , 8 P!@&"]P0.2?CI-XY0GS]&X"<6PDW!!_UK)'=N[G[0\<D8AP^"
M9=I0Y$S]%VCYEFDA' @<2B3RY+X_ZOX.DULKM9U#V:ZM2^R8T??ET2[V5.#B
MWLXVJ7DB0J3Q>'Y2[6:CEM)KHU55OS/?YRK<7%]XSC)?$SF)E$H#WZ?S[_'U
M].@#W]@_ ?QR'K?SV^XCQR94# & , 8 P!@# & , IRU2J,#7YR=<& B,/"R
M<FJ<1Z$B<>S7=F$/T!,?S$>@* CF#XEU:K0>'M>UR^2A3H^BZIJEK;Y?\/3\
M*[*EUV?51K>R[N6VR9?:7ASU#4M/P*TY69F=B8L$EOO+(OKJ6_RWFM_D6?XT
M12T?J.NOGI1"1L[J6MDDH8.A7<SLFY=(*#YOX_-\@#(@B8?,(I#V  /6:A_9
MKTN[3_"'AS.SDUJ7$M^K<5ZE8TE.[(US4\G)ILD^\ML!X=;E)[OEV711;FGB
MCF1R>,]2QJ6WBZ37AZ/B+_DIT[%KJG%[;KID/(DGV::?1O8D'F^C7HP!@# &
M , 8 P!@# & , 8!M/\ V1]>OQZ 1]._7T#U'T^P>H^P8!\9_#N+\/B1I-^V
M9L'77B!T_=VP=^<DAVK-<5QYSM-<W!Y4N1&T:A5Y-.>U?-N:]8) E1@X-.7.
MA)/2QLZ$K&@1@=HJR0+U\_F#ZR..(4\-$ZJ#7X;%"E!2X8*P&W%+FMLT(@$
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M'F+Z]?8/4 'H/R]/PSJJ*Z=4O-=O+^_=]^K9J+S;^/7OO]?IU\OZG-GT!@#
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M??HI.$[\A>_?KUSI-+9)?!;&KS=E0, 8 P!@# & , 8 P!@# & , 8 P!@#
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MO_[P:1_\5P/_ ,_@#]YFM_\ W@TC_P"*X'_Y_ '[S-;_ /O!I'_Q7 __ #^
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M *X5@9-XU6>PZBY0 JQX]=N94H 4XF  # .FIK;7:T))5I:ATU:N3$PI8I>
M5K$*K"2E@6D4IA:=D8H[(S%[,*RR",HI)N4%7JDBBD],N+DA50 K0  H 4H
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M>4IM6DK+54UDJQ89"OQ3R=K:3@H$<)P$NY:*2$.1<@ 18D<X;%5)_"H!@],
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M775U9T_-K+2@J0)J;4Y^5LT2FSA_@ 5O)!*2[LSA]\P8RZ(IH_#*"?F,!?G
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M.$T7-0-:8J75K[ELU7C5&ZC9$Q0*[<<'.,CI$S=;6Z)D#<GF?,<R?URPE_\
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M?+'<*-DP,AV , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & :"4H^H@ _?U_K\OZ[' -< T$ 'W !]!#U]?0??^_ -< 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!I
MY0]?3W]_S_7^OQ_$< UP!@&G0?@'OW_/U]?U]1P#7 & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MD::)GSRXT_O_ &_+O\P9\<J!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M/BHR6H"M6;1;DY[Q)5QBG)EE%G2!$XTS:5<"JL@9J(KIF !(54@@(CV!0)T
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M1M-T!9V+!YSZW;86$M.V^Z:Y86*.7JCR]N&3E"29SDJS%HNU41;$<@<R8E1
MH ?13I&_7_8E5=S6Q=13&F9M"6<,4*Q-6".L;ITQ21042E"/HQJT0(DNJJLB
M5 R7Q"F1,<PB!RX7KUL@8T.?=$VM;>9O$NU:,EW;7<6E-#<JMR:[K)I52+KN
MS)>KW#C;'2NJ+8IYQ:HP^SJA.62C)S3ENZ&K/YYC:$&[A6)*W4 AKH3FC?KH
M:5/J%_<:#3-Y\M.;5]G)YXRHL7=(B3UM#Z?:,]1F3W*ZBJI"2T?*6FPSED:
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M6)=Y/QQJ1*KJ24H#]Y\G4&6/ & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M+=0L]]+G)2'96)BK!NY"# EACX]K,K)0DA(0[=R^6;Q;]XQ20<*5!)? & ,
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M$L>(3<'>)19WX) [,P2>*J.TV9EOERN%#K%3!4PJ"!:R'XXZ"KH"$!I+4T*
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M#K\@( @'Z /K^N :_?K[?#$?YB?H1_F'H/Y8!IV/2?J/KYN_7W_A+[X!V
4[    []@] ]@P#7 & , 8 P#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g67046g51a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g51a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %HJ^5W X0DE-! 0      %H< 5H  QLE1QP"   "]RD< E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52+F1O8W@X0DE-!"4      ! U1Q>[T6))<R.NDQO^
MGJH6.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           !(P  !&@          0                         !
M          1H   !(P                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !(P    !29VAT;&]N9P  !&@    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   2,
M    4F=H=&QO;F<   1H     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      P2     0   *     I   !X
M3.    OV !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MH_O)*<Q_U;RG/@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@ G )= P$1  (1 0,1 ?_$ !X  0 " @(# 0             '" 8)
M 04" P0*_\0 71   00" @$!!@(#" H,"0T !0(#! 8!!P ($0D2$Q05(3$6
M44%A<1<8(C*!D<'P"ADC0G)X>:&QUS,U-SA8E[:WN-'A\28T.4A2672SUAHD
M)2=#1D=C:(>3F*;_Q  < 0$  04! 0              !@$" P0%!PC_Q !
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MSHK<VP:3H?>I[<.D#FC&+KU]VE1RNH;L'I>^; P*IVRR2B#)II%**L((0!A
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M/A)UPN##9:O,T,",DC5I(1"Q9E5D:D"<I:$-D4J4OTQ] 43N(UVG!5:@QJ^
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M.XZ;#>@U$[3&JEUML%#*TK=<4IIZGVW9^PY5RN!FZ[.MM6OSYT0/U]8-@E+
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M)=8>2MM>/*<\V*%R/(4JEZ&.>**Y6ALQQV87U[#&3QMD:R>"0!\,K6N DC>
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M6Q58V[3"-?NOLWL<\_+JA;H^"N+(>_GJ\>MMQ^.DM.]/$U^4UX"?_DV&M;:
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M$KHXM"L9Y!([=N3(79\)1DEKOKLB?E;K6N:^M!88'105'D:-JRQSNF9IZ:C
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MQ]/X?+T5:*=*VD<J94I9"PYC;/=/9F8]$D"@DV-+UWU@KXA$H<DP.*2R*89
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MXDN;[[?$67S#F^.G?:.%@<X%[F2031[;\;3.<B?PG@V"QS7=,_)LA;Y+=:
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M8FCZOD>UH^7G9\*/]*AR(K7PF2;9<CV*TO$+S9([OC+D,]=I\FRD!>5?QE-
MEDD@8GM?Q(0R,TG"$-I0GA<.ISU<!4EN-<S(9-]G-Y)CVD/BO9JS+DK%4[)=
MTT7610B#M%L56-H:UH:T2+G%ZM<Y)=BH/9)B\0RKQ_$R,_<GQN!JQ8JK< ]
M_(-JG(S:WU3VY7DESB3*_)0HDG")PB<(G"+#MB.+9H-V=;G-"W&JE8W&R;Y!
ML2R.6@--4F<Z5>A$FAK43./?N$'1\YN&E&9"X<E+>6%D7YN/['I;UP%<V/2:
MF?Z\6NS4W4.L0=JL^D/4#WIVX>L#XV7.'J-E-6;.CQJ=IH>4F1I$V'FC-HC.
M/O.@V&FQD",A!%^F"38J_#?7&EG!$62W+@P'&)!*&R\W.)XSD;"6TX\E:)9#
M"59A1U)P]*PE66$.>,^"+UQK-6YK[$6'8 DN5*=GLQ8T4K!D/R7A:\-DVH[+
M3ZW'G1SBDHGMMI4J&O.$R,-J^G"*BG1S/G:_J:>/_6#S?^A;TNX1;!^$3A$X
M1.$5 >]?8LCIL!0P-4WEK_0-@L6R-=,638VPZ>]?@P:DF[6T"15QM7AS8DN=
ML+:Y?.:9K2*EN5\1/8L!7$=R/7)RFB*@OJ!=9-L=J])-:W CMA6W8UQMVLC=
M0B;$M]3B[1EAJ?L>K'3FS)=%)UJ3UXT+6Z:-@8F)7"UTO95Z4_#IDLO3+ <(
M1YI%O5 !0%(JX>M!(L4'6JB#'A1,)+BDPQ(('!:A08^'I"U*Q'A0(K;?OGW5
M*]AK*W75*]I7"+1[TV[+=D/50L=MV\+AZ?U7UOZV]B-J4G6/QH&];*9WC=:)
M99HBE[,*#OQ3JYN/!H5;<BG0PF4X8#N;#.#[6S'8,46ON0"+:KU^TM>=4N[4
M-[0W*2WG=ME[ F69FUEJ56*.Y5:1&A1H-.U8(&59&(K]:I2?FT@9-G./%)TT
M^6(DW9!&?+ER2*(KA7]=7G=F>V%^4435^DX/:8?7)(=8[%#%RK8:K+X[=]DG
MUT25A K9BM@XF=<UZ(>@%4CK.B].1F&2<8/-C$70"'^S 2UZMU]JG&GH5HO#
MEPW?W&LNQA-QM$RA,72"]$UN#H8BM6:JQ"IQ9P2BD#(YXQ#@?@+6I8C[W!)F
M(V1(K!Z"T.5TM,V\6/[BV+N4]N#9"]CE2VPHU*B?AIS\+URJQ*C3XE,JU98'
M4T5 K<7Y0+(9*RX>77U.D),I^9+F$5B>$3A%5CN)M#:>H--+NVGQH\U;8FP-
M5"Y0>=3K/>'9U1L&Q*V%O7RL-4ID,DR5'U"<9+QB\K,D6';@/3YT"<AE$9TB
MUF7'N_ZC RT62%3NMSEH%PRQM578=TMLV!\_LX_;X.G-:6>-N&\0X<;&JIT_
M:+.YW(Z*L7<CK;A,-P8<F#DBP/NKV*[777TJ^X:[_P!9[-98=CT?V% DMH"E
M5;3@VN4J/164,6^PZFVI=(^R4)BSR5F&8@5Z$>E%8-208AMJ^>0&'"+]"B?[
M[_"S_1PB\N$3A$X1.$5>3[BK)V4H87.,/B]::XM=]()\^4P[5<R8VE4N0K[I
MPM5;A;29PE6$K]F1A32LIR[CDDKCW7BV1L;+9<KE*..C^773H137[S?39'O4
MF)/@D;:=@.#2N)-_S&>IPZ!CQ]"S=?Y!+;%N2.I5.O.B((\AY.B>H=.QU*CG
MJN=IS&C]:5>@:[LEF!;,V*:AR<SJ1*CQ[*$I@^:P.ERVG7(DQ45T]8280(/1
MA,)XBQ@XF 0:EP4MNSKV0\2@S^5N9/)U:MC$8R!T?;O,ZJUF]*QTD;2"Y@>V
MM7CGL2GXVQGL%[',E)9&?:!G9\91K4Z,L\5^Y*']RNXA\-:(AKW$M!+#-+)%
M%&=MZ_S-.+F!KHRZT";WJ>VZ2UXQ7+28OU3U;<;$YJ2*@+*$P+ILF8,*639W
M8S<DY\@]5+L8??G0P%9"C+2<BU7"T(=)R"4L;SJ\IFQV7IY[(FU4KXVYEJ-9
MN9<9V2S4,6V2.KBN,82-L;;M*N UUFW/-3KR6SU%L4<3)1SL'';Q]C%U/=YI
M+M>C/+^'AL3HX[-T]4][,9)Q<:MB8$]JM#%-*R !G4XR/C=L) Z6W!:73\K>
M^\CQX47,/SA&N]51F]5UJM!I$>)[FO2;G7L1-J6A8Z2F8GYNJV5]@JRZE4L
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M0;$D(G9&.IKF,G=.#N( V0W/,GZFTBJL:6C5^N728P!UAIT9+@/20(^SGGV
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M3[DC&5:YZW;>2^R]A<\ASSMSCU.]9MH=3%T.D5"CA$J0&IU:"584E?CVTC@
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M/M5:[9A--+((Z]8,=*=@2R=9TV*!KAITKSO6_A:T.>00WS<UNPYQ.@W^I)]
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M>YK&1QM<][WO(:UK6M!<YSG$   DD@ ;6P]S6-<][FL:T%SGO(:UK0"2YQ)
M  !))(  ))6O\CW'MMCL]NK^NJS3$"HRQ36NC14R:MU_V&S/&8>D&P^AZ@+:
MM\.LM$%8^5V:VGZC6C8%X=98IE(0I'F)]&BX34JU*5G*VKW?<)G92"&&O2QN
M-,<I:VO/R&]*:3K9C!$U6G6O6H++):KJYFB<U0R7E%B:>Q#0@J]O<;:,LKYK
M-RV'Q@]Z/#U6BR(.MS71S69Z<,E=\<YE9'('#,^GHJY:^TC+V+V7D1JKN795
MJ/7/;Q2TRZX&8BD5%E5.E"\/CR<P(-&#:*$J0T0,8*R4L*6M*EYG29",\WF,
MU'(Y]F,XLUUO"8NE7HX6*HRU.Y\0B]\R$NI8VV)9I,A8N26)71-+^D'RQK2M
M_CL5FEBWWLXYM?)W;,UC(RV7PQAKNX8*D?4QYB9$VK' (8^LEO4X'XG$*/[9
MN2V;;VU/G]=*4UN>!IFOD8E9/N&(833\C<5K8<C$7RMV<=7DH[2*3[J Q&IT
M,[*<>V(2;G."T0VIG.G3PE/"X=D7)KQP<N=M1/M56P23YIN#IOZHA#1:P]EM
M^\3+(^Z^NP#&Q&-LSI'1K0GR=G)9-TF%JG)Q8N"1D,QE9%C3D[ +93)8>6]W
MW2L QK:PE?U6Y XQ@-<Z5['3^RFP3^H46L=IH%1ZUL()>+\("G;E8#)+%9'S
M2-<ABY$ZL@!^<C+I@,<QF1'SCX@-">;=2E#C;O&K7>,8RMFO<I,[9OV\98Q^
M.FLUJ%>",6Y&167RMCM3R#NT3/7):0>B:5KF;<TCHSU<Y>FQHMLQ<56O>AN6
MXH)[4TCS78^2$,,D$;#V[8CE#3OXHXWA_P !#K?M^<(QA6,^<95]\8QG/US]
M?&/I]?\ MY#AZ#_?^_G_ $]%)%Y\JB<(O#+:<_?S^G]/Y_U^_P!_KGA$]VCS
MC/CZX_3_ $_7^N?&//VQPBTV^C[_ +>^K9_ED>VO_(#0?"+<KPB<(G")PB<(
MG"+JS1H3711 Z>*#P@41#D$2I<M,CCA@P?$:4]*G3YTMQJ+$B1FDJ=?D2'6V
MFFT*6XM*,*SBH#G$-8TN<XAK6CR7$G0  V2?T )0#9T/4^ M:S78NM0S:K]&
M.@"N_P#LY)'4'J[K2=(5+EUS6^%N3*I9+2,C>"%:!&6I$G<-_P D,C9\P:@5
M4(?Q9L(,CY[/NC^@1%DC:=+<]^SKI;)-H"2.(GX7N80*L'2"-DR/(:YQ67I/
MH1IK?+C]3Y)T=?R_IX^L]VB^4'IGJRF@9[E@O%UO-I;K=;&PXBR%TW%N*YR9
M$^>6*NQ6%L"T'3K[\^PV2>B/7:F,=;;6J- BP(6=-D4N2L2/:&QQQ,+I'$ZB
MK5HP &C9V0QI:V-@/6]V@"22531D<=:  )]-  ?0#Y_Y_59UJ'23%7/DMO;"
M:"6G?UR&Y'6>]QX",_AZLKE-SX>KJ')E-YGB-=@I++#K<+#C;]D,,NVBP8D%
MY2?AL<]GN-;7AZF4XGET49/[[R.DSR@>#-(T#J.@&_N-TT#=KG$CI\AH]!Z>
M?J?U\GRK#Y4G'GRK&/'USYSC[8^N?O\ J_S<U-^NO)'R^_16JHVL+=6MV]A]
MH7JNFA-BKFB(&-# I@N6U+1#OYMX;<MSM.*94I+F6(L+5 -IW/TCD M@BMKR
MK+^$]"Q%+4J01/8^-]QPMO#@1N&/JBK$ ^?)?8?].E[3X(\WD%K!L:ZB2=@@
M^-:W^GJ1_-6ZYH*Q.$3A%PI.%8\9_1GSC]6?^[.<?LSGA%XY0G[?7&,?HQGQ
MC_M_E_ISY(O1*3C$63GZ_2._X\Y__*5C[?;_ +?.<_7A% 743_>G]8O\7K2_
M_-Q6^$5A^$3A$X1.$3A$X1<9SC'USG&,?GG/CA%T-CM%>J0F2;LAH:#%Q<)]
M].(RFH[.%K5A+;*,N*PIZ0^O*6H\9G#DB0ZM#3#;CBTHSI9#)4,35DO9*W!3
MJQ:ZYIY&QMVXZ:QNSN21[M-CB8'22/(9&USB =_&8K)9JY%C\32LY"[,2(Z]
M6)\LA#02][@T:9%&T%\LLA9%%&UTDCVL:7"$8=SWC?#))JI4P)1-?K'P7@-]
MV"R0F6,P^\X\DA[G6$26&)BV6FTMKA.64R'EJPXT^\)=PIR*B'19;F6;N668
MO$4\'@C#"ZEF\\V>7(6GN<6S]''8IJ=BNQK1U0NR-JI(0YKI*KMNB$[GPG N
M/T*C\UG;W(^1^\68\EQWC#ZL.+H1L##6[G+9H;]2Y(\N<)X\30NP@M<R.\W3
M9G9EJ+6D[7((M&/VXA?[38;(4LMBN)4="%$"\F:MID?&7#@95'CPP@B+ "C8
M[2L,L08+3;+;+?AI/7XMQZ7C]*U'<RD^;R5^_8R&0RUJO#6L6Y90R.%ABA+F
M1PU*L4%6O&UQ;'#"QC0UH#!Q.9\HK\HR%.7'X2MQK$8S%U,5C,%2M6+E6G%7
M#Y+,S9[/YLMC(79K-^W*\=<MBP]SW/=\9EODG403A$X1<9SC&/.<XQC\\Y\8
M_P _")A2<^/"L9\_;QG&?/[.4!!]$7/*HJ[=I[5LBH:9L9+6.BI/8TM+7'"6
M#5\#9%9U64)4<TEX?;B8BU6]<<#\T$"'GI<,3+("%E7,?"QRX]_*)"2+2EZ(
MLWJRG:V]:9K7:_8>Y;SU#J35&J#FL]\UG1PV5I+25:-6== I@ZV]<H+^N=@3
M4E)1%!&Q%[4=N;C4.%F<P/9?<5,(OT;><?GPB><?GCA%KXZ.?[J_J:?Y0>9_
MT+>EW"+8/PB<(H^VI=TZYU_9[DF LO-#CE8"!&7$,R+#9B+[(JK5N(ZYG"$3
M+'8YPL)$4O\ @XDSV?.,X^F2*@ 3=%IK+)#KY2:K;X(RMA8KD_LNS%#&@^[M
MQ78C93>T*KU[ ?'RI%AO<.ZXLY6XV"P085"UK[V?)G,%(0>7#BD5-=4]FNOO
MI5=.]76KLB1<-;8M]U1K@#I_4V\<=M=ACV-G[5M1@**JUKMQH#8KTD\8(R[E
M?K5):9DS[,0Q7([L@#4Z6)#D7K[GZ,]0+U0-2S]<AZ33.M6G2MWUB>'5S<F7
MG;=.!U"^UVS%S=F$I!''?QHB&-F1Q%-+U)RBBY7NR+=BL\^.)+PR+=5J#0.E
M]!5.MTS3^M:A0 %2"9 !(U?"PX\YD:\Y'D34S33C3APO-,3(L<F?)EB$TF>+
M(R6,2II%:Y2B**J[L*D]L+,6@Z_M(*YZ5U%>IU:V"5KI*,4%W'<E(GLN2-;O
M2(BGVG0VMRJ892Z,)>;20M<</6G\RA8^TCIQ%D?92=L8U47M/Z,OKFM-W[-'
MS(U2V.BM!KDWJH*,DCU6?99*LV!B0$+M"(DMH0"%E&%QC-N-@1[JHL-<XD.(
MH2@ZIO%FVWI>GU'9/N=&]:YD\[V $$JB/)R>QN]"M?8*4^9.LKDI,X84H%JF
M,[DMLAI1".2NI.J0W6W9P=Z2((M@?")PB<(G"+A6?&,Y_K]^$44-[VTP[*9@
MM[9UOF;(N,_7D>)^-*]\2_?!<O, C3&6,D<..VB!.\0IH)&,DHLO/PST=#^<
M-Y(J3^IG=Z?L+TK^^-EHMJKMRKS_ %8WU#8.U8R./"'I0^EGXDZ.T1%R)41;
M\.4TY'DM)>RMAY"FW$I7C.,$6RY/]]_A9_HX1>7")PB];JU(1E2<8SG&?T^?
M'CQG]>/]/U^V/KG''W]_?HGW_@?[Z^1_N-2-O]2RYD#6Y@>E=!Q-D#=:7EC7
M8F\2;Y+$URR6*;&B-C6(2,TYR$3ED3;SP\6##V247+,,HGQ64#7<D&O8Z7LM
MIMKX6?.\B=BILGCW9&;'MQ[)K-6NPN?(Y[O?>N)D-<,DFGGJ,AB<XQN<90(G
M><V>=6#+D8\9B!>BIVA3BM^].;#-,X=+&AONX;(^24.$4,,[Y)&M+@&L/<%-
M=-:OVY?9IC;NS+9 K8_7C!01L&\O3!IZCOXNMWE7C;&D-+,PR:XKE@M+\J!3
M+)L,*3=*QCQ6XUQH@=<=!0 \US>6PV.CAP^+I26I\I)#-CJ#63U[S11H1T,1
MGLZY\76VM4;')<K8ZQ$V%]>*E9Z*X$\DL9QM'(VWR7[=KL0T&21VK+G1RUG/
MM67V;^*QG;>09YG.9!+8A>Y[9))ZY=-N)C=Z6G:,5K(DM:KHY&?V;L&:S8KN
M\P]\3%&.-,^Y TD/(4EM:JW2!BDB!B4)9:G3U&+"MAJ>?(97X!F\A!:FAJT.
MIN*QD;ZV/8]O0^8%P=8OSM&_^:OS#O3';BR,05@3'6B ]8Q=26O')8M]!R%Y
MS)K;FG;(B&],-.%Q#3[O48>W'L#J>99B ^9^ZZ[([3[<D[M,Z5ZV:7#[H?H]
M>A3-K6PC=XU3 :^L1R1[8*KOR)<9<8P;?#,2RLH/$G,38[2HZ7U1O[IGDEQ?
M%,,W P9WE6<FP4>0L2,Q%2*@^Y9R56!NI[361O+X(!.YD3)I(S&[9(ZO 7&O
M9_(G*2XS!8QF4?4B8Z_8=9;7AIS2N)C@+WCH?+VVN>8P\/!(:>G3B,!J>G^S
M?8%6PHO=.Q1Z;J>#:U+JNJ=6D(E68M8"$Q#(QBUYNX \5LJP4)Y2X[5>C'Q2
MI4V))(&528K(IIO>N9OBW&_PUW!*KK^9DI@6LSEXGVY*4[W.B,5''SUH*@LR
M-T]UAU:41L>V.%K2^7>M7QN<S(N-Y1.*N/9-^5CZ+F5X[,;0QX?9M1326.PP
M]3.T)6=;B7R//2S68ZMVCULUW9-@*U[IVZU2LKQ76"G8 )J>S'J/MCY=!F9R
M15M *//%+7'JC[\X3+LMF?S"=G.R\#BA!KVW\ZF6Q'*<I6QWXGF\?=N#ONBX
MY8S%.MD,0971_EG%3OK15'6V-9.RM5;UB,-[T43M-6?'Y'!4)+?N6.MUJOY+
M'9>&C9GIWQ&'[>V]$V9\[:[^J)TTSM.?OMO>T=0Q'9NS=2[\UB6W+>9(<]U%
MIDA<NH"RR\PHF_=EA2SPL,\\S-5$?<JXNY1FZY5 <U#"[3=&9)0A$<"# CA+
M;Q.*S/'LI!@\>V2OS/(-Z+L\([KN-XJQ&R:;I>T/8+LU)XMW)V%PIT7,AC?W
MYYQ%KY&]C\M1FRELMDX]3+C5A<2S\9O1DQQ[: V3W:.P#!7B=_YFT'2/;VXH
MB^ZFDZ#(UYKT&&*?"KM$_P".L]UDPL>(<R[VF:\>M;L+'_V8QDR0E0@D;Z(@
M@XHT='2B+#9;1"<YD&Y/)V+,76*L8CJ4&R?OLQ].-M>FU^_)E=#&V2P\_%+9
M?+*\ESR3)\73-*E%#(&]]Y?8MEG[KK=EYFL.;]&"1Y9$T>&1,C8WX6A2WSDK
MH)PB<(G"+#+'L2AU$N$K]HN=7KIRR1RLL (-G1HLD:B T1G#,H7"FR69$V,)
M;F1%DY$=MQJ"B5'5)6WAYOVB+HZYNK45P)" M3VAKVS&3X>7800D#<:^7(F
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MFSAZKI(V\?P=2FR;,<N:R66"_+CYIYF08VA0G;'#+E;5>U7DE]ZAJPVK-*Q
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MG&'F8;RC)F3,,E9T_+Y C+D,8F$4<&6I<LOFGDL5)W,!<XB]4\@O:T"-O=
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M^L./_P!/6E_OG.?_ ,.*W^G/UX16'X1.$3A$X1.$5<=@VVZ[$:.:_P!&&HX
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M63X!N]@K)JW?EC"NW(GFR$--4*LS<WUD0MI$>M7*Q;*@(^;TR,2;R435HPM
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MF9/9UBZS;4-H5),=EGQ6&SNC$=-]Y\^-F@M]IK6B205V=0:T-A#!VS8([Z>
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M$6HACO+I*\=D+Y/INA*[?=MZ*VC1>J@2_-&ZSC;Y2M[BM12%?8-,#?()UI%
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MGZ_J_FY30^@\^OZHHEWKM(;I/4U\VH46#:A4D ^8<38"A *+E.H<:8BCESA
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MXS&3(Q-C$7#-V]6-,5Z5(U/JZ2_$$ 'HXEA^CCU'?9,:U=G-K-.;:+,URZD
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M+#B*4?38-[V/]#>J!#LL.:@[L_<0H,.[S&[%"M+EID#0,0>+OLTN/SF,LKL
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M%:^)G2Y,M[VY#[KBR+)^$3A$X1.$3A$X1.$3A$X1.$3A$X1="'K5= 3+!.!
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><6M7E2LYR1?9PB<(G")PB<(G")PB<(G")PB<(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>g67046g51b02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g51b02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2.&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (VJ^D&8X0DE-! 0      %H< 5H  QLE1QP"   "]RD< E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52+F1O8W@X0DE-!"4      ! U1Q>[T6))<R.NDQO^
MGJH6.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           !>   !94          0                         !
M          65   !>                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !>     !29VAT;&]N9P  !94    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   7@
M    4F=H=&QO;F<   65     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,     !CR     0   *     J   !X
M3L   !C6 !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT
M<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M          $  /;6  $     TRU(4" @
M                                   18W!R=    5     S9&5S8P
M 80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA9
M6@   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(
M=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P
M   D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P
M!#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K
M87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M           2<U)'0B!)14,V,3DV-BTR+C$
M                                         %A96B        #S40 !
M     1;,6%E:(                     !865H@        ;Z(  #CU   #
MD%A96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@
M                        9&5S8P         N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                         &1E<V,         +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E
M<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                          !V:65W       3I/X %%\N !#/%  #[<P
M!!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                      */     G-I9R      0U)4(&-U<G8        $
M      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H
M &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4
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M0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T? 2 4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0'_P  1" "? ET# 1$  A$! Q$!_\0 '@ !  (" @,!
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MPR(%*YMFK-HK'I7A$_-&1.;OR6HL:RT&OBBJB>C]XB65[4>5'M'!)/VS=];
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ML<"R)E(5EP.8O&PO78<)(.,D3*PX4GLCJW4?:.7#9%9$J\T\F'1]XT9D-+\
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M5 [)=-X;V@.@BDZL"S08D)7]I5QM$H:]A0X$6#VV+9"Y&2(NC,%/R=(XQ^4
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ME.JWUCK<CL"L")JHENH$TZ^0KR/](V=,?"R&ORG0ZX8E$K %2;$J$RF03VP
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M^:JFB*>ZBFVNFFFN=MMMML:ZZZX^NVVVV?3&,8Q]<YSG&,8^N<XQRA( [)
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MS:N7*FJ>=$$%5-M=,HE9S'?GJ7''S83);@'1HV[AS*=(1^1QB= )'L$*NOA
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M7Y@UF8M94XCB@NPAD^CZT-#)'U]HS*W.XY@HB5^HWHIW<@UL,I@O;L>K@4A
MKD'1,BUM&Q;QUJ=A.SEMOJSH]&M9P"C$5LF*5([FD"EZ-CF3820G7,!1@F!#
M*,X8/4D2W/C^C=CQ!7N/';;LQK<-B#>W3K226.R@HVM6LE5<=9^L[P>JE"1!
M8X.!X&AW X-NFV*.L/5!VY-3*2SU1!)$V%\1'$1Q$<1-3_E.[1USU_BU/(S9
M[@@D'G>;^,P)@ZUUD,Y$4(BD<KR+"6R*3MWEU*^S1KK_ !_13#)PEH,<GGZR
M+AF)()81*E43UUB%2T. [+>8ZPR-L]J[>P^;+00M-+ EP=K%7DED<TK7K;6G
M7>#M [.U9+$1AY=P9CK:NK D&\L7-_"F"D<""'K=$KGK?K[N77##K-0_B6GT
M,IWK+98:8W1U>G16CZ'#!K-)3QY(Z+83F([S<!*P-9L22KWLY92(*%K&S.H6
M$!&K,W%9<<(/$22^A-6V_P!QQ%O2:=]@!+:CNSCNT)!:)(77D)#WGVS'*31Y
M H^_A[^6,9.ZK'JC#:7$P&JP8T $7E&)AI-5(U/&6&XJ?2]$C]ETOZET%Y#>
MM;"S-",7N'KNXN/LL0M:1RI+,9[&]<(; Y8\C]]7&0.(D"TH[%4O8I:*PZ82
M+<^Q>O0P-W-7@Q2.R2."HNB;I^H("SK DMK=KKPBXJ,R*V"FD:H"/(+&-#D,
MZC G&YFKFDT F&K?>(6I/R9HW/K4!M%7:C1T\B<9*.]E(6Q'"D23NV%2LK'J
MXF>%SL73%I52.D%@5!?I31GLRIF9# +[7\42/4@Z8CRU<N!_Q#"T(F9>MP,I
MA*I1@25:*Z,B@Y$UPAIW!A):%Q>C)27[E=Y[L<-:\F/>,)6[FT:;H-UH%(/Y
M?*WLTCK-S45/PR("4I'O75"0TXS<R>7JQP)/U%GTED=@KHFW>I*KB%+UW&*T
M@[1PWCT99K)IN'[I1^9-%"+QR7D,HD957&')J4RR0$"DEE)UW[3PW(2I(J\V
MW<NU=LHF:-P85F3(&F@D:U,%DF*!4LW8MD21-$9JOH-1(/DTM73U(?HY<Z,D
MW*JNC35POJAJGA53&R)VG$3"+*@S"SJ_FE=E7:P\7.(N=BA)\W%18ZNT8GQK
M@8Z72"3B/2V&%]TT7.^V!DKBTBCK[T^%,!28]5PS61-7#+PQ==Q;./LQ%J]@
M!6D3Q'9'&=69FI\-@-QQ(\X/1R\A(U6GU!;"6A<+Z@1$!:LDJ#$Q9HP C*>9
M,V+75%$@?O-T2ZN4A$?'M-XO4\5*7#4W>CQQ5-&KWDH("_N1>()]GHCJ1:DI
MFQ%#%/:/.C)HD8:BF8H/N],$/@1;!FJFT21-^WVXB.(CB(XB.(CB(XB>N^^N
MFN=MOIKCZYS^C'WSG/[V,?7/[W'TB5S:K.K#<GYA/" EK3H$BL\A0[5;9HQD
M# /KC*\SFR[G;#=\)3?MG+N+,=%<!7(W#8\0;O%U!BC+GT\^0?1JW65+Q-%A
M?%4&*+HKI \MFTO\65"U'?*@(H:KQOL6PM7[<!66Y!K]FYZ5XBBTOBJ\BJ:*
MZ/ZMVUF/B]/NHSY*P10](31:MA:KV^8'L>8(FMY#(P:(NHI!NP8Q5]EH[1DP
M9?.^J")N:LEM\ZC@4J663U%;:(IN0"*;':1HL5"+K S)5R&L7MHT4BOBKS77
ME?P8:*6)"K=K0L371J9Q[7X%:A5K-ZK[C^W?5R&L7G1II6OB=!KKR6%&752Q
M8J+]J%B$SZV9?8Z1;,X"?>U1K6%630S;202V;3M?77+/1UM!(PIGTSK\GBCE
MQJ?>Z9SZ83W)2]8NT6VTSG1RR "%L[YUU3]G8Q?[1KV[CUX>0PY?_P"C*S>_
M8/\ XFS6UR.1_4F>GO\ I$V,8]_7NW'^D/\ <,Q[['M9&<:''STILUM;6_7]
M29J22>AU&%LCE;V$+1BO%4QR@Q[Z;6\JJ^:CP"R:R:945$G(Y=D_DS@LU36!
MG?ES]F!;MG#E!T3<DVF@S2+Y6MN;K;-QQ6MJG^>7;W%KSL& MJR-64LTO<H.
M>\56)0$9U:UK4-4C.6I?GJ6R<:16U5GQS!+BO.P*BZK&:F2S6]R>5&@5V5YE
M5G6RU[4]F?O(+=EU9ZAH>[JYJJ3>,E&T56C!]JI$WV!^635J+;-%!Z,H9DE$
MW"?PX1K'B+=%)%13<SH,:D"K&_1RNKC!3D?C UKH4R-FN0Y']OP5*E0JNE;.
MF'C0N=@%5B;14CVI=IY;3Q@HQMQ:M;8AKR'+>GW-S6$5*50HNJNPAAXT)FL5
M55F][V:[;J\30-6]'';EW>=H/84*DR^SV,;5]'X<Z%AG:B7MXKQ^Y.0Z5$W)
M[9-+"H=R@L\_$+M1X,'.,OF[%)]J"_EL[L_-\G9BJTL7R_R_-D:JEBH_V"Q]
M&398^@=%J&5G^\MYUU_C6M7TUMYC,SV<[REF*G22^7^7YL;UT,5^./M:_%KM
M;2>@:&4N-+EZ:F-BUK9F-,UM)&-@3VU)8N8<;R@9&P,.1E11 A+0T8%ZN71%
MN8:CQS$&$W-EE4"ORD/NYU;Z)I:OE$2&'+?3;XCCM*<AOY34US'55FHQKJL6
MS73GJ\VM6U*ZUIH-UK+9[5+-XJJ"PBT.)N\/QNFOD>0Y76US'73ESXEU6+9L
MHRT^;VK<M=:44F^YA:*:2P4!?<ZN]P2S_.EG22BO:#H!4G;2=@)W94BFPMW&
M:^G5?BV,-;5J'6U0GD3F\->&E9D]KDM9JJPL9/C+\?#]YSFK74B'QR0GX$:*
MA&[G=$C*'^*;KJ!EA&1S ]8EPB90VL4C8U?VEM6Q:O[/LFW1LZCUG6Q- 8&M
MHTZ6D\QB5CRV(/XJ%)!*D: 2">HNMV))HV(IHD=^+:HZPHBVO*;4U,P*+5C6
M</[TQ5O%H+"@[,!& "!3I#U$.D4A0A@FBT9IO3),@3<ZHIZX5>O7"^WKNKMG
M*)M[XB.(CB(XB.(CB(XB.(E*>[O9\AUXJ]RSKD>I+>P$\;O@U-0%@+_$)0N=
MTU237-;QU-\/<E!@+#A)7+)-VVV+E%AH;1PVU?+/6<EQF)=F@&YA7CI*OJN9
MQ6JIWUX>9!"LY'0)!\1Y/T0I$OK3S/R?%1_4WZ#_ +G_ ,R#FT4I2R*\1OBR
MKPDNE\U$U0D>UCS]3>''^N<Y>#]=5P;:B,[CP$3'/]UEX\YC1(&:.6)'G28U
MS,)ANX%G,;)?51<<E&5#DTDH*:>K:]U/F#Y'9\FTCI7%JM6M+@O[=?XE.0LP
M;Q5>D/QXCY\@/CLL.B2?U^ /IUU\2&:G[U=B^R$LGM<P'%?@)B";@<C(7"HL
M2D,N'C51334S.IA9]@&Q-40V-D#CE)82'$Q"W)]'V:[F/2B":3 (4%I[.GB\
M>&NBZWWGJL-@-MKBJHL&ZKIJHJK;1:Z)\V,[Y:G/356>VRNU6K5 &/D021V2
M.NQW^'H#OL?'?RH/U!^9F,NZW7?5! IVVN;L ]O@A PH<QGKY+4G+:K7SX \
M(N1>(WF,L@@=_;F")=!A7LD2J0:,>2-1DW_ [,B^%EX_B39EO4<?FQC*+F=1
MLK(.@>84=6>X789B%+7U_>"P0'J[Q!5P=#U6J!1V?Q__ +?(/U^?T^.BQZ'?
MR9D70R6VOV>'[S_L>1?.SU&3Z7AH_"S43VA!5&7F'+XBA-9/&-0P1#?>&1 ^
ME65=ND6RS5YH,F$T<.7Y0Z,V 6\M3EP.*L*K[>JFHO:EHN5JT4(42P._0N=3
MHN4D%?.JL*JH?.EH5/A /Q#Z]D@ ==A2?U/9;Z]=@?$DSN)8M?'HI8\.L\H5
MCG6JKVH(EV9F(=.08*EE2+D(1BU+1%6*Y3DJ94UDI'I#.3 !3#X1&'@<"QWU
M>RYR3C6#CJ+DLHLH17VWEQAK<IXKX^2V:K!8#657ITK6S\+.'=NQ7XO2L$$$
M#MS\)^@/_P CWW]/R^.NR"3.X\?4O;3JNK;DH!K9.*\==@K(85:;LJRI!9;N
M4P,#\G #CT8>RMLC)(]$5WXPDW&1HRY*O6#EL_66+/=W6VVM.71J[LZ6&GWA
MCH-ZT4)G%=C@N4L6L^#V ,"SA4\@1^$#H1<.F _#WX@MXKX]$COY ^._\2^#
MA+*R*B6JFZ6RFFVF%4\ZX43SMKG7WB>=]=M<;Z>OM:YVTWU]K&/:TVQZZYBI
MAFHG7PO]958\^B1*;W"^BLF4E.+&BX_:F85&;%8G%QK^/"2,<KNFH@"@XZO#
M0EE(HJA3XVM]B4A^-*SQ29K%2F'C]_O]F)7SR4^/7K-!O'Y<,[EL(&7?>%;8
M<3>,=A;?C<%*W /E<YN"+'#Y<88B<0AT?C6RJ[C1FV91&-@!S=@T:I8:J+X7
M<KHF_P 2_P 'I_D:_P F.(GOQ$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$3%
MIM-(=7<6,36?RJ.P>&QYMAZ?EDM-#H[&P;+*R;?#TN;+.6@T:TPNNBELY>.4
M$==U-,;*8]K'JB:7?':$[P(7YL:NEUV?*0MY5EBJ7I,;GMJF;$ZY6/<I*?0M
M]4TGZ2 :[DQZ3Q&L/P=K8JSMJ<"PAJU OX@',!R<I9*D443>7Q$<1*>]7/W2
MN]G\,!'^:?U6XB7"XB<,@_9"V3LD1=M6 X>V</B#]\X1:,F+%HCNX=/'CI?;
M1!LU;()*+.'"V^B2*6FZBF^FFNVV$3#$+6K%U7&]PM;#A#JIM(PM-<V:UE0-
MS -H>@QW)K2G28(/MX_O'4QJ>[_<SH0V':M-=G&7'NM<[\1/G8\A?D)O*R#%
M;Q?K!+Y/14 #7S4PY]*DV\Z VK=AHUMN>BU2!QT;K2UCT-7MP)G!2%P([6!N
M02&):8LRXDZ9J?,17M]$TBS!G9]Y^28;V![7OYZ.FJ77+9?I_#9!<U*%Y%$W
M]06!/1H^ZKTLZC@4##C.OU,S:/7==\HL0O3^XH_#PL.BL5-V1O(=0A-$VV]%
MNJ4XKH'IV"MUCYC)_=U@,3Z9^[)6OU)3).84_D#PFS:P%B>G4M[!TW7QICJR
M.;0'4O&M=-U4<O@2+EJV201*KV?W%Z1S[I3\!T_-=H878SR6R(<Y[$63V*ZN
M0;LW/(/:=VKC+RBQ]K+;\<WG?C.2!2Y]*"14)6<F(;.QL*4AID#*AHA^FB;X
MP?4FCP-<ENU_:F.YIJ;16K1<=@Q&!2R1U_*>H?6N#MU%Z[HF"RRMRXPHF;8M
MUOFEEM0#DF+G5EF'T;'-SL,#0H6W1*CEO'#W'OZP:Q[/69:$2D12)@MIK7=?
MWI&D=+JC3"'R7\3U!UEM:5UPU#5@>K&RF3OYOVCP.@;24[64&A>J$DL8)7HQ
M5ZB;$1GE+ZJ/*\E$H2,320V%6Z,C%VQ0%85W-KBNZL["A&SEC.JSE4,K #)E
M!LCC$@8O@*Q%ZY:18@NWT)#SRX5TV(J(F1)5+.^Y@I,SV<!/H)UZ.LD'@+J2
MX<)X-38019YVQMVR)#73IB;T626QMFAHP26@3#55=I8Y>RW.S89&D2\$9C$=
MAD=!Q&) Q$9BT8$#P$=CH$>U$A 0,2U28BQ D8R219CQH]DBBU9LFJ2;=LW2
M322TUTUUQA$Z./697DLET]@,8F\4/S:K',?963$@QX:1D<#=RP,G(HNVEH9J
MX5?Q]:0 %4S(9,F@VV(C=]7C7"J&?;XB9SQ$<1'$1Q$UC^4S]SCJ-_VFGCK_
M )TD XB;..(CB(XB.(GCUQ^G'\?$3SQ$P^;SN+UV =R>6DTQ@=GE/3=;"3AV
MY7<+;X30:,1[%%R_(/%]\YPDT8MG#C?&N^^$O8TWVUU-FW-@H;3KL%5*>(+>
M+.69F"JB(@:RQV)'BB*S'Y('0/6KLVY>/SOIUVBFE.@6*N[%F("JE=:O98[$
M]!*T9C\D#H&0#9=UCBN$(0+!6&U%FF6Q&;2[6%2-@E$X"G[S)0ANT>,6<@37
M.)-W80:_:BU$V?MORZ2BN1"B6T%R/-5V>.*JGD$KN0V;=8Q:$^Z8?GW;/!T6
M\-<%:BNQ:B*R7N4L:2) <ES-=OAAJS\DE5Z&S=L&#36,> =^[8U=B5Z5;0%?
M/5:E1%?=MX)]A@8QA=]UO;TSD<>PXSI!:R(B6L*A0$,7*$9VJQ343T/OHR)8
M.2?X?C+UEJB(#*#DF;=SEB7+^BR8Q!K&XN>X[EMNC/Y 8>-LI3'CHINMLVFL
M%?O#YJJV<9L[H%JJ:OP5_"VTAEJ1([#Z@XSF=NC.MGC@XRVM,.*BF^V[D&K#
M+]XLRTTM;]VS.GC32:@BN$OO\66E4G][9)=_DXRD]+3X= 7(O5OM(-LQHNX>
M-'J#M KJ1B ,X^E;!JDW]C"6$![]^HFLILZ8#\IZ84GK.1M<7KIX?>F%JP/O
M!^[VET<,MON9*;WU5HJ@'M:['*DEZZRO1GGY&ZSWTU<+R%>%JO$WG[K<[I8'
M6U;<=&BS4B!0/Z:[7(8^==97HU0GL@'NH!5H"%%Q<5J;0FP)1H/-#1\44LF(
MQS91<JH<=;*9D3<(=>.QT=" 5V! S)2AM!V1&:BVVC)SRV[16W'\71BMIS<2
M+*[<].R[32_(8\I+6G0YZT+1>QKST4-7;?JNM#65>RI1N5WZ:WX_B<^&VG)Q
M/NU79:MVC15;R>/+W9<;RQ.E:-#M5GIH>NZ_5;>KVTBI?![#!68V^1CX1)Q[
MF'PJ.*#VZM1[Y7C\IU598T="G,UT9*-EA8?&S5%]&0X%QAB];H(OWA5YCU$#
MYZE$YRMZ="-DQYS6IXKR;/J#)TU3;165]JH%0^>F@^VZJKO=8&-5?0TI7SU;
MT:JFRX<[5(>([;/J\J_%ZFW"IE-5(**^6C._MV(JV/=8I]BNOP$&4L"Y$YK6
M#TZD+!CY9'84<.V:NBTV8LW@P>;>QYC-(I99&0(/B:#C9XY%,F\9'COD;==?
M)MV4:-8*BBS?RZ[N-?0*J*]6?%==R;J"B/75H>BO;DY)KTLM#>35*N=*UI[/
MNV.B\[1GLY#FEW\59H]G/5LS8;[^4<(:TLIKT69Z]V/E+- LN4AWI1<M5)SJ
M7-]EJ+ETE%S:&L91+.Q9BKYB%P]5:1+,CF!81@(-69I:I-P0R/UFU0>3-PYR
MYSH:$AOQ!C35),9NV1QNEMMZ*MN)-6KU#=QFRCW"F/[QKMI-%35J%6FK/QBB
MS8]GN'WZJ3HZZ%?B/)9O:*MV*O5K]1W<5MH%A7$=.RVGV*FJ5?&FK/Q2J^YK
M"_C?10- 7Q%9500<(C?8[L9$IW4T,L&N1PV)VE*@X6,'#K_+J8I@=U=&CG20
MI#W;;3:2Y3=#WF7+T,%SLEC?5R(^)76RSTLWJ'U!DW\5BW\=77EY3531FOOL
M+:Q0>PPT!&0?>2K)9Y-13\?#UEW/C'9_4GJ3)R'$8N2XNJO'RVNG/DONL+;5
MS_TO][5"@^]'SJ;MJ*1T2'J\V)79AC_US_JS^O/]?OC'VYZ-/2HXB.(FLCH=
M_P 9SRX_P[X-_,,Z;<1-F_$1Q$<1'$1Q$<1.C2DH!<\[BR)H0K)6 QF:?QY,
MFS4.,@Q%T\9#RSL3HME^W&/G@]^U9OUD-&KERR=MT5=U6R^B=Q5@H<JP1F*J
MY!"E@ 2H;Z%@""0#V 1W]8E)/(EVG>]7J%7,0HJHE<4QD\4BU7@A,7;6!)"[
ME8^/?2UT,@2A4.J>1%PEG(EE%-GS1DT?;CL.GK;==#.TEP^)=VP):H.:M+;+
MW:WV$4+6?;5KO!_#RM*#^DGKOH$3+57YM\_TCOOYZ[^/H#^OT_4COOKJ:Z9K
MUX[@S0O-<6&-J"UNRO9*J7KN5"F4FEL'9=>*2'(MQY.I(&:6&3,0!?6(Z)$(
M2A+=]]"1 J_F1ADZ68@S)=>8JW<;6*C0=-&'#H7P8I5<=FINV2_0@LI=EI"F
MT5_B1/!%([=%F;R0!>O)41@ ?PGS;ZENNB".Q\] ]CH=B6RI;J+#>RD9IFR>
MVC('85ET!N6K-&OV@8:TKZ*2.O5WL%.,3>KE(A(;+P[?"=9$R?RHUF-/-%QA
MP##(_H_>)OH_3OLQ6::>.8TT;"M_O>1:ZRNX"U2I^$H(\RK+6OF""C6N ",;
MV%.UK_"&_$3WV3Y#OX^@'7T'0[Z_.37:\SJ:;R4S1=>U_9$NN"C5XWE@ZJ&/
M-H0M2)"4@6Y:-D65HR_$;KH4.=@\M-S,4'DI5\\!:+!B\#D@_9<0KK45:*43
M7?917FT^8/WI_>&I*V\;0<]7N7L0Q(6QEK*O^);48!I158=,6 5OKY'Y8#X/
MQ^?]O\_!E>,$?($1O((/ORJH7-J(J*/1&SUDZ>([-24]G;!X;:"%T7\S4CXB
M1GH8Z^&FARO?A8B,0, HO(8S)'SC1M&">WUPXR,V/3;7LTM90%T#M::B%\N_
M -[:6#RJ2XM:Y#.EM:C_ %%N(J"'Q/3$D=GY '8_MV/+XZ/1^ 3^LB&T?)'7
M.T^5L'K3*88&'VG7?X%,VWV'&3FKZ@!S2"21^[B+M)%W&\3&7D4PQ>R@SO :
M/ZQM0TSB QY*T\X69XVJ.%N]GVMM5S-1=[J9\+4WZ7JL3JY2RV>U4/)<[+YN
M; K6,*C\&7+2?$AQ\JP8!0&8@@]@C\AWT>_G\QU^F5NZWC_;(H:IY.3EB73C
MK_N56LJT$9&KN4N.V'J*TIL(LUE8=5KG<IE\:*MS!=BBW' !3^2;Q]FKF80D
MS"\0N?CU32R*.3V%?8I\/PYLP 6A6K8?TL.O!3Y%W5"2#6ZV4\O;Z<#\;?TC
M_P" 4] ?Y^/RZ/?Z$&60\5IV2&>GT,0.P-["1PH]+4X8[?F-"KF<0P\<=3 '
M-54UG#@N/5))23=DJD<4R])J#LR%MML+,L/34YU:UY*TI:MK%:_="KXBJY$6
MMZQU^ @%.P4/0\O ],IEEX L/1[^!_@= #H?)^/COXZ _P"<V-<AYACB)K@\
MNG_)R]H?^JD7_P#,:&\1-CB?^#3_ ,C7_P ..(GOQ$<1'$1Q$<1'$1Q$<1'$
M1Q$<1'$1Q$<1'$2+KK$2X_5,[!P.+UM-9<7 .QH.*W"H_3J\V[>YT;[LYSJ+
M#2$@XC_PZBRKUDT#O%7^$]66/A]5]G2")K,Z">-@GU?MZ5=B7]SP]':P(D5
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M<K/'J^$&^B:>%G;QPX=N5?9]M=RNLNKMLJKOOMHDDGLDD_'R22?@= =G\@
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M =RKG/M9<*'CA=^947]K'M:J[/LY3V^J7L>F,8TGYWEW[[WW*#_^J>%:?/U
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MOAJIBUZFZJP 4]/DI-UZF_5-F>F$HM>WXKK+Z=HZ?!Y#.QC>*5K)!$)$3R8
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M%F)#,I7,:OMIF7TAZ2)LGH.!&ZJHRFJPDI,<:D5=59 (,=,"-2FHHJ8B<5%
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M5FNCNWU8M;L7.*7*P(93: JNQMLKNIG+Y1.8E9\<E,T@9.#1;:(E(3#3!-W
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M0P7> :6?7J]B?,W[76 MI@!<2[8.D00VW1.4KY0^D6KN5CV=QNCA*'S@77!
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JTB1!)JELY]EPYSCV==/?[ZZ:YPB63XB.(CB(XB.(CB(XB.(CB(XB?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>g67046g55v08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g55v08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1?R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %]:^80(X0DE-! 0      %H< 5H  QLE1QP"   "]RD< E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52+F1O8W@X0DE-!"4      ! U1Q>[T6))<R.NDQO^
MGJH6.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           !]   !.D          0                         !
M          3I   !]                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !]     !29VAT;&]N9P  !.D    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ?0
M    4F=H=&QO;F<   3I     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    '.$))300,      U>     0   *    !    !X
M>     U" !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MN=^ZU$P_K&S*^L67T,8[F.Q&&PWEP(='H^WTXW-_I*<8FR-^'=2+ZU\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0            ,$!08'" D* @L!_\0 <Q   0,$  (!"0T0"PH)"@<
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M/D1TU<5<>EC92UK7Y<E454<N=O\ F+8)Y7MW_/M;E?OVM?G:]12G]4_ DB4
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M ,SO?7M;(_FPS?\ 6CIFO!>Z-^0[M^U+#[+?3&O7FX_'7U9'LZKBI@"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4!^91N7]V#:WXR9S_:@I7T]<?Q*Y_);O_!@;>.9=R\#
MJWU!+Z_T7^*/9/N0:O)^7_P?E\LNWC:%B\^:^<O6>WRN&FO% * 4 H!0"@%
M* I0+ZAAOP4._1$:B.9=R\"99WWOQ*K4D"@% * 4 H!0"@% * 4 H!0"@% ?
MES.OIEQ]_6]TRKZGCF7<O W!W?\ F=[Z]K9'\V&;_K1TS7@O=&_(=V_:EA]E
MOIC7KS<?CKZLCV=5Q4P!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M1L3W5]0W_>Z-5?RMVM^L,_7!O+KX27S]5=/LMD:Z\^=?='P.NM>0+ H#77C
M^M+XHOYNN[?U:2:MCT/^5NB_VC<OM-D50]_'XT?%'YM-?2YMCUD?,WG[FW%+
M_+C6O]0RFN1^Z5^-]%?)[S_$LS"O>>'=+Q1Z6*YF8@H!0'Y<SKZ9<??UO=,J
M^IXYEW+P-P=W_F=[Z]K9'\V&;_K1TS7@O=&_(=V_:EA]EOIC7KS<?CKZLCV=
M5Q4P!0"@.7FY.K \%.B-GS34&PI1.F<U@1C,'(FHW7YLHQ1()H(.<L&Q!O\
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MG27R^^?:+0U,_?R^-+Q9GZL I% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% 4(O%XS('0=\>CH(V]CS[$F >%Q \DZ!DL>A?$@'</6ZRHQ]C=
M-.^+MEF@XMT,.2GSN/("@J:OUNJ[Q?902)=DV-')+GE@ &)X.)))0CR-2"1/
M$$VV"#X\8CA(D!(&7B2Y)R&)DABCF[(@\17 B9:SUOF@,:YZ_A&;4(')1X,V
MRB@') 0 ,H9M2X,8C=A=-@'*ME%&Y(8UQ29/D,\T72"J>66-P+I&"Q@0<Q#A
MAS$0)%M$& T6,:-V X<Q:IXHM63%BU32;-&C9'#!)!NW23113QQ33PQQQM:P
M$]0'YE&Y?W8-K?C)G/\ :@I7T]<?Q*Y_);O_  8&WCF7<O ZM]02^O\ 1?XH
M]D^Y!J\GY?\ P?E\LNWC:%B\^:^<O6>WRN&FO% * \!?5A/WR#B;_#D#_5-
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MLXS=FY9$X?AQ49-4M(PE@I1=:4QP9>-5&4* 4 H!0"@% * 4 H!0"@% * 4
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M^RO7W1:SLG&5@K'(R(*=:JUM,JM:4HJ9ZEFVL59*+4FZMK%4S4VG8:O'%@4
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M'M^A[]:=(]'7>^6L(0M+5VJE&"DHKJ[>TLE12E.2K&";K)XU:HG1:W=4\^L
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M">FDA3H6669YD6C(S'CHN3!%"0Y-RR4(B<RP=DD7'I/&BKX6H[:INF^:N*N
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M<0=@UVRCM%@*0U6V)%,2;AP^U,^S?PS2T+4)'8YUYN (LHVT@8!\,2[>$G!
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M)480#GB;$@,49O4G%NOY))@9)H!0$9#]MG]Y7]RSJ'F],?%$K/Z)>#(-20*
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M0"@(J7G*_>LOZ<: A4 H!0"@(S?T6WW*GN>="8YUWKQ(-"!0"@% 1L/05_\
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M8[;/_7[>TH?%4RY:^"Y#JK/L\9<QVV?^OV]I0^*IERU\%R'56?9XRYCML_\
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MRG1/\&-&VM+>9=U,YT#J"X* S($^I(_^*I?FU?CF7<O P9^_E\:7BRJ5)2*
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MJ%9-*?2;;[\Z_-;4*5[Z7S? E:%18$^VKKC5>$25V/-8["49W- FN8@XDA%
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MTE"J!I2< O1QQ6Z:;)09;,I)^AL:Y-I$\\M?SI))V?$NSXQ]#WZZT>P1#31
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MC9&+F$!:;D6[;9N5>S'%T54 *S"]/,H7L">[%1FDTD!;8BS-0VPDF,+=L6B
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C@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>g67046g56s00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g56s00.jpg
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MM"0X.5&RMS9"0__$ !X! 0 !!0$! 0$            ! @,$!08'" D*_\0
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M\75S ^^E9=7@G6;LY,:SDL$LLD;F,7ZO6Q*3<M/@)#7(Z(3>ES(=YK'YO1"
MV5%7$\L-@'*BQ"[B*[X+,$G_ *-XP$[I*N8="/'[._B[]^G3V>OL9MYWT[G%
M>F<-K^1!8!7$Z(3V7/8NEBU.QT#ZY145AB!?&M?0E9$(FDWFTA,+M4!(&(5E
M6<V+K.7&[XUD ';;D-V4@;GJ2.F_0;G\@^<@?#XLT C_ (V,LM2+TV6H'IB4
ML<_;'2&R.Z[P!);YCU=LX7'*BM!Y5\[B9$XO7TE^EE=2HYQ]5C8P7EP=?/P3
M,C'(Z.>%S@%_O_?=E11MOU[E!/0'KN-P1\W[<Q%U>+]8=ETE,L]/NNTCD,CS
MX:.O>*?S\Q:,4A+_ *[A;1@<J>5ZUC<?*Q:1M+?L&,O@9.3$ F'D3 .!8-/5
MD8)DR"8/5@( /KC_ //R]!OOL>OC! ZCNW[\EG:KM-?\#\#>CNT$1LHN$OJ4
M5)X>D@/6.W8@U2Q(Q;LWZ_#+'?+,G0I<)HI*F$MD39[H@+21;Z%%LCTVFZ:&
MR+"0"O8CIZ[_  !(_9FE=R^*7V6K&O/&EBS2)]K9S*J8O.Z8SU^O:MZGB,CI
M_KE'PU7PQY'A4QESD@-^B=8T;<D9.^V+1R4KHBRS1TLL[35U:(/R?L^?*@@$
MM]VQ"=P2=SNH@_&.G3-E('.^V_B =CK?HB+]Q;+ZF1/J1U8Z8RE4K4T5K(C+
MKDN_L]49&SEI_.2,\B,DT<5Y$4A6@1U!8VA'FQTBY?*N333=-'1!D$)2 =@K
M<J&QWZ $=!L1U^'<]._/5T(/[)'>E;02,["4^:[/$*?5&LNS0.&M7]0NIWL/
M5:)6FSA3<HX$.V*.N,&]QJ3KZM+F$E-L"4 .WT&FRCIS=QVW[O'MOW?CVSR%
MZP][+QJ>"=X[2(SKLIXB'5FL9% 8)UHO0%U_&3263VWV$#G#[L.1#,:/B<*3
MD_6.#ST(!%(V=D7J&#N'9(*(ED@9-<%=&5$ \NVR2=]QOT \6Y)/4^,>+;<@
M9Z:>&IW6,=Z^L%>7'**GLFK9D0A$ )3+$LJF9UK7LJDDFBC$Z5.460F3LDXG
MM79=KK)@Y2P+EFSAILT\\@Y45PKNR%)Y21N#U(Z'?N]GX<J:L;ZMZ9>'KW([
M3*S<CN3/.N]-B]>'^6HO"D&JNMB%BPZB]Q:6C##1TB\"UT*L9!0DF3V<.I6M
MZRNY;9T038V',!^('\?C^(]/R>SGCS179GM>1\/*\^TQ#L3XFBEJQSPY99=S
M$S?]$4U"NK3FRR-?!"[:2TE. ]7"R\QR+-/E3-?)$"SUH6B6KDJ3;D,)<960
MGG"=D[<X'0JWVWVZ[GV._P"')5VQ[(]^ A2/6,3MON-"^OX[IGU]G<)M?I+5
M]%7F$KJ\#M>*RFSIOWHJJ1 R=G+P)=SN--M&\:S'XQF&H.G0STK_ "=4:L@!
M/4=.;F( 45#IW#8CIOO[.;%1#Q.;3C?=TH P'[ ]T:8E?AY]4KCB;7J/2HR1
M1_2<6"YD[J2V]]6S\@C\GA\<GK1NRV$A#1XPY#Z:)B735)\U<KJ,<HY?$#SD
M=3X@!T]C?<^QFQW0?NE9N?!(BG>R\GQ2ZK)@_7+L#=LRW?NA48*SY6I3MJ%&
MH54@*!J"@B[\-$F()(BWC[I-EKA-XJP>J:*:+,A0'.4CH.;;\601?QN&E9QR
M42WM)U4E]%A'?3-AW<I+4):,6M<K:]=/Y'$(<A##+$4!C;>N++6DE@0I% ,[
M(24)@696($)".=#7(S+')W;$'UW*>\ 'O\?BZ'K\'=DHE/BYV-383L8!['=(
M)I7%_4?UW@O:>.TW ;9#W:QL>F9O936IG,@VG$5@HQS$W=;S!RIO:H_>%2':
M.QD:6DX!:6L&FFKACE'0A6X)(.XVV(_*=]_%\73*M0\5PE?]7=6+%AK /%7,
MR\2R@^M3QOUR[.U?;\0FX&>0V92)-I,39NHVD\CD4*KCL,)1 I=5=-63LL/8
M%8[)4PBF79!D%.QV._<3U!'4#?;O_P 1N/QC*EZS>(]V_MYKU)+71%7L8D]L
M]_NV%(1P-7EE0(=")J%JV)7$[&5_8;1>H#QIO%X.;AS.*-CH0J-DLE),&\\>
M$UQZJ\4<LJ4D#?;Q)2=CXM^7Q@]_7V"-B?'MFQPOQRJP?0*(3ES24J:;!NK7
M8OLYVCBB<N8N)3UI0H"=.J<2K1\Q5CC-O,YI8MW"SL!C&CUW VZ(X.YF3G"@
MK"C9!D<G7;?Q@#OV/-W'?V-MC^7+[\/#Q007>N7V16[^NHM7<\@,&KZST$Z\
MO"-]AH,;A5A;DVB31:=QB,Q-L"L2&EAGT5/8(^$J["%20=Z).'QC_#Q)D*3M
MMUWWW^#N_*>G7O\ 'UVZ=3ZK\93CC&.,8XQGX].Q/CL]U:L[ WI6,:"T8K'*
MYN.SH''U"D%DKHFH$B$U-Q\5N1=(3QHBY?[L!S?9XNBU;)+.,J*)MT=-L)Z^
MPUV@Z677P)3KD\.28<60X$/LA(6\PAQ82#')">91Y022!L"3WYG(CMJ0E1YM
MRE)/7QD ^QGK[WB[077#>G?0VX('+]X--;M[/]!8Y8+N/,&&6A2*W0? YL.+
MH-#+<OZH'-MR#AEY4U,DFK7S,-R.BVN5MO*)S*(\V9';YBVQ*D,H*B"HH:=6
MA/,0 "K9(W( !._0=V8G*.=2?$.?;_RA6W[,\F;L\6/M37_4CQ;V R/=L#=G
M4[WK[1US2/:"(U+#2]'4E7D,MZ'Q^(P8_-W#ULBR<1L+@H/VU*0^0/?,DH;9
MR1=+/-5&F)XS_ITZ#H?'_P#Z,J"!S([MB$DC?J=QU^']F;Y_6'MYWJ['][XU
M7W=N<=-(;TD5K"NJJ#P2)5:1&R>R9!43&S9':_8!U841DI"10)0F3;C!L2"O
MHP(WC(QR_P!G6I#=ZN]G*?6I"=TA15U)._0;D;#8CKT[_P#IGJ-9+#L&>Z9.
MV4+[%U17M_N*KC"I/M!I$&)2I@A1FW#.K%M(%$31A^&;"'()O)2T51.ERP
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MR5I2$@(V2 !N#OL!MU]=F[]I=-Z;N"I:3I:9)2=2%T#.:2L. :C3N&!761T
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MFP*_L)V\&O'4QBZDD(K/AJ+U9(FGA)JD2*%-$-,<9!622>G4@GIXQOL?\?\
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M.OI=T_3;8V30](IKMKC#L]9Z6IM0Z?TG:7D&#J/50G*T_4/N*3+M!6L]O,+
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M<:;J= T=3I_B33KJ;CS1S>L&I:-6)KG9DZELCHB7'<F/.PI,&6TY5^=$N ?
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MQG5#LHTR0Q(42ME"%1&8/9])H)783:N)I%R0P5*P9=L!'39N$%R8&P8L NK
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M)Y2=6NQ(*WYK46"ME4:KAR!+7J1L=E$>2KP=U#CI6@;EPJ4"2&^(J.%2<6J
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M6E?W78'\C"_,O'V0+@?[5<0_(-+_ #-CU.FO/NO3?E"=]5YUGO>FBR+-V/?
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MG=GRMQZB+@_[S=/Y0G?76/36XF>ZBP^2@_1L>W%X+OWJP/X3NSY6X]1%P?\
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M@-XWC:S4D&>N6#U%L_:K*H*J-EM=-\^9GE3'HRD]KV#VH'2PZIAX)DSN9IY
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MDCJ%VQ@IMNJEC5IGTFGG7R_JT2Q ,F^\,*><1O"9W;%&Q/.$=IN4; GG_L;
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MSE?/CV&.D_N?]7OP"JKY4X\_+KVXM/*$O^-CM'/MB_SE?/CV&.D_N?\ 5[\
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MNFK9'_.MY,^ >:-USJ706E-*3M+VCU-+O.(VD]+SK"+IY&JIS%3<IL$35U]
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M-CVF^MOO"4?^+$"_K_'G;8_<$W]%?_AXY%_W5?FGYLM>/R*/RP.QD,5.AI,
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M[[ G;O\ @_'G58]@*')S&9UV-NRHR%@5R,>&K"@K&R(:[F,$##]$U'Y:9QE
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M'3^EVI=M=3&X4"Q@.ZBU6N0IN6FN4_FXL=)6T:1-G:>J3518%A7U];64CM;
MG2*1UZ-)U/9PGG'V8L:RM5M1(+*GY,9]%;4):2MDR0C->[ 7BSF;RMQ"$5&\
M06/DU(XBIHLGE,3NZ4RSUU2<9RY21]%G7*"3C/K"2.4TU_(KKOC'SGQ#?TI*
MUUJZ1H5A<;1S^H;5W33"T/M]G3KENJA)0U*)E-,]B4EAJ2?"&F2VV^ ZE8'I
M>FV[AK3],U?N)=NVZZ(BT<26U!<U+*0^2IH!I:^?<.+:'9K<YE-^L(R(<X[-
MWCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9K_P!JO_ESN+_H<M_^&G/H
MWS(G_P 37!/_ ,>T_P#][F</Q*_[!:K_ .YY/[$Y^9_G]3>?GOCC&.,9=?7"
M;!:WO>J9W(I3-(.$BTT#EB,RKIF"(S>+(-U__P"01H?)F9 &^)"=]M'R;,@S
M73<Z(J(IZZK[I;ZX-DPY)@2V&FF'W'65H2S)+B6'21_PW5-%+B4K'3=*@02"
M3MOE*ANE0 !)!&Q[C\!VST<[47AU[OJ$4;3DS[;S>YI)6[B^)J=[72RGIB[-
M+M9.W9$:VI)H"/%1\T(,G!@3G4H:(.,1Z&."Z> .A(2@N@CSE5!L:]Z=,8J&
M(;4D0&&ZEJ8RE +1*9,Y3C:5L)4$+]8A.[CP1_2<B]B;2$J25*" G?E'(%#Q
M;[JW V[CW=YVZ[9-M?$1ZN3#IO>5&GNOAN G]J ING*NC FW9,8C$I?0NP-9
M6O)$6K.O6 N$DP\M<N[;E3@F\(O[/(X5BY(UIZ9!ZWL'3EHS<P)[=@B0WYX3
M9LMU<1I#K27X_9!HDR%*>0IH"(TE"4)BI_I4HZ<I=DL.)5S CG4H^M (W!&W
M>=]QLGNZ=XRL:,[;P+:+UC'NSUL2>W%+'E)"/6UO.E9]+A=4T?7PY0C6$#>H
MZMUR)P#/[K3B]DVJ-B&#3HE$*OAHIUJ1?O'X1/*G4\CM9+E7$:AB,VER(&!'
M95+G2%!,J0D[A+;D>"78T13W9I2]*>6.5*4KR5(.ZBE(&P!3ML.91/KE>+90
M3N$DGH5'Q9H]VP*4V9O&2$*(2"Z0!0% $MUXL(.1Z($)LUK^,-;,+0P#)60P
M^%B):Q$9.1CHTH,&+-A;EOHD+&-?5Q[;>U*)B(+29Y7X0')!V=6VX\E@R'51
M4/.-*4VMY$8M(<4A2@5 DK6=U&XCFY1S=^Y[]M]MSR[[$C?;;?;_ ![\UQYL
M<JQQC'&,_P!!GP@?_IO]7/\ I:6?_LN;<^>]7_\ :2U__F;_ /QV<ULC_C+_
M /+_ /:G/2?G-Y9QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&
M,<8QQC'&,<8QQC'&,<8QQC/.N5]*Q,U,2BPR-H;QYL8+GS;U%>-ME68INF_>
M;+[KD5Y"S3]7;I([*JN54D-$T\;;;XUUUSGGP/Q*\PI!XCZ]U/K9?$F95.ZG
MM%V1K&M*,SDQ%O(;0&$23?QE2-B@;+,=HDG;DZ=?H72O'V3IK3]50(TNS,35
MQA%3)5;.,J?Y5K5SED5SH025;<H<7MMWG*^@73"N+3BS"<5QV"'S:'%71IF+
MD\:CC$J"*+QXX2C9C(TFUE*C1^@S-B"0_+MHJLT74:[J-EED-DU=^+D?^S9B
M175,2>*UBP\@(4MIS13"'$AQM+J.9)U-NDJ;6E6Q (!V(!W&= ?-,3$G8Z.C
M@].ANW-^HW'_ /R_8.3'[.\?]Z[SX,0^9N6?L<-;[[<[]2X_\S9'JFI?N/C^
M6W/JO'V=X_[UWGP8A\S<?8X:WWVYWZEQ_P"9L>J:E^X^/Y;<^J\?9WC_ +UW
MGP8A\S<?8X:WWVYWZEQ_YFQZIJ7[CX_EMSZKQ]G>/^]=Y\&(?,W'V.&M]]N=
M^I<?^9L>J:E^X^/Y;<^J\?9WC_O7>?!B'S-Q]CAK??;G?J7'_F;'JFI?N/C^
M6W/JO'V=X_[UWGP8A\S<?8X:WWVYWZEQ_P"9L>J:E^X^/Y;<^J\?9WC_ +UW
MGP8A\S<?8X:WWVYWZEQ_YFQZIJ7[CX_EMSZKQ]G>/^]=Y\&(?,W'V.&M]]N=
M^I<?^9L>J:E^X^/Y;<^J\?9WC_O7>?!B'S-Q]CAK??;G?J7'_F;'JFI?N/C^
M6W/JO'V=X_[UWGP8A\S<?8X:WWVYWZEQ_P"9L>J:E^X^/Y;<^J\?9WC_ +UW
MGP8A\S<?8X:WWVYWZEQ_YFQZIJ7[CX_EMSZKQ]G>/^]=Y\&(?,W'V.&M]]N=
M^I<?^9L>J:E^X^/Y;<^J\?9WC_O7>?!B'S-Q]CAK??;G?J7'_F;'JFI?N/C^
M6W/JO'V=X_[UWGP8A\S<?8X:WWVYWZEQ_P"9L>J:E^X^/Y;<^J\?9WC_ +UW
MGP8A\S<?8X:WWVYWZEQ_YFQZIJ7[CX_EMSZKQ]G>/^]=Y\&(?,W'V.&M]]N=
M^I<?^9L>J:E^X^/Y;<^J\?9WC_O7>?!B'S-Q]CAK??;G?J7'_F;'JFI?N/C^
M6W/JO'V=X_[UWGP8A\S<?8X:WWVYWZEQ_P"9L>J:E^X^/Y;<^J\?9WC_ +UW
MGP8A\S<?8X:WWVYWZEQ_YFQZIJ7[CX_EMSZKQ]G>/^]=Y\&(?,W'V.&M]]N=
M^I<?^9L>J:E^X^/Y;<^J\?9WC_O7>?!B'S-Q]CAK??;G?J7'_F;'JFI?N/C^
M6W/JO'V=X_[UWGP8A\S<?8X:WWVYWZEQ_P"9L>J:E^X^/Y;<^J\?9WC_ +UW
MGP8A\S<?8X:WWVYWZEQ_YFQZIJ7[CX_EMSZKQ]G>/^]=Y\&(?,W'V.&M]]N=
M^I<?^9L>J:E^X^/Y;<^J\?9WC_O7>?!B'S-Q]CAK??;G?J7'_F;'JFI?N/C^
M6W/JO'V=X_[UWGP8A\S<?8X:WWVYWZEQ_P"9L>J:E^X^/Y;<^J\?9WC_ +UW
MGP8A\S<?8X:WWVYWZEQ_YFQZIJ7[CX_EMSZKQ]G>/^]=Y\&(?,W'V.&M]]N=
M^I<?^9L>J:E^X^/Y;<^J\?9WC_O7>?!B'S-Q]CAK??;G?J7'_F;'JFI?N/C^
M6W/JO'V=X_[UWGP8A\S<?8X:WWVYWZEQ_P"9L>J:E^X^/Y;<^J\?9WC_ +UW
MGP8A\S<?8X:WWVYWZEQ_YFQZIJ7[CX_EMSZKQ]G>/^]=Y\&(?,W'V.&M]]N=
M^I<?^9L>J:E^X^/Y;<^J\?9WC_O7>?!B'S-Q]CAK??;G?J7'_F;'JFI?N/C^
M6W/JO'V=X_[UWGP8A\S<?8X:WWVYWZEQ_P"9L>J:E^X^/Y;<^J\?9WC_ +UW
MGP8A\S<?8X:WWVYWZEQ_YFQZIJ7[CX_EMSZKR!6CX6PRS*\E\ 5NE^'3E@1V
M&W*)P)N^W8ZNL:XRXU:;2YKJXSIY/V)Y<(XV\O\ Y\<]#X2^8@@\*^).B^(K
M7$>7=NZ/O8EVBI<TNS 1/5$*B(RIB;Z6J,%\W5T1GBG;_AG-)J/S0,G4-%:4
MBM+,14V<-V(9*;=QY3(< _I T:YL.<NW]DN(W_O#/-W]6FC/O?G?P2'_ -T>
M?I_Z9;OM.W^FJ^BYX#X6?[@^,_-C]6FC/O?G?P2'_P!T>/3+=]IV_P!-5]%Q
MX6?[@^,_-C]6FC/O?G?P2'_W1X],MWVG;_35?1<>%G^X/C/S8_5IHS[WYW\$
MA_\ ='CTRW?:=O\ 35?1<>%G^X/C/S8_5IHS[WYW\$A_]T>/3+=]IV_TU7T7
M'A9_N#XS\V/U::,^]^=_!(?_ '1X],MWVG;_ $U7T7'A9_N#XS\V/U::,^]^
M=_!(?_='CTRW?:=O]-5]%QX6?[@^,_-C]6FC/O?G?P2'_P!T>/3+=]IV_P!-
M5]%QX6?[@^,_-C]6FC/O?G?P2'_W1X],MWVG;_35?1<>%G^X/C/S8_5IHS[W
MYW\$A_\ ='CTRW?:=O\ 35?1<>%G^X/C/S9!_P!7RIC%B;U)OWR12L[6+,IO
MK UJG"(2EQ$"!$L);2-D'6M71X_$?20(HR</&23A)DX:XT>[-\N&WIK_ *84
MWP?POSA)B]JICP@2G"T'DI0LMJ6(O*E?*XA02H@J!];OL=I\)5MOV?3?;?<[
M;].F^WPC/T7=2.O;?JIUUK'K\TE2TW;UL+*C4I2X#Z %B^"DD-2+*R@A,D7T
M991V,9:8TU(NL*:M\+9VTRKE+3SFVL#:V,JP+08,E:5EH+[0(Y6T-[!92CFW
MY-_[(VWVZ[;G&<7SK*MMM]NG?W #_IFQO-=E&.,8XQCC&.,8XQCC&.,8XQCC
M&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9YV=W.DKGO%1*5<LK
MKL*H7C%\>>-$(Z^47@<K<[E'.R ^RXBDJQ5E I!5#51AA(JS4$N]\D-$7^R>
M&BF_H+L4<SPE4&-,"@A)+J=GVAL-U1GB%!I9'11*%<P];NG??*V7.S._*E74
M]_>.I_LGQ'\G7/-N@O PFX&J(R'L?N/?M=S$>YD[<K$J;G"^*T8(:RX]D.]B
MVCM$:[3;'@>1LA?).V#-VB6*OTG+=-?137'46&NH[DMU<:E@265!HH>FL#PI
M1[%OG2[MSC=M?,VG92@4(3L2-LOKD J)#:2.G50]=W#O_$>GXLN+[$;'O^=R
M_CC'YCF'Z-Q[GJ;Y ?NY3X1^";^+'V(V/?\ .Y?QQC\QQZ-Q[GJ;Y ?NX\(_
M!-_%C[$;'O\ G<OXXQ^8X]&X]SU-\@/W<>$?@F_BQ]B-CW_.Y?QQC\QQZ-Q[
MGJ;Y ?NX\(_!-_%C[$;'O^=R_CC'YCCT;CW/4WR _=QX1^";^+'V(V/?\[E_
M'&/S''HW'N>IOD!^[CPC\$W\6/L1L>_YW+^.,?F./1N/<]3?(#]W'A'X)OXL
M?8C8]_SN7\<8_,<>C<>YZF^0'[N/"/P3?Q8^Q&Q[_G<OXXQ^8X]&X]SU-\@/
MW<>$?@F_BQ]B-CW_ #N7\<8_,<>C<>YZF^0'[N/"/P3?Q8^Q&Q[_ )W+^.,?
MF./1N/<]3?(#]W'A'X)OXL?8C8]_SN7\<8_,<>C<>YZF^0'[N/"/P3?Q8^Q&
MQ[_G<OXXQ^8X]&X]SU-\@/W<>$?@F_BQ]B-CW_.Y?QQC\QQZ-Q[GJ;Y ?NX\
M(_!-_%C[$;'O^=R_CC'YCCT;CW/4WR _=QX1^";^+'V(V/?\[E_'&/S''HW'
MN>IOD!^[CPC\$W\6/L1L>_YW+^.,?F./1N/<]3?(#]W'A'X)OXL?8C8]_P [
ME_'&/S''HW'N>IOD!^[CPC\$W\6/L1L>_P"=R_CC'YCCT;CW/4WR _=QX1^"
M;^+'V(V/?\[E_'&/S''HW'N>IOD!^[CPC\$W\6/L1L>_YW+^.,?F./1N/<]3
M?(#]W'A'X)OXL?8C8]_SN7\<8_,<>C<>YZF^0'[N/"/P3?Q8^Q&Q[_G<OXXQ
M^8X]&X]SU-\@/W<>$?@F_BQ]B-CW_.Y?QQC\QQZ-Q[GJ;Y ?NX\(_!-_%C[$
M;'O^=R_CC'YCCT;CW/4WR _=QX1^";^+'V(V/?\ .Y?QQC\QQZ-Q[GJ;Y ?N
MX\(_!-_%C[$;'O\ G<OXXQ^8X]&X]SU-\@/W<>$?@F_BQ]B-CW_.Y?QQC\QQ
MZ-Q[GJ;Y ?NX\(_!-_%C[$;'O^=R_CC'YCCT;CW/4WR _=QX1^";^+'V(V/?
M\[E_'&/S''HW'N>IOD!^[CPC\$W\6/L1L>_YW+^.,?F./1N/<]3?(#]W'A'X
M)OXL?8C8]_SN7\<8_,<>C<>YZF^0'[N/"/P3?Q8^Q&Q[_G<OXXQ^8X]&X]SU
M-\@/W<>$?@F_BQ]B-CW_ #N7\<8_,<>C<>YZF^0'[N/"/P3?Q8^Q&Q[_ )W+
M^.,?F./1N/<]3?(#]W'A'X)OXL?8C8]_SN7\<8_,<>C<>YZF^0'[N/"/P3?Q
M8^Q&Q[_G<OXXQ^8X]&X]SU-\@/W<>$?@F_BQ]B-CW_.Y?QQC\QQZ-Q[GJ;Y
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MA2&T\SB.F]8D@(([-.Y)Z ;)[AL2/'U[QTZ#O&?I#C87ZMQX)'_I8V>^A!3
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MF3FHMF7P_5TW;;:T1^6'>W]::ZN3'8CVD]AIV'&E*;4B(E^-R/.M*6&>7LW
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MFAIIV@+-;!MILGPAYMR)!1$KI[;H"(S2F6^0/.17"7'TNML]GLE#Z2A2CA8
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M?OY0"2-O84.H_P *[A_BMW#.^K/8+LR%K:G&2-'R>CJJ0A+B9/3#V261,IK
MXO8LE=&@Q91D!JO;67+XJTKZN5=']&+DR^>JM!RXYWD/:4AQ[6OJUR9BC.:G
M2R^&4H2U&98D.QF@A:.9R5_0CPI.Z WS!M*>97,F2RD+0@E7K@I6^VVP )2.
MO>KIZX=-OR[Y8\_[_=EJK=7;5\GKND9%=]5V[U1AHAW%RDX9UC(XWVI(O1X5
ML0R3W<R8%)HPY%NT'K]3UIF1;NF9=H T1T48JXT>@K)0@RFY,UN#*AVSS@=0
MP933E4D*64\NS3C3H6DI2-E)(4@N;[* -(/(H%02I*SUVY@4=_L @_X=Q.8^
M4^(3V@A5T2^JG--1:P5J',T5%+J0K"L^P,B6F)JW684X=+UM*1H<U"J\$PV/
MR1BZ%";8);%)XY$F$A#MCE9@GM4UIZL?ALRDS'8XGHGO0C*E5[88;AEQMM$I
MI2VWY*WW&B%KB)Y(X6@K"ME; T@I!YB.8**=U)&W+T (WW))!WY>[N[\GX3O
MG<3?M\]I*R81"*TKLA;,SK&OGDIC-JM75E-PPHD[B)F#7<':R2F2\GE:P_UE
M[6TB:0=_'F:C@>M)'IYG@>ZQUT,,TZ9T9]^3)3$8E2$M.Q"(I6M*7D/P5EN:
MAIH* 3):+Z7%;*[)+:N806D]GS DGE!.Q&P[M]TG96PW/4;^+IFO;7Q$;HGM
M6=HH]=$.C%22\/U2O&T(I6Z J]JMLO1W"A3S5;6(V7C+R$V5&D!SALZS9=9S
MB&R >]4:/PD779;+%1>P.G83$NK<A/.S&5VT&*])YX$N-ROK3R]M&Z/Q7"H$
M>#2F'FU *2XZ%;(77V*0I!22?7I!/K5 ;]>HZ%)^ @CX=SMDY/\ B!7M&HK;
M$CKB!U21K3IQ3G7*5W0ULN637-E6*M:M: + >-*\,)*.68I05'R6C-H<G"$C
M<RR3)K(Z:YRHJOBRWI^ Z[$:DR):9-S-LFH2HS3'@T<1)+D=)DH(25\[J25(
M8+89:V.W<,I[).Z02=UJ6$\H&PY5$=?B\7<,SM@>(7?H"1W=)XS7U3+TK0U[
M]=ZSD",B6FC2T)1'+[&UJIHL+1:._J]'S\6>SW15PN23)LR+;;5EJ)9N!BKP
MI;CZ>@.-06G9$L39\"QE-EH,*BMNP%R>BB1VCC;J8Y "2DI/KN<A02F TD\H
M)/,I*E=-MAR[[;^,@[>+K\?3;+K',9 EV)[S4@3+$S@"LK4KN?PMV6?.B#D,
M&OVMV$V,P]LLZ55V1$!)L.E1(,PTVPD-'2!NP:Z(L&S-LAJ;-EOSNHIR$(;<
ME19,=\(2$A:Z^2IA#Q  !6MA3*5J[U*;*E;J))H6!R-J\9!!_P#*K8'XMAXN
M[?-XN:/+>.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8
MXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQF C'^YD?\
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$XQG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>g67046g59a58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g59a58.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1_J4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585    !L 2 !0 "
M3 !A ', 90!R $H 90!T "  30 V #  -@ @ %4 4 !$ "  4 !# $P (  V
M       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E
M '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I
M;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
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M8VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M   .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L
M;VYG       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F
M   .             #^    X0DE-! T       0   !X.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      ,U
M!@              S    R@          0                         !
M              ,H    S                      !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG    S     !29VAT;&]N9P   R@    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M ,P     4F=H=&QO;F<   ,H     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M      EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A
M=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E
M9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO
M;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T
M;&]N9P      .$))300H       ,     C_P        .$))3001       !
M 0 X0DE-!!0       0    %.$))300,     !4F     0   *     H   !
MX   2P   !4* !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$
M;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M              $  /;6  $     TRU(4" @
M                                       18W!R=    5     S9&5S
M8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    4
M9UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0
M  "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P
M! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E12
M0P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U0
M86-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M               2<U)'0B!)14,V,3DV-BTR+C$
M                                             %A96B        #S
M40 !     1;,6%E:(                     !865H@        ;Z(  #CU
M   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D
M97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@
M                            9&5S8P         N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                             &1E<V,         +%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2
M969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                              !V:65W       3I/X %%\N !#/%  #
M[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M 0                        */     G-I9R      0U)4(&-U<G8
M   $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X
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M$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !) 2 # 1$
M A$! Q$!_\0 '@   00# 0$!              ,&!P@$!0D" 0K_Q !.$  !
M! $# 00%!@D(!PD!   " 0,$!08 !Q$2"!,4(14Q0974(E%456'3"18R-39T
M=;.U%R,D0F)QH? 8,U*!@L'A0T566)&2L='6\?_$ !T! 0 !!0$! 0
M       ! @,$!08'" G_Q !#$0 " 0,!!00'!@4"!@$%   ! @, !!$A!1(Q
M05$&$V%Q(E*!H:+1\ <4,I&QTB-"8L'A<K(5)#."DO$()31#4Y/_V@ , P$
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M9>8D=2*U)D.ARBB)"O3RA"BCPOK@@#=P2,MCB<'0G!&<<N>?9S<]==#T&OL
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MG4D=8FP?/^*Y]Q_+@[L=6U\?\:?6-3JZ*S<&IEFC5@T[5N$J(AF22(BJOSR
M0":%/:3S38)[3UARV=Q%DLF\@_G3)&.I! 8#QQI4%#C*X/'0Y!TXZ8/+AUI]
M@8. +C9"XV8H0&!(0$))R)"0JHD))YHJ*J*GFFL6J*])ZT]FE#P/.N>FZW;M
ML]G9V]4C*-C;6QQ'97.,/PBSO<6SRINKF^F996TF:O/U>*.45>\#N*[16DO=
M#*:\[5V3$JJPJRO])SI31@^OKWU']]1H1IX_F.E9*_A"-L'=QPPB.&,P*B#4
M;EYAD>6Y5N108XW&V]VPS_.-O[C+\4H/!65MG+<B9MAN+<A75 L%%I,8*9)F
M"MA&!%35N-KMVL+WBIKF\PE[(%C8[DLW$+V%E&'Y7@UW4Y'70:RQFUDZ@S*G
MH[IAUB'<5[RNE!\.XDA!:><('4">OA\P.OC]<HR=,C&?'S/3P^N<D-?G6@_;
M4;]Q)U;?BG^L?HU32]C^D.0_KL;^'1-%_')YK_M%*2U72C2E5RR*R/-<MDN&
M75BV%V+U=3Q4Y5BURJ'UQ[B^D)U=+P43ZO4-.R0HD:QCWE@7B#<JGX?SY]KO
M:Z5IQV6L)2D,:QR[7=&(,LC 2P69QC$<:;DTPR0[R1HP&XP;T/L?L=5C.U+A
M=YG++:*P'H*"5>8<]YSE5.FZH8C1AB@/:=[:.1]G;<C+,;>PBFLL'I=DL>R^
M!F$JRGLNQ]U\SN]U8N%X=?0V6O#Q<8R:OVFO*^%>-R&Y3>8S<?QX6)#F0Q"8
M\PV/L"+:MM!(+F2.>3:$T#0*BL/N-M%9M<7$3$@M-"U[$SQE67N5DD+((VWN
MHO-H/:S.AC4QK;JZR%B#W[F01QD< C=TPW]2'*KCT@:<<#MW8=>75_C^-;4;
MQ7MA$W%E[6X=(3'JFDH-Q<NJ<MS'$,@A8[E61WE/C40:63@6373_ *;M:YZ7
M01(\BO8DV<GT0U9;L[/%''+->V$2FT6\G4S/++:P206\\+2PPQ/*W>K=0Q@Q
MHP64L'W8U[PU#:<;%E2"=F$IAC]$*DLBO*C!9'*H-WNG)WB"5 *@DXIMWO;D
ML<3=RFQR_:/)J.HQ//-QL/:IH$W$,DR7,FL*QK%[J,]626<TJ:/&[)^5DT6*
M]#M7[*!)Z@!NWAM@]-;N1]GEF[A8+Z*22XMK2X,CB>*&V^\2S1X=3;O),F["
MY#($;.Z2N3BJ&VDRF0O RK'++'A61WDW$C92,,%4GO1E3O#@<C3+=R_\(GCU
M;FNT6!5-#38SE.6[BY+@^XF,;F97CU5D>,/4F5YSMK6UN*PZ&YMH>9W63Y[A
MD]VKD4L^?61,;KR]+I"NLBQZ"[>@[+S26]]<O*TL,%I#<6LUG#+)%-WD-O=.
M\QDC1H(XK>= P=5=I6.X'CBE<4OM51)!$J*DCRO',DKH&0J\D2K&$=A([RQL
M!NL5"CTB"R [NL[1'; LJ2JMV>S>TK4_':V[Y.ON(\J2$Z;<%8I%JG[_ ,1#
MMZ5F'24L#%KB3!+*Y.2-9@N1XMB]+<,L6GV7L1)&B.UR")GC!#(54*J;K,XB
M(='+22/+&#W*Q=R(99GCS4MW?LH;[IQ0, 01G4Y &=X,#NJ%8 -O;^\J@A;Z
M>E"PB[9S9E'&JMY(L+.X8HJM/TJJC3.0DV!* V.*&8RY$H5,WL<&UAD,EYJJ
M2-V7V6=KI-D;6BV'=RD[+VK*(X0[$I:7\AQ%(FGHI<$"&8+N@N\<AQNMO:;M
M5L=;RT:^A3%W:IO,% WI;=<ET/$$QCTTP3H"@XC%G^47S145%\T5/4J+ZE3U
M^2IZM?4->7#@*-*4PMQ9I1Z-F*!*)64UJ,7'DJLM Y*='YU$T8[LTX7D3453
MS\[]M&)+B%#PW]XYX812^O@=W!SI@]:J3\6N-!IXGR\.G^14*?WK\Z\ZZG_
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M5:KG4\.0TU\?(_Y&.<2_\U5555Y555>255]:J2JJJJ\JJJJJJKYZZ%55%"J
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MC^4#)Q@EB/2)\2<D^=7\5YU>I2;KS4=IQ]]UMEEH"<=>=,6VFFP15(W'#40
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MCC@\=?[8Y=1?Q2V[_P#"M7_ZR?O]:;=?UV_(_MJW6QIJC"L>LBN:;'*F!:E
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MDF<3:RM,+"36XO L5EF,4D)9CD)7R:@C,E1^O[%]GKG;^U49+9[BRV<8[R]
M!W71)%[NWS@[QG<>DB9D[A970%E4''EGL%FMK2_V@FS8[Z1K<73,@[K^&[EL
MN0J9*B)9'_AI+)&9"%R:AW9;M:;I5N2V#N1RXVY&QV,X _97^28]A3=26(9
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M8(^75W)/1J>,)ISY$XRZ"+PJ@7FFJ6VE=,, QIXJFOYLS#\EIWAZ8/7.=/+
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M\@1Y;H^?#E[^%/S&=HL/Q20DZNQR=(M>."N+6':VMJ2\^?\ 39X2'Q1?]D#
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%1I2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>g67046g64a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g64a10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[27X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )=R^EI(X0DE-! 0      %4< 5H  QLE1QP"   "'_T< E  "')R,3<V
M,S8R' (% #1-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52 #A"24T$)0      $.\+$"4P4C%CESQ32(#XY<PX
M0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0
M<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT
M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P
M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q 9,9_          IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M        /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      '/   $&          !                          $
M    !!@   '/                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   '/     %)G:'1L;VYG   $&     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !SP    !2
M9VAT;&]N9P  !!@    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     4X0DE-! P     &V@    !    H    $<   '@  "%(
M&TP &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="
M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M     0  ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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M<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MG;7[&7F%IPZ@V>?;,*;3XR,=R]B=&;'*0@$QKOS]XE:F<QL-MK=]+HUD>56
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M2KS%.!]-[[DKIKFR,$K"6">F=WQR)HVW/"VTA95BW4443]XIB[02,!O[#T#
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M\6[M*C5K24*-.K5FVE&%.$JDFWV2BG)OP6&S7KSKTYP1N&OZ- U+D?QUXW;
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MBK7M3J6.F6]E6L[^PK6]O<U*=[=UI5Y3EK%W!.%.K!QYJ,I/EVDLY-J/AE$
M\@ 0 /,  !_#FR:3ZGG1U,F3NB'3Z.OD AY^H#Y=.G7Z/IQCY^'N^ -26V>
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M^<, =0^? -5_"?\ S[NUG_EBXV?\.\)@&U# & , 8 P!@# & , 8 P!@# &
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M+*QSGKT[OL[YHOWN]UZ 'A+'ZB/0>GS]!Z>8#FEY9XRX27QBU\GE%)4@.4P
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M)>0/[P^Z_P"239/YF3>")='\'^1'WLSO]';P:_V3M!?[L:U@DF_@# & , 8
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MLE-(S4UJW:6X(R?JSV.ET(S8^P9J_P!.?-%':$8]14BWY0<L)!-N\%=E),W
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M*-)LY)OK>D5YBR@WU>J]68$F0DGKXSA(#TB8 P!@&J_A/_GW=K/_ "Q<;/\
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M2J.+E QZ,M.5)"Q0ZUGA8EP!!;RDM IO#2L='+%43,D^>-$6RA3D,14P& 1
M^]2N],O\6:<HMMK-TA"NW# TQ4YZ*L445\S/X;QD,A#NWC0';13]K=-A6!9
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M\EN?ECIZ0A=!/8\-3:6Y,7:EZ@A3537[U(D,C4H0&L/(M.\A[!*.Q;(A.M4
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M]RQN#D4R]0'S#IY>0]/+]>@^7Q !]0ZY(.2E O7IZCZC\_3ZN@?$?A@'; &
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M?[L:U@DF_@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P"C07W&X^^]@_."4P"LX P""_:4:N4W7PCY!:K;V?7%/=7.
MG(QJ%BV]9WE0UK&G:SD3*F6N,XQ0<.20AD6"J;YB5%1*51,:+<^&U>+JD U:
M=BH_UPCN;D#5J1 ]FH21KM%J*,_9^SYIFS&C=VN:;?D+%72]VB$:4V;02,F+
MIG$UV9D7[9V99P[3(CT, 'HSP!@# -5_"?\ S[NUG_EBXV?\.\)@&U# & ,
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M_G:]J<DDI2;:VP&\]VTME\/=X9)7J))JIG253(JFH0R:B:A2G(H0Q1*8ARF
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M#6SPTT\-X?4NUJ-:WJSHUZ52C5IX4Z=6$J<X-I-*49).+:::32RFGT)0@8!
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M=YX\,N0MR+KS1?)W2VV;R>+?S9:G0[[!6.>-$1@H!(201T<[5<BS9"Z;@Y7
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M7XUG#P<)#QK=-I'Q41$QZ+=A&QS%JDDW9L6:"+9L@F1)%(B92E "M8 P!@#
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M2>H402M%)4HB7^6WGZ?$])I?0.OKT_7_ +?#TP0<X P!@# & , 8 P!@# &
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MFB+B.EHMV@^CWR *'2%9HZ;G.DND"J:B?B)F,43$, #Y8!6\ 8 P!@# & ,
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M;FWT6R*- *59%B>!F@J;=805*X<5%XHHX,X,J4@&]3 & , 8 P!@# & , 8
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MTK'^RLXI]+L4W1VR<3)RM?;SD2>Q143(/I* +(,S3+1B#E'O@2-P!@# & ,
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M&F8QX0%&LA&2+-15J\9N$Q Z+A!0Z2A?,AA#J. 7!WBA_K!^,/Q?7YAY?2&
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MI$OT$G<>]37:N"%42,& 7)@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M_/L;T, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>g67046g76j62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g76j62.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:64&AO=&]S:&]P(#,N,  X0DE-! 0
M    %GJ^5U0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!Q@PY0
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  $D   %8P         !                          $
M!6,   $D                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   $D     %)G:'1L;VYG   %8P    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !)     !29VAT
M;&]N9P  !6,    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     #$X    !    H    "(   '@   _P   ##(
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MV*8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MK.WS]\\6(W:,F;1N11=TZ<KJ)H-VZ"9UEE3D33(8Y@ >J9E52S$*J@EF)
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M$Y(.).3>+',(B95T]=+KJ&$1$3'$1'6ZQQI%&D2 *D:*B*- %0!5 Z@ !5J
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M%4G](>0355\L(^<F8N:[3&,BH!<@[IK'O':LVZN[#=8N8L<!RA/*KT#=E#D
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M4+#//(]D[G)B6A8]LX)%-HZM^8C4)"5G,Q[K=I7<\R6;VTUK:Q,9$Y4 &YD
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MM7Y3VCS_ /S;K7^_>JJ3XR3Y[?:-),]I5^@IMF^5*X_DFUUU/</^-WWT>/\
MB&G[7QG^:/;50'6D5.KHL=*[ZGEM-^2F._&4GK%]O_+.T?I#?96JR?XU^T>P
M4P#5/35&BBC1159O>SBT<5;A[M'MD/+P=L<!>X "APGY*R+.'#UND' %(DQG
M$I9@BGSPFW;(C\0@(]OLN<7%G$2<O$.2?IR@ 4GM3=/:3V5#E7=<]!U'G]QS
M7B;0LG&Q1N"Q]8EW'@0\G*$J=B,8Y2(^XEE,2-76<&$P%\"->+,9<PF'@!CR
MF]./1>TH.^+.9 ,LJ\HF..]'X6!UL,K^]I7D;;K@\Q.#V'^LU6FW8.[V^W/[
MAW>3T0;9#7S5DT]R:D455;M+!\V,P61:,E5R)J*1S5<#-XTXD(!H]-L8A2D$
MH!W.SA"-GV0MR3"+6#DB>)3DEW2W0Q&K#IS71IC=7'#=&.S QZJ;?[/?MY+D
M[=S8<TS$>+FN[?*6XD8]=1,AVY<@7P'=;K:9P4*8#F;UY*Z2:1D^%&SUE'K=
MQ1$G=SO=E>\ALZ.U4X>\EPPY^1AP[ZYTRYB&N<@L*9N7W4W1Q8X/3@<?3H*N
MTZRZJ^L(R9]#?(/]2+7^(7^G8/CX?VL?VUKU>([1[:Y;VM[JWID/3,V%1G4$
MR[>\82N3'^+D:;C=>^)S$?5F]L5?JHV:NUX(P[)S.P!&Z9B3IW7F@<K& S8J
M7@""HJ$H]N[7;8]O#.L"SF6;DBK2&,*-QWWLA7SXN,8''.::EEY( [N]DXXX
M^XT[#WL[3_MO;+^!F+_VD:Y?X<R__CH_\RW_ (:8[[_[?^O_ -:/>SM/^V]L
MOX&8O_:1H^',O_XZ/_,M_P"&COO_ +?^O_UIB?3GZ4$'T]\@9!OD5FR5RDK?
M:<SJ*L9(41G4TXQ-I--ID'R;IM:9\SHZAFP-Q;F00*4IQ4\4PAV#2[:[H7VS
M##$UJMOR,AD#+*9-[*E<$&-,<<YR>RFI9N5 &[NX.?&SS8Z!3=-<[3%<YOJA
M_5!]VORQ6'_4:ZVG8'R-L[Z,GM-6D7Q2?-%1%QGC.\YCOE8QCC2ON+5>[E(A
M$UFO-7+!FXE9 45G/EDG,F[8L$3B@W64[W3M!( 3$!.!A* V,\\5K#)<3N(X
M8EWI'(8A5R!G"AF.I' $TLD*"2< <36=9XVS9[VQ6-A5,]8MM.,YJ69G?PZ<
M^U1/'S3-$Y$W"\).1KA]!S!&BBB23X(R1=&8JJI).RHJ*$*9JSO[._1I+.XC
MG53AMPD,A.H#HP5USS;RC.#C.#7BLKC*D$=7W\X\]:58D9*/6B<BNY:QYW2!
M'[IDT2?O&S,RI =+M&*[R.1>.44!.H@U6D&*3A4I45'C8AQ6)*;>"G= +8.Z
M"2H)Y@2 2 3Q.#CH-*JZ_P!*WI<[,J)6<=;MJA?WFYRR3D:E.T2X3T,RKU7I
M4@ F;N_<Z@I/)E>-O%>D$WD4_<6*;E7D')M%#1S.)?H>9-EVW]O[3F>;9TL(
ML41MV6)&9Y)1Q&],0H:)QAE"(H93X18:5 FFD)*8W -",ZD=NFA',!KSYI]^
MN1J-2H>MU]30W#?YQBC\\E!UT'<O\N6?]]_ DIZW^.3][[+50%UL%65.%Z=G
M21GNH%BFYY1BLW1&,4*?D)S03PTA1GEH5?*MJW7K",F1ZVLL(1NF<E@(U!J9
MNJ8#-CJ^.)503)S6VNZ-=CW,5N;4SF2 3;PE$>Z#)(F[@QOGQ"<Y''A3,LPB
M(!4G(SQQSXZ*GVY]FAO16ZQFF[.IJN@2.+=)QB>8;H*+ 413(LX3N[I1!(Q^
MT#JD;.#)E$3%14$ (-..[F/(SLYP,ZD7"DXZ@8@"?.*:[[7R#Z1[J0ENOVIY
M;V:YBF<+9BCH]"PQ[-G,1,S!NEWU9MM;DA7)'6.N/W+5BZ<QKE9J[9J$>,63
MYE(,GK!ZT0<M5"!U^SMHVVT[9;JV+;A)5D< 21NN-Y' ) (!!!!*D$$$@U)1
MU=0RYP?2.D8Z?/YZ^O:!NGR+L[SM3,T8\DWB P\BU:V^NI+G)&7:E.'*/S05
M68:]Y4'*#]D4YV"JY3'BI=%A+LS)/&*"I?-I;/AVE9RVLR@[RDQ/CPHI0#N2
M*>8@Z$?E*64Z,:'0.I4\#ZCS$=8KI-5*SP]VJM9N=><@\@+=7X:SP;POH#J'
MGXUM*QCD  1#A=D[05#@1]#?&.L1DC:*1XG&'C=HW'0R,58>8@BJH@@D'B"0
M>T:500ZR.X-3<!OWR^LR>'=57$KM'"E4()Q,DDE05'+2U+)"!SI'3>WUS:W;
M==("E78J,A$3"4#CKW<S9]Y[(MLC$ER#=2?WNL8/6(1&".9LU90+NQKTGPCY
M^'JP*6+%23J&DXZ79>!YR*?LY)IYELW>MO-,7";IOYAF[36:NT/%2)XK9RBJ
MW73[DEDSIG,4;YE#*RG.&!4X)!P1@X(((/0001Q!S3M-7#K@=2LH 4N>XT"@
M   !B;$(   '   !1^   ]  /0 USWP5V'^AM_F;K_S4QWM%T'_$:7QG?.^3
M=RF3I_,689MI9,A6=&(1G9QI!05=+(E@XAE!1BBT;7(Z+BP70BHYDS,NFS(L
MN1NF9<ZBG)QN;2T@L8$MK9"D,98HA=Y-W?8NV&D9FP68G!.!G32G54(H5= ,
MXY^))]IKQ\/9-G\+Y7QOENK*F2L.-KM6;M$\'$A%G=<EVDH5FOQ^_:OBMC,G
MB1N4UVJZR*A3)J&**KJ!+JVGMI/$GBDB;3. ZE<CK4G(Z" :](# J>!!![#7
M2\;25>SSA)*5@7*;JJYCQ<#V)=&,!DU8._U7Q6:B@I@?XV4J3Q2E QBF[B]O
M<'&L-*O:715QB2VGPP_7ADP1S<ZU5:JVO%6]8-<PV8B9& EI2"EVJC&6A9%]
M$R;)8 !5G(QSE5F]:J@ B *-W**J1P 1 #$$.=;NK*ZJZG*NH93TJP!!\X-6
MU.PZ &7XO&^^LM/FWR;)IFG&%JH46*Q@316M,>]AKK"H&4-\$JCII69B/:$,
M("X?/6S=,1553(?E^["V:?9/*HN3:SQS-CB(V5HG/F+H3T $\!D1[E<QY\D@
M^8Z?>#YJO+ZRFJ^C111HHHT45I+<O]+AN ^1+*WY"3VI5C^.V?TJW_BI2D\=
M?G+[17,4UNU6U&BBI\]/W?\ Y2V%98);:L9>RXWLJK-EE'&+EV=&,M,0BIP6
M1C3'$R,3;X=,ZRD'-E2-QWK1S]-S&/'* T^V=CP;7M^3?$<\8)MYP-8V/Y+:
M9:)M-]/WE(8 TW+$LBX.A'BMT?R/.*OZ[?-P>*MT&*:SF3#EE0LM-LS;N(;X
M",K!RJ)$_=.M66-!156'L4,LH"$E'+'. <I.VBSN-=LGKG(;RSN+"XDMKF,Q
MRQG]UUUW9$; #(P&58=8(# @5K*R,588(]?6.D5NK46DT:**-%%+#GNK?M"Q
M]N.R9MES)9I;$-RQU8&,&G9K5&+N:!9/=&$AYMLX;62&*_&!,1&7!)V%H91$
M>@9L<Y958#E*%ZG<[M*:R@O[6-;F*9&8I&P$R;KLA!C;&_JNG)EB<^*.-/"!
MR@=0&!&< ZCCS'CPYB3U4P2B9-QOE*'1L.-+_2\@P*Y0,C,TJSPMHC% $.0X
M>PCUZW[OLE%0#%'D#  @(:IY8)H&W)XI87'Y,L;1MZ& --%671@0>@@CVUG&
MFJ\JN+[1K8\)$V]XLK$V%??9[6R0TDJ(DBHT-;8.BIQ$P2YOW7A]SU"K2;SW
M!8BU<BDUD9HC%TU*NK"N#(=KW%)=&]N'3?%H("LW'DWEWDY(#\DR*-\Y&2JY
M!P&&9=J&WF.N[C7HWLC'G SYNVJ<.M+J;5Z_H$0<I$=/&LOI!-1-M9LIY.G(
M43]P I%HRC.O'43 P^B8RT!*%#M "B8AC  B(B.3]U[JVVI .*6\"-\XJ7^R
MZU7W/QO[H^^EO>TP_P )]H?] YE_&&.-77<-XFT?G6WLFIVTX/VK[#57'7?5
M+KI8[&?I+-I/]FS"/YMZWK#]K?*FT?IUU_'>JJ3XR3Y[?:-),]I5^@IMF^5*
MX_DFUUU'</\ C=]]'C_B&G[7QG^:/;50'6D5.KH2='[(=/OG3VVZ-JO.Q\H^
MI=2<TRUQK=VW5D:_8H*<E$'4?+,TU#KL%5VYFLFQ*Y(F9U%/V#Y(!1<IF''.
MZ2&2';-Z9$*B642QL00KHZJ0RDZ-@Y5B.#*PXBJV<$2MGGP1V8%,TU14S1HH
MHT44KCJA8N"=QQ5,J,&XF?T66-"3*B9?A'KME.D1!5<P (F(PG$&:2 "(%(,
MPY-\9O2]V%<;D[VY/@S+O+\]-=.U"V>G=%,3KE0W0<'L/\_;2, $0$#%'@0$
M!#CT$HAZ@(#]SCGD!^/@1]==74:H+]6&BD4RGBW<;&H&"-W&XSCGUG< 02I?
M/>QB#:A9&2] \,%Y)HSJ5O<  @<ZMK.J<GPP.I;=SDQ[WN+%CX5C<,L8)U-M
M/F:$]. 3)&.;$>.8U?6DG*0C75=#]W9KD#J&:LW]#+;T.$-BM2M4K'^3M>?)
ME_EF4.JF<KD:Z^31B*&@8R@%$6BU8C6U@:%*'A@-B74()O%$YN&[J[WOO:TL
M:G,=HHMUUR-]?"E(Z^48H?F#JIBX;>D(YE&//Q)^[S4X_7-4Q6$9,^AOD'^I
M%K_$+_3L'Q\/[6/[:UZO$=H]M<M[6]U;T_?V=F]5.J;RL@P-CG8V%D;Y@R;@
MZFE)O&[,)R<876DSBL+'&<*)^:E#Q$?)2*#%'O75:1KY4A!*W/QQ_=I#))LV
M!T1F6&[5I"H)W5:*5 S8X+O%5).F6 SJ*C70)C!&N&&>H$'7IQ[QGFJ[#K+Z
M@4:**-%%&BBN<WU0_J@^[7Y8K#_J-=;3L#Y&V=]&3VFK2+XI/FBO6Z47U1/:
MA\IA/Q!.:3W0_(NT/V'^]*\G^*?L'M%7?-^VS.E;XMO=FQ%8P:1EI;%4L.+[
MFJAXCBFWQDV6+&/C'(4RYX63*<\/96*8&%W#/%SH%)(M8YRVRO9&TY=E7D=S
M'EHSX$\6=)8B?"'1O+XT9YF SX)8&!'(8W##AP8=(]_..NN=?DG'5RQ'?;=C
M+(4&[K=UHT](5NRPKTH LQE(U<R"Y2G+RFX;+=I7#)X@91L^9K(/&JJK==)0
MVT03Q7,,<\+AXI45T8<ZL,C3B#S$'4'((!%68((!!R",@]5-\Z,O477VC9?3
MP]DZ<,EMWS#--6\FL^5'R6-[X[!O'1=Y2.<P$9PT@1-K#W/CM3"/3CII0P>X
M1DW/-]T^Q1M&V[Z@3-[;(2H .9X1EFBP.+J26BY\[R?EY#$\6^N\/&4>E>..
MWG'G'/5Z0IBG*4Y#%.0Y0,0Y1 Q3%, "4Q3 (@8I@$! 0$0$! 0'C6457TJ/
MK=?4T-PW^<8H_/)0==!W+_+EG_??P)*>M_CD_>^RU4!=;!5E5SCV;KZ4C-G]
MHR3_ #9XXUF/=M\I6OT%?X]Q_7FJ#=>.OS?O-6'CG(F0RBARD(0HF.<Y@*0A
M2AR8QC&$ *4 ]1$1  #U$=<;QX5%JD;U_P#<+BC->Z*A53&$[$VUQAR@O:M=
MK/!.FTC$C99:?<2QZPUDVAU6T@K6FQ2>Z1VRZR#*5E'T4H*;^/?HIZEW'V5S
M:V,TEPC1"YF62*-P5;<5-WE"IP5$A/@Y )50WBL#5A;*50DC&\<@=6!@^?\
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M'5ITK=G*YB *O;&H\E%,IS$Y'NTM.5L(+M1EK6?=8]$4XW3G^]6(#MJ/=+E
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MPP'2#GT@CV5$97V:K"0J'%'<QE1-(3"*9%:A4EE"DY^"4ZI'"!5# 'QF*BF
MCZ@0OQ:L?AQ=\]C;_62_SI??9\@>D^ZOS][4X6^V;RA]YE4_3-'PXN_T&W^L
MD]U'?9\@>D^ZCWM3A;[9O*'WF53],T?#B[_0;?ZR3W4=]GR!Z3[J<GL6V<5S
M8S@X<(5>YS=\C!N5@N(SL_',(M_YF?0BT%67E8Y15OX#<L6F9-3N\0XJG[@
M"EUS.U=I/M6[[[DB2)N32/<0EEPF]@Y;7)WJ8DDY1M[&- ,9SPS4R=5M-U'O
M.&V#$.X!!$][@E4YUF@+:.ML"X+&61DAR8Q6XN_!<-G[1,YS'2:2K-\W0.=0
M[=-%10YS3+6^N+0_@G\$G+1L-Y">G&00>M2#2&17XC7I''^NW2M X;V 5?"6
M38')56R9;7+B#5?E")D8V',WD(^28N8]W'OG#8K<QRG0<B<JJ:!/#<)(KD3
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M+O\ 0;?ZR3W4=]GR!Z3[JWSBWV>;9%2G[62OD_F'+ZB D,K#V&TQM8K3DY3
M8WBM:5"PEA AN +X9;3V]@F*;OY 2P[CNRVK*"L2VUL#P:.-GD Z,RNZ>?D_
M=26NI#P"KU@9/KT]5.EQEBO'&&:=%X_Q32:WC^EPI!)'5RK1;:*C43G OC.5
M$VY"G=OG)B@H\D'AUWSU7E9VX65$3CS,]Q/=2M-<2O-*_C/(Q9CT#)X <P&
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MNY9"N51RO;<AN<@UF,K+ME8X*&B$(Y",E1E2.FRD8NLHLJJH/A&(J!2%('<
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M<5U8I%\FR%,TBX7% $ROW(&*D)04[RB<!$A>(MS>3W90SN&,88+A57 ;&?%
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M4_./L%,YU24]2M]J9BFWN[O!*8# #R9*(@(" &+<4BF+R'H E,!BF#GD#%,
M\"'&KV_^2]G=@_ATRGQLE,WF/^B93^CGO_IE=4:\1VCVT]2WNEG] VZ_*E)?
MZ*K4P_WX^OZZNMO?C<?[!?MR4S!XA^<?8*DGO0^E>S'];_BPC^.8O4+9OX_;
M?M/]K4N3Q&[*A5/*ODNE3&BR,H'?$1"3PR8F P,5,OD(N B7U\,XBFFK]8R9
MSE-R4P@-FF/[?;/YQL=O('%-GXCS#[0J=.T=*+2VT86+#^'Y0U%B55O#X[?=
M1<%%IOD2^GB>[2C_ ,7GX7B]_=\+G55M L;ZZWN/+.!GR0<)_IW<=5.)C<7'
MDCTGCZZD7J'2ZP#*.-:QEZB6#'MO;J+PEA:%06.W,5-XQ=(*IN6$DP6.10J3
MV/>(HNFYCD42,9/PETE6ZBJ1WH)Y+>5)HSAT.1G@01@J1S@@D'MTUKQ@&!!X
M'^O52U&>#]\NV-,6F%+K$99QY'*JK,:?*@T(Y19F6%PJB6$G'#8[+N,90QT*
MO: 4<'.HHDV!97PPNC=;+OCFZB>WF88,J9()X9WE!SVO&<#B>>F=V5/%.\O0
M?9@_<16\\ ;W&V1+J3$.6Z1(8HRN)S-&T<^(\2BIB12;BX48D0DT&\G!R+A(
MBBS!@_\ .(/$P(FVE5W2S9NO%N]F&&+OFWE6XMN)92"R@G )W<JP!T9@00=2
MH&<*27)W6!5NOG..O49Y@?34]]5-.T:**-%%&BBC111HHHT44:**-%%&BBC1
M11HHHT44:**-%%&BBC111HHHT44:**-%%&BBC111HHHT44:**-%%&BBC112L
MLO\ U3# ?]16_P#E_P 4R;_N/_9_E"]MOD2\_:_?!3+?')\T^QJ:;JBIZE<4
MOZJ!DWY/$_R5HWW/^_U^QZ>FKN3Y"@^DM]J:F5^.?YH]BTT?5)3U*XEP_P"=
M&K0__;M3ZW_T-/<\#]ST_P"_5ZOR%)]('/\ ]R/^L>>F#\>.S[C7C[VYY'&N
MZ?;'E>Q-'P4V#331D9%HV4<>&,=85W$F5,I0X5<M&$JW>E:E,"SE,#$1 3 /
M"MF*9["^MT(,KZJI.,[R +J= "5(SS<]$APZ,> XFI5EWT;4S%*;Y[L:7N*!
MNT]>N0&+R #VF#YG1X,'/ ASZ#R&H']E;0_1F_QQ?\Z7RL?E>IO=6Y*'EG'N
M8:O-6+&]D;VB&CW+Z%>/F[*38D0E$8YL^5:&2E6+!<QR-7[-83II'1$%BE!0
M3E.4L:6WFMI%2=#&Y <*2I)4L0#X)(XJ1YJ4K!AE3D9QP(U\]0-Z6?T*\G?*
M4/Y.1''^CC5KMW\8@^CC[;TW!XA^<?8*^/=K0[)MYR="[P,0M3$0-((1^7:Z
MV$Z+"5;OU$6YI%ZDB42 QG^Q-G*K&(/E)\D3.$(J^7<+IJV?*EY ^S;@ZX+6
MSG4J1D[HSKE>*C.JEET  KR0%&$B]C#MTSY^!Z\&MZ[D-P5>_8>V#*--D@5;
MY%KC6NU=0#D(Z3?VTQHJ2:*@4Q_ E(-@$X=VB4QCH/(I=,# )/$")96;G:*6
M\@P89"TG1B/P@1TJYW<'G# \*6[CDRPYQ@>?3TC7SBL>VQ;2</(X(QNZO^,*
MC8[?-U]&QS$G.PJ#R1$UA55F&+-91P05"#'1CQDP%'T*0[<_IR(B*[[:%R;N
M<13RQQJY151R%\#P20 <>$06SUUXB*$7*@DC)) )UUY^@:5YVZ_:9B+YP>0I
M3'F,ZI6;;6HHMHCI&!AT&3X[:!73?S#/Q&Y/$43=0J4@0$1 2F7! P@ D P*
MV?M"X%W"LT\LD;MR;*[EAEQA3@G3#E=1KC/821%W#A5! SD#'#CPZL]6:Q*:
MR*.3^FG+V)TN+B494-A6)PQC^(N,K5;+%0:J[D0X'QY!NR:RI^>!$KXAAX[M
M+6'D-MJ@T4S[Z\W@R*6 '4,E>O'17A;>A)Y]W![1H?3QJ26R?Z5K#O\ 5]_^
M44SJ%M+\?N?VG^U:7'XB]E2FU!I=*PZE1W$'*;:KXNQ=N*_4+U,KS+ELGW^"
MH=W399JUY,)4RN'K6!E!:E4.0JAVQP[@X$0OMB8=;Z$$!Y85" GCI*I/3@%U
MSCIIB;0QMC16.?4<>?!J2[??9M4<-T5QRRQ;BLD144'%=N!%T>\H"*:Q"5]0
MI5""/:<"G.4# ( 8P<",$[*V@"?_ (['K#QX^W2^5C\KU-[JW'C#-F+<SH3*
M^,[8UM:$ HR0F3-X^78@R4DB.CLR*%EXY@97S!&;D0\ JI2@D(*"03$ T>>U
MGMBHGC,9<$KDJ<@8SXI/#(X]-*5E;.Z<XX\1[:6%B:_(;&]P.5L;96:2$7C/
M(DL%AJ-K08NWC!L@B[D%(IZ5)LDHJX:*QTC[DSODDG+F.E(QJ06XM146"\N(
MCM6SMY[<JT\*E)8R0&)P-X G SD;R X!5C@@Z%E3R3L&\5M01ZO4<' XCHJ:
M%QWV;::K7GTRQR$QMK]%LHI'UVN-I%U*2;KL$4&@&59(M8\%#]I57$@NW30)
MW'$#G*"1JR/95](X4P-&"=7? 51SGCD]B@D]FM.&5 ,YSU#GK373XH-M5+EC
M<%>(Y:+E<U6(\G#-7*2B"JD2K)2<X_E44U@!7W/E9.6*E'&4*45F\6#I,#MG
M+=523M>:/-O:1,&6UCW6(X;^%4#33*JNNIP6(T(-)B!\)B,;QR.G&ISV'/JI
MBTQ_T3*?T<]_],KJF7B.T>VGJ6]TL_7!MV'[.4I+XQY_^%:F'Q_]GW/\GV;K
M;WXW'^P7[<E,P>(?G'V"I)[T/I7LQ_U81_',7]CUU"V;^/VW[3_:U+D\1NRM
M?[9:/$9*V.TJA3H&]R;92K-#.E$P 5FWF[)8"H/6X'Y+YEBY!%XV$W( N@F)
MN0 =.WTK0[4EE3QHYD<9X'"IH>HC0]1->( 8P#P*X]-10P9G>R[*)B0V^[B8
M672I;:4?/:/>(QFX?L46;QR95PLT3 H'DZV^64&0X8"K*PD@X=M'D>J9P)&-
MA=6D>TU%Y9.IE*@31,0&R!@9Z' PNO@L "#TMJQB.X_#7!_KF/'I!XC72>/[
M,W:^#,KX<R58$3%[P3[987@!P \'CPC1?$/Z_O#-@/R AV\E'BJ_LV^SCO:3
M/#@,?XLX\^<4[RB>4*]RR[E<:0&%R9[9.)6SX[4?H,DGT'&JIOUTU+0>I.7:
M$=,C$KBBRE47 J@MX"BK= RK<JH'2!1"64[W/>A"QS8)W788SN<H 67>&2O1
MG70XUQZ77=W^*]0Z\<#CGK%8;>WM>FF!9!++,)'@).]1G,LYF*D$1^NF=H\C
MDU%#E^OY85R#\93F#UTXVS+]3@VSGK4JP]*L0//BO.40_E#UCVBH)WN]5W==
MO/P<.&6CV3B<:O8R4M%Y2C'4>DXCH2?3L#E;Q'"*+M..9)MACHI>12;"ZEI5
M5NV1%-5)5>UBB>PV9==\D*TX*QPE@2&92@TSC>.<L%SA5!)&#AHD22+NCQ3J
M>D Y]'0>D]E.7US=2*-%%&BBC111HHHT44:**-%%&BBC111HHHT44:**-%%&
MBBC111HHHT44:**-%%&BBC111HHHT44:**-%%&BBC111HHK$'M H\E:XV]2%
M2KSVYP[<&D5:7,4S6GHYJ4KLH-V<F=(SMNB!7[TH)I*E* .EPXX5/RX)95C:
M(2.(V.6C#$(QTU*YP3H.(YAT5Y@9S@9' XU]-9?INO:Q%"@TAK;7=];5.OH7
M9^U!D]M:44S)/NF@(MVX-G$H5('BJ (-&J/AG5$OAMT2<=J90!PRR&,1&1S&
M#D1[QW =3D+G&<DZXYS7F!G.!GIP,^GC67:;KVL1/0:0I;DK\I4Z^>[(-19(
MVPT4S-8$F@MU&@MDY44A>$0%JLJW\,JH%\)0Z?':80%SE9.3,7*/R1.3'O'<
M)SG)7.,Y UQG2O,#.<#/3C7TUZ-BJ]:MT:I#6NOPEFB%3E44C)^+8R[ ZI $
M$U1:2"#A#Q4^XWAJ>'WD$1$A@$=)1WC;>C=D;AO(Q5L=&5(-! .A (Z",UJW
M]C3M[_F5QE]YL%^A:?[\N_TF?ZU_?7FXGDK_ (1[JV%4J%2J'&.H:E52 JD2
M]=J/WD; 1;.+9.7JS=!JJZ7;,TDDE'"C9LW0.J<HG,D@DF(B4A0!J2625@TD
MCR,  &=BQ !) !))P"2<=)->@ < !V#'LHJ%"I- 9NX^CU2 J3%^Z\\]:5Z*
M9Q3=T\\(B'FET6:21%5_!232\4X"?L(4O/!0#1)++*0TLCR$# +L6(&<X!).
M!DDT  < !V#'LKVYB&B;#%OX.=C6,Q#RC95G)1<DV1>,'S18O:JW=-5R'171
M4#T,10ABCZ#QR :0K,C!E)5E(*LI(((X$$:@BO>/&L#5PMB->LM:6OC:E+5%
ME*'FV=:4KL8>#:RZB*R"DDWC#-Q:)/3HN%TS.")%5$BZP";]T/W.]\W <R":
M42%=TOOMO%<YW2V<D9 TSS5YNKC&Z,<<8&,].*V4BBDW22003(B@@F1%%%(I
M2)I))E B::9"@!2$(0H%(4H 4I0    #3/'C7M?PZ:MGS9PR>().FCM!9JZ;
M.$RJH.&SA,R2Z"R1P$BB2R1S)J)G 2G(8Q3 ("(:]!(((."""".((U!\U%8.
MPQ5C2+JLE1HZAU1C3)A<[J5JS6#CT8&1<J>5\1=Y&$0*T<*G\BS[CJ)&,/E4
M!$>4R\.&>9I%E:60R*,+(78NHUT#$Y'$\#SFO-U0, #!XC P?-640-?@ZM$,
M:_6XF/@H.,2,C'Q,4T18Q[)(ZJBYTVK1N1-%$AEE5%3%3(4!4.<PAR81%#NS
ML7=BS-J68DL3PR2=37H &@&!T"O7TFBO+F8.%L<:YA[#$1D[$/"@1W%S#!K)
MQSHA3 8I7#)ZDNV6*4P 8H*)& # !@X$ '2E9D8,C,C#@RDJP["""/-00#H1
MD=!K4H[:=O8B(CA7&/(B(CQ3(( Y'U] !D  'W   #ZP:?[\N_TF?ZU_?2=Q
M/)7_  CW5G--QQ0,>)OTJ)3:U4$Y4[=223KL.QB"OSM"K%:G=E9(H@N9N5PN
M"(J=PI@LH!>.\W+4DTLV.5D>3=SN[[,V,XSC).,X&<= KT #@ .P >ROKMU&
MIM_BQA;O5H&UQ7>*A&,_%LY1!%40[?';E=I*BV< 7X(+MQ26 O( < $0T1RR
MPMO12/&W2C%21QP<$9'4=*" 1@@$==:JA=J^W2O2"4I%8<HJ+Y!0%4%G,,E(
ME15*/<51)"2%VW34(;@R9R)%,F8"F()1*40?:^O'4JUS,5(P1OD9'0<8)'3G
MC7@1!P4>C/MK?Q2E(4I"%*0A2@4I2@!2E*4."E*4.  H        !P'IJ)2J
M_P .0BI#IJ%*=-0IB'(8 ,4Y#@)3%, ^@E,41 0'T$!$!T45BU0HE,H$>XB:
M/5H&I1CMX:0<L*]%M(IHX?'11;G=K(,TDDU'!D&Z")E3%$XIHID$>TA0!R26
M24AI9'D8# +L6(&2< DG3))QUUX !P '8,>RO5G8"$M$0^@+'%1\Y"2:0(2,
M3*-47L>]1!0BH).FK@AT5DP5334 BA#%[R%-QR :2K,C!D8JRG(9200>D$:@
MUZ0#H1D=!K^8"O054AV-?K41'0,'&IJ)1\1$M$6,>R3564<*$;-&Y$T42'76
M56,5,A0,HH<X_",(B.[2,7=F=FXLQ)8Z8U)U.@ H  T P.@5\=IIU3O$6>$N
M5:@[3$*&[S1T_%LY5H"G:)0631>HK%27* B!%T@(LGSR0Y1]=>I))$V]&[QM
MY2,5..C((R.D<#7A .A (Z",UI5':'MG;K>.GA>D&4[N_A:..X1[N1'_ !=P
MNJAQZC\'PNW[GH&I)VA?'3OJ;S.1ZQ@TGDT\D>BMX1-6K,# H5:$KT)$5EJ@
MLV;U^.BV3.%10<*JN'*1(QN@FS*1RX77<."^#PNNLLLMWJJG,:,TCNY=G9G)
M!+LQ+$@8'A$YT  &N@&*4  ,  #H T]%:<E]JFW&<>GD9'#5#,[5,)U3LX5&
M,34.(@(F4;1@LVQS&$.3B9$1./(FYY'F0M_>H-U;F;',"Y..PG)'II)1#Q4>
MBMHTW'U&QY'GBJ+4:[4H]0Q3KMH")91A7*A $"*NSM44U7BQ2B)2K.CJJ@7X
E('[> TQ)++,V]+(\C=+L6(ZADZ#J%*  X #L 'LK,--U[7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>g67046g80a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g80a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2A>4&AO=&]S:&]P(#,N,  X0DE-! 0
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M!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M    ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 =
M!U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&
MEN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M 2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F
M)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
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M!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
MYC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M      #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F
M<      #A"24T#[0      $ #%(,4  0 " ,4@Q0 !  (X0DE-!"8
MX             /X   #A"24T$#0      !    '@X0DE-!!D       0
M >.$))30/S       )           ! #A"24TG$       "@ !
M(X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M    $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _
M@      '   /____________________________\#Z     #___________
M__________________ ^@     _____________________________P/H
M   /____________________________\#Z   .$))300(       0     0
M   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M            )-   $VP         !                          $
M          !-L   )-                      $
M      $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M   %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M  0G1O;6QO;F<   )-     %)G:'1L;VYG   $VP    9S;&EC97-6;$QS
M   4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M    =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<F
MEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7
M!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M!4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "30
M    !29VAT;&]N9P  !-L    #=7)L5$585     $       !N=6QL5$585
M    $       !-<V=E5$585     $       9A;'1486=415A4     0
M  #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M  "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'
M0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F87
M5L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M  3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;V
MYG       X0DE-!"@       P    "/_         X0DE-!!$       $! #
MA"24T$%       !     0X0DE-! P     '<H    !    H    $P   '@
M".@   ':X &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G
M1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M           0  ]M8  0    #3+4A0("
M                                   !%C<')T   !4    #-D97-C
M !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%
ME:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (
MAV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M   "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8V
MMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M           !)S4D="($E%0S8Q.38V+3(N,0
M                                          6%E:(        /-1
M$    !%LQ865H@                     %A96B        !OH@  ./4
M.06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V
M,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R
M!H='1P.B\O=W=W+FEE8RYC:
M                        !D97-C         "Y)14,@-C$Y-C8M,BXQ($
M1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14
M,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                          9&5S8P         L4F5F97)E;F-E(%9I97
M=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F
M5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                           '9I97<      !.D_@ 47RX $,\4  /MS
M $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                       H\    "<VEG(     !#4E0@8W5R=@
M0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &
M@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0
M#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6
M !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"#
M(4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ N
ML"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #[
M/Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P!/X%#04<!2
ML%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&C
M:=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#
M((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)^P
MH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP"\@+X0OY#!
M(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-^ X3#BX.20
MYD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A$'X0FQ"Y$-
M<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q
M.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#%B86219L%H
M\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 911EK&9$9MQ
MG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC',P<]1T>'4
M<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@;""8(,0@\"
M$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-)'PDJR3:)0
MDE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."
MEK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,+4$M=BVK+>
M$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS
M+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]
M<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](C
MUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N0C!"<D*U0O
M=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UT
MD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\ 3T
ME/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE
M8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-
M9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV
M1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z
M=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77
M.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\
M)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'8
M2 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3
M&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-)
M:?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY GJZ?'9^+G_
MJ@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:
MH<JH^K JMUJ^FL7*S0K42MN*XMKJ&O%J^+L "P=;#JL6"QUK)+LL*S.+.NM"
M6TG+43M8JV ;9YMO"W:+?@N%FXT;E*N<*Z.[JP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MMB8H15B7\41C96?A&2<Y1V2#A:1&5V)F:(2&B*.EI__$ !P! 0 !!0$!
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M6@W!H.7?OXHB30J(VCSN86&'KS-L^KE#<,:\Y_9U*OY R&ID.$=VUY0:1ZM
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M'E7DD6\4WOAD9& /#H1<HBQ:IP<W)6"$<2$>]1'3R-W++;9F&?R//Y6E,M9
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M13 51)0IDEDQ$%$52'24*4Y#%!$^CN"J)0Y&GYRXY /TO6;?&80  ^8/RB(
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M]I$[ ;@:B8 $*?G(0$.0$-O6;1[!^I0])3[?(?WC8GW\D!4?]3\Y?[O6;O\
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M\>"^QY)XLM>M_!A!ZP;1[CN=Z*(%#-)S<, >I&F#Y0SKMY_KMHFM3/R?E/\
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M\+,/GX^XK_@M(AX68?/Q]Q7_  6D0\+,/GX^XK_@M(B2C+, G9#Y<;@T5#E
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M7;]D>46D2N5) S1\\:F=F5%N[<)"18_SQEM2V7E-CA%H;(O:E:P16*FM8UA
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M.\G/T8D?<HG\5Z1#O)S]&)'W*)_%>D1)28N1G'X>%Y .C%0XB/5Q7)N7D[P
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MDE9M\1&-E#M5(1M)HL5EV*9=0N1796_)4%I7%OL;?%,6RZFVPD#P-644D.0
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MSB_UR+W5?QRS?T7 _P K7-0]*?PS?^;I_AB6V:YS-=FI?\4)?IA\&?P,O/\
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MVB US"VX]YJP!QT&%7<8M9=P^$X\$$G#TB_KB_9#[^K)=.6D1)CO9D_Z61^
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M<@"I/6<^!I^#+-G5\LGG&;Y)!_/IJ)NS&\*H"(HQ\@X)VP<-P *-VJR8B'E
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M\3TE_K=(^KJ<WWT*]G4?IQ?JO]OY/]9[GXGE=I-J1N> Y')Q/;<9"'4,GCH
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M(\AT0.!>EVB7G@>*>[9]V]&_ZG5?KP(]-?C].^;67]6+-E'PHW^<R'\DR_\
M<-<,FBS76^*%':3G&VVT"$<E$MZOXCU[)XT#@8&!#@IG2"(''D.T""(@' B
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M9UK/=@86'U E5R+TQQ90[Y"E5IKR;<>W'N5'(V>V]VPG(,JEF3U22#QY >N
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MHYOUU3J'HD/_  E?TBX_OU]ORR];N)[(JVP2@*=\O$Q-=LG\E1<G3('1N#\
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M#;D9 1\>[OW.H6BI6*^1J4L J+9436$=:^W752>Z>+ W6JI>Q.TRV5!PW-&
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M%N>:'$Y.Q+8W-QHLZO)MXFP-*W:H]!XM#23J'DB$:S,)'2"?>LDR=-3"NT2
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MM#]US\;O_*\/_%=/"]+OPN?T:C_KEOD=*->_)[Y7(#S*HCV1,J80 (2'+\D
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M+<:NRS!--(6R[#S]U4\'I0]FM\9F4W,K%PU;25BAK!THL8+78%#)M:E056<
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MSAX.3_9,A_*#O\+I&A^7]I_G#P<G^R9#^4'?X72-#\O[3_.)"4<09U^ .GX
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MGH_FMCMT/I>7TUP<@YKY6=;F'):SM&IE[MEI5D(M+L'!<V#ELC<H 1[=^UM
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MK*O?RB1!78>@Y?H[BC*'7^D9/5.X:O>IQ\VW$[ 46"U7%=E?,V%JR&))' @
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MP!2U^R5N()7N)74+D-6]\KTO +4J#> &4KL(X9&+E2X-8%@-?@$UM99VF6P
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M!"_+TD2!VP# ^0:C8V=RLN0$KS0\24W*FUW&#$U]?60](+2,LPM2O5<90KK
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M/4T$22&TO$.0<04>WM<JSR%IR'><D3=^M%B1M1K@:5=R,+7(%FHK*#CG%J:
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M?/:7P IML;Q8I8NR5<F=!Z[.1QW?9OFH2M3JH*L!&G'MV*^('%M!4;0 )]5
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MGJ\$5 0*U9K\4^JEBR+*UF5BZ_!+FC8*.E(EXSAT"-_!R+8[5N9-$F-I$^&
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M3KA*IY@S-:LEVZ"GK.ZO<=BB;I5H2KV.,CPJT(2NQ,+4[FZH$/3FI[.[6>A
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MOT7-^^8/2(L:1#2(:1#2(:1#2(:1$6?]KC_NR(^%F>D1:TB5L=U7H<7.[/\
M*%\3D+W"W7'</'.J;.43)>2<>OXUS-W*I1LFHJ2@6JN(S(K,!.W2+-(R169%
M5S,BMCKK'.B>%IF6L#[4MZ^9,+7?.,)C&EK;<]KKO%50S'FZ4>*2EAG,F;HQ
MMSFKN<J7"4FIN7?.%:VTE5F[YZ[[W3KL:H<C)G$MD$2"^UVFY4;2'<]I/(Y;
M;2:5N9JN0JM<;_4]Y6XZ[6G+CZ;VV9 ND7#WNDVUQ5X'$CR1\!2%YBKGC.=E
M[53[K5H6M5IZQC;"_F$:?^_R?J^KQ^7Z(EF'<YZ"BSHU\S?&6K+TI3,[VM68
MQ+5<H9JR_F-.LX;JCF2@,?3C!UEVZW23BYO)[$'62; #!TR1(SL=>KRK4PUE
M-PO6)8SI$18'V([]-3_PT_TB,)N\H%>R#MXRFTL"EG0&MTBYW*!=U*[W>@S#
M&RP%.L"D.]3FJ#8*W,KIM5ESJ^#'#Y:+=+%14=,EU&Z!DT2K3!^2<4[6+/W.
M^4R9FY?&=)RWL-R%>KQ+9OSM:W<#<,ORK;:(\"2=R>6+I)M3V'O5U9G,;'-'
M")(]!Y/JQC)LF\DQ5?-^_P#8?]=1(_9.=Y9DYS=GN3ISE\_H%)WN8F3A<]5K
M=MF]A8Z+BAZ&VIS,N*)@*.(A@J]TP*_:9EX>/F[2UA;'%6":<OV#U-)-J_1'
MKV'9@R1;]Z,VA8<H*6EC;B[TQL5);YQN60;M6PH^XV!B,7$SK@&><K4/; YJ
M-,4>4^@H8Q(G\<&/<F?6H?"1# 9$OVTB>:DOFDK'UJ=]ZM=(GI!\0_4'2)0U
MFC#%8HV5>Z=355G,Q1KG$NPK&V5,8D^/_GI]%5/(]^B=\+:WV2&A9#([N%%_
M()4NG"FW58+LHA:"BG$0TCW"1%#(GJLXYKIVZ#'NR2D;=,JT#/4Z[S'4HC)]
M4I^YNUT!J[(?;%FZP%C,C9 PDM8KO D/.5D9INS=1S@DQ.P*+=VF )K.&Z)"
M.XY.R=C6CWNLW_)-SJBV,+MOE@H+#T;N[RA6EJ5E"M5;;G:L&/:CGNTR<'=,
M\TRH05NF)YKBBWKKVF:E\L.(RJX7R%7*(B,$B;*.'7ETD<28ND,D("UR(_QW
M27M]:F11;&;71U6HQ:TMS-VZ:3= R,X=^F**"2:*0EZ"29"%*4$1QC>(?J#]
MS2(@U3YEJUZ A_@YMI$J<[H_+0K;+&(&=GRACB @VN,\GRJ6*LWYWRIM1QQD
M"5&:I2);+4<^8X>ILDLO49D@X;PM1L<-.JI0UI>6.#&#59OY32(V4#C:B9LR
M9W-.]2OY)*,8YZV]7RV9"@[OG_,T+:9Q[2L18A-2GF08ZC7.GU$UK9]\N7LU
M(U^KUMG9)=](3#^*!=^LD5$COCV];DVN=XW+-)N64KP3!3/?E=+AA0UDFY>)
MS#B^,[HMDJB6*L,X&1=+M'=[I6-DFLSA@42)/$I*FPM!8N6=<L+]$J)YG%.8
MJ[DK&U5EMQ^5 1AGFTG%.0=JS+,VYO*VV"BY%E[7E?-".9[@IDFJ./5+/Y<J
ML!'XU:14.ZB[+:*3&#6EJW%P1;M-RRB)>SLGR-(Y:VF;><ARR=G2D[/BBHO'
MX763/,W!5XWC4F#AS:956M4Q:1L+M5H9U,/%ZG6W#A^LNHXA8Y83M$D21!OF
MD0]"O??L=I$7-(FM+AUAG*&L6$\VRC:?B:S:.Z590QQ8,PL]UN>;1;Y:IR6Y
M/,-#KU!L.W&SI,<-(T>==M*WC\ZC*=E5ZO ^#[3 0YYMBT1;(B;C'(,3:<<4
M='=;E99BDQV98CMFW*-S!N>R;MOH>0;[+9'S)'9WLKS*%.?'G[3E2I1,7BM"
M*9+L;78*E&O(I[68QF-MF9)-$E/:-QV:KYW,]*WL<?94J3)_M[Q]/-,WS&4(
M-[<1MC:]52NO:[+(L65(R0K:G#5)ZXE[([HM8;O5!>$>M&SMR= R)>('' <>
M+@/N:1$.P^Q&7IVN_#C#2(NZ1#2(:1#2(:1.JW:@W6?*@<3"^=$="40XZL2,
M6;+H /(](!!H"G(\=IQ+QP7D43M>/5" ?!B8Q23'QE_G'ZOG\_B\WD\8ZK]O
MK\'YQY/B(=4G^M_G-]_5-#YA$^E3(4>0+P/;V\B/C[/*/FTU]O;]<3GJL3JM
MVH-UGRH'$POG1'0E$..K$C%FRZ #R/2 0: IR/':<2\<%Y%$[6D3@*9!$1$.
M1'GGM'R_Q_2[/-Y-4(!]OV]O\X]D^=4G^M\WE'R>+RZ:'S#['?UQ]OV^W]L^
M=2D \] .1$!$>1[1 . Y[>WL[.W0 #V1,H!P' >(.P-5B=5NU!NL^5 XF%\Z
M(Z$HAQU8D8LV70 >1Z0"#0%.1X[3B7C@O(HG:TB8Q2(/')?%XNT?OZIH#]_R
MGY?J_P!/DB'4I\\] .>SMY'R>+RZ:'V^WZ_I\^V)\!!(!Y @ //2$>1[1
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MKDQ7B<B4SADV6,6023(DD_**B1A!ZDDFFFF[ >O(1,A"* 4A0!$4@  #@.P
MTB?1#D!#SAQI$ZK%FC',F;!OTNH8M6[-#ICTC]2V2(BETC<!TC= A>3<=H\C
MI$ZLI"0TVDFA,Q,=+((KIND49-DV?(I.4AY2<)I.DU2$63$.4U2E Y!]:8-(
MG<%HV,=)0R"0J(%.5%02%%1(J@%!0J1Q#I)@H!" <"" ' I0-R !I$X)1[%
MXJ(LVR*@@J45$D$TSB5=8SE<.F0I3<+.#&<*ASPHN8RI^5!$VD3J+P$&Z1:-
MW,/%N$&"A%F*"[!JLBR63[2*M$E$C$;*$'UIT2D,'D'2(I)I)(E B29$R!SP
M0A0*4.1Y'@H< '(]H\!VB(CXQ'2)B%HD+PCT>EUY&ZK4!Y^1ZI55)4W)?UW2
M1)P//BY#CMTB=G2)T_![#JRH]Y->J(X!T1+J$NK*Z!<7(.2DZ/1!P#@1< L
M=8"WRWI=/Y+2)UG$%"NTFJ#N(C'2#)4J[)%RQ;+I-%B>L5:IJI&(W5)XRJ)%
M(8H]H" ]ND3N&9-#HBV.U;G;CSRW.D0R \GZP>4C%%,>5/DQY+VG^2'M[=(G
M9TB=5VT2>$336Z712<M'9>B/1'KF3E)VB(CP/)051+TB_JB\AR'CTB=K2)__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>g67046g81b11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g81b11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2SV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    +-J^$4@CA"24T$!       6AP!6@ #&R5'' (   (MQ!P"4  (<G(R.3
M0Q-C4< @4 .4UI8W)O<V]F="!7;W)D("T@4U1/4DT@+2!&54Q,($)54TE.15
M-3(%-%0U1)3TX@4DE$15(N9&]C>#A"24T$)0      $(A!OL\&>X]Q V,V?.
M6&H8$X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0
M    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W
M!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M    ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 =
M!U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&
MEN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M 2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F
M)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
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M!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
MYC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M      #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F
M<      #A"24T#[0      $ #<     0 " -P    !  (X0DE-!"8
MX             /X   #A"24T$#0      !    '@X0DE-!!D       0
M >.$))30/S       )           ! #A"24TG$       "@ !
M(X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M    $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _
M@      '   /____________________________\#Z     #___________
M__________________ ^@     _____________________________P/H
M   /____________________________\#Z   .$))300(       0     0
M   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M            'F   "/P         !                          $
M           C\   'F                      $
M      $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M   %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M  0G1O;6QO;F<   'F     %)G:'1L;VYG   "/P    9S;&EC97-6;$QS
M   4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M    =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<F
MEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7
M!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M!4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !Y@
M    !29VAT;&]N9P   C\    #=7)L5$585     $       !N=6QL5$585
M    $       !-<V=E5$585     $       9A;'1486=415A4     0
M  #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M  "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'
M0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F87
M5L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M  3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;V
MYG       X0DE-!"@       P    "/_         X0DE-!!$       $! #
MA"24T$%       !     4X0DE-! P     (F(    !    H    (<   '@
M#](   (D8 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP
M"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,#
MP,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0
MP,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !
M$( (< H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #
M$"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P
M($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M
M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)
M7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#!
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M>=LC0G2&G9M9M_KJ?3\_)Q>H5Y=1W6:AT-W;PYI8[P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^% %FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( -0 ^P,!$0 "$0$#$0'_Q  ?   ! P4! 0$            &!0<(  ,$
M"0L" 0K_Q !7$  " P ! P(#! ,,!0@'! L" P$$!08'$1( $P@4(0D5(C$C
M05$*%A@R-E6!DI6QTM07)&%WM3-"4G%SD<+P&24F-7*ALB<H9=$T4UAB8X.%
MHZ7A\?_$ !T!   ' 0$!               #! 4&!P@" 0G_Q !!$0 " @(!
M! $# @4"! 8!  L! @,$!1$2  83(3$4(D$'414C,F%Q@<$D0I'P"!8S4J&Q
MT1<E&#1#8N'Q9(+5_]H # ,!  (1 Q$ /P#]^,^/8B+O,^<C'XB[=_+M$?2?
MI']'H=#K6GRS[8;[,?@W*.1\+Y;\:?1+ Y3Q+<U>,\EP[^UJC>QM_#O.S-?*
MN@&:8!;H7Z[ZM@!,X!JC'RF(B9ZXMZ.CH_!_UU_W_P!?CH?_ (W_ *?]GI!_
M]-=]E/\ _MT="/US_P"^]C\H_.?_ '7^4?M]#@WSQ.OWT?\ O_7H=?/_ $U_
MV4WU[?'3T'GM_P#CFO\ ]7\V?M^G?\O]OKWQO_[3_P# ^?\ )'_?Q[Z\V/W'
M5Y?VT_V5S36I?QQ]"38R1@!^_->)+RGL,Q)9D#/>>T=^_;O,1W^L=U$%"[:F
MBKP5W>6<ZA4E$\A)T"K.RJ5)]!MZWZZ\9U4%B?0]G6SZUO>AL_\ 3KU8^VE^
MROJ--%GXX^A"FK.5F'W]JLD3&9@A[KS3&9B8^O:9C]GH7*-JA/)5MQ>*>(ZD
MC\D4A4[(T3$\B[]?'+8_('7B2)(H=&!4C8/QZ_N#IA_J!UDG]LO]EZNBO59\
M:G1=66XX6G19H[X46LGOV!=HL>$&?>)_ +)+Z3]/I/I1)A<Q#03*2XO(18V0
MJ([\E.PE-RQ*J$L-&(F+,I"A6)/K7H@]<B>$R&(2QF4#9C#J7 ]>RN]@>Q[(
MUOU\@])__IKOLI_K_P#?IZ#?3]?W[K__ #_]5_GW_5_^?IN"LPV 3_W^WST9
ML?N/^O7J?MJ_LJ8F8_AS]!YF(\NT;NM,^/\ TOIF_E^V?U>O3')O01CH$GB"
MQ 'R=*#Z'Y/K77G-?W^"!^?DG0'Q\D_]^NO,?;6_943WB/CHZ#_3_P#'-?\
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M%1^^P-?GI2N?;$_9D9]?YJ[\9W1BK6@4D5ANEN"A?S$S"8<Z,F5H)O:?;!Q
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M:T&_HV"D6>V<B)^,F,277[%[ON368*N OV):;(MI8DC9:[2(7C65Q)P1G4;
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M\5'>/_:WHG])[]_WU\Q[S]/V3T[F(^O?_;/IP_\ V>^]1LB_VV"?_P#,R?\
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M8=2K1QV>O8&M#>NV,SF;9&=N9$UZU:&6S.BK]/(\KB3C'SFDGF,0DD94"C;
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M=9<I=PE6=HXZOU;RQK*$>>22*@)FED2-$>26Q'"T<0&Y)$WHEDUTE)*1I,X
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M*FO7(+(W/]-^QHLC>RF6NS)#V[BI(%L"[,]*>[CK8^KB>RD'FA(-01.\+RJ
M\BQE@PWU4WZUY;N:'MLTNT[#07I )\J]%T_BR8R,,;$6+>3CX+<ZQ3I!: =T
M9-I'(.824_4[CO2'J'R7J"&/PW%XI;RMK9I5L[C8HKY#@I5P)A<?OYQ$J,QE
MJ;2_98$0D$N5(L-:R;=&"QWZ<]YID<=BL.T%C$(:@L1A,;)(L_D+/6L4;+"5
M9'#^4R)R 8 J4) @?9>9R.'QO;D4UK+W8;>/K67O92:S-D@V0O3>&+)P3N0D
M\%5JJF<R/S+QZ)'+J-]?X/\ GVFS'H\9Y%5+<1GC<#C')5"[&<+TPRQ6JBP"
M2@#2;#(+"AA2%&UUE%R*M=L3ROZ0]PX^IB&[?RTV4L4D,<N(S J6<(HX%9TB
M6=@%28OPBA-9V< 2M/%+&F[(R/ZJ8O$P27+F(R5BCYIHI,ACHTDDCAKR,HM2
M 2*\BN5 01\WD9CQC,222+&CKCP?D_3GE[^.<S^5J<SPOE\ZW.&X;V/:17KC
M\I9H["C*;+ZJB&C;$O)BV5Q&7&0% TSWW'?KW*C9F&3%=S5:]:">M'$R5[-.
M.-OH+]:V)7D:1(.%659R90T*CDS(P$T[.[FQ/=V#K9K"^=L9?5IHH[L1K7$Y
M.RL)ZCDF-9>/EA)]-&P8 ;]2'^&OJAQW"V>/:O4>:VFX99FT]1P4WSF+)<QF
MELV9M5[E24VH%BH<H4N"0*7,*)@;O_3?O&LV-Q[]TVXK>0L$XV/),*,ZU*;'
M56OEIWF2>DTA!CC,E<1RAT;RR'9#'WWA+N1QEFEB8]K++$;%9B0L\;NBV.,;
MHT<RA"SE"3R9>)4@GJ2W5+H1C=3>3*Y37=B4U;M6?D*_',NO5EE9(+BN-QQ%
M"K:B0I#YO0^;S6FX[=BQ+!E*_*?HQA^X<M9RZ9=J]"Z#/'#1K02!I)3MRMF)
MQ%)"'VZ<(PX'V-(VB>JN[3OV.V,7/CJ63?)U,;8E#R9&ZUB99#R9PJ*$6H?J
M&FKQPA166)$\$,?'1'^&],][ISSVIP[-NW:5)^!K??.CBW"$KMM3A3\A<K,U
M$T(R+BZ:W6W(<FPNN=HO*5,]N7+M3L.;M?/8V'%Y'(6\,U62WD)9IY:P>U"'
MCA3Z0*8I(9)/YBD*90%D#2&/0;BUW#C>Z<+'W \4=I(<S2%2KE(C%'&16:>#
M)5F^D-B2S#--*E)90R/-&L9\;+OJS]J'QCX<>):?24.C^C;T>7;O$W;7.59^
MX.KQ7,NR.;5KKSR<RRSYLKZ=HF2N]97\H%-9S-@3F*>_6*V),K&;]>TDTPR+
MU%$[&N&BNI!'8\,C%(W2*.6*01(@D<*2"VCT;_X<\IWGE:7<$O<$UN7%5[5:
M&C_%*#4LA%==))<A!KA%Y($W$Y+Q@B250#Z<"$F!LZ7/.HO#>9:%A%;(RAQN
M%HT-L6ZP*O4<9ORMA^?6<EYRZPN;$2D@4#)$B*3&9E3A+]SNWO3MSNPI%#BL
M<]'MN"QDP+A?)Q8NQ+%-+3AEBTUBSRE#HZQJY4LQ?9ZON>%*6/N58T9I9C-:
M9(2(F*R2@LJNRD#2D*.6R -#UZ!/T3X+5ZE]9N,JYZ>MR+BE3EE+(O-QJC[;
M]BO&NB;&73!L^8>YG,<=-3(6OR(((O,B\V;'=O2]TYS-Y/NS*W+&+Q$MG'5L
MG5@>6">S#.37I1*ZO)% RS%HXS'HF0 RER08YWYFI>WNS<_>Q\L-"]'B;-BM
M+8>-4K3^ ^&9]Z4@3E0VOZCZ/$'8V#<9Z01T1^U%^"3B.3PS<X[A/^)7X>KF
M=NZM$,_]]F+8ZI<:MYFH-9::YHM"NP56\FU5JM$ZXK)!Q7&PU)^H=_%P5\7B
M,+B;&, QM>MDK4L5:!,B*FQ7D4U_O:7;R"V\BIR?QQE6$ ;J/?HMWF>].UX;
MMZ_4GS%::2#(48@RR4IE8^/:2%R8[%<16(65W1DEY!]DJO37Z"?ROZZ_[T>1
M_P#$+'JGA\M_G_8=7-U)J/R_I+^^?7O0ZL%/X)_[;M__ '(]#H=<MK[1?J4=
MCX@OB&I8''-.AFI^(;J%E[S0L.'9LZBN;\@J5;6/>L+"T=.]#4)93S["P);H
M1^D$9];9MSQP]L=GY;^%7EFKQ8/%SVJODH9%([56&.K'6EB\;WZENU,%:.*5
MD+3 ,-F51G[%=IP1=URYC)SR6,HMK,_33*[_ $GT,UII(H;4 D,0:M$H2)I(
M](ZOL_=]T8/@ XCN\0^-SI=2OOMS4NX_470^5:8$A-AO!^15SCP58L+BT$*6
MICI%1-!<1!%(]H@W:';^6[6_53&8ZS-;-"[#F<C'!+)Y(4FGQUEI"$2>>,3(
M5CB>Q]C2>,*20.(:_P#Q Y"O;_2+NE8@BF*YV_$'!T9%?,XYP^Y% *;=@>+/
MQ;9 Y>NOVI]2?B.PM/B7PBX?"N6<GH,Z4\.S,CJ/4H%L9%>+]33Q6L0 J;73
MLP-6E;$6*AJY$Q5!?I"&++PO95N'(_J-;RF.H2CN#)SV,++.*MAC%)7LJKL6
M#FL2\L9TQ5@1RUZ!ZREW-^I5*WBOTBI8++Y6 ]JX6I3[C@K?75%,T-VF\D:K
M&46Z/%!*JLH9#RX<@68"09_%#T+Y!UD^,?8L=0>1<,XQUUX;P/CG"N94.(;^
MEIYUO%XG5Q=.Z>/3;GZ*&TKBV?+0RW1BP(>:K01(S,,7L+NRGVQ^F=5,/2R=
M_M/*Y:]E,9-DZD$$T5F_+9KQ?52":%EEC90^HY2A^TQG1U8K?JEV+D>\OUGM
M2]Q9/"XWOW"8#'83-U\-?LVJTU+$Q4K<XIQ/6G$E>96"?SH@V@1*OH],WTFZ
MN=*>AO+.N=_,ZU\PZANYS\._)^+<4YT[A_(^+;B.HE]H#BYX!8VMO2HC0^1I
MVJO(2T*R:K#$%0DJH,.3=Q=N]P=V8[M2&QVMC<,F*[SQ^0R&)3)T<A3?"P*Q
MMSL4K5*\QG$TD<E(0.T@!+%@[*L*[2[O[6[%S/?EJIWQFNXGSWZ=97%8C.RX
M;)XB_%W';DC2C6U)>OV*ZUC4CDBR36HEB9D6-4X1-)6KUCZ#=;\#X:-#KMM[
M<<WX#KZ/&>K^DO'U=+4YCT^JIN:.#;L[N> V+UDK-3/Q['Z1NNL=O6T0,I&&
M.\K=M=W]J7.^H>TZM08K+UXKW;4)L5Z]?&9J1HX+D<568E(HPDLUE?L%5VJ5
MZ[*N]+Y;[R["[[H?IA/WU=O-G.W;<V,[RM"G9N7,UVU&CV\=/+?J@22V&F@J
MTV#,;JI=MW8Y' Y2I/Q?\[Z0=5W#RCA/7+1VJO&49W'^G71FOT@V.'\;XEQ@
M90FPBCNV-PL^;*UJ^:N6BPE6=,@14&:]:K2374?IMB>Y.W4./RW:D%:2Z\US
M-]SMW)7R=[)7],R22U5J"8(Y8I'&+;QP??(><DDK2$_K'GNS^[91E<%WS8NQ
MXQ*]#MSLI>SKF'QF&Q6HUECKWGOFN9$6+R32G'K+:VL(,<,4"1<YSJJ-0^L'
M6%MX[!FGJ9SE5.BA1,*[8+E.K,1+S)8(5$2,%XPYDSW$0_,HR?D(\8<_W)8R
M,D\ABS.26KCZT3E[LSW;.@TX81UXT) 8@22L3J./>]?1#M,,.TNU1'Q4'MS"
M\G8Z*J,95][())UH>]?W))/32VJ]RM;E=FLRL3BF1J6 -3%><3(C,&,',#':
M/*8&(_./K^<7M5[,$[1SUIZ;L>0AL1R0LJDGC]LRJQ&O^;6CHGW\]20<60%&
M#!1[9?:DC^X.AO\ U/\ ?HH9PO?S<)G(=6LG*S&V%UJ4:!+7<UWB0$U>36*)
MM6%5A\3MVU@-50^*V-EABHI#+VIF<=B)\QDH(<;4+Q15DOE4M9.8RKRCQU<A
MIG2%2);%@".%8P5\C$^,IUMPM-]/&6DEXEW";98@0>)D(]*7_P"0$ECK?'0Y
M=+VGU!C<R#';JEK\C"I6Q<>VQ":.3Q?!IQXPC,SJ8*0^];,_+YEJE_+1!M$F
MV&^XIXO=Y)D\6YRM?^)9WP+C<=)+!!5QG;V+B^TC'TZP$4MZ<'U8>.(UE13$
MS.%XE1TO!)N%_% 6::9!MI+$[GV9)6)*HOO[%)#; /%1IDG7W\_DR,A5C/KY
MFAE9Y(TM@[-^W9Y"Q?<D-L@8L\+4#XUX*#A?MBORD16,0WY3,TNXHL:EBI!C
M;^/HM#D,P]BY;GS<D*+].9D$+E)RH,:R2.45#HN$1$!L4#P-,RR-*DLG..(*
MD:U]ZY+&01M"VV.O>R?9WL?:O.M_/XM;XA1;5J95]PV+S*U"FG2M^,Q,UW:X
M)'093F8B?DRLS6B8[0N/*8DJMW=F:. L=O4Y*]2E;9C;FKP0Q7K"%P[137HU
M6Q)"QT#$[LO &/\ ],E3X].&2PMEU=I$7BG)W:-/G[Q$QX!]>N>@WSHZ]# H
MX?';6=7N6.3E7VF755Z^4K,NF"%F8 S0O:0L!:U*&2*%U$7K#)#M"XDI[ET<
M7A)J4%J7N%JV4GLQ0PXY,?:=:P:5$-RW?#QQQQ1JS2<*L5N8E0H0%B 8\LZR
M<%K<H0A9I?*OW$!M1QQ:]D^MLQ50/DZZ74CQ#BW)J];5H_OTR\G0O1I-H:EC
M.I\A5XQ%'V&%5.Q20#.S+,>!/;$FN240C/IQ9>V^W\Y!5O5?_,M7&VKG\0GJ
M7WKULMR1?HTA_DEZ\=9]FR.<CS,7C)4*-DL;%FN2CBG++&AC\D:RM"3OR<@&
M",VO2^] @$=8K]+B6G65EAAJP;-[DC+EGD8V=#0C/Q']@5EUL@($21GP96&.
M]YUNV0+#R4(E!)[%_MK(1)07$Q82:WFWMV<X)[5U*.,D9Q'2KXV- S1P*_)F
M$C3S-&NBH.D]6.S&3)YC,D=<*L'&./R3 MN5ICO3/H*!KBHV?9UUG9<<JXQ=
M^]N$ZW)5TG+>(Z^?4TLB+:J=DG+[ +3^90"ZX6S01L6N)[$)$LI]+*U;N7!R
M?Q+M*[GI*<L4CG(U<?>H16(JT\KJH1WE2U$D<:V70LZ*"R<24?KF<5K">*W%
M7+*5W%(R3<6<<2=\1HG94,!O_KT'U;)#HG<U5M;8)MBQ9%B8)DVVP;):Y1^
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M]&Y9K/!8CM0B*5U5;" !9N&^!D"C08J3Q/$[!(+NT:N&#A7##B0?8()]J?\
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M#.P.]!"Y9S2AL;%W5X_D6,4=7/BIH+T]1G)+)L?XE;;6OZ->;5<7D$0$^9V
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MBKW:WZ18[-6)LE;Q-1X*L</\*DNQ1PP/'&DYLO&K&QYWC5"BR-QD+2K&KNY
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M^EKF"*S.S04X#),(UDDW%!%SW)/X^7!&?;$C7R3TH THY/RXC18Z7>AH[V
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MU73:^A\D3X"O:OOO/(8@%VCLVABU>X,AV/VU9,.4P=-3<BEEMRFK#-<FF?\
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MB/'\$3Z@,F7K82BE' W[XR(M3KDKT1DKUK$->PQH_2 3[:%@JS,EBM$X8CY
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M@Y3I(H1Q[!KF)PI'G;;@U)YKTD]@QRU42N:T+CGXYXB[--HZ"MH@#>]@[/\
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MKXP?=69J4XCD-.M\X[/97=/R=P8(J5J\N2]F/&"^<J>80N0B&]YGM'-9\OB
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MZT3C\97R5#+9![L39"';QP29&I2LO(_&66R8KG%+L+L9H7CK63:CD"R& QN
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M06K<,T,4>YYZ4C@I65OS7,49G/C$SY$)1'U[QY=HB2\OQ#^<#,3$1'?MZR$
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M)PPAGA\_C=X7BD,BJL4Z&6)59XSH]$IIBDDHC$X20*(Y-CQNWH\=Z8$ $G1
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M<Q)%X^49CE?(3V\I1?[N2A9JY?[7"MP!($18<6ELN\7$&0MXN7P>>D5(V]@
MCB?R-:.NAIV-JLI3HSFZ$T0$F0[Y-\TP""@I\'^V:X")F.WXY@>_;O\ 7U'&
MQ.5:LU_^&7EJ -*; J6/I40^]^8QF,(H.P2W].A[WLF&9 QC$D?,^N/-.?L[
M]_!)T#[U^_OYZRK7)M/2S*F1<3G!7H3VJ%4QLFM>(?'P$77ZE!&A:F1^DC9>
M[Z_CG\41,*KF>R60H5<;92@:U4H*_AQ.,KVAQ7@JM;K5(;4H;?WB69_(VB^V
M /7BP)'+)*OD!D^YN<LC)L:)TA<QH/W*J/S\]6M7!VLO/3;MX^G24_P-5VU4
MLHK-!X^2A6;5BF?,(D@\2+S N\?3T7>PF8H4XK-W$9*E7E*LENS4L05Y1*.4
M2H\D:1[8 LI#MR!V!\==1RPR.RK+$[+L%%9'<%?ZN0!V I&MD?(]]$;Z>5;X
M]B5:%_/T^2WK,*9F5L:S2LYROJ"%-U6LKTK[WEV(E+KM@(/L5B2[Q#_-7QMO
M"8FI1N8_(=P7)TB-&MB)Z=FDA#A$ERCS5JMR:0A 4\$C L=3^@S$*\BS3&2-
MHZZ)L2F9'5R?;:B56:-1^"7&]>E^#T6<1Q]'$W;7'>8YV0HUX]FW3XYS0=L*
M5][UP]"<R,BU7<G2NP'C3L@T5D4R'XB\8A^[:Q>2QN5M=O\ <=6@A7'33T\%
MW*+[5K<\K*8EQII6(UBNS\&2*9#(SDNB!G('2:S+'/72>K)*P:95>>GXN<:@
MZ8R>964Q)L\QK8 )]?D/=E8FS:U3%U3A=NN7NU\+1C28KZ1,-JJT+8N>APSY
M>VK0F.\]PFQYQ]8VV-Q&4L9%A/6[3MPL&BPF1^N>(Z"B58\A85Y()=[98+B;
M^%$WR2J#RQK&I5K2GT9H_$#KUQ<HN@?6@2F_1!"ZV.D_B[K];719IY*-\JH.
M:W,LTYOUK-1825HFI&)9"A1!D;E^)I@?=%@S$3#?VW-=K96.>GBX<X\$4\DN
M.L5&O0SU$3_B2\0#.$5"6\J?=$!S5AKKNP$:(HTA@+$*) W!E8^D(/H;+$:!
M&B?6NDIPU[VG8FJ@<ZNUKVHKL:Q@5@[L8*(<S\3(7'Z(&,[$1>/D4EWGTAG6
M"[D+'TL4>/@EEGEKP33EXZR#E(L!GE"L_ #Q*S[9VX\B2Q/1B\TC7DYD8!>3
M#0Y>A[]#\^B=:!V?713Q_D)\.;-W)^ZM9^UA7LZ]4U,R+8Y;+3F**5 [\!7%
M"BO:K6EQV&7>)#Y+*"D&&S;=JNE[%OC\G8R>(LU+E>[2>3^'2R667@H=PKS!
M:\%B&5?L(EX.A(T4\]=;2\)?+&(9TE1HI.'DX#GIF7?V'FRNC?('K>]FN?;-
M/>VRUZV"GC5JXI9:>+47[6?6N+ %-?06P!-*;GM_,'7,9]E[' MDJ]N Y[RR
M%7*Y4Y&+%-A+MB-?XIC1'XZ\5R/2-/5W'$XCM+J9XWCY1S&0>1U8$"G"T,(B
M:9["K_Z<SG[W4[(5SK1*?TAODK[(V#TF8/*=7CZ=:G1)#:.[1+/U*%RNNU5L
M+*?-+X2SN*[M-OZ6E<7XOKLDI _%C -OPW<.0PD>1K5?!-4RU5JEZG;B%BM,
MI_\ 2G\1(XVJS$O6F4AHV)_J4E3W+6BG,3-L/$WDCD1N#*P],NP 2C@Z=3L,
MNO6P"%>O?O<:HZ.'K9OC7UZU71IB]:XL4;X>VZCI57]B<KW*Y&EZ1,5N2Z)*
M)):R%YKW<AVS2O8;+X]T@RE:ODJ"N(_-3R"\):62JS*K2H3$6BG173G%(-@,
M@*ELB6)$FC<[B+*VF)5XR-/&R[TVB-AOD,/[D$,D6V6S,#)L,B,H .\R4^4S
MXB,=_KV[_AB?U_3Z^H>PFLS$A6EFF8N0B[+NQY,55!K9)WI1K?Q\]*2 !H'0
M T!OWZU\[]_@G9_MOX'65FWV9-U-L4(<:2F85;5#D,B8F)ABC^DQ^PO+\)?]
M_I3C<A)B;T-Q(*\S0$MX;D G@?EM2LD9(.QO8(.U(V/8Z\=/(I4G0.MLIT?^
MH]:UL?D>CO7X<?6+0MQI5^.<P.[BLXZ/)-+&R@U<K+HV2BLO0SAS;S) YJE8
M$38J75VJ5Y*[ ,1$WR]:7*&\F)[@BM8V+#'N.SBL?'>I8ZE95H(K=.*C;F=%
M>+SE^<;,C(&XQHA #8E>H989[./A%J.<UX+,RP36"I)*2I,J<DYD<@"0X] G
M?KIL#>^; 6(/LQ2U+481"S6*U^*_ @\2$OK)3(SW(B*9F>\SZ@,EF=IXI_*R
M301Q1120GPE$AC$<?$Q\2K!1MF!!9RSDDL3TZ!1H@^N1VP(V-^B2=C\^MC?[
M;]#0-+N6K2P^-6LD+)FI8YV[%MCHHT]>UI7!JM6ZQ(I4B_5!+'^V4K2T3)LQ
M)^I;<QB9+!]O7,8)SP5<=EUM33_25LI;R%I:TL4T^H(H;L"QR3"$F.%]M(06
M])4<I-868J 3Y80@'-XEB5FVH]ED)*@Z][&A^3[XWQ:.4\YG%2_/Q@LZ%Y2#
M99(J"RK$XQI(L>Y/NPYBX15D3[M(U2)%,_7S#=N_^8N\FQ$4E/%QRY"XL(\Y
MEJ(]9Y&2K5L(RF82LBQ5VC=3('5E.RN^;=HUJ36-2RE8E)58R7(8;,A0 '[0
M=NNM@*VSULG;S[D#N):O',C!S=/8X?E*R<[.1L/W*]=*"=:^5*90BG:BK6>@
MEV6(E_D;"M636 +7I[ZZ2G@>Y<CCZF)AMXW'UK,N(E$^3LT<@L;--#/8D>)W
M(1T+0M BK(6=MG>\U3]E8=<Q'W)9S<^'JYJZV0N!J+4+@N3JM?B99IVNUWLS
M)*#%S\1"QB"!&^YAG[.\%Z'QU?!HQC$7 K?$IT1*TDU+ :&@WJ/AV!2"P&(
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MR?;O>6>R.#LY7%-#59HJT,N*BJFBO";BQ%622*C4G:4JMA++P*S<5<'1'2W
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M:2(#QF1@9C\0#/JRL/WGCJS81<OV_!?CP6%S&+@,4@BDM29)Y)()K7DB8?\
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M:)(8H.<$1D\*B4AAS '29Q0>0[6N[E'(N+9U&=2I:I9%;CF$M"O>RV">@-B
M8=AMV&^,W/O%,,<4*\"+M*8NK]+Z8I?Q#+Y"M(1<I+&D=&ANL4=G6(K<7D8Y
M [LTQD&U944DMQ5I=YL3@\;8HXO.W)Q1EJMDWRMV20M!E/Y50Q6FW]-"$)>
MU76.,(P<K_4)E;?--;@_3-'!^5T7VV\HX]7NX\93?DKE-R,ZS>32Y-2N8FU8
MM145N'=S:HG1SA;;KVL<FGWA5HR3/A.V*U'R7;>>L0V#C#63^(7G,TK3_:[Q
M".'C 4266PGA(B\;+-Q9&HC%=O5LOW*<YV[;CKV:.5:.3ZF1;T=E3?-<7<(U
M+(XYJHL+CC5NS64LVS&MF&Y"L;C>EKJ9@9E?FNU5P)O!F4P*Z*MH!IZ"B-:W
M6UG6="9B??:R5  1[JH"5P4=I+(?>&(B/<N7KXN&_4@J0MD):N<\-2[$SI'/
M;C"%DCE_FRN85@VKQD",%1OK;^&LVY<;5>_&L=I@J.L161"1\,LD19""-'Y]
M;WK\D/M;BCP*>.J7ND&E::YA:"YK,-I@5:O6.\VBVNU8I=-@*59\'!KDF#$3
M++9S$;8*EAX_+,4D>W))))=05Y&>1&J10M>GH30N@AF$\=.M,)"T9+C;,Z+$
M?,TI*C>E4*J'84;VQXAP0=KQYL-#?K?23<I6L]@)M :B<A%I'>/^4194+D._
M*?(&K8) 7_.[S';N,QZ:[=.S1D2*S$T3R0068@=$25[,2302J0VF61'# @Z!
M#(=,K &*RL"0W+3%#[!XLITXT?C^_P#\ZZR+*KE6I12Z?&M< M&L FN1(6,*
ML;O$3.0.3JRLH9 '(K&?'P\9DRS#=K5*<,[ 5;,;9"G&)$=2)6:O)*51F:-V
M>L8V1^+E8E)4KQ)YVK.Q^>)X-Z((( 8+L_(^\$:)79_&^L^WRCD6ABT.,W=S
M4MX&4\[6;D.N6&Y]&PT?%K*=9C)4@F 7@4K$9F.WE!>O6RN2DQT6)>[8?&03
MM:AHO(S00SNI1I$3>D)4L"%T#MB1R)/26#'T(+-B[!3K0W+846K<<4:36.
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M6Q7_ )]2:&:O))*S1L2R<653SV(+ 8QS&J D;\$25&Y^_.A5O*AC92L@9'4
MJP!7D0V%@1BQYG7%:PF!:M;#@9F/PD7U_&$R4_0/I$=^T1/TB:^G=6LL35$
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M*9DI_7_&F?+OZ99YY)Y7FF9I)I7>6:9V+O++(Q=Y'8[8LS$EB =D[^=GHP*
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M+[+GP9'< [23N<=H6,1A[N'DCCS-S(WY<M5KU;%6.G4DX/%$E:2>:!5AD#^
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M?+\HCOW[S$QZ84@FF8+#!-(Q3GQ6-W8H!]SA54GA\^R-#\D#H_DH&C\$D;)
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MT5>V;%&%) #.[20QUIR\;%HXXK#-M=.J;'4F#2EW00,%"J4D9HN+MHDJ!S+
M@ZWR0>MZ)]CK99\ OV&?VD_02[U7O<ZZ 9^9M;O T8G![.CU3Z4V,[+U\OD(
MZ*="CH<8Y]J;N7N6J_=N=:IIH5JQ/NHM7:Y,!OJX>PNY.T^UK@N7>[7FB$,^
M,-&''95HA56U(T,["6H8V@M(YM3Q)PDAD<JL3'EU1GZO]G=S]W3=KIB\9+;Q
MM#)6K.92&SC4NRP35HC'!'7R5J#'VJYG@$<T=OS(08G\3JK#J /5S]SQ_;*=
M1.I?..<M^%J+[N5\EV=IMMG6OX?@-QZ%USY:2SZI":R;!"9>4$?E,RR9.2]5
M)W5>I9+N+.7J$[STK61M35))8S&7@>5C$5C\<9C3AQ"(R(RHJJ5!&A;O:^%B
M[?[?P^%@22*'&4*U2-)G224"%%&I)(]H\@)/-E/ M_1I0!UMC^!C[&K[1"A\
M/G4KH+\4_1K>X;G:99:.)VZ74_HSR?.MY2+U73OT-#-QN=:JAN&>8C/K:MM1
MV:N===6KFM"_;]7'V/\ JK4QV!HXW/6*[RXJ9J\1N5+-DV<3/#X/I8Y*T,KA
M:P9BR3\5>(1(I<1%.L^?JC^G'><G>M#NOL+%U;LJ4Y9>5B6I&M++11SUXB5M
MY*A+]'-#.\BPU72,7 UB=)3-ZU0<G_<WGVKECFV[HXGPG4YXB_;TKN9C%UPZ
M'@T<@M!D4\[YC_23685F:$B:VDNJJ3C]+""F%16$P[;BS4UD7Z=_%"Q/9^A$
M66JM-76TR)5BD6M'X[#USYH SPP*-(TJD%#H'!)F(L'BZ^65WRL5"I#?L_\
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MR\4<D]N>&/0KU5WY"[LX?B!TBN&_&%-*)7"QNSIRC5Y''J*)&=A&@.]NQ/\
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FI?US_P 7H=#JO&/VE_7/_%Z'0Z^Q':.T?_.9G\_]L]Y]#H=?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>g67046g82c34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g82c34.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2RN4&AO=&]S:&]P(#,N,  X0DE-! 0
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M!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M    ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 =
M!U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&
MEN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M 2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F
M)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
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M!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
MYC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M      #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F
M<      #A"24T#[0      $ #<     0 " -P    !  (X0DE-!"8
MX             /X   #A"24T$#0      !    '@X0DE-!!D       0
M >.$))30/S       )           ! #A"24TG$       "@ !
M(X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M    $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _
M@      '   /____________________________\#Z     #___________
M__________________ ^@     _____________________________P/H
M   /____________________________\#Z   .$))300(       0     0
M   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M            'B   "60         !                          $
M           ED   'B                      $
M      $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M   %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M  0G1O;6QO;F<   'B     %)G:'1L;VYG   "60    9S;&EC97-6;$QS
M   4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M    =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<F
MEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7
M!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M!4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !X@
M    !29VAT;&]N9P   ED    #=7)L5$585     $       !N=6QL5$585
M    $       !-<V=E5$585     $       9A;'1486=415A4     0
M  #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M  "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'
M0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F87
M5L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M  3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;V
MYG       X0DE-!"@       P    "/_         X0DE-!!$       $! #
MA"24T$%       !     4X0DE-! P     (AH    !    H    (    '@
M#P    (?X &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP
M"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,#
MP,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0
MP,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !
M$( (  H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #
M$"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P
M($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M
M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)
M7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#!
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MC:'D_@B/\ \9WU59)=]I $#=]G> 2=0WW0N7ZMF4=0^HN?G#$HQW"QM6['
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MOTE)L1C,6JUUS0ZZT!K X_0@[O5V_1;:[^;]__ *3].(!MM:]_TFR0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( -(!!@,!$0 "$0$#$0'_Q  ?   !! (# 0$
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M*E# I_@4)'V*IDD)>28 E@>!4@#CX\1-B*<R. BN/ O%4=FT \@ VQ 'XC8
M]D;WU@:_XE_XDS#F>;/^_7[IG3[!5@57S?'OQ( $.II%%-,ZBX^G]H<KRVL(
M]XI42YK%5CW)6)>#)L,M:W@\'C,@,ME<C3QTLZPR-/#7NY%C]MCTM-R6>PD+
M1"T-E$L,Z$[7KT3$I-/)&L4<3/HLNBRQ_+E=_P K:.OZC3#YZE]_Q7_Q)^:>
M;SG/O8^X)"G0Y^?S(M@_BWXE:TYF0(U\G0Z;-1=W6)HTU9-ARVM0-->]H*9
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METV%:1:0#);[;_NSRSG/.B1;SZ"%8PU=!55LBM*M2RF<[R8Q+2&;7/>LWO$
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M"1\?F5) &]#^W7-H;1V><0X_.46000/9W6T R2]]MR2'^ 5HAY)8/Y>LR50
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M4F5[0S-FXL<./M9*U9EQV*J5H(L5EXZ=2OV_.HFW*N-R"/?AECBD.Y:4AB1
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M)<JD<M:&(2/9HM06O--DYGB4M7J-4DG2&S78S)8CDY/"%0L-8JK+?IS&9H!
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M>"G@SG]#U68@'Q#;E;:XQ1O0>:KTCMG_ &V-<BJPB 0C/7I20&<:@FE6!WL
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M -3.Y<O0SL&'S,B7;4,E.[)CCC9XS!9BKVLC!/CHE?A#;)EFR!8\7*B)@BH
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MIA>'&SX@D:V^9Y#>=TR*[^W7D5:T1VNE458"US[;[1%<60/-3EZ%F1G1QF?
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MTO\ Z_\ K?6I=R&O$#\[ZF'GL+/%E[C*-1BV4\]S80-IQ*S2\.E (YPT]?R
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M,L38J2;(RS#S$^2P:+YFL;067C+)*\ :. ")#(NG*A8/'*8&GL/Y!OS*%
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MM#%$V-J=W8Q%?$U+5JG7KW967G;DN40^X7A@,EJ.0_:P@21L.;%R6W9AQ>C
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M>U)+3RM:(S6*@QO<>2@QN5&5Q,/VZ467DL9<*TLSDO!"?+SD\$IX*O* @?B
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MS-BRT%T8_M^]"+4,RV3-#5S<RS1-CH[S1,TRU9!:C6P5W!-L@X;L231\6@1
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ML"N02PR6)]?-O>>?I]Z=W3]R5NV<?B?NHLI:H9,S&.YW/C[60MUZ=G(.\"B
M5XJ:U(H '$;B8.[\M+8J$#4ZIA>P;!4Q*R<5"0.B;8(0Q)WL'D3KB1^(()Z
M\@8$OHZV7K PVK3J@VGL*VJ)/K$]UMTCKJ]0Y ULM5U4U0V2-=<50U%0:M+3
M;R$Q_P#FS$W,ED\ <C;I-7O4Y<KCX#7JUJB**]FK+(S0*891_%CC""3BP("E
M% ?D-:9(X9_&2"CB)R'*O\JP7; $']_W _<#V^>&WBUXC>$O,]'SOAOVK.?C
M]*:&NNGGIT3O9:"%CYX78D$B U\ 3I7 ,#BPX--@F*&9IZ^*F&QV722=NWDR
M5I,7')DLY)0O-<[=Q[WT^]B@5+L501S"&H\L\T18B9(8I(RLI"D=D9>4W!/*
MPB@9X^%B4Q[0-M2^P2Q"J?0&]'6B0?"WPHY;L]CIO$[ON@W=_&C37'E9>WI6
MR.FZ9SV9*'4?>5OI' .A*%(6E6(BLV!23UM;R^C</C*68[OL]L]B9'(X;%XC
M'C)0]VM1J1+AUALT4F>S5^YA2+R1O<:G'6D>T\B0CB )GC8GE>O52:U%&\LK
MF-JZLY,C,I(X/P/+3< VUXCDQUZ -A>9[-5ME\>2N-YC)7C'3G0\B^8:R69(
MY[C +G545+"H%CM%': K4N.T^=:[SVE@>P^],IW%G?IWE^YNT\WBWQ= YV&S
M:NS9Z6>>16RF6H9:2W1OT\HZ)7^VMQF<!))S#$?'Q@KDMRK%!%D8H;,$ODD6
M JB"N@T1'&8E#HT:\6,@T- CX+'I(^(?B3X,X3O!^&^-1W*U L=>O%B965L<
MKT=/:J64G+UHQ.<2C('5D '%([VN6M[4I-1Y9GNPN\JF>[I[5P.3H9/+SP5<
MMW!F*F.HXK,0X;(6I(?T\HTRKC[,SQP3RR8F0AJ4_'44!E!E:]VC)#5LSHT,
M09XH(F=ID9HE#!R1LL!K0,FV$@];('77IW-BX7>+=?IBRNEUI)E]2[G :"Z@
M:#'*V13;FMBP1XL5!#(:>?I">:$L2UZS]1.-QD_T[S&&J9FI0OOCIZ=\51=@
MNU+%4@R1P2O$KHADXB3@^RJE2R<6Z)=UR$$Q@:2'R*\//@T<D;<5]J#H^O>B
M2"?>]'?4/ZMGG.[<;UL##)R#31*17!N8;>:1ULY9O9.PUU3J1:UXK1>BS PC
MK3SOY5M;ZEL_9I]P6KN:PV+K8UQ97[K#X]415ALS,L$M0/9+W9G<K%/!5I5E
MC)0I%HECY5C:O''#-,TFE 65SHGBHV9&T1H?_,S'D?1/OU$IX+L$(/=WF]<
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MSU(H:UVU.@E:>:W(L4,9,EJ3;1,4>0,6\:+-6?;B7PO!%&@8(RLHD+-& =<
M@(+:X)O>O?67VF,UH;VNG3+=YME0MPM<ZTVYH:X2)2LD/.>@@ 0/3?<L1DBY
MH]"E;FB\UJ 0X(R%[M?N[)R7NW*[8NM:J*V,BFMR9.UE[/"I0H5*:+&>$LS1
MFQ(RSR1")GU,W!%?F%+%6'C,XG*N>91%B6(%GD9S[)9%Y!- ;/XGX)Z';+\Y
MF=7.'=I1L09^:KZK$C0;/%(# JU]-AA67 'X];UO-SD(:(I'HBH.4>O]CBJD
M529;'A,V3O6I896D;R:K05FCV8J->!(V6!G)65Y-@ JO3J*2[L77B=>-5T %
MUMG._P#R8D@L-?'[_)DANE/@+ V.=2J"VUECY5JV^,&B9;.R0XK&W,5BM;*C
M>VB$#0D"@LYY2+24EX)>)#MVWFNU*'ZS%'1>+N&+*8L*L3E9H(;M*661&%L6
M([$L*Q5I2BI$093 P<CQ-3I#9<0_D#79)5T=>V1U!;8T=;9M'8! Y?T.-M=:
MUVG6Z77SS:&#HMC7L6F$E5#+RZ)J+#*P@O>I[4L2P*%M<K4$DIBQ5BD7]'T-
MW9W#FLOF#F,B8\;<F(:%*5>3''B08XHU9&2=OP)7RNTLK#TY<:TY5KQ0PB!"
M957?_<)DWLD^^0/L_P!M:_KKJ:>'W6@"MJUULCG>L!SM_G3F]"RIEL[O)"+3
M\]YL;1XO\^;*7NSC0G(=;(:%\O+9N."IFE:V3?N;"OVQD,=4L92IA+S8'N%K
MHIWL:E:&2<TY)'4C(I$@DGQE24AXK,0@59:\SUV9>'P3BQ'(RQR2 35UC9TE
M8G2RJJ^HV'\LKG\6!_+V-AYS=9#DLIM3DM%[\JV62=/@93^98U$P!O9X6*XV
M11'4U*YZ-;0Z]G_*578'2PZ$7;=**V=JXFYB>SKYOW\9<L=Q8NE?^W.+FMT9
M+^&2;(2&6"ZB+((8X1/+=QJS)0F:.&=;%8RE1K#I-:4+&RK7D>)W$P27C-Q3
MDHBVJ@L1^$K ,OL<64 F[P^T]3Q-KW_<YG,K)X6/A =ZA?G,[\PY]55<-V-<
MK"[;/R^<.P.LCK,D="PX6C(II2PX)G&$^K'<7TAC^P#8#N"IWKD;4JT<A(D$
M\-BTZO/5IUZ@5(X8DD>)JYJ1UX(AI$E50>BK&*KY/QD_<0-352)8U+;*'2EV
M] G9 !+;_KZZ]_/X/H$%OLN_#C%F E9&>-\>2K M>"7&(WB0$M8+:L16#3Z_
M4:D1YC)-AVFTU]4\/EJV;EER=/%P8:M8D<0XRL[2PU$B8Q"-)62,R \.9?@@
M8L6"@,!TZ(VC4(TGE8#1D^"Q_<D?(]^OW_U/7?<;^FK_ -E:_P"\G]>=>]-?
M316W+[\6F*UG%V(F9F(B(E!N)F9G]*^43Y^<^<1Y><Q/E]>@*6"L0%8@,2=
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M@T/Z"EBMBT]<@W<)ALI8X9&-:ZV%>M<I.$4O80^2&S$S:=2C*02R,P]*0HV
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M>*9K*05#$#1Q\W*2S1BC38B:1PQ>KPR7T^\$6/Y!#,TC?@P;D6\)VOIN(9F
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M_@WLGY71)&O>_0^.O06;^FK_ -E:_P"\G]"]==-W13,<YM^4^7_E.K^O\_\
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MV\?:H2XMX'A/G:P(;LWAR=2,(MN!(4E+ Q2JKH0#UFKS66$($4D<1642(Z3
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M2#*2I,9HS8GE\,EEOX:R%PBLF^9G8UDBBXK(7D=R^Y0#I7;DR#2KI5]A1^P
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MH]/G2L_I E-IVA#69#+*6DY2,SN[D.P#N\C,[.PT7+,Q+$DDD[/1T#Z  ]:
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MYGN*WVOA)TS0%^6K1N!$HB^(>;FRRM(4@0QH\@/D"LGY^@VNN_N!%62S8'@
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M><14BQ;4HNT#9SK6;:6]7FRL%7Y%;^8[P*OE>:^JM;4C,&D\^)[MABAL3/\
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M37I+GB1('FD6NYDQM<^VJ1V8%FLRN)4L\?&DH:[O-'MYHPT3#98\ @8D\%V
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M(C?TU?\ LK7_ 'D_KOKSIIZF?+E>@F8B8C$V9F)_FF(SW)\O_O\ 7A.@2?8
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MVJ2T1:@R0/VH]$9X*>7[EQ%'ZI=SYALI%BLKB*67Q,%<FX>W)@&JS8]F$5:
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M%RN;=:P]NI=0M!2>%)&8F-WDBXG4G%>:5(H3*/NB$232^7C+IN2-Q("M'_Y
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M;V3OW_7T!T3Z^1\?M_\ 7^O_ .H?'7H@-_35_P"RM?\ >3^G.ETT]322<KT
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M6UD*]['V[^.R6+O4?%:R]>Z\-VA(O-*L=?RLTA6M5<G,S)!#P@6%EEYQE1*
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MVA:[2I9RG.N/QU''3A7E$430R6\XT0D,,A:%0SQJ@]Q\G>26&L3&L2%H987
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MUDJZV6-.W#7FF*<;$:1!EB!Z]Q=B.>.5Y0JVJKR13*W%>,7-C$S"/2,?Y@Q
M_;8(/KJL>AX?F^*!$3EM+3T6S";Q5K4-<#QQ+N8S:-V"4H9+449!%R$BITV(
M.L8'G-+2[:[$R<\6*?&2?J/<4O!,QBIIZPM5DLQPVZ-Z"42EK=&Y2N0#RD@P
MVUDAD8$#7:74Y2\QXX!MH954A7*L4D1QI>#1NK'?_DA#*0.F/'(;4RZ\0K.2
MODKMEZ)_1?STQ:"AE$1K%&SL4"1ZN=[U?0) );4,<H:0*3WI%86M'<S*5,$L
MU.C0IR6<BU[(0UZBUY)($6Y)9N11&Q/"&B$-2!FE+3/&B(9'&G9.$1><B1GD
M5(PJ'D"H8E JGTI;DK,P^0-GT.K-?;QBJY>3H]71-&=IG3HKGLW_ .IOGJA7
M$:;4SV*QZ0O&8J.'Z4-:E0FI0=9FUK+L"]B<;G<UW'G+*OB^T,%+:GQLF--@
MY.3)+;IH*>3,BPXO)P21PI3,\;<Y+6D*%0>F\A'*\$,$"L)+,P'E#@"(1Z<L
M4]M)&1L,$(( V>0UU,6G.>MMYF!HZ7LN= >B6<Y\=M)<#3C%A+5LQ\240ELU
M6:^JYPTF1$\H'Z8M;W(_6V>/ 2OV)AI>U),7:\AI1Q8K(07\<':W-;R%B3A?
M-V ^*.O%7@91'))-+9DD=5518@B?=R?[H.A4$^12C@:$<:C\>)][) ^ O'TV
MVMC5B[L?!JT=]4-50#H%I>7GP%L"5O2=:8':D7+8Q8J<,%#2L08/JM2IP_5[
MZGSKD!/GI+:Y1)4N>6K3N&&I-7$/)$1/2)'PCA70(71)$@791Q6/7CJ)4*$%
M0)&795^8WI@?;?/L?)ZREDW6)JD9-6J3:[[#)<TA0L*IKS[M[,4,/SO6#3"Q
M6/8@)?,5IH.M*T^KIV[V3+.W;'<_U2[@MX3&Y>Q"N,R&3NF6ZE/$PS&.*Q3L
MU[%:M4M32U15L7/^P9=_Q&G 8*S<T+,&-A6:6%1RC55\?D=E#<7YJ[,J\BP7
MY(VI &NO@O!9X/RYD.WBZQFDQLV"F[5KXR[3!0J,Z!!!@2[5H($=1WK2E8#%
M?7)+?MZ3#V1]/IH[=FJN&[LCM&I;QF-P&1%/-/.9&K0T9,?);>T([JFO:L-(
M04EEMF2O&L<.XXW\@/P=9JQ0LDKSH&A"A>3,DJJ5T@Y #9(/'6_8Z?D!%(L/
M,1"F.\G"H)A6D5+:"EO8<^N*R>8$:DWO>T1YU-::CD<6M7Z5Q"5<IVY+@:N$
MDQM!:,>+,;11QQ1P$V*XJJ5FEFGAB,19W=%22O(K!%5G/5>G_@V!8:?R%F,W
MLE@6T/87B% 8'0'\W(:WO0+?XP9=3>'"6B)&9Z3*T4^=$,#K!;M@U:&O8]%K
M6,,S@+YGMGL"]AB 4=R36T_I^=TOT][^'=^6MY3&2+#D[]V2J$BJL<C8I7J]
M 5Z8I-(IX?>P2,I.R!(Y=P&;J_1Y"B:T4<;@E%3\B2!&)$,FW) 4$\3H['O7
MH$^Z/ED#+B(ECTS /-(0<C<C)14S!/:EGWIM/DHG)S>W$5BMIK<EIFUH]-C^
MXKSKC,-#+/'"PI1Y.W;",_W43RK*(2"7CHP)+N. 2(&9"[(CZ'7(4J9)2%9S
MS:-5V04/M005&W;_ ,F*D^_['K-!H.8^UN9/-Z,6G3(QCBV7ACG02P[%,+XR
M;47(%&VNL;TMD4B"P*+K@/05S>]*CNR3 R9R'M]IIZ]A#B\?EK:F3,Q8:!Y%
M\%3WPIBXC*9_%%Y%0B*)HPTA9G[5+ @:R C*1*\*$B$V- J7 V91&=%.1(!]
MZ+:(R>PYI2N6ETN9T62RL9!?-C.S:$%;/*F<671)JXJ^@S1E1$TSU(2QR@FK
M-HO4M8KQ8\G<&+F[FL+2Q45)J6&KXJ"K>9Q)6KJD$3V6JI466>NDMXV9++&5
MO-&SK+J,=*?#,*ZB20ORD,I9-:/MCHG8"-M0 OP1K]R)-'\',CF.6S&NI:UA
M0V/0#;+*!4W-=$R;,/T/NI7^2T\J'GYA=5L)%IC7]ST#B E%-Q@I]MX_#=OK
M<STEO$Y7(8S(SQTI8J]WM_,,U$Y6:9(6GFGKU<2L5>O)'("U_FQX-&400O8E
MGL\*ZH\<<D8,@+I9@')8@&UQ5GF+%@P/\(#9)(!QD^G+@])@MH)$V-)M:&NL
MQW3"T\[9;.6-($F7B]KA9-8*C+:]:@;2T_DV#2X2T!]9GG;=#*Y*'(C%-]TL
MD9NID199,M>%A_+? #P6UCS%>1&L11RJLCRRM7DC1UXGQ+)'&T1E/$@^,H%!
MA4C7$@[0F)]\25(T "#H]6'[?Q:T>]TP;>!X?:G,/&RL_G)QQ:)NASXZ3)F
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M0M^HR!+-N5"T#AN(\7_:9YY$VG\ZL0#I]>QL>AU5[W1X&]TNAH*4T-5.:Q>
M4$0(,N2 LH"TLVB/4W:HH,0MA5#:QI\_V8CSKUJ'&M9M5\+1DQU:0TZ>#:Y:
MKBU+]M]M'+:OJ@$*O;,<DTD44JI!+*>,C(FR<AE"(9'61@SO,RJ_$!N7XIO\
MCQ!" D$D G>^F]C8-=$*VPQ5XS.Y9QPCA[M,/7M0*Y@G8_:^0( EX#,A-2(F
M]II,>435K)U[UC/WI\G:FMWQ"([=R.S'?<LBEQ,EE9W25PK !C*R@(%+:&NN
MX_&L,:1@)&3M$"E /V]*0"/9]@_U)/[]-&#RZG4]V+!3A3/MZ7G7W;'.=6BN
M8NPR6,ZM 27Y+(!>SGA9%$5+8=2WK'KO%G[2[<R7>%T8_%2I3G:I:LU6LI::
M.-ZM5K21V9H(YGC:1XB#+M4+D!2SF-'%M65IQM-,ID59%CTA7E^;A?2MZ( ;
MU\[U^XZ*O-<XIB]XGHCZ#!W0WT_SC#9U7X7:'H\VU#*=.I2U:#;^/KJ00<16
ML0QZQ>V:2"L+ZLW=.(PW;U*Q_G#,UNX[&8C$8OXB2Y9R=#(U9=JV8I3$9-<9
M=AG:&8Q.MCQ+!/"6>(@BUY9K)05H&JK#L%)5 BDB<;80,FD\B'1]CY+ ^CLV
M7T.[XSJM!C> .N(_-7'*XZ!:D0&(<7!;RT"&5N/W;W+2J?QA$N.*V%28BD0+
MVOWK!_G.3(9;M##=RF2G=G6[+EA9L_8)7M25J$_^89(U6>!?M:XDED,L=9>,
M<4LG%CS9IS"FL45J2L.48*B(A3(Q4,X$*ZT.3'6@"Q+'WH]$_'PP:F2CL\9M
M).,P )M;/"*1[.4QYA#5AU-@8SU4*0L>V6/9$0)1><SZYH+4\E]=**4^U.Z(
M9Z\7V\YL]R=JV:-U[V.AL4I*T5ZID*4 C&'QT3E%DG$E2T)HB6$Q58XQ,*Q-
MJLRDJR\:]OF@24JX)5D=@?,[$GC[;Y  T2813F\]G=>T>E+LWCG[L&O5O/,N
M:*MVB2N"*0P!>P8%Y87LL#V02&?<)8MJU^JQF8?HAW%]2W[AR_>!R(S$1R,V
M,HJ(L5,F*JPK4?(9 ,9#)>"%H:5(P2$Q(DBIM_*_&^;@QP@AJ"$1:1)7Y/,3
M(Y+A(SL@1Z7;L'4#1))V>L#QC$C7 2OGT88S,-G!LP:[$@(LF76$$+XWRU]I
MDIK5>]JR]ZS)!S8DQ IFQ_?N9PW?-JUF<?'W#C<3]*J.+K0-_#HPR7\MEHH1
M8QU-2YL"+&8U?LY8I(3-(\>N"0:?G&P34E2"9JSS9*2=_P 1RD"11;97??X!
MY9E+*PX@!N(WOJL?:\\4/-]=V>9C:61R%]C'1Q2[&JG?H9UHN%GYT9GOTT*Y
MKF:['MZ, *I/_3#]ZQ9IZLEK#/I1R]Z%(9TGS$_E;[J=,[@JT)$M-IXBXM)7
ML16Z])GL#QSSD&$EX@QFN4/EC0\MB$:_$>&;?IPC <>2<"PX^^/HD@@& 9BZ
M.;O\R]O\WOVY%'/T4G4PV '6,T@M[#F@>\+!J%5;HM!4@Y?I:LP.%;&)>OZV
M"";+80=MV>^Z2?I4,N9Q^,HQUX*-IGIE^(L0/QGLRUK<U>:0V@QG\,H175"O
M3#!)A82C)_&'AD=]ET"N0200"!R164!= <E8@ [ZLCP5LK^!70WY=_;G#YQY
M**:&ACF(:RWQ2'N ^I2M*@J%J@ZV%>P)]MH,Q2:^7KK=/MVM-E>Y8U@R&=[1
MR4F.Q=S-5ER&&Q-*,2>>/-9)$6:&-Z;@LL-Q)$(Y.K(LO)7WL,$K,>$5Q!(Z
MPL8I96+ *(8P2K*&UOD"#Z_?WU+K8O7:JA-/'REXRU#8NH%@:H2B.9>3A'=D
MUZTF:5^6<U+,V&+WX#Z"$N.(^NIOI;],J&+_ %.U]3JL<$?_ $UB29R/OEL<
MDG7!5DB^YMR13Q1&8I'(D5?FDA+.KKS^IWVD$0H.7VS*-@A"!L&9ME5##0 #
M;Y:]G1'3\#%30&KI[3:N 1P:QET/?&319?D-2O>V(I*V3M,!M<MC4]-/7:U#
M7)-!WTCZ?9OMS!=F6I^QL%B.X,[3[F7MN'*9=QCI<C ]<VFR27'$H^PK)SD?
MR1Q1HH\>MA"([(136;82W/)%!)5,SI%^:HW+7CX @\^1)#*6)U\$$Z!&WU8M
M'Q!S%,4NSD)#%I9ZCN$:[\:J]!EEBHF7!+I-YS!ZE7O=5,EQ17S]NY*Q%<K?
M)=Y=U6([_=JY*U3S926OBX*S5,9,F/,2B.C5GD:HT<4M.O+<9I98R\3/*&9>
M)E5AJ5H>%7QJT2_Q)-CRHT@/\[<N8;\R%V>0V.('KHG<SS.3S7+&Z'0)=7LM
M-%Q#0RW%J7D*;VEZ<^HD(:7,FSGHK79H6P+P9EM>UJ7)Z1BD.UYLKE<^W>V6
M_3(>U\G)DL*N8L^6J_;J+CEKR9C"W1%'0&1A :CB8U#1UV21DCCX<@Q;\8B^
MSB,IFC,4_A1@QL!6Y>.5#MO$Q.W(*GC\G\B.DD2'#9@L\LFSO*1L$@!:WIZ!
MP6Y?:#YVBL5N<5JR6Q"3!)#2@RCM-R^B><RTZ=UXJWW?8@QI4/2Q]O)P?<.8
M6LR/#%.YBR*+/1KI!)DZ+0PP?<MRU.0 -EX8E-:=:B&4>G9$+ %BI_E&U)5]
M-P<'87WZ!ZCGBQT>GQS'A[C<\$S6OS5=43Z3Z/RU5?S?%&M5%I9X5[MF MHO
M38Q3%*%>,Z;0$E13-7P7?/>>0[HJY*/#MA\9V])D.W>U,9D8+CUJ--YK;6JF
M1GGD4SWHH;=1)G8I8*0P)N0$M(2]*K'5E1I1+)8\5FS*C('>1%10Z*/:*>+:
M7B 1^P!WU4Y?!=W(E:N#JV/BY9)T:4&(2^0JHS(4QL^_(Q9X9M!#M7/<16M)
M@@11ZBTCZ60K"T9[-;!95&Q%"<YM8J\T<566-?MZ]F8&NTD?YA);OE"R2RF<
M1"*.,%758*0LD\1\K@5V9P2YX\BHT1R)T2IC]A0"=G>\+)@N1NY6PID&VE,\
MJ&OKHW"0JHTA/4I<>H6!&$N!D=X6]\M;CCY=*UM:UZ1]0^#,:6J^0L8]\O2Q
M-B*]DJ,:S+&U2O8A!2Q/'&XA@GE9(GD8<=L(VV7T7)E+(\2R^%Y$9(I"PYAW
M5M,BL0"PT6THWL C]M.6RPIL[FYKL8U,M)K/(QD8W)"'.*OT-_CP)=VC%R?'
M2)/N,.2&(M:]K#7$ 5ZU'(8Z[V[;E[DFS;9&G';7)W,-3J<%KPY*Q8D?'03
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M6&7 4>T,31R>/RD><J6#<RDF+HU[J9;%6Y)SD+-(X\(UE3YY7CJ/4,B2,G\
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M53^L7Q3_ ,_]-_R?TNETOXNJG]8OBG_G_IO^3^ETNE_%U4_K%\4_\_\ 3?\
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?(M8<S$3/ZQ$S6LS$?I,Q'G_-'TNO/W'^A_\ TCK_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>g67046g83q94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g83q94.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1NX4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &YR^<&@X0DE-! 0      %H< 5H  QLE1QP"   "+<0< E  "')R,CDT
M,38U' (% #E-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52+F1O8W@X0DE-!"4      !"(0;[/!GN/<0-C-GSE
MAJ&!.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           "3@  !*H          0                         !
M          2J   "3@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   "3@    !29VAT;&]N9P  !*H    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   DX
M    4F=H=&QO;F<   2J     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,     !$C     0   *    !/   !X
ME"   !$' !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MJGI==;7%HNOW>GOG8UK!NMNLV^YS*]S/T;/YVVP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<8$C,E*AL='P%R1BDL$8,T*BX?$*-$-3LG+2&25$@B=45V.6U>+_Q  = 0$
M 04! 0$             ! $" P4&!P@)_\0 31$  @$# @,%!@0$! 0#!@0'
M 0(#  01!2$2,4$&$U%A<10B@9&A\ <RL=$5(\'A0E)B\18DDM(S<J(()31#
M4X(7-51C1&23I++"XO_:  P# 0 "$0,1 #\ ^_C2E-*4TI32E-*4TI32E-*4
MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32
ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E>5R
M]9LTQ5>.F[1(-]U'*R:! V[[G5,4H?F.E*LJ1RA28XQB'F4W2A0W$D>DL\#\
M 61(+??SV\;?;J.P:53(^_ORJSW6<(8#B2.AI5^/EX@H->;KW "'=' /01(
M^I=]4+  ECPXY\7NCTR<+]<>=5KP&R[9' ?W*C.BE'L=55\N ^FYB1Z!0]1
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MMTR*L,3?XDR.>ZD9(\N0]1\JI;B+KKT!\>,8B)_^-)(J"G7O^D0\,^X?_7L
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M;:F4M;D\*K<  6TK$X ?#,87)QGB)C WXU!X5U$]B\9)CRRC/N]0-N7CY>I
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MOR^-N/AJG('W2(%#W9$ Y"E-L0R? ZYVG.)+>S)15RKS;%F/@G@O(G<],XW
MFPVZC!<%F(R%Z9VYD;#X8Z[[[5A[/E #<@!T#8/(.WEU'MOO\_PZ!Y9J&KD%
MB6R3DDDY//?TS\_#QK8K&"%R2!R"@;8'ASSUWZ<R0<"K.>V+EYA$Q=_4!ZB
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M17VC:I/IB=4;O5 =%=1\K,LW*[)=BZ<,7:8'1>+LUD2.6CCP'3,YFKIN4CE
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M=]>U1[>X::2>(WLQ21[DE[EY$+D,9F9FE9A[Y9F?)8DQFMX1@]TH*@ -PJ&
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ME2X!GBD-RUPT&56'B;WQ?%#AD[Z/L+_-5B:PCTM:*]8CC\',;'J3;:WHRG@
MG-(/G?P9[6XHB)BN1!\>1>NBB@BW%%2))^%R'1XHSH3QW"S]U)JZ7!>XD"SR
MOA;9YTMEXHV[G\A[Q(<L8)4_G8Y-6LQV4MU'9NSCNN- W:07U^;IN\NKIH4.
MGF\%F!PVUY9N5MR'BCMYE,<B3-<4JD\6^.SKMW=MR:_B65B6:A' -<-,D8MW
ML#)3AW#=HBI$*&!BLA#@F11ZM[RRM[=(HE3J:CJ8W':/\)-)@TC1_8=.GM;U
M7B34;F*X>Y%R!H>@7$YX)9!'$QO-0E;@1<96;,B\:1CH>UU]V6AT#LM)I6@S
M:=J$@MOXM=M>W%RM\/\ AKLYJ,_#%)*1 TEQJ@<&+@[MN_9%X)5@@R>PXH\,
MN$&D>&6YX'TPJS;( 6E"+U%VM67$FX9(.0E10240M38*("Z[0PG#FM1>0JQ(
MX=(GX:Q1ZO8L^E2-"DP-QIW?<$5]Q3RQM UQ'/WD2B?@MDECDP;=/:2H): <
MVVHVZZWIJ?P"R*K=%)-*]KO/9;]_;)X3#)<"X$L*"6-K?BADC81(C\7OM5PD
MXC\8%CU(-KF:PJR[:+DI<L@:AD2>N"(X\C[C&F52&7.S192$Q(.HTZ9$@.Q8
MQB*BAE >@U)/@[!0'61*= :2V>TXCHYGE[I,V-N5NA>BY$YED=))I.)W1!)W
MHA9/^722FJ6G_$#N>REF]LUDD@T,:A?I!' UE;SF\2[6Z%PEP;8&?+2&-)YW
MD[G@(MAD1CQ/8EA%950,L3,B2%/.MDD7%,,D5X,6SCOA2BYDI;F34F7JLBU7
M.3=-DK&BX,18'Q&Z&6X[&(BW)@T^:S+74W<]VS2=WQ7,ZQPJ'N).)$>-[5B2
MS)%'%.9)#)[FNU*^@:*ZX-%L]//M4B\<%W=R^SDWER!;Q1S7$@[M C6J&0O)
MW4".[N7#5(6M<2.,))8\E$90EW+)@K)E!%*I&;M'B47(QI&1U"+22S@AI>->
MOGZQ4W(F8_"TV0$56=^*7KM#[.PKIEVOL$MW*LCA-0ED>&6V5T BQ;)<&)RN
M\Q9E8JP[LQRK*'CC6MW -)O./1;:]E#R_P#O%KBZCELU:*-%5(4G6!Q'(R2H
M[KGB9HF$J.!'+*C<1>.1."Y;JZ>L7!W2*)!@E6R954+ 6*9KD5*^5.A[Q&$-
M,* 8%#I<BC "JK%26)ZAV,N)^SQ :.>6RN#&+@L"H8EW,4ZQ\957$*-QD#!5
M>Z(+-',-!=,DEFA-LBR)N+E78LX+R*59>,J!E&5=M@F2<MOMBQ+D-&W1;=DX
M=IN'Z#1%=N[(8%"2L<<A!1>)J (@HH!3$\8^_P"D Q%PWYSE)[A&ZR(KHW$C
MJ'1O\R,,J<X .5P=O'KS.FK,FKZ4TI32E-*4TI32E-*4TI32E<" &#80W#^O
M32E?GD+Z#WW[C_V_#2E<\A?3]XZ4J*U]X(^&')V8HS/5YQD,YDV,>X^DADAN
MF0HVN34IB>7=6#%\K<,=Q%LC\<WJ6QY./7,O2I2Z5.??UF05][AW+-8B9B*5
M(JQV6 J<8>5L$HUBV15D6J:C@PBJ[?.!%-G'1[1,#NI*4?+""$?&,$7$@_<F
M(W9-UUS$3&Y$:0\**6."3CD .9)Y #J20!U(I59;F37;HKE(H0JZ2:Q2+)*(
M+$!4A3@51%4A%45  =E$E"$43-S%.4IP,&K?OQ_2E=OAEZ].H]!'<=_ZZ!I2
MN>0NVVW3M^(>@Z4KCD+\_/S\Q\_3?O\ 4?72E18F."7ABG\\)\2\QC(K[,2<
M_7+<:=5N-^"N.KG3JJ-'J-YD,:IVHF,)*^5>GC]FZ]>)"FN;9#0Y2,HZ8;I$
M*4%*E1R%WWV'?UW'UW_KS^>E*X$A1$1$._Y?PV\^N_??KOU'2E.0N^^WTZ>6
MWY_/??L'II2GAE]-_P 1'ZAZ"/F(;:4IR%]/3S'N'8?Q]/3R[CI2@IE$1'KN
M(  ]?3T]/RV_AI2GAE^?3KU'?^.E*>&7T[]!ZCU_$>_[_P#72E?H  H;!\Q^
MH[Z4KG2E-*4TI7 ]A_ =*5KAXF:P:$R(>6(&S6SL&\B3;L1VU(5@]3_$PH(N
MC=P$SH=A  V!2H[:4II2FE*:4II2JW7(A>?G8J&;/6L>YDGR#1N\>K';M4%U
M3<J)U5DR*')NIL0@E*)A4,0H;"8-*5MOJ\<_AZ_$Q<I)'F)!@Q;M7<FH7E4>
MK))E*9<Q1W-][;8#'$RAP#F4,*@F$5*KVE*:4II2FE*I[M^")R-T""Y>*%$Q
M&Y! .0O799PH(&!NW 0, J&*8QA 2))JJ;$&A/S^_A\Z5XS(I,B*RLNN4YVJ
M2BYUC[$:L42)F,J#9,1'D $P,!USB9PJ&Y>8J9BI$ >9/Z>H\*??W]_TJ.JC
MM:]S,E:Y(JB=>KZ2XQK(Q ,"H-B"X!(4S[D4.8A </0'?G4.@@ F2 ! R&1'
M7B9<JWO*!Q#_ ,O%D9P>H^57Q1F66.,8!>1(U+'8&1E4%N@4$^\V^!ZU8#6.
M;V.3/#OH^/\ >CH1CB+\-BW<%=-#@LT0<J^\,BB9!R=T<2*!_OQ;"H8I#- Y
M]2>SUG>%A/)=*J1F5 9(V' YX<'C@.^Q.,^\>[R/<4UT.JZ?%9V\,\-T+D&X
MGM)U/!Q13PCO.$*)9/S#(;8 >Y@Y!Q)EIBBHHUR!K1F3A)G7D]X]1@]=Q+A-
MZHF";J1\2+6:;O7)1436<& 3F27<([@1=8IZ2:%ILUK#:20LT,!+18EECD61
MCEIN\B:-^];+*SYR4=U/NNP/.AV#<8.&\1MBJ MP]XK7*"9H21(D1!=DFBC9
M;&BDE%O#&/(PR2:<H4J</**&%63CR@"#U0"'6*84TN36OV*[-/LVG87)PJW-
MVB*C9[R%56<!;>8LSSVZ@03.2\D;-O5_?2CE(W(@[\P>><\SYG<="*UR<7%)
M@*;9FE;ISE[4XM.IQR<X922E)9Q9$K2_FZ[3XY09B:!NUJN+Y.)0L#1FDFNF
MG+2<:D?PVBDBF_PVGX8=FM5O#90Z3" ;>0OW]SJ1A=/SQ6T@CNE1X8%@*V=O
M(6B@=E:%4=0:[;29^S6E=F;G7>T=O>:K-/K%GIEG9VE]':/;6]I-I]U?3NI=
M9)6NH+CV:)@RI'&EP7)9PRR<PIP_XMNV.X.;M#25G+01ZZ-.6!&V6QFO,7*O
MOW$6TR$NU0GUDF5Q=1K=HL5X@HJ6/;."1L:LI#H,0UBE_#3LM"[Q76D.LZ,6
M=OXAJK,TXD:2._$KWAE>^ ?$5^[->(F(TF"*!7.:O>64NH3SZ++.-+G,5U:0
MSR"6:U6:%)'LI9.!.-K.1GM>,*O>K"KD;Y.4O]D;!B8I'1K\\U.V5=+L%6MY
MNJ"L:ZE">'/O8Y1.> [1[9B<_P!HW:8@O,'675=*&6644-A/X;=C-\:2RG8I
MW>H:DAB;@$<SP<%V.Y>[0!+UX@K7BDBX,G$<ZX7,X((E<8S@9V&>>V,8\!R!
MP0 :TD<<&(FA>(>3QGCT+SCR%J&)%FU:0CS3J\;;8BS0%DF;+1ZG8)XS]H:1
ME@8-8FL4*&=H(&+"VI^Z8NVS8Q6L2W['V5G>WUOH&FW%LL,=GJDR1-=21,FG
M3S7\$$#O*X2&.\PR:;$5M7<RF6!E;"_2WX83_A_V>[&:7KO:F\T^YU/7>V^F
MZ2MM+J;P76EVFF7=A-!<W-G;R+)'I82:\N+V_F0G/L<,##$I79)PK\.6'\K\
M/.,[I=*E:'4[9:JV96-W.6&\0LI;V=8D7,-69&Q1BLPV7*W(VAV-DK46NF1"
MO+/@5C$F_B',HL_P\[(7MG!+<Z.TKR+,96N+K4EDNEDX8U-W')<!I%188GMH
M)U*V151;K'C)\<_$6RM=$[;]IM+TF]ANM.M]3?V::VN8[Z#NY%2Y[B.]3B6[
M6TDF>V]I1B)VA,F3QU(D_!Q@510S@]=GQ=K/4)EV]^W5T*\D+.R,L,;<9%<L
MZ4SZW1)%SMXR><^(]9,R-621@:,&"+66?PU[&GA)TIRZH1WAU#43*\O>3RI>
M22&[+27\4ES.T-ZY-S#WK".15X0.,]IG!)$K LP<\.%RR@ 'W0-N%54CDP10
MP.!5L9)X(,$WG#U\Q">K",!<SIS(-Y:0>61"+NS5L\32N\8C9E9ENPM+XSQR
M,Q-(H^\RAW+A=[XZZRIU)T/8?LY;6-[IEI:S6=GJ'LINHX+JX;^;:J$CNXUF
MDE1;QD5!-<\)EN&CC>X:5E#46YD5P[-QC$BL& 8%96+.,';=F+*#LCX88Q7S
MQ88Q/ABRPN=Y;)&/:W"0-&JMP>8RC$(&LL;&_3@RQL:^AK:B_I:B#-^<]4C5
MGCZ&;F/#!"WMT5K(-Y159KR5S^$6G2:9-JYO->33XFD2)UU"(2\,1?A:2,Z>
M&@+--@3J90)(Y" >\8M[#J?9+06[0=C^QUCVD-UKVIRZ3'J@>VM6TK3DUA(I
M2VG74=TZM):Q('E@G$#N+F%A(C/*L=_ML TXN,<I3%OPY6(S.%>L^*&-4K;"
MFQ!*\_7S-)M[O75Y)%:E?&T%G-BB9%1E&LQ/XT)(PU$<.$7HR;Q/0C\-M&6*
M5FO^T*3Q]Q&D8U&(%O:8F2+AD73048GC,:)&25=8,(C\*]3)^&6A/VH[-I8]
MLTFT"^A[5W5]K,ALX[NP_P"%;ZX>\$ &H-&%FC>W9'EF 9'N9D$T1A9\SUKA
M/X>X_!64K]D:HUQMEG"L<O/V*IQU<HCBL>\(W&;L5";.91>GJ. AV4J[1B[N
MY1271;UMJ@BEXD4E%K+[N_\ P=L;33DU34-0[0Q&6VDDA1]2MYR1#$D$?>L+
M+B$7ND!&7A]G'<KQPQ+CS1-,T;M)^(6F]ENSNM_Q*PO[K0[!M7O+;N)$,D$"
MW7\J:<1.+?NY(H(TECXX8[:V,D<@)&$H'A^IK.A(,)S"=?0S_'99PACZ!J#B
MM0XP)PM$#;K]62VA1W2!E/B<NT97<[]J(*L71+#CYQ-NVY861 VE/X;:*%9/
M;.T(N'N6A6)]2A<QF\[Z6$22G3B2.[A(9'4B:)X4E=5C'!Z1<?A?H;:REQ:]
MM(Y^S7_#?:O79M9:*U-Z1V=U*72[JW@A34<7$5Q)J-L\@:6.:[6/4A;V[$0F
M6QU<4TUI3*.[A,+5Z5G:CCE*XYV^+52*10K[:HWBR89>NHQ9*BBLF9@QC;@X
MM19PRCEE9Y"'F%DUDJA,D=8I/P[T>023^V]HWD=)+BY5]3C8Q#VMTE_FG3#+
M*4$3"=Y 'DD9';C=!(FZ3\(-#FUC5(KKMS%';:CV@L=*[-7*BQFFU:;4.S/\
M<MY=0)U!2P<:E96Z31,RSN9^*2&6>WADV[I>RFX5EJTWFPB'!8Y6#1DR(#3,
M?$?@R/30K92<HU0%"O@K(\Q0Y .2TBI8A '1Q;!O1^#^@L!+_%NT&"JMCVR'
M)7O#+PG%KQ<17 +#WC+_ #MY #7S,[2)<-:\%MQK.\!=47@+X]F+A_RXS_,5
M^IPQSSK6/C3 N)+FSOSC(^*H:IP,I@Z^YCQ2[KM*B)&2L<=XY<>ILP:*4E(7
MCQ[&HT^,AB5[E>-[820F&2*K:W0:3?6V'X:Z))- 9M0[1Q)'$MVLD5W'+*\-
MO)&TKJJ:>64 ,RIP,7BD0RQ@O)WI]Z[2_AAI^D#2UT?M1#K-_#VOTCLKK$#2
MV%LMC>WVD6ETMQ977ML@BC@:*ZC2>4"*%8H>*02VMQ#'++A@X&>%GB?H5IMS
MEB4CYO<KI69-D3'%1KCIM'RB$&B95!E+U4[E)!TSAV"D#((^*A&K%L#=J<7#
MJ1:L]A'^%79R\57@UWM-*(F50\EU#'(K1&7B"\5FN(V>3BCX 8XW#LGOO*:\
M[_$+LYJ?9+5K2RU*%O\ F]*M;V&2:>&\$BRAD?AFA>2,=R\7#W?NR(&XR )5
M)@_DW'N%:%DF[)3F,Z@WQ<%RS]CRIR1J[7&4Y*9&I$M7)8!E4R4A5HRK9;K7
M7;A19@@_3B,;S<C$M5EU*Y9@5U!_#728_:%%[VB-JTDT/>C4(A$EQI]M.I<Q
MIII2+"N9T'$_<1^T1Q@B6=!ZCI/X2Z9JNBZ3 G;&WCUR\T[L9V@N])?V VMO
MIG:G5KBT!@SJ"R37=A#>6T:Q2QVSQ74\\+]S%J%O<&8?"=P+XKS(.0HK+N-X
M:B9 Q_/UR4>PT;3ZH[8E9VYXMDF&.^"<J"+DCA:>"1>NXY)11J-,D(6NG6(H
MW=JEF6GX6:/>O,)-0[0P2PHB\!O()!PRQ,D98M81<@H<H"Z]TZPDJ@,8\[_$
M3LUI?9P:'>Z'KL7:/2M:@U+NKN6.W$R7&F:I-;SKW<,\[) X:/N6E,;NQGX0
M\825\#9.P#@['V<:)5:93:W,8<<W>E4:?M$C7*:]G3S+:SVA/=L@SJ:D8\:2
M\U84FD4JZ,J-B/%I1;OX;SP;E79:A^#EMIL$4KWW:,:?.\:]\FJ0^Y[6(D"O
M!_#F#$&)(9%F8]\)(8Y/Y<<.<W8?2>S7:C0M;MSVF>P[3VMAK]];:(]JD6G7
M<.EV=I>JSW$EU$LKSQ0W(E$4;/W5O!PI(;>135:QPSX<)Q#%I4MCB&C,&)9
MON+JY>'U4K*TTA8\*5B00!&7(ZI2,"[%TB\NDO,;+@,@R7@YHJI']5F6[G3I
M^&>C7%R+1=0[1&&6ZNK>&3VZ*7^?')Q&(1&P"%B$/$H8M+'_ #6+20@+O=0[
M Z;:]@/XRO::";7;'L[V?[3W6@2>RFS&G:UJ%Y:AHV]M,QN+6.XM))D%N"EV
MTHDC1)H99,=<)_#A@/($];W<M2VZ--'%%KR]B]=)I7ITQXZFVBTU!U$S2\K2
M$F)7#.L7"'A)=5H II3\+'6=0JC%Q66Z>YN^PVF:M':6=VVMV<:6?MMFYO%,
MT\26VC::#*9K$*!W6D0$@<8,US-,0RB%CO.WG8G3[33-(M--[1Z=JE[HW:_1
M^R.LQK':<%K?WW8[0(DN(6BOYN\MD.CW )9$#2$1\<<UO/#%(.]\(^*<?XDN
M$TK08U;)44YQK7Z;#$J==3C5I;)=3:T*"5?J)T\TPDN>/:O)!JDQ RZUS?LE
MMT9IR[(GKI_PMT&V"3_Q#M [PO;HJ"]ARQENF=?YAL6(D*<I.[8^T%;D#OFK
MF-'[&Z?K':?0[1>T$<.D3_\ $%S>ZK-[)[39P=GGN)[MX,W<40>6(1RJSR)F
M5I;M>\B,8:S'F"J2KCR$2CL-PSO.D]E7)&*)*G(UV%;039>!J,0%C9QSE"E!
M(GF6E.)!-V@&*DQBYEA<;$T<N(]0C<\:/\+]!"QXN-=-QWIM2GMMNIXXD#2*
MLPL 1[DB]V F(W621'[PEVVR_ASH_P#&KY[CM;%%V:MNR.F=IH]7"6PO9(]6
M>/3X('A%XR1@7,<J!>\>6.&2T1[=9)F$6?,%<+F(<QQU0L$O3(>-KU_<6N#D
M7D-7ZX!36E1O'-[$E%"[J*8MV7Q*N.'M>36 ',3!N7/-XCSXBF2?!^%79ZYC
M1S=ZQP2N"2+JVX696D#$ V*-G)#PG"]QF5XR3/)CG.V78^#LU<:WI\>L+?W6
MG)#?"-X[=4GL+JY9H93W5Q*!.(98>\"&5!<-($9DE1J_61\+4+'N;G]0@:)$
M/\<5B=IL+D6=5KD,TDXF3RC(1]H2<QJ+*JGC@0?OR0<%3VRZYQ%4L[65C(MI
M1D\)F7\-="M6EMX[G5Q#QQB;@NH$C#O%A"(EL&7/$X$9[SW(VDMP%1]Y'9_L
M39:OV334KC7ELM6U.'7[K2-+ MS!=QZ$@DG2X+7*3*X[F625NY(2V[F2 S2)
M+")B5[AVQPVN",<A M4*_P#:&P0C9^,!!^\&F(:4"RJHB@6"*@<%YE%XJ#=
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M2FE*:4II2FE*\SMTBS;K.G"R2"#=)1==98Y4TD44B"HJLH<X@4B:9"F.<YA
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M@?W3P$H2,8:4,".-LFDLVAQ03RK%?!HH99%+;KQI 0<@L?=[S=CL.(>Z.!D
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M1!,B22HV@)$%@,7X>]KZ3KF T>8EM[%I+1W'%::BV8[\MPQWP/"1I:R %3S
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M 8.X[AN(Z4JX2"D4?!()"F('^Z*)0,4H '_ '4  !#R -A#RVTI7I1\452>
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M:)HFD.\FF:7:V;O:+8LT2'WK1;F>\$#*Q9"HN[B6?\N>)L$\"JH]!,*-2_\
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MDTU7$:"H "OBI!S';GM.^A:O[##9VUP);.&Y)F>0=U)*\RLA1""RD1JXPZD
MC#9&:YB;LW;M<2317$T"NY<Q(%*JW%D]V3^0$Y(7!4$X(*^[7T2X6X=\7X&B
M%X_'T$9)_)@F,]:IAQ\6MMA52^\4TQ.+D!<Z"9Q,=K&LRLXAD91064<V%53?
MQ_5-8O\ 5Y5DO9N)8\]S @*00@C'\N,$@$@ ,[%I'P.)R  -K9V%M8J5@3#-
M^>5O>ED//WW.Y&=PHPJ] *SN0@$#8/S'S'OM]-]:RIM?K2E-*4TI32E-*5^%
M#D33444,!2)D.<YC#L4I"%$QC&'R   1$?( TI6J'*5\?W^V2$FLX4-&-UUF
ML(TYQ%!K'IJ"5,Q$]^0%G0%!PY. ")U3;;\B:8%4K'&E*:4K7W[4**L,SP99
M 852-6E[ I=<&*QK!%J^> JX:YSQTY!1PWCDEWHLFX)"X?*()'.BS266V $Q
M$%*U <4E0RI+9[SX]S36<:E(\XJO9QO+#(K8YNN5L$#5(?'^5V\G(V:HRAZW
M*W2J1+==L6Y0Y):,15,L=@,FT%9)0%*XXI\5*V+)<_<,:8VQ;/8YHW![PEKJ
M9*Q/AR<I<MBZ#8\2>4%KY=N$BH).)%>EVJ"CBO)AW6@MWOR-?*7WIU-@)6[U
M2IDU.4H&0O:362^X#J=1HUCQ%1LKT51*>+:\8/N+_,ET;Q]DG"V^SL:':7BN
M,,3QM>>F@[;+P5@=N[2\=I5&'?PD2@H:G7I_7']-_6E3LX%,A<5-]P_(R?%+
M1HJG6LEZR:PB7I)221M4W!QV5\@140VFZ6ZQ1C5G6H.'K$?66=+GF+RP+9*K
M9F=WET(%[) Q5??H:5,_5:4TI4BL)9CG:U88JOS4BYD*O)NF\?X3Q<ZYH=5P
MJ1%NZ9**B<Z#9-0X>\M2&! R0G4(F"Q2FTI6QT!WZ]/R_ /Z#U#8=*5SI2L)
M9K>&-&P<&B;=>4E .) 'J8B!02( E]#KN2;#M^LGTZ@ @I5-G$4VS=%JF <C
M9N1 @!T I4DB)!V#_#W'OMZB.MG;\AU&PY],D#<57I\1]_#^OI6"K(4FYNFX
M?>'8?/U#]_7;\]];NUR< GP /B<X_H#M6/C.1D<]@?CS_P!]^73%8#L;9$16
M^Z [ (CY[=1WWZ#_ - #MZ[^W)( .XZ9Z<^7@=A5F2N,'P/QW]=QGRZ==ZPY
M(1B(F.(I%'F'IV#N/4 Z!MMMT_EMMM8Y20,G<=1G(Y^O.K"S#)'+KO@_TS]=
M\_#%M@KZB:S:3BUG$=+1RZ3V.D6*RC5ZR>-E 6;.VSA$2*HKH*E*=-0A@,0P
M /38!"8&#HT4BAT=65T8 JZL,,I4@Y##F .8!&"*NCD.0&Z;YZ_8/]1MC%7Q
M,+X0XFHV2A<RU6@5;B+<,J[%PV4;2B[BZAD)&O2S=^SB;1(Q:B(5^7EFJ;F%
M=R:S9RV50=@9!)V1%M %T:17^@3++8][?:,7EDGL$2.6XMC+&4XH1-&[.D3<
M$JH,%C&H8@YDK*Z!Q^8AAC??EGRSMC;EZ9Q4(\RLAP/>VB.3>!2NPC%'(5EM
M+5R2S2<A4[1 2U:/"1,)"61K'*Q$@UCUS)S"11.+EH7PVZL8P5$ 2ZC3;B'5
M+5O8=<:60VEO;R$VEHEQ!<12<<T\L+ N)98QW+#A"<.>&1QO6(6[\62PQN=V
M/Y2,<)&.0.=_$?&L,5#)F/G:$'7D\%U.EOV])BJJ[MZ<_('.XEF^0Z_:).P+
MINT2)IG?0L6O%N0%8[Q1,1*FX75*@BIOHEEM[B2ZDNIFA::[ECB]GAX5CETJ
M]M8[93%&&:-KB6)P[#@5R.(8R]:;7M-N;W3#;6W"\IO=)DX7E" I;:Q874S<
M;>Z&2""1@I(+A2J D\)S8I9ZBCS22N'H9XQ>9%E+$>,>/2H(GJD:PEB-:4_,
M"IC(Q?B7U@L*:"2LFR)!7!P^C 2@53.),ME<"*?_ -[6X:/LU8QYCDC9S<//
M:NTB+W?"]Q$--E15#]S(T]HJNC7"\/!6>L=]>Z7&-)U].\[?:ZA:32I8XD3V
M.^A6XE<R82UD;4H^&<D!EAO&(/LY#X2:YGQHB^A'9^%"CK)1=GR%..VYK#+;
M23*W(ODH&*6,+$W*2J>^$]S6.54IP0#P$F8*"4FO]EOBL@&IW*F6"SB1Q;6J
MM$UJ5[R0#@(X[OA/& ^P=B"VV?53!R]]3C.W>9SQ>9Z ]2/7-9*Q+ R><6YJ
MAC?@PJTLY1QU&TV5N*\_*QU<KTFREB24G=K!87S9"-BS.X],[=TW</P?N$$S
M%3,_4*1$8E_J*:45N;S6YX0;V6Y2U$5N9)$:(1K90Q(&=T5SQAA&N&(#*NQH
M;9NK)G 78L23D98>]^8C//J2!C:I%WK*>%\#/;1&\,=6HLOGJV.3EF\L55D>
M3IF&B+U]E7I. Q',RB!'=AES%;/%1M2+9A$-CR:ZK9!PN==FWYU(]4UM8/XM
M-=1Z3;*.[LYRD=UJ3+*TL<VH11C$4:@HHMB6?**"6P34N&V6/^8_D54';&,X
MW)(!&^#Y#&QJ(M6P^J3QI:4%=Z^?++/'CQX95P[>/')S+N'3IRL)UUW*ZQSJ
MKKJG.JLJ<RBBAS"(ZZ:.XQPJF%C4 *B@*% P%4 8     '3&PP*R/<,V.'
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M%M>XMR0<P*8E9Y.\D[S^7A0R$(R\) V!J88X^!8RBE$P%4@$*%V4 8P.'<#
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MFPWRK0^4KW'NI6H45])(H6*PQ[,KX[AU'L3 !EDREC9#DW,0RPLW!42J"F8
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M9ND4UT%"!JM2'\Y7 (#IN",$$'?(.^<'?.XQCR%.$+C<^//ETP>77IUR*G8
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M'CRY>/,?>]6L, YQD;;\M\[[]-LU8;EIW VWR'\?R\^GXATZ[;ZGJQ.<GGC
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M6+,23G0 D8)SG!/D2!MCED>?PZBAHH,F7%=P9-6!8T\NEAZN,Y8D>.+%7Q_
M:7!H(O$;20D8=^2'23 H6MS\0]W(F+,"BFB"TB0N^A]I68R"-M1N'C9OXAP
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MA,WC60:MWK%RW>,W21%VSIJLFX;.$%"@9)9!=(QDE4E""!R*)F,0Q1 2F$!
M=1"&4E75D920RL,,I&Q!!W!!V((!!Y@5;RKTZI2FE*:4J$_%XL'C49ON.X)S
MJPAY=319 ']PAVTI4+]*4TI5=J\&I9K#&P22H("\,JJNN(<PMV;8H*.5@*.P
M&, "1),HCL*JJ8#T'6&XD,<3L/S8.-L]"3L2,[ ]0/.I%JJM/'QIQHK!G3)
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M[I2["(@4 '[H>0 'G_WUZ$2>@R>O3QWR>?PK!@> ^._G7[]S']D?\H:IEO\
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M-Q_+</+YZ\_U.Z$DC;\R<[Y)^! ].GB:UTC;DXQ@$#EYY/3QQYC.-Q4B@9;
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M>7,?T'71VW8S3X)N]$*9!V.%V&03R\<#Z^52QKU;95UHFW:(D2(F7E I0Y0
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MXEU?4I(F<Y(.62+/A'PC&1[V6[3.-)1@A)L5RKLI!LD\:+%YOTC==(JJ)MC
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MMA+S.O?]A]?_ #VX#Z" >6E*S_I2H]0Y?<\L6UJ(!L\:K+$Z#]\%3,78@'F
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M$-Q$-NOT]//?\!V^G368CPQ]^/S/Q\=ZN);Q?/\ Y3CY@X'WU.:Z?!W\M_\
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MB0879^%^!@!D#WN%O=K)',['!)#@'( \QN!D8YDGXX-9C\'Y?0N^M7EO]/\
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MT9V\.NS0TFOZ4-/]HO(^.72KKB;4S+.D5M81)#)##%96_ PX':0(%1,HP5@
MJAVK-"5Q)'G!<D'"[$DG&0<G!Y;9QL<\ZW&XNO25^KOO"YVR-EAUUHJV1*"3
MMN,7,-7+ELH3P'R:;DB#GW8R[<1\4@ *B +J*-U=O+M1M/8;C@4,;:11):S,
M5;O8V56YH2.)"_"PV(V) #"KT<NO%Q88?F R-\X\3CZ?.LE>"?Y?74'C7Q^A
M_:JY/B?F:>"?Y?73C7Q^A_:F3XGYFG@G^7UTXU\?H?VID^)^9IX)_E]=.-?'
MZ']J9/B?F:>"?Y?73C7Q^A_:F3XGYFN00.(@ ]OEU'5"ZCKGYC^GC]]*9/\
MF.?OKG^E>U)#;L7R[[>@;]?3;MMYCWW\\+29WW'@/#;;(Z#QY'/2JJ26&23]
M?OE_7;G551;[" [ ([!L.V_S]!V\P#M_*,[?$GSY?9Z<N=9\ D$@<P-Q\_@.
MOAFJVT;;G#8 ';Y 'G^'7Z?AOK!(Q\!DY'WUJAX1L  >IVY')^F#G'/&2/"^
M(]   !VVVZ &P!\O3Z]?,=]1'SG/3.V=_AR'J>A^%5&^WC]_>*\LBV^(7&F1
M&VX"\1=+%[[I&<IG4,(?X46:HAY!UWWUK+EN)P-]@3GQSMRYC&#OSR3L*-S\
MAZ[>6_3GS^0Z2F -M1JI5!>5B ?V*&MKJ'CW%FKT7/0<).K-R'DXN'M#F!>6
M*-8NA#Q$&<RZJ]=<2*)! CE6%CCJ (MD]E*B'=?9]<+T_"YX^QF)L>8NR%Q
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MJF#]D#I.T0$0]? <!V'];;80';2GPS_;UVY^-9#7$%"D5)U35(50A@Z@)5
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M1M,X9\W5Z>4QS=HK[/5AC=VC*@V;%M9N:MKF(.4C%RL8JX61B^;(J-OCDQ*
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M8W_Z"2$_C)E#N!4'B9CB.P["[ -P#8-*587%14U(RPPUS:%$B,NW".?*)@(
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MR>[@FU3;MS@!2>*0G.IV_9[CCMY0_*0MA6&%5.$YXD#$G*Y4C)8CD:R01&.
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MJ0PJRZH*-C2BT!'/$I8,PB"JLLS&-&SPJ!_,E\T4C9<[=X<*=^'C*E:>._\
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MC (B*@4Y9YD>'/Y#P^/H*5MR;.4'B*;ALH59%4H&34(("4Q1\P$/3J @/4#
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M4:L[<HK'3\.=S=I<AXFT6 UKG8PT0TCJX=D_L!W+OXCR+0JRS4Y'*R:3-9!
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M4J)WGOYAV'S#2E;6L<O5IFC52?8*E%R[A&'Q!N8=F[UVU;E:.SB/7P'8KH*
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MY(?.[ME'"^9*CA9@1]$4J+0/CQ3)M:GT,QNK_DY_5:4V;B>!\<LM()@TKWK
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M<)I&.!]GJ,C1V#0H 7O7CL49K22\@4SD!O:HXR&6$H65G!RI((4FIMPW#"$
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M-[ICDV(N+G3X+][=X8YESEERNW,==FY@D[K@U'JB<3F8>'FO1[9\^G+LK!,
M/8Z1E&NPM1N&/Y5P(+)QQ(Z6DIG(-RH2K(6;^&>1[JK.&S=XJ@G%13$C<Q>Y
MU'\,NP/:O4UUV+3M/M[V5N&VUC1KDS0:A& #QM-:10Z;#=]X2DRR17 9E![Y
MWS5@AA<M*$7<;F,#AR.?Y=ACIN.N-S6T*.R=-Y2PC5,G6FA2&,YJP).BFKL@
MHHJW?M$.3W.SP*CA-!Z>NS[=9-Y%B^;IKE)XI4E9!B5I*R"SL(].U";2[>\2
M^AM0BI<(-U+#WH90-N]A*A'X25SX'*C&\(P.'?8>O(['QQ@>=:^\LV0HG<E3
MYE3F,9,B:0"=50P@/*FDD4>910PB $(4!,8P@ !N.^O1=.AQC.P 'O'D!GF3
MC SS).V.O,TC0)[S$#&?$#)YY\0>6V,GK4?.)"S&P[BM'!Z+EJM<LM*0UKO9
MUB5.ZX]EZTJN9W1VE?G4V@S5?M38Q0&<8N$%DCIM%O 92?,V*IM=%MQJ>H'5
MW4K;:<)K>S&;JTO89P>"[>>+B6&XM6&!;N N"=WC!8U6(&:X+D^XF#Q+PD87
M<9!.1@G<]1M@5*C@SPW(4.A0E6EFTU&6:\3$7<\@4FX4Q(\E3D8)=L[HJ]7N
M;P3KF86(R!G[MN@9R<0]Z%N$./C(:YWM1J:7=W+<HT4D-G$]K97=I>-W=TTR
MLEXEQ:KMQP@B,,P R%/\PX>H\\@FFVX2O"!GAP,*001GIG8^0YUO7HD7[E%-
MB"0Q=DR]PVZ<H;!L/?IM^_OKQF^EXI&(WW(V]=M\YQT]1MBLZ>Z,GEC Y9YC
MIMR^%9!*GY@7\^X^GEN/[OGK7$D[9V\.GRH02.+;[V^]Z[/#-W #;AZ@(=?S
M[?GJE6Y.,9./#I7:FD8W4P#Z   &_P" ;!T_EI]_>PI7I2;B8X?=-MOYAM_I
M\]]_EL'7;5"0!][U<@RPSRS^_P /K562;%+V >X=^OYC_KTZ;?AK$6)YU)P%
MV&<$$>&?3EMY[\Z]Y">0?F/]?N#_ *ZMJW<X'R'^]63?;&,'&E9,!$\U+![N
MR(G]Y9)-0?#4<%(&YN<1'P6^P 85S 8H#X9BCA8Y/IRH=N6Y\0?@>6=OD?'
MJ[<>5 M5A$R+@4TJ_$CJ24[B502_HVI3=1$C8IC$$0'8ZPJG#H< +;5*R#I2
MFE*:4II2O'(2#"*9N)&4>M(V/9I&7=OG[E%HS:HEVYEG+EP=-%!(NX<RBIRD
M#<-Q#<-*5YXF<A9YDG)04O&34<L94B4A$OFLDR5.B<4UB)NF:JR!SI* 9-0I
M3B*9RF(< , AI2JD!@-OL/;\OX^GTTI5LUZH0-:5EG$6R$CV<?*R,S*/'+F1
MEY1R<ZADO?I1^NY?.&[)-06D6R.X%G$QY$8^-;M62"2!+F=G"!CLBX11@*O+
M.%&!ECNQQECDL=ZKD_?+Y<JNC5M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4
MII2FE*:4IVTI43N(7,B<&S<4BLNP-,OT#)33UN?<8EDJ'*=F0Q>I9!V01*?8
M>9HW$1'E653%-2H$:4J0_#"=0N4FX)@/*I"2Y%A 1_W0)I* !@#N7QDT1Z@(
M 8I!Z#L.E*V0Z4J*W%H<P4BO$ =BGM"6X=?O<L5)B #^&^X;_EI2H :4II2F
ME*:4II2FE*:4II2KEIJ1E[=5T2[\RE@ARAMWZR#?KY=@ZZ4K<$'GTV_[!W_A
M^6E*Y'L.E*U99QKJ]=R;9TSI&(WE7RDZS4$# 19&7,9VJ9(3"(B5-X=TW-V
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MM9M+C5-,M>TNNV%_I>K0Z?INI>U376DM)H<NG)/H2:+=R+;VG:*_D[9-;?\
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M(@/*8!#<!$!VZ".E*R'B.9- Y)I[\#B0AIELQ7'?8!;R8C'+@/J IN3=.G4
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M2.'&,$@L#@9&,#)!F%CS$N-L5RZSO$M26>2\3>T;52<DW-,CJSQ<>M F93,
M-<5:*19HUY(/)$J0*J(G!NLHY\('0I+GYR\O[V_A5=4N52*6S>VO-.LV(MY'
M$W'#,+@,) R(J \(/O;!BN5J)+--*2.+B X<$Y5=CG=-PV>>=O\ R\JDM0<2
M/Y1X1R[(NX5.LLJ8RXB)"'=N5'SDK5N'*V9-E'BRR_NC-%NU(<WW$B@4H%T-
M]JL4:%5*HH"@ 9WX%"H7.,NX0 !G+,0-R235B1,3D[YSGG@9R3@;X_\ MP/0
M<]@F.\<-X9!(10*00 HB;E#H(;;[#MW] Z^6_37!:CJ33,1DG?QWP?+R\,C
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(I32E-*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>g67046g86p72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g86p72.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1?:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %[Z^8'@X0DE-! 0      %H< 5H  QLE1QP"   "7:4< E  "%)2,3$W
M-3<R' (% #E-:6-R;W-O9G0@5V]R9" M(%-43U)-("T@1E5,3"!"55-)3D53
M4R!314-424].(%))1$52+F1O8W@X0DE-!"4      !!P1XQ$ CUH^O_);1\_
MA X%.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           !G0  !)$          0                         !
M          21   !G0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !G0    !29VAT;&]N9P  !)$    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   9T
M    4F=H=&QO;F<   21     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      U&     0   *     Y   !X
M:N    TJ !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M?8VJIGTGO(:T=M7.6>,_J;,J+\6IN$^P5TWLNWL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
MU@)= P$1  (1 0,1 ?_$ !\  0 " P # 0$!           ("04&!P$#! (*
M"__$ %(0  $$ @(! P$$ PH+ @P'  4" P0& 0< "!$)$A,4%18A,2)!40H7
M&!DC6&%QD=4D)3(X@9>8H;'7\+?1*#,T0E)4='9XN+G!0U-H<K7%\?_$ !L!
M 0 " P$!               #! $"!08'_\0 0!$  @(" 0($ P4%!0<% 0$
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MN5"!/DH31B9%:RK#LF*,6^F;(CM90OY'FF%MH]JO<K'C/@#.< < < < < <
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M:3(N=XMI$Z7LZI421)DE'I!#,G#4IMAD"I#KOZ4'82@:[]+.OW2@ZR67ZO\
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M/P0<Q#&U@/)'+*C@2\0)ZTJA)=E 73\ < < < < < < < < < < < < < <
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M7O@&V+V3!]1S/32S=7J\&-:0L]LUS0H% ME8[)V L,FQJW5ZL7CE"K0LL2&
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M$5G8A/7T>UE&M<%MC5T$M8L+=B-32/DFQ[&?F96MK)#*R2I;BP+%^ . . .
M. . . . . . . . . . . . . ?G*4YSYSC&<_MX!XRA&?SQ_OS_ $X_;_3G
M@'GV)_9_OS^O_3P#DMBT/J.V[<USO>RT<29VUJ,);Z[K6Z3E3'B--$WYF%%N
M,<(QF5@?&=L,0=#AD9N8:YKL-G$7$A+"E-J _5!T5J75UPVQ?Z#2!-9N.\K,
M,N.V#T!4S,RZV4,%CUT85*_427F4OPPT5B"RB(U&8PA*EY:RZM;B@.L>Q/[/
M^/\ 1G_[8_ZSG@'ZX X X X X X X X X X X X X X X X X X X X X X
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M1YDCK.^5:]P!,^0S]3'@DY=7*E(\"6_'_EV8TIQIYQG^50C*/TN =0X X X
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MQ:93=O3[:Z<E2KG",9V0\2*A.24;%Q[MP;2[;[--ZW1LIL-SN-KRE2H\.?)
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MTJ?I4O?9U; -O9^2#5:XF3)C!H7A+CSLB>9(?*9+DY+X'2> . . . . . .
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MMSL3K[3)5Q#,;).^Z_UE8W,1$?R6&Y%3BQV<8PW%ES6L8?R!-O@#@$!.H/\
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M=1*368<AIU^-)/3EX8DW0[#=4R6(QXH^&XZ#"B. ==X X X X X X X X X
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M$I;>&'FW%@46[4]0VD])](;7[';(H]XO-H[C]MR^O-0A*0' K+N3)^EJT&U
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M;G&.JY7-5PCQJFGWAM&$)2GVIQXQX\)QC&,?T8\8QX_T<[1V3]\ < < < <
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ML;*E;33J7/@K%/Q?!4UN*G98T]Q.M;%I5;JI_6F^-JPQ[<_.!=+/U!U,"75
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MNT=<48G7SM'K<&N5(1]\;3.IH)R'KT5JA=GA5"<4D!$W4AK<(+IA2V.173)
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M5E3-'NDCVB(N@MQ:[W9KFA#2#NU8X6Q:Z(7*BR"&RQ#5:KEAOY(XT2E6D?\
M=JL11H&$Z\^D.%T%:]?1V-Z'+;IJD$8U[E:YG4J(#LI_;J^M#G5TU:U[("6>
M/-"U<O29$TXW4! "//$V>2V_ MJ($9N'D#>>ME+H?5S='J21-; B4:MTX=H>
MYQPQFX6ZV2Y4YC214I):<L5V-68ZEJ4[%2VE#L]Z-$3G/TT=M/E&:N=D_!X6
M7E\5/X;'NOX.7%3\*N5G'EIZWQUO3_0J9^3\%@YF9P\1XF+D9*KWQYNBJ=JA
MRT]<N.MI-K>TF^S[_&W0/SI*'V2L0YV#]38 9QH-!=Q/>B1,X9H+XZ.ZI,?+
M[3JYYJ6E;B&L-JF^[*<*:QSR\.LU_P!BP^T63!PY747QIK?.48/6!*$7*$92
MBW9?8MQ37-]M1VO,QZY7_85?VFR:77&5]%_@UMV2A!M=.E"+<8.2Y6736U'2
MGMO6SE87:[^NJC($P]2;$:^^FS56IIP\A^+&FMMS@DLZ<:626Y*@U>45C"FX
M[K[:&X,2PLM.K>E,I<G\JCJKZ?BRIATGJ2>;U264OB$U&4?&JE??RLU*&-*V
M-2@VM5QOCW<E\_)HZK/I^*ZH=&ZFOCNJRRD[TXQFE;5._(3L;E5B66PI4.2C
M&$,J*W*45S^HIOW85;A/[@NHH0Z#C0G) ?7PMQCZP7:P\9BME69=D9C.YEPG
M5V::Y[UMR,19(^7!PAGXDO/[V=>ZAC52ZQG54RQZZ^=73ZI1\6K+IA#'OC+)
MC%J<&\F>MJ7"49II**UO;]H.HXE5G6<^FKX:-?.GIE4ESIRZ80Q;8SRE%\XM
MY,Y*7&7"5<X**45RRX^+M-%FPJ<1@6W3EN39-M7J(,&Q<3Z\%N8IUZFBE*^I
MQ+,.098YV3A(MEY*_IUS):/@5&]LM=?5%D[LLKRNCY?Q75<^NJJ*LQJLRF4L
M.N2Y<[O#G7*6J4T^+G+<4D2U0ZNLJ+G95E]%S5E=6ZA&NN"MQJ,ZF4L*K\?.
M]U3J<ON5+>G.<=))\O'FA6W"$6_5'9Q>I[ O53?7:@$ C!??C"Z3+7" !'1[
M&<K2JX.QDI4IV8AY.,ON)96W,Q&D<NJZGJ]D.H8?4KL3.SL5O,HKG7*4*L.:
MA10ZXKDWFM*+3L4VN3BM2T^95;5UFV'4,/JMV)U#/PV\S&JMKG*-6#.4<?'=
M<5M2S)149;L4M<G%.,]2W;M-9]3?=D%"J=LQG8&KBQ.C#!H&0\^=@X777!9B
M"R(^2.B;*B-8A+1*]JF69D9V-\Z%*>;Q>^U.5TI8M$,3*UG]+MMPJJL>;ED5
M_P"SRKNKC4Y+G.$57).3?>+BI?--.Y]JLKI+Q:(8N7OJ/2[[<&FK&L<LB'+&
M\/(KC2W%660CX;4N_&<7'EN4D13O&UII"K2Z19Q(I\G8X5;V,Q9KLR0$%,EY
M"FJPTXU$9:98<3($YP<C.X>^C:**FRY^9*4R?9Y7/ZM.W&G@95-+MR:\7J$,
MG/A91?XLDL7<:]+ERI7CPDMUJV4YV;7(\IG]8G;BV=/RZ:7=E5XW4X9/4(V4
MW2NDHXD7&N*CWG0OB*Y-JJ-KG*QR2F60=:3 *]-7'8XI7D.0L)0<(^5OXLQ&
MX;0P8^PGSC&,LI"5ZK)95X_DT,K:3[<)_'Z-]G+Z,]9?4Z=^%;D70JYK3@H*
MJJ4>_I&G&Q5](I.*[+O](^S=^/U".9U/'>Z;,FZJK<7%P5:JH<=/MKP<;%UK
MLDM+LN_=)2,W1+D.,E":Q[LIDD5LI4^91A7A<81ES&?A@N8Q[7R^$>Z0TK*1
M6?*_KV.[+>6G!)?#_M3:3E=W>X5;6E6UK=NOF3^[?_$7>FOBTX)?[,]<IM+=
MOGN%6T]0:6I6ZW)2:IDG\\?GGZGHTUAEMD0X*<BH2F&\#($ SL/*$XPE43$"
M2PTPM/C&4K2UA6,^<^?QSYBLZ7A324:G4XK471993*';2</#G&,9?GK?YD5G
M3,*:BE2ZW'2@Z+)TN'EWAX<HJ+6O1;[&'H.LRM4LEJ.G;N=N[9;$*+6F+"U&
M5)J8AA*URQL6=']F9?VE*4R_-D98CN/_ $$',C#SK7RYBP.FVXN1E7WYMV;X
MKA'&61&#GB4Q7SU0G'\2LGJ4GQ@WPCR4FMD>#TZ[%R,J^[.OS5<X1QHY"@Y8
ME,5\]4)QUS5L^,IR<8N7"'-SE':[!C'C&,8_+&,8_LYUCJ'G@#@#@#@#@#@#
M@#@#@$0>^M7*7/J/NVLAZ8]?IQ6LP6L5N-%LI&:Y$8L8263-#P]-/5>VV$G5
M!L>5:Q=8K5B#';.1"QJ^*GL323*N :=Z<C%MB]91,:WQ;CB5%NM^BA3E_![7
MI]NN=6C628S7KD9U_NZUW79VNY!Z A#Z:;:#[\H:TA$EF*/B3F(+ $4+]T%[
M,W[<>RMWE;3UN>O/[\>K;YIF;+K5X>%0-::8L]XGTC3EYK\;$1C V7&V9>KM
M:;2*(E31G:A>.2RANMB08@2]^_?\@:UU?])2V=?M@ZF>)[B"V36>K(<VQ,R
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M=/6]/7EO7;?TWY;_ "-?3>GK>MZ]3W< \><>?'G\?R\< \\ < < < < < <
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M-%CAFS=1UKJW60_8U1I-$OM:>;B4<'9*J7F+MCYY11BQBZL #51-=FU.POE
M/[I]F];NOGJ7[4ZD5:9>=B:S =3]&5W;LS56J[G!JME $MCF*K6QNJ-D3(<2
M>6'AFZYK.U5@\)&+KY>5'5&("33,5;#[H&Y3?3Y%JZJ;9T/TAEU_2D[5 .9H
M3J+<+V]9MA"M=K@VXE:=[V-@H5(%+1]1L.WW38^J;@UEX@/?C4P4S-%%P,-L
M%D"1'9$&:JT;K$U;IXTS9-@$M9]8;\4#CW! 8T1L]\U=<RQ@>*>D2G( U4;6
MMX9%BWY<E4>-9<QG7GUM>]0%D"?\G'Y9_JSYQ^?[?.?^/]GY< _7 ' ' ' '
M ' ' ' ' ' ' ' ' ' ' *\/5CAN$/3H[806A31IR7K7#"!S]8.W=EY3EC I
MPZ[2:VV\4NB(?GZU5/\ C4-M&(_V$<\ YY'. (G^B4S1V=:[MQ28^DH\?-UJ
MV2&-+=%KKT9@*D?=Z5\6;!5KG/G/7LC\?NQ'/CU-1Q3/R#G$96ZC.'O^H+OO
M<G_TL?VX_P"OUX_MX!XRK&,?AG'G^CQG/YX_[^'V3?T!1+O/:EBH797M,@!)
M&. =H&-5#+,))1',NDQ>OM;_ &$5%/._HN18)*6Z^PIZ \B7(BNM)0XS\B\*
M^7_:[[5\+;.E8?=U6V4]1KOK^2^KA"3KJG&2EP:<XV]XRG'M%KS/EWVP^UOA
M73Z3AZ^ZMLIZG#(J;A?0ZZ9>'5.$E)0ESE7:]P<T^,9:;WK3T4-: 5:@'S8Z
MMFCU9;55*X7A$ZQK0<*)FH9-)Q9EA<5:W8DEDW"2I;,N.[)B1&<293<1#;_E
M9PHRL?&CD75XMF1C1^%Q;(VXW3*J[KU;&^5RX=ZYPNJV^2<HPBI3A#4O*2A1
MEX^-7D9%6+?D8L5AXM\;L/I-55U]=D;Y71E#;A..3!/4E*48QYSC7%2Z!L[<
M5AW)3(3426$J]@#7>10\!AEA*-13M7Q!C1A%?$1DI?F%$$2++LP[*DKCP)&&
MJYC+[CK4>..Z'4^L9/6,."A.C%R*<^> Z:[[%&_%X*%-%,-2G8K)I67RGJN<
M5CKGR457T.J]:R>M84(PECXN33U"?3W13?:HY.&X)5440[V6QLL2LR+)N%<E
M'&^?DHPJUW4]>FV@%L_6=M,L:X%C*@#P7-6,DJ2"J<5@[]HNQ!PV:O\ P>5:
M+ @*_+1$*-I?1$(.IP\OZ5A-?I6/9EX_5.F9E\>G558=$;[K[=U8L%<YRA35
M/CX<LK(5.W"U)J,WIRXI5ND8MF3C]5Z7FW+I=5>%C1ONR+N>/B0C<YRA359+
M[N67D> VX6ZU"R47O@ET+KYODKKJ,6U^_77CV=E&K*6@3QQD82D5P:P-:%1(
M#-><>]ON@MC9BF@4AT:YF)B!'BQW4/I;YT/L]UZ[IT;.GSQWD_VGD95T+*KZ
M[)XM4:850I6/-_\ "\.>J)2K<8*,80:DD='[.]?MZ<[>G3QIY+ZID9>17.N^
MJZ6-3"F%4*XXK:25?A6:QYV5/AX:JKDI:?,;AM:EE;>#!5"D_<2F#S-&+0&V
M 4 />A1(:36A^%-*?%.41$YGRGC"(3S:L-S,M_ EM32DJY67U;!LRZ*,3!>!
M@U7]/NK4**Z<^F=5TXRKG;JQVT<I2N5?HWM237$Y>9U?"NS*,?$Z>^GX%=O3
M[ZE#&KHZA1;5;)3KG:E:[*%*4KHP])-\6N.GD#DLR W#)LANO7^K6VP+M-OI
MA ?!B%Y1<Z9AE\YND*M2'$.,0U05#\Q!$=]Y,=\;*;5.7)CJ8BSW3MQ^LO(O
MQ^HXN7D?&Y6'97&-TKK[X7KXRO%DX34'5X,H4J4E7X<DYRDI-2WSMQ^MO)OQ
MNI8F9DO-S,"RFJ%\[<BZN]2S(8TY*2J=7@.%*EJ#KG%V2FI*,_AG7.#MQ%5L
M^R7E$:NO6U5!QJRX 8J]H=GB)$4A&,FS IUDE%1+;^I;DU3ZB2/@JE86B0Y,
M80^W[N'V>KZO\+D=2?BXCZ=C41Q71'%R7;3978LBZZEJV/-*:EB\G77R24G/
MNO?P^SE76(XN3U27C8KZ9B8\<26-#$RG93.-OCW9%+5T?$7*,\3G*%?-\9<U
MM8WKUH6UCZ-41UAG7&A#*M=[67F4I<J%G%TC3I/PM-VSZ#"(LP,MEB/B(/6T
M]\B,3'7'W6)L-N!']G>AY-6#BU9$\W"JQ<[+NEARLAO-A.QJ"R_#2A.EJ,91
MJTT].3<HV14(OLYT')IZ=A59,\S AB9V9?/!\2'^W1LFU'XUU:A.G48N%6GO
MYW)N,H*$[VFD-I3A&/;A*$IPG&,83C&,8QC&$XQC&/&,8QXQC&,?EC&,<]SY
M>1[GR\CV< < < < < < < < < < < < @SZE->,6OI#V!KH(5'.$2M6#L8$2
MXU:GQ2,-%RK;Q2+($W6R5"EGFG1;<W"JU<;&+J=E3Y 65YX*1FQ7P,+Z9P2O
MU_JK71E8IP&B"6K7<W&J]6]/:/T4+8=>,N+>DMZ]Z\[%VGK."[*7GY7B ^W2
M291>?JB\*#+5EC $_P#SC]N/[> /<G_TL?VXX!157_4'ZS=1^T_J( ]PVLK"
M);$[=TZR HX !-._ $KG1/JCKT@0**C_ !XAHS>=8VRJQF$?42W2<-EY4=L6
M^J>UV,;H/4\NF%]5$?"LBI0E*R"<HN7'>M[6O/OZ=UOR)HT63CR26GW6VNZW
MK?[_ /,]^V?70TK1[('AT'6%IVA4S6M*]?8MFP:B4EU$^P6:"#56Y(VP"UH;
M=#PY3DN>09GR&%D$(&M-_2_.79OX_P!ELNV$G;?7CVPOE4ZI0E9N,8.7-2KE
M+M)N,8IJ+\Y-ZU%R1Q92C)RDHN+>UK?9+>^W^I,49ZAM,:(ZGK^P-1;AU9:]
MQ;H-Z=J]:N8(7 GQU"\^R!=B#CA5J,[433JT1HD\,Z7QB4U-:3EYJ,U(E\U]
M(N<<B=61C7UXN+5DV3JE*2?B:4JHZC_>P;[I\4EY]](C\%[EQG&2BD^2?9[6
M]?5/\FM[(\=Y-^:?[$"MP=)B3),(2#V()"N-AMC(X!496 -%L6XQJZO:))3#
M3DIJQT^K5:9\S<-]).R1!R69#$QY2+G3,3)PWC=47&<)5RG5"MN=BYW1QOO*
MXKDODLLFEY:KY/27?>J$J^-ND]I\4GW;E\OE_P#%MOZ:)U:N[-ZI.R=&ZOEV
MD5"VIM/20;:U=IL6/+QB56F!D=!*3#DM14CF&HLMDDU&A+D-2E,"YJFX^$1'
M.<N_!R(++O4'+&Q\J5$[FTOGE*3AN.]Z<>+;UI<H_4BE"7SR2^6,N+?;MW[$
M;Z!V'ZST3MAN=FQ;)UK7=E;K/ZRI\ -F7!Q;IUD $[Q1*R *?1M/2V\V */K
MI\#@@XU%RR?CX6XT_.BXD7+L//LZ=BRA1D3IQUDV.7%NI5RA1;.Q/RU&7.,M
M>33[+3WM*%CA%*,G&"DV]=MO3??\M-:^J?F1JJW>?I-</4&_?$1<IE1N(G5U
MCT06+WMV96JTW]C;%LF7I7U4HFNNMIDE08.(#4KXY!%FV-*DLQY\)YF+?LZ3
MU2OI'@^$K:W?#,C&KC9-JRFO2TDIII2F[%V4)1[II[<GA6^%K2<=J:TMO32W
MOMO233_+S\O/IM"[\[K*=V]H==Y>N@]QUQ%W2(H-4ML!+]->J%2A54F[;K#.
MD$G"C-[Q"N" P%QP?]DLQ"A""-^1<FS!(D>M9TFA=+HS5<Z[GBSOMK>K/$F[
M8*JN*6O#<JW.?E+<82DEI/6)U054)IM2<-M>>WM_N[>B7DMLE^3'W]SL&5W8
M,V!<)&IJ%54:T/:BBN-NU<R8>DX-639 Z*RSEV68IR9 X,_&PAZ=*3!LD.)+
M;?ALB9_.4ZEB1QI4U>/;8KX9/?Q(02<84M[24;-.?=;3=>NTMD7;@H\5R;Y*
M7JE]//R]?+\OJ2VARX\Z+'F19#$J++9;D19,=Q#K$B,^A+C#[#K>5(=:>:4A
MQMQ"E(<2K"T9]N<<H]UM/LUV:^C]4R,^K@#@#@#@#@#@#@#@#@#@#@%.?J"6
MRN[?V$8ZKV;7W8,B+KFK*O?B%MT9UWU[V+60&[DG[2HTVN%(&P]?6^+KR<,C
MZY<GBSHA]!$THL^UEN.T"PJ6!9>/'C:SI"",')OT017]5QH$+Z6"^]L^,-$U
M)N/&^G',PY$EZ^L16&_B@MCW7W+ C$=$)YS.&% ?STP5]\K/JKJ%%!A.YT.V
M5\7>0PF463<J],C;OC=LM=E0Q[LCDV1'RC^L7NL\FX1&)UP;*5F4G[>'PVL6
ME G"0.V=1P_J0QM:]H9,N%=6;J0UAJ.)*A=NB5UFA9_9"(1[!X[/%-,,TX@1
M,Q*"3KTO136O<5;$.@2B$5_%7BQU,&,K _A?Z4=1[M8;U5;OOF+V1U-KB;;*
M,(K5WI6B[7M7[U7UW>JZP8UW%'JG@X@HUANL6QXFMXBLR!E5I;\FO3URD84!
M_2YM;ICU6=]1?1\GL#UJZ\>GWIZ3M7L7,.UC?.X#) [W3UPG5H5YW80*972A
M;6U/GQI>2#&SZ_>KN-PN#8H.8<DP?F$4S )'T/4_;P!ZDG<DETAT2$/];]W4
MCJEI_P#A&W&44I0X!HF'4"-6N1_16R/MM;NQ3FO&OAC4]\:+,1Y ^M );TR:
MB$)>L./R^GOV_P!?H#^C7JEUPJW4C0.N^O=,M5_N]=UU#-1H-JVC846J]FG;
M!9S=M)2[ =;A#FYTC[4/S6HOQPHZ(P]N)$2E6&,+5D&#[3=2]?=MPFJP6PK+
MLBL1M0[LH.^*U*UK;WJ>0F6[7;TYX,..2V8LM<ZN2<D'_M" UB-*4XF/(A3X
M4J.T\D"46,83CQC\OQ_WY\__ 'X!YX X X X X X X X X X X X X X X!7
M+ZFVU=9U'08_4&RWM2P6NTEHGZ7J9?L)9I%)Z]C+0)U]=]U)SN>YC+15K#6J
MN4!ZF,@@DNN2I16??"M1"8BIAE)<R*!&[T;-&U/3U7[%D:CL7IE;XM^V%3R;
ME5Z2[,M>U-<4/ .ELA4,FK!=+?;3D0[9'VI1C(CWP!\9I+DB&T\Y,E.( XWV
M7TIVLL?8[O&YK;2G8POJ;: +T_9+LF'MBKB1NU@FD.QU@LG:VA:K?+;FA%J'
M+V#HR[C:^%'?1Z["6I%7MP*<1 2)8\@=#Z_T]_S_ (G.^GO5'U"*)NC2)3;0
M39<;8E5&!LF=_6K;(W8.I1FF6>FZJ% TA9Z*/VC!/W"X@NS#D2X6#Z6L,1+&
MH=(L\?:*'WXZL/U!.;1V@W]C[;[)B.P!2OV_:U5<JD:;;:.%(TL+'+78!8G,
M6$-12=OO4P'%EBVQ9 .,/66QYCI;0M,Q]"L^WYSB?9J&?UO[37]2QK81G?"/
M3\EQE'^_KOC;=2]\9^&O#2Y;C&6N2?I\XQ/LQ7U'KOVHR.J8MT>=U<.FY4E*
M"4+J;XSNI7)UVN"\!_-&48V12:36ES#LKI"T4:RU^IAY)ZT 0^KFVJ^?,Q84
M"&,>AV5PL0%D#2_HPRO.6)\@5">5B5\Q$>)CMR'%Q5J\W]I.B96%E8^)1/(R
MJ*>EM8U]L*ZX4RADNZRNV^2A3Y*QU0>YMVPICMRAOS7VGZ'EX67BXN/+(R:*
M.DJ./DW0A773*O+=UE5M_&%'E&<J:W\[<X4I2Y)OL<+IOLP]0Z;!D-TFFG M
MXD&S3<:8;EH/0'8F/98"4^,^J3DXX\I43(J H1%8A)2\U)CR%_"QV:_L?U"_
MI^%"4<'"OISY9%ZKLOL^(K<&OB;9P::R7+2=-7AU*+;C.,OP]N/V,ZG?@8-<
ME@8631U&61<JYY$U?!UR4<FZRMJ3RI2?&5-;IJC'O&<9:C'G5<ZMVR21VQI^
M!(IOWGAT^FY?L3\*Z1H>7GGV"#D.&2=D+B.)E9\)D/*&S$^&,_%#C_I8;Y^/
M]F,N5G5>CUSP_B:\/$<LEUY\(\I3C9*$+5)PDI-)2EQDUQ>H+?;F8OV5S)V=
M7Z/">#\57@X3EDNO.A!2E-6NNNUV<)*;B^34)^3:K@UI24UITR@T#%AN-OD0
M[/=(IXZ=KSPQ12..:%$AS;$Z#(BKPI[[2E)S,1%G1T.O#)"XDR*M]UK+7/1=
M,^QU?3_B<S*E#*S5D7Y%'A^+75X5E?S5SBW\ULOF4+%&3IFX2@NTHOTG2OL7
M5T[XG-RYUY6='(OR,=TNZ%<:K*TIURAYNZ7WBA8HN54O#G#<HN)SFOZWA@0X
M#;.NZWL6YUZ\RLZ\DTFP#HTNRB*\3E28<^UD)$UK"D$4%([DJ.Y\F!\=EZ#\
MLYEC$AU'/HZ="BJGJO3\;J6;CYK_ +.E@WUP>37C72E"S,MG9W\1VP<H/?AI
M3K<I12DU1Q^FPQZL?K'3L;J6;C]0?]G2P<FN$LNK&ME.%N9;98E+Q?&KW%[\
M.*G6W.*4IJ4^E:38UWC:=EV%6R#3D*UL#]7S;*P#FSQ%)C0Y:H8\)/A2"#[$
M:.HE)9>7]5E;^'/Y5^1(S,PCU/1L3)>=U7)ZACSBXY<8=,EDJB<Z<*$)\*Z)
MP<Y0@G.>_F;ER>Y2EO7I^BX>4L[JV5U&B>XY<:^ESR8XT[*,&$).-=$ZI62A
M!2MFFN3WV;E*?-*4Z483GSCS^7CQ^'C]O[.>F79)?0].?K@#@#@#@#@#@#@#
M@#@#@#@#@#@#@$$>_&W(FOJ!K[7TRE[#M[78:_S=39>U=0 .V+A5E0-<WW:B
M;%"U?::U::[=HZ?WM\AYHXP/1$'QRZSV7''13<5\#.]":!6=<]?XX:K#=M"H
M96^;"MI")N?6M=U!;\';59IIDRZQKJI5^L5NM5]Z9)6L)%$!HL=^+G,MQ4B5
M(D2'0*S=Q%^P\W:/;VLB@/>(OIZ1V9ZW'#,RJB-@B['/T:. 2P>Y@W7D]!6#
MF,BV-AKK+CP[7DJ*8*4>(7,QG"+;I"9(#W]33NH%<]2^+O\ TFYN9&\,W0-K
M[XMB$[\9(R.N,_62^G]?A4L38& I=X'.W/%[;YES;O,"CG+HL4W9I3DQRO.A
M,< J8[0=;^T^T.U_:6UV34A+8IFL7UZ'LM[2H^Z.TL%89^HFK5 ?#JL(MPM)
M@LUZ2&*L19N%S9,5R"PG&(=C#2)GTWI.?AT],Z?59E446NE:5EBWVN4)IK;U
MO;:[+BU+>]-'3JG!55IR2U'??\Y-O>M/2^NOJ:1V2I_92B:#TIKTO1[X)T#"
MH-'V6,=LVNH0O(6_VHD^*+03=Y^ZP,DUB41FR7A@*:6D?31"@IMW,QV/B6Q9
MPK<&[,RKHVU2S)66T3\.^4U.F$6HRC2K)0_"DI6**[QW%1BY)[0<'*<DXN;E
M**T^\H\5KMM^>WW7;MY>;/BWKV\[&]DJUJU>Q=B3;?8=:;&V<BCR@E3AC+,T
M0+01[K2) L?%A+81"9&04B7,N*("&)DIM,.2_"P_G;$Z9@8%E[II5==]%/B\
MY\H:BYI[;EY2E\TM]G+7_P 8YC5"N4N*_$OF;\DGW^K26_7NNWKHYYKFC[GW
MU6=_S&4"#QIBM:JCV,]?)M>"/,2I9<'*'2Y-YO$X(-!6 G$K;D-1&<7:)V14
MF6&:R2?-/9=FONQL.S$BU*,7+(=4:(SGOA7/E%5T\I3A%SY)<5&O2;6HHS)Q
MBX[\MR:27)=N_EI-I=^_Z_Y[2UOK:42]C;D"O-C,[/UUJVXU9AT;%<KHO7=(
MDP2;%LIC\+Q]=E%8EV0]&CE LE$>1AMD@Q[I.5R&XWA8[J=<JJXT79-=JY2C
M-W6MP=5K?>*=D:HMQE%/3D]:D8<8Z::U&3WW?FWY-/MW??7;?T_/BE L^P=F
M;EU6[#4;>(P+!IX,R8A05F3 C[L1X 6*=>DOH?G2FX?LFEEXG3$1$,(9B+D1
M84:&F-9LA3CXN1VCQ<,F>I2<%+Q-RX:7;TC7I1TVVFOF9O)*,7M=DGY/LGW:
M6VNW?OK\]^G?)[:V+0RAS8+%-T8.HKQ2S^\%.'VT[9)H%L5;&,R1[DN:ER 2
M<+S8$B4_(@LP4(F358&H8%I9@-8QZ+H1I=F9*Z,:UXD'7"$)+P^,7\J4DH+:
M2:Y<$^2Y]UB,7M-S<FUW23[IK:UV?DG^?9:V=H[&;-[(Z_M-4EV7=I*4/-U6
M78:9.HIX!&,L0[BEZ\RXMS9J!I1,-8G[:7%V>8*LLN08B9(0"V&X<J'&'QJV
M#3A70M56)!2A9&$U9&3KG*MNI2IE;#4H<$ZUX45&6W"2?=O6$82;U#6W\VT^
MZWI/\_EUMK]>VV7%=!_5A0")Z"ZX[6KL()0XVEVY-CV[+GG3)@E=94Y4YJSF
MG92<*0%FXD2(MJGJ03<9L"YA99",(CR41O-=8Z!RCEYM$^5KRN$,91A",:5%
M+A%)[YQ6N$>R<$EOD]%:['7SRBWOEVBUYI]M+26OR7Z+S+_@DV'3B4!B++B2
M=<7)]F14R,5]I^!7S1;*IJ S<QE:X^:Y9W'?K*L_A7TT4H\\ 8?^ G61S7D7
M&4U+>U=7MVIK4IQCJ+DT^ZG7V\1:W)?,TG&;=-]_332[_P"7K^OU.P\A,#@#
M@#@#@#@#@#@#@#@#@'H;C,-O.2$--XD/-,LNOX;1AYQIA3JV6UNX3A:VVE/O
M*:0I64MJ=<RC"<K7Y ]_ ' /RK&%8\>?^&?'YX_[_P#AP"DCTI>HX@)&C=O5
M;-V,3DW4;O7736FR!&&[J>KDAO:#9?U^PJ^%3$2_&NYT8#%A")A<A4ET6R[#
M6\Y%6S&C 6G;EZX:'[$!T =Y:BU[M88P+L 6$U>JF&L;PL;:X;(^RQ@\PE$?
MFA\&X4:-&)+&2(CLIJ-'2\M?P-90!U@*%%5P0*  A\02$!C8(<.*'QVHD 8+
M&1FH0\?"BLH0U&B0XC#,>,PTE+;3+:&T)PE*<8 R? ' ' ' ' ' ' ' ' '
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M61[$X:;11]W4:=K?90?(0Z1!+78*<2>?FBFR2QV2@=;SJL$ LT<1;]K4M"<
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M5>XQ)%&;M>KH0G?1BU:\H%5V0]*<6PJ/M4W6[)4QHM(DO&F/)3$+)B,$8N9
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M==ZG; [E[M6T+9L._E]G;#V%<H=8&&K5<"P>OUK$M0BF@JW6A,$=5ZG60(^
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M<C#EP@(NWGTM0U_&]@ QGMKV=8#=DMZT_?FQ@T&/UU0)F6&EUP'48%2<&R-
M289S7!.M4Z@";'3;:S8AUAC4<4@O]5]KVY5C LRJH637*T! 3#9"RR@H88*D
MV(M&"0BAU\?"9B/%R,*M"0%=ASB+C2IDJ,!!B [#SRVAHR##0S&: S_ ' '
M' ' (3=8ND%-ZP7:[7,%L"^7?[>"R:72 =O;J+0S5>N)6S]A[><H]9>K58 D
MS$7[Y;+-?XZM\X^=4$%5D8N<IX;.GE@)L\ KBV%Z<M7VYLS?%ZV5NK;!@#O&
M=J@NJDUN2$H#5'-Z1?(/ZS*5ZV5 :-MDU=><+E'E139*?$(RWHDZ:R[,%P'F
M )=]?M-!^O.D]4Z-KIRP60#J6AUN@B#MKG9)6,J/K0N.+BS"LS"6VUR7&HZ?
MY)EMJ-&;PW&BM-1V6FT@<H[+=6RG8FUZ1L3>YK;KT7I:ZJV"S3!-;I5GJ=TM
MD14#[LF[4,MP4JF3.I>&"4BJ92K,048+?>1N&JPA:Z3$ :)U)Z#4GJ+LC>6R
MZOLG85U*[T)((6&%:XU(@Q6WV[G?;O@N6DU&IUPG>+HN?L(F$=O-VG'+ NHA
MZO7$/M10V')($EM[Z1I'8O5UBU!L7[?^Z%H>!2">*S82E6,_-7+ +LXM44T'
M?CSXR6BX>"\\VASXI3+:XTEMV.ZXVH"%.G_3<B:5O'7FR5KL;MT_5^N=9M%=
MJ5"V!!I=W'R)-ZLUH/7>T(/&@+M@#VNRC;!#I[YX7-:(#*D%R& R!46QVQ!M
M[]_3^8+,O;^A[?/ZL_CX_;GS^7 *H-S^DAIG>E^V_LNY7JP)M>SI%*E#'1VM
M=!1A5<<HVV0&Y!;=H#IU1B!NYIVQUR#7G5[I:NLUFBODPD>8V5*3K"\!/[KY
MI2M=<=):PT53IY<K6-64\13@I(\H;DQ.AB6,-)E3D!AP<-&=?7E;B8(80+#C
MVU(@BAL$?'C16@/BV]HT-N:PZ8*68Z88!:<V?"VVU3X*8:0UTME?!FQM+^]3
MCT=V8Z,IQLTBZBH$)Z,AZUA*_/F*=0+:96!Q+K+T=IG62^76] ]@WV[.'P<B
METP';D5-L7J_7DK9M^V](IM=>KE:!E#++MWV.=D+,6V><+X$0P(IN2W@=)DD
M0)%[NU6/WAJ'9>GBUALM4%[.I%EHQ&R4Z;&'V@+"LPJ2)E$0<R;#(0FB$=F2
MM;&)D"7%<SC+4B.ZRM:,@5J4'T:M!4*3J(Y!V;N?%MU#L<?L -.KY\-KZGNQ
M(&Q2.S\4(;JO7P.MZZJM&<M!)Z3D570$*3G.5./SI#Z_D2!;[P"K3<?I2:8W
M3M/?.WSMSLM?MN[Z+*H2W*E3M1AV (PP6UH8M+IMS][Y^?M/%M3JJOU>PCMG
M3;(*)4 K:J?*AO1C6)<0";W7+1X7K?I:AZ4KAB>="4(=-'CB) ;7@JU-3S)(
MVN+#!5,2"K( *.?*.C:]7P(B * @8@T1"8PQ#0I0'";;T[LMCWIO;> WL5>J
MS-W9HBOZ$158-,UI/#4:OU>=8"P4T#EE:S**DR\<M=;U.=0?ED(<C%GS%<9S
M&#!T1 -#UAZ?QC6]QZNV5WLUL:XB.JNJH6IJ33;+2-6N I@B/#E!)MARJ%5X
MLL)=#-22$J!&T!W62J  14,;('IL%GP8 L?QCQC&/V8\< < < < < < < <
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MS"5HPXA"\(<3E#B,+3A7M<1G\4+3Y\*3G\4JQG&?RX!^^ . . . . . . .
M. . . . . . 0X[>[]VII577^M:8HM%OFP=^;K5J,+$V1<CU'J ?$?5FR]GR
MRY,S6ZI<RV<_2ZY>%QF& ;Z<R"3;KJDMM*PI[_J"%U.]:_K:_P#O7U+8U8O=
M8W)L*E[)L,C7E/8#[#;AG]12MN0[I6PDR"5&6$^S,=TG>I=,L&:D."V2 @)Y
MEP21=H>@"2-,]33K%L':>L]5T^;=#DC;UHM=1U]>8U90C6MC*TVH5>WF<"K;
M()LL%?8BTL@D0P\8B6;.A;(B8.B"0LDMP#7+EZK'5_7]UV-2K; V\*=UR9V?
M4Y%C_>U)2ZK;;YJ--3>MNO:.6ARWUGKA]->*O*$P%18<0DV4PTU/1*B3H\8#
M3;7ZO/7@!!=@L43>#FP4C=_(5KHW1&:N9&7?KQ5YMIM^MS9$L92(Q;)XZ.Q)
M%1:U*M6/LN;&.3L11"_JN 9 IZI6O(];ZJD@VI=KV2Q=C+1I^M6.HBP<B--U
M"K<.GSNWQ,DN:,Q1=;N*AP<#+9F,U(M,2AB.0FOOQ'XC Z:!BQGK+].9=CZY
MU,M^^U43G:1NOS]4P;=KQX/)GUNX6<?2:5<9T3)5^<W6+?;9^0X>:/BDY++4
M&>?,PA-782;< P=)]9#K_MR[Z[IFEM?[8V0Y;NP.- VHD+@U;$+7Y*5K6V[,
M%V@C)@6<L/)B9XBG%U+@Q"#)<;"$V"43A19@N(+*@9*F^LWU+M;%;*3*UV"I
M54LE<J5P:O5YU 2#4\95=AZTMVUM=GBQ=@D04Q!OM8H%X36,18TR3*GUF2S*
M8AQR(*65 PH+UONEEKUVC9E4C;JM%<8'[,/V#[MZT<.3*A3]1!:+:;Y=;+@8
M:E08E9"U38=>L+\J'/GS$1_M 4]!:L<)P+D";/6#L\SV6D;T1&UM<Z QI/>U
M[TBJ;:E#'(5U?I,AAAZS5YP=*?6B!+P^VZN)+:0[$0_%]LB3\R\,@2KX X X
M X X X X X X X X X X X X!"_MAV/VEI2RZ-HNG-25K;UZW2?V"-A![7LI
MW5XJ /UQK<WL@LXV>;J%R;=*$X(1T6)C380\=]=(9<(%H41+KS8$>M6^LATI
MV:V'B,VJU5VP3=6:2V^6"'*K/\URG[TG:T$UPB6)0U28+,0(8VW2X5FG..-1
MH+,Z23C+FC!Q"5% DCICO7U[WWM)K3NN3%HG721J2%O"*R5IAX(*F:W*6!%=
M#G89<C%9A24F7GHI(4TRXO,T1)3+:5E<:>Q# Y "]5CJ590<HP#E;;(3E3:%
M"K%28TOL+-SV)G9,:\2JK-US7<AL2K<)DM:SV$J68'*R,@-T\O(DRD1/HI$P
M#3KUZO'5X&#(%M?0MH;AGC8O5<T\!I5!L#$]ZJ]M;UKREZ[.PTFH@]Q]UO\
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M X X X X X X X X!I]=O],MIZ^5BM6,89L&L+$.J>P1,%_Y9E2LA>H5J_#
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M,ZIQ1Y9MB2T*#BLMI2C.6(V07W\ < < < < < < < < < < < < < < < <
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MUK6XU1=D 4F9#6;$2ER$QG'7T. ?VA\ < < < < < < < < < < < < < <
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8 X X X X X X X X X X X X X X!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>g67046g89m60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g89m60.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1IZ4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585    !L 2 !0 "
M3 !A ', 90!R $H 90!T "  30 V #  -@ @ %4 4 !$ "  4 !# $P (  V
M       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E
M '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I
M;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
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M8VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M   .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L
M;VYG       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F
M   .             #^    X0DE-! T       0   !X.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      ,U
M!@             !E@   ]X          0                         !
M              />   !E@                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !E@    !29VAT;&]N9P   ]X    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M 98     4F=H=&QO;F<   />     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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MP  1" !" * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M]+ZWO_X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M7D]QUH'('>M)TU0V&XZ11MDZV@M36Z[VQVTJMQKZ,V+6\*7"IUA)A8&9G;5
M&\ K-QRA0<&%^ E3 X$Z, 8 P!@# & , 8 P!@# & , 8 P!@# & , IUY#=
M+ASR3W=SNO%UN$!%T[E+QQXY:QU@^A2RAMA:FVWQ]L&Q;=7-HI*J,$&#-6#M
M%FK$O *Q$LM(+>RY1H](T0<E].!$W1G25YE\?Z1P@V+7MO<=;MRMXH;%Y=6R
MV1UQ:[#8Z.V7&<MI.;>6,\?-P%>2NU4L5>/(H2#-RG57\>\4%W$*MTFAB/E
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MS#$O)^7LKQA%(*F%TB<#TE<X^)\3R[X6;ZXFL58:L([2U3*TBH/G30R<)4K
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MJQ&O2<!NRF73DC0N1>KV-*HW(.-HNYY"\;0IUAOES?V&U72O[GNGW7-T$/:
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M]6:ZO@;@RL+FENC%K9EPORK)NJW;IHIJU_U@Q"'G4T1,H#Z?K_OL%_V , 8
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M!6;8A>7&O)B%6U:IK2=U]LMY%PZ-@@)5RW?R+Z'G:RUL[>*<(LEEFL@!E&Z
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M_P"SY_<'G@ 3E#_2#S_+Y?I]W]_R8!R!@'W" X!S@# & , 8 P!@# & , 8
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M4@]$KV5:E,FV4*0PJ"0I@+-2"(AW'OY_.';_ *!_U^OY  ^L 8 P!@# & ,
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MGE@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@$8[5Q3US<.3]6Y5S+NQKWJJZ&OG'=K $?,"4U_1=BVNMVZ?<24>
M,6:75G"OJPR:LW3>;;,TF"[M-5@LN=)PB!'KB1TPM&</MG2^UJC?=_[/LQ:*
MZU1KLN]MJO=F1VEM2/K,E;WNM-4H/H]FY@JT\GFL:Z='DW<U,N$HF.:J2ID$
M5"+ :6ZF  7E9T;  /\ &Y]3OO'W?^Z_O01^OOV^7O\ */O]P%Q)?<'U!^S
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MI# .< 8 P"H_I(?Y-ZCW^UJYN_\ 'Z?@%N& , 8 P!@# & , 8 P!@# & ,
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M[)1EKU[6GK\]&2_"S,5)Y6)DXRD]1=]%M*D_72=D([>O.EY,@RXUA@# & ,
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M^J.6HRLW*R:J,BITTWW665T=V+1OY<)R<8=S;VTO+WZ>46!9F(,, 8 P!@#
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M>7F ?(   =_S_+]6;9 _]6_R_!?1+V1P*H"!NP"(=A[CY!V\A]_<0[!Y>_\
M0& 1,XB6JO/=+R,NTF8MQ%I[BY&D4D4W[46*8I[]V2J?QN_2^A*)4E"*CW.
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M14:<>E*$%M>%&*W^+(@[PZE_$S3+Y6K_ -('])VR/2G:,=::?CGNQ;4]D0
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M]CZK6^-X2OG+:)/+/H1!8Q1.5JI+/Y$OB AX],P 0VM'J//P'V\_Q%^+!?\
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MX$572KD#TY<G^.M0Y8:-V'Q[V%/7NN4;9\6U@K5(:VLRM/MRT(E*,)-]$LK
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MTSP?/X_/XO)LP^2PLOC\NF3A;BYN-=BY%<HO3C.FZ$+(M/UW%&0@J4>_;MV
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MNE6BR<E-SUKEAR&K4'L&*USJ'84/:=R; AJ;.7-K>I&VL'["$3V7*LK/=(V
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MGF92TDWJ*TDM+7W4OH5;]M^-)?\ 9O\ O_H2B  #W![\YNE_/Z^_]2ASE0,
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M\!CBS<BJX/XT?"1-0^Q&_)L[I6M0E)_>55C<9Z7:NY*%<?1+?C;:V_)&,VO
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MMPQ:*Y1AMRTG"N/^:4GOU\^OA%SDY:VEX6DDM+_7R2%#R  ^8 S4+3G & ,
M8 P!@$:]_P"KJI:XUI.RZEJ,^+:-<Q@(Q>P+] 196ZU]KZ!E1@X"RQD(+],C
MI4Z,F:/&206*W<(NTG#1LJEM8V3;3+MA&EIJ3_Q**+);<7_FLJG+7A:7<EOV
M\L&[:E4XFF11(6%6F5F*2RZQ1GK+8[9( HX/XU /,6J7FY=1,!#LD@H^,B@7
MXJ*9"^68++)VS[[.SN[4GV5UUQ\?]-<(17YZ\^X,GRP# & , 8 P!@# & ,
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MUUUD[;;;)MRG.RR;E.<Y2;<I2;;;;;;.P*4"^X.WN[_E[>[OEQB/K & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 8];?8?W+6
M,;.8"5LL%,&L"AE'")$X0(YR,JH=5F8CM(A&'K!C*-3%<I@ F0,54"B '@^W
M/3ND39X.ORO!;I&<AN2U7V%M>DZ/JO(K9G(;EEHWC%*[-V=;V]#JT1&6FP[K
M=6JV)*VAZ1E+@QK,4S8I$7,O(I(E%9,#VM\3M;RFG>->B=5S=4IM$E]?:KIE
M1D:7KR:M%DH]5>P<&S8N("JV"[NY"WS4'%J)&:1TG8W[R8>MTRN'SI9=0QS
M2'P!@%.O4S_SKNC5_K]3W_*]O7 +B2^X/J#]F <X P!@# & , 8 P!@# & ,
M 8 P!@&O[?KUC<U">T)RT,VQ%8UR5A$3 Q['UR(D$)1@[,D1L=07"+YLV7$_
MI?"<4$R&()/$!KX3<'M*+_\ ]14O7P_7\/UZ[&40<2,*R*R&2E97PJ*J"[F7
M8/7IQ4,!O"9<J2("0GF5,HD 2E\NX^_+6]O>DOR6D#N,H!@# & , 8 P!@#
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MC:7D!#B,5#N9IPF=\M'QP^J-U%CIMP!(H#@&Q< 8!3KU,_\ .NZ-7^OU/?\
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MX ]HQ_X<S_64/W\ >T8_\.9_K*'[^ /:,?\ AS/]90_?P![1C_PYG^LH?OX
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ML%QDX3<^NI5A5(%3C;NJ+)-V5XQL:[>#B3R3YC'ED911JT,]>-&H+>G<(IG
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MQJ82+E*2DHF):U6[PCM[6X-0C6 J0V0S^1;5R)CTCG04.LB 'U']"?ICQ(/
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M3Z-L:QR/(?; 0!9,EH )TQ#5_P!EJ1ZT@)CN(P[)PB<[=5(Y@+6L 8 P!@#
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M!=8_PU@#X-?I[?0BXJ?V"ZQ_AK /D_39Z>Q2B;[R/BH'A\P'^@76/O >X?\
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M 5<(RR1368C_ $Q $0(KZH\1](4.X ?Q!W\NXU!EV , 8 P!@'PIW OE[^X
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M!974JU%4RM5ZGP+;U."JL%#UR%:]Q,#6)@X]M%QK8#CV\8(,VJ*7B[!XO!W
M #RP#(\ 8 P!@# /D_?PCV[]_P G?_I_?Z_=@%0[3IJ[E5YI;-Y76GF8^N56
MVH$E49C3=BT!0I4]<T8\82;!'2% V7+3LG9J#5U!D0E+ [J;*+7ML^FM,SK9
MTY73%L!E/!/IB1?"J].KJ]WWL'>AJQIF XUZ)C+O7ZQ!IZ:X]UBTR5MBJ$W>
M5ULBO<)89)ZS;.[=- B_<1<'$,09MR(G,<"U /<'R>0?W^3]F <X P!@# &
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M5=%?2SE!NHLZ>RDN^(@V3>3$S)NGLO*NDFS9)Q(/7*J3=!,Y4B ;PP!@# &
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MDASN&R8'K$* @  /D/G[OK'^_P OUC@'U@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"A_K*1VQHG<O2SW72]&;RW
MC5^/G+Z;V)LZ(T)K*?VG;X6J!K66BDY(:_ I>($UW[I-J@=XY9H*K>)(JPJ
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MC(.W,A+.Y"7E9.2D';I])2TO(/I.1>.%G+UVNLH8X@;EP!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#@1 />(!W]W<>V <X [A
M\X8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!W ?<(#@# & <=P^</TX \1?G#YO>'O^; '</G#](8 [A\X?I# '<.W?N';Y
M^X=OTX  0'W" ]O?V'O@'. , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@'4S<U&UZ*D)N8>MXZ)B&3J3E)%VH"+1A',$#NGCQRL/Q4D
M&[=-1990WQ2)D,(Y;*481E.;4813<I-Z226]O\%[F;'Q[\O(HQ,:N5V3DVUT
M44P6YVVVSC"NN"\;G.<HQBM^9-(A#:^I=PDKM9G+"VY(ZJG5H6&DI9"%A+2S
M>RTRJR9K.4(R,:IB*CA\^52*V:HD 1.LH!1   PAQK.H^%A7;-<EB3=49MPC
M='N;BM]J6TVV]):^J/5\#X$?%G.SL+$ET/U!B5Y>7CXTLO(P+(8^/&^U5.^Z
M?GMIK3<YS2?W8/6S"M(]5+B#M#5].O-MW)K[5EFG8LB]@H%LL[-K-5B53.9!
MZP<@J*1EVX+$,HQ? 0A'K0Z*Y"$$QB%P8/5'#9F+5DRSL?'<X_?JNMA"=<NY
M1<9)OPU)I?U:VMLZW57[.WQ4Z;Y_D^'QNE.8YS%P;E&CEN-P[+L/,HLBI575
M2TM;3[9Q2U"Q.._*)]42^4_9U3A[S0+)$6ZHV!!1U"6*"=)O8F3;IKJMCK,W
M21C$63(NBJD8Q1\CIG+[PSO4W59%<+J+(6U6+NA97)2A.+]'&2VFOQ1X[RW$
M\EP7(97$\QA9''<EA6*K+PLJMUY&/8XQFH60?F,NV49:^C1"7EERZM?&#D+P
MGI\G58&0TAR@VK.Z+N5Z=N9%"<H>S9B""1U DT(F?V4M$7*7:R4$]]>("Z3O
MU K53Q+F(;(<XBIKWK%ZU1A=@; W1"R47K^Q;UW5K_B[$ZEI%^VAL;9VJ..J
MR$%MO=-AKE<8R2L=3H"S$DA<S3=%O&L8A)J*@K/%1+@'0I];G0E?Y*[<U_>U
M':G'R!H/%F^:JW;K^C;!ND7(PW(N'<.RV+9LI%Q3N$H=58RSF"AV#^5&/<'=
MR"C99NJX;N"M@-K->K1I.C/]NQVVYQ:RV"K<CMGZ6H5$T)K':U]V%*0VK:W"
MV6URDY5R0Z[UY]R,;*D>VNS0!#5)LBX8HM'2KM0R6 8\/6 U-!;[VS7[>GZ/
M1,!I+C%L?3]DK56NTSMG:UPY(2=F805#A];IL0FWTTY+!HC%PS6';RR9@?&D
M"I(H&43 LEXY<C]4\J-:L]KZ>G'LQ5W$M-UR0:S,-)UFS5FTUF17B+'5;75Y
MMLSF*[8X*2;K,Y**D6J*Z*A2G %$%$55 -\>_ & :LVAMV@ZJC <W*Y5^J.G
M[*44@R3KY-F60=1[<%3IHE4["KZ,RB0*E#MV*H'F41*8,D*K+=_+A*?:MOM3
M>E]7K\BC:6MM+;TM_4\V/&/G5U3>4VF*EO*#Y8=-;6,1>G=D/%4B_4C9YK;#
M,H2US-<;IRXQCUPP.NZ+$@[(9NL)3I+IB)@$396-%\EW1JG*/U46_;?T^FOI
M]?.RK\>KU^#TOH_S]_[EE72JY_S7*S1*CSD)?M2GWU';SW-J52+UVFZB(6QM
M-:VUW7HN8@HB3<NI$&\RU9*R*"BQRG6;*)G%-(P&*%ORK.V4^R7;#^.6GJ/M
MY>OJ4VOJO3?\OK^1;H81$"B4??V'Y>XE\A$/R=P\N_;N B';MEA4J$MW4*V9
M7VW6,6;5&GJGZ=%&+:-7@J:4$+H[-QA+O 4;KX7)?"@%@,,5_P!S"U,$5V$1
M]9\*N ?D)UG^+M,<5VF;:3V=';!8TWCE8=M2-0U3;K+K36JW)"M0DO2I*QW2
M/3=1\'6GTI,HPR+N36!R#T?0)(NR)+KI ;WC.I[Q<F-YS^BX]]LQPXK-IME"
MF=L):KN"VA&=_HD&>Q7.E+[<0CU*VWGJO%I.%)LKM1O',7#9PT5D2N4?1& U
M1#]:+A/+U>^7165V[7JU3=3S^]824M^GKC5&NW-0U>680D]?M,+3K1BC?X2-
M?2D>9P#$Z#P&CM)^5F++Q+)@8G:.L!I*T4^0DM02EBJ-FK.Y.-U%LD1O?36R
M*N[?5+D3.(M*79:U! DPEW47<8T'8UBQKE+&MUT!<2K,K8R9U0) ,>J!Q4?/
M*6U&PVN/3O?(+=7&B(?2E76:1K39&@8B;G=D'F'9G8EC:U'1=>DG+*=4 R;T
MB0>%%/N(E UEKCK(\/\ :D\PKU20WXL\L&M[WMZDJOM";!8-MCZUH3QE'O+=
MK<%(TSJ[1<](/BLJQ[":NG$BLW7%RW8(@DJL!J;=G6IUA38"B/=5:GV_?K,_
MY@T'BGM>B/Z!,-;GJV2M+ M@=.'4)&.7R,K.R5>,16EQC644;3+\SENY<)*1
M[AJ8"0%:ZNG"NQ[&G]<JW6X5H8-#;HL[];M>V> U9<I/04,^G]UUZB7UTT&'
MM-AUG%Q<HYLT9''$R9(U[[.4D ;G\0&L>-?52B^6'-JNZ$U;1+E"Z>G>*LMR
M 9VK:6N;GK>YSBY;U!5^L2E796-)M'3NO[/7I8TS%S3$BZB_9+TAD#"=$ ,6
MY'=4JZZ6Z@VON.D+KJ!GN-,).Z3UIR;W.Y=NTY75VV^3SBW-=&0C-,CE.,]F
M.3UEFK;%GJ9U(IO8XE<PI$7;E7!?U_(TUOGJV[UUOS]NW$R.@N,NKX:F676T
M128;DS9]F:WMW)V%N4=$R%CGM-;)0KSG3\6YKRC]>)AX*Q2BKZ<EVPM3 @8P
MD('Z9\[JZI'-1W;N1EOXP::XLFXU\5ML/-'6FS\E]WN-6W7=FV*Y',Y"Y4[4
MQS A3X=5@9TK&5]W<9=BG-R"'IA\#<56Z(&A^7/6TY':FY!7G7&O'G!7656H
M_'#4&]T8WE-M:R0MOODEL:K/+')T/7,IKL;!6;C+Q2[$8I%>*7%BY4>1[EJ\
M<HN@.0"5WPN.W9FP],V"B^*ESJ3#FE/:A:[9O%Y;+L*/KD=HUZS2S2B4E\HY
M9S%IO?@KCF;6,M$DC(2N&CS2R@2,NW;I 6!\M>?FCN&<[KFK;5C]ISMGVO&W
MR5HU;U7K:?V5.3#;6\8SFK6(1M?(HY;^SX=X,F=9=--F5FT>+.'+<B( <#4V
MC^K;PYY#/+$VU[:+RV9P>B)+DE'V*[:WM5$J]TU#"./9UBM5'G;*Q8-K&SK4
MT(P4THT $4)1-9)JL\104<$ BEPNZK^W^0>C.8%JVYJ*NZIW'I/2:O*74-**
MYDE(Z\\=K[KJ9O6F+7,E=.3/TY!XK#K1%O;,S)IQ[M1!),&ZZGHR 2.Z=O5'
MUCS9K>JZM-1=MU]R M^@ZMNN0J=DUY;Z74K?#R -8^SSVGYRSMB)W:JUVR+^
MR',@T<*"456ZZ8NFJQ'0@6L (#YA@&'W^[U[6E*M6P;:\/'5:EP$M9K"^3;K
M.SLX:%9JOY!R1LW*==<R+9!0Y4D2'54$/ 0HF$,OJIMR+JJ*%W6W61KA'NC%
M.4VDEW2\+U]?S*I;>E[_ ,O[OP4N[SZ\/$&M:QLDIHZ=EMH;1,R,WJ%8=5>?
M@8DTHZ3$C>4G9*4:LR)PL8<Y';Y!J95^[(0&K9,AUO3IS_C/AIU#DYE5>=37
MB8G=%W9#OIL<82\M04)N3G+7;'PEN6_"6E<H2;T_'KZ:?IY]-^3JN.O7CXL6
MC5\(]Y#RTAJO;+9,6-H@XNM3L_7Y!R@!0+.5Y[&-WITXV1)X5O4GX)/&*XJ-
MQ]82*1RKDY7X9\]CYUU7&QKS<)-NNQWUUV**6W&SYDHMR7HW%OU3_*LX=OX+
M2]?7?NM>OKZ>-/SY\:+I-4;.J&Y]>5':= DE9>EWF%:V"M22S1RQ4>Q3SQ"W
M7.S>$3<MC& INZ:R:9P[^91  SS_ ",:[#OMQ<B*A=1-PLBI=VI+Z/W7T?I]
M&8R /58Y3[8XWZ-H58XYRU5B>3/)+<]+T-H]]<D&;NMP4[/DDIVQ7&P-7I5&
MYZ_5*K R;N0651732<.6"9DCF73*.$$%=L]23E5;NFAQ<Y/Z%JL\E;[7?&6N
MN8=LU[J9+>EPX_&I+.WUS:MDK^G&\W$(V0K;9E7:1A_'(';14#-%DTVKG_LX
M@!@5=ZE'*S;NJ>*&CN-F]>->WN1O*;<VX]?LN2SN@7"GU36]#TW6$+C/N=BZ
M.L#=C,PV]$(Q\R9N**@#NNCZ5&3:R"[%QZPD7X^0:(V5U6.6FM^&V_WJO+OB
MML#:NF^2O'_7;;D;JC7]AE_4=7[:LQ82?F=E:&F(!!6*G*\JRF",4*TXEU+
M@T5"/*10C=R]#]?K_P!F\^ ?4AYO[EI7,"1JQZWU%(/5C'6[71.Y*)JZ6XQ5
MBS[,MCR787K7]E0OR$8F6+U0Q;PMMM<O&LG<DWBY(6;=L\?.FB! + ^$'/\
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MMXT6.F '1[RZ)*^^[9-[*OW)V9L^TS5#C&A7;O9=:5IR178W'%W;%AMEUJL
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F!$3@D!1 MD   .P>0!@# & , 8 P!@# & , 8 P!@# & , __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>g67046g90h45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g90h45.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %A2^5E(X0DE-! 0      %T< 5H  QLE1QP!6@ #&R5'' (   *.#QP"
M4  (<G(Q-S8S-C(< @4 -$UI8W)O<V]F="!7;W)D("T@4U1/4DT@+2!&54Q,
M($)54TE.15-3(%-%0U1)3TX@4DE$15( .$))300E       0(Q=O!5JZ%E23
MZ.U@-+"(^3A"24T$.@     !&0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M&P!( %  ( !, &$ <P!E '( 2@!E '0 ( !- #8 ,  V "  50!0 $0 ( !0
M $, 3  @ #8       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O
M &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU
M;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O
M;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O
M;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0               !"
M;&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 9L<*0
M  IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             !_@
M!'T          0                         !              1]   !
M_@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
M_@    !29VAT;&]N9P  !'T    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ?X     4F=H=&QO;F<
M  1]     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8U
MPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0 " P$!               ! @,$!08'_\0 31$  @$# 00&!P0) @0$! <
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MQL+!Q#=I&1<>V)]1!FQ;(-T2_533*& 5%@# & , 8 P!@# & , 8 P!@# &
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MI+A*-GXY(:4E9JZY/3N][[F[GMX\+7\).HNX7%:T?SR^AM7[->JL82N[UCD
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MUE4TS1\>";V>4)V"(B!D&!3%[*J\\I@-YS /F2;@(','1SB1,0$\=VOC;SV
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M3)\^J4ZE*I.E5A*G4IR<9PDK.,D[-->>RZLWSVG%M-6:PTRLLH0, 8 P!@#
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M[+NY=VIUF:Q@& , 8 P!@# & , QU>+A_%J<P?Y.(#^="@YU_0'ZXV'^.?\
M2S+0_%AWOX,^=)GUDZ8P!@# & , 8 P!@# & :@(E'L!$! 0$!#Y@(?(0_3D
M-)^_W]G'N8Y]JL^X^AA^#J>*(YY8Z7=\5=RSZC_?W'^N,3UR;DW J2&R]/-5
M$(B,DE5EE57#^RT1RJP@+$X5*11]&/ZW*"+Q\K-N$OFOZ1^BEL5=;52CN[/M
M$GO1Q:E6RY*ZPH5,R@M4U)/@C0VBENO?6DF[]C;P_%:]NAZ7\\T:PP!@# &
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M!@# ,=7BX?Q:G,'^3B _G0H.=?T!^N-A_CG_ $LRT/Q8=[^#/G29]9.F, 8
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M+<H+KOUJDG*=66GK5)-S:NO5;<%A*-DB4DN&O&][OF[W]UE?.M[V;S9)& ,
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M:CBG/E*]N&CW3D2$&FX2,_A@!5(#*>NT3!3SIF1 17%N183.""B!1.YCW?\
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MP#CJNVZ*R#=19$CAUZGPZ!U2$67](OG5]%,P@=7TB?74!,#"0@>8W0>^ <C
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M:]:;K4*W8+@Z,QJ,%/V6&AYBTOB&2*HQKD9(O&SV<>$,NB4[:,0<K%,JF42
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M^]R3NWX%8,.6%#<B 2=-MD)VH &.RF(BRE!,?X1_(K'U4PF /X*0"(#T >H
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M=V:=N.$[KGSJQC-5.34,1C;(990#E("*:BLFJ)C"'E$QJV2PL42_6Z$ZCXI
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MRRAU%#B)CF$1$<W5&*22C%)*R2222Y))62[$6X6X<N!Q,FR6B2\ ,D# & ,
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M_0;AUN,OFU"V1V_KQ9QM0OT@:*$VMT4[$92\ $JF>,$:R63 )%,[,1!R44P
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MVB%:[A/>2NI1:W9QDL[LX-*4))?EDK^XE-.[6+<\6[[VT]G'0MS\LV-21@#
M& , 8 P!@# ,G?@R:X':7B@<-*X+;XI"+V['WQTF*0K)@WUI&2>P1,LET('0
M]2MIE6 WU/3,;SB!>QSC^GJG1>BMLE>SE2=-.[3O4E&"6.:;X<#'6;5*=G;'
MQQ\]>!]50/D'Z@SY,M%W>=3EF-C8_AGZVV?R)NF^;%M;;:<3L*^Z4VA<=-1P
M:V0U_-7[C[7 KNKY\9M?7KG:<86%*49![%0FP8R)FW9S)2S-VP$K0LCSY\_
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MV]L^MWDJUM\]+,)(UG86(^K"V:0DH=E&LZK -[9+V6'BZ6W:U5&+-$,(YNT
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MT0L?//XV BJ5%L:[%&=4QDP.V<5*T2D71=9,9>PQ+U)X[1U5KHY ;NJVBX6
MKRF\4J;57M"F)2Y;.O\ 8=>2UTF(6PWBR1;N0<+WFH$I$LV>MJ[7ZW#(LF\
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ML=3HMIHS;LM]*3=K;LNJ[WQ;-P>:?Y>WW?O]OO\ MSV#U??YT-A:+N&0!@#
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M.40,4Y0$!#K-R<5)2O=IQ::YK-UXDVOCG@D1RQBF'Y7G6P())!.L;RKM>WE
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M6@KSH55NU4OVDKN,H7QOPE*+YW=B4[\&GVM<[<[Y[O%ZED^A^[-JZYKVDC)
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M'<XR7NOW=G-=J/?@'R#]09\_- UP!@# & , 8 P!@# & , 8 P!@# & , 8
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M+J3=2;D^.G=P)LYI%!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M:E#H-HM^!6BY22:M3JM4:KDU^2$)].[\:,7EVM66%O+5-8YIZ]G+4BSF^6&
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MO&5L/3X=WQ\V>(%9%5NLJW<)*(.$%#I+H+$,FJBJF8Q%$E4S@4Z:A#E,0Y#
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MB6].3=DL1A'-HPBFTHI>+?6=Y-LYLYRF[R?=V(E)FL5& , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M>[7]EOB6:S:)&5EH_#375: DQR(:"PK7%QI[@']#3"/ +[_4"6VQM^7$ #V
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MK*6ZI)$>QZL'>+"DLLHW$&1[ & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MU']*-KHPE".S;*U*I4JNZK^M4FYO"K:)NR[$2MKFM(Q7A[-=+<+>-RGXK\%
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M$'?8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@%H
MML:1H&Z%M8.;XQ?/E=/[5J^Z*09E).XT&5\IS>5;0;YX#4Y D&2*4P^*O&N0
M.U<BH052"*9< C?M'PZ>,>W]^-^2%Q@K>?9;9S4Y%<\5>[)%5F3EZ-!6"KUB
M9E:LU>!#O9.*KMGF(=NX.W H-'0F,F9R'Q A?AY\]A3ZOAC<535R!KS")V!
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, , 8 P!@# & ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>g67046g93m60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g67046g93m60.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1BD4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585    !L 2 !0 "
M3 !A ', 90!R $H 90!T "  30 V #  -@ @ %4 4 !$ "  4 !# $P (  V
M       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E
M '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I
M;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
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M8VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M   .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L
M;VYG       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F
M   .             #^    X0DE-! T       0   !X.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      ,U
M!@             !Q   !&T          0                         !
M              1M   !Q                      !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !Q     !29VAT;&]N9P  !&T    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M <0     4F=H=&QO;F<   1M     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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MP  1" !  * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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MSV*WBXF/B5>CCMV5R7;9)U//TRY)3GT=-=DL%MMF9BO;[&UFX3#2[0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  (1 Q$ /P#]_&B)HB:(FB)HB:(FB)HB:(FB)HB:(N!,4H")A H  B(B(
M <B(B/8  .XCX .XZ(M &,/;A5A[)[QK3D^NU.2Q%AW&-DW"X!'#LD2;R1D#
M!E#S=:\!W)Y<8B=LR46SN V.+IUS@VC8\ Q=4G(,(MT.%B>]N"*8S^UJGY_-
MN \(TK9UF12S9#W/7/;9EJ$N%NPI7[#BN0KNW=;<="V!@9IE"6J]N;S6/%F]
MS51CK%RQK,%:XHXJ9#"JTJS$4#43V[^+JKC7!KW+E-OUZL]^A&MJR#<Z="XL
MQU 4:JVC-^:<7UN>6Q];<VO[I9&L0PPQ;Y>U)8P)D9S#Q,&27F$HAQ8HF'$B
MDC&WMZMM>8V%<;XFQ3E?)5[N66<9XEJF-Z+:]O-LG921S+BS,N5<:2LA8H#-
MLACVHC+QN#;G!V2H7.XU_(..YP8]&_52O-G(.=$4M;B/:4RD5[/S#^]3;E5/
M45S5DW"-"A*]D['-[O\ ,UA+)V56.,;*F_QAAF:-=[M:ZH^/*),:M0I24>V2
M38I-('XJ+UH5<G18>X[]MI.,X*FY#SM42M&,-AS=A9<JXSQ?CV496M>V8,W7
MX*V\U=T1AE*^5^YXEGGT5E-*Q36%L@5MY9X]*;1"6LL4^AV\9.$62^0_;!5R
M,IEJ@:=MTSN?<K&S>XBFC@V4:8J6L--?;?,25G+EOR!:)=OE<E"EJ/%53(./
MIHK"JW:8MD[\?+!0T&YFT5FA"* MMWMC[?-P]3;Y1QQ:\R9&R:OL[HM#QSA*
MF4NI.?[4-P.T"Y[D9A+\19#S''0TC7I)S09MDS=RIZH%45>,&3L\W'E=3S8B
MR CO;7X)LUKVS5&AX=S-<I'<LQP@[8%2>X>K+N@K9YNN1:+5F5B@;CE.!LUG
M4A)7$N0G-Q?8RAKQ#UJ.@VR\A))JSD(@^(NO=AOMW:8IW#;J*5A:G[>[!C/9
MYM"QGNROL/DI"_1M^R'$VF;S2G:ZQ3[K!VI*JU-_%UW$:SN"6G*/849&7?D8
MNE&Z*Q%VY%=$)[8S",])Q3MCB'.(XLEKL]PZVS>>)I2=!#/\=@YQGYYA=>(6
MNR.2F<ZG36CJ-+:7]#:4(UM1/736<CP# 4BMC%7MK</91D\<H_\ )XW&TNN9
M LF!*XK=K6TQ$6NU,^Z.F/+E@"0GDX3+$Q.JL\B(Q<O&)IP\-)/*P[9-U[>V
M@F<Q$+O"*PWOMH\99&F75,Q2T>5.YT;<[M,Q9>D'DEA#.<;,TG<5D*XT](L=
M*X1SW98*H6(BE%FF4_%VF90O>/%GD,[F<=R'Q%)J!%/F!_:N5'<*@L2A;8MR
M1Y:6Q&QS;BZ >LL4FE<P4%+*R&'+G)4\D?E%ZWBUJ%;ECK3+.\+U1U*0+96:
MK24PT4:F<$4T;X=WEAVOQE&4I5?@+7.K(W#+N2H2:3DUG,/M<PDWA'N>[U )
M1;]@H-EKY+A2HVNE?>\Q2DK84"/FRR)3"4BCC)^_J0PM>,_*9/CH6L4+'5%G
M<B8,A'%-N0/]T-*K^%8G)#^PXRSB>8+B9>R,[<-MJ<SA\D,]O=?JM6)DV353
MJT]&*"14W,N\S+6$*'?5;-8,2R>8:[ XBGTL>1V"\]M64/&Y#S7BW&4_,5^8
M>VL4MPD'6&62T&?O&-%*Y(K6YHPC746V<RYH6-(N0WHY]=84K&6("BXNGH-7
M=M#X,L%UD?QM26LSC>1SE3L*A::UBJ56E+E6KXI8;+-PLE4;Y98\U2DZ/-/I
M,DB#^*@U2+)W<[N2=X2;,ZU4J!9LDY-LF-<R9+K\%7EJPS:Q-2PU%5D;;;9I
MW;;)5V#IG%6"_P"/X9*OQCYQ8)EQ9"G8L_<(^6?L"+"T_M-FLEM[M$A ,XM[
MFNH;8FM[FI,'=:5KC/-1]K<+N/7A3X\3M9LBEI:$%.QJBEN7B4*>29=IT@EF
M5L8>@8BE. ]H-4ZX.4F5^C[;+RE35S?)UD8VLU^$1M)\-S.+Z]*XQJ*07666
MG;>XE\K4UM6WLL%=_$YYTB01[!Q'N40(OE[[43#K9K?)!C2+S96%-C+H_:!4
MI''EDEIUSCO*E8PY:XAS!1MV5DZ3)JW*TM#4]"_H5DEX@V$K,5]5PDQ62 BF
M:*WF5YQDAOAN?QM>ZOEA;+%0Q@:DO5ZC)/"L+=AI]F@F3D'T+97\>]QO$1,%
M;:I)S39<[H+O4)N$9L':8L'CPBS,*/(<CY^H=^P_;OW_ ,_;1%SHB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HBX$0#R(!^H\:(N>0^_CSHB<A]PT1-$3D/
MN&B+CD/N'\_MYTD<?9R1.0^X?STD9S;BB<A]P_GHBY\^-$31$T1-$321Q1-$
M31%QR'W#^8:(G(?</I]?OX_G]/OHBYT1<<@/@0'^.B+G1$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31%0;37(ZX5JPU.7,])$V:#EJ])FC7[R*DBQ\TP<1K
MTT?*QZS>0C'H-G*HM9!BX0>,U_3<M5DETDU"D6O6R^R+]G[9:?4*..W^OUF$
MIN,;)AYHM0WTO0YR?Q];8F%AYZ#O5AJ;V)F[Z+Q.O0\B#^W/I>10G&2<X@Z3
ME#*.3D4JS_L_MLMBNH9'<U>TQE[3SM7MQ[:V5K)%_JTZRRG7,6-,)HOV4E7[
M''.6U?F<5M/P5:J>FH%8M4,\D6\]%O\ X@\%8BUA6KV&,>PW-T')F#LPL<7X
M/JU=QQ2)#&;N/R78+1_9S6;YDB\93QR69+E6.J=UK6>4<K7BJ6Q3)M2MCRK5
MRPO6]0%FHDD(D6R*A>SDVQ8];8K:Q$;E"8:82R;5LLXD97K..8,A,\>66DT.
M]8UJ,;5&EUNLXVAJ97:;DBW14926":%92]_;.5(U1S%1:K,BN">V#;;Y_;93
MMIYX*X0N'L?6FO7:DM*IDJ_5.XUBV5.]+9)KE@A<B0%A87=A*0]S7-,LG;:<
M3605*FDF8J*29"D45.?9-;'WL-\%?XTL$B#BK9!JDW,2>3<CREHMJ&5,H8XS
M'D&>N=ID;0ZL-LN5HR!B>C3$A;YZ2?6 48D\8D^3C'CMJJ171DGV9FT/*TQ/
MV*UTBTHV*SY$M^39NPU7*.2J1.OIO(6-:KB+($,I+U&U0S\*1><?4JM5ZVT8
M%PJ\ZWC2JOXQ5PLNJH1<4/V9&SK&MDHELJ&.92-F\;6S$EVJ#A2\71XC'6+!
MV%[7M_QLZ5:/)U=L^1@\776Q0BS-XDLUE7;Q.:DTG4LT;.TB+ I?V+TM1MW^
M)<];<<]CA;&&+8_"U=BJ8T8Y%E[S&4;%UIN5IMN/FT\?)[:FV^#R^O>K%&V.
M3R52K9,UJ*D5&M75;E;I=9%L%S?[.+:WN)RO/9ARG W^6L=PI%.QM?X"&S#E
M2HXZR70Z#-V*Q52JY,QQ5+=#4V_0D7+VN>=%86B'DFRX2+A%PFJ@<4]$7P]]
MFQM"?Y2F<MKX[F"SDW.6"XN:LWR#?VV*FF1;3CYSBJ>RK$8B0LA,;0V4Y#'C
MQW5%,@QM8;6@D8Y7*G(D65.L)%3XKV8FS:'KD=4V>-) T!%O-N;YLP=7:YNR
M&7VI5QY5,)E<G<3AU72%<@W[MK(H.#J)60RQEY\L@MP<"*RZ+[(C8YCI9HO7
M:!=ECQDSA*8ABV+,>6+6E $VZ6>SV[#,!7TK'<),D'4*-,7">&*J46#2O^Y.
MR1Z\>JT012(123"^SCVKUFMUBK5FK7"LQ].Q2YPK7'5=RAD6#G(S';S*T7FE
MY#M[!%V5K-%7>7^':2#N3]^^).(T[R 5=&@WKM@L13+D3:GM[R]>5\B99Q12
M\H652AH8V9GR% Q]RBH2JIRTO-NT*W"6%"1B:](S+^8,:?F8AHTE9M"*KS62
M=N6\!%)M2*SHO9)@5E'5&OR\7;KW3*%63U2FX^R5D"Y9"H5>C%<>.L3KJL*K
M;9F5BOB"^.I*;J1WKE!PH2*LEE(B"2T])K."+QCL8P$Z(Z).LKU;1/$4^MQ2
MUPR;>[,ZK%6HN1ZWEBNU>LO9:=<O(N%1N].J<F^1*NJXE6]=BHV2=.H]L#8Q
M%4[ELRPO=8JV0;K\=P$1=\SLL_V2/J&0K56&S[*<::CNV%@32C)%(K)%O.8\
MKEJ&(8@WB7%K"7L#IFO(SLNL\(KSRQMLQGFE*LA>"VP7]5@K94V,[6[O::?8
MWE/OS"*C[W49B=K$I%R4I6[DG 5YU88MTN9%Y)UZ"E2>C(13-PD16/'[)\#1
M%:N%)B(RW1=%O^.F6,[G2(_(%Q:U2QP\?CB$Q$VFI2&2F"MEKD&-ZU7:JM;"
M@G,.64%$.7+A61CVKU(B]3[9;MYDU*TJ^ICARI4\Z*;C88REAG^2935*T%62
M> $D 2$&HZC(:4/4WH+ULTQ!0DJ:,%]$L5D"+T'V@8:/"W*IBC=0HUWE7\[(
MX^+D.Y%HD7,2][9Y,F)"MU<DR6-@%I.\M!L"Y8])))!P^E6\>FS92L@V<$7P
M?;3!N=Y2>[5ZNR--16WEE@J!CVS9PF]$'-_GKI.34VY.Y,R>@Q;.HZ*J)4&:
M+V(2FKZ#EVY;SK9%J192Z(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+
M7C[1?)]PQC1<$JU2YWRCM+KN?Q+0+I*XRA%['?'%&L2\HG88ZK0K*N6V5DYI
MTW1*,<QAJ[+2KMZF@W9,':RA6RN_[/X2ABJVT.^H8>N[#[+QF)H,Q3Q2H#$4
MPP4G57NJT6-8"[XC4J-:!F1F+M%H)=(!W6.< X2)$9^:QNQ=O&W14.F'QY<<
M5N;_ ),KN.,V;B%9',UE0PW:5MN%*N[R!Q^I88R,I4P7^U6R1Z"QW44^AZPU
MCD$&;J?4CEG:X(['$[(V56K#$4<6,/A*F(P.S@,)3.,HC:5?#MJ8EM)YJM!P
ME%Y^%[*E8ODMI%\";CJ;"=X. ;+6PT3\1%YDV@P#$A4UO[1_*$+8-R669JHQ
M$Y@6DX)VSY2QW26L@[0OC>3SY#(K5B-<GCZ.\/(*34Q*(-[4)Y%\2KHQZ!JV
MSL2CURW0J/9O#OI[,PC:KZ>T,1M':F#Q58AIPV[LYY%5[=ZJTM#&":9@=Z2=
M\T@W>,=RT[H!,ES@28 ^'.YB]C8Y9SHI>A=_V:IYUC>I-]K,A Y!R7EBTXRK
MR61)/)^*:9+,H'')\A(W:$?9)PI6+R^@P30?0LH@OC]FZ;24>N5B,@FLV.IC
M/V!@Z8Q-8[495P^%PE'%5#A1A,96::F)_+NH/&%QM:@RH 14:>_<US7-#BPF
MU/=@;Q+P  "(+7&[@((:XQF<IR6/$WO[S_D5*T6^IP<+2\8/?9MYHW(+0+6V
M))7NLW2A6"=J+^;K-G<XRG6+B>B['%&C*ZPDVZM:7A%T[;*M/BS<*PYS6; V
M?AS3I5:C\1B6]I<!LP5#3_[-5H8BDVJ&5*+<33JECZ=3>>YI#P]HI,< \516
M*3&P"9?WP9!%HD22+:$<BLA*S[0=<N9\.X3&F-[7#7.=HN,YN_L9B\2,O7KQ
M8\3$R"0EID$L0Q&(OBQS)'1?5F-R46V^@L:<3JK6/3<(--=5[/ 8#&XWONYJ
M4*=?%TJ#F8=C:N'I8T8<.HTSC'XS<^,%E1V%-*VX:LW-/=#<+R<@7 6@@.#;
M$7$W.0BPN5#SS,V:FOL<\?96@LI6F.S)/,\/17]J3UV%AM22]RW&5.DRD@N\
MGB2'Q!R>OR[QB)W@*G] P 0Z9R)G)FMP6!/;'%8.IAJ+L%3?CWC"D%E**.S:
MM>FV&;I:UM5K7P(N,C=5-:S\P06@M&\2,A 83$:"8Z:\5##G>WN%R-)[4:S
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M;-\^;'=SK\-A^OVN'=V^PIX^:J*2M;7<R98]A^$)ENG,-TG$?)E9O#/T(PF
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MS-B7&^5X^,<PS+(M*K=Q;1+M9-PYC4[!%-9+W!9PD4B:YVAG H"N0A"K= *
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MN6$G;D*;\29R?P]ZG(PC>7^(,%)V"0F(DDO'+1"SQ%YR0A%59'>C@NC)R_\
M;!D2@XY<I7K+%3K3(]L-87EF88@E(V.MLF@T91#=XWE(%*59OK976[:16JK+
MWE\^?KQK%^_;$5S6_>%MFHMEI%0LV8Z@TL>1TZ4K28QBY=3JD\CDET\9X]<-
MUX!K)M6[>\KQLF%1</EVJ-B3BI5>)4=HQC]1N1=>3MSV-L+WT]=RO;:+0:BC
M0XFW.;?9KJVCGR,E/Y C\>5^'/6EHX#!'3$W*,V+&P?&.A:<<-H-.-.LNFX
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MY'4_XAAQ%WW_ .0_0^-IMXI^0Q'^EO\ [A;KY3T7S_SD&V?_ -Y7+_X2<_\
M>=0-HX8F)>#S:?O\D& Q)D[K;?\ .%DSB+-=&S=6%;=15Y)>&1E'40<\G'GC
MG'OC-)LLL ('44$4P([1Z5.K@PB8./E'653JMJ"6SE-Q"QJE)U,PZ.%C-U*X
M*D-XY'MSX^G\=27@$B]NGW5!! DBQ7/6'V'^G^.F^.!]/NH3K#[#_3_'3?'
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M]->OV14CO&+2SPKV$<O&A%P,B9RU1?'70*J4R9E4R <HE$0$BP7RS[-S%^8
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MTS$PTXQ(KQ7]G;63W^(EV^6[^VQ%!;@['N8C<#EB*4I50R7=J;:ZA=/>[2K
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MS_T%^]X+69!7^QV:4";F)E\ZD%E?5]3WE5,C81,/";5),Y4VJ*7/!$T2D
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M^KSI9P9%/_;5/'O4BF4(0!Y$$G74(!^[R' Y7YLC.\YP<H@3&>G4WNK)P;2
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M('^K*X6;"5!0X>!$@%43 ?/"I@ 0Y'GY9_XK\'C*G8SL[M*@7'"[,[44!CF
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M3T6X7^XT>Z)Q-$J-@NDTG#1[.4.M$5F&=S<@,<M[^U075.S9+>[ X.T(HJ)
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MA=4R%-TJD( =^>>1  #N(_;CQX#[B(  CKQ>T>W#&[S65;D0&M(WK@Q#0-2
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MQU7*]3#V7:OOPO\ ANX8^NEH87*!DMK>0VN(3EGG*D8R"*E+&I98RTPTS6Y
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M.'I-<ZI6Q56G28&M;)NX@.)&0;\3LF@F L@<-8-M-^=MIZX(.(:LIF(NG'N
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M12ZQS'6<+1BCA4ZBBQCC\Z_B/LBCLGM/B?R[13H;0I4]H,I@ !CZ[GMKM $
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M.,H5G4*M1Y##5H%CX(!)%UM,'M?:6R:AJ;,Q^-V?5<-U]3!8JKAG/ BSS3<
M]HS#7 QP&2_;13=NF+J:X*]85]%T^*')74@'O:Q1[#R!E>>.. X[<]B\]P'7
MR_LCL[L#8%)U'8FQ-D[(I._53V9L["8%CH,C?&'I,+W3<N>7$FZL8_:NT]JO
M%3:6T<=M![3+7XW%UL4YIR^'O7N#8%AN@0)4]HM4T2E(0A$R$ H$33*!2%
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MXS?E^W6?84VO:QR/";C3P/CF0%D9&(^D>,,FH(&Z"ID3Z2F R14R\](AR82
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M \+V&EK*Z:0=I?\ S$#/K$>^=U;VU7;[A;=ENPN> KJM)T.8RQ3Y^WXDR95
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MICJ!T1!,4' F])8%"FZBG(J)!$W28A1.4P"!@ZN?N(.)(!@7%_?'PX*M[8;
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MS"Q;=4JBFV%D1&2'TN7R1&@BU(FZ%4A6_P"Q* )?+HBMTV-\>&B(ZOFH=,-
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M"B4>1#SR(!P'/;SV[<>-<LPO:#>=!XB;@NX3Q,1D(/1:7:WX<4#1<ZBVX!@
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M@%79"%$QF#A_')Q\F*15%4X]XZ5;D,X(D75WLWV[J;"VQA=I =XVB][:C&D
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MYR52*C,+,DI)&+L=DBH=^K'KK.&R+U-J^=(+':JN&CI%-<I!3,JW6(!A,F8
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M$>>>.0\<<?GQWY"H&-)!T]^G#-4%DF2;C*V0X<_?%))94"&)Z744?W1/TE,
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MY 0'IZB\AP(CVU,S?CG,VMRZV%X@:9V=PDVR\+7UD3,9\LE;$E*$3EFIBG
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M@HJD*<ARJ$.4IB'*<# )3  E,0P<@("40$HAR'''';1%]=) \C^G)N/'\N?
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MAU-A .F2BXFX(SI7\/PJ2R[]DN>.4420.NX%5DN9 JI4!()T5!*)#E,<O &
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M)ZGDEDT7B;#8+._3EJZ]FI."=2:<L1I.M&D?+HP\$JY7BFY%?^XP/_4=@/\
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M?SY,MN%9'=;N\F'*AE'#S<MF?U%#B83&*WR+/-DPY,(B($22(0H<_*0A2AV
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M8;$8G&LIBB*N&>"75C=S':-:[G.N5^-]Q194P#BVL^A2#,^[< (YWN3\YU4
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ML+-9A-IMDQ2=6&8<,':1'+'W^3;A'LTUB$5.U9N%R]2)P$8RC0#IS\O#Q"O
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MPK4Y$2B7@>F5;*2:1N_?YDG1# /V$/OKYO[9O#^U6WG-,M&T\0V0<]P[A_\
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MVI4E%3&:.G9"+E*8S1<Q!:E.?9]G]M8*C@*F'Q8 QM,#=<P.=3<Z[B7O<01
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M>6M^=K1EJ.2S($>$>'G[\2LH\!@ 7D1 .!^!2(\]O/J-._C^??6SPHBJV/\
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M&@@HW(;H*_62$QDQ.4PG*;IT3NRS*U5M7!X/$/)W@'4\/4=$BQ)#0V <]X@
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MA@^S&.?L>DRIWL8?'UFU!WN%P=66U:S*8!+RZU)S@X=U3>ZKDUSFU.)-G6/
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M^/TP=H1W'_S&_)WTE9N _P"\7_T.@\Y'OJ5KMIM;?9,O<-7&@'*@Y>%4>..
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MI%I,#A_I/0Z3-I&87Z[\<W&,R'1:9?X13U8>\5*NVZ*4[<GC['$M)=H(\"(
M;T'9 ,'(\& 0U\[XK#/P>)Q&$J?W,+7JX=__ %T7NIN]6F%:5[ZL(FB)HB:(
MFB)HB:(FB)HB:(FB)HBQ0WB)BIB^**!NGBYQIA,/C@(:P<AS].>0'^&L/'?V
M,I^-MO-9>#D5K?Z3\Q]86/NSEL@:_P!D4$IE#$JYQ(8X\]'5)LP.)>1Y#JZ!
M >.!^40'D!#6#@&-<\ES0=TR)&49:0!$B-1!Z9VT7.: UI@$ P"<R=3/D<O&
M8V1F[=/_ &0_J(CK9+6-OO?]1]  M27M#6!6]^QG, 5?J>P$XP4,)2@@4(V2
M;+I]"@%Y$YOB8B<@FY I!\CSSK=H7-/_ -(\1QY:<)Z6V>SQ'>"+02(TFYGA
M<9="H@J,N21A&IAZ3+MT2(*E#DPG.4>D3\< '!O(!SV#OQK#J[Q<!O2(F#/I
MS'&UX66QQ<QC29:TN(XYZ1<"3,:>2A^<^%S5KESJ-C^\(J(,VIC' OKBR#W<
MQRCS\Q?>4U1Z>>H.3B4!Z^]ESG,LUQ (B!%QE!G.<M,KZJO<;(<0-X7:8!(O
M;PX'IG"QWRHWZY%=92251%RY1351* *)D3(J1!0I4@X.<GI=8<!W$ _='@0&
MEI.\#KUC0C145*%*J_?J4VN>#GE>YN 8)X'6(NK]J9@IPHM6Y%PKCYPDX%^J
MU<))I?(HDH7UCH)MS H9,ADQ(<X%+P(F 0  NZ?$=;S'ET/@3RR5P  ",A86
MM;WP^:FI-S'/T> ,51%T0_I"J8%$5TP'TS ("/!B?,(#P <ASQ]Q$2T--VM,
M@&X!XP=?EHJPX\>&GR&7*!$V-A*LFRTN#,T55/#1#H>A)-LDDF"+=N "(@<J
M75P8P\\&,)O4 >0#Y2@ 2XS&])R X@3QT S5( D\^ F]@,\AEJ)ZJVXJH1K:
M,2;DB4E%S.SJ&=*KBH)?G*<R1#'6.)42]BD)V*4HCP <ZC2T>\[#Y*9B(C0^
M@^4G69O8W5YG*DV,D90[!D"1!*0K,/VG3V3. F I>./W1^?O].>.\:_2Y,93
MG;30ZWS2\&\]9FY!G4";3?USMRW6IC7HAT<%#F.@D15%H0A#.GQC@8")D)SZ
MAE#F^1(!#H$3!U"';F1P_CH.FG[&  ) ^]Q!DY<1RX=(DQ*]7N3J7M#I0T,[
M4G'1%8TP)";T8M<$4$%^@QB^HJ#<B@@01 /4 3=(]/,SE[]_(V@J]'RXYCZQ
M-^&JG)^I%P=@BIDBZR3IO.MU5$2JF431)ZR972I6O?I*=JH8JO07DW)A ! 1
MU%A\_,_4JP8DQEI'[^^"G.USJ$#"/)!=7Y6Z"OIE#@164$QBMR$[B;U53@4.
M>Q2ASU"7ZH$V M:UN<'EEQSF%%_OR].-O%1SLH:A,[FZ.LY5-ZB1K-+)G3-Q
MRNW@I9P0ANH!$2G$YBB'8>P<]AY'(PEZ[1J--3!&D<YL,IC)6,60V@9&;@'
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M7/+75VZ6.X43L;^/155'J,5C%K%BV#<!'P1JP:-VR!?]A-$A X ._6JD"A1
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M'RMYY:JW,9:$7-Q;+2>,<N8E11BP&J[!_+,I!5L5],S#IZU*9+@Q1E%DD#)
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M^G3WF4)=( =7<(<Z 012;G28<CO?U#%RT%S5.41,ZY9\H^:FHA"D*!2AP
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M%O7C:/GZS"DC)J+>3C'K3X:9Y(N4SH% "$,N)A:I<"0!$"=0F$>1,8A -WY
M.^K\& #?*X^]K1KG?74?I\O+09&_FKHFZN^A8"),[05 %8R-!)8 **:G2S1
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MY\YGV?!7;@JK0CBNQ4EZB9WB_0HJ!0#H.^55.9XD"7( 3TW1UTB)B B4I X
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MMHX[#5L+AZ>$Q J]T:[',-=U2D'"EW(<7L#]USWM  -XJ=4+H$$ 0#-I&?\
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M!#&-QZ1ND0^4>KGMP C.7OWFHOEPTX3?U7C@REFZR>0.H7H<I@^CUP HJ((
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M^_7/./')>#+]G31AEX1NN"KAXFG[V)52"DDBF8JAD>W)NI8P&* ?<#B8>>
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LHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
